Immune	NNP	O
reconstitution	NN	O
after	IN	O
allogeneic	JJ	O
marrow	NN	O
transplantation	NN	O
compared	VBN	O
with	IN	O
blood	NN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

Allogeneic	NNP	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cell	NN	O
grafts	NNS	O
contain	VBP	O
about	IN	O
10	CD	O
times	NNS	O
more	RBR	O
T	NNP	O
and	CC	O
B	NNP	O
cells	NNS	O
than	IN	O
marrow	JJ	O
grafts	NNS	O
.	.	O

Because	IN	O
these	DT	O
cells	NNS	O
may	MD	O
survive	VB	O
in	IN	O
transplant	JJ	O
recipients	NNS	O
for	IN	O
a	DT	O
long	JJ	O
time	NN	O
,	,	O
recipients	NNS	O
of	IN	O
blood	NN	O
stem	NN	O
cells	NNS	O
may	MD	O
be	VB	O
less	JJR	O
immunocompromised	JJ	O
than	IN	O
recipients	NNS	O
of	IN	O
marrow	NN	O
.	.	O

Immune	NNP	O
reconstitution	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
115	CD	O
patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
allogeneic	JJ	O
marrow	NN	O
or	CC	O
filgrastim-mobilized	JJ	O
blood	NN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

Between	NNP	O
day	NN	O
30	CD	O
and	CC	O
365	CD	O
after	IN	O
transplantation	NN	O
,	,	O
counts	NNS	Physical
of	IN	Physical
most	JJS	Physical
lymphocyte	JJ	Physical
subsets	NNS	Physical
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
blood	NN	O
stem	NN	O
cell	NN	O
recipients	NNS	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
most	RBS	O
striking	JJ	O
for	IN	O
CD4	NNP	Physical
T	NNP	Physical
cells	NNS	Physical
(	(	O
about	IN	O
4-fold	CD	O
higher	JJR	O
counts	NNS	O
for	IN	O
CD45RA	NNP	O
(	(	O
high	JJ	O
)	)	O
CD4	NNP	O
T	NNP	O
cells	NNS	O
and	CC	O
about	IN	O
2-fold	JJ	O
higher	JJR	O
counts	NNS	O
for	IN	O
CD45RA	NNP	Physical
(	(	Physical
low/-	JJ	Physical
)	)	Physical
CD4	NNP	Physical
T	NNP	Physical
cells	NNS	Physical
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

On	IN	O
assessment	NN	O
using	VBG	O
phytohemagglutinin	NN	O
and	CC	O
herpesvirus	VB	O
antigen-stimulated	JJ	O
proliferation	NN	O
,	,	O
T	NNP	Physical
cells	NNS	Physical
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
appeared	VBD	Others
equally	RB	Others
functional	JJ	Others
.	.	O

Median	JJ	Physical
serum	NN	Physical
IgG	NNP	Physical
levels	NNS	Physical
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
definite	NN	Physical
infections	NNS	Physical
after	IN	Physical
engraftment	NN	Physical
was	VBD	O
1.7-fold	JJ	O
higher	JJR	O
in	IN	O
marrow	NN	O
recipients	NNS	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
severe	JJ	Physical
(	(	Physical
inpatient	JJ	Physical
treatment	NN	Physical
required	VBN	Physical
)	)	Physical
definite	NN	Physical
infections	NNS	Physical
after	IN	Physical
engraftment	NN	Physical
was	VBD	O
2.4-fold	JJ	O
higher	JJR	O
in	IN	O
marrow	NN	O
recipients	NNS	O
(	(	O
P	NNP	O
=.002	NNP	O
)	)	O
.	.	O

The	DT	O
difference	NN	Physical
in	IN	Physical
the	DT	Physical
rates	NNS	Physical
of	IN	Physical
definite	JJ	Physical
infections	NNS	Physical
was	VBD	O
greatest	JJS	O
for	IN	O
fungal	JJ	O
infections	NNS	O
,	,	O
intermediate	NN	O
for	IN	O
bacterial	JJ	O
infections	NNS	O
,	,	O
and	CC	O
lowest	JJS	O
for	IN	O
viral	JJ	O
infections	NNS	O
.	.	O

Death	NNP	Mortality
associated	VBD	O
with	IN	O
a	DT	O
fungal	NN	O
or	CC	O
bacterial	JJ	O
infection	NN	O
occurred	VBD	O
between	IN	O
day	NN	O
30	CD	O
and	CC	O
day	NN	O
365	CD	O
after	IN	O
transplantation	NN	O
in	IN	O
9	CD	O
marrow	NN	O
recipients	NNS	O
and	CC	O
no	DT	O
blood	NN	O
stem	NN	O
cell	NN	O
recipients	NNS	O
(	(	O
P	NNP	O
=.008	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
blood	NN	O
stem	NN	O
cell	NN	O
recipients	NNS	O
have	VBP	O
higher	JJR	O
lymphocyte-subset	JJ	Physical
counts	NNS	Physical
and	CC	O
this	DT	O
appears	VBZ	O
to	TO	O
result	VB	O
in	IN	O
fewer	JJR	O
infections	NNS	Physical
.	.	O

(	(	O
Blood	NNP	O
.	.	O

2001	CD	O
;	:	O
97:3380-3389	CD	O
)	)	O
A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
heparinized	VBN	O
and	CC	O
nonheparinized	JJ	O
solutions	NNS	O
for	IN	O
maintenance	NN	Physical
of	IN	Physical
perioperative	JJ	Physical
radial	JJ	Physical
arterial	JJ	Physical
catheter	NN	Physical
patency	NN	Physical
and	CC	O
subsequent	JJ	Physical
occlusion	NN	Physical
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
,	,	O
we	PRP	O
compared	VBN	O
heparinized	VBN	O
and	CC	O
nonheparinized	VBN	O
infusions	NNS	O
for	IN	O
the	DT	O
maintenance	NN	Physical
of	IN	Physical
perioperative	JJ	Physical
arterial	JJ	Physical
catheter	NN	Physical
patency	NN	Physical
and	CC	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
subsequent	JJ	Physical
radial	JJ	Physical
arterial	JJ	Physical
occlusion	NN	Physical
.	.	O

Two-hundred	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
heparinized	VBN	O
(	(	O
group	NN	O
H	NNP	O
,	,	O
n	JJ	O
=	NNP	O
100	CD	O
)	)	O
or	CC	O
nonheparinized	VBN	O
(	(	O
group	NN	O
S	NNP	O
,	,	O
n	JJ	O
=	NNP	O
100	CD	O
)	)	O
flush	NN	O
solutions	NNS	O
.	.	O

Radial	NNP	Physical
and	CC	Physical
ulnar	JJ	Physical
blood	NN	Physical
flows	NNS	Physical
were	VBD	O
assessed	VBN	O
using	VBG	O
Doppler	NNP	Others
probe	NN	Others
and	CC	Others
pulse	JJ	Others
oximetry	NN	Others
before	IN	O
,	,	O
just	RB	O
after	IN	O
,	,	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
decannulation	NN	Others
by	IN	O
the	DT	O
same	JJ	O
investigator	NN	O
.	.	O

The	DT	O
cannulation	NN	O
site	NN	O
was	VBD	O
examined	VBN	O
for	IN	O
complications	NNS	Adverseeffect
such	JJ	Adverseeffect
as	IN	Adverseeffect
hematoma	NN	Adverseeffect
,	,	Adverseeffect
nerve	JJ	Adverseeffect
injury	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
infection	NN	Adverseeffect
.	.	O

The	DT	O
mean	JJ	O
duration	NN	O
of	IN	O
cannulations	NNS	Others
was	VBD	O
378	CD	O
+/-	JJ	O
159.0	CD	O
min	NN	O
in	IN	O
group	NN	O
H	NNP	O
and	CC	O
332	CD	O
+/-	JJ	O
154.6	CD	O
min	NN	O
in	IN	O
group	NN	O
S.	NNP	O
The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
corrective	JJ	O
interventions	NNS	O
caused	VBN	O
by	IN	O
dampening	VBG	O
of	IN	O
the	DT	O
pressure	NN	O
wave	NN	O
(	(	O
mean	JJ	O
number	NN	O
of	IN	O
positional	JJ	O
changes	NNS	O
[	VBP	O
group	NN	O
S	NNP	O
,	,	O
1.5	CD	O
+/-	JJ	O
2.0	CD	O
;	:	O
group	NN	O
H	NNP	O
,	,	O
1.4	CD	O
+/-	JJ	O
3.8	CD	O
]	NN	O
and	CC	O
mean	JJ	O
number	NN	O
of	IN	O
manual	JJ	O
flushes	NNS	O
[	VBP	O
group	NN	O
S	NNP	O
,	,	O
1.3	CD	O
+/-	JJ	O
1.7	CD	O
;	:	O
group	NN	O
H	NNP	O
,	,	O
1.2	CD	O
+/-	JJ	O
1.2	CD	O
]	NN	O
)	)	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

After	IN	O
decannulation	NN	O
,	,	O
partial	JJ	Physical
or	CC	Physical
total	JJ	Physical
occlusion	NN	Physical
developed	VBD	O
in	IN	O
20	CD	O
group	NN	O
H	NNP	O
patients	NNS	O
and	CC	O
16	CD	O
group	NN	O
S	NNP	O
patients	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
occlusion	NN	Physical
was	VBD	O
correlated	VBN	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
hematoma	NN	Physical
at	IN	O
the	DT	O
puncture	NN	O
site	NN	O
after	IN	O
decannulation	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
,	,	O
long	JJ	Others
duration	NN	Others
of	IN	Others
cannulation	NN	Others
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
and	CC	O
age	NN	O
<	VBP	O
65	CD	O
yr	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.009	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
heparinized	VBN	O
and	CC	O
nonheparinized	VBN	O
flush	JJ	O
solutions	NNS	O
for	IN	O
the	DT	O
maintenance	NN	Others
of	IN	Others
perioperative	JJ	Others
radial	JJ	Others
artery	NN	Others
catheter	NN	Others
patency	NN	Others
.	.	O

Prospective	JJ	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
fast-track	JJ	O
elective	JJ	O
open	JJ	O
infrarenal	JJ	O
aneurysm	NN	O
repair	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
Fast-track	NNP	O
programs	NNS	O
have	VBP	O
been	VBN	O
introduced	VBN	O
in	IN	O
many	JJ	O
surgical	JJ	O
fields	NNS	O
to	TO	O
minimize	VB	O
postoperative	JJ	Others
morbidity	NN	Others
and	CC	O
mortality	NN	Mortality
.	.	O

Morbidity	NN	Physical
after	IN	O
elective	JJ	O
open	JJ	O
infrarenal	JJ	O
aneurysm	NN	O
repair	NN	O
is	VBZ	O
as	RB	O
high	JJ	O
as	IN	O
30	CD	O
%	NN	O
;	:	O
mortality	NN	Physical
ranges	VBZ	O
up	IN	O
to	TO	O
10	CD	O
%	NN	O
.	.	O

In	IN	O
terms	NNS	O
of	IN	O
open	JJ	O
infrarenal	JJ	O
aneurysm	NN	O
repair	NN	O
,	,	O
no	DT	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
exist	VBP	O
to	TO	O
introduce	VB	O
and	CC	O
evaluate	VB	O
such	JJ	O
patient	JJ	O
care	NN	O
programs	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
study	NN	O
involved	VBD	O
prospective	JJ	O
randomization	NN	O
of	IN	O
82	CD	O
patients	NNS	O
in	IN	O
a	DT	O
traditional	JJ	O
and	CC	O
a	DT	O
fast-track	JJ	O
treatment	NN	O
arm	NN	O
.	.	O

Main	NNP	O
differences	NNS	O
consisted	VBD	O
in	IN	O
preoperative	JJ	O
bowel	NN	O
washout	NN	O
(	(	O
none	NN	O
vs.	FW	O
3	CD	O
l	NN	O
cleaning	VBG	O
solution	NN	O
)	)	O
and	CC	O
analgesia	$	O
(	(	O
patient	NN	O
controlled	VBN	O
analgesia	JJ	O
vs.	FW	O
patient	NN	O
controlled	VBD	O
epidural	JJ	O
analgesia	NN	O
)	)	O
.	.	O

Study	NN	O
endpoints	NNS	O
were	VBD	O
morbidity	NN	Physical
and	CC	O
mortality	NN	Mortality
,	,	O
need	VBP	Others
for	IN	Others
postoperative	JJ	Others
mechanical	JJ	Others
ventilation	NN	Others
,	,	O
and	CC	O
length	NN	Others
of	IN	Others
stay	NN	Others
(	(	Others
LOS	NNP	Others
)	)	Others
on	IN	Others
intensive	JJ	Others
care	NN	Others
unit	NN	Others
(	(	Others
ICU	NNP	Others
)	)	Others
.	.	O

RESULTS	VB	O
The	DT	O
need	NN	O
for	IN	O
assisted	JJ	Others
postoperative	JJ	Others
ventilation	NN	Others
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
traditional	JJ	O
group	NN	O
(	(	O
33.3	CD	O
%	NN	O
vs.	FW	O
5.4	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.011	CD	O
)	)	O
.	.	O

Median	JJ	Others
LOS	NNP	Others
on	IN	Others
ICU	NNP	Others
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
fast-track	JJ	O
group	NN	O
,	,	O
41	CD	O
vs.	FW	O
20	CD	O
h.	PDT	O
The	DT	O
rate	NN	Adverseeffect
of	IN	Adverseeffect
postoperative	JJ	Adverseeffect
medical	JJ	Adverseeffect
complications	NNS	Adverseeffect
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
fast-track	JJ	O
group	NN	O
,	,	O
16.2	CD	O
%	NN	O
vs.	FW	O
35.7	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.045	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
We	PRP	O
introduced	VBD	O
and	CC	O
evaluated	VBD	O
an	DT	O
optimized	JJ	O
patient	NN	O
care	NN	O
program	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
infrarenal	JJ	O
aortic	JJ	O
aneurysm	NN	O
repair	NN	O
which	WDT	O
showed	VBD	O
a	DT	O
significant	JJ	O
advantage	NN	O
for	IN	O
fast-track	JJ	O
patients	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
postoperative	JJ	Physical
morbidity	NN	Physical
.	.	O

Influence	NN	O
of	IN	O
ibopamine	NN	O
on	IN	O
heart	NN	Physical
rate	NN	Physical
and	CC	Physical
arrhythmic	JJ	Physical
pattern	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
multicentre	NN	O
study	NN	O
.	.	O

Ibopamine	NNP	O
is	VBZ	O
a	DT	O
dopaminergic	NN	O
and	CC	O
adrenergic	JJ	O
receptor	NN	O
agonist	NN	O
,	,	O
which	WDT	O
is	VBZ	O
active	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Since	IN	O
the	DT	O
long-term	JJ	O
prognosis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
remains	VBZ	O
very	RB	O
poor	JJ	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
is	VBZ	O
high	JJ	O
,	,	O
every	DT	O
new	JJ	O
drug	NN	O
to	TO	O
be	VB	O
employed	VBN	O
against	IN	O
this	DT	O
disease	NN	O
should	MD	O
be	VB	O
thoroughly	RB	O
tested	VBN	O
in	IN	O
order	NN	O
to	TO	O
rule	VB	O
out	RP	O
any	DT	O
possible	JJ	O
arrhythmogenic	JJ	Physical
action	NN	Physical
.	.	O

This	DT	O
multicentre	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
ibopamine	NN	O
versus	NN	O
placebo	NN	O
in	IN	O
double-blind	JJ	O
conditions	NNS	O
on	IN	O
heart	NN	Physical
rate	NN	Physical
,	,	Physical
rhythm	NN	Physical
and	CC	Physical
electrical	JJ	Others
safety	NN	Others
.	.	O

Ibopamine	NNP	O
was	VBD	O
employed	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
100	CD	O
mg	NN	O
t.i.d	NN	O
.	.	O

in	IN	O
97	CD	O
patients	NNS	O
(	(	O
aged	VBN	O
31-83	CD	O
years	NNS	O
)	)	O
belonging	VBG	O
to	TO	O
NYHA	NNP	O
class	NN	O
II	NNP	O
and	CC	O
III	NNP	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
of	IN	O
different	JJ	O
aetiology	NN	O
,	,	O
but	CC	O
without	IN	O
any	DT	O
complex	JJ	O
ventricular	NN	O
arrhythmias	NN	O
in	IN	O
basal	NN	O
conditions	NNS	O
(	(	O
couplets	NNS	O
with	IN	O
R'-R	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
400	CD	O
msec	NNS	O
,	,	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
R	NNP	O
on	IN	O
T	NNP	O
phenomena	NN	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
random	JJ	O
cross-over	NN	O
design	NN	O
the	DT	O
patients	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
48	CD	O
hr	NN	O
.	.	O

Holter	NNP	Others
recordings	NNS	Others
in	IN	O
basal	NN	O
conditions	NNS	O
and	CC	O
following	VBG	O
7	CD	O
days	NNS	O
of	IN	O
ibopamine	NN	O
and	CC	O
placebo	NN	O
treatment	NN	O
.	.	O

No	DT	O
influence	NN	O
on	IN	O
heart	NN	Physical
rhythm	NN	Physical
was	VBD	O
noted	VBN	O
.	.	O

No	DT	O
significant	JJ	O
variations	NNS	O
in	IN	O
maximum	JJ	Physical
heart	NN	Physical
rate	NN	Physical
(	(	O
ibopamine	JJ	O
117.7	CD	O
+/-	JJ	O
20.9	CD	O
;	:	O
placebo	NN	O
118.1	CD	O
+/-	JJ	O
20.7	CD	O
)	)	O
,	,	O
medium	JJ	Physical
heart	NN	Physical
rate	NN	Physical
(	(	O
ibopamine	JJ	O
71.8	CD	O
+/-	JJ	O
10.2	CD	O
;	:	O
placebo	NN	O
72.6	CD	O
+/-	JJ	O
10.1	CD	O
)	)	O
or	CC	O
minimum	JJ	Physical
heart	NN	Physical
rate	NN	Physical
(	(	O
ibopamine	JJ	O
55.3	CD	O
+/-	JJ	O
11.7	CD	O
;	:	O
placebo	NN	O
54.6	CD	O
+/-	JJ	O
10.6	CD	O
)	)	O
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
mean	JJ	O
number/hr	NN	O
.	.	O

of	IN	O
ectopic	JJ	Physical
supraventricular	JJ	Physical
beats	NNS	Physical
was	VBD	O
26.1	CD	O
+/-	JJ	O
61.9	CD	O
after	IN	O
ibopamine	NN	O
and	CC	O
21.7	CD	O
+/-	JJ	O
35.8	CD	O
after	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
ns	NN	O
)	)	O
.	.	O

The	DT	O
complexity	NN	O
of	IN	O
ectopic	NN	Physical
supraventricular	JJ	Physical
beats	NNS	Physical
did	VBD	O
not	RB	O
change	NN	O
.	.	O

The	DT	O
mean	JJ	O
number/hr	NN	O
.	.	O

of	IN	O
ectopic	JJ	Physical
ventricular	JJ	Physical
beats	NNS	Physical
was	VBD	O
31.1	CD	O
+/-	JJ	O
52.5	CD	O
after	IN	O
ibopamine	NN	O
and	CC	O
30.4	CD	O
+/-	JJ	O
57.8	CD	O
after	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
ns	NN	O
)	)	O
.	.	O

Neither	CC	O
the	DT	O
distribution	NN	O
of	IN	O
the	DT	O
patients	NNS	O
among	IN	O
Lown	JJ	Physical
classification	NN	Physical
nor	CC	Physical
the	DT	Physical
Final	NNP	Physical
Score	NN	Physical
of	IN	Physical
the	DT	Physical
Italian	JJ	Physical
Lown	NNP	Physical
Classification	NNP	Physical
(	(	O
26.1	CD	O
+/-	JJ	O
18.0	CD	O
and	CC	O
26.6	CD	O
+/-	JJ	O
17.9	CD	O
in	IN	O
the	DT	O
1st	CD	O
and	CC	O
2nd	CD	O
day	NN	O
of	IN	O
monitoring	NN	O
after	IN	O
ibopamine	NN	O
and	CC	O
25.7	CD	O
+/-	JJ	O
18.6	CD	O
and	CC	O
25.7	CD	O
+/-	JJ	O
18.8	CD	O
after	IN	O
placebo	NN	O
;	:	O
p	CC	O
=	NNP	O
ns	NN	O
)	)	O
showed	VBD	O
any	DT	O
difference	NN	O
between	IN	O
active	JJ	O
treatment	NN	O
and	CC	O
placebo	NN	O
.	.	O

Similar	JJ	O
results	NNS	O
were	VBD	O
achieved	VBN	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
sub-divided	JJ	O
into	IN	O
subgroups	NNS	O
according	VBG	O
to	TO	O
sequences	NNS	O
of	IN	O
treatment	NN	O
(	(	O
basal	NN	O
--	:	O
--	:	O
ibopamine	NN	O
--	:	O
--	:	O
placebo	NN	O
and	CC	O
basal	NN	O
--	:	O
--	:	O
placebo	NN	O
--	:	O
--	:	O
ibopamine	NN	O
)	)	O
,	,	O
NYHA	NNP	O
class	NN	O
II	NNP	O
or	CC	O
III	NNP	O
,	,	O
aetiology	NN	O
of	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
dilatative	JJ	O
cardiomyopathy	NN	O
,	,	O
ischemic	JJ	O
cardiomyopathy	NN	O
and	CC	O
other	JJ	O
aetiologies	NNS	O
)	)	O
,	,	O
associated	VBN	O
treatment	NN	O
with	IN	O
digitalis	NN	O
or	CC	O
diuretics	NNS	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
complexity	NN	O
of	IN	O
base	NN	O
ectopic	NN	O
ventricular	JJ	O
beats	NNS	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
experienced	VBD	O
sustained	JJ	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
400	CD	O
WORDS	NNP	O
)	)	O
[	JJ	O
Efficacy	NNP	Physical
and	CC	O
safety	NN	Physical
of	IN	O
extended-release	JJ	O
niacin	JJ	O
alone	NN	O
or	CC	O
with	IN	O
atorvastatin	NN	O
for	IN	O
lipid	JJ	O
profile	JJ	O
modification	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Physical
and	CC	O
safety	NN	Physical
of	IN	O
extended-release	JJ	O
niacin	NN	O
(	(	O
niacin	JJ	O
ER	NNP	O
)	)	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
atorvastatin	NN	O
for	IN	O
the	DT	O
lipid	JJ	O
profile	NN	O
modification	NN	O
in	IN	O
the	DT	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
and	CC	O
its	PRP$	O
equivalents	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
ten	JJ	O
patients	NNS	O
with	IN	O
CHD	NNP	O
and	CC	O
its	PRP$	O
equivalents	NNS	O
with	IN	O
serum	JJ	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
>	VBD	O
or	CC	O
=	$	O
3.5	CD	O
mmol/L	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
three	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
atorvastatin	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
,	,	O
receiving	VBG	O
atorvastatin	NN	O
10	CD	O
mg/d	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
;	:	O
(	(	O
2	CD	O
)	)	O
niacin	NN	O
ER	NNP	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
,	,	O
given	VBN	O
niacin	NNS	O
ER	NNP	O
500	CD	O
mg/d	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
1000	CD	O
mg/d	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
;	:	O
(	(	O
3	CD	O
)	)	O
combination	NN	O
treatment	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
34	CD	O
)	)	O
,	,	O
treated	VBN	O
with	IN	O
atorvastatin	NN	O
(	(	O
10	CD	O
mg/d	NN	O
)	)	O
plus	CC	O
niacin	JJ	O
ER	NNP	O
,	,	O
with	IN	O
the	DT	O
dose	JJ	O
initiating	NN	O
from	IN	O
500	CD	O
mg/d	NN	O
,	,	O
and	CC	O
increasing	VBG	O
to	TO	O
1000	CD	O
mg/d	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
,	,	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
serums	NNS	Physical
lipid	JJ	Physical
profiles	NNS	Physical
and	CC	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
assessed	VBN	O
in	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
before	IN	O
treatment	NN	O
,	,	O
and	CC	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
(	(	O
1	CD	O
)	)	O
After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
serum	JJ	Physical
level	NN	Physical
of	IN	Physical
triglyceride	NN	Physical
(	(	Physical
TG	NNP	Physical
)	)	Physical
and	CC	O
high-density	JJ	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
HDL-C	NNP	Physical
)	)	Physical
were	VBD	O
reduced	VBN	O
by	IN	O
30	CD	O
%	NN	O
and	CC	O
16	CD	O
%	NN	O
respectively	RB	O
in	IN	O
the	DT	O
niacin	JJ	O
ER	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
values	NNS	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
,	,	O
the	DT	O
TC	NNP	Physical
,	,	O
low-density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
LDL-C	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
TG	NNP	Physical
in	IN	O
the	DT	O
atorvastatin	NN	Physical
group	NN	O
decreased	VBN	O
by	IN	O
19	CD	O
%	NN	O
,	,	O
26	CD	O
%	NN	O
,	,	O
and	CC	O
17	CD	O
%	NN	O
respectively	RB	O
compared	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
values	NNS	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Combination	NNP	O
treatment	NN	O
decreased	VBD	O
the	DT	O
TC	NNP	Physical
,	,	O
LDL-C	NNP	Physical
,	,	O
and	CC	O
TG	NNP	Physical
levels	NNS	Physical
by	IN	O
28	CD	O
%	NN	O
,	,	O
38	CD	O
%	NN	O
,	,	O
and	CC	O
39	CD	O
%	NN	O
respectively	RB	O
,	,	O
and	CC	O
increased	VBD	O
the	DT	O
HDL-C	NNP	Physical
level	NN	Physical
by	IN	O
23	CD	O
%	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
in	IN	O
TC	NNP	Physical
and	CC	O
LDL-C	NNP	Physical
achieved	VBN	O
by	IN	O
combination	NN	O
treatment	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
treatment	NN	O
of	IN	O
atorvastatin	NN	O
alone	RB	O
and	CC	O
treatment	NN	O
of	IN	O
niacin	JJ	O
ER	NNP	O
alone	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

(	(	O
2	CD	O
)	)	O
The	DT	O
rate	NN	O
of	IN	O
achieving	VBG	O
the	DT	O
LDL-C	JJ	Physical
goal	NN	O
of	IN	O
The	DT	O
National	NNP	O
Cholesterol	NNP	O
Education	NNP	O
Program	NNP	O
(	(	O
NCEP	NNP	O
)	)	O
in	IN	O
Adult	NNP	O
Treatment	NNP	O
Panel	NNP	O
III	NNP	O
(	(	O
ATP	NNP	O
III	NNP	O
)	)	O
in	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
group	NN	O
was	VBD	O
73.5	CD	O
%	NN	O
,	,	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
atorvastatin	NN	O
and	CC	O
niacin	JJ	O
groups	NNS	O
(	(	O
47.7	CD	O
%	NN	O
and	CC	O
42.1	CD	O
%	NN	O
respectively	RB	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

(	(	O
3	CD	O
)	)	O
Adverse	NNP	O
effect	NN	O
,	,	O
such	JJ	O
as	IN	O
flushing	NN	Adverseeffect
(	(	O
15.8	CD	O
%	NN	O
)	)	O
and	CC	O
gastrointestinal	JJ	Adverseeffect
symptoms	NNS	Adverseeffect
(	(	O
23.7	CD	O
%	NN	O
)	)	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
niacin	JJ	O
ER	NNP	O
group	NN	O
,	,	O
however	RB	O
,	,	O
no	DT	O
more	JJR	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Niacin	NNP	O
ER	NNP	O
has	VBZ	O
a	DT	O
favorable	JJ	O
effect	NN	O
in	IN	O
modulating	VBG	O
the	DT	O
blood	NN	O
lipid	JJ	O
profile	NN	O
,	,	O
especially	RB	O
in	IN	O
reducing	VBG	Others
TG	NNP	Physical
and	CC	O
elevating	VBG	Others
HDL-C	NNP	Physical
.	.	O

Combined	VBN	O
statin	NN	O
with	IN	O
niacin	NN	O
may	MD	O
produce	VB	O
a	DT	O
more	JJR	O
global	JJ	Physical
and	CC	Physical
effective	JJ	Physical
improvement	NN	Physical
in	IN	Physical
lipid	JJ	Physical
blood	NN	Physical
levels	NNS	Physical
than	IN	O
monotherapy	NN	O
and	CC	O
is	VBZ	O
generally	RB	O
safe	JJ	Physical
and	CC	O
well	RB	Physical
tolerable	JJ	Physical
.	.	O

A	DT	O
plaque	NN	O
index	NN	O
for	IN	O
occlusal	NN	O
surfaces	NNS	O
and	CC	O
fissures	NNS	O
.	.	O

Measurement	NN	O
of	IN	O
repeatability	NN	O
and	CC	O
plaque	NN	O
removal	NN	O
.	.	O

Plaque	NNP	O
indices	NNS	O
have	VBP	O
largely	RB	O
been	VBN	O
developed	VBN	O
for	IN	O
buccal	JJ	O
and	CC	O
lingual	JJ	O
tooth	NN	O
surfaces	NNS	O
.	.	O

There	EX	O
has	VBZ	O
been	VBN	O
minimal	JJ	O
interest	NN	O
in	IN	O
plaque	JJ	O
accumulation	NN	O
on	IN	O
occlusal	NN	O
surfaces	NNS	O
despite	IN	O
the	DT	O
predilection	NN	O
for	IN	O
caries	NNS	O
at	IN	O
these	DT	O
sites	NNS	O
.	.	O

A	DT	O
numerical	JJ	O
plaque	NN	O
index	NN	O
(	(	O
0-5	JJ	O
)	)	O
is	VBZ	O
described	VBN	O
based	VBN	O
on	IN	O
the	DT	O
presence	NN	O
and	CC	O
distribution	NN	O
of	IN	O
plaque	NN	O
in	IN	O
the	DT	O
fissures	NNS	O
and	CC	O
over	IN	O
the	DT	O
occlusal	JJ	O
surfaces	NNS	O
of	IN	O
permanent	JJ	O
molar	NN	O
and	CC	O
premolar	JJ	O
teeth	NNS	O
.	.	O

The	DT	O
repeatability	NN	O
of	IN	O
a	DT	O
single	JJ	O
examiner	NN	O
in	IN	O
scoring	VBG	O
the	DT	O
index	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
4	CD	O
groups	NNS	O
of	IN	O
10	CD	O
subjects	NNS	O
.	.	O

Each	DT	O
group	NN	O
of	IN	O
volunteers	NNS	O
suspended	VBN	O
tooth	RB	O
cleaning	VBG	O
for	IN	O
48	CD	O
h	NN	O
and	CC	O
the	DT	O
index	NN	O
scored	VBD	O
after	IN	O
disclosing	VBG	O
plaque	NN	O
deposits	NNS	O
.	.	O

The	DT	O
index	NN	O
was	VBD	O
rescored	VBN	O
60-90	JJ	O
min	NN	O
later	RB	O
.	.	O

Plaque	NNP	O
area	NN	O
was	VBD	O
also	RB	O
determined	VBN	O
by	IN	O
drawing	VBG	O
the	DT	O
outline	NN	O
of	IN	O
plaque	NN	O
onto	IN	O
grids	NNS	O
.	.	O

Except	IN	O
for	IN	O
one	CD	O
condition	NN	O
of	IN	O
repeatability	NN	O
for	IN	O
one	CD	O
group	NN	O
,	,	O
the	DT	O
4	CD	O
conditions	NNS	O
of	IN	O
repeatability	NN	O
in	IN	O
scoring	VBG	O
the	DT	O
index	NN	O
were	VBD	O
met	VBN	O
for	IN	O
all	DT	O
4	CD	O
groups	NNS	O
of	IN	O
subjects	NNS	O
.	.	O

The	DT	O
sensitivity	NN	Others
of	IN	Others
the	DT	Others
index	NN	Others
and	CC	Others
area	NN	Others
recordings	NNS	Others
to	TO	O
detect	VB	O
plaque	NN	O
removed	VBN	O
by	IN	O
brushing	VBG	O
was	VBD	O
then	RB	O
evaluated	VBN	O
.	.	O

A	DT	O
group	NN	O
of	IN	O
10	CD	O
subjects	NNS	O
had	VBD	O
plaque	VBN	O
scored	VBN	O
by	IN	O
index	NN	O
and	CC	O
area	NN	O
after	IN	O
suspending	VBG	O
toothcleaning	VBG	O
for	IN	O
48	CD	O
h.	JJ	O
Subjects	NNS	O
were	VBD	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
brush	VB	O
or	CC	O
not	RB	O
brush	VB	O
their	PRP$	O
teeth	NNS	O
and	CC	O
plaque	NN	O
rescored	VBN	O
.	.	O

The	DT	O
experiment	NN	O
was	VBD	O
then	RB	O
repeated	VBN	O
and	CC	O
brushing	VBG	O
or	CC	O
not	RB	O
brushing	VBG	O
crossed	VBN	O
over	IN	O
.	.	O

Highly	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
brushing	VBG	O
and	CC	O
no	DT	O
brushing	NN	O
plaque	NN	Others
indices	NNS	Others
and	CC	O
areas	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
occlusal	JJ	Others
fissure	NN	Others
plaque	NN	Others
index	NN	Others
was	VBD	O
easy	JJ	O
to	TO	O
apply	VB	O
,	,	O
repeatable	JJ	O
and	CC	O
sufficiently	RB	O
sensitive	JJ	O
to	TO	O
detect	VB	O
plaque	NN	O
removed	VBN	O
by	IN	O
brushing	VBG	O
.	.	O

The	DT	O
index	NN	O
could	MD	O
find	VB	O
use	NN	O
as	IN	O
an	DT	O
additional	JJ	O
measure	NN	O
of	IN	O
oral	JJ	O
hygiene	NN	O
,	,	O
in	IN	O
clinical	JJ	O
trials	NNS	O
on	IN	O
plaque	NN	O
control	NN	O
and	CC	O
possibly	RB	O
epidemiological	JJ	O
studies	NNS	O
relating	VBG	O
to	TO	O
caries	NNS	O
.	.	O

Effect	NN	O
of	IN	O
micronutrient	NN	O
supplement	NN	O
on	IN	O
health	NN	Physical
and	CC	Physical
nutritional	JJ	Physical
status	NN	Physical
of	IN	O
schoolchildren	NNS	O
:	:	O
study	NN	O
design	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
supplementation	NN	O
with	IN	O
a	DT	O
micronutrient-fortified	JJ	O
beverage	NN	O
improves	VBZ	O
micronutrient	JJ	O
status	NN	O
and	CC	O
physical	JJ	O
and	CC	O
mental	JJ	O
development	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
schoolchildren	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
middle-income	JJ	O
students	NNS	O
in	IN	O
two	CD	O
residential	JJ	O
schools	NNS	O
that	WDT	O
catered	VBD	O
to	TO	O
children	NNS	O
from	IN	O
a	DT	O
semi-urban	JJ	O
population	NN	O
near	IN	O
Hyderabad	NNP	O
,	,	O
India	NNP	O
.	.	O

Included	NNP	O
were	VBD	O
869	CD	O
children	NNS	O
who	WP	O
were	VBD	O
6	CD	O
to	TO	O
16	CD	O
y	NN	O
of	IN	O
age	NN	O
in	IN	O
grades	NNS	O
1	CD	O
to	TO	O
10	CD	O
.	.	O

Because	IN	O
children	NNS	O
at	IN	O
each	DT	O
grade	NN	O
were	VBD	O
distributed	VBN	O
across	IN	O
two	CD	O
classrooms	NNS	O
(	(	O
clusters	NNS	O
)	)	O
and	CC	O
were	VBD	O
homogeneous	JJ	O
,	,	O
each	DT	O
grade	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
consist	VB	O
of	IN	O
a	DT	O
matched	JJ	O
pair	NN	O
.	.	O

There	EX	O
were	VBD	O
thus	RB	O
10	CD	O
pairs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Classes	NNS	O
in	IN	O
each	DT	O
grade	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
or	CC	O
a	DT	O
placebo	NN	O
without	IN	O
added	JJ	O
micronutrients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double	RB	O
blinded	VBN	O
and	CC	O
the	DT	O
duration	NN	O
was	VBD	O
14	CD	O
mo	NN	O
,	,	O
with	IN	O
supervised	JJ	O
feeding	NN	O
of	IN	O
the	DT	O
micronutrient-enriched	JJ	O
beverage	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
micronutrients	NNS	O
on	IN	O
the	DT	O
outcome	NN	Physical
variables	NNS	Physical
growth	NN	Physical
,	,	Physical
biochemical	JJ	Physical
status	NN	Physical
,	,	O
mental	JJ	Mental
function	NN	Mental
,	,	O
and	CC	O
bone	NN	Physical
health	NN	Physical
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
matched	JJ	O
pairs	NNS	O
varied	VBD	O
between	IN	O
seven	CD	O
and	CC	O
eight	CD	O
,	,	O
and	CC	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
treatment	NN	O
group	NN	O
ranged	VBD	O
from	IN	O
32	CD	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
bone	NN	O
heath	NN	O
to	TO	O
177	CD	O
for	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
power	NN	O
of	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
ranged	VBD	O
from	IN	O
74	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
and	CC	O
was	VBD	O
adequate	NN	O
for	IN	O
successful	JJ	O
pairing	NN	O
.	.	O

The	DT	O
effect	NN	O
assessed	VBD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
supplementation	NN	O
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
beneficial	JJ	Others
.	.	O

CONCLUSIONS	NNP	O
Designing	VBG	O
an	DT	O
intervention	NN	O
,	,	O
choosing	VBG	O
outcome	NN	O
variables	NNS	O
,	,	O
and	CC	O
implementing	VBG	O
the	DT	O
protocol	NN	O
in	IN	O
a	DT	O
typical	JJ	O
Indian	JJ	O
school	NN	O
setting	VBG	O
were	VBD	O
achieved	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
two-month	JJ	O
vocal	JJ	O
exercising	NN	O
with	IN	O
and	CC	O
without	IN	O
spectral	JJ	O
biofeedback	NN	O
on	IN	O
student	NN	O
actors	NNS	O
'	POS	O
speaking	NN	O
voice	NN	O
.	.	O

Twelve	NNP	O
student	NN	O
actors	NNS	O
(	(	O
6	CD	O
males	NNS	O
,	,	O
6	CD	O
females	NNS	O
)	)	O
were	VBD	O
given	VBN	O
voice	NN	O
training	VBG	O
for	IN	O
two	CD	O
months	NNS	O
.	.	O

Randomly	NNP	O
selected	VBD	O
,	,	O
half	NN	O
of	IN	O
the	DT	O
students	NNS	O
(	(	O
3	CD	O
males	NNS	O
,	,	O
3	CD	O
females	NNS	O
)	)	O
was	VBD	O
trained	VBN	O
in	IN	O
the	DT	O
traditional	JJ	O
way	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
half	NN	O
was	VBD	O
given	VBN	O
biofeedback	RP	O
with	IN	O
real-time	JJ	O
spectrum	NN	O
analysis	NN	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
a	DT	O
ringing	JJ	Others
voice	NN	Others
quality	NN	Others
with	IN	Others
strong	JJ	Others
overtones	NNS	Others
at	IN	Others
3-5	JJ	Others
kHz	NN	Others
.	.	O

Text	NNP	O
samples	VBZ	O
read	VBP	O
at	IN	O
different	JJ	O
loudness	NN	O
levels	NNS	O
were	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
training	NN	O
.	.	O

Fundamental	JJ	Others
frequency	NN	Others
(	(	Others
F0	NNP	Others
)	)	Others
,	,	Others
sound	JJ	Others
pressure	NN	Others
level	NN	Others
(	(	Others
SPL	NNP	Others
)	)	Others
and	CC	O
long-term-average	JJ	Others
spectrum	NN	Others
(	(	Others
LTAS	NNP	Others
)	)	Others
analyses	NNS	Others
were	VBD	O
made	VBN	O
.	.	O

Voice	NNP	Others
quality	NN	Others
was	VBD	O
evaluated	VBN	O
by	IN	O
two	CD	O
voice	NN	O
trainers	NNS	O
.	.	O

Sound	NNP	Others
energy	NN	Others
at	IN	Others
3-5	JJ	Others
kHz	NNS	Others
increased	VBN	O
by	IN	O
3-4	JJ	O
dB	NN	O
(	(	O
1.5-14.5	JJ	O
dB	NN	O
)	)	O
across	IN	O
groups	NNS	O
after	IN	O
training	VBG	O
.	.	O

This	DT	O
change	NN	O
,	,	O
which	WDT	O
was	VBD	O
slightly	RB	O
larger	JJR	O
for	IN	O
the	DT	O
biofeedback	NN	O
(	(	O
BF	NNP	O
)	)	O
group	NN	O
,	,	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
SPL	NNP	Others
.	.	O

F0	NNP	Others
increased	VBD	O
slightly	RB	O
in	IN	O
the	DT	O
BF	NNP	O
group	NN	O
and	CC	O
decreased	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
relative	JJ	Others
dB	NN	Others
level	NN	Others
of	IN	Others
fundamental	JJ	Others
decreased	VBN	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
BF	NNP	O
group	NN	O
probably	RB	O
suggesting	VBG	O
a	DT	O
tighter	JJR	O
adduction	NN	O
.	.	O

Voice	NNP	Others
quality	NN	Others
improved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Visual	JJ	O
feedback	NN	O
seems	VBZ	O
to	TO	O
add	VB	O
some	DT	O
efficacy	NN	Others
in	IN	O
voice	NN	O
training	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
danger	NN	O
of	IN	O
hyperfunctional	JJ	O
voice	NN	O
production	NN	O
if	IN	O
other	JJ	O
sensory	JJ	O
feedback	NN	O
is	VBZ	O
neglected	VBN	O
.	.	O

The	DT	O
treatment	NN	O
of	IN	O
senile	JJ	Physical
dementia	NN	Physical
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
:	:	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
buflomedil	NN	O
and	CC	O
dihydrogenated	VBD	O
ergot	JJ	O
alkaloids	NNS	O
.	.	O

Seventy-six	JJ	O
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
buflomedil	NN	O
hydrochloride	NN	O
and	CC	O
dihydrogenated	VBD	O
ergot	JJ	O
alkaloids	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
senile	JJ	Physical
dementia	NN	Physical
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
.	.	O

Efficacy	NN	Others
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
'	POS	O
performance	NN	O
in	IN	O
four	CD	O
psychometric	JJ	Mental
tests	NNS	Mental
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
a	DT	O
trend	NN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
buflomedil	NN	O
group	NN	O
in	IN	O
three	CD	O
of	IN	O
the	DT	O
tests	NNS	O
became	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
the	DT	O
fourth	JJ	O
.	.	O

Both	DT	O
drugs	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	Others
,	,	O
causing	VBG	O
no	DT	O
marked	JJ	O
adverse	JJ	Adverseeffect
reactions	NNS	Adverseeffect
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
buflomedil	NN	O
is	VBZ	O
as	IN	O
effective	JJ	O
or	CC	O
more	RBR	O
effective	JJ	O
than	IN	O
dihydrogenated	VBN	O
ergot	JJ	O
alkaloids	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
senile	JJ	Physical
dementia	NN	Physical
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
and	CC	O
could	MD	O
prove	VB	O
a	DT	O
valuable	JJ	O
addition	NN	O
to	TO	O
long-term	JJ	O
therapy	NN	O
if	IN	O
further	JJ	O
studies	NNS	O
support	VBP	O
the	DT	O
trend	NN	O
shown	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
methods	NNS	O
for	IN	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
fat	JJ	O
emulsion	NN	O
during	IN	O
extracorporeal	JJ	O
membrane	JJ	O
oxygenation	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
characterize	VB	O
the	DT	O
effects	NNS	O
of	IN	O
infusing	VBG	O
fat	JJ	O
emulsion	NN	O
during	IN	O
neonatal	JJ	O
extracorporeal	JJ	O
membrane	NN	O
oxygenation	NN	O
(	(	O
ECMO	NNP	O
)	)	O
by	IN	O
comparing	VBG	O
results	NNS	O
from	IN	O
patients	NNS	O
receiving	VBG	O
fat	JJ	O
emulsion	NN	O
through	IN	O
the	DT	O
ECMO	NNP	O
circuit	NN	O
with	IN	O
those	DT	O
receiving	VBG	O
fat	JJ	O
emulsion	NN	O
through	IN	O
separate	JJ	O
intravenous	JJ	O
access	NN	O
.	.	O

A	DT	O
second	JJ	O
goal	NN	O
was	VBD	O
to	TO	O
identify	VB	O
the	DT	O
optimal	JJ	O
route	NN	O
for	IN	O
administration	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
open-label	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Neonatal	NNP	O
intensive	JJ	O
care	NN	O
unit	NN	O
in	IN	O
a	DT	O
106-bed	JJ	O
quaternary	JJ	O
care	NN	O
pediatric	JJ	O
hospital	NN	O
.	.	O

SUBJECTS	NNP	O
Nine	NNP	O
neonates	VBZ	O
receiving	VBG	O
ECMO	NNP	O
who	WP	O
required	VBD	O
intravenous	JJ	O
nutrition	NN	O
.	.	O

Intervention	NNP	O
.	.	O

Patients	NNS	O
received	VBD	O
1-3	JJ	O
g/kg/day	NN	O
of	IN	O
fat	JJ	O
emulsion	NN	O
into	IN	O
either	CC	O
the	DT	O
ecmo	NN	O
circuit	NN	O
or	CC	O
separate	JJ	O
intravenous	JJ	O
access	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
The	DT	O
ECMO	NNP	O
circuit	NN	O
and	CC	O
samples	NNS	O
of	IN	O
blood	NN	O
were	VBD	O
evaluated	VBN	O
hourly	RB	O
for	IN	O
phase	NN	O
separation	NN	O
,	,	O
layering	VBG	O
out	IN	O
of	IN	O
the	DT	O
emulsion	NN	O
from	IN	O
blood	NN	O
,	,	O
agglutination	NN	O
,	,	O
and	CC	O
blood	NN	O
clots	NNS	O
.	.	O

After	IN	O
completion	NN	O
,	,	O
the	DT	O
oxygenators	NNS	O
were	VBD	O
dissected	VBN	O
and	CC	O
examined	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
an	DT	O
unpaired	JJ	O
t	NN	O
test	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
similar	JJ	O
,	,	O
except	IN	O
for	IN	O
a	DT	O
higher	JJR	O
mean	JJ	O
weight	NN	Physical
in	IN	O
the	DT	O
ECMO	NNP	O
circuit	NN	O
group	NN	O
(	(	O
3.6	CD	O
+/-	JJ	O
0.3	CD	O
kg	NN	O
vs	NN	O
2.8	CD	O
+/-	JJ	O
0.4	CD	O
kg	NN	O
,	,	O
p=0.03	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	Physical
+/-	JJ	Physical
SD	NNP	Physical
triglyceride	NN	Physical
level	NN	Physical
during	IN	O
the	DT	O
study	NN	O
was	VBD	O
87	CD	O
+/-	JJ	O
79	CD	O
mg/dl	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
had	VBD	O
elevated	VBN	O
triglyceride	NN	Physical
levels	NNS	Physical
.	.	O

No	DT	O
cases	NNS	O
of	IN	O
phase	NN	Physical
separation	NN	Physical
occurred	VBD	O
.	.	O

In	IN	O
the	DT	O
five	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
fat	JJ	O
emulsion	NN	O
into	IN	O
the	DT	O
ECMO	NNP	O
circuit	NN	O
,	,	O
three	CD	O
had	VBD	O
layering	VBG	Physical
out	IN	Physical
of	IN	Physical
the	DT	Physical
emulsion	NN	Physical
and	CC	O
agglutination	NN	Physical
,	,	O
and	CC	O
all	DT	O
developed	JJ	O
clots	NNS	Physical
in	IN	O
the	DT	O
circuit	NN	O
despite	IN	O
adequate	JJ	O
anticoagulation	NN	O
.	.	O

Of	IN	O
the	DT	O
four	CD	O
patients	NNS	O
in	IN	O
the	DT	O
intravenous-access	JJ	O
group	NN	O
,	,	O
one	CD	O
had	VBD	O
layering	NN	O
and	CC	O
agglutination	NN	O
,	,	O
and	CC	O
two	CD	O
had	VBD	O
blood	NN	O
clots	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
both	DT	O
methods	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
layering	VBG	Physical
out	RP	Physical
,	,	Physical
agglutination	NN	Physical
,	,	Physical
and	CC	Physical
clot	NN	Physical
formation	NN	Physical
,	,	O
these	DT	O
effects	NNS	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
with	IN	O
administration	NN	O
into	IN	O
the	DT	O
ECMO	NNP	O
circuit	NN	O
,	,	O
particularly	RB	O
in	IN	O
areas	NNS	O
of	IN	O
stasis	NN	O
.	.	O

This	DT	O
may	MD	O
result	VB	O
in	IN	O
disruption	NN	O
of	IN	O
normal	JJ	O
ECMO	NNP	O
blood	NN	O
flow	NN	O
and	CC	O
impaired	JJ	O
delivery	NN	O
of	IN	O
calories	NNS	O
.	.	O

Fat	NNP	O
emulsion	NN	O
should	MD	O
therefore	RB	O
be	VB	O
administered	VBN	O
through	IN	O
separate	JJ	O
intravenous	JJ	O
access	NN	O
during	IN	O
ECMO	NNP	O
whenever	WRB	O
possible	JJ	O
.	.	O

Effect	NN	O
of	IN	O
desonide	NN	O
ointment	NN	O
,	,	O
0.05	CD	O
%	NN	O
,	,	O
on	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
of	IN	O
children	NNS	O
with	IN	O
atopic	NN	O
dermatitis	NN	O
.	.	O

Desonide	NNP	O
ointment	NN	O
has	VBZ	O
demonstrated	VBN	O
a	DT	O
good	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
profile	NN	O
during	IN	O
the	DT	O
many	JJ	O
years	NNS	O
it	PRP	O
has	VBZ	O
been	VBN	O
used	VBN	O
in	IN	O
treating	VBG	O
dermatoses	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
its	PRP$	O
systemic	JJ	O
safety	NN	O
when	WRB	O
used	VBN	O
in	IN	O
treating	VBG	O
children	NNS	O
.	.	O

Suppression	NN	O
of	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
can	MD	O
occur	VB	O
after	IN	O
repeated	JJ	O
application	NN	O
of	IN	O
topical	JJ	O
corticosteroids	NNS	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
degree	NN	Physical
of	IN	Physical
suppression	NN	Physical
of	IN	Physical
the	DT	Physical
HPA	NNP	Physical
axis	NN	Physical
function	NN	Physical
is	VBZ	O
related	VBN	O
to	TO	O
the	DT	O
daily	JJ	O
dosage	NN	O
of	IN	O
steroid	JJ	O
given	VBN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
its	PRP$	O
administration	NN	O
,	,	O
the	DT	O
extent	NN	O
of	IN	O
body	NN	O
surface	NN	O
covered	VBN	O
,	,	O
and	CC	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
corticosteroid	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
comparative	JJ	O
effects	NNS	O
of	IN	O
0.05	CD	O
percent	NN	O
desonide	NN	O
and	CC	O
2.5	CD	O
percent	NN	O
hydrocortisone	NN	O
ointments	NNS	O
on	IN	O
the	DT	O
HPA	NNP	O
axis	NN	O
of	IN	O
children	NNS	O
with	IN	O
atopic	NN	O
dermatitis	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
suppression	NN	Physical
of	IN	Physical
early	JJ	Physical
morning	NN	Physical
cortisol	NN	Physical
in	IN	O
either	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
ACTH-stimulated	JJ	Physical
mean	NN	Physical
cortisol	NN	Physical
values	NNS	Physical
after	IN	O
four	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
baseline	NN	O
values	VBZ	O
for	IN	O
either	DT	O
treatment	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
neither	CC	O
0.05	CD	O
percent	NN	O
desonide	NN	O
ointment	NN	O
nor	CC	O
2.5	CD	O
percent	NN	O
hydrocortisone	NN	O
ointment	NN	O
compromised	VBD	O
the	DT	O
HPA	NNP	O
axis	NN	O
of	IN	O
children	NNS	O
with	IN	O
atopic	NN	O
dermatitis	NN	O
treated	VBD	O
topically	RB	O
for	IN	O
four	CD	O
weeks	NNS	O
.	.	O

Physiologic	NNP	O
modeling	NN	O
of	IN	O
the	DT	O
intravenous	JJ	Physical
glucose	JJ	Physical
tolerance	NN	Physical
test	NN	Physical
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
:	:	O
a	DT	O
new	JJ	O
approach	NN	O
to	TO	O
the	DT	O
insulin	NN	O
compartment	NN	O
.	.	O

The	DT	O
minimal	JJ	O
model	NN	O
of	IN	O
Bergman	NNP	O
et	FW	O
al	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
to	TO	O
yield	VB	O
estimates	NNS	O
of	IN	O
insulin	NN	Physical
sensitivity	NN	Physical
(	(	Physical
Si	NNP	Physical
)	)	Physical
and	CC	O
glucose	JJ	Physical
effectiveness	NN	Physical
(	(	Physical
Sg	NNP	Physical
)	)	Physical
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
by	IN	O
incorporating	VBG	O
exogenous	JJ	O
insulin	NN	O
protocols	NNS	O
into	IN	O
the	DT	O
regular	JJ	O
intravenous	JJ	O
glucose	NN	O
tolerance	NN	O
test	NN	O
(	(	O
IVGTT	NNP	O
)	)	O
.	.	O

These	DT	O
estimates	NNS	O
,	,	O
however	RB	O
,	,	O
are	VBP	O
influenced	VBN	O
by	IN	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
the	DT	O
dose	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
the	DT	O
physiologic	JJ	O
response	NN	O
to	TO	O
a	DT	O
glucose	JJ	O
load	NN	O
.	.	O

Moreover	RB	O
,	,	O
most	JJS	O
studies	NNS	O
have	VBP	O
related	VBN	O
to	TO	O
type	VB	O
2	CD	O
diabetes	NNS	O
subjects	NNS	O
whose	WP$	O
diabetes	NNS	O
was	VBD	O
relatively	RB	O
mild	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
therapeutic	JJ	O
requirements	NNS	O
.	.	O

To	TO	O
develop	VB	O
a	DT	O
minimal	JJ	O
disturbance	NN	O
approach	NN	O
in	IN	O
estimating	VBG	O
Si	NNP	Physical
and	CC	O
Sg	NNP	Physical
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
,	,	O
we	PRP	O
have	VBP	O
used	VBN	O
a	DT	O
reduced	JJ	O
glucose	JJ	O
load	NN	O
(	(	O
200	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
a	DT	O
physiologic	JJ	O
insulin	NN	O
infusion	NN	O
throughout	IN	O
the	DT	O
IVGTT	NNP	O
in	IN	O
a	DT	O
series	NN	O
of	IN	O
8	CD	O
patients	NNS	O
,	,	O
5	CD	O
of	IN	O
whom	WP	O
were	VBD	O
insulin-requiring	JJ	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
approach	NN	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
modelling	VBG	O
program	NN	O
CONSAM	NNP	O
to	TO	O
apply	VB	O
the	DT	O
Bergman	NNP	O
model	NN	O
,	,	O
either	RB	O
unmodified	JJ	O
(	(	O
BMM	NNP	O
)	)	O
,	,	O
or	CC	O
incorporating	VBG	O
an	DT	O
additional	JJ	O
delay	NN	O
element	NN	O
between	IN	O
the	DT	O
plasma	NN	O
and	CC	O
remote	JJ	O
insulin	NN	O
compartments	NNS	O
(	(	O
MMD	NNP	O
)	)	O
.	.	O

Application	NN	O
of	IN	O
the	DT	O
MMD	NNP	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
IVGTT	NNP	O
from	IN	O
3	CD	O
to	TO	O
5	CD	O
hours	NNS	O
improved	VBN	O
successful	JJ	O
resolution	NN	Physical
of	IN	Physical
Si	NNP	Physical
and	CC	Physical
Sg	NNP	Physical
from	IN	O
37.5	CD	O
%	NN	O
(	(	O
BMM	NNP	O
,	,	O
3-hour	JJ	O
IVGTT	NNP	O
)	)	O
to	TO	O
100	CD	O
%	NN	O
(	(	O
MMD	NNP	O
,	,	O
5-hour	JJ	O
IVGTT	NNP	O
)	)	O
.	.	O

Si	NNP	Physical
was	VBD	O
reduced	VBN	O
in	IN	O
these	DT	O
type	NN	O
2	CD	O
diabetes	VBZ	O
patients	NNS	O
compared	VBN	O
with	IN	O
normal	JJ	O
subjects	NNS	O
(	(	O
1.86	CD	O
+/-	JJ	O
0.60	CD	O
v.	JJ	O
8.65	CD	O
+/-	JJ	O
2.27	CD	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
microU	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
mL	JJ	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
validated	VBN	O
in	IN	O
the	DT	O
type	NN	O
2	CD	O
diabetes	NNS	O
group	NN	O
using	VBG	O
a	DT	O
2-stage	JJ	O
euglycemic	JJ	O
clamp	NN	O
(	(	O
(	(	O
Si	NNP	O
)	)	O
CLAMP	NNP	O
=	$	O
2.02	CD	O
+/-	JJ	O
0.42	CD	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
microU	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
mL	JJ	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
P	NNP	O
>	NNP	O
.4	NNP	O
)	)	O
.	.	O

Sg	NNP	Physical
was	VBD	O
not	RB	O
significantly	RB	O
reduced	VBN	O
(	(	O
2.00	CD	O
+/-	JJ	O
0.25	CD	O
type	NN	O
2	CD	O
diabetes	NNS	O
v.	JJ	O
1.55	CD	O
+/-	JJ	O
0.26	CD	O
normal	JJ	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

Data	NNS	O
from	IN	O
a	DT	O
group	NN	O
of	IN	O
normal	JJ	O
nondiabetic	JJ	O
subjects	NNS	O
was	VBD	O
then	RB	O
analyzed	VBN	O
using	VBG	O
the	DT	O
MMD	NNP	O
,	,	O
but	CC	O
this	DT	O
approach	NN	O
did	VBD	O
not	RB	O
enhance	VB	O
the	DT	O
fit	NN	O
of	IN	O
the	DT	O
model	NN	O
compared	VBN	O
with	IN	O
the	DT	O
BMM	NNP	O
.	.	O

This	DT	O
result	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
delay	NN	O
in	IN	O
insulin	JJ	O
action	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetes	VBZ	O
represents	VBZ	O
an	DT	O
abnormality	NN	O
whereby	WRB	O
the	DT	O
onset	NN	O
of	IN	O
insulin	JJ	O
action	NN	O
can	MD	O
not	RB	O
be	VB	O
described	VBN	O
as	IN	O
a	DT	O
single	JJ	O
phase	NN	O
in	IN	O
the	DT	O
transfer	NN	O
of	IN	O
insulin	NN	O
from	IN	O
plasma	NN	O
to	TO	O
the	DT	O
remote	JJ	O
compartment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
postulated	VBN	O
that	IN	O
the	DT	O
physiologic	JJ	O
basis	NN	O
for	IN	O
this	DT	O
delayed	JJ	O
action	NN	O
may	MD	O
relate	VB	O
to	TO	O
transcapillary	JJ	O
endothelial	JJ	O
transfer	NN	O
of	IN	O
insulin	NN	O
,	,	O
this	DT	O
process	NN	O
limiting	VBG	O
the	DT	O
rate	NN	O
of	IN	O
onset	NN	O
of	IN	O
insulin	JJ	O
action	NN	O
.	.	O

Physical	JJ	O
activity	NN	O
in	IN	O
first-degree	JJ	O
relatives	NNS	O
of	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
evaluate	VB	O
physical	JJ	O
activity	NN	O
in	IN	O
women	NNS	O
at	IN	O
moderate	JJ	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
,	,	O
the	DT	O
correlates	NNS	O
of	IN	O
engaging	VBG	O
in	IN	O
regular	JJ	O
physical	JJ	O
activity	NN	O
,	,	O
and	CC	O
whether	IN	O
physical	JJ	O
activity	NN	O
relates	VBZ	O
to	TO	O
psychological	JJ	Mental
well-being	NN	Mental
.	.	Physical

The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
55	CD	O
%	NN	O
of	IN	O
women	NNS	O
were	VBD	O
regularly	RB	O
active	JJ	O
.	.	O

Logistic	JJ	O
regression	NN	O
models	NNS	O
indicated	VBD	O
that	IN	O
positive	JJ	O
affect	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
and	CC	O
negative	JJ	O
affect	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
decreased	JJ	O
overall	JJ	O
and	CC	O
leisure	NN	Mental
activity	NN	Mental
.	.	Others

Older	JJR	O
,	,	O
married	VBN	O
,	,	O
and	CC	O
employed	JJ	O
women	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
engage	VB	O
in	IN	O
household/occupational	JJ	Mental
activity	NN	Mental
,	,	O
whereas	JJ	O
women	NNS	O
who	WP	O
perceived	VBD	O
their	PRP$	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
as	IN	O
high	JJ	O
were	VBD	O
less	RBR	O
likely	JJ	O
.	.	O

More	RBR	O
educated	JJ	O
women	NNS	O
and	CC	O
those	DT	O
with	IN	O
higher	JJR	O
perceived	VBN	O
risk	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
engage	VB	O
in	IN	O
leisure	NN	Mental
activity	NN	Mental
,	,	O
and	CC	O
married	JJ	O
women	NNS	O
were	VBD	O
less	RBR	O
likely	JJ	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
a	DT	O
need	NN	O
to	TO	O
increase	VB	O
activity	NN	O
levels	NNS	O
in	IN	O
women	NNS	O
at	IN	O
moderate	JJ	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
,	,	O
provide	VBP	O
variables	NNS	O
upon	IN	O
which	WDT	O
interventions	NNS	O
can	MD	O
be	VB	O
tailored	VBN	O
to	TO	O
promote	VB	O
activity	NN	O
,	,	O
and	CC	O
point	NN	O
to	TO	O
psychological	JJ	O
benefits	NNS	O
of	IN	O
activity	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
masking	VBG	O
study	NN	O
participants	NNS	O
to	TO	O
intravitreal	VB	O
injections	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
success	NN	Others
of	IN	O
masking	VBG	O
study	NN	O
participants	NNS	O
to	TO	O
treatment	NN	O
allocation	NN	O
using	VBG	O
sham	JJ	O
intravitreal	JJ	O
injections	NNS	O
.	.	O

METHODS	NNP	O
Eyes	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
sham	NN	O
injections	NNS	O
plus	CC	O
prompt	JJ	O
laser	NN	O
,	,	O
intravitreal	JJ	O
ranibizumab	NN	O
injections	NNS	O
plus	CC	O
prompt	JJ	O
laser	NN	O
,	,	O
intravitreal	JJ	O
ranibizumab	NN	O
injections	NNS	O
plus	CC	O
deferred	JJ	O
laser	NN	O
,	,	O
or	CC	O
intravitreal	VB	O
triamcinolone	JJ	O
acetonide	JJ	O
injections	NNS	O
plus	CC	O
prompt	NN	O
laser	NN	O
up	RB	O
to	TO	O
every	DT	O
16	CD	O
weeks	NNS	O
with	IN	O
sham	JJ	O
injections	NNS	O
intermittently	RB	O
.	.	O

All	DT	O
eyes	NNS	O
could	MD	O
receive	VB	O
treatment	NN	O
or	CC	O
sham	NN	O
as	RB	O
often	RB	O
as	IN	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

Participants	NNS	O
with	IN	O
2	CD	O
study	NN	O
eyes	NNS	O
had	VBD	O
1	CD	O
eye	NN	O
randomized	VBN	O
to	TO	O
sham	VB	O
plus	JJ	O
prompt	JJ	O
laser	NN	O
and	CC	O
1	CD	O
eye	NN	O
randomized	VBN	O
to	TO	O
a	DT	O
real	JJ	O
injection	NN	O
group	NN	O
.	.	O

Sham	NNP	O
injections	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
pressing	VBG	O
the	DT	O
syringe	NN	O
hub	NN	O
against	IN	O
the	DT	O
conjunctiva	NN	O
to	TO	O
mimic	VB	O
a	DT	O
real	JJ	O
injection	NN	O
.	.	O

Laser	NNP	O
treatment	NN	O
was	VBD	O
not	RB	O
masked	VBN	O
.	.	O

At	IN	O
the	DT	O
1-year	JJ	O
visit	NN	O
,	,	O
participants	NNS	O
were	VBD	O
asked	VBN	O
if	IN	O
they	PRP	O
believed	VBD	O
that	IN	O
the	DT	O
injections	NNS	O
received	VBD	O
during	IN	O
the	DT	O
study	NN	O
were	VBD	O
real	JJ	O
,	,	O
sham	NN	O
,	,	O
or	CC	O
sometimes	RB	O
real	JJ	O
and	CC	O
sometimes	RB	O
sham	JJ	O
.	.	O

RESULTS	NNP	O
Among	IN	O
423	CD	O
participants	NNS	O
with	IN	O
1	CD	O
study	NN	O
eye	NN	O
,	,	O
the	DT	O
correct	JJ	Others
assignment	NN	Others
was	VBD	O
stated	VBN	O
by	IN	O
9.9	CD	O
%	NN	O
of	IN	O
the	DT	O
sham	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
,	,	O
88.0	CD	O
%	NN	O
of	IN	O
the	DT	O
ranibizumab	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
,	,	O
89.6	CD	O
%	NN	O
of	IN	O
the	DT	O
unmasked	JJ	O
ranibizumab	NN	O
plus	CC	O
deferred	JJ	O
laser	NN	O
group	NN	O
,	,	O
and	CC	O
44.0	CD	O
%	NN	O
of	IN	O
the	DT	O
triamcinolone	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
.	.	O

Among	IN	O
112	CD	O
participants	NNS	O
with	IN	O
2	CD	O
study	NN	O
eyes	NNS	O
,	,	O
the	DT	O
correct	JJ	Others
assignment	NN	Others
was	VBD	O
stated	VBN	O
for	IN	O
24.1	CD	O
%	NN	O
of	IN	O
the	DT	O
sham	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
eyes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Successful	NNP	Others
masking	NN	Others
of	IN	O
an	DT	O
intravitreal	JJ	O
injection	NN	O
can	MD	O
be	VB	O
accomplished	VBN	O
when	WRB	O
a	DT	O
sham	NN	O
injection	NN	O
procedure	NN	O
carefully	RB	O
mimics	VBZ	O
a	DT	O
real	JJ	O
injection	NN	O
procedure	NN	O
.	.	O

Masking	VBG	Others
seems	VBZ	O
less	RBR	O
successful	JJ	Others
when	WRB	O
one	CD	O
eye	NN	O
is	VBZ	O
receiving	VBG	O
a	DT	O
real	JJ	O
injection	NN	O
and	CC	O
the	DT	O
other	JJ	O
eye	NN	O
is	VBZ	O
receiving	VBG	O
a	DT	O
sham	JJ	O
injection	NN	O
or	CC	O
when	WRB	O
an	DT	O
individual	JJ	O
eye	NN	O
receives	VBZ	O
both	DT	O
real	JJ	O
and	CC	O
sham	JJ	O
injections	NNS	O
.	.	O

Plerixafor	NNP	O
plus	CC	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
versus	NN	O
placebo	NN	O
plus	CC	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
for	IN	O
mobilization	NN	O
of	IN	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
hematopoietic	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NNS	O
and	CC	O
low	JJ	O
peripheral	JJ	O
blood	NN	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
subset	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Preapheresis	NNP	O
peripheral	JJ	O
blood	NN	O
(	(	O
PB	NNP	O
)	)	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
is	VBZ	O
a	DT	O
strong	JJ	O
predictor	NN	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
(	(	O
HSC	NNP	O
)	)	O
mobilization	NN	O
and	CC	O
is	VBZ	O
routinely	RB	O
used	VBN	O
to	TO	O
optimize	VB	O
the	DT	O
timing	NN	O
,	,	O
cost	NN	O
,	,	O
and	CC	O
success	NN	O
of	IN	O
HSC	NNP	O
collection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
uniform	JJ	O
PB	NNP	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
that	WDT	O
predicts	VBZ	O
mobilization	NN	O
failure	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
defined	VBN	O
,	,	O
resulting	VBG	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
institute-specific	JJ	O
algorithms	NN	O
for	IN	O
mobilization	NN	O
,	,	O
particularly	RB	O
regarding	VBG	O
the	DT	O
decision	NN	O
of	IN	O
when	WRB	O
to	TO	O
use	VB	O
the	DT	O
novel	JJ	O
stem	NN	O
cell	NN	O
mobilization	NN	O
agent	NN	O
plerixafor	NN	O
.	.	O

In	IN	O
this	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
mobilization	NN	O
efficacy	NN	O
of	IN	O
plerixafor	JJ	O
plus	CC	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
versus	NN	O
placebo	JJ	O
plus	CC	O
G-CSF	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
,	,	O
stratified	VBN	O
by	IN	O
preapheresis	NN	O
PB	NNP	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
:	:	O
<	JJ	O
10	CD	O
,	,	O
<	FW	O
15	CD	O
,	,	O
<	FW	O
20	CD	O
,	,	O
and	CC	O
?20	NNP	O
cells/?L	NN	O
.	.	O

Regardless	NNP	O
of	IN	O
the	DT	O
PB	NNP	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
,	,	O
the	DT	O
total	JJ	O
yield	NN	O
of	IN	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
from	IN	O
apheresis	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
plerixafor	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
significantly	RB	O
more	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
plerixafor	NN	O
group	NN	O
collected	VBD	O
the	DT	O
minimum	NN	O
(	(	O
?2	VB	O
?	.	O
10	CD	O
(	(	O
6	CD	O
)	)	O
cells/kg	NN	O
)	)	O
and	CC	O
optimum	JJ	O
(	(	O
?6	VB	O
?	.	O
10	CD	O
(	(	O
6	CD	O
)	)	O
cells/kg	NN	O
)	)	O
stem	NN	O
cell	NN	O
yields	NNS	O
on	IN	O
each	DT	O
day	NN	O
of	IN	O
apheresis	NN	O
.	.	O

As	IN	O
a	DT	O
corollary	NN	O
,	,	O
the	DT	O
greater	JJR	O
stem	NN	O
cell	NN	O
collection	NN	O
in	IN	O
plerixafor-treated	JJ	O
patients	NNS	O
resulted	VBD	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
significantly	RB	O
fewer	JJR	O
days	NNS	O
of	IN	O
apheresis	NN	O
to	TO	O
reach	VB	O
minimum	JJ	O
and	CC	O
optimum	JJ	O
cell	NN	O
doses	NNS	O
across	IN	O
all	DT	O
cell	NN	O
count	NN	O
groups	NNS	O
.	.	O

For	IN	O
all	DT	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
groups	NNS	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
proceeding	VBG	O
to	TO	O
transplantation	NN	O
and	CC	O
the	DT	O
median	JJ	O
time	NN	O
to	TO	O
platelet	VB	O
and	CC	O
neutrophil	VB	O
engraftment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
plerixafor	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
.	.	O

Our	PRP$	O
findings	NNS	O
demonstrate	VBP	O
that	IN	O
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NNS	O
who	WP	O
might	MD	O
be	VB	O
predicted	VBN	O
to	TO	O
fail	VB	O
mobilization	NN	O
based	VBN	O
on	IN	O
low	JJ	O
PB	NNP	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
plerixafor	NN	O
to	TO	O
G-CSF	NNP	O
allows	NNS	O
for	IN	O
collection	NN	O
of	IN	O
the	DT	O
minimal	JJ	O
and	CC	O
optimal	JJ	O
cell	NN	O
doses	NNS	O
in	IN	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	O
compared	VBN	O
with	IN	O
G-CSF	NNP	O
alone	RB	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
plerixafor	JJ	O
plus	CC	O
G-CSF	NNP	O
significantly	RB	O
improves	VBZ	O
the	DT	O
likelihood	NN	O
of	IN	O
optimal	JJ	O
HSC	NNP	O
collection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
higher	JJR	O
preapheresis	NN	O
PB	NNP	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
counts	NNS	O
(	(	O
?20	NNP	O
cells/?L	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	JJ	O
plus	CC	O
G-CSF	NNP	O
.	.	O

Collectively	RB	O
,	,	O
this	DT	O
analysis	NN	O
of	IN	O
predicted	JJ	O
poor	JJ	O
mobilizers	NNS	O
validates	VBZ	O
the	DT	O
superiority	NN	O
of	IN	O
plerixafor	JJ	O
plus	CC	O
G-CSF	JJ	O
compared	VBN	O
with	IN	O
G-CSF	NNP	O
alone	RB	O
,	,	O
which	WDT	O
had	VBD	O
been	VBN	O
demonstrated	VBN	O
previously	RB	O
in	IN	O
the	DT	O
overall	JJ	O
patient	JJ	O
population	NN	O
.	.	O

The	DT	O
additive	JJ	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
in	IN	O
dental	JJ	O
pain	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
trial	NN	O
the	DT	O
analgesic	JJ	O
contribution	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	O
,	,	O
60	CD	O
mg	NN	O
,	,	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
2	CD	O
X	NN	O
2	CD	O
factorial	JJ	O
experiment	NN	O
in	IN	O
which	WDT	O
120	CD	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pain	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
oral	JJ	O
surgery	NN	O
rated	VBD	O
their	PRP$	O
pain	NN	Pain
intensity	NN	Pain
and	CC	O
pain	NN	Pain
relief	NN	Pain
for	IN	O
up	IN	O
to	TO	O
5	CD	O
hours	NNS	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
one	CD	O
of	IN	O
:	:	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
,	,	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
plus	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
factorial	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
both	DT	O
1000	CD	O
mg	NN	O
acetaminophen	NN	O
and	CC	O
60	CD	O
mg	NN	O
codeine	NN	O
made	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
contribution	NN	O
to	TO	O
the	DT	O
analgesic	JJ	Others
effectiveness	NN	Others
of	IN	Pain
the	DT	Pain
combination	NN	Pain
on	IN	Pain
all	DT	Pain
measures	NNS	Pain
of	IN	Pain
efficacy	NN	Pain
(	(	O
sum	NN	Pain
of	IN	Pain
pain	NN	Pain
intensity	NN	Pain
differences	NNS	Pain
,	,	O
largest	JJS	Pain
pain	NN	Pain
intensity	NN	Pain
difference	NN	Pain
,	,	O
total	JJ	Pain
pain	NN	Pain
relief	NN	Pain
,	,	O
largest	JJS	Pain
pain	NN	Pain
relief	NN	Pain
,	,	O
and	CC	O
time	NN	Pain
to	TO	Pain
remedication	NN	Pain
)	)	O
.	.	O

The	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
differ	VB	O
among	IN	O
the	DT	O
treatments	NNS	O
,	,	O
including	VBG	O
placebo	NN	O
.	.	O

Single-dose	JJ	O
and	CC	O
multi-dose	JJ	O
clindamycin	NN	O
therapy	NN	O
fails	VBZ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
in	IN	O
preventing	VBG	O
infectious	JJ	O
and	CC	O
inflammatory	JJ	O
complications	NNS	O
in	IN	O
third	JJ	O
molar	JJ	O
surgery	NN	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
single-	JJ	O
and	CC	O
multi-dose	JJ	O
(	(	O
5-day	JJ	O
)	)	O
clindamycin	NN	O
therapy	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
inflammatory	JJ	O
complications	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
lower	JJR	O
third	JJ	O
molar	JJ	O
surgical	JJ	O
extraction	NN	O
with	IN	O
bone	NN	O
removal	NN	O
.	.	O

Patients	NNS	O
who	WP	O
qualified	VBD	O
for	IN	O
the	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
single	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
clindamycin	NN	O
administered	VBN	O
preoperatively	RB	O
(	(	O
single-dose	JJ	O
group	NN	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
clindamycin	NN	O
administered	VBD	O
preoperatively	RB	O
with	IN	O
continued	JJ	O
therapy	NN	O
for	IN	O
5	CD	O
days	NNS	O
(	(	O
5-day	JJ	O
group	NN	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
a	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
following	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
on	IN	O
the	DT	O
first	JJ	O
,	,	O
second	JJ	O
and	CC	O
seventh	JJ	O
days	NNS	O
postsurgery	NN	O
:	:	O
trismus	NN	Others
,	,	Others
facial	JJ	Others
swelling	NN	Others
,	,	Others
body	NN	Others
temperature	NN	Others
,	,	Others
lymphadenopathy	JJ	Others
,	,	Others
alveolar	JJ	Others
osteitis	NN	Others
and	CC	Others
subjective	JJ	Others
pain	NN	Others
sensations	NNS	Others
.	.	Others

There	EX	O
were	VBD	O
86	CD	O
patients	NNS	O
(	(	O
31	CD	O
in	IN	O
the	DT	O
single-dose	JJ	O
group	NN	O
,	,	O
28	CD	O
in	IN	O
the	DT	O
5-day	JJ	O
group	NN	O
and	CC	O
27	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
enrolled	VBD	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
postoperative	JJ	Physical
inflammatory	JJ	Physical
complications	NNS	Physical
in	IN	O
patients	NNS	O
during	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
days	NNS	O
postsurgery	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
variation	NN	Physical
in	IN	O
body	NN	Physical
temperature	NN	Physical
was	VBD	O
reported	VBN	O
on	IN	O
the	DT	O
seventh	JJ	O
day	NN	O
.	.	O

Analysis	NN	O
of	IN	O
the	DT	O
postoperative	JJ	Physical
analgesic	JJ	Physical
intake	NN	Physical
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
examined	VBN	O
groups	NNS	O
.	.	O

Clindamycin	NNP	O
applied	VBD	O
in	IN	O
a	DT	O
single	JJ	O
preoperative	NN	O
dose	NN	O
of	IN	O
600	CD	O
mg	NN	O
with	IN	O
or	CC	O
without	IN	O
subsequent	JJ	O
5-day	JJ	O
therapy	NN	O
does	VBZ	O
not	RB	O
demonstrate	VB	O
efficacy	NN	Physical
in	IN	O
prophylaxis	NN	O
for	IN	O
postoperative	JJ	O
inflammatory	NN	O
complications	NNS	O
after	IN	O
third	JJ	O
molar	JJ	O
surgery	NN	O
.	.	O

Postoperative	JJ	O
radiotherapy	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
--	:	O
long-term	JJ	O
results	NNS	O
from	IN	O
the	DT	O
Oslo	NNP	O
study	NN	O
.	.	O

The	DT	O
long-term	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
postoperative	JJ	O
radiotherapy	NN	O
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
radical	JJ	O
mastectomy	NN	O
are	VBP	O
presented	VBN	O
.	.	O

There	EX	O
were	VBD	O
1115	CD	O
patients	NNS	O
including	VBG	O
27	CD	O
protocol	JJ	O
deviants	NNS	O
.	.	O

The	DT	O
follow-up	JJ	O
time	NN	O
is	VBZ	O
11-20	JJ	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
part	NN	O
a	DT	O
conventional	JJ	O
roentgen	NN	O
unit	NN	O
was	VBD	O
used	VBN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
second	JJ	O
part	NN	O
a	DT	O
60Co	CD	O
unit	NN	O
,	,	O
with	IN	O
considerably	RB	O
increased	VBN	O
dosage	NN	O
and	CC	O
altered	VBD	O
treatment	NN	O
plan	NN	O
.	.	O

Both	DT	O
types	NNS	O
of	IN	O
radiation	NN	O
techniques	NNS	O
lowered	VBD	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
loco-regional	JJ	Physical
recurrences	NNS	Physical
significantly	RB	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
influence	NN	O
on	IN	O
the	DT	O
overall	JJ	Mortality
survival	NN	Mortality
.	.	Mortality

The	DT	Mortality
relapse-free	JJ	Mortality
survival	NN	Mortality
was	VBD	O
significantly	RB	O
improved	VBN	O
by	IN	O
60Co	CD	O
radiation	NN	O
in	IN	O
Stage	NNP	O
II	NNP	O
patients	NNS	O
,	,	O
but	CC	O
was	VBD	O
unaffected	VBN	O
by	IN	O
radiation	NN	O
in	IN	O
the	DT	O
other	JJ	O
subgroups	NNS	O
.	.	O

Regarding	VBG	O
survival	NN	Mortality
,	,	O
Stage	NNP	O
II	NNP	O
patients	NNS	O
with	IN	O
medially	RB	O
located	VBN	O
tumors	NNS	O
seemed	VBD	O
to	TO	O
benefit	VB	O
more	JJR	O
from	IN	O
60Co	CD	O
radiation	NN	O
than	IN	O
those	DT	O
with	IN	O
lateral	JJ	O
tumors	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	Mortality
of	IN	Mortality
deaths	NNS	Mortality
caused	VBN	Mortality
by	IN	Mortality
myocardial	JJ	Mortality
infarction	NN	Mortality
was	VBD	O
observed	VBN	O
in	IN	O
Stage	NNP	O
I	PRP	O
patients	NNS	O
having	VBG	O
60Co	CD	O
radiation	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
radiation	NN	O
dose	NN	O
to	TO	O
the	DT	O
heart	NN	O
is	VBZ	O
of	IN	O
significance	NN	O
.	.	O

The	DT	O
SPEM	NNP	O
(	(	O
Studio	NNP	O
Policentrico	NNP	O
Elettrocateteri	NNP	O
Membrane	NNP	O
)	)	O
:	:	O
a	DT	O
multicenter	NN	O
study	NN	O
on	IN	O
membrane	NN	O
leads	NNS	O
.	.	O

SPEM	NNP	O
is	VBZ	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
double-blind	NN	O
study	NN	O
performed	VBD	O
to	TO	O
test	VB	O
the	DT	O
acute	NN	Physical
and	CC	Physical
chronic	JJ	Physical
electrophysiological	JJ	Physical
behavior	NN	Physical
of	IN	O
three	CD	O
different	JJ	O
ventricular	JJ	O
leads	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
an	DT	O
ion	NN	O
exchange	NN	O
membrane	NN	O
with	IN	O
30-microgram	JJ	O
dexamethasone	NN	O
elution	NN	O
in	IN	O
a	DT	O
contoured	JJ	O
activated	JJ	O
carbon	NN	O
tip	NN	O
lead	NN	O
(	(	O
Membrane	NNP	O
1400T	CD	O
,	,	O
30	CD	O
patients	NNS	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
the	DT	O
same	JJ	O
lead	NN	O
design	NN	O
without	IN	O
steroid	NN	O
(	(	O
Membrane	NNP	O
1401T	CD	O
,	,	O
24	CD	O
patients	NNS	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
same	JJ	O
lead	NN	O
design	NN	O
without	IN	O
steroid	NN	O
or	CC	O
membrane	NN	O
(	(	O
control	NN	O
group	NN	O
,	,	O
27	CD	O
patients	NNS	O
)	)	O
.	.	O

Twenty-three	CD	O
of	IN	O
the	DT	O
81	CD	O
patients	NNS	O
were	VBD	O
women	NNS	O
;	:	O
the	DT	O
mean	JJ	O
age	NN	O
for	IN	O
all	DT	O
patients	NNS	O
was	VBD	O
74	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
.	.	O

Parameters	NNS	O
are	VBP	O
calculated	VBN	O
both	DT	O
in	IN	O
uni-	JJ	O
and	CC	O
bipolar	JJ	O
configuration	NN	O
at	IN	O
implant	JJ	O
and	CC	O
at	IN	O
follow-up	JJ	O
after	IN	O
1	CD	O
,	,	O
5	CD	O
,	,	O
15	CD	O
,	,	O
30	CD	O
,	,	O
90	CD	O
,	,	O
180	CD	O
,	,	O
and	CC	O
360	CD	O
days	NNS	O
.	.	O

Implant	JJ	O
threshold	NN	O
(	(	O
chronaxie	JJ	O
=	$	O
0.413	CD	O
+/-	JJ	O
0.280	CD	O
ms	NN	O
,	,	O
rheobase	VB	O
=	JJ	O
0.264	CD	O
+/-	JJ	O
0.099	CD	O
V	NNP	O
)	)	O
,	,	O
signal	JJ	O
amplitude	NN	O
(	(	O
13.45	CD	O
+/-	JJ	O
5.87	CD	O
mV	NN	O
)	)	O
,	,	O
and	CC	O
slew	JJ	O
rate	NN	O
(	(	O
2.05	CD	O
+/-	JJ	O
1.38	CD	O
V/s	NNP	O
)	)	O
reveal	VBP	O
no	DT	O
significant	JJ	O
differences	NNS	O
.	.	O

Pacing	VBG	Others
impedance	NN	Others
values	NNS	Others
both	DT	O
at	IN	O
implant	NN	O
(	(	O
unipolar	JJ	O
571	CD	O
+/-	JJ	O
165	CD	O
omega	NN	O
;	:	O
bipolar	JJ	O
605	CD	O
+/-	JJ	O
123	CD	O
omega	NN	O
)	)	O
and	CC	O
at	IN	O
follow-ups	NNS	O
(	(	O
unipolar	JJ	O
480	CD	O
+/-	JJ	O
72	CD	O
omega	NN	O
;	:	O
bipolar	JJ	O
518	CD	O
+/-	JJ	O
75	CD	O
omega	NN	O
)	)	O
are	VBP	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
unipolar	JJ	O
configuration	NN	O
.	.	O

At	IN	O
15	CD	O
and	CC	O
30-day	JJ	O
follow-ups	NNS	O
,	,	O
control	NN	O
group	NN	O
and	CC	O
nonsteroid	JJ	O
leads	VBZ	O
show	VB	O
a	DT	O
higher	JJR	O
threshold	JJ	Others
value	NN	O
growth	NN	O
(	(	O
in	IN	O
unipolar	NN	O
from	IN	O
0.16	CD	O
+/-	JJ	O
0.11	CD	O
to	TO	O
1.19	CD	O
+/-	JJ	O
0.85	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	NN	O
from	IN	O
0.18	CD	O
+/-	JJ	O
0.13	CD	O
to	TO	O
1.24	CD	O
+/-	JJ	O
0.88	CD	O
microJ	NN	O
)	)	O
than	IN	O
the	DT	O
membrane	NN	O
steroid	NN	O
leads	VBZ	O
(	(	O
in	IN	O
unipolar	NN	O
from	IN	O
0.13	CD	O
+/-	JJ	O
0.11	CD	O
to	TO	O
0.70	CD	O
+/-	JJ	O
0.39	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	NN	O
from	IN	O
0.23	CD	O
+/-	JJ	O
0.32	CD	O
to	TO	O
0.76	CD	O
+/-	JJ	O
0.36	CD	O
microJ	NN	O
)	)	O
;	:	O
the	DT	O
threshold	NN	Physical
of	IN	O
nonsteroid	JJ	O
leads	NNS	O
decreases	NNS	O
after	IN	O
1-3	JJ	O
months	NNS	O
and	CC	O
it	PRP	O
settles	VBZ	O
at	IN	O
the	DT	O
same	JJ	O
threshold	JJ	Physical
level	NN	O
of	IN	O
the	DT	O
leads	NNS	O
with	IN	O
membrane	NN	O
and	CC	O
steroid	NN	O
(	(	O
in	IN	O
unipolar	JJ	O
0.60	CD	O
+/-	JJ	O
0.33	CD	O
microJ	NN	O
;	:	O
in	IN	O
bipolar	JJ	O
0.55	CD	O
+/-	JJ	O
0.26	CD	O
microJ	NN	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
been	VBN	O
stable	JJ	O
since	IN	O
the	DT	O
first	JJ	O
month	NN	O
.	.	O

The	DT	O
ion	NN	O
exchange	NN	O
membrane	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
chronic	JJ	Physical
pacing	NN	Physical
threshold	NN	Physical
like	IN	O
acute	JJ	O
steroid	JJ	O
elution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
,	,	O
but	CC	O
membrane	FW	O
alone	RB	O
does	VBZ	O
not	RB	O
prevent	VB	O
an	DT	O
acute	JJ	Physical
pacing	NN	Physical
threshold	JJ	Physical
increase	NN	O
through	IN	O
the	DT	O
first	JJ	O
month	NN	O
postimplant	NN	O
.	.	O

Treatment	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
infection	NN	O
with	IN	O
interferon	NN	O
.	.	O

Factors	NNS	O
predicting	VBG	O
response	NN	O
to	TO	O
interferon	VB	O
.	.	O

Several	JJ	O
randomised	VBD	O
controlled	VBN	O
trials	NNS	O
have	VBP	O
been	VBN	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
alpha-interferon	NN	O
in	IN	O
the	DT	O
therapy	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
HBe	NNP	O
antigen-positive	JJ	O
disease	NN	O
acquired	VBD	O
in	IN	O
adult	NN	O
life	NN	O
the	DT	O
response	NN	O
rates	NNS	O
vary	VBP	O
from	IN	O
25-50	CD	O
%	NN	O
.	.	O

In	IN	O
those	DT	O
infected	VBN	O
at	IN	O
birth	NN	O
,	,	O
response	NN	O
rates	NNS	O
are	VBP	O
lower	JJR	O
.	.	O

Twenty-one	CD	O
pretreatment	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
their	PRP$	O
significance	NN	O
in	IN	O
response	NN	Physical
prediction	NN	O
using	VBG	O
data	NNS	O
from	IN	O
114	CD	O
patients	NNS	O
given	VBN	O
alpha-interferon	NNS	O
for	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
infection	NN	O
.	.	O

In	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
a	DT	O
minimum	NN	O
of	IN	O
90	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
total	NN	O
dose	NN	O
over	IN	O
12	CD	O
weeks	NNS	O
,	,	O
a	DT	O
negative	JJ	O
anti-human	JJ	Physical
immunodeficiency	NN	Physical
virus	NN	Physical
antibody	NN	Physical
status	NN	Physical
(	(	O
p	RB	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
,	,	O
chronic	JJ	Physical
active	JJ	Physical
hepatitis	NN	Physical
on	IN	Physical
liver	NN	Physical
biopsy	NN	Physical
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
,	,	O
high	JJ	O
AST	NNP	Physical
level	NN	Physical
(	(	O
p	RB	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
,	,	O
low	JJ	O
hepatitis	NN	Physical
B	NNP	Physical
virus	NN	Physical
DNA	NNP	Physical
level	NN	Physical
(	(	O
p	RB	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
history	NN	O
of	IN	O
acute	JJ	Physical
hepatitis	NN	Physical
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
were	VBD	O
all	DT	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
likelihood	NN	O
of	IN	O
response	NN	O
on	IN	O
univariate	JJ	O
analysis	NN	O
.	.	O

On	IN	O
stepwise	NN	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
DNA	NNP	O
,	,	O
AST	NNP	O
and	CC	O
a	DT	O
history	NN	O
of	IN	O
acute	JJ	O
hepatitis	NN	O
predicted	VBD	O
response	NN	O
independently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
reliable	JJ	O
combination	NN	O
of	IN	O
predictive	JJ	O
factors	NNS	O
was	VBD	O
a	DT	O
negative	JJ	O
anti-human	JJ	Physical
immunodeficiency	NN	Physical
virus	NN	Physical
antibody	NN	Physical
status	NN	Physical
,	,	O
with	IN	O
either	DT	O
a	DT	O
positive	JJ	O
history	NN	O
of	IN	O
acute	JJ	Physical
icteric	JJ	Physical
hepatitis	NN	Physical
and	CC	O
AST	NNP	O
greater	JJR	O
than	IN	O
45	CD	O
IU	NNP	O
per	IN	O
liter	NN	O
or	CC	O
no	DT	O
history	NN	O
of	IN	O
acute	JJ	O
icteric	JJ	O
hepatitis	NN	O
and	CC	O
AST	NNP	O
greater	JJR	O
than	IN	O
85	CD	O
IU	NNP	O
per	IN	O
liter	NN	O
,	,	O
which	WDT	O
predicted	VBD	O
response	NN	O
in	IN	O
77	CD	O
%	NN	O
with	IN	O
a	DT	O
specificity	NN	O
of	IN	O
79	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
loss	NN	O
of	IN	O
HBsAg	NNP	Physical
in	IN	O
addition	NN	O
to	TO	O
HBeAg	NNP	Physical
and	CC	O
hepatitis	NN	Physical
B	NNP	Physical
virus	NN	Physical
DNA	NN	Physical
was	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
occur	VB	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
infection	NN	O
of	IN	O
less	JJR	O
than	IN	O
2	CD	O
years	NNS	O
duration	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Pre-treatment	JJ	O
proliferation	NN	O
and	CC	O
the	DT	O
outcome	NN	O
of	IN	O
conventional	JJ	O
and	CC	O
accelerated	JJ	O
radiotherapy	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
influence	NN	O
of	IN	O
pre-treatment	JJ	O
proliferation	NN	O
characteristics	NNS	O
,	,	O
assessed	VBN	O
by	IN	O
Ki-67	NNP	O
staining	NN	O
,	,	O
in	IN	O
patients	NNS	O
treated	VBN	O
in	IN	O
the	DT	O
CHART	NNP	O
trial	NN	O
of	IN	O
accelerated	JJ	O
radiotherapy	NN	O
in	IN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
.	.	O

Histological	JJ	O
material	NN	O
from	IN	O
402	CD	O
patients	NNS	O
was	VBD	O
collected	VBN	O
and	CC	O
stained	VBN	O
for	IN	O
the	DT	O
presence	NN	O
and	CC	O
pattern	NN	O
of	IN	O
Ki-67	NNP	O
staining	NN	O
.	.	O

Locoregional	NNP	Physical
control	NN	Physical
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
the	DT	O
main	JJ	O
clinical	JJ	O
endpoints	NNS	O
.	.	O

Increasing	VBG	O
Ki-67	NNP	O
positivity	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
decreasing	VBG	O
differentiation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
increasing	VBG	O
N-stage	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.004	CD	O
)	)	O
.	.	O

Increasing	VBG	O
N-stage	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
the	DT	O
progression	NN	O
of	IN	O
proliferation	NN	O
pattern	NN	O
from	IN	O
marginal	JJ	O
to	TO	O
random	VB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
multivariate	NN	O
model	NN	O
,	,	O
a	DT	O
trend	NN	O
was	VBD	O
seen	VBN	O
towards	NNS	O
a	DT	O
greater	JJR	O
benefit	NN	O
from	IN	O
CHART	NNP	O
in	IN	O
the	DT	O
lower	JJR	O
Ki-67	NNP	O
tumours	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.08	CD	O
)	)	O
;	:	O
this	DT	O
became	VBD	O
significant	JJ	O
by	IN	O
pooling	VBG	O
the	DT	O
low	JJ	O
and	CC	O
intermediate	JJ	O
Ki-67	NNP	O
groups	NNS	O
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
high	JJ	O
Ki-67	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.032	CD	O
)	)	O
.	.	O

Tumours	$	O
with	IN	O
marginal	JJ	O
proliferation	NN	O
pattern	NN	O
showed	VBD	O
a	DT	O
lower	JJR	O
hazard	NN	O
ratio	NN	O
with	IN	O
CHART	NNP	O
versus	VBP	O
conventional	JJ	O
for	IN	O
locoregional	JJ	O
control	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

The	DT	O
data	NN	O
presented	VBN	O
in	IN	O
this	DT	O
study	NN	O
do	VBP	O
not	RB	O
support	VB	O
that	IN	O
a	DT	O
high	JJ	O
pre-treatment	JJ	O
Ki-67	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
therapeutic	JJ	Others
benefit	NN	Others
from	IN	O
accelerated	VBN	O
radiotherapy	NN	O
.	.	O

Paromomycin	NNP	O
for	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effects	NNS	O
of	IN	O
paromomycin	NN	O
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
and	CC	O
cryptosporidiosis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
paromomycin	VB	O
or	CC	O
placebo	VB	O
in	IN	O
a	DT	O
double-blind	JJ	O
trial	NN	O
.	.	O

After	IN	O
14	CD	O
days	NNS	O
,	,	O
patients	NNS	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
for	IN	O
14	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Measures	NNS	O
included	VBD	O
the	DT	O
number	NN	Physical
and	CC	Physical
character	NN	Physical
of	IN	Physical
each	DT	Physical
stool	NN	Physical
and	CC	O
weekly	JJ	O
24-h	JJ	O
stool	NN	Physical
specimens	NNS	Physical
for	IN	Physical
weight	NN	Physical
and	CC	O
oocyst	NN	Physical
excretion	NN	Physical
.	.	O

During	IN	O
the	DT	O
paromomycin	NN	O
treatment	NN	O
phase	NN	O
,	,	O
oocyst	JJ	Physical
excretion	NN	Physical
decreased	VBD	O
from	IN	O
314	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
to	TO	O
109	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
24	CD	O
h	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Oocyst	NNP	Physical
excretion	NN	Physical
increased	VBD	O
for	IN	O
the	DT	O
4	CD	O
patients	NNS	O
initially	RB	O
on	IN	O
placebo	NNS	O
compared	VBN	O
to	TO	O
a	DT	O
median	JJ	O
decrease	NN	O
of	IN	O
128	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/24	NN	O
h	NN	O
for	IN	O
the	DT	O
6	CD	O
initially	RB	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Stool	NNP	Others
frequency	NN	Others
also	RB	O
decreased	VBD	O
more	RBR	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
3.6	CD	O
fewer	JJR	O
vs.	NN	O
1.25	CD	O
fewer/24	NN	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Trends	NNS	O
favored	JJ	O
drug	NN	O
over	IN	O
placebo	NN	O
for	IN	O
stool	NN	Physical
weight	NN	Physical
,	,	Physical
stool	JJ	Physical
character	NN	Physical
,	,	O
and	CC	O
Karnofsky	NNP	Others
score	NN	Others
.	.	O

Paromomycin	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
both	DT	O
clinical	JJ	O
and	CC	O
parasitologic	JJ	O
parameters	NNS	O
in	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
.	.	O

Dark-phase	NNP	O
light	JJ	O
contamination	NN	O
disrupts	NNS	O
circadian	JJ	O
rhythms	NN	O
in	IN	O
plasma	JJ	Physical
measures	NNS	O
of	IN	O
endocrine	NN	O
physiology	NN	Physical
and	CC	O
metabolism	NN	Physical
in	IN	O
rats	NNS	O
.	.	O

Dark-phase	NNP	O
light	JJ	O
contamination	NN	O
can	MD	O
significantly	RB	O
disrupt	VB	O
chronobiologic	JJ	Physical
rhythms	NN	Physical
,	,	O
thereby	RB	O
potentially	RB	O
altering	VBG	O
the	DT	O
endocrine	NN	O
physiology	NN	O
and	CC	O
metabolism	NN	O
of	IN	O
experimental	JJ	O
animals	NNS	O
and	CC	O
influencing	VBG	O
the	DT	O
outcome	NN	O
of	IN	O
scientific	JJ	O
investigations	NNS	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
exposure	NN	O
to	TO	O
low-level	JJ	O
light	JJ	O
contamination	NN	O
during	IN	O
the	DT	O
dark	JJ	O
phase	NN	O
influenced	VBD	O
the	DT	O
normally	RB	O
entrained	JJ	O
circadian	JJ	O
rhythms	NN	O
of	IN	O
various	JJ	O
substances	NNS	O
in	IN	O
plasma	NN	O
.	.	O

Male	JJ	O
Sprague-Dawley	JJ	O
rats	NNS	O
(	(	O
n	JJ	O
=	$	O
6	CD	O
per	IN	O
group	NN	O
)	)	O
were	VBD	O
housed	VBN	O
in	IN	O
photobiologic	JJ	O
light-exposure	JJ	O
chambers	NNS	O
configured	VBD	O
to	TO	O
create	VB	O
1	CD	O
)	)	O
a	DT	O
12:12-h	JJ	O
light	NN	O
:	:	O
dark	JJ	O
cycle	NN	O
without	IN	O
dark-phase	JJ	O
light	JJ	O
contamination	NN	O
(	(	O
control	JJ	O
condition	NN	O
;	:	O
123	CD	O
?W/cm	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
lights	NNS	O
on	IN	O
at	IN	O
0600	CD	O
)	)	O
,	,	O
2	CD	O
)	)	O
experimental	NN	O
exposure	NN	O
to	TO	O
a	DT	O
low	JJ	O
level	NN	O
of	IN	O
light	NN	O
during	IN	O
the	DT	O
12-h	JJ	O
dark	NN	O
phase	NN	O
(	(	O
with	IN	O
0.02	CD	O
,	,	O
0.05	CD	O
,	,	O
0.06	CD	O
,	,	O
or	CC	O
0.08	CD	O
?W/cm	NNS	O
(	(	O
2	CD	O
)	)	O
light	NN	O
at	IN	O
night	NN	O
)	)	O
,	,	O
or	CC	O
3	CD	O
)	)	O
constant	JJ	O
bright	JJ	O
light	NN	O
(	(	O
123	CD	O
?W/cm	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

Dietary	NNP	O
and	CC	O
water	NN	O
intakes	NNS	O
were	VBD	O
recorded	VBN	O
daily	RB	O
.	.	O

After	IN	O
2	CD	O
wk	NN	O
,	,	O
rats	VB	O
underwent	JJ	O
6	CD	O
low-volume	JJ	O
blood	NN	O
draws	NNS	O
at	IN	O
4-h	JJ	O
intervals	NNS	O
(	(	O
beginning	VBG	O
at	IN	O
0400	CD	O
)	)	O
during	IN	O
both	DT	O
the	DT	O
light	NN	O
and	CC	O
dark	JJ	O
phases	NNS	O
.	.	O

Circadian	JJ	O
rhythms	NN	O
in	IN	O
dietary	JJ	O
and	CC	O
water	NN	O
intake	NN	O
and	CC	O
levels	NNS	Physical
of	IN	Physical
plasma	NN	Physical
total	JJ	Physical
fatty	JJ	Physical
acids	NNS	Physical
and	CC	O
lipid	JJ	Physical
fractions	NNS	Physical
remained	VBD	O
entrained	JJ	O
during	IN	O
exposure	NN	O
to	TO	O
either	DT	O
control	NN	O
conditions	NNS	O
or	CC	O
low-intensity	NN	O
light	NN	O
during	IN	O
the	DT	O
dark	JJ	O
phase	NN	O
.	.	O

However	RB	O
,	,	O
these	DT	O
patterns	NNS	O
were	VBD	O
disrupted	VBN	O
in	IN	O
rats	NNS	O
exposed	VBN	O
to	TO	O
constant	VB	O
bright	JJ	O
light	NN	O
.	.	O

Circadian	JJ	O
patterns	NNS	O
of	IN	O
plasma	NN	O
melatonin	NN	O
,	,	O
glucose	NN	O
,	,	O
lactic	JJ	O
acid	NN	O
,	,	O
and	CC	O
corticosterone	NN	O
were	VBD	O
maintained	VBN	O
in	IN	O
all	DT	O
rats	NNS	O
except	IN	O
those	DT	O
exposed	VBN	O
to	TO	O
constant	VB	O
bright	JJ	O
light	NN	O
or	CC	O
the	DT	O
highest	JJS	O
level	NN	O
of	IN	O
light	NN	O
during	IN	O
the	DT	O
dark	JJ	O
phase	NN	O
.	.	O

Therefore	RB	O
even	RB	O
minimal	JJ	O
light	JJ	O
contamination	NN	O
during	IN	O
the	DT	O
dark	JJ	O
phase	NN	O
can	MD	O
disrupt	VB	O
normal	JJ	O
circadian	JJ	O
rhythms	NN	O
of	IN	O
endocrine	JJ	O
metabolism	NN	O
and	CC	O
physiology	NN	O
and	CC	O
may	MD	O
alter	VB	O
the	DT	O
outcome	NN	O
of	IN	O
scientific	JJ	O
investigations	NNS	O
.	.	O

Double-blind	NNP	O
trial	NN	O
comparing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
homeopathic	JJ	O
preparation	NN	O
Galphimia	NNP	O
potentiation	NN	O
D6	NNP	O
,	,	O
Galphimia	NNP	O
dilution	NN	O
10	CD	O
(	(	O
-6	NN	O
)	)	O
and	CC	O
placebo	NN	O
on	IN	O
pollinosis	NN	Physical
.	.	Physical

The	DT	O
preparation	NN	O
of	IN	O
homeopathic	JJ	O
drugs	NNS	O
is	VBZ	O
based	VBN	O
on	IN	O
potentiation	NN	O
.	.	O

In	IN	O
this	DT	O
potentiation	NN	O
the	DT	O
primary	JJ	O
substance	NN	O
is	VBZ	O
specially	RB	O
mixed	JJ	O
with	IN	O
a	DT	O
carrier	NN	O
(	(	O
typically	RB	O
90	CD	O
%	NN	O
ethanol	NN	O
)	)	O
in	IN	O
the	DT	O
ratio	NN	O
1:10	CD	O
.	.	O

Usually	RB	O
this	DT	O
potentiation	NN	O
is	VBZ	O
done	VBN	O
repeatedly	RB	O
and	CC	O
the	DT	O
final	JJ	O
drug	NN	O
is	VBZ	O
labeled	VBN	O
,	,	O
e.g.	NN	O
,	,	O
D6	NNP	O
which	WDT	O
means	VBZ	O
a	DT	O
6	CD	O
times	NNS	O
decimal	JJ	O
potentiation	NN	O
.	.	O

In	IN	O
a	DT	O
controlled	JJ	O
randomized	VBN	O
strictly	RB	O
double-blind	JJ	O
trial	NN	O
with	IN	O
164	CD	O
patients	NNS	O
the	DT	O
effectiveness	NN	O
of	IN	O
homeopathically	RB	O
prepared	JJ	O
Galphimia	NNP	O
D6	NNP	O
,	,	O
a	DT	O
conventional	JJ	O
Galphimia	NNP	O
dilution	NN	O
10	CD	O
(	(	O
-6	NN	O
)	)	O
and	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
investigated	VBN	O
for	IN	O
the	DT	O
therapy	NN	O
of	IN	O
pollinosis	NN	O
.	.	O

The	DT	O
average	JJ	Others
duration	NN	Others
of	IN	Others
treatment	NN	Others
was	VBD	O
about	RB	O
5	CD	O
weeks	NNS	O
.	.	O

Although	IN	O
no	DT	O
statistical	JJ	O
significance	NN	O
was	VBD	O
achieved	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
remarkable	JJ	O
that	IN	O
there	EX	O
was	VBD	O
a	DT	O
clear	JJ	O
trend	NN	O
for	IN	O
the	DT	O
superiority	NN	Others
of	IN	O
Galphimia	NNP	Physical
D6	NNP	Physical
while	IN	O
the	DT	O
Galphimia	NNP	O
dilution	NN	O
10	CD	O
(	(	O
-6	NN	O
)	)	O
was	VBD	O
about	IN	O
equally	RB	O
effective	JJ	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
study	NN	O
itself	PRP	O
demonstrates	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
do	VB	O
strictly	RB	O
controlled	VBN	O
trials	NNS	O
for	IN	O
homeopathic	JJ	O
drugs	NNS	O
and	CC	O
with	IN	O
medical	JJ	O
practitioners	NNS	O
.	.	O

HOXB13	NNP	O
G84E	NNP	O
mutation	NN	O
in	IN	O
Finland	NNP	O
:	:	O
population-based	JJ	O
analysis	NN	O
of	IN	O
prostate	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
risk	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
recently	RB	O
identified	VBN	O
germline	NN	O
mutation	NN	O
G84E	NNP	O
in	IN	O
HOXB13	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

In	IN	O
a	DT	O
family-based	JJ	O
analysis	NN	O
by	IN	O
The	DT	O
International	NNP	O
Consortium	NNP	O
for	IN	O
Prostate	NNP	O
Cancer	NNP	O
Genetics	NNP	O
(	(	O
ICPCG	NNP	O
)	)	O
,	,	O
the	DT	O
G84E	NNP	O
mutation	NN	O
was	VBD	O
most	RBS	O
prevalent	JJ	O
in	IN	O
families	NNS	O
from	IN	O
the	DT	O
Nordic	NNP	O
countries	NNS	O
of	IN	O
Finland	NNP	O
(	(	O
22.4	CD	O
%	NN	O
)	)	O
and	CC	O
Sweden	NNP	O
(	(	O
8.2	CD	O
%	NN	O
)	)	O
.	.	O

METHODS	NNP	O
To	TO	O
further	VB	O
investigate	VB	O
the	DT	O
importance	NN	O
of	IN	O
G84E	NNP	O
in	IN	O
the	DT	O
Finns	NNP	O
,	,	O
we	PRP	O
determined	VBD	O
its	PRP$	O
frequency	NN	O
in	IN	O
more	JJR	O
than	IN	O
4,000	CD	O
prostate	JJ	O
cancer	NN	O
cases	NNS	O
and	CC	O
5,000	CD	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
986	CD	O
breast	NN	O
cancer	NN	O
and	CC	O
442	CD	O
colorectal	JJ	O
cancer	NN	O
(	(	O
CRC	NNP	O
)	)	O
cases	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Genotyping	VBG	O
was	VBD	O
conducted	VBN	O
using	VBG	O
TaqMan	NNP	O
,	,	O
MassARRAY	NNP	O
iPLEX	NN	O
,	,	O
and	CC	O
sequencing	VBG	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
using	VBG	O
Fisher	NNP	O
exact	JJ	O
test	NN	O
,	,	O
and	CC	O
overall	JJ	Mortality
survival	NN	Mortality
was	VBD	O
analyzed	VBN	O
using	VBG	O
Cox	NNP	O
modeling	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
frequency	NN	Physical
of	IN	Physical
the	DT	Physical
G84E	NNP	Physical
mutation	NN	Physical
was	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
and	CC	O
highest	JJS	O
among	IN	O
patients	NNS	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
hereditary	JJ	O
prostate	NN	O
cancer	NN	O
[	VBZ	O
8.4	CD	O
%	NN	O
vs.	FW	O
1.0	CD	O
%	NN	O
in	IN	O
controls	NNS	O
;	:	O
OR	CC	O
8.8	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
4.9-15.7	JJ	O
]	NN	O
.	.	O

The	DT	O
mutation	NN	Physical
contributed	VBD	O
significantly	RB	O
to	TO	O
younger	JJR	O
age	NN	O
(	(	O
?55	CD	O
years	NNS	O
)	)	O
at	IN	O
onset	NN	O
and	CC	O
high	JJ	O
prostate-specific	JJ	O
antigen	NN	O
(	(	O
PSA	NNP	O
;	:	O
?20	NNP	O
ng/mL	NN	O
)	)	O
at	IN	O
diagnosis	NN	O
.	.	O

An	DT	O
association	NN	O
with	IN	O
increased	JJ	Physical
prostate	NN	Physical
cancer	NN	Physical
risk	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
prior	JJ	O
benign	NN	O
prostate	NN	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
diagnosis	NN	O
was	VBD	O
also	RB	O
revealed	VBN	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
evidence	NN	O
for	IN	O
a	DT	O
contribution	NN	O
in	IN	O
CRC	NNP	O
risk	NN	O
was	VBD	O
detected	VBN	O
,	,	O
but	CC	O
a	DT	O
suggestive	JJ	O
role	NN	O
for	IN	O
the	DT	O
mutation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
familial	JJ	O
BRCA1/2-negative	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
confirm	VBP	O
an	DT	O
increased	JJ	O
cancer	NN	O
risk	NN	O
associated	VBN	O
with	IN	O
the	DT	O
G84E	NNP	O
mutation	NN	O
in	IN	O
the	DT	O
Finnish	JJ	O
population	NN	O
,	,	O
particularly	RB	O
for	IN	O
early-onset	JJ	O
prostate	NN	O
cancer	NN	O
and	CC	O
cases	NNS	O
with	IN	O
substantially	RB	O
elevated	VBN	O
PSA	NNP	O
.	.	O

IMPACT	NNP	O
This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
overall	JJ	O
importance	NN	O
of	IN	O
the	DT	O
HOXB13	NNP	O
G84E	NNP	O
mutation	NN	O
in	IN	O
prostate	NN	O
cancer	NN	O
susceptibility	NN	O
.	.	O

Drug-drug	JJ	O
interaction	NN	O
study	NN	O
of	IN	O
ACT-178882	NNP	O
,	,	O
a	DT	O
new	JJ	O
renin	NN	O
inhibitor	NN	O
,	,	O
and	CC	O
diltiazem	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
OBJECTIVE	NNP	O
The	DT	O
cytochrome	NN	O
P450	NNP	O
(	(	O
CYP	NNP	O
)	)	O
enzyme	NN	O
,	,	O
CYP3A4	NNP	O
,	,	O
metabolizes	VBZ	O
ACT-178882	NNP	O
,	,	O
a	DT	O
new	JJ	O
direct	JJ	O
renin	NN	O
inhibitor	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	Others
of	IN	O
diltiazem	NN	O
,	,	O
a	DT	O
moderate	JJ	O
inhibitor	NN	O
of	IN	O
CYP3A4	NNP	O
,	,	O
on	IN	O
the	DT	O
single-dose	JJ	O
pharmacokinetics	NNS	O
of	IN	O
ACT-178882	NNP	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
open-label	JJ	O
,	,	O
two-way	JJ	O
crossover	NN	O
,	,	O
drug-drug	JJ	O
interaction	NN	O
study	NN	O
,	,	O
healthy	JJ	O
young	JJ	O
male	JJ	O
subjects	NNS	O
received	VBD	O
treatments	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
in	IN	O
a	DT	O
randomized	JJ	O
fashion	NN	O
.	.	O

Treatment	VB	O
A	NNP	O
consisted	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
100	CD	O
mg	JJ	O
ACT-178882	NNP	O
and	CC	O
treatment	NN	O
B	NNP	O
of	IN	O
diltiazem	NN	O
300	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
for	IN	O
13	CD	O
days	NNS	O
and	CC	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
100	CD	O
mg	JJ	O
ACT-178882	JJ	O
on	IN	O
day	NN	O
4	CD	O
.	.	O

Serial	JJ	O
blood	NN	O
samples	NNS	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ACT-178882	NNP	O
were	VBD	O
drawn	VBN	O
pre-dose	NN	O
and	CC	O
up	RB	O
to	TO	O
120	CD	O
h	JJ	O
post-dose	JJ	O
during	IN	O
treatment	NN	O
A	NNP	O
and	CC	O
pre-dose	JJ	O
ACT-178882	NNP	O
and	CC	O
up	RB	O
to	TO	O
240	CD	O
h	JJ	O
post-dose	JJ	O
during	IN	O
treatment	NN	O
B.	NNP	O
Trough	NNP	O
blood	NN	O
samples	NNS	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
diltiazem	NN	O
were	VBD	O
taken	VBN	O
on	IN	O
days	NNS	O
1-5	CD	O
of	IN	O
dosing	VBG	O
during	IN	O
treatment	NN	O
B	NNP	O
.	.	O

Safety	NNP	O
was	VBD	O
assessed	VBN	O
by	IN	O
recording	VBG	O
of	IN	O
vital	JJ	O
signs	NNS	O
and	CC	O
electrocardiogram	NN	O
,	,	O
clinical	JJ	O
laboratory	NN	O
tests	NNS	O
and	CC	O
adverse	JJ	O
event	NN	O
reporting	NN	O
.	.	O

RESULTS	NNP	O
Fourteen	JJ	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
diltiazem	NN	O
,	,	O
the	DT	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
)	)	O
maximum	NN	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
and	CC	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
from	IN	O
time	NN	O
zero	CD	O
to	TO	O
infinity	NN	O
(	(	O
AUC?	NNP	O
)	)	O
were	VBD	O
26.8	CD	O
(	(	O
20.1-35.8	JJ	O
)	)	O
ng/mL	NN	O
and	CC	O
454	CD	O
(	(	O
351-587	CD	O
)	)	O
ng?h/mL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
presence	NN	O
of	IN	O
diltiazem	NN	O
these	DT	O
values	NNS	O
were	VBD	O
43.5	CD	O
(	(	O
36.8-51.4	CD	O
)	)	O
ng/mL	NN	O
and	CC	O
918	CD	O
(	(	O
781-1078	CD	O
)	)	O
ng?h/mL	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
to	TO	O
Cmax	NNP	O
(	(	O
tmax	NN	O
)	)	O
for	IN	O
ACT-178882	NNP	O
was	VBD	O
prolonged	VBN	O
from	IN	O
3.5	CD	O
to	TO	O
5.0	CD	O
h	NN	O
by	IN	O
diltiazem	JJ	O
whereas	NNS	O
its	PRP$	O
apparent	JJ	O
terminal	JJ	O
half-life	NN	O
(	(	O
t?	NN	O
)	)	O
was	VBD	O
unaffected	VBN	O
by	IN	O
diltiazem	NN	O
,	,	O
22.9	CD	O
and	CC	O
24.2	CD	O
h	NN	O
for	IN	O
treatments	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
.	.	O

Using	VBG	O
treatment	NN	O
A	NNP	O
as	IN	O
reference	NN	O
,	,	O
the	DT	O
geometric	JJ	O
mean	NN	O
ratio	NN	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
)	)	O
was	VBD	O
1.62	CD	O
(	(	O
1.36-1.94	CD	O
)	)	O
for	IN	O
Cmax	NNP	O
and	CC	O
2.02	CD	O
(	(	O
1.75-2.34	CD	O
)	)	O
for	IN	O
AUC?	NNP	O
,	,	O
indicating	VBG	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
ACT-178882	NNP	O
and	CC	O
diltiazem	NN	O
.	.	O

One	CD	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
and	CC	O
3	CD	O
(	(	O
21.3	CD	O
%	NN	O
)	)	O
of	IN	O
14	CD	O
subjects	NNS	O
reported	VBD	O
an	DT	O
adverse	JJ	O
event	NN	O
during	IN	O
treatment	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
headache	NN	O
being	VBG	O
the	DT	O
most	RBS	O
frequently	RB	O
reported	VBN	O
,	,	O
with	IN	O
three	CD	O
events	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
relevant	JJ	O
effects	NNS	O
of	IN	O
treatments	NNS	O
on	IN	O
vital	JJ	O
signs	NNS	O
,	,	O
electrocardiogram	NN	O
or	CC	O
clinical	JJ	O
laboratory	NN	O
variables	NNS	O
.	.	O

CONCLUSION	NNP	O
Concomitant	NNP	O
administration	NN	O
of	IN	O
diltiazem	NN	O
doubled	VBD	O
the	DT	O
exposure	NN	O
to	TO	O
ACT-178882	NNP	O
without	IN	O
affecting	VBG	O
t?	NN	O
.	.	O

The	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
this	DT	O
increase	NN	O
is	VBZ	O
at	IN	O
present	JJ	O
unknown	JJ	O
and	CC	O
will	MD	O
need	VB	O
to	TO	O
be	VB	O
investigated	VBN	O
in	IN	O
future	JJ	O
clinical	JJ	O
studies	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
ACT-178882	NNP	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
diltiazem	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
Saccharomyces	NNP	O
boulardii	NN	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

AIM	NNP	O
Certain	NNP	O
probiotic	JJ	O
agents	NNS	O
,	,	O
e.g	NN	O
.	.	O

Lactobacillus	CC	O
GG	NNP	O
,	,	O
have	VBP	O
shown	VBN	O
efficacy	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
childhood	NN	O
diarrhoea	NN	O
,	,	O
but	CC	O
few	JJ	O
studies	NNS	O
have	VBP	O
examined	VBN	O
the	DT	O
effect	NN	O
of	IN	O
Saccharomyces	NNP	O
boulardii	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
S.	NNP	O
boulardii	NN	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
children	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
S.	NNP	O
boulardii	NN	O
in	IN	O
a	DT	O
granulated	JJ	O
form	NN	O
in	IN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
250	CD	O
mg	NN	O
(	(	O
S.	NNP	O
boulardii	NNP	O
group	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
placebo	JJ	O
group	NN	O
)	)	O
for	IN	O
5	CD	O
d.	JJ	O
Clinical	NNP	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
on	IN	O
admission	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
medians	NNS	Physical
of	IN	Physical
the	DT	Physical
average	JJ	Physical
stool	NN	Physical
frequency	NN	Physical
after	IN	O
the	DT	O
second	JJ	O
day	NN	O
of	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
duration	NN	Physical
of	IN	Physical
diarrhoea	NN	Physical
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
4.7	CD	O
vs	RB	O
5.5	CD	O
d	NN	O
,	,	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
S.	NNP	O
boulardii	NN	O
on	IN	O
watery	NN	Physical
diarrhoea	NN	Physical
became	VBD	O
apparent	JJ	O
after	IN	O
the	DT	O
second	JJ	O
day	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
duration	NN	Others
of	IN	Others
hospital	NN	Others
stay	NN	Others
was	VBD	O
shorter	JJR	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
2.9	CD	O
vs	RB	O
3.9	CD	O
d	NN	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Four	CD	O
children	NNS	O
from	IN	O
the	DT	O
placebo	NN	O
group	NN	O
versus	VBD	O
only	RB	O
one	CD	O
child	NN	O
from	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
had	VBD	O
persisting	VBG	Physical
diarrhoea	NN	Physical
.	.	Physical

CONCLUSION	VB	O
The	DT	O
placebo-controlled	JJ	O
study	NN	O
suggested	VBD	O
that	IN	O
S.	NNP	O
boulardii	VBP	O
significantly	RB	O
reduced	VBN	O
the	DT	O
duration	NN	Physical
of	IN	Physical
acute	JJ	Physical
diarrhoea	NN	Physical
and	CC	O
the	DT	O
duration	NN	Others
of	IN	Others
hospital	NN	Others
stay	NN	Others
.	.	Others

S.	NNP	O
boulardii	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
promising	JJ	O
agent	NN	O
for	IN	O
the	DT	O
amelioration	NN	O
of	IN	O
the	DT	O
course	NN	O
of	IN	O
acute	JJ	O
diarrhoea	NN	O
in	IN	O
children	NNS	O
when	WRB	O
used	VBN	O
therapeutically	RB	O
.	.	O

Placebo-controlled	JJ	O
trial	NN	O
evaluating	VBG	O
safety	NN	O
with	IN	O
12-months	JJ	O
continuous	JJ	O
use	NN	O
of	IN	O
6	CD	O
%	NN	O
hydrogen	NN	O
peroxide	IN	O
whitening	VBG	O
strips	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
6	CD	O
%	NN	O
hydrogen	NN	O
peroxide	IN	O
whitening	VBG	O
strips	NNS	O
over	IN	O
12	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
80	CD	O
adults	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
equally	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatments	NNS	O
:	:	O
6	CD	O
%	NN	O
hydrogen	NN	O
peroxide	JJ	O
strips	NNS	O
or	CC	O
placebo	VB	O
strips	NNS	O
.	.	O

Strips	NNS	O
were	VBD	O
worn	JJ	O
5	CD	O
min	JJ	O
daily	RB	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

Safety	NNP	O
and	CC	O
tolerability	NN	O
were	VBD	O
assessed	VBN	O
via	IN	O
oral	JJ	O
status	NN	O
interviews	NNS	O
and	CC	O
oral	JJ	O
examinations	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
use	NN	O
.	.	O

RESULTS	NNP	O
Tooth	NNP	O
sensitivity	NN	O
and	CC	O
oral	JJ	O
irritation	NN	O
were	VBD	O
the	DT	O
two	CD	O
most	JJS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

After	IN	O
12	CD	O
months	NNS	O
use	RB	O
,	,	O
tooth	DT	O
sensitivity	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
10	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
6	CD	O
%	NN	O
strip	NN	O
group	NN	O
with	IN	O
a	DT	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
of	IN	O
(	(	O
2.8	CD	O
%	NN	O
,	,	O
23.7	CD	O
%	NN	O
)	)	O
and	CC	O
5	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
with	IN	O
a	DT	O
95	CD	O
%	NN	O
CI	NNP	O
of	IN	O
(	(	O
0.6	CD	O
%	NN	O
,	,	O
16.9	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
reported	VBN	O
oral	JJ	O
irritation	NN	O
was	VBD	O
0	CD	O
%	NN	O
in	IN	O
the	DT	O
6	CD	O
%	NN	O
strip	NN	O
group	NN	O
with	IN	O
a	DT	O
95	CD	O
%	NN	O
CI	NNP	O
of	IN	O
(	(	O
0	CD	O
%	NN	O
,	,	O
8.8	CD	O
%	NN	O
)	)	O
and	CC	O
2.5	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
strip	NN	O
group	NN	O
with	IN	O
a	DT	O
95	CD	O
%	NN	O
CI	NNP	O
of	IN	O
(	(	O
0.1	CD	O
%	NN	O
,	,	O
13.2	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
observed	JJ	O
oral	JJ	O
irritation	NN	O
was	VBD	O
also	RB	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
(	(	O
p	JJ	O
>	NNP	O
0.67	CD	O
)	)	O
for	IN	O
the	DT	O
percent	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
each	DT	O
type	NN	O
of	IN	O
adverse	JJ	O
event	NN	O
.	.	O

In	IN	O
the	DT	O
6	CD	O
%	NN	O
strip	NN	O
group	NN	O
,	,	O
two	CD	O
subjects	NNS	O
discontinued	VBN	O
product	NN	O
use	NN	O
due	JJ	O
to	TO	O
an	DT	O
adverse	JJ	O
event	NN	O
(	(	O
tooth	JJ	O
sensitivity	NN	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
subjects	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
(	(	O
p	JJ	O
>	NNP	O
0.49	CD	O
)	)	O
with	IN	O
respect	NN	O
to	TO	O
this	DT	O
outcome	NN	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
6	CD	O
%	NN	O
hydrogen	NN	O
peroxide	IN	O
whitening	VBG	O
strips	NNS	O
over	IN	O
12	CD	O
months	NNS	O
resulted	VBN	O
in	IN	O
a	DT	O
safety	NN	O
profile	NN	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
with	IN	O
placebo	JJ	O
strips	NNS	O
.	.	O

Midazolam	NNP	O
as	IN	O
a	DT	O
main	JJ	O
anesthesia	NN	O
induction	NN	O
agent	NN	O
--	:	O
a	DT	O
comparison	NN	O
with	IN	O
thiopental	JJ	O
and	CC	O
diazepam	NN	O
.	.	O

A	DT	O
clinical	JJ	O
randomized	JJ	O
investigation	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	Others
of	IN	O
midazolam	NN	O
as	IN	O
a	DT	O
narcotic	JJ	O
adjuvant	NN	O
for	IN	O
anesthetic	JJ	O
induction	NN	O
.	.	O

Thirty	NNP	O
ASA	NNP	O
I-II	NNP	O
adult	NN	O
patients	NNS	O
undergoing	VBG	O
selective	JJ	O
surgery	NN	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
midazolam	NN	O
0.3	CD	O
mg/kg	NN	O
,	,	O
thiopental	JJ	O
5	CD	O
mg/kg	NN	O
,	,	O
or	CC	O
diazepam	VB	O
0.4	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
induction	NN	Others
time	NN	Others
as	IN	Others
measured	VBN	Others
from	IN	Others
the	DT	Others
onset	NN	Others
of	IN	Others
injection	NN	Others
to	TO	Others
loss	NN	Others
of	IN	Others
the	DT	Others
eyelash	NN	Others
reflex	NN	Others
was	VBD	O
shortest	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
thiopental	NN	O
;	:	O
while	IN	O
a	DT	O
lower	JJR	Physical
frequency	NN	Physical
of	IN	Physical
apnea	NN	Physical
,	,	Physical
lesser	JJR	Physical
suppression	NN	Physical
of	IN	Physical
circulation	NN	Physical
,	,	O
and	CC	O
lack	NN	Physical
of	IN	Physical
venous	JJ	Physical
irritation	NN	Physical
were	VBD	O
points	NNS	O
favoring	VBG	O
midazolam	NN	O
.	.	O

However	RB	O
,	,	O
further	JJ	O
study	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
moderate	JJ	Physical
cardiovascular	JJ	Physical
response	NN	Physical
seen	VBN	O
during	IN	O
intubation	NN	O
in	IN	O
some	DT	O
cases	NNS	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
elucidate	VB	O
any	DT	O
patient	JJ	O
population	NN	O
differences	NNS	O
.	.	O

Anabolic	JJ	O
steroids	NNS	O
in	IN	O
athelics	NNS	O
:	:	O
crossover	RB	O
double-blind	VBP	O
trial	NN	O
on	IN	O
weightlifters	NNS	O
.	.	O

Thirteen	NNP	O
experienced	VBD	O
male	JJ	O
weightlifters	NNS	O
taking	VBG	O
high-protein	JJ	O
diets	NNS	O
and	CC	O
regular	JJ	O
exercise	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
methandienone	NN	O
10	CD	O
or	CC	O
25	CD	O
mg/day	NN	O
to	TO	O
seeif	VB	O
the	DT	O
drug	NN	O
improved	VBD	O
athletic	JJ	Mental
performance	NN	Mental
.	.	O

Their	PRP$	O
improvemments	NNS	O
were	VBD	O
significantly	RB	O
greater	JJR	Others
on	IN	O
methandienone	NN	O
than	IN	O
on	IN	O
placebo	NN	O
;	:	O
their	PRP$	O
body	NN	Physical
weights	NNS	Physical
rose	VBD	Physical
(	(	O
though	IN	O
this	DT	O
seemed	VBD	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
water	NN	O
retention	NN	O
)	)	O
;	:	O
and	CC	O
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
rose	VBD	Physical
significantly	RB	O
.	.	O

Methandienone	NNP	O
caused	VBD	O
many	JJ	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
,	,	O
and	CC	O
three	CD	O
men	NNS	O
had	VBD	O
to	TO	O
withdraw	VB	O
because	IN	O
of	IN	O
them	PRP	O
.	.	O

All	DT	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
disappeared	VBD	O
after	IN	O
the	DT	O
drug	NN	O
was	VBD	O
stopped	VBN	O
.	.	O

Anabolic	JJ	O
steroids	NNS	O
are	VBP	O
effective	JJ	O
only	RB	O
when	WRB	O
given	VBN	O
combination	NN	O
with	IN	O
exercise	NN	O
and	CC	O
high-protein	JJ	O
diet	NN	O
.	.	O

We	PRP	O
deprecate	VBP	O
their	PRP$	O
use	NN	O
in	IN	O
athletics	NNS	O
but	CC	O
can	MD	O
suggest	VB	O
no	DT	O
way	NN	O
of	IN	O
stopping	VBG	O
it	PRP	O
.	.	O

Can	MD	O
incentives	VB	O
undermine	JJ	O
intrinsic	JJ	Mental
motivation	NN	Mental
to	TO	O
participate	VB	O
in	IN	O
epidemiologic	JJ	O
surveys	NNS	O
?	.	O
Response	JJ	O
rates	NNS	O
to	TO	O
surveys	NNS	O
are	VBP	O
decreasing	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
in	IN	O
an	DT	O
epidemiologic	JJ	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
self-administered	JJ	O
questionnaire	NN	O
was	VBD	O
sent	VBN	O
to	TO	O
parents	NNS	O
in	IN	O
the	DT	O
municipality	NN	O
of	IN	O
Stockholm	NNP	O
,	,	O
Sweden	NNP	O
,	,	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
in	IN	O
a	DT	O
study	NN	O
addressing	VBG	O
stress	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
cancer	NN	O
.	.	O

A	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
450	CD	O
parents	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
incentive	JJ	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
no	DT	O
incentive	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
;	:	O
(	(	O
c	NN	O
)	)	O
a	DT	O
promised	JJ	O
incentive	NN	O
of	IN	O
one	CD	O
lottery	NN	O
ticket	NN	O
to	TO	O
be	VB	O
received	VBN	O
upon	IN	O
reply	NN	O
and	CC	O
an	DT	O
additional	JJ	O
lottery	NN	O
ticket	NN	O
upon	IN	O
reply	NN	O
within	IN	O
1	CD	O
week	NN	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	Mental
rate	NN	Mental
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
65.3	CD	O
%	NN	O
.	.	O

The	DT	O
response	NN	Mental
rate	NN	Mental
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
(	(	O
69.3	CD	O
%	NN	O
)	)	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
one	CD	O
plus	CC	O
one	CD	O
lottery	NN	O
ticket	NN	O
group	NN	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	Mortality
analysis	NN	Mortality
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
response	NN	O
curves	NNS	O
was	VBD	O
significant	JJ	O
by	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
having	VBG	O
a	DT	O
shorter	JJR	O
time	NN	O
to	TO	O
response	NN	O
than	IN	O
the	DT	O
incentive	NN	O
group	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	O
tickets	NNS	O
as	IN	O
incentives	NNS	O
to	TO	O
increase	VB	Mental
participation	NN	Mental
in	IN	O
a	DT	O
mail	NN	Others
questionnaire	NN	Others
among	IN	O
parents	NNS	O
may	MD	O
be	VB	O
less	RBR	O
valuable	JJ	O
or	CC	O
even	RB	O
harmful	JJ	O
.	.	O

Incentives	NNS	O
may	MD	O
undermine	VB	O
motivation	NN	Mental
in	IN	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
intrinsic	JJ	O
motivation	NN	O
of	IN	O
the	DT	O
respondents	NNS	O
is	VBZ	O
already	RB	O
high	JJ	O
.	.	O

Rye	NNP	O
bran	NN	O
bread	NN	O
intake	VB	O
elevates	NNS	O
urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
ferulic	JJ	Physical
acid	NN	Physical
in	IN	O
humans	NNS	O
,	,	O
but	CC	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
susceptibility	NN	Physical
of	IN	Physical
LDL	NNP	Physical
to	TO	Physical
oxidation	VB	Physical
ex	FW	O
vivo	FW	O
.	.	O

BACKGROUND	NNP	O
Rye	NNP	O
bread	NN	O
contributes	VBZ	O
an	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
whole	JJ	O
grain	NN	O
intake	NN	O
in	IN	O
the	DT	O
Scandinavian	JJ	O
diet	NN	O
.	.	O

Ferulic	NNP	O
acid	NN	O
is	VBZ	O
the	DT	O
major	JJ	O
phenolic	JJ	O
compound	NN	O
in	IN	O
rye	NN	O
bran	NN	O
and	CC	O
is	VBZ	O
an	DT	O
antioxidant	NN	O
in	IN	O
vitro	NN	O
and	CC	O
may	MD	O
,	,	O
therefore	RB	O
,	,	O
contribute	NN	O
to	TO	O
cardioprotective	JJ	O
effects	NNS	O
of	IN	O
whole	JJ	O
grain	NN	O
consumption	NN	O
.	.	O

AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
Firstly	NNP	O
,	,	O
to	TO	O
evaluate	VB	O
the	DT	O
bioavailability	NN	Others
and	CC	Adverseeffect
potential	JJ	Others
antioxidative	JJ	Others
effects	NNS	Others
in	IN	O
humans	NNS	O
of	IN	O
ferulic	JJ	O
acid	NN	O
from	IN	O
rye	NN	O
.	.	O

Secondly	RB	O
,	,	O
to	TO	O
evaluate	VB	O
urine	JJ	Physical
levels	NNS	Physical
of	IN	Physical
ferulic	JJ	Physical
acid	NN	Physical
as	IN	O
a	DT	O
possible	JJ	O
biomarker	NN	O
of	IN	O
the	DT	O
ordinary	JJ	O
dietary	JJ	O
intake	NN	O
of	IN	O
ferulic	JJ	O
acid	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
determined	VBD	O
the	DT	O
urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
ferulic	JJ	Physical
acid	NN	Physical
in	IN	O
18	CD	O
postmenopausal	JJ	O
women	NNS	O
after	IN	O
a	DT	O
dietary	JJ	O
intake	NN	O
of	IN	O
rye	NN	O
bran	NN	O
or	CC	O
an	DT	O
inert	JJ	O
wheat	NN	O
bran	NN	O
(	(	O
control	NN	O
)	)	O
in	IN	O
a	DT	O
crossover	NN	O
study	NN	O
(	(	O
2	CD	O
x	RB	O
6	CD	O
weeks	NNS	O
with	IN	O
4	CD	O
weeks	NNS	O
washout	NN	O
)	)	O
.	.	O

The	DT	O
potential	JJ	O
antioxidative	JJ	O
effect	NN	O
of	IN	O
the	DT	O
rye	NN	O
bran	NN	O
intervention	NN	O
was	VBD	O
investigated	VBN	O
by	IN	O
measuring	VBG	O
low-density	NN	Physical
lipoprotein	NN	Physical
(	(	Physical
LDL	NNP	Physical
)	)	Physical
susceptibility	NN	Physical
to	TO	Physical
copper	VB	Physical
oxidation	NN	Physical
ex	FW	Physical
vivo	NN	Physical
.	.	O

The	DT	O
subjects	NNS	O
ingested	VBN	O
rye	NN	O
bran	NN	O
enriched	VBD	O
breads	NNS	O
equivalent	JJ	O
to	TO	O
approximately	RB	O
10.2	CD	O
mg	NNS	O
ferulic	JJ	O
acid	JJ	O
per	IN	O
day	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
ferulic	JJ	Physical
acid	NNS	Physical
averaged	VBD	O
approximately	RB	O
4.8	CD	O
mg	NNS	O
per	IN	O
day	NN	O
during	IN	O
intervention	NN	O
with	IN	O
rye	NN	O
bran	NN	O
breads	NNS	O
and	CC	O
approximately	RB	O
1.9	CD	O
mg	NNS	O
per	IN	O
day	NN	O
on	IN	O
the	DT	O
control	NN	O
breads	VBZ	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Rye	NNP	O
bran	NN	O
intervention	NN	O
had	VBD	O
no	DT	O
influence	NN	O
on	IN	O
lag	NN	Physical
time	NN	Physical
or	CC	Physical
propagation	NN	Physical
rate	NN	Physical
of	IN	Physical
the	DT	Physical
LDL	NNP	Physical
oxidation	NN	Physical
ex	NN	O
vivo	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
ferulic	JJ	O
acid	NN	O
from	IN	O
rye	NN	O
bran	NN	O
is	VBZ	O
bioavailable	JJ	O
and	CC	O
that	IN	O
the	DT	O
urinary	JJ	O
concentration	NN	O
of	IN	O
ferulic	JJ	O
acid	NN	O
reflects	VBZ	O
the	DT	O
dietary	JJ	O
intake	NN	O
of	IN	O
this	DT	O
hydroxycinnamic	JJ	O
acid	NN	O
.	.	O

Within	IN	O
the	DT	O
period	NN	O
of	IN	O
intervention	NN	O
,	,	O
the	DT	O
elevated	JJ	O
ferulic	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
produce	VB	O
a	DT	O
measurable	JJ	O
antioxidative	JJ	Physical
effect	NN	Physical
on	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
LDL	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
determination	NN	O
of	IN	O
ferulic	JJ	O
acid	NN	O
in	IN	O
urine	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
biomarker	NN	O
to	TO	O
assess	VB	O
the	DT	O
intake	NN	Physical
of	IN	Physical
ferulic	JJ	Physical
acid	NN	Physical
from	IN	O
a	DT	O
regular	JJ	O
diet	NN	O
.	.	O

Effects	NNS	O
of	IN	O
strontium	NN	O
on	IN	O
the	DT	O
quality	NN	Physical
of	IN	Physical
bone	NN	Physical
apatite	JJ	Physical
crystals	NNS	Physical
:	:	Physical
a	DT	O
paired	JJ	O
biopsy	NN	O
study	NN	O
in	IN	O
postmenopausal	JJ	O
osteoporotic	JJ	O
women	NNS	O
.	.	O

UNLABELLED	NN	O
In	IN	O
paired	JJ	O
biopsies	NNS	O
of	IN	O
osteoporotic	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
either	DT	O
strontium	NN	O
ranelate	NN	O
or	CC	O
a	DT	O
placebo	NN	O
for	IN	O
36	CD	O
months	NNS	O
,	,	O
characteristics	NNS	O
of	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
were	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
strontium	NN	O
.	.	O

The	DT	O
mean	JJ	Others
rate	NN	Others
of	IN	Others
substitutions	NNS	Others
of	IN	O
calcium	NN	O
by	IN	O
strontium	NN	O
ions	NNS	O
was	VBD	O
4.5	CD	O
%	NN	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
potential	JJ	O
effect	NN	O
of	IN	O
strontium	NN	O
(	(	O
Sr	NNP	O
)	)	O
on	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
paired	JJ	O
biopsies	NNS	O
of	IN	O
osteoporotic	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
either	DT	O
strontium	NN	O
ranelate	NN	O
(	(	O
SrRan	NNP	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
for	IN	O
36	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
ten	NN	O
paired	JJ	O
biopsies	NNS	O
,	,	O
crystallinity	NN	Physical
,	,	Physical
apparent	JJ	Physical
length	NN	Physical
and	CC	Physical
width/thickness	NN	Physical
of	IN	Physical
crystals	NNS	Physical
,	,	Physical
interplanar	NN	Physical
distances	NNS	Physical
,	,	Physical
and	CC	Physical
lattice	JJ	Physical
parameters	NNS	Physical
of	IN	Physical
unit	NN	Physical
cells	NNS	Physical
were	VBD	O
assessed	VBN	O
by	IN	O
X-ray	JJ	O
diffraction	NN	O
and	CC	O
selected	VBN	O
area	NN	O
electron	NN	O
diffraction	NN	O
.	.	O

RESULTS	VB	O
All	PDT	O
these	DT	O
parameters	NNS	O
,	,	O
reflecting	VBG	O
crystal	NN	O
and	CC	O
unit	NN	O
cell	NN	O
characteristics	NNS	O
,	,	O
were	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
Sr	NNP	O
and	CC	O
were	VBD	O
similar	JJ	O
in	IN	O
SrRan	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
after	IN	O
36	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
mean	JJ	Physical
rate	NN	Physical
of	IN	Physical
substitutions	NNS	Physical
of	IN	Physical
calcium	NN	Physical
by	IN	Physical
Sr	NNP	Physical
ions	NNS	Physical
was	VBD	O
4.5	CD	O
%	NN	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
the	DT	O
quality	NN	Physical
of	IN	Physical
bone	NN	Physical
apatite	JJ	Physical
crystals	NNS	Physical
was	VBD	O
maintained	VBN	O
after	IN	O
36	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
SrRan	NNP	O
.	.	O

Expectancies	NNS	O
,	,	O
not	RB	O
aroma	RB	O
,	,	O
explain	JJ	O
impact	NN	O
of	IN	O
lavender	NN	O
aromatherapy	NN	O
on	IN	O
psychophysiological	JJ	O
indices	NNS	O
of	IN	O
relaxation	NN	O
in	IN	O
young	JJ	O
healthy	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
In	IN	O
aromatherapy	NN	O
,	,	O
lavender	JJR	O
aroma	NN	O
is	VBZ	O
reputed	VBN	O
to	TO	O
assist	VB	O
with	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
while	IN	O
there	EX	O
is	VBZ	O
much	JJ	O
anecdotal	JJ	O
evidence	NN	O
to	TO	O
that	DT	O
effect	NN	O
,	,	O
the	DT	O
empirical	JJ	O
literature	NN	O
is	VBZ	O
very	RB	O
inconsistent	JJ	O
.	.	O

Failure	NN	O
to	TO	O
employ	VB	O
adequate	JJ	O
placebos	NNS	O
,	,	O
proper	JJ	O
blinding	NN	O
,	,	O
objective	JJ	O
measures	NNS	O
,	,	O
or	CC	O
screening	NN	O
of	IN	O
prior	JJ	O
beliefs	NNS	O
about	IN	O
aromatherapy	NN	O
means	NNS	O
that	IN	O
many	JJ	O
previous	JJ	O
findings	NNS	O
could	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
sought	VBD	O
to	TO	O
establish	VB	O
whether	IN	O
lavender	NN	O
aroma	NN	O
and/or	JJ	O
expectancies	NNS	O
affect	VBP	O
post-stress	JJ	O
relaxation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
double-blind	NN	O
,	,	O
3	CD	O
(	(	O
aroma	NN	O
)	)	O
x	VBZ	O
3	CD	O
(	(	O
instruction	NN	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
time	NN	O
in	IN	O
minutes	NNS	O
)	)	O
mixed-factorial	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
laboratory	NN	O
,	,	O
96	CD	O
healthy	JJ	O
undergraduate	JJ	O
women	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
lavender	VB	O
,	,	O
placebo	NN	O
,	,	O
or	CC	O
no	DT	O
aroma	NN	O
during	IN	O
physiologically	RB	O
assessed	VBN	O
relaxation	NN	O
after	IN	O
an	DT	O
arousing	VBG	O
cognitive	JJ	O
task	NN	O
.	.	O

Where	WRB	O
an	DT	O
aroma	NN	O
was	VBD	O
presented	VBN	O
,	,	O
an	DT	O
instructional	JJ	O
priming	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
manipulate	VB	O
participants	NNS	O
'	POS	O
expectancies	NNS	O
about	IN	O
the	DT	O
aroma	NN	O
's	POS	O
likely	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
relax	VB	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
showed	VBD	O
no	DT	O
effect	NN	O
of	IN	O
aroma	NN	Others
on	IN	Others
galvanic	JJ	Others
skin	NN	Others
response	NN	Others
during	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
instructional	JJ	O
prime	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
relaxation	NN	Mental
patterns	NNS	Mental
:	:	O
when	WRB	O
expecting	VBG	O
the	DT	O
aroma	NN	O
to	TO	O
inhibit	VB	O
them	PRP	O
,	,	O
participants	NNS	O
relaxed	VBD	Mental
more	RBR	O
;	:	O
when	WRB	O
expecting	VBG	O
facilitation	NN	O
,	,	O
participants	NNS	O
relaxed	VBD	Mental
less	RBR	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
regard	NN	O
to	TO	O
self-reported	JJ	Mental
relaxation	NN	Mental
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
state	NN	O
anxiety	NN	O
)	)	O
and	CC	O
was	VBD	O
independent	JJ	O
of	IN	O
ratings	NNS	O
of	IN	O
attitudes	NNS	Mental
towards	NNS	O
aromatherapy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
imply	VBP	O
that	IN	O
the	DT	O
previous	JJ	O
associations	NNS	O
of	IN	O
lavender	NN	O
aroma	NN	O
with	IN	O
assisted	JJ	O
relaxation	NN	O
may	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
relevant	JJ	O
expectancies	NNS	O
are	VBP	O
easily	RB	O
manipulable	JJ	O
.	.	O

Effects	NNS	O
of	IN	O
short-term	JJ	O
isotonic	JJ	O
&	CC	O
isometric	JJ	O
training	NN	O
on	IN	O
cardiovascular	JJ	Physical
&	CC	Physical
pulmonary	JJ	Physical
function	NN	Physical
.	.	Physical

A	DT	O
randomised	JJ	O
control	NN	O
trial	NN	O
of	IN	O
short-term	JJ	O
exercises	NNS	O
on	IN	O
specific	JJ	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
parameters	NNS	O
was	VBD	O
undertaken	VBN	O
in	IN	O
normal	JJ	O
male	JJ	O
college	NN	O
students	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
isotonic	JJ	O
training	NN	O
(	(	O
5BX	CD	O
programme	NN	O
)	)	O
and	CC	O
isometric	JJ	O
training	NN	O
(	(	O
a	DT	O
programme	NN	O
of	IN	O
isometric	JJ	O
exercises	NNS	O
working	VBG	O
all	DT	O
major	JJ	O
groups	NNS	O
of	IN	O
muscles	NNS	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
with	IN	O
no	DT	O
specific	JJ	O
workout	NN	O
.	.	O

Both	DT	O
isotonic	JJ	O
and	CC	O
isometric	JJ	O
training	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	Physical
cardiovascular	JJ	Physical
improvement	NN	Physical
but	CC	O
seemed	VBD	O
inadequate	JJ	O
to	TO	O
improve	VB	O
vital	JJ	Physical
capacity	NN	Physical
and	CC	Physical
flow	NN	Physical
rates	NNS	Physical
.	.	Physical

Isotonic	JJ	O
training	NN	O
in	IN	O
addition	NN	O
,	,	O
improved	JJ	O
ventilatory	NN	Others
efficiency	NN	Others
.	.	Physical

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
such	JJ	O
isotonic	JJ	O
or	CC	O
isometric	JJ	O
training	NN	O
of	IN	O
thrice	NN	O
a	DT	O
week	NN	O
for	IN	O
ten	JJ	O
weeks	NNS	O
,	,	O
requiring	VBG	O
no	DT	O
equipment	NN	O
,	,	O
less	JJR	O
time	NN	O
and	CC	O
space	NN	O
can	MD	O
be	VB	O
promoted	VBN	O
to	TO	O
improve	VB	O
physical	JJ	Physical
fitness	NN	Physical
.	.	Physical

Pimecrolimus	NNP	O
cream	VBZ	O
1	CD	O
%	NN	O
vs.	FW	O
betamethasone	CD	O
17-valerate	JJ	O
0.1	CD	O
%	NN	O
cream	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
seborrhoeic	JJ	O
dermatitis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
open-label	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Seborrhoeic	NNP	O
dermatitis	NN	O
is	VBZ	O
a	DT	O
chronic	JJ	O
inflammatory	NN	O
disease	NN	O
with	IN	O
remissions	NNS	O
and	CC	O
exacerbations	NNS	O
,	,	O
characterized	VBN	O
by	IN	O
erythema	NN	O
,	,	O
scaling	VBG	O
and	CC	O
pruritus	JJ	O
primarily	RB	O
on	IN	O
the	DT	O
face	NN	O
,	,	O
scalp	NN	O
and	CC	O
chest	NN	O
.	.	O

Corticosteroids	NNP	O
and	CC	O
antifungals	NNS	O
are	VBP	O
the	DT	O
mainstay	NN	O
of	IN	O
therapy	NN	O
.	.	O

However	RB	O
,	,	O
chronic	JJ	O
use	NN	O
of	IN	O
corticosteroids	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
side-effects	NNS	O
such	JJ	O
as	IN	O
skin	JJ	O
atrophy	NN	O
and	CC	O
telangiectasia	NN	O
.	.	O

Pimecrolimus	NNP	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
calcineurin	NN	O
,	,	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
in	IN	O
one	CD	O
patient	NN	O
with	IN	O
seborrhoeic	JJ	O
dermatitis	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
open-label	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
pimecrolimus	NN	O
in	IN	O
comparison	NN	O
with	IN	O
a	DT	O
potent	NN	O
corticosteroid	NN	O
(	(	O
betamethasone	CD	O
17-valerate	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
seborrhoeic	JJ	O
dermatitis	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
patients	NNS	O
with	IN	O
seborrhoeic	JJ	O
dermatitis	NN	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
11	CD	O
patients	NNS	O
in	IN	O
the	DT	O
pimecrolimus	JJ	O
1	CD	O
%	NN	O
cream	NN	O
group	NN	O
and	CC	O
nine	CD	O
patients	NNS	O
in	IN	O
the	DT	O
betamethasone	NN	O
17-valerate	JJ	O
0.1	CD	O
%	NN	O
cream	NN	O
group	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
use	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
the	DT	O
study	NN	O
products	NNS	O
twice	RB	O
daily	RB	O
at	IN	O
the	DT	O
lesional	JJ	O
area	NN	O
and	CC	O
to	TO	O
discontinue	VB	O
treatment	NN	O
as	RB	O
soon	RB	O
as	IN	O
symptoms	NNS	O
were	VBD	O
absent	JJ	O
.	.	O

Clinical	JJ	O
measures	NNS	O
assessed	VBN	O
were	VBD	O
erythema	RB	Physical
,	,	Physical
scaling	VBG	Physical
and	CC	Physical
pruritus	NN	Physical
which	WDT	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
four-point	JJ	O
scale	NN	O
(	(	O
0-3	JJ	O
)	)	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
pimecrolimus	FW	O
and	CC	O
betamethasone	NN	O
were	VBD	O
highly	RB	O
effective	JJ	Others
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
seborrhoeic	JJ	O
dermatitis	NN	O
.	.	O

Betamethasone	NNP	O
reduced	VBD	O
all	DT	O
three	CD	O
parameters	NNS	O
,	,	O
erythema	NN	Physical
,	,	O
scaling	VBG	Physical
and	CC	O
pruritus	NN	Physical
,	,	O
faster	JJR	O
than	IN	O
pimecrolimus	NN	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
in	IN	O
reduction	NN	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Relapses	NNS	Physical
were	VBD	O
observed	VBN	O
more	RBR	O
frequently	RB	O
and	CC	O
were	VBD	O
more	JJR	O
severe	JJ	O
with	IN	O
betamethasone	NN	O
than	IN	O
with	IN	O
pimecrolimus	NN	O
.	.	O

Moreover	RB	O
,	,	O
pruritus	NN	Physical
was	VBD	O
not	RB	O
observed	VBN	O
after	IN	O
discontinuation	NN	O
of	IN	O
treatment	NN	O
from	IN	O
day	NN	O
15	CD	O
and	CC	O
beyond	IN	O
in	IN	O
the	DT	O
pimecrolimus	NN	O
group	NN	O
,	,	O
whereas	IN	O
it	PRP	O
was	VBD	O
reported	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
of	IN	O
the	DT	O
betamethasone	NN	O
group	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
appears	VBZ	O
that	IN	O
pimecrolimus	NN	O
,	,	O
a	DT	O
nonsteroidal	JJ	O
topical	JJ	O
treatment	NN	O
,	,	O
may	MD	O
be	VB	O
an	DT	O
excellent	JJ	O
alternative	JJ	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
treating	VBG	O
seborrhoeic	JJ	O
dermatitis	NN	O
.	.	O

Rizatriptan	NNP	O
5	CD	O
mg	NN	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	Physical
in	IN	O
adolescents	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
tolerability	NN	Others
and	CC	Others
efficacy	NN	Others
of	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
in	IN	O
adolescent	JJ	O
migraineurs	NNS	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
12	CD	O
to	TO	O
17	CD	O
years	NNS	O
received	VBD	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
149	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
for	IN	O
a	DT	O
moderate	JJ	O
or	CC	O
severe	JJ	O
headache	NN	O
and	CC	O
for	IN	O
up	RB	O
to	TO	O
two	CD	O
recurrences	NNS	O
.	.	O

Headache	NNP	Physical
severity	NN	Physical
,	,	O
presence	NN	Physical
or	CC	Physical
absence	NN	Physical
of	IN	Physical
associated	VBN	Physical
symptoms	NNS	Physical
,	,	O
and	CC	O
functional	JJ	Physical
disability	NN	Physical
were	VBD	O
assessed	VBN	O
over	IN	O
a	DT	O
4-hour	JJ	O
postdose	JJ	O
period	NN	O
,	,	O
and	CC	O
any	DT	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
was	VBD	O
pain-free	JJ	Pain
status	NN	Pain
at	IN	Pain
2	CD	Pain
hours	NNS	Pain
postdose	RB	Pain
.	.	O

RESULTS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
(	(	O
all	DT	O
with	IN	O
incidence	NN	O
of	IN	O
5	CD	O
%	NN	O
or	CC	O
less	JJR	O
)	)	O
among	IN	O
patients	NNS	O
receiving	VBG	O
rizatriptan	NNS	O
were	VBD	O
dry	JJ	Adverseeffect
mouth	NN	Adverseeffect
,	,	Adverseeffect
dizziness	NN	Adverseeffect
,	,	Adverseeffect
asthenia/fatigue	NN	Adverseeffect
,	,	Adverseeffect
nausea	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
somnolence	NN	Adverseeffect
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
pain-free	JJ	Pain
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
32	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
versus	NN	O
28	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.474	NNP	O
)	)	O
.	.	O

The	DT	O
percentage	NN	Pain
of	IN	Pain
patients	NNS	Pain
with	IN	Pain
pain	NN	Pain
relief	NN	Pain
(	(	O
reduction	NN	O
of	IN	O
predose	JJ	Pain
pain	NN	Pain
intensity	NN	Pain
to	TO	O
mild	VB	O
or	CC	O
none	NN	O
)	)	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
66	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
versus	NN	O
56	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.079	NNP	O
)	)	O
.	.	O

Placebo	NNP	Physical
response	NN	Physical
rates	NNS	Physical
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
typically	RB	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
rizatriptan	NN	O
in	IN	O
adults	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
rizatriptan	VBP	O
significantly	RB	O
improved	VBN	O
functional	JJ	Physical
disability	NN	Physical
at	IN	O
1.5	CD	O
and	CC	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
nausea	NN	Adverseeffect
at	IN	O
1	CD	O
and	CC	O
1.5	CD	O
hours	NNS	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rizatriptan	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
pain	NN	Pain
relief	NN	Pain
when	WRB	O
their	PRP$	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
weekends	NNS	O
(	(	O
65	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
,	,	O
P=.046	NNP	O
)	)	O
compared	VBN	O
with	IN	O
weekdays	NNS	O
(	(	O
66	CD	O
%	NN	O
versus	IN	O
61	CD	O
%	NN	O
,	,	O
P=.365	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
weekend	NN	O
placebo	NN	O
response	NN	Physical
rate	NN	Physical
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
adults	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
and	CC	Others
effective	JJ	Others
on	IN	O
some	DT	O
measures	NNS	O
when	WRB	O
used	VBN	O
in	IN	O
adolescents	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
migraine	JJ	O
attack	NN	O
.	.	O

Naltrexone	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
replication	NN	O
study	NN	O
and	CC	O
learning	NN	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
expanded	VBD	O
upon	RB	O
previous	JJ	O
work	NN	O
on	IN	O
naltrexone	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
and	CC	O
assessed	JJ	O
performance	NN	O
on	IN	O
learning	VBG	O
measures	NNS	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.0	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
,	,	O
bringing	VBG	O
to	TO	O
24	CD	O
the	DT	O
combined	VBN	O
study	NN	O
sample	NN	O
.	.	O

Naltrexone	NNP	O
,	,	O
1.0	CD	O
mg/kg	NN	O
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
were	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	Mental
Global	NNP	Mental
Impressions	NNP	Mental
(	(	Mental
CGI	NNP	Mental
)	)	Mental
and	CC	O
Naltrexone	NNP	Adverseeffect
Side	NNP	Adverseeffect
Effects	NNP	Adverseeffect
Rating	NNP	Adverseeffect
Scale	NNP	Adverseeffect
(	(	Adverseeffect
SE	NNP	Adverseeffect
)	)	Adverseeffect
,	,	Adverseeffect
Conners	NNPS	Mental
Parent	NNP	Mental
Impulsivity/Hyperactivity	NNP	Mental
Factor	NNP	Mental
,	,	O
Teacher	NNP	Mental
Hyperactivity	NNP	Mental
Factor	NNP	Mental
,	,	O
laboratory	NN	O
CGI	NNP	O
,	,	O
and	CC	O
analysis	NN	O
of	IN	O
videotaped	JJ	O
behavior	NN	O
.	.	O

Learning	VBG	O
measures	NNS	O
were	VBD	O
the	DT	O
Early	JJ	Mental
Intervention	NNP	Mental
Developmental	NNP	Mental
Profile-Language	NNP	Mental
and	CC	O
paired-associate	JJ	Others
learning	NN	Others
.	.	O

RESULTS	JJ	O
Comparisons	NNPS	O
between	IN	O
naltrexone	NN	O
and	CC	O
baseline	NN	O
,	,	O
but	CC	O
not	RB	O
naltrexone	RB	O
and	CC	O
placebo	NN	O
,	,	O
on	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
ratings	NNS	O
showed	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Three	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Side	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
mild	JJ	O
.	.	O

Administering	VBG	O
naltrexone	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

The	DT	O
combined	JJ	O
study	NN	O
sample	NN	O
showed	VBD	O
improvement	NN	O
on	IN	O
all	DT	O
parent	NN	Mental
measures	NNS	Mental
and	CC	O
on	IN	O
Teacher	NNP	Mental
CGI	NNP	Mental
and	CC	O
SE-Restlessness	NNP	Mental
compared	VBN	O
with	IN	O
baseline	NN	O
and	CC	O
placebo	NN	O
.	.	O

Eleven	NNP	O
of	IN	O
the	DT	O
24	CD	O
children	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Scores	NNS	O
on	IN	O
learning	VBG	Mental
measures	NNS	Mental
did	VBD	O
not	RB	O
change	VB	O
across	IN	O
conditions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	Mental
in	IN	O
11	CD	O
of	IN	O
24	CD	O
children	NNS	O
,	,	O
but	CC	O
learning	VBG	Mental
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Clinical	JJ	Physical
pharmacology	NN	Physical
of	IN	O
methadone	NN	O
in	IN	O
dogs	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
pharmacokinetics	NNS	Physical
and	CC	O
effects	NNS	Physical
of	IN	O
methadone	NN	O
on	IN	O
behaviour	NN	Mental
and	CC	O
plasma	JJ	Physical
concentrations	NNS	Physical
of	IN	Physical
cortisol	NN	Physical
and	CC	Physical
vasopressin	NN	Physical
in	IN	O
healthy	JJ	O
dogs	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Randomized	NNP	O
,	,	O
cross-over	NN	O
,	,	O
experimental	JJ	O
trial	NN	O
.	.	O

ANIMALS	NNP	O
Nine	NNP	O
adult	NN	O
dogs	NNS	O
(	(	O
beagle	NN	O
and	CC	O
beagle	NN	O
cross	NN	O
breeds	NNS	O
)	)	O
,	,	O
four	CD	O
males	NNS	O
and	CC	O
five	CD	O
females	NNS	O
.	.	O

METHODS	NNP	O
Methadone	NNP	O
hydrochloride	NN	O
,	,	O
0.4	CD	O
mg	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
and	CC	O
subcutaneously	RB	O
(	(	O
SC	NNP	O
)	)	O
with	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

Drug	NNP	Physical
and	CC	Physical
hormone	NN	Physical
analyses	NNS	Physical
in	IN	Physical
plasma	NN	Physical
were	VBD	O
performed	VBN	O
using	VBG	O
Liquid	NNP	O
Chromatography-Electrospray	NNP	O
Ionization-Tandem	NNP	O
Mass	NNP	O
Spectrometry	NNP	O
and	CC	O
radioimmunoassay	VB	O
respectively	RB	O
.	.	O

Behavioural	NNP	Mental
data	NNS	Mental
were	VBD	O
collected	VBN	O
using	VBG	O
a	DT	O
standardized	JJ	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
IV	NNP	O
administration	NN	O
,	,	O
the	DT	O
plasma	JJ	Physical
concentration	NN	Physical
of	IN	Physical
methadone	NN	Physical
at	IN	O
10	CD	O
minutes	NNS	O
was	VBD	O
82.1	CD	O
+/-	JJ	O
9.2	CD	O
ng	JJ	O
mL	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
the	DT	O
terminal	JJ	O
half-life	NN	O
was	VBD	O
3.9	CD	O
+/-	JJ	O
1.0	CD	O
hours	NNS	O
,	,	O
the	DT	O
volume	NN	O
of	IN	O
distribution	NN	O
9.2	CD	O
+/-	JJ	O
3.3	CD	O
L	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
and	CC	O
plasma	JJ	O
clearance	NN	O
27.9	CD	O
+/-	JJ	O
7.6	CD	O
mL	NNS	O
minute	NN	O
(	(	O
-1	NNP	O
)	)	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

After	IN	O
SC	NNP	O
administration	NN	O
,	,	O
time	NN	O
to	TO	O
maximal	VB	O
plasma	JJ	O
concentration	NN	O
was	VBD	O
1.26	CD	O
+/-	JJ	O
1.04	CD	O
hours	NNS	O
and	CC	O
maximal	JJ	Physical
plasma	NN	Physical
concentration	NN	Physical
of	IN	Physical
methadone	NN	Physical
was	VBD	O
23.9	CD	O
+/-	JJ	O
14.4	CD	O
ng	JJ	O
mL	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
the	DT	O
terminal	JJ	O
half-life	NN	O
was	VBD	O
10.7	CD	O
+/-	JJ	O
4.3	CD	O
hours	NNS	O
and	CC	O
bioavailability	NN	Physical
was	VBD	O
79	CD	O
+/-	JJ	O
22	CD	O
%	NN	O
.	.	O

Concentrations	NNS	Physical
of	IN	Physical
both	DT	Physical
cortisol	NNS	Physical
and	CC	Physical
vasopressin	NN	Physical
were	VBD	O
increased	VBN	O
for	IN	O
an	DT	O
hour	NN	O
following	VBG	O
IV	NNP	O
methadone	NN	O
.	.	O

The	DT	O
observed	JJ	O
behavioural	JJ	O
effects	NNS	O
of	IN	O
methadone	NN	O
were	VBD	O
decreased	VBN	O
licking	NN	Mental
and	CC	Mental
swallowing	NN	Mental
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
whining	VBG	Mental
after	IN	O
SC	NNP	O
administration	NN	O
.	.	O

The	DT	O
latter	JJ	O
finding	NN	O
is	VBZ	O
notable	JJ	O
as	IN	O
it	PRP	O
can	MD	O
be	VB	O
misinterpreted	VBN	O
as	IN	O
pain	NN	Pain
when	WRB	O
methadone	NN	O
is	VBZ	O
used	VBN	O
as	IN	O
an	DT	O
analgesic	JJ	O
.	.	O

CONCLUSION	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
When	WRB	O
methadone	NN	O
was	VBD	O
administered	VBN	O
by	IN	O
the	DT	O
SC	NNP	O
route	NN	O
,	,	O
the	DT	O
half-life	NN	O
was	VBD	O
longer	RBR	O
,	,	O
but	CC	O
the	DT	O
individual	JJ	O
variation	NN	Physical
in	IN	Physical
plasma	JJ	Physical
concentrations	NNS	Physical
was	VBD	O
greater	JJR	O
compared	VBN	O
with	IN	O
IV	NNP	O
administration	NN	O
.	.	O

Increased	VBD	O
frequency	NN	Mental
of	IN	Mental
whining	VBG	Mental
occurred	VBN	O
after	IN	O
administration	NN	O
of	IN	O
methadone	NN	O
and	CC	O
may	MD	O
be	VB	O
a	DT	O
drug	NN	O
effect	NN	O
and	CC	O
not	RB	O
a	DT	O
sign	NN	O
of	IN	O
pain	NN	O
.	.	O

Cortisol	NNP	Mental
and	CC	Mental
vasopressin	JJ	Mental
concentrations	NNS	Mental
in	IN	Mental
plasma	NN	Mental
may	MD	O
not	RB	O
be	VB	O
suitable	JJ	O
for	IN	O
evaluating	VBG	O
analgesia	NN	Pain
after	IN	O
methadone	NN	O
treatment	NN	O
.	.	O

Diode	NNP	O
laser	NN	O
photocoagulation	NN	O
for	IN	O
threshold	JJ	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
peripheral	JJ	O
cryotherapy	NN	O
decreases	VBZ	O
the	DT	O
incidence	NN	O
of	IN	O
unfavorable	JJ	O
anatomic	JJ	O
outcomes	NNS	O
in	IN	O
threshold	JJ	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
(	(	O
ROP	NNP	O
)	)	O
,	,	O
apnea	RB	O
,	,	O
bradycardia	NN	O
,	,	O
and	CC	O
lid	JJ	O
edema	NN	O
can	MD	O
occur	VB	O
.	.	O

Argon	NNP	O
laser	NN	O
indirect	JJ	O
ophthalmoscope	NN	O
photocoagulation	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
cryotherapy	VB	O
,	,	O
with	IN	O
fewer	JJR	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

Retinal	JJ	O
lesions	NNS	O
placed	VBN	O
with	IN	O
diode	NN	O
lasers	NNS	O
are	VBP	O
deeper	JJR	O
than	IN	O
similar	JJ	O
argon	NN	O
laser	NN	O
lesions	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
difference	NN	O
could	MD	O
influence	VB	O
the	DT	O
response	NN	Others
to	TO	O
ablative	JJ	O
therapy	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
enrolled	VBN	O
under	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
protocol	NN	O
.	.	O

One	CD	O
eye	NN	O
of	IN	O
each	DT	O
patient	NN	O
with	IN	O
symmetric	JJ	O
,	,	O
threshold	JJ	O
ROP	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
an	DT	O
814/815	CD	O
nm	JJ	O
diode	NN	O
laser	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
eye	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
cryotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
asymmetric	JJ	O
diseases	NNS	O
also	RB	O
were	VBD	O
randomized	VBN	O
for	IN	O
treatment	NN	O
in	IN	O
the	DT	O
threshold	NN	O
eye	NN	O
.	.	O

RESULTS	NNP	O
Nineteen	JJ	O
infants	NNS	O
(	(	O
33	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
treated	VBN	O
,	,	O
ranging	VBG	O
from	IN	O
485	CD	O
to	TO	O
863	CD	O
g	NNS	O
birth	JJ	O
weight	NN	O
(	(	O
23	CD	O
to	TO	O
27	CD	O
weeks	NNS	O
gestational	JJ	O
age	NN	O
)	)	O
;	:	O
18	CD	O
patients	NNS	O
(	(	O
32	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
followed	VBN	O
for	IN	O
3	CD	O
months	NNS	O
or	CC	O
longer	JJR	O
.	.	O

Four	CD	O
patients	NNS	O
(	(	O
8	CD	O
eyes	NNS	O
)	)	O
had	VBD	O
bilateral	JJ	O
zone	CD	O
1	CD	O
disease	NN	O
.	.	O

Postconceptional	JJ	O
age	NN	O
was	VBD	O
36	CD	O
to	TO	O
45	CD	O
weeks	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
diode	NN	O
laser	NN	O
treatment	NN	O
was	VBD	O
better	RBR	O
tolerated	VBN	Others
than	IN	O
cryotherapy	NN	O
,	,	O
and	CC	O
the	DT	O
treatment	NN	O
apparatus	NN	O
was	VBD	O
more	RBR	O
easily	RB	O
transported	VBN	O
.	.	O

Apneic	NNP	Physical
episodes	VBZ	Physical
requiring	VBG	Physical
intubation	NN	Physical
resulted	VBD	O
from	IN	O
two	CD	O
cryotherapy	NN	O
sessions	NNS	O
but	CC	O
no	DT	O
diode	NN	O
laser	NN	O
sessions	NNS	O
.	.	O

Five	CD	O
cryotherapy-treated	JJ	O
eyes	NNS	O
required	VBN	O
retreatment	NN	Others
because	IN	O
of	IN	O
persistent	JJ	O
disease	NN	O
with	IN	O
adjacent	JJ	O
skip	NN	O
areas	NNS	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
followed	VBD	O
for	IN	O
3	CD	O
to	TO	O
15	CD	O
months	NNS	O
,	,	O
1	CD	O
cryotherapy-treated	JJ	O
eye	NN	O
and	CC	O
1	CD	O
diode	NN	O
laser-treated	JJ	O
eye	NN	O
progressed	VBD	Physical
to	TO	Physical
stage	VB	Physical
5	CD	Physical
retinal	JJ	Physical
detachment	NN	Physical
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
cryotherapy	NN	O
,	,	O
the	DT	O
diode	NN	O
laser	NN	O
was	VBD	O
more	RBR	O
convenient	JJ	O
,	,	O
technically	RB	O
easier	JJR	O
to	TO	O
administer	VB	O
,	,	O
and	CC	O
better	RB	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

Although	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
was	VBD	O
too	RB	O
small	JJ	O
for	IN	O
meaningful	JJ	O
statistical	JJ	O
analysis	NN	O
of	IN	O
outcome	NN	O
,	,	O
diode	VB	O
laser	RBR	O
peripheral	JJ	O
retinal	JJ	O
ablation	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
cryotherapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
threshold	JJ	O
ROP	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
fenoterol	NN	O
on	IN	O
inspiratory	JJ	O
effort	NN	O
sensation	NN	O
and	CC	O
fatigue	NN	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	O
on	IN	O
the	DT	O
relationship	NN	O
between	IN	O
inspiratory	NN	O
effort	NN	O
sensation	NN	O
(	(	O
IES	NNP	O
)	)	O
and	CC	O
inspiratory	JJ	O
muscle	NN	O
fatigue	NN	O
induced	VBN	O
by	IN	O
inspiratory	NN	O
threshold	NN	O
loading	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
threshold	NN	O
was	VBD	O
60	CD	O
%	NN	O
of	IN	O
maximal	JJ	O
static	JJ	O
inspiratory	NN	O
mouth	NN	O
pressure	NN	O
(	(	O
PI	NNP	O
,	,	O
mmax	NN	O
)	)	O
at	IN	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
,	,	O
and	CC	O
the	DT	O
duty	NN	O
cycle	NN	O
was	VBD	O
0.5	CD	O
.	.	O

Subjects	NNS	O
continued	VBD	O
the	DT	O
threshold	NN	O
loaded	VBD	O
breathing	NN	O
until	IN	O
the	DT	O
target	NN	O
mouth	NN	O
pressure	NN	O
could	MD	O
no	RB	O
longer	RB	O
be	VB	O
maintained	VBN	O
(	(	O
endurance	JJ	O
time	NN	O
)	)	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
was	VBD	O
scored	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
Borg	NNP	O
scale	NN	O
.	.	O

Either	CC	O
fenoterol	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
given	VBN	O
orally	RB	O
2	CD	O
h	NN	O
before	IN	O
loading	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
protocol	NN	O
.	.	O

The	DT	O
endurance	NN	Physical
time	NN	Physical
with	IN	O
fenoterol	NN	O
(	(	O
34.4	CD	O
+/-	JJ	O
8.6	CD	O
min	NN	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
22.2	CD	O
+/-	JJ	O
7.1	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	Physical
of	IN	Physical
high-	JJ	Physical
to	TO	Physical
low-frequency	JJ	Physical
power	NN	Physical
of	IN	Physical
the	DT	Physical
diaphragmatic	JJ	Physical
electromyogram	NN	Physical
(	(	Physical
EMGdi	NNP	Physical
)	)	Physical
decreased	VBD	O
during	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
less	RBR	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
EMGdi	NNP	Physical
also	RB	O
decreased	VBD	O
with	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
greater	JJR	O
on	IN	O
fenoterol	NN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
PI	NNP	Physical
,	,	Physical
mmax	NN	Physical
and	CC	Physical
maximal	JJ	Physical
transdiaphragmatic	JJ	Physical
pressure	NN	Physical
(	(	Physical
Pdi	NNP	Physical
)	)	Physical
were	VBD	O
similarly	RB	O
decreased	VBN	O
after	IN	O
loading	VBG	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
intensity	NN	Physical
of	IN	Physical
the	DT	Physical
IES	NNP	Physical
rose	VBD	Physical
with	IN	Physical
time	NN	Physical
during	IN	O
loading	VBG	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
lower	JJR	O
with	IN	O
fenoterol	NN	O
than	IN	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	Physical
of	IN	Physical
Pdi	NNP	Physical
to	TO	O
integrated	JJ	O
activity	NN	O
of	IN	O
the	DT	O
EMGdi	NNP	O
increased	VBD	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fenoterol	NNP	O
treatment	NN	O
increased	VBD	O
both	DT	O
superimposed	VBN	Physical
Pdi	NNP	Physical
twitch	NN	Physical
and	CC	Physical
Pdi	NNP	Physical
twitch	NN	Physical
of	IN	Physical
relaxed	JJ	Physical
diaphragm	NN	Physical
and	CC	O
decreased	VBD	O
the	DT	O
value	NN	Physical
of	IN	Physical
(	(	Physical
1-superimposed	JJ	Physical
Pdi	NNP	Physical
twitch/Pdi	NN	Physical
twitch	NN	Physical
of	IN	Physical
relaxed	JJ	Physical
diaphragm	NN	Physical
)	)	Physical
.	.	Physical

Thus	IN	O
we	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
fenoterol	JJ	O
reduces	NNS	O
diaphragmatic	JJ	O
fatigue	NN	O
and	CC	O
decreases	VBZ	O
the	DT	O
motor	NN	O
command	NN	O
to	TO	O
the	DT	O
diaphragm	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
IES	NNP	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
endurance	NN	O
.	.	O

[	VB	O
The	DT	O
effect	NN	O
of	IN	O
losartan	JJ	O
versus	NN	O
atenolol	NN	O
on	IN	O
cardiovascular	JJ	Mortality
morbidity	NN	Mortality
and	CC	Mortality
mortality	NN	Mortality
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
in	IN	O
the	DT	O
LIFE-study	NNP	O
]	NNP	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
most	RBS	O
suitable	JJ	O
antihypertensive	JJ	O
drug	NN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
diabetes	VBZ	O
is	VBZ	O
unclear	JJ	O
.	.	O

In	IN	O
a	DT	O
prespecified	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
LIFE-study	NNP	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
losartan	NN	O
and	CC	O
atenolol	NN	O
on	IN	O
cardiovascular	JJ	Physical
morbidity	NN	Physical
and	CC	Physical
mortality	NN	Mortality
in	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
1195	CD	O
patients	NNS	O
in	IN	O
the	DT	O
LIFE-study	NNP	O
had	VBD	O
diabetes	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
randomisation	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
for	IN	O
double-blind	JJ	O
treatment	NN	O
with	IN	O
losartan	JJ	O
versus	NN	O
atenolol	NN	O
.	.	O

The	DT	O
patients	NNS	O
had	VBD	O
ECG-verified	JJ	O
left	JJ	O
ventricular	NN	O
hypertrophy	NN	O
,	,	O
mean	JJ	O
age	NN	O
67	CD	O
years	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
177/96	CD	O
mmHg	NN	O
after	IN	O
two	CD	O
weeks	NNS	O
placebo	JJ	O
run-in	JJ	O
period	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
at	IN	O
least	JJS	O
four	CD	O
years	NNS	O
(	(	O
mean	JJ	O
4.7	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
composite	JJ	O
endpoint	NN	O
was	VBD	O
cardiovascular	JJ	Physical
death	NN	Physical
,	,	Physical
stroke	VBD	Physical
or	CC	Physical
myocardial	JJ	Physical
infarction	NN	Physical
.	.	O

RESULTS	NNP	O
Blood	NNP	Physical
pressure	NN	Physical
was	VBD	O
reduced	VBN	O
to	TO	O
146/79	CD	O
and	CC	O
148/79	CD	O
in	IN	O
losartan-treated	JJ	O
patients	NNS	O
and	CC	O
atenolol-treated	JJ	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
occurred	VBD	O
in	IN	O
103	CD	O
patients	NNS	O
assigned	VBN	O
losartan	JJ	O
(	(	O
n	JJ	O
=	NNP	O
586	CD	O
)	)	O
and	CC	O
139	CD	O
assigned	VBN	O
atenolol	NN	O
(	(	O
n	JJ	O
=	NNP	O
609	CD	O
)	)	O
.	.	O

Relative	JJ	Physical
risk	NN	Physical
reduction	NN	Physical
24	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.031	CD	O
)	)	O
.	.	O

Cardiovascular	JJ	Physical
mortality	NN	Physical
was	VBD	O
reduced	VBN	O
by	IN	O
37	CD	O
%	NN	O
in	IN	O
favour	NN	O
of	IN	O
losartan	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.028	CD	O
)	)	O
,	,	O
and	CC	O
all	DT	O
cause	NN	O
mortality	NN	Mortality
by	IN	O
39	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.002	CD	O
)	)	O
.	.	O

DISCUSSION	NNP	O
Losartan	NNP	O
was	VBD	O
very	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
cardiovascular	JJ	Physical
morbidity	NN	Physical
and	CC	Physical
mortality	NN	Mortality
as	RB	O
compared	VBN	O
to	TO	O
atenolol	VB	O
.	.	O

These	DT	O
results	NNS	O
will	MD	O
have	VB	O
a	DT	O
major	JJ	O
impact	NN	O
on	IN	O
the	DT	O
choice	NN	O
of	IN	O
anti-hypertensive	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
diabetes	NNS	O
.	.	O

Perioperative	JJ	O
enteral	JJ	O
nutrition	NN	O
and	CC	O
quality	NN	Others
of	IN	Others
life	NN	Others
of	IN	O
severely	RB	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
perioperative	JJ	O
nutritional	JJ	O
support	NN	O
on	IN	O
Quality	NN	Others
of	IN	Others
Life	NNP	Others
(	(	Others
QOL	NNP	Others
)	)	Others
in	IN	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

METHODS	NNP	O
49	CD	O
Malnourished	NNP	O
(	(	O
weight	JJ	O
loss	NN	O
>	VBZ	O
10	CD	O
%	NN	O
)	)	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
who	WP	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
nutrition	NN	O
intervention	NN	O
trial	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
preoperative	JJ	O
and	CC	O
standard	JJ	O
postoperative	JJ	O
tube-feeding	NN	O
(	(	O
group	NN	O
I	PRP	O
)	)	O
,	,	O
standard	JJ	O
preoperative	NN	O
and	CC	O
postoperative	JJ	O
tube-feeding	NN	O
(	(	O
group	NN	O
II	NNP	O
)	)	O
or	CC	O
arginine-supplemented	JJ	O
preoperative	NN	O
and	CC	O
postoperative	JJ	O
tube-feeding	NN	O
(	(	O
group	NN	O
III	NNP	O
)	)	O
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
31	CD	O
completed	VBD	O
a	DT	O
full	JJ	O
QOL	NNP	Others
assessment	NN	Others
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
preoperative	JJ	O
nutritional	JJ	O
support	NN	O
,	,	O
one	CD	O
day	NN	O
before	IN	O
surgery	NN	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Both	CC	O
a	DT	O
disease-specific	NN	O
(	(	O
EORTC	NNP	O
QLQ-C30	NNP	O
)	)	O
and	CC	O
a	DT	O
generic	JJ	O
questionnaire	NN	O
(	(	O
COOP-WONCA	NNP	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O

One	CD	O
way	NN	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
and	CC	O
the	DT	O
Kruskal-Wallis	NNP	O
test	NN	O
were	VBD	O
applied	VBN	O
for	IN	O
testing	VBG	O
differences	NNS	O
in	IN	O
scores	NNS	O
between	IN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
baseline	NN	O
and	CC	O
the	DT	O
day	NN	O
before	IN	O
surgery	NN	O
,	,	O
both	DT	O
preoperatively	RB	O
fed	VBN	O
groups	NNS	O
revealed	VBD	O
a	DT	O
positive	JJ	O
change	NN	O
for	IN	O
the	DT	O
dimensions	NNS	O
physical	JJ	Mental
and	CC	Mental
emotional	JJ	Mental
functioning	NN	Mental
and	CC	O
dyspnea	NN	Physical
(	(	O
with	IN	O
significance	NN	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
P=0.050,0.031,0.045	NNP	O
respectively	RB	O
)	)	O
.	.	O

Group	NNP	O
III	NNP	O
showed	VBD	O
a	DT	O
negative	JJ	O
change	NN	O
in	IN	O
appetite	NN	Physical
(	(	O
P=0.049	NNP	O
)	)	O
.	.	O

Between	NNP	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
group	NN	O
I	PRP	O
and	CC	O
both	DT	O
pre-fed	JJ	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
favour	NN	O
of	IN	O
group	NN	O
III	NNP	O
compared	VBN	O
to	TO	O
group	NN	O
II	NNP	O
.	.	O

CONCLUSION	NNP	O
Enteral	NNP	O
nutrition	NN	O
improves	VBZ	O
QOL	NNP	Others
of	IN	O
severely	RB	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
in	IN	O
the	DT	O
period	NN	O
preceding	VBG	O
surgery	NN	O
.	.	O

No	DT	O
benefit	NN	O
of	IN	O
preoperative	JJ	O
enteral	JJ	O
feeding	NN	O
on	IN	O
QOL	NNP	Others
could	MD	O
be	VB	O
demonstrated	VBN	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Nitrous	JJ	O
oxide	JJ	O
diffusion	NN	O
into	IN	O
tracheal	JJ	O
tube	JJ	O
cuffs	NNS	Physical
--	:	Physical
efficacy	NN	Others
of	IN	O
a	DT	O
new	JJ	O
prototype	NN	O
cuff	NN	O
pressure	NN	O
release	NN	O
valve	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	Others
of	IN	O
a	DT	O
new	JJ	O
cuff	NN	Physical
pressure	NN	Physical
release	NN	O
valve	NN	O
(	(	O
CPRV	NNP	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
release	NN	O
pressure	NN	O
can	MD	O
be	VB	O
adjusted	VBN	O
from	IN	O
10	CD	O
to	TO	O
25	CD	O
cmH2O	NNS	O
,	,	O
particularly	RB	O
intended	VBN	O
to	TO	O
control	VB	O
pressure	NN	O
in	IN	O
paediatric	JJ	O
cuffed	NN	O
tracheal	NN	O
tubes	NNS	O
and	CC	O
to	TO	O
avoid	VB	O
cuff	NN	O
hyperinflation	NN	O
caused	VBN	O
by	IN	O
N2O	NNP	O
diffusion	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
vitro	NN	O
:	:	O
the	DT	O
PRV	NNP	O
was	VBD	O
set	VBN	O
to	TO	O
10	CD	O
,	,	O
15	CD	O
,	,	O
20	CD	O
or	CC	O
25	CD	O
cmH2O	JJ	O
release	NN	O
pressure	NN	O
and	CC	O
connected	VBN	O
to	TO	O
a	DT	O
cuffed	NN	O
tube	NN	O
placed	VBD	O
into	IN	O
a	DT	O
box	NN	O
flushed	VBN	O
with	IN	O
66	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
.	.	O

The	DT	O
cuff	NN	Physical
pressure	NN	Physical
was	VBD	O
monitored	VBN	O
with	IN	O
and	CC	O
without	IN	O
CPRV	NNP	O
for	IN	O
60	CD	O
min	NN	O
.	.	O

Experiments	NNS	O
were	VBD	O
performed	VBN	O
four	CD	O
times	NNS	O
using	VBG	O
two	CD	O
different	JJ	O
CPRVs	NNP	O
.	.	O

In	IN	O
vivo	NN	O
:	:	O
with	IN	O
Institutional	NNP	O
Review	NNP	O
Board	NNP	O
approval	NN	O
,	,	O
CPRV	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
50	CD	O
children	NNS	O
undergoing	VBG	O
general	JJ	O
anaesthesia	NN	O
with	IN	O
tracheal	JJ	O
intubation	NN	O
and	CC	O
standardized	JJ	O
anaesthesia	NN	O
technique	NN	O
(	(	O
including	VBG	O
66	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
)	)	O
and	CC	O
ventilator	JJ	O
settings	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
CPRV	NNP	O
)	)	O
.	.	O

The	DT	O
cuff	JJ	Physical
pressure	NN	Physical
baseline	NN	O
was	VBD	O
20	CD	O
cmH2O	NN	O
and	CC	O
CPRV	NNP	O
was	VBD	O
set	VBN	O
to	TO	O
25	CD	O
cmH2O	NN	O
.	.	O

If	IN	O
the	DT	O
cuff	NN	Physical
pressure	NN	Physical
exceeded	VBD	O
25	CD	O
cmH2O	NN	O
,	,	O
it	PRP	O
was	VBD	O
manually	RB	O
released	VBN	O
to	TO	O
20	CD	O
cmH2O	NN	O
.	.	O

The	DT	O
numbers	NNS	O
of	IN	O
deflations	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
noted	VBN	O
and	CC	O
compared	VBN	O
by	IN	O
Mann-Whitney	NNP	O
U-test	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
vitro	NN	O
:	:	O
the	DT	O
cuff	NN	Physical
pressure	NN	Physical
exceeded	VBD	O
50	CD	O
cmH2O	NN	O
after	IN	O
60	CD	O
min	NN	O
without	IN	O
CPRV	NNP	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
settings	NNS	O
with	IN	O
CPRV	NNP	O
.	.	O

In	IN	O
vivo	NN	O
:	:	O
there	EX	O
was	VBD	O
no	DT	O
need	NN	O
to	TO	O
manually	RB	O
deflate	VB	O
the	DT	O
cuff	NN	O
in	IN	O
the	DT	O
CPRV	NNP	O
group	NN	O
but	CC	O
,	,	O
in	IN	O
every	DT	O
patient	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
three	CD	O
(	(	O
two	CD	O
to	TO	O
seven	CD	O
)	)	O
deflating	VBG	O
manoeuvres	NNS	O
were	VBD	O
required	VBN	O
within	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
anaesthesia	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
CPRV	NNP	O
allows	VBZ	O
reliable	JJ	Physical
cuff	NN	Physical
pressure	NN	Physical
release	NN	Physical
at	IN	O
various	JJ	O
pressure	NN	O
levels	NNS	O
and	CC	O
reliably	RB	O
prevents	NNS	O
cuff	JJ	Physical
pressure	NN	Physical
increases	NNS	O
caused	VBN	O
by	IN	O
N2O	NNP	O
.	.	O

Effect	NN	O
of	IN	O
perception	NN	O
of	IN	O
mechanical	JJ	O
loading	NN	O
on	IN	O
human	JJ	Physical
respiratory	NN	Physical
pattern	NN	Physical
regulation	NN	O
.	.	O

We	PRP	O
applied	VBD	O
external	JJ	O
flow	NN	O
resistive	NN	O
(	(	O
R	NNP	O
)	)	O
and	CC	O
elastic	JJ	O
(	(	O
E	NNP	O
)	)	O
mechanical	JJ	O
loads	NNS	O
over	IN	O
the	DT	O
entire	JJ	O
respiratory	NN	O
cycle	NN	O
to	TO	O
five	CD	O
normal	JJ	O
subjects	NNS	O
by	IN	O
using	VBG	O
a	DT	O
pseudorandom	NN	O
loading	VBG	O
protocol	NN	O
.	.	O

Loads	NNP	O
ranged	VBD	O
in	IN	O
magnitude	NN	O
from	IN	O
imperceptible	JJ	O
(	(	O
R0/E0	NNP	O
)	)	O
through	IN	O
just	RB	O
perceptible	JJ	O
(	(	O
R1/E1	NNP	O
)	)	O
to	TO	O
large	JJ	O
(	(	O
R2/E2	NNP	O
)	)	O
and	CC	O
resulted	VBN	O
in	IN	O
respiratory	NN	O
pattern	NN	O
responses	NNS	O
that	WDT	O
were	VBD	O
due	JJ	O
to	TO	O
reflex	JJ	O
responses	NNS	O
alone	RB	O
(	(	O
R0/E0	NNP	O
)	)	O
or	CC	O
to	TO	O
a	DT	O
combination	NN	O
of	IN	O
reflex	JJ	O
responses	NNS	O
and	CC	O
behavioral	JJ	O
reactions	NNS	O
to	TO	O
the	DT	O
perception	NN	O
of	IN	O
impeded	JJ	O
breathing	NN	O
(	(	O
R1/E1	NNP	O
and	CC	O
R2/E2	NNP	O
)	)	O
.	.	O

Pattern	NNP	Physical
regulation	NN	Physical
dynamics	NNS	Physical
were	VBD	O
estimated	VBN	O
from	IN	O
the	DT	Physical
computed	VBN	Physical
impulse	JJ	Physical
responses	NNS	Physical
of	IN	Physical
tidal	JJ	Physical
volume	NN	Physical
and	CC	Physical
inspiratory	NN	Physical
and	CC	Physical
expiratory	JJ	Physical
durations	NNS	Physical
.	.	O

We	PRP	O
anticipated	VBD	O
that	IN	O
emergence	NN	O
of	IN	O
behavioral	JJ	O
contributions	NNS	O
would	MD	O
be	VB	O
marked	VBN	O
by	IN	O
increased	JJ	O
variability	NN	Physical
in	IN	Physical
response	NN	Physical
strategies	NNS	Physical
and	CC	O
by	IN	O
increased	JJ	O
nonlinearity	NN	Physical
in	IN	O
the	DT	O
observed	JJ	O
responses	NNS	O
.	.	O

Regarding	VBG	O
the	DT	O
immediate	JJ	O
pattern	NN	O
response	NN	O
to	TO	O
loading	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
tendency	NN	O
for	IN	O
increased	JJ	O
qualitative	JJ	Physical
variation	NN	Physical
across	NN	O
subjects	NNS	O
as	IN	O
the	DT	O
load	NN	O
size	NN	O
increased	VBD	O
,	,	O
but	CC	O
the	DT	O
within-subject	JJ	O
variability	NN	O
(	(	O
coefficient	NN	O
of	IN	O
variation	NN	O
)	)	O
was	VBD	O
unaffected	JJ	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
evidence	NN	O
for	IN	O
increased	JJ	O
nonlinearity	NN	O
as	IN	O
loads	NNS	O
became	VBD	O
perceptible	JJ	O
.	.	O

The	DT	O
emergence	NN	O
of	IN	O
behavioral	JJ	O
control	NN	O
in	IN	O
some	DT	O
instances	NNS	O
seemed	VBD	O
to	TO	O
be	VB	O
marked	VBN	O
by	IN	O
reduction	NN	O
of	IN	O
complexity	NN	O
of	IN	O
the	DT	O
impulse	JJ	O
response	NN	O
to	TO	O
one	CD	O
dominated	VBN	O
by	IN	O
the	DT	O
zeroth-order	NN	O
lag	NN	O
,	,	O
leading	VBG	O
to	TO	O
dynamically	RB	O
simpler	VB	O
responses	NNS	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

Fusidic	NNP	O
acid	VBZ	O
prophylaxis	NN	O
before	IN	O
cataract	JJ	O
surgery	NN	O
:	:	O
patient	JJ	O
self-administration	NN	O
.	.	O

In	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
authors	NNS	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
patient-administered	JJ	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
viscous	JJ	O
eye	NN	O
drops	NNS	O
in	IN	O
clearing	VBG	O
the	DT	O
commonest	JJS	O
organisms	JJ	O
causing	VBG	O
pseudophakic	NN	O
endophthalmitis	NN	O
(	(	O
Staphylococcus	NNP	O
epidermidis	RB	O
and	CC	O
aureus	RB	O
)	)	O
from	IN	O
the	DT	O
lids	NNS	O
and	CC	O
conjunctivae	NN	O
of	IN	O
79	CD	O
patients	NNS	O
before	IN	O
cataract	JJ	O
surgery	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
self-administered	JJ	O
fusidic	JJ	O
acid	NN	O
viscous	JJ	O
eye	NN	O
drops	VBZ	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
;	:	O
the	DT	O
placebo	NN	O
group	NN	O
received	VBD	O
inert	JJ	O
ophthalmic	JJ	O
drops	NNS	O
.	.	O

Fellow	NNP	O
eyes	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
remained	VBD	O
untreated	JJ	O
as	IN	O
a	DT	O
natural	JJ	O
control	NN	O
.	.	O

Lower	JJR	O
fornix	NN	O
and	CC	O
lid	JJ	O
margin	NN	O
cultures	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
both	DT	O
eyes	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Before	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
organism	NN	Physical
counts	NNS	Physical
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
eyes	NNS	O
receiving	VBG	O
fusidic	JJ	O
acid	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
free	JJ	O
of	IN	O
clinically	RB	O
relevant	JJ	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

than	IN	O
all	DT	O
pre-treatment	JJ	O
eyes	NNS	O
(	(	O
for	IN	O
lids	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
conjunctivae	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
number	NN	Physical
of	IN	Physical
lid	JJ	Physical
margins	NNS	Physical
were	VBD	O
rendered	VBN	O
'clinically	RB	O
clean	JJ	O
'	''	O
(	(	O
i.e.	FW	O
,	,	O
0-49	JJ	O
organisms/swab	NN	O
)	)	O
by	IN	O
fusidic	JJ	O
acid	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
untreated	JJ	O
eyes	NNS	O
.	.	O

Treatment	NNP	O
also	RB	O
effectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
reduced	VBD	O
the	DT	O
numbers	NNS	Physical
of	IN	Physical
bacteria	NNS	Physical
isolated	VBN	Physical
from	IN	Physical
conjunctivae	NN	Physical
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
Staphylococcus	NNP	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
non-Staphylococcus	JJ	O
spp	NN	O
.	.	O

(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
attainment	NN	O
of	IN	O
sterile	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
at	IN	O
operation	NN	O
gained	VBN	O
by	IN	O
patient	JJ	O
self-administration	NN	O
of	IN	O
1	CD	O
%	NN	O
fusidic	JJ	O
acid	RB	O
four	CD	O
times	NNS	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
before	IN	O
surgery	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
sedative	JJ	O
drugs	NNS	O
under	IN	O
peribulbar	NN	O
or	CC	O
topical	JJ	O
anesthesia	NN	O
during	IN	O
phacoemulsification	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
dexmedetomidine	NN	O
and	CC	O
midazolam+fentanyl	JJ	O
sedation	NN	O
primarily	RB	O
based	VBN	O
on	IN	O
patient	JJ	O
satisfaction	NN	O
during	IN	O
phacoemulsification	NN	O
under	IN	O
topical	JJ	O
and	CC	O
peribulbar	JJ	O
anesthesia	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBN	O
,	,	O
and	CC	O
double-blind	NN	O
study	NN	O
of	IN	O
80	CD	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiology	NNP	O
grade	VBD	O
I-II	NNP	O
patients	NNS	O
who	WP	O
underwent	JJ	O
phacoemulsification	NN	O
with	IN	O
local	JJ	O
anesthesia	NN	O
under	IN	O
sedation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
(	(	O
20	CD	O
patients	NNS	O
for	IN	O
each	DT	O
)	)	O
:	:	O
dexmedetomidine	NN	O
and	CC	O
topical	JJ	O
anesthesia	NN	O
,	,	O
dexmedetomidine	NN	O
and	CC	O
peribulbar	NN	O
anesthesia	NN	O
,	,	O
midazolam+fentanyl	NN	O
and	CC	O
topical	JJ	O
anesthesia	NN	O
,	,	O
and	CC	O
midazolam+fentanyl	NN	O
and	CC	O
peribulbar	NN	O
anesthesia	NN	O
.	.	O

Patient	NNP	O
and	CC	O
surgeon	JJ	O
satisfaction	NN	O
were	VBD	O
determined	VBN	O
on	IN	O
a	DT	O
5-point	JJ	O
scale	NN	O
.	.	O

The	DT	O
pain	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
verbal	JJ	O
pain	NN	O
scale	NN	O
intraoperatively	RB	O
and	CC	O
postoperatively	RB	O
.	.	O

Drugs	NNS	O
were	VBD	O
given	VBN	O
to	TO	O
a	DT	O
Ramsay	NNP	O
sedation	NN	O
scale	NN	O
of	IN	O
3	CD	O
.	.	O

Topical	JJ	O
and	CC	O
peribulbar	JJ	O
anesthesia	NN	O
were	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
ophthalmologist	NN	O
.	.	O

Hemodynamic	NNP	O
,	,	O
respiratory	NN	O
,	,	O
and	CC	O
intraocular	JJ	O
pressure	NN	O
monitoring	NN	O
was	VBD	O
done	VBN	O
.	.	O

Operative	NNP	O
and	CC	O
recovery	NN	O
times	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
midazolam+fentanyl	NN	O
groups	NNS	O
,	,	O
better	JJR	O
patient	NN	Others
and	CC	Others
surgeon	JJ	Others
satisfaction	NN	Others
scores	NNS	Others
were	VBD	O
obtained	VBN	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
,	,	O
verbal	JJ	Pain
pain	NN	Pain
scale	NN	Pain
scores	NNS	Pain
were	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
patients	NNS	O
needed	VBN	O
less	RBR	O
postoperative	JJ	Others
analgesia	NN	Others
.	.	O

Ramsay	NNP	Others
sedation	NN	Others
scale	NN	Others
scores	NNS	Others
were	VBD	O
between	IN	O
3	CD	O
and	CC	O
4	CD	O
in	IN	O
all	DT	O
patients	NNS	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
.	.	O

Intraocular	JJ	Physical
pressure	NN	Physical
alterations	NNS	Physical
were	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Recovery	JJ	Others
time	NN	Others
was	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
dexmedetomidine	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
the	DT	O
midazolam+fentanyl	NN	O
combination	NN	O
provided	VBD	O
high-level	JJ	O
patient	JJ	Others
satisfaction	NN	Others
scores	NNS	Others
,	,	O
low-level	JJ	O
pain	NN	Pain
scores	NNS	Pain
,	,	O
and	CC	O
shorter	JJR	O
recovery	NN	Others
time	NN	Others
.	.	O

Also	RB	O
,	,	O
both	DT	O
of	IN	O
the	DT	O
peribulbar	NN	O
and	CC	O
topical	JJ	O
anesthesia	NN	O
procedures	NNS	O
showed	VBD	O
similar	JJ	O
efficiency	NN	O
.	.	O

A	DT	O
potent	JJ	O
oral	JJ	O
P-selectin	NNP	O
blocking	NN	O
agent	NN	O
improves	VBZ	O
microcirculatory	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	O
a	DT	O
marker	NN	Physical
of	IN	Physical
endothelial	JJ	Physical
cell	NN	Physical
injury	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
sickle	JJ	O
cell	NN	O
disease	NN	O
.	.	O

Abnormal	JJ	Physical
blood	NN	Physical
flow	NN	Physical
accounts	NNS	O
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
clinical	JJ	O
morbidity	NN	O
of	IN	O
sickle	NN	O
cell	NN	O
disease	NN	O
(	(	O
SCD	NNP	O
)	)	O
[	VBD	O
1,2	CD	O
]	NNP	O
.	.	O

Most	JJS	O
notably	RB	O
,	,	O
occlusion	NN	O
of	IN	O
flow	NN	O
in	IN	O
the	DT	O
microvasculature	NN	O
causes	VBZ	O
the	DT	O
acute	NN	O
pain	NN	O
crises	NNS	O
[	VBP	O
3	CD	O
]	NN	O
that	WDT	O
are	VBP	O
the	DT	O
commonest	NN	O
cause	NN	O
for	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
to	TO	O
seek	VB	O
medical	JJ	O
attention	NN	O
[	VBD	O
4	CD	O
]	NN	O
and	CC	O
major	JJ	O
determinants	NNS	O
of	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
[	$	O
5	CD	O
]	NNP	O
.	.	O

Based	VBN	O
on	IN	O
evidence	NN	O
that	IN	O
endothelial	JJ	O
P-selectin	NNP	O
is	VBZ	O
central	JJ	O
to	TO	O
the	DT	O
abnormal	JJ	Physical
blood	NN	Physical
flow	NN	Physical
in	IN	Physical
SCD	NNP	Physical
we	PRP	O
provide	VBP	O
results	NNS	O
from	IN	O
four	CD	O
of	IN	O
our	PRP$	O
studies	NNS	O
that	WDT	O
are	VBP	O
germane	VBN	O
to	TO	O
microvascular	VB	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
.	.	O

A	DT	O
proof-of-principle	JJ	O
study	NN	O
established	VBD	O
that	IN	O
doses	NNS	O
of	IN	O
heparin	NN	O
lower	JJR	O
than	IN	O
what	WP	O
are	VBP	O
used	VBN	O
for	IN	O
anticoagulation	NN	O
but	CC	O
sufficient	JJ	O
to	TO	O
block	VB	O
P-selectin	NNP	O
improved	JJ	O
microvascular	JJ	Physical
blood	NN	Physical
flow	NN	Physical
inpatients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

An	DT	O
in	IN	O
vitro	NN	O
study	NN	O
showed	VBD	O
that	IN	O
Pentosan	NNP	O
Polysulfate	NNP	O
Sodium	NNP	O
(	(	O
PPS	NNP	O
)	)	O
had	VBD	O
greater	JJR	O
P-selectin	JJ	O
blocking	NN	O
activity	NN	O
than	IN	O
heparin	NN	O
.	.	O

A	DT	O
Phase	NN	O
I	PRP	O
clinical	VBP	O
study	NN	O
demonstrated	VBD	O
that	IN	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
PPS	NNP	O
increased	VBD	O
microvascular	JJ	Others
blood	NN	Others
flow	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

A	NNP	O
Phase	NNP	O
II	NNP	O
clinical	JJ	O
study	NN	O
that	WDT	O
was	VBD	O
not	RB	O
completed	VBN	O
documented	VBD	O
that	IN	O
daily	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
PPS	NNP	O
administered	VBD	O
for	IN	O
8	CD	O
weeks	NNS	O
lowered	VBD	O
plasma	JJ	O
levels	NNS	O
of	IN	O
sVCAM-1	NN	O
and	CC	O
tended	VBD	O
to	TO	O
improve	VB	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

These	DT	O
data	NNS	O
support	NN	O
the	DT	O
concept	NN	O
that	IN	O
P-selectin	NNP	O
on	IN	O
the	DT	O
microvascular	JJ	O
endothelium	NN	O
is	VBZ	O
critical	JJ	O
to	TO	O
both	DT	O
acute	JJ	Others
vascular	NN	Others
occlusion	NN	Others
and	CC	Others
chronically	RB	Others
impaired	JJ	Others
microvascular	JJ	Others
blood	NN	Others
flow	NN	Others
in	IN	Others
SCD	NNP	Others
.	.	Others

They	PRP	O
also	RB	O
demonstrate	VBP	O
that	IN	O
oral	JJ	O
PPS	NNP	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
microvascular	VB	O
sickle	NN	O
cell	NN	O
blood	NN	O
flow	NN	O
and	CC	O
has	VBZ	O
potential	JJ	O
as	IN	O
an	DT	O
efficacious	JJ	O
agent	NN	O
for	IN	O
long-term	JJ	O
prophylactic	JJ	O
therapy	NN	O
of	IN	O
SCD	NNP	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Sinemet	NNP	O
CR	NNP	O
,	,	O
a	DT	O
controlled	JJ	O
release	NN	O
carbidopa/levodopa	NN	O
preparation	NN	O
,	,	O
was	VBD	O
compared	VBN	O
to	TO	O
conventional	JJ	O
carbidopa/levodopa	NN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Comparable	JJ	Others
clinical	JJ	Others
benefits	NNS	Others
and	CC	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
noted	VBN	O
with	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

However	RB	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
dosing	NN	O
was	VBD	O
necessary	JJ	O
with	IN	O
Sinemet	NNP	O
CR	NNP	O
.	.	O

Theory-driven	JJ	O
intervention	NN	O
improves	VBZ	O
calcium	JJ	Physical
intake	NN	Physical
,	,	O
osteoporosis	NN	Mental
knowledge	NN	Mental
,	,	O
and	CC	O
self-efficacy	NN	Mental
in	IN	O
community-dwelling	JJ	O
older	JJR	O
Black	NNP	O
adults	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
an	DT	O
osteoporosis	JJ	O
education	NN	O
program	NN	O
to	TO	O
improve	VB	O
calcium	NN	Physical
intake	NN	Physical
,	,	O
knowledge	NN	Mental
,	,	O
and	CC	O
self-efficacy	NN	Mental
in	IN	O
community-dwelling	JJ	O
older	JJR	O
Black	NNP	O
adults	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
repeated	VBD	O
measures	NNS	O
experimental	JJ	O
design	NN	O
.	.	O

SETTING	NN	O
Churches	NNP	O
and	CC	O
community-based	JJ	O
organizations	NNS	O
.	.	O

PARTICIPANTS	NNP	O
Men	NNP	O
and	CC	O
women	NNS	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
50	CD	O
years	NNS	O
old	JJ	O
and	CC	O
older	JJR	O
from	IN	O
3	CD	O
south	JJ	O
Florida	NNP	O
counties	NNS	O
.	.	O

INTERVENTION	NNP	O
Participants	NNP	O
randomly	RB	O
assigned	VBD	O
to	TO	O
either	DT	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
1	CD	O
(	(	O
experimental	JJ	O
group	NN	O
)	)	O
or	CC	O
Group	NNP	O
2	CD	O
(	(	O
wait-list	JJ	O
control	NN	O
group	NN	O
)	)	O
.	.	O

Group	NNP	O
1	CD	O
participated	VBD	O
in	IN	O
6	CD	O
weekly	JJ	O
education	NN	O
program	NN	O
sessions	NNS	O
immediately	RB	O
following	VBG	O
baseline	NN	O
assessment	NN	O
,	,	O
and	CC	O
Group	NNP	O
2	CD	O
started	VBD	O
the	DT	O
program	NN	O
following	VBG	O
Group	NNP	O
1	CD	O
's	POS	O
program	NN	O
completion	NN	O
.	.	O

A	DT	O
tested	JJ	O
curriculum	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
meet	VB	O
the	DT	O
needs	NNS	O
of	IN	O
the	DT	O
target	NN	O
population	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Dietary	NNP	Physical
calcium	NN	Physical
intake	NN	Physical
,	,	O
osteoporosis	NN	Others
knowledge	NN	Others
,	,	O
health	NN	Others
beliefs	NNS	Others
,	,	O
and	CC	O
self-efficacy	NN	Mental
.	.	O

ANALYSIS	NNP	O
Descriptive	NNP	O
and	CC	O
summary	JJ	O
statistics	NNS	O
,	,	O
repeated	VBD	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
,	,	O
and	CC	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
total	JJ	O
participants	NNS	O
,	,	O
84.6	CD	O
%	NN	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
70.2	CD	O
years	NNS	O
)	)	O
.	.	O

Overall	UH	O
,	,	O
an	DT	O
educational	JJ	O
program	NN	O
developed	VBN	O
with	IN	O
a	DT	O
theoretical	JJ	O
background	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
calcium	NN	Physical
intake	NN	Physical
,	,	O
knowledge	NN	Mental
,	,	O
and	CC	O
self-efficacy	NN	Mental
,	,	O
with	IN	O
no	DT	O
effect	NN	O
on	IN	O
most	JJS	O
health	NN	Physical
belief	NN	Physical
subscales	NNS	Physical
.	.	O

Assigned	VBN	O
group	NN	O
was	VBD	O
the	DT	O
major	JJ	O
predictor	NN	O
of	IN	O
change	NN	O
in	IN	O
calcium	NN	Physical
intake	NN	Physical
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
IMPLICATIONS	NNP	O
A	NNP	O
theory-driven	JJ	O
approach	NN	O
is	VBZ	O
valuable	JJ	O
in	IN	O
improving	VBG	O
behavior	NN	O
to	TO	O
promote	VB	O
bone	NN	O
health	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Health	NNP	O
professionals	NNS	O
should	MD	O
consider	VB	O
using	VBG	O
more	JJR	O
theory-driven	JJ	O
approaches	NNS	O
in	IN	O
intervention	NN	O
studies	NNS	O
.	.	O

Effects	NNS	Others
of	IN	O
telmisartan	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
renoprotection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
Blocking	VBG	O
the	DT	O
renin-angiotensin	NN	O
system	NN	O
(	(	O
RAS	NNP	O
)	)	O
with	IN	O
angiotensin	NN	O
receptor	NN	O
blockers	NNS	O
or	CC	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
protects	VBZ	O
against	IN	O
renal	JJ	O
injury	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
chronic	JJ	O
effects	NNS	O
of	IN	O
telmisartan	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
proteinuria	NN	O
,	,	O
urinary	JJ	Physical
liver-type	JJ	Physical
fatty	JJ	Physical
acid-binding	JJ	Physical
protein	NN	Physical
(	(	Physical
L-FABP	NNP	Physical
)	)	Physical
and	CC	O
endothelin	$	Physical
(	(	Physical
ET	NNP	Physical
)	)	Physical
-1	NN	Physical
levels	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
CKD	NNP	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty	NNP	O
CKD	NNP	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
renal	JJ	O
insufficiency	NN	O
(	(	O
20	CD	O
men	NNS	O
and	CC	O
10	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
37	CD	O
years	NNS	O
;	:	O
estimated	VBN	Physical
glomerular	JJ	Physical
filtration	NN	Physical
rate	NN	Physical
(	(	Physical
eGFR	NN	Physical
)	)	Physical
>	VBZ	O
60	CD	O
mL	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
and	CC	O
blood	NN	O
pressure	NN	O
>	VBZ	O
130/85	CD	O
mmHg	NN	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
telmisartan	NN	O
at	IN	O
80	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
enalapril	VBN	O
at	IN	O
10	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
.	.	O

We	PRP	O
measured	VBD	O
blood	NN	Physical
pressure	NN	Physical
,	,	O
serum	JJ	Physical
creatinine	NN	Physical
,	,	Physical
eGFR	NN	Physical
,	,	O
urinary	JJ	Physical
protein	NN	Physical
,	,	O
L-FABP	NNP	Physical
and	CC	O
ET-1	NNP	Physical
before	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
and	CC	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
blood	NN	Physical
pressure	NN	Physical
reduction	NN	Physical
rate	NN	Physical
was	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Urinary	JJ	Physical
protein	NN	Physical
,	,	O
L-FABP	NNP	Physical
and	CC	O
ET-1	NNP	Physical
levels	NNS	Physical
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
after	IN	O
treatment	NN	O
,	,	O
but	CC	O
the	DT	O
reduction	NN	Physical
rates	NNS	Physical
were	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
telmisartan	NN	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
enalapril	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Estimated	VBN	O
glomerular	JJ	Physical
filtration	NN	Physical
rate	NN	Physical
was	VBD	O
increased	VBN	O
similarly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
study	NN	O
results	NNS	O
suggest	VBP	O
that	IN	O
telmisartan	JJ	O
results	NNS	O
in	IN	O
a	DT	O
greater	JJR	O
reduction	NN	O
of	IN	O
urinary	JJ	Physical
markers	NNS	Physical
than	IN	O
does	VBZ	O
enalapril	VB	O
and	CC	O
that	IN	O
this	DT	O
effect	NN	O
occurs	VBZ	O
by	IN	O
a	DT	O
mechanism	NN	O
independent	JJ	O
of	IN	O
blood	NN	O
pressure	NN	O
reduction	NN	O
.	.	O

It	PRP	O
would	MD	O
be	VB	O
needed	VBN	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
differences	NNS	O
may	MD	O
be	VB	O
distinct	JJ	O
or	CC	O
not	RB	O
the	DT	O
same	JJ	O
when	WRB	O
other	JJ	O
dosages	NNS	O
are	VBP	O
used	VBN	O
.	.	O

Enhanced	NNP	O
baroreceptor	NN	O
control	NN	O
of	IN	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
by	IN	O
polyunsaturated	JJ	O
Fatty	NNP	O
acids	NNS	O
in	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
intention	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
,	,	O
in	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
,	,	O
dietary	JJ	O
supplementation	NN	O
of	IN	O
polyunsaturated	JJ	O
fatty	JJ	O
acids	NNS	O
(	(	O
PUFA	NNP	O
)	)	O
enhances	VBZ	O
arterial	JJ	O
baroreceptor	NN	O
control	NN	O
of	IN	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
.	.	O

BACKGROUND	NNP	O
Administration	NNP	O
of	IN	O
PUFA	NNP	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
life-threatening	JJ	O
arrhythmias	NNS	O
in	IN	O
patients	NNS	O
surviving	VBG	O
myocardial	JJ	O
infarction	NN	O
.	.	O

This	DT	O
might	MD	O
result	VB	O
from	IN	O
potentiation	NN	O
of	IN	O
arterial	JJ	O
baroreflexes	NNS	O
,	,	O
but	CC	O
whether	IN	O
or	CC	O
not	RB	O
PUFA	NNP	O
enhance	NN	O
baroreflex	NN	O
function	NN	O
has	VBZ	O
never	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
humans	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
post-myocardial	JJ	O
infarction	NN	O
left	VBD	O
ventricular	JJ	O
dysfunction	NN	O
underwent	JJ	O
beat-to-beat	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
(	(	O
Finapres	NNP	O
,	,	O
Ohmeda	NNP	O
Inc.	NNP	O
,	,	O
Englewood	NNP	O
,	,	O
Colorado	NNP	O
)	)	O
and	CC	O
R-R	JJ	O
interval	NN	O
(	(	O
electrocardiogram	NN	O
)	)	O
recording	NN	O
;	:	O
baroreceptor	NN	O
reflexes	NNS	O
were	VBD	O
assessed	VBN	O
from	IN	O
the	DT	O
bradycardic	NN	O
and	CC	O
depressor	NN	O
responses	NNS	O
to	TO	O
graded	VB	O
neck	NN	O
suction	NN	O
(	(	O
NS	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
computation	NN	O
of	IN	O
the	DT	O
alpha	NN	O
spontaneous	JJ	O
baroreflex	JJ	O
sensitivity	NN	O
index	NN	O
.	.	O

Assessments	NNS	O
were	VBD	O
repeated	VBN	O
after	IN	O
prolonged	JJ	O
treatment	NN	O
with	IN	O
PUFA	NNP	O
(	(	O
2	CD	O
g/die	NN	O
,	,	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	Physical
BP	NNP	Physical
and	CC	O
R-R	NNP	Physical
interval	NN	Physical
were	VBD	O
unaffected	VBN	O
by	IN	O
PUFA	NNP	O
.	.	O

Both	DT	O
reflex	JJ	Physical
depressor	NN	Physical
and	CC	Physical
bradycardic	JJ	Physical
responses	NNS	Physical
to	TO	Physical
NS	NNP	Physical
increased	VBN	O
after	IN	O
PUFA	NNP	O
(	(	O
respectively	RB	O
from	IN	O
-0.09	JJ	O
+/-	JJ	O
0.01	CD	O
to	TO	O
-0.16	VB	O
+/-	JJ	O
0.01	CD	O
mm	NN	O
Hg	NNP	O
x	NNP	O
mm	NN	O
Hg	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
p	JJ	O
<	NN	O
0.01	CD	O
,	,	O
and	CC	O
from	IN	O
1.25	CD	O
+/-	JJ	O
0.9	CD	O
to	TO	O
1.76	CD	O
+/-	JJ	O
1.1	CD	O
ms	NN	O
x	NNP	O
mm	NN	O
Hg	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
p	JJ	O
<	NNP	O
0.04	CD	O
)	)	O
but	CC	O
not	RB	O
after	IN	O
placebo	NN	O
.	.	O

The	DT	O
spontaneous	JJ	Physical
baroreflex	JJ	Physical
sensitivity	NN	Physical
increased	VBN	O
in	IN	O
the	DT	O
PUFA	NNP	O
(	(	O
from	IN	O
8.99	CD	O
+/-	JJ	O
1.4	CD	O
to	TO	O
12.2	CD	O
+/-	JJ	O
1.2	CD	O
ms	NN	O
x	NNP	O
mm	NN	O
Hg	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Polyunsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
(	(	O
but	CC	O
not	RB	O
placebo	VB	O
)	)	O
treatment	NN	O
also	RB	O
significantly	RB	O
increased	VBD	O
R-R	NNP	Physical
interval	JJ	Physical
total	JJ	Physical
variance	NN	Physical
and	CC	O
low-frequency	NN	O
and	CC	O
high-frequency	NN	O
spectral	JJ	O
powers	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Dietary	NNP	O
PUFA	NNP	O
supplementation	NN	O
markedly	RB	O
potentiates	VBZ	O
baroreflex	JJ	O
function	NN	O
and	CC	O
enhances	NNS	O
heart	NN	Physical
rate	NN	Physical
variability	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Social	JJ	O
robots	NNS	O
as	IN	O
embedded	JJ	O
reinforcers	NNS	O
of	IN	O
social	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
examined	VBD	O
the	DT	O
social	JJ	O
behaviors	NNS	O
of	IN	O
4-	JJ	O
to	TO	O
12-year-old	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
;	:	O
N	NNP	O
=	NNP	O
24	CD	O
)	)	O
during	IN	O
three	CD	O
tradic	JJ	O
interactions	NNS	O
with	IN	O
an	DT	O
adult	NN	O
confederate	NN	O
and	CC	O
an	DT	O
interaction	NN	O
partner	NN	O
,	,	O
where	WRB	O
the	DT	O
interaction	NN	O
partner	NN	O
varied	VBD	O
randomly	RB	O
among	IN	O
(	(	O
1	CD	O
)	)	O
another	DT	O
adult	NN	O
human	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
a	DT	O
touchscreen	JJ	O
computer	NN	O
game	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
a	DT	O
social	JJ	O
dinosaur	NN	O
robot	NN	O
.	.	O

Children	NNP	O
spoke	VBD	O
more	RBR	O
in	IN	O
general	JJ	O
,	,	O
and	CC	O
directed	VBD	O
more	JJR	O
speech	NN	O
to	TO	O
the	DT	O
adult	NN	O
confederate	NN	O
,	,	O
when	WRB	O
the	DT	O
interaction	NN	O
partner	NN	O
was	VBD	O
a	DT	O
robot	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
human	NN	O
or	CC	O
computer	NN	O
game	NN	O
interaction	NN	O
partner	NN	O
.	.	O

Children	NNP	O
spoke	VBD	O
as	RB	O
much	JJ	O
to	TO	O
the	DT	O
robot	NN	O
as	IN	O
to	TO	O
the	DT	O
adult	NN	O
interaction	NN	O
partner	NN	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
largest	JJS	O
demonstration	NN	O
of	IN	O
social	JJ	O
human-robot	JJ	O
interaction	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
to	TO	O
date	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
social	JJ	O
robots	NNS	O
may	MD	O
be	VB	O
developed	VBN	O
into	IN	O
useful	JJ	O
tools	NNS	O
for	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
communication	NN	O
therapies	NNS	O
,	,	O
specifically	RB	O
by	IN	O
embedding	VBG	O
social	JJ	O
interaction	NN	O
into	IN	O
intrinsic	JJ	O
reinforcers	NNS	O
and	CC	O
motivators	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
weakness	NN	Physical
progression	NN	Physical
in	IN	O
inclusion	NN	O
body	NN	O
myositis	NN	O
during	IN	O
treatment	NN	O
with	IN	O
methotrexate	NN	O
or	CC	O
placebo	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
5	CD	O
to	TO	O
20mg	CD	O
per	IN	O
week	NN	O
oral	JJ	O
methotrexate	NN	O
could	MD	O
slow	VB	O
down	RP	O
disease	NN	Physical
progression	NN	Physical
in	IN	O
44	CD	O
patients	NNS	O
with	IN	O
inclusion	NN	O
body	NN	O
myositis	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Mean	NNP	Physical
change	NN	Physical
of	IN	Physical
quantitative	JJ	Physical
muscle	NN	Physical
strength	NN	Physical
testing	VBG	Physical
sum	NN	Physical
scores	NNS	Physical
was	VBD	O
the	DT	O
primary	JJ	O
study	NN	O
outcome	JJ	O
measure	NN	O
.	.	O

Quantitative	JJ	O
muscle	NN	O
strength	NN	O
testing	VBG	O
sum	NN	O
scores	NNS	O
declined	VBD	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
-0.2	CD	O
%	NN	O
for	IN	O
methotrexate	NN	O
and	CC	O
-3.4	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
=	NNP	O
-2.5	NNP	O
%	NN	O
to	TO	O
+9.1	CD	O
%	NN	O
for	IN	O
difference	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
differences	NNS	O
in	IN	O
manual	JJ	Physical
muscle	NN	Physical
testing	VBG	Physical
sum	JJ	Physical
scores	NNS	Physical
,	,	Physical
activity	NN	Physical
scale	NN	Physical
scores	NNS	Physical
and	CC	Physical
patients	NNS	Physical
'	POS	Physical
own	JJ	Physical
assessments	NNS	Physical
after	IN	O
48	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Serum	NNP	Physical
creatine	JJ	Physical
kinase	NN	Physical
activity	NN	Physical
decreased	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
methotrexate	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
oral	JJ	O
methotrexate	NN	O
did	VBD	O
not	RB	O
slow	VB	O
down	RP	O
progression	NN	Physical
of	IN	Physical
muscle	NN	Physical
weakness	NN	Physical
but	CC	O
decreased	VBD	O
serum	JJ	Physical
creatine	JJ	Physical
kinase	NN	Physical
activity	NN	Physical
.	.	O

A	DT	O
communication-based	JJ	O
intervention	NN	O
for	IN	O
nonverbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
what	WP	O
changes	NNS	O
?	.	O
Who	WP	O
benefits	NNS	O
?	.	O
OBJECTIVE	IN	O
This	DT	O
article	NN	O
examines	VBZ	O
the	DT	O
form	NN	O
and	CC	O
function	NN	O
of	IN	O
spontaneous	JJ	O
communication	NN	O
and	CC	O
outcome	NN	O
predictors	NNS	O
in	IN	O
nonverbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
following	VBG	O
classroom-based	JJ	O
intervention	NN	O
(	(	O
Picture	NNP	O
Exchange	NNP	O
Communication	NNP	O
System	NNP	O
[	NNP	O
PECS	NNP	O
]	NNP	O
training	NN	O
)	)	O
.	.	O

METHOD	$	O
84	CD	O
children	NNS	O
from	IN	O
15	CD	O
schools	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
of	IN	O
PECS	NNP	O
(	(	O
P.	NNP	O
Howlin	NNP	O
,	,	O
R.	NNP	O
K.	NNP	O
Gordon	NNP	O
,	,	O
G.	NNP	O
Pasco	NNP	O
,	,	O
A	NNP	O
.	.	O

Wade	NNP	O
,	,	O
&	CC	O
T.	NNP	O
Charman	NNP	O
,	,	O
2007	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
aged	VBN	O
4-10	JJ	O
years	NNS	O
(	(	O
73	CD	O
boys	NNS	O
)	)	O
.	.	O

Primary	JJ	O
outcome	JJ	O
measure	NN	O
was	VBD	O
naturalistic	JJ	Mental
observation	NN	Mental
of	IN	Mental
communication	NN	Mental
in	IN	O
the	DT	O
classroom	NN	O
.	.	O

Multilevel	NNP	O
Poisson	NNP	O
regression	NN	O
was	VBD	O
used	VBN	O
to	TO	O
test	VB	O
for	IN	O
intervention	NN	Mental
effects	NNS	Mental
and	CC	Mental
outcome	JJ	Mental
predictors	NNS	Mental
.	.	O

RESULTS	NNP	O
Spontaneous	JJ	Mental
communication	NN	Mental
using	VBG	Mental
picture	NN	Mental
cards	NNS	Mental
,	,	Mental
speech	NN	Mental
,	,	Mental
or	CC	Mental
both	DT	Mental
increased	VBN	O
significantly	RB	O
following	VBG	O
training	NN	O
(	(	O
rate	NN	O
ratio	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
=1.90	NNP	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
1.46	CD	O
,	,	O
2.48	CD	O
]	NN	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
;	:	O
RR	NNP	O
=	VBZ	O
1.77	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
1.35	CD	O
,	,	O
2.32	CD	O
]	NN	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
;	:	O
RR	NNP	O
=	VBZ	O
3.74	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
2.19	CD	O
,	,	O
6.37	CD	O
]	NN	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Spontaneous	JJ	Mental
communication	NN	Mental
to	TO	Mental
request	VB	Mental
objects	NNS	Mental
significantly	RB	O
increased	VBD	O
(	(	O
RR	NNP	O
=	NNP	O
2.17	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
1.75	CD	O
,	,	O
2.68	CD	O
]	NN	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
but	CC	O
spontaneous	JJ	O
requesting	NN	O
for	IN	O
social	JJ	O
purposes	NNS	O
did	VBD	O
not	RB	O
(	(	O
RR	NNP	O
=	NNP	O
1.34	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
0.83	CD	O
,	,	O
2.18	CD	O
]	NN	O
,	,	O
p	NN	O
=	NNP	O
.237	NNP	O
)	)	O
.	.	O

Only	RB	O
the	DT	O
effect	NN	O
on	IN	O
spontaneous	JJ	Mental
speech	NN	Mental
persisted	VBN	O
by	IN	O
follow-up	NN	O
(	(	O
9	CD	O
months	NNS	O
later	RB	O
)	)	O
.	.	O

Less	CC	O
severe	JJ	Mental
baseline	NN	Mental
autism	NN	Mental
symptomatology	NN	Mental
(	(	Mental
lower	JJR	Mental
Autism	NNP	Mental
Diagnosis	NNP	Mental
Observation	NNP	Mental
Schedule	NNP	Mental
[	NNP	Mental
ADOS	NNP	Mental
]	NNP	Mental
score	NN	Mental
;	:	O
C.	NNP	O
Lord	NNP	O
et	VBZ	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
increase	NN	O
in	IN	O
spontaneous	JJ	Mental
speech	NN	Mental
(	(	O
RR	NNP	O
=	NNP	O
0.90	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
0.83	CD	O
,	,	O
0.98	CD	O
]	NN	O
,	,	O
p	NN	O
=	NNP	O
.011	NNP	O
)	)	O
and	CC	O
less	RBR	O
severe	JJ	Mental
baseline	NN	Mental
expressive	JJ	Mental
language	NN	Mental
impairment	NN	Mental
(	(	O
lower	JJR	O
ADOS	NNP	O
item	NN	O
A1	NNP	O
score	NN	O
)	)	O
,	,	O
with	IN	O
larger	JJR	O
increases	NNS	O
in	IN	O
spontaneous	JJ	Mental
use	NN	Mental
of	IN	Mental
speech	NN	Mental
and	CC	Mental
pictures	VBZ	Mental
together	RB	Mental
(	(	O
RR	NNP	O
=	NNP	O
0.62	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
0.44	CD	O
,	,	O
0.88	CD	O
]	NN	O
,	,	O
p	NN	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
PECS	NNP	O
appeared	VBD	O
to	TO	O
enhance	VB	O
children	NNS	O
's	POS	O
spontaneous	JJ	O
communication	NN	O
for	IN	O
instrumental	JJ	O
requesting	VBG	O
using	VBG	O
pictures	NNS	O
,	,	O
speech	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
both	DT	O
.	.	O

Some	DT	O
effects	NNS	O
of	IN	O
training	NN	O
were	VBD	O
moderated	VBN	O
by	IN	O
baseline	NN	O
factors	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
PECS	NNP	O
appears	VBZ	O
to	TO	O
have	VB	O
increased	VBN	O
spontaneous	JJ	O
speech	NN	O
in	IN	O
children	NNS	O
who	WP	O
could	MD	O
talk	VB	O
a	DT	O
little	JJ	O
at	IN	O
baseline	NN	O
.	.	O

[	JJ	O
Potentials	NNS	O
of	IN	O
monocular	NN	O
augmented	VBN	O
reality	NN	O
technology	NN	O
in	IN	O
automobile	NN	O
production	NN	O
]	NNP	O
.	.	O

INTRODUCTION	NNP	O
Augmented	NNP	O
reality	NN	O
(	(	O
AR	NNP	O
)	)	O
technologies	NNS	O
can	MD	O
enrich	VB	O
the	DT	O
real	JJ	O
environment	NN	O
with	IN	O
visual	JJ	O
data	NNS	O
,	,	O
which	WDT	O
has	VBZ	O
potential	JJ	O
benefits	NNS	O
for	IN	O
optimising	VBG	O
the	DT	O
operator	NN	O
's	POS	O
working	VBG	O
process	NN	O
.	.	O

It	PRP	O
offers	VBZ	O
the	DT	O
possibility	NN	O
to	TO	O
provide	VB	O
context-sensitive	JJ	O
information	NN	O
independently	RB	O
of	IN	O
the	DT	O
user	NN	O
's	POS	O
location	NN	O
and	CC	O
position	NN	O
.	.	O

Data	NNS	O
are	VBP	O
presented	VBN	O
to	TO	O
the	DT	O
dominant	JJ	O
eye	NN	O
on	IN	O
a	DT	O
semi-transparent	JJ	O
mirror	NN	O
using	VBG	O
a	DT	O
head-mounted	JJ	O
display	NN	O
(	(	O
HMD	NNP	O
)	)	O
unit	NN	O
that	WDT	O
works	VBZ	O
with	IN	O
retinal	JJ	O
laser	NN	O
technology	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
drawbacks	NNS	O
of	IN	O
this	DT	O
new	JJ	O
AR	NNP	O
technology	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
45	CD	O
participants	NNS	O
without	IN	O
any	DT	O
visual	JJ	O
impairment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
3	CD	O
groups	NNS	O
and	CC	O
completed	VBD	O
a	DT	O
variety	NN	O
of	IN	O
tasks	NNS	O
during	IN	O
a	DT	O
simulated	JJ	O
working	JJ	O
day	NN	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
conventional	JJ	O
working	JJ	O
aids	NNS	O
(	(	O
paper-based	JJ	O
documents	NNS	O
)	)	O
to	TO	O
support	VB	O
the	DT	O
task	NN	O
processing	NN	O
.	.	O

Group	NNP	O
2	CD	O
additionally	RB	O
wore	VBD	O
an	DT	O
HMD	NNP	O
unit	NN	O
that	WDT	O
was	VBD	O
switched	VBN	O
off	RP	O
.	.	O

Group	NNP	O
3	CD	O
wore	VBD	O
a	DT	O
functioning	NN	O
HMD	NNP	O
without	IN	O
any	DT	O
additional	JJ	O
aids	NNS	O
.	.	O

Evaluation	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
standardised	JJ	O
questionnaire	NN	O
(	(	O
BMS	NNP	O
)	)	O
and	CC	O
a	DT	O
concentration	NN	O
test	NN	O
(	(	O
d2	JJ	O
Aufmerksamkeits-Belastungs-Test	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
3	CD	O
groups	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
mental	JJ	Mental
strain	NN	Mental
,	,	O
concentration-test	JJ	Mental
performance	NN	Mental
and	CC	O
physical	JJ	Physical
or	CC	Physical
mental	JJ	Physical
complaints	NNS	Physical
reported	VBN	O
in	IN	O
a	DT	O
follow-up	JJ	O
interview	NN	O
.	.	O

Around	IN	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
noticed	VBD	O
a	DT	O
higher	JJR	Physical
pressure	NN	Physical
and	CC	O
blurred	JJ	Physical
vision	NN	Physical
in	IN	Physical
both	DT	Physical
eyes	NNS	Physical
as	RB	O
well	RB	O
as	IN	O
headaches	NNS	Physical
.	.	O

Half	NNP	O
of	IN	O
the	DT	O
participants	NNS	O
complained	VBD	O
about	IN	O
deficiencies	NNS	O
concerning	VBG	O
the	DT	O
ergonomic	JJ	Physical
hardware	NN	Physical
design	NN	Physical
of	IN	O
the	DT	O
AR	NNP	O
system	NN	O
.	.	O

DISCUSSION	NNP	O
Changes	NNP	O
in	IN	O
objective	JJ	O
ophthalmological	JJ	O
investigation	NN	O
parameters	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
.	.	O

Subjects	NNS	O
reported	VBD	O
reduced	JJ	O
acceptance	NN	O
of	IN	O
the	DT	O
HMD	NNP	O
based	VBN	O
on	IN	O
non-ophthalmological	JJ	O
reasons	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
weight	NN	O
of	IN	O
the	DT	O
unit	NN	O
or	CC	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
cable	NN	O
.	.	O

However	RB	O
,	,	O
for	IN	O
some	DT	O
specific	JJ	O
working	VBG	O
tasks	NNS	O
,	,	O
advantages	NNS	O
in	IN	O
process	NN	O
optimisation	NN	O
and	CC	O
operator	NN	O
support	NN	O
were	VBD	O
observed	VBN	O
.	.	O

Improving	VBG	O
RBC	NNP	O
K	NNP	O
transport	NN	O
and	CC	O
hemoglobin-O2	JJ	O
binding	NN	O
by	IN	O
amiloride	NN	O
:	:	O
A	DT	O
novel	JJ	O
therapeutic	JJ	O
approach	NN	O
for	IN	O
reversion	NN	O
of	IN	O
angina	NN	O
and	CC	O
myocardial	JJ	O
ischemia	NN	O
in	IN	O
coronary	JJ	O
heart	NN	O
diseases	NNS	O
.	.	O

UNLABELLED	NNP	O
Coronary	NNP	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
leading	VBG	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
across	IN	O
the	DT	O
entire	JJ	O
world	NN	O
,	,	O
in	IN	O
which	WDT	O
reversion	NN	O
of	IN	O
angina	NN	O
or	CC	O
improvement	NN	O
of	IN	O
ECG	NNP	O
remains	VBZ	O
an	DT	O
unrealistic	JJ	O
therapeutic	JJ	O
option	NN	O
for	IN	O
most	JJS	O
patients	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
microvascular	JJ	O
dysfunction	NN	O
or	CC	O
impaired	JJ	O
oxygen	NN	O
delivery	NN	O
might	MD	O
be	VB	O
critical	JJ	O
factors	NNS	O
in	IN	O
CHD	NNP	O
.	.	O

This	DT	O
research	NN	O
article	NN	O
,	,	O
thus	RB	O
presents	VBZ	O
the	DT	O
rationale	JJ	O
basis	NN	O
,	,	O
clinical	JJ	O
and	CC	O
experimental	JJ	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
therapeutic	JJ	O
innovation	NN	O
addressing	VBG	O
the	DT	O
role	NN	O
of	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
H/K	NNP	O
and	CC	O
O2/CO2	NNP	O
exchanges	NNS	O
in	IN	O
CHD	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
randomized	JJ	O
single-blind	JJ	O
trial	NN	O
of	IN	O
Amiloride	NNP	O
and	CC	O
Optimal	NNP	O
Medical	NNP	O
Therapy	NNP	O
(	(	O
OMT	NNP	O
,	,	O
n=35	JJ	O
cases	NNS	O
)	)	O
vs	VBP	O
OMT	NNP	O
alone	RB	O
(	(	O
n=35	JJ	O
cases	NNS	O
)	)	O
in	IN	O
patients	NNS	O
having	VBG	O
angina	RB	O
,	,	O
ST-T	JJ	O
alteration	NN	O
and	CC	O
a	DT	O
defective	JJ	O
RBC-K	JJ	O
transport	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
serial	JJ	O
clinical	JJ	O
evaluation	NN	O
,	,	O
Ion	NNP	O
Transport	NNP	O
Studies	NNP	O
,	,	O
ECGs	NNP	O
and	CC	O
non-invasive	JJ	O
aortic	JJ	O
waveform	NN	O
and	CC	O
cardiovascular	JJ	O
hemodynamic	JJ	O
recordings	NNS	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
SAS	NNP	O
.	.	O

RESULTS	NNP	O
Amiloride	NNP	O
rapidly	RB	O
improved	VBD	O
RBC-K	NNP	O
(	(	O
93.5	CD	O
?4	NNP	O
vs	NN	O
84.5	CD	O
?4	NN	O
mmol/lc	NN	O
,	,	O
p=	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
angina	RB	O
(	(	O
80	CD	O
%	NN	O
of	IN	O
cases	NNS	O
,	,	O
1.5	CD	O
?0.3	JJ	O
weeks	NNS	O
,	,	O
CI:1.72	NNP	O
to	TO	O
1.45	CD	O
)	)	O
,	,	O
CCS	NNP	O
Class	NNP	O
(	(	O
1.3	CD	O
?0.5	NNP	O
vs	NN	O
3.1	CD	O
?0.8	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
vs	NN	O
patients	NNS	O
with	IN	O
OMT	NNP	O
alone	RB	O
CCS	NNP	O
Class	NNP	O
(	(	O
3.2	CD	O
?	.	O
0.4	CD	O
vs	NN	O
3.3	CD	O
?	.	O
0.5	CD	O
,	,	O
p	FW	O
=0.21	NN	O
)	)	O
.	.	O

Reversion	NN	O
of	IN	O
angina	NN	O
was	VBD	O
sustained	VBN	O
through	IN	O
the	DT	O
next	JJ	O
6-months	JJ	O
(	(	O
87	CD	O
%	NN	O
vs	JJ	O
26	CD	O
%	NN	O
in	IN	O
OMT	NNP	O
,	,	O
RR	NNP	O
2.1	CD	O
,	,	O
odds	NNS	O
ratio	VBP	O
6.31	CD	O
,	,	O
Pearson	NNP	O
x2	NNP	O
34.6	CD	O
,	,	O
p	NN	O
<	VBD	O
0.0001	CD	O
at	IN	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
and	CC	O
1-year	JJ	O
(	(	O
85	CD	O
%	NN	O
vs	JJ	O
37	CD	O
%	NN	O
OMT	NNP	O
)	)	O
.	.	O

At	IN	O
6-months	JJ	O
of	IN	O
amiloride	NN	O
,	,	O
ECG	NNP	O
became	VBD	O
normal	JJ	O
(	(	O
29	CD	O
%	NN	O
vs	JJ	O
0	CD	O
%	NN	O
,	,	O
RR	NNP	O
?	.	O
uncalculated-time	JJ	O
,	,	O
odds	NNS	O
ratio	NN	O
?	.	O
,	,	O
Pearson	NNP	O
x2	VBD	O
42.4	CD	O
at	IN	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
improved	VBN	O
(	(	O
55	CD	O
%	NN	O
vs	JJ	O
29	CD	O
%	NN	O
;	:	O
RR2.1	NNP	O
,	,	O
odds	VBZ	O
ratio	NN	O
3.16	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
or	CC	O
unchanged	JJ	O
(	(	O
15	CD	O
%	NN	O
vs	JJ	O
67	CD	O
%	NN	O
OMT	NNP	O
)	)	O
.	.	O

At	IN	O
1-year	JJ	O
,	,	O
seven	CD	O
patients	NNS	O
on	IN	O
amiloride	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
evidence	NN	O
of	IN	O
electrical	JJ	O
regeneration	NN	O
of	IN	O
the	DT	O
heart	NN	O
,	,	O
not	RB	O
observed	VBN	O
with	IN	O
placebo	NN	O
.	.	O

IN	NNP	O
CONCLUSION	NNP	O
This	DT	O
therapeutical	JJ	O
innovation	NN	O
of	IN	O
amiloride	JJ	O
improves	NNS	O
RBC	NNP	O
H/K	NNP	O
and	CC	O
O2/CO2	NNP	O
function	NN	O
,	,	O
and	CC	O
reverses	VBZ	O
angina	NNS	O
,	,	O
ST-T	JJ	O
alterations	NNS	O
while	IN	O
inducing	VBG	O
electrical	JJ	O
regeneration	NN	O
of	IN	O
the	DT	O
heart	NN	O
,	,	O
in	IN	O
patients	NNS	O
receiving	VBG	O
optimal	JJ	O
medical	JJ	O
treatment	NN	O
for	IN	O
angina	NN	O
.	.	O

The	DT	O
article	NN	O
has	VBZ	O
short	JJ	O
discussion	NN	O
on	IN	O
the	DT	O
relevant	JJ	O
patents	NNS	O
to	TO	O
the	DT	O
topic	NN	O
.	.	O

[	IN	O
The	DT	O
effects	NNS	O
of	IN	O
antidepressant	JJ	O
treatment	NN	O
on	IN	O
efficacy	NN	Others
of	IN	O
antihypertensive	JJ	O
therapy	NN	O
in	IN	O
elderly	JJ	O
hypertension	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
antidepressant	JJ	O
treatment	NN	O
on	IN	O
antihypertensive	JJ	O
therapy	NN	O
of	IN	O
senile	JJ	O
hypertension	NN	Physical
.	.	O

METHODS	NNP	O
138	CD	O
cases	NNS	O
of	IN	O
senile	JJ	O
hypertension	NN	O
complicating	VBG	O
with	IN	O
depression	NN	O
were	VBD	O
studied	VBN	O
.	.	O

103	CD	O
senile	JJ	O
hypertensive	JJ	O
patients	NNS	O
without	IN	O
depression	NN	O
in	IN	O
the	DT	O
same	JJ	O
period	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
as	IN	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
for	IN	O
study	NN	O
.	.	O

12.5	CD	O
mg/d	JJ	O
hydrochlorothiazide	NN	O
and	CC	O
30	CD	O
mg/d	JJ	O
release-controlling	JJ	O
tablets	NNS	O
of	IN	O
nifedipine	NN	O
were	VBD	O
orally	RB	O
administrated	VBN	O
as	IN	O
basic	JJ	O
antihypertensive	JJ	O
medication	NN	O
each	DT	O
group	NN	O
.	.	O

Besides	NNP	O
,	,	O
20	CD	O
mg/d	NN	O
fluoxetine	NN	O
was	VBD	O
additionally	RB	O
given	VBN	O
to	TO	O
groups	NNS	O
A	NNP	O
and	CC	O
one	CD	O
tablet	NN	O
of	IN	O
almitrine	JJ	O
l/d	NN	O
and	CC	O
20	CD	O
mg	NN	O
oryzanol	NN	O
3/d	CD	O
were	VBD	O
given	VBN	O
to	TO	O
group	NN	O
B	NNP	O
.	.	O

The	DT	O
treatment	NN	O
lasted	VBD	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
comparison	NN	O
with	IN	O
pre-treatment	NN	O
,	,	O
the	DT	O
blood	NN	Physical
pressure	NN	Physical
at	IN	O
base	NN	O
line	NN	O
in	IN	O
sitting	VBG	O
position	NN	O
and	CC	O
the	DT	O
average	JJ	Physical
circadian	JJ	Physical
SBP	NNP	Physical
and	CC	Physical
DBP	NNP	Physical
monitored	VBD	Physical
with	IN	Physical
24-hour	JJ	Physical
ambulatory	NN	Physical
blood	NN	Physical
pressure	NN	Physical
monitoring	NN	Physical
(	(	Physical
ABPM	NNP	Physical
)	)	Physical
was	VBD	O
remarkably	RB	O
decreased	VBN	O
in	IN	O
group	NN	O
A	NNP	O
with	IN	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
blood	NN	Physical
pressure	NN	Physical
parameters	NNS	Physical
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
also	RB	O
decreased	VBN	O
as	IN	O
compared	VBN	O
ith	IN	O
the	DT	O
pretreatment	JJ	O
level	NN	O
brt	NN	O
with	IN	O
less	JJR	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
also	RB	O
noted	VBN	O
tha	NN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
antidepressant	JJ	O
fluoxetine	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
of	IN	O
depression	NN	Mental
ere	RB	O
alleviated	VBN	O
as	IN	O
shown	VBN	O
by	IN	O
Hamilton	NNP	Mental
depression	NN	Mental
(	(	Mental
HAMD	NNP	Mental
)	)	Mental
scale	NN	Mental
.	.	O

untoward	JJ	O
reactions	NNS	O
such	JJ	O
as	IN	O
nausea	NN	Adverseeffect
,	,	Physical
perspiration	NN	Adverseeffect
and	CC	Physical
skin	NN	Adverseeffect
rash	NN	Adverseeffect
were	VBD	O
noted	VBN	O
in	IN	O
a	DT	O
few	JJ	O
patients	NNS	O
,	,	O
but	CC	O
none	NN	O
withdrew	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Antidepressant	NNP	O
and	CC	O
antianxiety	NN	O
treatment	NN	O
is	VBZ	O
of	IN	O
benefit	NN	O
to	TO	O
the	DT	O
antihypertensive	JJ	O
therapy	NN	O
in	IN	O
senile	JJ	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
complications	NNS	O
of	IN	O
depression	NN	O
and/or	NN	O
anxiety	NN	O
neurosis	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
routine	JJ	O
administration	NN	O
of	IN	O
antidepressants	NNS	O
and	CC	O
antianxiety	NN	O
drugs	NNS	O
should	MD	O
be	VB	O
carried	VBN	O
out	RP	O
in	IN	O
senile	JJ	O
hypertensive	JJ	O
patients	NNS	O
complicating	VBG	O
with	IN	O
depression	NN	O
or	CC	O
anxiety	NN	O
.	.	O

Using	VBG	O
the	DT	O
virtual	JJ	O
reality-cognitive	JJ	O
rehabilitation	NN	O
approach	NN	O
to	TO	O
improve	VB	O
contextual	JJ	Mental
processing	NN	Mental
in	IN	Mental
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
investigated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
novel	JJ	O
virtual	JJ	O
reality-cognitive	JJ	O
rehabilitation	NN	O
(	(	O
VR-CR	NNP	O
)	)	O
intervention	NN	O
to	TO	O
improve	VB	O
contextual	JJ	Mental
processing	NN	Mental
of	IN	O
objects	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Previous	JJ	O
research	NN	O
supports	VBZ	O
that	IN	O
children	NNS	O
with	IN	O
autism	NN	O
show	NN	O
deficits	NNS	O
in	IN	O
contextual	JJ	Mental
processing	NN	Mental
,	,	O
as	RB	O
well	RB	O
as	IN	O
deficits	NNS	O
in	IN	O
its	PRP$	O
elementary	JJ	O
components	NNS	O
:	:	O
abstraction	NN	Mental
and	CC	Mental
cognitive	JJ	Mental
flexibility	NN	Mental
.	.	Mental

METHODS	NNP	O
Four	CD	O
children	NNS	O
with	IN	O
autism	NN	O
participated	VBN	O
in	IN	O
a	DT	O
multiple-baseline	JJ	O
,	,	O
single-subject	JJ	O
study	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
taught	JJ	O
how	WRB	O
to	TO	O
see	VB	O
objects	NNS	O
in	IN	O
context	NN	O
by	IN	O
reinforcing	VBG	O
attention	NN	O
to	TO	O
pivotal	JJ	O
contextual	JJ	O
information	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
children	NNS	O
demonstrated	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
contextual	JJ	Mental
processing	NN	Mental
and	CC	O
cognitive	JJ	Mental
flexibility	NN	Mental
.	.	O

Mixed	JJ	O
results	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
the	DT	O
control	NN	O
test	NN	O
and	CC	O
changes	NNS	O
in	IN	O
context-related	JJ	Mental
behaviours	NNS	Mental
.	.	Mental

CONCLUSIONS	NNP	O
Larger-scale	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
usability	NN	O
in	IN	O
comprehensive	JJ	O
educational	JJ	O
programs	NNS	O
.	.	O

Modafinil	NNP	O
effects	NNS	O
during	IN	O
acute	JJ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
withdrawal	NN	O
:	:	O
a	DT	O
randomized	JJ	O
crossover	NN	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

RATIONALE	NNP	O
Continuous	NNP	O
positive	JJ	O
airway	NN	O
pressure	NN	O
(	(	O
CPAP	NNP	O
)	)	O
use	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
reduced	JJ	O
motor	NN	O
vehicle	NN	O
accidents	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
obstructive	JJ	O
sleep	NN	O
apnea	NN	O
(	(	O
OSA	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
interruption	NN	O
of	IN	O
CPAP	NNP	O
therapy	NN	O
is	VBZ	O
common	JJ	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decline	NN	O
in	IN	O
daytime	JJ	O
function	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
wakefulness	NN	O
promoter	NN	O
,	,	O
modafinil	NN	O
,	,	O
would	MD	O
ameliorate	VB	O
this	DT	O
decline	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
admitted	VBN	O
to	TO	O
the	DT	O
laboratory	NN	O
for	IN	O
three	CD	O
consecutive	JJ	O
nights	NNS	O
.	.	O

CPAP	NNP	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
first	JJ	O
night	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
baseline	NN	O
day	NN	O
,	,	O
and	CC	O
was	VBD	O
then	RB	O
withdrawn	NN	O
for	IN	O
the	DT	O
two	CD	O
subsequent	JJ	O
nights	NNS	O
(	(	O
nasal	JJ	O
airflow	RB	O
monitored	VBD	O
)	)	O
.	.	O

On	IN	O
each	DT	O
of	IN	O
the	DT	O
mornings	NNS	O
after	IN	O
the	DT	O
two	CD	O
CPAP	NNP	O
withdrawal	NN	O
nights	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
200	CD	O
mg	NNS	O
modafinil	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
.	.	O

Treatment	NN	O
periods	NNS	O
were	VBD	O
separated	VBN	O
by	IN	O
a	DT	O
5-week	JJ	O
washout	NN	O
.	.	O

Driving	NNP	Mental
simulator	NN	Mental
performance	NN	Mental
,	,	Mental
neurocognitive	JJ	Mental
performance	NN	Mental
,	,	O
and	CC	O
subjective	JJ	Mental
alertness	NN	Mental
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
AusEd	NNP	O
driving	NN	O
simulator	NN	O
,	,	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
,	,	O
and	CC	O
Karolinska	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
,	,	O
respectively	RB	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
During	IN	O
CPAP	NNP	O
withdrawal	NN	O
,	,	O
severe	JJ	Physical
sleep-disordered	JJ	Physical
breathing	NN	Physical
was	VBD	O
evident	JJ	O
and	CC	O
administration	NN	O
of	IN	O
modafinil	NNS	O
improved	VBN	O
simulated	JJ	Mental
driving	NN	Mental
performance	NN	Mental
(	(	Mental
steering	VBG	Mental
variability	NN	Mental
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
;	:	O
mean	JJ	Mental
reaction	NN	Mental
time	NN	Mental
,	,	O
P	NNP	O
<	NNP	O
or=	VBZ	O
0.0002	CD	O
;	:	O
lapses	NNS	Mental
,	,	O
P	NNP	O
<	NNP	O
or=	VBZ	O
0.01	CD	O
on	IN	O
a	DT	O
concurrent	JJ	O
task	NN	O
)	)	O
,	,	O
psychomotor	JJ	Mental
vigilance	NN	Mental
task	NN	Mental
(	(	O
mean	JJ	O
1/reaction	CD	O
time	NN	O
and	CC	O
lapses	NNS	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
or=	IN	O
0.0002	CD	O
)	)	O
,	,	O
and	CC	O
subjective	JJ	Mental
sleepiness	NN	Mental
(	(	O
P	NNP	O
<	NNP	O
or=	IN	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Modafinil	NNP	O
prevented	VBD	O
the	DT	O
decline	NN	O
in	IN	O
simulated	JJ	O
driving	NN	Mental
performance	NN	Mental
,	,	O
neurocognitive	JJ	Mental
performance	NN	Mental
,	,	O
and	CC	O
subjective	JJ	Mental
sleepiness	NN	Mental
in	IN	O
patients	NNS	O
with	IN	O
OSA	NNP	O
with	IN	O
acutely	RB	O
interrupted	VBN	O
CPAP	NNP	O
therapy	NN	O
.	.	O

Clinical	JJ	O
trial	NN	O
registered	VBD	O
with	IN	O
the	DT	O
Australian	JJ	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
at	IN	O
www.anzctr.org.au	NN	O
(	(	O
ACTRN12606000027516	NNP	O
)	)	O
.	.	O

Protective	JJ	O
effect	NN	O
of	IN	O
high-dose	JJ	O
medroxyprogesterone	NN	O
acetate	NN	O
(	(	O
HD-MPA	NNP	O
)	)	O
on	IN	O
hematological	JJ	Physical
toxicity	NN	Physical
induced	VBN	O
by	IN	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	O
solid	JJ	O
tumors	NNS	O
:	:	O
a	DT	O
multicentric	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

MPA-Hematology	NNP	O
Italian	JJ	O
Cooperative	NNP	O
Group	NNP	O
.	.	O

A	NNP	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
comparing	VBG	O
active	JJ	O
treatment	NN	O
with	IN	O
placebo	NN	O
in	IN	O
227	CD	O
patients	NNS	O
with	IN	O
breast	NN	O
,	,	O
colorectal	NN	O
,	,	O
lung	NN	O
and	CC	O
other	JJ	O
solid	JJ	O
forms	NNS	O
of	IN	O
cancer	NN	O
.	.	O

Combination	NNP	O
therapy	NN	O
,	,	O
(	(	O
CT	NNP	O
)	)	O
conventionally	RB	O
employed	VBN	O
for	IN	O
the	DT	O
various	JJ	O
types	NNS	O
of	IN	O
tumor	NN	O
involved	VBN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
MPA	NNP	O
(	(	O
117	CD	O
patients	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
110	CD	O
patients	NNS	O
)	)	O
.	.	O

MPA	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
as	IN	O
tablets	NNS	O
,	,	O
as	IN	O
a	DT	O
dose	NN	O
of	IN	O
500	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
,	,	O
briefly	NN	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
incidence	NN	Physical
of	IN	Physical
leukopenia	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
MPA	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
breast	NN	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

Tumors	NNS	Physical
of	IN	Physical
the	DT	Physical
lung	NN	Physical
and	CC	Physical
other	JJ	Physical
solid	JJ	Physical
forms	NNS	Physical
showed	VBD	O
no	DT	O
such	JJ	O
difference	NN	O
.	.	O

The	DT	O
incidence	NN	Physical
of	IN	Physical
thrombocytopenia	NN	Physical
was	VBD	O
the	DT	O
same	JJ	O
in	IN	O
all	DT	O
disease	NN	O
groups	NNS	O
.	.	O

Objective	JJ	Physical
responses	NNS	Physical
(	(	Physical
CR	NNP	Physical
+	NNP	Physical
PR	NNP	Physical
)	)	Physical
were	VBD	O
observed	VBN	O
in	IN	O
23/46	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
of	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
CT	NNP	O
+	NNP	O
MPA	NNP	O
,	,	O
and	CC	O
in	IN	O
13/47	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
of	IN	O
those	DT	O
given	VBN	O
CT	NNP	O
+	NNP	O
placebo	NN	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

Subjective	JJ	Others
parameters	NNS	Others
also	RB	O
showed	VBD	O
more	RBR	O
improvement	NN	O
in	IN	O
the	DT	O
MPA	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
patients	NNS	O
given	VBN	O
CT	NNP	O
alone	RB	O
.	.	O

No	UH	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
other	JJ	O
types	NNS	O
of	IN	O
tumor	NN	O
,	,	O
but	CC	O
the	DT	O
numbers	NNS	O
in	IN	O
this	DT	O
population	NN	O
were	VBD	O
very	RB	O
limited	JJ	O
.	.	O

In	IN	O
a	DT	O
group	NN	O
of	IN	O
45	CD	O
patients	NNS	O
,	,	O
antithrombin	JJ	Physical
III	NNP	Physical
a	DT	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
,	,	Physical
antithrombin	JJ	Physical
III	NNP	Physical
R	NNP	Physical
:	:	Physical
Ag	NNP	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
,	,	Physical
plasminogen	NN	Physical
(	(	Physical
mg/dl	NN	Physical
)	)	Physical
,	,	Physical
alpha-2	JJ	Physical
macroglobulin	NN	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
,	,	Physical
factor	NN	Physical
VIII	NNP	Physical
C	NNP	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
,	,	Physical
factor	NN	Physical
VIII	NNP	Physical
R	NNP	Physical
:	:	Physical
Ag	NNP	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
and	CC	Physical
factor	NN	Physical
IX	NNP	Physical
C	NNP	Physical
(	(	Physical
%	NN	Physical
)	)	Physical
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
most	RBS	O
interesting	JJ	O
post-treatment	JJ	O
findings	NNS	O
were	VBD	O
an	DT	O
increase	NN	O
in	IN	O
anti-thrombin	JJ	Physical
III	NNP	Physical
(	(	Physical
activity	NN	Physical
and	CC	Physical
antigen	NN	Physical
level	NN	Physical
)	)	Physical
and	CC	Physical
in	IN	Physical
plasminogen	NN	Physical
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
MPA	NNP	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
thrombosis	NN	O
,	,	O
and	CC	O
might	MD	O
even	RB	O
,	,	O
to	TO	O
some	DT	O
extent	NN	O
,	,	O
impede	VB	O
tumor-induced	JJ	O
thrombophilia	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Marimastat	NNP	O
as	IN	O
maintenance	NN	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

This	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
orally	RB	O
administered	VBN	O
matrix	JJ	O
metalloproteinase	NN	O
inhibitor	NN	O
,	,	O
marimastat	NN	O
,	,	O
to	TO	O
prolong	VB	O
survival	NN	Mortality
in	IN	O
patients	NNS	O
with	IN	O
non-resectable	JJ	O
gastric	JJ	O
and	CC	O
gastro-oesophageal	JJ	O
adenocarcinoma	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
and	CC	O
sixty-nine	JJ	O
patients	NNS	O
with	IN	O
histological	JJ	O
proof	NN	O
of	IN	O
adenocarcinoma	NN	O
,	,	O
who	WP	O
had	VBD	O
received	VBN	O
no	RB	O
more	RBR	O
than	IN	O
a	DT	O
single	JJ	O
regimen	NN	O
of	IN	O
5-fluorouracil-based	JJ	O
chemotherapy	NN	O
,	,	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
marimastat	NN	O
(	(	O
10	CD	O
mg	NN	O
b.d	NN	O
.	.	O

)	)	O
or	CC	O
placebo	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
was	VBD	O
tolerable	JJ	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
overall	JJ	Mortality
survival	NN	Mortality
with	IN	O
secondary	JJ	O
endpoints	NNS	O
of	IN	O
time	NN	O
to	TO	O
disease	VB	Physical
progression	NN	Physical
and	CC	O
quality	NN	Mental
of	IN	Mental
life	NN	Mental
.	.	O

At	IN	O
the	DT	O
point	NN	O
of	IN	O
protocol-defined	JJ	O
study	NN	O
completion	NN	O
(	(	O
85	CD	O
%	NN	O
mortality	NN	O
in	IN	O
the	DT	O
placebo	NN	O
arm	NN	O
)	)	O
there	EX	O
was	VBD	O
a	DT	O
modest	JJ	O
difference	NN	O
in	IN	O
survival	NN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
population	NN	O
in	IN	O
favour	NN	O
of	IN	O
marimastat	NN	O
(	(	O
P=0.07	NNP	O
log-rank	JJ	O
test	NN	O
,	,	O
hazard	NN	O
ratio=1.23	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.98-1.55	NNP	O
)	)	O
)	)	O
.	.	O

This	DT	O
survival	JJ	Mortality
benefit	NN	Mortality
was	VBD	O
maintained	VBN	O
over	IN	O
a	DT	O
further	JJ	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
(	(	O
P=0.024	NNP	O
,	,	O
hazard	NN	O
ratio=1.27	NN	O
(	(	O
1.03-1.57	JJ	O
)	)	O
)	)	O
.	.	O

The	DT	O
median	JJ	Mortality
survival	NN	Mortality
was	VBD	O
138	CD	O
days	NNS	O
for	IN	O
placebo	NN	O
and	CC	O
160	CD	O
days	NNS	O
for	IN	O
marimastat	NN	O
,	,	O
with	IN	O
2-year	JJ	O
survival	NN	O
of	IN	O
3	CD	O
%	NN	O
and	CC	O
9	CD	O
%	NN	O
respectively	RB	O
.	.	O

A	DT	O
significant	JJ	Mortality
survival	JJ	Mortality
benefit	NN	Mortality
was	VBD	O
identified	VBN	O
at	IN	O
study	NN	O
completion	NN	O
in	IN	O
the	DT	O
pre-defined	JJ	O
sub-group	NN	O
of	IN	O
123	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
prior	RB	O
chemotherapy	NN	O
(	(	O
P=0.045	NNP	O
,	,	O
hazard	NN	O
ratio=1.53	NN	O
(	(	O
1.00-2.34	JJ	O
)	)	O
)	)	O
.	.	O

This	DT	O
benefit	NN	O
increased	VBD	O
with	IN	O
2	CD	O
years	NNS	O
additional	JJ	O
follow-up	NN	O
(	(	O
P=0.006	NNP	O
,	,	O
hazard	NN	O
ratio=1.68	NN	O
(	(	O
1.16-2.44	JJ	O
)	)	O
)	)	O
,	,	O
with	IN	O
2-year	JJ	Mortality
survival	NN	Mortality
of	IN	O
5	CD	O
%	NN	O
and	CC	O
18	CD	O
%	NN	O
respectively	RB	O
.	.	O

Progression-free	JJ	Mortality
survival	NN	Mortality
was	VBD	O
also	RB	O
significantly	RB	O
longer	RBR	O
for	IN	O
patients	NNS	O
receiving	VBG	O
marimastat	NNS	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
P=0.009	NNP	O
,	,	O
hazard	NN	O
ratio=1.32	NN	O
(	(	O
1.07-1.63	JJ	O
)	)	O
)	)	O
.	.	O

Marimastat	NNP	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
musculoskeletal	JJ	Pain
pain	NN	Pain
and	CC	Pain
inflammation	NN	Pain
.	.	O

Events	NNS	Physical
of	IN	Physical
anaemia	NN	Physical
,	,	Physical
abdominal	JJ	Physical
pain	NN	Physical
,	,	Physical
jaundice	NN	Physical
and	CC	Physical
weight	JJ	Physical
loss	NN	Physical
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

This	DT	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
demonstrations	NNS	O
of	IN	O
a	DT	O
therapeutic	JJ	O
benefit	NN	O
for	IN	O
a	DT	O
matrix	JJ	O
metalloproteinase	NN	O
inhibitor	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

The	DT	O
greatest	JJS	O
benefit	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
received	VBN	O
chemotherapy	NN	O
.	.	O

A	DT	O
further	RB	O
randomised	VBN	O
study	NN	O
of	IN	O
marimastat	NN	O
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
warranted	VBN	O
.	.	O

Photodynamic	NNP	O
therapy	NN	O
with	IN	O
5-aminolaevulinic	JJ	O
acid	NN	O
or	CC	O
placebo	NN	O
for	IN	O
recalcitrant	JJ	O
foot	NN	Physical
and	CC	Physical
hand	NN	Physical
warts	NNS	Physical
:	:	Physical
randomised	VBN	O
double-blind	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Photodynamic	NNP	O
therapy	NN	O
(	(	O
PDT	NNP	O
)	)	O
with	IN	O
topical	JJ	O
5-aminolaevulinic	JJ	O
acid	NN	O
(	(	O
ALA	NNP	O
)	)	O
followed	VBN	O
by	IN	O
irradiation	NN	O
with	IN	O
incoherent	JJ	O
light	NN	O
(	(	O
ALA-PDT	NNP	O
)	)	O
for	IN	O
recalcitrant	NN	O
warts	NNS	O
have	VBP	O
had	VBN	O
beneficial	JJ	O
results	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
undertook	VBP	O
a	DT	O
randomised	JJ	O
,	,	O
parallel	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
ALA-PDT	NNP	O
versus	NN	O
placeboPDT	NN	O
for	IN	O
recalcitrant	JJ	O
foot	NN	O
and	CC	O
hand	NN	O
warts	NNS	O
.	.	O

METHODS	NNP	O
Recalcitrant	NNP	O
foot	NN	O
and	CC	O
hand	NN	O
warts	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
six	CD	O
repetitive	JJ	O
ALA-PDT	NNP	O
or	CC	O
placebo-PDT	JJ	O
interventions	NNS	O
combined	VBN	O
with	IN	O
standard	JJ	O
treatment	NN	O
encompassing	VBG	O
paring	VBG	O
followed	VBN	O
by	IN	O
a	DT	O
keratolytic	JJ	O
(	(	O
Verucid	NNP	O
)	)	O
.	.	O

Standardised	VBN	O
photographs	NN	O
of	IN	O
each	DT	O
wart	NN	O
were	VBD	O
taken	VBN	O
before	RB	O
,	,	O
during	IN	O
(	(	O
week	NN	O
7	CD	O
)	)	O
and	CC	O
after	IN	O
treatment	NN	O
(	(	O
weeks	NNS	O
14	CD	O
and	CC	O
18	CD	O
)	)	O
.	.	O

The	DT	O
area	NN	Physical
of	IN	Physical
each	DT	Physical
wart	NN	Physical
compared	VBN	Physical
with	IN	Physical
entry	NN	Physical
area	NN	Physical
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
,	,	O
measured	VBN	O
from	IN	O
photographs	NN	O
by	IN	O
an	DT	O
evaluator	NN	O
unaware	NN	O
of	IN	O
treatment	NN	O
allocation	NN	O
for	IN	O
intervention	NN	O
.	.	O

Pain	NNP	Pain
intensity	NN	Pain
immediately	RB	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
each	DT	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
five-point	JJ	O
scale	NN	O
.	.	O

FINDINGS	CC	O
A	NNP	O
total	NN	O
of	IN	O
232	CD	O
foot	NN	O
and	CC	O
hand	NN	O
warts	NNS	O
in	IN	O
45	CD	O
patients	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
the	DT	O
trial	NN	O
:	:	O
117	CD	O
warts	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
ALA-PDT	NNP	O
and	CC	O
115	CD	O
warts	NNS	O
to	TO	O
placebo-PDT	NN	O
.	.	O

In	IN	O
week	NN	O
14	CD	O
,	,	O
the	DT	O
median	JJ	Physical
relative	JJ	Physical
reduction	NN	Physical
in	IN	Physical
wart	JJ	Physical
area	NN	Physical
was	VBD	O
98	CD	O
%	NN	O
in	IN	O
the	DT	O
ALA-PDT	NNP	O
group	NN	O
(	(	O
interquartile	JJ	O
range	VBP	O
100	CD	O
%	NN	O
,	,	O
55	CD	O
%	NN	O
)	)	O
versus	VBZ	O
52	CD	O
%	NN	O
(	(	O
100	CD	O
%	NN	O
,	,	O
0	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p=0.0006	NN	O
)	)	O
.	.	O

In	IN	O
week	NN	O
18	CD	O
,	,	O
the	DT	O
median	JJ	Physical
relative	JJ	Physical
reduction	NN	Physical
in	IN	Physical
wart	JJ	Physical
area	NN	Physical
was	VBD	O
100	CD	O
%	NN	O
in	IN	O
the	DT	O
ALA-PDT	NNP	O
group	NN	O
(	(	O
100	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
)	)	O
versus	VBZ	O
71	CD	O
%	NN	O
(	(	O
100	CD	O
%	NN	O
,	,	O
0	CD	O
)	)	O
in	IN	O
the	DT	O
placebo-PDT	JJ	O
arm	NN	O
(	(	O
p=0.008	NN	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
number	NN	Others
of	IN	Others
vanishing	VBG	Others
warts	NNS	Others
and	CC	O
the	DT	O
difference	NN	Others
in	IN	Others
relative	JJ	Others
wart	JJ	Others
area	NN	Others
of	IN	Others
persisting	VBG	Others
warts	NNS	Others
at	IN	O
week	NN	O
14	CD	O
and	CC	O
18	CD	O
were	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
favour	NN	O
of	IN	O
ALA-PDT	NNP	O
.	.	O

Significantly	RB	O
more	RBR	O
ALA-PDT	JJ	O
warts	NNS	O
were	VBD	O
graded	VBN	O
at	IN	O
a	DT	O
higher	JJR	Pain
pain	NN	Pain
intensity	NN	Pain
after	IN	O
treatment	NN	O
than	IN	O
placebo-PDT	JJ	O
warts	NNS	O
.	.	O

INTERPRETATION	NNP	O
ALA-PDT	NNP	O
is	VBZ	O
superior	JJ	O
to	TO	O
placebo-PDT	NN	O
when	WRB	O
both	DT	O
wart	VBP	O
area	NN	Physical
and	CC	Physical
number	NN	Physical
of	IN	Physical
vanishing	VBG	Physical
warts	NNS	Physical
are	VBP	O
considered	VBN	O
.	.	O

Omeprazole	JJ	O
ameliorates	VBZ	O
aspirin-induced	JJ	O
gastroduodenal	JJ	O
injury	NN	O
.	.	O

Aspirin	NNP	O
and	CC	O
nonsteroidal	JJ	O
antiinflammatory	NN	O
drugs	NNS	O
(	(	O
NSAIDs	NNP	O
)	)	O
damage	VBP	O
the	DT	O
gastroduodenal	JJ	O
epithelium	NN	O
by	IN	O
two	CD	O
mechanisms	NNS	O
:	:	O
direct	JJ	O
toxic	NN	O
effects	NNS	O
and	CC	O
effects	NNS	O
related	VBN	O
to	TO	O
the	DT	O
depletion	NN	O
of	IN	O
endogenous	JJ	O
prostaglandins	NNS	O
.	.	O

The	DT	O
prostaglandin-depleted	JJ	O
mucosa	NN	O
has	VBZ	O
increased	VBN	O
susceptibility	NN	O
to	TO	O
luminal	JJ	O
aggressive	JJ	O
factors	NNS	O
,	,	O
yet	RB	O
the	DT	O
role	NN	O
of	IN	O
acid	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
the	DT	O
NSAID	NNP	O
ulcer	NN	O
is	VBZ	O
controversial	JJ	O
.	.	O

In	IN	O
humans	NNS	O
,	,	O
standard	JJ	O
doses	NNS	O
of	IN	O
H2-receptor	NNP	O
antagonists	NNS	O
prevent	VBP	O
only	RB	O
duodenal	JJ	O
injury	NN	O
and	CC	O
provide	VB	O
no	DT	O
protection	NN	O
for	IN	O
the	DT	O
gastric	JJ	O
mucosa	NN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
more	RBR	O
potent	JJ	O
suppression	NN	O
of	IN	O
acid	NN	O
can	MD	O
prevent	VB	O
NSAID	NNP	O
damage	NN	O
.	.	O

Twenty	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
omeprazole	JJ	O
,	,	O
40	CD	O
mg/day	NN	O
prevents	NNS	O
gastroduodenal	JJ	O
injury	NN	O
due	JJ	O
to	TO	O
two	CD	O
weeks	NNS	O
of	IN	O
aspirin	JJ	O
administration	NN	O
(	(	O
650	CD	O
mg	RB	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
)	)	O
.	.	O

The	DT	O
severity	NN	Physical
of	IN	Physical
mucosal	JJ	Physical
injury	NN	Physical
was	VBD	O
quantitated	VBN	O
by	IN	O
endoscopy	NN	O
and	CC	O
stratified	VBN	O
by	IN	O
a	DT	O
scale	NN	O
from	IN	O
0	CD	O
(	(	O
normal	JJ	O
)	)	O
to	TO	O
4	CD	O
(	(	O
ulcer	NN	O
)	)	O
.	.	O

Fourteen	CD	O
of	IN	O
the	DT	O
20	CD	O
subjects	NNS	O
had	VBD	O
less	RBR	O
gastric	JJ	Physical
injury	NN	Physical
during	IN	O
cotherapy	NN	O
with	IN	O
omeprazole	JJ	O
.	.	O

All	DT	O
six	CD	O
with	IN	O
no	DT	O
difference	NN	O
received	VBD	O
aspirin	JJ	O
plus	CC	O
omeprazole	JJ	O
in	IN	O
the	DT	O
first	JJ	O
treatment	NN	O
period	NN	O
.	.	O

Omeprazole	NNP	O
significantly	RB	O
decreased	VBD	O
aspirin-induced	JJ	Physical
gastric	JJ	Physical
mucosal	NN	Physical
injury	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
Wilcoxon	NNP	O
signed-rank	JJ	O
test	NN	O
)	)	O
.	.	O

Omeprazole	NNP	O
protected	VBD	O
85	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
from	IN	O
extensive	JJ	Physical
gastric	JJ	Physical
erosions	NNS	Physical
(	(	O
often	RB	O
associated	VBN	O
with	IN	O
evidence	NN	O
of	IN	O
intraluminal	JJ	O
bleeding	NN	O
)	)	O
or	CC	O
ulceration	NN	Physical
,	,	O
whereas	RB	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
developed	VBD	O
aspirin-induced	JJ	Physical
grades	NNS	Physical
3	CD	Physical
and	CC	Physical
4	CD	Physical
gastric	JJ	Physical
injury	NN	Physical
on	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	RB	O
0.01	CD	O
by	IN	O
chi	NNS	O
2	CD	O
)	)	O
.	.	O

No	UH	O
subject	JJ	O
taking	VBG	O
omeprazole	NN	O
developed	VBD	O
duodenal	JJ	Physical
injury	NN	Physical
of	IN	Physical
any	DT	Physical
grade	NN	Physical
,	,	O
while	IN	O
50	CD	O
%	NN	O
taking	VBG	O
placebo	NN	O
developed	VBD	O
erosions	NNS	Physical
and	CC	O
15	CD	O
%	NN	O
had	VBD	O
ulcer	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Medication	NNP	O
side	JJ	O
effects	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
subjects	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
a	DT	O
UK	JJ	O
population	NN	O
:	:	O
a	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Common	NNP	O
clinical	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
older	JJR	O
women	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
most	JJS	O
of	IN	O
these	DT	O
risk	NN	O
factors	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
confirmed	VBN	O
in	IN	O
a	DT	O
UK	NNP	O
population	NN	O
.	.	O

AIM	NNP	O
To	TO	O
confirm	VB	O
the	DT	O
important	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
older	JJR	O
women	NNS	O
.	.	O

DESIGN	NNP	O
Comprehensive	NNP	O
cohort	NN	O
study	NN	O
(	(	O
CCS	NNP	O
)	)	O
with	IN	O
a	DT	O
nested	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
CCS	NNP	O
included	VBD	O
4292	CD	O
women	NNS	O
aged	VBD	O
>	JJ	O
70	CD	O
years	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
potential	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
,	,	O
and	CC	O
followed-up	JJ	O
participants	NNS	O
for	IN	O
24	CD	O
months	NNS	O
for	IN	O
incidence	NN	O
of	IN	O
non-vertebral	JJ	O
fractures	NNS	O
.	.	O

RESULTS	NNP	O
Odds	NNP	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
for	IN	O
predicting	VBG	O
any	DT	O
non-vertebral	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	Physical
fracture	NN	Physical
,	,	O
2.67	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
2.10-3.40	CD	O
)	)	O
;	:	O
a	DT	Physical
fall	NN	Physical
in	IN	Physical
the	DT	Physical
last	JJ	Physical
12	CD	Physical
months	NNS	Physical
,	,	O
2.06	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.63-2.59	CD	O
)	)	O
;	:	O
and	CC	O
age	NN	Others
(	(	O
per	IN	O
year	NN	O
increase	NN	O
)	)	O
,	,	O
1.03	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.01-1.05	CD	O
)	)	O
.	.	O

ORs	NNP	O
for	IN	O
predicting	VBG	O
hip	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	Physical
fracture	NN	Physical
,	,	O
2.31	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.31-4.08	CD	O
)	)	O
;	:	O
low	JJ	Physical
body	NN	Physical
weight	NN	Physical
(	(	O
<	JJ	O
58	CD	O
kg	NN	O
)	)	O
,	,	O
2.20	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.28-3.77	CD	O
)	)	O
;	:	O
maternal	JJ	Physical
history	NN	Physical
of	IN	Physical
hip	NN	Physical
fracture	NN	Physical
,	,	O
1.68	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.85-3.31	NN	O
)	)	O
;	:	O
a	DT	Physical
fall	NN	Physical
in	IN	Physical
the	DT	Physical
last	JJ	Physical
12	CD	Physical
months	NNS	Physical
,	,	O
2.92	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.70-5.01	CD	O
)	)	O
;	:	O
and	CC	O
age	NN	Others
(	(	O
per	IN	O
year	NN	O
increase	NN	O
)	)	O
,	,	O
1.09	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.04-1.13	CD	O
)	)	O
.	.	O

ORs	NNP	O
for	IN	O
predicting	VBG	O
wrist	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	Physical
fracture	NN	Physical
,	,	O
2.29	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.56-3.34	CD	O
)	)	O
;	:	O
and	CC	O
a	DT	Physical
fall	NN	Physical
in	IN	Physical
the	DT	Physical
last	JJ	Physical
12	CD	Physical
months	NNS	Physical
,	,	O
1.60	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.10-2.31	CD	O
)	)	O
.	.	O

Being	VBG	O
a	DT	O
current	JJ	Mental
smoker	NN	Mental
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
risk	NN	O
,	,	O
and	CC	O
was	VBD	O
consistent	JJ	O
across	IN	O
all	DT	O
fracture	NN	O
types	NNS	O
.	.	O

DISCUSSION	NNP	O
Older	NNP	O
women	NNS	O
with	IN	O
the	DT	O
clinical	JJ	O
risk	NN	O
factors	NNS	O
identified	VBN	O
in	IN	O
this	DT	O
study	NN	O
should	MD	O
be	VB	O
investigated	VBN	O
for	IN	O
osteoporosis	NN	O
or	CC	O
offered	VBN	O
preventive	JJ	O
treatment	NN	O
.	.	O

The	DT	O
treatment	NN	O
of	IN	O
localized	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
in	IN	O
children	NNS	O
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Investigators	NNS	O
of	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
entered	VBD	O
73	CD	O
children	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
localized	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
on	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
systemic	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
a	DT	O
four-drug	JJ	O
program	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
methotrexate	NN	O
,	,	O
prednisone	NN	O
[	NNP	O
COMP	NNP	O
]	NNP	O
)	)	O
or	CC	O
a	DT	O
10-drug	JJ	O
(	(	O
LSA2-L2	NNP	O
modified	VBN	O
)	)	O
program	NN	O
of	IN	O
18	CD	O
months	NNS	O
duration	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
with	IN	O
intrathecal	JJ	O
methotrexate	NN	O
and	CC	O
most	JJS	O
received	JJ	O
local	JJ	O
or	CC	O
regional	JJ	O
radiation	NN	O
treatment	NN	O
.	.	O

The	DT	O
three-year	JJ	Mortality
relapse-free	JJ	Mortality
survival	NN	Mortality
rate	NN	Mortality
for	IN	O
all	DT	O
patients	NNS	O
(	(	O
N	NNP	O
=	NNP	O
73	CD	O
)	)	O
was	VBD	O
84	CD	O
%	NN	O
;	:	O
for	IN	O
COMP	NNP	O
(	(	O
N	NNP	O
=	NNP	O
42	CD	O
)	)	O
was	VBD	O
85	CD	O
%	NN	O
,	,	O
and	CC	O
for	IN	O
LSA2-L2	NNP	O
(	(	O
N	NNP	O
=	NNP	O
31	CD	O
)	)	O
was	VBD	O
84	CD	O
%	NN	O
.	.	O

Of	IN	O
the	DT	O
12	CD	O
patients	NNS	O
who	WP	O
suffered	VBD	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
eight	CD	O
relapsed	VBN	Others
and	CC	O
four	CD	O
died	NN	Mortality
of	IN	Mortality
toxicity	NN	Mortality
.	.	O

Histopathology	NNP	O
was	VBD	O
reviewed	VBN	O
centrally	RB	O
.	.	O

Of	IN	O
32	CD	O
patients	NNS	O
with	IN	O
nonlymphoblastic	JJ	O
disease	NN	O
treated	VBD	O
with	IN	O
COMP	NNP	O
only	RB	O
one	CD	O
relapsed	VBD	Physical
.	.	O

Of	IN	O
26	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
LSA2-L2	NNP	O
,	,	O
four	CD	O
relapsed	VBN	Physical
.	.	O

Patients	NNS	O
with	IN	O
localized	JJ	Physical
lymphoblastic	JJ	Physical
disease	NN	Physical
were	VBD	O
uncommon	JJ	O
.	.	O

None	NN	O
of	IN	O
three	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
LSA2-L2	NNP	O
relapsed	VBD	O
compared	VBN	O
with	IN	O
three	CD	O
of	IN	O
nine	CD	O
treated	VBN	O
with	IN	O
COMP	NNP	O
.	.	O

COMP	NNP	O
is	VBZ	O
an	DT	O
excellent	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
localized	JJ	O
disease	NN	O
of	IN	O
nonlymphoblastic	JJ	O
type	NN	O
,	,	O
but	CC	O
the	DT	O
relative	JJ	O
value	NN	O
of	IN	O
the	DT	O
two	CD	O
regimens	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
localized	JJ	O
lymphoblastic	JJ	O
disease	NN	O
is	VBZ	O
uncertain	JJ	O
.	.	O

Relationship	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
intravenous	JJ	O
gammaglobulin	NN	O
to	TO	O
the	DT	O
prevention	NN	O
of	IN	O
infections	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
common	JJ	O
variable	JJ	O
immunodeficiency	NN	O
.	.	O

The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
3	CD	O
dosages	NNS	O
of	IN	O
intravenous	JJ	O
gammaglobulins	NNS	O
to	TO	O
prevent	VB	O
infectious	JJ	O
episodes	NNS	O
in	IN	O
adult	NN	O
common	JJ	O
variable	JJ	O
immunodeficiency	NN	O
.	.	O

We	PRP	O
designed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
dose-assessing	JJ	O
study	NN	O
.	.	O

The	DT	O
setting	NN	O
was	VBD	O
at	IN	O
University	NNP	O
Hospital	NNP	O
,	,	O
Out-patient	NNP	O
Clinic	NNP	O
.	.	O

Our	PRP$	O
patients	NNS	O
were	VBD	O
twenty-one	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
common	JJ	O
variable	JJ	O
immunodeficiency	NN	O
.	.	O

The	DT	O
measurements	NNS	O
were	VBD	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
number	NN	Physical
and	CC	Physical
severity	NN	Physical
of	IN	Physical
infections	NNS	Physical
using	VBG	O
3	CD	O
various	JJ	O
dosages	NNS	O
of	IN	O
intravenous	JJ	O
gammaglobulins	NNS	O
,	,	O
each	DT	O
given	VBN	O
monthly	RB	O
for	IN	O
M	NNP	O
least	JJS	O
6	CD	O
months	NNS	O
.	.	O

Results	NNS	O
indicated	VBD	O
four	CD	O
hundred	CD	O
and	CC	O
eighty-four	JJ	O
infectious	JJ	Physical
episodes	NNS	Physical
occurred	VBD	O
while	IN	O
giving	VBG	O
305	CD	O
infusions	NNS	O
of	IN	O
IVIG	NNP	O
200	CD	O
mg/kg	NN	O
;	:	O
205	CD	O
infectious	JJ	O
episodes	NNS	O
while	IN	O
giving	VBG	O
170	CD	O
infusions	NNS	O
of	IN	O
400	CD	O
mg/kg	NNS	O
and	CC	O
436	CD	O
infectious	JJ	O
episodes	NNS	O
while	IN	O
giving	VBG	O
247	CD	O
infusions	NNS	O
of	IN	O
600	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
morbidity	NN	Mortality
scores	NNS	Mortality
(	(	Mortality
infection/infusion	NN	Mortality
)	)	Mortality
were	VBD	O
1.59	CD	O
,	,	O
1.21	CD	O
and	CC	O
1.77	CD	O
respectively	RB	O
(	(	O
p	JJ	O
-	:	O
N/S	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
severity	NN	Physical
of	IN	Physical
infections	NNS	Physical
on	IN	O
the	DT	O
above	JJ	O
3	CD	O
dosages	NNS	O
,	,	O
and	CC	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
duration	NN	Physical
of	IN	Physical
infection-free	JJ	Physical
intervals	NNS	Physical
.	.	O

The	DT	O
conclusions	NNS	O
resulted	VBD	O
in	IN	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
morbidity	NN	Mortality
in	IN	O
adult	NN	O
patients	NNS	O
with	IN	O
common	JJ	O
variable	JJ	O
immunodeficiency	NN	O
treated	VBN	O
in	IN	O
cross-over	JJ	O
pattern	NN	O
with	IN	O
IVIG	NNP	O
200	CD	O
mg/kg	NN	O
,	,	O
400	CD	O
mg/kg	NN	O
and	CC	O
600	CD	O
mg/kg	NN	O
.	.	O

Thus	NNP	O
,	,	O
high	JJ	O
dosages	NNS	O
of	IN	O
IVIG	NNP	O
are	VBP	O
not	RB	O
conferring	VBG	O
better	JJR	O
protection	NN	O
against	IN	O
infections	NNS	O
in	IN	O
such	JJ	O
patients	NNS	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
educational	JJ	O
interventions	NNS	O
to	TO	O
enhance	VB	O
the	DT	O
adoption	NN	Physical
of	IN	Physical
fee-based	JJ	Physical
arsenic	JJ	Physical
testing	NN	Physical
in	IN	O
Bangladesh	NNP	O
:	:	O
a	DT	O
cluster	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

Arsenic	NNP	O
(	(	O
As	IN	O
)	)	O
testing	NN	O
could	MD	O
help	VB	O
22	CD	O
million	CD	O
people	NNS	O
,	,	O
using	VBG	O
drinking	NN	O
water	NN	O
sources	NNS	O
that	WDT	O
exceed	VBP	O
the	DT	O
Bangladesh	NNP	O
As	NNP	O
standard	NN	O
,	,	O
to	TO	O
identify	VB	O
safe	JJ	O
sources	NNS	O
.	.	O

A	DT	O
cluster	NN	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	Physical
of	IN	Physical
household	NN	Physical
education	NN	Physical
and	CC	Physical
local	JJ	Physical
media	NNS	Physical
in	IN	O
the	DT	O
increasing	VBG	O
demand	NN	O
for	IN	O
fee-based	JJ	O
As	IN	O
testing	VBG	O
.	.	O

Randomly	RB	O
selected	VBN	O
households	NNS	O
(	(	O
N	NNP	O
=	NNP	O
452	CD	O
)	)	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
interventions	NNS	O
implemented	VBN	O
by	IN	O
community	NN	O
workers	NNS	O
:	:	O
1	CD	O
)	)	O
fee-based	JJ	O
As	IN	O
testing	VBG	O
with	IN	O
household	NN	O
education	NN	O
(	(	O
HE	NNP	O
)	)	O
;	:	O
2	CD	O
)	)	O
fee-based	JJ	O
As	IN	O
testing	VBG	O
with	IN	O
household	NN	O
education	NN	O
and	CC	O
a	DT	O
local	JJ	O
media	NNS	O
campaign	NN	O
(	(	O
HELM	NNP	O
)	)	O
;	:	O
and	CC	O
3	CD	O
)	)	O
fee-based	JJ	O
As	IN	O
testing	VBG	O
alone	RB	O
(	(	O
Control	NNP	O
)	)	O
.	.	O

The	DT	O
fee	NN	O
for	IN	O
the	DT	O
As	NNP	O
test	NN	O
was	VBD	O
US	NNP	O
$	$	O
0.28	CD	O
,	,	O
higher	JJR	O
than	IN	O
the	DT	O
cost	NN	O
of	IN	O
the	DT	O
test	NN	O
(	(	O
US	NNP	O
$	$	O
0.16	CD	O
)	)	O
.	.	O

Of	IN	O
households	NNS	O
with	IN	O
untested	JJ	O
wells	NNS	O
,	,	O
93	CD	O
%	NN	O
in	IN	O
both	DT	O
intervention	NN	O
groups	NNS	O
HE	NNP	Physical
and	CC	Physical
HELM	NNP	Physical
purchased	VBD	Physical
an	DT	Physical
As	IN	Physical
test	NN	Physical
,	,	O
whereas	IN	O
only	RB	O
53	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
fee-based	JJ	Others
As	IN	Others
testing	VBG	Others
with	IN	O
household	NN	Physical
education	NN	Physical
is	VBZ	Physical
effective	JJ	Physical
in	IN	Physical
the	DT	Physical
increasing	VBG	Physical
demand	NN	Physical
for	IN	Physical
As	IN	Physical
testing	VBG	Physical
in	IN	O
rural	JJ	O
Bangladesh	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
weight	NN	O
training	NN	O
on	IN	O
bone	JJ	Physical
mineral	JJ	Physical
density	NN	Physical
and	CC	O
bone	NN	Physical
turnover	NN	Physical
in	IN	O
postmenopausal	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
with	IN	O
bone	JJ	O
loss	NN	O
:	:	O
a	DT	O
24-month	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

SUMMARY	VB	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
24	CD	O
months	NNS	O
of	IN	O
weight	JJ	O
training	NN	O
exercises	NNS	O
enhanced	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
risedronate	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
vitamin	NN	O
D	NNP	O
in	IN	O
maintaining	VBG	O
or	CC	O
improving	VBG	O
bone	JJ	Physical
mineral	JJ	Physical
density	NN	Physical
(	(	Physical
BMD	NNP	Physical
)	)	Physical
in	IN	O
223	CD	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	O
had	VBN	O
no	DT	O
improvement	NN	O
in	IN	O
BMD	NNP	Physical
but	CC	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	Physical
.	.	O

INTRODUCTION	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
(	(	O
1	CD	O
)	)	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
(	(	O
BCS	NNP	O
)	)	O
with	IN	O
bone	NN	O
loss	NN	O
taking	VBG	O
24	CD	O
months	NNS	O
of	IN	O
risedronate	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
vitamin	NN	O
D	NNP	O
had	VBD	O
increased	VBN	O
bone	RB	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
,	,	O
femoral	JJ	O
neck	NN	O
,	,	O
L1-L4	NNP	O
spine	NN	O
,	,	O
total	JJ	O
radius	NN	O
and	CC	O
33	CD	O
%	NN	O
radius	NN	O
,	,	O
and	CC	O
decreased	VBD	O
bone	NN	Physical
turnover	NN	Physical
;	:	O
(	(	O
2	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
participated	VBD	O
in	IN	O
strength/weight	JJ	O
training	NN	O
(	(	O
ST	NNP	O
)	)	O
exercises	NNS	O
had	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
BMD	NNP	Physical
and	CC	O
greater	JJR	O
decreases	NNS	O
in	IN	O
bone	NN	Physical
turnover	NN	Physical
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
exercised	VBD	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
preserve	VB	O
(	(	O
at	IN	O
least	JJS	O
maintain	NN	O
)	)	O
BMD	NNP	Physical
.	.	O

METHODS	NNP	O
Postmenopausal	NNP	O
BCS	NNP	O
(	(	O
223	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
exercise	VB	O
plus	JJ	O
medication	NN	O
or	CC	O
medication	NN	O
only	RB	O
groups	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
24	CD	O
months	NNS	O
of	IN	O
1,200	CD	O
mg	NN	O
of	IN	O
calcium	NN	O
and	CC	O
400	CD	O
IU	NNP	O
of	IN	O
vitamin	NNP	O
D	NNP	O
daily	RB	O
and	CC	O
35	CD	O
mg	NN	O
of	IN	O
risedronate	JJ	O
weekly	JJ	O
,	,	O
and	CC	O
the	DT	O
exercise	NN	O
group	NN	O
additionally	RB	O
had	VBD	O
ST	NNP	O
exercises	NNS	O
twice	RB	O
weekly	RB	O
.	.	O

RESULTS	NNP	O
After	IN	O
24	CD	O
months	NNS	O
,	,	O
women	NNS	O
who	WP	O
took	VBD	O
medications	NNS	O
without	IN	O
exercising	VBG	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
BMD	NNP	Physical
at	IN	Physical
the	DT	Physical
total	JJ	Physical
hip	NN	Physical
(	(	O
+1.81	CD	O
%	NN	O
)	)	O
and	CC	O
spine	NN	Physical
(	(	O
+2.85	CD	O
%	NN	O
)	)	O
and	CC	O
significant	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	Physical
B	NNP	Physical
(	(	O
-8.7	NNP	O
%	NN	O
)	)	O
and	CC	O
serum	JJ	Physical
NTx	NNP	Physical
(	(	O
-16.7	NNP	O
%	NN	O
)	)	O
.	.	O

Women	NNS	O
who	WP	O
also	RB	O
exercised	VBD	O
had	VBD	O
additional	JJ	O
increases	NNS	O
in	IN	O
BMD	NNP	Physical
at	IN	Physical
the	DT	Physical
femoral	JJ	Physical
neck	NN	Physical
(	(	O
+0.29	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	Physical
hip	NN	Physical
(	(	O
+0.34	CD	O
%	NN	O
)	)	O
,	,	O
spine	NN	Physical
(	(	O
+0.23	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	Physical
radius	NN	Physical
(	(	O
+0.30	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
additional	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	Physical
B	NNP	Physical
(	(	O
-2.4	NNP	O
%	NN	O
)	)	O
and	CC	O
Serum	NNP	Physical
NTx	NNP	Physical
(	(	O
-6.5	NNP	O
%	NN	O
)	)	O
.	.	O

Additional	JJ	O
changes	NNS	O
in	IN	O
BMD	NNP	Physical
and	CC	O
bone	NN	Physical
turnover	NN	Physical
with	IN	O
exercise	NN	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	Physical
at	IN	O
the	DT	O
total	JJ	Physical
hip	NN	Physical
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.66	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
femoral	JJ	Physical
neck	NN	Physical
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.63	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Strength/weight	NNP	O
training	NN	O
exercises	NNS	O
may	MD	O
prevent	VB	O
loss	NN	O
of	IN	O
BMD	NNP	Physical
in	IN	O
postmenopausal	NN	O
BCS	NNP	O
at	IN	O
risk	NN	O
for	IN	O
bone	NN	O
loss	NN	O
.	.	O

[	NN	O
Simvastatin	NNP	O
versus	NN	O
gemfibrozil	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
hypercholesterolemia	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
hydrochlorothiazide	JJ	O
]	NN	O
.	.	O

Recent	JJ	O
pharmacological	JJ	O
studies	NNS	O
confirmed	VBD	O
the	DT	O
role	NN	O
of	IN	O
hypercholesterolemia	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
coronary	JJ	O
atherosclerosis	NN	O
.	.	O

A	DT	O
10	CD	O
%	NN	O
reduction	NN	O
in	IN	O
cholesterol	NN	O
levels	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
by	IN	O
15	CD	O
%	NN	O
.	.	O

However	RB	O
many	JJ	O
hypercholesterolemic	JJ	O
patients	NNS	O
often	RB	O
suffer	VBP	O
from	IN	O
arterial	JJ	O
hypertension	NN	O
and	CC	O
drugs	NNS	O
such	JJ	O
as	IN	O
thiazide	JJ	O
diuretics	NNS	O
cause	VBP	O
an	DT	O
imbalance	NN	O
in	IN	O
lipid	JJ	O
metabolism	NN	O
.	.	O

The	DT	O
efficacy	NN	Others
and	CC	Others
the	DT	Others
tolerability	NN	Others
of	IN	O
simvastatin	NN	O
(	(	O
a	DT	O
inhibitor	NN	O
of	IN	O
HGM-CoA	NNP	O
reductase	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
gemfibrozil	NN	O
(	(	O
a	DT	O
fibric	NN	O
acid	NN	O
derivative	NN	O
,	,	O
which	WDT	O
can	MD	O
reduce	VB	O
the	DT	O
VLDL	NNP	O
level	NN	O
)	)	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
2	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
hypercholesterolemia	NN	O
and	CC	O
mild-to-moderate	JJ	O
essential	JJ	O
hypertension	NN	O
treated	VBN	O
with	IN	O
hydrochlorothiazide	NN	O
.	.	O

After	IN	O
10	CD	O
weeks	NNS	O
standard	JJ	O
hypolipidemic	JJ	O
diet	NN	O
and	CC	O
hydrochlorothiazide	NN	O
(	(	O
25	CD	O
mg	RB	O
od	NN	O
)	)	O
therapy	NN	O
,	,	O
30	CD	O
patients	NNS	O
whose	WP$	O
cholesterol	NN	Physical
levels	NNS	Physical
were	VBD	O
still	RB	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
250	CD	O
mg/100	NNS	O
ml	NN	O
and	CC	O
whose	WP$	O
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	O
was	VBD	O
less	JJR	O
than	IN	O
95	CD	O
mmHg	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
treatments	NNS	O
:	:	O
simvastatin	NN	O
,	,	O
20	CD	O
mg	NN	O
od	NN	O
,	,	O
gemfibrozil	NN	O
,	,	O
600	CD	O
mg	NN	O
bid	NN	O
or	CC	O
placebo	NN	O
,	,	O
while	IN	O
continuing	VBG	O
dietetic	JJ	O
and	CC	O
diuretic	JJ	O
treatment	NN	O
.	.	O

After	IN	O
24	CD	O
weeks	NNS	O
treatment	NN	O
,	,	O
simvastatin	NN	O
induced	VBD	O
a	DT	O
37	CD	O
%	NN	O
reduction	NN	O
in	IN	O
cholesterol	NN	Physical
plasma	NN	Physical
levels	NNS	Physical
,	,	O
a	DT	O
9	CD	O
%	NN	O
increase	NN	O
of	IN	O
HDL	NNP	Physical
and	CC	O
a	DT	O
16	CD	O
%	NN	O
reduction	NN	O
of	IN	O
LDL	NNP	Physical
.	.	Physical

APO-A1	NNP	Physical
showed	VBD	O
a	DT	O
4	CD	O
%	NN	O
increase	NN	O
,	,	O
while	IN	O
APO-B	NNP	O
showed	VBD	O
a	DT	O
3	CD	O
%	NN	O
reduction	NN	O
.	.	O

Gemfibrozil	NNP	O
induced	VBD	O
a	DT	O
20	CD	O
%	NN	O
reduction	NN	O
in	IN	O
plasma	NN	Physical
triglycerides	NNS	Physical
and	CC	O
a	DT	O
13	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	NN	Physical
cholesterol	NN	Physical
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
19	CD	O
%	NN	O
increase	NN	O
in	IN	O
HDL	NNP	Physical
and	CC	O
a	DT	O
11	CD	O
%	NN	O
reduction	NN	O
in	IN	O
LDL	NNP	Physical
.	.	Physical

No	NNP	O
significant	JJ	O
variations	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
lipid	JJ	O
parameters	NNS	O
monitored	VBD	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Treatment	NN	O
with	IN	O
simvastatin	NN	O
or	CC	O
gemfibrozil	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
in	IN	O
hydrochlorothiazide	JJ	O
monotherapy	NN	O
can	MD	O
reduce	VB	O
total	JJ	Physical
cholesterol	NN	Physical
and	CC	Physical
LDL-cholesterol	NNP	Physical
plasma	NN	Physical
levels	NNS	Physical
,	,	O
while	IN	O
significantly	RB	O
increasing	VBG	O
HDL	NNP	Physical
plasma	NN	Physical
levels	NNS	Physical
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Simvastatin	NNP	O
,	,	O
however	RB	O
,	,	O
resulted	VBD	O
more	RBR	O
efficient	JJ	O
than	IN	O
gemfibrozil	NN	O
on	IN	O
total	JJ	Physical
cholesterol	NN	Physical
or	CC	Physical
cholesterol	NN	Physical
fractions	NNS	Physical
.	.	Physical

Yohimbine	NN	O
in	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
.	.	O

Pathophysiological	JJ	O
implications	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
if	IN	O
increased	VBN	O
sympathetic	JJ	O
stimulation	NN	O
is	VBZ	O
an	DT	O
essential	JJ	O
requirement	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
(	(	O
NMS	NNP	O
)	)	O
by	IN	O
manipulating	VBG	O
overall	JJ	O
sympathetic	JJ	O
outflow	NN	O
in	IN	O
subjects	NNS	O
susceptible	JJ	O
to	TO	O
tilt-induced	JJ	O
syncope	NN	O
.	.	O

Eight	NNP	O
previously	RB	O
characterized	VBD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
NMS	NNP	O
(	(	O
five	CD	O
females	NNS	O
and	CC	O
three	CD	O
males	NNS	O
;	:	O
34+/-2	JJ	O
yr	NN	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
the	DT	O
Vanderbilt	NNP	O
Syncope	NNP	O
Unit	NNP	O
and	CC	O
eight	CD	O
age-matched	JJ	O
controls	NNS	O
underwent	JJ	O
initial	JJ	O
administration	NN	O
of	IN	O
clonidine	NN	O
(	(	O
CLO	NNP	O
)	)	O
or	CC	O
yohimbine	NN	O
(	(	O
YHO	NNP	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
done	VBN	O
,	,	O
prospectively	RB	O
,	,	O
to	TO	O
determine	VB	O
doses	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
that	WDT	O
would	MD	O
increase	VB	O
or	CC	O
decrease	VB	O
plasma	JJ	Physical
norepinephrine	NN	Physical
levels	NNS	Physical
by	IN	O
>	NNP	O
/=	NNP	O
30	CD	O
%	NN	O
.	.	O

On	IN	O
a	DT	O
different	JJ	O
day	NN	O
,	,	O
in	IN	O
all	DT	O
subjects	NNS	O
we	PRP	O
determined	VBD	O
intraarterial	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	Physical
EKG	NNP	Physical
and	CC	Physical
muscle	NN	Physical
sympathetic	JJ	Physical
nerve	NN	Physical
activity	NN	Physical
(	(	Physical
MSNA	NNP	Physical
)	)	Physical
both	DT	O
supine	JJ	O
and	CC	O
during	IN	O
upright	JJ	O
tilt	NN	O
.	.	O

After	IN	O
this	DT	O
,	,	O
subjects	VBZ	O
randomly	RB	O
received	VBN	O
either	CC	O
CLO	NNP	O
or	CC	O
YHO	NNP	O
,	,	O
and	CC	O
3	CD	O
h	NN	O
later	RB	O
another	DT	O
tilt	NN	O
was	VBD	O
performed	VBN	O
.	.	O

After	IN	O
1	CD	O
wk	NN	O
,	,	O
a	DT	O
similar	JJ	O
procedure	NN	O
with	IN	O
the	DT	O
other	JJ	O
drug	NN	O
was	VBD	O
performed	VBN	O
.	.	O

During	IN	O
the	DT	O
two	CD	O
basal	NN	O
tilts	NNS	O
,	,	O
all	PDT	O
the	DT	O
control	NN	O
subjects	VBZ	O
completed	VBN	O
the	DT	O
study	NN	O
,	,	O
whereas	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
developed	VBD	O
syncope	NN	O
.	.	O

Reduction	NN	Physical
in	IN	Physical
sympathetic	JJ	Physical
tone	NN	Physical
by	IN	O
CLO	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
decreased	JJ	O
tolerance	NN	Physical
to	TO	Physical
tilt	VB	Physical
in	IN	O
three	CD	O
out	IN	O
of	IN	O
eight	CD	O
controls	NNS	O
and	CC	O
in	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
YHO	NNP	O
not	RB	O
only	RB	O
increased	VBD	O
basal	NN	Physical
plasma	NN	Physical
NorEpi	NNP	Physical
levels	NNS	Physical
and	CC	O
MSNA	NNP	Physical
,	,	O
but	CC	O
also	RB	O
prevented	VBD	O
syncope	NN	Physical
in	IN	O
seven	CD	O
out	IN	O
of	IN	O
eight	CD	O
patients	NNS	O
.	.	O

In	IN	O
a	DT	O
selected	JJ	O
population	NN	O
of	IN	O
patients	NNS	O
,	,	O
increased	VBD	O
sympathetic	JJ	Physical
activity	NN	Physical
is	VBZ	O
not	RB	O
a	DT	O
prerequisite	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
syncope	NN	O
.	.	O

Yohimbine-induced	JJ	O
enhancement	NN	O
of	IN	O
sympathetic	JJ	O
tone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NMS	NNP	O
improves	VBZ	O
orthostatic	JJ	O
tolerance	NN	O
and	CC	O
raises	VBZ	O
the	DT	O
possibility	NN	O
that	IN	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NMS	NNP	O
.	.	O

Endovascular	JJ	O
aneurysm	NN	O
repair	NN	O
and	CC	O
outcome	NN	O
in	IN	O
patients	NNS	O
unfit	JJ	O
for	IN	O
open	JJ	O
repair	NN	O
of	IN	O
abdominal	JJ	O
aortic	JJ	O
aneurysm	NN	O
(	(	O
EVAR	NNP	O
trial	NN	O
2	CD	O
)	)	O
:	:	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Endovascular	NNP	O
aneurysm	NN	O
repair	NN	O
(	(	O
EVAR	NNP	O
)	)	O
to	TO	O
exclude	VB	O
abdominal	JJ	O
aortic	JJ	O
aneurysm	NN	O
(	(	O
AAA	NNP	O
)	)	O
was	VBD	O
introduced	VBN	O
for	IN	O
patients	NNS	O
of	IN	O
poor	JJ	O
health	NN	O
status	NN	O
considered	VBN	O
unfit	NN	O
for	IN	O
major	JJ	O
surgery	NN	O
.	.	O

We	PRP	O
instigated	VBD	O
EVAR	NNP	O
trial	NN	O
2	CD	O
to	TO	O
identify	VB	O
whether	IN	O
EVAR	NNP	O
improves	VBZ	O
survival	JJ	Mortality
compared	VBN	O
with	IN	O
no	DT	O
intervention	NN	O
in	IN	O
patients	NNS	O
unfit	JJ	O
for	IN	O
open	JJ	O
repair	NN	O
of	IN	O
aortic	JJ	O
aneurysm	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
did	VBD	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
of	IN	O
338	CD	O
patients	NNS	O
aged	VBN	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
who	WP	O
had	VBD	O
aneurysms	NNS	O
of	IN	O
at	IN	O
least	JJS	O
5.5	CD	O
cm	NN	O
in	IN	O
diameter	NN	O
and	CC	O
who	WP	O
had	VBD	O
been	VBN	O
referred	VBN	O
to	TO	O
one	CD	O
of	IN	O
31	CD	O
hospitals	NNS	O
in	IN	O
the	DT	O
UK	NNP	O
.	.	O

We	PRP	O
assigned	VBD	O
patients	NNS	O
to	TO	O
receive	VB	O
either	DT	O
EVAR	NNP	O
(	(	O
n=166	NN	O
)	)	O
or	CC	O
no	DT	O
intervention	NN	O
(	(	O
n=172	JJ	O
)	)	O
.	.	O

Our	PRP$	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
all-cause	JJ	Mortality
mortality	NN	Mortality
,	,	O
with	IN	O
secondary	JJ	O
endpoints	NNS	O
of	IN	O
aneurysm-related	JJ	Mortality
mortality	NN	Mortality
,	,	O
health-related	JJ	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
(	(	Physical
HRQL	NNP	Physical
)	)	Physical
,	,	O
postoperative	JJ	Adverseeffect
complications	NNS	Adverseeffect
,	,	O
and	CC	O
hospital	NN	Others
costs	NNS	Others
.	.	Others

Analyses	NNS	O
were	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

FINDINGS	NNP	O
197	CD	O
patients	NNS	O
underwent	JJ	O
aneurysm	JJ	O
repair	NN	O
(	(	O
47	CD	O
assigned	VBN	O
no	DT	O
intervention	NN	O
)	)	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
adhered	VBN	O
to	TO	O
protocol	VB	O
.	.	O

The	DT	O
30-day	JJ	Mortality
operative	JJ	Mortality
mortality	NN	Mortality
in	IN	Mortality
the	DT	Mortality
EVAR	NNP	Mortality
group	NN	Mortality
was	VBD	O
9	CD	O
%	NN	O
(	(	O
13	CD	O
of	IN	O
150	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
5-15	CD	O
)	)	O
and	CC	O
the	DT	O
no	DT	O
intervention	NN	O
group	NN	O
had	VBD	O
a	DT	O
rupture	NN	O
rate	NN	O
of	IN	O
9.0	CD	O
per	IN	O
100	CD	O
person	NN	O
years	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
6.0-13.5	CD	O
)	)	O
.	.	O

By	IN	O
end	NN	O
of	IN	O
follow	JJ	O
up	IN	O
142	CD	O
patients	NNS	O
had	VBD	O
died	VBN	Mortality
,	,	O
42	CD	O
of	IN	O
aneurysm-related	JJ	O
factors	NNS	O
;	:	O
overall	JJ	Mortality
mortality	NN	Mortality
after	IN	O
4	CD	O
years	NNS	O
was	VBD	O
64	CD	O
%	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
EVAR	NNP	O
group	NN	O
and	CC	O
the	DT	O
no	DT	O
intervention	NN	O
group	NN	O
for	IN	O
all-cause	JJ	Mortality
mortality	NN	Mortality
(	(	O
hazard	JJ	O
ratio	NN	O
1.21	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.87-1.69	CD	O
,	,	O
p=0.25	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
aneurysm-related	JJ	Mortality
mortality	NN	Mortality
.	.	O

The	DT	O
mean	JJ	Others
hospital	NN	Others
costs	NNS	Others
per	IN	Others
patient	NN	Others
over	IN	Others
4	CD	Others
years	NNS	Others
were	VBD	O
UK	NNP	O
pound	NN	O
sterling	NN	O
13,632	CD	O
in	IN	O
the	DT	O
EVAR	NNP	O
group	NN	O
and	CC	O
pound	NN	O
sterling	NN	O
4983	CD	O
in	IN	O
the	DT	O
no	DT	O
intervention	NN	O
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
pound	NN	O
sterling	NN	O
8649	CD	O
,	,	O
SE	NNP	O
1248	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
in	IN	O
HRQL	NNP	O
scores	NNS	O
.	.	O

INTERPRETATION	NNP	O
EVAR	NNP	O
had	VBD	O
a	DT	O
considerable	JJ	O
30-day	JJ	Mortality
operative	JJ	Mortality
mortality	NN	Mortality
in	IN	O
patients	NNS	O
already	RB	O
unfit	JJ	O
for	IN	O
open	JJ	O
repair	NN	O
of	IN	O
their	PRP$	O
aneurysm	NN	O
.	.	O

EVAR	NNP	O
did	VBD	O
not	RB	O
improve	VB	O
survival	NN	O
over	IN	O
no	DT	O
intervention	NN	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
need	NN	O
for	IN	O
continued	JJ	O
surveillance	NN	O
and	CC	O
reinterventions	NNS	O
,	,	O
at	IN	O
substantially	RB	O
increased	VBN	O
cost	NN	O
.	.	O

Ongoing	VBG	O
follow-up	NN	O
and	CC	O
improved	JJ	O
fitness	NN	O
of	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
a	DT	O
priority	NN	O
.	.	O

Clinical	JJ	O
usefulness	NN	O
of	IN	O
serum	NN	O
prostate	NN	O
specific	JJ	O
antigen	NN	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
preserved	VBN	O
in	IN	O
men	NNS	O
receiving	VBG	O
the	DT	O
dual	JJ	O
5alpha-reductase	JJ	O
inhibitor	NN	O
dutasteride	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
whether	IN	O
the	DT	O
decrease	NN	O
in	IN	O
serum	NN	O
PSA	NNP	O
seen	VBN	O
with	IN	O
5alpha-reductase	JJ	O
inhibitors	NNS	O
affects	VBZ	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
PSA	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
using	VBG	O
data	NNS	O
from	IN	O
2	CD	O
dutasteride	JJ	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
studies	NNS	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
2,802	CD	O
men	NNS	O
50	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
,	,	O
no	DT	O
history	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
PSA	NNP	O
1.5	CD	O
to	TO	O
10	CD	O
ng/ml	NNS	O
,	,	O
prostate	NN	O
volume	NN	O
30	CD	O
cc	NN	O
or	CC	O
greater	JJR	O
,	,	O
an	DT	O
American	NNP	O
Urological	NNP	O
Association	NNP	O
symptom	VBD	O
score	NN	O
of	IN	O
12	CD	O
or	CC	O
greater	JJR	O
and	CC	O
peak	JJ	O
urinary	JJ	O
flow	NN	O
rate	NN	O
15	CD	O
ml	NN	O
per	IN	O
second	NN	O
or	CC	O
less	JJR	O
were	VBD	O
randomized	VBN	O
to	TO	O
0.5	CD	O
mg	NNS	O
dutasteride	JJ	O
daily	RB	O
or	CC	O
matching	VBG	O
placebo	NN	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Increases	NNS	O
in	IN	O
PSA	NNP	O
from	IN	O
baseline	NN	O
and	CC	O
the	DT	O
maximum	JJ	O
increase	NN	O
from	IN	O
nadir	JJ	O
to	TO	O
month	NN	O
24	CD	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
and	CC	O
analyzed	VBN	O
by	IN	O
prostate	NN	O
cancer	NN	O
status	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
PSA	NNP	O
driven	JJ	O
biopsy	NN	O
and	CC	O
an	DT	O
advised	JJ	O
cutoff	NN	O
of	IN	O
more	JJR	O
than	IN	O
4	CD	O
ng/ml	NNS	O
after	IN	O
doubling	VBG	O
to	TO	O
correct	VB	O
for	IN	O
dutasteride	JJ	O
treatment	NN	O
with	IN	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
calculated	VBN	O
for	IN	O
each	DT	O
.	.	O

RESULTS	NNP	O
In	IN	O
placebo	NN	O
treated	VBN	O
men	NNS	O
without	IN	O
prostate	NN	O
cancer	NN	O
there	EX	O
was	VBD	O
an	DT	O
8.3	CD	O
%	NN	O
median	JJ	Physical
increase	NN	Physical
in	IN	Physical
PSA	NNP	Physical
at	IN	Physical
month	NN	Physical
24	CD	Physical
compared	VBN	O
with	IN	O
-59.5	CD	O
%	NN	O
in	IN	O
those	DT	O
who	WP	O
received	VBD	O
dutasteride	RB	O
,	,	O
using	VBG	O
doubled	VBD	O
values	NNS	O
to	TO	O
correct	VB	O
for	IN	O
dutasteride	JJ	O
treatment	NN	O
.	.	O

In	IN	O
those	DT	O
with	IN	O
prostate	JJ	O
cancer	NN	O
these	DT	O
changes	NNS	O
were	VBD	O
23.8	CD	O
%	NN	O
and	CC	O
-37.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Using	VBG	Physical
the	DT	Physical
upper	JJ	Physical
PSA	NNP	Physical
limit	NN	Physical
of	IN	Physical
4	CD	Physical
ng/ml	JJ	Physical
sensitivity	NN	Physical
for	IN	O
prostate	NN	O
cancer	NN	O
in	IN	O
men	NNS	O
receiving	VBG	O
dutasteride	NN	O
vs	NN	O
placebo	NN	O
was	VBD	O
0.737	CD	O
vs	NN	O
0.804	CD	O
,	,	O
while	IN	O
specificity	NN	Others
was	VBD	O
0.671	CD	O
vs	JJ	O
0.578	CD	O
.	.	O

Using	VBG	Physical
a	DT	Physical
PSA	NNP	Physical
increase	NN	Physical
from	IN	O
nadir	NN	O
of	IN	O
0.8	CD	O
ng/ml	IN	O
the	DT	O
sensitivity	NN	Others
of	IN	O
dutasteride	NN	O
was	VBD	O
0.548	CD	O
and	CC	O
its	PRP$	O
specificity	NN	Others
was	VBD	O
0.795	CD	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
doubling	JJ	O
factor	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
maintaining	VBG	O
the	DT	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
of	IN	O
PSA	NNP	Physical
for	IN	O
prostate	NN	O
cancer	NN	O
detection	NN	O
in	IN	O
men	NNS	O
on	IN	O
dutasteride	NN	O
.	.	O

Increases	VBZ	O
in	IN	O
serum	NN	Physical
PSA	NNP	Physical
in	IN	O
men	NNS	O
receiving	VBG	O
dutasteride	NN	O
should	MD	O
be	VB	O
considered	VBN	O
suspicious	JJ	O
and	CC	O
serial	JJ	O
PSA	NNP	Physical
measurements	NNS	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
evaluate	VB	O
changes	NNS	O
from	IN	O
nadir	NN	O
.	.	O

Plasma	NNP	O
3,4-dihydroxyphenylethyleneglycol	CD	O
and	CC	O
3-methoxy-4-hydroxyphenylethyleneglycol	JJ	O
as	IN	O
indicators	NNS	O
of	IN	O
central	JJ	O
noradrenergic	JJ	O
activity	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
on	IN	O
control	NN	O
subjects	NNS	O
and	CC	O
depressed	JJ	O
patients	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
interspecies	NNS	O
differences	NNS	O
in	IN	O
brain	NN	O
norepinephrine	NN	O
(	(	O
NE	NNP	O
)	)	O
metabolism	NN	O
,	,	O
especially	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
relative	JJ	O
proportions	NNS	O
of	IN	O
3,4-dihydroxyphenylethyleneglycol	JJ	O
(	(	O
DOPEG	NNP	O
)	)	O
compared	VBN	O
to	TO	O
3-methoxy-4-hydroxyphenylethyleneglycol	CD	O
(	(	O
MOPEG	NNP	O
)	)	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
question	VB	O
the	DT	O
value	NN	O
of	IN	O
both	DT	O
glycol	JJ	O
metabolites	NNS	O
as	IN	O
peripheral	JJ	O
indices	NNS	O
of	IN	O
central	JJ	Physical
noradrenergic	JJ	Physical
activity	NN	Physical
,	,	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
plasma	NN	O
DOPEG	NNP	O
and	CC	O
MOPEG	NNP	O
(	(	O
measured	VBN	O
by	IN	O
HPLC	NNP	O
)	)	O
related	VBD	O
to	TO	O
depression	NN	O
,	,	O
sex	NN	O
,	,	O
age	NN	O
and	CC	O
diagnostic	JJ	O
categories	NNS	O
(	(	O
DSM-III	NNP	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
depressed	JJ	O
and	CC	O
control	JJ	O
subjects	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
two	CD	O
groups	NNS	O
of	IN	O
8	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
submitted	VBN	O
to	TO	O
a	DT	O
desipramine	NN	O
150	CD	O
mg/day	NN	O
,	,	O
or	CC	O
a	DT	O
metapramine	JJ	O
450	CD	O
mg/day	JJ	O
antidepressant	JJ	O
treatment	NN	O
influencing	VBG	O
the	DT	O
formation	NN	O
of	IN	O
DOPEG	NNP	O
and	CC	O
MOPEG	NNP	O
in	IN	O
a	DT	O
different	JJ	O
way	NN	O
.	.	O

The	DT	O
study	NN	O
did	VBD	O
not	RB	O
demonstrate	VB	O
any	DT	O
difference	NN	O
between	IN	O
DOPEG	NNP	O
and	CC	O
MOPEG	NNP	O
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
experimental	JJ	O
factors	NNS	O
.	.	O

We	PRP	O
found	VBD	O
also	RB	O
a	DT	O
significant	JJ	O
positive	JJ	Physical
correlation	NN	Physical
between	IN	Physical
plasma	NN	Physical
levels	NNS	Physical
of	IN	Physical
DOPEG	NNP	Physical
and	CC	Physical
MOPEG	NNP	Physical
.	.	O

Our	PRP$	O
results	NNS	O
support	VB	O
the	DT	O
idea	NN	O
that	IN	O
each	DT	O
of	IN	O
these	DT	O
two	CD	O
biological	JJ	O
indices	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
central	JJ	Physical
noradrenergic	JJ	Physical
activity	NN	Physical
.	.	O

Efficacy	NN	Others
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
vs	NN	O
patient	JJ	O
education	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
hip	JJ	O
osteoarthritis	NN	O
:	:	O
a	DT	O
single	JJ	O
blind	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
patient	JJ	O
education	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
with	IN	O
that	DT	O
of	IN	O
patient	JJ	O
education	NN	O
alone	RB	O
for	IN	O
the	DT	O
management	NN	Pain
of	IN	Pain
pain	NN	Pain
in	IN	O
patients	NNS	O
with	IN	O
hip	NN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blind	IN	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Recruitment	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
hospitals	NNS	O
,	,	O
primary	JJ	O
health	NN	O
care	NN	O
and	CC	O
advertisement	NN	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
109	CD	O
patients	NNS	O
with	IN	O
radiographic	JJ	O
and	CC	O
symptomatic	JJ	O
hip	NN	O
OA	NNP	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Patient	NNP	O
education	NN	O
(	(	O
PE	NNP	O
)	)	O
.	.	O

Patient	JJ	O
education	NN	O
and	CC	O
supervised	VBN	O
exercise	NN	O
(	(	O
PE+SE	NNP	O
)	)	O
.	.	O

PRIMARY	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
pain	NN	Pain
subscale	NN	Pain
of	IN	Pain
the	DT	Pain
Western	NNP	Pain
Ontario	NNP	Pain
and	CC	O
McMaster	NNP	Pain
Universities	NNP	Pain
Osteoarthritis	NNP	Pain
Index	NNP	Pain
(	(	Pain
WOMAC	NNP	Pain
pain	NN	Pain
)	)	Pain
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	Pain
pain	NN	Pain
over	IN	O
the	DT	O
16-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
WOMAC	NNP	Physical
physical	JJ	Physical
function	NN	Physical
(	(	O
P=0.011	NNP	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PE+SE	NNP	O
compared	VBN	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
PE	NNP	O
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	Physical
stiffness	NN	Physical
,	,	O
the	DT	O
SF-36	JJ	O
subscales	NNS	O
or	CC	O
the	DT	O
activity	NN	O
scale	NN	O
.	.	O

The	DT	O
effect	NN	O
sizes	VBZ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
WOMAC	NNP	Pain
pain	NN	Pain
were	VBD	O
-0.26	NNP	O
(	(	O
0.11	CD	O
,	,	O
-0.64	NN	O
)	)	O
,	,	O
-0.35	NNP	O
(	(	O
0.07	CD	O
,	,	O
-0.77	NN	O
)	)	O
,	,	O
and	CC	O
-0.30	NNP	O
(	(	O
0.15	CD	O
,	,	O
-0.75	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
WOMAC	NNP	Physical
physical	JJ	Physical
function	NN	Physical
-0.29	NNP	O
(	(	O
0.09	CD	O
,	,	O
-0.67	NN	O
)	)	O
,	,	O
-0.48	NNP	O
(	(	O
-0.06	NNP	O
,	,	O
-0.91	NNP	O
)	)	O
,	,	O
and	CC	O
-0.47	NNP	O
(	(	O
-0.02	NNP	O
,	,	O
-0.93	NNP	O
)	)	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
both	DT	O
PE	NNP	O
and	CC	O
SE	NNP	O
.	.	O

All	DT	O
patients	NNS	O
attended	VBD	O
the	DT	O
three-session	JJ	O
PE	NNP	O
program	NN	O
,	,	O
and	CC	O
75	CD	O
%	NN	O
performed	VBN	O
?16	JJ	O
sessions	NNS	O
of	IN	O
the	DT	O
12-week	JJ	O
SE	NNP	O
program	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
study	NN	O
could	MD	O
not	RB	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
reduction	NN	O
over	IN	O
time	NN	O
between	IN	O
PE+SE	NNP	O
vs	NNP	O
PE	NNP	O
alone	RB	O
.	.	O

Adding	VBG	O
SE	NNP	O
to	TO	O
PE	NNP	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
possible	JJ	O
benefit	NN	O
is	VBZ	O
unknown	JJ	O
as	IN	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
around	IN	O
the	DT	O
mean	JJ	O
difference	NN	O
were	VBD	O
wide	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinical	NNP	O
Trials	NNP	O
NCT00319423	NNP	O
.	.	O

Somatostatin	NNP	O
and	CC	O
ranitidine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
non-variceal	JJ	O
upper	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	NN	O
,	,	O
controlled	VBN	O
study	NN	O
.	.	O

BACKGROUND/AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
somatostatin	NN	O
vs.	FW	O
ranitidine	NN	O
in	IN	O
controlling	VBG	O
acute	JJ	Physical
non-variceal	JJ	Physical
gastrointestinal	JJ	Physical
bleeding	NN	Physical
.	.	O

METHODOLOGY	NNP	O
A	NNP	O
total	NN	O
of	IN	O
48	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
upper	JJ	O
gastrointestinal	NN	O
bleeding	NN	O
due	JJ	O
to	TO	O
duodenal	JJ	O
or	CC	O
gastric	JJ	O
ulcer	NN	O
were	VBD	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
consisted	VBD	O
of	IN	O
15	CD	O
patients	NNS	O
with	IN	O
Forrest	NNP	O
IB	NNP	O
and	CC	O
Group	NNP	O
II	NNP	O
consisted	VBD	O
of	IN	O
30	CD	O
patients	NNS	O
with	IN	O
Forrest	NNP	O
II	NNP	O
.	.	O

Two	CD	O
regimens	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
all	DT	O
patients	NNS	O
within	IN	O
half	PDT	O
an	DT	O
hour	NN	O
after	IN	O
the	DT	O
endoscopic	JJ	O
procedure	NN	O
:	:	O
1	CD	O
)	)	O
somatostatin-UCB	NN	O
250	CD	O
mcg	NN	O
i.v	NN	O
.	.	O

bolus	CC	O
followed	VBN	O
by	IN	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
6	CD	O
mg/d	NN	O
for	IN	O
72	CD	O
h	NN	O
,	,	O
or	CC	O
2	CD	O
)	)	O
ranitidine	NN	O
300	CD	O
mg/d	NN	O
by	IN	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
for	IN	O
72	CD	O
h.	JJ	O
RESULTS	NNP	O
In	IN	O
Group	NNP	O
I	PRP	O
,	,	O
although	IN	O
mean	JJ	Physical
blood	NN	Physical
transfusion	NN	Physical
requirements	NNS	Physical
(	(	O
no	DT	O
.	.	O

of	IN	O
units	NNS	O
)	)	O
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
somatostatin	NN	O
than	IN	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
ranitidine	NN	O
,	,	O
this	DT	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
2.56	CD	O
+/-	JJ	O
3.05	CD	O
vs.	FW	O
5.17	CD	O
+/-	JJ	O
4.96	CD	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
;	:	O
the	DT	O
time	NN	Physical
of	IN	Physical
bleeding	VBG	Physical
stop	NN	Physical
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
somatostatin	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
ranitidine	NN	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
3.24	CD	O
+/-	JJ	O
2.45	CD	O
vs.	FW	O
11.25	CD	O
+/-	JJ	O
11.63	CD	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.0383	CD	O
)	)	O
.	.	O

The	DT	O
rebleeding	NN	Physical
and	CC	O
the	DT	O
mortality	NN	Mortality
rates	NNS	Mortality
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
both	DT	O
Group	NNP	O
I	PRP	O
and	CC	O
Group	NNP	O
II	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Somatostatin	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	Others
than	IN	O
ranitidine	NN	O
in	IN	O
controlling	VBG	O
acute	JJ	Physical
non-variceal	JJ	Physical
gastrointestinal	JJ	Physical
bleeding	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
Forrest	NNP	O
IB	NNP	O
bleeding	NN	O
activity	NN	O
.	.	O

Somatostatin	NNP	O
has	VBZ	O
no	DT	O
additional	JJ	Others
benefit	NN	Others
in	IN	O
those	DT	O
with	IN	O
Forrest	NNP	O
II	NNP	O
bleeding	NN	O
activity	NN	O
.	.	O

Acute	NNP	O
pressor	NN	O
and	CC	O
hormonal	JJ	O
effects	NNS	O
of	IN	O
beta-endorphin	NN	O
at	IN	O
high	JJ	O
doses	NNS	O
in	IN	O
healthy	JJ	O
and	CC	O
hypertensive	JJ	O
subjects	NNS	O
:	:	O
role	NN	O
of	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

CONTEXT	VB	O
The	DT	O
opioid	NN	O
system	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
regulation	NN	O
in	IN	O
both	DT	O
normal	JJ	O
humans	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high-dose	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	NN	O
,	,	O
an	DT	O
opioid	JJ	O
peptide	NN	O
,	,	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
on	IN	O
the	DT	O
hormonal	JJ	O
profile	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
the	DT	O
mediation	NN	O
played	VBN	O
by	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
randomized	VBN	O
double-blind	NN	O
design	NN	O
,	,	O
11	CD	O
healthy	JJ	O
subjects	NNS	O
(	(	O
controls	NNS	O
)	)	O
and	CC	O
12	CD	O
hypertensive	JJ	O
inpatients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
38.9	CD	O
and	CC	O
40.4	CD	O
yr	NN	O
,	,	O
respectively	RB	O
)	)	O
received	VBD	O
1-h	JJ	O
iv	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	JJ	O
(	(	O
250	CD	O
mug/h	NN	O
)	)	O
and	CC	O
,	,	O
on	IN	O
another	DT	O
occasion	NN	O
,	,	O
the	DT	O
same	JJ	O
infusion	NN	O
protocol	NN	O
preceded	VBN	O
by	IN	O
the	DT	O
opioid	JJ	O
antagonist	NN	O
naloxone	NN	O
(	(	O
8	CD	O
mg	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Hemodynamic	NNP	Physical
and	CC	Physical
hormonal	JJ	Physical
measurements	NNS	Physical
were	VBD	O
performed	VBN	O
at	IN	O
established	VBN	O
times	NNS	O
during	IN	O
the	DT	O
infusion	NN	O
protocols	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
circulating	VBG	Physical
beta-endorphin	JJ	Physical
,	,	Physical
norepinephrine	JJ	Physical
,	,	Physical
and	CC	Physical
endothelin-1	NN	Physical
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

In	IN	O
controls	NNS	O
,	,	O
beta-endorphin	JJ	O
reduced	VBD	O
blood	NN	Physical
pressure	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
circulating	VBG	Physical
norepinephrine	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
and	CC	O
increased	VBD	O
plasma	JJ	Physical
atrial	JJ	Physical
natriuretic	JJ	Physical
factor	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.003	CD	O
)	)	O
and	CC	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
beta-endorphin	JJ	O
decreased	JJ	O
systemic	JJ	Physical
vascular	NN	Physical
resistance	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
blood	NN	Physical
pressure	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
plasma	JJ	Physical
norepinephrine	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
endothelin-1	JJ	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
raised	VBD	O
circulating	VBG	Physical
atrial	JJ	Physical
natriuretic	JJ	Physical
factor	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
GH	NNP	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
IGF-I	NNP	Physical
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

These	DT	O
hemodynamic	JJ	Physical
and	CC	Physical
hormonal	JJ	Physical
responses	NNS	Physical
to	TO	O
beta-endorphin	JJ	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
greater	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
but	CC	O
were	VBD	O
annulled	VBN	O
in	IN	O
all	DT	O
individuals	NNS	O
when	WRB	O
naloxone	NN	O
preceded	VBD	O
beta-endorphin	JJ	O
infusion	NN	O
.	.	O

CONCLUSIONS	NNP	O
High	NNP	O
doses	NNS	O
of	IN	O
beta-endorphin	JJ	O
induce	NN	O
hypotensive	NN	O
and	CC	O
beneficial	JJ	O
hormonal	JJ	O
effects	NNS	O
in	IN	O
humans	NNS	O
,	,	O
which	WDT	O
are	VBP	O
enhanced	VBN	O
in	IN	O
essential	JJ	O
hypertension	NN	O
and	CC	O
are	VBP	O
mediated	VBN	O
by	IN	O
opioid	JJ	O
receptors	NNS	O
.	.	O

Cardiovascular	JJ	Others
safety	NN	Others
and	CC	Others
gastrointestinal	JJ	Others
tolerability	NN	Others
of	IN	O
etoricoxib	JJ	O
vs	NN	O
diclofenac	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
The	DT	O
MEDAL	NNP	O
study	NN	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
cardiovascular	JJ	Others
(	(	Others
CV	NNP	Others
)	)	Others
and	CC	Others
other	JJ	Others
safety	NN	Others
and	CC	Others
efficacy	NN	Others
parameters	NNS	Others
of	IN	O
etoricoxib	JJ	O
60	CD	O
and	CC	O
90	CD	O
mg	NN	O
,	,	O
and	CC	O
diclofenac	VBZ	O
150	CD	O
mg.	NN	O
METHODS	NNP	O
This	DT	O
double-blind	NN	O
study	NN	O
randomized	VBD	O
OA	NNP	O
patients	NNS	O
to	TO	O
etoricoxib	VB	O
90	CD	O
mg	NN	O
,	,	O
then	RB	O
to	TO	O
60	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
vs	NNS	O
diclofenac	VBP	O
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
;	:	O
RA	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
etoricoxib	VB	O
90	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
or	CC	O
diclofenac	JJ	O
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
non-inferiority	NN	O
of	IN	O
etoricoxib	JJ	O
vs	NN	O
diclofenac	NN	O
for	IN	O
thrombotic	JJ	O
CV	NNP	O
events	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
upper	JJ	O
bound	NN	O
of	IN	O
hazard	NN	O
ratio	NN	O
<	NNP	O
1.30	CD	O
)	)	O
.	.	O

Other	JJ	Others
safety	NN	Others
and	CC	Others
efficacy	NN	Others
parameters	NNS	Others
were	VBD	O
evaluated	VBN	O
in	IN	O
cohorts	NNS	O
of	IN	O
patients	NNS	O
based	VBN	O
on	IN	O
etoricoxib	NN	O
dose	NN	O
and	CC	O
disease	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
23	CD	O
504	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
with	IN	O
mean	JJ	O
treatment	NN	O
duration	NN	O
from	IN	O
19.4	CD	O
to	TO	O
20.8	CD	O
months	NNS	O
.	.	O

The	DT	O
thrombotic	JJ	Others
CV	NNP	Others
risk	NN	Others
hazard	NN	Others
ratio	NN	Others
(	(	Physical
HR	NNP	Physical
)	)	Physical
(	(	O
etoricoxib	UH	O
to	TO	O
diclofenac	VB	O
)	)	O
was	VBD	O
0.96	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.81	CD	O
,	,	O
1.15	CD	O
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
non-inferiority	NN	O
of	IN	O
etoricoxib	NN	O
to	TO	O
diclofenac	VB	O
.	.	O

The	DT	O
cumulative	JJ	Adverseeffect
gastrointestinal	NN	Adverseeffect
(	(	Adverseeffect
GI	NNP	Adverseeffect
)	)	Adverseeffect
/liver	VBP	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
(	(	Adverseeffect
AEs	NNP	Adverseeffect
)	)	Adverseeffect
discontinuation	NN	Adverseeffect
rate	NN	Adverseeffect
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
etoricoxib	JJR	O
than	IN	O
diclofenac	NN	O
in	IN	O
each	DT	O
patient	NN	O
cohort	NN	O
;	:	O
HR	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
of	IN	O
0.46	CD	O
(	(	O
0.39	CD	O
,	,	O
0.54	CD	O
)	)	O
,	,	O
0.52	CD	O
(	(	O
0.42	CD	O
,	,	O
0.63	CD	O
)	)	O
and	CC	O
0.49	CD	O
(	(	O
0.39	CD	O
,	,	O
0.62	CD	O
)	)	O
for	IN	O
the	DT	O
60	CD	O
mg	NN	O
OA	NNP	O
,	,	O
90	CD	O
mg	NN	O
OA	NNP	O
and	CC	O
RA	NNP	O
cohorts	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
in	IN	O
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	O
BP	NNP	O
)	)	O
with	IN	O
etoricoxib	NN	O
was	VBD	O
3.4-3.6	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
1.0-1.5	JJ	O
mmHg	NN	O
)	)	O
,	,	O
while	IN	O
diclofenac	NN	O
produced	VBD	O
a	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
of	IN	O
0.9-1.9	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
0.0-0.5	JJ	O
mmHg	NN	O
)	)	O
.	.	O

Both	DT	O
agents	NNS	O
resulted	VBD	O
in	IN	O
similar	JJ	O
efficacy	NN	Others
regardless	NN	O
of	IN	O
etoricoxib	NN	O
dose	NN	O
.	.	O

CONCLUSION	NNP	O
Long-term	NNP	O
etoricoxib	NN	O
use	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
risk	NN	Physical
of	IN	Physical
thrombotic	JJ	Physical
CV	NNP	Physical
events	NNS	Physical
comparable	JJ	O
with	IN	O
that	DT	O
of	IN	O
diclofenac	NN	O
.	.	O

Compared	VBN	O
with	IN	O
diclofenac	NN	O
,	,	O
etoricoxib	RB	O
demonstrated	VBD	O
a	DT	O
greater	JJR	O
risk	NN	O
of	IN	O
renovascular	JJ	Physical
AEs	NNP	Physical
,	,	O
but	CC	O
a	DT	O
more	RBR	O
favourable	JJ	O
GI/liver	NNP	Others
tolerability	NN	Others
profile	NN	Others
.	.	Others

Does	VBZ	O
short-term	JJ	O
treatment	NN	O
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
cause	VBP	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
?	.	O
BACKGROUND	NNP	O
Rebound	NNP	O
acid	VBZ	O
hypersecretion	NN	O
might	MD	O
occur	VB	O
after	IN	O
treatment	NN	O
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
.	.	O

This	DT	O
study	NN	O
looks	VBZ	O
for	IN	O
a	DT	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
after	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
lansoprazole	NN	O
.	.	O

STUDY	NNP	O
Sixty-two	JJ	O
patients	NNS	O
(	(	O
19	CD	O
men	NNS	O
and	CC	O
43	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
54	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
32-77	CD	O
years	NNS	O
)	)	O
with	IN	O
heartburn	NN	O
and	CC	O
regurgitation	NN	O
and	CC	O
normal	JJ	O
upper	JJ	O
endoscopy	NN	O
findings	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
with	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
5-day	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
lansoprazole	JJ	O
60	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
or	CC	O
placebo	NN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
9-day	JJ	O
washout	NN	O
period	NN	O
.	.	O

Reflux	NNP	Physical
,	,	Physical
total	JJ	Physical
,	,	Physical
and	CC	Physical
antacid	JJ	Physical
scores	NNS	Physical
were	VBD	O
calculated	VBN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
treatment	NN	O
periods	NNS	O
.	.	O

Higher	JJR	O
scores	NNS	O
during	IN	O
the	DT	O
placebo	JJ	O
period	NN	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
lansoprazole	VBZ	O
first	RB	O
than	IN	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
placebo	VBP	O
first	RB	O
indicated	VBN	O
a	DT	O
rebound	NN	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
symptom	NN	Physical
scores	NNS	Physical
during	IN	O
the	DT	O
placebo	JJ	O
period	NN	O
in	IN	O
the	DT	O
groups	NNS	O
given	VBN	O
lansoprazole	VBP	O
first	JJ	O
and	CC	O
placebo	NN	O
first	RB	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
reflux	NN	Physical
score	NN	Physical
,	,	O
21.5	CD	O
and	CC	O
17.6	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
;	:	O
total	JJ	Physical
score	NN	Physical
,	,	O
11.2	CD	O
and	CC	O
10.3	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
;	:	O
and	CC	O
antacid	VB	Physical
score	NN	Physical
,	,	O
8.2	CD	O
and	CC	O
7.2	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
indication	NN	O
of	IN	O
a	DT	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
12	CD	O
to	TO	O
14	CD	O
days	NNS	O
after	IN	O
a	DT	O
5-day	JJ	O
treatment	NN	O
with	IN	O
lansoprazole	JJ	O
60	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
reflux	NN	O
symptoms	NNS	O
.	.	O

A	DT	O
randomised	JJ	O
group	NN	O
comparison	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
'preschoolers	NNS	O
with	IN	O
autism	NN	O
'	''	O
:	:	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
skills	NNS	O
training	VBG	O
intervention	NN	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
parent	NN	O
education	NN	O
on	IN	O
adaptive	JJ	Mental
behaviour	NN	Mental
,	,	O
autism	NN	Physical
symptoms	NNS	Physical
and	CC	O
cognitive/language	NN	Mental
skills	NNS	Mental
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomised	VBD	O
group	NN	O
comparison	NN	O
design	NN	O
involving	VBG	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
counselling	VBG	O
intervention	NN	O
and	CC	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
intervention	NN	O
to	TO	O
control	VB	O
for	IN	O
parent	NN	O
skills	NNS	O
training	NN	O
and	CC	O
a	DT	O
control	NN	O
sample	NN	O
.	.	O

Two	CD	O
rural	JJ	O
and	CC	O
two	CD	O
metropolitan	JJ	O
regions	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
intervention	NN	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

Parents	NNS	O
from	IN	O
autism	NN	O
assessment	NN	O
services	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
regions	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
parent	VB	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
or	CC	O
parent	JJ	O
education	NN	O
and	CC	O
counselling	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

RESULTS	JJ	O
Parent	JJ	O
education	NN	O
and	CC	O
behaviour	VB	O
management	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
improvement	NN	O
in	IN	O
adaptive	JJ	Mental
behaviour	NN	Mental
and	CC	O
autism	NN	Physical
symptoms	NNS	Physical
at	IN	O
6	CD	O
months	NNS	O
follow-up	RB	O
for	IN	O
children	NNS	O
with	IN	O
greater	JJR	O
delays	NNS	O
in	IN	O
adaptive	JJ	Mental
behaviour	NN	Mental
.	.	O

Parent	NN	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
parent	VB	O
education	NN	O
and	CC	O
counselling	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
20-week	JJ	O
parent	NN	O
education	NN	O
programme	NN	O
including	VBG	O
skills	NNS	O
training	VBG	O
for	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
provides	VBZ	O
significant	JJ	O
improvements	NNS	O
in	IN	O
child	JJ	Mental
adaptive	JJ	Mental
behaviour	NN	Mental
and	CC	O
symptoms	NNS	Mental
of	IN	Mental
autism	NN	Mental
for	IN	O
low-functioning	JJ	O
children	NNS	O
.	.	O

Several	JJ	O
indicators	NNS	Others
of	IN	Others
oxidative	JJ	Others
stress	NN	Others
,	,	Others
immunity	NN	Others
,	,	Others
and	CC	Others
illness	NN	Others
improved	VBN	O
in	IN	O
trained	JJ	O
men	NNS	O
consuming	VBG	O
an	DT	O
encapsulated	JJ	O
juice	NN	O
powder	NN	O
concentrate	NN	O
for	IN	O
28	CD	O
weeks	NNS	O
.	.	O

Phytonutrients	NNS	O
from	IN	O
plant	NN	O
foods	NNS	O
provide	VBP	O
numerous	JJ	O
antioxidants	NNS	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	DT	O
supplementation	NN	O
for	IN	O
28	CD	O
wk	NN	O
with	IN	O
a	DT	O
commercially	RB	O
available	JJ	O
encapsulated	JJ	O
juice	NN	O
powder	NN	O
concentrate	NN	O
(	(	O
JPC	NNP	O
)	)	O
could	MD	O
influence	VB	O
indicators	NNS	O
of	IN	O
oxidative	JJ	Others
stress	NN	Others
,	,	O
immunity	NN	Others
,	,	O
and	CC	O
illness	NN	Others
.	.	O

Trained	VBN	O
men	NNS	O
(	(	O
n	JJ	O
=	VBZ	O
41	CD	O
;	:	O
34	CD	O
+/-	JJ	O
5	CD	O
y	NN	O
;	:	O
maximum	JJ	O
oxygen	NN	O
uptake	JJ	O
=	JJ	O
55	CD	O
+/-	JJ	O
7	CD	O
mL	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
from	IN	O
a	DT	O
homogenous	JJ	O
police	NN	O
Special	JJ	O
Forces	NNS	O
unit	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
manner	NN	O
to	TO	O
either	DT	O
JPC	NNP	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
.	.	O

We	PRP	O
used	VBD	O
multiple	JJ	O
7-d	JJ	Others
food	NN	Others
records	NNS	Others
to	TO	O
assess	VB	O
dietary	JJ	O
intake	NN	O
and	CC	O
found	VBD	O
inadequate	JJ	O
mean	JJ	O
daily	JJ	O
fruit	NN	O
and	CC	O
vegetable	JJ	O
consumption	NN	O
(	(	O
3.2	CD	O
+/-	JJ	O
1.2	CD	O
servings	NNS	O
)	)	O
.	.	O

The	DT	O
group	NN	O
physician	NN	O
documented	VBD	O
all	DT	O
duty	NN	O
days	NNS	O
lost	VBD	O
due	JJ	O
to	TO	O
illness	VB	Physical
.	.	O

We	PRP	O
collected	VBD	O
plasma	NN	O
at	IN	O
baseline	NN	O
and	CC	O
study	NN	O
wk	VBP	O
4	CD	O
,	,	O
8	CD	O
,	,	O
16	CD	O
,	,	O
and	CC	O
28	CD	O
for	IN	O
analysis	NN	O
of	IN	O
carbonyl	NN	Others
groups	NNS	Others
on	IN	Others
protein	NN	Physical
(	(	Physical
CP	NNP	Physical
)	)	Physical
and	CC	Physical
TNFalpha	NNP	Physical
.	.	O

Over	IN	O
the	DT	O
28-wk	JJ	O
investigation	NN	O
,	,	O
CP	NNP	Physical
was	VBD	O
lower	RBR	O
in	IN	O
the	DT	O
JPC	NNP	O
group	NN	O
,	,	O
with	IN	O
both	DT	O
a	DT	O
treatment	NN	O
and	CC	O
a	DT	O
time	NN	O
x	JJ	O
treatment	NN	O
interaction	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Concentrations	NNS	O
of	IN	O
both	DT	O
CP	NNP	Physical
and	CC	O
TNFalpha	NNP	Physical
at	IN	O
16	CD	O
and	CC	O
28	CD	O
wk	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
JPC	NNP	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TNFalpha	NNP	Physical
increased	VBD	O
during	IN	O
the	DT	O
first	JJ	O
8	CD	O
wk	NN	O
followed	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
in	IN	O
both	DT	O
groups	NNS	O
for	IN	O
the	DT	O
following	JJ	O
20	CD	O
wk	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Over	IN	O
the	DT	O
final	JJ	O
20	CD	O
wk	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
placebo	NN	O
group	NN	O
tended	VBD	O
to	TO	O
have	VB	O
more	JJR	O
days	NNS	O
of	IN	O
illness	NN	Physical
than	IN	O
the	DT	O
JPC	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.068	CD	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
beneficial	JJ	O
JPC	NNP	O
effects	NNS	O
with	IN	O
regard	NN	O
to	TO	O
reduction	NN	O
of	IN	O
duty	NN	O
days	NNS	O
lost	VBD	O
due	JJ	O
to	TO	O
illness	VB	Physical
and	CC	O
reduction	NN	O
of	IN	O
CP	NNP	Physical
and	CC	O
TNFalpha	NNP	Physical
concentrations	NNS	Physical
in	IN	O
this	DT	O
group	NN	O
of	IN	O
trained	JJ	O
men	NNS	O
over	IN	O
28	CD	O
wk	NNS	O
.	.	O

The	DT	O
Relaxation	NNP	O
Inventory	NN	O
:	:	O
self-report	JJ	O
scales	NNS	O
of	IN	O
relaxation	NN	O
training	NN	O
effects	NNS	O
.	.	O

The	DT	O
development	NN	O
of	IN	O
a	DT	O
self-report	JJ	O
measure	NN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
relaxation	NN	O
training	NN	O
was	VBD	O
examined	VBN	O
.	.	O

A	DT	O
rigorous	JJ	O
statistical	JJ	O
method	NN	O
of	IN	O
scale	JJ	O
construction	NN	O
consisting	NN	O
of	IN	O
a	DT	O
modification	NN	O
of	IN	O
the	DT	O
scale	JJ	O
discrimination	NN	O
technique	NN	O
was	VBD	O
employed	VBN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
45-item	JJ	O
questionnaire	NN	O
representing	VBG	O
three	CD	O
orthogonally	RB	O
derived	VBN	O
scales	NNS	O
.	.	O

The	DT	O
three	CD	O
scales	NNS	O
,	,	O
Physiological	NNP	O
Tension	NNP	O
,	,	O
Physical	NNP	O
Assessment	NNP	O
,	,	O
and	CC	O
Cognitive	NNP	O
Tension	NNP	O
,	,	O
demonstrated	VBD	O
adequate	JJ	O
internal	JJ	O
consistency	NN	O
with	IN	O
KR20	NNP	O
reliability	NN	O
coefficients	NNS	O
of	IN	O
.89	NNP	O
,	,	O
.95	NNP	O
,	,	O
and	CC	O
.81	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
study	NN	O
of	IN	O
predictive	JJ	O
validity	NN	O
,	,	O
40	CD	O
individuals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
conditions	NNS	O
:	:	O
relaxation	NN	O
training	NN	O
,	,	O
tension	NN	O
inducement	NN	O
,	,	O
pre-postcontrol	NN	O
,	,	O
or	CC	O
postcontrol	NN	O
.	.	O

Univariate	NNP	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBN	O
significant	JJ	O
findings	NNS	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
dimensions	NNS	O
of	IN	O
the	DT	O
inventory	NN	O
.	.	O

The	DT	O
Physiological	JJ	O
Tension	NNP	O
Scale	NNP	O
detected	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
tension	NN	Physical
following	VBG	O
tension	NN	O
inducement	NN	O
,	,	O
whereas	IN	O
the	DT	O
Physical	NNP	O
Assessment	NNP	O
Scale	NNP	O
and	CC	O
Cognitive	NNP	O
Tension	NNP	O
Scale	NNP	O
detected	VBD	O
increases	NNS	O
in	IN	O
relaxation	NN	Physical
following	VBG	O
relaxation	NN	O
training	NN	O
.	.	O

Recommendations	NNS	O
were	VBD	O
made	VBN	O
for	IN	O
future	JJ	O
research	NN	O
on	IN	O
the	DT	O
inventory	NN	O
.	.	O

A	DT	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
preoperative	JJ	O
to	TO	O
perioperative	JJ	O
chemotherapy	NN	O
in	IN	O
early-stage	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
IFCT	NNP	O
0002	CD	O
trial	NN	O
)	)	O
.	.	O

HYPOTHESIS	NNP	O
There	EX	O
will	MD	O
be	VB	O
a	DT	O
detectable	JJ	O
increase	NN	O
in	IN	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
using	VBG	O
preoperative	JJ	O
(	(	O
PRE	NNP	O
)	)	O
as	IN	O
opposed	VBN	O
to	TO	O
perioperative	VB	O
(	(	O
PERI	NNP	O
)	)	O
chemotherapy	NN	O
in	IN	O
resectable	JJ	O
StageI-II	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
multicenter	NN	O
,	,	O
open-label	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
with	IN	O
a	DT	O
2?2	CD	O
factorial	JJ	O
design	NN	O
first	RB	O
compared	VBN	O
two	CD	O
chemotherapy	NN	O
strategies	NNS	O
(	(	O
PRE	NNP	O
versus	NNP	O
PERI	NNP	O
)	)	O
,	,	O
then	RB	O
two	CD	O
chemotherapy	NN	O
regimens	NNS	O
(	(	O
gemcitabine-cisplatin	JJ	O
[	NNP	O
GP	NNP	O
]	NNP	O
versus	IN	O
paclitaxel-carboplatin	JJ	O
[	NNP	O
TC	NNP	O
]	NNP	O
)	)	O
.	.	O

The	DT	O
PRE	NNP	O
group	NN	O
received	VBD	O
two	CD	O
preoperative	JJ	O
cycles	NNS	O
followed	VBN	O
by	IN	O
two	CD	O
additional	JJ	O
preoperative	NN	O
cycles	NNS	O
,	,	O
while	IN	O
the	DT	O
PERI	NNP	O
group	NN	O
underwent	VBD	O
two	CD	O
preoperative	JJ	O
cycles	NNS	O
followed	VBN	O
by	IN	O
two	CD	O
postoperative	JJ	O
cycles	NNS	O
,	,	O
the	DT	O
3rd	CD	O
and	CC	O
4th	CD	O
cycles	NNS	O
being	VBG	O
given	VBN	O
only	RB	O
to	TO	O
responders	NNS	O
in	IN	O
both	DT	O
cases	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
528	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
,	,	O
267	CD	O
of	IN	O
which	WDT	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
PRE	NNP	O
group	NN	O
and	CC	O
261	CD	O
to	TO	O
the	DT	O
PERI	NNP	O
group	NN	O
.	.	O

Three-year	JJ	O
OS	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
67.4	CD	O
%	NN	O
and	CC	O
67.7	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	NN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
=1.01	VBP	O
[	JJ	O
0.79-1.30	JJ	O
]	NN	O
,	,	O
p=0.92	NN	O
)	)	O
,	,	O
nor	CC	O
did	VBD	O
3-year	JJ	O
disease-free	JJ	O
survival	NN	O
,	,	O
response	NN	O
rates	NNS	O
,	,	O
toxicity	NN	O
,	,	O
or	CC	O
postoperative	JJ	O
mortality	NN	O
.	.	O

Pathological	NNP	O
complete	JJ	O
response	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
22	CD	O
(	(	O
8.2	CD	O
%	NN	O
)	)	O
and	CC	O
16	CD	O
patients	NNS	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Although	IN	O
quality	NN	O
of	IN	O
life	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
,	,	O
chemotherapy	NN	O
compliance	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
responders	NNS	O
who	WP	O
received	VBD	O
Cycles	NNP	O
3	CD	O
and	CC	O
4	CD	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
(	(	O
90.4	CD	O
%	NN	O
versus	IN	O
75.2	CD	O
%	NN	O
,	,	O
p=0.001	NN	O
)	)	O
.	.	O

In	IN	O
responders	NNS	O
,	,	O
the	DT	O
dose	JJ	O
intensity	NN	O
of	IN	O
Cycles	NNP	O
3	CD	O
and	CC	O
4	CD	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
PERI	NNP	O
group	NN	O
(	(	O
mean	JJ	O
relative	VBP	O
dose	JJ	O
intensity	NN	O
of	IN	O
90.4	CD	O
%	NN	O
versus	IN	O
82.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
p=0.0007	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
GP	NNP	O
and	CC	O
TC	NNP	O
in	IN	O
3-year	JJ	O
OS	NNP	O
(	(	O
HR=0.97	NNP	O
[	RB	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
0.76-1.25	JJ	O
]	NN	O
,	,	O
p=0.80	NN	O
)	)	O
or	CC	O
response	NN	O
rates	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
regimens	NNS	O
'	POS	O
toxicity	NN	O
profiles	NNS	O
differed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
any	DT	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
patients	NNS	O
receiving	VBG	O
preoperative	JJ	O
and	CC	O
perioperative	JJ	O
chemotherapy	NN	O
in	IN	O
early-stage	JJ	O
NSCLC	NNP	O
.	.	O

The	DT	O
increase	NN	O
from	IN	O
two	CD	O
to	TO	O
four	CD	O
preoperative	JJ	O
chemotherapy	NN	O
cycles	NNS	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
pathological	JJ	O
response	NN	O
rate	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
cetrorelix	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
premature	NN	Physical
luteinizing	VBG	Physical
hormone	NN	Physical
surge	NN	Physical
during	IN	O
controlled	JJ	O
ovarian	JJ	O
stimulation	NN	O
using	VBG	O
letrozole	JJ	O
and	CC	O
gonadotropins	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
GnRH	NNP	O
antagonist	NN	O
in	IN	O
preventing	VBG	O
premature	NN	Physical
LH	NNP	Physical
surge	NN	Physical
under	IN	O
a	DT	O
letrozole	NN	O
and	CC	O
gonadotropin	NN	O
protocol	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	VB	O
A	DT	O
teaching	JJ	O
hospital	NN	O
and	CC	O
tertiary	JJ	O
medical	JJ	O
center	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Sixty-one	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
two	CD	O
letrozole	JJ	O
and	CC	O
gonadotropin-treated	JJ	O
groups	NNS	O
.	.	O

These	DT	O
were	VBD	O
distinguished	VBN	O
by	IN	O
the	DT	O
absence	NN	O
(	(	O
group	NN	O
I	PRP	O
)	)	O
or	CC	O
presence	NN	O
(	(	O
group	NN	O
II	NNP	O
)	)	O
of	IN	O
supplementation	NN	O
with	IN	O
0.25	CD	O
mg	NNS	O
of	IN	O
cetrorelix	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Controlled	VBD	O
ovarian	JJ	O
stimulation	NN	O
with	IN	O
letrozole	JJ	O
and	CC	O
gonadotropins	NNS	O
,	,	O
cetrorelix	NN	O
and	CC	O
intrauterine	JJ	O
insemination	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Rate	NNP	Physical
of	IN	Physical
premature	NN	Physical
LH	NNP	Physical
surge	NN	Physical
.	.	Physical

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Compared	NNP	O
with	IN	O
group	NN	O
I	PRP	O
,	,	O
the	DT	O
rate	NN	Physical
of	IN	Physical
premature	NN	Physical
LH	NNP	Physical
surge	NN	Physical
was	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
for	IN	O
group	NN	O
II	NNP	O
(	(	O
43.4	CD	O
%	NN	O
[	CC	O
13/30	CD	O
]	NN	O
vs.	FW	O
19.4	CD	O
%	NN	O
[	CC	O
6/31	CD	O
]	NN	O
)	)	O
,	,	O
but	CC	O
the	DT	O
amount	NN	Physical
of	IN	Physical
gonadotropins	NNS	Physical
used	VBN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
higher	JJR	O
(	(	O
817.5	CD	O
+/-	JJ	O
28.5	CD	O
vs.	FW	O
907.5	CD	O
+/-	JJ	O
27.3	CD	O
IU	NNP	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
premature	JJ	Physical
LH	NNP	Physical
surge	NN	Physical
had	VBD	O
a	DT	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
pregnancy	NN	Physical
rate	NN	Physical
(	(	O
21.4	CD	O
%	NN	O
[	CC	O
9/42	CD	O
]	NN	O
vs.	FW	O
0	CD	O
[	$	O
0/18	CD	O
]	NNP	O
)	)	O
relative	VBP	O
to	TO	O
their	PRP$	O
unaffected	JJ	O
counterparts	NNS	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
flexible	JJ	O
protocol	NN	O
of	IN	O
0.25	CD	O
mg	NN	O
of	IN	O
cetrorelix	NN	O
for	IN	O
IUI	NNP	O
cycles	NNS	O
appears	VBZ	O
to	TO	O
suppress	VB	O
the	DT	O
rate	NN	O
of	IN	O
premature	NN	Physical
LH	NNP	Physical
surge	NN	Physical
during	IN	O
ovarian	JJ	O
stimulation	NN	O
with	IN	O
letrozole	JJ	O
and	CC	O
gonadotropins	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
premature	NN	Physical
LH	NNP	Physical
surge	NN	Physical
remains	VBZ	O
too	RB	O
high	JJ	O
,	,	O
and	CC	O
modification	NN	O
will	MD	O
be	VB	O
necessary	JJ	O
before	IN	O
the	DT	O
application	NN	O
of	IN	O
cetrorelix	NN	O
to	TO	O
IVF	NNP	O
treatment	NN	O
.	.	O

Administrative	JJ	O
Data	NNP	O
Feedback	NNP	O
for	IN	O
Effective	NNP	Physical
Cardiac	NNP	Physical
Treatment	NNP	Physical
:	:	O
AFFECT	NNP	O
,	,	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
Hospital	NNP	O
report	NN	O
cards	NNS	O
are	VBP	O
increasingly	RB	O
being	VBG	O
implemented	VBN	O
for	IN	O
quality	NN	O
improvement	NN	O
despite	IN	O
lack	NN	O
of	IN	O
strong	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
their	PRP$	O
use	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
hospital	JJ	O
report	NN	O
cards	NNS	O
constructed	VBN	O
using	VBG	O
linked	VBN	O
hospital	NN	O
and	CC	O
prescription	NN	O
administrative	JJ	O
databases	NNS	O
are	VBP	O
effective	JJ	O
for	IN	O
improving	VBG	O
quality	NN	Others
of	IN	Others
care	NN	Others
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
The	DT	O
Administrative	NNP	O
Data	NNP	O
Feedback	NNP	O
for	IN	O
Effective	NNP	O
Cardiac	NNP	O
Treatment	NNP	O
(	(	O
AFFECT	NNP	O
)	)	O
study	NN	O
,	,	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
AND	CC	O
PATIENTS	NNP	O
Patients	NNPS	O
with	IN	O
AMI	NNP	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
76	CD	O
acute	NN	O
care	NN	O
hospitals	NNS	O
in	IN	O
Quebec	NNP	O
that	WDT	O
treated	VBD	O
at	IN	O
least	JJS	O
30	CD	O
AMI	NNP	O
patients	NNS	O
per	IN	O
year	NN	O
between	IN	O
April	NNP	O
1	CD	O
,	,	O
1999	CD	O
,	,	O
and	CC	O
March	NNP	O
31	CD	O
,	,	O
2003	CD	O
.	.	O

INTERVENTION	NN	O
Hospitals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
rapid	JJ	O
(	(	O
immediate	JJ	O
;	:	O
n	CC	O
=	$	O
38	CD	O
hospitals	NNS	O
and	CC	O
2533	CD	O
patients	NNS	O
)	)	O
or	CC	O
delayed	VBN	O
(	(	O
14	CD	O
months	NNS	O
;	:	O
n	CC	O
=	$	O
38	CD	O
hospitals	NNS	O
and	CC	O
3142	CD	O
patients	NNS	O
)	)	O
confidential	JJ	O
feedback	NN	O
on	IN	O
quality	NN	O
indicators	NNS	O
constructed	VBD	O
using	VBG	O
administrative	JJ	O
data	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Quality	NNP	O
indicators	NNS	O
pertaining	VBG	O
to	TO	O
processes	NNS	O
of	IN	O
care	NN	O
and	CC	O
outcomes	NNS	O
of	IN	O
patients	NNS	O
admitted	VBN	O
between	IN	O
4	CD	O
and	CC	O
10	CD	O
months	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
indicator	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
elderly	JJ	O
survivors	NNS	O
of	IN	O
AMI	NNP	O
at	IN	O
each	DT	O
study	NN	O
hospital	NN	O
who	WP	O
filled	VBD	O
a	DT	O
prescription	NN	O
for	IN	O
a	DT	O
beta-blocker	NN	O
within	IN	O
30	CD	O
days	NNS	O
after	IN	O
discharge	NN	O
.	.	O

RESULTS	VB	O
At	IN	O
follow-up	JJ	O
,	,	O
adjusted	JJ	O
prescription	NN	O
rates	NNS	O
within	IN	O
30	CD	O
days	NNS	O
after	IN	O
discharge	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
early	JJ	O
vs	NN	O
late	JJ	O
groups	NNS	O
(	(	O
for	IN	O
beta-blockers	NNS	O
,	,	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
,	,	O
1.06	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.82-1.37	NNP	O
;	:	O
for	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
,	,	O
OR	NNP	O
,	,	O
1.17	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.90-1.52	NNP	O
;	:	O
for	IN	O
lipid-lowering	NN	O
drugs	NNS	O
,	,	O
OR	NNP	O
,	,	O
1.14	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.86-1.50	NNP	O
;	:	O
and	CC	O
for	IN	O
aspirin	NN	O
,	,	O
OR	NNP	O
,	,	O
1.05	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.84-1.33	NN	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
adjusted	VBN	Mortality
mortality	NN	Mortality
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
as	IN	O
were	VBD	O
length	NN	Others
of	IN	Others
in-hospital	JJ	Others
stay	NN	Others
,	,	O
physician	JJ	Others
visits	NNS	Others
after	IN	Others
discharge	NN	Others
,	,	O
waiting	VBG	Others
times	NNS	Others
for	IN	Others
invasive	JJ	Others
cardiac	NN	Others
procedures	NNS	Others
,	,	Others
and	CC	O
readmissions	NNS	Others
for	IN	Others
cardiac	JJ	Others
complications	NNS	Others
.	.	O

CONCLUSIONS	NNP	O
Feedback	NNP	O
based	VBN	O
on	IN	O
one-time	JJ	O
,	,	O
confidential	JJ	O
report	NN	O
cards	NNS	O
constructed	VBN	O
using	VBG	O
administrative	JJ	O
data	NNS	O
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
strategy	NN	O
for	IN	O
quality	NN	O
improvement	NN	O
regarding	VBG	O
care	NN	O
of	IN	O
patients	NNS	O
with	IN	O
AMI	NNP	O
.	.	O

A	NNP	O
need	NN	O
exists	VBZ	O
for	IN	O
further	JJ	O
studies	NNS	O
to	TO	O
rigorously	VB	O
evaluate	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
more	RBR	O
intensive	JJ	O
report	NN	O
card	NN	O
interventions	NNS	O
.	.	O

[	JJ	O
Impact	NNP	O
of	IN	O
heparin	NN	O
on	IN	O
coagulation	NN	Physical
index	NN	Physical
during	IN	O
the	DT	O
therapy	NN	O
of	IN	O
molecular	JJ	O
adsorbent	NN	O
recirculating	VBG	O
system	NN	O
in	IN	O
patients	NNS	O
with	IN	O
liver	JJ	O
failure	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
impact	NN	O
of	IN	O
coagulative	JJ	O
parameters	NNS	O
on	IN	O
different	JJ	Others
anticoagulation	NN	Others
systems	NNS	Others
in	IN	O
molecular	JJ	O
adsorbent	NN	O
recirculating	VBG	O
system	NN	O
(	(	O
MARS	NNP	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
liver	JJ	O
failure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
of	IN	O
different	JJ	O
anticoagulation	NN	Physical
methods	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
experimental	JJ	O
observation	NN	O
was	VBD	O
designed	VBN	O
.	.	O

According	VBG	O
to	TO	O
anticoagulation	NN	O
Methods	NNP	O
,	,	O
174	CD	O
MARS	NNP	O
treatment	NN	O
sessions	NNS	O
for	IN	O
146	CD	O
patients	NNS	O
with	IN	O
liver	JJ	O
failure	NN	O
and	CC	O
prothrombin	JJ	O
time	NN	O
activity	NN	O
percentage	NN	O
(	(	O
PTA	NNP	O
)	)	O
?	.	O
40	CD	O
%	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
:	:	O
92	CD	O
MARS	NNP	O
treatment	NN	O
sessions	NNS	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
and	CC	O
82	CD	O
in	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
.	.	O

Time	NNP	O
points	NNS	O
of	IN	O
0	CD	O
,	,	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
6	CD	O
h	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
observe	VB	O
the	DT	O
coagulation	NN	O
changes	NNS	O
of	IN	O
prothrombin	NN	O
time	NN	O
(	(	O
PT	NNP	O
)	)	O
,	,	O
PTA	NNP	O
,	,	O
thrombin	JJ	O
time	NN	O
(	(	O
TT	NNP	O
)	)	O
,	,	O
activated	VBN	O
partial	JJ	O
thromboplastin	NN	O
time	NN	O
(	(	O
APTT	NNP	O
)	)	O
and	CC	O
international	JJ	O
normalized	VBN	O
ratio	NN	O
(	(	O
INR	NNP	O
)	)	O
dynamically	RB	O
.	.	O

Adverse	JJ	O
events	NNS	O
such	JJ	O
as	IN	O
line	NN	O
/	VBP	O
filter	NN	O
coagulation	NN	O
,	,	O
rupture	NN	O
and	CC	O
bleeding	NN	O
were	VBD	O
also	RB	O
investigated	VBN	O
and	CC	O
compared	VBN	O
due	JJ	O
to	TO	O
frequency	NN	O
and	CC	O
severity	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
PT	NNP	O
,	,	O
PTA	NNP	O
,	,	O
INR	NNP	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
,	,	O
but	CC	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
APTT	NNP	O
and	CC	O
TT	NNP	O
and	CC	O
fibrinogen	NN	O
(	(	O
Fbg	NNP	O
)	)	O
.	.	O

APTT	NNP	O
and	CC	O
TT	NNP	O
levels	NNS	O
in	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
was	VBD	O
increased	VBN	O
rapidly	RB	O
after	IN	O
the	DT	O
first	JJ	O
given	VBN	O
dose	NN	O
of	IN	O
anticoagulant	JJ	O
heparin	NN	O
and	CC	O
reached	VBD	O
the	DT	O
peak	NN	O
within	IN	O
30	CD	O
min.The	NN	O
levels	NNS	O
at	IN	O
each	DT	O
time	NN	O
point	NN	O
was	VBD	O
statistically	RB	O
different	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
Fbg	NNP	O
level	NN	O
was	VBD	O
obtained	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
it	PRP	O
was	VBD	O
stabilized	VBN	O
and	CC	O
increased	VBN	O
slightly	RB	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

While	IN	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
it	PRP	O
was	VBD	O
decreased	VBN	O
gradually	RB	O
and	CC	O
reached	VBD	O
a	DT	O
ravine	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

A	DT	O
curve	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
2.5	CD	O
h	NN	O
treatment	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P=0.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
2	CD	O
cases	NNS	O
of	IN	O
severe	JJ	O
bleeding	NN	O
after	IN	O
MARS	NNP	O
was	VBD	O
finished	VBN	O
in	IN	O
the	DT	O
heparin	NN	O
group	NN	O
,	,	O
and	CC	O
1	CD	O
was	VBD	O
terminated	VBN	O
because	IN	O
of	IN	O
degree	JJ	O
III	NNP	O
clotting	NN	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Fibrinogen	NNP	O
should	MD	O
be	VB	O
adsorbed	VBN	O
while	IN	O
the	DT	O
blood	NN	O
touches	VBZ	O
the	DT	O
MARS	NNP	O
circuit	NN	O
path	NN	O
and	CC	O
anticoagulants	NNS	O
can	MD	O
prevent	VB	O
it	PRP	O
.	.	O

Comprehensive	JJ	O
analysis	NN	O
of	IN	O
blood	NN	O
platelet	NN	O
count	NN	O
(	(	O
BPC	NNP	O
)	)	O
,	,	O
fibrin	JJ	O
degradation	NN	O
products	NNS	O
(	(	O
FDP	NNP	O
)	)	O
,	,	O
D-dimer	NNP	O
and	CC	O
clinical	JJ	O
symptoms	NNS	O
is	VBZ	O
critical	JJ	O
and	CC	O
required	VBN	O
to	TO	O
determine	VB	O
the	DT	O
coagulation	NN	O
status	NN	O
to	TO	O
select	VB	O
an	DT	O
anticoagulation	NN	O
system	NN	O
before	IN	O
MARS	NNP	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
low	JJ	O
dose	JJ	O
heparin	NN	O
in	IN	O
MARS	NNP	O
improves	VBZ	O
the	DT	O
disorder	NN	O
of	IN	O
hypercoagulable	JJ	O
state	NN	O
during	IN	O
the	DT	O
high	JJ	O
coaguation	NN	O
period	NN	O
,	,	O
while	IN	O
heparin-free	JJ	O
during	IN	O
low	JJ	O
coagulation	NN	O
period	NN	O
can	MD	O
effectively	RB	O
prevent	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
bleeding	NN	O
and	CC	O
improve	VB	O
the	DT	O
mechanism	NN	O
of	IN	O
blood	NN	O
coagulation	NN	O
by	IN	O
reducing	VBG	O
heparin-like	JJ	O
substance	NN	O
in	IN	O
the	DT	O
blood	NN	O
.	.	O

Safety	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
cold-adapted	JJ	O
influenza	NN	O
vaccine	NN	O
,	,	O
trivalent	NN	O
,	,	O
in	IN	O
infants	NNS	O
younger	JJR	O
than	IN	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

OBJECTIVE	NNP	O
Young	NNP	O
children	NNS	O
are	VBP	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
influenza-related	JJ	O
complications	NNS	O
.	.	O

Vaccination	NN	O
of	IN	O
close	JJ	O
household	NN	O
contacts	NNS	O
is	VBZ	O
recommended	VBN	O
to	TO	O
provide	VB	O
indirect	JJ	O
protection	NN	O
to	TO	O
children	NNS	O
<	$	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
live	JJ	O
,	,	O
cold-adapted	JJ	O
influenza	NN	O
vaccine	NN	O
,	,	O
trivalent	NN	O
,	,	O
is	VBZ	O
efficacious	JJ	O
in	IN	O
children	NNS	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
risks	NNS	O
associated	VBN	O
with	IN	O
inadvertent	JJ	O
exposure	NN	O
of	IN	O
infants	NNS	O
to	TO	O
vaccine	VB	O
viruses	NNS	O
from	IN	O
vaccinated	JJ	O
contacts	NNS	O
,	,	O
this	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
cold-adapted	JJ	O
influenza	NN	O
vaccine	NN	O
,	,	O
trivalent	NN	O
,	,	O
administered	VBN	O
intranasally	RB	O
to	TO	O
healthy	JJ	O
children	NNS	O
6	CD	O
to	TO	O
<	VB	O
24	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O

METHODS	NNP	O
Healthy	NNP	O
infants	NNS	O
aged	VBD	O
6	CD	O
to	TO	O
<	VB	O
16	CD	O
weeks	NNS	O
and	CC	O
16	CD	O
to	TO	O
<	VB	O
24	CD	O
weeks	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
2	CD	O
doses	NNS	O
of	IN	O
influenza	JJ	O
vaccine	NN	O
,	,	O
or	CC	O
placebo	VB	O
intranasally	RB	O
35	CD	O
+/-	JJ	O
7	CD	O
days	NNS	O
apart	RB	O
.	.	O

Reactogenicity	NN	O
events	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
11	CD	O
days	NNS	O
after	IN	O
each	DT	O
dose	NN	O
.	.	O

Other	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
monitored	VBN	O
through	IN	O
28	CD	O
to	TO	O
35	CD	O
days	NNS	O
after	IN	O
dose	JJ	O
2	CD	O
.	.	O

RESULTS	NN	O
Of	IN	O
the	DT	O
infants	NNS	O
aged	VBD	O
6	CD	O
to	TO	O
<	VB	O
16	CD	O
weeks	NNS	O
,	,	O
31	CD	O
received	VBD	O
influenza	JJ	O
vaccine	NN	O
and	CC	O
28	CD	O
received	VBD	O
placebo	NN	O
,	,	O
and	CC	O
of	IN	O
those	DT	O
aged	VBN	O
16	CD	O
to	TO	O
<	VB	O
24	CD	O
weeks	NNS	O
,	,	O
30	CD	O
received	VBD	O
influenza	JJ	O
vaccine	NN	O
and	CC	O
31	CD	O
received	VBD	O
placebo	NN	O
.	.	O

In	IN	O
the	DT	O
6-	JJ	O
to	TO	O
<	VB	O
16-week	JJ	O
cohort	NN	O
,	,	O
more	JJR	O
influenza	JJ	O
vaccine	NN	O
,	,	O
recipients	NNS	O
experienced	VBD	O
irritability	NN	Adverseeffect
(	(	O
66.7	CD	O
%	NN	O
vs	JJ	O
35.7	CD	O
%	NN	O
)	)	O
and	CC	O
runny	JJ	Physical
nose	NN	Physical
or	CC	Physical
nasal	JJ	Physical
congestion	NN	Physical
(	(	O
63.3	CD	O
%	NN	O
vs	JJ	O
33.3	CD	O
%	NN	O
)	)	O
after	IN	O
dose	JJ	O
1	CD	O
but	CC	O
not	RB	O
dose	JJ	O
2	CD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
increases	NNS	O
in	IN	O
any	DT	O
other	JJ	O
reactogenicity	NN	Adverseeffect
events	NNS	Adverseeffect
or	CC	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
in	IN	O
the	DT	O
vaccine	NN	O
recipients	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
mild	JJ	Adverseeffect
reactogenicity	NN	Adverseeffect
events	NNS	Adverseeffect
in	IN	O
children	NNS	O
6	CD	O
to	TO	O
<	VB	O
16	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
,	,	O
cold-adapted	JJ	O
influenza	NN	O
vaccine	NN	O
,	,	O
trivalent	NN	O
,	,	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
in	IN	O
infants	NNS	O
6	CD	O
to	TO	O
<	VB	O
24	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O

These	DT	O
findings	NNS	O
support	NN	O
further	JJ	O
evaluation	NN	O
of	IN	O
cold-adapted	JJ	O
influenza	NN	O
vaccine	NN	O
,	,	O
trivalent	NN	O
,	,	O
in	IN	O
infants	NNS	O
<	VBP	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

A	DT	O
randomised	JJ	O
double-blind	JJ	O
trial	NN	O
of	IN	O
cyclosporin	NN	O
and	CC	O
azathioprine	NN	O
in	IN	O
refractory	NN	O
rheumatoid	NN	O
arthritis	NN	O
.	.	O

Fifty-two	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
from	IN	O
four	CD	O
Australian	JJ	O
centres	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
cyclosporin	NN	O
A	NNP	O
(	(	O
CSA	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
or	CC	O
azathioprine	NN	O
(	(	O
AZA	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
for	IN	O
six	CD	O
months	NNS	O
.	.	O

Initial	JJ	O
mean	JJ	O
doses	NNS	O
of	IN	O
CSA	NNP	O
and	CC	O
AZA	NNP	O
were	VBD	O
4.2	CD	O
mg/kg	NNS	O
and	CC	O
1.7	CD	O
mg/kg	NN	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
doses	NNS	O
of	IN	O
CSA	NNP	O
and	CC	O
AZA	NNP	O
at	IN	O
six	CD	O
months	NNS	O
were	VBD	O
3.4	CD	O
mg/kg	NNS	O
and	CC	O
1.9	CD	O
mg/kg	NN	O
.	.	O

Assessments	NNS	O
of	IN	O
side-effects	NNS	O
and	CC	O
outcomes	NNS	O
of	IN	O
benefit	NN	O
were	VBD	O
made	VBN	O
monthly	RB	O
by	IN	O
independent	JJ	O
,	,	O
blinded	VBD	O
observers	NNS	O
.	.	O

Both	DT	O
treatment	NN	O
groups	NNS	O
exhibited	VBD	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
standard	JJ	O
outcome	NN	O
parameters	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
baseline	NN	O
values	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
these	DT	O
parameters	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
serum	JJ	Physical
creatinine	NN	Physical
concentration	NN	Physical
associated	VBN	O
with	IN	O
CSA	NNP	O
;	:	O
no	DT	O
persons	NNS	O
were	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
for	IN	O
this	DT	O
reason	NN	O
.	.	O

Seven	NNP	O
CSA	NNP	O
recipients	NNS	O
(	(	Physical
three	CD	Physical
gastrointestinal	NN	Physical
symptoms	NNS	Physical
,	,	Physical
two	CD	Physical
neurological	JJ	Physical
symptoms	NNS	Physical
,	,	Physical
two	CD	Physical
other	JJ	Physical
)	)	Physical
and	CC	O
12	CD	O
AZA	NNP	O
recipients	NNS	O
(	(	O
six	CD	Physical
gastrointestinal	NN	Physical
symptoms	NNS	Physical
,	,	O
four	CD	Physical
inefficacy	NN	Physical
,	,	O
two	CD	Physical
other	JJ	Physical
)	)	O
withdrew	VBD	O
from	IN	O
treatment	NN	O
prematurely	RB	O
.	.	O

Seven	NNP	O
CSA	NNP	O
recipients	NNS	O
became	VBD	O
hypertensive	JJ	Physical
and	CC	O
four	CD	O
required	VBN	O
anti-hypertensive	JJ	Physical
therapy	NN	Physical
.	.	O

Adverse	JJ	O
events	NNS	O
not	RB	O
requiring	VBG	O
cessation	NN	O
of	IN	O
therapy	NN	O
were	VBD	O
more	JJR	O
commonly	JJ	O
seen	VBN	O
among	IN	O
CSA	JJ	O
patients	NNS	O
.	.	O

In	IN	O
this	DT	O
group	NN	O
of	IN	O
severely	RB	O
affected	JJ	O
patients	NNS	O
with	IN	O
RA	NNP	O
both	DT	O
cyclosporin	NN	O
and	CC	O
azathioprine	NN	O
were	VBD	O
effective	JJ	O
therapies	NNS	O
.	.	O

CSA	NNP	Physical
toxicities	NNS	Physical
were	VBD	O
predictable	JJ	O
and	CC	O
manageable	JJ	O
but	CC	O
required	VBD	O
close	JJ	O
monitoring	NN	O
.	.	O

Does	NNS	O
waiting	VBG	O
matter	NN	O
?	.	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
new	JJ	O
non-urgent	JJ	O
rheumatology	NN	O
out-patient	JJ	O
referrals	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
waiting	VBG	O
times	NNS	O
on	IN	O
the	DT	O
health	NN	O
status	NN	O
of	IN	O
patients	NNS	O
referred	VBN	O
for	IN	O
a	DT	O
non-urgent	JJ	O
rheumatology	NN	O
opinion	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
evaluating	VBG	O
a	DT	O
'fast	JJ	O
track	NN	O
'	POS	O
appointment	NN	O
with	IN	O
a	DT	O
6-week	JJ	O
target	NN	O
waiting	VBG	O
time	NN	O
against	IN	O
an	DT	O
'ordinary	JJ	O
'	POS	O
appointment	NN	O
in	IN	O
the	DT	O
main	JJ	O
city	NN	O
out-patient	JJ	O
clinic	NN	O
of	IN	O
the	DT	O
rheumatology	NN	O
service	NN	O
for	IN	O
the	DT	O
Lothian	JJ	O
and	CC	O
Borders	NNPS	O
region	NN	O
(	(	O
population	NN	O
approximately	RB	O
1	CD	O
million	CD	O
)	)	O
.	.	O

Health	NNP	Physical
status	NN	Physical
was	VBD	O
measured	VBN	O
using	VBG	O
the	DT	O
SF12	NNP	Physical
physical	JJ	Physical
and	CC	Physical
mental	JJ	Physical
summary	JJ	Physical
component	NN	Physical
T-scores	NNS	Physical
and	CC	O
pain	NN	Pain
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
100	CD	O
mm	NN	O
visual	JJ	Others
analogue	NN	Others
pain	NN	Others
scale	NN	Others
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
health	NN	Physical
utility	NN	Physical
and	CC	Physical
perceived	VBD	Physical
health	NN	Physical
both	DT	O
measured	VBN	O
with	IN	O
the	DT	O
EuroQol	NNP	O
instrument	NN	O
,	,	O
mental	JJ	O
health	NN	O
measured	VBN	O
with	IN	O
the	DT	O
Hospital	NNP	O
Anxiety	NNP	Mental
and	CC	Mental
Depression	NNP	Mental
scale	NN	Mental
,	,	O
disability	NN	Physical
with	IN	O
the	DT	O
modified	JJ	O
Health	NNP	O
Assessment	NNP	O
Questionnaire	NNP	O
and	CC	O
economic	JJ	O
costs	NNS	O
measured	VBN	O
from	IN	O
a	DT	O
societal	JJ	O
perspective	NN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	Others
waiting	VBG	Others
times	NNS	Others
were	VBD	O
43	CD	O
days	NNS	O
(	(	O
sigma	JJ	O
=	NNP	O
+/-16	NN	O
)	)	O
and	CC	O
105	CD	O
days	NNS	O
(	(	O
sigma	JJ	O
=	NNP	O
+/-51	NN	O
)	)	O
for	IN	O
'fast	$	O
track	NN	O
'	''	O
and	CC	O
'ordinary	NNP	O
'	POS	O
appointments	NNS	O
,	,	O
respectively	RB	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
mean	JJ	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
]	NN	O
scores	NNS	O
for	IN	O
pain	NN	Pain
:	:	O
11	CD	O
(	(	O
7	CD	O
,	,	O
16	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
physical	JJ	Physical
health	NN	Physical
status	NN	Physical
:	:	O
4	CD	O
(	(	O
2	CD	O
,	,	O
5	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
mental	JJ	Mental
health	NN	Mental
status	NN	Mental
:	:	O
2	CD	O
(	(	O
0.1	CD	O
,	,	O
4	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
;	:	O
and	CC	O
health	NN	Physical
utility	NN	Physical
:	:	O
0.11	CD	O
(	(	O
0.07	CD	O
,	,	O
0.16	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
15-month	JJ	O
period	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Rationing	NNP	O
by	IN	O
delay	NN	O
was	VBD	O
not	RB	O
detrimental	JJ	O
to	TO	O
either	DT	O
mental	JJ	O
or	CC	O
physical	JJ	O
health	NN	O
and	CC	O
patients	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
of	IN	O
the	DT	O
study	NN	O
showed	VBD	O
significant	JJ	O
and	CC	O
similar	JJ	O
improvement	NN	O
in	IN	O
health	NN	O
by	IN	O
15	CD	O
months	NNS	O
.	.	O

Expenditure	NN	O
of	IN	O
resources	NNS	O
on	IN	O
waiting	VBG	O
times	NNS	O
without	IN	O
regard	NN	O
to	TO	O
clinical	JJ	O
outcomes	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
wasteful	JJ	O
and	CC	O
additional	JJ	O
resources	NNS	O
should	MD	O
be	VB	O
directed	VBN	O
at	IN	O
achieving	VBG	O
the	DT	O
greatest	JJS	O
clinical	JJ	O
benefit	NN	O
.	.	O

More	JJR	O
research	NN	O
into	IN	O
effective	JJ	O
methods	NNS	O
of	IN	O
controlling	VBG	O
demand	NN	O
and	CC	O
better	JJR	O
identification	NN	O
of	IN	O
those	DT	O
who	WP	O
would	MD	O
benefit	VB	O
from	IN	O
access	NN	O
to	TO	O
specialist	VB	O
care	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
non-depolarizing	JJ	O
neuromuscular	JJ	O
blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NN	O
disease	NN	O
.	.	O

To	TO	O
compare	VB	O
haemodynamic	JJ	O
responses	NNS	O
associated	VBN	O
with	IN	O
equipotent	JJ	O
doses	NNS	O
of	IN	O
neuromuscular	JJ	O
blockers	NNS	O
and	CC	O
high-dose	JJ	O
fentanyl	NN	O
(	(	O
50	CD	O
micrograms.kg-1	NN	O
)	)	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NNS	O
stenosis	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
20	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
insufficiency	NN	O
(	(	O
AI	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
four	CD	O
study	NN	O
groups	NNS	O
to	TO	O
receive	VB	O
the	DT	O
following	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
pancuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
vecuronium	NN	O
0.12	CD	O
mg.kg-1	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
atracurium	NN	O
0.4	CD	O
mg.kg-1	NN	O
,	,	O
or	CC	O
(	(	O
4	CD	O
)	)	O
pancuronium-metocurine	NN	O
mixture	NN	O
(	(	O
0.4	CD	O
mg	NN	O
+	VBD	O
1.6	CD	O
mg/ml	NN	O
)	)	O
:	:	O
1	CD	O
ml/10	NNS	O
kg	NN	O
)	)	O
.	.	O

Neuromuscular	JJ	O
blockers	NNS	O
were	VBD	O
injected	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
with	IN	O
the	DT	O
fentanyl	NN	O
;	:	O
haemodynamics	NNS	O
were	VBD	O
recorded	VBN	O
with	IN	O
the	DT	O
patients	NNS	O
awake	VBP	O
(	(	O
baseline	NN	O
)	)	O
,	,	O
at	IN	O
two	CD	O
minutes	NNS	O
post-induction	NN	O
,	,	O
and	CC	O
at	IN	O
two	CD	O
and	CC	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
AS	NNP	O
,	,	O
pancuronium	NN	O
increased	VBD	O
heart	NN	Physical
rate	NN	Physical
more	JJR	O
than	IN	O
vecuronium	NN	O
or	CC	O
atracurium	NN	O
;	:	O
heart	NN	Physical
rates	NNS	Physical
were	VBD	O
also	RB	O
higher	JJR	O
with	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
than	IN	O
with	IN	O
vecuronium	NN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
no	DT	O
ECG	NNP	Physical
signs	NNS	Physical
of	IN	Physical
ischaemia	NN	Physical
,	,	O
one	CD	O
patient	NN	O
given	VBN	O
pancuronium	NN	O
developed	VBD	O
severe	JJ	Physical
hypotension	NN	Physical
associated	VBN	Physical
with	IN	Physical
tachycardia	NN	Physical
.	.	O

Reductions	NNS	O
in	IN	O
SVR	NNP	Physical
after	IN	O
atracurium	NN	O
allowed	VBD	O
small	JJ	O
but	CC	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
decreases	NNS	O
in	IN	O
MAP	NNP	Physical
which	WDT	O
were	VBD	O
well	RB	Others
tolerated	VBN	Others
;	:	O
one	CD	O
patient	NN	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
develop	VB	O
severe	JJ	Physical
hypotension	NN	Physical
.	.	O

Intubation	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
increases	NNS	O
in	IN	O
MAP	NNP	Physical
in	IN	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
group	NN	O
.	.	O

Vecuronium	NNP	O
permitted	VBD	O
the	DT	O
most	RBS	O
stable	JJ	O
overall	JJ	Physical
haemodynamic	JJ	Physical
course	NN	Physical
at	IN	O
all	DT	O
measurement	JJ	O
times	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
patients	NNS	O
with	IN	O
AI	NNP	O
showed	VBD	O
stable	JJ	Physical
haemodynamics	NNS	Physical
after	IN	O
vecuronium	NN	O
,	,	O
pancuronium	NN	O
and	CC	O
the	DT	O
pancuronium-metocurine	JJ	O
mixture	NN	O
;	:	O
one	CD	O
patient	NN	O
became	VBD	O
tachycardic	JJ	Physical
following	VBG	O
vecuronium	NN	O
.	.	O

Atracurium	NNP	O
caused	VBD	O
unexplained	JJ	O
elevations	NNS	Physical
in	IN	Physical
diastolic	JJ	Physical
and	CC	Physical
mean	JJ	Physical
arterial	NN	Physical
pressures	NNS	Physical
which	WDT	O
were	VBD	O
significant	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
vecuronium	VB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
in	IN	O
increases	NNS	O
in	IN	O
PCWP	NNP	Physical
;	:	O
mean	JJ	Physical
PA	NNP	Physical
pressures	NNS	Physical
and	CC	O
CVP	NNP	Physical
were	VBD	O
also	RB	O
increased	VBN	Others
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
atracurium	NN	O
inpatients	NNS	O
with	IN	O
Al	NNP	O
need	VBP	O
further	JJ	O
evaluation	NN	O
.	.	O

Oxaprozin	NNP	O
versus	NN	O
diclofenac	NN	O
in	IN	O
NSAID-refractory	NNP	O
periarthritis	NN	O
pain	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oxaprozin	NN	O
in	IN	O
comparison	NN	O
with	IN	O
diclofenac	NN	O
in	IN	O
patients	NNS	O
with	IN	O
periarthritis	NN	O
pain	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
previously	RB	O
unsuccessfully	RB	O
treated	VBN	O
with	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
other	JJ	O
than	IN	O
diclofenac	NNS	O
and	CC	O
oxaprozin	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
open	JJ	O
,	,	O
multicentre	NN	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
,	,	O
eligible	JJ	O
patients	NNS	O
with	IN	O
periarthritis	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	RB	O
oxaprozin	JJ	O
1200	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
or	CC	O
diclofenac	$	O
50	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
(	(	O
n	JJ	O
=	NNP	O
47	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
period	NN	O
was	VBD	O
15	CD	O
+/-	JJ	O
1	CD	O
days	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
planned	VBN	O
on	IN	O
a	DT	O
hypothesis	NN	O
of	IN	O
equivalence	NN	O
between	IN	O
the	DT	O
two	CD	O
study	NN	O
drugs	NNS	O
.	.	O

The	DT	O
primary	JJ	O
study	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
change	NN	Pain
from	IN	Pain
baseline	NN	Pain
at	IN	Pain
day	NN	Pain
15	CD	Pain
in	IN	Pain
the	DT	Pain
patient-assessed	JJ	Pain
shoulder	NN	Pain
pain	NN	Pain
score	NN	Pain
.	.	O

Secondary	JJ	O
efficacy	NN	O
variables	NNS	O
included	VBD	O
investigator-assessed	JJ	Physical
shoulder	NN	Physical
function	NN	Physical
,	,	O
patient-assessed	JJ	O
quality	NN	O
of	IN	O
life	NN	O
on	IN	O
the	DT	O
Short-Form-36	NNP	O
(	(	O
SF-36	NNP	O
)	)	O
Acute	NNP	O
Health	NNP	O
Survey	NNP	O
and	CC	O
both	DT	O
patients	NNS	O
'	POS	O
and	CC	O
investigators	NNS	O
'	POS	O
overall	JJ	O
assessment	NN	O
of	IN	O
efficacy	NN	Others
.	.	O

RESULTS	NNP	O
At	IN	O
day	NN	O
15	CD	O
,	,	O
the	DT	O
mean	NN	O
changes	NNS	O
in	IN	O
shoulder	NN	Pain
pain	NN	Pain
score	NN	Pain
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
oxaprozin	NN	O
and	CC	O
diclofenac	NN	O
groups	NNS	O
were	VBD	O
-5.85	JJ	O
+/-	JJ	O
SD	NNP	O
4.62	CD	O
and	CC	O
-5.54	JJ	O
+/-	JJ	O
SD	NNP	O
4.41	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
difference	NN	Others
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
,	,	O
confirming	VBG	O
the	DT	O
hypothesis	NN	O
of	IN	O
the	DT	O
study	NN	O
that	IN	O
oxaprozin	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
diclofenac	NN	O
.	.	O

Investigator-assessed	JJ	Physical
shoulder	NN	Physical
function	NN	Physical
improved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
more	JJR	O
so	RB	O
in	IN	O
the	DT	O
oxaprozin	NN	O
group	NN	O
(	(	O
p	JJ	O
=	RB	O
0.028	CD	O
at	IN	O
day	NN	O
15	CD	O
)	)	O
.	.	O

Quality	NN	Physical
of	IN	Physical
life	NN	Physical
as	IN	Physical
measured	VBN	Physical
by	IN	Physical
SF-36	NNP	Physical
total	JJ	Physical
score	NN	Physical
was	VBD	O
also	RB	O
improved	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
with	IN	O
a	DT	O
trend	NN	O
toward	IN	O
greater	JJR	O
improvement	NN	O
in	IN	O
the	DT	O
oxaprozin	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
a	DT	O
significantly	RB	O
more	RBR	O
favourable	JJ	O
effect	NN	Others
on	IN	O
the	DT	O
SF-36	NNP	Physical
'mental	NNP	Physical
health	NN	Physical
'	''	Physical
item	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
oxaprozin	NN	O
compared	VBN	O
with	IN	O
diclofenac-treated	JJ	O
patients	NNS	O
at	IN	O
day	NN	O
15	CD	O
(	(	O
p	NN	O
=	RB	O
0.0202	CD	O
)	)	O
.	.	O

As	IN	O
assessed	VBN	O
by	IN	O
investigators	NNS	O
,	,	O
the	DT	O
overall	JJ	O
efficacy	NN	O
of	IN	O
oxaprozin	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
that	DT	O
for	IN	O
diclofenac	NN	O
at	IN	O
visit	NN	O
3	CD	O
(	(	O
8	CD	O
+/-	JJ	O
1	CD	O
days	NNS	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0067	CD	O
)	)	O
.	.	O

Patients	NNS	O
also	RB	O
assessed	VBD	O
the	DT	O
overall	JJ	O
efficacy	NN	Others
of	IN	O
oxaprozin	NN	O
as	IN	O
superior	JJ	O
to	TO	O
that	DT	O
of	IN	O
diclofenac	NN	O
at	IN	O
visits	NNS	O
3	CD	O
(	(	O
8	CD	O
+/-	JJ	O
1	CD	O
days	NNS	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0235	CD	O
)	)	O
and	CC	O
4	CD	O
(	(	O
15	CD	O
+/-	JJ	O
1	CD	O
days	NNS	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0272	CD	O
)	)	O
.	.	O

Only	RB	O
six	CD	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
,	,	O
all	DT	O
of	IN	O
which	WDT	O
were	VBD	O
mild	NNS	O
or	CC	O
moderate	VB	O
in	IN	O
intensity	NN	O
and	CC	O
occurred	VBD	O
in	IN	O
four	CD	O
diclofenac	NN	O
recipients	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
As	IN	O
expected	VBN	O
,	,	O
once-daily	JJ	O
oxaprozin	NN	O
proved	VBD	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
diclofenac	NN	O
three	CD	O
times	NNS	O
daily	RB	O
in	IN	O
reducing	VBG	O
the	DT	O
primary	JJ	O
efficacy	NN	O
variable	NN	O
of	IN	O
patient-assessed	JJ	Pain
shoulder	NN	Pain
pain	NN	Pain
score	NN	Pain
in	IN	O
patients	NNS	O
with	IN	O
periarthritis	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
refractory	NN	O
to	TO	O
previous	JJ	O
treatments	NNS	O
with	IN	O
other	JJ	O
NSAIDs	NNP	O
.	.	O

Oxaprozin	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
superior	JJ	O
to	TO	O
diclofenac	VB	O
in	IN	O
improving	VBG	O
shoulder	NN	Physical
function	NN	Physical
and	CC	O
was	VBD	O
considered	VBN	O
by	IN	O
investigators	NNS	O
and	CC	O
patients	NNS	O
to	TO	O
have	VB	O
greater	JJR	O
overall	JJ	O
efficacy	NN	O
than	IN	O
diclofenac	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
oxaprozin	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superior	JJ	O
results	NNS	O
in	IN	O
improving	VBG	O
patients	NNS	O
'	POS	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
compared	VBN	O
with	IN	O
diclofenac	NN	O
.	.	O

A	DT	O
trend	NN	O
towards	VBZ	O
better	JJR	O
tolerability	NN	Others
results	NNS	Others
for	IN	O
oxaprozin	JJ	O
compared	VBN	O
with	IN	O
diclofenac	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
.	.	O

Safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
an	DT	O
oral	JJ	O
,	,	O
inactivated	JJ	O
,	,	O
whole-cell	JJ	O
vaccine	NN	O
for	IN	O
Shigella	NNP	O
sonnei	NN	O
:	:	O
preclinical	JJ	O
studies	NNS	O
and	CC	O
a	DT	O
Phase	NNP	O
I	PRP	O
trial	NN	O
.	.	O

Orally	RB	O
delivered	VBN	O
,	,	O
inactivated	VBN	O
whole-cell	NN	O
vaccines	NNS	O
are	VBP	O
safe	JJ	O
methods	NNS	O
of	IN	O
inducing	VBG	O
local	JJ	O
and	CC	O
systemic	JJ	O
immunity	NN	O
.	.	O

To	TO	O
increase	VB	O
surface	NN	Physical
proteins	NNS	Physical
associated	VBN	O
with	IN	O
adherence	NN	O
and	CC	O
invasion	NN	O
,	,	O
Shigella	NNP	O
sonnei	NN	O
were	VBD	O
grown	VBN	O
in	IN	O
BHI	NNP	O
broth	CC	O
containing	VBG	O
deoxycholate	NN	O
.	.	O

A	DT	O
whole-cell	JJ	O
vaccine	NN	O
(	(	O
SsWC	NNP	O
)	)	O
was	VBD	O
then	RB	O
produced	VBN	O
by	IN	O
formalin	JJ	O
inactivation	NN	O
.	.	O

In	IN	O
pre-clinical	JJ	O
studies	NNS	O
,	,	O
the	DT	O
SsWC	NNP	O
vaccine	NN	O
was	VBD	O
immunogenic	JJ	O
and	CC	O
protected	VBN	O
against	IN	O
S.	NNP	O
sonnei-induced	JJ	O
keratoconjunctivitis	NN	O
in	IN	O
the	DT	O
guinea	NN	O
pig	NN	O
model	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
Phase	NNP	O
I	PRP	O
study	VBP	O
,	,	O
10	CD	O
evaluable	JJ	O
subjects	NNS	O
received	VBD	O
either	DT	O
three	CD	O
doses	NNS	O
of	IN	O
SsWC	NNP	O
on	IN	O
Days	NNP	O
0	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
28	CD	O
(	(	O
N	NNP	O
=	NNP	O
3	CD	O
)	)	O
;	:	O
five	CD	O
doses	NNS	O
of	IN	O
SsWC	NNP	O
on	IN	O
Days	NNP	O
0	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
28	CD	O
(	(	O
N	NNP	O
=	NNP	O
4	CD	O
)	)	O
;	:	O
or	CC	O
placebo	VB	O
(	(	O
N	NNP	O
=	NNP	O
3	CD	O
)	)	O
.	.	O

Each	DT	O
dose	NN	O
contained	VBD	O
2.0	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
inactivated	VBN	O
cells	NNS	O
.	.	O

Serum	NNP	Physical
and	CC	Physical
fecal	JJ	Physical
antibodies	NNS	Physical
against	IN	Physical
SsWC	NNP	Physical
,	,	Physical
LPS	NNP	Physical
,	,	Physical
and	CC	Physical
IpaC	NNP	Physical
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O

A	NNP	O
>	NN	O
or	CC	O
=	VB	O
4-fold	JJ	O
increase	NN	O
in	IN	O
titer	NN	O
was	VBD	O
considered	VBN	O
significant	JJ	O
.	.	O

Both	DT	O
SsWC	NNP	O
dosing	NN	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	Others
.	.	O

No	DT	O
fever	NN	Adverseeffect
or	CC	Adverseeffect
severe	JJ	Adverseeffect
gastrointestinal	JJ	Adverseeffect
symptoms	NNS	Adverseeffect
were	VBD	O
noted	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
vaccinated	JJ	O
subjects	NNS	O
.	.	O

Antibody	NN	Physical
responses	NNS	Physical
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
dosing	VBG	O
groups	NNS	O
.	.	O

Serum	NNP	Physical
IgG	NNP	Physical
or	CC	Physical
IgA	NNP	Physical
responses	NNS	Physical
to	TO	O
SsWC	NNP	O
were	VBD	O
seen	VBN	O
in	IN	O
six	CD	O
of	IN	O
seven	CD	O
vaccinees	NNS	O
(	(	O
86	CD	O
%	NN	O
)	)	O
,	,	O
to	TO	O
LPS	NNP	O
in	IN	O
four	CD	O
of	IN	O
seven	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
to	TO	O
IpaC	NNP	O
in	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
.	.	O

Fecal	JJ	Physical
IgA	NNP	Physical
responses	NNS	Physical
to	TO	O
these	DT	O
three	CD	O
antigens	NNS	O
developed	VBN	O
in	IN	O
five	CD	O
of	IN	O
five	CD	O
,	,	O
three	CD	O
of	IN	O
five	CD	O
,	,	O
and	CC	O
three	CD	O
of	IN	O
five	CD	O
subjects	NNS	O
,	,	O
respectively	RB	O
.	.	O

Among	IN	O
the	DT	O
seven	CD	O
vaccinees	NNS	O
,	,	O
geometric	JJ	O
mean	NN	O
rises	NNS	O
in	IN	O
serum	JJ	Physical
IgA	NNP	Physical
levels	NNS	Physical
to	TO	O
all	DT	O
three	CD	O
immunogens	NNS	O
were	VBD	O
significant	JJ	O
;	:	O
IgG	NNP	Physical
increases	VBZ	Physical
trended	VBD	O
toward	IN	O
significance	NN	O
(	(	O
paired	JJ	O
one-tailed	JJ	O
t-test	NN	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
SsWC	NNP	O
was	VBD	O
immunogenic	JJ	O
and	CC	O
protective	JJ	Others
in	IN	O
animal	JJ	O
studies	NNS	O
and	CC	O
well	RB	O
tolerated	VBN	Others
and	CC	O
immunogenic	JJ	O
in	IN	O
a	DT	O
Phase	NNP	O
I	PRP	O
trial	NN	O
.	.	O

Transthoracic	NNP	O
versus	NN	O
transesophageal	NN	O
cardioversion	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	O
or	CC	O
a	DT	O
transthoracic	JJ	O
approach	NN	O
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	Physical
rhythm	NN	Physical
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	Pain
score	NN	Pain
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	Adverseeffect
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	Others
and	CC	Others
effectively	RB	Others
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

The	DT	O
nature	NN	O
and	CC	O
importance	NN	O
of	IN	O
changes	NNS	O
in	IN	O
toe-brachial	JJ	O
pressure	NN	O
indices	NNS	O
following	VBG	O
percutaneous	JJ	O
transluminal	JJ	O
angioplasty	NN	O
for	IN	O
leg	NN	O
ischaemia	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
document	VB	O
changes	NNS	O
in	IN	O
toe-brachial	JJ	Physical
pressure	NN	Physical
indices	NNS	Physical
(	(	Physical
TBPI	NNP	Physical
)	)	Physical
during	IN	O
the	DT	O
6	CD	O
months	NNS	O
following	VBG	O
percutaneous	JJ	O
transluminal	JJ	O
angioplasty	NN	O
(	(	O
PTA	NNP	O
)	)	O
and	CC	O
relate	VB	O
these	DT	O
changes	NNS	O
to	TO	O
restenosis	VB	O
.	.	O

Furthermore	RB	O
,	,	O
to	TO	O
ascertain	VB	O
the	DT	O
effect	NN	Others
of	IN	O
administering	VBG	O
a	DT	O
vasodilator	NN	O
,	,	O
glyceryl	JJ	O
trinitrate	NN	O
(	(	O
GTN	NNP	O
)	)	O
,	,	O
immediately	RB	O
following	VBG	O
PTA	NNP	O
.	.	O

DESIGN	NNP	O
Eighty-three	JJ	O
technically	RB	O
successful	JJ	O
PTA	NNP	O
procedures	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Fifty-six	CD	O
were	VBD	O
for	IN	O
intermittent	JJ	O
claudication	NN	O
,	,	O
14	CD	O
for	IN	O
ischaemic	JJ	O
rest	NN	O
pain	NN	O
,	,	O
and	CC	O
13	CD	O
for	IN	O
non-healing	JJ	O
ulcers	NNS	O
.	.	O

Immediately	RB	O
following	VBG	O
balloon	NN	O
dilatation	NN	O
an	DT	O
intra-arterial	JJ	O
bolus	NN	O
of	IN	O
either	CC	O
150	CD	O
micrograms	NNS	O
GTN	NNP	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
10	CD	O
mg	NN	O
GTN	NNP	O
patch	NN	O
for	IN	O
24	CD	O
h	NN	O
,	,	O
or	CC	O
a	DT	O
saline	JJ	O
placebo	NN	O
was	VBD	O
administered	VBN	O
.	.	O

TBPI	NNP	Physical
were	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
for	IN	O
6	CD	O
h	NN	O
after	IN	O
PTA	NNP	O
and	CC	O
then	RB	O
at	IN	O
24	CD	O
h	NN	O
,	,	O
1	CD	O
week	NN	O
,	,	O
1	CD	O
month	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

At	IN	O
this	DT	O
time	NN	O
,	,	O
patency	NN	O
at	IN	O
the	DT	O
PTA	NNP	O
site	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
arteriography	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
continuing	VBG	O
TBPI	NNP	Physical
improvement	NN	O
over	IN	O
1	CD	O
month	NN	O
in	IN	O
patients	NNS	O
given	VBN	O
saline	JJ	O
following	VBG	O
PTA	NNP	O
.	.	O

In	IN	O
patients	NNS	O
given	VBN	O
GTN	NNP	O
,	,	O
peak	NN	Physical
TBPI	NNP	Physical
was	VBD	O
achieved	VBN	O
by	IN	O
1	CD	O
week	NN	O
,	,	O
and	CC	O
corresponded	VBD	O
with	IN	O
the	DT	O
TBPI	NNP	Physical
observed	VBD	O
immediately	RB	O
following	VBG	O
GTN	NNP	O
administration	NN	O
.	.	O

Restenosis	NNP	Physical
occurred	VBD	O
in	IN	O
27	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
was	VBD	O
significantly	RB	O
more	RBR	O
frequent	JJ	O
following	VBG	O
the	DT	O
procedures	NNS	O
for	IN	O
rest	NN	O
pain	NN	O
or	CC	O
ulceration	NN	O
,	,	O
or	CC	O
where	WRB	O
a	DT	O
TBPI	NNP	Physical
increase	NN	O
of	IN	O
more	JJR	O
than	IN	O
0.15	CD	O
by	IN	O
1	CD	O
week	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Haemodynamic	NNP	O
changes	NNS	O
following	VBG	O
PTA	NNP	O
continue	VBP	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
,	,	O
can	MD	O
be	VB	O
modified	VBN	O
by	IN	O
GTN	NNP	O
administration	NN	O
,	,	O
and	CC	O
are	VBP	O
predictive	JJ	O
of	IN	O
subsequent	JJ	O
restenosis	NN	O
.	.	O

Measuring	VBG	O
the	DT	O
TBPI	NNP	O
increase	NN	O
during	IN	O
the	DT	O
first	JJ	O
week	NN	O
following	VBG	O
PTA	NNP	O
underestimates	NNS	O
total	JJ	O
improvement	NN	O
,	,	O
and	CC	O
may	MD	O
give	VB	O
false	JJ	O
reassurance	NN	O
with	IN	O
respect	NN	O
to	TO	O
recurrent	VB	O
disease	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
decision	NN	O
aid	NN	O
for	IN	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
hereditary	JJ	O
nonpolyposis	NN	O
colorectal	NN	O
cancer	NN	O
risk	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
genetic	JJ	O
testing	VBG	O
for	IN	O
hereditary	JJ	O
nonpolyposis	NN	O
colorectal	NN	O
cancer	NN	O
(	(	O
HNPCC	NNP	O
)	)	O
risk	NN	O
,	,	O
individuals	NNS	O
can	MD	O
find	VB	O
the	DT	O
genetic	JJ	O
testing	VBG	O
decision-making	JJ	O
process	NN	O
complicated	VBN	O
and	CC	O
challenging	VBG	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
the	DT	O
current	JJ	O
study	NN	O
was	VBD	O
to	TO	O
measure	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	Others
a	DT	Others
tailored	JJ	Others
decision	NN	Others
aid	NN	Others
designed	VBN	O
specifically	RB	O
to	TO	O
assist	VB	O
individuals	NNS	O
to	TO	O
make	VB	O
informed	JJ	O
decisions	NNS	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
risk	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
153	CD	O
individuals	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
the	DT	O
decision	NN	O
aid	NN	O
or	CC	O
a	DT	O
control	JJ	O
pamphlet	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
their	PRP$	O
first	JJ	O
genetic	JJ	O
counseling	NN	O
consultation	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
109	CD	O
(	(	O
71.2	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
first	JJ	O
questionnaire	NN	Others
1	CD	O
week	NN	O
after	IN	O
consultation	NN	O
,	,	O
whereas	IN	O
95	CD	O
(	(	O
62.1	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
6-month	JJ	O
follow-up	JJ	Others
questionnaire	NN	Others
.	.	Others

RESULTS	CC	O
Although	IN	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
postdecisional	JJ	O
regret	NN	O
or	CC	O
actual	JJ	O
genetic	JJ	O
testing	VBG	O
decision	NN	O
,	,	O
the	DT	O
trial	NN	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
participants	NNS	O
who	WP	O
received	VBD	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	O
levels	NNS	O
of	IN	O
decisional	JJ	Others
conflict	NN	Others
(	(	Others
ie	JJ	Others
,	,	Others
uncertainty	NN	Others
)	)	Others
regarding	VBG	O
genetic	JJ	Physical
testing	NN	Physical
(	(	O
chi-square	JJ	O
(	(	O
1	CD	O
)	)	O
=	NN	O
8.97	CD	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
classified	VBN	O
as	IN	O
having	VBG	O
made	VBN	O
an	DT	O
informed	JJ	Others
choice	NN	Others
concerning	VBG	O
genetic	JJ	O
testing	NN	O
(	(	O
chi-square	JJ	O
(	(	O
1	CD	O
)	)	O
=	NN	O
4.37	CD	O
;	:	O
P	NNP	O
=	NNP	O
.037	NNP	O
)	)	O
than	IN	O
participants	NNS	O
who	WP	O
received	VBD	O
a	DT	O
control	NN	O
pamphlet	NN	O
.	.	O

Also	RB	O
,	,	O
men	NNS	O
who	WP	O
received	VBD	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	Others
knowledge	NN	Others
levels	NNS	Others
regarding	VBG	O
genetic	JJ	O
testing	NN	O
compared	VBN	O
with	IN	O
men	NNS	O
who	WP	O
received	VBD	O
the	DT	O
control	NN	O
pamphlet	NN	O
,	,	O
whereas	JJ	O
no	DT	O
such	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
women	NNS	O
(	(	O
chi-square	NN	O
(	(	O
2	CD	O
)	)	O
=	NN	O
6.76	CD	O
;	:	O
P	NNP	O
=	NNP	O
.034	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
decision	NN	O
aid	NN	O
for	IN	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
reduce	VB	O
uncertainty	NN	O
and	CC	O
assist	JJ	O
individuals	NNS	O
to	TO	O
make	VB	O
an	DT	O
informed	JJ	O
choice	NN	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
after	IN	O
genetic	JJ	O
counseling	NN	O
.	.	O

Primary	JJ	O
stenting	NN	O
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	O
intracoronary	JJ	O
stent	NN	O
placement	NN	O
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	O
angioplasty	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	O
implantation	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	Physical
minimal	JJ	Physical
luminal	JJ	Physical
diameter	NN	Physical
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	Physical
minimal	JJ	Physical
luminal	JJ	Physical
diameter	NN	Physical
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	Physical
diameter	NN	Physical
stenosis	NN	Physical
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	Physical
angiographic	JJ	Physical
restenosis	NN	Physical
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	Others
rates	NNS	Others
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	Others
of	IN	Others
target	NN	Others
lesion	NN	Others
revascularization	NN	Others
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	O
angioplasty	JJ	O
alone	RB	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	Physical
lesion	NN	Physical
revascularization	NN	Physical
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	Physical
rate	NN	Physical
.	.	O

Oxidative	JJ	O
DNA	NNP	O
damage	NN	O
measured	VBD	O
in	IN	O
human	JJ	O
lymphocytes	NNS	O
:	:	O
large	JJ	O
differences	NNS	O
between	IN	O
sexes	NNS	O
and	CC	O
between	IN	O
countries	NNS	O
,	,	O
and	CC	O
correlations	NNS	O
with	IN	O
heart	NN	O
disease	NN	O
mortality	NN	O
rates	NNS	O
.	.	O

The	DT	O
'antioxidant	JJ	O
hypothesis	NN	O
'	POS	O
proposes	NNS	O
that	IN	O
vitamin	NN	O
C	NNP	O
,	,	O
vitamin	NN	O
E	NNP	O
,	,	O
carotenoids	NNS	O
,	,	O
and	CC	O
other	JJ	O
antioxidants	NNS	O
occurring	VBG	O
in	IN	O
fruit	NN	O
and	CC	O
vegetables	NNS	O
afford	VBP	O
protection	NN	O
against	IN	O
heart	NN	O
disease	NN	O
and	CC	O
cancer	NN	O
by	IN	O
preventing	VBG	O
oxidative	JJ	O
damage	NN	O
to	TO	O
lipids	NNS	O
and	CC	O
to	TO	O
DNA	NNP	O
,	,	O
respectively	RB	O
.	.	O

To	TO	O
test	VB	O
elements	NNS	O
of	IN	O
this	DT	O
hypothesis	NN	O
,	,	O
we	PRP	O
have	VBP	O
measured	VBN	O
blood	NN	O
levels	NNS	O
of	IN	O
dietary	JJ	O
antioxidants	NNS	O
,	,	O
and	CC	O
8-oxodeoxyguanosine	JJ	O
(	(	O
8-oxo-dG	JJ	O
)	)	O
concentrations	NNS	O
in	IN	O
lymphocyte	NN	O
DNA	NN	O
,	,	O
in	IN	O
healthy	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
from	IN	O
five	CD	O
European	JJ	O
countries	NNS	O
:	:	O
France	NNP	O
,	,	O
Ireland	NNP	O
,	,	O
The	DT	O
Netherlands	NNP	O
,	,	O
Spain	NNP	O
,	,	O
and	CC	O
the	DT	O
U.K	NNP	O
.	.	O

Volunteers	NNS	O
,	,	O
aged	VBD	O
25	CD	O
45	CD	O
,	,	O
all	DT	O
nonsmokers	NNS	O
,	,	O
gave	VBD	O
blood	NN	O
samples	NNS	O
before	IN	O
and	CC	O
after	IN	O
a	DT	O
12-wk	JJ	O
carotenoid	NN	O
supplementation	NN	O
regime	NN	O
.	.	O

Vitamin	NNP	O
C	NNP	O
was	VBD	O
measured	VBN	O
in	IN	O
plasma	NN	O
and	CC	O
vitamin	NN	O
E	NNP	O
and	CC	O
carotenoids	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
serum	NN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
(	(	O
HPLC	NNP	O
)	)	O
.	.	O

8-oxo-dG	CD	O
was	VBD	O
assayed	VBN	O
by	IN	O
HPLC	NNP	O
(	(	O
with	IN	O
coulometric	JJ	O
detection	NN	O
)	)	O
in	IN	O
DNA	NNP	O
isolated	VBD	O
from	IN	O
lymphocytes	NNS	O
from	IN	O
the	DT	O
same	JJ	O
blood	NN	O
samples	NNS	O
.	.	O

Mean	JJ	O
values	NNS	O
were	VBD	O
calculated	VBN	O
for	IN	O
groups	NNS	O
of	IN	O
volunteers	NNS	O
at	IN	O
each	DT	O
sampling	NN	O
time	NN	O
according	VBG	O
to	TO	O
country	NN	O
,	,	O
sex	NN	O
,	,	O
and	CC	O
supplementation	NN	O
(	(	O
between	IN	O
9	CD	O
and	CC	O
24	CD	O
individual	JJ	O
samples	NNS	O
contributing	VBG	O
to	TO	O
each	DT	O
mean	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
8-oxo-dG	JJ	Physical
levels	NNS	Physical
in	IN	Physical
lymphocyte	NN	Physical
DNA	NNP	Physical
vary	NN	O
significantly	RB	O
according	VBG	O
to	TO	O
sex	NN	O
and	CC	O
country	NN	O
.	.	O

A	DT	O
low	JJ	O
mean	JJ	Physical
8-oxo-dG	JJ	Physical
concentration	NN	Physical
is	VBZ	O
seen	VBN	O
in	IN	O
DNA	NNP	O
of	IN	O
women	NNS	O
from	IN	O
all	DT	O
five	CD	O
countries	NNS	O
,	,	O
and	CC	O
of	IN	O
men	NNS	O
from	IN	O
France	NNP	O
and	CC	O
Spain	NNP	O
.	.	O

8-oxo-dG	NN	Physical
is	VBZ	O
significantly	RB	O
higher	JJR	O
(	(	O
up	IN	O
to	TO	O
about	IN	O
threefold	NN	O
)	)	O
in	IN	O
lymphocyte	NN	O
DNA	NN	O
from	IN	O
men	NNS	O
in	IN	O
Ireland	NNP	O
and	CC	O
the	DT	O
U.K.	NNP	O
Oxidative	NNP	Physical
DNA	NNP	Physical
damage	NN	Physical
is	VBZ	O
not	RB	O
significantly	RB	O
affected	VBN	O
by	IN	O
carotenoid	JJ	O
supplementation	NN	O
;	:	O
nor	CC	O
is	VBZ	O
there	EX	O
any	DT	O
association	NN	O
with	IN	O
mean	JJ	Physical
baseline	NN	Physical
levels	NNS	Physical
of	IN	Physical
antioxidants	NNS	Physical
,	,	O
which	WDT	O
are	VBP	O
generally	RB	O
similar	JJ	O
in	IN	O
the	DT	O
five	CD	O
countries	NNS	O
.	.	O

The	DT	O
five	CD	O
countries	NNS	O
sampled	VBN	O
lie	NN	O
on	IN	O
an	DT	O
axis	NN	O
from	IN	O
northern	JJ	O
to	TO	O
southern	JJ	O
Europe	NNP	O
with	IN	O
a	DT	O
steep	JJ	O
gradient	NN	O
in	IN	O
terms	NNS	O
of	IN	O
premature	JJ	O
heart	NN	O
disease	NN	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
association	NN	O
between	IN	O
premature	NN	Mortality
coronary	JJ	Mortality
heart	NN	Mortality
disease	NN	Mortality
mortality	NN	Mortality
in	IN	O
men	NNS	O
and	CC	O
the	DT	O
mean	JJ	O
levels	NNS	O
of	IN	O
8-oxo-dG	NN	O
for	IN	O
the	DT	O
five	CD	O
countries	NNS	O
(	(	O
r	NN	O
=	VBZ	O
0.95	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Women	NNS	O
have	VBP	O
low	JJ	O
coronary	JJ	Mortality
heart	NN	Mortality
disease	NN	Mortality
mortality	NN	Mortality
rates	NNS	Mortality
,	,	O
which	WDT	O
do	VBP	O
not	RB	O
correlate	VB	O
with	IN	O
8-oxo-dG	JJ	O
.	.	O

In	IN	O
terms	NNS	O
of	IN	O
cancer	NN	O
deaths	NNS	O
,	,	O
only	RB	O
colorectal	JJ	O
cancer	NN	O
in	IN	O
men	NNS	O
shows	VBZ	O
a	DT	O
significant	JJ	Others
positive	JJ	Others
correlation	NN	Others
(	(	O
r	JJ	O
=	NN	O
0.91	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
stomach	NN	Physical
cancer	NN	Physical
in	IN	O
women	NNS	O
is	VBZ	O
negatively	RB	O
correlated	VBN	O
with	IN	O
DNA	NNP	O
oxidation	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.92	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

Analgesic	JJ	Others
efficacy	NN	Others
of	IN	O
caudal	JJ	O
block	NN	O
versus	NN	O
diclofenac	NN	O
suppository	NN	O
and	CC	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
following	VBG	O
pediatric	JJ	O
laparoscopy	NN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
analgesic	JJ	Physical
efficacy	NN	O
of	IN	O
caudal	JJ	O
block	NN	O
with	IN	O
diclofenac	JJ	O
suppository	NN	O
and	CC	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
laparoscopy	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
50	CD	O
children	NNS	O
undergoing	JJ	O
laparoscopy	NN	O
for	IN	O
diagnostic	JJ	O
and	CC	O
therapeutic	JJ	O
purposes	NNS	O
.	.	O

Their	PRP$	O
ages	NNS	O
ranged	VBN	O
from	IN	O
3	CD	O
to	TO	O
13	CD	O
years	NNS	O
,	,	O
and	CC	O
all	DT	O
belonged	VBD	O
to	TO	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
class	NN	O
I	PRP	O
or	CC	O
II	NNP	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
the	DT	O
standard	JJ	O
procedure	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
caudal	JJ	O
block	NN	O
with	IN	O
bupivacaine	NN	O
1	CD	O
mL/kg	NN	O
after	IN	O
anesthetic	JJ	O
induction	NN	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
diclofenac	JJ	O
suppository	JJ	O
3	CD	O
mg/kg	JJ	O
postinduction	NN	O
and	CC	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
at	IN	O
the	DT	O
port	NN	O
sites	VBZ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

Pain	NN	Pain
was	VBD	Pain
assessed	VBN	Pain
using	VBG	O
the	DT	O
Hannallah	NNP	Pain
objective	JJ	Pain
pain	NN	Pain
scale	NN	Pain
at	IN	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
,	,	O
120	CD	O
,	,	O
and	CC	O
360	CD	O
minutes	NNS	O
postextubation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
pain	NN	Pain
scores	NNS	Pain
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
all	DT	O
times	NNS	O
.	.	O

Twelve	NNP	O
percent	NN	O
of	IN	O
caudal	JJ	O
block	NN	O
patients	NNS	O
and	CC	O
20	CD	O
%	NN	O
of	IN	O
diclofenac	NN	O
patients	NNS	O
needed	VBN	O
rescue	NN	Others
analgesic	NN	Others
,	,	O
a	DT	O
statistically	RB	O
insignificant	JJ	O
difference	NN	O
.	.	O

In	IN	O
2	CD	O
patients	NNS	O
,	,	O
caudal	JJ	O
block	NN	O
was	VBD	O
technically	RB	O
difficult	JJ	O
and	CC	O
they	PRP	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
was	VBD	O
low	JJ	O
in	IN	O
our	PRP$	O
study	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
find	VBP	O
the	DT	O
analgesic	JJ	Physical
efficacy	NN	O
of	IN	O
diclofenac	JJ	O
suppository	NN	O
combined	VBN	O
with	IN	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
at	IN	O
port	NN	O
sites	NNS	O
comparable	JJ	O
to	TO	O
caudal	VB	O
block	NN	O
.	.	O

Given	VBN	O
the	DT	O
necessarily	RB	O
invasive	JJ	O
nature	NN	O
of	IN	O
caudal	NN	O
block	NN	O
,	,	O
we	PRP	O
suggest	VBP	O
the	DT	O
combined	JJ	O
use	NN	O
of	IN	O
diclofenac	JJ	O
suppository	NN	O
with	IN	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
at	IN	O
port	NN	O
sites	NNS	O
as	IN	O
a	DT	O
useful	JJ	O
and	CC	O
more	RBR	O
economical	JJ	O
alternative	NN	O
for	IN	O
analgesia	NN	O
following	VBG	O
pediatric	JJ	O
laparoscopy	NN	O
.	.	O

Effects	NNS	O
of	IN	O
static	JJ	O
stretching	VBG	O
on	IN	O
repeated	VBN	Physical
sprint	NN	Physical
and	CC	Mental
change	NN	Mental
of	IN	Mental
direction	NN	Mental
performance	NN	Mental
.	.	O

PURPOSE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
static	JJ	O
stretching	VBG	O
during	IN	O
the	DT	O
recovery	NN	O
periods	NNS	O
of	IN	O
field-based	JJ	O
team	NN	O
sports	NNS	O
on	IN	O
subsequent	NN	O
repeated	VBN	Physical
sprint	JJ	Physical
ability	NN	Physical
(	(	Physical
RSA	NNP	Physical
)	)	Physical
and	CC	O
change	NN	Mental
of	IN	Mental
direction	NN	Mental
speed	NN	Mental
(	(	Mental
CODS	NNP	Mental
)	)	Mental
performance	NN	Mental
.	.	O

METHODS	NNP	O
On	IN	O
four	CD	O
separate	JJ	O
occasions	NNS	O
,	,	O
12	CD	O
male	JJ	O
team-sport	NN	O
players	NNS	O
performed	VBD	O
a	DT	O
standardized	JJ	O
warm-up	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
test	NN	O
of	IN	O
either	DT	O
RSA	NNP	Physical
or	CC	O
CODS	NNP	O
(	(	O
on	IN	O
two	CD	O
occasions	NNS	O
each	DT	O
)	)	O
in	IN	O
a	DT	O
counterbalanced	JJ	O
design	NN	O
.	.	O

Both	DT	O
tests	NNS	O
involved	VBD	O
three	CD	O
sets	NNS	O
of	IN	O
six	CD	O
maximal	JJ	O
sprint	NN	O
repetitions	NNS	O
,	,	O
with	IN	O
a	DT	O
4-min	JJ	O
recovery	NN	O
between	IN	O
sets	NNS	O
.	.	O

During	IN	O
the	DT	O
break	NN	O
between	IN	O
sets	NNS	O
,	,	O
the	DT	O
participants	NNS	O
either	CC	O
rested	VBN	O
(	(	O
control	VB	O
[	NNP	O
CON	NNP	O
]	NNP	O
)	)	O
or	CC	O
completed	VBN	O
a	DT	O
static	JJ	O
stretching	NN	O
protocol	NN	O
(	(	O
static	JJ	O
stretch	NN	O
[	NNP	O
SS	NNP	O
]	NNP	O
)	)	O
.	.	O

The	DT	O
RSA	NNP	O
test	NN	O
involved	VBN	O
straight-line	JJ	O
sprints	NNS	O
,	,	O
whereas	IN	O
the	DT	O
CODS	NNP	O
test	NN	O
required	VBD	O
a	DT	O
change	NN	O
of	IN	O
direction	NN	O
(	(	O
100	CD	O
degrees	NNS	O
)	)	O
every	DT	O
4	CD	O
m	NN	O
(	(	O
total	JJ	O
of	IN	O
four	CD	O
)	)	O
.	.	O

Mean	NNP	O
,	,	O
total	NN	O
(	(	O
sum	NN	O
of	IN	O
six	CD	O
sprints	NNS	O
)	)	O
,	,	O
first	RB	Others
,	,	Others
and	CC	Others
best	JJS	Mental
sprint	NN	Mental
times	NNS	Mental
(	(	O
MST	NNP	O
,	,	O
TST	NNP	O
,	,	O
FST	NNP	O
,	,	O
and	CC	O
BST	NNP	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
recorded	VBN	O
for	IN	O
each	DT	O
set	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
consistent	JJ	O
tendency	NN	O
for	IN	O
RSA	NNP	Physical
times	NNS	Physical
to	TO	O
be	VB	O
slower	JJR	O
after	IN	O
the	DT	O
static	JJ	O
stretching	NN	O
intervention	NN	O
,	,	O
which	WDT	O
was	VBD	O
supported	VBN	O
by	IN	O
statistical	JJ	O
significance	NN	O
for	IN	O
three	CD	O
performance	NN	O
variables	NNS	O
(	(	O
MST	NNP	O
0-5	NNP	O
m	NN	O
set	NN	O
2	CD	O
,	,	O
MST	NNP	O
0-20	NNP	O
m	NN	O
set	NN	O
2	CD	O
,	,	O
and	CC	O
TST	NNP	O
set	VBD	O
2	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
tendency	NN	O
was	VBD	O
also	RB	O
supported	VBN	O
by	IN	O
moderate	JJ	O
effect	NN	O
sizes	NNS	O
and	CC	O
qualitative	JJ	O
indications	NNS	O
of	IN	O
likely	JJ	O
harmful	NN	O
or	CC	O
detrimental	JJ	O
effects	NNS	O
associated	VBN	O
with	IN	O
RSA-SS	NNP	O
.	.	O

Further	NNP	O
,	,	O
sprint	NN	Mental
times	NNS	Mental
again	RB	O
tended	VBD	O
to	TO	O
be	VB	O
slower	JJR	O
in	IN	O
the	DT	O
CODS-SS	NNP	O
trial	NN	O
compared	VBN	O
with	IN	O
the	DT	O
CODS-CON	NNP	O
across	IN	O
all	DT	O
sprint	NN	O
variables	NNS	O
,	,	O
with	IN	O
a	DT	O
significantly	RB	O
slower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
BST	NNP	O
recorded	VBD	O
for	IN	O
set	NN	O
3	CD	O
after	IN	O
static	JJ	O
stretching	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
an	DT	O
acute	NN	O
bout	NN	O
(	(	O
4	CD	O
min	NN	O
)	)	O
of	IN	O
static	JJ	O
stretching	NN	O
of	IN	O
the	DT	O
lower	JJR	O
limbs	NN	O
during	IN	O
recovery	NN	O
periods	NNS	O
between	IN	O
efforts	NNS	O
may	MD	O
compromise	VB	O
RSA	NNP	Physical
performance	NN	Physical
but	CC	O
has	VBZ	O
less	JJR	O
effect	NN	O
on	IN	O
CODS	NNP	Mental
performance	NN	Mental
.	.	O

Contingency	NNP	O
management	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antipsychotic-induced	JJ	O
weight	JJ	Physical
gain	NN	Physical
:	:	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Weight	NNP	O
gain	NN	O
is	VBZ	O
common	JJ	O
for	IN	O
individuals	NNS	O
with	IN	O
serious	JJ	O
mental	JJ	O
illness	NN	O
(	(	O
SMI	NNP	O
)	)	O
receiving	VBG	O
antipsychotic	JJ	O
drug	NN	O
therapy	NN	O
.	.	O

Contingency	NNP	O
management	NN	O
(	(	O
CM	NNP	O
)	)	O
is	VBZ	O
a	DT	O
behavioral	JJ	O
intervention	NN	O
that	IN	O
rewards	NNS	O
positive	JJ	O
performance	NN	O
and	CC	O
has	VBZ	O
demonstrated	VBN	O
effectiveness	NN	O
in	IN	O
reducing	VBG	O
drug	NN	O
use	NN	O
in	IN	O
SMI	NNP	O
populations	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
using	VBG	O
CM	NNP	O
to	TO	O
promote	VB	O
weight	JJ	O
loss	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
SMI	NNP	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

METHOD	NNP	O
30	CD	O
individuals	NNS	O
(	(	O
BMI	NNP	O
?	.	O
28	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
conditions	NNS	O
:	:	O
i	NN	O
)	)	O
The	DT	O
combination	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
lifestyle	NN	O
modification	NN	O
(	(	O
LM	NNP	O
)	)	O
program	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
SMI	NNP	O
and	CC	O
payment	NN	O
for	IN	O
group	NN	O
attendance	NN	O
(	(	O
CM	NNP	O
(	(	O
attendance	NN	O
)	)	O
)	)	O
,	,	O
ii	NN	O
)	)	O
The	DT	O
combination	NN	O
of	IN	O
LM	NNP	O
and	CC	O
payment	NN	O
for	IN	O
weight	JJ	O
loss	NN	O
(	(	O
CM	NNP	O
(	(	O
weight	NN	O
)	)	O
)	)	O
,	,	O
and	CC	O
iii	NN	O
)	)	O
waitlist	NN	O
control	NN	O
(	(	O
CON	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
waitlist	JJ	O
period	NN	O
,	,	O
those	DT	O
participants	NNS	O
joined	VBD	O
a	DT	O
LM	NNP	O
group	NN	O
and	CC	O
received	VBD	O
payment	NN	O
for	IN	O
behavioral	JJ	O
change	NN	O
(	(	O
CM	NNP	O
(	(	O
behavior	NN	O
)	)	O
)	)	O
.	.	O

RESULTS	JJ	O
Subjects	NNPS	O
in	IN	O
the	DT	O
CM	NNP	O
(	(	O
attendance	NN	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
CM	NNP	O
(	(	O
weight	NN	O
)	)	O
group	NN	O
lost	VBD	O
a	DT	O
mean	NN	O
of	IN	O
1.16	CD	O
kg	NNS	O
and	CC	O
1.23	CD	O
kg	NN	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
CON	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
0.68	CD	O
kg	NNS	O
.	.	O

Subjects	NNS	O
receiving	VBG	O
CM	NNP	O
(	(	O
behavior	NN	O
)	)	O
,	,	O
lost	VBD	O
a	DT	O
mean	NN	O
of	IN	O
2.54	CD	O
kg	NNS	O
,	,	O
which	WDT	O
was	VBD	O
a	DT	O
significant	JJ	O
weight	NN	O
loss	NN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
period	NN	O
.	.	O

CONCLUSION	NNP	O
LM	NNP	O
supplemented	VBD	O
with	IN	O
CM	NNP	O
may	MD	O
facilitate	VB	O
weight	NN	O
loss	NN	O
in	IN	O
patients	NNS	O
taking	VBG	O
antipsychotic	JJ	O
medications	NNS	O
;	:	O
financial	JJ	O
reimbursement	NN	O
for	IN	O
behavioral	JJ	O
change	NN	O
may	MD	O
be	VB	O
particularly	RB	O
effective	JJ	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Adjvant	NNP	O
treatment	NN	O
of	IN	O
tongue	NN	O
and	CC	O
floor	NN	O
of	IN	O
the	DT	O
mouth	NN	O
cancers	NNS	O
.	.	O

Since	IN	O
January	NNP	O
1974	CD	O
,	,	O
95	CD	O
patients	NNS	O
with	IN	O
anterior	JJ	O
tongue	NN	O
and	CC	O
floor	NN	O
of	IN	O
the	DT	O
mouth	NN	O
cancers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

After	IN	O
stratification	NN	O
according	VBG	O
to	TO	O
staging	VBG	O
and	CC	O
initial	JJ	O
treatment	NN	O
,	,	O
one-third	NN	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
chemotherapy	NN	O
for	IN	O
2	CD	O
years	NNS	O
(	(	O
methotrexate	VB	O
400	CD	O
mg	NN	O
followed	VBN	O
by	IN	O
citrovorum	NN	O
factor	NN	O
100	CD	O
mg	NN	O
+	NNP	O
bleomycin	VBZ	O
60	CD	O
mg/week	NN	O
,	,	O
during	IN	O
the	DT	O
first	JJ	O
15	CD	O
weeks	NNS	O
)	)	O
,	,	O
one-third	JJ	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
immunotherapy	JJ	O
with	IN	O
weekly	JJ	O
C.	NNP	O
parvum	NN	O
injections	NNS	O
during	IN	O
2	CD	O
years	NNS	O
,	,	O
while	IN	O
the	DT	O
remaining	VBG	O
third	NN	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
treatment	NN	O
.	.	O

If	IN	O
adjuvant	JJ	O
treatment	NN	O
seems	VBZ	O
to	TO	O
delay	VB	Others
recurrence	NN	Others
it	PRP	O
did	VBD	O
not	RB	O
significantly	RB	O
decrease	VB	O
the	DT	O
recurrence	NN	Others
rate	NN	Others
.	.	O

Survival	NN	Mortality
is	VBZ	O
also	RB	O
not	RB	O
signigicantly	RB	O
modified	VBN	O
by	IN	O
adjuvant	JJ	O
treatment	NN	O
and	CC	O
was	VBD	O
better	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
small	JJ	O
tumors	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
previously	RB	O
received	VBD	O
radiotherapy	NN	O
did	VBD	O
not	RB	O
benefit	VB	O
from	IN	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

Long-stay	JJ	O
versus	NN	O
short-stay	JJ	O
hospital	NN	O
treatment	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
contrast	VB	O
early	JJ	O
discharge	NN	O
versus	NN	O
attempted	VBD	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
in	IN	O
hospital	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
(	(	O
PEM	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Field	NNP	O
experiment	NN	O
,	,	O
two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
with	IN	O
one	CD	O
between	IN	O
group	NN	O
(	(	O
short-	JJ	O
versus	IN	O
long-stay	NN	O
)	)	O
and	CC	O
one	CD	O
repeated	VBN	O
measures	NNS	O
factor	NN	O
(	(	O
admission	NN	O
,	,	O
then	RB	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
30	CD	O
and	CC	O
36	CD	O
months	NNS	O
post-admission	NN	O
)	)	O
.	.	O

Covariates	NNPS	O
introduced	VBD	O
.	.	O

SETTING	NNP	O
Primary	NNP	O
health	NN	O
care	NN	O
,	,	O
Kingston	NNP	O
,	,	O
Jamaica	NNP	O
.	.	O

SUBJECTS	NNP	O
n	JJ	O
=	NNP	O
81	CD	O
;	:	O
mean	JJ	O
age	NN	O
11	CD	O
months	NNS	O
;	:	O
79	CD	O
contribute	VBP	O
longitudinal	JJ	O
data	NNS	O
;	:	O
44	CD	O
every	DT	O
measurement	NN	O
.	.	O

INTERVENTIONS	NNP	O
When	WRB	O
concurrent	NN	O
illnesses	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
and	CC	O
normal	JJ	O
feeding	VBG	O
re-established	JJ	O
(	(	O
weight	JJ	O
gain	NN	O
5	CD	O
g/kg.day-1	NN	O
)	)	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
short-stay	NN	O
(	(	O
SS	NNP	O
)	)	O
or	CC	O
long-stay	JJ	O
(	(	O
LS	NNP	O
)	)	O
group	NN	O
.	.	O

LS	NNP	O
retained	VBD	O
in	IN	O
hospital	NN	O
for	IN	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
mean	VB	O
40	CD	O
days	NNS	O
)	)	O
.	.	O

SS	NNP	O
discharged	VBD	O
immediately	RB	O
(	(	O
mean	JJ	O
18	CD	O
days	NNS	O
)	)	O
for	IN	O
standard	JJ	O
Health	NNP	O
Service	NNP	O
care	NN	O
at	IN	O
home	NN	O
for	IN	O
6	CD	O
months	NNS	O
plus	CC	O
high-energy	JJ	O
supplement	NN	O
(	(	O
3.31	CD	O
MJ	NNP	O
with	IN	O
20.6	CD	O
g	NNS	O
protein	JJ	O
daily	JJ	O
)	)	O
for	IN	O
first	JJ	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
discharge	NN	O
LS	NNP	O
received	VBD	O
6	CD	O
months	NNS	O
home	NN	O
care	NN	O
,	,	O
but	CC	O
without	IN	O
supplementation	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
advantages	VBZ	O
for	IN	O
LS	NNP	O
group	NN	O
on	IN	O
NCHS	NNP	Physical
weight	NN	Physical
&	CC	Physical
length	NN	Physical
for	IN	Physical
age	NN	Physical
at	IN	Physical
discharge	NN	Physical
,	,	O
and	CC	O
at	IN	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
and	CC	O
for	IN	O
length	NN	O
also	RB	O
30	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
to	TO	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Weight	NNP	Physical
advantage	NN	Physical
peaked	VBD	O
at	IN	O
12	CD	O
and	CC	O
18	CD	O
months	NNS	O
,	,	O
length	NN	O
later	RB	O
at	IN	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
earlier	VB	O
reports	NNS	O
,	,	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
hospital	NN	O
for	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
PEM	NNP	O
.	.	O

Although	IN	O
in	IN	O
the	DT	O
long-term	JJ	O
both	DT	O
groups	NNS	O
move	VBP	O
towards	NNS	O
expected	VBN	O
levels	NNS	O
in	IN	O
their	PRP$	O
home	NN	O
community	NN	O
,	,	O
a	DT	O
significant	JJ	O
advantage	NN	O
maintained	VBD	O
for	IN	O
approximately	RB	O
2	CD	O
years	NNS	O
is	VBZ	O
developmentally	RB	O
advantageous	JJ	O
during	IN	O
the	DT	O
critical	JJ	O
time	NN	O
after	IN	O
weaning	VBG	O
.	.	O

[	JJ	O
New	NNP	O
approaches	NNS	O
to	TO	O
evaluation	NN	O
of	IN	O
nonspecific	JJ	O
inhalation	NN	O
provocation	NN	O
(	(	O
dose-response	JJ	O
relationship	NN	O
)	)	O
in	IN	O
the	DT	O
comparative	JJ	O
evaluation	NN	O
of	IN	O
bronchial	JJ	O
hyperreactivity	NN	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
clinical	JJ	O
trials	NNS	O
]	VBP	O
.	.	O

For	IN	O
the	DT	O
performance	NN	O
of	IN	O
clinical	JJ	O
drug	NN	O
trials	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
for	IN	O
bronchial	JJ	O
hyperresponsiveness	NN	O
,	,	O
unspecific	JJ	O
inhalatory	JJ	O
provocation	NN	O
tests	NNS	O
are	VBP	O
generally	RB	O
employed	VBN	O
to	TO	O
judge	VB	O
therapeutic	JJ	O
success	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
parameter-specific	JJ	O
provocation	NN	O
doses	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
the	DT	O
main	JJ	O
target	NN	O
values	NNS	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
must	MD	O
be	VB	O
considered	VBN	O
that	IN	O
these	DT	O
provocation	NN	O
doses	NNS	O
are	VBP	O
not	RB	O
equally	RB	O
calculable	JJ	O
for	IN	O
every	DT	O
patient	NN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
and	CC	O
at	IN	O
any	DT	O
examination	NN	O
time	NN	O
.	.	O

This	DT	O
leads	VBZ	O
to	TO	O
the	DT	O
fact	NN	O
that	IN	O
the	DT	O
number	NN	O
of	IN	O
evaluable	JJ	O
case	NN	O
studies	NNS	O
is	VBZ	O
often	RB	O
appreciably	RB	O
lower	JJR	O
than	IN	O
the	DT	O
number	NN	O
of	IN	O
test	NN	O
participants	NNS	O
and	CC	O
that	IN	O
a	DT	O
meaningful	JJ	O
therapy	NN	O
group	NN	O
comparison	NN	O
may	MD	O
even	RB	O
not	RB	O
be	VB	O
possible	JJ	O
under	IN	O
certain	JJ	O
circumstances	NNS	O
.	.	O

An	DT	O
evaluation	NN	O
model	NN	O
is	VBZ	O
presented	VBN	O
here	RB	O
in	IN	O
order	NN	O
to	TO	O
fully	RB	O
exploit	VB	O
the	DT	O
obtained	VBN	O
data	NNS	O
;	:	O
in	IN	O
this	DT	O
the	DT	O
percentile	JJ	O
changes	NNS	O
of	IN	O
the	DT	O
function	NN	O
parameters	NNS	O
(	(	O
estimated	VBN	O
by	IN	O
linear	JJ	O
regression	NN	O
)	)	O
at	IN	O
a	DT	O
defined	JJ	O
dose	NN	O
of	IN	O
the	DT	O
provocation	NN	O
substance	NN	O
are	VBP	O
analyzed	VBN	O
.	.	O

In	IN	O
analogy	NN	O
,	,	O
a	DT	O
survival	JJ	Mortality
time	NN	Mortality
model	NN	Mortality
and	CC	O
,	,	O
as	IN	O
a	DT	O
supplement	NN	O
,	,	O
a	DT	O
best	JJS	O
case/worst	JJ	O
case	NN	O
analysis	NN	O
are	VBP	O
performed	VBN	O
for	IN	O
further	JJ	O
statistical	JJ	O
evaluation	NN	O
.	.	O

With	IN	O
the	DT	O
present	JJ	O
procedure	NN	O
,	,	O
an	DT	O
evaluation	NN	O
with	IN	O
inclusion	NN	O
of	IN	O
all	DT	O
test	NN	O
participants	NNS	O
is	VBZ	O
possible	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
previously	RB	O
used	VBN	O
evaluation	NN	O
procedures	NNS	O
,	,	O
this	DT	O
allows	VBZ	O
a	DT	O
reliable	JJ	O
statistical	JJ	O
confirmation	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
clinical	JJ	O
tests	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
for	IN	O
bronchial	JJ	O
hyperresponsiveness	NN	O
.	.	O

Risperidone	NN	O
and	CC	O
adaptive	JJ	Mental
behavior	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
risperidone	NN	O
on	IN	O
adaptive	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
who	WP	O
have	VBP	O
serious	JJ	O
behavior	NN	O
problems	NNS	O
and	CC	O
to	TO	O
examine	VB	O
different	JJ	O
methods	NNS	O
of	IN	O
scoring	VBG	O
the	DT	O
Vineland	NNP	O
Adaptive	NNP	O
Behavior	NNP	O
Scales	NNP	O
to	TO	O
measure	VB	O
change	NN	O
.	.	O

METHOD	NNP	O
Forty-eight	JJ	O
children	NNS	O
(	(	O
5	CD	O
years	NNS	O
to	TO	O
16	CD	O
years	NNS	O
,	,	O
5	CD	O
months	NNS	O
)	)	O
who	WP	O
showed	VBD	O
behavioral	JJ	O
improvement	NN	Mental
during	IN	O
acute	JJ	O
treatment	NN	O
with	IN	O
risperidone	NN	O
were	VBD	O
followed	VBN	O
for	IN	O
6	CD	O
months	NNS	O
and	CC	O
assessed	VBN	O
with	IN	O
the	DT	O
Vineland	NNP	O
Scales	NNP	O
.	.	O

RESULTS	NNP	O
Raw	NNP	Others
scores	VBZ	Others
,	,	Others
age-equivalents	NNS	Others
,	,	Others
and	CC	Others
special	JJ	Others
norm	NN	Others
percentile	NN	Others
scores	VBZ	Others
all	DT	O
showed	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
adaptive	JJ	Mental
behavior	NN	Mental
in	IN	Mental
the	DT	Mental
areas	NNS	Mental
of	IN	Mental
communication	NN	Mental
,	,	Mental
daily	JJ	Mental
living	NN	Mental
skills	NNS	Mental
,	,	Mental
and	CC	Mental
socialization	NN	Mental
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

During	IN	O
a	DT	O
period	NN	O
of	IN	O
6	CD	O
to	TO	O
8	CD	O
months	NNS	O
,	,	O
children	NNS	O
gained	VBD	O
an	DT	O
average	NN	O
of	IN	O
7.8	CD	O
age-equivalent	JJ	O
months	NNS	O
in	IN	O
the	DT	O
area	NN	Mental
of	IN	Mental
socialization	NN	Mental
,	,	O
a	DT	O
>	JJ	O
6	CD	O
%	NN	O
improvement	NN	O
beyond	IN	O
what	WP	O
would	MD	O
be	VB	O
expected	VBN	O
based	VBN	O
on	IN	O
baseline	JJ	O
growth	NN	O
rates	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
limited	VBN	O
by	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
these	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
risperidone	NN	O
may	MD	O
improve	VB	O
adaptive	JJ	Mental
skills	NNS	Mental
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
accompanied	VBN	O
by	IN	O
serious	JJ	O
behavioral	JJ	O
problems	NNS	O
.	.	O

Vineland	NNP	O
age-equivalent	JJ	O
scores	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
most	RBS	O
useful	JJ	O
in	IN	O
assessing	VBG	O
change	NN	O
with	IN	O
treatment	NN	O
over	IN	O
time	NN	O
.	.	O

Interferential	JJ	O
therapy	NN	O
electrode	NN	O
placement	NN	O
technique	NN	O
in	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
preliminary	JJ	O
investigation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
interferential	JJ	O
therapy	NN	O
(	(	O
IFT	NNP	O
)	)	O
electrode	VBP	O
placement	NN	O
technique	NN	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single-blind	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physiotherapy	NN	O
departments	NNS	O
in	IN	O
hospital	NN	O
and	CC	O
university	NN	O
settings	NNS	O
.	.	O

PATIENTS	VB	O
A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
60	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
back	JJ	O
pain	NN	O
(	(	O
28	CD	O
men	NNS	O
,	,	O
32	CD	O
women	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
by	IN	O
general	JJ	O
practitioners	NNS	O
and	CC	O
self-referral	JJ	O
for	IN	O
physiotherapy	NN	O
treatment	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

INTERVENTIONS	NNP	O
(	(	O
1	CD	O
)	)	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
,	,	O
(	(	O
2	CD	O
)	)	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
Control	NN	O
,	,	O
The	DT	O
Back	NNP	O
Book	NNP	O
only	RB	O
.	.	O

Standardized	VBN	O
IFT	NNP	O
stimulation	NN	O
parameters	NNS	O
were	VBD	O
used	VBN	O
:	:	O
carrier	NN	O
frequency	NN	O
3.85	CD	O
kHz	NN	O
;	:	O
140	CD	O
Hz	NNP	O
constant	NN	O
;	:	O
pulse	JJ	O
duration	NN	O
130	CD	O
micros	NN	O
;	:	O
30	CD	O
minutes	NNS	O
'	POS	O
duration	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Pain	NNP	Physical
Rating	NNP	Physical
Index	NNP	Physical
,	,	Physical
Roland-Morris	NNP	Physical
Disability	NNP	Physical
Questionnaire	NNP	Physical
(	(	Physical
RMDQ	NNP	Physical
)	)	Physical
,	,	Physical
and	CC	Physical
EuroQol	NNP	Physical
were	VBD	O
completed	VBN	O
by	IN	O
subjects	NNS	O
pretreatment	JJ	O
,	,	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
all	DT	O
outcomes	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

Subjects	NNS	O
managed	VBN	O
by	IN	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
displayed	VBD	O
both	DT	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
.030	NNP	O
)	)	O
and	CC	O
clinically	RB	O
meaningful	JJ	O
reduction	NN	Physical
in	IN	Physical
functional	JJ	Physical
disability	NN	Physical
(	(	Physical
RMDQ	NNP	Physical
)	)	Physical
,	,	O
compared	VBN	O
with	IN	O
management	NN	O
via	IN	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
combined	VBD	O
or	CC	O
The	DT	O
Back	JJ	O
Book	NNP	O
alone	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
showed	VBD	O
that	IN	O
IFT	NNP	O
electrode	FW	O
placement	NN	O
technique	NN	O
affects	VBZ	O
LBP-specific	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
providing	VBG	O
preliminary	JJ	O
implications	NNS	O
for	IN	O
future	JJ	O
clinical	JJ	O
studies	NNS	O
.	.	O

Evaluating	VBG	O
online	NN	O
continuing	VBG	O
medical	JJ	O
education	NN	O
seminars	NNS	O
:	:	O
evidence	NN	O
for	IN	O
improving	VBG	O
clinical	JJ	O
practices	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
potential	NN	O
for	IN	O
online	NN	O
continuing	VBG	O
medical	JJ	O
education	NN	O
(	(	O
CME	NNP	O
)	)	O
seminars	VBZ	O
to	TO	O
improve	VB	Others
quality	NN	Others
of	IN	Others
care	NN	Others
.	.	Others

Primary	NNP	O
care	NN	O
physicians	NNS	O
(	(	O
113	CD	O
)	)	O
participated	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
an	DT	O
online	NN	O
CME	NNP	O
series	NN	O
.	.	O

Physicians	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
view	VB	O
either	CC	O
a	DT	O
seminar	NN	O
about	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
or	CC	O
a	DT	O
seminar	NN	O
about	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Following	VBG	O
the	DT	O
seminar	NN	O
,	,	O
physicians	NNS	O
were	VBD	O
presented	VBN	O
with	IN	O
4	CD	O
clinical	JJ	O
vignettes	NNS	O
and	CC	O
asked	VBD	O
to	TO	O
describe	VB	O
what	WP	O
tests	NNS	O
,	,	O
treatments	NNS	O
,	,	O
counseling	VBG	O
,	,	O
or	CC	O
referrals	NNS	O
they	PRP	O
would	MD	O
recommend	VB	O
.	.	O

Physicians	NNPS	O
who	WP	O
viewed	VBD	O
the	DT	O
seminars	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
recommend	VB	Mental
guideline-consistent	JJ	Mental
care	NN	Mental
to	TO	O
patients	NNS	O
in	IN	O
the	DT	O
vignettes	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
physicians	NNS	O
who	WP	O
viewed	VBD	O
the	DT	O
diabetes	NNS	O
seminar	VBP	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
order	NN	Mental
an	DT	Mental
eye	NN	Mental
exam	NN	Mental
for	IN	Mental
diabetes	NNS	Mental
patients	NNS	Mental
(	(	O
63	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
physicians	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
27	CD	O
%	NN	O
)	)	O
.	.	O

For	IN	O
some	DT	O
guidelines	NNS	O
there	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	VBZ	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
early	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
online	JJ	O
CME	NNP	O
programs	NNS	O
to	TO	O
improve	VB	Others
physician	JJ	Others
clinical	JJ	Others
practice	NN	Others
.	.	Others

[	JJ	O
Effect	NNP	O
of	IN	O
Selaginella	NNP	O
combined	VBD	O
with	IN	O
radiotherapy	NN	O
on	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
Chinese	JJ	O
herbal	JJ	O
medicine	NN	O
Selaginella-induced	NNP	O
radiosensitization	NN	O
of	IN	O
terminal	JJ	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Totally	RB	O
180	CD	O
patients	NNS	O
with	IN	O
NPC	NNP	O
were	VBD	O
divided	VBN	O
equally	RB	O
into	IN	O
3	CD	O
groups	NNS	O
with	IN	O
the	DT	O
same	JJ	O
radiotherapeutic	JJ	O
protocols	NNS	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
received	VBD	O
radiotherapy	NN	O
alone	RB	O
,	,	O
those	DT	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
given	VBN	O
daily	JJ	O
Selaginella	NNP	O
(	(	O
30	CD	O
g	NN	O
)	)	O
prepared	VBD	O
into	IN	O
50	CD	O
ml	JJ	O
decoction	NN	O
during	IN	O
the	DT	O
entire	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
,	,	O
and	CC	O
those	DT	O
in	IN	O
group	NN	O
C	NNP	O
had	VBD	O
Selaginella	NNP	O
30	CD	O
g	JJ	O
daily	RB	O
in	IN	O
the	DT	O
late	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	Physical
remission	NN	Physical
rate	NN	Physical
of	IN	Physical
nasopharyngeal	JJ	Physical
primary	JJ	Physical
lesions	NNS	Physical
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
with	IN	O
also	RB	O
significantly	RB	O
higher	JJR	O
complete	JJ	O
remission	NN	Physical
rates	NNS	Physical
of	IN	Physical
the	DT	Physical
cervical	JJ	Physical
lymph	NN	Physical
nodes	NNS	Physical
.	.	O

The	DT	O
acute	JJ	Physical
toxicity	NN	Physical
of	IN	Physical
the	DT	Physical
skin	NN	Physical
and	CC	Physical
mucous	JJ	Physical
membrane	NN	Physical
was	VBD	O
milder	RBR	O
in	IN	O
the	DT	O
latter	JJ	O
two	CD	O
groups	NNS	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Selaginella	NNP	O
may	MD	O
induce	VB	O
radiosensitization	NN	O
for	IN	O
terminal	JJ	O
NPC	NNP	O
and	CC	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

[	JJ	O
Hepatoprotective	NNP	Physical
activity	NN	Physical
of	IN	O
remaxol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatic	JJ	O
disorders	NNS	O
]	VBP	O
.	.	O

This	DT	O
milticentre	NN	O
randomized	VBD	O
clinical	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficiency	NN	Others
of	IN	O
remaxol	JJ	O
infusion	NN	O
solution	NN	O
(	(	O
hepatoprotective	JJ	O
medicine	NN	O
for	IN	O
chronic	JJ	O
liver	NN	O
dysfunction	NN	O
)	)	O
included	VBD	O
494	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
and	CC	O
C.	NNP	O
294	CD	O
of	IN	O
them	PRP	O
staying	VBG	O
in	IN	O
7	CD	O
clinics	NNS	O
were	VBD	O
given	VBN	O
remaxol	NNS	O
and	CC	O
200	CD	O
ones	NNS	O
received	VBD	O
placebo	NN	O
.	.	O

Randomization	NN	O
was	VBD	O
achieved	VBN	O
by	IN	O
the	DT	O
envelope	NN	O
method	NN	O
.	.	O

A	DT	O
detailed	JJ	O
description	NN	O
of	IN	O
clinical	JJ	O
and	CC	O
laboratory	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
diseases	NNS	O
is	VBZ	O
presented	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
remaxol	NN	O
vs	NN	O
placebo	NN	O
on	IN	O
the	DT	O
functional	JJ	Physical
activity	NN	Physical
of	IN	O
affected	VBN	O
liver	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Results	NNS	O
of	IN	O
laboratory	NN	O
and	CC	O
clinical	JJ	O
analysis	NN	O
indicate	VBP	O
that	IN	O
mechanism	NN	O
of	IN	O
remaxol	JJ	O
action	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
hepatoprotective	JJ	Physical
,	,	Physical
antioxidative	JJ	Physical
,	,	Physical
and	CC	Physical
anticholestatic	JJ	Physical
activities	NNS	Physical
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Tissue	NN	O
microarray	NN	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
South	JJ	O
African	JJ	O
patients	NNS	O
with	IN	O
DLBCL	NNP	O
.	.	O

Tissue	NN	O
samples	NNS	O
from	IN	O
93	CD	O
de	NNS	O
novo	FW	O
diffuse	RB	O
large	JJ	O
B-cell	NNP	O
lymphoma	NN	O
patients	NNS	O
seen	VBN	O
between	IN	O
1995	CD	O
and	CC	O
2009	CD	O
randomly	NN	O
receiving	VBG	O
either	CC	O
standard	JJ	O
combination	NN	O
chemotherapy	NN	O
(	(	O
CHOP	NNP	O
,	,	O
n=48	NN	O
)	)	O
or	CC	O
the	DT	O
identical	JJ	O
program	NN	O
with	IN	O
rituximab	NN	O
(	(	O
n=45	JJ	O
)	)	O
were	VBD	O
subtyped	VBN	O
using	VBG	O
an	DT	O
investigational	JJ	O
immunohistochemical	NN	O
(	(	O
IHC	NNP	O
)	)	O
based	VBN	O
tissue	NN	O
microarray	NN	O
(	(	O
TMA	NNP	O
)	)	O
and	CC	O
contrasted	VBN	O
to	TO	O
the	DT	O
approximately	RB	O
corresponding	JJ	O
categories	NNS	O
as	IN	O
defined	VBN	O
either	CC	O
by	IN	O
Hans	NNPS	O
and	CC	O
associates	NNS	O
using	VBG	O
a	DT	O
three	CD	O
marker	NN	O
panel	NN	O
into	IN	O
germinal	JJ	O
or	CC	O
non-germinal	JJ	O
centre	NN	O
subtypes	NNS	O
or	CC	O
by	IN	O
Choi	NNP	O
and	CC	O
colleagues	NNS	O
with	IN	O
two	CD	O
additional	JJ	O
antibodies	NNS	O
into	IN	O
germinal	JJ	O
centre	NN	O
(	(	O
GCB	NNP	O
)	)	O
or	CC	O
activated	VBN	O
B-cells	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

Each	DT	O
of	IN	O
these	DT	O
primary	JJ	O
subdivisions	NNS	O
was	VBD	O
further	RBR	O
evaluated	VBN	Physical
for	IN	Physical
expression	NN	Physical
of	IN	Physical
BCL2	NNP	Physical
and	CC	Physical
LMO2	NNP	Physical
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
recognised	VBN	O
to	TO	O
predicate	VB	O
response	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
rituximab	NN	O
to	TO	O
the	DT	O
uniform	JJ	O
drug	NN	O
regimen	NNS	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
5	CD	O
years	NNS	O
overall	JJ	Others
(	(	O
63	CD	O
%	NN	O
versus	IN	O
59	CD	O
%	NN	O
,	,	O
p	RB	O
0.68	CD	O
)	)	O
or	CC	Others
event-free	JJ	Others
survival	NN	Others
(	(	O
42	CD	O
%	NN	O
versus	IN	O
39	CD	O
%	NN	O
,	,	O
p	RB	O
0.94	CD	O
)	)	O
,	,	O
for	IN	O
CHOP	NNP	O
versus	NN	O
R-CHOP	NNP	O
comparisons	NNS	O
.	.	O

Similarly	RB	O
no	DT	O
differences	NNS	O
were	VBD	O
evident	JJ	O
in	IN	O
subtype	JJ	O
analysis	NN	O
.	.	O

Interestingly	RB	O
however	RB	O
,	,	O
when	WRB	O
segregated	VBN	O
on	IN	O
the	DT	O
Choi	NNP	O
criteria	NNS	O
,	,	O
cytotoxic	NN	O
drugs	NNS	O
alone	RB	O
showed	VBD	O
a	DT	O
non-significant	JJ	O
trend	NN	O
in	IN	O
improved	JJ	O
survival	NN	O
(	(	O
74	CD	O
%	NN	O
versus	IN	O
55	CD	O
%	NN	O
,	,	O
p	RB	O
0.32	CD	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
event-free	JJ	O
survival	NN	O
(	(	O
44	CD	O
%	NN	O
versus	IN	O
40	CD	O
%	NN	O
,	,	O
p	RB	O
0.42	CD	O
)	)	O
for	IN	O
the	DT	O
germinal	JJ	O
centre	NN	O
as	IN	O
opposed	VBN	O
to	TO	O
the	DT	O
activated	VBN	O
B-cell	NNP	O
subtype	NN	O
.	.	O

Nevertheless	NNP	O
not	RB	O
even	RB	O
a	DT	O
small	JJ	O
difference	NN	O
could	MD	O
be	VB	O
demonstrated	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
anti	JJ	O
CD	NN	O
20	CD	O
monoclonal	JJ	O
antibody	NN	O
.	.	O

According	VBG	O
to	TO	O
Choi	NNP	O
,	,	O
both	DT	O
regimens	NNS	O
(	(	O
chemotherapy	NN	O
or	CC	O
immunotherapy	VB	O
antibody	NN	O
)	)	O
revealed	VBD	O
similar	JJ	O
results	NNS	O
to	TO	O
the	DT	O
Hans	NNPS	O
algorithm	VBP	O
on	IN	O
5	CD	O
years	NNS	O
OS	NNP	O
as	RB	O
well	RB	O
as	IN	O
3	CD	O
year	NN	O
EFS	NNP	O
when	WRB	O
comparing	VBG	O
GCB	NNP	O
versus	NN	O
ABC	NNP	O
or	CC	O
non-GCB	JJ	O
subgroups	NNS	O
.	.	O

BCL2	NNP	O
and	CC	O
LMO2	NNP	O
marker	NNP	O
expression	NN	O
of	IN	O
the	DT	O
respective	JJ	O
immunohistochemical	JJ	O
(	(	O
IHC	NNP	O
)	)	O
subtype	NN	O
,	,	O
despite	IN	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
revealed	VBD	O
the	DT	O
following	NN	O
.	.	O

Analysis	NN	O
by	IN	O
Choi	NNP	O
criteria	NNS	O
on	IN	O
survival	NN	O
for	IN	O
BCL2	NNP	O
,	,	O
no	DT	O
matter	NN	O
for	IN	O
which	WDT	O
subsets	NNS	O
(	(	O
GCB	NNP	O
or	CC	O
ABC	NNP	O
)	)	O
or	CC	O
treatment	NN	O
modality	NN	O
(	(	O
chemotherapy	NN	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
addition	NN	O
of	IN	O
rituximab	NN	O
)	)	O
showed	VBD	O
no	DT	O
difference	NN	O
in	IN	O
5	CD	O
years	NNS	O
OS	NNP	O
or	CC	O
EFS	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
a	DT	O
significant	JJ	O
difference	NN	O
for	IN	O
better	JJR	O
EFS	NNP	O
(	(	O
p=0.0015	NN	O
)	)	O
in	IN	O
the	DT	O
BCL2	NNP	O
positive	JJ	O
group	NN	O
of	IN	O
the	DT	O
ABC	NNP	O
subgroups	NNS	O
subtypes	NNS	O
treated	VBN	O
with	IN	O
rituximab	NN	O
containing	VBG	O
chemotherapy	NN	O
.	.	O

For	IN	O
LMO2	NNP	O
similar	JJ	O
results	NNS	O
on	IN	O
survival	JJ	O
outcome	NN	O
were	VBD	O
seen	VBN	O
thus	RB	O
showing	VBG	O
no	DT	O
difference	NN	O
in	IN	O
5	CD	Mortality
years	NNS	Mortality
OS	NNP	Mortality
or	CC	Mortality
EFS	NNP	Mortality
-	:	O
regardless	NN	O
of	IN	O
subtype	NN	O
or	CC	O
treatment	NN	O
modality	NN	O
.	.	O

Also	RB	O
here	RB	O
,	,	O
this	DT	O
was	VBD	O
contrasted	VBN	O
by	IN	O
better	JJR	O
EFS	NNP	O
(	(	O
p=0.039	NN	O
)	)	O
in	IN	O
the	DT	O
LMO2	NNP	O
positive	JJ	O
group	NN	O
of	IN	O
ABC	NNP	O
subtypes	NNS	O
when	WRB	O
treated	VBN	O
with	IN	O
the	DT	O
rituximab	NN	O
containing	VBG	O
regimen	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
the	DT	O
IHC	NNP	O
based	VBN	O
TMA	NNP	O
methodology	NN	O
has	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
simple	JJ	Others
,	,	Others
cost	NN	Others
effective	JJ	Others
and	CC	Others
a	DT	Others
robust	JJ	Others
alternative	NN	Others
to	TO	Others
gene	NN	Others
expression	NN	Others
profiling	VBG	Others
(	(	Others
GEP	NNP	Others
)	)	Others
which	WDT	O
is	VBZ	O
currently	RB	O
regarded	VBN	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
for	IN	O
the	DT	O
classification	NN	O
in	IN	O
lymphomas	NN	O
.	.	O

It	PRP	O
provides	VBZ	O
a	DT	O
useful	JJ	O
prognostic	JJ	O
tool	NN	O
in	IN	O
stratifying	VBG	O
DLBCL	NNP	O
or	CC	O
other	JJ	O
entities	NNS	O
in	IN	O
future	JJ	O
,	,	O
even	RB	O
when	WRB	O
frozen	JJ	O
tissue	NN	O
samples	NNS	O
are	VBP	O
not	RB	O
available	JJ	O
for	IN	O
GEP	NNP	O
analysis	NN	O
.	.	O

With	IN	O
the	DT	O
current	JJ	O
budgetary	JJ	O
limitations	NNS	O
in	IN	O
South	JJ	O
African	JJ	O
public	JJ	O
hospitals	NNS	O
chemotherapy	VBP	O
protocols	NNS	O
for	IN	O
lymphoproliferative	JJ	O
disorders	NNS	O
exclude	VBP	O
agents	NNS	O
such	JJ	O
as	IN	O
rituximab	NN	O
.	.	O

Local	JJ	O
therapeutic	JJ	O
drug	NN	O
committees	NNS	O
consider	VBP	O
the	DT	O
approximately	RB	O
15	CD	O
%	NN	O
overall	JJ	O
survival	NN	Others
benefit	NN	Others
seen	VBN	O
at	IN	O
5	CD	O
years	NNS	O
for	IN	O
DLBCL	NNP	O
when	WRB	O
rituximab	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
combination	VB	O
chemotherapy	NN	O
as	IN	O
too	RB	O
marginal	JJ	O
for	IN	O
justifying	VBG	O
the	DT	O
arising	VBG	O
additional	JJ	O
expenses	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
demonstration	NN	O
that	IN	O
a	DT	O
specific	JJ	O
molecular	JJ	O
subtype	NN	O
accounts	NNS	O
for	IN	O
superior	JJ	O
outcome	NN	O
,	,	O
when	WRB	O
using	VBG	O
these	DT	O
regimens	NNS	O
,	,	O
is	VBZ	O
needed	VBN	O
.	.	O

Such	JJ	O
an	DT	O
option	NN	O
would	MD	O
provide	VB	O
convincing	VBG	O
evidence	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
immunochemotherapy	NN	O
in	IN	O
a	DT	O
resource	NN	O
constrained	VBD	O
setting	NN	O
.	.	O

Abdominal	NNP	O
surgical	JJ	O
wound	NN	O
infection	NN	O
is	VBZ	O
lowered	VBN	O
with	IN	O
improved	JJ	O
perioperative	JJ	O
enterococcus	NN	O
and	CC	O
bacteroides	NNS	O
therapy	NN	O
.	.	O

Perioperative	JJ	O
antibiotics	NNS	O
decrease	VBP	O
surgical	JJ	Physical
wound	NN	Physical
infection	NN	Physical
(	(	Physical
SWI	NNP	Physical
)	)	Physical
in	IN	O
trauma	NN	O
patients	NNS	O
requiring	VBG	O
abdominal	JJ	O
exploration	NN	O
.	.	O

This	DT	O
investigation	NN	O
evaluated	VBD	O
24	CD	O
hours	NNS	O
of	IN	O
cefoxitin	NN	O
or	CC	O
ampicillin/sulbactam	NN	O
used	VBN	O
for	IN	O
early	JJ	O
therapy	NN	O
in	IN	O
such	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
evaluated	VBN	O
was	VBD	O
SWI	NNP	Physical
,	,	O
which	WDT	O
was	VBD	O
defined	VBN	O
as	IN	O
purulent	JJ	O
drainage	NN	O
or	CC	O
active	JJ	O
wound	NN	O
treatment	NN	O
.	.	O

Five	CD	O
hundred	VBD	O
ninety-two	JJ	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
:	:	O
283	CD	O
received	VBD	O
ampicillin/sulbactam	NN	O
and	CC	O
309	CD	O
received	VBD	O
cefoxitin	NN	O
.	.	O

The	DT	O
incidence	NN	Physical
of	IN	Physical
wound	JJ	Physical
infection	NN	Physical
among	IN	O
the	DT	O
ampicillin/sulbactam	NN	O
patients	NNS	O
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
among	IN	O
cefoxitin	JJ	O
patients	NNS	O
it	PRP	O
was	VBD	O
7	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
cefoxitin	NN	O
patients	NNS	O
with	IN	O
colon	NN	O
injuries	NNS	O
were	VBD	O
analyzed	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.007	CD	O
)	)	O
.	.	O

The	DT	O
major	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
an	DT	O
increased	JJ	O
incidence	NN	Physical
of	IN	Physical
enterococcal	JJ	Physical
infections	NNS	Physical
in	IN	O
the	DT	O
cefoxitin-treated	JJ	O
patients	NNS	O
.	.	O

A	DT	O
single	JJ	O
broad-spectrum	JJ	O
antibiotic	JJ	O
given	VBN	O
for	IN	O
24	CD	O
hour	NN	O
perioperatively	RB	O
effectively	RB	O
controls	VBZ	O
SWI	NNP	O
.	.	O

Use	NNP	O
of	IN	O
ampicillin/sulbactam	JJ	O
results	NNS	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
SWI	NNP	Physical
rate	NN	Physical
than	IN	O
use	NN	O
of	IN	O
cefoxitin	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
a	DT	O
result	NN	O
of	IN	O
improved	JJ	O
enterococcal	JJ	Physical
and	CC	Physical
Bacteroides	NNP	Physical
coverage	NN	Physical
.	.	Physical

Concurrent	JJ	O
training	NN	O
enhances	NNS	O
athletes	VBZ	O
'	POS	O
cardiovascular	JJ	O
and	CC	O
cardiorespiratory	JJ	O
measures	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
concurrent	JJ	O
strength	NN	O
and	CC	O
aerobic	JJ	O
endurance	NN	O
training	NN	O
on	IN	O
cardiovascular	NN	O
and	CC	O
cardiorespiratory	NN	O
adaptations	NNS	O
in	IN	O
college	NN	O
athletes	NNS	O
and	CC	O
compared	VBN	O
two	CD	O
concurrent	JJ	O
exercise	NN	O
(	(	O
CE	NNP	O
)	)	O
protocols	NNS	O
.	.	O

Separate	JJ	O
experiments	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
30	CD	O
women	NNS	O
(	(	O
mean	JJ	O
age	NN	O
19.6	CD	O
years	NNS	O
)	)	O
and	CC	O
20	CD	O
men	NNS	O
(	(	O
20.4	CD	O
years	NNS	O
)	)	O
.	.	O

In	IN	O
both	DT	O
experiments	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
serial	JJ	O
CE	NNP	O
and	CC	O
integrated	VBN	O
CE	NNP	O
)	)	O
matched	VBD	O
for	IN	O
initial	JJ	O
physical	JJ	O
condition	NN	O
and	CC	O
trained	VBN	O
in	IN	O
a	DT	O
vigorous	JJ	O
3-day	JJ	O
per	IN	O
week	NN	O
CE	NNP	O
program	NN	O
of	IN	O
9	CD	O
(	(	O
men	NNS	O
)	)	O
to	TO	O
11	CD	O
(	(	O
women	NNS	O
)	)	O
weeks	NNS	O
.	.	O

The	DT	O
two	CD	O
CE	NNP	O
training	NN	O
protocols	NNS	O
were	VBD	O
equilibrated	VBN	O
for	IN	O
exercise	NN	O
mode	NN	O
,	,	O
intensity	NN	O
,	,	O
and	CC	O
volume	NN	O
,	,	O
differing	VBG	O
only	RB	O
in	IN	O
the	DT	O
timing	NN	O
and	CC	O
sequence	NN	O
of	IN	O
exercises	NNS	O
.	.	O

During	IN	O
training	NN	O
,	,	O
serial	JJ	O
CE	NNP	O
discernibly	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
increased	VBD	O
cardiovascular	JJ	O
adaptation	NN	O
in	IN	O
women	NNS	O
,	,	O
indicated	VBN	O
by	IN	O
reduction	NN	O
(	(	O
-5.7	CD	O
%	NN	O
)	)	O
in	IN	O
active	JJ	Physical
heart	NN	Physical
rate	NN	Physical
(	(	O
HR	NNP	O
)	)	O
(	(	O
HR/aerobic	NNP	O
exercise	VBP	O
intensity	NN	O
)	)	O
,	,	O
whereas	RB	O
integrated	JJ	O
CE	NNP	O
discernibly	RB	O
reduced	VBD	O
active	JJ	Physical
HR	NNP	Physical
in	IN	Physical
women	NNS	Physical
(	(	O
-10.7	CD	O
%	NN	O
)	)	O
and	CC	O
men	NNS	O
(	(	O
-9.1	CD	O
%	NN	O
)	)	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
comparisons	NNS	O
in	IN	O
the	DT	O
larger	JJR	O
sample	NN	O
of	IN	O
women	NNS	O
showed	VBD	O
that	IN	O
serial	JJ	O
CE	NNP	O
discernibly	RB	O
reduced	VBD	O
systolic	JJ	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	O
BP	NNP	O
)	)	O
(	(	O
-8.7	CD	O
%	NN	O
and	CC	O
-14.0	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
increased	VBD	O
estimated	VBN	O
[	NNP	O
latin	JJ	O
capital	NN	O
V	NNP	O
with	IN	O
dot	NN	O
above	IN	Physical
]	NNP	Physical
o2max	NN	Physical
(	(	O
18.9	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
produced	VBD	O
a	DT	O
trend	NN	O
(	(	O
0.10	CD	O
>	NNP	O
p	NN	O
>	NNP	O
0.05	CD	O
)	)	O
toward	IN	O
reduced	VBN	O
resting	VBG	Physical
HR	NNP	Physical
(	(	O
-4.9	NNP	O
%	NN	O
)	)	O
.	.	O

Integrated	VBN	O
CE	NNP	O
in	IN	O
women	NNS	O
discernibly	RB	O
reduced	VBD	O
systolic	JJ	Physical
and	CC	Physical
diastolic	JJ	Physical
BP	NNP	Physical
(	(	O
-13.2	CD	O
%	NN	O
and	CC	O
-12.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
increased	VBD	O
estimated	VBN	O
[	NNP	O
latin	JJ	O
capital	NN	O
V	NNP	O
with	IN	O
dot	NN	O
above	IN	O
]	NNP	O
o2max	NN	Physical
(	(	O
22.9	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
produced	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
reduced	VBN	O
resting	VBG	Physical
HR	NNP	Physical
(	(	O
-2.4	NNP	O
%	NN	O
)	)	O
.	.	O

Integrated	VBN	O
CE	NNP	O
produced	VBD	O
discernibly	RB	O
larger	JJR	O
gains	NNS	O
than	IN	O
serial	JJ	O
CE	NNP	O
or	CC	O
a	DT	O
trend	NN	O
for	IN	O
four	CD	O
of	IN	O
six	CD	O
training	NN	O
adaptations	NNS	O
.	.	O

Effect	JJ	O
sizes	NNS	O
were	VBD	O
generally	RB	O
large	JJ	O
(	(	O
60.0	CD	O
%	NN	O
of	IN	O
discernible	JJ	O
differences	NNS	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
,	,	O
for	IN	O
cardiovascular	JJ	O
and	CC	O
cardiorespiratory	JJ	O
adaptations	NNS	O
in	IN	O
athletes	NNS	O
,	,	O
strength	NN	O
and	CC	O
endurance	NN	O
training	NN	O
are	VBP	O
compatible	JJ	O
and	CC	O
that	DT	O
exercise	NN	O
timing	NN	O
and	CC	O
sequence	NN	O
significantly	RB	O
influence	JJ	O
training	NN	O
adaptations	NNS	O
,	,	O
complimenting	VBG	O
our	PRP$	O
previous	JJ	O
similar	JJ	O
conclusions	NNS	O
for	IN	O
strength	NN	Physical
,	,	Physical
muscle	NN	Physical
endurance	NN	Physical
,	,	Physical
body	NN	Physical
composition	NN	Physical
,	,	Physical
and	CC	Physical
flexibility	NN	Physical
.	.	O

Predictive	JJ	O
and	CC	O
prognostic	JJ	O
roles	NNS	O
of	IN	O
BRAF	NNP	O
mutation	NN	O
in	IN	O
stage	NN	O
III	NNP	O
colon	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
intergroup	JJ	O
trial	NN	O
CALGB	NNP	O
89803	CD	O
.	.	O

PURPOSE	NNP	O
Alterations	NNPS	O
in	IN	O
the	DT	O
RAS-RAF-MAP2K	NNP	O
(	(	O
MEK	NNP	O
)	)	O
-MAPK	VBP	O
signaling	VBG	O
pathway	NN	O
are	VBP	O
major	JJ	O
drivers	NNS	O
in	IN	O
colorectal	JJ	O
carcinogenesis	NN	O
.	.	O

In	IN	O
colorectal	JJ	O
cancer	NN	O
,	,	O
BRAF	NNP	O
mutation	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
microsatellite	JJ	O
instability	NN	O
(	(	O
MSI	NNP	O
)	)	O
,	,	O
and	CC	O
typically	RB	O
predicts	VBZ	O
inferior	JJ	O
prognosis	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
BRAF	NNP	O
mutation	NN	O
on	IN	O
survival	NN	O
and	CC	O
treatment	NN	O
efficacy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
colon	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
assessed	VBD	O
status	NN	O
of	IN	O
BRAF	NNP	O
c.1799T	NN	O
>	VBZ	O
A	NNP	O
(	(	O
p.V600E	NN	O
)	)	O
mutation	NN	O
and	CC	O
MSI	NNP	O
in	IN	O
506	CD	O
stage	NN	O
III	NNP	O
colon	NN	O
cancer	NN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
adjuvant	NN	O
chemotherapy	NN	O
trial	NN	O
[	NNP	O
5-fluorouracil	CD	O
and	CC	O
leucovorin	NN	O
(	(	O
FU/LV	NNP	O
)	)	O
vs.	FW	O
irinotecan	JJ	O
(	(	O
CPT11	NNP	O
)	)	O
,	,	O
FU	NNP	O
and	CC	O
LV	NNP	O
(	(	O
IFL	NNP	O
)	)	O
;	:	O
CALGB	$	O
89803	CD	O
]	NNP	O
.	.	O

Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
model	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
prognostic	JJ	O
role	NN	O
of	IN	O
BRAF	NNP	O
mutation	NN	O
,	,	O
adjusting	VBG	O
for	IN	O
clinical	JJ	O
features	NNS	O
,	,	O
adjuvant	JJ	O
chemotherapy	NN	O
arm	NN	O
,	,	O
and	CC	O
MSI	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
431	CD	O
BRAF	NNP	O
wild-type	JJ	O
patients	NNS	O
,	,	O
75	CD	O
BRAF-mutated	JJ	O
patients	NNS	O
experienced	VBD	O
significantly	RB	O
worse	JJR	O
overall	JJ	Mortality
survival	NN	Mortality
[	NNP	Mortality
OS	NNP	Mortality
;	:	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
0.015	CD	O
;	:	O
multivariate	NN	O
HR	NNP	O
=	NNP	O
1.66	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.05-2.63	JJ	O
]	NN	O
.	.	O

By	IN	O
assessing	VBG	O
combined	JJ	O
status	NN	O
of	IN	O
BRAF	NNP	O
and	CC	O
MSI	NNP	O
,	,	O
it	PRP	O
seemed	VBD	O
that	IN	O
BRAF-mutated	NNP	O
MSS	NNP	O
(	(	O
microsatellite	JJ	O
stable	NN	O
)	)	O
tumor	NN	O
was	VBD	O
an	DT	O
unfavorable	JJ	O
subtype	NN	O
,	,	O
whereas	JJ	O
BRAF	NNP	O
wild-type	JJ	O
MSI-high	NNP	O
tumor	NN	O
was	VBD	O
a	DT	O
favorable	JJ	O
subtype	NN	O
,	,	O
and	CC	O
BRAF-mutated	JJ	O
MSI-high	JJ	O
tumor	NN	O
and	CC	O
BRAF	NNP	O
wild-type	JJ	O
MSS	NNP	O
tumor	NN	O
were	VBD	O
intermediate	JJ	O
subtypes	NNS	O
.	.	O

Among	IN	O
patients	NNS	O
with	IN	O
BRAF-mutated	JJ	O
tumors	NNS	O
,	,	O
a	DT	O
nonsignificant	JJ	O
trend	NN	O
toward	IN	O
improved	JJ	O
OS	NNP	Physical
was	VBD	O
observed	VBN	O
for	IN	O
IFL	NNP	O
versus	NN	O
FU/LV	NNP	O
arm	NN	O
(	(	O
multivariate	JJ	O
HR	NNP	O
=	NNP	O
0.52	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.25-1.10	NN	O
)	)	O
.	.	O

Among	IN	O
patients	NNS	O
with	IN	O
BRAF	NNP	O
wild-type	JJ	O
cancer	NN	O
,	,	O
IFL	NNP	O
conferred	VBD	O
no	DT	O
suggestion	NN	O
of	IN	O
benefit	NN	O
beyond	IN	O
FU/LV	NNP	O
alone	RB	O
(	(	O
multivariate	JJ	O
HR	NNP	O
=	NNP	O
1.02	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.72-1.46	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
BRAF	NNP	O
mutation	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
inferior	JJ	O
survival	NN	Mortality
in	IN	O
stage	NN	O
III	NNP	O
colon	NN	O
cancer	NN	O
.	.	O

Additional	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
assess	VB	O
whether	IN	O
there	EX	O
is	VBZ	O
any	DT	O
predictive	JJ	O
role	NN	O
of	IN	O
BRAF	NNP	O
mutation	NN	O
for	IN	O
irinotecan-based	JJ	O
therapy	NN	O
.	.	O

Efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
a	DT	O
very-low-protein	JJ	O
diet	NN	O
when	WRB	O
postponing	VBG	O
dialysis	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
multicenter	NN	O
controlled	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
A	NNP	O
supplemented	VBD	O
very-low-protein	JJ	O
diet	NN	O
(	(	O
sVLPD	NN	O
)	)	O
seems	VBZ	O
to	TO	O
be	VB	O
safe	JJ	Others
when	WRB	O
postponing	VBG	O
dialysis	NN	O
therapy	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
multicenter	NN	O
randomized	VBD	O
controlled	VBN	O
study	NN	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
noninferiority	NN	O
of	IN	O
diet	JJ	O
versus	JJ	O
dialysis	NN	O
in	IN	O
1-year	JJ	O
mortality	NN	O
assessed	VBN	O
by	IN	O
using	VBG	O
intention-to-treat	JJ	O
and	CC	O
per-protocol	JJ	O
analysis	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
Italian	JJ	O
uremic	JJ	O
patients	NNS	O
without	IN	O
diabetes	NNS	O
older	JJR	O
than	IN	O
70	CD	O
years	NNS	O
with	IN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
of	IN	O
5	CD	O
to	TO	O
7	CD	O
mL/min	NN	O
(	(	O
0.08	CD	O
to	TO	O
0.12	CD	O
mL/s	NN	O
)	)	O
.	.	O

INTERVENTION	NNP	O
Randomization	NNP	O
to	TO	O
an	DT	O
sVLPD	NN	O
(	(	O
diet	JJ	O
group	NN	O
)	)	O
or	CC	O
dialysis	NN	O
.	.	O

The	DT	O
sVLPD	NN	O
is	VBZ	O
a	DT	O
vegan	JJ	O
diet	NN	O
(	(	O
35	CD	O
kcal	NN	O
;	:	O
proteins	NNS	O
,	,	O
0.3	CD	O
g/kg	NN	O
body	NN	O
weight	VBD	O
daily	RB	O
)	)	O
supplemented	VBD	O
with	IN	O
keto-analogues	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
and	CC	O
vitamins	NNS	O
.	.	O

Patients	NNS	O
following	VBG	O
an	DT	O
sVLPD	NN	O
started	VBD	O
dialysis	NN	O
therapy	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
malnutrition	NN	O
,	,	O
intractable	JJ	O
fluid	NN	O
overload	NN	O
,	,	O
hyperkalemia	NN	O
,	,	O
or	CC	O
appearance	NN	O
of	IN	O
uremic	JJ	O
symptoms	NNS	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
MEASUREMENTS	NNP	O
Mortality	NNP	Mortality
,	,	O
hospitalization	NN	Physical
,	,	O
and	CC	O
metabolic	JJ	Physical
markers	NNS	Physical
.	.	O

RESULTS	VB	O
56	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
each	DT	O
group	NN	O
,	,	O
median	JJ	O
follow-up	NN	O
was	VBD	O
26.5	CD	O
months	NNS	O
(	(	O
interquartile	JJ	O
range	NN	O
,	,	O
40	CD	O
)	)	O
,	,	O
and	CC	O
patients	NNS	O
in	IN	O
the	DT	O
diet	JJ	O
group	NN	O
spent	VBD	O
a	DT	O
median	NN	O
of	IN	O
10.7	CD	O
months	NNS	O
(	(	O
interquartile	JJ	O
range	NN	O
,	,	O
11	CD	O
)	)	O
following	VBG	O
an	DT	O
sVLPD	NN	O
.	.	O

Forty	CD	O
patients	NNS	O
in	IN	O
the	DT	O
diet	JJ	O
group	NN	O
started	VBD	O
dialysis	NN	O
treatment	NN	O
because	IN	O
of	IN	O
either	DT	O
fluid	JJ	Physical
overload	NN	Physical
or	CC	Physical
hyperkalemia	NN	Physical
.	.	O

There	EX	O
were	VBD	O
31	CD	O
deaths	NNS	O
(	(	O
55	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
dialysis	NN	O
group	NN	O
and	CC	O
28	CD	O
deaths	NNS	Mortality
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
diet	JJ	O
group	NN	O
.	.	O

One-year	JJ	Mortality
observed	JJ	Mortality
survival	NN	Mortality
rates	NNS	Mortality
at	IN	O
intention	NN	O
to	TO	O
treat	VB	O
were	VBD	O
83.7	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
74.5	CD	O
to	TO	O
94.0	CD	O
)	)	O
in	IN	O
the	DT	O
dialysis	NN	O
group	NN	O
versus	VBD	O
87.3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
78.9	CD	O
to	TO	O
96.5	CD	O
)	)	O
in	IN	O
the	DT	O
diet	JJ	O
group	NN	O
(	(	O
log-rank	JJ	O
test	NN	O
for	IN	O
noninferiority	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
for	IN	O
superiority	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.6	CD	O
)	)	O
:	:	O
the	DT	O
difference	NN	O
in	IN	O
survival	NN	Mortality
was	VBD	O
-3.6	JJ	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-17	NNP	O
to	TO	O
+10	VB	O
;	:	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

The	DT	Others
hazard	NN	Others
ratio	NN	Others
for	IN	Others
hospitalization	NN	Others
was	VBD	O
1.50	CD	O
for	IN	O
the	DT	O
dialysis	NN	O
group	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.11	CD	O
to	TO	O
2.01	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

LIMITATIONS	VB	O
The	DT	O
unblinded	JJ	O
nature	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
exclusion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
,	,	O
and	CC	O
incomplete	JJ	O
enrollment	NN	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
sVLPD	NN	O
was	VBD	O
effective	JJ	Others
and	CC	Others
safe	JJ	Others
when	WRB	O
postponing	VBG	O
dialysis	NN	O
treatment	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
without	IN	O
diabetes	NNS	O
.	.	O

Omitting	VBG	O
radiotherapy	NN	O
in	IN	O
early	JJ	O
positron	NN	O
emission	NN	O
tomography-negative	JJ	O
stage	NN	O
I/II	NNP	O
Hodgkin	NNP	O
lymphoma	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
early	JJ	O
relapse	NN	O
:	:	O
Clinical	JJ	O
results	NNS	O
of	IN	O
the	DT	O
preplanned	JJ	O
interim	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
randomized	JJ	O
EORTC/LYSA/FIL	NNP	O
H10	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Combined-modality	NNP	O
treatment	NN	O
is	VBZ	O
standard	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
clinical	JJ	O
stage	NN	O
I/II	NNP	O
Hodgkin	NNP	O
lymphoma	NN	O
(	(	O
HL	NNP	O
)	)	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
an	DT	O
early	JJ	O
positron	NN	O
emission	NN	O
tomography	NN	O
(	(	O
PET	NNP	O
)	)	O
scan	NN	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
adapt	VB	O
treatment	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
started	VBD	O
the	DT	O
randomized	VBN	O
EORTC/LYSA/FIL	NNP	O
Intergroup	NNP	O
H10	NNP	O
trial	NN	O
evaluating	VBG	O
whether	IN	O
involved-node	JJ	O
radiotherapy	NN	O
(	(	O
IN-RT	NNP	O
)	)	O
could	MD	O
be	VB	O
omitted	VBN	O
without	IN	O
compromising	VBG	O
progression-free	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
attaining	VBG	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	NNP	O
scan	NN	O
after	IN	O
two	CD	O
cycles	NNS	O
of	IN	O
ABVD	NNP	O
(	(	O
doxorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
and	CC	O
dacarbazine	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
combined-modality	NN	O
treatment	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNP	O
age	NN	O
15	CD	O
to	TO	O
70	CD	O
years	NNS	O
with	IN	O
untreated	JJ	O
clinical	JJ	O
stage	NN	O
I/II	NNP	O
HL	NNP	O
were	VBD	O
eligible	JJ	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
the	DT	O
clinical	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
preplanned	JJ	O
interim	JJ	O
futility	NN	O
analysis	NN	O
scheduled	VBN	O
to	TO	O
occur	VB	O
after	IN	O
documentation	NN	O
of	IN	O
34	CD	O
events	NNS	O
in	IN	O
the	DT	O
early	JJ	O
PET-negative	JJ	O
group	NN	O
.	.	O

Because	IN	O
testing	VBG	O
for	IN	O
futility	NN	O
in	IN	O
this	DT	O
noninferiority	NN	O
trial	NN	O
corresponds	NNS	O
to	TO	O
testing	VBG	O
the	DT	O
hypothesis	NN	O
of	IN	O
no	DT	O
difference	NN	O
,	,	O
a	DT	O
one-sided	JJ	O
superiority	NN	O
test	NN	O
was	VBD	O
conducted	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
analysis	NN	O
included	VBD	O
1,137	CD	O
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
favorable	JJ	O
subgroup	NN	O
,	,	O
85.8	CD	O
%	NN	O
had	VBD	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	JJ	O
scan	JJ	O
(	(	O
standard	JJ	O
arm	NN	O
,	,	O
one	CD	O
event	NN	O
v	NN	O
experimental	JJ	O
arm	NN	O
,	,	O
nine	CD	O
events	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
unfavorable	JJ	O
subgroup	NN	O
,	,	O
74.8	CD	O
%	NN	O
had	VBD	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	JJ	O
scan	JJ	O
(	(	O
standard	JJ	O
arm	NN	O
,	,	O
seven	CD	O
events	NNS	O
v	JJ	O
experimental	JJ	O
arm	NN	O
,	,	O
16	CD	O
events	NNS	O
)	)	O
.	.	O

The	DT	O
independent	JJ	O
data	NNS	O
monitoring	NN	O
committee	NN	O
concluded	VBD	O
it	PRP	O
was	VBD	O
unlikely	JJ	O
that	IN	O
we	PRP	O
would	MD	O
show	VB	O
noninferiority	NN	O
in	IN	O
the	DT	O
final	JJ	O
results	NNS	O
for	IN	O
the	DT	O
experimental	JJ	O
arm	NN	O
and	CC	O
advised	VBD	O
stopping	VBG	O
random	JJ	O
assignment	NN	O
for	IN	O
early	JJ	O
PET-negative	JJ	O
patients	NNS	O
.	.	O

CONCLUSION	NNP	O
On	IN	O
the	DT	O
basis	NN	O
of	IN	O
this	DT	O
analysis	NN	O
,	,	O
combined-modality	NN	O
treatment	NN	O
resulted	VBD	O
in	IN	O
fewer	JJR	O
early	JJ	O
progressions	NNS	O
in	IN	O
clinical	JJ	Physical
stage	NN	Physical
I/II	NNP	Physical
HL	NNP	Physical
,	,	O
although	IN	O
early	JJ	O
outcome	NN	O
was	VBD	O
excellent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
final	JJ	O
analysis	NN	O
will	MD	O
reveal	VB	O
whether	IN	O
this	DT	O
finding	NN	O
is	VBZ	O
maintained	VBN	O
over	IN	O
time	NN	O
.	.	O

Effect	NN	O
of	IN	O
TENS	NNP	O
on	IN	O
pain	NN	Pain
,	,	O
medications	NNS	Others
,	,	O
and	CC	O
pulmonary	JJ	Physical
function	NN	Physical
following	VBG	O
coronary	JJ	O
artery	JJ	O
bypass	NN	O
graft	NN	O
surgery	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
(	(	O
TENS	NNP	O
)	)	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
narcotic	JJ	O
medications	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postoperative	JJ	Pain
pain	NN	Pain
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
patients	NNS	O
following	VBG	O
coronary	JJ	O
artery	JJ	O
bypass	NN	O
graft	NN	O
(	(	O
CABG	NNP	O
)	)	O
surgery	NN	O
with	IN	O
the	DT	O
right	NN	O
or	CC	O
left	VBD	O
internal	JJ	O
thoracic	NN	O
artery	NN	O
(	(	O
ITA	NNP	O
)	)	O
.	.	O

Forty-five	JJ	O
male	JJ	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
57	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
(	(	O
1	CD	O
)	)	O
TENS	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
placebo	NN	O
TENS	NNP	O
,	,	O
or	CC	O
(	(	O
3	CD	O
)	)	O
control	NN	O
treatments	NNS	O
(	(	O
n	JJ	O
=	RB	O
15	CD	O
each	DT	O
)	)	O
,	,	O
following	VBG	O
extubation	NN	O
and	CC	O
during	IN	O
the	DT	O
24-	JJ	O
to	TO	O
72-h	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

Two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
tests	NNS	O
indicated	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
among	IN	O
treatment	NN	O
groups	NNS	O
for	IN	O
(	(	O
1	CD	O
)	)	O
pain	NN	Pain
with	IN	Pain
cough	NN	Pain
,	,	O
(	(	O
2	CD	O
)	)	O
narcotic	JJ	Pain
medication	NN	Pain
intake	NN	Pain
,	,	O
(	(	O
3	CD	O
)	)	O
FVC	NNP	Physical
,	,	O
(	(	O
4	CD	O
)	)	O
FEV1	NNP	Physical
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
PEFR	NNP	Physical
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
pain	VBP	Pain
at	IN	Pain
rest	NN	Pain
reported	VBN	O
by	IN	O
the	DT	O
TENS	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
reported	VBN	O
by	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
treatment	NN	O
main	JJ	O
effect	NN	O
;	:	O
p	CC	O
<	VB	O
0.04	CD	O
)	)	O
,	,	O
although	IN	O
no	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
TENS	NNP	O
and	CC	O
placebo	NN	O
or	CC	O
between	IN	O
the	DT	O
placebo	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

All	DT	O
six	CD	O
criterion	NN	O
measures	NNS	O
were	VBD	O
characterized	VBN	O
by	IN	O
significant	JJ	O
changes	NNS	O
over	IN	O
time	NN	O
for	IN	O
the	DT	O
entire	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
45	CD	O
;	:	O
time	NN	O
main	JJ	O
effect	NN	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
pain	NN	Pain
and	CC	O
medication	NN	Pain
intake	NN	Pain
were	VBD	O
similar	JJ	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
but	CC	O
were	VBD	O
significantly	RB	O
less	JJR	O
on	IN	O
day	NN	O
3	CD	O
,	,	O
and	CC	O
pulmonary	JJ	Physical
functions	NNS	Physical
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
preoperatively	RB	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
decreased	VBD	O
further	RBR	O
on	IN	O
day	NN	O
2	CD	O
,	,	O
and	CC	O
despite	IN	O
an	DT	O
improvement	NN	O
on	IN	O
day	NN	O
3	CD	O
,	,	O
remained	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
preoperative	JJ	O
values	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
TENS	NNP	O
,	,	O
applied	VBD	O
continuously	RB	O
during	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
following	VBG	O
CABG	NNP	O
with	IN	O
ITA	NNP	O
,	,	O
may	MD	O
not	RB	O
be	VB	O
advantageous	JJ	O
in	IN	O
pain	NN	Others
management	NN	Others
or	CC	O
the	DT	O
prevention	NN	O
of	IN	O
pulmonary	JJ	Physical
dysfunction	NN	Physical
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
,	,	O
randomized	VBD	O
,	,	O
multicenter	NN	O
study	NN	O
evaluating	VBG	O
the	DT	O
combination	NN	O
of	IN	O
lapatinib	NN	O
and	CC	O
vinorelbine	NN	O
in	IN	O
women	NNS	O
with	IN	O
ErbB2	NNP	O
overexpressing	VBG	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

Lapatinib	NNP	O
is	VBZ	O
approved	VBN	O
in	IN	O
combination	NN	O
with	IN	O
capecitabine	NN	O
for	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
HER2	NNP	O
)	)	O
-positive	VBP	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
who	WP	O
have	VBP	O
progressed	VBN	O
on	IN	O
prior	JJ	O
trastuzumab	NN	O
in	IN	O
the	DT	O
metastatic	JJ	O
setting	NN	O
.	.	O

Vinorelbine	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
chemotherapy	NN	O
option	NN	O
for	IN	O
MBC	NNP	O
.	.	O

We	PRP	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	JJ	O
,	,	O
compared	VBN	O
with	IN	O
lapatinib	JJ	O
plus	CC	O
capecitabine	JJ	O
,	,	O
in	IN	O
women	NNS	O
with	IN	O
HER2-positive	JJ	O
MBC	NNP	O
.	.	O

In	IN	O
this	DT	O
open-label	JJ	O
,	,	O
multicenter	NN	O
,	,	O
phase	NN	O
II	NNP	O
study	NN	O
,	,	O
eligible	JJ	O
patients	NNS	O
(	(	O
N	NNP	O
=	NNP	O
112	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
2:1	CD	O
to	TO	O
lapatinib	VB	O
plus	JJ	O
vinorelbine	NN	O
[	NNP	O
(	(	O
N	NNP	O
=	NNP	O
75	CD	O
)	)	O
1,250	CD	O
mg	NN	O
orally	RB	O
once	RB	O
daily	JJ	O
(	(	O
QD	NNP	O
)	)	O
continuously	RB	O
plus	CC	O
20	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
intravenously	RB	O
]	VBZ	O
or	CC	O
lapatinib	JJ	O
plus	CC	O
capecitabine	JJ	O
[	NNP	O
(	(	O
N	NNP	O
=	NNP	O
37	CD	O
)	)	O
1,250	CD	O
mg	NN	O
orally	RB	O
QD	NNP	O
continuously	RB	O
plus	CC	O
2,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
orally	RB	O
,	,	O
2	CD	O
doses	NNS	O
]	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
progression-free	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
PFS	NNP	Mortality
)	)	Mortality
.	.	O

Other	JJ	O
endpoints	NNS	O
included	VBD	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
and	CC	Mortality
safety	NN	Mortality
.	.	O

Patients	NNS	O
progressing	VBG	O
within	IN	O
the	DT	O
study	NN	O
were	VBD	O
given	VBN	O
the	DT	O
option	NN	O
of	IN	O
crossover	NN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
arm	NN	O
;	:	O
time	NN	O
to	TO	O
second	JJ	O
progression	NN	O
was	VBD	O
an	DT	O
exploratory	JJ	O
endpoint	NN	O
.	.	O

Patient	JJ	Mental
demographics	NNS	Mental
,	,	O
stratification	NN	Physical
,	,	O
and	CC	O
prognostic	JJ	Physical
factors	NNS	Physical
were	VBD	O
well	RB	O
balanced	VBN	O
between	IN	O
treatments	NNS	O
.	.	O

Median	JJ	Mortality
PFS	NNP	Mortality
in	IN	O
both	DT	O
arms	NNS	O
was	VBD	O
6.2	CD	O
months	NNS	O
[	RB	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
4.2	CD	O
,	,	O
8.8	CD	O
(	(	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	JJ	O
)	)	O
;	:	O
4.4	CD	O
,	,	O
8.3	CD	O
(	(	O
lapatinib	JJ	O
plus	CC	O
capecitabine	NN	O
)	)	O
]	NN	O
.	.	O

Median	JJ	Mortality
OS	NNP	Mortality
on	IN	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	NN	O
was	VBD	O
24.3	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
16.4	CD	O
,	,	O
NE	NNP	O
)	)	O
and	CC	O
19.4	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
16.4	CD	O
,	,	O
27.2	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
capecitabine	NN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
42	CD	O
patients	NNS	O
opted	VBN	O
to	TO	O
cross	VB	O
over	RP	O
;	:	O
median	JJ	O
PFS	NNP	O
was	VBD	O
3.2	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.7	CD	O
,	,	O
5.1	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
vinorelbine	NN	O
and	CC	O
4.0	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
2.1	CD	O
,	,	O
5.8	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
capecitabine	NN	O
.	.	O

Lapatinib	NNP	O
plus	CC	O
vinorelbine	NN	O
offers	NNS	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
patients	NNS	O
with	IN	O
HER2-overexpressing	NNP	O
MBC	NNP	O
,	,	O
having	VBG	O
displayed	VBN	O
comparable	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
rates	NNS	O
to	TO	O
lapatinib	VB	O
plus	JJ	O
capecitabine	NN	O
.	.	O

Effects	NNS	O
of	IN	O
frusemide	NN	O
and	CC	O
hypoxia	NN	O
on	IN	O
the	DT	O
pulmonary	JJ	O
vascular	NN	O
bed	NN	O
in	IN	O
man	NN	O
.	.	O

AIMS	NNP	O
Diuretic	NNP	O
therapy	NN	O
is	VBZ	O
conventionally	RB	O
used	VBN	O
to	TO	O
treat	VB	O
oedema	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
hypoxic	JJ	O
cor	NN	O
pulmonale	NN	O
.	.	O

This	DT	O
condition	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
activation	NN	O
of	IN	O
the	DT	O
renin	NN	O
angiotensin	NN	O
system	NN	O
(	(	O
RAS	NNP	O
)	)	O
with	IN	O
elevated	JJ	O
levels	NNS	O
of	IN	O
angiotensin	NN	O
II	NNP	O
(	(	O
ANG	NNP	O
II	NNP	O
)	)	O
,	,	O
a	DT	O
potent	JJ	O
pulmonary	JJ	O
pressor	NN	O
agent	NN	O
.	.	O

We	PRP	O
explored	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
RAS	NNP	O
activation	NN	O
by	IN	O
diuretic	JJ	O
therapy	NN	O
might	MD	O
therefore	VB	O
worsen	JJ	O
hypoxic	NN	O
pulmonary	JJ	O
vasoconstriction	NN	O
via	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ANG	NNP	O
II	NNP	O
on	IN	O
the	DT	O
pulmonary	JJ	O
vascular	NN	O
bed	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
normal	JJ	O
volunteers	NNS	O
were	VBD	O
studied	VBN	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

They	PRP	O
either	DT	O
received	VBD	O
40	CD	O
mg	NNS	O
frusemide	JJ	O
daily	RB	O
or	CC	O
placebo	VB	O
for	IN	O
4	CD	O
days	NNS	O
and	CC	O
were	VBD	O
then	RB	O
rendered	VBN	O
hypoxaemic	NN	O
,	,	O
by	IN	O
breathing	VBG	O
an	DT	O
N2/O2	NNP	O
mixture	NN	O
for	IN	O
20	CD	O
min	NN	O
to	TO	O
achieve	VB	O
an	DT	O
SaO2	NNP	O
of	IN	O
85-90	CD	O
%	NN	O
adjusted	VBN	O
for	IN	O
a	DT	O
further	JJ	O
20	CD	O
min	NN	O
to	TO	O
achieve	VB	O
an	DT	O
SaO2	NNP	O
of	IN	O
75-80	CD	O
%	NN	O
.	.	O

Pulsed	VBN	O
wave	VBP	O
doppler	NN	O
echocardiography	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
mean	JJ	Physical
pulmonary	JJ	Physical
artery	NN	Physical
pressure	NN	Physical
,	,	Physical
cardiac	JJ	Physical
output	NN	Physical
and	CC	O
hence	RB	O
pulmonary	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
(	(	Physical
PVR	NNP	Physical
)	)	Physical
.	.	Physical

RESULTS	NNP	O
Plasma	NNP	Physical
renin	NN	Physical
activity	NN	Physical
(	(	Physical
PRA	NNP	Physical
)	)	Physical
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
increased	VBN	O
after	IN	O
prior	JJ	O
treatment	NN	O
with	IN	O
frusemide	JJ	O
compared	VBN	O
with	IN	O
placebo	NN	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
.	.	O

Prior	NNP	O
treatment	NN	O
with	IN	O
frusemide	NN	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
increased	VBD	O
PVR	NNP	Physical
compared	VBN	O
with	IN	O
placebo	NN	O
at	IN	O
baseline	NN	O
:	:	O
185	CD	O
+/-	JJ	O
17	CD	O
vs	JJ	O
132	CD	O
+/-	JJ	O
10	CD	O
dyn	JJ	O
s	JJ	O
cm-5	NN	O
at	IN	O
an	DT	O
SaO2	NNP	O
of	IN	O
85-90	JJ	O
%	NN	O
:	:	O
291	CD	O
+/-	JJ	O
18	CD	O
vs	JJ	O
229	CD	O
+/-	JJ	O
16	CD	O
dyn	JJ	O
s	JJ	O
cm-5	NN	O
and	CC	O
at	IN	O
SaO2	NNP	O
of	IN	O
75-80	CD	O
%	NN	O
:	:	O
356	CD	O
+/-	JJ	O
12	CD	O
vs	JJ	O
296	CD	O
+/-	JJ	O
17	CD	O
dyn	JJ	O
s	JJ	O
cm-5	NN	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
delta-PVR	JJ	Physical
response	NN	Physical
to	TO	Physical
hypoxaemia	NN	Physical
was	VBD	O
not	RB	O
significantly	RB	O
altered	VBN	O
by	IN	O
frusemide	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
its	PRP$	O
effect	NN	O
on	IN	O
the	DT	O
pulmonary	JJ	O
vasculature	NN	O
prior	JJ	O
treatment	NN	O
with	IN	O
frusemide	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	O
systemic	JJ	Physical
haemodynamic	JJ	Physical
parameters	NNS	Physical
either	CC	O
at	IN	O
baseline	NN	O
or	CC	O
during	IN	O
hypoxia	NN	O
.	.	O

CONCLUSIONS	NNP	O
Thus	NNP	O
,	,	O
prior	JJ	O
treatment	NN	O
with	IN	O
frusemide	NN	O
increased	VBD	O
baseline	JJ	O
pulmonary	JJ	Physical
vascular	NN	Physical
resistance	NN	Physical
and	CC	O
significantly	RB	O
augmented	VBD	O
the	DT	O
hypoxaemic	JJ	Physical
pulmonary	JJ	Physical
vascular	NN	Physical
response	NN	Physical
in	IN	O
additive	JJ	O
fashion	NN	O
.	.	O

It	PRP	O
is	VBZ	O
hypothesised	VBN	O
that	IN	O
this	DT	O
effect	NN	O
of	IN	O
frusemide	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
RAS	NNP	O
activation	NN	O
with	IN	O
ANG	NNP	O
II	NNP	O
mediated	VBD	O
pulmonary	JJ	O
vasoconstriction	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
fixed-dose	JJ	O
study	NN	O
of	IN	O
aripiprazole	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	Others
and	CC	O
safety	NN	Others
of	IN	O
aripiprazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
Two	CD	O
hundred	VBD	O
eighteen	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
aged	VBN	O
6-17	CD	O
years	NNS	O
)	)	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
and	CC	O
with	IN	O
behaviors	NNS	O
such	JJ	O
as	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
symptoms	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
1:1:1:1	CD	O
to	TO	O
aripiprazole	VB	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
this	DT	O
8-week	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Efficacy	NNP	Others
was	VBD	O
evaluated	VBN	O
using	VBG	O
the	DT	O
caregiver-rated	JJ	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
Irritability	NNP	Mental
subscale	NN	Mental
(	(	Mental
primary	JJ	Mental
efficacy	NN	Mental
measure	NN	Mental
)	)	Mental
and	CC	O
the	DT	O
clinician-rated	JJ	Mental
Clinical	JJ	Mental
Global	NNP	Mental
Impressions-Improvement	NNP	Mental
score	NN	Mental
.	.	O

Safety	NNP	Others
and	CC	Others
tolerability	NN	Others
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
8	CD	O
,	,	O
all	DT	O
aripiprazole	JJ	O
doses	NNS	O
produced	VBN	O
significantly	RB	O
greater	JJR	O
improvement	NN	Others
than	IN	O
placebo	NN	O
in	IN	O
mean	JJ	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
Irritability	NNP	Mental
subscale	NN	Mental
scores	NNS	Mental
(	(	O
5	CD	O
mg/day	NN	O
,	,	O
-12.4	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
,	,	O
-13.2	NNP	O
;	:	O
15	CD	O
mg/day	NN	O
,	,	O
-14.4	NNP	O
;	:	O
versus	NN	O
placebo	NN	O
,	,	O
-8.4	NNP	O
;	:	O
all	DT	O
p	VBP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	DT	O
aripiprazole	JJ	O
doses	NNS	O
demonstrated	VBN	O
significantly	RB	O
greater	JJR	O
improvements	NNS	Mental
in	IN	Mental
mean	JJ	Mental
Clinical	JJ	Mental
Global	NNP	Mental
Impressions-Improvement	NNP	Mental
score	NN	Mental
than	IN	O
placebo	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

Discontinuation	NN	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	VB	O
7.7	CD	O
%	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
9.4	CD	O
%	NN	O
,	,	O
10	CD	O
mg/day	JJ	O
13.6	CD	O
%	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	JJ	O
7.4	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	Adverseeffect
event	NN	Adverseeffect
leading	VBG	O
to	TO	O
discontinuation	NN	O
was	VBD	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
serious	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
:	:	O
presyncope	NN	Adverseeffect
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
and	CC	O
aggression	NN	Adverseeffect
(	(	O
10	CD	O
mg/day	NN	O
)	)	O
.	.	O

At	IN	O
week	NN	O
8	CD	O
,	,	O
mean	JJ	O
weight	NN	Physical
change	NN	Physical
(	(	O
last	JJ	O
observation	NN	O
carried	VBD	O
forward	RB	O
)	)	O
was	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	NN	O
+0.3	NNP	O
kg	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
+1.3	NNP	O
kg	NN	O
,	,	O
10	CD	O
mg/day	NN	O
+1.3	NNP	O
kg	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	NN	O
+1.5	NNP	O
kg	NN	O
;	:	O
all	DT	O
p	VBP	O
<	JJ	O
.05	NNP	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	O
was	VBD	O
efficacious	JJ	Others
and	CC	O
generally	RB	O
safe	JJ	Others
and	CC	O
well	RB	Others
tolerated	VBN	Others
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

A	DT	O
two-part	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
cediranib	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
solid	JJ	O
tumours	NN	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
single-dose	JJ	O
pharmacokinetics	NNS	O
and	CC	O
an	DT	O
evaluation	NN	O
of	IN	O
safety	NN	Others
,	,	Others
efficacy	NN	Others
and	CC	Others
imaging	VBG	Others
pharmacodynamics	NNS	Others
.	.	Others

BACKGROUND	NNP	O
Cediranib	NNP	O
(	(	O
RECENTIN?	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
,	,	O
highly	RB	O
potent	JJ	O
VEGF	NNP	O
inhibitor	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
cediranib	NN	O
and	CC	O
compared	VBN	O
the	DT	O
administration	NN	O
of	IN	O
continual	JJ	O
cediranib	NN	O
via	IN	O
two	CD	O
dosing	VBG	O
strategies	NNS	O
using	VBG	O
this	DT	O
as	IN	O
a	DT	O
platform	NN	O
to	TO	O
investigate	VB	O
pharmacodynamic	JJ	O
imaging	NN	O
biomarkers	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
two	CD	O
single	JJ	O
doses	NNS	O
of	IN	O
cediranib	NN	O
in	IN	O
either	CC	O
fed/fasted	VBD	O
or	CC	O
fasted/fed	JJ	O
state	NN	O
(	(	O
Part	NNP	O
A	NNP	O
)	)	O
.	.	O

In	IN	O
continual	JJ	O
dosage	NN	O
phase	NN	O
(	(	O
Part	NNP	O
B	NNP	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
a	DT	O
fixed-dose	JJ	O
or	CC	O
dose-escalation	JJ	O
arm	NN	O
.	.	O

Exploratory	JJ	O
pharmacodynamic	JJ	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
DCE-MRI	NNP	O
and	CC	O
CT	NNP	O
enhancing	VBG	O
fraction	NN	O
(	(	O
EnF	NNP	O
)	)	O
.	.	O

RESULTS	VBN	O
In	IN	O
part	NN	O
A	NNP	O
,	,	O
plasma	NN	Physical
AUC	NNP	Physical
and	CC	Physical
C	NNP	Physical
(	(	Physical
max	NN	Physical
)	)	Physical
of	IN	Physical
cediranib	NN	Physical
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
food	NN	O
by	IN	O
a	DT	O
mean	NN	O
of	IN	O
24	CD	O
and	CC	O
33	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
94	CD	O
%	NN	O
CI	NNP	O
:	:	O
AUC	NNP	O
,	,	O
12-34	CD	O
%	NN	O
and	CC	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
20-43	JJ	O
%	NN	O
)	)	O
,	,	O
indicating	VBG	O
food	NN	O
reduces	NNS	O
cediranib	VBP	O
plasma	JJ	O
exposure	NN	O
.	.	O

In	IN	O
part	NN	O
B	NNP	O
,	,	O
cediranib	VBZ	O
30	CD	O
mg/day	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
sustainable	JJ	O
for	IN	O
chronic	JJ	O
dosing	NN	O
.	.	O

Continuous	JJ	O
cediranib	NN	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
sustained	JJ	O
antivascular	JJ	O
effects	NNS	O
up	RB	O
to	TO	O
16	CD	O
weeks	NNS	O
,	,	O
with	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
DCE-MRI	NNP	Physical
parameters	NNS	Physical
and	CC	Physical
CT	NNP	Physical
EnF	NNP	Physical
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
cediranib	NN	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
1	CD	O
h	NN	O
before	IN	O
or	CC	O
2	CD	O
h	NN	O
after	IN	O
food	NN	O
.	.	O

Evidence	NN	O
of	IN	O
antitumour	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
,	,	O
with	IN	O
significant	JJ	O
sustained	JJ	O
effects	NNS	O
upon	IN	O
imaging	VBG	O
vascular	JJ	O
parameters	NNS	O
.	.	O

Use	NNP	O
of	IN	O
the	DT	O
oral	JJ	O
neuraminidase	NN	O
inhibitor	NN	O
oseltamivir	NN	O
in	IN	O
experimental	JJ	O
human	JJ	O
influenza	NN	O
:	:	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
for	IN	O
prevention	NN	O
and	CC	O
treatment	NN	O
.	.	O

CONTEXT	NNP	O
Influenza	NNP	O
virus	NN	O
neuraminidase	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
essential	JJ	O
for	IN	O
virus	JJ	O
replication	NN	O
in	IN	O
humans	NNS	O
;	:	O
however	RB	O
,	,	O
to	TO	O
date	NN	O
,	,	O
available	JJ	O
neuraminidase	NN	O
inhibitors	NNS	O
are	VBP	O
limited	VBN	O
to	TO	O
zanamivir	CD	O
,	,	O
which	WDT	O
is	VBZ	O
topically	RB	O
administered	VBN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
safety	NN	Others
,	,	Others
tolerability	NN	Others
,	,	Others
and	CC	Others
antiviral	JJ	Others
activity	NN	Others
of	IN	O
oral	JJ	O
neuraminidase	NN	O
inhibitor	NN	O
oseltamivir	NN	O
(	(	O
GS4104/Ro64-0796	NNP	O
)	)	O
for	IN	O
prevention	NN	O
and	CC	O
the	DT	O
early	JJ	O
treatment	NN	O
of	IN	O
influenza	NN	O
in	IN	O
experimentally	RB	O
infected	JJ	O
humans	NNS	O
.	.	O

DESIGN	NNP	O
Two	CD	O
randomized	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trials	NNS	O
conducted	VBN	O
between	IN	O
June	NNP	O
and	CC	O
July	NNP	O
1997	CD	O
.	.	O

SETTING	VBG	O
Individual	JJ	O
hotel	NN	O
rooms	NNS	O
;	:	O
2	CD	O
large	JJ	O
US	NNP	O
university	NN	O
medical	JJ	O
schools	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
117	CD	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
(	(	O
aged	VBN	O
18-40	CD	O
years	NNS	O
;	:	O
median	JJ	O
age	NN	O
,	,	O
21	CD	O
years	NNS	O
)	)	O
who	WP	O
were	VBD	O
susceptible	JJ	O
(	(	O
hemagglutination-inhibition	NN	O
antibody	NN	O
titer	NN	O
<	NN	O
or	CC	O
=1:8	NN	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
All	DT	O
subjects	NNS	O
were	VBD	O
inoculated	VBN	O
intranasally	RB	O
with	IN	O
influenza	JJ	O
A/Texas/36/91	NNP	O
(	(	O
H1N1	NNP	O
)	)	O
virus	NN	O
.	.	O

For	IN	O
the	DT	O
prophylaxis	NN	O
study	NN	O
,	,	O
oral	JJ	O
oseltamivir	NN	O
(	(	O
100	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
[	NNP	O
n	NN	O
=	VBD	O
12	CD	O
]	NNP	O
,	,	O
100	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
[	JJ	O
n	JJ	O
=	NN	O
12	CD	O
]	NN	O
,	,	O
or	CC	O
matching	VBG	O
placebo	JJ	O
[	JJ	O
n	NN	O
=	VBD	O
13	CD	O
]	NN	O
,	,	O
starting	VBG	O
26	CD	O
hours	NNS	O
before	IN	O
virus	JJ	O
inoculation	NN	O
)	)	O
was	VBD	O
administered	VBN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
study	NN	O
,	,	O
the	DT	O
same	JJ	O
drug	NN	O
was	VBD	O
given	VBN	O
(	(	O
20	CD	O
mg	NN	O
,	,	O
100	CD	O
mg	NN	O
,	,	O
or	CC	O
200	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
,	,	O
200	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
,	,	O
or	CC	O
matching	VBG	O
placebo	JJ	O
[	JJ	O
n	NN	O
=	VBD	O
16	CD	O
]	NN	O
,	,	O
in	IN	O
each	DT	O
group	NN	O
starting	VBG	O
28	CD	O
hours	NNS	O
after	IN	O
inoculation	NN	O
)	)	O
.	.	O

All	DT	O
regimens	NNS	O
were	VBD	O
continued	VBN	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Comparing	NNP	O
placebo	NN	O
groups	NNS	O
with	IN	O
pooled	JJ	O
treatment	NN	O
groups	NNS	O
,	,	O
for	IN	O
prophylaxis	NN	O
,	,	O
outcomes	RB	O
included	JJ	O
frequency	NN	Others
of	IN	Others
infection	NN	Others
and	CC	Others
viral	JJ	Others
shedding	NN	Others
;	:	Physical
for	IN	O
treatment	NN	O
,	,	O
viral	JJ	O
shedding	VBG	O
in	IN	O
titers	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
prophylaxis	NN	O
study	NN	O
,	,	O
8	CD	O
(	(	O
67	CD	O
%	NN	O
)	)	O
of	IN	O
12	CD	O
placebo	NN	O
and	CC	O
8	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
21	CD	O
oseltamivir	JJ	O
recipients	NNS	O
became	VBD	O
infected	JJ	Physical
(	(	O
P	NNP	O
=	NNP	O
.16	NNP	O
;	:	O
efficacy	NN	O
,	,	O
61	CD	O
%	NN	O
)	)	O
;	:	O
6	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
placebo	NN	O
compared	VBN	O
with	IN	O
0	CD	O
oseltamivir	NN	O
recipients	NNS	O
shed	VBN	O
virus	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
;	:	O
efficacy	NN	O
,	,	O
100	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
33	CD	O
%	NN	O
of	IN	O
placebo	NN	O
but	CC	O
no	DT	O
oseltamivir	JJ	O
recipient	NN	O
had	VBD	O
infection-related	JJ	O
respiratory	NN	O
illness	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Among	IN	O
infected	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
study	NN	O
(	(	O
n	JJ	O
=	NNP	O
69	CD	O
)	)	O
,	,	O
the	DT	O
viral	JJ	Others
titer	NN	Others
area	NN	Others
under	IN	Others
the	DT	Others
curve	NN	Others
of	IN	O
the	DT	O
combined	JJ	O
oseltamivir	NN	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
was	VBD	O
lower	JJR	O
(	(	O
median	JJ	O
[	NN	O
interquartile	NN	O
range	NN	O
[	NNP	O
IQR	NNP	O
]	NNP	O
]	NNP	O
,	,	O
80	CD	O
[	JJ	O
23-151	JJ	O
]	NN	O
vs	NN	O
273	CD	O
[	JJ	O
79-306	JJ	O
]	NN	O
log10	JJ	O
tissue	NN	O
culture-infective	JJ	O
doses50	NN	O
per	IN	O
milliliter	NN	O
x	FW	O
hour	NN	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
median	NN	Others
(	(	Others
IQR	NNP	Others
)	)	Others
duration	NN	Others
of	IN	Others
viral	JJ	Others
shedding	VBG	Others
with	IN	O
therapy	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
107	CD	O
(	(	O
83-131	CD	O
)	)	O
to	TO	O
58	CD	O
(	(	O
35-59	CD	O
)	)	O
hours	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Oseltamivir	NNP	O
treatment	NN	O
also	RB	O
reduced	VBD	O
symptom	JJ	Physical
scores	NNS	Physical
(	(	O
median	JJ	O
[	NNP	O
IQR	NNP	O
]	NNP	O
score-hours	NN	O
,	,	O
225	CD	O
[	JJ	O
97-349	CD	O
]	NNP	O
vs	FW	O
400	CD	O
[	JJ	O
189-645	JJ	O
]	NN	O
;	:	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
,	,	O
and	CC	O
nasal	JJ	Physical
proinflammatory	JJ	Physical
cytokine	NN	Physical
levels	NNS	Physical
.	.	Physical

Transient	NNP	O
mild	NN	Adverseeffect
to	TO	Adverseeffect
moderate	VB	Adverseeffect
nausea	NN	Adverseeffect
after	IN	O
dosing	VBG	O
was	VBD	O
observed	VBN	O
in	IN	O
15	CD	O
(	(	O
17	CD	O
%	NN	O
)	)	O
of	IN	O
88	CD	O
oseltamivir	NNS	O
and	CC	O
2	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
of	IN	O
29	CD	O
placebo	NN	O
recipients	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
difference	NN	O
,	,	O
-11	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
largely	RB	O
prevented	VBN	O
by	IN	O
ingestion	NN	O
with	IN	O
food	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
these	DT	O
trials	NNS	O
,	,	O
prophylaxis	NN	O
and	CC	O
early	JJ	O
treatment	NN	O
with	IN	O
oral	JJ	O
oseltamivir	NNS	O
were	VBD	O
both	DT	O
associated	VBN	O
with	IN	O
significant	JJ	O
antiviral	JJ	O
and	CC	O
clinical	JJ	O
effects	NNS	O
in	IN	O
experimental	JJ	O
human	JJ	O
influenza	NN	O
.	.	O

Large-dose	JJ	O
intravenous	JJ	O
ferric	NNS	O
carboxymaltose	VBP	O
injection	NN	O
for	IN	O
iron	NN	O
deficiency	NN	O
anemia	NN	O
in	IN	O
heavy	JJ	O
uterine	JJ	O
bleeding	NN	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
rapid	JJ	O
,	,	O
large-dose	JJ	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
administration	NN	O
of	IN	O
ferric	JJ	O
carboxymaltose	NN	O
compared	VBN	O
to	TO	O
oral	JJ	O
iron	NN	O
in	IN	O
correcting	VBG	O
iron	NN	O
deficiency	NN	O
anemia	NN	O
due	JJ	O
to	TO	O
heavy	JJ	O
uterine	JJ	O
bleeding	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
,	,	O
477	CD	O
women	NNS	O
with	IN	O
anemia	NN	O
,	,	O
iron	NN	O
deficiency	NN	O
,	,	O
and	CC	O
heavy	JJ	O
uterine	JJ	O
bleeding	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
IV	NNP	O
ferric	NN	O
carboxymaltose	NN	O
(	(	O
<	JJ	O
or=1000	NN	O
mg	NN	O
over	IN	O
15	CD	O
min	NNS	O
,	,	O
repeated	VBD	O
weekly	JJ	O
to	TO	O
achieve	VB	O
a	DT	O
total	JJ	O
calculated	JJ	O
replacement	NN	O
dose	NN	O
)	)	O
or	CC	O
325	CD	O
mg	NN	O
of	IN	O
ferrous	JJ	O
sulfate	NN	O
(	(	O
65	CD	O
mg	NN	O
elemental	JJ	O
iron	NN	O
)	)	O
prescribed	VBD	O
orally	RB	O
thrice	JJ	O
daily	RB	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
to	TO	O
those	DT	O
assigned	VBN	O
to	TO	O
ferrous	JJ	O
sulfate	NN	O
,	,	O
more	JJR	O
patients	NNS	O
assigned	VBD	O
to	TO	O
ferric	VB	O
carboxymaltose	NN	O
responded	VBN	O
with	IN	O
a	DT	O
hemoglobin	NN	Physical
(	(	Physical
Hb	NNP	Physical
)	)	Physical
increase	NN	O
of	IN	O
2.0	CD	O
g/dL	NN	O
or	CC	O
more	JJR	O
(	(	O
82	CD	O
%	NN	O
vs.	FW	O
62	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
treatment	NN	O
difference	NN	O
12.2-28.3	CD	O
,	,	O
p	VBZ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
more	JJR	O
achieved	VBD	O
a	DT	O
3.0	CD	O
g/dL	NN	O
or	CC	O
more	JJR	O
increase	NN	O
(	(	O
53	CD	O
%	NN	O
vs.	FW	O
36	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
more	JJR	O
achieved	JJ	O
correction	NN	Physical
(	(	O
Hb	NNP	O
>	NNP	O
or=	VBD	O
12	CD	O
g/dL	NN	O
)	)	O
of	IN	O
anemia	NN	O
(	(	O
73	CD	O
%	NN	O
vs.	FW	O
50	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
ferric	JJ	O
carboxymaltose	NN	O
compared	VBN	O
to	TO	O
those	DT	O
prescribed	VBN	O
ferrous	JJ	O
sulfate	NN	O
reported	VBD	O
greater	JJR	O
gains	NNS	O
in	IN	O
vitality	NN	Physical
and	CC	Physical
physical	JJ	Physical
function	NN	Physical
and	CC	Physical
experienced	JJ	Physical
greater	JJR	Physical
improvement	NN	Physical
in	IN	Physical
symptoms	NNS	Physical
of	IN	Physical
fatigue	NN	Physical
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	Adverseeffect
adverse	JJ	Adverseeffect
drug	NN	Adverseeffect
events	NNS	Adverseeffect
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
iron	NN	O
deficiency	NN	O
anemia	NN	O
due	JJ	O
to	TO	O
heavy	JJ	O
uterine	JJ	O
bleeding	NN	O
,	,	O
rapid	JJ	O
IV	NNP	O
administration	NN	O
of	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
new	JJ	O
iron	NN	O
agent	NN	O
,	,	O
ferric	JJ	O
carboxymaltose	NN	O
,	,	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
oral	JJ	O
iron	NN	O
therapy	NN	O
in	IN	O
correcting	VBG	Physical
anemia	NN	Physical
,	,	O
replenishing	VBG	Physical
iron	NN	Physical
stores	NNS	Physical
,	,	O
and	CC	O
improving	VBG	Others
quality	NN	Others
of	IN	Others
life	NN	Others
.	.	O

Effects	NNS	O
of	IN	O
omeprazole	NN	O
and	CC	O
amoxycillin	NN	O
on	IN	O
the	DT	O
human	JJ	O
oral	JJ	O
and	CC	O
gastrointestinal	JJ	O
microflora	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Fourteen	JJ	O
patients	NNS	O
with	IN	O
Helicobacter	NNP	O
pylori	FW	O
infection	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
omeprazole	JJ	O
capsules	NNS	O
20	CD	O
mg	NNS	O
and	CC	O
amoxycillin	NN	O
capsules	NNS	O
1000	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
and	CC	O
14	CD	O
patients	NNS	O
with	IN	O
omeprazole	JJ	O
capsules	NNS	O
20	CD	O
mg	NNS	O
and	CC	O
placebo	VB	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Samples	NNS	O
from	IN	O
saliva	NN	O
,	,	O
dental	JJ	O
plaque	NN	O
and	CC	O
faeces	NNS	O
and	CC	O
biopsies	NNS	O
from	IN	O
antrum	NN	O
and	CC	O
corpus	NN	O
were	VBD	O
analysed	VBN	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
ecological	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
microflora	NN	O
.	.	O

Several	JJ	O
microorganisms	NNS	O
were	VBD	O
affected	VBN	O
by	IN	O
both	DT	O
treatment	NN	O
regimens	NNS	O
.	.	O

Two	CD	O
patients	NNS	O
were	VBD	O
colonised	VBN	O
with	IN	O
enterobacteria	NNS	O
in	IN	O
the	DT	O
oral	JJ	O
cavity	NN	O
and	CC	O
stomach	NN	O
during	IN	O
the	DT	O
omeprazole	JJ	O
plus	CC	O
amoxycillin	JJ	O
treatment	NN	O
.	.	O

A	DT	O
general	JJ	Others
increase	NN	Others
in	IN	Others
the	DT	Others
number	NN	Others
of	IN	Others
microorganisms	NNS	Others
from	IN	Others
gastric	JJ	Others
mucosa	NN	Others
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

A	DT	O
selection	NN	Others
of	IN	Others
resistant	JJ	Others
enterobacteria	NN	Others
and	CC	O
an	DT	O
increase	NN	Others
in	IN	Others
beta-lactamase	JJ	Others
production	NN	Others
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
faecal	JJ	O
samples	NNS	O
during	IN	O
the	DT	O
omeprazole	JJ	O
plus	CC	O
amoxycillin	JJ	O
treatment	NN	O
.	.	O

Eradication	NN	Others
of	IN	Others
H.	NNP	Others
pylori	NN	Others
in	IN	Others
the	DT	Others
omeprazole-amoxycillin	JJ	Others
group	NN	Others
was	VBD	O
50	CD	O
%	NN	O
and	CC	O
in	IN	O
the	DT	O
omeprazole	JJ	O
placebo	NN	O
group	NN	O
0	CD	O
%	NN	O
four	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	Others
viable	JJ	Others
H.	NNP	Others
pylori	NN	Others
were	VBD	O
cultivated	VBN	O
in	IN	O
the	DT	O
saliva	NN	Physical
,	,	O
dental	JJ	Physical
plaque	NN	Physical
or	CC	O
faecal	JJ	Physical
samples	NNS	Physical
.	.	O

Treatment	NN	O
with	IN	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
and	CC	O
amoxycillin	NN	O
1000	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
altered	VBD	O
the	DT	O
normal	JJ	O
microflora	NN	O
in	IN	O
the	DT	O
oral	JJ	O
,	,	O
gastric	JJ	O
and	CC	O
intestinal	JJ	O
tract	NN	O
and	CC	O
antibiotic	JJ	O
resistant	JJ	O
microorganisms	NNS	O
increased	VBD	O
in	IN	O
numbers	NNS	O
in	IN	O
the	DT	O
intestinal	JJ	Physical
microflora	NN	Physical
.	.	Physical

Effects	NNS	O
of	IN	O
early	JJ	O
enteral	JJ	O
feeding	NN	O
on	IN	O
fecal	JJ	Physical
elastase	NN	Physical
1	CD	Physical
and	CC	Physical
plasma	JJ	Physical
secretin	NN	Physical
.	.	Physical

BACKGROUND	NNP	O
Enteral	NNP	O
feeding	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
gut	NN	O
hormone	NN	O
secretion	NN	O
and	CC	O
pancreatic	JJ	O
exocrine	NN	O
function	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
extremely	RB	O
early	JJ	O
enteral	JJ	O
feedings	NNS	O
on	IN	O
the	DT	O
development	NN	O
in	IN	O
very	RB	O
low-birthweight	JJ	O
(	(	O
VLBW	NNP	O
)	)	O
infants	NNS	O
.	.	O

METHODS	NNP	O
Fecal	NNP	Physical
elastase	VBD	Physical
1	CD	Physical
and	CC	Physical
plasma	VB	Physical
secretin	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
measured	VBN	O
at	IN	O
four	CD	O
different	JJ	O
periods	NNS	O
during	IN	O
the	DT	O
first	JJ	O
28	CD	O
days	NNS	O
of	IN	O
life	NN	O
in	IN	O
VLBW	NNP	O
infants	NNS	O
,	,	O
with	IN	O
extremely	RB	O
early	JJ	O
enteral	JJ	O
feeding	NN	O
starting	VBG	O
within	IN	O
24	CD	O
h	NN	O
of	IN	O
birth	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
control	NN	O
infants	NNS	O
.	.	O

RESULTS	NNP	O
Fecal	JJ	Physical
concentrations	NNS	Physical
of	IN	Physical
elastase	NN	Physical
1	CD	Physical
at	IN	O
7	CD	O
,	,	O
14	CD	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
birth	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
at	IN	O
1	CD	O
or	CC	O
2	CD	O
days	NNS	O
in	IN	O
both	DT	O
the	DT	O
early	JJ	O
feeding	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Fecal	JJ	Physical
elastase	NN	Physical
1	CD	Physical
levels	NNS	Physical
in	IN	O
the	DT	O
early	JJ	O
feeding	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
at	IN	O
7	CD	O
and	CC	O
14	CD	O
days	NNS	O
after	IN	O
birth	NN	O
.	.	O

The	DT	O
plasma	JJ	Physical
concentration	NN	Physical
of	IN	Physical
secretin	NN	Physical
at	IN	O
14	CD	O
days	NNS	O
after	IN	O
birth	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
at	IN	O
1	CD	O
or	CC	O
2	CD	O
days	NNS	O
and	CC	O
7	CD	O
days	NNS	O
after	IN	O
birth	NN	O
in	IN	O
the	DT	O
early	JJ	O
feeding	NN	O
group	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
plasma	NN	Physical
secretin	NN	Physical
levels	NNS	Physical
were	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
early	JJ	O
feeding	NN	O
and	CC	O
control	NN	O
groups	NNS	O
at	IN	O
1	CD	O
or	CC	O
2	CD	O
days	NNS	O
,	,	O
7	CD	O
days	NNS	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
birth	NN	O
,	,	O
but	CC	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
secretin	JJ	Physical
level	NN	Physical
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
at	IN	O
14	CD	O
days	NNS	O
after	IN	O
birth	NN	O
.	.	O

CONCLUSIONS	NNP	O
Extremely	RB	O
early	JJ	O
enteral	JJ	O
feedings	NNS	O
may	MD	O
play	VB	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
pancreatic	JJ	Physical
exocrine	NN	Physical
function	NN	Physical
and	CC	Physical
secretin	JJ	Physical
secretion	NN	Physical
in	IN	O
the	DT	O
early	JJ	O
period	NN	O
of	IN	O
life	NN	O
in	IN	O
VLBW	NNP	O
infants	NNS	O
.	.	O

Different	NNP	O
aprotinin	NN	O
applications	NNS	O
influencing	VBG	O
hemostatic	JJ	O
changes	NNS	O
in	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
different	JJ	O
aprotinin	NN	O
applications	NNS	O
on	IN	O
hemostatic	JJ	O
changes	NNS	O
and	CC	O
blood	NN	O
product	NN	O
requirements	NNS	O
in	IN	O
orthotopic	JJ	O
liver	NN	O
transplantation	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
open	JJ	O
,	,	O
and	CC	O
randomized	VBD	O
study	NN	O
.	.	O

From	IN	O
November	NNP	O
1989	CD	O
to	TO	O
June	NNP	O
1990	CD	O
,	,	O
13	CD	O
patients	NNS	O
received	VBD	O
aprotinin	RB	O
as	IN	O
a	DT	O
bolus	NN	O
of	IN	O
0.5	CD	O
Mill	NNP	O
.	.	O

Kallikrein	NNP	O
inactivator	JJ	O
units	NNS	O
(	(	O
KIU	NNP	O
)	)	O
on	IN	O
three	CD	O
occasions	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
an	DT	O
OLT	NNP	O
,	,	O
whereas	RB	O
10	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
continuous	JJ	O
aprotinin	JJ	O
infusion	NN	O
of	IN	O
0.1-0.4	JJ	O
Mill	NNP	O
.	.	O

KIU/hr	NNP	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
reperfusion	NN	O
of	IN	O
the	DT	O
graft	NN	Physical
liver	NN	Physical
,	,	Physical
signs	NNS	Physical
of	IN	Physical
hyperfibrinolysis	NN	Physical
,	,	O
measured	VBN	O
by	IN	O
thrombelastography	NN	O
,	,	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Tissue-type	JJ	Physical
plasminogen	NN	Physical
activator	NN	Physical
(	(	Physical
t-PA	JJ	Physical
)	)	Physical
activity	NN	Physical
increased	VBD	O
during	IN	O
the	DT	O
anhepatic	JJ	O
phase	NN	O
but	CC	O
to	TO	O
a	DT	O
significantly	RB	O
lesser	JJR	O
extent	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Blood	NNP	Physical
product	NN	Physical
requirements	NNS	Physical
during	IN	O
OLT	NNP	O
were	VBD	O
tendentiously	RB	O
higher	JJR	O
in	IN	O
the	DT	O
bolus	NN	O
group	NN	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
packed	JJ	Physical
red	JJ	Physical
blood	NN	Physical
cells	NNS	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
fresh	JJ	O
frozen	NN	O
plasma	NN	Others
requirements	NNS	Others
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
23	CD	O
patients	NNS	O
have	VBP	O
survived	VBN	Mortality
,	,	O
and	CC	O
only	RB	O
one	CD	O
woman	NN	O
of	IN	O
each	DT	O
group	NN	O
required	VBN	O
retransplantation	NN	Physical
due	JJ	O
to	TO	O
severe	VB	O
host-versus-graft	JJ	Physical
reactions	NNS	Physical
.	.	Physical

Furthermore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
perfusate	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
detected	JJ	O
signs	NNS	O
of	IN	O
a	DT	O
decreased	JJ	O
t-PA	JJ	Physical
release	NN	Physical
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
demonstrate	VBP	O
an	DT	O
advantage	NN	O
of	IN	O
aprotinin	NN	O
given	VBN	O
as	IN	O
continuous	JJ	O
infusion	NN	O
over	IN	O
bolus	JJ	O
application	NN	O
in	IN	O
OLT	NNP	O
.	.	O

Dexamethasone	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
authors	NNS	O
'	POS	O
goal	NN	O
was	VBD	O
to	TO	O
assess	VB	O
dexamethasone	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
.	.	O

METHOD	NNP	O
Thirty-seven	JJ	O
outpatients	NNS	O
(	(	O
11	CD	O
men	NNS	O
and	CC	O
26	CD	O
women	NNS	O
)	)	O
meeting	VBG	O
DSM-III-R	JJ	O
criteria	NNS	O
for	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
or	CC	O
4	CD	O
mg/day	NN	O
of	IN	O
oral	JJ	O
dexamethasone	NN	O
for	IN	O
4	CD	O
days	NNS	O
.	.	O

Baseline	NNP	O
Hamilton	NNP	Physical
depression	NN	Physical
scale	NN	Physical
scores	NNS	Physical
were	VBD	O
compared	VBN	O
with	IN	O
scores	NNS	O
obtained	VBN	O
14	CD	O
days	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
study	NN	O
medication	NN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
two-sample	JJ	O
t	NN	O
tests	NNS	O
,	,	O
chi-square	JJ	O
methods	NNS	O
,	,	O
and	CC	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

RESULTS	VB	O
Seven	NNP	O
(	(	O
37	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
19	CD	O
patients	NNS	O
given	VBN	O
dexamethasone	NN	O
but	CC	O
only	RB	O
one	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
18	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	O
responded	VBD	O
positively	RB	O
.	.	O

No	UH	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
or	CC	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
reported	VBN	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
who	WP	O
entered	VBD	O
the	DT	O
study	NN	O
completed	VBD	O
it	PRP	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
brief	JJ	O
course	NN	O
of	IN	O
oral	JJ	O
dexamethasone	NN	O
(	(	O
4	CD	O
days	NNS	O
)	)	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
within	IN	O
14	CD	O
days	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
depressed	JJ	O
outpatients	NNS	O
.	.	O

Symptomatic	JJ	O
treatment	NN	O
versus	NN	O
combination	NN	O
chemotherapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
non-small	NN	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
87	CD	O
patients	NNS	O
with	IN	O
inoperable	JJ	O
,	,	O
extensive	JJ	O
non-small	NN	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
combination	NN	O
chemotherapy	NN	O
(	(	O
cisplatin	NN	O
at	IN	O
70	CD	O
mg/m2	NN	O
intravenously	RB	O
[	NNP	O
i.v	NN	O
.	.	O

]	VB	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
etoposide	VB	O
at	IN	O
100	CD	O
mg/m2	NN	O
i.v	NN	O
.	.	O

on	IN	O
day	NN	O
1	CD	O
and	CC	O
200	CD	O
mg/m2	NNS	O
orally	RB	O
on	IN	O
days	NNS	O
2	CD	O
and	CC	O
3	CD	O
)	)	O
or	CC	O
symptomatic	JJ	O
treatment	NN	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
survival	JJ	Mortality
time	NN	Mortality
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
techniques	NNS	O
.	.	O

A	DT	O
major	JJ	O
problem	NN	O
in	IN	O
the	DT	O
interpretation	NN	O
of	IN	O
the	DT	O
results	NNS	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
semicurative	JJ	O
radiation	NN	O
therapy	NN	O
(	(	O
3000	CD	O
to	TO	O
4200	CD	O
cGy	NN	O
)	)	O
to	TO	O
the	DT	O
primary	JJ	O
tumor	NN	O
and	CC	O
mediastinum	NN	O
,	,	O
which	WDT	O
was	VBD	O
given	VBN	O
with	IN	O
symptomatic	JJ	O
intent	NN	O
.	.	O

Three	CD	Mortality
long-term	JJ	Mortality
survivors	NNS	Mortality
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
.	.	O

Valsartan	NNP	O
alone	RB	O
or	CC	O
with	IN	O
a	DT	O
diuretic	JJ	O
or	CC	O
ACE	NNP	O
inhibitor	NN	O
as	IN	O
treatment	NN	O
for	IN	O
African	JJ	O
American	JJ	O
hypertensives	NNS	O
:	:	O
relation	NN	O
to	TO	O
salt	VB	O
intake	NN	O
.	.	O

Previous	JJ	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
demonstrated	VBN	O
the	DT	O
important	JJ	O
influence	NN	O
of	IN	O
ethnicity	NN	O
and	CC	O
dietary	JJ	O
salt	NN	O
on	IN	O
the	DT	O
antihypertensive	JJ	O
efficacy	NN	O
of	IN	O
drugs	NNS	O
that	WDT	O
block	VBP	O
the	DT	O
renin	NN	O
angiotensin	NN	O
system	NN	O
.	.	O

Angiotensin	NNP	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
are	VBP	O
a	DT	O
new	JJ	O
therapeutic	JJ	O
entity	NN	O
that	WDT	O
have	VBP	O
not	RB	O
been	VBN	O
widely	RB	O
studied	VBN	O
in	IN	O
African	JJ	O
American	JJ	O
hypertensives	NNS	O
,	,	O
either	RB	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
therapies	NNS	O
such	JJ	O
as	IN	O
diuretics	NNS	O
or	CC	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitors	NNS	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
pilot	NN	O
,	,	O
prospective	JJ	O
,	,	O
open	JJ	O
label	NN	O
,	,	O
randomized	VBN	O
design	NN	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
valsartan	NN	O
(	(	O
160	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
on	IN	O
systolic	NN	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
in	IN	O
hypertensive	JJ	O
African	JJ	O
Americans	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
88	CD	O
)	)	O
on	IN	O
a	DT	O
low	JJ	O
salt	NN	O
(	(	O
100	CD	O
mEq	NNS	O
Na+/day	NNP	O
)	)	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
the	DT	O
same	JJ	O
diet	NN	O
supplemented	VBN	O
by	IN	O
100	CD	O
mEq	NNS	O
Na+	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

After	IN	O
this	DT	O
evaluation	NN	O
,	,	O
while	IN	O
continuing	VBG	O
the	DT	O
Na+	NNP	O
supplementation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
valsartan	VB	O
320	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
,	,	O
or	CC	O
the	DT	O
addition	NN	O
of	IN	O
hydrochlorothiazide	NN	O
(	(	O
HCTZ	NNP	O
)	)	O
12.5	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
,	,	O
or	CC	O
benazepril	VB	O
20	CD	O
mg/day	NN	O
to	TO	O
the	DT	O
valsartan	NN	O
160	CD	O
mg/day	NN	O
for	IN	O
an	DT	O
additional	JJ	O
6	CD	O
weeks	NNS	O
.	.	O

Valsartan	NNP	O
(	(	O
160	CD	O
mg/day	NN	O
)	)	O
lowered	VBD	O
blood	NN	Physical
pressure	NN	Physical
significantly	RB	O
in	IN	O
African	JJ	O
American	JJ	O
patients	NNS	O
on	IN	O
both	DT	O
low	JJ	O
salt	NN	O
(	(	O
-6.4/-4.8	JJ	O
mm	NN	O
Hg	NNP	O
:	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
a	DT	O
high	JJ	O
salt	NN	O
diet	NN	O
(	(	O
-4.9/-3.8	JJ	O
mm	NN	O
Hg	NNP	O
:	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

The	DT	O
high	JJ	O
salt	NN	O
diet	NN	O
attenuated	VBD	O
the	DT	O
antihypertensive	JJ	Physical
effect	NN	Physical
slightly	RB	O
(	(	O
1.6/1.3	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
three	CD	O
randomized	VBN	O
therapeutic	JJ	O
regimens	NNS	O
while	IN	O
on	IN	O
the	DT	O
Na+	NNP	O
supplement	NN	O
,	,	O
the	DT	O
valsartan	NN	O
160	CD	O
mg/HCTZ	NN	O
12.5	CD	O
mg	NN	O
was	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
therapy	NN	O
with	IN	O
an	DT	O
incremental	JJ	O
reduction	NN	O
in	IN	O
blood	NN	Physical
pressure	NN	Physical
of	IN	O
-10.5/-6.9	NNP	O
mm	FW	O
Hg	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
valsartan	VB	O
160	CD	O
mg/day	JJ	O
alone	RB	O
.	.	O

Doubling	VBG	O
the	DT	O
dose	NN	O
of	IN	O
valsartan	NN	O
to	TO	O
320	CD	O
mg	NNS	O
incrementally	RB	O
lowered	VBD	O
blood	NN	Physical
pressure	NN	Physical
by	IN	O
-3.8/-3.3	NNP	O
mm	NN	O
Hg	NNP	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
least	JJS	O
effective	JJ	O
approach	NN	O
was	VBD	O
adding	VBG	O
benazepril	RB	O
20	CD	O
mg/day	NN	O
to	TO	O
valsartan	VB	O
160	CD	O
mg/day	NN	O
with	IN	O
no	DT	O
incremental	JJ	O
reduction	NN	O
in	IN	O
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
reduction	NN	O
of	IN	O
only	RB	O
1.7	CD	O
mm	NNS	O
Hg	NNP	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
our	PRP$	O
open	JJ	O
label	NN	O
pilot	NN	O
study	NN	O
,	,	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
valsartan	NN	O
is	VBZ	O
not	RB	O
significantly	RB	O
attenuated	VBN	O
by	IN	O
supplemented	JJ	O
salt	NN	O
diet	NN	O
in	IN	O
hypertensive	JJ	O
African	JJ	O
Americans	NNPS	O
.	.	O

Moreover	RB	O
,	,	O
adding	VBG	O
a	DT	O
low	JJ	O
dose	NN	O
of	IN	O
HCTZ	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
strategy	NN	O
in	IN	O
enhancing	VBG	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
this	DT	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
in	IN	O
contrast	NN	O
to	TO	O
either	DT	O
doubling	VBG	O
the	DT	O
dose	NN	O
or	CC	O
adding	VBG	O
an	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
.	.	O

Prevention	NN	O
of	IN	O
subsequent	JJ	O
exercise-induced	JJ	Physical
periinfarct	NN	Physical
ischemia	NN	Physical
by	IN	O
emergency	NN	O
coronary	JJ	O
angioplasty	NN	O
in	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
comparison	NN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
emergency	NN	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
and	CC	O
intracoronary	JJ	O
streptokinase	NN	O
in	IN	O
preventing	VBG	O
exercise-induced	JJ	O
periinfarct	NN	O
ischemia	NN	O
,	,	O
28	CD	O
patients	NNS	O
presenting	VBG	O
within	IN	O
12	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
14	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
and	CC	O
14	CD	O
patients	NNS	O
received	VBD	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

Recatheterization	NN	O
and	CC	O
submaximal	JJ	O
exercise	NN	O
thallium-201	JJ	O
single	JJ	O
photon	NN	O
emission	NN	O
computed	VBD	O
tomography	NN	O
were	VBD	O
performed	VBN	O
before	IN	O
hospital	JJ	O
discharge	NN	O
.	.	O

Periinfarct	NNP	Physical
ischemia	NN	Physical
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reversible	JJ	O
thallium	NN	O
defect	NN	O
adjacent	NN	O
to	TO	O
a	DT	O
fixed	VBN	O
defect	NN	O
assessed	VBN	O
qualitatively	RB	O
.	.	O

Successful	JJ	Physical
reperfusion	NN	Physical
was	VBD	O
achieved	VBN	O
in	IN	O
86	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
and	CC	O
86	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
(	(	O
p	JJ	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Residual	JJ	Physical
stenosis	NN	Physical
of	IN	Physical
the	DT	Physical
infarct-related	JJ	Physical
coronary	JJ	Physical
artery	NN	Physical
shown	VBN	Physical
at	IN	Physical
predischarge	NN	Physical
angiography	NN	Physical
was	VBD	O
43.8	CD	O
+/-	JJ	O
31.4	CD	O
%	NN	O
for	IN	O
the	DT	O
angioplasty	JJ	O
group	NN	O
and	CC	O
75.0	CD	O
+/-	JJ	O
15.6	CD	O
%	NN	O
for	IN	O
the	DT	O
streptokinase	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
angioplasty	JJ	O
group	NN	O
,	,	O
9	CD	O
%	NN	O
developed	VBD	O
exercise-induced	JJ	Physical
periinfarct	NN	Physical
ischemia	NN	Physical
compared	VBN	O
with	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
streptokinase	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
had	VBD	O
significantly	RB	O
less	RBR	O
severe	JJ	Physical
residual	JJ	Physical
coronary	JJ	Physical
stenosis	NN	Physical
and	CC	O
exercise-induced	JJ	Physical
periinfarct	NN	Physical
ischemia	NN	Physical
than	IN	O
did	VBD	O
those	DT	O
treated	VBN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
further	JJ	O
application	NN	O
of	IN	O
coronary	JJ	O
angioplasty	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Development	NNP	O
of	IN	O
autistic	JJ	O
children	NNS	O
based	VBN	O
on	IN	O
maternal	JJ	O
responses	NNS	O
to	TO	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
.	.	O

BACKGROUND	NNP	O
language	NN	O
and	CC	O
speech-language	JJ	O
intervention	NN	O
.	.	O

AIM	NNP	O
to	TO	O
evaluate	VB	O
the	DT	O
development	NN	O
process	NN	O
of	IN	O
autistic	JJ	O
children	NNS	O
,	,	O
in	IN	O
a	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
context	NN	O
based	VBN	O
on	IN	O
the	DT	O
responses	NNS	O
of	IN	O
mothers	NNS	O
to	TO	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
.	.	O

METHOD	NNP	O
the	DT	O
research	NN	O
sample	NN	O
consisted	VBD	O
of	IN	O
11	CD	O
mothers	NNS	O
of	IN	O
children	NNS	O
diagnosed	VBN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
criteria	NNS	O
established	VBN	O
by	IN	O
the	DT	O
DSM	NNP	O
IVtr	NNP	O
(	(	O
APA	NNP	O
,	,	O
2002	CD	O
)	)	O
,	,	O
with	IN	O
autism	NN	O
(	(	O
six	CD	O
)	)	O
and	CC	O
with	IN	O
Asperger	NNP	O
Syndrome	NNP	O
(	(	O
five	CD	O
)	)	O
and	CC	O
who	WP	O
were	VBD	O
seen	VBN	O
at	IN	O
the	DT	O
Investigation	NNP	O
Laboratory	NNP	O
of	IN	O
Global	NNP	O
Developmental	NNP	O
Disorders	NNP	O
of	IN	O
the	DT	O
Federal	NNP	O
University	NNP	O
of	IN	O
S?o	NNP	O
Paulo	NNP	O
.	.	O

These	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
Six	CD	O
were	VBD	O
receiving	VBG	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
intervention	NN	O
(	(	O
TG	NNP	O
)	)	O
,	,	O
and	CC	O
five	CD	O
were	VBD	O
receiving	VBG	O
indirect	JJ	O
intervention	NN	O
exclusively	RB	O
(	(	O
OG	NNP	O
)	)	O
.	.	O

The	DT	O
Autism	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
(	(	O
Krug	NNP	O
et	RB	O
al.	RB	O
,	,	O
1993	CD	O
)	)	O
was	VBD	O
used	VBN	O
,	,	O
adapted	VBD	O
to	TO	O
the	DT	O
Portuguese	JJ	O
language	NN	O
by	IN	O
Marteleto	NNP	O
(	(	O
2003	CD	O
)	)	O
.	.	O

This	DT	O
behavior	JJ	O
checklist	NN	O
(	(	O
57	CD	O
items	NNS	O
)	)	O
allows	VBZ	O
the	DT	O
detailed	JJ	O
description	NN	O
of	IN	O
non-adaptable	JJ	O
characteristics	NNS	O
regarding	VBG	O
the	DT	O
following	JJ	O
areas	NNS	O
:	:	O
sensory	NN	Mental
,	,	Mental
use	NN	Mental
of	IN	Mental
the	DT	Mental
body	NN	Mental
and	CC	Mental
object	NN	Mental
,	,	Mental
Language	NNP	Mental
,	,	Mental
Psycho-social	NNP	Mental
and	CC	Mental
Relational	NNP	Mental
.	.	O

The	DT	O
questionnaire	NN	O
was	VBD	O
filled	VBN	O
in	IN	O
during	IN	O
an	DT	O
interview	NN	O
on	IN	O
three	CD	O
occasions	NNS	O
:	:	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
intervention	NN	O
,	,	O
after	IN	O
six	CD	O
months	NNS	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
12	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
after	IN	O
statistical	JJ	O
analysis	NN	O
it	PRP	O
was	VBD	O
observed	VBN	O
that	IN	O
there	EX	O
was	VBD	O
a	DT	O
greater	JJR	O
development	NN	O
in	IN	O
the	DT	O
total	JJ	O
scores	NNS	O
and	CC	O
in	IN	O
the	DT	O
areas	NNS	Mental
of	IN	Mental
language	NN	Mental
,	,	Mental
psycho-social	JJ	Mental
and	CC	Mental
relational	JJ	Mental
for	IN	O
the	DT	O
TG	NNP	O
.	.	O

This	DT	O
suggests	VBZ	O
a	DT	O
greater	JJR	O
development	NN	O
pattern	NN	O
during	IN	O
the	DT	O
studied	JJ	O
period	NN	O
for	IN	O
this	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
the	DT	O
mothers	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
observed	VBD	O
behavioral	JJ	O
changes	NNS	O
.	.	O

The	DT	O
better	JJR	O
scores	NNS	O
observed	VBD	O
for	IN	O
the	DT	O
TG	NNP	O
is	VBZ	O
probably	RB	O
related	VBN	O
to	TO	O
the	DT	O
effectiveness	NN	O
of	IN	O
direct	JJ	O
intervention	NN	O
,	,	O
and	CC	O
not	RB	O
to	TO	O
the	DT	O
lack	NN	O
of	IN	O
attention	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
OG	NNP	O
in	IN	O
recognizing	VBG	O
behavioral	JJ	O
changes	NNS	O
in	IN	O
their	PRP$	O
children	NNS	O
.	.	O

Effect	NN	O
of	IN	O
soy	NN	O
protein	NN	O
containing	VBG	O
isoflavones	NNS	O
on	IN	O
blood	NN	Physical
lipids	NNS	Physical
in	IN	O
moderately	RB	O
hypercholesterolemic	JJ	O
adults	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dietary	NNP	O
intake	NN	O
of	IN	O
soy	JJ	O
protein	NN	O
with	IN	O
isoflavones	NNS	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
serum	NN	O
cholesterol	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
water-washed	JJ	O
soy	NN	O
protein	NN	O
concentrate	NN	O
with	IN	O
a	DT	O
milk-protein	JJ	O
based	VBN	O
control	NN	O
on	IN	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
hyperlipidemic	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

METHODS	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
including	VBG	O
159	CD	O
subjects	NNS	O
.	.	O

After	IN	O
a	DT	O
3-week	JJ	O
run-in	JJ	O
period	NN	O
during	IN	O
which	WDT	O
all	DT	O
subjects	NNS	O
consumed	VBD	O
a	DT	O
milk	NN	O
protein-based	JJ	O
supplement	NN	O
,	,	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
continued	VBN	O
milk	NN	O
protein	NN	O
)	)	O
and	CC	O
an	DT	O
intervention	NN	O
group	NN	O
(	(	O
soy	JJ	O
protein	NN	O
)	)	O
for	IN	O
a	DT	O
five-week	JJ	O
period	NN	O
.	.	O

Fasting	VBG	O
venous	JJ	O
blood	NN	O
draws	NN	O
for	IN	O
lipid	JJ	O
measurement	NN	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
towards	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

Blood	NNP	Physical
isoflavone	NN	Physical
concentrations	NNS	Physical
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
Blood	NNP	Physical
lipid	JJ	Physical
levels	NNS	Physical
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
at	IN	O
any	DT	O
point	NN	O
in	IN	O
time	NN	O
;	:	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
associations	NNS	O
between	IN	O
blood	NN	Physical
isoflavones	NNS	Physical
and	CC	O
lipid	JJ	Physical
levels	NNS	Physical
.	.	O

Significant	JJ	O
decreases	NNS	Others
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
(	(	O
19	CD	O
mg/dL	NN	O
)	)	O
,	,	O
and	CC	O
LDL-cholesterol	NNP	Physical
(	(	O
11	CD	O
mg/dL	NN	O
)	)	O
,	,	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
,	,	O
with	IN	O
no	DT	O
further	JJ	O
decreases	NNS	O
in	IN	O
lipids	NNS	O
during	IN	O
the	DT	O
intervention	NN	O
period	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
water-washed	JJ	O
soy	NN	O
protein	NN	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
blood	NN	Physical
lipids	NNS	Physical
.	.	O

Several	JJ	O
hypotheses	NNS	O
are	VBP	O
discussed	VBN	O
,	,	O
highlighting	VBG	O
the	DT	O
selective	JJ	O
nature	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
soy	NN	O
consumption	NN	O
in	IN	O
the	DT	O
population	NN	O
.	.	O

The	DT	O
cholesterol-lowering	JJ	O
effect	NN	O
during	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
may	MD	O
be	VB	O
explained	VBN	O
by	IN	O
the	DT	O
regression	NN	O
to	TO	O
the	DT	O
mean	JJ	O
effect	NN	O
and	CC	O
by	IN	O
other	JJ	O
factors	NNS	O
related	VBN	O
to	TO	O
study	VB	O
participation	NN	O
,	,	O
mainly	RB	O
nutrient	JJ	O
displacement	NN	O
induced	VBN	O
by	IN	O
the	DT	O
protein	NN	O
supplement	NN	O
.	.	O

Different	JJ	O
cardiac	JJ	O
biomarkers	NNS	O
to	TO	O
detect	VB	O
peri-procedural	JJ	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
contemporary	JJ	O
coronary	JJ	O
stent	NN	O
trials	NNS	O
:	:	O
impact	NN	O
on	IN	O
outcome	NN	O
reporting	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
differential	JJ	O
implications	NNS	O
of	IN	O
cardiac	JJ	O
biomarker	NN	O
type	NN	O
on	IN	O
peri-procedural	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
PMI	NNP	O
)	)	O
reporting	NN	O
.	.	O

SETTING	CC	O
The	DT	O
Resolute	NNP	O
'All-Comers	NNS	O
'	POS	O
stent	JJ	O
trial	NN	O
.	.	O

INTERVENTIONS	NNP	O
Blood	NNP	O
samples	NNS	O
for	IN	O
creatine	NN	O
kinase	NN	O
(	(	O
CK	NNP	O
)	)	O
,	,	O
CK-myoband	NNP	O
(	(	O
CK-MB	NNP	O
)	)	O
mass	NN	O
or	CC	O
cardiac	JJ	O
troponin	NN	O
(	(	O
cTn	NN	O
)	)	O
(	(	O
optional	JJ	O
)	)	O
were	VBD	O
collected	VBN	O
before	RB	O
and	CC	O
at	IN	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
18	CD	O
h	NN	O
after	IN	O
the	DT	O
assigned	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
or	CC	O
at	IN	O
discharge	NN	O
.	.	O

PMIs	NNP	O
were	VBD	O
adjudicated	VBN	O
using	VBG	O
either	CC	O
the	DT	O
2007	CD	O
universal	JJ	O
definition	NN	O
of	IN	O
MI	NNP	O
(	(	O
type-4a	JJ	O
)	)	O
or	CC	O
the	DT	O
extended	JJ	O
historical	JJ	O
definition	NN	O
of	IN	O
MI	NNP	O
.	.	O

PATIENTS	NNP	O
2121/2292	CD	O
patients	NNS	O
(	(	O
92.5	CD	O
%	NN	O
)	)	O
had	VBD	O
an	DT	O
analysable	JJ	O
dataset	NN	O
for	IN	O
either	DT	O
biomarker	NN	O
.	.	O

890/2121	CD	O
patients	NNS	O
(	(	O
42	CD	O
%	NN	O
)	)	O
presented	VBN	O
with	IN	O
an	DT	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
(	(	O
ACS	NNP	O
)	)	O
.	.	O

267/890	CD	O
patients	NNS	O
(	(	O
30	CD	O
%	NN	O
)	)	O
were	VBD	O
within	IN	O
24	CD	O
h	NN	O
of	IN	O
an	DT	O
ST-segment	JJ	O
elevation	NN	O
MI	NNP	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Type-4a	NNP	Physical
MI	NNP	Physical
was	VBD	O
diagnosed	VBN	O
in	IN	O
208/2121	CD	O
patients	NNS	O
(	(	O
9.8	CD	O
%	NN	O
)	)	O
when	WRB	O
cTn	NN	O
was	VBD	O
used	VBN	O
(	(	O
CK-MB	JJ	O
mass	NN	O
if	IN	O
cTn	NN	O
not	RB	O
available	JJ	O
)	)	O
,	,	O
and	CC	O
in	IN	O
93/2121	CD	O
of	IN	O
patients	NNS	O
(	(	O
4.4	CD	O
%	NN	O
)	)	O
when	WRB	O
CK-MB	JJ	O
mass	NN	O
was	VBD	O
used	VBN	O
(	(	O
cTn	JJ	O
if	IN	O
CK-MB	NNP	O
mass	NN	O
not	RB	O
available	JJ	O
)	)	O
.	.	O

With	IN	O
the	DT	O
extended	JJ	O
historical	JJ	O
CK-based	JJ	O
definition	NN	O
of	IN	O
MI	NNP	O
,	,	O
PMI	NNP	Physical
was	VBD	O
diagnosed	VBN	O
in	IN	O
65/2121	CD	O
patients	NNS	O
(	(	O
3.1	CD	O
%	NN	O
)	)	O
.	.	O

Adjudication	NN	O
of	IN	O
type-4a	JJ	Physical
MI	NNP	Physical
in	IN	O
patients	NNS	O
with	IN	O
an	DT	O
ACS	NNP	O
was	VBD	O
problematic	JJ	O
with	IN	O
<	JJ	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
potential	JJ	O
type-4a	NN	O
MI	NNP	O
being	VBG	O
confirmed	VBN	O
as	IN	O
an	DT	O
event	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
approximately	RB	O
95	CD	O
%	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

Type-4a	NNP	O
MI	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
the	DT	O
subsequent	JJ	O
hazard	NN	O
for	IN	O
cardiac	JJ	Mortality
mortality	NN	Mortality
(	(	O
p=0.6	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
percentage	NN	O
of	IN	O
adjudicated	JJ	O
PMI	NNP	Physical
events	NNS	Physical
is	VBZ	O
driven	VBN	O
by	IN	O
the	DT	O
MI-definition	NNP	O
criteria	NNS	O
and	CC	O
biomarker	NN	O
type	NN	O
.	.	O

Type-4a	JJ	O
MI	NNP	O
may	MD	O
not	RB	O
be	VB	O
a	DT	O
reliable	JJ	O
component	NN	O
of	IN	O
the	DT	O
primary	JJ	O
composite	JJ	O
end	NN	O
point	NN	O
in	IN	O
coronary	JJ	O
stent	NN	O
investigations	NNS	O
which	WDT	O
recruit	VBP	O
patients	NNS	O
with	IN	O
ACS	NNP	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
http	NN	O
:	:	O
//www.ClinicalTrials.gov	NN	O
;	:	O
Unique	NNP	O
identifier	NN	O
:	:	O
NCT00617084	NNP	O
.	.	O

Combined	VBN	O
descriptive	JJ	O
and	CC	O
explanatory	JJ	O
information	NN	O
improves	VBZ	O
peers	NNS	Mental
'	POS	Mental
perceptions	NNS	Mental
of	IN	Mental
autism	NN	Mental
.	.	O

Authors	NNS	O
examined	VBD	O
the	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
descriptive	JJ	O
and	CC	O
explanatory	JJ	O
information	NN	O
on	IN	O
peers	NNS	Mental
'	POS	Mental
perceptions	NNS	Mental
and	CC	Mental
behavioral	JJ	Mental
intentions	NNS	Mental
toward	IN	O
an	DT	O
unfamiliar	JJ	O
child	NN	O
with	IN	O
autism	NN	O
.	.	O

Children	NNP	O
(	(	O
N	NNP	O
=	NNP	O
576	CD	O
;	:	O
M	NNP	O
age	NN	O
=	VBD	O
10.06	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
view	VB	O
two	CD	O
videotapes	NNS	O
of	IN	O
a	DT	O
boy	NN	O
engaging	VBG	O
in	IN	O
typical	JJ	O
and	CC	O
autistic	JJ	O
behaviors	NNS	O
receiving	VBG	O
either	RB	O
descriptive	JJ	O
(	(	O
AUT-D	NNP	O
)	)	O
or	CC	O
descriptive	JJ	O
and	CC	O
explanatory	JJ	O
information	NN	O
(	(	O
AUT-D	NNP	O
+	NNP	O
E	NNP	O
)	)	O
.	.	O

Children	NNP	O
responded	VBD	O
to	TO	O
measures	NNS	O
of	IN	O
attitudes	NNS	O
(	(	O
Adjective	NNP	Mental
Checklist	NNP	Mental
)	)	O
and	CC	O
behavioral	JJ	O
intentions	NNS	O
(	(	O
Shared	NNP	Mental
Activities	NNP	Mental
Questionnaire	NNP	Mental
)	)	O
.	.	O

Children	NNP	O
rated	VBD	O
the	DT	O
typical	JJ	O
boy	NN	O
more	RBR	O
favorably	RB	O
than	IN	O
the	DT	O
boy	NN	O
showing	VBG	O
autistic	JJ	O
symptoms	NNS	O
.	.	O

When	WRB	O
compared	VBN	O
to	TO	O
descriptive	VB	O
information	NN	O
alone	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
descriptive	JJ	O
and	CC	O
explanatory	JJ	O
information	NN	O
resulted	VBD	O
in	IN	O
improved	JJ	O
third-	JJ	O
and	CC	O
fourth-graders	NNS	O
'	''	O
but	CC	O
not	RB	O
fifth-graders	NNS	O
'	POS	O
attitudes	NNS	O
toward	IN	O
the	DT	O
child	NN	O
with	IN	O
autism	NN	O
.	.	O

Combined	VBN	O
information	NN	O
improved	VBN	O
behavioral	JJ	O
intentions	NNS	O
across	IN	O
grades	NNS	O
;	:	O
however	RB	O
,	,	O
girls	NNS	O
(	(	O
vs.	FW	O
boys	NNS	O
)	)	O
were	VBD	O
more	RBR	O
responsive	JJ	Mental
to	TO	Mental
information	NN	Mental
as	IN	O
evidenced	VBN	O
by	IN	O
differences	NNS	O
in	IN	O
academic	JJ	O
intentions	NNS	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
descriptive	JJ	O
and	CC	O
explanatory	JJ	O
information	NN	O
about	IN	O
autism	NN	O
appears	VBZ	O
to	TO	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
children	NNS	Mental
's	POS	Mental
attitudes	NNS	Mental
and	CC	Mental
behavioral	JJ	Mental
intentions	NNS	Mental
.	.	O

Implications	NNS	O
of	IN	O
the	DT	O
findings	NNS	O
are	VBP	O
briefly	RB	O
discussed	VBN	O
as	RB	O
well	RB	O
as	IN	O
study	NN	O
limitations	NNS	O
and	CC	O
recommendations	NNS	O
for	IN	O
future	JJ	O
research	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
amantadine	JJ	O
hydrochloride	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
amantadine	JJ	O
hydrochloride	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
treatment	NN	O
for	IN	O
behavioral	JJ	Mental
disturbances	NNS	Mental
--	:	O
for	IN	O
example	NN	O
,	,	O
hyperactivity	NN	Mental
and	CC	Mental
irritability	NN	Mental
--	:	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Thirty-nine	JJ	O
subjects	NNS	O
(	(	O
intent	NN	O
to	TO	O
treat	VB	O
;	:	O
5-19	CD	O
years	NNS	O
old	JJ	O
;	:	O
IQ	NNP	O
>	NNP	O
35	CD	O
)	)	O
had	VBD	O
autism	NN	O
diagnosed	VBN	O
according	VBG	O
to	TO	O
DSM-IV	NNP	O
and	CC	O
ICD-10	NNP	O
criteria	NNS	O
using	VBG	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Interview-Revised	JJ	O
and	CC	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule-Generic	NNP	O
.	.	O

The	DT	O
Aberrant	JJ	Mental
Behavior	NNP	Mental
Checklist-Community	NNP	Mental
Version	NNP	Mental
(	(	Mental
ABC-CV	NNP	Mental
)	)	Mental
and	CC	Mental
Clinical	JJ	Mental
Global	NNP	Mental
Impressions	NNP	Mental
(	(	Mental
CGI	NNP	Mental
)	)	Mental
scale	NN	O
were	VBD	O
used	VBN	O
as	IN	O
outcome	JJ	O
variables	NNS	O
.	.	O

After	IN	O
a	DT	O
1-week	JJ	O
,	,	O
single-blind	JJ	O
placebo	NN	O
run-in	NN	O
,	,	O
patients	NNS	O
received	VBD	O
a	DT	O
single	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
amantadine	NN	O
(	(	O
2.5	CD	O
mg/kg	NNS	O
per	IN	O
day	NN	O
)	)	O
or	CC	O
placebo	NN	O
for	IN	O
the	DT	O
next	JJ	O
week	NN	O
,	,	O
and	CC	O
then	RB	O
bid	VB	O
dosing	VBG	O
(	(	O
5.0	CD	O
mg/kg	NNS	O
per	IN	O
day	NN	O
)	)	O
for	IN	O
the	DT	O
subsequent	JJ	O
3	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
When	WRB	O
assessed	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
parent-rated	JJ	O
ABC-CV	NNP	O
ratings	NNS	O
of	IN	O
irritability	NN	Mental
and	CC	O
hyperactivity	NN	Mental
,	,	O
the	DT	O
mean	JJ	O
placebo	NN	O
response	NN	O
rate	NN	O
was	VBD	O
37	CD	O
%	NN	O
versus	NN	O
amantadine	NN	O
at	IN	O
47	CD	O
%	NN	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
amantadine-treated	JJ	O
group	NN	O
there	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
absolute	JJ	O
changes	NNS	O
in	IN	O
clinician-rated	JJ	O
ABC-CVs	NNP	O
for	IN	O
hyperactivity	NN	Mental
(	(	O
amantadine	JJ	O
-6.4	NNP	O
versus	NN	O
placebo	NN	O
-2.1	NNP	O
;	:	O
p	CC	O
=	NNP	O
.046	NNP	O
)	)	O
and	CC	O
inappropriate	JJ	Mental
speech	NN	Mental
(	(	O
-1.9	JJ	O
versus	NN	O
0.4	CD	O
;	:	O
p	NN	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

CGI	NNP	Mental
scale	JJ	Mental
ratings	NNS	Mental
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
:	:	O
53	CD	O
%	NN	O
improved	JJ	O
versus	NN	O
25	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
.076	NNP	O
)	)	O
.	.	O

Amantadine	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Parents	NNPS	O
did	VBD	O
not	RB	O
report	VB	O
statistically	RB	O
significant	JJ	O
behavioral	JJ	Mental
change	NN	Mental
with	IN	O
amantadine	NN	O
.	.	O

However	RB	O
,	,	O
clinician-rated	JJ	O
improvements	NNS	O
in	IN	O
behavioral	JJ	Mental
ratings	NNS	Mental
following	VBG	O
treatment	NN	O
with	IN	O
amantadine	JJ	O
suggest	VBP	O
that	IN	O
further	JJ	O
studies	NNS	O
with	IN	O
this	DT	O
or	CC	O
other	JJ	O
drugs	NNS	O
acting	VBG	O
on	IN	O
the	DT	O
glutamatergic	NN	O
system	NN	O
are	VBP	O
warranted	VBN	O
.	.	O

The	DT	O
design	NN	O
of	IN	O
these	DT	O
and	CC	O
similar	JJ	O
drug	NN	O
trials	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
must	MD	O
take	VB	O
into	IN	O
account	NN	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
large	JJ	O
placebo	NN	O
response	NN	O
.	.	O

A	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
three	CD	O
drainage	NN	O
systems	NNS	O
following	VBG	O
cholecystectomy	NN	O
.	.	O

The	DT	O
efficacy	NN	Others
of	IN	O
low	JJ	O
pressure	NN	O
,	,	O
high	JJ	O
pressure	NN	O
and	CC	O
passive	JJ	O
drainage	NN	O
systems	NNS	O
have	VBP	O
been	VBN	O
compared	VBN	O
after	IN	O
cholecystectomy	NN	O
.	.	O

Symptoms	NNS	Pain
of	IN	Pain
pain	NN	Pain
,	,	Physical
discomfort	NN	Adverseeffect
and	CC	Adverseeffect
nausea	NN	Adverseeffect
were	VBD	O
compared	VBN	O
using	VBG	O
linear	JJ	O
analogue	NN	O
scales	NNS	O
and	CC	O
spirometry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
pre-operative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	Physical
function	NN	Physical
.	.	Physical

The	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
removed	VBD	O
an	DT	O
intraperitoneal	NN	Physical
marker	NN	Physical
,	,	Physical
gentamicin	NN	Physical
,	,	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
high	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
,	,	O
but	CC	O
not	RB	O
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
passive	JJ	O
drain	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
postoperative	JJ	Physical
respiratory	NN	Physical
function	NN	Physical
nor	CC	O
in	IN	O
the	DT	O
amount	NN	Pain
of	IN	Pain
pain	NN	Pain
or	CC	Pain
discomfort	NN	Pain
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
passive	JJ	O
drain	NN	O
group	NN	O
reported	VBD	O
less	JJR	O
nausea	NN	Physical
than	IN	O
the	DT	O
suction	NN	O
drain	NN	O
groups	NNS	O
.	.	O

If	IN	O
a	DT	O
negative	JJ	O
pressure	NN	O
drainage	NN	O
system	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
a	DT	O
low	JJ	O
pressure	NN	O
suction	NN	O
drain	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
a	DT	O
high	JJ	O
pressure	NN	O
system	NN	O
.	.	O

Ongoing	VBG	O
Telmisartan	NNP	O
Alone	NNP	O
and	CC	O
in	IN	O
Combination	NNP	O
With	IN	O
Ramipril	NNP	O
Global	NNP	O
Endpoint	NNP	O
Trial	NNP	O
(	(	O
ONTARGET	NNP	O
)	)	O
:	:	O
implications	NNS	O
for	IN	O
reduced	JJ	O
cardiovascular	JJ	Physical
risk	NN	Physical
.	.	O

The	DT	O
recently	RB	O
published	VBN	O
Ongoing	NNP	O
Telmisartan	NNP	O
Alone	NNP	O
and	CC	O
in	IN	O
Combination	NNP	O
With	IN	O
Ramipril	NNP	O
Global	NNP	O
Endpoint	NNP	O
Trial	NNP	O
(	(	O
ONTARGET	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
high-risk	JJ	O
diabetes	NNS	O
,	,	O
as	IN	O
the	DT	O
largest	JJS	O
published	VBN	O
comparative	JJ	O
trial	NN	O
of	IN	O
these	DT	O
agent	NN	O
classes	NNS	O
,	,	O
provides	VBZ	O
further	JJ	O
evidence	NN	O
concerning	VBG	O
the	DT	O
comparison	NN	O
between	IN	O
the	DT	O
angiotensin-receptor	NN	O
blockers	NNS	O
(	(	O
ARBs	NNP	O
)	)	O
and	CC	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
(	(	O
ACEIs	NNP	O
)	)	O
.	.	O

In	IN	O
this	DT	O
trial	NN	O
,	,	O
telmisartan	NN	O
(	(	O
an	DT	O
ARB	NNP	O
)	)	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
ramipril	VB	O
(	(	O
an	DT	O
ACEI	NNP	O
)	)	O
in	IN	O
reducing	VBG	O
fatal	JJ	Physical
and	CC	Physical
nonfatal	JJ	Physical
cardiovascular	JJ	Physical
events	NNS	Physical
.	.	O

Moreover	RB	O
,	,	O
ONTARGET	NNP	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
high-quality	JJ	O
noninferiority	NN	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
the	DT	O
2	CD	O
agents	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
more	JJR	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
benefit	NN	O
.	.	O

The	DT	O
study	NN	O
differed	VBD	O
from	IN	O
several	JJ	O
other	JJ	O
comparative	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
dose	NN	O
and	CC	O
choice	NN	O
of	IN	O
ACEI	NNP	O
was	VBD	O
left	VBN	O
to	TO	O
individual	JJ	O
physicians	NNS	O
.	.	O

Further	NNP	O
,	,	O
in	IN	O
ONTARGET	NNP	O
,	,	O
the	DT	O
ACEI	NNP	O
was	VBD	O
not	RB	O
titrated	VBN	O
to	TO	O
the	DT	O
maximum	JJ	O
dose	NN	O
and	CC	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Effect	NN	O
of	IN	O
perioperative	JJ	O
parecoxib	NN	O
on	IN	O
postoperative	JJ	Pain
pain	NN	Pain
and	CC	Pain
local	JJ	Pain
inflammation	NN	Pain
factors	NNS	O
PGE2	NNP	O
and	CC	O
IL-6	NNP	O
for	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
postoperative	JJ	O
pain	NN	O
management	NN	O
and	CC	O
the	DT	O
concentration	NN	O
change	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
with	IN	O
parecoxib	NN	O
after	IN	O
postoperative	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
,	,	O
100	CD	O
patients	NNS	O
experiencing	VBG	O
primary	JJ	O
TKA	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
study	NN	O
group	NN	O
,	,	O
receiving	VBG	O
parecoxib	NN	O
sodium	NN	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
at	IN	O
the	DT	O
completion	NN	O
of	IN	O
surgery	NN	O
and	CC	O
once	RB	O
every	DT	O
12	CD	O
h	NN	O
for	IN	O
totally	RB	O
6	CD	O
times	NNS	O
postoperatively	RB	O
,	,	O
and	CC	O
placebo	NN	O
group	NN	O
,	,	O
receiving	VBG	O
normal	JJ	O
saline	JJ	O
2	CD	O
mL	NN	O
IV	NNP	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
points	NNS	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
total	JJ	O
amount	NN	O
of	IN	O
morphine	NN	O
consumed	VBN	O
,	,	O
pain	VBP	O
intensity	NN	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
the	DT	O
concentration	NN	O
change	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
postoperatively	RB	O
.	.	O

Patients	NNS	O
in	IN	O
study	NN	O
group	NN	O
consumed	VBD	O
significantly	RB	O
less	JJR	O
morphine	NN	O
,	,	O
experienced	VBD	O
significant	JJ	O
less	JJR	O
pain	NN	O
scores	NNS	O
,	,	O
and	CC	O
obtained	VBD	O
significantly	RB	O
more	RBR	O
ROM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
placebo	NN	O
group	NN	O
during	IN	O
3	CD	O
days	NNS	O
postoperatively	RB	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
in	IN	O
study	NN	O
group	NN	O
are	VBP	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
during	IN	O
24	CD	O
h	NNS	O
postoperatively	RB	O
.	.	O

The	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
PONV	NNP	O
was	VBD	O
low	JJ	O
and	CC	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
the	DT	O
perioperative	JJ	O
administration	NN	O
of	IN	O
parecoxib	NN	O
after	IN	O
primary	JJ	O
TKA	NNP	O
resulted	VBD	O
in	IN	O
significantly	RB	O
improved	VBN	O
postoperative	JJ	O
analgesic	JJ	O
management	NN	O
as	IN	O
defined	VBN	O
by	IN	O
reduction	NN	O
in	IN	O
opioid	JJ	O
requirement	NN	O
,	,	O
lower	JJR	O
pain	NN	O
scores	NNS	O
and	CC	O
ROM	NNP	O
,	,	O
and	CC	O
significantly	RB	O
lowered	VBD	O
local	JJ	O
inflammation	NN	O
factors	NNS	O
PGE2	NNP	O
and	CC	O
IL-6	NNP	O
.	.	O

Safety	NN	O
of	IN	O
an	DT	O
astaxanthin-rich	JJ	O
Haematococcus	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

A	DT	O
growing	VBG	O
body	NN	O
of	IN	O
scientific	JJ	O
literature	NN	O
indicates	VBZ	O
that	IN	O
astaxanthin	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
powerful	JJ	O
antioxidant	JJ	O
than	IN	O
other	JJ	O
carotenoids	NNS	O
and	CC	O
vitamin	NN	O
E	NNP	O
and	CC	O
may	MD	O
confer	VB	O
numerous	JJ	O
health	NN	O
benefits	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
conduct	VB	O
a	DT	O
human	JJ	O
safety	NN	O
study	NN	O
with	IN	O
a	DT	O
Haematococcus	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
astaxanthin	NN	O
.	.	O

Thirty-five	JJ	O
healthy	JJ	O
adults	NNS	O
age	NN	O
35-69	CD	O
years	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
'	POS	O
duration	NN	O
.	.	O

All	DT	O
participants	NNS	O
took	VBD	O
three	CD	O
gelcaps	NNS	O
per	IN	O
day	NN	O
,	,	O
one	CD	O
at	IN	O
each	DT	O
meal	NN	O
.	.	O

Nineteen	JJ	O
participants	NNS	O
received	VBD	O
gelcaps	NNS	O
with	IN	O
an	DT	O
algal	JJ	O
extract	NN	O
in	IN	O
safflower	JJR	O
oil	NN	O
,	,	O
containing	VBG	O
2	CD	O
mg	NN	O
of	IN	O
astaxanthin	JJ	O
each	DT	O
(	(	O
treatment	NN	O
)	)	O
;	:	O
16	CD	O
participants	NNS	O
received	VBD	O
gelcaps	NNS	O
containing	VBG	O
safflower	NN	O
oil	NN	O
only	RB	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
,	,	O
including	VBG	O
a	DT	O
comprehensive	JJ	O
metabolic	JJ	O
panel	NN	O
and	CC	O
cell	NN	O
blood	NN	O
count	NN	O
,	,	O
were	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
trial	NN	O
and	CC	O
after	IN	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
of	IN	O
supplementation	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
the	DT	O
placebo	NN	O
groups	NNS	O
after	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
supplementation	NN	O
with	IN	O
the	DT	O
algal	JJ	O
extract	NN	O
in	IN	O
the	DT	O
parameters	NNS	O
analyzed	VBD	O
,	,	O
except	IN	O
for	IN	O
serum	NN	Physical
calcium	NN	Physical
,	,	Physical
total	JJ	Physical
protein	NN	Physical
,	,	Physical
and	CC	Physical
eosinophils	NNS	Physical
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
differences	NNS	O
in	IN	O
these	DT	O
three	CD	O
parameters	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
,	,	O
they	PRP	O
were	VBD	O
very	RB	O
small	JJ	O
and	CC	O
are	VBP	O
of	IN	O
no	DT	O
clinical	JJ	O
importance	NN	O
.	.	O

These	DT	O
results	NNS	O
reveal	VBP	O
that	IN	O
6	CD	O
mg	NN	O
of	IN	O
astaxanthin	JJ	O
per	IN	O
day	NN	O
from	IN	O
a	DT	O
H.	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
can	MD	O
be	VB	O
safely	RB	Others
consumed	VBN	O
by	IN	O
healthy	JJ	O
adults	NNS	O
.	.	O

Modified	VBN	O
constraint-induced	JJ	O
movement	NN	O
therapy	NN	O
improved	VBD	O
upper	JJ	O
limb	NN	O
function	NN	O
in	IN	O
subacute	JJ	O
poststroke	NN	O
patients	NNS	O
:	:	O
a	DT	O
small-scale	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Constraint-induced	JJ	O
movement	NN	O
therapy	NN	O
(	(	O
CIMT	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
facilitating	VBG	O
motor	NN	O
function	NN	O
in	IN	O
poststroke	NN	O
patients	NNS	O
;	:	O
however	RB	O
,	,	O
the	DT	O
evidence	NN	O
for	IN	O
its	PRP$	O
efficacy	NN	O
is	VBZ	O
controversial	JJ	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
modified	VBN	O
CIMT	NNP	O
on	IN	O
improving	VBG	O
paretic	JJ	O
arm	NN	O
function	NN	O
in	IN	O
poststroke	NN	O
patients	NNS	O
during	IN	O
a	DT	O
subacute	JJ	O
rehabilitation	NN	O
period	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-blinded	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Loewenstein	NNP	O
Rehabilitation	NNP	O
Hospital	NNP	O
,	,	O
Israel	NNP	O
.	.	O

Twenty-eight	NNP	O
subacute	JJ	O
stroke	VBD	O
patients	NNS	O
with	IN	O
arm	JJ	O
paresis	NN	O
after	IN	O
a	DT	O
first	JJ	O
ischemic	JJ	O
stroke	NN	O
in	IN	O
the	DT	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
area	NN	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
modified	JJ	O
CIMT	NNP	O
or	CC	O
control	VB	O
group	NN	O
by	IN	O
a	DT	O
1:2	CD	O
ratio	NN	O
.	.	O

The	DT	O
modified	JJ	O
CIMT	NNP	O
group	NN	O
received	VBD	O
1-hour	JJ	O
daily	JJ	O
physical	JJ	O
rehabilitation	NN	O
sessions	NNS	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
unaffected	JJ	O
arm	NN	O
was	VBD	O
restrained	VBN	O
during	IN	O
the	DT	O
sessions	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
encouraged	VBN	O
to	TO	O
wear	VB	O
a	DT	O
restrictive	NN	O
mitten	VBZ	O
up	RP	O
to	TO	O
4	CD	O
hours	NNS	O
a	DT	O
day	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
similar	JJ	O
intensive	JJ	O
regular	JJ	O
rehabilitation	NN	O
.	.	O

Three	CD	O
upper	JJ	O
limb	NN	O
function	NN	O
tests	NNS	O
,	,	O
developed	VBD	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
were	VBD	O
used	VBN	O
as	IN	O
outcome	JJ	O
measures	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
the	DT	O
following	JJ	O
tasks	NNS	O
,	,	O
with	IN	O
the	DT	O
affected	JJ	O
hand	NN	O
for	IN	O
30	CD	O
seconds	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
transfer	NN	O
pegs	NN	O
from	IN	O
a	DT	O
saucer	NN	O
to	TO	O
a	DT	O
pegboard	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
grasp	NN	O
,	,	O
carry	NN	O
,	,	O
and	CC	O
release	VB	O
a	DT	O
hard	JJ	O
rubber	NN	O
ball	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
eating	NN	O
,	,	O
using	VBG	O
a	DT	O
spoon	NN	O
to	TO	O
remove	VB	O
the	DT	O
jelly	NN	O
from	IN	O
the	DT	O
plate	NN	O
,	,	O
bring	VBG	O
it	PRP	O
towards	IN	O
the	DT	O
mouth	NN	O
,	,	O
and	CC	O
then	RB	O
place	VB	O
it	PRP	O
on	IN	O
another	DT	O
plate	NN	O
.	.	O

The	DT	Others
number	NN	Others
of	IN	Others
repetitions	NNS	Others
in	IN	Others
each	DT	Others
test	NN	Others
was	VBD	O
recorded	VBN	O
as	IN	O
an	DT	O
outcome	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
modified	JJ	O
CIMT	NNP	O
group	NN	O
showed	VBD	O
significantly	RB	O
higher	JJR	O
changes	NNS	O
in	IN	O
all	DT	O
3	CD	O
tests	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
standard	JJ	O
rehabilitation	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
study	NN	O
provides	VBZ	O
additional	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
modified	JJ	O
CIMT	NNP	O
during	IN	O
a	DT	O
subacute	JJ	O
rehabilitation	NN	O
period	NN	O
of	IN	O
poststroke	NN	O
patients	NNS	O
.	.	O

CIMT	NNP	O
may	MD	O
facilitate	VB	O
functional	JJ	O
improvement	NN	O
of	IN	O
a	DT	O
plegic	JJ	O
hand	NN	O
.	.	O

[	JJ	O
Results	NNP	O
of	IN	O
a	DT	O
cooperative	JJ	O
prospective	JJ	O
study	NN	O
of	IN	O
treatment	NN	O
of	IN	O
primary	JJ	O
digestive	JJ	O
localizations	NNS	O
of	IN	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
]	NN	O
.	.	O

We	PRP	O
report	VBP	O
the	DT	O
results	NNS	O
of	IN	O
chemotherapy	JJ	O
treatment	NN	O
in	IN	O
82	CD	O
patients	NNS	O
presenting	VBG	O
with	IN	O
primary	JJ	O
digestive	JJ	O
lymphoma	NN	O
and	CC	O
included	VBD	O
in	IN	O
a	DT	O
study	NN	O
conducted	VBN	O
between	IN	O
October	NNP	O
1977	CD	O
and	CC	O
October	NNP	O
1985	CD	O
.	.	O

There	EX	O
were	VBD	O
31	CD	O
gastric	JJ	O
lymphoma	NN	O
,	,	O
18	CD	O
small	JJ	O
intestinal	JJ	O
lymphomas	NN	O
,	,	O
and	CC	O
19	CD	O
with	IN	O
multiple	JJ	O
involvement	NN	O
:	:	O
63	CD	O
patients	NNS	O
had	VBD	O
had	VBN	O
a	DT	O
surgical	JJ	O
staging	NN	O
with	IN	O
total	JJ	O
tumor	NN	O
resection	NN	O
in	IN	O
15	CD	O
cases	NNS	O
.	.	O

Nineteen	JJ	O
patients	NNS	O
with	IN	O
limited	JJ	O
disease	NN	O
(	(	O
ID	NNP	O
and	CC	O
IID	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
3-week	JJ	O
chemotherapy	NN	O
regimen	NNS	O
associated	VBN	O
with	IN	O
whole	JJ	O
abdominal	JJ	O
radiotherapy	NN	O
or	CC	O
chemotherapy	NN	O
for	IN	O
3	CD	O
years	NNS	O
.	.	O

Twenty-seven	JJ	O
stage	NN	O
IIID	NNP	O
and	CC	O
thirty-six	JJ	O
stage	NN	O
IV	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
alone	RB	O
for	IN	O
3	CD	O
years	NNS	O
.	.	O

Low	JJ	O
grade	NN	O
lymphomas	NN	O
(	(	O
16	CD	O
patients	NNS	O
)	)	O
received	VBD	O
a	DT	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
association	NN	O
.	.	O

Intermediate	NNP	O
(	(	O
56	CD	O
patients	NNS	O
)	)	O
and	CC	O
high	JJ	O
grade	NN	O
(	(	O
10	CD	O
patients	NNS	O
)	)	O
lymphomas	VBP	O
received	VBN	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
adriamycin	NN	O
,	,	O
prednisone	NN	O
.	.	O

The	DT	O
overall	JJ	Physical
complete	JJ	Physical
remission	NN	Physical
obtained	VBN	O
was	VBD	O
63	CD	O
p.	NN	O
100	CD	O
(	(	O
51	CD	O
patients	NNS	O
)	)	O
with	IN	O
17	CD	O
patients	NNS	O
in	IN	O
relapse	NN	Physical
within	IN	O
6	CD	O
to	TO	O
40	CD	O
months	NNS	O
.	.	O

Overall	JJ	Mortality
survival	NN	Mortality
was	VBD	O
46	CD	O
p.	JJ	O
100	CD	O
at	IN	O
5	CD	O
years	NNS	O
.	.	O

Survival	NN	Mortality
was	VBD	O
dependent	JJ	O
on	IN	O
abdominal	JJ	Physical
extension	NN	Physical
,	,	Physical
histologic	NN	Physical
grade	VBD	Physical
according	VBG	Physical
to	TO	Physical
the	DT	Physical
new	JJ	Physical
working	VBG	Physical
formulation	NN	Physical
used	VBN	Physical
for	IN	Physical
lymph-node	JJ	Physical
lymphomas	NN	Physical
,	,	Physical
initial	JJ	Physical
localization	NN	Physical
(	(	O
gastric	JJ	O
lymphomas	NN	O
have	VBP	O
the	DT	O
best	JJS	O
survival	NN	O
)	)	O
and	CC	O
achievement	NN	O
of	IN	O
complete	JJ	Physical
remission	NN	Physical
.	.	O

Chemotherapy	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	Others
for	IN	O
primary	JJ	O
digestive	JJ	O
lymphomas	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
surgery	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
lymphomas	NN	O
has	VBZ	O
to	TO	O
be	VB	O
defined	VBN	O
by	IN	O
further	JJ	O
studies	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
tunnelling	VBG	O
on	IN	O
epidural	JJ	Physical
catheter	NN	Physical
migration	NN	Physical
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
of	IN	O
82	CD	O
patients	NNS	O
having	VBG	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
tunnelling	NN	O
of	IN	O
an	DT	O
epidural	JJ	O
catheter	NN	O
influences	VBZ	Physical
its	PRP$	Physical
migration	NN	Physical
.	.	O

Tunnelling	NN	O
of	IN	O
the	DT	O
catheter	NN	O
subcutaneously	RB	O
for	IN	O
a	DT	O
distance	NN	O
of	IN	O
5	CD	O
cm	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	Others
of	IN	Others
inward	JJ	Others
migration	NN	Others
of	IN	O
1	CD	O
cm	NN	O
or	CC	O
more	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
compared	VBN	O
to	TO	O
a	DT	O
standard	JJ	O
method	NN	Physical
of	IN	Physical
fixation	NN	Physical
with	IN	O
a	DT	O
transparent	JJ	Physical
adhesive	JJ	Physical
dressing	NN	Physical
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
more	RBR	O
marked	JJ	O
if	IN	O
the	DT	O
epidural	JJ	O
catheter	NN	O
was	VBD	O
sited	VBN	O
in	IN	O
the	DT	O
thoracic	NN	O
rather	RB	O
than	IN	O
the	DT	O
lumbar	JJ	O
area	NN	O
.	.	O

Sixty	CD	O
two	CD	O
percent	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
of	IN	O
tunnelled	JJ	O
catheters	NNS	O
remained	VBD	Others
within	IN	Others
0.5	CD	Others
cm	NNS	Others
of	IN	Others
their	PRP$	Others
original	JJ	Others
position	NN	Others
compared	VBN	O
to	TO	O
38	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
of	IN	O
non-tunnelled	JJ	O
catheters	NNS	O
,	,	O
although	IN	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Outward	NNP	Physical
catheter	NN	Physical
migration	NN	Physical
was	VBD	O
not	RB	O
reduced	VBN	O
by	IN	O
subcutaneous	JJ	O
tunnelling	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
azelastine	NN	O
and	CC	O
fluticasone	NN	O
in	IN	O
a	DT	O
single	JJ	O
nasal	NN	O
spray	NN	O
delivery	NN	O
device	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
proof-of-concept	JJ	O
study	NN	O
suggested	VBD	O
that	IN	O
combination	NN	O
therapy	NN	O
with	IN	O
commercial	JJ	O
azelastine	NN	O
hydrochloride	NN	O
nasal	NN	O
spray	NN	O
and	CC	O
fluticasone	NN	O
propionate	NN	O
nasal	NN	O
spray	NN	O
significantly	RB	O
improved	VBN	O
nasal	JJ	Physical
symptoms	NNS	Physical
of	IN	Physical
seasonal	JJ	Physical
allergic	JJ	Physical
rhinitis	NN	Physical
compared	VBN	O
with	IN	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
an	DT	O
azelastine-fluticasone	JJ	O
combination	NN	O
nasal	NN	O
spray	NN	O
administered	VBN	O
in	IN	O
a	DT	O
single-delivery	JJ	O
device	NN	O
with	IN	O
a	DT	O
commercially	RB	O
available	JJ	O
azelastine	NN	O
nasal	NN	O
spray	NN	O
and	CC	O
fluticasone	NN	O
nasal	NN	O
spray	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
14-day	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
during	IN	O
the	DT	O
Texas	NNP	O
mountain	NN	O
cedar	NN	O
season	NN	O
.	.	O

After	IN	O
a	DT	O
5-day	JJ	O
placebo	NN	O
lead-in	NN	O
,	,	O
610	CD	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
nasal	NN	O
symptoms	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
(	(	O
1	CD	O
)	)	O
azelastine	NN	O
nasal	NN	O
spray	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
fluticasone	NN	O
nasal	NN	O
spray	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
combination	NN	O
azelastine	NN	O
and	CC	O
fluticasone	NN	O
nasal	NN	O
spray	NN	O
,	,	O
or	CC	O
(	(	O
4	CD	O
)	)	O
placebo	NN	O
nasal	JJ	O
spray	NN	O
.	.	O

All	DT	O
treatments	NNS	O
were	VBD	O
given	VBN	O
as	IN	O
1	CD	O
spray	NN	O
per	IN	O
nostril	JJ	O
twice	JJ	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
variable	NN	O
was	VBD	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
total	JJ	Physical
nasal	JJ	Physical
symptom	NN	Physical
score	NN	Physical
(	(	Physical
TNSS	NNP	Physical
)	)	Physical
,	,	Physical
consisting	VBG	Physical
of	IN	Physical
nasal	JJ	Physical
congestion	NN	Physical
,	,	Physical
runny	NN	Physical
nose	RB	Physical
,	,	Physical
itchy	NN	Physical
nose	NN	Physical
,	,	Physical
and	CC	Physical
sneezing	VBG	Physical
.	.	O

RESULTS	NNP	O
All	DT	O
3	CD	O
active	JJ	O
groups	NNS	O
were	VBD	O
statistically	RB	O
superior	JJ	O
(	(	O
P	NNP	O
<	NNP	O
or=	NNP	O
.02	NNP	O
)	)	O
to	TO	O
placebo	VB	O
,	,	O
and	CC	O
the	DT	O
combination	NN	O
was	VBD	O
statistically	RB	O
superior	JJ	O
(	(	O
P	NNP	O
<	NNP	O
or=	NNP	O
.003	NNP	O
)	)	O
to	TO	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

The	DT	O
TNSS	NNP	Physical
improved	VBN	O
by	IN	O
28.4	CD	O
%	NN	O
with	IN	O
combination	NN	O
azelastine-fluticasone	NN	O
,	,	O
20.4	CD	O
%	NN	O
with	IN	O
fluticasone	NN	O
,	,	O
16.4	CD	O
%	NN	O
with	IN	O
azelastine	NN	O
,	,	O
and	CC	O
11.2	CD	O
%	NN	O
with	IN	O
placebo	NN	O
.	.	O

All	DT	O
3	CD	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combination	NN	O
azelastine-fluticasone	NN	O
nasal	NN	O
spray	NN	O
provided	VBD	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
TNSS	NNP	Physical
and	CC	O
additive	JJ	O
clinical	JJ	O
benefit	NN	O
compared	VBN	O
with	IN	O
either	DT	O
agent	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00660517	NN	O
.	.	O

Impact	NN	O
of	IN	O
surgical	JJ	O
staging	NN	O
in	IN	O
evaluating	VBG	O
the	DT	O
radiotherapeutic	JJ	O
outcome	NN	O
in	IN	O
RTOG	NNP	O
#	#	O
77-06	NNP	O
,	,	O
a	DT	O
phase	NN	O
III	NNP	O
study	NN	O
for	IN	O
T1BN0M0	NNP	O
(	(	O
A2	NNP	O
)	)	O
and	CC	O
T2N0M0	NNP	O
(	(	O
B	NNP	O
)	)	O
prostate	NN	O
carcinoma	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
survival	NN	O
and	CC	O
time	NN	O
to	TO	O
metastatic	JJ	O
disease	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
localized	JJ	O
prostatic	JJ	O
carcinoma	NN	O
in	IN	O
a	DT	O
Phase	NNP	O
III	NNP	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
protocol	NN	O
,	,	O
Radiation	NNP	O
Therapy	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
RTOG	NNP	O
)	)	O
77-06	NN	O
.	.	O

Patients	NNS	O
with	IN	O
T18N0M0	NNP	O
(	(	O
A2	NNP	O
)	)	O
or	CC	O
T2N0M0	NNP	O
(	(	O
B	NNP	O
)	)	O
disease	NN	O
after	IN	O
lymphangiogram	NN	O
(	(	O
LAG	NNP	O
)	)	O
or	CC	O
staging	VBG	O
laparotomy	NN	O
(	(	O
SL	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
between	IN	O
prophylactic	JJ	O
radiation	NN	O
to	TO	O
the	DT	O
pelvic	JJ	O
lymph	NN	O
nodes	NNS	O
and	CC	O
prostatic	JJ	O
bed	NN	O
vs.	FW	O
prostatic	JJ	O
bed	NN	O
alone	RB	O
.	.	O

The	DT	O
outcome	NN	O
of	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
LAG	NNP	O
group	NN	O
,	,	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
SL	NNP	O
group	NN	O
,	,	O
are	VBP	O
updated	VBN	O
.	.	O

METHODS	NNP	O
AND	NNP	O
MATERIALS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
449	CD	O
eligible	JJ	O
males	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
RTOG	NNP	O
protocol	NN	O
7706	CD	O
between	IN	O
1978	CD	O
and	CC	O
1983	CD	O
.	.	O

Lymph	NNP	O
node	IN	O
staging	VBG	O
was	VBD	O
mandatory	JJ	O
but	CC	O
at	IN	O
the	DT	O
physician	NN	O
's	POS	O
discretion	NN	O
;	:	O
117	CD	O
(	(	O
26	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
SL	NNP	O
,	,	O
while	IN	O
332	CD	O
(	(	O
74	CD	O
%	NN	O
)	)	O
had	VBD	O
LAG	NNP	O
.	.	O

Follow-up	NNP	O
was	VBD	O
a	DT	O
median	NN	O
of	IN	O
12	CD	O
years	NNS	O
and	CC	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	O
years	NNS	O
.	.	O

For	IN	O
those	DT	O
randomized	VBN	O
to	TO	O
receive	VB	O
prophylactic	JJ	O
pelvic	NNS	O
lymph	VBP	O
nodal	JJ	O
irradiation	NN	O
,	,	O
45	CD	O
Gy	NNP	O
of	IN	O
megavoltage	NN	O
RT	NNP	O
was	VBD	O
delivered	VBN	O
via	IN	O
multiple	JJ	O
portals	NNS	O
in	IN	O
4.5-5	JJ	O
weeks	NNS	O
,	,	O
while	IN	O
all	DT	O
patients	NNS	O
received	VBD	O
65	CD	O
Gy	NNP	O
in	IN	O
6.5-8	JJ	O
weeks	NNS	O
to	TO	O
the	DT	O
prostatic	JJ	O
bed	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
survival	JJ	Mortality
whether	IN	O
treatment	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
the	DT	O
prostate	NN	O
or	CC	O
prostate	NN	O
and	CC	O
pelvic	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

The	DT	O
SL	NNP	O
group	NN	O
had	VBD	O
greater	JJR	O
12-year	JJ	Mortality
survival	NN	Mortality
than	IN	O
the	DT	O
LAG	NNP	O
group	NN	O
(	(	O
48	CD	O
%	NN	O
vs.	FW	O
38	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Disease-free	JJ	Mortality
survival	NN	Mortality
was	VBD	O
statistically	RB	O
significant	JJ	O
,	,	O
with	IN	O
38	CD	O
%	NN	O
for	IN	O
the	DT	O
SL	NNP	O
group	NN	O
vs.	FW	O
26	CD	O
%	NN	O
for	IN	O
the	DT	O
LAG	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

Bone	NNP	Physical
metastasis	NN	Physical
was	VBD	O
less	JJR	O
common	JJ	O
in	IN	O
the	DT	O
SL	NNP	O
group	NN	O
(	(	O
14	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
LAG	NNP	O
group	NN	O
(	(	O
27	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
At	IN	O
12-year	JJ	O
median	JJ	O
follow-up	NN	O
,	,	O
there	EX	O
still	RB	O
was	VBD	O
no	DT	O
survival	JJ	O
difference	NN	O
in	IN	O
those	DT	O
patients	NNS	O
treated	VBD	O
prophylactically	RB	O
to	TO	O
the	DT	O
pelvic	JJ	O
nodes	NNS	O
and	CC	O
prostatic	JJ	O
bed	NN	O
vs.	IN	O
the	DT	O
prostatic	JJ	O
bed	NN	O
alone	RB	O
.	.	O

Those	DT	O
patients	NNS	O
not	RB	O
surgically	RB	O
staged	VBN	O
with	IN	O
only	RB	O
LAG	NNP	O
for	IN	O
lymph	JJ	O
node	JJ	O
evaluation	NN	O
were	VBD	O
less	RBR	O
accurately	RB	O
staged	VBN	O
,	,	O
as	IN	O
reflected	VBN	O
by	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduced	VBN	O
survival	NN	O
and	CC	O
earlier	JJR	O
metastases	NNS	O
.	.	O

A	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
glutathione	NN	O
supplementation	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
Recent	NNP	O
evidence	NN	O
shows	VBZ	O
that	IN	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
have	VBP	O
significantly	RB	O
lower	JJR	O
levels	NNS	O
of	IN	O
glutathione	NN	O
than	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
use	NN	O
of	IN	O
two	CD	O
commonly	NNS	O
used	VBD	O
glutathione	NN	O
supplements	NNS	O
in	IN	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
an	DT	O
ASD	NNP	O
to	TO	O
determine	VB	O
their	PRP$	O
efficacy	NN	O
in	IN	O
increasing	VBG	O
blood	NN	Physical
glutathione	NN	Physical
levels	NNS	Physical
in	IN	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
an	DT	O
ASD	NNP	O
.	.	O

MATERIAL/METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
an	DT	O
eight-week	JJ	O
,	,	O
open-label	JJ	O
trial	NN	O
using	VBG	O
oral	JJ	O
lipoceutical	JJ	O
glutathione	NN	O
(	(	O
n=13	JJ	O
)	)	O
or	CC	O
transdermal	JJ	O
glutathione	NN	O
(	(	O
n=13	JJ	O
)	)	O
in	IN	O
children	NNS	O
,	,	O
3-13	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
an	DT	O
ASD	NNP	O
.	.	O

Subjects	NNPS	O
underwent	JJ	O
pre-	JJ	O
and	CC	O
post-treatment	JJ	O
lab	NN	O
testing	VBG	O
to	TO	O
evaluate	VB	O
plasma	NN	Physical
reduced	VBN	Physical
glutathione	NN	Physical
,	,	Physical
oxidized	VBD	Physical
glutathione	NN	Physical
,	,	Physical
cysteine	NN	Physical
,	,	Physical
taurine	NN	Physical
,	,	Physical
free	JJ	Physical
and	CC	Physical
total	JJ	Physical
sulfate	NN	Physical
,	,	Physical
and	CC	Physical
whole-blood	JJ	Physical
glutathione	NN	Physical
levels	NNS	Physical
.	.	Physical

RESULTS	VB	O
The	DT	O
oral	JJ	O
treatment	NN	O
group	NN	O
showed	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
plasma	NN	Physical
reduced	VBD	Physical
glutathione	NN	Physical
,	,	O
but	CC	O
not	RB	O
whole-blood	JJ	Physical
glutathione	NN	Physical
levels	NNS	O
following	VBG	O
supplementation	NN	O
.	.	O

Both	CC	O
the	DT	O
oral	JJ	O
and	CC	O
transdermal	JJ	O
treatment	NN	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
plasma	NN	Physical
sulfate	NN	Physical
,	,	O
cysteine	NN	Physical
,	,	O
and	CC	O
taurine	NN	Physical
following	VBG	O
supplementation	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
oral	JJ	O
and	CC	O
transdermal	JJ	O
glutathione	NN	O
supplementation	NN	O
may	MD	O
have	VB	O
some	DT	O
benefit	NN	O
in	IN	O
improving	VBG	O
some	DT	O
of	IN	O
the	DT	O
transsulfuration	NN	O
metabolites	VBZ	O
.	.	O

Future	JJ	O
studies	NNS	O
among	IN	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
an	DT	O
ASD	NNP	O
should	MD	O
further	RB	O
explore	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
glutathione	NN	O
supplementation	NN	O
and	CC	O
evaluate	VB	O
the	DT	O
potential	JJ	O
effects	NNS	O
of	IN	O
glutathione	NN	O
supplementation	NN	O
upon	IN	O
clinical	JJ	O
symptoms	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
arch	NN	O
dimension	NN	O
changes	NNS	O
in	IN	O
1-phase	JJ	O
vs	JJ	O
2-phase	JJ	O
treatment	NN	O
of	IN	O
Class	NNP	O
II	NNP	O
malocclusion	NN	O
.	.	O

INTRODUCTION	NNP	O
We	PRP	O
compared	VBN	O
arch	JJ	O
dimension	NN	O
changes	NNS	O
in	IN	O
1-phase	JJ	O
and	CC	O
2-phase	JJ	O
treatment	NN	O
of	IN	O
Class	NNP	O
II	NNP	O
malocclusion	NN	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
conducted	VBN	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Orthodontics	NNP	O
at	IN	O
the	DT	O
University	NNP	O
of	IN	O
Florida	NNP	O
between	IN	O
1990	CD	O
and	CC	O
2003	CD	O
.	.	O

METHODS	NNP	O
During	IN	O
phase	NN	O
1	CD	O
treatment	NN	O
,	,	O
86	CD	O
subjects	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
bionator	NN	O
,	,	O
93	CD	O
were	VBD	O
treated	VBN	O
with	IN	O
headgear/biteplane	NN	O
,	,	O
and	CC	O
81	CD	O
served	VBD	O
as	IN	O
the	DT	O
observation	NN	O
group	NN	O
.	.	O

For	IN	O
phase	NN	O
2	CD	O
,	,	O
all	DT	O
subjects	NNS	O
were	VBD	O
then	RB	O
treated	VBN	O
with	IN	O
full	JJ	O
orthodontic	JJ	O
appliances	NNS	O
.	.	O

Arch	VBP	O
dimensions	NNS	O
were	VBD	O
followed	VBN	O
;	:	O
maxillary	JJ	O
and	CC	O
mandibular	JJ	O
alginate	NN	O
impressions	NNS	O
were	VBD	O
taken	VBN	O
at	IN	O
baseline	NN	O
,	,	O
end	NN	O
of	IN	O
early	JJ	O
Class	NNP	O
II	NNP	O
treatment	NN	O
or	CC	O
observation	NN	O
,	,	O
beginning	VBG	O
of	IN	O
fixed	JJ	O
appliance	NN	O
treatment	NN	O
,	,	O
end	NN	O
of	IN	O
orthodontic	JJ	O
treatment	NN	O
,	,	O
and	CC	O
approximately	RB	O
3	CD	O
years	NNS	O
posttreatment	NN	O
.	.	O

Alginate	NNP	O
impressions	NNS	O
were	VBD	O
taken	VBN	O
of	IN	O
each	DT	O
dental	JJ	O
arch	NN	O
at	IN	O
each	DT	O
data	NN	O
collection	NN	O
point	NN	O
.	.	O

These	DT	O
were	VBD	O
poured	VBN	O
in	IN	O
orthodontic	JJ	O
stone	NN	O
,	,	O
trimmed	VBN	O
,	,	O
and	CC	O
photocopied	VBD	O
from	IN	O
the	DT	O
occlusal	NN	O
aspect	NN	O
.	.	O

These	DT	O
images	NNS	O
were	VBD	O
then	RB	O
scanned	VBN	O
and	CC	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
Although	IN	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
both	DT	O
the	DT	O
maxillary	NN	O
and	CC	O
mandibular	JJ	O
arches	NNS	O
after	IN	O
phase	NN	O
1	CD	O
,	,	O
these	DT	O
differences	NNS	O
were	VBD	O
no	RB	O
longer	RBR	O
evident	JJ	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
full	JJ	O
orthodontic	JJ	O
treatment	NN	O
or	CC	O
after	IN	O
posttreatment	JJ	O
retention	NN	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
arch	NN	Others
dimensions	NNS	Others
after	IN	O
1-phase	JJ	O
or	CC	O
2-phase	JJ	O
treatment	NN	O
of	IN	O
Class	NNP	O
II	NNP	O
malocclusion	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
liberal	JJ	O
versus	NN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
transfusion	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

OBJECTIVE	NNP	O
Although	IN	O
many	JJ	O
centers	NNS	O
have	VBP	O
introduced	VBN	O
more	RBR	O
restrictive	JJ	O
transfusion	NN	O
policies	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
in	IN	O
recent	JJ	O
years	NNS	O
,	,	O
the	DT	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
consequences	NNS	O
of	IN	O
allowing	VBG	O
lower	JJR	O
hematocrit	NN	O
levels	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
transfusions	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
number	NN	Others
of	IN	Others
transfusions	NNS	Others
without	IN	O
adverse	JJ	O
consequences	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
enrolled	VBD	O
100	CD	O
hospitalized	JJ	O
preterm	NN	O
infants	NNS	O
with	IN	O
birth	JJ	O
weights	NNS	O
of	IN	O
500	CD	O
to	TO	O
1300	CD	O
g	NN	O
into	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
2	CD	O
levels	NNS	O
of	IN	O
hematocrit	NN	O
threshold	NN	O
for	IN	O
RBC	NNP	O
transfusion	NN	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
infants	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
either	VB	O
the	DT	O
liberal-	NN	O
or	CC	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
.	.	O

For	IN	O
each	DT	O
group	NN	O
,	,	O
transfusions	NNS	O
were	VBD	O
given	VBN	O
only	RB	O
when	WRB	O
the	DT	O
hematocrit	NN	O
level	NN	O
fell	VBD	O
below	IN	O
the	DT	O
assigned	JJ	O
value	NN	O
.	.	O

In	IN	O
each	DT	O
group	NN	O
,	,	O
the	DT	O
transfusion	NN	O
threshold	NN	O
levels	NNS	O
decreased	VBN	O
with	IN	O
improving	VBG	O
clinical	JJ	O
status	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
We	PRP	O
recorded	VBD	O
the	DT	O
number	NN	Others
of	IN	Others
transfusions	NNS	Others
,	,	O
the	DT	O
number	NN	Others
of	IN	Others
donor	JJ	Others
exposures	NNS	Others
,	,	O
and	CC	O
various	JJ	Others
clinical	JJ	Others
and	CC	Others
physiologic	JJ	Others
outcomes	NNS	Others
.	.	O

RESULTS	JJ	O
Infants	NNS	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
received	VBD	O
more	JJR	O
RBC	JJ	Physical
transfusions	NNS	Physical
(	(	O
5.2	CD	O
+/-	JJ	O
4.5	CD	O
[	JJ	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
]	NNP	O
vs	VBD	O
3.3	CD	O
+/-	JJ	O
2.9	CD	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
number	NN	Physical
of	IN	Physical
donors	NNS	Physical
to	TO	O
whom	WP	O
the	DT	O
infants	NNS	O
were	VBD	O
exposed	VBN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
2.8	CD	O
+/-	JJ	O
2.5	CD	O
vs	JJ	O
2.2	CD	O
+/-	JJ	O
2.0	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	Physical
of	IN	Physical
infants	NNS	Physical
who	WP	Physical
avoided	VBD	Physical
transfusions	NNS	Physical
altogether	RB	Physical
(	(	O
12	CD	O
%	NN	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
versus	VBD	O
10	CD	O
%	NN	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

Infants	NNS	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
intraparenchymal	JJ	Physical
brain	NN	Physical
hemorrhage	NN	Physical
or	CC	Physical
periventricular	JJ	Physical
leukomalacia	NN	Physical
,	,	O
and	CC	O
they	PRP	O
had	VBD	O
more	RBR	Physical
frequent	JJ	Physical
episodes	NNS	Physical
of	IN	Physical
apnea	NN	Physical
,	,	O
including	VBG	O
both	DT	O
mild	JJ	Physical
and	CC	Physical
severe	JJ	Physical
episodes	NNS	Physical
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
both	DT	O
transfusion	NN	O
programs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
our	PRP$	O
finding	NN	O
of	IN	O
more	RBR	O
frequent	JJ	O
major	JJ	Adverseeffect
adverse	JJ	Adverseeffect
neurologic	NN	Adverseeffect
events	NNS	Adverseeffect
in	IN	O
the	DT	O
restrictive	JJ	O
RBC-transfusion	NNP	O
group	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
restrictive	JJ	O
transfusions	NNS	O
may	MD	O
be	VB	O
harmful	JJ	O
to	TO	O
preterm	VB	O
infants	NNS	O
.	.	O

Acipimox	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
hyperlipidaemia	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
trial	NN	O
.	.	O

Fifty-two	JJ	O
patients	NNS	O
with	IN	O
Fredrickson	NNP	O
Type	NNP	O
IIb	NNP	O
or	CC	O
Type	NNP	O
IV	NNP	O
hyperlipidaemia	NN	O
,	,	O
in	IN	O
whom	WP	O
diet	NN	O
had	VBD	O
not	RB	O
achieved	VBN	O
satisfactory	JJ	O
lipid	JJ	O
levels	NNS	O
,	,	O
completed	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
study	NN	O
of	IN	O
acipimox	JJ	O
versus	NN	O
placebo	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
acipimox	NNS	O
,	,	O
250	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
or	CC	O
placebo	VB	O
for	IN	O
a	DT	O
three	CD	O
month	NN	O
period	NN	O
,	,	O
and	CC	O
plasma	JJ	Physical
lipids	NNS	Physical
and	CC	Physical
glucose	VB	Physical
were	VBD	O
monitored	VBN	O
.	.	O

The	DT	O
patients	NNS	O
receiving	VBG	O
acipimox	NN	O
showed	VBD	O
a	DT	O
fall	NN	O
in	IN	O
the	DT	O
mean	JJ	O
concentration	NN	O
of	IN	O
plasma	JJ	Physical
triglyceride	NN	Physical
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
0.74	CD	O
mmol/l	NN	O
)	)	O
and	CC	O
this	DT	O
was	VBD	O
most	RBS	O
marked	JJ	O
in	IN	O
patients	NNS	O
whose	WP$	O
initial	JJ	O
plasma	NN	Physical
triglyceride	NN	Physical
levels	NNS	Physical
were	VBD	O
greater	JJR	O
than	IN	O
3	CD	O
mmol/l	NN	O
(	(	O
1.0	CD	O
mmol/l	NN	O
,	,	O
confidence	NN	O
limits	NNS	O
0.18	CD	O
,	,	O
1.82	CD	O
)	)	O
.	.	O

Acipimox	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
,	,	O
and	CC	O
could	MD	O
be	VB	O
a	DT	O
useful	JJ	O
addition	NN	O
to	TO	O
the	DT	O
drugs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
hypertriglyceridaemia	NN	O
.	.	O

Clinical	JJ	Others
performance	NN	Others
of	IN	O
the	DT	O
Reichert	NNP	O
AT550	NNP	O
:	:	O
a	DT	O
new	JJ	O
non-contact	JJ	O
tonometer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
level	NN	Others
of	IN	Others
accuracy	NN	Others
for	IN	Others
measurements	NNS	Others
of	IN	O
intra-ocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
obtained	VBD	O
with	IN	O
a	DT	O
new	JJ	O
non-contact	JJ	O
tonometer	NN	O
(	(	O
NCT	NNP	O
)	)	O
the	DT	O
Reichert	NNP	O
AT550	NNP	O
.	.	O

Measurements	NNS	O
were	VBD	O
compared	VBN	O
against	IN	O
those	DT	O
obtained	VBN	O
with	IN	O
the	DT	O
Reichert	NNP	O
Xpert	NNP	O
Plus	NNP	O
,	,	O
Goldmann	NNP	O
applanation	NN	O
tonometer	NN	O
and	CC	O
Perkins	NNP	O
tonometer	NN	O
.	.	O

Thirty-five	JJ	O
university	NN	O
students	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
four	CD	O
tonometers	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
order	NN	O
,	,	O
with	IN	O
non-contact	JJ	O
tonometry	NN	O
performed	VBD	O
first	RB	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
four	CD	O
measurement	NN	O
devices	NNS	O
had	VBD	O
its	PRP$	O
own	JJ	O
trained	JJ	O
clinical	JJ	O
observer	NN	O
.	.	O

Plots	NNP	O
of	IN	O
differences	NNS	O
of	IN	O
IOP	NNP	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
mean	NN	O
for	IN	O
each	DT	O
pair	NN	O
of	IN	O
instruments	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
when	WRB	O
comparing	VBG	O
the	DT	O
AT550	NNP	O
NCT	NNP	O
with	IN	O
contact	JJ	O
applanation	NN	O
tonometry	NN	O
(	(	O
AT	NNP	O
)	)	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
displaying	VBG	O
the	DT	O
closest	JJS	O
level	NN	Others
of	IN	Others
agreement	NN	Others
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
the	DT	O
lowest	JJS	Others
mean	JJ	Others
difference	NN	Others
and	CC	Others
the	DT	Others
narrowest	JJS	Others
confidence	NN	Others
interval	NN	Others
)	)	Others
with	IN	O
the	DT	O
Goldmann	NNP	O
tonometer	NN	O
(	(	O
limits	NNS	O
of	IN	O
agreement	NN	O
,	,	O
0.12+/-2.17	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
readings	NNS	Others
of	IN	Others
IOP	NNP	Others
with	IN	O
the	DT	O
AT550	NNP	O
NCT	NNP	O
are	VBP	O
clinically	RB	O
comparable	JJ	O
with	IN	O
those	DT	O
obtained	VBN	O
with	IN	O
Goldmann	NNP	O
tonometry	NN	O
in	IN	O
a	DT	O
population	NN	O
with	IN	O
IOP	NNP	O
within	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
adjunctive	JJ	O
exenatide	NN	O
therapy	NN	O
in	IN	O
pediatric	JJ	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

OBJECTIVE	NNP	O
Exenatide	NNP	O
improves	VBZ	O
postprandial	JJ	O
glycemic	JJ	Physical
excursions	NNS	Physical
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Exenatide	NNP	O
could	MD	O
benefit	VB	O
type	JJ	O
1	CD	O
diabetes	NNS	O
as	RB	O
well	RB	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
glucose-lowering	NN	Physical
adjuvant	JJ	O
exenatide	NN	O
dose	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Eight	NNP	O
subjects	NNS	O
completed	VBD	O
a	DT	O
three-part	JJ	O
double-blinded	JJ	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
of	IN	O
premeal	JJ	O
exenatide	NN	O
.	.	O

Two	CD	O
doses	NNS	O
of	IN	O
exenatide	NN	O
(	(	O
1.25	CD	O
and	CC	O
2.5	CD	O
microg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
insulin	NN	O
monotherapy	NN	O
.	.	O

Prandial	JJ	O
insulin	NN	O
dose	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
20	CD	O
%	NN	O
.	.	O

Gastric	NNP	O
emptying	VBG	O
and	CC	O
hormones	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
300	CD	O
min	JJ	O
postmeal	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
exenatide	JJ	O
versus	NN	O
insulin	NN	O
monotherapy	NN	O
significantly	RB	O
reduced	VBD	Physical
glucose	JJ	Physical
excursions	NNS	Physical
over	IN	O
300	CD	O
min	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Exenatide	NNP	O
administration	NN	O
failed	VBD	Physical
to	TO	Physical
suppress	VB	Physical
glucagon	NN	Physical
but	CC	Physical
delayed	VBD	Physical
gastric	JJ	Physical
emptying	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Adjunctive	NNP	O
exenatide	NN	O
therapy	NN	O
reduces	VBZ	Physical
postprandial	JJ	Physical
hyperglycemia	NN	Physical
in	IN	O
adolescents	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

This	DT	O
reduction	NN	O
in	IN	O
glucose	JJ	Physical
excursion	NN	Physical
occurs	VBZ	O
despite	IN	O
reduction	NN	O
in	IN	O
insulin	NN	O
dose	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	DT	O
exenatide	NN	O
has	VBZ	O
therapeutic	JJ	O
potential	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

Resource	NNP	O
utilization	NN	O
and	CC	O
costs	NNS	Others
of	IN	Others
care	NN	Others
in	IN	O
the	DT	O
diabetes	NNS	O
control	NN	O
and	CC	O
complications	NNS	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
in	IN	O
detail	NN	O
the	DT	O
resources	NNS	Others
used	VBN	O
and	CC	O
costs	NNS	Others
incurred	VBN	Others
in	IN	O
the	DT	O
clinical	JJ	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
insulin-dependent	JJ	O
diabetes	NNS	O
mellitus	FW	O
(	(	O
IDDM	NNP	O
)	)	O
in	IN	O
the	DT	O
Diabetes	NNP	O
Control	NNP	O
and	CC	O
Complications	NNP	O
Trial	NNP	O
(	(	O
DCCT	NNP	O
)	)	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
The	DT	O
resources	NNS	O
used	VBN	O
for	IN	O
intensive	JJ	O
and	CC	O
conventional	JJ	O
therapy	NN	O
and	CC	O
to	TO	O
deal	VB	O
with	IN	O
the	DT	O
side	NN	O
effects	NNS	O
of	IN	O
therapy	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
each	DT	O
of	IN	O
the	DT	O
29	CD	O
DCCT	NNP	O
clinics	NNS	O
and	CC	O
summarized	VBN	O
.	.	O

Unit	NN	O
costs	NNS	O
were	VBD	O
derived	VBN	O
from	IN	O
the	DT	O
DCCT	NNP	O
,	,	O
manufacturers	NNS	O
,	,	O
and	CC	O
Medicare	NNP	O
and	CC	O
chosen	VBN	O
to	TO	O
reflect	VB	O
what	WP	O
an	DT	O
item	NN	O
would	MD	O
cost	VB	O
to	TO	O
a	DT	O
single-payer	JJ	O
national	JJ	O
health	NN	O
system	NN	O
.	.	O

Costs	NNS	Others
were	VBD	O
calculated	VBN	O
as	IN	O
the	DT	O
product	NN	O
of	IN	O
resources	NNS	O
used	VBN	O
and	CC	O
unit	NN	O
costs	NNS	O
.	.	O

The	DT	O
costs	NNS	Others
of	IN	O
the	DT	O
research	NN	O
component	NN	O
of	IN	O
the	DT	O
DCCT	NNP	O
were	VBD	O
not	RB	O
included	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
DCCT	NNP	O
,	,	O
the	DT	O
annual	JJ	Others
cost	NN	Others
of	IN	Others
intensive	JJ	Others
therapy	NN	Others
(	(	O
$	$	O
4,000	CD	O
and	CC	O
$	$	O
5,800/year	CD	O
for	IN	O
multiple	JJ	O
daily	JJ	O
injections	NNS	O
and	CC	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
,	,	O
respectively	RB	O
)	)	O
was	VBD	O
approximately	RB	O
three	CD	O
times	NNS	O
the	DT	O
cost	NN	Others
of	IN	Others
conventional	JJ	Others
therapy	NN	Others
(	(	O
$	$	O
1,700/year	CD	O
)	)	O
.	.	O

A	DT	O
large	JJ	O
portion	NN	O
of	IN	O
the	DT	O
difference	NN	O
in	IN	O
cost	NN	Others
was	VBD	O
related	VBN	O
to	TO	O
the	DT	O
greater	JJR	O
frequency	NN	Others
of	IN	Others
outpatient	JJ	Others
visits	NNS	Others
and	CC	O
the	DT	O
greater	JJR	O
resources	NNS	Others
used	VBN	Others
in	IN	Others
self-care	NN	Others
.	.	O

CONCLUSIONS	NNP	O
DCCT	NNP	O
intensive	JJ	O
therapy	NN	O
is	VBZ	O
more	RBR	O
expensive	JJ	O
than	IN	O
conventional	JJ	O
therapy	NN	O
,	,	O
but	CC	O
it	PRP	O
offers	VBZ	O
the	DT	O
hope	NN	O
of	IN	O
cost	NN	O
savings	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
averted	JJ	O
complications	NNS	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effects	NNS	O
of	IN	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
on	IN	O
parent-reported	JJ	Mental
autism	NN	Mental
symptoms	NNS	Mental
in	IN	O
school-age	JJ	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
effect	NN	O
of	IN	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
on	IN	O
parent-reported	JJ	O
autism	NN	O
symptoms	NNS	O
.	.	O

Nineteen	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
an	DT	O
anxiety	NN	O
disorder	NN	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	O
or	CC	O
a	DT	O
waitlist	JJ	O
condition	NN	O
.	.	O

The	DT	O
CBT	NNP	O
program	NN	O
emphasized	VBN	O
in	IN	O
vivo	NN	O
exposure	NN	O
supported	VBN	O
by	IN	O
parent	NN	O
training	NN	O
and	CC	O
school	NN	O
consultation	NN	O
to	TO	O
promote	VB	O
social	JJ	O
communication	NN	O
and	CC	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
.	.	O

Parents	NNS	O
completed	VBD	O
a	DT	O
standardized	JJ	Others
autism	NN	Others
symptom	JJ	Others
checklist	NN	Others
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
and	CC	O
3-month	JJ	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

CBT	NNP	O
outperformed	VBD	O
the	DT	O
waitlist	JJ	O
condition	NN	O
at	IN	O
posttreatment/postwaitlist	NN	O
on	IN	O
total	JJ	Mental
parent-reported	JJ	Mental
autism	NN	Mental
symptoms	NNS	Mental
(	(	O
Cohen	NNP	O
's	POS	O
d	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
.77	NNP	O
)	)	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Further	JJ	O
investigation	NN	O
of	IN	O
this	DT	O
intervention	NN	O
modality	NN	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
broader	JJR	O
outcome	NN	O
measures	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
indicated	VBN	O
.	.	O

Clinical	JJ	O
and	CC	O
radiographic	JJ	O
evaluation	NN	O
of	IN	O
guided	JJ	O
tissue	NN	O
regeneration	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
class	NN	O
II	NNP	O
furcation	NN	O
defects	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
treatment	NN	O
outcomes	RB	O
after	IN	O
guided	VBN	O
tissue	NN	O
regeneration	NN	O
(	(	O
GTR	NNP	O
)	)	O
with	IN	O
a	DT	O
bioabsorbable	JJ	O
membrane	NN	O
in	IN	O
Class	NNP	O
II	NNP	O
furcation	NN	O
defects	NNS	O
in	IN	O
mandibular	JJ	O
molars	NNS	O
.	.	O

The	DT	O
open	JJ	O
flap	NN	O
debridement	NN	O
(	(	O
OFD	NNP	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
control	NN	O
.	.	O

METHODS	NNP	O
Nine	NNP	O
patients	NNS	O
,	,	O
with	IN	O
two	CD	O
comparable	JJ	O
Class	NNP	O
II	NNP	O
furcation	NN	O
defects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
initial	JJ	O
preparation	NN	O
,	,	O
the	DT	O
defects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
each	DT	O
patient	NN	O
to	TO	O
either	DT	O
GTR-group	NNP	O
or	CC	O
OFD-group	NNP	O
.	.	O

Clinical	JJ	O
parameters	NNS	O
and	CC	O
standardized	JJ	O
radiographs	NN	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
surgeries	NNS	O
.	.	O

The	DT	O
radiographs	NN	O
were	VBD	O
analyzed	VBN	O
by	IN	O
subtraction	NN	O
radiography	NN	O
.	.	O

RESULTS	NNP	O
Comparing	NNP	O
baseline	NN	O
to	TO	O
6-month	JJ	O
results	NNS	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
probing	VBG	Physical
depth	NN	Physical
reduction	NN	Physical
(	(	Physical
PD	NNP	Physical
)	)	Physical
,	,	O
horizontal	JJ	Physical
clinical	JJ	Physical
attachment	NN	Physical
level	NN	Physical
(	(	Physical
CAL-h	NNP	Physical
)	)	Physical
gain	NN	Physical
,	,	O
and	CC	O
increase	VB	Physical
in	IN	Physical
gingival	JJ	Physical
recession	NN	Physical
(	(	Physical
GR	NNP	Physical
)	)	Physical
.	.	O

The	DT	O
vertical	JJ	Physical
clinical	JJ	Physical
attachment	NN	Physical
level	NN	Physical
(	(	Physical
CAL-v	NNP	Physical
)	)	Physical
gain	NN	Physical
was	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
OFD-group	NNP	O
.	.	O

Comparing	VBG	O
the	DT	O
two	CD	O
treatments	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
PD	NNP	Physical
reduction	NN	Physical
(	(	O
GTR	NNP	O
:	:	O
1.67	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
2.51	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.26	CD	O
)	)	O
,	,	O
CAL-v	JJ	Physical
gain	NN	Physical
(	(	O
GTR	NNP	O
:	:	O
0.62	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.16	CD	O
mm	NN	O
,	,	O
P=	NNP	O
0.37	CD	O
)	)	O
,	,	O
and	CC	O
GR	NNP	Physical
increase	NN	Physical
(	(	O
GTR	NNP	O
:	:	O
1.04	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.24	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.31	CD	O
)	)	O
.	.	O

GTR	NNP	O
provided	VBD	O
complete	JJ	O
closure	NN	Physical
of	IN	Physical
the	DT	Physical
furcation	NN	Physical
defect	NN	Physical
in	IN	O
two	CD	O
sites	NNS	O
and	CC	O
superior	JJ	Physical
horizontal	JJ	Physical
clinical	JJ	Physical
attachment	NN	Physical
level	NN	Physical
gain	NN	Physical
(	(	O
GTR	NNP	O
:	:	O
2.27	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.01	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

Subtraction	NN	O
radiography	NN	O
showed	VBD	O
significant	JJ	O
difference	NN	O
in	IN	O
bone	NN	O
height	NN	O
change	NN	O
between	IN	O
GTR-group	NNP	O
and	CC	O
OFD-group	NNP	O
(	(	O
-0.14	NNP	O
mm	NN	O
and	CC	O
0.86	CD	O
mm	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

[	JJ	O
Treatment	NNP	O
of	IN	O
essential	JJ	Physical
headache	NN	Physical
in	IN	O
developmental	JJ	O
age	NN	O
with	IN	O
L-5-HTP	NNP	O
(	(	O
cross	NN	O
over	IN	O
double-blind	JJ	O
study	NN	O
versus	IN	O
placebo	NN	O
)	)	O
]	NN	O
.	.	O

Thirty	NN	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
10.38	CD	O
years	NNS	O
)	)	O
affected	VBN	O
by	IN	O
primary	JJ	Physical
headache	NN	Physical
were	VBD	O
selected	VBN	O
for	IN	O
a	DT	O
double-blind	JJ	O
cross-over	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
homogeneous	JJ	O
groups	NNS	O
of	IN	O
15	CD	O
and	CC	O
treated	VBD	O
for	IN	O
12	CD	O
weeks	NNS	O
with	IN	O
L-5-HTP	NNP	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
and	CC	O
placebo	NN	O
as	IN	O
per	IN	O
the	DT	O
following	JJ	O
design	NN	O
:	:	O
placebo	NN	O
-	:	O
L-5-HTP	NNP	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
L-5-HTP	NNP	O
-	:	O
placebo	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Evaluation	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
every	DT	O
3	CD	O
weeks	NNS	O
by	IN	O
the	DT	O
Migraine	NNP	Others
Index	NNP	Others
supplying	VBG	O
a	DT	O
general	JJ	Others
assessment	NN	Others
of	IN	Others
the	DT	Others
attacks	NNS	Others
,	,	O
i.e	NN	O
.	.	O

severity	NN	Physical
,	,	O
duration	NN	Physical
and	CC	O
frequency	NN	Others
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
mean	JJ	Others
score	NN	Others
values	NNS	Others
was	VBD	O
directly	RB	O
proportional	JJ	O
to	TO	O
L-5-HTP	NNP	O
treatment	NN	O
,	,	O
and	CC	O
statistical	JJ	O
significance	NN	O
(	(	O
Wilcoxon	NNP	Others
's	POS	Others
test	NN	Others
)	)	O
was	VBD	O
observed	VBN	O
only	RB	O
for	IN	O
L-5-HTP	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
from	IN	O
0.05	CD	O
to	TO	O
0.01	CD	O
.	.	O

Improvement	NN	O
,	,	O
as	IN	O
evaluated	VBN	O
by	IN	O
CGI	NNP	O
on	IN	O
percentage	NN	O
distribution	NN	O
of	IN	O
the	DT	O
patients	NNS	O
,	,	O
was	VBD	O
homogeneous	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Enamel	NNP	O
and	CC	O
dentin	VB	O
bond	NN	O
strength	NN	O
following	VBG	O
gaseous	JJ	O
ozone	NN	O
application	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
gaseous	JJ	O
ozone	NN	O
application	NN	O
on	IN	O
enamel	NN	O
and	CC	O
dentin	VB	O
bond	NN	O
strength	NN	O
produced	VBN	O
by	IN	O
two	CD	O
self-etching	JJ	O
adhesive	JJ	O
systems	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
shear	JJ	O
bond	NN	O
strength	NN	O
test	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
adhesion	NN	O
on	IN	O
enamel	NN	O
(	(	O
protocol	JJ	O
1	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
microtensile	JJ	O
bond	NN	O
strength	NN	O
test	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
dentin	NN	O
(	(	O
protocol	JJ	O
2	CD	O
)	)	O
.	.	O

Protocol	$	O
1	CD	O
:	:	O
96	CD	O
bovine	NN	O
incisors	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
,	,	O
and	CC	O
enamel	JJ	O
surfaces	NNS	O
were	VBD	O
bonded	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
following	JJ	O
treatments	NNS	O
:	:	O
(	(	O
1E	CD	O
)	)	O
ozone	NN	O
+	NN	O
Clearfil	NNP	O
Protect	NNP	O
Bond	NNP	O
;	:	O
(	(	O
2E	CD	O
)	)	O
Clearfil	NNP	O
Protect	NNP	O
Bond	NNP	O
(	(	O
control	NN	O
)	)	O
;	:	O
(	(	O
3E	CD	O
)	)	O
ozone	NN	O
+	JJ	O
Xeno	NNP	O
III	NNP	O
;	:	O
(	(	O
4E	CD	O
)	)	O
Xeno	NN	O
III	NNP	O
(	(	O
control	NN	O
)	)	O
.	.	O

Ozone	NNP	O
gas	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
80	CD	O
s.	JJ	O
Shear	NNP	O
bond	NN	O
strength	NN	O
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

Protocol	CC	O
2	CD	O
:	:	O
40	CD	O
noncarious	JJ	O
human	JJ	O
molars	NNS	O
were	VBD	O
selected	VBN	O
.	.	O

Middle/deep	NNP	O
dentin	NN	O
was	VBD	O
exposed	VBN	O
and	CC	O
bonded	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
following	JJ	O
treatments	NNS	O
:	:	O
(	(	O
1D	CD	O
)	)	O
ozone+Clearfil	NN	O
Protect	NNP	O
Bond	NNP	O
;	:	O
(	(	O
2D	CD	O
)	)	O
Clearfil	NNP	O
Protect	NNP	O
Bond	NNP	O
(	(	O
control	NN	O
)	)	O
;	:	O
(	(	O
3D	CD	O
)	)	O
ozone+Xeno	NN	O
III	NNP	O
(	(	O
4D	CD	O
)	)	O
Xeno	NN	O
III	NNP	O
(	(	O
control	NN	O
)	)	O
.	.	O

Four-mm-thick	JJ	O
buildups	NNS	O
were	VBD	O
built	VBN	O
on	IN	O
the	DT	O
adhesives	NNS	O
,	,	O
then	RB	O
specimens	NNS	O
were	VBD	O
sectioned	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
nontrimming	NN	O
technique	NN	O
.	.	O

Specimens	NNS	O
were	VBD	O
stressed	VBN	O
until	IN	O
failure	NN	O
occurred	VBD	O
,	,	O
and	CC	O
failure	NN	O
modes	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Shear	JJ	Physical
bond	NN	Physical
and	CC	Physical
microtensile	NN	Physical
bond	NN	Physical
strength	NN	Physical
data	NNS	Physical
were	VBD	O
analyzed	VBN	O
using	VBG	O
two-way	JJ	O
ANOVA	NNP	O
and	CC	O
Tukey	NNP	O
's	POS	O
post-hoc	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
ozone	NN	O
treated	VBN	O
specimens	NNS	O
and	CC	O
controls	NNS	O
,	,	O
neither	CC	O
on	IN	O
enamel	JJ	Physical
nor	CC	O
on	IN	O
dentin	JJ	Physical
irrespective	NN	O
of	IN	O
the	DT	O
tested	JJ	O
adhesive	NN	O
.	.	O

Clearfil	NNP	O
Protect	NNP	O
Bond	NNP	O
showed	VBD	O
higher	JJR	O
bond	NN	Physical
strength	NN	Physical
to	TO	O
enamel	VB	O
than	IN	O
Xeno	NNP	O
III	NNP	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
ozone	NN	O
treatment	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
use	NN	O
of	IN	O
ozone	NN	O
gas	NN	O
to	TO	O
disinfect	VB	O
the	DT	O
cavity	NN	O
before	IN	O
placing	VBG	O
a	DT	O
restoration	NN	O
had	VBD	O
no	DT	O
influence	NN	O
on	IN	O
immediate	JJ	O
enamel	NN	O
and	CC	O
dentin	VB	O
bond	NN	O
strength	NN	O
.	.	O

Relationships	NNS	O
between	IN	O
age	NN	O
at	IN	O
diagnosis	NN	O
,	,	O
clinical	JJ	O
features	NNS	O
,	,	O
and	CC	O
outcome	NN	O
of	IN	O
therapy	NN	O
in	IN	O
children	NNS	O
treated	VBN	O
in	IN	O
the	DT	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
AML	NNP	O
10	CD	O
and	CC	O
12	CD	O
trials	NNS	O
for	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
.	.	O

Between	NNP	O
May	NNP	O
1988	CD	O
and	CC	O
June	NNP	O
2000	CD	O
,	,	O
698	CD	O
children	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
the	DT	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
acute	VBZ	O
myeloid	JJ	O
leukemia	NN	O
10	CD	O
and	CC	O
12	CD	O
trials	NNS	O
.	.	O

The	DT	O
presenting	NN	O
features	NNS	O
and	CC	O
outcomes	NNS	O
of	IN	O
therapy	NN	O
in	IN	O
these	DT	O
children	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
age	NN	O
.	.	O

Although	IN	O
there	EX	O
was	VBD	O
no	DT	O
single	JJ	O
cutoff	NN	O
in	IN	O
age	NN	O
,	,	O
younger	JJR	O
children	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
intermediate	JJ	O
risk	NN	O
and	CC	O
less	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
favorable	JJ	Physical
cytogenetics	NNS	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
they	PRP	O
had	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	Physical
of	IN	Physical
translocations	NNS	Physical
involving	VBG	Physical
chromosome	NN	Physical
11q23	CD	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
distribution	NN	O
of	IN	O
French-American-British	NNP	O
(	(	O
FAB	NNP	O
)	)	O
types	NNS	O
also	RB	O
varied	VBD	O
with	IN	O
age	NN	O
;	:	O
FAB	NNP	Physical
types	VBZ	Physical
M5	NNP	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
M7	NNP	Others
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
early	JJ	O
childhood	NN	O
,	,	O
whereas	IN	O
older	JJR	O
children	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
FAB	NNP	Others
types	NNS	Others
M0	NNP	Others
(	(	O
P	NNP	O
=.03	NNP	O
)	)	O
,	,	O
M1	NNP	O
(	(	O
P	NNP	O
=.04	NNP	O
)	)	O
,	,	O
M2	NNP	Others
(	(	O
P	NNP	O
=.005	NNP	O
)	)	O
,	,	O
and	CC	O
M3	NNP	Others
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Involvement	NN	O
of	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
at	IN	O
diagnosis	NN	O
was	VBD	O
also	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
youngest	JJS	O
children	NNS	O
(	(	O
P	NNP	O
=.01	NNP	O
)	)	O
.	.	O

Younger	JJR	O
children	NNS	O
had	VBD	O
more	RBR	O
severe	JJ	Physical
diarrhea	NN	Physical
(	(	O
P	NNP	O
=.002	NNP	O
)	)	O
,	,	O
whereas	JJ	O
older	JJR	O
children	NNS	O
had	VBD	O
worse	JJR	O
nausea	NN	Physical
and	CC	Physical
vomiting	NN	Physical
(	(	O
P	NNP	O
=.01	NNP	O
)	)	O
after	IN	O
chemotherapy	NN	O
.	.	O

When	WRB	O
adjusted	VBN	O
for	IN	O
other	JJ	O
important	JJ	O
factors	NNS	O
,	,	O
complete	JJ	Physical
remission	NN	Physical
rates	NNS	Physical
were	VBD	O
similar	JJ	O
(	(	O
P	NNP	O
=.5	NNP	O
)	)	O
and	CC	O
although	IN	O
there	EX	O
was	VBD	O
less	RBR	O
resistant	JJ	O
disease	NN	O
in	IN	O
younger	JJR	O
children	NNS	O
(	(	O
P	NNP	O
=.003	NNP	O
)	)	O
,	,	O
this	DT	O
was	VBD	O
partially	RB	O
balanced	VBN	O
by	IN	O
a	DT	O
slight	JJ	O
increase	NN	O
in	IN	O
deaths	NNS	Mortality
during	IN	O
induction	NN	O
therapy	NN	O
in	IN	O
younger	JJR	O
patients	NNS	O
(	(	O
P	NNP	O
=.06	NNP	O
)	)	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	O
P	NNP	O
=.02	NNP	O
)	)	O
,	,	O
event-free	JJ	Mortality
survival	NN	Mortality
(	(	O
P	NNP	O
=.02	NNP	O
)	)	O
,	,	O
and	CC	O
disease-free	JJ	Mortality
survival	NN	Mortality
were	VBD	O
better	JJR	O
(	(	O
P	NNP	O
=.06	NNP	O
)	)	O
in	IN	O
younger	JJR	O
children	NNS	O
due	JJ	O
to	TO	O
a	DT	O
lower	JJR	O
relapse	NN	Physical
rate	NN	Physical
(	(	O
P	NNP	O
=.02	NNP	O
)	)	O
especially	RB	O
in	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
(	(	O
P	NNP	O
=.02	NNP	O
)	)	O
.	.	O

Clinical	JJ	O
significance	NN	O
and	CC	O
prognostic	JJ	O
importance	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
in	IN	O
non-Q-wave	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Left	NNP	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
hypertrophy	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
an	DT	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiac	JJ	O
death	NN	O
,	,	O
but	CC	O
its	PRP$	O
significance	NN	O
in	IN	O
non-Q-wave	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
assessed	VBN	O
previously	RB	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
diltiazem-placebo-controlled	JJ	O
therapeutic	JJ	O
trial	NN	O
of	IN	O
non-Q-wave	JJ	O
AMI	NNP	O
confirmed	VBN	O
by	IN	O
creatine	NN	O
kinase-MB	NN	O
(	(	O
CK-MB	NNP	O
)	)	O
,	,	O
126	CD	O
of	IN	O
544	CD	O
patients	NNS	O
(	(	O
23	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
LV	NNP	O
hypertrophy	NN	O
using	VBG	O
standard	JJ	O
voltage	NN	O
criteria	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
were	VBD	O
significantly	RB	O
older	JJR	O
(	(	O
65	CD	O
vs	RB	O
60	CD	O
years	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
had	VBD	O
smaller	JJR	O
peak	NN	O
adjusted	VBN	O
CK	NNP	O
levels	NNS	O
(	(	O
490	CD	O
+/-	JJ	O
376	CD	O
vs	JJ	O
666	CD	O
+/-	JJ	O
726	CD	O
IU/liter	NNP	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
than	IN	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
acute	JJ	O
mortality	NN	Mortality
during	IN	O
hospitalization	NN	Others
,	,	O
progression	NN	Physical
to	TO	Physical
Q	NNP	Physical
waves	NNS	Physical
,	,	O
reinfarction	NN	Physical
by	IN	Physical
CK-MB	NNP	Physical
criteria	NNS	Physical
or	CC	O
angina	NNS	Physical
associated	VBN	O
with	IN	O
transient	JJ	O
electrocardiographic	JJ	O
changes	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
those	DT	O
patients	NNS	O
with	IN	O
non-Q-wave	JJ	O
AMI	NNP	O
and	CC	O
LV	NNP	O
hypertrophy	NN	O
had	VBD	O
a	DT	O
2-fold	JJ	O
higher	JJR	O
incidence	NN	O
of	IN	O
reinfarction	NN	Physical
(	(	O
24	CD	O
vs	RB	O
12	CD	O
%	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
and	CC	O
death	NN	O
(	(	O
19	CD	O
vs	RB	O
9	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.044	CD	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Multivariate	NNP	O
regression	NN	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
relative	JJ	O
risk	NN	Mortality
of	IN	Mortality
death	NN	Mortality
and	CC	O
reinfarction	NN	Physical
during	IN	O
the	DT	O
initial	JJ	O
year	NN	O
after	IN	O
AMI	NNP	O
was	VBD	O
increased	VBN	O
by	IN	O
a	DT	O
factor	NN	O
of	IN	O
1.7	CD	O
and	CC	O
2.1	CD	O
among	IN	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
was	VBD	O
therefore	RB	O
concluded	VBD	O
that	IN	O
,	,	O
although	IN	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
and	CC	O
non-Q-wave	JJ	O
AMI	NNP	O
have	VBP	O
smaller	JJR	O
enzymatic	JJ	O
infarcts	NNS	O
and	CC	O
the	DT	O
same	JJ	O
short-term	JJ	O
prognosis	NN	O
as	IN	O
do	JJ	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
their	PRP$	O
reinfarction	NN	O
and	CC	O
mortality	NN	O
rates	NNS	O
are	VBP	O
significantly	RB	O
increased	VBN	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Comparison	NNP	O
of	IN	O
remifentanil	NN	O
with	IN	O
fentanyl	NN	O
for	IN	O
deep	JJ	Physical
sedation	NN	Physical
in	IN	O
oral	JJ	O
surgery	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
recovery	NN	O
for	IN	O
oral	JJ	O
surgery	NN	O
patients	NNS	O
given	VBN	O
a	DT	O
deep	JJ	O
sedation	NN	O
regimen	NNS	O
of	IN	O
midazolam	NN	O
,	,	O
propofol	NN	O
,	,	O
and	CC	O
remifentanil	NN	O
with	IN	O
a	DT	O
standard	JJ	O
control	NN	O
of	IN	O
fentanyl	NN	O
in	IN	O
place	NN	O
of	IN	O
remifentanil	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	NN	O
,	,	O
prospective	JJ	O
,	,	O
single-blinded	JJ	O
controlled	VBD	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
,	,	O
the	DT	O
control	NN	O
,	,	O
received	VBD	O
midazolam	JJ	O
0.03	CD	O
mg/kg	NN	O
,	,	O
fentanyl	VBP	O
1	CD	O
microg/kg	NN	O
,	,	O
and	CC	O
propofol	VB	O
initially	RB	O
at	IN	O
140	CD	O
microg/kg/min	NN	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
midazolam	RB	O
0.03	CD	O
mg/kg	NN	O
,	,	O
remifentanil	NN	O
:	:	O
propofol	NN	O
(	(	O
1:500	CD	O
)	)	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
propofol	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
40	CD	O
microg/kg/min	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
time	NN	Others
to	TO	Others
response	NN	Others
to	TO	Others
verbal	JJ	Others
command	NN	Others
,	,	O
Aldrete	NNP	Physical
score	VBD	Physical
=	JJ	Physical
9	CD	Physical
,	,	O
Postanesthesia	NNP	Others
Discharge	NNP	Others
Scoring	NNP	Others
System	NNP	Others
=	VBD	Physical
7	CD	Physical
,	,	O
and	CC	O
assessment	NN	Physical
by	IN	Physical
the	DT	Physical
Digit	NNP	Physical
Symbol	NNP	Physical
Substitution	NNP	Physical
Test	NNP	Physical
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
subjects	NNS	O
were	VBD	O
entered	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Baseline	NNP	O
findings	NNS	O
were	VBD	O
homogenous	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
2	CD	O
recovered	VBN	O
earlier	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
and	CC	O
required	VBN	O
less	JJR	O
propofol	NN	O
for	IN	O
both	DT	O
the	DT	O
induction	NN	Physical
(	(	O
0.8	CD	O
+/-	JJ	O
0.4	CD	O
versus	NN	O
1.2	CD	O
+/-	JJ	O
0.6	CD	O
mg/kg	NN	O
;	:	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
maintenance	NN	Others
of	IN	Others
deep	JJ	Others
sedation	NN	Others
(	(	O
46	CD	O
+/-	JJ	O
9	CD	O
versus	NN	O
131	CD	O
+/-	JJ	O
17	CD	O
microg/kg/min	NN	O
;	:	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
minor	JJ	O
differences	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
this	DT	O
remifentanil	JJ	O
regimen	NNS	O
provided	VBD	O
significantly	RB	O
more	RBR	O
rapid	JJ	Others
recovery	NN	Others
and	CC	O
used	VBD	O
significantly	RB	O
less	JJR	O
propofol	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
fentanyl	JJ	O
regimen	NNS	O
.	.	O

Low	JJ	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
in	IN	O
anxiety	NN	Mental
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
between-patient	JJ	O
trial	NN	O
comparing	VBG	O
two	CD	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
(	(	O
15	CD	O
and	CC	O
30	CD	O
mg	NN	O
)	)	O
with	IN	O
placebo	NN	O
,	,	O
each	DT	O
given	VBN	O
once	RB	O
daily	JJ	O
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
92	CD	O
outpatients	NNS	O
affected	VBN	O
by	IN	O
generalized	JJ	O
anxiety	NN	O
disorders	NNS	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
,	,	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

After	IN	O
1-week	JJ	O
washout	NN	O
period	NN	O
47	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ketazolam	VB	O
15	CD	O
mg	NN	O
,	,	O
and	CC	O
45	CD	O
to	TO	O
placebo	VB	O
for	IN	O
15	CD	O
days	NNS	O
(	(	O
first	JJ	O
period	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
period	NN	O
,	,	O
if	IN	O
the	DT	O
patient	NN	O
experienced	VBD	O
a	DT	O
decrease	NN	O
on	IN	O
the	DT	O
total	JJ	Physical
Hamilton	NNP	Physical
Anxiety	NNP	Physical
Rating	NNP	Physical
Scale	NNP	Physical
(	(	Physical
HAM-A	NNP	Physical
)	)	Physical
of	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
of	IN	O
basal	NN	O
value	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
kept	VBN	O
unchanged	JJ	O
for	IN	O
a	DT	O
further	JJ	O
15	CD	O
days	NNS	O
,	,	O
otherwise	RB	O
15	CD	O
mg	NN	O
of	IN	O
ketazolam	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
previous	JJ	O
treatment	NN	O
(	(	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Anxiety	NN	O
was	VBD	O
rated	VBN	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
with	IN	O
the	DT	O
Italian	JJ	Mental
HAM-A	NNP	Mental
scale	NN	Mental
and	CC	O
with	IN	O
a	DT	O
4-point	JJ	Mental
scale	NN	Mental
(	(	Mental
patient	NN	Mental
's	POS	Mental
assessment	NN	Mental
)	)	Mental
.	.	Mental

Seventy-eight	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
first	JJ	O
period	NN	O
and	CC	O
75	CD	O
the	DT	O
whole	NN	O
study	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
period	NN	O
the	DT	O
percentage	NN	O
of	IN	O
responders	NNS	O
was	VBD	O
almost	RB	O
identical	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
but	CC	O
during	IN	O
the	DT	O
second	JJ	O
period	NN	O
a	DT	O
further	JJ	O
slight	NN	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
early	JJ	O
placebo	NN	O
responders	NNS	O
,	,	O
while	IN	O
the	DT	O
HAM-A	NNP	Others
score	NN	Others
of	IN	O
patients	NNS	O
on	IN	O
ketazolam	NNS	O
continued	VBN	O
to	TO	O
improve	VB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Likewise	VB	O
a	DT	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
difference	NN	O
between	IN	O
treatments	NNS	O
was	VBD	O
observed	VBN	O
,	,	O
on	IN	O
the	DT	O
4-point	JJ	Others
scale	NN	Others
,	,	O
in	IN	O
the	DT	O
population	NN	O
as	IN	O
a	DT	O
whole	NN	O
(	(	O
end	NN	O
of	IN	O
first	JJ	O
period	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
responder	NN	O
patients	NNS	O
(	(	O
end	JJ	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Tolerability	NN	Others
was	VBD	O
good	JJ	O
,	,	O
except	IN	O
in	IN	O
1	CD	O
patient	NN	O
on	IN	O
placebo	NN	O
,	,	O
who	WP	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	Physical
headache	NN	Physical
.	.	O

Femoral	NNP	O
vein	NN	O
delivery	NN	O
of	IN	O
contrast	NN	O
medium	NN	O
enhances	VBZ	O
transthoracic	JJ	Others
echocardiographic	JJ	Others
detection	NN	Others
of	IN	O
patent	NN	Physical
foramen	NNS	Physical
ovale	VBP	Physical
.	.	O

OBJECTIVES	IN	O
We	PRP	O
postulated	VBD	O
that	IN	O
femoral	JJ	O
vein	JJ	O
delivery	NN	O
of	IN	O
contrast	NN	O
medium	NN	O
because	IN	O
of	IN	O
streaming	NN	O
,	,	O
might	MD	O
enhance	VB	O
precordial	JJ	Others
echocardiographic	JJ	Others
detection	NN	Others
of	IN	O
patent	NN	O
foramen	NNS	O
ovale	VBP	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
precordial	JJ	O
contrast	NN	O
echocardiography	NN	O
is	VBZ	O
widely	RB	O
used	VBN	O
to	TO	O
diagnose	VB	O
patent	JJ	O
foramen	NNS	O
ovale	RB	O
,	,	O
this	DT	O
method	NN	O
is	VBZ	O
limited	VBN	O
by	IN	O
poor	JJ	O
sensitivity	NN	O
.	.	O

Previous	JJ	O
investigators	NNS	O
have	VBP	O
demonstrated	VBN	O
enhanced	JJ	O
detection	NN	O
of	IN	O
atrial	JJ	Physical
defects	NNS	Physical
by	IN	O
the	DT	O
dye-dilution	NN	O
technique	NN	O
after	IN	O
delivery	NN	O
of	IN	O
contrast	NN	O
medium	NN	O
into	IN	O
the	DT	O
inferior	NN	O
rather	RB	O
than	IN	O
the	DT	O
superior	JJ	O
vena	NN	O
cava	NN	O
.	.	O

METHODS	NNP	O
Transthoracic	NNP	O
contrast	NN	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
randomly	RB	O
selected	VBN	O
group	NN	O
of	IN	O
70	CD	O
patients	NNS	O
(	(	O
without	IN	O
previous	JJ	O
history	NN	O
of	IN	O
cerebral	JJ	O
or	CC	O
systemic	JJ	O
embolus	NN	O
)	)	O
undergoing	VBG	O
cardiac	JJ	O
catheterization	NN	O
.	.	O

Paired	VBN	O
contrast	NN	O
agent	NN	O
injections	NNS	O
(	(	O
10	CD	O
ml	NN	O
dextrose	NN	O
in	IN	O
water/0.25	NN	O
ml	NNP	O
air	NN	O
)	)	O
were	VBD	O
administered	VBN	O
from	IN	O
an	DT	O
upper	JJ	O
extremity	NN	O
vein	NN	O
and	CC	O
femoral	JJ	O
vein	NN	O
in	IN	O
each	DT	O
patient	NN	O
during	IN	O
spontaneous	JJ	O
respiration	NN	O
,	,	O
cough	NN	O
and	CC	O
Valsalva	NNP	O
maneuvers	NNS	O
.	.	O

Studies	NNS	O
were	VBD	O
interpreted	VBN	O
by	IN	O
an	DT	O
experienced	JJ	O
echocardiographer	NN	O
unaware	NN	O
of	IN	O
the	DT	O
sequence	NN	O
and	CC	O
site	NN	O
of	IN	O
injections	NNS	O
.	.	O

Positive	JJ	O
studies	NNS	O
were	VBD	O
semiquantitatively	RB	O
graded	VBN	O
from	IN	O
+1	NNP	O
(	(	O
minimal	JJ	O
left	VBD	O
ventricular	JJ	O
opacification	NN	O
)	)	O
to	TO	O
+4	VB	O
(	(	O
intense	JJ	O
left	VBD	O
ventricular	JJ	O
opacification	NN	O
)	)	O
.	.	O

Catheterization	NN	Others
and	CC	Physical
echocardiographic	JJ	Others
assessment	NN	Others
of	IN	Physical
patent	NN	Physical
foramen	NNS	Physical
ovale	VBP	Physical
were	VBD	O
compared	VBN	O
in	IN	O
21	CD	O
subjects	NNS	O
.	.	O

RESULTS	NNP	O
Patent	NNP	O
foramen	NNS	O
ovale	NN	O
was	VBD	O
detected	VBN	O
significantly	RB	O
more	RBR	O
often	RB	O
during	IN	O
femoral	JJ	O
vein	NNS	O
versus	VBP	O
upper	JJ	O
extremity	NN	O
contrast	NN	O
delivery	NN	O
(	(	O
23	CD	O
of	IN	O
70	CD	O
patients	NNS	O
[	JJ	O
prevalence	RB	O
33	CD	O
%	NN	O
]	NNP	O
vs.	IN	O
9	CD	O
of	IN	O
70	CD	O
patients	NNS	O
[	JJ	O
prevalence	RB	O
13	CD	O
%	NN	O
]	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
intensity	NN	Others
of	IN	Others
left	JJ	Others
ventricular	JJ	Others
opacification	NN	Others
was	VBD	O
also	RB	O
greater	JJR	O
during	IN	O
femoral	JJ	O
vein	NNS	O
contrast	NN	O
injection	NN	O
.	.	O

Precordial	JJ	O
echocardiography	NN	O
combined	VBN	O
with	IN	O
femoral	JJ	O
contrast	NN	O
delivery	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
sensitive	JJ	Physical
than	IN	O
cardiac	JJ	O
catheterization	NN	O
for	IN	O
assessment	NN	Physical
of	IN	Physical
patent	NN	Physical
foramen	NNS	Physical
ovale	VBP	Physical
(	(	O
8	CD	O
of	IN	O
21	CD	O
patients	NNS	O
vs.	FW	O
2	CD	O
of	IN	O
21	CD	O
patients	NNS	O
,	,	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Femoral	NNP	O
vein	NNP	O
contrast	NN	O
delivery	NN	O
significantly	RB	O
enhances	VBZ	O
the	DT	O
ability	NN	Others
of	IN	Others
precordial	JJ	Others
contrast	NN	Others
echocardiography	NN	Others
to	TO	Others
diagnose	VB	Others
patent	JJ	Others
foramen	NNS	Others
ovale	VBP	Others
.	.	Others

Physiologic	NNP	O
patency	NN	O
of	IN	O
the	DT	O
foramen	NNS	O
ovale	VBP	O
is	VBZ	O
more	RBR	O
common	JJ	O
(	(	O
prevalence	JJ	O
33	CD	O
%	NN	O
)	)	O
than	IN	O
previously	RB	O
documented	VBN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	NN	O
and	CC	O
beta	VB	O
2-agonist	JJ	O
and	CC	O
combination	NN	O
therapy	NN	O
on	IN	O
respiratory	NN	O
impedance	NN	O
in	IN	O
COPD	NNP	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
three	CD	O
different	JJ	O
regimens	NNS	O
of	IN	O
inhaled	JJ	O
bronchodilators	NNS	O
on	IN	O
spirometry	NN	O
and	CC	O
respiratory	JJ	O
impedance	NN	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
technique	NN	O
of	IN	O
forced	JJ	O
oscillations	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
22	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
FEV1	NNP	O
less	JJR	O
than	IN	O
70	CD	O
percent	NN	O
predicted	VBN	O
)	)	O
.	.	O

On	IN	O
three	CD	O
trial	NN	O
days	NNS	O
,	,	O
patients	NNS	O
inhaled	VBD	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
40	CD	O
micrograms	NNS	O
ipratropium	JJ	O
bromide	NN	O
,	,	O
200	CD	O
micrograms	NNS	O
fenoterol	JJ	O
hydrobromide	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
40	CD	O
micrograms	NNS	O
ipratropium	NN	O
and	CC	O
100	CD	O
micrograms	NNS	O
fenoterol	VBP	O
from	IN	O
a	DT	O
powder	NN	O
inhaler	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
the	DT	O
same	JJ	O
drug	NN	O
after	IN	O
60	CD	O
min	NN	O
.	.	O

The	DT	O
effects	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
20	CD	O
,	,	O
40	CD	O
,	,	O
60	CD	O
,	,	O
and	CC	O
120	CD	O
min	NN	O
after	IN	O
the	DT	O
first	JJ	O
inhalation	NN	O
.	.	O

No	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
total	JJ	Physical
respiratory	NN	Physical
resistance	NN	Physical
at	IN	Physical
8	CD	Physical
Hz	NNP	Physical
(	(	Physical
Rrs	NNP	Physical
[	VBZ	Physical
8	CD	Physical
]	NN	Physical
)	)	Physical
was	VBD	O
observed	VBN	O
after	IN	O
ipratropium	NN	O
,	,	O
whereas	JJ	O
Rrs	NNP	O
(	(	O
8	CD	O
)	)	O
decreased	VBD	O
significantly	RB	O
20	CD	O
min	NNS	O
after	IN	O
fenoterol	NN	O
and	CC	O
40	CD	O
min	NN	O
after	IN	O
the	DT	O
combination	NN	O
regimen	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

All	DT	O
three	CD	O
studied	VBD	O
drugs	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
reactance	NN	Physical
(	(	Physical
p	NN	Physical
less	JJR	Physical
than	IN	Physical
0.01	CD	Physical
)	)	Physical
and	CC	O
decrease	NN	O
in	IN	O
resonant	JJ	Physical
frequency	NN	Physical
.	.	O

Both	DT	O
fenoterol	NN	O
(	(	O
delta	JJ	O
FEV1	NNP	O
34	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
the	DT	O
combination	NN	O
regimen	NNS	O
(	(	O
delta	JJ	O
FEV1	NNP	O
38	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
larger	JJR	O
increase	NN	O
in	IN	O
FEV1	NNP	Physical
than	IN	O
ipratropium	NN	O
alone	RB	O
(	(	O
delta	JJ	O
FEV1	NNP	O
17	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

A	DT	O
second	JJ	Others
dose	NN	Others
of	IN	O
fenoterol	NN	O
and	CC	O
of	IN	O
the	DT	O
combination	NN	O
regimen	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
further	JJ	O
significant	JJ	O
increase	NN	O
in	IN	O
FEV1	NNP	O
after	IN	O
120	CD	O
min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
dose	NN	O
of	IN	O
ipratropium	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
further	JJ	O
significant	JJ	O
increase	NN	O
in	IN	O
FEV1	NNP	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
respiratory	NN	O
impedance	NN	O
were	VBD	O
qualitatively	RB	O
similar	JJ	O
for	IN	O
all	DT	O
three	CD	O
drug	NN	O
regimens	NNS	O
,	,	O
but	CC	O
larger	JJR	O
in	IN	O
absolute	NN	O
terms	NNS	O
after	IN	O
fenoterol	NN	O
and	CC	O
the	DT	O
combination	NN	O
regimen	NNS	O
than	IN	O
after	IN	O
ipratropium	NN	O
.	.	O

The	DT	O
similar	JJ	O
effect	NN	O
of	IN	O
these	DT	O
drugs	NNS	O
on	IN	O
the	DT	O
reactance	NN	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
capacitance	NN	Physical
of	IN	Physical
the	DT	Physical
respiratory	NN	Physical
system	NN	Physical
,	,	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
frequency	NN	O
dependence	NN	O
of	IN	O
resistance	NN	O
,	,	O
by	IN	O
assuming	VBG	O
a	DT	O
decrease	NN	O
in	IN	O
peripheral	JJ	O
airway	NN	O
resistance	NN	O
.	.	O

Intracapillary	JJ	Physical
glomerular	NN	Physical
metastases	NNS	Physical
in	IN	O
a	DT	O
nephrectomy	JJ	O
specimen	NNS	O
removed	VBD	O
for	IN	O
ipsilateral	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
.	.	O

A	DT	O
case	NN	O
of	IN	O
intraglomerular	JJ	O
metastases	NNS	O
observed	VBN	O
in	IN	O
a	DT	O
nephrectomy	JJ	O
specimen	NNS	O
removed	VBD	O
for	IN	O
primary	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
is	VBZ	O
reported	VBN	O
.	.	O

The	DT	O
intraglomerular	JJ	O
metastases	NNS	O
arose	VBP	O
by	IN	O
dissemination	NN	O
of	IN	O
malignant	JJ	O
cells	NNS	O
into	IN	O
the	DT	O
systemic	JJ	O
circulation	NN	O
via	IN	O
invasion	NN	O
of	IN	O
the	DT	O
renal	JJ	O
veins	NNS	O
.	.	O

Intraglomerular	JJ	O
metastases	NNS	O
are	VBP	O
therefore	RB	O
an	DT	O
indicator	NN	O
of	IN	O
malignant	JJ	O
dissemination	NN	O
which	WDT	O
in	IN	O
turn	NN	O
should	MD	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
poor	JJ	O
prognosis	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
in	IN	O
nephrectomies	NNS	O
undertaken	VBP	O
for	IN	O
primary	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
at	IN	O
least	JJS	O
one	CD	O
random	NN	O
block	NN	O
of	IN	O
renal	JJ	O
cortex	NN	O
should	MD	O
be	VB	O
examined	VBN	O
to	TO	O
confirm	VB	O
or	CC	O
exclude	VB	O
intraglomerular	JJ	O
metastases	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
effectiveness	NN	Others
trial	NN	O
of	IN	O
collaborative	JJ	O
care	NN	O
for	IN	O
patients	NNS	O
with	IN	O
panic	JJ	O
disorder	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

BACKGROUND	NNP	O
Effectiveness	NNP	Others
studies	NNS	O
have	VBP	O
tested	VBN	O
interventions	NNS	O
to	TO	O
improve	VB	O
quality	NN	Others
of	IN	Others
care	NN	Others
for	IN	O
depression	NN	O
in	IN	O
primary	JJ	O
care	NN	O
,	,	O
but	CC	O
none	NN	O
,	,	O
to	TO	O
our	PRP$	O
knowledge	NN	O
,	,	O
have	VBP	O
been	VBN	O
completed	VBN	O
for	IN	O
panic	JJ	O
disorder	NN	O
(	(	O
PD	NNP	O
)	)	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
test	VB	O
the	DT	O
clinical	JJ	Others
effectiveness	NN	Others
of	IN	O
PD	NNP	O
pharmacotherapy	NN	O
embedded	VBD	O
in	IN	O
a	DT	O
disease	NN	O
management	NN	O
framework	NN	O
of	IN	O
collaborative	JJ	O
care	NN	O
(	(	O
CC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
fifteen	JJ	O
patients	NNS	O
with	IN	O
PD	NNP	O
from	IN	O
3	CD	O
primary	JJ	O
care	NN	O
clinics	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
CC	NNP	O
or	CC	O
usual	JJ	O
care	NN	O
(	(	O
UC	NNP	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
CC	NNP	O
(	(	O
n	JJ	O
=	NNP	O
57	CD	O
)	)	O
received	VBD	O
educational	JJ	O
videotapes	NNS	O
and	CC	O
pamphlets	NNS	O
;	:	O
pharmacotherapy	NN	O
with	IN	O
the	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitor	NN	O
paroxetine	NN	O
;	:	O
2	CD	O
psychiatrist	NN	O
visits	NNS	O
and	CC	O
2	CD	O
telephone	NN	O
calls	NNS	O
in	IN	O
the	DT	O
first	JJ	O
8	CD	O
weeks	NNS	O
;	:	O
and	CC	O
up	RB	O
to	TO	O
5	CD	O
telephone	NN	O
calls	NNS	O
between	IN	O
3	CD	O
and	CC	O
12	CD	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

Usual	NNP	O
care	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
58	CD	O
)	)	O
were	VBD	O
treated	VBN	O
by	IN	O
their	PRP$	O
primary	JJ	O
care	NN	O
physician	NN	O
.	.	O

Telephone	CD	O
assessments	NNS	O
of	IN	O
panic	NN	Mental
,	,	O
anxiety	NN	Mental
sensitivity	NN	Mental
,	,	O
depression	NN	Mental
,	,	O
and	CC	O
disability	NN	Mental
variables	NNS	Mental
were	VBD	O
performed	VBN	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

Adequacy	NNP	Others
of	IN	Others
pharmacotherapy	NN	Others
was	VBD	O
assessed	VBN	O
with	IN	O
an	DT	O
algorithm	NN	Others
based	VBN	O
on	IN	O
a	DT	O
review	NN	O
of	IN	O
efficacy	NN	O
studies	NNS	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
in	IN	O
CC	NNP	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
receive	VB	O
adequate	NN	Others
(	(	Others
type	NN	Others
,	,	Others
dose	NN	Others
,	,	Others
duration	NN	Others
)	)	Others
medication	NN	Others
and	CC	O
more	RBR	O
likely	JJ	O
to	TO	O
adhere	VB	Physical
to	TO	Physical
this	DT	Physical
medication	NN	Physical
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

Random	NNP	O
regression	NN	O
analyses	NNS	O
showed	VBD	O
that	IN	O
CC	NNP	O
patients	NNS	O
improved	VBD	Mental
significantly	RB	O
more	RBR	O
over	IN	O
time	NN	O
compared	VBN	O
with	IN	O
UC	NNP	O
patients	NNS	O
on	IN	O
anxiety	NN	Mental
,	,	O
depression	NN	Mental
,	,	O
and	CC	O
disability	NN	Mental
measures	NNS	Mental
,	,	O
with	IN	O
the	DT	O
greatest	JJS	O
effects	NNS	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
UC	NNP	O
,	,	O
CC	NNP	O
interventions	NNS	O
significantly	RB	O
improved	VBN	O
both	DT	O
quality	NN	Others
of	IN	Others
care	NN	Others
and	CC	O
clinical	JJ	Others
and	CC	Others
functional	JJ	Others
outcomes	NNS	Others
in	IN	O
primary	JJ	O
care	NN	O
PD	NNP	O
patients	NNS	O
.	.	O

Clinical	JJ	O
differences	NNS	O
were	VBD	O
greatest	JJS	O
in	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
,	,	O
corresponding	VBG	O
to	TO	O
the	DT	O
greater	JJR	O
quality	NN	Others
of	IN	Others
care	NN	Others
and	CC	O
the	DT	O
greater	JJR	O
intensity	NN	Mental
of	IN	O
intervention	NN	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
clinical	JJ	O
,	,	O
laboratory	NN	O
,	,	O
and	CC	O
histological	JJ	O
characteristics	NNS	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
:	:	O
improved	JJ	O
definition	NN	O
of	IN	O
risk	NN	O
groups	NNS	O
.	.	O

Follow-up	NNP	O
data	NN	O
of	IN	O
320	CD	O
multiple	JJ	O
myeloma	NN	O
(	(	O
MM	NNP	O
)	)	O
patients	NNS	O
entering	VBG	O
the	DT	O
German	JJ	O
Myeloma	NNP	O
Treatment	NNP	O
Group	NNP	O
(	(	O
GMTG	NNP	O
)	)	O
trial	NN	O
MM01	NNP	O
were	VBD	O
analysed	VBN	O
for	IN	O
factors	NNS	O
predicting	VBG	O
overall	JJ	Mortality
(	(	Mortality
OAS	NNP	Mortality
)	)	Mortality
and	CC	Mortality
tumour	$	Mortality
related	VBN	Mortality
survival	NN	Mortality
(	(	Mortality
TRS	NNP	Mortality
)	)	Mortality
.	.	O

Response	NN	O
to	TO	O
primary	JJ	O
induction	NN	O
chemotherapy	NN	O
was	VBD	O
relevant	JJ	O
for	IN	O
prognosis	NN	O
if	IN	O
a	DT	O
limit	NN	O
of	IN	O
25	CD	O
%	NN	O
tumour	NN	O
cell	NN	O
mass	NN	O
(	(	O
TCM	NNP	O
)	)	O
reduction	NN	O
was	VBD	O
used	VBN	O
to	TO	O
separate	JJ	O
responders	NNS	O
from	IN	O
non-responders	NNS	O
.	.	O

Furthermore	NNP	O
,	,	O
TCM	NNP	O
,	,	O
histological	JJ	O
grading	NN	O
of	IN	O
myeloma	NN	O
cells	NNS	O
,	,	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
infiltration	NN	O
,	,	O
haemoglobin	NN	O
,	,	O
platelet	NN	O
counts	NNS	O
,	,	O
calcium	NN	O
,	,	O
creatinine	NN	O
,	,	O
albumin	NN	O
,	,	O
beta	NN	O
2M	CD	O
,	,	O
and	CC	O
Bence	NNP	O
Jones	NNP	O
proteinuria	NNS	O
correlated	VBD	O
to	TO	O
both	DT	O
OAS	NNP	O
and	CC	O
TRS	NNP	O
.	.	O

Age	NNP	O
was	VBD	O
relevant	JJ	O
for	IN	O
OAS	NNP	O
only	RB	O
.	.	O

The	DT	O
multivariate	NN	O
analysis	NN	O
revealed	VBD	O
histological	JJ	Physical
grading	NN	Physical
,	,	Physical
TCM	NNP	Physical
and	CC	Physical
platelets	NNS	Physical
as	IN	O
the	DT	O
most	RBS	O
reliable	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
the	DT	O
Durie/Salmon	NNP	O
classification	NN	O
could	MD	O
be	VB	O
improved	VBN	O
by	IN	O
defining	VBG	O
poor	JJ	O
prognosis	NN	O
patients	NNS	O
(	(	O
50	CD	O
%	NN	O
TRS	NNP	O
:	:	O
16	CD	O
months	NNS	O
)	)	O
characterised	VBN	O
by	IN	O
pretreatment	JJ	O
platelets	NNS	O
of	IN	O
<	NN	O
or	CC	O
=	$	O
150,000	CD	O
and/or	JJ	O
poorly	RB	O
differentiated	VBN	O
myeloma	NN	O
cell	NN	O
morphology	NN	O
.	.	O

Patients	NNS	O
lacking	VBG	O
both	DT	O
risk	NN	O
factors	NNS	O
displayed	VBD	O
50	CD	O
%	NN	O
survival	JJ	Mortality
times	NNS	Mortality
of	IN	O
46	CD	O
months	NNS	O
in	IN	O
stage	NN	O
III	NNP	O
and	CC	O
88	CD	O
months	NNS	O
in	IN	O
stage	NN	O
II	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
high	JJ	O
and	CC	O
low	JJ	O
dose	NN	O
of	IN	O
the	DT	O
inhaled	JJ	O
steroid	NN	O
,	,	O
budesonide	RB	O
,	,	O
as	IN	O
an	DT	O
initial	JJ	O
treatment	NN	O
in	IN	O
newly	RB	O
detected	VBN	O
asthma	NN	O
.	.	O

The	DT	O
importance	NN	O
of	IN	O
early	JJ	O
initiation	NN	O
of	IN	O
inhaled	JJ	O
steroids	NNS	O
even	RB	O
in	IN	O
mild	JJ	O
asthma	NN	O
has	VBZ	O
been	VBN	O
documented	VBN	O
in	IN	O
several	JJ	O
studies	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
,	,	O
however	RB	O
,	,	O
clear	JJ	O
whether	IN	O
the	DT	O
treatment	NN	O
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
a	DT	O
high	JJ	O
or	CC	O
a	DT	O
low	JJ	O
dose	NN	O
of	IN	O
the	DT	O
inhaled	JJ	O
steroid	NN	O
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
high	JJ	O
and	CC	O
low	JJ	O
dose	NN	O
inhaled	VBN	O
steroid	NN	O
,	,	O
budesonide	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
detected	VBN	O
asthma	NN	O
.	.	O

We	PRP	O
studied	VBD	O
101	CD	O
adult	NN	O
patients	NNS	O
with	IN	O
newly	RB	O
detected	VBN	O
bronchial	JJ	O
asthma	NN	O
who	WP	O
were	VBD	O
without	IN	O
inhaled	VBN	O
steroid	NN	O
or	CC	O
any	DT	O
regular	JJ	O
pharmacological	JJ	O
treatment	NN	O
for	IN	O
their	PRP$	O
asthma	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
one	CD	O
to	TO	O
receive	VB	O
800	CD	O
microg	NN	O
inhaled	VBD	O
budesonide	JJ	O
per	IN	O
day	NN	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
receive	VB	O
200	CD	O
microg	NN	O
inhaled	VBD	O
budesonide	JJ	O
per	IN	O
day	NN	O
.	.	O

The	DT	O
drugs	NNS	O
were	VBD	O
given	VBN	O
with	IN	O
a	DT	O
Turbuhaler	NNP	O
dry	JJ	O
powder	NN	O
inhaler	NN	O
.	.	O

During	IN	O
the	DT	O
3-month	JJ	O
treatment	NN	O
period	NN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
morning	NN	Physical
or	CC	Physical
evening	NN	Physical
PEF	NNP	Physical
values	VBZ	Physical
,	,	O
in	IN	O
spirometric	JJ	O
parameters	NNS	O
,	,	O
in	IN	O
asthmatic	JJ	O
symptoms	NNS	O
or	CC	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
rescue	NN	O
beta2-agonists	NNS	O
.	.	O

The	DT	O
decrease	NN	Physical
in	IN	Physical
bronchial	JJ	Physical
hyperresponsiveness	NN	Physical
was	VBD	O
,	,	O
however	RB	O
,	,	O
more	JJR	Others
marked	VBN	Others
in	IN	O
the	DT	O
high	JJ	O
dose	JJ	O
budesonide	NN	O
group	NN	O
,	,	O
reaching	VBG	O
a	DT	O
borderline	NN	O
significance	NN	O
(	(	O
P=0.10	NNP	O
high	RB	O
vs.	FW	O
low	JJ	O
dose	JJ	O
budesonide	NN	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
in	IN	O
serum	JJ	Physical
markers	NNS	Physical
of	IN	Physical
asthmatic	JJ	Physical
inflammation	NN	Physical
significant	JJ	O
differences	NNS	O
were	VBD	O
shown	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
decrease	NN	Physical
in	IN	Physical
the	DT	Physical
number	NN	Physical
of	IN	Physical
blood	NN	Physical
eosinophils	NNS	Physical
during	IN	O
the	DT	O
treatment	NN	O
was	VBD	O
more	RBR	Others
marked	JJ	Others
in	IN	O
the	DT	O
high	JJ	O
dose	JJ	O
budesonide	NN	O
group	NN	O
(	(	O
P=0.02	NNP	O
;	:	O
high	JJ	O
vs.	FW	O
low	JJ	O
dose	JJ	O
budesonide	NN	O
)	)	O
.	.	O

In	IN	O
serum	JJ	Physical
ECP	NNP	Physical
no	DT	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
low	JJ	O
dose	JJ	O
budesonide	NN	O
group	NN	O
,	,	O
but	CC	O
a	DT	O
marked	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
high-dose	JJ	O
budesonide	NN	O
group	NN	O
(	(	O
P=0.008	NNP	O
;	:	O
high	JJ	O
vs.	FW	O
low	JJ	O
dose	JJ	O
budesonide	NN	O
)	)	O
.	.	O

The	DT	O
change	NN	O
was	VBD	O
even	RB	O
more	JJR	O
marked	JJ	Others
with	IN	O
regard	NN	Physical
to	TO	Physical
serum	VB	Physical
EPX	NNP	Physical
(	(	O
P=0.005	NNP	O
;	:	O
high	JJ	O
vs.	FW	O
low	JJ	O
dose	JJ	O
budesonide	NN	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
support	VB	O
the	DT	O
view	NN	O
that	IN	O
the	DT	O
treatment	NN	O
of	IN	O
newly	RB	O
detected	VBN	O
asthma	NN	O
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
a	DT	O
high	JJ	O
dose	NN	O
of	IN	O
inhaled	JJ	O
steroid	NN	O
.	.	O

The	DT	O
low	JJ	O
dose	NN	O
may	MD	O
not	RB	O
be	VB	O
enough	RB	O
to	TO	O
suppress	VB	O
asthmatic	JJ	O
inflammation	NN	O
despite	IN	O
good	JJ	O
clinical	JJ	O
primary	JJ	O
response	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
fatty	JJ	O
acid	NN	O
ethyl	NN	O
esters	NNS	O
increases	VBZ	O
large	JJ	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	Physical
in	IN	O
obese	JJ	O
adults	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
.	.	O

Increased	VBN	O
arterial	JJ	O
stiffness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
obese	JJ	O
individuals	NNS	O
.	.	O

Whether	NNP	O
n3	JJ	O
fatty	RB	O
acid	JJ	O
ethyl	NN	O
ester	NN	O
(	(	O
FAEE	NNP	O
)	)	O
supplementation	NN	O
improves	VBZ	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
obese	JJ	O
participants	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
12-wk	JJ	O
randomized	NN	O
,	,	O
single-blind	JJ	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
25	CD	O
%	NN	O
energy	NN	O
deficit	NN	O
weight	VBD	O
loss	NN	O
diet	NN	O
alone	RB	O
(	(	O
WL	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
WL	NNP	O
plus	CC	O
4	CD	O
g/d	NN	O
Omacor	NNP	O
(	(	O
46	CD	O
%	NN	O
EPA	NNP	O
and	CC	O
38	CD	O
%	NN	O
DHA	NNP	O
)	)	O
supplementation	NN	O
(	(	O
WL+FAEE	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
on	IN	O
arterial	JJ	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Large	NNP	Physical
(	(	Physical
C1	NNP	Physical
)	)	Physical
and	CC	Physical
small	JJ	Physical
artery	NN	Physical
elasticity	NN	Physical
(	(	Physical
C2	NNP	Physical
)	)	Physical
were	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
contour	NN	O
analysis	NN	O
of	IN	O
the	DT	O
radial	JJ	O
artery	NN	O
.	.	O

WL	NNP	O
alone	RB	O
reduced	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
in	IN	O
all	DT	O
)	)	O
body	NN	Physical
weight	NN	Physical
(	(	O
-3	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
cardiac	JJ	O
output	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-25	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
homeostasis	NN	O
model	NN	O
assessment	NN	O
(	(	O
HOMA	NNP	O
)	)	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBD	Physical
plasma	NN	Physical
HDL	NNP	Physical
cholesterol	NN	Physical
(	(	O
+9	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	NN	O
(	(	O
+18	CD	O
%	NN	O
)	)	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
WL	NNP	O
alone	RB	O
did	VBD	O
not	RB	O
alter	VB	O
C1	NNP	O
and	CC	O
C2	NNP	O
.	.	O

The	DT	O
WL+FAEE	NNP	O
intervention	NN	O
significantly	RB	O
reduced	VBN	O
body	NN	O
weight	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	Physical
(	(	O
-8	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	Physical
(	(	O
-5	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
pulse	JJ	Physical
pressure	NN	Physical
(	(	O
-5	CD	O
%	NN	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	Physical
TG	NNP	Physical
concentration	NN	Physical
(	(	O
-36	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
HOMA	NNP	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	JJ	Physical
stroke	NN	Physical
volume	NN	Physical
(	(	O
+3	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+6	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	JJ	O
concentrations	NNS	O
(	(	O
+28	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
C1	NNP	O
(	(	O
+20	NNP	O
%	NN	O
)	)	O
and	CC	O
C2	NNP	O
(	(	O
+22	NNP	O
%	NN	O
)	)	O
artery	NN	O
elasticity	NN	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	O
heart	NN	Physical
rate	NN	Physical
,	,	O
plasma	NN	Physical
TGs	NNP	Physical
,	,	O
C1	NNP	Physical
,	,	O
and	CC	O
C2	NNP	Physical
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
WL+FAEE	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
WL	NNP	O
group	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	O
FAEEs	NNP	O
improves	VBZ	O
C1	NNP	Physical
and	CC	O
C2	NNP	Physical
independently	RB	O
of	IN	O
weight	JJ	Physical
loss	NN	Physical
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Recovery	NN	O
following	VBG	O
outpatient	JJ	O
anesthesia	NN	O
:	:	O
use	NN	O
of	IN	O
enflurane	NN	O
versus	NN	O
propofol	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
intraoperative	JJ	O
conditions	NNS	O
and	CC	O
postoperative	JJ	O
recovery	NN	O
of	IN	O
patients	NNS	O
following	VBG	O
the	DT	O
use	NN	O
of	IN	O
either	DT	O
propofol-nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
or	CC	O
enflurane-N2O	JJ	O
for	IN	O
maintenance	NN	O
of	IN	O
outpatient	JJ	O
anesthesia	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
single-blind	NN	O
study	NN	O
.	.	O

SETTING	NNP	O
University	NNP	O
hospital	NN	O
outpatient	NN	O
surgery	NN	O
center	NN	O
.	.	O

PATIENTS	CC	O
61	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
healthy	JJ	O
female	NN	O
outpatients	NNS	O
undergoing	VBG	O
laparoscopic	NN	O
surgery	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
anesthetic	JJ	O
regimens	NNS	O
.	.	O

Group	NNP	O
1	CD	O
(	(	O
control	NN	O
)	)	O
received	VBD	O
thiopental	JJ	O
sodium	NN	O
4	CD	O
mg/kg	NN	O
intravenously	RB	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
,	,	O
followed	VBN	O
by	IN	O
0.5	CD	O
%	NN	O
to	TO	O
1.5	CD	O
%	NN	O
enflurane	NN	O
and	CC	O
67	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
oxygen	NN	O
(	(	O
O2	NNP	O
)	)	O
.	.	O

Group	NNP	O
2	CD	O
received	VBD	O
propofol	JJ	O
2	CD	O
mg/kg	NN	O
i.v.	NN	O
,	,	O
followed	VBN	O
by	IN	O
0.5	CD	O
%	NN	O
to	TO	O
1.5	CD	O
%	NN	O
enflurane	NN	O
and	CC	O
67	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
.	.	O

Group	NNP	O
3	CD	O
received	VBD	O
propofol	JJ	O
2	CD	O
mg/kg	NN	O
i.v.	NN	O
,	,	O
followed	VBN	O
by	IN	O
propofol	NN	O
50	CD	O
to	TO	O
160	CD	O
micrograms/kg/min	NN	O
i.v	NN	O
.	.	O

and	CC	O
67	CD	O
%	NN	O
N2O	NNP	O
in	IN	O
O2	NNP	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
succinylcholine	JJ	O
1	CD	O
mg/kg	NN	O
i.v	NN	O
.	.	O

to	TO	O
facilitate	VB	O
tracheal	JJ	O
intubation	NN	O
and	CC	O
atracurium	NN	O
10	CD	O
to	TO	O
20	CD	O
mg	NN	O
i.v	NN	O
.	.	O

to	TO	O
provide	VB	O
adequate	JJ	O
relaxation	NN	O
during	IN	O
the	DT	O
maintenance	NN	O
period	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Recovery	NNP	Physical
from	IN	Physical
anesthesia	NN	Physical
was	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
research	NN	O
nurse	NN	O
who	WP	O
was	VBD	O
unaware	NN	O
of	IN	O
the	DT	O
anesthetic	JJ	O
technique	NN	O
used	VBN	O
.	.	O

The	DT	O
mean	JJ	Physical
+/-	JJ	Physical
SD	NNP	Physical
time	NN	Physical
to	TO	Physical
eye	NN	Physical
opening	NN	Physical
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
the	DT	O
thiopental-enflurane-N2O	JJ	O
group	NN	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
propofol-propofol-N2O	JJ	O
group	NN	O
(	(	O
Group	NNP	O
3	CD	O
)	)	O
(	(	O
6.1	CD	O
+/-	JJ	O
2.5	CD	O
minutes	NNS	O
vs.	IN	O
3.5	CD	O
+/-	JJ	O
2.8	CD	O
minutes	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
mean	JJ	Physical
time	NN	Physical
to	TO	Physical
respond	VB	Physical
to	TO	Physical
verbal	VB	Physical
commands	NNS	Physical
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
propofol	NN	O
induction	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
thiopental	JJ	O
induction	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
enflurane	NN	O
versus	NN	O
propofol	NN	O
for	IN	O
maintenance	NN	O
of	IN	O
anesthesia	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
prolong	IN	O
the	DT	O
time	NN	Physical
from	IN	Physical
arrival	NN	Physical
in	IN	Physical
the	DT	Physical
recovery	NN	Physical
room	NN	Physical
to	TO	Physical
sitting	VBG	Physical
,	,	Physical
tolerating	VBG	Physical
oral	JJ	Physical
fluids	NNS	Physical
,	,	Physical
walking	VBG	Physical
,	,	Physical
or	CC	Physical
being	VBG	Physical
judged	VBN	Physical
fit	NN	Physical
for	IN	Physical
discharge	NN	Physical
.	.	Physical

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
postoperative	VB	Pain
pain	NN	Pain
or	CC	Pain
analgesic	JJ	Pain
requirements	NNS	Pain
.	.	O

Finally	RB	O
,	,	O
patients	NNS	O
who	WP	O
received	VBD	O
enflurane	NN	O
for	IN	O
maintenance	NN	O
of	IN	O
anesthesia	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	Adverseeffect
frequency	NN	Adverseeffect
of	IN	Adverseeffect
nausea	NN	Adverseeffect
and	CC	Adverseeffect
vomiting	NN	Adverseeffect
than	IN	O
the	DT	O
propofol	JJ	O
maintenance	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Induction	NNP	O
of	IN	O
anesthesia	NN	O
with	IN	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
more	RBR	Physical
rapid	JJ	Physical
emergence	NN	Physical
from	IN	Physical
anesthesia	NN	Physical
than	IN	O
induction	NN	O
with	IN	O
thiopental	JJ	O
.	.	O

Maintenance	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
enflurane	NN	O
did	VBD	O
not	RB	O
prolong	JJ	O
recovery	NN	Physical
compared	VBN	O
with	IN	O
maintenance	NN	O
with	IN	O
propofol	NN	O
,	,	O
but	CC	O
enflurane	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
frequency	NN	Adverseeffect
of	IN	Adverseeffect
postoperative	JJ	Adverseeffect
nausea	NN	Adverseeffect
and	CC	Adverseeffect
vomiting	NN	Adverseeffect
.	.	O

Efficacy	NN	Others
of	IN	O
amantadine	NN	O
on	IN	O
quality	NN	Others
of	IN	Others
life	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
treated	VBD	O
with	IN	O
interferon-alpha	JJ	O
and	CC	O
ribavirin	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

AIM	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
amantadine	JJ	O
reduces	NNS	O
deterioration	NN	Others
of	IN	Others
quality	NN	Others
of	IN	Others
life	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
during	IN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
interferon-alpha	JJ	O
(	(	O
IFN-alpha	NNP	O
)	)	O
and	CC	O
ribavirin	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
,	,	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
[	NN	O
17	CD	O
]	NN	O
and	CC	O
randomized	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
amantadine	NN	O
(	(	O
200	CD	O
mg/day	NN	O
,	,	O
orally	RB	O
,	,	O
n=136	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=131	JJ	O
)	)	O
.	.	O

Quality	NN	Others
of	IN	Others
life	NN	Others
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
'Profile	NN	Mental
of	IN	Mental
Mood	NNP	Mental
States	NNPS	Mental
'	POS	Mental
scale	NN	Mental
and	CC	Others
the	DT	Others
'Everyday	JJ	Others
Life	NNP	Others
'	POS	Others
questionnaire	NN	Others
at	IN	O
baseline	NN	O
,	,	O
treatment	NN	O
week	NN	O
(	(	O
TW	NNP	O
)	)	O
8	CD	O
,	,	O
TW24	NNP	O
,	,	O
TW48	NNP	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
Early	JJ	O
during	IN	O
treatment	NN	O
at	IN	O
TW8	NNP	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
amantadine	NN	O
group	NN	O
.	.	O

At	IN	O
TW24	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
amantadine	NN	O
group	NN	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
modalities	NNS	Physical
depression	NN	Physical
,	,	O
fatigue	NN	Physical
,	,	Physical
and	CC	Physical
vigor	NN	Physical
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Especially	RB	O
,	,	O
nonresponders	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
lower	JJR	Physical
deterioration	NN	Physical
of	IN	Physical
depression	NN	Physical
,	,	O
anger	NN	Physical
,	,	Mental
mind	NN	Physical
function	NN	Physical
,	,	Mental
everyday	JJ	Mental
life	NN	Mental
,	,	Mental
and	CC	Mental
zest	JJS	Mental
for	IN	Mental
life	NN	Mental
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
beneficial	JJ	Others
effects	NNS	Others
of	IN	O
amantadine	NN	O
disappeared	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
addition	NN	O
of	IN	O
amantadine	NN	O
to	TO	O
IFN-alpha	NNP	O
plus	CC	O
ribavirin	JJ	O
combination	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
deterioration	NN	Physical
of	IN	Physical
depression	NN	Physical
,	,	O
fatigue	NN	Physical
,	,	O
and	CC	O
vigor	NN	Physical
during	IN	O
treatment	NN	O
but	CC	O
does	VBZ	O
not	RB	O
affect	JJ	O
quality	NN	Others
of	IN	Others
life	NN	Others
after	IN	O
treatment	NN	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
mitoxantrone	NN	O
with	IN	O
doxorubicin	NN	O
in	IN	O
previously	RB	O
treated	VBN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
twenty-five	JJ	O
women	NNS	O
with	IN	O
metastatic	JJ	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
breast	NN	O
who	WP	O
had	VBD	O
failed	VBN	O
one	CD	O
prior	JJ	O
chemotherapeutic	JJ	O
regimen	NNS	O
for	IN	O
advanced	JJ	O
disease	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
14	CD	O
mg/m2	NN	O
of	IN	O
mitoxantrone	NN	O
or	CC	O
75	CD	O
mg/m2	NN	O
of	IN	O
doxorubicin	NN	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

Enrollment	NN	O
was	VBD	O
closed	VBN	O
on	IN	O
October	NNP	O
31	CD	O
,	,	O
1984	CD	O
,	,	O
after	IN	O
165	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
mitoxantrone	VB	O
and	CC	O
160	CD	O
patients	NNS	O
to	TO	O
doxorubicin	VB	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
response	NN	Others
rate	NN	Others
,	,	Others
duration	NN	Others
of	IN	Others
response	NN	Others
,	,	Others
time	NN	Others
to	TO	Others
progression	NN	Others
or	CC	Physical
death	NN	Mortality
,	,	Physical
time	NN	Others
to	TO	Others
treatment	NN	Others
failure	NN	Others
(	(	Others
TTF	NNP	Others
)	)	Others
,	,	Physical
and	CC	Physical
survival	NN	Mortality
.	.	Physical

The	DT	O
response	NN	Physical
rate	NN	Physical
to	TO	O
mitoxantrone	NN	O
was	VBD	O
20.6	CD	O
%	NN	O
,	,	O
to	TO	O
doxorubicin	VB	O
29.3	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.07	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	Others
response	NN	Others
duration	NN	Others
was	VBD	O
151	CD	O
days	NNS	O
for	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
and	CC	O
126	CD	O
days	NNS	O
for	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.16	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	Others
TTF	NNP	Others
was	VBD	O
70	CD	O
days	NNS	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
and	CC	O
104	CD	O
days	NNS	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.36	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	Mortality
survival	NN	Mortality
of	IN	O
patients	NNS	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
mitoxantrone	NN	O
was	VBD	O
273	CD	O
days	NNS	O
;	:	O
for	IN	O
doxorubicin	NN	O
268	CD	O
days	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.40	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
responses	NNS	O
among	IN	O
77	CD	O
patients	NNS	O
crossed	VBN	O
over	IN	O
to	TO	O
mitoxantrone	VB	O
after	IN	O
initial	JJ	O
treatment	NN	O
with	IN	O
doxorubicin	NN	O
.	.	O

The	DT	Others
major	JJ	Others
dose-limiting	JJ	Others
toxicity	NN	Others
for	IN	O
both	DT	O
drugs	NNS	O
was	VBD	O
leukopenia	RB	Adverseeffect
.	.	Adverseeffect

There	EX	O
was	VBD	O
significantly	RB	O
less	JJR	Others
severe	JJ	Others
and	CC	Others
less	RBR	Others
frequent	JJ	Others
toxicity	NN	Others
with	IN	O
mitoxantrone	JJ	O
administration	NN	O
.	.	O

Severe	NNP	Adverseeffect
nausea	NN	Adverseeffect
and	CC	Adverseeffect
vomiting	NN	Adverseeffect
occurred	VBD	O
in	IN	O
9.5	CD	O
%	NN	O
of	IN	O
mitoxantrone	NN	O
patients	NNS	O
and	CC	O
25.3	CD	O
%	NN	O
of	IN	O
doxorubicin	NN	O
patients	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.001	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
severe	JJ	Adverseeffect
stomatitis	NN	Adverseeffect
and	CC	Adverseeffect
mucositis	NN	Adverseeffect
was	VBD	O
0.6	CD	O
%	NN	O
in	IN	O
the	DT	O
mitoxantrone	NN	O
group	NN	O
and	CC	O
8.4	CD	O
%	NN	O
in	IN	O
the	DT	O
doxorubicin	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Severe	JJ	O
alopecia	NN	Adverseeffect
occurred	VBD	O
in	IN	O
5.1	CD	O
%	NN	O
of	IN	O
mitoxantrone	NN	O
patients	NNS	O
and	CC	O
61.0	CD	O
%	NN	O
of	IN	O
doxorubicin	NN	O
patients	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.001	NN	O
)	)	O
.	.	O

A	DT	O
life-table	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
cumulative	JJ	O
dose	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
cardiac	JJ	O
event	NN	O
showed	VBD	O
that	IN	O
mitoxantrone	NN	O
had	VBD	O
significantly	RB	O
less	JJR	O
cardiotoxicity	NN	Physical
than	IN	O
doxorubicin	NN	O
(	(	O
P	NNP	O
=	NNP	O
.0005	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
mitoxantrone	NN	O
is	VBZ	O
active	JJ	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
metastatic	JJ	Physical
breast	NN	Physical
cancer	NN	Physical
.	.	Physical

Compared	VBN	O
with	IN	O
doxorubicin	NN	O
it	PRP	O
appears	VBZ	O
to	TO	O
be	VB	O
marginally	RB	Others
less	RBR	Others
active	JJ	Others
and	CC	Others
significantly	RB	Others
less	JJR	Others
toxic	JJ	Others
.	.	Others

We	PRP	O
conclude	VBP	O
that	IN	O
mitoxantrone	NN	O
can	MD	O
be	VB	O
used	VBN	O
alone	RB	O
or	CC	O
with	IN	O
other	JJ	O
standard	NN	O
drugs	NNS	O
to	TO	O
palliate	VB	O
the	DT	O
symptoms	NNS	O
of	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
especially	RB	O
in	IN	O
settings	NNS	O
where	WRB	O
drug	NN	Others
toxicity	NN	Others
is	VBZ	O
an	DT	O
important	JJ	O
consideration	NN	O
.	.	O

Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
(	(	O
CYBOCS	NNP	O
)	)	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
Raters	NNPS	O
from	IN	O
five	CD	O
Research	NNP	O
Units	NNS	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
were	VBD	O
trained	VBN	O
to	TO	O
reliability	NN	O
.	.	O

The	DT	O
modified	JJ	O
scale	NN	O
(	(	O
CYBOCS-PDD	NNP	O
)	)	O
,	,	O
which	WDT	O
contains	VBZ	O
only	RB	O
the	DT	O
five	CD	O
Compulsion	NNP	O
severity	NN	O
items	NNS	O
(	(	O
range	VB	O
0-20	NN	O
)	)	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
172	CD	O
medication-free	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
8.2	CD	O
+/-	JJ	O
2.6	CD	O
years	NNS	O
)	)	O
with	IN	O
PDD	NNP	O
(	(	O
autistic	JJ	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
152	CD	O
;	:	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
6	CD	O
;	:	O
PDD	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
participating	NN	O
in	IN	O
RUPP	NNP	O
clinical	JJ	O
trials	NNS	O
.	.	O

Reliability	NNP	Mental
was	VBD	O
assessed	VBN	O
by	IN	O
intraclass	NN	O
correlation	NN	O
coefficient	NN	O
(	(	O
ICC	NNP	O
)	)	O
and	CC	O
internal	JJ	O
consistency	NN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	JJ	O
coefficient	NN	O
.	.	O

Correlations	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
and	CC	O
disruptive	JJ	O
behavior	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
validity	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
raters	NNS	O
showed	VBD	O
excellent	JJ	O
reliability	NN	Mental
(	(	O
ICC	NNP	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	Mental
CYBOCS	NNP	Mental
score	NN	Mental
was	VBD	O
14.4	CD	O
(	(	O
+/-	JJ	O
3.86	CD	O
)	)	O
with	IN	O
excellent	JJ	O
internal	JJ	Others
consistency	NN	Others
(	(	O
alpha	JJ	O
=	NNP	O
.85	NNP	O
)	)	O
.	.	O

Correlations	NNS	O
with	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
ranged	VBD	O
from	IN	O
r	NN	O
=	$	O
0.11	CD	O
to	TO	O
r	VB	O
=	JJ	O
0.28	CD	O
and	CC	O
were	VBD	O
similar	JJ	O
to	TO	O
correlations	NNS	O
with	IN	O
measures	NNS	Mental
of	IN	Mental
irritability	NN	Mental
(	(	O
r	JJ	O
=	NNP	O
0.24	CD	O
)	)	O
and	CC	O
hyperactivity	NN	Mental
(	(	O
r	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
CYBOCS-PDD	NNP	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
maladaptive	JJ	Mental
behaviors	NNS	Mental
and	CC	O
lower	JJR	Mental
adaptive	JJ	Mental
functioning	NN	Mental
.	.	O

CONCLUSIONS	VB	O
The	DT	O
five-item	JJ	O
CYBOCS-PDD	NNP	O
is	VBZ	O
reliable	JJ	O
,	,	O
distinct	JJ	O
from	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
,	,	O
and	CC	O
sensitive	JJ	O
to	TO	O
change	VB	O
.	.	O

[	JJ	O
Assessment	NNP	O
of	IN	O
natriuretic	JJ	O
peptide	NN	O
indices	NNS	O
and	CC	O
oxidative	JJ	O
stress	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
]	NNP	O
.	.	O

The	DT	O
authors	NNS	O
have	VBP	O
studied	VBN	O
indices	NNS	O
of	IN	O
natriuretic	JJ	O
peptide	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
.	.	O

52	CD	O
male	JJ	O
patients	NNS	O
with	IN	O
postinfarction	NN	O
cardiosclerosis	NN	O
(	(	O
PICS	NNP	O
)	)	O
who	WP	O
have	VBP	O
developed	VBN	O
CHF	NNP	O
have	VBP	O
been	VBN	O
observed	VBN	O
.	.	O

The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
varied	VBD	O
from	IN	O
38	CD	O
till	NN	O
60	CD	O
.	.	O

It	PRP	O
was	VBD	O
established	VBN	O
that	IN	O
CHF	NNP	O
patients	NNS	O
with	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
had	VBD	O
worsening	NN	O
of	IN	O
their	PRP$	O
clinical	JJ	Physical
condition	NN	Physical
together	RB	O
with	IN	O
an	DT	O
increase	NN	O
of	IN	O
oxidative	JJ	Physical
stress	NN	Physical
which	WDT	O
was	VBD	O
characterized	VBN	O
through	IN	O
decrease	NN	O
of	IN	O
NO	NNP	Physical
metabolites	NNS	Physical
,	,	O
NADPH	NNP	Physical
--	:	Physical
diaphorase	NN	Physical
(	(	Physical
eNOS	NN	Physical
)	)	Physical
,	,	O
increase	NN	O
of	IN	O
nitrite	JJ	Physical
reductase	NN	Physical
(	(	Physical
iNOS	NN	Physical
)	)	Physical
and	CC	O
peroxinitrite	JJ	Physical
(	(	Physical
ONOO	NNP	Physical
)	)	Physical
,	,	O
correlative	JJ	O
increase	NN	O
the	DT	O
level	NN	O
of	IN	O
brain	NN	Physical
natriuretic	JJ	Physical
peptide	NN	Physical
in	IN	Physical
blood	NN	Physical
plazma	NN	Physical
.	.	O

Reliable	JJ	O
connection	NN	O
between	IN	O
considerable	JJ	O
increase	NN	O
of	IN	O
oxidative	JJ	Physical
stress	NN	Physical
and	CC	O
the	DT	O
level	NN	Physical
of	IN	Physical
NT-pro	NNP	Physical
BNP	NNP	Physical
was	VBD	O
noted	VBN	O
in	IN	O
CHF	NNP	O
patients	NNS	O
,	,	O
which	WDT	O
demands	VBZ	O
necessity	NN	O
of	IN	O
correction	NN	O
of	IN	O
observed	JJ	O
disorders	NNS	O
.	.	O

Propofol	NNP	O
and	CC	O
midazolam	NNP	O
act	NN	O
synergistically	RB	O
in	IN	O
combination	NN	O
.	.	O

We	PRP	O
have	VBP	O
studied	VBN	O
interactions	NNS	O
between	IN	O
i.v	NN	O
.	.	O

propofol	NN	O
and	CC	O
midazolam	NN	O
for	IN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
in	IN	O
200	CD	O
unpremedicated	JJ	O
female	NN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
gynaecological	JJ	O
surgery	NN	O
.	.	O

Using	VBG	O
end-points	NNS	O
of	IN	O
hypnosis	NN	Mental
(	(	Mental
loss	NN	Mental
of	IN	Mental
response	NN	Mental
to	TO	Mental
verbal	JJ	Mental
command	NN	Mental
)	)	Mental
and	CC	O
anaesthesia	$	Mental
(	(	Mental
loss	NN	Mental
of	IN	Mental
response	NN	Mental
to	TO	Mental
a	DT	Mental
5-s	JJ	Mental
transcutaneous	JJ	Mental
tetanic	JJ	Mental
stimulus	NN	Mental
)	)	Physical
,	,	O
we	PRP	O
determined	VBD	O
dose-response	JJ	O
curves	NNS	O
for	IN	O
propofol	NN	O
and	CC	O
midazolam	VB	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
.	.	O

For	IN	O
hypnosis	NN	Mental
,	,	Mental
synergistic	JJ	Mental
interaction	NN	Mental
was	VBD	O
found	VBN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
combination	NN	O
having	VBG	O
1.44	CD	O
times	NNS	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
individual	JJ	O
agents	NNS	O
.	.	O

Although	IN	O
midazolam	NN	O
failed	VBD	O
to	TO	O
produce	VB	O
anaesthesia	NN	Pain
in	IN	O
the	DT	O
dose	NN	O
range	NN	O
used	VBN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
propofol	NN	O
required	VBN	Mental
to	TO	Mental
produce	VB	Mental
anaesthesia	NN	Mental
was	VBD	O
reduced	VBN	O
by	IN	O
52	CD	O
%	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
midazolam	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	Physical
pressure	NN	Physical
at	IN	Physical
induction	NN	Physical
was	VBD	O
the	DT	O
same	JJ	O
for	IN	O
the	DT	O
combination	NN	O
as	IN	O
for	IN	O
the	DT	O
individual	JJ	O
agents	NNS	O
.	.	O

The	DT	O
cause	NN	O
of	IN	O
the	DT	O
synergism	NN	O
was	VBD	O
not	RB	O
clear	JJ	O
,	,	O
but	CC	O
may	MD	O
have	VB	O
been	VBN	O
interaction	NN	O
at	IN	O
CNS	NNP	O
GABAA	NNP	O
receptors	NNS	O
.	.	O

[	NN	O
Evaluating	VBG	O
an	DT	O
interactive	JJ	O
,	,	O
multi-media	JJ	O
learning	NN	O
system	NN	O
for	IN	O
the	DT	O
study	NN	O
of	IN	O
primary	JJ	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
]	NNP	O
.	.	O

Using	VBG	O
the	DT	O
interactive	JJ	O
multimedia	NN	O
learning	NN	O
system	NN	O
for	IN	O
studying	VBG	O
open-angle	JJ	O
glaucoma	NN	O
[	$	O
3	CD	O
]	CC	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
case-controlled	JJ	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
this	DT	O
new	JJ	O
form	NN	O
of	IN	O
learning	VBG	O
in	IN	O
terms	NNS	O
of	IN	O
acceptance	NN	Mental
and	CC	Mental
the	DT	Mental
imparting	NN	Mental
of	IN	Mental
knowledge	NN	Mental
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
details	NNS	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
presents	NNS	O
their	PRP$	O
results	NNS	O
.	.	O

Results	NNS	O
were	VBD	O
established	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
targeted	JJ	O
questions	NNS	O
asked	VBD	O
prior	JJ	O
to	TO	O
and	CC	O
after	IN	O
the	DT	O
learning	NN	O
phase	NN	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
analysis	NN	O
of	IN	O
frequencies	NNS	O
and	CC	O
significance	NN	O
testing	NN	O
by	IN	O
the	DT	O
Chi	NNP	O
squared	VBD	O
method	NN	O
.	.	O

It	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
the	DT	O
imparting	NN	Mental
of	IN	Mental
knowledge	NN	Mental
is	VBZ	O
significantly	RB	O
improved	VBN	O
when	WRB	O
this	DT	O
learning	NN	O
system	NN	O
is	VBZ	O
employed	VBN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
after	IN	O
its	PRP$	O
first	JJ	O
use	NN	O
,	,	O
acceptance	NN	Mental
of	IN	Mental
this	DT	Mental
new	JJ	Mental
medium	NN	Mental
rose	VBD	O
dramatically	RB	O
.	.	O

Dose-response	JJ	O
characteristics	NNS	O
during	IN	O
long-term	JJ	O
inhalation	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
acute	JJ	O
respiratory	NN	O
distress	JJ	O
syndrome	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
.	.	O

Inhaled	VBN	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
improves	VBZ	O
systemic	JJ	O
oxygenation	NN	O
(	(	O
PaO2/FIO2	NNP	O
)	)	O
in	IN	O
adult	NN	O
patients	NNS	O
with	IN	O
acute	JJ	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
(	(	O
ARDS	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
individual	JJ	O
response	NN	O
varies	NNS	O
,	,	O
and	CC	O
previous	JJ	O
trials	NNS	O
demonstrated	VBD	O
no	DT	O
outcome	NN	O
benefit	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
in	IN	O
40	CD	O
ARDS	NNP	O
patients	NNS	O
analyzed	VBD	O
dose-response	JJ	Physical
(	(	Physical
DR	NNP	Physical
)	)	Physical
characteristics	NNS	Physical
during	IN	O
long-term	JJ	O
inhaled	JJ	O
NO	NNP	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
for	IN	O
conventional	JJ	O
therapy	NN	O
(	(	O
control	NN	O
)	)	O
or	CC	O
continuous	JJ	O
treatment	NN	O
with	IN	O
10	CD	O
parts	NNS	O
per	IN	O
million	CD	O
(	(	O
ppm	NN	O
)	)	O
inhaled	VBD	O
NO	NNP	O
until	IN	O
weaning	VBG	O
was	VBD	O
initiated	VBN	O
.	.	O

We	PRP	O
measured	VBD	O
DR	NNP	Others
curves	NNS	Others
of	IN	Others
PaO2/FIO2	NNP	Others
versus	IN	Others
the	DT	Others
inhaled	JJ	Others
NO	NNP	Others
dose	NN	Others
at	IN	O
regular	JJ	O
intervals	NNS	O
.	.	O

Before	IN	O
treatment	NN	O
(	(	O
Day	NNP	O
0	CD	O
)	)	O
,	,	O
peak	JJ	O
improvement	NN	O
in	IN	O
PaO2/FIO2	NNP	Others
was	VBD	O
achieved	VBN	O
at	IN	O
10	CD	O
ppm	NN	O
for	IN	O
both	DT	O
control	NN	O
and	CC	O
NO-treated	JJ	O
patients	NNS	O
.	.	O

After	IN	O
4	CD	O
days	NNS	O
,	,	O
the	DT	O
DR	NNP	Others
curve	NN	Others
of	IN	Others
the	DT	Others
NO-treated	JJ	Others
patients	NNS	Others
was	VBD	O
left	VBN	O
shifted	VBN	O
with	IN	O
a	DT	O
peak	JJ	O
response	NN	O
at	IN	O
1	CD	O
ppm	NN	O
.	.	O

At	IN	O
higher	JJR	O
doses	NNS	O
(	(	O
10	CD	O
and	CC	O
100	CD	O
ppm	NN	O
)	)	O
,	,	O
oxygenation	NN	Physical
deteriorated	VBD	Physical
,	,	O
and	CC	O
the	DT	O
response	NN	O
to	TO	O
inhaled	VB	O
NO	RB	O
disappeared	VBN	O
in	IN	O
several	JJ	O
patients	NNS	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
inhaled	JJ	O
NO	NNP	O
on	IN	O
duration	NN	O
of	IN	O
mechanical	JJ	Others
ventilation	NN	Others
or	CC	Others
stay	VB	Others
at	IN	Others
the	DT	Others
intensive	JJ	Others
care	NN	Others
unit	NN	Others
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
long-term	JJ	O
inhaled	VBD	O
NO	NNP	O
with	IN	O
constant	JJ	O
doses	NNS	O
of	IN	O
10	CD	O
ppm	NNS	O
leads	VBZ	O
to	TO	O
enhanced	VB	O
sensitivity	NN	O
after	IN	O
several	JJ	O
days	NNS	O
and	CC	O
does	VBZ	O
do	VB	O
not	RB	O
allow	VB	O
reduction	NN	O
of	IN	O
ventilation	NN	O
parameters	NNS	O
.	.	O

Hence	NNP	O
,	,	O
previous	JJ	O
trials	NNS	O
on	IN	O
therapy	NN	O
with	IN	O
inhaled	JJ	O
NO	NNP	O
in	IN	O
ARDS	NNP	O
should	MD	O
be	VB	O
carefully	RB	O
interpreted	VBN	O
,	,	O
as	IN	O
they	PRP	O
used	VBD	O
constant	JJ	O
NO	NNP	O
concentrations	NNS	O
,	,	O
which	WDT	O
may	MD	O
have	VB	O
become	VBN	O
overdoses	NNS	O
leading	VBG	O
to	TO	O
deterioration	NN	O
of	IN	O
oxygenation	NN	Physical
after	IN	O
several	JJ	O
days	NNS	O
.	.	O

[	JJ	O
Cardiac	NNP	O
protection	NN	O
is	VBZ	O
a	DT	O
clinical	JJ	O
evidence	NN	O
]	NN	O
.	.	O

AIM	NNP	O
Anaesthetics	NNPS	O
may	MD	O
have	VB	O
protective	JJ	O
effect	NN	O
against	IN	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
if	IN	O
sevoflurane	JJ	O
administration	NN	O
could	MD	O
exert	VB	O
myocardial	JJ	Physical
protection	NN	Physical
during	IN	O
following	VBG	O
coronary	JJ	O
occlusion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
a	DT	O
)	)	O
.	.	O

EXPERIMENTAL	NNP	O
DESIGN	NNP	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

b	NN	O
)	)	O
.	.	O

SETTING	NN	O
University	NNP	O
Hospital	NNP	O
,	,	O
cardiac	JJ	O
surgical	JJ	O
operative	NN	O
theatre	NN	O
.	.	O

c	NN	O
)	)	O
.	.	O

PATIENTS	$	O
42	CD	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
coronary	JJ	O
surgery	NN	O
.	.	O

INCLUSION	NNP	O
CRITERIA	NNP	O
severe	JJ	O
coronary	JJ	O
stenosis	NN	O
of	IN	O
anterior	JJ	O
descending	VBG	O
coronary	JJ	O
artery	NN	O
;	:	O
no	DT	O
collateral	NN	O
flow	NN	O
on	IN	O
angiography	NN	O
;	:	O
at	IN	O
least	JJS	O
two	CD	O
normokinetic	JJ	O
segments	NNS	O
in	IN	O
the	DT	O
myocardial	JJ	O
region	NN	O
supplied	VBN	O
by	IN	O
the	DT	O
vessel	NN	O
being	VBG	O
bypassed	VBN	O
.	.	O

PATIENTS	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
(	(	O
group	NN	O
S	NNP	O
)	)	O
or	CC	O
not	RB	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
sevoflurane	NN	O
administration	NN	O
for	IN	O
15	CD	O
min	NN	O
just	RB	O
before	RB	O
coronary	JJ	O
occlusion	NN	O
.	.	O

d	NN	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Transoesophageal	NNP	O
Tissue	NNP	O
Doppler	NNP	O
echocardiographic	JJ	O
examination	NN	O
of	IN	O
myocardial	JJ	O
systolic	NN	O
and	CC	O
early	JJ	O
diastolic	NN	O
velocities	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
basally	RB	O
and	CC	O
60	CD	O
s	NN	O
after	IN	O
coronary	JJ	O
occlusion	NN	O
by	IN	O
the	DT	O
surgeon	NN	O
.	.	O

e	NN	O
)	)	O
.	.	O

MEASURES	NNP	O
systolic	JJ	Physical
and	CC	Physical
early	JJ	Physical
diastolic	JJ	Physical
velocities	NNS	Physical
were	VBD	O
registered	VBN	O
by	IN	O
Tissue	NNP	O
Doppler	NNP	O
from	IN	O
a	DT	O
long-axis	JJ	O
view	NN	O
of	IN	O
the	DT	O
interventricular	JJ	O
septum	NN	O
or	CC	O
the	DT	O
anterior	JJ	O
wall	NN	O
of	IN	O
the	DT	O
left	JJ	O
ventricle	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
C	NNP	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
systolic	JJ	Physical
and	CC	Physical
diastolic	JJ	Physical
intramyocardial	JJ	Physical
velocities	NNS	Physical
was	VBD	O
found	VBN	O
during	IN	O
myocardial	JJ	O
ischemia	NN	O
due	JJ	O
to	TO	O
coronary	JJ	O
occlusion	NN	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
sevoflurane	NN	O
before	IN	O
coronary	JJ	O
occlusion	NN	O
seem	VBP	O
effective	JJ	O
in	IN	O
reducing	VBG	O
functional	JJ	Physical
myocardial	JJ	Physical
impairment	NN	Physical
due	JJ	O
to	TO	O
ischemia	VB	O
.	.	O

Ilioinguinal-iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
within	IN	O
travenous	JJ	O
dexketoprofen	NN	O
improves	VBZ	O
postoperative	JJ	O
analgesia	NN	O
in	IN	O
abdominal	JJ	O
hysterectomies	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
intravenous	JJ	O
dexketoprofen	NNS	O
trometamol	VBP	O
with	IN	O
ilioinguinal	JJ	O
and	CC	O
iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
on	IN	O
analgesic	JJ	O
quality	NN	O
and	CC	O
morphine	NN	O
consumption	NN	O
after	IN	O
total	JJ	O
abdominal	JJ	O
hysterectomy	NN	O
operations	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
clinical	JJ	O
study	NN	O
on	IN	O
61	CD	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
the	DT	O
operation	NN	O
room	NN	O
,	,	O
post-anesthesia	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
inpatient	JJ	O
clinic	NN	O
.	.	O

We	PRP	O
randomly	RB	O
grouped	VBD	O
the	DT	O
61	CD	O
patients	NNS	O
into	IN	O
control	NN	O
group	NN	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
,	,	O
block	NN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
and	CC	O
dexketoprofen-block	JJ	O
group	NN	O
(	(	O
group	NN	O
DB	NNP	O
)	)	O
.	.	O

Before	IN	O
the	DT	O
skin	NN	O
incision	NN	O
performed	VBD	O
after	IN	O
anesthesia	JJ	O
induction	NN	O
,	,	O
we	PRP	O
performed	VBD	O
ilioinguinal	JJ	O
iliohypogastric	JJ	O
block	NN	O
(	(	O
group	NN	O
C	NNP	O
given	VBN	O
saline	NN	O
and	CC	O
group	NN	O
P	NNP	O
and	CC	O
DB	NNP	O
given	VBN	O
levobupivacaine	NN	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
group	NN	O
C	NNP	O
and	CC	O
B	NNP	O
,	,	O
group	NN	O
DB	NNP	O
was	VBD	O
given	VBN	O
dexketoprofen	RB	O
.	.	O

We	PRP	O
administered	VBD	O
morphine	JJ	O
analgesia	NN	O
to	TO	O
all	DT	O
patients	NNS	O
by	IN	O
patient-controlled	JJ	O
analgesia	NN	O
(	(	O
PCA	NNP	O
)	)	O
during	IN	O
the	DT	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
.	.	O

We	PRP	O
recorded	VBD	O
Visual	NNP	Mental
Analogue	NNP	Mental
Scale	NNP	Mental
(	(	Mental
VAS	NNP	Mental
)	)	Mental
,	,	O
satisfaction	NN	Others
scores	NNS	Others
,	,	O
morphine	NN	Physical
consumption	NN	Physical
and	CC	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
during	IN	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
the	DT	O
DB	NNP	O
group?s	NN	O
VAS	NNP	Mental
scores	VBZ	Mental
to	TO	O
be	VB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
block	NN	O
group?s	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
values	NNS	O
at	IN	O
postoperative	JJ	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
6th	CD	O
and	CC	O
12th	CD	O
hours	NNS	O
.	.	O

VAS	NNP	O
scores	NNS	O
of	IN	O
group	NN	O
C	NNP	O
were	VBD	O
higher	JJR	O
than	IN	O
of	IN	O
group	NN	O
B	NNP	O
at	IN	O
postoperative	JJ	O
fi	NN	O
rst	VBD	O
2	CD	O
hours	NNS	O
.	.	O

Time	NNP	O
to	TO	O
fi	VB	O
rst	JJ	O
PCA	NNP	O
demand	NN	O
was	VBD	O
longer	RBR	O
,	,	O
morphine	JJ	Physical
consumption	NN	Physical
values	NNS	Physical
were	VBD	O
lower	JJR	O
and	CC	O
satisfaction	NN	O
scores	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
DB	NNP	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Ilioinguinal-iliohypogastric	JJ	O
nerve	NN	O
block	NN	O
with	IN	O
IV	NNP	O
dexketoprofen	NN	O
increases	NNS	O
patient	JJ	O
satisfaction	NN	O
by	IN	O
decreasing	VBG	O
opioid	JJ	O
consumption	NN	O
,	,	O
increasing	VBG	O
patient	JJ	O
satisfaction	NN	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
dexketoprofen	NN	O
trometamol	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
analgesic	NN	O
in	IN	O
postoperative	JJ	O
analgesia	NN	O
.	.	O

Detection	NN	O
of	IN	O
traumatic	JJ	O
arthrotomy	NN	O
of	IN	O
the	DT	O
knee	NN	O
using	VBG	O
the	DT	O
saline	JJ	O
solution	NN	O
load	NN	O
test	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
saline	JJ	O
solution	NN	O
load	NN	O
test	NN	O
helps	VBZ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
wound	NN	O
extends	VBZ	O
into	IN	O
the	DT	O
knee	NN	O
joint	NN	O
.	.	O

Little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
volume	NN	O
of	IN	O
injected	JJ	O
intra-articular	JJ	O
saline	NN	O
solution	NN	O
that	WDT	O
is	VBZ	O
needed	VBN	O
to	TO	O
effectively	RB	O
rule	VB	O
in	IN	O
or	CC	O
rule	VB	O
out	IN	O
a	DT	O
traumatic	JJ	O
arthrotomy	NN	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
appropriate	JJ	Others
volume	NN	Others
and	CC	O
needle	JJ	Others
location	NN	Others
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
a	DT	O
traumatic	JJ	O
knee	NN	O
arthrotomy	NN	O
and	CC	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
associated	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
knee	NN	O
circumference	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
and	CC	O
sex	NN	O
.	.	O

METHODS	NNP	O
Fifty-six	NNP	O
consecutive	JJ	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
knee	NN	O
arthroscopy	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

A	DT	O
standard	JJ	O
inferolateral	JJ	O
arthroscopic	NN	O
portal	NN	O
was	VBD	O
made	VBN	O
with	IN	O
a	DT	O
single	JJ	O
stab	NN	O
incision	NN	O
with	IN	O
use	NN	O
of	IN	O
a	DT	O
number-11	JJ	O
blade	NN	O
.	.	O

Injection	NN	O
sites	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	VB	O
a	DT	O
superomedial	NN	O
or	CC	O
inferomedial	JJ	O
location	NN	O
.	.	O

The	DT	O
injection	NN	O
of	IN	O
normal	JJ	O
saline	JJ	O
solution	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
5	CD	O
mL/sec	NNS	O
through	IN	O
an	DT	O
18-gauge	JJ	O
needle	NN	O
was	VBD	O
continued	VBN	O
while	IN	O
the	DT	O
knee	NN	O
was	VBD	O
moved	VBN	O
through	IN	O
a	DT	O
range	NN	O
of	IN	O
motion	NN	O
until	IN	O
fluid	NNS	O
extravasated	VBN	O
from	IN	O
the	DT	O
iatrogenic	JJ	O
laceration	NN	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
injected	JJ	O
fluid	NN	O
was	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
group	NN	O
included	VBD	O
thirty-one	JJ	O
female	NN	O
patients	NNS	O
and	CC	O
twenty-five	JJ	O
male	NN	O
patients	NNS	O
with	IN	O
a	DT	O
combined	JJ	O
average	JJ	O
age	NN	O
of	IN	O
fifty	JJ	O
years	NNS	O
and	CC	O
an	DT	O
average	JJ	Physical
body	NN	Physical
mass	NN	Physical
index	NN	Physical
of	IN	O
30.9	CD	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
effectively	RB	O
diagnose	VB	Others
50	CD	Others
%	NN	Others
of	IN	Others
the	DT	Others
arthrotomies	NNS	Others
,	,	O
75	CD	O
mL	NN	O
of	IN	O
injected	JJ	O
fluid	NN	O
was	VBD	O
needed	VBN	O
;	:	O
the	DT	O
volumes	NNS	Others
that	WDT	Others
were	VBD	Others
needed	VBN	Others
in	IN	Others
order	NN	Others
to	TO	Others
effectively	RB	Others
diagnose	VB	Others
75	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
,	,	O
and	CC	O
99	CD	O
%	NN	O
of	IN	O
the	DT	O
arthrotomies	NNS	O
were	VBD	O
110	CD	O
,	,	O
145	CD	O
,	,	O
155	CD	O
,	,	O
and	CC	O
175	CD	O
mL	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	Physical
volumes	NNS	Physical
of	IN	Physical
injected	JJ	Physical
fluid	NN	Physical
needed	VBN	Physical
for	IN	Physical
a	DT	Physical
positive	JJ	Physical
result	NN	Physical
at	IN	Physical
the	DT	Physical
inferomedial	JJ	Physical
and	CC	Physical
superomedial	JJ	Physical
needle	JJ	Physical
locations	NNS	Physical
were	VBD	O
64.0	CD	O
and	CC	O
95.2	CD	O
mL	NN	O
,	,	O
respectively	RB	O
;	:	O
this	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
necessary	JJ	O
injection	NN	O
volume	NN	O
and	CC	O
sex	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
or	CC	O
knee	VB	O
circumference	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
order	NN	O
to	TO	O
detect	VB	O
95	CD	O
%	NN	O
of	IN	O
1-cm	JJ	O
inferolateral	JJ	O
arthrotomies	NNS	O
of	IN	O
the	DT	O
knee	NN	O
with	IN	O
use	NN	O
of	IN	O
the	DT	O
saline	JJ	O
solution	NN	O
load	NN	O
test	NN	O
,	,	O
155	CD	O
mL	NN	O
must	MD	O
be	VB	O
injected	VBN	O
.	.	O

An	DT	O
inferomedial	JJ	O
injection	NN	O
location	NN	O
requires	VBZ	O
significantly	RB	Others
less	JJR	Others
fluid	NN	Others
than	IN	O
a	DT	O
superomedial	JJ	O
injection	NN	O
location	NN	O
does	VBZ	O
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
inferolateral	JJ	O
arthrotomies	NNS	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

Effects	NNS	O
of	IN	O
tryptophan	JJ	O
depletion	NN	O
in	IN	O
drug-free	JJ	O
adults	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
behavioral	JJ	O
and	CC	O
biochemical	JJ	O
responses	NNS	O
to	TO	O
acute	VB	O
tryptophan	JJ	O
depletion	NN	O
in	IN	O
drug-free	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
drug-free	JJ	O
adults	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
(	(	O
16	CD	O
men	NNS	O
and	CC	O
4	CD	O
women	NNS	O
)	)	O
(	(	O
mean	JJ	O
[	NNP	O
+/-	NN	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
30.5	CD	O
+/-	JJ	O
8.5	CD	O
years	NNS	O
)	)	O
underwent	JJ	O
short-term	JJ	O
tryptophan	NN	O
depletion	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
a	DT	O
24-hour	JJ	O
,	,	O
low-tryptophan	JJ	O
diet	NN	O
followed	VBD	O
the	DT	O
next	JJ	O
morning	NN	O
by	IN	O
an	DT	O
amino	NN	O
acid	NN	O
drink	NN	O
.	.	O

Behavioral	JJ	O
ratings	NNS	O
were	VBD	O
obtained	VBN	O
on	IN	O
the	DT	O
morning	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
drink	NN	O
(	(	O
baseline	NN	O
)	)	O
and	CC	O
180	CD	O
,	,	O
300	CD	O
,	,	O
and	CC	O
420	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
drink	NN	O
.	.	O

Plasma	NNP	Physical
free	JJ	Physical
and	CC	Physical
total	JJ	Physical
tryptophan	NN	Physical
levels	NNS	Physical
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
5	CD	O
hours	NNS	O
after	IN	O
the	DT	O
drink	NN	O
.	.	O

The	DT	O
active	JJ	O
and	CC	O
sham	JJ	O
testing	NN	O
sessions	NNS	O
were	VBD	O
separated	VBN	O
by	IN	O
7	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
(	(	O
65	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
17	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
both	DT	O
test	NN	O
days	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
global	JJ	O
worsening	NN	O
of	IN	O
behavioral	JJ	O
symptoms	NNS	O
with	IN	O
short-term	JJ	O
tryptophan	NN	O
depletion	NN	O
,	,	O
but	CC	O
none	NN	O
of	IN	O
the	DT	O
17	CD	O
patients	NNS	O
showed	VBD	O
any	DT	O
significant	JJ	O
change	NN	O
in	IN	O
clinical	JJ	O
status	NN	O
from	IN	O
baseline	NN	O
after	IN	O
sham	JJ	O
depletion	NN	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Tryptophan	NNP	O
depletion	NN	O
led	VBD	O
to	TO	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
behaviors	NNS	O
such	JJ	O
as	IN	O
whirling	NN	Mental
,	,	Mental
flapping	NN	Mental
,	,	Mental
pacing	NN	Mental
,	,	Mental
banging	NN	Mental
and	CC	Mental
hitting	VBG	Mental
self	NN	Mental
,	,	Mental
rocking	NN	Mental
,	,	Mental
and	CC	Mental
toe	NN	Mental
walking	NN	Mental
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
patients	NNS	O
were	VBD	O
significantly	RB	O
less	JJR	O
calm	JJ	Mental
and	CC	Mental
happy	JJ	Mental
and	CC	Mental
more	RBR	Mental
anxious	JJ	Mental
.	.	Mental

No	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
social	JJ	Mental
relatedness	NN	Mental
or	CC	Mental
repetitive	JJ	Mental
thoughts	NNS	Mental
and	CC	Mental
behavior	NN	Mental
.	.	Mental

Plasma	NNP	Physical
total	JJ	Physical
and	CC	Physical
free	JJ	Physical
tryptophan	NN	Physical
levels	NNS	Physical
were	VBD	O
reduced	VBN	O
86	CD	O
%	NN	O
and	CC	O
69	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
5	CD	O
hours	NNS	O
after	IN	O
the	DT	O
tryptophan-deficient	JJ	O
amino	NN	O
acid	NN	O
drink	NN	O
.	.	O

Patients	NNS	O
who	WP	O
had	VBD	O
a	DT	O
significant	JJ	O
global	JJ	O
exacerbation	NN	O
of	IN	O
symptoms	NNS	O
had	VBD	O
significantly	RB	O
higher	JJR	O
baseline	NN	Physical
plasma	IN	Physical
total	JJ	Physical
tryptophan	NN	Physical
levels	NNS	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
Autism	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
scores	NNS	Mental
(	(	O
P	NNP	O
=	NNP	O
.005	NNP	O
)	)	O
than	IN	O
did	VBD	O
patients	NNS	O
who	WP	O
showed	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
symptoms	NNS	O
after	IN	O
tryptophan	JJ	O
depletion	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
are	VBP	O
consistent	JJ	O
with	IN	O
previous	JJ	O
research	NN	O
that	WDT	O
has	VBZ	O
implicated	VBN	O
a	DT	O
dysregulation	NN	O
in	IN	O
serotonin	JJ	O
function	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
autism	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
short-term	JJ	O
reduction	NN	O
of	IN	O
serotonin	NN	O
precursor	NN	O
availability	NN	O
may	MD	O
exacerbate	VB	O
some	DT	O
symptoms	NNS	Mental
characteristic	JJ	Mental
of	IN	Mental
autism	NN	Mental
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Continued	JJ	O
investigation	NN	O
into	IN	O
the	DT	O
role	NN	O
of	IN	O
serotonin	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
and	CC	O
treatment	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Antiinflammatory	JJ	Physical
effects	NNS	Physical
of	IN	O
the	DT	O
phosphodiesterase-4	JJ	O
inhibitor	NN	O
cilomilast	NN	O
(	(	O
Ariflo	NNP	O
)	)	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

Cilomilast	NNP	O
(	(	O
Ariflo	NNP	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
oral	JJ	O
phosphodiesterase-4	JJ	O
selective	JJ	O
inhibitor	NN	O
,	,	O
improves	VBZ	O
lung	JJ	Physical
function	NN	Physical
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
its	PRP$	O
antiinflammatory	JJ	Physical
effects	NNS	Physical
in	IN	O
59	CD	O
patients	NNS	O
with	IN	O
COPD	NNP	O
randomized	VBD	O
to	TO	O
receive	VB	O
cilomilast	NN	O
,	,	O
15	CD	O
mg	NN	O
two	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
or	CC	O
placebo	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Induced	NNP	Physical
sputum	JJ	Physical
differential	NN	Physical
cell	NN	Physical
counts	NNS	Physical
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
five	CD	O
further	JJ	O
visits	NNS	O
.	.	O

Interleukin-8	NNP	Physical
and	CC	Physical
neutrophil	JJ	Physical
elastase	NN	Physical
were	VBD	O
measured	VBN	O
in	IN	O
sputum	NN	O
supernatant	NN	O
.	.	O

Bronchial	JJ	O
biopsies	NNS	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
Week	NNP	O
10	CD	O
were	VBD	O
immunostained	VBN	O
and	CC	O
counted	VBN	O
for	IN	O
neutrophils	NNS	Physical
,	,	Physical
CD8+	NNP	Physical
and	CC	Physical
CD4+	NNP	Physical
T-lymphocyte	NNP	Physical
subsets	NNS	Physical
,	,	Physical
and	CC	Physical
CD68+	NNP	Physical
macrophages	NNS	Physical
.	.	O

Cells	NNP	O
expressing	VBG	O
the	DT	O
genes	NNS	Physical
for	IN	Physical
interleukin-8	NN	Physical
and	CC	Physical
tumor	NN	Physical
necrosis	NN	Physical
factor-alpha	NN	Physical
were	VBD	O
identified	VBN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
quantified	VBD	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
of	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
showed	VBD	O
that	IN	O
cilomilast	NN	O
did	VBD	O
not	RB	O
alter	VB	O
any	DT	O
sputum	JJ	Physical
endpoint	NN	Physical
or	CC	Physical
FEV1	NNP	Physical
.	.	O

However	RB	O
,	,	O
bronchial	JJ	O
biopsies	NNS	O
demonstrated	VBD	O
that	IN	O
cilomilast	NN	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reductions	NNS	Physical
in	IN	Physical
CD8+	NNP	Physical
(	(	O
p	JJ	O
=	VBZ	O
0.001	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
and	CC	O
CD68+	NNP	Physical
cells	NNS	Physical
(	(	O
p	JJ	O
<	VBZ	O
0.05	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
by	IN	O
Poisson	NNP	O
analysis	NN	O
,	,	O
comparison	NN	O
of	IN	O
cell	NN	O
counts	NNS	O
analyzed	VBN	O
as	IN	O
a	DT	O
ratio	NN	O
of	IN	O
active	JJ	O
to	TO	O
placebo	VB	O
demonstrated	JJ	O
reductions	NNS	Physical
of	IN	Physical
CD8+	NNP	Physical
(	(	O
48	CD	O
%	NN	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
CD68+	NNP	Physical
(	(	O
47	CD	O
%	NN	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
cells	NNS	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
demonstration	NN	O
of	IN	O
reduction	NN	O
by	IN	O
any	DT	O
agent	NN	O
of	IN	O
airway	JJ	Physical
tissue	NN	Physical
inflammatory	NN	Physical
cells	NNS	Physical
characteristic	JJ	O
of	IN	O
COPD	NNP	O
.	.	O

Phosphodiesterase-4	JJ	O
inhibitors	NNS	O
represent	VBP	O
a	DT	O
promising	JJ	O
new	JJ	O
class	NN	O
of	IN	O
substances	NNS	O
for	IN	O
use	NN	O
in	IN	O
antiinflammatory	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
disease	NN	O
.	.	O

Caudal	NNP	O
neostigmine	NN	O
with	IN	O
bupivacaine	NN	O
produces	VBZ	O
a	DT	O
dose-independent	JJ	O
analgesic	JJ	O
effect	NN	O
in	IN	O
children	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	Others
the	DT	O
analgesic	JJ	Others
efficacy	NN	Others
and	CC	Others
duration	NN	Others
of	IN	O
varying	VBG	O
doses	NNS	O
of	IN	O
caudal	JJ	O
neostigmine	NN	O
with	IN	O
plain	JJ	O
bupivacaine	NN	O
and	CC	O
its	PRP$	O
side	NN	O
effects	NNS	O
in	IN	O
children	NNS	O
undergoing	VBG	O
genito-urinary	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
prospective	JJ	O
study	NN	O
80	CD	O
boys	NNS	O
aged	VBN	O
two	CD	O
to	TO	O
eight	CD	O
years	NNS	O
scheduled	VBN	O
for	IN	O
surgical	JJ	O
repair	NN	O
of	IN	O
hypospadias	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
(	(	O
n	JJ	O
=	RB	O
20	CD	O
each	DT	O
)	)	O
and	CC	O
received	VBD	O
either	CC	O
only	RB	O
caudal	JJ	O
0.25	CD	O
%	NN	O
plain	NN	O
bupivacaine	NN	O
0.5	CD	O
mL.kg	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
Group	NNP	O
I	PRP	O
)	)	O
or	CC	O
0.25	CD	O
%	NN	O
plain	NN	O
bupivacaine	NN	O
0.5	CD	O
mL.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
with	IN	O
neostigmine	NN	O
(	(	O
Groups	NNP	O
II-IV	NNP	O
)	)	O
in	IN	O
doses	NNS	O
of	IN	O
2	CD	O
,	,	O
3	CD	O
and	CC	O
4	CD	O
microg.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
respectively	RB	O
.	.	O

Postoperative	JJ	Pain
pain	NN	Pain
was	VBD	O
assessed	VBN	O
for	IN	O
24	CD	O
hr	NN	O
using	VBG	O
an	DT	O
objective	JJ	Pain
pain	NN	Pain
score	NN	Pain
.	.	Pain

Blood	NNP	Physical
pressure	NN	Physical
,	,	Physical
heart	NN	Physical
rate	NN	Physical
,	,	Physical
oxygen	NN	Physical
saturation	NN	Physical
,	,	Physical
total	JJ	Physical
amount	NN	Physical
of	IN	Physical
analgesic	JJ	Physical
consumed	VBN	Physical
and	CC	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
duration	NN	Pain
of	IN	Pain
postoperative	JJ	Pain
analgesia	NN	Pain
in	IN	O
Group	NNP	O
I	PRP	O
(	(	O
5.1	CD	O
+/-	JJ	O
2.3	CD	O
hr	NN	O
)	)	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
three	CD	O
groups	NNS	O
(	(	O
II	NNP	O
-16.6	NNP	O
+/-	JJ	O
4.9	CD	O
hr	NN	O
;	:	O
III	NNP	O
-	:	O
17.2	CD	O
+/-	JJ	O
5.5	CD	O
hr	NN	O
;	:	O
IV	NNP	O
-	:	O
17.0	CD	O
+/-	JJ	O
5.8	CD	O
hr	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Total	JJ	Physical
analgesic	JJ	Physical
(	(	Physical
paracetamol	NN	Physical
)	)	Physical
consumption	NN	Physical
was	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
Group	NNP	O
I	PRP	O
(	(	O
697.6	CD	O
+/-	JJ	O
240.7	CD	O
mg	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
caudal	JJ	O
neostigmine	NN	O
(	(	O
II	NNP	O
-	:	O
248.0	CD	O
+/-	JJ	O
178.4	CD	O
;	:	O
III	NNP	O
-	:	O
270.2	CD	O
+/-	JJ	O
180.8	CD	O
and	CC	O
IV	NNP	O
-230.6	NNP	O
+/-	JJ	O
166.9	CD	O
mg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Groups	NNP	O
II	NNP	O
,	,	O
III	NNP	O
and	CC	O
IV	NNP	O
were	VBD	O
comparable	JJ	O
with	IN	O
regards	NNS	O
to	TO	O
duration	NN	Pain
of	IN	Pain
postoperative	JJ	Pain
analgesia	NN	Pain
and	CC	Pain
total	JJ	Pain
analgesic	JJ	Pain
consumption	NN	Pain
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Incidence	NN	O
of	IN	O
nausea	NN	Adverseeffect
and	CC	O
vomiting	NN	Adverseeffect
were	VBD	O
comparable	JJ	O
in	IN	O
all	DT	O
four	CD	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
alteration	NN	O
in	IN	O
vital	JJ	Adverseeffect
signs	NNS	Adverseeffect
or	CC	O
any	DT	O
other	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Caudal	NNP	O
neostigmine	NN	O
(	(	O
2	CD	O
,	,	O
3	CD	O
and	CC	O
4	CD	O
microg.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
with	IN	O
bupivacaine	NN	O
produces	VBZ	O
a	DT	O
dose-independent	JJ	O
analgesic	JJ	Physical
effect	NN	Physical
(	(	O
approximately	RB	O
16-17	JJ	O
hr	NN	O
)	)	O
in	IN	O
children	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
caudal	JJ	O
bupivacaine	NN	O
alone	RB	O
(	(	O
approximately	RB	O
five	CD	O
hours	NNS	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
postoperative	JJ	Physical
rescue	NN	Physical
analgesic	JJ	Physical
consumption	NN	Physical
without	IN	O
increasing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

Fecal	JJ	Physical
butyrate	NN	Physical
levels	NNS	Physical
vary	VBP	O
widely	RB	O
among	IN	O
individuals	NNS	O
but	CC	O
are	VBP	O
usually	RB	O
increased	VBN	O
by	IN	O
a	DT	O
diet	JJ	O
high	JJ	O
in	IN	O
resistant	JJ	O
starch	NN	O
.	.	O

Butyrate	NNP	O
and	CC	O
other	JJ	O
SCFA	NNP	O
produced	VBN	O
by	IN	O
bacterial	JJ	O
fermentation	NN	O
of	IN	O
resistant	JJ	O
starch	NN	O
(	(	O
RS	NNP	O
)	)	O
or	CC	O
nonstarch	JJ	O
polysaccharides	NNS	O
(	(	O
NSP	NNP	O
)	)	O
promote	VBP	O
human	JJ	Physical
colonic	JJ	Physical
health	NN	Physical
.	.	O

To	TO	O
examine	VB	O
variation	NN	O
in	IN	O
fecal	JJ	Physical
variables	NNS	Physical
,	,	O
especially	RB	O
butyrate	JJ	Physical
,	,	O
among	IN	O
individuals	NNS	O
and	CC	O
the	DT	O
response	NN	O
to	TO	O
these	DT	O
fibers	NNS	O
,	,	O
a	DT	O
randomized	VBN	O
cross-over	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
that	IN	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
foods	NNS	O
supplying	VBG	O
25	CD	O
g	NN	O
of	IN	O
NSP	NNP	O
or	CC	O
25	CD	O
g	NN	O
of	IN	O
NSP	NNP	O
plus	CC	O
22	CD	O
g	NN	O
of	IN	O
RS/d	NNP	O
over	IN	O
4	CD	O
wk	NNS	O
in	IN	O
46	CD	O
healthy	JJ	O
adults	NNS	O
(	(	O
16	CD	O
males	NNS	O
,	,	O
30	CD	O
females	NNS	O
;	:	O
age	NN	O
31-66	JJ	O
y	NN	O
)	)	O
.	.	O

Fecal	JJ	Physical
SCFA	NNP	Physical
levels	NNS	Physical
varied	VBD	O
widely	RB	O
among	IN	O
participants	NNS	O
at	IN	O
entry	NN	O
(	(	O
butyrate	JJ	O
concentrations	NNS	O
:	:	O
3.5-32.6	JJ	O
mmol/kg	NN	O
;	:	O
butyrate	JJ	O
excretions	NNS	O
:	:	O
0.3-18.2	JJ	O
mmol/48	NN	O
h	NN	O
)	)	O
.	.	O

BMI	NNP	O
explained	VBD	O
27	CD	O
%	NN	O
of	IN	O
inter-individual	JJ	O
butyrate	NN	O
variation	NN	O
,	,	O
whereas	JJ	O
protein	NN	O
,	,	O
starch	NN	O
,	,	O
carbohydrate	NN	O
,	,	O
fiber	NN	O
,	,	O
and	CC	O
fat	JJ	O
intake	NN	O
explained	VBD	O
up	RB	O
to	TO	O
16	CD	O
,	,	O
6	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
2	CD	O
%	NN	O
of	IN	O
butyrate	NN	O
variation	NN	O
,	,	O
respectively	RB	O
.	.	O

Overall	JJ	O
,	,	O
acetate	NN	Physical
,	,	O
butyrate	NN	Physical
,	,	O
and	CC	O
total	JJ	Physical
SCFA	NNP	Physical
concentrations	NNS	Physical
were	VBD	O
higher	JJR	O
when	WRB	O
participants	NNS	O
consumed	VBD	O
RS	NNP	O
compared	VBN	O
with	IN	O
entry	NN	O
and	CC	O
NSP	NNP	O
diets	NNS	O
,	,	O
but	CC	O
individual	JJ	O
responses	NNS	O
varied	VBD	O
.	.	O

Individual	NNP	Physical
and	CC	Physical
total	JJ	Physical
fecal	JJ	Physical
SCFA	NNP	Physical
excretion	NN	Physical
,	,	O
weight	NN	Physical
,	,	O
and	CC	O
moisture	NN	Physical
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
for	IN	O
habitual	JJ	O
diets	NNS	O
when	WRB	O
either	DT	O
fiber	NN	O
diet	NN	O
was	VBD	O
consumed	VBN	O
.	.	O

SCFA	NNP	Physical
concentrations	NNS	Physical
(	(	Physical
except	IN	Physical
butyrate	NN	Physical
)	)	Physical
and	CC	O
excretions	NNS	Physical
were	VBD	O
higher	JJR	O
for	IN	O
males	NNS	O
than	IN	O
for	IN	O
females	NNS	O
.	.	O

Butyrate	NNP	Physical
levels	NNS	Physical
increased	VBD	O
in	IN	O
response	NN	O
to	TO	O
RS	NNP	O
in	IN	O
most	JJS	O
individuals	NNS	O
but	CC	O
often	RB	O
decreased	VBD	O
when	WRB	O
entry	NN	O
levels	NNS	O
were	VBD	O
high	JJ	O
.	.	O

Fecal	JJ	Physical
butyrate	NN	Physical
and	CC	O
ammonia	JJ	Physical
excretions	NNS	Physical
were	VBD	O
positively	RB	O
associated	VBN	O
(	(	O
(	(	O
2	CD	O
)	)	O
=	NN	O
0.76	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
fecal	JJ	Physical
butyrate	NN	Physical
levels	NNS	Physical
vary	VBP	O
widely	RB	O
among	IN	O
individuals	NNS	O
but	CC	O
consuming	VBG	O
a	DT	O
diet	JJ	O
high	JJ	O
in	IN	O
RS	NNP	O
usually	RB	O
increases	VBZ	O
levels	NNS	O
and	CC	O
may	MD	O
help	VB	O
maintain	VB	O
colorectal	JJ	Physical
health	NN	Physical
.	.	O

Transitions	NNS	O
during	IN	O
effective	JJ	O
treatment	NN	O
for	IN	O
cocaine-abusing	JJ	O
homeless	JJ	O
persons	NNS	O
:	:	O
establishing	VBG	O
abstinence	NN	O
,	,	O
lapse	NN	O
,	,	O
and	CC	O
relapse	NN	O
,	,	O
and	CC	O
reestablishing	VBG	O
abstinence	NN	O
.	.	O

Data	NNS	O
are	VBP	O
reported	VBN	O
on	IN	O
drug	NN	O
use	NN	O
among	IN	O
cocaine-dependent	JJ	O
homeless	NN	O
persons	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
day	NN	O
treatment	NN	O
only	RB	O
(	(	O
DT	NNP	O
,	,	O
n	JJ	O
=	NNP	O
69	CD	O
)	)	O
with	IN	O
day	NN	O
treatment	NN	O
plus	CC	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
(	(	O
DT+	NNP	O
,	,	O
n	JJ	O
=	NNP	O
72	CD	O
)	)	O
.	.	O

Drug	NNP	Physical
use	NN	Physical
was	VBD	Physical
measured	VBN	Physical
with	IN	Physical
multiple	JJ	Physical
weekly	JJ	Physical
urine	NN	Physical
toxicologies	NNS	Physical
.	.	Physical

Compared	VBN	O
with	IN	O
DT	NNP	O
participants	NNS	O
,	,	O
more	JJR	O
DT+	JJ	O
participants	NNS	O
established	VBN	O
abstinence	NN	Mental
,	,	Mental
maintained	VBD	Mental
abstinence	NN	Mental
for	IN	Mental
longer	JJR	Mental
durations	NNS	Mental
,	,	O
were	VBD	O
marginally	RB	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
lapse	VB	Mental
,	,	O
and	CC	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
relapse	VB	Mental
.	.	O

Of	IN	O
all	DT	O
participants	NNS	O
who	WP	O
established	VBD	O
abstinence	NN	O
and	CC	O
then	RB	O
relapsed	VBD	O
,	,	O
DT+	NNP	O
participants	NNS	O
relapsed	VBD	O
later	RB	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
reestablish	VB	Mental
abstinence	NN	Mental
.	.	Others

These	DT	O
analyses	NNS	O
yield	VBP	O
information	NN	O
on	IN	O
the	DT	O
processes	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
manner	NN	O
in	IN	O
which	WDT	O
drug	NN	O
use	NN	O
changes	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
abstinent-contingent	JJ	O
housing	NN	O
and	CC	O
work	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
thyrotropin	NN	O
and	CC	O
thyroid	VB	O
hormone	NN	O
withdrawal	NN	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
thyroid	JJ	O
remnant	NN	O
or	CC	O
cancer	NN	O
.	.	O

Recombinant	NNP	O
human	JJ	O
TSH	NNP	O
has	VBZ	O
been	VBN	O
developed	VBN	O
to	TO	O
facilitate	VB	O
monitoring	NN	O
for	IN	O
thyroid	JJ	O
carcinoma	NN	O
recurrence	NN	O
or	CC	O
persistence	NN	O
without	IN	O
the	DT	O
attendant	JJ	O
morbidity	NN	O
of	IN	O
hypothyroidism	NN	O
seen	VBN	O
after	IN	O
thyroid	JJ	O
hormone	NN	O
withdrawal	NN	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
administered	VBN	O
recombinant	JJ	O
human	JJ	O
TSH	NN	O
with	IN	O
thyroid	JJ	O
hormone	NN	O
withdrawal	NN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
radioiodine	JJ	O
whole	JJ	O
body	NN	O
scanning	VBG	O
(	(	O
WBS	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thyroglobulin	NN	O
(	(	O
Tg	NNP	O
)	)	O
levels	NNS	O
.	.	O

Two	CD	O
hundred	CD	O
and	CC	O
twenty-nine	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
requiring	VBG	O
radioiodine	NN	O
WBS	NNP	O
were	VBD	O
studied	VBN	O
.	.	O

Radioiodine	NNP	O
WBS	NNP	O
and	CC	O
serum	VB	O
Tg	NNP	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
after	IN	O
administration	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
TSH	NNP	O
and	CC	O
again	RB	O
after	IN	O
thyroid	JJ	O
hormone	NN	O
withdrawal	NN	O
in	IN	O
each	DT	O
patient	NN	O
.	.	O

Radioiodine	NNP	O
whole	JJ	O
body	NN	O
scans	NNS	O
were	VBD	O
concordant	JJ	O
between	IN	O
the	DT	O
recombinant	JJ	Physical
TSH-stimulated	JJ	Physical
and	CC	O
thyroid	JJ	Physical
hormone	NN	Physical
withdrawal	NN	Physical
phases	NNS	Physical
in	IN	O
195	CD	O
of	IN	O
220	CD	O
(	(	O
89	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Of	IN	O
the	DT	O
discordant	NN	O
scans	NNS	O
,	,	O
8	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
had	VBD	O
superior	JJ	O
scans	NNS	O
after	IN	O
recombinant	JJ	O
human	JJ	O
TSH	NNP	O
administration	NN	O
,	,	O
and	CC	O
17	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
had	VBD	O
superior	JJ	O
scans	NNS	O
after	IN	O
thyroid	JJ	O
hormone	NN	O
withdrawal	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.108	CD	O
)	)	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
serum	NN	Physical
Tg	NNP	Physical
level	NN	Physical
of	IN	O
2	CD	O
ng/mL	NNS	O
or	CC	O
more	JJR	O
,	,	O
thyroid	JJ	O
tissue	NN	O
or	CC	O
cancer	NN	O
was	VBD	O
detected	VBN	O
during	IN	O
thyroid	JJ	O
hormone	NN	O
therapy	NN	O
in	IN	O
22	CD	O
%	NN	O
,	,	O
after	IN	O
recombinant	JJ	O
human	JJ	O
TSH	NNP	O
stimulation	NN	O
in	IN	O
52	CD	O
%	NN	O
,	,	O
and	CC	O
after	IN	O
thyroid	JJ	O
hormone	NN	O
withdrawal	NN	O
in	IN	O
56	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
disease	NN	O
or	CC	O
tissue	NN	O
limited	VBN	O
to	TO	O
the	DT	O
thyroid	NN	O
bed	NN	O
and	CC	O
in	IN	O
80	CD	O
%	NN	O
,	,	O
100	CD	O
%	NN	O
,	,	O
and	CC	O
100	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
metastatic	JJ	O
disease	NN	O
.	.	O

A	DT	O
combination	NN	O
of	IN	O
radioiodine	NN	O
WBS	NNP	O
and	CC	O
serum	NN	O
Tg	NNP	O
after	IN	O
recombinant	JJ	O
human	JJ	O
TSH	NNP	O
stimulation	NN	O
detected	VBD	O
thyroid	JJ	Physical
tissue	NN	Physical
or	CC	O
cancer	NN	Physical
in	IN	O
93	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
disease	NN	O
or	CC	O
tissue	NN	O
limited	VBN	O
to	TO	O
the	DT	O
thyroid	NN	O
bed	NN	O
and	CC	O
100	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
disease	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
recombinant	JJ	O
human	JJ	O
TSH	NNP	O
administration	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
means	NNS	O
of	IN	O
stimulating	VBG	O
radioiodine	JJ	O
uptake	NN	O
and	CC	O
serum	NN	O
Tg	NNP	O
levels	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
evaluation	NN	O
for	IN	O
thyroid	JJ	O
cancer	NN	O
persistence	NN	O
and	CC	O
recurrence	NN	O
.	.	O

Clinical	JJ	O
efficacy	NN	O
of	IN	O
antazoline	NN	O
in	IN	O
rapid	JJ	Physical
cardioversion	NN	Physical
of	IN	Physical
paroxysmal	JJ	Physical
atrial	JJ	Physical
fibrillation	NN	Physical
--	:	Physical
a	DT	Physical
protocol	NN	O
of	IN	O
a	DT	O
single	JJ	O
center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
(	(	O
the	DT	O
AnPAF	NNP	O
Study	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Rapid	NNP	Physical
conversion	NN	Physical
of	IN	Physical
atrial	JJ	Physical
fibrillation	NN	Physical
(	(	Physical
AF	NNP	Physical
)	)	Physical
to	TO	Physical
sinus	VB	Physical
rhythm	NN	Physical
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
class	NN	O
IA	NNP	O
,	,	O
IC	NNP	O
and	CC	O
III	NNP	O
antiarrhythmic	JJ	O
drugs	NNS	O
or	CC	O
vernakalant	JJ	O
hydrochloride	NN	O
.	.	O

However	RB	O
,	,	O
that	IN	O
treatment	NN	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
potential	JJ	O
pro-arrhythmia	NN	O
,	,	O
lack	NN	O
of	IN	O
efficacy	NN	O
or	CC	O
the	DT	O
exceptionally	RB	O
high	JJ	O
cost	NN	O
of	IN	O
a	DT	O
compound	NN	O
used	VBN	O
.	.	O

Antazoline	NNP	O
is	VBZ	O
a	DT	O
first	JJ	O
generation	NN	O
antihistaminic	JJ	O
agent	NN	O
with	IN	O
chinidin-like	JJ	O
properties	NNS	O
.	.	O

When	WRB	O
administered	VBN	O
intravenously	RB	O
,	,	O
antazoline	JJ	O
exerts	VBZ	O
a	DT	O
strong	JJ	Physical
antiarrhythmic	JJ	Physical
effect	NN	Physical
on	IN	O
supraventricular	JJ	Physical
arrhythmia	NN	Physical
,	,	O
especially	RB	O
on	IN	O
AF	NNP	Physical
,	,	O
facilitating	VBG	O
rapid	JJ	Physical
conversion	NN	Physical
to	TO	Physical
sinus	VB	Physical
rhythm	NN	Physical
.	.	O

Despite	IN	O
a	DT	O
relative	JJ	O
lack	NN	O
of	IN	O
published	VBN	O
data	NNS	O
antazoline	NN	O
has	VBZ	O
been	VBN	O
marketed	VBN	O
in	IN	O
Poland	NNP	O
and	CC	O
widely	RB	O
used	VBN	O
in	IN	O
cardiology	NN	O
wards	NNS	O
and	CC	O
emergency	NN	O
rooms	NNS	O
for	IN	O
many	JJ	O
years	NNS	O
due	JJ	O
to	TO	O
its	PRP$	O
efficacy	NN	O
,	,	O
safety	NN	O
and	CC	O
rapid	JJ	O
onset	NN	O
of	IN	O
action	NN	O
within	IN	O
minutes	NNS	O
of	IN	O
administration	NN	O
.	.	O

METHODS/DESIGN	CC	O
A	DT	O
randomized	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
superiority	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
clinical	JJ	Others
efficacy	NN	Others
of	IN	O
antazoline	NN	O
in	IN	O
rapid	JJ	O
conversion	NN	O
of	IN	O
AF	NNP	O
to	TO	O
sinus	VB	O
rhythm	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
will	MD	O
present	VB	O
AF	NNP	O
lasting	VBG	O
less	JJR	O
than	IN	O
43	CD	O
hours	NNS	O
,	,	O
will	MD	O
be	VB	O
in	IN	O
stable	JJ	O
cardio-pulmonary	JJ	O
condition	NN	O
and	CC	O
will	MD	O
have	VB	O
no	DT	O
prior	JJ	O
history	NN	O
of	IN	O
advanced	JJ	O
heart	NN	O
failure	NN	O
or	CC	O
significant	JJ	O
valvular	JJ	O
disease	NN	O
.	.	O

Long-term	JJ	O
antiarrhythmic	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
considered	VBN	O
an	DT	O
exclusion	NN	O
criterion	NN	O
.	.	O

Subjects	NNS	O
who	WP	O
fulfill	VBP	O
selection	NN	O
criteria	NNS	O
will	MD	O
be	VB	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
intravenously	RB	O
either	DT	O
antazoline	NN	O
or	CC	O
placebo	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
and	CC	O
observed	VBD	O
for	IN	O
1.5	CD	O
hours	NNS	O
after	IN	O
conversion	NN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
or	CC	O
after	IN	O
the	DT	O
last	JJ	O
i.v	NN	O
.	.	O

bolus	NN	O
.	.	O

Primary	JJ	O
end	NN	O
point	NN	O
will	MD	O
be	VB	O
the	DT	O
conversion	NN	Physical
of	IN	Physical
AF	NNP	Physical
to	TO	Physical
sinus	VB	Physical
rhythm	NN	Physical
confirmed	VBN	Physical
in	IN	Physical
an	DT	Physical
electrocardiogram	NN	Physical
(	(	Physical
ECG	NNP	Physical
)	)	Physical
during	IN	O
the	DT	O
observation	NN	O
period	NN	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
will	MD	O
be	VB	O
comprised	VBN	Physical
of	IN	Physical
time	NN	Physical
to	TO	Physical
conversion	NN	Physical
and	CC	Physical
return	NN	Physical
of	IN	Physical
AF	NNP	Physical
during	IN	O
the	DT	O
observation	NN	O
period	NN	O
.	.	O

Special	JJ	O
consideration	NN	O
will	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
observation	NN	O
of	IN	O
any	DT	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

A	DT	O
sample	JJ	O
size	NN	O
of	IN	O
80	CD	O
patients	NNS	O
was	VBD	O
calculated	VBN	O
based	VBN	O
on	IN	O
the	DT	O
following	JJ	O
assumptions	NNS	O
:	:	O
two-tailed	JJ	O
test	NN	O
,	,	O
a	DT	O
type	NN	O
I	PRP	O
error	VBP	O
of	IN	O
0.01	CD	O
,	,	O
a	DT	O
power	NN	O
of	IN	O
90	CD	O
%	NN	O
,	,	O
efficacy	NN	Others
of	IN	O
placebo	JJ	O
5	CD	O
%	NN	O
,	,	O
efficacy	NN	O
of	IN	O
antazoline	JJ	O
50	CD	O
%	NN	O
and	CC	O
20	CD	O
%	NN	O
drop-out	JJ	O
rate	NN	O
to	TO	O
fulfill	VB	O
the	DT	O
criteria	NNS	O
of	IN	O
intention-to-treat	JJ	O
analysis	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
presumed	JJ	O
lack	NN	O
of	IN	O
statistical	JJ	O
power	NN	O
,	,	O
the	DT	O
secondary	JJ	O
end	NN	O
points	NNS	O
and	CC	O
safety	NN	O
endpoints	NNS	O
will	MD	O
be	VB	O
considered	VBN	O
exploratory	JJ	O
.	.	O

CLINICAL	JJ	O
TRIALS	NNP	O
REGISTRY	NNP	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT01527279	NNP	O
.	.	O

The	DT	O
memory	NN	O
support	NN	O
system	NN	O
for	IN	O
mild	JJ	O
cognitive	JJ	O
impairment	NN	O
:	:	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
cognitive	JJ	O
rehabilitation	NN	O
intervention	NN	O
.	.	O

OBJECTIVE	JJ	O
Individuals	NNS	O
with	IN	O
amnestic	JJ	O
mild	NNS	O
cognitive	JJ	O
impairment	NN	O
(	(	O
MCI	NNP	O
)	)	O
have	VBP	O
few	JJ	O
empirically	RB	O
based	VBN	O
treatment	NN	O
options	NNS	O
for	IN	O
combating	VBG	O
their	PRP$	O
memory	NN	Mental
loss	NN	Mental
.	.	Mental

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
a	DT	O
calendar/notebook	NN	O
rehabilitation	NN	O
intervention	NN	O
,	,	O
the	DT	O
memory	NN	Mental
support	NN	Mental
system	NN	Mental
(	(	Mental
MSS	NNP	Mental
)	)	Mental
,	,	O
for	IN	O
individuals	NNS	O
with	IN	O
amnestic	JJ	O
MCI	NNP	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
individuals	NNS	O
with	IN	O
single	JJ	O
domain	NN	O
amnestic	JJ	O
MCI	NNP	O
and	CC	O
their	PRP$	O
program	NN	O
partners	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
the	DT	O
MSS	NNP	O
,	,	O
either	RB	O
with	IN	O
training	NN	O
or	CC	O
without	IN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

Measures	NNS	Others
of	IN	Others
adherence	NN	Others
,	,	O
activities	NNS	Mental
of	IN	Mental
daily	JJ	Mental
living	NN	Mental
,	,	Mental
and	CC	Mental
emotional	JJ	Mental
impact	NN	Mental
were	VBD	O
completed	VBN	O
at	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
intervention	NN	O
sessions	NNS	O
and	CC	O
again	RB	O
at	IN	O
8	CD	O
weeks	NNS	O
and	CC	O
6	CD	O
months	NNS	O
post	VBN	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Training	NNP	O
in	IN	O
use	NN	O
of	IN	O
a	DT	O
notebook/calendar	NN	O
system	NN	O
significantly	RB	O
improved	VBN	O
adherence	NN	O
over	IN	O
those	DT	O
who	WP	O
received	VBD	O
the	DT	O
calendars	NNS	O
but	CC	O
no	DT	O
training	NN	O
.	.	O

Functional	NNP	Mental
ability	NN	Mental
and	CC	O
memory	NN	Mental
self-efficacy	NN	Mental
significantly	RB	O
improved	VBN	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
MSS	NNP	O
training	NN	O
.	.	O

Change	NN	O
in	IN	O
functional	JJ	O
ability	NN	O
remained	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
out	IN	O
to	TO	O
8-week	JJ	O
follow-up	NN	O
.	.	O

Care	NNP	O
partners	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
demonstrated	VBD	O
improved	VBN	O
mood	NN	Mental
by	IN	O
8-week	JJ	O
and	CC	O
6-month	JJ	O
follow-ups	NNS	O
,	,	O
whereas	NNS	O
control	VBP	O
care	NN	O
partners	NNS	O
reported	VBD	O
worse	JJR	O
caregiver	NN	Mental
burden	NN	Mental
by	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	NNP	O
Memory	NNP	O
support	NN	O
system	NN	O
training	NN	O
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
and	CC	O
sense	NN	O
of	IN	O
memory	NN	O
self-efficacy	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
MCI	NNP	O
.	.	O

Although	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	VBG	O
benefits	NNS	O
were	VBD	O
maintained	VBN	O
out	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
post	NN	O
intervention	NN	O
,	,	O
future	JJ	O
inclusion	NN	O
of	IN	O
booster	NN	O
sessions	NNS	O
may	MD	O
help	VB	O
extend	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
out	IN	O
even	RB	O
further	RBR	O
.	.	O

Improved	VBN	O
mood	NN	O
of	IN	O
care	NN	O
partners	NNS	O
of	IN	O
trained	JJ	O
individuals	NNS	O
and	CC	O
worsening	VBG	O
sense	NN	O
of	IN	O
caregiver	NN	O
burden	NN	O
over	IN	O
time	NN	O
for	IN	O
partners	NNS	O
of	IN	O
untrained	JJ	O
individuals	NNS	O
further	RBR	O
support	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
MSS	NNP	O
for	IN	O
MCI	NNP	O
.	.	O

Marginal	NNP	O
zone	NN	O
B	NNP	O
cell	NN	O
lymphoma	NN	O
of	IN	O
the	DT	O
parotid	JJ	O
glands	NNS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
radiotherapy	NN	O
to	TO	O
combined	VBN	O
therapy	NN	O
.	.	O

39	CD	O
patients	NNS	O
with	IN	O
marginal	JJ	O
zone	NN	O
B	NNP	O
cell	NN	O
lymphoma	NN	O
(	(	O
MZBCL	NNP	O
)	)	O
of	IN	O
the	DT	O
parotid	NN	O
glands	NNS	O
(	(	O
stages	NNS	O
I	PRP	O
or	CC	O
II	NNP	O
)	)	O
were	VBD	O
studied	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
be	VB	O
treated	VBN	O
with	IN	O
either	DT	O
radiotherapy	NN	O
alone	RB	O
(	(	O
extended	JJ	O
fields	NNS	O
,	,	O
4500	CD	O
cGy	NN	O
)	)	O
or	CC	O
radiotherapy	NN	O
(	(	O
the	DT	O
same	JJ	O
schedule	NN	O
)	)	O
plus	CC	O
adjuvant	JJ	O
chemotherapy	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
and	CC	O
prednisone	NN	O
)	)	O
.	.	O

The	DT	O
end	NN	Physical
points	NNS	Physical
were	VBD	O
survival	JJ	Mortality
and	CC	Mortality
time	NN	Mortality
to	TO	Mortality
treatment	NN	Mortality
failure	NN	Mortality
(	(	Mortality
TTF	NNP	Mortality
)	)	Mortality
.	.	Mortality

Patients	NNPS	O
who	WP	O
received	VBD	O
radiotherapy	VB	O
alone	RB	O
had	VBD	O
a	DT	O
complete	JJ	Physical
remission	NN	Physical
rate	NN	Physical
of	IN	O
100	CD	O
%	NN	O
,	,	O
the	DT	O
TTF	NNP	Others
was	VBD	O
90	CD	O
%	NN	O
at	IN	O
5	CD	O
years	NNS	O
and	CC	O
overall	JJ	Mortality
survival	NN	Mortality
at	IN	O
5	CD	O
years	NNS	O
was	VBD	O
90	CD	O
%	NN	O
with	IN	O
no	DT	O
statistical	JJ	O
difference	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
combined	JJ	O
therapy	NN	O
[	NN	O
100	CD	O
,	,	O
80	CD	O
and	CC	O
95	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.5	CD	O
)	)	O
]	NN	O
.	.	O

Although	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
,	,	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
therapeutic	JJ	O
approach	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
stage	NN	O
MZBCL	NNP	O
did	VBD	O
not	RB	O
offer	VB	O
any	DT	O
advantage	NN	O
over	IN	O
radiotherapy	NN	O
alone	RB	O
as	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
.	.	O

Until	IN	O
now	RB	O
,	,	O
radiotherapy	NN	O
was	VBD	O
considered	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
in	IN	O
this	DT	O
clinical	JJ	O
setting	NN	O
of	IN	O
patients	NNS	O
.	.	O

Pain	NN	O
relief	NN	O
can	MD	O
reduce	VB	O
hypoxemia	NN	Physical
in	IN	O
distressed	JJ	O
neonates	NNS	O
during	IN	O
routine	JJ	O
treatment	NN	O
procedures	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
opioids	NNS	O
could	MD	O
reduce	VB	O
the	DT	O
hypoxemia	NN	Physical
and	CC	Physical
hemodynamic	JJ	Physical
instability	NN	Physical
associated	VBN	O
with	IN	O
routine	JJ	O
intensive	JJ	O
care	NN	O
procedures	NNS	O
in	IN	O
neonates	NNS	O
with	IN	O
respiratory	JJ	O
distress	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
Physiological	NNP	O
,	,	O
plasma	JJ	O
beta-endorphin	NN	O
,	,	O
cortisol	NN	O
,	,	O
and	CC	O
glucose	JJ	O
responses	NNS	O
to	TO	O
routine	VB	O
treatment	NN	O
procedures	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
84	CD	O
mechanically	RB	O
ventilated	VBN	O
distressed	JJ	O
neonates	NNS	O
randomized	VBN	O
into	IN	O
groups	NNS	O
receiving	VBG	O
1	CD	O
mg/kg	JJ	O
meperidine	NN	O
or	CC	O
0.9	CD	O
%	NN	O
saline	NN	O
15	CD	O
minutes	NNS	O
before	IN	O
tracheal	JJ	O
suction	NN	O
or	CC	O
routine	JJ	O
nursing	NN	O
care	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
duration	NN	Physical
of	IN	Physical
hypoxemia	NN	Physical
(	(	Physical
transcutaneous	JJ	Physical
partial	JJ	Physical
pressure	NN	Physical
of	IN	Physical
O2	NNP	Physical
<	NNP	O
6.6	CD	O
kPa	NN	O
(	(	O
<	JJ	O
50	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
and/or	VBP	O
arterial	JJ	Physical
blood	NN	Physical
oxygen	NN	Physical
saturation	NN	Physical
<	VBD	O
80	CD	O
%	NN	O
)	)	O
during	IN	O
treatment	NN	O
procedures	NNS	O
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
the	DT	O
saline	NN	O
group	NN	O
(	(	O
mean	JJ	O
82	CD	O
vs	NN	O
36	CD	O
seconds	NNS	O
,	,	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
and	CC	O
distress	JJ	O
quantified	VBN	O
by	IN	O
a	DT	O
novel	JJ	O
behavioral	JJ	O
scoring	VBG	O
method	NN	O
was	VBD	O
much	RB	O
higher	JJR	O
.	.	O

Changes	NNS	O
in	IN	O
arterial	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	Physical
heart	NN	Physical
rate	NN	Physical
,	,	Physical
or	CC	Physical
plasma	VB	Physical
beta-endorphin	JJ	Physical
,	,	Physical
cortisol	NN	Physical
,	,	Physical
and	CC	Physical
glucose	JJ	Physical
concentration	NN	Physical
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Newborns	NNP	O
with	IN	O
respiratory	JJ	O
difficulties	NNS	O
often	RB	O
suffer	VBP	O
from	IN	O
hypoxemia	NN	O
during	IN	O
essential	JJ	O
treatment	NN	O
procedures	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
opioid	JJ	O
analgesia	NN	O
may	MD	O
reduce	VB	O
the	DT	O
duration	NN	Physical
of	IN	Physical
hypoxemia	NN	Physical
and	CC	O
the	DT	O
associated	JJ	O
distress	NN	Physical
and	CC	O
,	,	O
therefore	RB	O
,	,	O
may	MD	O
improve	VB	O
the	DT	O
long-term	JJ	O
results	NNS	O
of	IN	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
.	.	O

Alternative	JJ	O
voice	NN	O
after	IN	O
laryngectomy	NN	O
using	VBG	O
a	DT	O
sound-producing	JJ	O
voice	NN	O
prosthesis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
improve	VB	Physical
the	DT	Physical
voice	NN	Physical
quality	NN	Physical
of	IN	O
female	JJ	O
laryngectomees	NNS	O
and/or	VBP	O
laryngectomees	NNS	O
with	IN	O
a	DT	O
hypotonic	JJ	O
pharyngoesophageal	NN	O
(	(	O
PE	NNP	O
)	)	O
segment	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
pneumatic	JJ	Physical
artificial	JJ	Physical
source	NN	Physical
of	IN	Physical
voice	NN	Physical
incorporated	VBN	Physical
in	IN	Physical
a	DT	Physical
regular	JJ	Physical
tracheoesophageal	NN	Physical
(	(	Physical
TE	NNP	Physical
)	)	Physical
shunt	NN	Physical
valve	NN	Physical
.	.	Physical

STUDY	NNP	O
DESIGN	NNP	O
Experimental	NNP	O
,	,	O
randomized	VBD	O
,	,	O
crossover	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
new	JJ	O
sound	NN	O
source	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	O
silicone	NN	O
lip	NN	O
,	,	O
which	WDT	O
performs	VBZ	O
an	DT	O
oscillatory	JJ	O
movement	NN	O
driven	VBN	O
by	IN	O
expired	JJ	O
pulmonary	JJ	O
air	NN	O
flowing	VBG	O
along	IN	O
the	DT	O
outward-striking	JJ	O
lip	NN	O
through	IN	O
the	DT	O
TE	NNP	O
shunt	NN	O
valve	NN	O
.	.	O

A	DT	O
prototype	NN	O
of	IN	O
this	DT	O
pneumatic	JJ	O
sound	NN	O
source	NN	O
is	VBZ	O
evaluated	VBN	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
six	CD	O
laryngectomees	NNS	O
.	.	O

In	IN	O
vivo	JJ	O
evaluation	NN	O
includes	VBZ	O
speech	JJ	Physical
rate	NN	Physical
,	,	Physical
maximal	JJ	Physical
phonation	NN	Physical
time	NN	Physical
,	,	Physical
perceptual	JJ	Physical
voice	NN	Physical
evaluation	NN	Physical
of	IN	Physical
read-aloud	JJ	Physical
prose	NN	Physical
by	IN	Physical
an	DT	Physical
expert	NN	Physical
listener	NN	Physical
,	,	Physical
speech	JJ	Physical
intelligibility	NN	Physical
measurements	NNS	Physical
with	IN	Physical
12	CD	Physical
listeners	NNS	Physical
,	,	Physical
and	CC	Physical
self-assessment	JJ	Physical
by	IN	Physical
the	DT	Physical
patients	NNS	Physical
.	.	Physical

Moreover	RB	O
,	,	O
extensive	JJ	Others
acoustical	JJ	Others
and	CC	Others
aerodynamic	JJ	Physical
in	IN	Physical
vivo	JJ	Physical
registrations	NNS	Physical
are	VBP	O
performed	VBN	O
using	VBG	O
a	DT	O
newly	RB	Others
developed	VBN	Others
data	NNS	Others
acquisition	NN	Others
system	NN	Others
.	.	Others

RESULTS	VB	O
The	DT	O
current	JJ	O
prototype	NN	O
seems	VBZ	O
beneficial	JJ	O
in	IN	O
female	JJ	O
laryngectomees	NNS	O
with	IN	O
a	DT	O
hypotonic	JJ	O
PE	NNP	O
segment	NN	O
only	RB	O
.	.	O

For	IN	O
them	PRP	O
the	DT	O
sound-producing	JJ	O
voice	NN	O
prosthesis	NN	O
improves	VBZ	Physical
voice	JJ	Physical
quality	NN	Physical
and	CC	Physical
increases	VBZ	Physical
the	DT	Physical
average	JJ	Physical
pitch	NN	Physical
of	IN	Physical
voice	NN	Physical
,	,	Physical
without	IN	Physical
decreasing	VBG	Physical
intelligibility	NN	Physical
or	CC	Physical
necessitating	VBG	Physical
other	JJ	Physical
pressure	NN	Physical
and	CC	Physical
airflow	NN	Physical
rates	NNS	Physical
than	IN	Physical
regular	JJ	Physical
TE	NNP	Physical
shunt	NN	Physical
speech	NN	Physical
.	.	Physical

Pitch	NNP	Physical
regulation	NN	Physical
of	IN	O
this	DT	O
prosthetic	JJ	O
voice	NN	O
is	VBZ	O
possible	JJ	O
,	,	O
yet	RB	O
limited	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
mechanism	NN	O
is	VBZ	O
feasible	JJ	Others
and	CC	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
unacceptable	JJ	O
airflow	JJ	O
resistance	NN	O
.	.	O

For	IN	O
this	DT	O
new	JJ	O
mechanism	NN	O
of	IN	O
alaryngeal	JJ	O
voice	NN	O
to	TO	O
become	VB	O
an	DT	O
established	JJ	O
technique	NN	O
for	IN	O
postlaryngectomy	JJ	O
voice	NN	O
restoration	NN	O
,	,	O
a	DT	O
voice	NN	O
suitably	RB	O
pitched	VBN	O
for	IN	O
male	NN	O
laryngectomees	NNS	O
has	VBZ	O
to	TO	O
be	VB	O
generated	VBN	O
and	CC	O
a	DT	O
large	JJ	O
part	NN	O
of	IN	O
the	DT	O
melodic	NN	O
and	CC	O
dynamic	JJ	O
range	NN	O
of	IN	O
the	DT	O
sound	NN	O
source	NN	O
has	VBZ	O
to	TO	O
be	VB	O
attainable	JJ	O
within	IN	O
physiological	JJ	O
airflow	JJ	O
rates	NNS	O
.	.	O

Topical	JJ	O
administration	NN	O
of	IN	O
diclofenac	NN	O
(	(	O
1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
miosis	NN	Physical
during	IN	O
vitrectomy	NN	O
.	.	O

PURPOSE	VB	O
A	NNP	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
usefulness	NN	O
of	IN	O
preoperative	JJ	O
diclofenac	NN	O
eye	NN	O
drops	NNS	O
in	IN	O
maintaining	VBG	O
mydriasis	NN	Physical
during	IN	O
vitrectomy	NN	O
and	CC	O
in	IN	O
reducing	VBG	O
postoperative	JJ	Physical
inflammation	NN	Physical
.	.	Physical

METHODS	NNP	O
Fifty	NNP	O
consecutive	JJ	O
patients	NNS	O
undergoing	VBG	O
vitrectomy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
diclofenac	VB	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
standard	JJ	O
preoperative	JJ	O
regimen	NNS	O
of	IN	O
cyclopentolate	NN	O
(	(	O
2	CD	O
%	NN	O
)	)	O
and	CC	O
phenylephrine	JJ	O
hydrochloride	NN	O
(	(	O
2.5	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
diclofenac	NN	O
group	NN	O
also	RB	O
received	VBD	O
diclofenac	NNS	O
(	(	O
1	CD	O
%	NN	O
)	)	O
preoperatively	RB	O
.	.	O

Pupillary	JJ	Physical
diameter	NN	Physical
was	VBD	O
recorded	VBN	O
at	IN	O
four	CD	O
time	NN	O
points	NNS	O
during	IN	O
surgery	NN	O
.	.	O

Inflammatory	JJ	Physical
indices	NNS	Physical
were	VBD	O
measured	VBN	O
postoperatively	RB	O
using	VBG	O
slit-lamp	JJ	O
examination	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
the	DT	O
decrease	NN	Physical
in	IN	Physical
pupil	JJ	Physical
size	NN	Physical
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.112	CD	O
)	)	O
,	,	O
but	CC	O
for	IN	O
the	DT	O
next	JJ	O
two	CD	O
stages	NNS	O
,	,	O
it	PRP	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
diclofenac	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.012	CD	O
and	CC	O
P	NNP	O
=	NNP	O
0.003	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
anterior	JJ	Physical
chamber	NN	Physical
cells	NNS	Physical
and	CC	O
redness	NN	Physical
in	IN	Physical
the	DT	Physical
eye	NN	Physical
postoperatively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.609	CD	O
and	CC	O
P	NNP	O
=	NNP	O
0.123	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

However	RB	O
,	,	O
anterior	JJ	Physical
chamber	NN	Physical
flare	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
and	CC	O
patients	NNS	O
felt	VBD	O
significantly	RB	O
more	RBR	O
pain	NN	Pain
in	IN	O
this	DT	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Topical	NNP	O
administration	NN	O
of	IN	O
diclofenac	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
maintaining	VBG	Physical
mydriasis	NN	Physical
during	IN	O
vitrectomy	NN	O
and	CC	O
in	IN	O
reducing	VBG	O
postoperative	JJ	Pain
pain	NN	Pain
and	CC	O
anterior	JJ	Physical
chamber	NN	Physical
flare	NN	Physical
as	IN	O
determined	VBN	O
by	IN	O
slit-lamp	JJ	O
evaluations	NNS	O
.	.	O

Flutamide-metformin	JJ	O
plus	CC	O
ethinylestradiol-drospirenone	JJ	O
for	IN	O
lipolysis	NN	Physical
and	CC	Physical
antiatherogenesis	NN	Physical
in	IN	O
young	JJ	O
women	NNS	O
with	IN	O
ovarian	JJ	O
hyperandrogenism	NN	O
:	:	O
the	DT	O
key	JJ	O
role	NN	O
of	IN	O
early	JJ	O
,	,	O
low-dose	JJ	O
flutamide	NN	O
.	.	O

A	DT	O
low-dose	JJ	O
combination	NN	O
of	IN	O
flutamide-metformin	JJ	O
and	CC	O
ethinylestradiol-drospirenone	NN	O
was	VBD	O
recently	RB	O
found	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
excess	NN	Physical
of	IN	Physical
total	JJ	Physical
and	CC	Physical
abdominal	JJ	Physical
fat	NN	Physical
,	,	O
to	TO	O
diminish	VB	O
the	DT	O
deficit	NN	O
in	IN	O
lean	JJ	Physical
mass	NN	Physical
,	,	O
and	CC	O
to	TO	O
attenuate	VB	O
the	DT	O
dysadipocytokinemia	NN	Physical
of	IN	O
young	JJ	O
women	NNS	O
with	IN	O
ovarian	JJ	O
hyperandrogenism	NN	O
,	,	O
a	DT	O
variant	NN	O
of	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

We	PRP	O
questioned	VBD	O
the	DT	O
need	NN	O
to	TO	O
give	VB	O
flutamide	NN	O
,	,	O
an	DT	O
androgen	NN	O
receptor	NN	O
blocker	NN	O
,	,	O
together	RB	O
with	IN	O
an	DT	O
oral	JJ	O
contraceptive	NN	O
that	WDT	O
contains	VBZ	O
drospirenone	NN	O
,	,	O
a	DT	O
progestin	NN	O
claimed	VBN	O
to	TO	O
have	VB	O
antiandrogen	NN	O
properties	NNS	O
.	.	O

The	DT	O
additive	JJ	O
effects	NNS	O
of	IN	O
low-dose	JJ	O
flutamide	NN	O
(	(	O
62.5	CD	O
mg/d	NN	O
)	)	O
were	VBD	O
assessed	VBN	O
over	IN	O
3	CD	O
months	NNS	O
in	IN	O
young	JJ	O
patients	NNS	O
with	IN	O
hyperinsulinemic	JJ	O
ovarian	JJ	O
hyperandrogenism	NN	O
(	(	O
n	JJ	O
=	VBZ	O
40	CD	O
;	:	O
age	NN	O
,	,	O
approximately	RB	O
17	CD	O
yr	NNS	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
approximately	RB	O
22	CD	O
kg/m	NNS	O
(	(	O
2	CD	O
)	)	O
)	)	O
;	:	O
all	DT	O
participants	NNS	O
started	VBD	O
on	IN	O
metformin	NN	O
(	(	O
850	CD	O
mg/d	NN	O
)	)	O
and	CC	O
a	DT	O
fourth-generation	JJ	O
contraceptive	NN	O
(	(	O
ethinylestradiol	JJ	O
30	CD	O
microg	NN	O
plus	CC	O
drospirenone	NN	O
3	CD	O
mg	NN	O
,	,	O
21	CD	O
d/month	NN	O
)	)	O
,	,	O
and	CC	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
flutamide	NN	O
in	IN	O
addition	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
not	RB	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
.	.	O

Fasting	VBG	Physical
blood	NN	Physical
glucose	NN	Physical
,	,	O
serum	JJ	Physical
insulin	NN	Physical
,	,	O
lipid	JJ	Physical
profile	NN	Physical
,	,	O
testosterone	NN	Physical
,	,	O
adiponectin	NN	Physical
,	,	O
and	CC	O
IL-6	NNP	Physical
were	VBD	O
determined	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
together	RB	O
with	IN	O
body	NN	O
composition	NN	O
(	(	O
by	IN	O
dual	JJ	O
x-ray	JJ	O
absorptiometry	NN	O
)	)	O
and	CC	O
with	IN	O
Doppler	NNP	O
assessment	NN	O
of	IN	O
ovarian	JJ	O
arterial	JJ	O
resistance	NN	O
.	.	O

At	IN	O
start	NN	O
,	,	O
the	DT	O
pulsatility	NN	Others
and	CC	O
resistance	NN	Others
indices	NNS	Others
of	IN	O
ovarian	JJ	O
arteries	NNS	O
were	VBD	O
elevated	VBN	O
.	.	O

By	IN	O
comparison	NN	O
of	IN	O
3-month	JJ	O
changes	NNS	O
between	IN	O
randomized	VBN	O
subgroups	NNS	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
low-dose	JJ	O
flutamide	NN	O
was	VBD	O
found	VBN	O
to	TO	O
have	VB	O
consistently	RB	O
(	(	O
more	RBR	O
)	)	O
normalizing	VBG	O
effects	NNS	O
on	IN	O
low-density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
,	,	Physical
IL-6	NNP	Physical
,	,	O
and	CC	O
adiponectin	NN	Physical
,	,	Physical
lean	JJ	Physical
body	NN	Physical
mass	NN	Physical
,	,	O
total	JJ	Physical
and	CC	Physical
abdominal	JJ	Physical
fat	JJ	Physical
mass	NN	Physical
,	,	O
and	CC	O
arterial	JJ	Physical
flow	NN	Physical
in	IN	Physical
the	DT	Physical
ovaries	NNS	Physical
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
low-dose	JJ	O
flutamide	NN	O
is	VBZ	O
herewith	JJ	O
identified	VBN	O
as	IN	O
a	DT	O
pivotal	JJ	O
component	NN	O
within	IN	O
a	DT	O
first	JJ	O
contraceptive	JJ	O
combination	NN	O
therapy	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
attenuate	VB	O
the	DT	O
hypoadiponectinemia	NN	Physical
,	,	O
ovarian	JJ	Physical
vascular	NN	Physical
hyperresistance	NN	Physical
,	,	O
lean	JJ	Physical
mass	NN	Physical
deficit	NN	Physical
,	,	O
and	CC	O
central	JJ	Physical
adiposity	NN	Physical
of	IN	O
young	JJ	O
women	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

Finally	RB	O
,	,	O
these	DT	O
data	NNS	O
challenge	VBP	O
any	DT	O
claim	NN	O
that	IN	O
drospirenone	NN	O
,	,	O
as	IN	O
currently	RB	O
used	VBN	O
in	IN	O
a	DT	O
contraceptive	NN	O
,	,	O
is	VBZ	O
a	DT	O
clinically	RB	O
significant	JJ	O
antiandrogen	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
single-dose	JJ	O
intravenous	JJ	O
secretin	NN	O
as	IN	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
whether	IN	O
a	DT	O
single	JJ	O
injection	NN	O
of	IN	O
intravenous	JJ	O
secretin	NN	O
results	NNS	O
in	IN	O
measurable	JJ	O
improvements	NNS	O
in	IN	O
socialization	NN	O
and/or	NN	O
communication	NN	O
skills	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Sixty	NNP	O
subjects	VBZ	O
with	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
selected	VBN	O
and	CC	O
assigned	VBN	O
to	TO	O
either	DT	O
treatment	NN	O
or	CC	O
placebo	NN	O
group	NN	O
.	.	O

Subjects	VBZ	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
2.0	CD	O
clinical	JJ	O
units	NNS	O
of	IN	O
secretin	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
as	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
.	.	O

Subjects	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
received	VBD	O
normal	JJ	O
saline	JJ	O
solution	NN	O
.	.	O

Neurodevelopmental	NNP	O
and	CC	O
behavioral	JJ	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
for	IN	O
all	DT	O
subjects	NNS	O
before	IN	O
injection	NN	O
and	CC	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
.	.	O

RESULTS	NNP	O
Assessment	NNP	Mental
of	IN	Mental
language	NN	Mental
skills	NNS	Mental
and	CC	Mental
parents	NNS	Mental
'	POS	Mental
behavioral	JJ	Mental
assessments	NNS	Mental
revealed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
.	.	O

Raters	NNS	Others
'	POS	Others
assessments	NNS	Others
of	IN	Others
severity	NN	Mental
of	IN	Mental
autistic	JJ	Mental
symptoms	NNS	Mental
did	VBD	O
not	RB	O
differ	VB	O
for	IN	O
the	DT	O
2	CD	O
groups	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
.	.	O

A	DT	O
marginally	RB	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
autistic	JJ	O
behaviors	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
at	IN	O
3	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
(	(	O
P	NNP	O
=.051	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intravenous	JJ	O
secretin	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
have	VB	O
significant	JJ	O
effects	NNS	O
on	IN	O
either	DT	O
parents	NNS	O
'	POS	O
perception	NN	O
of	IN	O
autistic	JJ	O
behaviors	NNS	O
or	CC	O
language	NN	O
skills	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
.	.	O

Transient	NNP	O
,	,	O
marginally	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
autistic	JJ	O
behaviors	NNS	O
may	MD	O
occur	VB	O
in	IN	O
some	DT	O
children	NNS	O
.	.	O

Lessons	NNS	O
learnt	VBP	O
in	IN	O
conducting	VBG	O
a	DT	O
clinical	JJ	O
drug	NN	O
trial	NN	O
in	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
Syndrome	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
describe	VB	O
the	DT	O
authors	NNS	O
'	POS	O
experience	NN	O
of	IN	O
conducting	VBG	O
a	DT	O
clinical	JJ	O
drug	NN	O
trial	NN	O
in	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
Syndrome	NNP	O
,	,	O
including	VBG	O
the	DT	O
pitfalls	NNS	O
encountered	VBD	O
and	CC	O
lessons	NNS	O
learnt	VBP	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
main	JJ	O
barrier	NN	O
encountered	VBD	O
was	VBD	O
in	IN	O
the	DT	O
recruitment	NN	Others
of	IN	Others
children	NNS	Others
:	:	O
it	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
recruit	VB	O
the	DT	O
target	NN	O
of	IN	O
60	CD	O
patients	NNS	O
.	.	O

The	DT	O
recruitment	NN	Others
of	IN	Others
children	NNS	Others
is	VBZ	O
often	RB	O
the	DT	O
major	JJ	O
barrier	NN	O
to	TO	O
the	DT	O
progress	NN	O
of	IN	O
a	DT	O
successful	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Conducting	VBG	O
the	DT	O
clinical	JJ	O
drug	NN	O
trial	NN	O
was	VBD	O
greatly	RB	O
facilitated	VBN	O
by	IN	O
the	DT	O
appropriate	JJ	O
setting	NN	O
and	CC	O
experienced	VBD	O
clinical	JJ	O
pharmacology	NN	O
staff	NN	O
.	.	O

Pharmacokinetic	JJ	O
and	CC	O
safety	NN	O
evaluation	NN	O
of	IN	O
high-dose	JJ	O
combinations	NNS	O
of	IN	O
fosamprenavir	NN	O
and	CC	O
ritonavir	NN	O
.	.	O

High-dose	JJ	O
combinations	NNS	O
of	IN	O
fosamprenavir	NN	O
(	(	O
FPV	NNP	O
)	)	O
and	CC	O
ritonavir	NN	O
(	(	O
RTV	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
healthy	JJ	O
adult	NN	O
subjects	NNS	O
in	IN	O
order	NN	O
to	TO	O
select	VB	O
doses	NNS	O
for	IN	O
further	JJ	O
study	NN	O
in	IN	O
multiple	JJ	O
protease	NN	O
inhibitor	NN	O
(	(	O
PI	NNP	O
)	)	O
-experienced	VBD	O
patients	NNS	O
infected	VBN	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
type	NN	O
1	CD	O
.	.	O

Two	CD	O
high-dose	JJ	O
regimens	NNS	O
,	,	O
FPV	NNP	O
1,400	CD	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
(	(	O
BID	NNP	O
)	)	O
plus	CC	O
RTV	$	O
100	CD	O
mg	NN	O
BID	NNP	O
and	CC	O
FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
were	VBD	O
planned	VBN	O
to	TO	O
be	VB	O
compared	VBN	O
to	TO	O
the	DT	O
approved	JJ	O
regimen	NNS	O
,	,	O
FPV	NNP	O
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
three-period	NN	O
crossover	NN	O
study	NN	O
.	.	O

Forty-two	NNP	O
healthy	JJ	O
adult	NN	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
and	CC	O
39	CD	O
subjects	NNS	O
completed	VBN	O
period	NN	O
1	CD	O
.	.	O

Due	JJ	O
to	TO	O
marked	VB	O
hepatic	JJ	O
transaminase	NN	O
elevations	NNS	O
,	,	O
predominantly	RB	O
with	IN	O
FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
prematurely	RB	O
.	.	O

For	IN	O
FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
values	NNS	Physical
for	IN	Physical
plasma	NN	Physical
amprenavir	NN	Physical
(	(	Physical
APV	NNP	Physical
)	)	Physical
area	NN	Physical
under	IN	Others
the	DT	Others
concentration-time	JJ	Others
profile	NN	Others
over	IN	O
the	DT	O
dosing	VBG	O
interval	NN	O
(	(	O
tau	NN	O
)	)	O
at	IN	O
steady	JJ	O
state	NN	O
[	NNS	O
AUC	NNP	O
(	(	O
0-tau	JJ	O
)	)	O
]	NN	O
,	,	O
maximum	JJ	Others
concentration	NN	Others
of	IN	Others
drug	NN	Others
in	IN	Others
plasma	NN	Others
(	(	Others
C	NNP	Others
(	(	Others
max	NN	Others
)	)	Others
)	)	Others
,	,	O
and	CC	O
plasma	JJ	Physical
concentration	NN	Physical
at	IN	Physical
the	DT	Physical
end	NN	Physical
of	IN	Physical
tau	NN	Physical
at	IN	Physical
steady	JJ	Physical
state	NN	Physical
(	(	Others
C	NNP	Others
(	(	Others
tau	NN	Others
)	)	Others
)	)	Others
were	VBD	O
54	CD	O
,	,	O
81	CD	O
,	,	O
and	CC	O
26	CD	O
%	NN	O
higher	JJR	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
values	NNS	Physical
for	IN	Physical
plasma	NN	Physical
RTV	NNP	Physical
AUC	NNP	Physical
(	(	Physical
0-tau	JJ	Physical
)	)	Physical
,	,	O
C	NNP	Others
(	(	Others
max	NN	Others
)	)	Others
,	,	O
and	CC	O
C	NNP	Others
(	(	Others
tau	NN	Others
)	)	Others
were	VBD	O
49	CD	O
%	NN	O
higher	JJR	O
,	,	O
71	CD	O
%	NN	O
higher	JJR	O
,	,	O
and	CC	O
11	CD	O
%	NN	O
lower	JJR	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
those	DT	O
for	IN	O
FPV	NNP	O
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
.	.	O

For	IN	O
FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
values	NNS	Physical
for	IN	Physical
plasma	NN	Physical
APV	NNP	Physical
AUC	NNP	Physical
(	(	Physical
0-tau	JJ	Physical
)	)	Physical
,	,	O
C	NNP	Others
(	(	Others
max	NN	Others
)	)	Others
,	,	O
and	CC	O
C	NNP	Others
(	(	Others
tau	NN	Others
)	)	Others
were	VBD	O
26	CD	O
,	,	O
48	CD	O
,	,	O
and	CC	O
32	CD	O
%	NN	O
higher	JJR	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
values	NNS	O
for	IN	O
plasma	NN	Physical
RTV	NNP	Physical
AUC	NNP	Physical
(	(	Physical
0-tau	JJ	Physical
)	)	Physical
,	,	O
C	NNP	Physical
(	(	Physical
max	NN	Physical
)	)	Physical
,	,	O
and	CC	O
C	NNP	Physical
(	(	Physical
tau	NN	Physical
)	)	Others
increased	VBD	O
4.15-fold	JJ	O
,	,	O
4.17-fold	JJ	O
,	,	O
and	CC	O
3.99-fold	JJ	O
,	,	O
respectively	RB	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
for	IN	O
FPV	NNP	O
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
.	.	O

FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
200	CD	O
mg	NN	O
BID	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
due	JJ	O
to	TO	O
an	DT	O
increased	VBN	O
rate	NN	Physical
of	IN	Physical
marked	VBN	Physical
hepatic	JJ	Physical
transaminase	NN	Physical
elevations	NNS	Physical
and	CC	O
lack	NN	Others
of	IN	Others
pharmacokinetic	JJ	Others
advantage	NN	Others
.	.	Others

FPV	NNP	O
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
is	VBZ	O
currently	RB	O
under	IN	O
clinical	JJ	O
evaluation	NN	O
in	IN	O
multiple	JJ	O
PI-experienced	JJ	O
patients	NNS	O
.	.	O

Role	NNP	O
of	IN	O
diltiazem	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
silent	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

Silent	JJ	O
myocardial	JJ	O
ischemia	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
finding	NN	O
when	WRB	O
Holter	NNP	O
monitoring	NN	O
is	VBZ	O
done	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
coronary	JJ	O
disease	NN	O
.	.	O

Silent	JJ	O
ischemia	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
worse	JJR	O
prognosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
or	CC	O
unstable	JJ	O
angina	NN	O
,	,	O
survivors	NNS	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
populations	NNS	O
at	IN	O
risk	NN	O
for	IN	O
coronary	JJ	O
disease	NN	O
.	.	O

Whether	NNP	O
medical	JJ	O
therapy	NN	O
for	IN	O
silent	JJ	O
ischemia	NN	O
improves	VBZ	O
prognosis	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
of	IN	O
60	CD	O
patients	NNS	O
with	IN	O
documented	JJ	O
coronary	JJ	O
disease	NN	O
,	,	O
positive	JJ	O
exercise	NN	O
tests	NNS	O
,	,	O
and	CC	O
ischemic	JJ	O
episodes	NNS	O
on	IN	O
Holter	NNP	O
monitoring	NN	O
,	,	O
long-acting	JJ	O
diltiazem	NN	O
reduced	VBD	O
ischemic	JJ	Physical
episodes	NNS	Physical
by	IN	O
50	CD	O
%	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
5.6	CD	O
to	TO	O
2.8	CD	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

Efficacy	NN	Others
was	VBD	O
maintained	VBN	O
over	IN	O
24	CD	O
h	NNS	O
and	CC	O
diltiazem	NN	O
also	RB	O
significantly	RB	O
improved	VBN	O
exercise	NN	Others
test	NN	Others
parameters	NNS	Others
.	.	O

Three	CD	O
smaller	JJR	O
studies	NNS	O
also	RB	O
demonstrated	VBD	O
that	IN	O
diltiazem	NN	O
effectively	RB	O
reduces	VBZ	O
ambulatory	JJ	Physical
ischemia	NN	Physical
;	:	O
however	RB	O
,	,	O
results	NNS	O
with	IN	O
nifedipine	JJ	O
are	VBP	O
conflicting	VBG	O
,	,	O
with	IN	O
several	JJ	O
studies	NNS	O
showing	VBG	O
no	DT	O
benefit	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
beta-blockers	NNS	O
reliably	RB	O
reduce	VB	O
ischemic	JJ	Physical
episodes	NNS	Physical
.	.	O

The	DT	O
role	NN	O
of	IN	O
medical	JJ	O
therapy	NN	O
for	IN	O
silent	JJ	O
ischemia	NN	O
will	MD	O
be	VB	O
clarified	VBN	O
only	RB	O
when	WRB	O
its	PRP$	O
effect	NN	O
upon	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
are	VBP	O
determined	VBN	O
.	.	O

Effectiveness	NN	O
of	IN	O
manual	JJ	O
physical	JJ	O
therapy	NN	O
and	CC	O
exercise	NN	O
in	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Few	JJ	O
investigations	NNS	O
include	VBP	O
both	DT	O
subjective	JJ	O
and	CC	O
objective	JJ	O
measurements	NNS	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
for	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

Beneficial	JJ	O
interventions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
disability	NN	Physical
associated	VBN	O
with	IN	O
osteoarthritis	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
more	RBR	O
invasive	JJ	O
treatments	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
physical	JJ	O
therapy	NN	O
for	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
,	,	O
applied	VBN	O
by	IN	O
experienced	JJ	O
physical	JJ	O
therapists	NNS	O
with	IN	O
formal	JJ	O
training	NN	O
in	IN	O
manual	JJ	O
therapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physical	JJ	O
therapy	NN	O
department	NN	O
of	IN	O
a	DT	O
large	JJ	O
military	JJ	O
medical	JJ	O
center	NN	O
.	.	O

PATIENTS	CC	O
83	CD	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
(	(	O
n	JJ	O
=	VBZ	O
42	CD	O
;	:	O
15	CD	O
men	NNS	O
and	CC	O
27	CD	O
women	NNS	O
[	JJ	O
mean	JJ	O
age	NN	O
,	,	O
60	CD	O
+/-	JJ	O
11	CD	O
years	NNS	O
]	RB	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	VBZ	O
41	CD	O
;	:	O
19	CD	O
men	NNS	O
and	CC	O
22	CD	O
women	NNS	O
[	JJ	O
mean	JJ	O
age	NN	O
,	,	O
62	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
]	RB	O
)	)	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
manual	JJ	O
therapy	NN	O
,	,	O
applied	VBN	O
to	TO	O
the	DT	O
knee	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
the	DT	O
lumbar	NN	O
spine	NN	O
,	,	O
hip	NN	O
,	,	O
and	CC	O
ankle	RB	O
as	IN	O
required	VBN	O
,	,	O
and	CC	O
performed	VBD	O
a	DT	O
standardized	JJ	O
knee	NN	O
exercise	NN	O
program	NN	O
in	IN	O
the	DT	O
clinic	NN	O
and	CC	O
at	IN	O
home	NN	O
.	.	O

The	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
subtherapeutic	JJ	O
ultrasound	NN	O
to	TO	O
the	DT	O
knee	NN	O
at	IN	O
an	DT	O
intensity	NN	O
of	IN	O
0.1	CD	O
W/cm2	NNP	O
with	IN	O
a	DT	O
10	CD	O
%	NN	O
pulsed	JJ	O
mode	NN	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
treated	VBN	O
at	IN	O
the	DT	O
clinic	JJ	O
twice	JJ	O
weekly	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Distance	NNP	Physical
walked	VBD	Physical
in	IN	Physical
6	CD	Physical
minutes	NNS	Physical
and	CC	Physical
sum	NN	Physical
of	IN	Physical
the	DT	Physical
function	NN	Physical
,	,	O
pain	NN	Pain
,	,	O
and	CC	O
stiffness	JJ	Physical
subscores	NNS	Physical
of	IN	Physical
the	DT	Physical
Western	NNP	Physical
Ontario	NNP	Physical
and	CC	Physical
McMaster	NNP	Physical
Universities	NNP	Physical
Osteoarthritis	NNP	Physical
Index	NNP	Physical
(	(	Physical
WOMAC	NNP	Physical
)	)	Physical
.	.	O

A	DT	O
tester	NN	O
who	WP	O
was	VBD	O
blinded	VBN	O
to	TO	O
group	NN	O
assignment	NN	O
made	VBD	O
group	NN	O
comparisons	NNS	O
at	IN	O
the	DT	O
initial	JJ	O
visit	NN	O
(	(	O
before	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
)	)	O
,	,	O
4	CD	O
weeks	NNS	O
,	,	O
8	CD	O
weeks	NNS	O
,	,	O
and	CC	O
1	CD	O
year	NN	O
.	.	O

RESULTS	NNP	O
Clinically	NNP	O
and	CC	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
6-minute	JJ	Physical
walk	NN	Physical
distance	NN	Physical
and	CC	O
WOMAC	NNP	Physical
score	NN	Physical
at	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
8	CD	O
weeks	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

By	IN	O
8	CD	O
weeks	NNS	O
,	,	O
average	JJ	O
6-minute	JJ	Physical
walk	NN	Physical
distances	NNS	Physical
had	VBD	O
improved	VBN	O
by	IN	O
13.1	CD	O
%	NN	O
and	CC	O
WOMAC	NNP	Physical
scores	NNS	Physical
had	VBD	O
improved	VBN	O
by	IN	O
55.8	CD	O
%	NN	O
over	IN	O
baseline	NN	O
values	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
controlling	VBG	O
for	IN	O
potential	JJ	O
confounding	NN	O
variables	NNS	O
,	,	O
the	DT	O
average	JJ	O
distance	NN	Physical
walked	VBD	Physical
in	IN	Physical
6	CD	Physical
minutes	NNS	Physical
at	IN	O
8	CD	O
weeks	NNS	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
170	CD	O
m	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
71	CD	O
to	TO	O
270	CD	O
m	NN	O
)	)	O
more	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
the	DT	O
average	JJ	O
WOMAC	JJ	Physical
scores	NNS	Physical
were	VBD	O
599	CD	O
mm	NN	O
higher	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
197	CD	O
to	TO	O
1002	CD	O
mm	NN	O
)	)	O
.	.	O

At	IN	O
1	CD	O
year	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
gains	NNS	O
over	IN	O
baseline	JJ	Physical
WOMAC	NNP	Physical
scores	NNS	Physical
and	CC	O
walking	VBG	Physical
distance	NN	Physical
;	:	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
undergone	JJ	O
knee	NN	Physical
arthroplasty	NN	Physical
.	.	O

CONCLUSIONS	VB	O
A	DT	O
combination	NN	O
of	IN	O
manual	JJ	O
physical	JJ	O
therapy	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
yields	NNS	O
functional	JJ	Others
benefits	NNS	Others
for	IN	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
and	CC	O
may	MD	O
delay	VB	O
or	CC	O
prevent	VB	O
the	DT	O
need	NN	O
for	IN	O
surgical	JJ	Others
intervention	NN	Others
.	.	O

Effectiveness	NN	Others
of	IN	O
aromatherapy	JJ	O
massage	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
anxiety	NN	Mental
and	CC	Mental
depression	NN	Mental
in	IN	O
patients	NNS	O
with	IN	O
cancer	NN	O
:	:	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
supplementing	VBG	O
usual	JJ	O
supportive	JJ	O
care	NN	O
with	IN	O
aromatherapy	JJ	O
massage	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
anxiety	NN	O
and	CC	O
depression	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
through	IN	O
a	DT	O
pragmatic	JJ	O
two-arm	NN	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
in	IN	O
four	CD	O
United	NNP	O
Kingdom	NNP	O
cancer	NN	O
centers	NNS	O
and	CC	O
a	DT	O
hospice	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Two	CD	O
hundred	VBD	O
eighty-eight	JJ	O
cancer	NN	O
patients	NNS	O
,	,	O
referred	VBD	O
to	TO	O
complementary	JJ	O
therapy	NN	O
services	NNS	O
with	IN	O
clinical	JJ	O
anxiety	NN	O
and/or	NN	O
depression	NN	O
,	,	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
a	DT	O
course	NN	O
of	IN	O
aromatherapy	JJ	O
massage	NN	O
or	CC	O
usual	JJ	O
supportive	JJ	O
care	NN	O
alone	RB	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
who	WP	O
received	VBD	O
aromatherapy	JJ	O
massage	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
clinical	JJ	Mental
anxiety	NN	Mental
and/or	NN	Mental
depression	NN	Mental
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
usual	JJ	O
care	NN	O
at	IN	O
10	CD	O
weeks	NNS	O
postrandomization	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
,	,	O
1.3	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.9	CD	O
to	TO	O
1.7	CD	O
;	:	O
P	NNP	O
=	NNP	O
.1	NNP	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
at	IN	O
6	CD	O
weeks	NNS	O
postrandomization	NN	O
(	(	O
OR	NNP	O
,	,	O
1.4	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.1	CD	O
to	TO	O
1.9	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Patients	NNS	O
receiving	VBG	O
aromatherapy	JJ	O
massage	NN	O
also	RB	O
described	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
self-reported	JJ	Mental
anxiety	NN	Mental
at	IN	O
both	DT	O
6	CD	O
and	CC	O
10	CD	O
weeks	NNS	O
postrandomization	NN	O
(	(	O
OR	NNP	O
,	,	O
3.4	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.2	CD	O
to	TO	O
6.7	CD	O
;	:	O
P	NNP	O
=	NNP	O
.04	NNP	O
and	CC	O
OR	NNP	O
,	,	O
3.4	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.2	CD	O
to	TO	O
6.6	CD	O
;	:	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	NNP	O
Aromatherapy	NNP	O
massage	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
confer	VB	O
benefit	NN	O
on	IN	O
cancer	NN	O
patients	NNS	O
'	POS	O
anxiety	NN	Physical
and/or	NN	O
depression	NN	Physical
in	IN	O
the	DT	O
long-term	JJ	O
,	,	O
but	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
clinically	RB	O
important	JJ	O
benefit	NN	Others
up	IN	O
to	TO	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
relative	JJ	O
efficacy	NN	Others
of	IN	O
formoterol	NN	O
and	CC	O
salmeterol	NN	O
in	IN	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Studies	NNS	O
performed	VBD	O
on	IN	O
airway	NN	O
smooth	JJ	O
muscle	NN	O
in	IN	O
vitro	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
salmeterol	NN	O
is	VBZ	O
a	DT	O
partial	JJ	O
agonist	NN	O
on	IN	O
the	DT	O
beta2-receptor	NN	O
in	IN	O
comparison	NN	O
to	TO	O
formoterol	VB	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
evaluated	VBD	O
whether	IN	O
these	DT	O
pharmacological	JJ	O
differences	NNS	O
between	IN	O
salmeterol	NN	O
and	CC	O
formoterol	NN	O
also	RB	O
are	VBP	O
applicable	JJ	O
to	TO	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
protective	JJ	O
effects	NNS	O
by	IN	O
increasing	VBG	O
cumulative	JJ	O
doses	NNS	O
of	IN	O
formoterol	NN	O
(	(	O
12	CD	O
,	,	O
60	CD	O
,	,	O
120	CD	O
micrograms	NNS	O
)	)	O
and	CC	O
salmeterol	NN	O
(	(	O
50	CD	O
,	,	O
250	CD	O
,	,	O
500	CD	O
micrograms	NNS	O
)	)	O
on	IN	O
methacholine-induced	JJ	O
bronchoconstriction	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
regularly	RB	O
treated	VBN	O
with	IN	O
salbutamol	JJ	O
200	CD	O
micrograms	NNS	O
twice	RB	O
daily	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
to	TO	O
avoid	VB	O
variability	NN	O
in	IN	O
beta2-adrenoceptor	JJ	Physical
tolerance	NN	Physical
.	.	O

S-potassium	NN	Others
,	,	O
heart	NN	Others
rate	NN	Others
corrected	VBD	Others
Q-T	NNP	Others
interval	NN	Others
(	(	Others
Q-Tc	NNP	Others
)	)	Others
,	,	O
and	CC	O
tremor	NN	Others
score	NN	Others
were	VBD	O
followed	VBN	O
as	IN	O
measures	NNS	O
of	IN	O
systemic	JJ	O
effects	NNS	O
.	.	O

Formoterol	NNP	O
dose-dependently	RB	O
protected	VBD	O
against	IN	O
methacholine	NN	O
responsiveness	NN	O
(	(	O
4.6	CD	O
doubling	VBG	O
doses	NNS	O
after	IN	O
120	CD	O
micrograms	NNS	O
)	)	O
.	.	O

Salmeterol	NNP	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
a	DT	O
flatter	JJ	O
dose-response	JJ	O
curve	NN	O
,	,	O
and	CC	O
a	DT	O
significantly	RB	O
weaker	JJR	O
maximal	JJ	O
protective	JJ	O
effect	NN	O
(	(	O
2.8	CD	O
doubling	VBG	O
doses	NNS	O
after	IN	O
250	CD	O
micrograms	NNS	O
)	)	O
.	.	O

Formoterol	NNP	O
caused	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
tremor	NN	Others
score	NN	Others
and	CC	O
a	DT	O
larger	JJR	O
drop	NN	O
in	IN	O
S-potassium	NNP	Physical
than	IN	O
salmeterol	NN	O
at	IN	O
the	DT	O
highest	JJS	O
doses	NNS	O
.	.	O

These	DT	O
data	NNS	O
show	VBP	O
that	IN	O
salmeterol	NN	O
is	VBZ	O
a	DT	O
partial	JJ	O
agonist	NN	O
on	IN	O
the	DT	O
beta2-receptor	NN	O
in	IN	O
relation	NN	O
to	TO	O
formoterol	VB	O
in	IN	O
human	JJ	O
airways	NNS	O
in	IN	O
vivo	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
document	VB	O
the	DT	O
clinical	JJ	O
consequences	NNS	O
of	IN	O
this	DT	O
finding	NN	O
,	,	O
for	IN	O
example	NN	O
in	IN	O
severe	JJ	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
anesthetic	JJ	O
and	CC	O
recovery	NN	O
profile	NN	O
of	IN	O
two	CD	O
doses	NNS	O
(	(	O
60	CD	O
and	CC	O
80	CD	O
mg	NN	O
)	)	O
of	IN	O
plain	NN	O
mepivacaine	NN	O
for	IN	O
ambulatory	JJ	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

UNLABELLED	JJ	O
Reports	NNS	O
of	IN	O
transient	JJ	O
neurological	JJ	O
symptoms	NNS	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
subarachnoid	JJ	O
lidocaine	NN	O
has	VBZ	O
generated	VBN	O
interest	NN	O
in	IN	O
alternate	JJ	O
local	JJ	O
anesthetics	NNS	O
of	IN	O
intermediate	JJ	O
duration	NN	O
,	,	O
such	JJ	O
as	IN	O
mepivacaine	NN	O
.	.	O

This	DT	O
prospective	JJ	O
randomized	NN	O
,	,	O
double-blinded	JJ	O
,	,	O
dose-response	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
anesthetic	JJ	O
and	CC	O
recovery	NN	O
profiles	NNS	O
of	IN	O
60-	JJ	O
and	CC	O
80-mg	JJ	O
doses	NNS	O
of	IN	O
preservative-free	JJ	O
plain	NN	O
mepivacaine	NN	O
for	IN	O
ambulatory	JJ	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Sixty	CD	O
patients	NNS	O
undergoing	JJ	O
ambulatory	JJ	O
anterior	JJ	O
cruciate	NN	O
ligament	NN	O
repair	NN	O
of	IN	O
the	DT	O
knee	NN	O
under	IN	O
spinal	JJ	O
anesthesia	NN	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
Group	NNP	O
1	CD	O
(	(	O
29	CD	O
patients	NNS	O
)	)	O
received	VBD	O
4	CD	O
mL	NN	O
of	IN	O
1.5	CD	O
%	NN	O
(	(	O
60-mg	JJ	O
dose	NN	O
)	)	O
and	CC	O
Group	NNP	O
2	CD	O
(	(	O
31	CD	O
patients	NNS	O
)	)	O
received	VBD	O
4	CD	O
mL	NN	O
of	IN	O
2	CD	O
%	NN	O
(	(	O
80-mg	CD	O
dose	NN	O
)	)	O
of	IN	O
plain	NN	O
mepivacaine	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
combined	JJ	O
spinal-epidural	JJ	O
anesthetic	JJ	O
technique	NN	O
.	.	O

The	DT	O
epidural	JJ	O
catheter	NN	O
was	VBD	O
used	VBN	O
only	RB	O
in	IN	O
the	DT	O
event	NN	O
the	DT	O
surgery	NN	O
outlasted	VBD	O
the	DT	O
duration	NN	O
of	IN	O
surgical	JJ	O
anesthesia	NN	O
with	IN	O
subarachnoid	JJ	O
mepivacaine	NN	O
.	.	O

Epidural	JJ	O
supplementation	NN	O
was	VBD	O
administered	VBN	O
in	IN	O
three	CD	O
patients	NNS	O
(	(	O
12	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
1	CD	O
and	CC	O
one	CD	O
patient	NN	O
(	(	O
3	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
2	CD	O
when	WRB	O
the	DT	O
sensory	JJ	O
block	NN	O
regressed	VBD	O
to	TO	O
L-1	NNP	O
with	IN	O
surgery	NN	O
expected	VBN	O
to	TO	O
last	JJ	O
longer	JJR	O
than	IN	O
15	CD	O
min	NN	O
.	.	O

The	DT	O
cephalad	JJ	Physical
dermatome	JJ	Physical
level	NN	Physical
of	IN	Physical
the	DT	Physical
block	NN	Physical
and	CC	O
degree	NN	Physical
of	IN	Physical
motor	NN	Physical
block	NN	Physical
was	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Times	NNS	Physical
to	TO	Physical
two-segment	JJ	Physical
and	CC	O
T-10	JJ	Physical
regression	NN	Physical
were	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
112	CD	O
+/-	JJ	O
26	CD	O
min	NN	O
in	IN	O
Group	NNP	O
1	CD	O
versus	NN	O
122	CD	O
+/-	JJ	O
28	CD	O
min	NN	O
in	IN	O
Group	NNP	O
2	CD	O
)	)	O
.	.	O

Time	NN	Physical
to	TO	Physical
L-1	NNP	Physical
regression	NN	Physical
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
Group	NNP	O
2	CD	O
(	(	O
146	CD	O
+/-	JJ	O
28	CD	O
min	NN	O
in	IN	O
Group	NNP	O
1	CD	O
versus	NN	O
159	CD	O
+/-	JJ	O
19	CD	O
min	NN	O
in	IN	O
Group	NNP	O
2	CD	O
)	)	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
ambulatory	JJ	O
milestones	NNS	O
were	VBD	O
significantly	RB	O
faster	RBR	O
in	IN	O
Group	NNP	O
1	CD	O
.	.	O

Side	NN	O
effects	NNS	O
,	,	O
such	JJ	O
as	IN	O
hypotension	NN	Physical
and	CC	Adverseeffect
emesis	NN	Physical
were	VBD	O
negligible	JJ	O
,	,	O
severe	JJ	O
bradycardia	NN	Physical
and	CC	O
urinary	JJ	Physical
retention	NN	Physical
did	VBD	O
not	RB	O
occur	VB	O
,	,	O
and	CC	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
reported	VBD	O
transient	JJ	Physical
neurological	JJ	Physical
symptoms	NNS	Physical
over	IN	O
24	CD	O
h.	NNS	O
In	IN	O
conclusion	NN	O
,	,	O
plain	VBP	O
mepivacaine	NN	O
in	IN	O
a	DT	O
60-	JJ	O
or	CC	O
80-mg	JJ	O
dose	NN	O
is	VBZ	O
a	DT	O
suitable	JJ	O
local	JJ	O
anesthetic	JJ	O
choice	NN	O
for	IN	O
ambulatory	JJ	O
spinal	JJ	O
anesthesia	NN	O
with	IN	O
respect	NN	O
to	TO	O
anesthetic	JJ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
recovery	NN	O
profiles	NNS	O
.	.	O

IMPLICATIONS	NNP	O
We	PRP	O
evaluated	VBD	O
the	DT	O
anesthetic	JJ	O
and	CC	O
recovery	NN	O
profiles	NNS	O
of	IN	O
60-	JJ	O
and	CC	O
80-mg	JJ	O
doses	NNS	O
of	IN	O
plain	NN	O
mepivacaine	NN	O
for	IN	O
ambulatory	JJ	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Both	DT	O
doses	NNS	O
produced	VBD	O
comparable	JJ	O
sensory	NN	O
and	CC	O
motor	NN	O
block	NN	O
.	.	O

Sensory	NNP	Physical
and	CC	Physical
motor	NN	Physical
regression	NN	Physical
and	CC	O
ambulatory	JJ	O
milestones	NNS	O
were	VBD	O
20-30	JJ	O
min	NN	O
longer	RBR	O
with	IN	O
the	DT	O
80-mg	JJ	O
dose	NN	O
.	.	O

Side	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
negligible	JJ	O
and	CC	O
transient	JJ	Physical
neurological	JJ	Physical
symptoms	NNS	Physical
were	VBD	O
not	RB	O
reported	VBN	O
during	IN	O
a	DT	O
24-h	JJ	O
follow-up	NN	O
.	.	O

Effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
short-term	JJ	O
training	NN	O
programs	NNS	O
on	IN	O
the	DT	O
physical	JJ	O
and	CC	O
technical	JJ	O
abilities	NNS	O
of	IN	O
adolescent	JJ	O
basketball	NN	O
players	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
and	CC	O
compared	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
two	CD	O
different	JJ	O
off-season	JJ	O
,	,	O
short-term	JJ	O
basketball	NN	O
training	NN	O
programs	NNS	O
on	IN	O
physical	JJ	O
and	CC	O
technical	JJ	O
abilities	NNS	O
of	IN	O
young	JJ	O
basketball	NN	O
players	NNS	O
.	.	O

Twenty-seven	JJ	O
adolescent	JJ	O
basketball	NN	O
players	NNS	O
(	(	O
14.7+/-0.5	CD	O
years	NNS	O
;	:	O
Tanner	NNP	O
stage	NN	O
:	:	O
3.5+/-0.5	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
specialized	JJ	O
basketball	NN	O
training	NN	O
group	NN	O
(	(	O
SP	NNP	O
,	,	O
n=10	NN	O
)	)	O
,	,	O
a	DT	O
mixed	JJ	O
basketball	NN	O
plus	CC	O
conditioning	VBG	O
training	NN	O
group	NN	O
(	(	O
MX	NNP	O
,	,	O
n=10	NN	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n=7	RB	O
)	)	O
.	.	O

Training	VBG	O
included	VBD	O
five	CD	O
sessions	NNS	O
per	IN	O
week	NN	O
(	(	O
100-120	JJ	O
min	NNS	O
each	DT	O
)	)	O
and	CC	O
was	VBD	O
performed	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Maximal	NNP	Physical
oxygen	NN	Physical
uptake	NN	Physical
was	VBD	O
similarly	RB	O
improved	VBN	O
after	IN	O
SP	NNP	O
(	(	O
4.9+/-1.8	CD	O
%	NN	O
)	)	O
and	CC	O
MX	NNP	O
(	(	O
4.9+/-1.4	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
effect	NN	O
on	IN	O
ventilatory	NN	Physical
threshold	NN	Physical
.	.	Physical

Peak	NNP	Physical
and	CC	Physical
mean	JJ	Physical
power	NN	Physical
output	NN	Physical
measured	VBD	O
during	IN	O
the	DT	O
Wingate	NNP	O
test	NN	O
were	VBD	O
also	RB	O
improved	VBN	O
by	IN	O
a	DT	O
similar	JJ	O
magnitude	NN	O
after	IN	O
SP	NNP	O
(	(	O
21+/-5	CD	O
%	NN	O
)	)	O
and	CC	O
MX	NNP	O
(	(	O
15+/-6	CD	O
%	NN	O
)	)	O
.	.	O

Trunk	NNP	Physical
muscle	NN	Physical
endurance	NN	Physical
was	VBD	O
equally	RB	O
increased	VBN	O
(	(	O
SP	JJ	O
:	:	O
23+/-4	JJ	O
%	NN	O
,	,	O
MX	NNP	O
:	:	O
25+/-5	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
arms	NNS	Physical
endurance	NN	Physical
was	VBD	O
improved	VBN	O
significantly	RB	O
more	RBR	O
after	IN	O
MX	NNP	O
(	(	O
50+/-11	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
SP	NNP	O
(	(	O
11+/-14	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Performance	NN	Mental
in	IN	O
four	CD	O
basketball	NN	Others
technical	JJ	Others
skills	NNS	Others
was	VBD	O
similarly	RB	O
increased	VBN	O
(	(	O
by	IN	O
17-27	CD	O
%	NN	O
)	)	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
a	DT	O
tendency	NN	O
for	IN	O
greater	JJR	O
improvement	NN	O
of	IN	O
the	DT	O
SP	NNP	O
groups	NNS	O
in	IN	O
the	DT	O
technical	JJ	O
skills	NNS	O
of	IN	O
shooting	NN	Mental
and	CC	Mental
passing	NN	Mental
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
a	DT	O
SP	NNP	O
basketball	NN	O
training	NN	O
program	NN	O
,	,	O
performed	VBD	O
exclusively	RB	O
on-court	NN	O
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
a	DT	O
MX	NNP	O
training	NN	O
program	NN	O
in	IN	O
terms	NNS	O
of	IN	O
aerobic	NN	O
and	CC	O
anaerobic	JJ	O
fitness	NN	O
improvement	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
decrease	NN	O
of	IN	O
the	DT	O
total	JJ	O
on-court	JJ	O
training	NN	O
time	NN	O
in	IN	O
the	DT	O
MX	NNP	O
group	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
tendency	NN	O
for	IN	O
a	DT	O
smaller	JJR	O
improvement	NN	O
of	IN	O
basketball	NN	O
technical	JJ	O
skills	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
SP	NNP	O
and	CC	O
MX	NNP	O
training	NN	O
are	VBP	O
equally	RB	O
effective	JJ	O
in	IN	O
order	NN	O
to	TO	O
limit	VB	O
and/or	JJ	O
reverse	VB	O
the	DT	O
detraining	NN	O
effects	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
the	DT	O
off-season	NN	O
in	IN	O
basketball	NN	O
.	.	O

Efficacy	NN	Others
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
combined	VBN	O
with	IN	O
salbutamol	NN	O
and	CC	O
ipratropium	NN	O
bromide	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
efficacy	NN	Others
of	IN	O
nebulized	JJ	O
corticosteroids	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
exacerbation	NN	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
poorly	RB	O
studied	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
and	CC	O
tolerability	NN	Others
of	IN	O
nebulized	JJ	O
flunisolide	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
+	VBZ	O
salbutamol/ipratropium	JJ	O
bromide	NN	O
(	(	O
1,875/375	CD	O
microg	NN	O
)	)	O
b.i.d	NN	O
.	.	O

in	IN	O
comparison	NN	O
with	IN	O
placebo	NN	O
+	NNP	O
salbutamol/ipratropium	NN	O
bromide	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
114	CD	O
patients	NNS	O
with	IN	O
COPD	NNP	O
of	IN	O
moderate-to-severe	JJ	O
degree	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	Physical
of	IN	Physical
severe	JJ	Physical
exacerbations	NNS	Physical
over	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
respiratory	NN	Physical
symptoms	NNS	Physical
,	,	Physical
forced	VBD	Physical
expiratory	JJ	Physical
volume	NN	Physical
in	IN	Physical
1	CD	Physical
s	NN	Physical
(	(	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
)	)	Physical
,	,	Physical
shuttle	JJ	Physical
walking	VBG	Physical
test	NN	Physical
distance	NN	Physical
and	CC	Physical
St.	NNP	Physical
George	NNP	Physical
's	POS	Physical
Respiratory	NNP	Physical
Questionnaire	NNP	Physical
scores	NNS	Physical
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	Physical
number	NN	Physical
of	IN	Physical
exacerbations	NNS	Physical
was	VBD	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
19	CD	O
vs.	FW	O
34	CD	O
,	,	O
p	NN	O
=	NNP	O
0.054	CD	O
)	)	O
;	:	O
the	DT	O
number	NN	Physical
of	IN	Physical
patients	NNS	Physical
experiencing	VBG	Physical
at	IN	Physical
least	JJS	Physical
one	CD	Physical
exacerbation	NN	Physical
during	IN	Physical
the	DT	Physical
study	NN	Physical
was	VBD	O
also	RB	O
decreased	VBN	O
(	(	O
16	CD	O
vs.	FW	O
26	CD	O
,	,	O
p	NN	O
=	NNP	O
0.059	CD	O
)	)	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
type	JJ	Physical
3	CD	Physical
Anthonisens	NNP	Physical
's	POS	Physical
exacerbations	NNS	Physical
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
flunisolide	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.044	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
scores	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
flunisolide	JJ	O
group	NN	O
but	CC	O
nonsignificant	NN	O
for	IN	O
dyspnea	NN	Adverseeffect
,	,	Adverseeffect
cough	NN	Adverseeffect
,	,	Adverseeffect
sputum	NN	Adverseeffect
amount	NN	Adverseeffect
and	CC	Adverseeffect
purulence	NN	Adverseeffect
.	.	O

FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
was	VBD	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
to	TO	O
baseline	VB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
the	DT	O
area	NN	Physical
under	IN	Physical
the	DT	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
-time	NN	Physical
curve	NN	Physical
during	IN	Physical
the	DT	Physical
6-month	JJ	Physical
period	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	O
group	NN	O
(	(	O
5.2	CD	O
+/-	JJ	O
10.6	CD	O
vs.	FW	O
2.1	CD	O
+/-	JJ	O
5.0	CD	O
,	,	O
flunisolide	RB	O
vs.	FW	O
placebo	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.047	CD	O
)	)	O
.	.	O

For	IN	O
shuttle	JJ	Physical
walking	VBG	Physical
test	NN	Physical
distance	NN	Physical
and	CC	Physical
scores	NNS	Physical
of	IN	Physical
the	DT	Physical
St.	NNP	Physical
George	NNP	Physical
's	POS	Physical
Respiratory	NNP	Physical
Questionnaire	NNP	Physical
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
evaluation	NN	O
and	CC	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nebulized	NNP	O
flunisolide	NN	O
is	VBZ	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
other	JJ	O
inhaled	JJ	O
corticosteroids	NNS	O
when	WRB	O
added	VBN	O
to	TO	O
nebulized	JJ	O
salbutamol/ipratropium	NN	O
bromide	NN	O
in	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
moderate-to-severe	JJ	O
COPD	NNP	O
patients	NNS	O
.	.	O

Elastic	JJ	O
stable	JJ	O
intramedullary	JJ	O
nailing	VBG	O
versus	NN	O
nonoperative	JJ	O
treatment	NN	O
of	IN	O
displaced	JJ	O
midshaft	NN	O
clavicular	JJ	O
fractures-a	JJ	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
elastic	JJ	O
stable	JJ	O
intramedullary	JJ	O
nailing	NN	O
(	(	O
ESIN	NNP	O
)	)	O
with	IN	O
nonoperative	JJ	O
treatment	NN	O
of	IN	O
fully	RB	O
displaced	VBN	O
midshaft	NN	O
clavicular	NN	O
fractures	NNS	O
in	IN	O
adults	NNS	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
controlled	VBN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Level	NNP	O
1	CD	O
trauma	NN	O
center	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
between	IN	O
18	CD	O
and	CC	O
65	CD	O
years	NNS	O
of	IN	O
age	NN	O
participated	VBN	O
and	CC	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
operative	JJ	O
or	CC	O
nonoperative	JJ	O
treatment	NN	O
with	IN	O
a	DT	O
2-year	JJ	O
follow-up	NN	O
.	.	O

INTERVENTION	NNP	O
Thirty	NNP	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
simple	JJ	O
shoulder	NN	O
sling	NN	O
and	CC	O
30	CD	O
patients	NNS	O
with	IN	O
ESIN	NNP	O
within	IN	O
3	CD	O
days	NNS	O
after	IN	O
trauma	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASUREMENT	NNP	O
Complications	NNP	Adverseeffect
after	IN	O
operative	JJ	O
and	CC	O
nonoperative	JJ	O
treatments	NNS	O
,	,	O
Disabilities	NNS	Physical
of	IN	Physical
the	DT	Physical
Arm	NNP	Physical
,	,	O
Shoulder	NNP	Physical
and	CC	Physical
Hand	NNP	Physical
(	(	Physical
DASH	NNP	Physical
)	)	Physical
score	NN	Physical
and	CC	O
Constant	JJ	Physical
Shoulder	NNP	Physical
Score	NNP	Physical
for	IN	O
outcome	JJ	O
measurement	NN	O
,	,	O
and	CC	O
clavicular	JJ	Physical
shortening	NN	Physical
.	.	O

RESULTS	NNP	O
Fracture	NNP	Physical
union	NN	Physical
was	VBD	O
achieved	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
in	IN	O
the	DT	O
operative	JJ	O
group	NN	O
,	,	O
whereas	IN	O
nonunion	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
3	CD	O
of	IN	O
30	CD	O
patients	NNS	O
of	IN	O
the	DT	O
nonoperative	JJ	O
group	NN	O
.	.	O

Two	CD	O
symptomatic	JJ	Others
malunions	NNS	Others
required	VBN	O
corrective	JJ	O
osteotomy	NN	O
in	IN	O
the	DT	O
nonoperative	JJ	O
group	NN	O
.	.	O

Medial	NNP	Others
nail	JJ	Others
protrusion	NN	Others
occurred	VBD	O
in	IN	O
7	CD	O
cases	NNS	O
in	IN	O
the	DT	O
operative	JJ	O
group	NN	O
.	.	O

Implant	JJ	Others
failure	NN	Others
with	IN	Others
revision	NN	Others
surgery	NN	Others
was	VBD	O
necessary	JJ	O
in	IN	O
2	CD	O
patients	NNS	O
after	IN	O
an	DT	O
additional	JJ	O
adequate	NN	O
trauma	NN	O
.	.	O

DASH	NNP	Physical
scores	NNS	Physical
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
operative	JJ	O
group	NN	O
throughout	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
and	CC	O
2	CD	O
years	NNS	O
after	IN	O
trauma	NN	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
difference	NN	O
during	IN	O
the	DT	O
first	JJ	O
18	CD	O
weeks	NNS	O
.	.	O

Constant	JJ	Physical
scores	NNS	Physical
were	VBD	O
significantly	RB	O
higher	JJR	O
after	IN	O
6	CD	O
months	NNS	O
and	CC	O
2	CD	O
years	NNS	O
after	IN	O
intramedullary	JJ	O
stabilization	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
operative	JJ	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
posttraumatic	JJ	Physical
clavicular	JJ	Physical
shortening	NN	Physical
;	:	O
they	PRP	O
were	VBD	O
also	RB	O
more	RBR	O
satisfied	JJ	Others
with	IN	O
cosmetic	JJ	O
appearance	NN	O
and	CC	O
overall	JJ	Mental
outcome	NN	Mental
.	.	O

CONCLUSIONS	NNP	O
ESIN	NNP	O
of	IN	O
displaced	JJ	O
midshaft	NN	O
clavicular	NN	O
fractures	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
lower	JJR	O
rate	NN	O
of	IN	O
nonunion	NN	Others
and	CC	O
delayed	VBN	Others
union	NN	Others
,	,	O
a	DT	O
faster	JJR	O
return	NN	Others
to	TO	Others
daily	JJ	Others
activities	NNS	Others
,	,	O
and	CC	O
a	DT	O
better	JJR	O
functional	JJ	Others
outcome	NN	Others
.	.	O

Clavicular	JJ	Physical
shortening	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
,	,	O
and	CC	O
overall	JJ	Others
satisfaction	NN	Others
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
operative	JJ	O
group	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
percutaneous	JJ	O
transmitral	JJ	O
commissurotomy	NN	O
with	IN	O
Inoue	NNP	O
balloon	NN	O
technique	NN	O
and	CC	O
metallic	JJ	O
commissurotomy	NN	O
:	:	O
immediate	JJ	O
and	CC	O
short-term	JJ	O
follow-up	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
Inoue	NNP	O
balloon	NN	O
technique	NN	O
for	IN	O
mitral	JJ	O
commissurotomy	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
and	CC	O
carried	VBN	O
out	RP	O
worldwide	NN	O
.	.	O

Metallic	NNP	O
commissurotomy	NN	O
is	VBZ	O
reported	VBN	O
to	TO	O
be	VB	O
a	DT	O
cheaper	JJR	O
and	CC	O
effective	JJ	O
alternative	NN	O
to	TO	O
balloon	VB	O
mitral	JJ	O
commissurotomy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
to	TO	O
undergo	VB	O
percutaneous	JJ	O
transmitral	JJ	O
commissurotomy	NN	O
(	(	O
PTMC	NNP	O
)	)	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
Inoue	NNP	O
balloon	NN	O
technique	NN	O
(	(	O
IBMC	NNP	O
,	,	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
or	CC	O
metallic	JJ	O
commissurotomy	NN	O
(	(	O
PMMC	NNP	O
,	,	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
the	DT	O
other	JJ	O
technique	NN	O
when	WRB	O
the	DT	O
initial	JJ	O
technique	NN	O
was	VBD	O
a	DT	O
failure	NN	O
.	.	O

Success	NN	Others
of	IN	Others
valvotomy	NN	Others
,	,	O
procedure-related	JJ	Adverseeffect
complications	NNS	Adverseeffect
,	,	O
and	CC	O
follow-up	JJ	Physical
events	NNS	Physical
of	IN	O
the	DT	O
2	CD	O
techniques	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Basal	NNP	Physical
echocardiographic	JJ	Physical
and	CC	O
hemodynamic	JJ	Physical
data	NNS	Physical
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Procedural	NNP	O
success	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
:	:	O
45	CD	O
of	IN	O
49	CD	O
procedures	NNS	O
(	(	O
91.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
46	CD	O
of	IN	O
51	CD	O
procedures	NNS	O
(	(	O
90.18	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
1.0	CD	O
)	)	O
.	.	O

Crossover	NNP	O
was	VBD	O
also	RB	O
comparable	JJ	O
,	,	O
with	IN	O
1	CD	O
occurring	VBG	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
3	CD	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
.	.	O

Complications	NNS	O
such	JJ	O
as	IN	O
cardiac	JJ	Adverseeffect
tamponade	NN	Adverseeffect
and	CC	Adverseeffect
mitral	JJ	Adverseeffect
regurgitation	NN	Adverseeffect
(	(	O
requiring	VBG	O
or	CC	O
not	RB	O
requiring	VBG	O
mitral	JJ	O
valve	FW	O
replacement	NN	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
3	CD	O
complications	NNS	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
4	CD	O
complications	NNS	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
(	(	O
P	NNP	O
=.29	NNP	O
)	)	O
.	.	O

After	IN	O
a	DT	O
follow-up	JJ	O
period	NN	O
of	IN	O
approximately	RB	O
4	CD	O
months	NNS	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
similar	JJ	O
event	NN	O
rates	NNS	O
and	CC	O
comparable	JJ	O
hemodynamic	JJ	O
parameters	NNS	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
IBMC	NNP	O
and	CC	O
PMMC	NNP	O
are	VBP	O
successful	JJ	O
means	NNS	O
of	IN	O
providing	VBG	O
relief	NN	O
from	IN	O
severe	JJ	O
mitral	JJ	O
stenosis	NN	O
with	IN	O
a	DT	O
gain	NN	O
in	IN	O
valve	JJ	O
area	NN	O
and	CC	O
reduction	NN	O
in	IN	O
transmitral	JJ	O
gradient	NN	O
.	.	O

Both	DT	O
techniques	NNS	O
have	VBP	O
similar	JJ	O
procedural	JJ	O
success	NN	O
,	,	O
complication	NN	O
rates	NNS	O
,	,	O
and	CC	O
follow-up	JJ	O
events	NNS	O
.	.	O

Position	NN	O
of	IN	O
anterior	JJ	O
capsulorhexis	NN	O
and	CC	O
posterior	JJ	O
capsule	NN	O
opacification	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
whether	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
continuous	JJ	O
curvilinear	NN	O
capsulorhexis	NN	O
influences	VBZ	O
the	DT	O
rate	NN	Physical
of	IN	Physical
posterior	JJ	Physical
capsule	NN	Physical
opacification	NN	Physical
(	(	Physical
PCO	NNP	Physical
)	)	Physical
.	.	O

METHODS	CC	O
A	DT	O
total	NN	O
of	IN	O
119	CD	O
patients	NNS	O
,	,	O
aged	VBN	O
61-86	CD	O
years	NNS	O
,	,	O
underwent	JJ	O
cataract	NN	O
surgery	NN	O
with	IN	O
phacoemulsification	NN	O
performed	VBN	O
by	IN	O
a	DT	O
single	JJ	O
surgeon	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
implantation	NN	O
with	IN	O
either	CC	O
a	DT	O
silicone	NN	O
intraocular	NN	O
lens	NNS	O
(	(	O
IOL	NNP	O
)	)	O
(	(	O
SI40NB	NNP	O
,	,	O
Allergan	NNP	O
)	)	O
or	CC	O
an	DT	O
AcrySof	NNP	O
IOL	NNP	O
(	(	O
MA60BM	NNP	O
,	,	O
Alcon	NNP	O
)	)	O
.	.	O

Three	CD	O
years	NNS	O
after	IN	O
surgery	NN	O
,	,	O
the	DT	O
rate	NN	Physical
of	IN	Physical
PCO	NNP	Physical
was	VBD	O
analysed	VBN	O
using	VBG	O
the	DT	O
evaluation	NN	O
of	IN	O
posterior	JJ	O
capsule	NN	O
opacification	NN	O
computer	NN	O
software	NN	O
(	(	O
EPCO	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
related	VBN	O
to	TO	O
the	DT	O
capsulorhexis	NN	O
position	NN	O
,	,	O
which	WDT	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
retroillumination	NN	O
photograph	NN	O
.	.	O

RESULTS	VB	O
If	IN	O
the	DT	O
capsulorhexis	NN	Physical
was	VBD	O
located	VBN	O
partially	RB	O
or	CC	O
completely	RB	O
off	IN	O
the	DT	O
optics	NNS	Physical
of	IN	Physical
the	DT	Physical
IOL	NNP	Physical
,	,	O
compared	VBN	O
to	TO	O
totally	RB	Physical
on	IN	Physical
the	DT	Physical
IOL	NNP	Physical
,	,	O
significantly	RB	O
more	JJR	O
PCO	NNP	Physical
was	VBD	O
found	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.0014	CD	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
within	IN	O
each	DT	O
IOL	NNP	O
type	NN	O
,	,	O
patients	NNS	O
with	IN	O
AcrySof	NNP	O
IOLs	NNP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
significantly	RB	O
less	JJR	O
PCO	NNP	Physical
when	WRB	O
the	DT	O
capsulorhexis	NN	O
was	VBD	O
totally	RB	O
on	IN	O
the	DT	O
optic	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.0048	CD	O
)	)	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
also	RB	O
significant	JJ	O
in	IN	O
the	DT	O
silicone	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.041	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	NNP	O
relatively	RB	O
small	JJ	O
and	CC	O
central	JJ	O
capsulorhexis	NN	O
allowing	VBG	O
for	IN	O
the	DT	O
complete	JJ	O
covering	NN	O
of	IN	O
the	DT	O
IOL	NNP	O
optics	NNS	O
by	IN	O
the	DT	O
rhexis	NN	O
edges	VBZ	O
seems	VBZ	O
to	TO	O
protect	VB	O
against	IN	O
PCO	NNP	Physical
in	IN	O
cataract	NN	O
surgery	NN	O
,	,	O
with	IN	O
both	DT	O
round-edged	JJ	O
silicone	NN	O
IOLs	NNP	O
and	CC	O
sharp-edged	JJ	O
hydrophobic	JJ	O
acrylic	JJ	O
IOLs	NNP	O
.	.	O

Effect	NN	O
of	IN	O
topical	JJ	O
anesthesia	NN	O
and	CC	O
age	NN	O
on	IN	O
pain	NN	Pain
scores	NNS	Pain
during	IN	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
screening	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
efficacy	NN	Others
of	IN	O
topical	JJ	O
anesthesia	NN	O
during	IN	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
(	(	O
ROP	NNP	O
)	)	O
screening	NN	O
has	VBZ	O
been	VBN	O
a	DT	O
controversial	JJ	O
issue	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
(	(	O
0.5	CD	O
%	NN	O
)	)	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
Premature	NNP	Pain
Infant	NNP	Pain
Pain	NNP	Pain
Profile	NNP	Pain
(	(	Pain
PIPP	NNP	Pain
)	)	Pain
scores	VBZ	O
in	IN	O
40	CD	O
preterm	JJ	O
infants	NNS	O
undergoing	VBG	O
ROP	NNP	O
screening	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
double	JJ	O
masked	JJ	O
cross-over	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
units	NNS	O
for	IN	O
infants	NNS	O
undergoing	VBG	O
routine	JJ	O
ROP	NNP	O
screening	VBG	O
exams	NNS	O
.	.	O

Baseline	NNP	Physical
PIPP	NNP	Physical
scores	NNS	Physical
and	CC	O
post-examination	NN	Physical
PIPP	NNP	Physical
scores	VBZ	Physical
at	IN	O
1	CD	O
and	CC	O
5	CD	O
min	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
those	DT	O
receiving	VBG	O
saline	JJ	O
vs	NN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
(	(	O
2	CD	O
)	)	O
first	RB	O
ROP	NNP	O
screening	VBG	O
vs	JJ	O
second	JJ	O
ROP	NNP	O
screening	NN	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
eye	NN	O
drops	NNS	O
used	VBN	O
.	.	O

Wilcoxon	NNP	O
signed-ranks	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
to	TO	O
pair	VB	O
pain	NN	O
scores	NNS	O
.	.	O

RESULT	NNP	O
Forty	NNP	O
preterm	NN	O
infants	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Mean	NNP	O
gestational	JJ	O
age	NN	O
(	(	O
GA	NNP	O
)	)	O
at	IN	O
first	JJ	O
and	CC	O
second	JJ	O
examinations	NNS	O
was	VBD	O
33.3	CD	O
and	CC	O
35.3	CD	O
weeks	NNS	O
,	,	O
respectively	RB	O
.	.	O

Proparacaine	NNP	O
use	VBP	O
significantly	RB	O
lowered	VBN	O
mean	JJ	O
PIPP	NNP	O
scores	NNS	O
(	(	O
P=0.027	NNP	O
)	)	O
and	CC	O
delta	JJ	O
scores	NNS	O
(	(	O
P=0.013	NNP	O
)	)	O
at	IN	O
1	CD	O
min	NN	O
after	IN	O
examination	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
at	IN	O
5	CD	O
min	NN	O
after	IN	O
examination	NN	O
.	.	O

Second	JJ	O
examinations	NNS	O
showed	VBD	O
significantly	RB	O
lower	JJR	O
mean	JJ	O
PIPP	NNP	O
scores	NNS	O
after	IN	O
examination	NN	O
(	(	O
1	CD	O
min	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
5	CD	O
min	NN	O
(	(	O
P=0.025	NNP	O
)	)	O
)	)	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
drop	NN	O
used	VBN	O
.	.	O

CONCLUSION	NNP	O
Proparacaine	NNP	O
eye	NN	O
drops	NNS	O
offer	VBP	O
significant	JJ	O
relief	NN	O
of	IN	O
pain	NN	O
that	WDT	O
is	VBZ	O
apparently	RB	O
short	JJ	O
lived	VBD	O
.	.	O

Significantly	NNP	O
lower	JJR	O
PIPP	NNP	O
scores	NNS	O
at	IN	O
second	JJ	O
ROP	NNP	O
examinations	NNS	O
suggested	VBD	O
that	IN	O
infants	NNS	O
of	IN	O
older	JJR	O
GA	NNP	O
may	MD	O
have	VB	O
a	DT	O
greater	JJR	O
ability	NN	O
to	TO	O
tolerate	VB	O
ROP	NNP	O
screening	VBG	O
.	.	O

We	PRP	O
recommend	VBP	O
the	DT	O
use	NN	O
of	IN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
for	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
immediate	JJ	O
relief	NN	O
of	IN	O
pain	NN	O
during	IN	O
ROP	NNP	O
screening	VBG	O
in	IN	O
preterm	JJ	O
infants	NNS	O
of	IN	O
lesser	JJR	O
GA	NNP	O
.	.	O

Magnocellular	JJ	O
visual	JJ	O
evoked	VBN	O
potential	JJ	O
delay	NN	O
with	IN	O
high	JJ	O
autism	NN	O
spectrum	JJ	O
quotient	NN	O
yields	NNS	O
a	DT	O
neural	JJ	O
mechanism	NN	O
for	IN	O
altered	JJ	Physical
perception	NN	Physical
.	.	Physical

Everyone	NN	O
has	VBZ	O
autistic	JJ	O
characteristics	NNS	O
to	TO	O
a	DT	O
greater	JJR	O
or	CC	O
lesser	JJR	O
degree	NN	O
,	,	O
encapsulated	VBN	O
in	IN	O
the	DT	O
Autism	NNP	Physical
Spectrum	NNP	Physical
Quotient	NNP	Physical
,	,	O
a	DT	O
scale	NN	O
that	WDT	O
measures	VBZ	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
an	DT	O
adult	NN	O
of	IN	O
normal	JJ	O
intelligence	NN	O
displays	NNS	O
traits	NNS	O
associated	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Recent	JJ	O
psychophysical	JJ	O
analyses	NNS	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
point	VBP	O
to	TO	O
superior	VB	O
local	JJ	O
processing	NN	O
,	,	O
and	CC	O
impaired	VBD	O
or	CC	O
ignored	VBN	O
global	JJ	O
and	CC	O
contextual	JJ	O
processing	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
whether	IN	O
low-	JJ	O
and	CC	O
high-scoring	JJ	O
individuals	NNS	O
on	IN	O
the	DT	O
Autism	NNP	O
Spectrum	NNP	O
Quotient	NNP	O
differ	NN	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
local	JJ	Physical
and	CC	Physical
global	JJ	Physical
processing	NN	Physical
,	,	O
motion	NN	O
processing	NN	O
and	CC	O
visual	JJ	O
pathway	NN	O
integrity	NN	O
.	.	O

Fifteen	NNP	O
low-scoring	JJ	O
individuals	NNS	O
and	CC	O
14	CD	O
high-scoring	JJ	O
individuals	NNS	O
derived	VBN	O
from	IN	O
a	DT	O
normal	JJ	O
population	NN	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
initial	JJ	O
cortical	JJ	Physical
response	NN	Physical
to	TO	O
the	DT	O
magnocellular	JJ	O
afferents	NNS	O
is	VBZ	O
weaker	JJR	O
at	IN	O
low	JJ	O
contrast	NN	O
in	IN	O
the	DT	O
high	JJ	O
autistic	JJ	O
tendency	NN	O
group	NN	O
and	CC	O
that	IN	O
a	DT	O
second-order	JJ	O
response	NN	O
,	,	O
reflecting	VBG	O
magnocellular	JJ	O
activity	NN	O
,	,	O
demonstrated	VBD	O
a	DT	Others
delay	NN	Others
for	IN	O
high	JJ	O
versus	NN	O
low	JJ	O
scorers	NNS	O
when	WRB	O
the	DT	O
parvocellular	JJ	O
pathway	NN	O
was	VBD	O
also	RB	O
active	JJ	O
in	IN	O
response	NN	O
to	TO	O
a	DT	O
high	JJ	O
contrast	NN	O
stimulus	NN	O
.	.	O

High-scoring	JJ	O
individuals	NNS	O
also	RB	O
demonstrated	VBD	O
difficulty	NN	O
in	IN	O
identifying	VBG	Others
the	DT	Others
global	JJ	Others
components	NNS	Others
of	IN	O
locally	RB	O
salient	JJ	O
hierarchical	JJ	O
Navon	NNP	O
figures	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
cross-validated	JJ	O
discriminant	NN	O
analysis	NN	O
,	,	O
using	VBG	O
four	CD	O
physiologically	RB	O
and	CC	O
three	CD	O
psychophysically	RB	O
derived	JJ	O
parameters	NNS	O
,	,	O
correctly	RB	O
classified	VBD	O
83	CD	O
%	NN	O
of	IN	O
individuals	NNS	O
who	WP	O
scored	VBD	O
either	CC	O
high	JJ	O
or	CC	O
low	JJ	O
on	IN	O
the	DT	O
Autism	NNP	O
Spectrum	NNP	O
Quotient	NNP	O
.	.	O

These	DT	O
findings	NNS	O
in	IN	O
the	DT	O
group	NN	O
scoring	VBG	O
high	JJ	O
on	IN	O
the	DT	O
Autism	NNP	O
Spectrum	NNP	O
Quotient	NNP	O
indicate	VBP	O
that	IN	O
a	DT	O
delay	NN	O
in	IN	O
primary	JJ	O
visual/prestriate	JJ	O
cortical	JJ	O
processing	NN	O
of	IN	O
magnocellular	JJ	O
input	NN	O
diminishes	VBZ	O
the	DT	O
advantage	NN	O
of	IN	O
its	PRP$	O
early	JJ	O
arrival	NN	O
to	TO	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
.	.	O

This	DT	O
appears	VBZ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
impaired	JJ	Others
global	JJ	Others
visual	JJ	Others
perception	NN	Others
,	,	O
predicting	VBG	O
with	IN	O
high	JJ	O
accuracy	NN	O
behavioural	JJ	Physical
tendencies	NNS	Physical
associated	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
perceptual	JJ	O
impairment	NN	O
in	IN	O
autism	NN	O
may	MD	O
be	VB	O
attributed	VBN	O
to	TO	O
a	DT	O
dysfunction	NN	O
of	IN	O
horizontal	JJ	O
connections	NNS	O
within	IN	O
early	JJ	O
visual	JJ	O
areas	NNS	O
,	,	O
presumably	RB	O
parvocellular	JJ	O
in	IN	O
nature	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
timing	NN	O
of	IN	O
such	JJ	O
form	NN	O
processing	NN	O
aberrations	NNS	O
is	VBZ	O
much	RB	O
later	RBR	O
than	IN	O
the	DT	O
timing	NN	O
of	IN	O
abnormal	JJ	O
magnocellular	JJ	O
visual	JJ	O
processing	NN	O
measured	VBN	O
directly	RB	O
here	RB	O
.	.	O

Thus	VB	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
a	DT	O
magnocellular	JJ	O
processing	NN	O
delay	NN	O
decreases	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
autistic	JJ	O
individuals	NNS	O
to	TO	O
benefit	VB	O
perceptually	RB	O
from	IN	O
feedback	NN	O
normally	RB	O
associated	VBN	O
with	IN	O
the	DT	O
magnocellular	JJ	O
advantage	NN	O
.	.	O

How	WRB	O
well	RB	O
do	VB	O
blood	NN	Physical
folate	VB	Physical
concentrations	NNS	Physical
predict	VBP	O
dietary	JJ	O
folate	NN	O
intakes	NNS	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
Canadian	JJ	O
lactating	VBG	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
folate	NN	O
?	.	O
An	DT	O
observational	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
1998	CD	O
,	,	O
mandatory	JJ	O
folic	JJ	O
acid	JJ	O
fortification	NN	O
of	IN	O
white	JJ	O
flour	NN	O
and	CC	O
select	JJ	O
cereal	NN	O
grain	NN	O
products	NNS	O
was	VBD	O
implemented	VBN	O
in	IN	O
Canada	NNP	O
with	IN	O
the	DT	O
intention	NN	O
to	TO	O
increase	VB	O
dietary	JJ	O
folate	JJ	O
intakes	NNS	O
of	IN	O
reproducing	VBG	O
women	NNS	O
.	.	O

Folic	NNP	O
acid	JJ	O
fortification	NN	O
has	VBZ	O
produced	VBN	O
a	DT	O
dramatic	JJ	O
increase	NN	O
in	IN	O
blood	NN	O
folate	JJ	O
concentrations	NNS	O
among	IN	O
reproductive	JJ	O
age	NN	O
women	NNS	O
,	,	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
neural	JJ	O
tube	NN	O
defect	NN	O
(	(	O
NTD	NNP	O
)	)	O
-affected	VBD	O
pregnancies	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
improved	VBN	O
blood	NN	O
folate	NN	O
concentrations	NNS	O
,	,	O
many	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
are	VBP	O
asking	VBG	O
whether	IN	O
a	DT	O
folic	JJ	O
acid	NN	O
supplement	NN	O
is	VBZ	O
necessary	JJ	O
for	IN	O
NTD	NNP	O
prevention	NN	O
among	IN	O
women	NNS	O
with	IN	O
high	JJ	O
blood	NN	O
folate	NN	O
values	NNS	O
,	,	O
and	CC	O
how	WRB	O
reliably	RB	O
high	JJ	O
RBC	NNP	O
folate	NN	O
concentrations	NNS	O
predict	VBP	O
folate	JJ	O
intakes	NNS	O
shown	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
to	TO	O
be	VB	O
protective	JJ	O
against	IN	O
NTDs	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
how	WRB	O
predictive	JJ	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	Physical
and	CC	O
folate	NN	Physical
intakes	NNS	Physical
are	VBP	O
of	IN	O
each	DT	O
other	JJ	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
well-educated	JJ	O
lactating	VBG	O
Canadian	JJ	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
synthetic	JJ	O
folate	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	Physical
and	CC	O
dietary	JJ	Physical
folate	NN	Physical
intakes	NNS	Physical
,	,	O
determined	VBN	O
by	IN	O
weighed	VBN	O
food	NN	O
records	NNS	O
,	,	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
predominantly	RB	O
university-educated	JJ	O
lactating	VBG	O
women	NNS	O
(	(	O
32	CD	O
+/-	JJ	O
4	CD	O
yr	NN	O
)	)	O
at	IN	O
4-	JJ	O
(	(	O
n	JJ	O
=	NNP	O
53	CD	O
)	)	O
and	CC	O
16-wk	JJ	O
postpartum	NN	O
(	(	O
n	JJ	O
=	NNP	O
55	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	Physical
of	IN	O
all	DT	O
participants	NNS	O
were	VBD	O
well	RB	O
above	IN	O
plasma	NN	O
and	CC	O
RBC	NNP	O
folate	VBP	O
cut-off	NN	O
levels	NNS	O
indicative	CD	O
of	IN	O
deficiency	NN	O
(	(	O
6.7	CD	O
and	CC	O
317	CD	O
nmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
all	DT	O
,	,	O
except	IN	O
for	IN	O
2	CD	O
subjects	NNS	O
,	,	O
were	VBD	O
above	IN	O
the	DT	O
cut-off	NN	O
for	IN	O
NTD-risk	NNP	O
reduction	NN	O
(	(	O
>	$	O
906	CD	O
nmol/L	NN	O
)	)	O
.	.	O

Only	RB	O
modest	JJ	O
associations	NNS	O
existed	VBD	O
between	IN	O
total	JJ	Physical
folate	NN	Physical
intakes	NNS	Physical
and	CC	O
plasma	NN	Physical
(	(	O
r	JJ	O
=	NN	O
0.46	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
RBC	NNP	O
(	(	O
r	VB	O
=	RB	O
0.36	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
folate	NN	Physical
concentrations	NNS	Physical
at	IN	O
16-wk	JJ	O
postpartum	NN	O
.	.	O

Plasma	NNP	Physical
and	CC	Physical
RBC	NNP	Physical
folate	VBP	Physical
values	NNS	Physical
at	IN	O
16-wk	JJ	O
postpartum	NN	O
correctly	RB	O
identified	VBD	O
the	DT	O
quartile	NN	O
of	IN	O
folate	JJ	O
intake	NN	O
of	IN	O
only	RB	O
26	CD	O
of	IN	O
55	CD	O
(	(	O
47	CD	O
%	NN	O
)	)	O
and	CC	O
18	CD	O
of	IN	O
55	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
of	IN	O
subjects	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
RBC	NNP	Physical
folate	NN	Physical
concentration	NN	Physical
of	IN	O
women	NNS	O
consuming	VBG	O
151-410	JJ	O
microg/d	NN	O
of	IN	O
synthetic	JJ	O
folate	NN	O
(	(	O
2nd	CD	O
quartile	NN	O
of	IN	O
intake	NN	O
)	)	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
women	NNS	O
consuming	VBG	O
>	JJ	O
410	CD	O
microg/d	NN	O
(	(	O
3rd	CD	O
and	CC	O
4th	CD	O
quartile	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Folate	NNP	Physical
intakes	NNS	Physical
,	,	O
estimated	VBN	O
by	IN	O
food	NN	O
composition	NN	O
tables	NNS	O
,	,	O
and	CC	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	Physical
are	VBP	O
not	RB	O
predictive	JJ	O
of	IN	O
each	DT	O
other	JJ	O
in	IN	O
Canadian	JJ	O
lactating	VBG	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
folate	NN	Physical
.	.	O

Synthetic	JJ	O
intakes	NNS	O
>	VBP	O
151-410	JJ	O
microg/d	NN	O
in	IN	O
these	DT	O
women	NNS	O
produced	VBD	O
little	JJ	O
additional	JJ	O
benefit	NN	O
in	IN	O
terms	NNS	O
of	IN	O
maximizing	VBG	O
RBC	NNP	O
content	NN	O
.	.	O

More	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
between	IN	O
blood	NN	Physical
folate	NN	Physical
concentration	NN	Physical
and	CC	O
NTD	NNP	O
risk	NN	O
.	.	O

Until	IN	O
data	NNS	O
from	IN	O
such	JJ	O
studies	NNS	O
are	VBP	O
available	JJ	O
,	,	O
women	NNS	O
planning	VBG	O
a	DT	O
pregnancy	NN	O
should	MD	O
continue	VB	O
to	TO	O
consume	VB	O
a	DT	O
daily	JJ	O
folic	JJ	O
acid	JJ	O
supplement	NN	O
of	IN	O
400	CD	O
microg	NN	O
.	.	O

The	DT	O
IDvIP	NNP	O
trial	NN	O
:	:	O
a	DT	O
two-centre	JJ	O
randomised	JJ	O
double-blind	NN	O
controlled	VBD	O
trial	NN	O
comparing	VBG	O
intramuscular	JJ	O
diamorphine	NN	O
and	CC	O
intramuscular	JJ	O
pethidine	NN	O
for	IN	O
labour	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
Intramuscular	NNP	O
pethidine	NN	O
is	VBZ	O
routinely	RB	O
used	VBN	O
throughout	IN	O
the	DT	O
UK	NNP	O
for	IN	O
labour	JJ	O
analgesia	NN	O
.	.	O

Studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
pethidine	NN	O
provides	VBZ	O
little	JJ	O
pain	NN	O
relief	NN	O
in	IN	O
labour	NN	O
and	CC	O
has	VBZ	O
a	DT	O
number	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
affecting	VBG	O
mother	NN	O
and	CC	O
neonate	NN	O
.	.	O

It	PRP	O
can	MD	O
cause	VB	O
nausea	NN	O
,	,	O
vomiting	VBG	O
and	CC	O
dysphoria	NNS	O
in	IN	O
mothers	NNS	O
and	CC	O
can	MD	O
cause	VB	O
reduced	VBN	O
fetal	JJ	O
heart	NN	O
rate	NN	O
variability	NN	O
and	CC	O
accelerations	NNS	O
.	.	O

Neonatal	JJ	O
effects	NNS	O
include	VBP	O
respiratory	JJ	O
depression	NN	O
and	CC	O
impaired	JJ	O
feeding	NN	O
.	.	O

There	EX	O
are	VBP	O
few	JJ	O
large	JJ	O
studies	NNS	O
comparing	VBG	O
the	DT	O
relative	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
efficacy	NN	O
of	IN	O
different	JJ	O
opioids	NNS	O
in	IN	O
labour	NN	O
.	.	O

A	DT	O
small	JJ	O
trial	NN	O
comparing	VBG	O
intramuscular	JJ	O
pethidine	NN	O
with	IN	O
diamorphine	NN	O
,	,	O
showed	VBD	O
diamorphine	NN	O
to	TO	O
have	VB	O
some	DT	O
benefits	NNS	O
over	IN	O
pethidine	NN	O
when	WRB	O
used	VBN	O
for	IN	O
labour	JJ	O
analgesia	NN	O
but	CC	O
the	DT	O
study	NN	O
did	VBD	O
not	RB	O
investigate	VB	O
the	DT	O
adverse	JJ	O
effects	NNS	O
of	IN	O
either	DT	O
opioid	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
Intramuscular	NNP	O
Diamorphine	NNP	O
versus	IN	O
Intramuscular	NNP	O
Pethidine	NNP	O
(	(	O
IDvIP	NNP	O
)	)	O
trial	NN	O
is	VBZ	O
a	DT	O
randomised	JJ	O
double-blind	NN	O
two	CD	O
centre	NN	O
controlled	VBD	O
trial	NN	O
comparing	VBG	O
intramuscular	JJ	O
diamorphine	NN	O
and	CC	O
pethidine	NN	O
regarding	VBG	O
their	PRP$	O
analgesic	JJ	O
efficacy	NN	O
in	IN	O
labour	NN	O
and	CC	O
their	PRP$	O
side	NN	O
effects	NNS	O
in	IN	O
mother	NN	O
,	,	O
fetus	NN	O
and	CC	O
neonate	NN	O
.	.	O

Information	NN	O
about	IN	O
the	DT	O
trial	NN	O
will	MD	O
be	VB	O
provided	VBN	O
to	TO	O
women	NNS	O
in	IN	O
the	DT	O
antenatal	JJ	O
period	NN	O
or	CC	O
in	IN	O
early	JJ	O
labour	NN	O
.	.	O

Consent	NN	O
and	CC	O
recruitment	NN	O
to	TO	O
the	DT	O
trial	NN	O
will	MD	O
be	VB	O
obtained	VBN	O
when	WRB	O
the	DT	O
mother	NN	O
requests	VBZ	O
opioid	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
sample	NN	O
size	NN	O
requirement	NN	O
is	VBZ	O
406	CD	O
women	NNS	O
with	IN	O
data	NNS	O
on	IN	O
primary	JJ	O
outcomes	NNS	O
.	.	O

The	DT	O
maternal	JJ	O
primary	NN	O
outcomes	NNS	O
are	VBP	O
pain	JJ	Pain
relief	NN	Pain
during	IN	Pain
the	DT	Pain
first	JJ	Pain
3	CD	Pain
hours	NNS	Pain
after	IN	Pain
trial	NN	Pain
analgesia	NN	Pain
and	CC	O
specifically	RB	O
pain	VBP	Pain
relief	NN	Pain
after	IN	Pain
60	CD	Pain
minutes	NNS	Pain
.	.	Pain

The	DT	O
neonatal	JJ	O
primary	JJ	O
outcomes	NNS	O
are	VBP	O
need	VBN	Physical
for	IN	Physical
resuscitation	NN	Physical
and	CC	Physical
Apgar	NNP	Physical
Score	NNP	Physical
<	VBD	Physical
7	CD	Physical
at	IN	Physical
1	CD	Physical
minute	NN	Physical
.	.	Physical

The	DT	O
secondary	JJ	O
outcomes	NNS	O
are	VBP	O
an	DT	O
additional	JJ	O
measure	NN	O
of	IN	O
pain	NN	O
relief	NN	O
,	,	O
maternal	JJ	O
sedation	NN	O
,	,	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
maternal	JJ	O
oxygen	NN	O
saturation	NN	O
,	,	O
satisfaction	NN	O
with	IN	O
analgesia	NN	O
,	,	O
whether	IN	O
method	NN	O
of	IN	O
analgesia	NN	O
would	MD	O
be	VB	O
used	VBN	O
again	RB	O
,	,	O
use	NN	O
of	IN	O
Entonox	NNP	O
,	,	O
umbilical	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
pH	NN	O
,	,	O
fetal	JJ	O
heart	NN	O
rate	NN	O
,	,	O
meconium	NN	O
staining	NN	O
,	,	O
time	NN	O
from	IN	O
delivery	NN	O
to	TO	O
first	JJ	O
breath	NN	O
,	,	O
Apgar	NNP	O
scores	VBZ	O
at	IN	O
5	CD	O
mins	NNS	O
,	,	O
naloxone	JJ	O
requirement	NN	O
,	,	O
transfer	NN	O
to	TO	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
,	,	O
neonatal	JJ	O
haemoglobin	NN	O
oxygen	NN	O
saturation	NN	O
at	IN	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
,	,	O
and	CC	O
120	CD	O
mins	NNS	O
after	IN	O
delivery	NN	O
,	,	O
and	CC	O
neonatal	JJ	O
sedation	NN	O
and	CC	O
feeding	VBG	O
behaviour	NN	O
during	IN	O
first	JJ	O
2	CD	O
hours	NNS	O
.	.	O

DISCUSSION	NNP	O
If	IN	O
the	DT	O
trial	NN	O
demonstrates	VBZ	O
that	IN	O
diamorphine	NN	O
provides	VBZ	O
better	RBR	O
analgesia	NN	O
with	IN	O
fewer	JJR	O
side	NN	O
effects	NNS	O
in	IN	O
mother	NN	O
and	CC	O
neonate	NN	O
this	DT	O
could	MD	O
lead	VB	O
to	TO	O
a	DT	O
change	NN	O
in	IN	O
national	JJ	O
practice	NN	O
and	CC	O
result	NN	O
in	IN	O
diamorphine	NN	O
becoming	VBG	O
the	DT	O
preferred	JJ	O
intramuscular	JJ	O
opioid	NN	O
for	IN	O
analgesia	NN	O
in	IN	O
labour	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ISRCTN14898678Eudra	NNP	O
No	NNP	O
:	:	O
2006-003250-18	JJ	O
,	,	O
REC	NNP	O
Reference	NNP	O
No	NNP	O
:	:	O
06/Q1702/95	CD	O
,	,	O
MHRA	NNP	O
Authorisation	NNP	O
No	NNP	O
:	:	O
1443/0001/001-0001	JJ	O
,	,	O
NIHR	NNP	O
UKCRN	NNP	O
reference	NN	O
6895	CD	O
,	,	O
RfPB	NNP	O
grant	NN	O
PB-PG-0407-13170_IR5	NNP	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockade	NN	O
and	CC	O
the	DT	O
DASH	NNP	O
diet	NN	O
on	IN	O
markers	NNS	Physical
of	IN	O
endogenous	JJ	O
fibrinolysis	NN	O
.	.	O

Hypertension	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
impaired	JJ	O
fibrinolysis	NN	O
.	.	O

Both	DT	O
angiotensin	JJ	O
receptor	NN	O
blockers	NNS	O
(	(	O
ARB	NNP	O
)	)	O
and	CC	O
the	DT	O
DASH	NNP	O
(	(	O
Dietary	NNP	O
Approaches	NNP	O
to	TO	O
Stop	NNP	O
Hypertension	NNP	O
)	)	O
diet	VBP	O
effectively	RB	O
lower	JJR	O
blood	NN	Physical
pressure	NN	Physical
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Some	DT	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
treatment	NN	O
with	IN	O
ARBs	NNP	O
could	MD	O
increase	VB	O
fibrinolysis	NN	O
,	,	O
however	RB	O
,	,	O
data	NNS	O
is	VBZ	O
conflicting	VBG	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
the	DT	O
DASH	NNP	O
diet	NN	O
on	IN	O
fibrinolytic	JJ	Physical
parameters	NNS	Physical
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Fifty-five	JJ	O
hypertensive	JJ	O
participants	NNS	O
(	(	O
35	CD	O
African-American	JJ	O
,	,	O
20	CD	O
white	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
8	CD	O
weeks	NNS	O
of	IN	O
either	CC	O
a	DT	O
control	NN	O
diet	NN	O
or	CC	O
the	DT	O
DASH	NNP	O
diet	NN	O
.	.	O

The	DT	O
diets	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
sodium	NN	O
content	NN	O
(	(	O
approximately	RB	O
3	CD	O
g/day	NN	O
)	)	O
.	.	O

Within	IN	O
each	DT	O
diet	NN	O
,	,	O
individuals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
losartan	NN	O
or	CC	O
placebo	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
fashion	NN	O
.	.	O

Tissue	NNP	Physical
plasminogen	NN	Physical
activator	NN	Physical
(	(	Physical
t-PA	JJ	Physical
)	)	Physical
antigen	NN	Physical
,	,	O
t-PA	JJ	Physical
activity	NN	Physical
,	,	O
plasminogen	NN	Physical
activator	NN	Physical
inhibitor-1	JJ	Physical
(	(	Physical
PAI-1	NNP	Physical
)	)	Physical
activity	NN	Physical
and	CC	O
plasma	NN	Physical
renin	NN	Physical
activity	NN	Physical
(	(	Physical
PRA	NNP	Physical
)	)	Physical
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
2-week	JJ	O
run-in	JJ	O
period	NN	O
on	IN	O
the	DT	O
control	NN	O
diet	NN	O
and	CC	O
after	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
DASH	NNP	O
diet	NN	O
did	VBD	O
not	RB	O
affect	JJ	O
markers	NNS	O
of	IN	O
fibrinolysis	NN	O
.	.	O

Losartan	NNP	O
significantly	RB	O
lowered	VBD	O
t-PA	JJ	Physical
antigen	NN	Physical
levels	NNS	Physical
(	(	O
-1.8	NNP	O
ng/mL	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.045	CD	O
)	)	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
t-PA	NN	Physical
or	CC	Physical
PAI-1	JJ	Physical
activities	NNS	Physical
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
whites	NNS	O
(	(	O
-4.1	JJ	O
ng/mL	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
)	)	O
compared	VBN	O
with	IN	O
African-Americans	NNP	O
(	(	O
-0.3	JJ	O
ng/mL	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.7	CD	O
)	)	O
,	,	O
P-interaction	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
not	RB	O
materially	RB	O
affected	VBN	O
by	IN	O
adjustment	NN	O
for	IN	O
basline	NN	O
values	NNS	O
or	CC	O
changes	NNS	O
in	IN	O
blood	NN	Physical
pressure	NN	Physical
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
losartan	JJ	O
reduces	NNS	O
t-PA	JJ	Physical
antigen	NN	Physical
levels	NNS	Physical
in	IN	O
white	JJ	O
,	,	O
but	CC	O
not	RB	O
African-American	JJ	O
hypertensive	JJ	O
individuals	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
DASH	NNP	O
diet	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
markers	NNS	Physical
of	IN	Physical
fibrinolysis	NN	Physical
in	IN	O
whites	NNS	O
or	CC	O
African-Americans	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
monotherapy	NN	O
and	CC	O
combination	NN	O
therapy	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
control	NN	O
and	CC	O
target	NN	O
organ	JJ	O
damage	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
intervention	NN	O
study	NN	O
in	IN	O
a	DT	O
large	JJ	O
population	NN	O
of	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
monotherapy	NN	O
and	CC	O
different	JJ	O
combination	NN	O
therapies	NNS	O
on	IN	O
cardiovascular	JJ	O
target	NN	O
organ	JJ	O
damage	NN	O
and	CC	O
metabolic	JJ	O
profile	NN	O
in	IN	O
520	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
a	DT	O
single	JJ	O
agent	NN	O
:	:	O
carvedilol	NN	O
25	CD	O
mg	NN	O
,	,	O
amlodipine	VBP	O
10	CD	O
mg	NN	O
,	,	O
enalapril	VBZ	O
20	CD	O
mg	NN	O
,	,	O
or	CC	O
losartan	VBZ	O
50	CD	O
mg	NN	O
(	(	O
groups	NNS	O
C	NNP	O
,	,	O
A	NNP	O
,	,	O
E	NNP	O
,	,	O
and	CC	O
L	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

After	IN	O
2	CD	O
months	NNS	O
(	(	O
level	JJ	O
2	CD	O
)	)	O
,	,	O
nonresponders	NNS	O
received	VBD	O
a	DT	O
low-dose	JJ	O
thiazide	NN	O
diuretic	NN	O
,	,	O
and	CC	O
after	IN	O
4	CD	O
months	NNS	O
(	(	O
level	JJ	O
3	CD	O
)	)	O
,	,	O
amlodipine	JJ	O
(	(	O
groups	NNS	O
E	NNP	O
,	,	O
C	NNP	O
,	,	O
and	CC	O
L	NNP	O
)	)	O
and	CC	O
carvedilol	NN	O
(	(	O
group	NN	O
A	DT	O
)	)	O
.	.	O

Twenty-four-hour	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
was	VBD	O
significantly	RB	O
lowered	VBN	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Blood	NNP	Physical
pressure	NN	Physical
control	NN	Physical
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
two	CD	O
or	CC	O
three	CD	O
drugs	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
carotid	JJ	Physical
intima-media	JJ	Physical
thickness	NN	Physical
decreased	VBN	O
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
left	VBD	Physical
ventricular	JJ	Physical
mass	NN	Physical
index	NN	Physical
in	IN	O
groups	NNS	O
E	NNP	O
and	CC	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
.001	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
with	IN	O
a	DT	O
concomitant	JJ	O
reduction	NN	O
in	IN	O
cholesterol	NN	Physical
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.03	NNP	O
)	)	O
.	.	O

Diastolic	NNP	Physical
function	NN	Physical
improved	VBD	O
significantly	RB	O
in	IN	O
group	NN	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
describes	VBZ	O
the	DT	O
need	NN	O
to	TO	O
control	VB	O
blood	NN	Physical
pressure	NN	Physical
with	IN	O
two	CD	O
or	CC	O
more	JJR	O
drugs	NNS	O
in	IN	O
most	JJS	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
illustrates	NNS	O
good	JJ	O
clinical	JJ	O
outcomes	NNS	O
,	,	O
independent	JJ	O
of	IN	O
blood	NN	O
pressure	NN	O
lowering	NN	O
,	,	O
using	VBG	O
combination	NN	O
therapy	NN	O
with	IN	O
losartan	JJ	O
,	,	O
low-dose	JJ	O
thiazide	NN	O
,	,	O
and	CC	O
amlodipine	NN	O
.	.	O

A	DT	O
good	JJ	O
response	NN	O
to	TO	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
fatty	JJ	O
acids	NNS	O
in	IN	O
body	NN	Physical
fat	JJ	Physical
and	CC	O
blood	NN	Physical
lipid	JJ	Physical
profiles	NNS	Physical
of	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
clarify	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oil	NN	O
with	IN	O
medium-	NN	O
and	CC	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
MLCT	NNP	O
)	)	O
on	IN	O
body	NN	Physical
fat	JJ	Physical
and	CC	O
blood	NN	Physical
lipid	JJ	Physical
profiles	NNS	Physical
in	IN	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

One-hundred-and-twelve	JJ	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
those	DT	O
that	IN	O
consumed	VBD	O
MLCT	NNP	O
oil	NN	O
and	CC	O
those	DT	O
that	WDT	O
consumed	VBD	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
LCT	NNP	O
)	)	O
oil	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
requested	VBN	O
to	TO	O
consume	VB	O
25-30	JJ	O
g	NN	O
of	IN	O
the	DT	O
oils	NNS	O
daily	RB	O
and	CC	O
maintain	VB	O
a	DT	O
fixed	JJ	O
level	NN	O
of	IN	O
energy	NN	O
intake	NN	O
and	CC	O
exercise	NN	O
.	.	O

Anthropometric	NNP	Physical
and	CC	Physical
blood	NN	Physical
biochemical	JJ	Physical
parameters	NNS	Physical
were	VBD	O
measured	VBN	O
when	WRB	O
the	DT	O
study	NN	O
was	VBD	O
initiated	VBN	O
and	CC	O
completed	VBN	O
.	.	O

The	DT	O
LCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
50	CD	O
subjects	NNS	O
(	(	O
34	CD	O
men	NNS	O
and	CC	O
16	CD	O
women	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
51	CD	O
subjects	NNS	O
(	(	O
33	CD	O
men	NNS	O
and	CC	O
18	CD	O
women	NNS	O
)	)	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Larger	NNP	O
decreases	VBZ	O
in	IN	O
body	NN	Physical
weight	NN	Physical
,	,	Physical
body	NN	Physical
mass	NN	Physical
index	NN	Physical
,	,	Physical
waist	NN	Physical
circumference	NN	Physical
,	,	Physical
body	NN	Physical
fat	NN	Physical
,	,	Physical
total	JJ	Physical
fat	JJ	Physical
area	NN	Physical
and	CC	Physical
subcutaneous	JJ	Physical
fat	JJ	Physical
area	NN	Physical
in	IN	Physical
the	DT	Physical
abdomen	NNS	Physical
and	CC	Physical
serum	NN	Physical
triglycerides	NNS	Physical
,	,	Physical
low-density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
,	,	Physical
apolipoprotein	NN	Physical
B	NNP	Physical
,	,	Physical
C2	NNP	Physical
,	,	Physical
C3	NNP	Physical
and	CC	Physical
E	NNP	Physical
were	VBD	O
observed	VBN	O
in	IN	O
male	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
MLCT	NNP	O
group	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
LCT	NNP	O
group	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
these	DT	Others
parameters	NNS	Others
between	IN	O
the	DT	O
female	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
consumption	NN	O
of	IN	O
medium-and	JJ	O
long-chain	JJ	O
triglycerides	NNS	O
can	MD	O
reduce	VB	O
body	NN	Physical
weight	NN	Physical
and	CC	O
body	NN	Physical
fat	NN	Physical
and	CC	O
improve	VB	O
blood	NN	Physical
lipid	JJ	Physical
profiles	NNS	Others
in	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

Uncomplicated	VBN	O
moderate	JJ	O
coronary	JJ	O
artery	NN	O
dissections	NNS	O
after	IN	O
balloon	NN	O
angioplasty	NN	O
:	:	O
good	JJ	O
outcome	NN	O
without	IN	O
stenting	VBG	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
relation	NN	O
between	IN	O
moderate	JJ	O
coronary	JJ	O
dissections	NNS	O
,	,	O
coronary	JJ	O
flow	NN	O
velocity	NN	O
reserve	NN	O
(	(	O
CFVR	NNP	O
)	)	O
,	,	O
and	CC	O
long	JJ	O
term	NN	O
outcome	NN	O
.	.	O

METHODS	NNP	O
523	CD	O
patients	NNS	O
undergoing	JJ	O
balloon	NN	O
angioplasty	NN	O
and	CC	O
sequential	JJ	O
intracoronary	JJ	O
Doppler	NN	O
measurements	NNS	O
were	VBD	O
examined	VBN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
DEBATE	NNP	O
II	NNP	O
trial	NN	O
(	(	O
Doppler	NNP	O
endpoints	VBZ	O
balloon	NN	O
angioplasty	JJ	O
trial	NN	O
Europe	NNP	O
)	)	O
.	.	O

After	IN	O
successful	JJ	O
balloon	NN	O
angioplasty	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
stenting	VBG	O
or	CC	O
no	DT	O
further	JJ	O
treatment	NN	O
.	.	O

Dissections	NNS	O
were	VBD	O
graded	VBN	O
at	IN	O
the	DT	O
core	NN	O
laboratory	NN	O
by	IN	O
two	CD	O
observers	NNS	O
and	CC	O
divided	VBD	O
into	IN	O
four	CD	O
categories	NNS	O
:	:	O
none	NN	O
,	,	O
mild	NN	O
(	(	O
type	JJ	O
A-B	NNP	O
)	)	O
,	,	O
moderate	JJ	O
(	(	O
type	JJ	O
C	NNP	O
)	)	O
,	,	O
severe	JJ	O
(	(	O
types	NNS	O
D	NNP	O
to	TO	O
F	NNP	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
severe	JJ	O
dissections	NNS	O
(	(	O
n	JJ	O
=	NNP	O
128	CD	O
)	)	O
or	CC	O
without	IN	O
available	JJ	O
reference	NN	O
vessel	NN	O
CFVR	NNP	O
(	(	O
n	JJ	O
=	NNP	O
139	CD	O
)	)	O
were	VBD	O
excluded	VBN	O
.	.	O

The	DT	O
remaining	VBG	O
256	CD	O
patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
according	VBG	O
to	TO	O
the	DT	O
presence	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
absence	NN	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
211	CD	O
)	)	O
of	IN	O
moderate	JJ	O
dissection	NN	O
.	.	O

RESULTS	NNP	O
Following	VBG	O
balloon	NN	O
angioplasty	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
CFVR	NNP	Physical
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

At	IN	O
12	CD	O
months	NNS	O
follow	VBP	O
up	RP	O
,	,	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
major	JJ	Adverseeffect
adverse	JJ	Adverseeffect
cardiac	NN	Adverseeffect
events	NNS	Adverseeffect
was	VBD	O
observed	VBN	O
overall	JJ	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
10	CD	O
(	(	O
22	CD	O
%	NN	O
)	)	O
v	NN	O
23	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
,	,	O
p	JJ	O
=	NNP	O
0.041	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
risk	NN	Adverseeffect
of	IN	Adverseeffect
major	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
subgroups	NNS	O
receiving	VBG	O
balloon	NN	O
angioplasty	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
6	CD	O
(	(	O
19	CD	O
%	NN	O
)	)	O
v	NN	O
group	NN	O
B	NNP	O
,	,	O
16	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
,	,	O
NS	NNP	O
)	)	O
.	.	O

Among	IN	O
group	NN	O
A	NNP	O
patients	NNS	O
,	,	O
the	DT	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
risk	NN	Adverseeffect
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
randomised	VBN	O
to	TO	O
stenting	VBG	O
(	(	O
odds	JJ	O
ratios	NNS	O
6.603	CD	O
v	NN	O
1.197	CD	O
,	,	O
p	NN	O
=	NNP	O
0.046	CD	O
)	)	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
risk	NN	O
if	IN	O
the	DT	O
group	NN	O
was	VBD	O
analysed	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
the	DT	O
CFVR	NNP	O
was	VBD	O
<	JJ	O
2.5	CD	O
or	CC	O
>	VB	O
/=	CD	O
2.5	CD	O
after	IN	O
balloon	NN	O
angioplasty	NN	O
.	.	O

CONCLUSIONS	NNP	O
Moderate	NNP	O
dissections	NNS	O
left	VBD	O
untreated	JJ	O
result	NN	O
in	IN	O
no	DT	O
increased	VBN	O
risk	NN	Adverseeffect
of	IN	Adverseeffect
major	JJ	Adverseeffect
adverse	JJ	Adverseeffect
cardiac	NN	Adverseeffect
events	NNS	Adverseeffect
.	.	O

Additional	JJ	O
stenting	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
the	DT	O
long	JJ	O
term	NN	O
outcome	NN	O
.	.	O

A	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
the	DT	O
efficacy	NN	Others
of	IN	O
scheduled	JJ	O
dosing	NN	O
of	IN	O
acetaminophen	NN	O
and	CC	O
hydrocodone	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
in	IN	O
children	NNS	O
after	IN	O
tonsillectomy	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
around-the-clock	NN	O
(	(	O
ATC	NNP	O
)	)	O
analgesic	JJ	O
administration	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
nurse	JJ	O
coaching	NN	O
,	,	O
compared	VBN	O
with	IN	O
standard	JJ	O
care	NN	O
with	IN	O
as	RB	O
needed	VBN	O
(	(	O
PRN	NNP	O
)	)	O
dosing	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
outpatient	JJ	O
tonsillectomy	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
6	CD	O
to	TO	O
15	CD	O
years	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
acetaminophen	NN	O
and	CC	O
hydrocodone	NN	O
(	(	O
167	CD	O
mg/2.5	NN	O
mg/5	NN	O
mL	NN	O
)	)	O
for	IN	O
3	CD	O
days	NNS	O
after	IN	O
surgery	NN	O
:	:	O
Group	NNP	O
A	NNP	O
(	(	O
N=39	NNP	O
)	)	O
-every	VBD	O
4	CD	O
hours	NNS	O
PRN	NNP	O
,	,	O
with	IN	O
standard	JJ	O
postoperative	JJ	O
instructions	NNS	O
;	:	O
Group	NNP	O
B	NNP	O
(	(	O
N=34	NNP	O
)	)	O
-every	VBD	O
4	CD	O
hours	NNS	O
ATC	NNP	O
,	,	O
with	IN	O
standard	JJ	O
postoperative	JJ	O
instructions	NNS	O
,	,	O
without	IN	O
nurse	JJ	O
coaching	NN	O
;	:	O
and	CC	O
Group	NNP	O
C	NNP	O
(	(	O
N=40	NNP	O
)	)	O
-every	VBD	O
4	CD	O
hours	NNS	O
ATC	NNP	O
,	,	O
with	IN	O
standard	JJ	O
postoperative	JJ	O
instructions	NNS	O
,	,	O
with	IN	O
coaching	NN	O
.	.	O

Parents	NNS	Pain
completed	VBD	Pain
a	DT	Pain
medication	NN	Others
log	NN	Others
,	,	Pain
and	CC	Pain
recorded	VBD	Pain
the	DT	Pain
presence	NN	Pain
and	CC	Pain
severity	NN	Pain
of	IN	Pain
opioid-related	JJ	Pain
adverse	JJ	Pain
effects	NNS	Pain
and	CC	Pain
children	NNS	Pain
's	POS	Pain
reports	NNS	Pain
of	IN	Pain
pain	NN	Pain
intensity	NN	Pain
using	VBG	Pain
a	DT	Pain
0	CD	Pain
to	TO	Pain
10	CD	Pain
numeric	JJ	Pain
rating	NN	Pain
scale	NN	Pain
.	.	Pain

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
analgesic	JJ	O
administration	NN	O
or	CC	O
pain	JJ	Pain
intensity	NN	Pain
scores	NNS	Pain
between	IN	O
the	DT	O
2	CD	O
ATC	NNP	O
groups	NNS	O
.	.	O

Therefore	RB	O
,	,	O
they	PRP	O
were	VBD	O
combined	VBN	O
for	IN	O
comparison	NN	O
with	IN	O
the	DT	O
PRN	NNP	O
group	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
ATC	NNP	O
group	NN	O
received	VBD	O
more	JJR	O
analgesic	JJ	Others
than	IN	O
those	DT	O
in	IN	O
the	DT	O
PRN	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
PRN	NNP	O
group	NN	O
had	VBD	O
higher	JJR	O
pain	NN	Pain
intensity	NN	Pain
scores	NNS	Pain
compared	VBN	O
to	TO	O
children	NNS	O
in	IN	O
the	DT	O
ATC	NNP	O
group	NN	O
,	,	O
both	DT	O
at	IN	O
rest	NN	O
(	(	O
P=0.017	NNP	O
)	)	O
and	CC	O
with	IN	O
swallowing	NN	O
(	(	O
P=0.017	NNP	O
)	)	O
.	.	O

Pain	NNP	Pain
intensity	NN	Pain
scores	NNS	Pain
for	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
morning	NN	O
compared	VBN	O
with	IN	O
the	DT	O
evening	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
constipation	NN	Adverseeffect
,	,	O
scheduled	VBN	O
analgesic	JJ	O
dosing	VBG	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
frequency	NN	Adverseeffect
or	CC	Adverseeffect
severity	NN	Adverseeffect
of	IN	Adverseeffect
opioid-related	JJ	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	Physical

DISCUSSION	NNP	O
Scheduled	VBD	O
dosing	NN	O
of	IN	O
acetaminophen	NN	O
and	CC	O
hydrocodone	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
PRN	NNP	O
dosing	VBG	O
in	IN	O
reducing	VBG	O
pain	NN	O
intensity	NN	O
in	IN	O
children	NNS	O
after	IN	O
tonsillectomy	NN	O
.	.	O

Nurse	CC	O
coaching	VBG	O
does	VBZ	O
not	RB	O
impact	VB	O
parent	NN	O
's	POS	O
adherence	NN	O
to	TO	O
ATC	NNP	O
dosing	NN	O
.	.	O

Diverting	VBG	Physical
stoma	NN	Physical
after	IN	O
low	JJ	O
anterior	JJ	O
resection	NN	O
:	:	O
more	JJR	O
arguments	NNS	O
in	IN	O
favor	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
necessity	NN	O
of	IN	O
a	DT	O
protective	JJ	O
stoma	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
low	JJ	O
anterior	JJ	O
resection	NN	O
with	IN	O
total	JJ	O
mesorectal	JJ	O
excision	NN	O
for	IN	O
primary	JJ	O
rectal	JJ	O
cancer	NN	O
is	VBZ	O
discussed	VBN	O
controversially	RB	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
pilot-study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
diverting	VBG	Physical
ileostomy	NN	Physical
in	IN	O
patients	NNS	O
undergoing	VBG	O
low	JJ	O
anterior	JJ	O
resection	NN	O
[	NNP	O
NCT00457327	NNP	O
]	NNP	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
patients	NNS	O
after	IN	O
elective	JJ	O
sphincter-saving	JJ	O
low	JJ	O
anterior	JJ	O
resection	NN	O
were	VBD	O
eligible	JJ	O
for	IN	O
intraoperative	JJ	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
demonstrate	VB	O
similar	JJ	Adverseeffect
risks	NNS	Adverseeffect
after	IN	O
the	DT	O
resection	NN	O
with	IN	O
both	DT	O
techniques	NNS	O
.	.	O

A	DT	O
priori	JJ	O
stopping	NN	O
rules	NNS	O
were	VBD	O
defined	VBN	O
for	IN	O
early	JJ	O
termination	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
July	NNP	O
4	CD	O
,	,	O
2006	CD	O
and	CC	O
March	NNP	O
12	CD	O
,	,	O
2007	CD	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
41	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
34	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

Eighteen	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
stoma	NN	O
group	NN	O
and	CC	O
16	CD	O
patients	NNS	O
to	TO	O
the	DT	O
nonstoma	NN	O
group	NN	O
The	DT	Physical
symptomatic	JJ	Physical
anastomotic	JJ	Physical
leakage	NN	Physical
rate	NN	Physical
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
nonstoma	NN	O
group	NN	O
(	(	O
37.5	CD	O
percent	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
stoma	NN	O
group	NN	O
(	(	O
5.5	CD	O
percent	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
all	DT	O
six	CD	O
cases	NNS	O
in	IN	O
the	DT	O
nonstoma	NN	O
group	NN	O
,	,	O
reoperations	NNS	Physical
were	VBD	O
necessary	JJ	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
stopped	VBN	O
after	IN	O
34	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
.	.	O

A	DT	O
meta-analysis	NN	O
of	IN	O
the	DT	O
available	JJ	O
data	NNS	O
confirmed	VBD	O
the	DT	O
value	NN	O
of	IN	O
a	DT	O
protective	JJ	O
ostomy	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
low	JJ	O
anterior	JJ	O
resection	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
data	NN	O
demonstrate	NN	O
a	DT	O
high	JJ	O
risk	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
low	JJ	O
anterior	JJ	O
resection	NN	O
without	IN	O
diverting	VBG	O
ileostomy	NN	O
.	.	O

Effects	NNS	O
of	IN	O
the	DT	O
810-nm	JJ	O
diode	NN	O
laser	NN	O
on	IN	O
hair	NN	O
and	CC	O
on	IN	O
the	DT	O
biophysical	JJ	O
properties	NNS	O
of	IN	O
skin	NN	O
.	.	O

INTRODUCTION	NNP	O
Laser	NNP	O
therapy	NN	O
is	VBZ	O
clinically	RB	O
effective	JJ	O
in	IN	O
hair	NN	O
removal	NN	O
;	:	O
however	RB	O
,	,	O
despite	IN	O
the	DT	O
development	NN	O
of	IN	O
various	JJ	O
strategies	NNS	O
,	,	O
laser	NN	O
procedures	NNS	O
still	RB	O
present	VBP	O
a	DT	O
risk	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
due	JJ	O
to	TO	O
the	DT	O
overheating	NN	O
of	IN	O
the	DT	O
skin	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
810-nm	JJ	O
diode	NN	O
laser	RBR	O
treatment	NN	O
on	IN	O
hair	NN	O
and	CC	O
on	IN	O
the	DT	O
biophysical	JJ	O
properties	NNS	O
of	IN	O
skin	NN	O
by	IN	O
using	VBG	O
various	JJ	O
non-invasive	JJ	O
techniques	NNS	O
on	IN	O
various	JJ	O
parameters	NNS	O
,	,	O
including	VBG	O
hair	NN	O
analysis	NN	O
,	,	O
surface	NN	O
color	NN	O
changes	NNS	O
,	,	O
integrity	NN	O
of	IN	O
skin	NN	O
barrier	NN	O
,	,	O
sebum	JJ	O
production	NN	O
rate	NN	O
and	CC	O
pH	NN	O
level	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
right-left	JJ	O
comparison	NN	O
study	NN	O
,	,	O
35	CD	O
women	NNS	O
with	IN	O
axillary	JJ	O
hair	NN	O
received	VBD	O
single-session	JJ	O
diode	NN	O
laser	NN	O
therapy	NN	O
.	.	O

Hair	NNP	O
analysis	NN	O
and	CC	O
biophysical	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
skin	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
weeks	NNS	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
after	IN	O
the	DT	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
Hair	NNP	Physical
density	NN	Physical
and	CC	Physical
thicknesses	NNS	Physical
statistically	RB	Physical
significantly	RB	Physical
decreased	VBN	Physical
after	IN	O
the	DT	O
first	JJ	O
post-treatment	JJ	O
evaluation	NN	O
.	.	O

Regarding	VBG	O
comparison	NN	O
of	IN	O
the	DT	O
biophysical	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
skin	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
assessments	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
increase	NN	O
determined	VBD	O
during	IN	O
the	DT	O
second	JJ	O
week	NN	O
in	IN	O
the	DT	O
erythema	NN	Physical
index	NN	Physical
in	IN	O
the	DT	O
laser-treated	JJ	O
areas	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
showed	VBD	O
that	IN	O
the	DT	O
diode	NN	O
laser	NN	O
can	MD	O
perform	VB	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
hair	NN	Physical
amount	NN	Physical
without	IN	O
significant	JJ	O
epidermal	JJ	O
damage	NN	O
,	,	O
at	IN	O
least	JJS	O
for	IN	O
a	DT	O
short	JJ	O
period	NN	O
.	.	O

Matched-pair	JJ	O
analysis	NN	O
of	IN	O
all-polyethylene	JJ	O
versus	NN	O
metal-backed	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

Forty-eight	NNP	O
matched	VBD	O
pairs	NNS	O
of	IN	O
osteoarthritic	JJ	O
knees	NNS	O
from	IN	O
patients	NNS	O
who	WP	O
underwent	VBP	O
primary	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
with	IN	O
a	DT	O
round-on-round	NN	O
,	,	O
Apollo	NNP	O
Knee	NNP	O
System	NNP	O
were	VBD	O
studied	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
outcome	NN	O
between	IN	O
all-polyethylene	JJ	O
and	CC	O
metal-backed	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
matched	VBN	O
for	IN	O
patient	JJ	O
factors	NNS	O
,	,	O
preoperative	JJ	O
deformities	NNS	O
,	,	O
cruciate	JJ	O
salvage	NN	O
or	CC	O
sacrifice	NN	O
,	,	O
and	CC	O
surgical	JJ	O
technique	NN	O
.	.	O

At	IN	O
the	DT	O
last	JJ	O
follow-up	JJ	O
(	(	O
average	JJ	O
,	,	O
38.4	CD	O
months	NNS	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
knee	NN	Physical
scores	NNS	Physical
,	,	O
patient	JJ	Physical
self-assessment	NN	Physical
,	,	O
and	CC	O
radiographic	JJ	Physical
outcomes	NNS	Physical
.	.	O

No	DT	O
component	NN	O
required	VBN	O
revision	NN	O
,	,	O
and	CC	O
no	DT	O
revisions	NNS	O
were	VBD	O
pending	VBG	O
.	.	O

Maintenance	NN	O
of	IN	O
these	DT	O
results	NNS	O
over	IN	O
time	NN	O
would	MD	O
project	VB	O
into	IN	O
better	JJR	O
long-term	JJ	O
success	NN	O
for	IN	O
all-polyethylene	JJ	O
tibial	JJ	O
components	NNS	O
because	IN	O
of	IN	O
the	DT	O
amount	NN	O
of	IN	O
wear	NN	O
and	CC	O
osteolysis	NN	O
with	IN	O
current	JJ	O
modular	JJ	O
metal-backed	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

We	PRP	O
advocate	VBP	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
more	RBR	O
cost-effective	JJ	O
all-polyethylene	JJ	O
tibial	JJ	O
component	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
(	(	O
>	JJ	O
70	CD	O
years	NNS	O
old	JJ	O
)	)	O
who	WP	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
need	VB	O
the	DT	O
versatility	NN	O
of	IN	O
exchange	NN	O
of	IN	O
a	DT	O
modular	JJ	O
polyethylene	NN	O
insert	NN	O
because	IN	O
of	IN	O
wear	NN	O
.	.	O

Prospective	JJ	O
study	NN	O
of	IN	O
short	JJ	O
and	CC	O
ultrashort	JJ	O
regimens	NNS	O
of	IN	O
gonadotropin-releasing	JJ	O
hormone	NN	O
agonist	NN	O
in	IN	O
an	DT	O
in	IN	O
vitro	JJ	O
fertilization	NN	O
program	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
usefulness	NN	Others
of	IN	O
the	DT	O
ultrashort	JJ	O
regimen	NNS	O
of	IN	O
gonadotropin-releasing	JJ	O
hormone	NN	O
agonist	NN	O
(	(	O
GnRH-a	NNP	O
)	)	O
in	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
an	DT	O
in	IN	O
vitro	JJ	O
fertilization	NN	O
(	(	O
IVF	NNP	O
)	)	O
program	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
short	JJ	O
and	CC	O
ultrashort	JJ	O
regimens	NNS	O
of	IN	O
GnRH-a	NNP	O
.	.	O

SETTING	NN	O
Aberdeen	NNP	O
Assisted	NNP	O
Reproduction	NNP	O
Unit	NNP	O
.	.	O

PATIENTS	NNP	O
Forty-eight	JJ	O
patients	NNS	O
having	VBG	O
IVF	NNP	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
were	VBD	O
randomized	VBN	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Response	NNP	Physical
to	TO	Physical
ovarian	JJ	Physical
stimulation	NN	Physical
and	CC	Physical
occurrence	NN	Physical
of	IN	Physical
spontaneous	JJ	Physical
luteinizing	VBG	Physical
hormone	NN	Physical
(	(	Physical
LH	NNP	Physical
)	)	Physical
surges	VBZ	Physical
.	.	Physical

RESULTS	NNP	O
In	IN	O
ovulation	NN	Physical
induction	NN	Physical
,	,	Physical
fertilization	NN	Physical
,	,	Physical
and	CC	Physical
pregnancy	NN	Physical
rates	NNS	Physical
the	DT	O
ultrashort	JJ	O
regimen	NNS	O
produces	VBZ	O
results	NNS	O
that	WDT	O
were	VBD	O
no	DT	O
different	JJ	O
to	TO	O
the	DT	O
short	JJ	O
regimen	NNS	O
but	CC	O
it	PRP	O
did	VBD	O
not	RB	O
always	RB	O
prevent	VB	O
an	DT	O
LH	NNP	Physical
surge	NN	Physical
.	.	O

CONCLUSION	VB	O
The	DT	O
ultrashort	JJ	O
regimen	NNS	O
can	MD	O
be	VB	O
a	DT	O
useful	JJ	O
alternative	NN	O
for	IN	O
ovarian	JJ	O
stimulation	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
IVF	NNP	O
.	.	O

Long-term	JJ	O
psychosocial	NN	O
and	CC	O
health	NN	O
economy	NN	O
consequences	NNS	O
of	IN	O
ADHD	NNP	O
,	,	O
autism	NN	O
,	,	O
and	CC	O
reading-writing	JJ	O
disorder	NN	O
:	:	O
a	DT	O
prospective	JJ	O
service	NN	O
evaluation	NN	O
project	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
evaluate	VB	O
psychosocial	JJ	O
,	,	O
societal	JJ	O
,	,	O
and	CC	O
family	NN	O
cost	NN	O
consequences	NNS	O
of	IN	O
a	DT	O
psychoeducational	JJ	O
intervention	NN	O
program	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
boys	VBZ	O
with	IN	O
ADHD	NNP	O
,	,	O
Asperger	NNP	O
syndrome/high-functioning	JJ	O
autism	NN	O
(	(	O
AS/HFA	NNP	O
)	)	O
,	,	O
and	CC	O
reading	NN	O
and	CC	O
writing	VBG	O
disorder	NN	O
(	(	O
RD/WD	NNP	O
)	)	O
were	VBD	O
allocated	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
service	NN	O
evaluation	NN	O
project	NN	O
.	.	O

Every	DT	O
other	JJ	O
boy	NN	O
in	IN	O
each	DT	O
diagnostic	JJ	O
group	NN	O
was	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	RB	O
(	(	O
a	DT	O
)	)	O
a	DT	O
special	JJ	O
education	NN	O
program	NN	O
(	(	O
clinical	JJ	O
index	NN	O
group	NN	O
)	)	O
or	CC	O
(	(	O
b	NN	O
)	)	O
follow-up	NN	O
without	IN	O
the	DT	O
special	JJ	O
education	NN	O
program	NN	O
(	(	O
clinical	JJ	O
comparison	NN	O
group	NN	O
)	)	O
.	.	O

Nine	CD	O
years	NNS	O
after	IN	O
initial	JJ	O
assessments	NNS	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
psychosocial	NN	O
and	CC	O
economic	JJ	O
resource	NN	O
consequences	NNS	O
over	IN	O
time	NN	O
was	VBD	O
studied	VBN	O
.	.	O

RESULTS	NNP	O
ADHD	NNP	O
,	,	O
AS/HFA	NNP	O
,	,	O
and	CC	O
RD/WD	NNP	O
all	DT	O
had	VBD	O
severe	JJ	O
impact	NN	O
on	IN	O
family	NN	Others
life	NN	Others
quality	NN	Others
.	.	Others

The	DT	O
societal	JJ	O
costs	NNS	O
were	VBD	O
high	JJ	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
resource	NN	Others
use	NN	Others
or	CC	Others
in	IN	Others
total	JJ	Others
costs	NNS	Others
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
clinical	JJ	O
index	NN	O
and	CC	O
the	DT	O
comparison	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
underscore	VBP	O
the	DT	O
very	RB	O
long-term	JJ	O
need	NN	O
for	IN	O
support	NN	O
including	VBG	O
individually	RB	O
tailored	VBN	O
reevaluations	NNS	O
and	CC	O
carefully	RB	O
monitored	VBN	O
intervention	NN	O
programs	NNS	O
adapted	VBD	O
to	TO	O
family	NN	O
needs	NNS	O
and	CC	O
severity	NN	O
of	IN	O
child	NN	O
disorder	NN	O
.	.	O

Tomato	NNP	O
paste	NN	O
rich	JJ	O
in	IN	O
lycopene	JJ	O
protects	NNS	O
against	IN	O
cutaneous	JJ	Physical
photodamage	NN	Physical
in	IN	O
humans	NNS	O
in	IN	O
vivo	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
epidemiological	JJ	O
,	,	O
animal	JJ	O
and	CC	O
human	JJ	O
data	NNS	O
report	NN	O
that	IN	O
lycopene	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
ultraviolet	NN	Physical
radiation	NN	Physical
(	(	Physical
UVR	NNP	Physical
)	)	Physical
-induced	VBD	Physical
erythema	NN	Physical
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
tomato	NN	O
paste	NN	O
--	:	O
rich	JJ	O
in	IN	O
lycopene	NN	O
,	,	O
a	DT	O
powerful	JJ	O
antioxidant	NN	O
--	:	O
can	MD	O
protect	VB	O
human	JJ	O
skin	NN	O
against	IN	O
UVR-induced	JJ	O
effects	NNS	O
partially	RB	O
mediated	VBN	O
by	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
i.e	NN	O
.	.	O

erythema	NN	O
,	,	O
matrix	NN	O
changes	NNS	O
and	CC	O
mitochondrial	JJ	O
DNA	NNP	O
(	(	O
mtDNA	NN	O
)	)	O
damage	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
,	,	O
20	CD	O
healthy	JJ	O
women	NNS	O
(	(	O
median	JJ	O
age	NN	O
33	CD	O
years	NNS	O
,	,	O
range	VBP	O
21-47	JJ	O
;	:	O
phototype	JJ	O
I/II	NNP	O
)	)	O
ingested	VBD	O
55	CD	O
g	NN	O
tomato	NN	O
paste	NN	O
(	(	O
16	CD	O
mg	RB	O
lycopene	NN	O
)	)	O
in	IN	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
olive	JJ	O
oil	NN	O
alone	RB	O
,	,	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Pre-	NNP	O
and	CC	O
postsupplementation	NN	O
,	,	O
UVR	NNP	O
erythemal	JJ	Physical
sensitivity	NN	Physical
was	VBD	O
assessed	VBN	O
visually	RB	O
as	IN	O
the	DT	O
minimal	JJ	O
erythema	NN	O
dose	NN	O
(	(	O
MED	NNP	O
)	)	O
and	CC	O
quantified	VBN	O
with	IN	O
a	DT	O
reflectance	NN	O
instrument	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
unexposed	JJ	O
and	CC	O
UVR-exposed	JJ	O
(	(	O
3	CD	O
?	.	O
MED	NNP	O
24	CD	O
h	NN	O
earlier	RBR	O
)	)	O
buttock	NN	O
skin	JJ	O
pre-	NN	O
and	CC	O
postsupplementation	NN	O
,	,	O
and	CC	O
analysed	VBD	O
immunohistochemically	RB	O
for	IN	O
procollagen	NN	O
(	(	O
pC	NN	O
)	)	O
I	PRP	O
,	,	O
fibrillin-1	JJ	O
and	CC	O
matrix	JJ	O
metalloproteinase	NN	O
(	(	O
MMP	NNP	O
)	)	O
-1	NN	O
,	,	O
and	CC	O
by	IN	O
quantitative	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
for	IN	O
mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
.	.	O

RESULTS	VB	O
Mean	NNP	O
?	.	O
SD	NNP	O
erythemal	JJ	O
D	NNP	O
(	(	O
30	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
following	VBG	O
tomato	JJ	O
paste	NN	O
vs.	FW	O
control	NN	O
(	(	O
baseline	NN	O
,	,	O
26?5	CD	O
?	.	O
7?5	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
23	CD	O
?	.	O
6?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
36?6	CD	O
?	.	O
14?7	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MED	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
(	(	O
baseline	NN	O
,	,	O
35?1	CD	O
?	.	O
9?9	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
32?6	CD	O
?	.	O
9?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
42?2	CD	O
?	.	O
11?3	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
.	.	O

Presupplementation	NN	O
,	,	O
UVR	NNP	O
induced	VBD	O
an	DT	O
increase	NN	O
in	IN	O
MMP-1	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
.	.	O

Postsupplementation	NN	O
,	,	O
UVR-induced	JJ	O
MMP-1	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
tomato	NN	O
paste	NN	O
vs.	FW	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?04	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
UVR-induced	JJ	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
was	VBD	O
similarly	RB	O
abrogated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
pCI	JJ	O
deposition	NN	O
was	VBD	O
seen	VBN	O
following	VBG	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?05	CD	O
)	)	O
.	.	O

mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
following	VBG	O
3	CD	O
?	.	O
MED	NNP	O
UVR	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
postsupplementation	NN	O
with	IN	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tomato	NNP	O
paste	NN	O
containing	VBG	O
lycopene	NNP	O
provides	VBZ	O
protection	NN	O
against	IN	O
acute	NN	O
and	CC	O
potentially	RB	O
longer-term	JJ	O
aspects	NNS	O
of	IN	O
photodamage	NN	O
.	.	O

Acceleration	NN	O
of	IN	O
insulin	NN	O
pharmacodynamic	JJ	O
profile	NN	O
by	IN	O
a	DT	O
novel	JJ	O
insulin	NN	O
infusion	NN	O
site	NN	O
warming	VBG	O
device	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Subcutaneously	NNP	O
injected	VBD	O
rapid-acting	JJ	O
insulin	NN	O
analogs	NNS	O
do	VBP	O
not	RB	O
replicate	VB	O
physiologic	JJ	O
insulin	NN	O
action	NN	O
due	JJ	O
to	TO	O
delays	NNS	O
in	IN	O
their	PRP$	O
onset	NN	O
and	CC	O
peak	JJ	O
action	NN	O
resulting	VBG	O
in	IN	O
postprandial	JJ	O
glucose	JJ	O
excursions	NNS	O
.	.	O

The	DT	O
InsuPatch	NNP	O
(	(	O
IP	NNP	O
)	)	O
is	VBZ	O
a	DT	O
novel	JJ	O
insulin	NN	O
infusion	NN	O
site	NN	O
warming	VBG	O
device	NN	O
developed	VBD	O
to	TO	O
accelerate	VB	O
insulin	NN	O
action	NN	O
by	IN	O
increasing	VBG	O
blood	NN	O
flow	NN	O
to	TO	O
the	DT	O
area	NN	O
of	IN	O
insulin	NN	O
absorption	NN	O
.	.	O

Thirteen	JJ	O
adolescents	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
(	(	O
T1D	NNP	O
,	,	O
mean	JJ	O
age	NN	O
14	CD	O
?	.	O
4	CD	O
yr	NN	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
IP	NNP	O
on	IN	O
the	DT	O
pharmacodynamics	NNS	O
and	CC	O
pharmacokinetics	NNS	O
of	IN	O
a	DT	O
0.2	CD	O
unit/kg	JJ	O
bolus	NN	O
dose	NN	O
of	IN	O
aspart	JJ	O
insulin	NN	O
using	VBG	O
the	DT	O
euglycemic	JJ	O
clamp	NN	O
technique	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Each	DT	O
subject	JJ	O
underwent	JJ	O
two	CD	O
euglycemic	JJ	O
clamp	NN	O
procedures	NNS	O
on	IN	O
separate	JJ	O
occasions	NNS	O
:	:	O
one	CD	O
with	IN	O
IP	NNP	O
and	CC	O
one	CD	O
without	IN	O
IP	NNP	O
activation	NN	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

RESULTS	VB	O
When	WRB	O
the	DT	O
insulin	NN	O
bolus	NN	O
was	VBD	O
given	VBN	O
with	IN	O
IP	NNP	O
activation	NN	O
as	IN	O
compared	VBN	O
to	TO	O
without	IN	O
IP	NNP	O
activation	NN	O
,	,	O
time	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
insulin	JJ	O
action	NN	O
(	(	O
T	NNP	O
(	(	O
GIRmax	NNP	O
)	)	O
)	)	O
and	CC	O
to	TO	O
reach	VB	O
50	CD	O
%	NN	O
maximum	JJ	O
action	NN	O
(	(	O
T	NNP	O
(	(	O
50	CD	O
%	NN	O
GIRmax	NNP	O
)	)	O
)	)	O
were	VBD	O
35	CD	O
and	CC	O
18	CD	O
min	NNS	O
earlier	RB	O
(	(	O
125	CD	O
?	.	O
8	CD	O
min	NN	O
vs.	FW	O
90	CD	O
?	.	O
6	CD	O
min	NN	O
,	,	O
p	NN	O
=	VBD	O
0.002	CD	O
and	CC	O
58	CD	O
?	.	O
5	CD	O
min	NN	O
.	.	O

vs.	FW	O
40	CD	O
?	.	O
3	CD	O
min	NN	O
,	,	O
p	NN	O
=	VBD	O
0.01	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
under	IN	O
curve	NN	O
,	,	O
AUC	NNP	O
(	(	O
GIR	NNP	O
0-90	NNP	O
min	NN	O
)	)	O
,	,	O
reflecting	VBG	O
early	JJ	O
glucodynamic	JJ	O
action	NN	O
,	,	O
was	VBD	O
significantly	RB	O
greater	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

IP	NNP	O
activation	NN	O
also	RB	O
accelerated	VBD	O
the	DT	O
rise	NN	O
in	IN	O
plasma	JJ	O
insulin	NN	O
levels	NNS	O
after	IN	O
the	DT	O
bolus	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
resulted	VBN	O
in	IN	O
a	DT	O
higher	JJR	O
peak	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
and	CC	O
greater	JJR	O
overall	JJ	O
increase	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
in	IN	O
plasma	JJ	O
insulin	NN	O
levels	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
insulin	NN	O
infusion	NN	O
site	NN	O
warming	VBG	O
with	IN	O
IP	NNP	O
activation	NN	O
accelerates	VBZ	O
the	DT	O
time	NN	O
action	NN	O
profile	NN	O
of	IN	O
aspart	NN	O
insulin	NN	O
which	WDT	O
may	MD	O
be	VB	O
of	IN	O
benefit	NN	O
to	TO	O
current	JJ	O
open-loop	JJ	O
and	CC	O
future	JJ	O
closed-loop	JJ	O
insulin	NN	O
delivery	NN	O
in	IN	O
patients	NNS	O
with	IN	O
T1D	NNP	O
.	.	O

Azelnidipine	NNP	O
and	CC	O
amlodipine	VB	O
anti-coronary	JJ	O
atherosclerosis	NN	O
trial	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
intervention	NN	O
by	IN	O
serial	JJ	O
volumetric	JJ	O
intravascular	NN	O
ultrasound	NN	O
analysis	NN	O
in	IN	O
Juntendo	NNP	O
university	NN	O
(	(	O
ALPS-J	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Many	JJ	O
trials	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
(	(	O
CCBs	NNP	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
cardiovascular	NN	Physical
(	(	Physical
CV	NNP	Physical
)	)	Physical
events	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
mechanisms	NN	O
of	IN	O
this	DT	O
effect	NN	O
could	MD	O
be	VB	O
associated	VBN	O
with	IN	O
plaque	JJ	O
regression	NN	O
due	JJ	O
to	TO	O
the	DT	O
anti-atherosclerotic	JJ	O
properties	NNS	O
of	IN	O
CCBs	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
CCB	NNP	O
on	IN	O
volumetric	JJ	O
quantitative	JJ	O
changes	NNS	O
of	IN	O
coronary	JJ	O
plaques	NNS	O
accessed	VBN	O
by	IN	O
intravascular	JJ	O
ultrasound	NN	O
(	(	O
IVUS	NNP	O
)	)	O
.	.	O

To	TO	O
confirm	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
trial	NN	O
of	IN	O
CCBs	NNP	O
treatment	NN	O
with	IN	O
azelnidipine	NN	O
or	CC	O
amlodipine	NN	O
will	MD	O
be	VB	O
conducted	VBN	O
in	IN	O
hypertensive	JJ	O
CAD	NNP	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Patients	NNPS	O
who	WP	O
have	VBP	O
hypertension	NN	O
and	CC	O
are	VBP	O
scheduled	VBN	O
for	IN	O
PCI	NNP	O
will	MD	O
be	VB	O
enrolled	VBN	O
.	.	O

Subjects	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
azelnidipine	VB	O
or	CC	O
amlodipine	VB	O
and	CC	O
observed	VB	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
will	MD	O
be	VB	O
the	DT	O
percent	NN	Physical
change	NN	Physical
of	IN	Physical
coronary	JJ	Physical
plaque	NN	Physical
volume	NN	Physical
.	.	O

The	DT	O
secondary	JJ	O
endpoint	NN	O
will	MD	O
include	VB	O
inflammatory	JJ	Physical
markers	NNS	Physical
,	,	Physical
antioxidant	JJ	Physical
activity	NN	Physical
,	,	Physical
and	CC	Physical
incidence	NN	Physical
of	IN	Physical
composite	JJ	Physical
cardiovascular	JJ	Physical
events	NNS	Physical
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
will	MD	O
investigate	VB	O
the	DT	O
improvement	NN	O
of	IN	O
coronary	JJ	Physical
plaque	NN	Physical
with	IN	O
IVUS	NNP	O
by	IN	O
treatment	NN	O
with	IN	O
two	CD	O
dihydropyridine	NN	O
CCBs	NNP	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

This	DT	O
result	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
discovery	NN	O
of	IN	O
more	RBR	O
effective	JJ	O
drug	NN	O
therapy	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
coronary	JJ	Physical
events	NNS	Physical
.	.	O

A	DT	O
parent-mediated	JJ	O
intervention	NN	O
to	TO	O
increase	VB	O
responsive	JJ	Mental
parental	JJ	Mental
behaviors	NNS	Mental
and	CC	O
child	JJ	Mental
communication	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Longitudinal	NNP	O
research	NN	O
has	VBZ	O
demonstrated	VBN	O
that	IN	O
responsive	JJ	Mental
parental	JJ	Mental
behaviors	NNS	Mental
reliably	RB	O
predict	VBP	O
subsequent	JJ	O
language	NN	Mental
gains	NNS	Mental
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
underlying	JJ	O
causal	NN	O
mechanisms	NNS	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
an	DT	O
experimental	JJ	O
intervention	NN	O
(	(	O
Focused	JJ	O
Playtime	NNP	O
Intervention	NNP	O
,	,	O
FPI	NNP	O
)	)	O
that	WDT	O
aims	VBZ	O
to	TO	O
enhance	VB	O
responsive	JJ	Mental
parental	JJ	Mental
communication	NN	Mental
(	(	O
N	NNP	O
=	NNP	O
70	CD	O
)	)	O
.	.	O

Results	$	O
showed	VBD	O
a	DT	O
significant	JJ	O
treatment	NN	O
effect	NN	O
of	IN	O
FPI	NNP	O
on	IN	O
responsive	JJ	Mental
parental	JJ	Mental
behaviors	NNS	Mental
.	.	O

Findings	NNS	O
also	RB	O
revealed	VBD	O
a	DT	O
conditional	JJ	O
effect	NN	O
of	IN	O
FPI	NNP	O
on	IN	O
children	NNS	Mental
's	POS	Mental
expressive	JJ	Mental
language	NN	Mental
outcomes	NNS	Mental
at	IN	O
12-month	JJ	O
follow	VBP	O
up	RP	O
,	,	O
suggesting	VBG	O
that	IN	O
children	NNS	O
with	IN	O
baseline	NN	O
language	NN	O
skills	NNS	O
below	IN	O
12	CD	O
months	NNS	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
are	VBP	O
most	RBS	O
likely	JJ	O
to	TO	O
benefit	VB	O
from	IN	O
FPI	NNP	O
.	.	O

Parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
more	RBR	O
advanced	JJ	O
language	NN	Mental
skills	NNS	Mental
may	MD	O
require	VB	O
intervention	NN	O
strategies	NNS	O
that	WDT	O
go	VBP	O
beyond	IN	O
FPI	NNP	O
's	POS	O
focus	NN	O
on	IN	O
responsive	JJ	Mental
communication	NN	Mental
.	.	O

Virtual	JJ	O
reality	NN	O
for	IN	O
acute	NN	O
pain	NN	O
reduction	NN	O
in	IN	O
adolescents	NNS	O
undergoing	VBG	O
burn	NN	O
wound	NN	O
care	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Effective	NNP	O
pain	NN	O
management	NN	O
remains	VBZ	O
a	DT	O
challenge	NN	O
for	IN	O
adolescents	NNS	O
during	IN	O
conscious	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
procedures	NNS	O
.	.	O

Virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
shows	VBZ	O
promise	NN	O
as	IN	O
a	DT	O
non-pharmacological	JJ	O
adjunct	NN	O
in	IN	O
reducing	VBG	O
pain	NN	O
.	.	O

AIMS	VB	O
This	DT	O
study	NN	O
assessed	VBD	O
off-the-shelf	JJ	O
VR	NNP	O
for	IN	O
(	(	O
1	CD	O
)	)	O
its	PRP$	O
effect	NN	O
on	IN	O
reducing	VBG	O
acute	JJ	O
pain	NN	O
intensity	NN	O
during	IN	O
adolescent	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
in	IN	O
a	DT	O
busy	JJ	O
hospital	NN	O
setting	NN	O
.	.	O

METHODS	NNP	O
Forty-one	CD	O
adolescents	NNS	O
(	(	O
11-17	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

Acute	NNP	O
pain	NN	O
outcomes	NNS	O
including	VBG	O
adolescent	JJ	O
self-report	NN	O
,	,	O
nursing	VBG	O
staff	NN	O
behavioral	JJ	O
observation	NN	O
,	,	O
caregiver	NN	O
observation	NN	O
and	CC	O
physiological	JJ	O
measures	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Length	NNP	O
of	IN	O
procedure	NN	O
times	NNS	O
and	CC	O
adolescent	JJ	O
reactions	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
to	TO	O
inform	VB	O
clinical	JJ	O
utility	NN	O
.	.	O

RESULTS	NNP	O
Nursing	JJ	O
staff	NN	O
reported	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
pain	NN	Physical
scores	NNS	Physical
during	IN	O
dressing	VBG	O
removal	NN	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
rescue	JJ	Physical
doses	NNS	Physical
of	IN	Physical
Entonox	NNP	Physical
given	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
standard	JJ	O
distraction	NN	O
.	.	O

For	IN	O
all	DT	O
other	JJ	O
pain	NN	O
outcomes	NNS	O
and	CC	O
length	NN	O
of	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
lower	JJR	O
pain	NN	Others
scores	NNS	Others
and	CC	Others
treatment	NN	Others
times	NNS	Others
for	IN	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Despite	IN	O
only	RB	O
minimal	JJ	O
pain	NN	O
reduction	NN	O
achieved	VBD	O
using	VBG	O
off-the-shelf	JJ	O
VR	NNP	O
,	,	O
other	JJ	O
results	NNS	O
from	IN	O
this	DT	O
trial	NN	O
and	CC	O
previous	JJ	O
research	NN	O
on	IN	O
younger	JJR	O
children	NNS	O
with	IN	O
burns	NNS	O
suggest	VBP	O
a	DT	O
customized	JJ	O
,	,	O
adolescent	JJ	O
and	CC	O
hospital	JJ	O
friendly	JJ	O
device	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
pain	NN	O
reduction	NN	O
.	.	O

Recurrent	JJ	Physical
tuberculosis	NN	Physical
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
:	:	O
relapse	NN	O
or	CC	O
reinfection	NN	O
?	.	O
Recurrence	NN	Physical
of	IN	Physical
active	JJ	Physical
tuberculosis	NN	Physical
after	IN	O
treatment	NN	O
can	MD	O
be	VB	O
due	JJ	O
to	TO	O
relapse	VB	O
of	IN	O
infection	NN	O
with	IN	O
the	DT	O
same	JJ	O
strain	NN	O
or	CC	O
reinfection	NN	O
with	IN	O
a	DT	O
new	JJ	O
strain	NN	O
of	IN	O
Mycobacterium	NNP	O
tuberculosis	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
recurrent	JJ	Physical
tuberculosis	NN	Physical
cases	NNS	Physical
caused	VBN	O
by	IN	O
reinfection	NN	Physical
has	VBZ	O
varied	VBN	O
widely	RB	O
in	IN	O
previous	JJ	O
studies	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
cases	NNS	O
of	IN	O
recurrent	JJ	Physical
tuberculosis	NN	Physical
in	IN	O
two	CD	O
prospective	JJ	O
clinical	JJ	O
trials	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
two	CD	O
regimens	NNS	O
for	IN	O
the	DT	O
last	JJ	O
4	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,075	CD	O
)	)	O
and	CC	O
a	DT	O
study	NN	O
of	IN	O
a	DT	O
twice-weekly	JJ	O
rifabutin-containing	JJ	O
regimen	NNS	O
for	IN	O
human	JJ	O
immunodeficiency	NN	O
virus-infected	JJ	O
tuberculosis	NN	O
(	(	O
n	JJ	O
=	NNP	O
169	CD	O
)	)	O
.	.	O

Isolates	VBZ	O
at	IN	O
diagnosis	NN	O
and	CC	O
from	IN	O
positive	JJ	O
cultures	NNS	O
after	IN	O
treatment	NN	O
completion	NN	O
underwent	NN	O
genotyping	VBG	O
using	VBG	O
IS6110	NNP	O
(	(	O
with	IN	O
secondary	JJ	O
genotyping	NN	O
for	IN	O
isolates	NNS	O
with	IN	O
less	JJR	O
than	IN	O
six	CD	O
copies	NNS	O
of	IN	O
IS6110	NNP	O
)	)	O
.	.	O

Of	IN	O
85	CD	O
patients	NNS	O
having	VBG	O
a	DT	O
positive	JJ	O
culture	NN	O
after	IN	O
completing	VBG	O
treatment	NN	O
,	,	O
6	CD	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
were	VBD	O
classified	VBN	O
as	IN	O
false-positive	JJ	O
cultures	NNS	O
by	IN	O
a	DT	O
review	NN	O
committee	NN	O
blinded	VBD	O
to	TO	O
treatment	NN	O
assignment	NN	O
.	.	O

Of	IN	O
the	DT	O
remaining	VBG	O
75	CD	O
cases	NNS	O
with	IN	O
recurrent	JJ	O
tuberculosis	NN	O
and	CC	O
genotyping	VBG	O
data	NNS	O
available	JJ	O
,	,	O
72	CD	O
(	(	O
96	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
88.8-99.2	CD	O
%	NN	O
)	)	O
paired	VBD	O
isolates	NNS	O
had	VBD	O
the	DT	O
same	JJ	O
genotype	NN	O
;	:	O
only	RB	O
3	CD	O
(	(	O
4	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.8-11.2	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
different	JJ	O
genotype	NN	O
and	CC	O
were	VBD	O
categorized	VBN	O
as	IN	O
reinfection	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
recurrent	NN	O
tuberculosis	NN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
,	,	O
countries	NNS	O
with	IN	O
low	JJ	O
rates	NNS	O
of	IN	O
tuberculosis	NN	O
,	,	O
is	VBZ	O
rarely	RB	O
due	JJ	O
to	TO	O
reinfection	VB	O
with	IN	O
a	DT	O
new	JJ	O
strain	NN	O
of	IN	O
M.	NNP	O
tuberculosis	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
lidocaine	NN	O
in	IN	O
human	JJ	O
inferior	JJ	O
alveolar	JJ	O
nerve	NN	O
block	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
measure	VB	O
the	DT	O
degree	NN	Physical
of	IN	Physical
anesthesia	NN	Physical
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
3.6	CD	O
ml	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	JJ	O
solutions	NNS	O
with	IN	O
either	DT	O
1:50,000	CD	O
,	,	O
1:80,000	CD	O
,	,	O
or	CC	O
1:100,000	CD	O
for	IN	O
inferior	JJ	O
alveolar	JJ	O
nerve	NN	O
block	NN	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
results	NNS	O
with	IN	O
those	DT	O
obtained	VBN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
1.8	CD	O
ml	NN	O
of	IN	O
the	DT	O
same	JJ	O
solutions	NNS	O
(	(	O
1	CD	O
)	)	O
.	.	O

With	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
repeated	JJ	O
measures	NNS	O
design	NN	O
,	,	O
30	CD	O
subjects	NNS	O
randomly	RB	O
received	VBD	O
an	DT	O
inferior	JJ	O
alveolar	JJ	O
injection	NN	O
at	IN	O
three	CD	O
successive	JJ	O
appointments	NNS	O
.	.	O

The	DT	O
first	JJ	O
molar	NN	O
,	,	O
first	RB	O
premolar	JJ	O
,	,	O
lateral	JJ	O
incisor	NN	O
,	,	O
and	CC	O
contralateral	JJ	O
canine	NN	O
(	(	O
control	NN	O
)	)	O
were	VBD	O
blindly	RB	O
tested	VBN	O
with	IN	O
an	DT	O
Analytic	NNP	O
Technology	NNP	O
pulp	NN	O
tester	NN	O
at	IN	O
3-min	JJ	O
cycles	NNS	O
for	IN	O
50	CD	O
min	NN	O
.	.	O

The	DT	O
degree	NN	Physical
of	IN	Physical
anesthesia	NN	Physical
was	VBD	O
comparable	JJ	O
for	IN	O
the	DT	O
three	CD	O
solutions	NNS	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
3.6	CD	O
ml	NNS	O
of	IN	O
each	DT	O
solution	NN	O
.	.	O

Retrospective	JJ	O
evaluation	NN	O
showed	VBD	O
that	IN	O
the	DT	O
volume	NN	O
of	IN	O
the	DT	O
solution	NN	O
influenced	VBD	O
the	DT	O
degree	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
knee	NN	O
position	NN	O
on	IN	O
blood	NN	Physical
loss	NN	Physical
and	CC	O
range	NN	Physical
of	IN	Physical
motion	NN	Physical
following	VBG	O
total	JJ	O
knee	JJ	O
arthroplasty	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
prospectively	RB	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
knee	JJ	O
position	NN	O
on	IN	O
blood	NN	Physical
loss	NN	Physical
and	CC	O
range	NN	Physical
of	IN	Physical
motion	NN	Physical
after	IN	O
primary	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
(	(	O
TKA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
ten	VB	O
consecutive	JJ	O
TKA	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
flexion	NN	O
group	NN	O
and	CC	O
extension	NN	O
group	NN	O
.	.	O

Both	DT	O
groups	NNS	O
had	VBD	O
the	DT	O
leg	NN	O
elevated	VBD	O
30?	CD	O
at	IN	O
the	DT	O
hip	NN	O
over	IN	O
an	DT	O
inactive	JJ	O
CPM	NNP	O
for	IN	O
72	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

The	DT	O
flexion	NN	O
group	NN	O
had	VBD	O
the	DT	O
knee	NN	O
flexed	VBD	O
to	TO	O
30?	CD	O
during	IN	O
this	DT	O
period	NN	O
.	.	O

The	DT	O
extension	NN	O
group	NN	O
had	VBD	O
the	DT	O
knee	NN	O
extended	VBD	O
fully	RB	O
.	.	O

Perioperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
hidden	JJ	O
blood	NN	O
loss	NN	O
,	,	O
knee	NN	O
swelling	NN	O
,	,	O
ecchymosis	NN	O
,	,	O
analgesia	NN	O
requirements	NNS	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
fixed	VBN	O
flexion	NN	O
deformity	NN	O
(	(	O
FFD	NNP	O
)	)	O
,	,	O
straight-leg	JJ	O
raising	VBG	O
action	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
complications	NNS	O
within	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
surgery	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
evaluation	NN	O
and	CC	O
comparison	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
postoperative	JJ	O
hidden	JJ	O
blood	NN	O
loss	NN	O
,	,	O
knee	NN	O
swelling	NN	O
,	,	O
and	CC	O
scope	NN	O
of	IN	O
ecchymosis	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flexion	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
extension	NN	O
group	NN	O
,	,	O
and	CC	O
ROM	NNP	O
and	CC	O
straight-leg	JJ	O
raising	VBG	O
action	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
during	IN	O
the	DT	O
early	JJ	O
period	NN	O
after	IN	O
operation	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
perioperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
morphine	NN	O
used	VBN	O
,	,	O
or	CC	O
FFD	NNP	O
in	IN	O
the	DT	O
early	JJ	O
postoperative	JJ	O
period	NN	O
or	CC	O
in	IN	O
ROM	NNP	O
and	CC	O
FFD	NNP	O
at	IN	O
6	CD	O
weeks	NNS	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
flexion	NN	O
of	IN	O
the	DT	O
knee	NN	O
to	TO	O
30?	CD	O
with	IN	O
the	DT	O
leg	NN	O
elevated	VBD	O
30?	CD	O
at	IN	O
the	DT	O
hip	NN	O
after	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
may	MD	O
mitigate	VB	O
knee	NN	O
swelling	VBG	O
and	CC	O
provide	VB	O
other	JJ	O
beneficial	JJ	O
results	NNS	O
during	IN	O
the	DT	O
early	JJ	O
rehabilitation	NN	O
following	VBG	O
TKA	NNP	O
.	.	O

LEVEL	NNP	O
OF	IN	O
EVIDENCE	NNP	O
Prospective	NNP	O
comparative	NN	O
study	NN	O
,	,	O
Level	NNP	O
I	PRP	O
.	.	O

Randomized	VBN	O
study	NN	O
of	IN	O
chlorambucil	NN	O
(	(	O
CB	NNP	O
)	)	O
compared	VBN	O
to	TO	O
interferon	VB	O
(	(	O
alfa-2b	JJ	O
)	)	O
combined	VBN	O
with	IN	O
CB	NNP	O
in	IN	O
low-grade	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
:	:	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Non-Hodgkin	NNP	O
's	POS	O
Lymphoma	NNP	O
Cooperative	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Alpha	NNP	O
interferon	NN	O
has	VBZ	O
shown	VBN	O
initial	JJ	O
promise	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
low-grade	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
(	(	O
NHL	NNP	O
)	)	O
,	,	O
especially	RB	O
with	IN	O
the	DT	O
nodular	JJ	O
form	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
enrolled	VBD	O
70	CD	O
NHL	NNP	O
patients	NNS	O
who	WP	O
received	VBD	O
either	CC	O
chlorambucil	NN	O
(	(	O
CB	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
)	)	O
or	CC	O
CB	NNP	O
plus	CC	O
interferon	JJ	O
alfa-2b	NN	O
(	(	O
5	CD	O
million	CD	O
units	NNS	O
(	(	O
MU	NNP	O
)	)	O
/m2	VBD	O
subcutaneously	RB	O
three	CD	O
times	NNS	O
a	DT	O
week	NN	O
)	)	O
.	.	O

Among	IN	O
63	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
similar	JJ	O
response	NN	O
rates	NNS	O
(	(	O
62.1	CD	O
%	NN	O
and	CC	O
64.7	CD	O
%	NN	O
respectively	RB	O
)	)	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
arms	NNS	O
.	.	O

In	IN	O
patients	NNS	O
receiving	VBG	O
no	DT	O
maintenance	NN	O
therapy	NN	O
,	,	O
those	DT	O
who	WP	O
received	VBD	O
interferon	JJ	O
alfa-2b	JJ	O
during	IN	O
the	DT	O
induction	NN	O
phase	NN	O
showed	VBD	O
a	DT	O
favourable	JJ	O
trend	NN	O
in	IN	O
terms	NNS	O
of	IN	O
incidence	NN	Physical
of	IN	Physical
relapse	NN	Physical
compared	VBN	O
to	TO	O
those	DT	O
who	WP	O
had	VBD	O
received	VBN	O
chlorambucil	NN	O
alone	RB	O
.	.	O

During	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
interferon	JJ	O
alfa-2b	NN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
occurrence	NN	Physical
of	IN	Physical
relapse	NN	Physical
have	VBP	O
yet	RB	O
been	VBN	O
seen	VBN	O
compared	VBN	O
to	TO	O
patients	NNS	O
on	IN	O
no	DT	O
maintenance	NN	O
therapy	NN	O
.	.	O

A	NNP	O
longer	JJR	O
observation	NN	O
period	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
make	VB	O
a	DT	O
definitive	JJ	O
conclusion	NN	O
about	IN	O
the	DT	O
usefulness	NN	O
of	IN	O
interferon	JJ	O
maintenance	NN	O
therapy	NN	O
and	CC	O
to	TO	O
evaluate	VB	O
further	RBR	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
combined	JJ	O
schedule	NN	O
of	IN	O
chlorambucil	NN	O
and	CC	O
interferon	NN	O
induction	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
remission	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
granules	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
clinical	JJ	O
therapeutic	JJ	Adverseeffect
effect	NN	Adverseeffect
of	IN	O
acupuncture	NN	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
and	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
intelligence	NN	Physical
,	,	Physical
daily	JJ	Physical
life	NN	Physical
and	CC	Physical
social	JJ	Physical
activity	NN	Physical
ability	NN	Physical
.	.	Physical

METHODS	NNP	O
Eighty-four	JJ	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
,	,	O
28	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
acupuncture	NN	O
at	IN	O
Baihui	NNP	O
(	(	O
GV	NNP	O
20	CD	O
)	)	O
,	,	O
Sishencong	NNP	O
(	(	O
EX-HN	NNP	O
1	CD	O
)	)	O
,	,	O
Dazhui	NNP	O
(	(	O
GV	NNP	O
14	CD	O
)	)	O
,	,	O
Guanyuan	NNP	O
(	(	O
CV	NNP	O
4	CD	O
)	)	O
,	,	O
etc	FW	O
.	.	O

and	CC	O
oral	JJ	O
administration	NN	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
;	:	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
,	,	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
with	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Aricept	NNP	O
.	.	O

The	DT	O
scores	NNS	Others
for	IN	Others
the	DT	Others
Mini-Mental	JJ	Others
State	NNP	Others
Examination	NNP	Others
(	(	Others
MMSE	NNP	Others
)	)	Others
,	,	O
Ability	NNP	Physical
of	IN	Physical
Daily	NNP	Physical
Life	NNP	Physical
(	(	Physical
ADL	NNP	Physical
)	)	Physical
and	CC	O
the	DT	Adverseeffect
therapeutic	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
assessed	VBN	O
and	CC	O
compared	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
after	IN	O
treatment	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
MMSE	NNP	Physical
and	CC	Physical
ADL	NNP	Physical
were	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
,	,	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
,	,	O
which	WDT	O
were	VBD	O
better	RBR	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
total	JJ	Physical
effective	JJ	Physical
rate	NN	Physical
of	IN	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	O
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
71.4	CD	O
%	NN	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
67.9	CD	O
%	NN	O
in	IN	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Acupuncture	NNP	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
has	VBZ	O
a	DT	O
significant	JJ	O
therapeutic	JJ	Physical
effect	NN	Physical
on	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
which	WDT	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
or	CC	O
Aricept	NNP	O
.	.	O

[	RB	O
Clinical	NNP	O
study	NN	O
on	IN	O
treatment	NN	O
of	IN	O
endometriosis-related	JJ	O
infertility	NN	O
patients	NNS	O
by	IN	O
laparoscopic	NN	O
surgery	NN	O
in	IN	O
combination	NN	O
of	IN	O
quyu	JJ	O
jiedu	NN	O
recipe	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
clinical	JJ	Others
efficacy	NN	Others
of	IN	O
the	DT	O
laparoscopic	NN	O
surgery	NN	O
in	IN	O
combination	NN	O
of	IN	O
Quyu	NNP	O
Jiedu	NNP	O
Recipe	NNP	O
(	(	O
QYJDR	NNP	O
)	)	O
on	IN	O
endometriosis	NN	O
(	(	O
EMs	NNP	O
)	)	O
-related	VBD	O
infertility	NN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
130	CD	O
EMs-related	JJ	O
infertility	NN	O
patients	NNS	O
of	IN	O
blood	NN	O
stasis	NN	O
and	CC	O
toxin	NN	O
accumulation	NN	O
syndrome	NN	O
diagnosed	VBD	O
and	CC	O
treated	VBN	O
by	IN	O
laparoscopic	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
i.e.	FW	O
,	,	O
the	DT	O
test	NN	O
group	NN	O
(	(	O
75	CD	O
cases	NNS	O
)	)	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
55	CD	O
cases	NNS	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
routine	JJ	O
progesterone	NN	O
treatment	NN	O
after	IN	O
laparoscopic	NN	O
surgery	NN	O
.	.	O

QYJDR	NNP	O
was	VBD	O
given	VBN	O
to	TO	O
patients	NNS	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
after	IN	O
laparoscopic	NN	O
surgery	NN	O
,	,	O
lasting	VBG	O
for	IN	O
twelve	JJ	O
months	NNS	O
.	.	O

The	DT	O
pregnancy	NN	Physical
rate	NN	Physical
within	IN	O
one	CD	O
year	NN	O
after	IN	O
laparoscopic	NN	O
surgery	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
Chinese	JJ	Physical
medicine	NN	Physical
syndrome	NN	Physical
integrals	NNS	Physical
,	,	Physical
serum	JJ	Physical
endometrium	NN	Physical
antibody	NN	Physical
(	(	Physical
EMAb	NNP	Physical
)	)	Physical
and	CC	Physical
cancer	NN	Physical
antigen	NN	Physical
125	CD	Physical
(	(	Physical
CA125	NNP	Physical
)	)	Physical
levels	NNS	Physical
were	VBD	O
compared	VBN	O
between	IN	O
before	RB	O
drug	NN	O
therapy	NN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
drug	NN	O
therapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
pregnancy	NN	Physical
rate	NN	Physical
within	IN	O
one	CD	O
year	NN	O
after	IN	O
laparoscopic	NN	O
surgery	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
[	VBD	O
61.33	CD	O
%	NN	O
(	(	O
46/75	CD	O
)	)	O
vs	FW	O
45.45	CD	O
%	NN	O
(	(	O
25/55	CD	O
)	)	O
]	NN	O
,	,	O
showing	VBG	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
Chinese	JJ	Physical
medicine	NN	Physical
syndrome	JJ	Physical
integral	NN	Physical
was	VBD	O
(	(	O
16.07	CD	O
+/-	JJ	O
6.77	CD	O
)	)	O
score	NN	O
and	CC	O
(	(	O
7.25	CD	O
+/-	JJ	O
3.27	CD	O
)	)	O
score	NN	O
before	IN	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
(	(	O
15.92	CD	O
+/-	JJ	O
7.51	CD	O
)	)	O
score	NN	O
and	CC	O
(	(	O
12.73	CD	O
+/-	JJ	O
6.12	CD	O
)	)	O
score	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
Chinese	JJ	Physical
medicine	NN	Physical
syndrome	JJ	Physical
integral	JJ	Physical
after	IN	O
drug	NN	O
therapy	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
before	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
the	DT	O
same	JJ	O
group	NN	O
.	.	O

Besides	IN	O
,	,	O
the	DT	O
integral	JJ	O
difference	NN	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
drug	NN	O
therapy	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
[	NNP	O
(	(	O
9.12	CD	O
+/-	JJ	O
6.16	CD	O
)	)	O
score	NN	O
vs	NN	O
(	(	O
3.48	CD	O
+/-	JJ	O
2.06	CD	O
)	)	O
score	NN	O
)	)	O
]	NN	O
,	,	O
showing	VBG	O
statistical	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
three-month	JJ	O
drug	NN	O
therapy	NN	O
,	,	O
the	DT	O
serum	NN	Physical
EMAb	NNP	Physical
negative	JJ	Physical
conversion	NN	Physical
rate	NN	Physical
was	VBD	O
obviously	RB	O
higher	JJR	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
44.44	CD	O
%	NN	O
vs	JJ	O
15.62	CD	O
%	NN	O
)	)	O
,	,	O
showing	VBG	O
statistical	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
serum	NN	Physical
CA125	NNP	Physical
level	NN	Physical
was	VBD	O
(	(	O
31.88	CD	O
+/-	JJ	O
15.78	CD	O
)	)	O
U/mL	NNP	O
before	IN	O
drug	NN	O
therapy	NN	O
and	CC	O
(	(	O
18.82	CD	O
+/-	JJ	O
10.08	CD	O
)	)	O
U/mL	NNP	O
three	CD	O
months	NNS	O
after	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
the	DT	O
test	NN	O
group	NN	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
(	(	O
30.63	CD	O
+/-	JJ	O
19.28	CD	O
)	)	O
U/mL	NN	O
and	CC	O
(	(	O
18.05	CD	O
+/-	JJ	O
11.20	CD	O
)	)	O
U/mL	NNP	O
respectively	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

It	PRP	O
was	VBD	O
lowered	VBN	O
after	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
statistical	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
after	IN	O
drug	NN	O
therapy	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
laparoscopic	NN	O
surgery	NN	O
in	IN	O
combination	NN	O
of	IN	O
QYJDR	NNP	O
could	MD	O
effectively	RB	O
improve	VB	O
clinical	JJ	O
symptoms	NNS	O
of	IN	O
EMs	NNP	O
patients	NNS	O
of	IN	O
blood	NN	Physical
stasis	NN	Physical
and	CC	O
toxin	NN	Physical
accumulation	NN	Physical
syndrome	NN	Physical
,	,	O
promote	VBP	O
negative	JJ	Physical
conversion	NN	Physical
of	IN	Physical
EMAb	NNP	Physical
,	,	O
lower	JJR	O
serum	NN	Physical
CA125	NNP	Physical
levels	NNS	Physical
,	,	O
and	CC	O
elevate	VB	O
the	DT	O
clinical	JJ	Physical
pregnancy	NN	Physical
rate	NN	Physical
.	.	O

QYJDR	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
formula	NN	O
in	IN	O
treatment	NN	O
of	IN	O
EMs-related	JJ	Physical
infertility	NN	Physical
.	.	O

Ambulation	NN	O
in	IN	O
labour	NN	O
.	.	O

In	IN	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
study	NN	O
of	IN	O
68	CD	O
women	NNS	O
in	IN	O
spontaneous	JJ	O
labour	JJ	O
half	NN	O
were	VBD	O
allocated	VBN	O
to	TO	O
an	DT	O
ambulant	JJ	O
group	NN	O
and	CC	O
half	NN	O
to	TO	O
a	DT	O
recumbent	NN	O
group	NN	O
.	.	O

The	DT	O
duration	NN	Others
of	IN	Others
labour	NN	Others
was	VBD	O
significantly	RB	O
shorter	JJR	O
,	,	O
the	DT	O
need	NN	Pain
for	IN	Pain
analgesia	NN	Pain
significantly	RB	O
less	RBR	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
fetal	JJ	Physical
heart	NN	Physical
abnormalities	NNS	Physical
significantly	RB	O
smaller	JJR	O
in	IN	O
the	DT	O
ambulant	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
recumbent	NN	O
group	NN	O
.	.	O

Apgar	NNP	Physical
scores	VBZ	Physical
at	IN	O
one	CD	O
and	CC	O
five	CD	O
minutes	NNS	O
were	VBD	O
also	RB	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
ambulant	JJ	O
group	NN	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
recumbent	NN	O
group	NN	O
required	VBD	O
augmentations	NNS	Others
with	IN	Others
oxytocic	JJ	Others
drugs	NNS	Others
.	.	Others

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
third	JJ	Others
stage	NN	Others
loss	NN	Others
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Ambulation	NNP	O
in	IN	O
labour	NN	O
should	MD	O
be	VB	O
encouraged	VBN	O
:	:	O
it	PRP	O
may	MD	O
bring	VB	O
human	JJ	O
benefits	NNS	O
while	IN	O
allowing	VBG	O
the	DT	O
advantages	NNS	O
of	IN	O
hospital	JJ	O
supervision	NN	O
.	.	O

Effects	NNS	O
of	IN	O
piracetam	NN	O
on	IN	O
regional	JJ	O
cerebral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	O
mental	JJ	Mental
functions	NNS	Mental
in	IN	O
patients	NNS	O
with	IN	O
organic	JJ	O
dementia	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
piracetam	NN	O
(	(	O
Nootropil	NNP	O
,	,	O
UCB6215	NNP	O
)	)	O
on	IN	O
mental	JJ	Mental
functions	NNS	Mental
and	CC	O
on	IN	O
regional	JJ	Physical
cerebral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
(	(	Physical
rCBF	NN	Physical
)	)	Physical
were	VBD	O
investigated	VBN	O
in	IN	O
eight	CD	O
patients	NNS	O
in	IN	O
the	DT	O
presenile	JJ	O
age	NN	O
who	WP	O
displayed	VBD	O
symptoms	NNS	O
of	IN	O
moderate	JJ	O
dementia	NN	O
.	.	O

The	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
included	VBD	O
nine	CD	O
measurement	NN	O
occasions	NNS	O
,	,	O
each	DT	O
involving	VBG	O
rCBF	NN	Physical
measurement	NN	Physical
by	IN	O
the	DT	O
133-Xe	JJ	O
inhalation	NN	O
method	NN	O
,	,	O
ratings	NNS	O
of	IN	O
symptoms	NNS	O
of	IN	O
dementia	NN	O
,	,	O
personality	NN	O
changes	NNS	O
,	,	O
and	CC	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
a	DT	O
psychometric	JJ	O
investigation	NN	O
.	.	O

Three	CD	O
investigations	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
each	DT	O
of	IN	O
three	CD	O
treatment	NN	O
periods	NNS	O
.	.	O

The	DT	O
first	JJ	O
investigation	NN	O
in	IN	O
a	DT	O
period	NN	O
was	VBD	O
made	VBN	O
without	IN	O
medication	NN	O
.	.	O

Then	RB	O
either	DT	O
placebo	NN	O
or	CC	O
piracetam	VB	O
4.8	CD	O
g/day	NN	O
or	CC	O
9.6	CD	O
g/day	NN	O
was	VBD	O
given	VBN	O
during	IN	O
four	CD	O
weeks	NNS	O
with	IN	O
measurements	NNS	O
after	IN	O
2	CD	O
weekks	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
.	.	O

There	EX	O
were	VBD	O
intervals	NNS	O
of	IN	O
4	CD	O
weeks	NNS	O
without	IN	O
medication	NN	O
between	IN	O
the	DT	O
treatment	NN	O
periods	NNS	O
.	.	O

Piracetam	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
either	CC	O
mental	JJ	Mental
functions	NNS	Mental
or	CC	O
rCBF	NN	Mental
.	.	O

Effects	NNS	O
of	IN	O
application	NN	O
in	IN	O
spring	NN	O
of	IN	O
urea	JJ	O
fertiliser	NN	O
on	IN	O
aspects	NNS	O
of	IN	O
reproductive	JJ	O
performance	NN	O
of	IN	O
pasture-fed	JJ	O
dairy	NN	O
cows	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
assess	VB	O
if	IN	O
raising	VBG	O
concentrations	NNS	O
of	IN	O
crude	NN	O
protein	NN	O
(	(	O
CP	NNP	O
)	)	O
in	IN	O
pasture	NN	O
in	IN	O
spring	NN	O
by	IN	O
the	DT	O
frequent	JJ	O
application	NN	O
of	IN	O
urea	JJ	O
fertiliser	NN	O
would	MD	O
affect	VB	O
ovarian	JJ	Physical
follicular	JJ	Physical
dynamics	NNS	Physical
,	,	O
luteal	JJ	Physical
function	NN	Physical
,	,	O
onset	NN	Physical
of	IN	Physical
oestrus	NN	Physical
and	CC	O
reproductive	JJ	Physical
performance	NN	Physical
of	IN	O
dairy	NN	O
cows	NNS	O
under	IN	O
farming	VBG	O
conditions	NNS	O
in	IN	O
New	NNP	O
Zealand	NNP	O
.	.	O

METHODS	NNP	O
Spring-calved	JJ	O
dairy	NN	O
cows	NNS	O
were	VBD	O
grazed	VBN	O
for	IN	O
101	CD	O
days	NNS	O
in	IN	O
paddocks	NNS	O
that	WDT	O
were	VBD	O
either	RB	O
not	RB	O
fertilised	VBN	O
(	(	O
Control	NNP	O
;	:	O
n=20	CC	O
)	)	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
or	CC	O
were	VBD	O
fertilised	VBN	O
with	IN	O
40-50	JJ	O
kg	NNS	O
nitrogen	NN	O
(	(	O
N	NNP	O
)	)	O
/ha	VBP	O
every	DT	O
4-6	JJ	O
weeks	NNS	O
(	(	O
High-N	NNP	O
;	:	O
n=20	NN	O
)	)	O
.	.	O

Similar	JJ	O
generous	JJ	O
pasture	NN	O
allowances	NNS	O
were	VBD	O
offered	VBN	O
to	TO	O
both	DT	O
groups	NNS	O
.	.	O

Concentrations	NNS	Physical
of	IN	Physical
CP	NNP	Physical
in	IN	Physical
pasture	NN	Physical
,	,	O
urea	JJ	Physical
in	IN	Physical
serum	NN	Physical
and	CC	O
progesterone	NN	Physical
in	IN	Physical
milk	NN	Physical
were	VBD	O
measured	VBN	O
.	.	O

Ovarian	JJ	Physical
follicular	NN	Physical
and	CC	Physical
luteal	JJ	Physical
dynamics	NNS	Physical
were	VBD	O
determined	VBN	O
using	VBG	O
ultrasonography	NN	O
.	.	O

Oestrous	JJ	Others
behaviour	NN	Others
and	CC	Others
the	DT	Others
number	NN	Others
,	,	Others
time	NN	Others
and	CC	Others
outcome	NN	Others
of	IN	Others
inseminations	NNS	Others
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	Physical
concentrations	NNS	Physical
of	IN	Physical
CP	NNP	Physical
in	IN	Physical
pasture	NN	Physical
and	CC	Others
urea	NN	Physical
in	IN	Physical
serum	NN	Physical
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
High-N	NNP	O
than	IN	O
the	DT	O
Control	NNP	O
group	NN	O
(	(	O
25.2	CD	O
vs	NN	O
21.6	CD	O
and	CC	O
8.3	CD	O
vs	NN	O
5.4	CD	O
mmol/L	NN	O
for	IN	O
CP	NNP	O
and	CC	O
urea	JJ	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
<	$	O
0.001	CD	O
)	)	O
.	.	O

Intervals	NNS	Physical
between	IN	Physical
calving	VBG	Physical
and	CC	Physical
first	JJ	Physical
oestrus	NN	Physical
,	,	O
first	JJ	Physical
insemination	NN	Physical
and	CC	Physical
conception	NN	Physical
,	,	O
the	DT	Physical
time	NN	Physical
of	IN	Physical
first	JJ	Physical
emergence	NN	Physical
of	IN	Physical
a	DT	Physical
dominant	JJ	Physical
follicle	NN	Physical
,	,	O
milk	NN	Physical
progesterone	NN	Physical
concentration	NN	Physical
,	,	O
and	CC	O
the	DT	O
diameter	NN	Physical
of	IN	Physical
the	DT	Physical
corpus	NN	Physical
luteum	NN	Physical
(	(	Physical
CL	NNP	Physical
)	)	Physical
in	IN	Physical
the	DT	Physical
first	JJ	Physical
luteal	JJ	Physical
phase	NN	Physical
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
interval	NN	Physical
from	IN	Physical
calving	VBG	Physical
to	TO	Physical
first	JJ	Physical
ovulation	NN	Physical
tended	VBN	O
(	(	O
p=0.10	NN	O
)	)	O
to	TO	O
be	VB	O
lower	JJR	O
and	CC	O
the	DT	O
diameter	NN	Physical
of	IN	Physical
the	DT	Physical
dominant	JJ	Physical
follicle	NN	Physical
of	IN	Physical
the	DT	Physical
oestrous	JJ	Physical
cycle	NN	Physical
at	IN	Physical
which	WDT	Physical
cows	VBZ	Physical
conceived	VBN	Others
was	VBD	O
greater	JJR	O
(	(	O
p=0.02	NN	O
)	)	O
in	IN	O
Control	NNP	O
than	IN	O
High-N	NNP	O
cows	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
large	JJ	O
amounts	NNS	O
of	IN	O
urea	JJ	O
fertiliser	NN	O
during	IN	O
spring	NN	O
and	CC	O
the	DT	O
consequent	NN	O
increases	NNS	O
in	IN	O
concentrations	NNS	Physical
of	IN	Physical
CP	NNP	Physical
in	IN	Physical
pasture	NN	Physical
and	CC	Others
urea	NN	Physical
in	IN	Physical
serum	NN	Physical
did	VBD	O
not	RB	O
negatively	RB	O
affect	JJ	O
any	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
of	IN	O
reproductive	JJ	Physical
performance	NN	Physical
of	IN	O
pasture-fed	JJ	O
dairy	NN	O
cows	NNS	O
that	WDT	O
were	VBD	O
assessed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Effect	NN	O
of	IN	O
ischemic	JJ	Physical
postconditioning	NN	Physical
in	IN	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

Inappropriate	NNP	O
myocardial	JJ	O
protection	NN	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
main	JJ	O
causes	NNS	O
of	IN	O
mortality	NN	O
and	CC	O
morbidity	NN	O
in	IN	O
the	DT	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
(	(	O
TOF	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
previous	JJ	O
reports	NNS	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
on	IN	O
myocardial	JJ	Physical
protection	NN	Physical
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
are	VBP	O
very	RB	O
encouraging	JJ	O
.	.	O

This	DT	O
randomized	JJ	O
and	CC	O
controlled	JJ	O
trial	NN	O
aimed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ischemic	JJ	Physical
postconditioning	VBG	Physical
on	IN	O
protection	NN	Physical
against	IN	Physical
myocardial	JJ	Physical
ischemia	NN	Physical
reperfusion	NN	O
injury	NN	O
in	IN	O
TOF	NNP	O
patients	NNS	O
receiving	VBG	O
cardioplegia	NN	O
.	.	O

From	IN	O
January	NNP	O
2008	CD	O
to	TO	O
June	NNP	O
2010	CD	O
,	,	O
80	CD	O
consecutive	JJ	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
TOF	NNP	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
postconditioning	NN	O
group	NN	O
(	(	O
three	CD	O
cycles	NNS	O
of	IN	O
30	CD	O
seconds	NNS	O
of	IN	O
ischemia	NN	O
and	CC	O
30	CD	O
seconds	NNS	O
of	IN	O
reperfusion	NN	O
using	VBG	O
re-clamping	JJ	O
and	CC	O
de-clamping	JJ	O
starting	VBG	O
30	CD	O
seconds	NNS	O
after	IN	O
the	DT	O
initial	JJ	O
de-clamping	NN	O
of	IN	O
the	DT	O
aorta	NN	O
,	,	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
.	.	O

Cardiac	NNP	Physical
troponin	NN	Physical
I	PRP	Physical
(	(	O
cTnI	NN	O
)	)	O
was	VBD	O
assayed	VBN	O
preoperatively	RB	O
,	,	O
and	CC	O
then	RB	O
4	CD	O
hours	NNS	O
,	,	O
8	CD	O
hours	NNS	O
,	,	O
12	CD	O
hours	NNS	O
,	,	O
20	CD	O
hours	NNS	O
,	,	O
and	CC	O
48	CD	O
hours	NNS	O
after	IN	O
persistent	JJ	O
reperfusion	NN	O
.	.	O

The	DT	O
pre-	JJ	O
,	,	O
intra-	JJ	O
and	CC	O
postoperative	JJ	O
relevant	JJ	O
data	NNS	O
of	IN	O
all	DT	O
selected	VBN	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
reduced	VBD	O
postoperative	JJ	Others
peak	NN	Others
release	NN	Others
by	IN	O
45	CD	O
%	NN	O
for	IN	O
cTnI	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
0.43	CD	O
?	.	O
0.18	CD	O
ng/mL	JJ	O
versus	NN	O
0.78	CD	O
?	.	O
0.15	CD	O
ng/mL	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Ischemic	NNP	O
postconditioned	VBD	O
patients	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
peak	NN	O
inotropic	NN	O
score	NN	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
(	(	O
5.6	CD	O
?	.	O
2.2	CD	O
?g/kg/minute	JJ	O
versus	NN	O
8.6	CD	O
?	.	O
3.6	CD	O
?g/kg/minute	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
extubation	JJ	O
time	NN	O
(	(	O
21.5	CD	O
?	.	O
7.3	CD	O
hours	NNS	O
versus	IN	O
30.2	CD	O
?	.	O
12.4	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
and	CC	O
length	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
(	(	O
43.4	CD	O
?	.	O
12.6	CD	O
hours	NNS	O
versus	IN	O
56.3	CD	O
?	.	O
17.8	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
while	IN	O
they	PRP	O
had	VBD	O
a	DT	O
higher	JJR	O
cardiac	JJ	O
output	NN	O
on	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
(	(	O
1.41	CD	O
?	.	O
0.26	CD	O
L/minute	NNP	O
versus	NN	O
1.28	CD	O
?	.	O
0.25	CD	O
L/minute	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.0255	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
may	MD	O
to	TO	O
some	DT	O
extent	NN	O
provide	VBP	O
myocardial	JJ	O
protection	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

Domperidone	NN	O
,	,	O
metoclopramide	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

All	DT	O
give	JJ	O
symptomatic	JJ	Others
improvement	NN	Others
in	IN	Others
gastroesophageal	JJ	Others
reflux	NN	Others
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
of	IN	O
two	CD	O
gastric	JJ	O
prokinetic	JJ	O
drugs	NNS	O
in	IN	O
23	CD	O
patients	NNS	O
with	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
a	DT	O
dual-isotope	JJ	O
mixed-meal	JJ	O
study	NN	O
of	IN	O
their	PRP$	O
gastric	JJ	O
emptying	NN	O
(	(	O
GE	NNP	O
)	)	O
.	.	O

Group	NNP	O
I	PRP	O
had	VBD	O
normal	JJ	O
GE	NNP	O
and	CC	O
group	NN	O
II	NNP	O
delayed	VBD	O
GE	NNP	O
.	.	O

Nine	NNP	O
gastrointestinal	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
frequency	NN	O
and	CC	O
severity	NN	O
before	IN	O
treatment	NN	O
.	.	O

The	DT	O
trial	NN	O
had	VBD	O
three	CD	O
1-month	JJ	O
treatment	NN	O
periods	NNS	O
using	VBG	O
metoclopramide	RB	O
10	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
domperidone	NN	O
20	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
or	CC	O
placebo	NN	O
on	IN	O
a	DT	O
random	JJ	O
basis	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
reassessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
month	NN	O
.	.	O

Taken	NNP	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
the	DT	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
symptomatic	JJ	Physical
response	NN	Physical
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
patients	NNS	O
with	IN	O
delayed	JJ	O
or	CC	O
normal	JJ	O
GE	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
their	PRP$	O
symptomatic	JJ	O
response	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
complained	VBD	O
of	IN	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
with	IN	O
metoclopramide	NN	O
and	CC	O
three	CD	O
stopped	VBD	O
therapy	NN	O
before	IN	O
the	DT	O
1-month	JJ	O
course	NN	O
was	VBD	O
completed	VBN	O
.	.	O

Two	CD	O
patients	NNS	O
described	JJ	O
side	JJ	O
effects	NNS	O
with	IN	O
domperidone	NN	O
,	,	O
including	VBG	O
one	CD	O
woman	NN	O
with	IN	O
galactorrhea	NN	Physical
after	IN	O
36	CD	O
h	NN	O
of	IN	O
treatment	NN	O
.	.	O

Three	CD	O
patients	NNS	O
on	IN	O
placebo	NN	O
also	RB	O
complained	VBD	O
of	IN	O
important	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
placebo	NN	O
effect	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
symptomatic	JJ	Others
improvement	NN	Others
between	IN	O
placebo	NN	O
,	,	O
domperidone	NN	O
,	,	O
and	CC	O
metoclopramide	RB	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
the	DT	O
monoamine	NN	O
oxidase	NN	O
B	NNP	O
inhibitor	NN	O
mofegiline	NN	O
assessed	VBN	O
during	IN	O
a	DT	O
phase	NN	O
I	PRP	O
dose	VBP	O
tolerance	JJ	O
trial	NN	O
.	.	O

The	DT	O
safety	NN	O
,	,	O
pharmacokinetics	NNS	O
,	,	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
48	CD	O
mg	NNS	O
and	CC	O
daily	JJ	O
(	(	O
for	IN	O
28	CD	O
days	NNS	O
)	)	O
doses	NNS	O
of	IN	O
up	IN	O
24	CD	O
mg	NNS	O
mofegiline	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

Plasma	NNP	O
pharmacokinetics	NNS	O
indicated	VBD	O
rapid	JJ	O
absorption	NN	O
and	CC	O
elimination	NN	O
:	:	O
time	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
concentration	NN	O
occurred	VBD	O
at	IN	O
about	IN	O
1	CD	O
hour	NN	O
;	:	O
half-life	JJ	O
ranged	VBD	O
from	IN	O
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
.	.	O

Maximal	NNP	Others
plasma	JJ	Others
concentration	NN	Others
and	CC	Others
area	NN	Others
under	IN	Others
the	DT	Others
plasma	JJ	Others
concentration-time	JJ	Others
curve	NN	Others
increased	VBD	O
and	CC	O
oral	JJ	O
clearance	NN	O
decreased	VBD	O
disproportionately	RB	O
with	IN	O
dose	JJ	O
.	.	O

Mofegiline	NNP	Physical
rapidly	RB	Physical
and	CC	Physical
markedly	RB	Physical
inhibited	JJ	Physical
platelet	NN	Physical
monoamine	NN	Physical
oxidase	NN	Physical
B	NNP	Physical
(	(	Physical
MAOB	NNP	Physical
)	)	Physical
activity	NN	Physical
,	,	O
which	WDT	O
returned	VBD	O
to	TO	O
baseline	VB	O
within	IN	O
14	CD	O
days	NNS	O
.	.	O

Urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
phenylethylamine	NN	Physical
increased	VBN	O
proportionately	RB	O
with	IN	O
doses	NNS	O
up	RB	O
to	TO	O
24	CD	O
mg.	NN	O
No	NNP	O
changes	NNS	O
in	IN	O
urinary	JJ	Physical
elimination	NN	Physical
of	IN	Physical
catecholamines	NNS	Physical
,	,	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	Physical
heart	NN	Physical
rate	NN	Physical
,	,	Physical
or	CC	Physical
ECG	NNP	Physical
were	VBD	O
observed	VBN	O
.	.	O

A	DT	O
classic	JJ	O
maximum	NN	Others
tolerated	VBD	Others
dose	NN	Others
was	VBD	O
not	RB	O
achieved	VBN	O
in	IN	O
these	DT	O
studies	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
48	CD	O
mg	NN	O
single	JJ	O
dose	NN	O
and	CC	O
the	DT	O
24	CD	O
mg	NN	O
multiple	JJ	O
daily	JJ	O
dose	NN	O
far	RB	O
exceeded	VBD	O
the	DT	O
dose	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
that	WDT	O
was	VBD	O
associated	VBN	O
with	IN	O
>	JJ	O
90	CD	O
%	NN	O
platelet	NN	O
MAOB	NNP	O
inhibition	NN	O
.	.	O

Postoperative	JJ	O
pain	NN	O
relief	NN	O
following	VBG	O
laparoscopic	NN	O
tubal	JJ	O
sterilization	NN	O
with	IN	O
silastic	JJ	O
bands	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
postoperative	JJ	O
pain	NN	O
relief	NN	O
of	IN	O
intramuscular	JJ	O
ketorolac	NN	O
,	,	O
topical	JJ	O
bupivacaine	NN	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
tubal	JJ	O
sterilization	NN	O
with	IN	O
silastic	JJ	O
bands	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
five	CD	O
women	NNS	O
undergoing	VBG	O
laparoscopic	NN	O
tubal	JJ	O
sterilization	NN	O
with	IN	O
silastic	JJ	O
bands	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
one	CD	O
received	VBD	O
intramuscular	JJ	O
ketorolac	NN	O
and	CC	O
topical	JJ	O
placebo	NN	O
applied	VBN	O
to	TO	O
the	DT	O
fallopian	JJ	O
tubes	NN	O
,	,	O
the	DT	O
second	JJ	O
received	VBD	O
intramuscular	JJ	O
placebo	NN	O
and	CC	O
topical	JJ	O
bupivacaine	NN	O
,	,	O
and	CC	O
the	DT	O
third	JJ	O
received	VBD	O
intramuscular	JJ	O
placebo	NN	O
and	CC	O
topical	JJ	O
placebo	NN	O
.	.	O

Surgical	JJ	O
procedures	NNS	O
,	,	O
anesthesia	NN	O
,	,	O
and	CC	O
recovery	NN	O
were	VBD	O
conducted	VBN	O
with	IN	O
standardized	JJ	O
protocols	NNS	O
.	.	O

Postoperative	JJ	O
pain	NN	O
perception	NN	O
was	VBD	O
graded	VBN	O
using	VBG	O
the	DT	O
modified	VBN	O
McGill	NNP	O
pain	VBP	O
intensity	NN	O
scale	NN	O
at	IN	O
30	CD	O
minutes	NNS	O
postoperatively	RB	O
,	,	O
at	IN	O
discharge	NN	O
from	IN	O
the	DT	O
recovery	NN	O
room	NN	O
,	,	O
and	CC	O
the	DT	O
next	JJ	O
morning	NN	O
by	IN	O
telephone	NN	O
interview	NN	O
.	.	O

Other	JJ	O
measured	VBD	O
variables	NNS	O
included	VBD	O
postoperative	JJ	O
vomiting	NN	O
,	,	O
additional	JJ	O
analgesia	NN	O
requirement	NN	O
,	,	O
and	CC	O
length	NN	O
of	IN	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
recovery	NN	O
room	NN	O
.	.	O

RESULTS	NNP	O
Only	RB	O
topical	JJ	O
bupivacaine	NN	O
was	VBD	O
found	VBN	O
to	TO	O
decrease	VB	O
postoperative	JJ	Pain
pain	NN	Pain
scores	NNS	Pain
significantly	RB	O
over	IN	O
those	DT	O
with	IN	O
placebo	NN	O
,	,	O
at	IN	O
30	CD	O
minutes	NNS	O
postoperatively	RB	O
(	(	O
median	JJ	O
score	NN	O
2	CD	O
compared	VBN	O
with	IN	O
4	CD	O
,	,	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
and	CC	O
at	IN	O
discharge	NN	O
from	IN	O
the	DT	O
recovery	NN	O
room	NN	O
(	(	O
median	JJ	O
score	NN	O
2	CD	O
compared	VBN	O
with	IN	O
3	CD	O
,	,	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
pain	NN	Pain
scores	NNS	Pain
with	IN	O
intramuscular	JJ	O
ketorolac	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
pain	NN	Pain
scores	NNS	Pain
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
at	IN	O
the	DT	O
next	JJ	O
morning	NN	O
phone	NN	O
call	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
requirements	NNS	Pain
for	IN	Pain
supplemental	JJ	Pain
pain	NN	Pain
medications	NNS	Pain
in	IN	O
the	DT	O
recovery	NN	O
room	NN	O
,	,	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
postoperative	JJ	Adverseeffect
vomiting	NN	Adverseeffect
,	,	O
or	CC	O
length	NN	Others
of	IN	Others
time	NN	Others
spent	VBN	Others
in	IN	Others
the	DT	Others
recovery	NN	Others
room	NN	Others
.	.	O

CONCLUSION	NNP	O
Topical	NNP	O
bupivacaine	NN	O
decreases	VBZ	O
postoperative	JJ	O
pain	NN	O
scores	NNS	O
significantly	RB	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
women	NNS	O
undergoing	VBG	O
laparoscopic	NN	O
tubal	JJ	O
sterilization	NN	O
with	IN	O
silastic	JJ	O
bands	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
insufficient	JJ	O
sleep	NN	O
on	IN	O
blood	NN	Physical
pressure	NN	Physical
in	IN	O
hypertensive	JJ	O
patients	NNS	O
:	:	O
a	DT	O
24-h	JJ	O
study	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
acute	JJ	O
sleep	JJ	O
deprivation	NN	O
during	IN	O
the	DT	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
night	NN	O
on	IN	O
24-h	JJ	O
blood	NN	Physical
pressure	NN	Physical
monitoring	NN	O
(	(	O
ABPM	NNP	O
)	)	O
was	VBD	O
studied	VBN	O
in	IN	O
36	CD	O
never-treated	JJ	O
mild	NN	O
to	TO	O
moderate	VB	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

According	VBG	O
to	TO	O
a	DT	O
crossover	NN	O
design	NN	O
,	,	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
have	VB	O
either	DT	O
sleep	JJ	O
deprivation	NN	O
or	CC	O
a	DT	O
full	JJ	O
night	NN	O
's	POS	O
sleep	NN	O
1	CD	O
week	NN	O
apart	RB	O
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
monitored	VBN	O
with	IN	O
ABPM	NNP	O
.	.	O

Urine	NNP	O
samples	NNS	O
for	IN	O
analysis	NN	O
of	IN	O
nocturnal	JJ	O
urinary	JJ	O
excretion	NN	Physical
of	IN	Physical
norepinephrine	NN	Physical
were	VBD	O
collected	VBN	O
.	.	O

During	IN	O
the	DT	O
sleep-deprivation	JJ	O
day	NN	O
,	,	O
both	DT	O
mean	JJ	O
24-h	JJ	O
blood	NN	Physical
pressure	NN	Physical
and	CC	O
mean	JJ	O
24-h	JJ	O
heart	NN	O
rate	NN	O
were	VBD	O
higher	JJR	O
in	IN	O
comparison	NN	O
with	IN	O
those	DT	O
recorded	VBN	O
during	IN	O
the	DT	O
routine	JJ	O
workday	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
more	RBR	O
pronounced	JJ	O
during	IN	O
the	DT	O
nighttime	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
norepinephrine	NN	Physical
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
at	IN	O
night	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Blood	NNP	Physical
pressure	NN	Physical
and	CC	O
heart	NN	Physical
rate	NN	Physical
significantly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
morning	NN	O
after	IN	O
a	DT	O
sleep-insufficient	JJ	O
night	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
lack	NN	O
of	IN	O
sleep	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
may	MD	O
increase	VB	O
sympathetic	JJ	Physical
nervous	JJ	Physical
activity	NN	Physical
during	IN	O
the	DT	O
night	NN	O
and	CC	O
the	DT	O
following	JJ	O
morning	NN	O
,	,	O
leading	VBG	O
to	TO	O
increased	VBN	O
blood	NN	Physical
pressure	NN	Physical
and	CC	O
heart	NN	Physical
rate	NN	Physical
.	.	O

This	DT	O
situation	NN	O
might	MD	O
represent	VB	O
an	DT	O
increased	VBN	O
risk	NN	Physical
for	IN	Physical
both	DT	Physical
target	NN	Physical
organ	JJ	Physical
damage	NN	Physical
and	CC	Physical
acute	JJ	Physical
cardiovascular	JJ	Physical
diseases	NNS	Physical
.	.	O

Evidence	NN	O
for	IN	O
poorer	JJR	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
receiving	VBG	O
prolonged	JJ	O
exposure	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
:	:	O
implications	NNS	O
for	IN	O
treatment	NN	O
matching	NN	O
in	IN	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
.	.	O

In	IN	O
the	DT	O
current	JJ	O
article	NN	O
,	,	O
we	PRP	O
address	VBP	O
the	DT	O
existing	VBG	O
assumption	NN	O
in	IN	O
the	DT	O
literature	NN	O
on	IN	O
cognitive	JJ	O
behavioral	JJ	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
that	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
negative	JJ	O
trauma-related	JJ	O
cognitions	NNS	O
would	MD	O
benefit	VB	O
more	RBR	O
from	IN	O
a	DT	O
treatment	NN	O
package	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
techniques	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
treatment	NN	O
that	WDT	O
includes	VBZ	O
exposure	NN	O
only	RB	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
assumption	NN	O
,	,	O
54	CD	O
PTSD	NN	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
prolonged	VB	O
exposure	NN	O
therapy	NN	O
or	CC	O
prolonged	JJ	O
exposure	NN	O
therapy	NN	O
plus	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

Contrary	NNP	O
to	TO	O
expectations	NNS	O
,	,	O
findings	NNS	O
revealed	VBD	O
that	IN	O
patients	NNS	O
characterized	VBN	O
by	IN	O
more	JJR	O
severe	JJ	O
pretreatment	NN	O
trauma-related	JJ	O
cognitions	NNS	O
(	(	O
and	CC	O
more	RBR	O
severe	JJ	O
pretreatment	NN	O
PTSD	NNP	O
symptoms	NNS	O
)	)	O
fared	VBD	O
slightly	RB	O
worse	JJR	O
in	IN	O
treatment	NN	O
combining	NN	O
exposure	NN	O
and	CC	O
cognitive	JJ	O
restructuring	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
relationship	NN	O
between	IN	O
pre-	NN	O
and	CC	O
post-treatment	JJ	Mental
measures	NNS	Mental
of	IN	Mental
negative	JJ	Mental
cognitions	NNS	Mental
and	CC	Physical
PTSD	NNP	Physical
symptoms	NNS	Physical
in	IN	O
the	DT	O
exposure	NN	O
alone	RB	O
group	NN	O
.	.	O

The	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
for	IN	O
examining	VBG	O
Person	NNP	O
X	NNP	O
Treatment	NNP	O
interactions	NNS	O
and	CC	O
the	DT	O
efficacy	NN	Others
of	IN	O
combining	VBG	O
treatments	NNS	O
for	IN	O
PTSD	NNP	O
are	VBP	O
discussed	VBN	O
.	.	O

Aortic	JJ	O
valve	NN	O
replacement	NN	O
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
comparing	VBG	O
the	DT	O
Bj?rk-Shiley	NNP	O
and	CC	O
Lillehei-Kaster	NNP	O
disc	NN	O
valves	NNS	O
.	.	O

Late	JJ	O
haemodynamics	NNS	O
related	VBN	O
to	TO	O
clinical	JJ	O
results	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
78	CD	O
randomized	VBD	O
patients	NNS	O
with	IN	O
either	DT	O
Bj?rk-Shiley	NNP	O
(	(	O
B-S	NNP	O
)	)	O
or	CC	O
Lillehei-Kaster	JJ	O
(	(	O
L-K	NNP	O
)	)	O
aortic	JJ	O
disc	NN	O
valve	NN	O
prostheses	NNS	O
were	VBD	O
re-admitted	JJ	O
for	IN	O
clinical	JJ	O
and	CC	O
haemodynamic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
selected	VBN	O
that	IN	O
those	DT	O
with	IN	O
narrow	JJ	O
aortic	JJ	O
roots	NNS	O
were	VBD	O
over-represented	JJ	O
.	.	O

Cine-aortography	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
75	CD	O
patients	NNS	O
and	CC	O
left	VBD	O
ventricular	JJ	O
catheterisation	NN	O
via	IN	O
the	DT	O
transseptal	JJ	O
approach	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
42	CD	O
.	.	O

The	DT	O
clinical	JJ	O
improvement	NN	O
was	VBD	O
striking	VBG	O
,	,	O
although	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
still	RB	O
incapacitated	VBN	O
was	VBD	O
relatively	RB	O
large	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
small	JJ	O
L-K	JJ	O
valves	NNS	O
(	(	O
Nos	NNP	O
.	.	O

14	CD	O
&	CC	O
16	CD	O
)	)	O
.	.	O

Peak-to-peak	JJ	O
and	CC	O
mean	JJ	O
systolic	JJ	O
pressure	NN	O
differences	NNS	O
across	IN	O
the	DT	O
valves	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
B-S	NNP	O
than	IN	O
in	IN	O
the	DT	O
L-K	NNP	O
valves	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
the	DT	O
small	JJ	O
valve	NN	O
sizes	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

Left	NNP	O
ventricular	JJ	O
end-diastolic	JJ	O
pressure	NN	O
(	(	O
LVEDP	NNP	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
elevated	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
before	IN	O
operation	NN	O
,	,	O
decreased	VBN	O
significantly	RB	O
to	TO	O
normal	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
B-S	NNP	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
L-K	NNP	O
group	NN	O
,	,	O
LVEDP	NNP	O
did	VBD	O
not	RB	O
decrease	VB	O
significantly	RB	O
and	CC	O
was	VBD	O
on	IN	O
the	DT	O
average	NN	O
still	RB	O
above	IN	O
the	DT	O
normal	JJ	O
level	NN	O
after	IN	O
operation	NN	O
,	,	O
probably	RB	O
due	JJ	O
to	TO	O
the	DT	O
relatively	RB	O
large	JJ	O
pressure	NN	O
gradients	NNS	O
.	.	O

The	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
L-K	NNP	O
valves	NNS	O
Nos	NNP	O
.	.	O

14	CD	O
&	CC	O
16	CD	O
in	IN	O
particular	JJ	O
represents	VBZ	O
a	DT	O
resistance	NN	O
to	TO	O
flow	VB	O
that	DT	O
is	VBZ	O
too	RB	O
large	JJ	O
to	TO	O
be	VB	O
acceptable	JJ	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
supplementation	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	O
g/d	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
(	(	O
.84	JJ	O
g/d	NN	O
eicosapentaenoic	NN	O
acid	NN	O
,	,	O
.7	NNP	O
g/d	NN	O
docosahexaenoic	NN	O
acid	NN	O
)	)	O
supplementation	NN	O
in	IN	O
13	CD	O
children	NNS	O
(	(	O
aged	VBN	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
(	(	Mental
ABC	NNP	Mental
)	)	Mental
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	Physical
and	CC	Physical
stereotypy	NN	Physical
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	Physical
.	.	Physical

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
surgical	JJ	O
trauma	NN	O
and	CC	O
insulin	NN	O
on	IN	O
whole-body	NN	Physical
protein	NN	Physical
turnover	NN	Physical
in	IN	O
parenterally-fed	JJ	O
undernourished	JJ	O
patients	NNS	O
.	.	O

Ten	CD	O
undernourished	JJ	O
patients	NNS	O
receiving	VBG	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
and	CC	O
undergoing	JJ	O
major	JJ	O
intestinal	JJ	O
surgery	NN	O
were	VBD	O
restarted	VBN	O
on	IN	O
intravenous	JJ	O
feeds	NNS	O
identical	JJ	O
to	TO	O
their	PRP$	O
pre-operative	JJ	O
regimens	NNS	O
within	IN	O
24	CD	O
h	NNS	O
of	IN	O
their	PRP$	O
operation	NN	O
.	.	O

Five	CD	O
,	,	O
chosen	VBN	O
at	IN	O
random	NN	O
,	,	O
received	VBD	O
post-operatively	RB	O
1-2	JJ	O
units	NNS	O
insulin/kg	VBP	O
body	NN	O
weight/24	JJ	O
h	NN	O
with	IN	O
their	PRP$	O
feed	NN	O
,	,	O
while	IN	O
the	DT	O
other	JJ	O
five	CD	O
received	VBD	O
the	DT	O
feed	NN	O
only	RB	O
.	.	O

Pre-operatively	RB	O
,	,	O
and	CC	O
2	CD	O
h	NN	O
after	IN	O
commencing	VBG	O
their	PRP$	O
post-operative	JJ	O
feeds	NNS	O
,	,	O
rates	NNS	Physical
of	IN	Physical
whole-body	NN	Physical
protein	NN	Physical
synthesis	NN	Physical
and	CC	Physical
breakdown	NN	Physical
were	VBD	O
measured	VBN	O
over	IN	O
a	DT	O
9-h	JJ	O
period	NN	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
of	IN	O
a	DT	O
single	JJ	O
tracer	NN	O
dose	NN	O
of	IN	O
15N-glycine	JJ	O
by	IN	O
the	DT	O
ammonia	NN	O
and	CC	O
urea	JJ	O
end-product	NN	O
methods	NNS	O
.	.	O

During	IN	O
these	DT	O
9-h	CD	O
study	NN	O
periods	NNS	O
measurements	NNS	O
were	VBD	O
also	RB	O
made	VBN	O
of	IN	O
blood	NN	Physical
glucose	NN	Physical
,	,	O
plasma	JJ	Physical
insulin	NN	Physical
and	CC	Physical
glucagon	NN	Physical
,	,	O
urinary	JJ	Physical
ammonia	NN	Physical
,	,	O
nitrogen	NN	Physical
,	,	O
creatinine	NN	Physical
and	CC	O
3-methylhistidine	JJ	Physical
.	.	O

Blood	NNP	Physical
glucose	NN	Physical
and	CC	O
plasma	JJ	Physical
insulin	NN	Physical
and	CC	Physical
glucagon	NN	Physical
concentrations	NNS	Physical
rose	VBD	O
post-operatively	RB	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
,	,	O
but	CC	O
the	DT	O
increment	NN	O
in	IN	O
insulin	NN	Physical
concentration	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
when	WRB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

Apparent	JJ	Physical
nitrogen	NN	Physical
balance	NN	Physical
was	VBD	O
positive	JJ	O
pre-operatively	RB	O
and	CC	O
became	VBD	O
less	RBR	O
so	RB	O
post-operatively	RB	O
whether	IN	O
insulin	NN	O
was	VBD	O
given	VBN	O
or	CC	O
not	RB	O
.	.	O

Similarly	RB	O
,	,	O
post-operative	JJ	O
increments	NNS	O
in	IN	O
urinary	JJ	Physical
excretion	NN	Physical
of	IN	Physical
ammonia	NN	Physical
,	,	O
creatinine	NN	Physical
and	CC	Physical
3-methylhistidine	JJ	Physical
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
addition	NN	O
of	IN	O
insulin	NN	O
.	.	O

Protein	NNP	Physical
turnover	NN	Physical
,	,	O
as	IN	O
estimated	VBN	O
by	IN	O
the	DT	O
ammonia	JJ	Physical
end-product	NN	Physical
method	NN	O
,	,	O
tended	VBD	O
to	TO	O
rise	VB	O
post-operatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
increases	NNS	O
observed	VBD	O
with	IN	O
or	CC	O
without	IN	O
insulin	NN	O
.	.	O

The	DT	O
urea	JJ	O
end-product	NN	O
method	NN	O
suggested	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
whole-body	NN	Physical
protein	NN	Physical
turnover	NN	Physical
after	IN	O
surgery	NN	O
,	,	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	O
was	VBD	O
given	VBN	O
.	.	O

This	DT	O
study	NN	O
does	VBZ	O
not	RB	O
support	VB	O
the	DT	O
clinical	JJ	O
use	NN	O
of	IN	O
insulin	NN	Physical
as	IN	O
a	DT	O
means	NN	O
of	IN	O
modifying	VBG	O
protein	JJ	O
metabolic	JJ	O
losses	NNS	O
after	IN	O
major	JJ	O
surgery	NN	O
.	.	O

A	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
prevention	NN	O
trial	NN	O
of	IN	O
aspirin	NN	O
and/or	NN	O
resistant	JJ	O
starch	NN	O
in	IN	O
young	JJ	O
people	NNS	O
with	IN	O
familial	JJ	Physical
adenomatous	JJ	Physical
polyposis	NN	Physical
.	.	Physical

Evidence	NN	O
supporting	VBG	O
aspirin	NNS	O
and	CC	O
resistant	JJ	O
starch	NN	O
(	(	O
RS	NNP	O
)	)	O
for	IN	O
colorectal	JJ	O
cancer	NN	O
prevention	NN	O
comes	VBZ	O
from	IN	O
epidemiologic	JJ	O
and	CC	O
laboratory	JJ	O
studies	NNS	O
(	(	O
aspirin	NN	O
and	CC	O
RS	NNP	O
)	)	O
and	CC	O
randomized	VBN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
(	(	O
aspirin	NN	O
)	)	O
.	.	O

Familial	NNP	O
adenomatous	JJ	O
polyposis	NN	O
(	(	O
FAP	NNP	O
)	)	O
strikes	VBZ	O
young	JJ	O
people	NNS	O
and	CC	O
,	,	O
untreated	JJ	O
,	,	O
confers	NNS	O
virtually	RB	O
a	DT	O
100	CD	O
%	NN	O
risk	NN	O
of	IN	O
colorectal	JJ	O
cancer	NN	O
and	CC	O
early	JJ	O
death	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
an	DT	O
international	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
aspirin	NN	O
(	(	O
600	CD	O
mg/d	NN	O
)	)	O
and/or	NN	O
RS	NNP	O
(	(	O
30	CD	O
g/d	NN	O
)	)	O
for	IN	O
from	IN	O
1	CD	O
to	TO	O
12	CD	O
years	NNS	O
to	TO	O
prevent	VB	O
disease	NN	O
progression	NN	O
in	IN	O
FAP	NNP	O
patients	NNS	O
from	IN	O
10	CD	O
to	TO	O
21	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

In	IN	O
a	DT	O
2	CD	O
?	.	O
2	CD	O
factorial	JJ	O
design	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
following	VBG	O
four	CD	O
study	NN	O
arms	NNS	O
:	:	O
aspirin	NN	O
plus	CC	O
RS	NNP	O
placebo	NN	O
;	:	O
RS	NNP	O
plus	CC	O
aspirin	JJ	O
placebo	NN	O
;	:	O
aspirin	CC	O
plus	CC	O
RS	NNP	O
;	:	O
RS	NNP	O
placebo	NN	O
plus	CC	O
aspirin	JJ	O
placebo	NN	O
;	:	O
they	PRP	O
were	VBD	O
followed	VBN	O
with	IN	O
standard	JJ	O
annual	JJ	O
clinical	JJ	O
examinations	NNS	O
including	VBG	O
endoscopy	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
polyp	JJ	O
number	NN	O
in	IN	O
the	DT	O
rectum	NN	O
and	CC	O
sigmoid	JJ	O
colon	NN	O
(	(	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
intervention	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
major	JJ	O
secondary	JJ	O
endpoint	NN	O
was	VBD	O
size	NN	O
of	IN	O
the	DT	O
largest	JJS	O
polyp	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
206	CD	O
randomized	JJ	O
FAP	NNP	O
patients	NNS	O
commenced	VBD	O
intervention	NN	O
,	,	O
of	IN	O
whom	WP	O
133	CD	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
follow-up	JJ	O
endoscopy	NN	O
and	CC	O
were	VBD	O
therefore	RB	O
included	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
analysis	NN	O
.	.	O

Neither	CC	O
intervention	NN	O
significantly	RB	O
reduced	VBN	O
polyp	NN	O
count	NN	O
in	IN	O
the	DT	O
rectum	NN	O
and	CC	O
sigmoid	JJ	O
colon	NN	O
:	:	O
aspirin	JJ	O
relative	JJ	O
risk	NN	O
=	VBP	O
0.77	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.54-1.10	NNP	O
;	:	O
versus	NN	O
nonaspirin	IN	O
arms	NNS	O
)	)	O
;	:	O
RS	NNP	O
relative	VBP	O
risk	NN	O
=	VBP	O
1.05	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.73-1.49	NNP	O
;	:	O
versus	CD	O
non-RS	JJ	O
arms	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
a	DT	O
smaller	JJR	O
size	NN	O
of	IN	O
largest	JJS	O
polyp	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
aspirin	JJ	O
versus	NN	O
nonaspirin	NN	O
--	:	O
mean	JJ	O
3.8	CD	O
mm	NN	O
versus	NN	O
5.5	CD	O
mm	NN	O
for	IN	O
patients	NNS	O
treated	JJ	O
1	CD	O
or	CC	O
more	JJR	O
years	NNS	O
(	(	O
adjusted	VBN	O
P	NNP	O
=	NNP	O
0.09	CD	O
)	)	O
and	CC	O
mean	$	O
3.0	CD	O
mm	NN	O
versus	NN	O
6.0	CD	O
mm	NN	O
for	IN	O
patients	NNS	O
treated	VBD	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
;	:	O
there	EX	O
were	VBD	O
similar	JJ	O
weaker	JJR	O
trends	NNS	O
with	IN	O
RS	NNP	O
versus	IN	O
non-RS	JJ	O
.	.	O

Exploratory	NNP	O
translational	JJ	O
endpoints	NNS	O
included	VBD	O
crypt	JJ	O
length	NN	O
(	(	O
which	WDT	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
normal-appearing	JJ	O
mucosa	NN	O
in	IN	O
the	DT	O
RS	NNP	O
group	NN	O
over	IN	O
time	NN	O
)	)	O
and	CC	O
laboratory	JJ	O
measures	NNS	O
of	IN	O
proliferation	NN	O
(	(	O
including	VBG	O
Ki67	NNP	O
)	)	O
.	.	O

This	DT	O
clinical	JJ	O
trial	NN	O
is	VBZ	O
the	DT	O
largest	JJS	O
ever	RB	O
conducted	VBN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
FAP	NNP	O
and	CC	O
found	VBD	O
a	DT	O
trend	NN	O
of	IN	O
reduced	JJ	O
polyp	NN	O
load	NN	O
(	(	O
number	NN	O
and	CC	O
size	NN	O
)	)	O
with	IN	O
600	CD	O
mg	NNS	O
of	IN	O
aspirin	JJ	O
daily	JJ	O
.	.	O

RS	NNP	O
had	VBD	O
no	DT	O
clinical	JJ	O
effect	NN	O
on	IN	O
adenomas	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
versus	NN	O
placebo	NN	O
for	IN	O
cervical	JJ	O
ripening	VBG	O
prior	JJ	O
to	TO	O
operative	JJ	O
hysteroscopy	NN	O
using	VBG	O
a	DT	O
sequential	JJ	O
trial	NN	O
design	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
impact	NN	O
of	IN	O
1000-microgram	JJ	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
versus	IN	O
self-administered	JJ	O
vaginal	JJ	O
placebo	NN	O
at	IN	O
home	NN	O
on	IN	O
preoperative	JJ	O
cervical	JJ	O
ripening	NN	O
in	IN	O
both	DT	O
premenopausal	NN	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
prior	RB	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
sequential	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Norwegian	JJ	O
university	NN	O
teaching	VBG	O
hospital	NN	O
.	.	O

SAMPLE	NNP	O
Premenopausal	NNP	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
referred	VBD	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
women	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
1000	CD	O
micrograms	NNS	O
of	IN	O
self-administered	JJ	O
vaginal	JJ	O
misoprostol	NN	O
or	CC	O
self-administered	JJ	O
vaginal	JJ	O
placebo	NN	O
the	DT	O
evening	NN	O
before	IN	O
outpatient	JJ	O
resectoscopy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Preoperative	NNP	Physical
cervical	JJ	Physical
dilatation	NN	Physical
,	,	O
acceptability	NN	Others
and	CC	O
complications	NNS	Adverseeffect
.	.	O

RESULTS	NNP	O
(	(	O
a	DT	O
)	)	O
Intraoperative	JJ	O
findings	NNS	O
and	CC	O
distribution	NN	O
of	IN	O
cervical	JJ	O
dilatation	NN	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
or	CC	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
b	NN	O
)	)	O
Acceptability	NN	Others
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
completely	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
and	CC	O
completely	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
c	NN	O
)	)	O
Pain	NN	Pain
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Pain	NNP	Pain
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
score	NN	O
,	,	O
scale	JJ	O
ranges	NNS	O
from	IN	O
0	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
10	CD	O
(	(	O
unbearable	JJ	O
pain	NN	O
)	)	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
.	.	O

(	(	O
d	NN	O
)	)	O
Occurrence	NN	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
e	NN	O
)	)	O
Complications	NNPS	Physical
,	,	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

Learning	VBG	O
through	IN	O
interaction	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
preliminary	JJ	O
data	NNS	O
from	IN	O
asocial-communication-based	JJ	O
intervention	NN	O
.	.	O

The	DT	O
study	NN	O
evaluates	VBZ	O
a	DT	O
social-communication-based	JJ	O
approach	NN	O
to	TO	O
autism	VB	O
intervention	NN	O
aimed	VBN	O
at	IN	O
improving	VBG	O
the	DT	O
social	JJ	Mental
interaction	NN	Mental
skills	NNS	Mental
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

We	PRP	O
report	VBP	O
preliminary	JJ	O
results	NNS	O
from	IN	O
an	DT	O
ongoing	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
51	CD	O
children	NNS	O
aged	VBN	O
2	CD	O
years	NNS	O
0	CD	O
months	NNS	O
to	TO	O
4	CD	O
years	NNS	O
11	CD	O
months	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
target	NN	O
treatment	NN	O
or	CC	O
community	NN	O
treatment	NN	O
group	NN	O
.	.	O

Families	NNS	O
in	IN	O
the	DT	O
target	NN	O
treatment	NN	O
group	NN	O
were	VBD	O
given	VBN	O
2	CD	O
hours	NNS	O
of	IN	O
therapy	NN	O
and	CC	O
coaching	VBG	O
each	DT	O
week	NN	O
in	IN	O
an	DT	O
intervention	NN	O
emphasizing	VBG	O
social-interaction	NN	O
and	CC	O
the	DT	O
parent-child	JJ	O
relationship	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
community	NN	O
treatment	NN	O
group	NN	O
received	VBD	O
a	DT	O
variety	NN	O
of	IN	O
services	NNS	O
averaging	VBG	O
3.9	CD	O
hours	NNS	O
per	IN	O
week	NN	O
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
outcomes	NNS	O
were	VBD	O
measured	VBN	O
to	TO	O
determine	VB	O
changes	NNS	O
in	IN	O
the	DT	O
groups	NNS	O
in	IN	O
social	JJ	O
interaction	NN	O
and	CC	O
communication	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
regression	NN	O
analysis	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
changes	NNS	O
in	IN	O
social	JJ	O
interaction	NN	O
skills	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
language	NN	O
development	NN	O
.	.	O

Results	NNS	O
suggest	VBP	O
that	IN	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
greater	JJR	O
gains	NNS	Mental
in	IN	Mental
social	JJ	Mental
interaction	NN	Mental
skills	NNS	Mental
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
community	NN	O
treatment	NN	O
group	NN	O
,	,	O
but	CC	O
no	DT	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
standard	JJ	Mental
language	NN	Mental
assessments	NNS	Mental
.	.	O

Initiation	NN	Mental
of	IN	Mental
joint	JJ	Mental
attention	NN	Mental
,	,	Mental
involvement	NN	Mental
,	,	Mental
and	CC	Mental
severity	NN	Mental
of	IN	Mental
language	NN	Mental
delay	NN	Mental
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
associated	VBN	O
with	IN	O
improvement	NN	O
of	IN	O
language	NN	Mental
skills	NNS	Mental
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Finally	RB	O
caregiver	JJ	O
skills	NNS	O
targeted	VBN	O
by	IN	O
the	DT	O
intervention	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
associated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
children	NNS	Mental
's	POS	Mental
interaction	NN	Mental
skills	NNS	Mental
.	.	O

The	DT	O
overt	JJ	O
aggression	NN	O
scale	NN	O
for	IN	O
rating	NN	O
aggression	NN	O
in	IN	O
outpatient	JJ	O
youth	NN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
preliminary	JJ	O
findings	NNS	O
.	.	O

Aggression	NNP	O
is	VBZ	O
a	DT	O
common	JJ	O
and	CC	O
costly	JJ	O
problem	NN	O
in	IN	O
youth	NN	O
with	IN	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

Rating	VBG	O
scales	NNS	O
that	WDT	O
accurately	RB	O
capture	NN	O
and	CC	O
measure	NN	O
subtypes	NNS	O
of	IN	O
aggression	NN	O
phenomenology	NN	O
,	,	O
frequency	NN	O
and	CC	O
severity	NN	O
are	VBP	O
urgently	RB	O
needed	VBN	O
,	,	O
in	IN	O
both	DT	O
clinical	JJ	O
practice	NN	O
and	CC	O
research	NN	O
.	.	O

The	DT	O
authors	NNS	O
studied	VBD	O
the	DT	O
Overt	NNP	Mental
Aggression	NNP	Mental
Scale	NNP	Mental
(	(	Mental
OAS	NNP	Mental
)	)	Mental
in	IN	O
a	DT	O
preliminary	JJ	O
sample	NN	O
of	IN	O
eight	CD	O
outpatients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
an	DT	O
ongoing	JJ	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
valproate	NN	O
for	IN	O
aggression	NN	O
in	IN	O
autism	NN	O
.	.	O

Subjects	NNS	O
'	POS	O
OAS	NNP	Mental
aggression	NN	Mental
scores	NNS	Mental
showed	VBD	O
significant	JJ	O
correlation	NN	O
with	IN	O
the	DT	O
already	RB	O
validated	VBN	O
retrospectively	RB	O
rated	VBN	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
Community	NNP	Mental
Scale	NNP	Mental
irritability	NN	Mental
subscale	NN	Mental
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
the	DT	O
OAS	NNP	Mental
in	IN	O
outpatients	NNS	O
with	IN	O
aggression	NN	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
is	VBZ	O
warranted	VBN	O
.	.	O

Sham	NNP	O
device	NN	O
v	NN	O
inert	NN	O
pill	NN	O
:	:	O
randomised	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
two	CD	O
placebo	NN	O
treatments	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
whether	IN	O
a	DT	O
sham	JJ	O
device	NN	O
(	(	O
a	DT	O
validated	VBN	O
sham	NN	O
acupuncture	NN	O
needle	NN	O
)	)	O
has	VBZ	O
a	DT	O
greater	JJR	O
placebo	NN	O
effect	NN	O
than	IN	O
an	DT	O
inert	NN	O
pill	NN	O
in	IN	O
patients	NNS	O
with	IN	O
persistent	JJ	O
arm	NN	O
pain	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
single	JJ	O
blind	NN	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
created	VBD	O
from	IN	O
the	DT	O
two	CD	O
week	NN	O
placebo	IN	O
run-in	JJ	O
periods	NNS	O
for	IN	O
two	CD	O
nested	JJ	O
trials	NNS	O
that	WDT	O
compared	VBN	O
acupuncture	NN	O
and	CC	O
amitriptyline	NN	O
with	IN	O
their	PRP$	O
respective	JJ	O
placebo	NN	O
controls	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
participants	NNS	O
who	WP	O
remained	VBD	O
on	IN	O
placebo	NN	O
continued	VBN	O
beyond	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

SETTING	NNP	O
Academic	NNP	O
medical	JJ	O
centre	NN	O
.	.	O

PARTICIPANTS	CC	O
270	CD	O
adults	NNS	O
with	IN	O
arm	NN	O
pain	NN	O
due	JJ	O
to	TO	O
repetitive	VB	O
use	NN	O
that	WDT	O
had	VBD	O
lasted	VBN	O
at	IN	O
least	JJS	O
three	CD	O
months	NNS	O
despite	IN	O
treatment	NN	O
and	CC	O
who	WP	O
scored	VBD	O
>	NNP	O
or	CC	O
=3	VBN	O
on	IN	O
a	DT	O
10	CD	O
point	NN	O
pain	NN	O
scale	NN	O
.	.	O

INTERVENTIONS	NNP	O
Acupuncture	NNP	O
with	IN	O
sham	JJ	O
device	NN	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
six	CD	O
weeks	NNS	O
or	CC	O
placebo	NN	O
pill	NN	O
once	RB	O
a	DT	O
day	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Arm	NNP	Pain
pain	NN	Pain
measured	VBD	O
on	IN	O
a	DT	O
10	CD	Pain
point	NN	Pain
pain	NN	Pain
scale	NN	Pain
.	.	O

Secondary	JJ	Physical
outcomes	NNS	Physical
were	VBD	Physical
symptoms	NNS	Physical
measured	VBN	Physical
by	IN	Physical
the	DT	Physical
Levine	NNP	Physical
symptom	NN	Physical
severity	NN	Physical
scale	NN	Physical
,	,	O
function	NN	O
measured	VBN	O
by	IN	O
Pransky	NNP	O
's	POS	O
upper	JJ	O
extremity	NN	O
function	NN	O
scale	NN	O
,	,	O
and	CC	O
grip	JJ	O
strength	NN	O
.	.	O

RESULTS	NNP	O
Pain	NNP	Pain
decreased	VBD	O
during	IN	O
the	DT	O
two	CD	O
week	NN	O
placebo	JJ	O
run-in	JJ	O
period	NN	O
in	IN	O
both	CC	O
the	DT	O
sham	NN	O
device	NN	O
and	CC	O
placebo	NN	O
pill	NN	O
groups	NNS	O
,	,	O
but	CC	O
changes	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
-0.14	NNP	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
-0.52	NN	O
to	TO	O
0.25	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.49	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
severity	NN	Physical
scores	NNS	Physical
for	IN	Physical
arm	NN	Physical
symptoms	NNS	Physical
and	CC	Physical
grip	JJ	Physical
strength	NN	Physical
were	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
,	,	O
but	CC	O
arm	JJ	O
function	NN	O
improved	VBD	O
more	RBR	O
in	IN	O
the	DT	O
placebo	NN	O
pill	NN	O
group	NN	O
(	(	O
2.0	CD	O
,	,	O
0.06	CD	O
to	TO	O
3.92	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Longitudinal	JJ	O
regression	NN	O
analyses	VBZ	O
that	IN	O
followed	VBD	O
participants	NNS	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
downward	JJ	O
slopes	NNS	O
per	IN	O
week	NN	O
on	IN	O
the	DT	O
10	CD	Pain
point	NN	Pain
arm	NN	Pain
pain	NN	Pain
scale	NN	Pain
in	IN	O
the	DT	O
sham	JJ	O
device	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
pill	NN	O
group	NN	O
(	(	O
-0.33	NNP	O
(	(	O
-0.40	UH	O
to	TO	O
-0.26	VB	O
)	)	O
v	FW	O
-0.15	FW	O
(	(	O
-0.21	UH	O
to	TO	O
-0.09	VB	O
)	)	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
symptom	JJ	O
severity	NN	O
scale	NN	O
(	(	O
-0.07	NNP	O
(	(	O
-0.09	UH	O
to	TO	O
-0.05	VB	O
)	)	O
v	FW	O
-0.05	FW	O
(	(	O
-0.06	UH	O
to	TO	O
-0.03	VB	O
)	)	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Differences	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
,	,	O
however	RB	O
,	,	O
on	IN	O
the	DT	O
function	NN	O
scale	NN	O
or	CC	O
for	IN	O
grip	JJ	O
strength	NN	O
.	.	O

Reported	VBN	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
different	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
sham	NN	O
device	NN	O
had	VBD	O
greater	JJR	O
effects	NNS	O
than	IN	O
the	DT	O
placebo	NN	O
pill	NN	O
on	IN	O
self	NN	O
reported	VBN	O
pain	NN	O
and	CC	O
severity	NN	O
of	IN	O
symptoms	NNS	O
over	IN	O
the	DT	O
entire	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
but	CC	O
not	RB	O
during	IN	O
the	DT	O
two	CD	O
week	NN	O
placebo	NNS	O
run	VBP	O
in	IN	O
.	.	O

Placebo	NNP	O
effects	NNS	O
seem	VBP	O
to	TO	O
be	VB	O
malleable	JJ	O
and	CC	O
depend	VB	O
on	IN	O
the	DT	O
behaviours	NN	O
embedded	VBD	O
in	IN	O
medical	JJ	O
rituals	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
antiemetic	JJ	O
effect	NN	O
of	IN	O
ramosetron	NN	O
and	CC	O
combined	VBN	O
ramosetron	NN	O
and	CC	O
midazolam	NN	O
in	IN	O
children	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
randomised	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
Postoperative	NNP	O
nausea	NN	O
and	CC	O
vomiting	NN	O
remains	VBZ	O
a	DT	O
clinically	RB	O
important	JJ	O
problem	NN	O
after	IN	O
strabismus	NN	O
surgery	NN	O
in	IN	O
children	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
study	VB	O
the	DT	O
benefit	NN	O
of	IN	O
adding	VBG	O
midazolam	NN	O
to	TO	O
ramosetron	VB	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
,	,	O
retching	VBG	O
or	CC	O
vomiting	VBG	O
and	CC	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
agitation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
comparison	NN	O
.	.	O

SETTING	CC	O
The	DT	O
operating	NN	O
theatre	NN	O
suite	NN	O
and	CC	O
day	NN	O
care	NN	O
unit	NN	O
of	IN	O
Seoul	NNP	O
National	NNP	O
University	NNP	O
Hospital	NNP	O
.	.	O

The	DT	O
study	NN	O
period	NN	O
was	VBD	O
January	NNP	O
to	TO	O
December	NNP	O
2010	CD	O
.	.	O

PATIENTS	VB	O
In	IN	O
total	JJ	O
,	,	O
405	CD	O
paediatric	JJ	O
patients	NNS	O
(	(	O
aged	VBN	O
4-12	CD	O
years	NNS	O
)	)	O
undergoing	VBG	O
strabismus	JJ	O
surgery	NN	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
,	,	O
ramosetron	NN	O
or	CC	O
ramosetron	NN	O
with	IN	O
midazolam	NN	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
received	VBD	O
either	DT	O
ramosetron	NN	O
6	CD	O
?g	JJ	O
kg	NN	O
or	CC	O
ramosetron	VB	O
6	CD	O
?g	NNP	O
kg	NN	O
and	CC	O
midazolam	$	O
0.1	CD	O
mg	NN	O
kg	NN	O
prior	RB	O
to	TO	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
incidences	NNS	O
of	IN	O
nausea	NN	O
,	,	O
retching	VBG	O
or	CC	O
vomiting	VBG	O
in	IN	O
the	DT	O
first	JJ	O
48	CD	O
h	NN	O
after	IN	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
emergence	NN	O
agitation	NN	O
in	IN	O
the	DT	O
post-anaesthetic	JJ	O
care	NN	O
unit	NN	O
.	.	O

RESULT	VB	O
The	DT	O
incidences	NNS	O
of	IN	O
nausea	NN	O
,	,	O
retching	VBG	O
or	CC	O
vomiting	VBG	O
during	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
24-h	JJ	O
periods	NNS	O
after	IN	O
surgery	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
small	JJ	O
,	,	O
clinically	RB	O
insignificant	JJ	O
reduction	NN	O
in	IN	O
delirium	NN	O
scores	NNS	O
in	IN	O
the	DT	O
ramosetron	NN	O
with	IN	O
midazolam	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Adding	NNP	O
midazolam	NN	O
to	TO	O
ramosetron	VB	O
had	VBD	O
no	DT	O
advantages	NNS	O
over	IN	O
ramosetron	NN	O
alone	RB	O
in	IN	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
strabismus	NN	O
surgery	NN	O
.	.	O

Social	NNP	O
skills	NNS	O
training	VBG	O
for	IN	O
young	JJ	O
adults	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
pilot	NN	O
study	NN	O
.	.	O

Despite	IN	O
the	DT	O
psychosocial	JJ	O
difficulties	NNS	O
common	JJ	O
among	IN	O
young	JJ	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
,	,	O
little	JJ	O
to	TO	O
no	DT	O
evidence-based	JJ	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
exist	VBP	O
for	IN	O
this	DT	O
population	NN	O
.	.	O

Using	VBG	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
design	NN	O
,	,	O
the	DT	O
current	JJ	O
study	NN	O
tested	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
evidence-based	JJ	O
,	,	O
caregiver-assisted	JJ	O
social	JJ	O
skills	NNS	O
intervention	NN	O
known	VBN	O
as	IN	O
PEERS	NNP	O
for	IN	O
Young	NNP	O
Adults	NNP	O
with	IN	O
high-functioning	JJ	O
young	JJ	O
adults	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
ages	VBZ	O
18-23	CD	O
)	)	O
using	VBG	O
self-	JJ	Others
and	CC	Others
caregiver-report	JJ	Others
measures	NNS	Others
.	.	Physical

Results	NNS	O
revealed	VBD	O
that	IN	O
treated	JJ	O
young	JJ	O
adults	NNS	O
reported	VBD	O
significantly	RB	O
less	JJR	O
loneliness	JJ	Mental
and	CC	O
improved	VBN	Mental
social	JJ	Mental
skills	NNS	Mental
knowledge	VBP	Mental
,	,	O
while	IN	O
caregivers	NNS	O
reported	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
young	JJ	O
adults	NNS	O
'	POS	O
overall	JJ	Mental
social	JJ	Mental
skills	NNS	Mental
,	,	Others
social	JJ	Mental
responsiveness	NN	Mental
,	,	Others
empathy	NN	Mental
,	,	Others
and	CC	Others
frequency	NN	Mental
of	IN	Mental
get-togethers	NNS	Mental
.	.	Others

Results	NNS	O
support	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
using	VBG	O
this	DT	O
caregiver-assisted	JJ	O
,	,	O
manualized	VBN	O
intervention	NN	O
for	IN	O
young	JJ	O
adults	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Atomoxetine	NNP	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
fluoxetine	NN	O
for	IN	O
treating	VBG	O
ADHD	NNP	O
with	IN	O
comorbid	JJ	O
depressive	NN	O
or	CC	O
anxiety	NN	O
symptoms	NNS	O
.	.	O

OBJECTIVE	NNP	O
Symptoms	NNP	O
of	IN	O
depression	NN	O
and	CC	O
anxiety	NN	O
are	VBP	O
commonly	RB	O
comorbid	JJ	O
with	IN	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
assessed	VBD	O
the	DT	O
safety	NN	Others
and	CC	O
effectiveness	NN	Others
of	IN	O
atomoxetine	NN	O
monotherapy	NN	O
compared	VBN	O
with	IN	O
combined	JJ	O
atomoxetine/fluoxetine	NN	O
therapy	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ADHD	NNP	O
and	CC	O
concurrent	NN	O
symptoms	NNS	O
of	IN	O
depression	NN	O
or	CC	O
anxiety	NN	O
.	.	O

METHOD	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
fluoxetine	NN	O
(	(	O
n	JJ	O
=	NNP	O
127	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	O
)	)	O
under	IN	O
double-blind	JJ	O
conditions	NNS	O
for	IN	O
8	CD	O
weeks	NNS	O
,	,	O
with	IN	O
concomitant	JJ	O
atomoxetine	NN	O
use	IN	O
the	DT	O
last	JJ	O
5	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
end	JJ	O
point	NN	O
,	,	O
reductions	NNS	Physical
in	IN	Physical
ADHD	NNP	Physical
,	,	O
depressive	NN	Physical
,	,	Physical
and	CC	Physical
anxiety	NN	Physical
symptoms	NNS	Physical
were	VBD	O
marked	VBN	O
for	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
.001	NN	O
for	IN	O
the	DT	O
relevant	JJ	O
scale	NN	O
in	IN	O
each	DT	O
symptom	NN	O
cluster	NN	O
)	)	O
.	.	O

Some	DT	O
differences	NNS	Physical
between	IN	O
treatment	NN	O
groups	NNS	O
for	IN	O
depressive	JJ	Physical
symptoms	NNS	Physical
were	VBD	O
significant	JJ	Physical
,	,	O
but	CC	O
the	DT	O
magnitudes	NNS	Physical
of	IN	O
the	DT	O
differences	NNS	O
were	VBD	O
small	JJ	Physical
and	CC	O
likely	JJ	O
of	IN	O
limited	JJ	O
clinical	JJ	O
importance	NN	O
.	.	O

Completion	NN	Physical
rates	NNS	Physical
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
,	,	O
as	IN	O
were	VBD	O
discontinuation	NN	Others
rates	NNS	Others
for	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

The	DT	O
combination	NN	O
group	NN	O
had	VBD	O
greater	JJR	Physical
increases	NNS	Physical
in	IN	Physical
blood	NN	Physical
pressure	NN	Physical
and	CC	Physical
pulse	NN	Physical
than	IN	O
did	VBD	O
the	DT	O
monotherapy	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
and	CC	O
comorbid	NN	O
symptoms	NNS	O
of	IN	O
depression	NN	O
or	CC	O
anxiety	NN	O
,	,	O
atomoxetine	JJ	O
monotherapy	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
for	IN	O
treating	VBG	O
ADHD	NNP	O
.	.	O

Anxiety	NNP	Mental
and	CC	Mental
depressive	JJ	Mental
symptoms	NNS	Mental
also	RB	O
improved	VBN	O
,	,	O
but	CC	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
placebo-only	JJ	O
arm	NN	O
does	VBZ	O
not	RB	O
allow	VB	O
us	PRP	O
to	TO	O
conclude	VB	O
that	IN	O
these	DT	O
effects	NNS	O
are	VBP	O
specifically	RB	O
the	DT	O
result	NN	O
of	IN	O
treatment	NN	O
with	IN	O
atomoxetine	NN	O
.	.	O

Combined	VBN	O
atomoxetine/fluoxetine	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Intensive	JJ	O
insulin	NN	O
therapy	NN	O
on	IN	O
infection	NN	O
rate	NN	O
,	,	O
days	NNS	O
in	IN	O
NICU	NNP	O
,	,	O
in-hospital	JJ	Mortality
mortality	NN	Mortality
and	CC	O
neurological	JJ	Physical
outcome	NN	Physical
in	IN	O
severe	JJ	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVES	NNP	O
Evaluate	NNP	O
the	DT	O
impact	NN	O
of	IN	O
an	DT	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
and	CC	O
conventional	JJ	O
glucose	NN	O
control	NN	O
protocol	NN	O
during	IN	O
staying	VBG	O
in	IN	O
neurological	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
NICU	NNP	O
)	)	O
on	IN	O
infection	NN	Physical
rate	NN	Physical
,	,	Physical
days	NNS	Others
in	IN	Others
NICU	NNP	Others
,	,	O
in-hospital	JJ	Mortality
mortality	NN	Mortality
and	CC	O
long-term	JJ	Physical
neurological	JJ	Physical
outcome	NN	Physical
in	IN	O
severe	JJ	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
(	(	O
TBI	NNP	O
)	)	O
patients	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
240	CD	O
patients	NNS	O
with	IN	O
severe	JJ	O
TBI	NNP	O
(	(	O
GCS	NNP	O
score	RB	O
3-8	JJ	O
)	)	O
admitted	VBD	O
to	TO	O
NICU	NNP	O
were	VBD	O
prospectively	RB	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBD	O
either	DT	O
to	TO	O
conventional	JJ	O
insulin	NN	O
therapy	NN	O
or	CC	O
to	TO	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
.	.	O

Patients	NNS	O
in	IN	O
intensive	JJ	O
glucose	NNS	O
control	NN	O
group	NN	O
(	(	O
n=121	NN	O
)	)	O
received	VBD	O
continuous	JJ	O
insulin	NN	O
infusion	NN	O
to	TO	O
maintain	VB	O
glucose	JJ	O
levels	NNS	O
between	IN	O
4.4	CD	O
m	NNS	O
mol/l	NN	O
(	(	O
80	CD	O
mg/dl	NN	O
)	)	O
and	CC	O
6.1	CD	O
m	NN	O
mol/l	NN	O
(	(	O
110	CD	O
mg/dl	NN	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
conventional	JJ	O
treatment	NN	O
group	NN	O
(	(	O
n=119	RB	O
)	)	O
were	VBD	O
not	RB	O
given	VBN	O
insulin	NN	O
unless	IN	O
glucose	JJ	Physical
levels	NNS	Physical
were	VBD	O
greater	JJR	O
than	IN	O
11.1	CD	O
m	JJ	O
mol/l	NN	O
(	(	O
200mg/dl	CD	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
insulin	JJ	O
infusion	NN	O
to	TO	O
maintain	VB	O
normoglycemia	RB	O
after	IN	O
leaving	VBG	O
NICU	NNP	O
.	.	O

Comparison	NNP	O
was	VBD	O
made	VBN	O
against	IN	O
conventional	JJ	O
insulin	NN	O
therapy	NN	O
using	VBG	O
a	DT	O
randomized	JJ	O
trial	NN	O
design	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
is	VBZ	O
the	DT	O
mortality	NN	Mortality
rate	NN	Mortality
at	IN	O
6	CD	O
months	NNS	O
follow-up	RB	O
.	.	O

The	DT	O
second	JJ	O
outcomes	NNS	O
including	VBG	O
ICU	NNP	Physical
infection	NN	Physical
rate	NN	Physical
,	,	O
duration	NN	Others
of	IN	Others
ICU	NNP	Others
stay	NN	Others
,	,	O
in-hospital	JJ	Mortality
mortality	NN	Mortality
rate	NN	Mortality
and	CC	O
neurologic	JJ	Physical
outcome	NN	Physical
at	IN	O
6	CD	O
months	NNS	O
follow-up	RB	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
gender	NN	O
(	(	O
66	CD	O
%	NN	O
vs.	FW	O
67	CD	O
%	NN	O
male	NN	O
)	)	O
,	,	O
age	NN	O
(	(	O
46+/-11	CD	O
years	NNS	O
vs.	IN	O
45+/-10	CD	O
years	NNS	O
)	)	O
,	,	O
APACHE	NNP	O
II	NNP	O
score	NN	O
(	(	O
30	CD	O
vs.	FW	O
29	CD	O
)	)	O
,	,	O
TISS-28	NNP	Physical
score	NN	Physical
(	(	O
47	CD	O
vs.	FW	O
46	CD	O
)	)	O
,	,	O
and	CC	O
Glasgow	NNP	Physical
Coma	NNP	Physical
Score	NNP	Physical
(	(	O
GCS	NNP	O
,	,	O
5.3	CD	O
vs.	FW	O
5.3	CD	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Overall	JJ	Mortality
mortality	NN	Mortality
rates	NNS	Mortality
at	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
61	CD	O
of	IN	O
117	CD	O
,	,	O
52.1	CD	O
%	NN	O
vs.	FW	O
62	CD	O
of	IN	O
116	CD	O
,	,	O
53.4	CD	O
%	NN	O
;	:	O
P=0.8	NNP	O
)	)	O
.	.	O

The	DT	O
infection	NN	Physical
rate	NN	Physical
during	IN	O
the	DT	O
study	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
conventional	JJ	O
insulin	NN	O
therapy	NN	O
than	IN	O
that	DT	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
(	(	O
46.2	CD	O
%	NN	O
vs.	FW	O
31.4	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
days	NNS	Others
stay	VBP	Others
in	IN	Others
NICU	NNP	Others
was	VBD	O
shorter	RBR	O
in	IN	O
intensive	JJ	O
insulin	NN	O
control	NN	O
group	NN	O
than	IN	O
that	DT	O
in	IN	O
conventional	JJ	O
therapy	NN	O
group	NN	O
[	VBD	O
4.2	CD	O
days	NNS	O
vs.	FW	O
5.6	CD	O
days	NNS	O
(	(	O
medians	NNS	O
)	)	O
P	NNP	O
<	$	O
0.05	CD	O
]	NNP	O
.	.	O

The	DT	O
in-hospital	JJ	Mortality
mortality	NN	Mortality
during	IN	O
the	DT	O
study	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
conventional	JJ	O
and	CC	O
intensive	JJ	O
therapy	NN	O
groups	NNS	O
(	(	O
34	CD	O
of	IN	O
119	CD	O
,	,	O
28.6	CD	O
%	NN	O
vs.	FW	O
35	CD	O
of	IN	O
121	CD	O
,	,	O
28.9	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
and	CC	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
groups	NNS	O
;	:	O
P=0.85	NNP	O
)	)	O
.	.	O

The	DT	O
neurologic	JJ	O
outcome	NN	O
according	VBG	O
to	TO	O
Glasgow	NNP	Physical
Outcome	NNP	Physical
Score	NNP	Physical
(	(	Physical
GOS	NNP	Physical
)	)	Physical
at	IN	O
6	CD	O
months	NNS	O
(	(	O
GOS	NNP	O
5	CD	O
and	CC	O
4	CD	O
)	)	O
was	VBD	O
better	RBR	O
in	IN	O
the	DT	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
group	NN	O
(	(	O
34	CD	O
of	IN	O
117	CD	O
,	,	O
29.1	CD	O
%	NN	O
)	)	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
conventional	JJ	O
therapy	NN	O
group	NN	O
(	(	O
26	CD	O
of	IN	O
116	CD	O
,	,	O
22.4	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Mortality	NNP	Mortality
rates	NNS	Mortality
at	IN	O
6	CD	O
months	NNS	O
follow-up	NNS	O
are	VBP	O
not	RB	O
affected	VBN	O
by	IN	O
intensive	JJ	O
glucose	NNS	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
TBI	NNP	O
.	.	O

Intensive	JJ	O
insulin	NN	O
therapy	NN	O
decreases	VBZ	O
infection	NN	Physical
rate	NN	Physical
and	CC	O
days	NNS	Others
in	IN	Others
NICU	NNP	Others
and	CC	O
improves	VBZ	O
the	DT	O
neurological	JJ	Physical
outcome	NN	Physical
at	IN	O
6	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
while	IN	O
has	VBZ	O
no	DT	O
obvious	JJ	O
influence	NN	O
on	IN	O
in-hospital	JJ	Mortality
mortality	NN	Mortality
of	IN	O
severe	JJ	O
TBI	NNP	O
patients	NNS	O
.	.	O

Ipilimumab	NNP	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	O
:	:	O
a	DT	O
retrospective	JJ	O
analysis	NN	O
of	IN	O
HLA	NNP	O
subtype	NN	O
from	IN	O
four	CD	O
trials	NNS	O
.	.	O

Ipilimumab	NNP	O
is	VBZ	O
a	DT	O
fully	RB	O
human	JJ	O
,	,	O
monoclonal	JJ	O
antibody	NN	O
that	WDT	O
blocks	VBZ	O
cytotoxic	JJ	O
T-lymphocyte	JJ	O
antigen-4	NN	O
to	TO	O
potentiate	VB	O
an	DT	O
antitumor	JJ	O
T-cell	NNP	O
response	NN	O
.	.	O

This	DT	O
agent	NN	O
improved	VBD	O
overall	JJ	O
survival	NN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
in	IN	O
previously	RB	O
treated	VBN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	O
.	.	O

Because	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
for	IN	O
ipilimumab	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
HLA	NNP	O
independent	JJ	O
,	,	O
most	JJS	O
trials	NNS	O
enrolled	VBD	O
patients	NNS	O
without	IN	O
regard	NN	O
to	TO	O
HLA	NNP	O
subtype	NN	O
.	.	O

However	RB	O
,	,	O
enrollment	NN	O
in	IN	O
the	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
was	VBD	O
restricted	VBN	O
to	TO	O
class-I	JJ	O
HLA-A*0201-positive	JJ	O
patients	NNS	O
because	IN	O
two	CD	O
of	IN	O
the	DT	O
three	CD	O
arms	NNS	O
contained	VBD	O
an	DT	O
HLA-A*0201-restricted	JJ	O
gp100	NN	O
vaccine	NN	O
.	.	O

HLA	NNP	O
typing	NN	O
was	VBD	O
also	RB	O
performed	VBN	O
prospectively	RB	O
in	IN	O
several	JJ	O
phase	NN	O
II	NNP	O
trials	NNS	O
and	CC	O
was	VBD	O
available	JJ	O
for	IN	O
93.5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

In	IN	O
this	DT	O
retrospective	JJ	O
analysis	NN	O
,	,	O
pooled	VBD	Others
efficacy	NN	Others
and	CC	Others
safety	NN	Others
data	NNS	Others
are	VBP	O
presented	VBN	O
according	VBG	O
to	TO	O
HLA-A*0201	NNP	O
status	NN	O
and	CC	O
dose	NN	O
from	IN	O
pretreated	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
0.3	CD	O
,	,	O
3	CD	O
,	,	O
or	CC	O
10	CD	O
mg/kg	NNS	O
ipilimumab	VBP	O
in	IN	O
four	CD	O
phase	NN	O
II	NNP	O
trials	NNS	O
.	.	O

Median	JJ	Mortality
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
was	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
187	CD	O
HLA-A*0201-positive	JJ	O
[	JJ	O
9.3	CD	O
months	NNS	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
(	(	O
confidence	NN	O
interval	NN	O
)	)	O
7.4-11.5	CD	O
]	NN	O
and	CC	O
266	CD	O
HLA-A*0201-negative	JJ	O
patients	NNS	O
[	VBP	O
11.4	CD	O
months	NNS	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
9.3-15.1	CD	O
]	NNP	O
randomized	VBD	O
to	TO	O
ipilimumab	VB	O
at	IN	O
all	DT	O
doses	NNS	O
across	IN	O
the	DT	O
four	CD	O
phase	NN	O
II	NNP	O
trials	NNS	O
.	.	O

These	DT	O
data	NNS	O
are	VBP	O
comparable	JJ	O
to	TO	O
the	DT	O
OS	NNP	Mortality
for	IN	O
the	DT	O
137	CD	O
HLA-A*0201-positive	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
ipilimumab	VB	O
in	IN	O
the	DT	O
phase	NN	O
III	NNP	O
study	NN	O
[	VBD	O
10.1	CD	O
months	NNS	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
8.0-13.8	CD	O
]	NNP	O
.	.	O

Ipilimumab-induced	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
and	CC	Adverseeffect
immune-related	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
(	(	Adverseeffect
skin	NN	Adverseeffect
,	,	Adverseeffect
gastrointestinal	JJ	Adverseeffect
,	,	Adverseeffect
hepatic	JJ	Adverseeffect
,	,	Adverseeffect
other	JJ	Adverseeffect
)	)	Adverseeffect
also	RB	O
occurred	VBD	O
at	IN	O
similar	JJ	O
frequencies	NNS	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
phase	NN	O
II	NNP	O
and	CC	O
III	NNP	O
trials	NNS	O
,	,	O
regardless	RB	O
of	IN	O
HLA-A*0201	NNP	O
status	NN	O
.	.	O

These	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	IN	O
ipilimumab-treated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NNS	O
have	VBP	O
similar	JJ	O
outcomes	NNS	O
regardless	RB	O
of	IN	O
their	PRP$	O
HLA-A*0201	JJ	O
status	NN	O
.	.	O

Efficiency	NN	Others
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
following	VBG	O
curative	JJ	O
resection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
curative	JJ	O
resection	NN	O
,	,	O
50	CD	O
%	NN	O
-90	CD	O
%	NN	O
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
die	VBP	O
of	IN	O
disease	NN	Physical
relapse	NN	Physical
.	.	O

Although	IN	O
some	DT	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
chemotherapy	NN	O
and	CC	O
immunochemotherapy	NN	O
may	MD	O
be	VB	O
effective	JJ	O
modalities	NNS	O
,	,	O
more	RBR	O
recent	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
able	JJ	O
to	TO	O
define	VB	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
BCG	NNP	O
(	(	O
bacille	IN	O
Calmette-Guerin	NNP	O
)	)	O
and	CC	O
FAM	NNP	O
(	(	O
5-fluorouracil	JJ	O
,	,	O
adriamycin	JJ	O
,	,	O
mitomycin	JJ	O
C	NNP	O
)	)	O
chemotherapy	NN	O
on	IN	O
the	DT	O
survival	NN	Mortality
of	IN	Mortality
patients	NNS	Mortality
with	IN	O
locally	RB	O
advanced	VBN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
156	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
gastric	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
undergone	JJ	O
curative	JJ	O
resection	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
(	(	O
immunochemotherapy	NN	O
)	)	O
,	,	O
FAM	NNP	O
(	(	O
chemotherapy	NN	O
)	)	O
,	,	O
and	CC	O
control	NN	O
(	(	O
surgery	NN	O
only	RB	O
)	)	O
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
2	CD	O
years	NNS	O
or	CC	O
until	IN	O
death	NN	O
.	.	O

Further	NNP	O
postsurgical	JJ	O
follow	VBP	O
up	RP	O
was	VBD	O
carried	VBN	O
on	IN	O
for	IN	O
up	IN	O
to	TO	O
10	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Overall	JJ	O
10-year	JJ	Mortality
survival	NN	Mortality
was	VBD	O
47.1	CD	O
%	NN	O
for	IN	O
the	DT	O
immunochemotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.037	CD	O
vs	NN	O
FAM	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.0006	CD	O
vs	NNS	O
control	NN	O
)	)	O
,	,	O
30	CD	O
%	NN	O
for	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
(	(	O
vs	FW	O
control	NN	O
,	,	O
NS	NNP	O
)	)	O
,	,	O
and	CC	O
15.2	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
primary	JJ	O
tumors	NNS	O
,	,	O
10-year	JJ	Mortality
survival	NN	Mortality
was	VBD	O
55.3	CD	O
%	NN	O
for	IN	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
vs	VBD	O
28.2	CD	O
%	NN	O
for	IN	O
FAM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
14.6	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.00018	CD	O
)	)	O
.	.	O

BCG	NNP	O
+	NNP	O
FAM	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
survival	NN	Mortality
of	IN	Mortality
patients	NNS	Mortality
with	IN	O
intestinal-type	JJ	O
but	CC	O
not	RB	O
diffuse-type	JJ	O
cancer	NN	O
.	.	O

Immunochemotherapy	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
indicates	VBZ	O
that	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
(	(	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
)	)	O
may	MD	O
prolong	VB	O
the	DT	O
survival	NN	Mortality
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
after	IN	O
curative	JJ	O
gastrectomy	NN	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
tumors	NNS	O
and	CC	O
intestinal-type	JJ	O
primary	JJ	O
tumors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
survival	JJ	Mortality
benefit	NN	Mortality
from	IN	O
FAM	NNP	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
amantadine	NN	O
and	CC	O
pemoline	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
multiple	JJ	O
sclerosis	NN	O
.	.	O

BACKGROUND	NNP	O
Amantadine	NNP	O
hydrochloride	NN	O
and	CC	O
pemoline	NN	O
,	,	O
both	DT	O
frequently	RB	O
used	VBN	O
to	TO	O
treat	VB	O
the	DT	O
fatigue	NN	O
of	IN	O
multiple	JJ	O
sclerosis	NN	O
(	(	O
MS	NNP	O
)	)	O
,	,	O
may	MD	O
also	RB	O
improve	VB	O
attention	NN	O
and	CC	O
other	JJ	O
cognitive	JJ	O
functions	NNS	O
in	IN	O
MS.	NNP	O
To	TO	O
our	PRP$	O
knowledge	NN	O
,	,	O
these	DT	O
agents	NNS	O
have	VBP	O
never	RB	O
been	VBN	O
compared	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
patients	NNS	O
with	IN	O
MS	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
amantadine	NN	O
and	CC	O
pemoline	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
MS.	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
45	CD	O
ambulatory	JJ	O
patients	NNS	O
with	IN	O
MS	NNP	O
and	CC	O
severe	JJ	O
fatigue	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
amantadine	NN	O
,	,	O
pemoline	NN	O
,	,	O
or	CC	O
placebo	NN	O
using	VBG	O
a	DT	O
parallel	JJ	O
group	NN	O
design	NN	O
.	.	O

They	PRP	O
underwent	VBD	O
comprehensive	JJ	O
neuropsychological	JJ	O
testing	NN	O
to	TO	O
determine	VB	O
treatment	NN	O
effects	NNS	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
.	.	O

Primary	JJ	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
tests	NNS	O
of	IN	O
attention	NN	O
(	(	O
Digit	NNP	Mental
Span	NNP	Mental
,	,	Mental
Trail	NNP	Mental
Making	NNP	Mental
Test	NNP	Mental
,	,	Mental
and	CC	Mental
Symbol	NNP	Mental
Digit	NNP	Mental
Modalities	NNP	Mental
Test	NNP	Mental
)	)	Mental
,	,	O
verbal	JJ	Mental
memory	NN	Mental
(	(	Mental
Selective	JJ	Mental
Reminding	NNP	Mental
Test	NNP	Mental
)	)	Mental
,	,	Mental
nonverbal	JJ	Mental
memory	NN	Mental
(	(	Mental
Benton	NNP	Mental
Visual	NNP	Mental
Retention	NNP	Mental
Test	NNP	Mental
)	)	Mental
,	,	Mental
and	CC	O
motor	NN	Mental
speed	NN	Mental
(	(	Mental
Finger	NNP	Mental
Tapping	NNP	Mental
Test	NNP	Mental
)	)	Mental
.	.	O

RESULTS	NNP	O
Fatigue	NNP	Mental
did	VBD	O
not	RB	O
significantly	RB	O
correlate	VB	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
neuropsychological	JJ	O
outcome	NN	O
measures	NNS	O
at	IN	O
baseline	NN	O
or	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
improved	VBN	O
on	IN	O
tests	NNS	Mental
of	IN	Mental
attention	NN	Mental
(	(	O
P	NNP	O
<	NNP	O
.003	NNP	O
)	)	O
,	,	O
verbal	JJ	Mental
memory	NN	Mental
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
motor	NN	Mental
speed	NN	Mental
(	(	O
P	NNP	O
<	NNP	O
.002	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
amantadine	NN	O
,	,	O
pemoline	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cognitive	NNP	O
functioning	NN	O
in	IN	O
MS	NNP	O
is	VBZ	O
independent	JJ	O
of	IN	O
fatigue	NN	O
.	.	O

Neither	CC	O
amantadine	JJ	O
nor	CC	O
pemoline	JJ	O
enhances	NNS	O
cognitive	JJ	O
performance	NN	O
in	IN	O
MS	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Measuring	VBG	O
adherence	NN	O
in	IN	O
a	DT	O
hypertension	NN	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Non-adherence	NNP	O
in	IN	O
hypertension	NN	O
is	VBZ	O
a	DT	O
global	JJ	O
problem	NN	O
and	CC	O
promoting	VBG	O
adherence	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
decrease	VB	O
cardiovascular	JJ	O
mortality	NN	O
.	.	O

AIMS	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
paper	NN	O
is	VBZ	O
to	TO	O
examine	VB	O
the	DT	O
measurement	NN	O
of	IN	O
adherence	NN	Mental
to	TO	O
medication	NN	O
taking	VBG	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Adherence	NNP	O
was	VBD	O
evaluated	VBN	O
primarily	RB	O
by	IN	O
means	NNS	O
of	IN	O
MEMS	NNP	Mental
(	(	Mental
Medication	NNP	Mental
Event	NNP	Mental
Monitoring	NNP	Mental
System	NNP	Mental
,	,	O
Aprex	NNP	O
Corporation	NNP	O
,	,	O
Fremont	NNP	O
,	,	O
California	NNP	O
)	)	O
an	DT	O
electronic	JJ	O
system	NN	O
that	WDT	O
records	VBZ	O
the	DT	O
date	NN	O
and	CC	O
time	NN	O
of	IN	O
opening	NN	O
of	IN	O
the	DT	O
study	NN	O
medication	NN	O
container	NN	O
.	.	O

Additional	JJ	O
measurements	NNS	O
such	JJ	O
as	IN	O
change	NN	O
in	IN	O
urinary	JJ	Physical
potassium	NN	Physical
level	NN	Physical
,	,	Mental
capsule	NN	Physical
count	NN	Physical
,	,	Mental
client	NN	Mental
self	PRP	Mental
report	NN	Mental
and	CC	Mental
physician	JJ	Mental
estimate	NN	Mental
of	IN	Mental
adherence	NN	Mental
were	VBD	O
recorded	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assign	VB	O
patients	NNS	O
to	TO	O
receive	VB	O
the	DT	O
study	NN	O
medication	NN	O
(	(	O
potassium	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Descriptive	JJ	O
statistics	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
answer	VB	O
the	DT	O
research	NN	O
questions	NNS	O
.	.	O

Frequency	NNP	O
and	CC	O
percentage	NN	O
of	IN	O
responses	NNS	O
to	TO	O
different	JJ	O
measures	NNS	O
of	IN	O
adherence	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
as	RB	O
well	RB	O
as	IN	O
correlation	NN	O
between	IN	O
the	DT	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
seven	CD	O
subjects	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
26	CD	O
and	CC	O
80	CD	O
participated	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
adherence	NN	O
measures	NNS	O
varied	VBN	O
with	IN	O
lowest	JJS	O
adherence	NN	Physical
from	IN	O
two	CD	O
items	NNS	O
of	IN	O
self-report	NN	Physical
related	VBN	Physical
to	TO	Physical
forgetfulness	VB	Physical
(	(	O
46	CD	O
and	CC	O
55	CD	O
%	NN	O
)	)	O
and	CC	O
stringent	JJ	O
electronic	JJ	Physical
monitoring	NN	Physical
with	IN	Physical
the	DT	Physical
MEMS	NNP	Physical
(	(	O
58	CD	O
%	NN	O
)	)	O
to	TO	O
percentages	NNS	O
in	IN	O
the	DT	O
80-90	JJ	O
range	NN	O
for	IN	O
other	JJ	O
self-report	JJ	O
items	NNS	O
and	CC	O
the	DT	O
general	JJ	O
adherence	NN	O
scale	NN	O
.	.	O

Electronic	JJ	O
monitoring	NN	O
correlated	VBD	O
best	JJS	O
with	IN	O
capsule	NN	Physical
count	NN	Physical
at	IN	O
visit	NN	O
5	CD	O
.	.	O

Implications	NNS	O
for	IN	O
health	NN	O
care	NN	O
providers	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
propofol	NN	O
,	,	O
droperidol	NN	O
,	,	O
and	CC	O
metoclopramide	NN	O
for	IN	O
prophylaxis	NN	O
of	IN	O
postoperative	JJ	Physical
nausea	NN	Physical
and	CC	Physical
vomiting	NN	Physical
after	IN	O
breast	NN	O
cancer	NN	O
surgery	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
Japanese	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Breast	NNP	O
cancer	NN	O
surgery	NN	O
performed	VBN	O
with	IN	O
the	DT	O
patient	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
relatively	RB	O
high	JJ	O
incidence	NN	O
of	IN	O
postoperative	JJ	Physical
nausea	NN	Physical
and	CC	Physical
vomiting	NN	Physical
(	(	Physical
PONV	NNP	Physical
)	)	Physical
.	.	O

Between	$	O
60	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
who	WP	O
undergo	VBP	O
mastectomy	NNS	O
(	(	O
with	IN	O
axillary	JJ	O
dissection	NN	O
)	)	O
experience	NN	O
PONV	NNP	Physical
.	.	Physical

We	PRP	O
previously	RB	O
reported	VBD	O
that	IN	O
propofol	NN	O
at	IN	O
a	DT	O
subhypnotic	JJ	O
dose	NN	O
of	IN	O
0.5	CD	O
mg/kg	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
preventing	VBG	O
PONV	NNP	O
in	IN	O
women	NNS	O
who	WP	O
undergo	VBP	O
mastectomy	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
a	DT	O
subhypnotic	JJ	O
dose	NN	O
of	IN	O
propofol	NN	O
with	IN	O
the	DT	O
conventional	JJ	O
antiemetics	NNS	O
droperidol	NN	O
and	CC	O
metoclopramide	NN	O
for	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
PONV	NNP	O
after	IN	O
breast	NN	O
cancer	NN	O
surgery	NN	O
in	IN	O
Japanese	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
Japanese	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
1	CD	O
of	IN	O
4	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
IV	NNP	O
administration	NN	O
of	IN	O
propofol	JJ	O
0.5	CD	O
mg/kg	NN	O
,	,	O
droperidol	VBZ	O
20	CD	O
microg/kg	NN	O
,	,	O
metoclopramide	RB	O
0.2	CD	O
mg/kg	NN	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
isotonic	JJ	O
saline	NN	O
)	)	O
immediately	RB	O
after	IN	O
skin	JJ	O
suture	NN	O
.	.	O

A	DT	O
standard	JJ	O
general	JJ	O
anesthetic	JJ	O
technique	NN	O
,	,	O
including	VBG	O
sevoflurane	NN	O
and	CC	O
air	NN	O
in	IN	O
oxygen	NN	O
,	,	O
was	VBD	O
used	VBN	O
.	.	O

All	DT	O
episodes	NNS	O
of	IN	O
PONV	NNP	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
anesthesia	JJ	O
administration	NN	O
were	VBD	O
recorded	VBN	O
by	IN	O
an	DT	O
investigator	NN	O
who	WP	O
was	VBD	O
blinded	VBN	O
to	TO	O
treatment	NN	O
assignment	NN	O
.	.	O

The	DT	O
investigator	NN	O
questioned	VBD	O
the	DT	O
patients	NNS	O
as	IN	O
to	TO	O
whether	IN	O
they	PRP	O
experienced	VBD	O
extrapyramidal	NN	Physical
symptoms	NNS	Physical
.	.	Physical

To	TO	O
maintain	VB	O
the	DT	O
integrity	NN	O
of	IN	O
the	DT	O
study	NN	O
results	NNS	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
preanesthetic	JJ	O
medication	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
100	CD	O
women	NNS	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
52	CD	O
[	NN	O
7	CD	O
]	CD	O
years	NNS	O
;	:	O
height	VBD	O
,	,	O
154	CD	O
[	NN	O
6	CD	O
]	NNP	O
cm	NN	O
;	:	O
weight	NN	O
,	,	O
54	CD	O
[	NN	O
7	CD	O
]	NNP	O
kg	NN	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Each	DT	O
study	NN	O
group	NN	O
comprised	VBD	O
25	CD	O
patients	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
patient	VB	O
demographics	NNS	O
,	,	O
surgery	NN	O
type	NN	O
,	,	O
or	CC	O
awakening	VBG	O
time	NN	O
.	.	O

The	DT	O
prevalences	NNS	O
of	IN	O
PONV	NNP	O
0	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
anesthesia	NN	O
were	VBD	O
28	CD	O
%	NN	O
with	IN	O
propofol	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
32	CD	O
%	NN	O
with	IN	O
droperidol	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
,	,	O
and	CC	O
60	CD	O
%	NN	O
with	IN	O
metoclopramide	NN	O
(	(	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
68	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
PONV	NNP	O
was	VBD	O
found	VBN	O
between	IN	O
patients	NNS	O
receiving	VBG	O
propofol	NN	O
and	CC	O
those	DT	O
receiving	VBG	O
droperidol	NN	O
,	,	O
and	CC	O
propofol	NN	O
and	CC	O
droperidol	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
lower	JJR	O
prevalences	NNS	O
of	IN	O
PONV	NNP	O
compared	VBN	O
with	IN	O
metoclopramide	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.022	CD	O
and	CC	O
P	NNP	O
=	NNP	O
0.043	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Extrapyramidal	NNP	O
symptoms	NNS	O
were	VBD	O
not	RB	O
reported	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
prevalences	NNS	O
of	IN	O
PONV	NNP	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
propofol	NN	O
0.5	CD	O
mg/kg	NN	O
and	CC	O
droperidol	NN	O
20	CD	O
microg/kg	NN	O
0	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
anesthesia	NN	O
in	IN	O
this	DT	O
small	JJ	O
,	,	O
select	JJ	O
group	NN	O
of	IN	O
Japanese	JJ	O
women	NNS	O
who	WP	O
underwent	VBP	O
breast	NN	O
cancer	NN	O
surgery	NN	O
.	.	O

The	DT	O
prevalences	NNS	O
of	IN	O
PONV	NNP	O
were	VBD	O
significantly	RB	O
lower	JJR	O
with	IN	O
propofol	NN	O
and	CC	O
droperidol	NN	O
compared	VBN	O
with	IN	O
metoclopramide	JJ	O
0.2	CD	O
mg/kg	NN	O
and	CC	O
placebo	NN	O
.	.	O

Drug	NN	O
preference	NN	O
in	IN	O
normal	JJ	O
volunteers	NNS	O
:	:	O
effects	NNS	O
of	IN	O
age	NN	O
and	CC	O
time	NN	O
of	IN	O
day	NN	O
.	.	O

These	DT	O
experiments	NNS	O
assessed	VBD	O
the	DT	O
influence	NN	O
of	IN	O
two	CD	O
variables	NNS	O
,	,	O
age	NN	O
of	IN	O
subjects	NNS	O
and	CC	O
time	NN	O
of	IN	O
drug	NN	O
administration	NN	O
,	,	O
on	IN	O
the	DT	O
reinforcing	VBG	O
properties	NNS	O
of	IN	O
amphetamine	NN	O
and	CC	O
of	IN	O
diazepam	NN	O
in	IN	O
normal	JJ	O
volunteers	NNS	O
.	.	O

Three	CD	O
groups	NNS	O
of	IN	O
subjects	NNS	O
were	VBD	O
tested	VBN	O
:	:	O
i	NN	O
)	)	O
a	DT	O
group	NN	O
of	IN	O
40-55-year-old	JJ	O
subjects	NNS	O
(	(	O
AGE	NNP	O
group	NN	O
;	:	O
N	NNP	O
=	NNP	O
11	CD	O
)	)	O
who	WP	O
were	VBD	O
tested	VBN	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
ii	NN	O
)	)	O
a	DT	O
group	NN	O
of	IN	O
21-35-year-old	JJ	O
subjects	NNS	O
(	(	O
CTL	NNP	O
group	NN	O
;	:	O
N	NNP	O
=	NNP	O
12	CD	O
)	)	O
who	WP	O
were	VBD	O
also	RB	O
tested	VBN	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
and	CC	O
iii	NN	O
)	)	O
a	DT	O
group	NN	O
of	IN	O
21-35-year-olds	NNS	O
who	WP	O
were	VBD	O
tested	VBN	O
in	IN	O
the	DT	O
late	JJ	O
afternoon	NN	O
(	(	O
AFT	NNP	O
group	NN	O
;	:	O
N	NNP	O
=	NNP	O
13	CD	O
)	)	O
.	.	O

All	DT	O
subjects	NNS	O
participated	VBN	O
in	IN	O
three	CD	O
separate	JJ	O
experiments	NNS	O
comparing	VBG	O
one	CD	O
drug	NN	O
(	(	O
5	CD	O
mg	NN	O
d	NN	O
,	,	O
l-amphetamine	JJ	O
,	,	O
5	CD	O
mg	NN	O
diazepam	NN	O
or	CC	O
10	CD	O
mg	NNS	O
diazepam	RB	O
)	)	O
to	TO	O
placebo	VB	O
.	.	O

Each	DT	O
experiment	NN	O
consisted	VBN	O
of	IN	O
nine	CD	O
sessions	NNS	O
:	:	O
On	IN	O
the	DT	O
first	JJ	O
four	CD	O
sessions	NNS	O
subjects	NNS	O
sampled	VBD	O
two	CD	O
color-coded	JJ	O
capsules	NNS	O
on	IN	O
alternate	JJ	O
sessions	NNS	O
and	CC	O
on	IN	O
the	DT	O
following	JJ	O
five	CD	O
sessions	NNS	O
they	PRP	O
chose	VBD	O
and	CC	O
ingested	VBD	O
the	DT	O
capsule	NN	O
they	PRP	O
preferred	VBD	O
.	.	O

Subjective	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
drugs	NNS	O
were	VBD	O
monitored	VBN	O
using	VBG	O
the	DT	O
Profile	NNP	Mental
of	IN	Mental
Mood	NNP	Mental
States	NNPS	Mental
(	(	Mental
POMS	NNP	Mental
)	)	Mental
and	CC	O
a	DT	O
shortened	JJ	Mental
version	NN	Mental
of	IN	Mental
the	DT	Mental
Addiction	NNP	Mental
Research	NNP	Mental
Center	NNP	Mental
Inventory	NNP	Mental
(	(	Mental
ARCI	NNP	Mental
)	)	Mental
.	.	Mental

Subjects	NNS	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
chose	VBD	O
5	CD	O
mg	NN	O
diazepam	NN	O
as	RB	O
often	RB	O
as	IN	O
placebo	NNS	O
but	CC	O
preferred	JJ	O
placebo	NN	O
to	TO	O
10	CD	O
mg	NN	O
diazepam	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
they	PRP	O
chose	VBD	O
amphetamine	NN	O
either	CC	O
as	RB	O
often	RB	O
as	IN	O
or	CC	O
more	RBR	O
often	RB	O
than	IN	O
placebo	NNS	O
.	.	O

The	DT	O
subjective	JJ	O
effects	NNS	O
of	IN	O
diazepam	NN	O
(	(	O
i.e	JJ	O
.	.	O

sedation	NN	O
)	)	O
were	VBD	O
similar	JJ	O
across	IN	O
all	DT	O
three	CD	O
groups	NNS	O
,	,	O
but	CC	O
after	IN	O
amphetamine	VBP	O
the	DT	O
AGE	NNP	O
group	NN	O
showed	VBD	O
greater	JJR	O
stimulant	JJ	O
effects	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
AFT	NNP	O
group	NN	O
showed	VBD	O
fewer	JJR	O
positive	JJ	O
mood	NN	O
effects	NNS	O
after	IN	O
amphetamine	NN	O
than	IN	O
the	DT	O
CTL	NNP	O
group	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Neridronate	NNP	O
prevents	NNS	O
bone	NN	Physical
loss	NN	Physical
in	IN	O
patients	NNS	O
receiving	VBG	O
androgen	JJ	O
deprivation	NN	O
therapy	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

UNLABELLED	VBN	O
Today	NN	O
,	,	O
androgen	NN	O
deprivation	NN	O
therapy	NN	O
is	VBZ	O
a	DT	O
cornerstone	NN	O
of	IN	O
treatment	NN	O
for	IN	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
,	,	O
although	IN	O
it	PRP	O
presents	VBZ	O
important	JJ	O
complications	NNS	O
such	JJ	O
as	IN	O
osteoporosis	NN	Physical
.	.	O

Neridronate	NNP	O
,	,	O
a	DT	O
relatively	RB	O
new	JJ	O
bisphosphonate	NN	O
,	,	O
is	VBZ	O
able	JJ	O
to	TO	O
prevent	VB	O
bone	NN	Physical
loss	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
during	IN	O
androgen	JJ	O
ablation	NN	O
.	.	O

INTRODUCTION	NNP	O
Androgen-deprivation	NNP	O
therapy	NN	O
(	(	O
ADT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
cornerstone	NN	O
of	IN	O
treatment	NN	O
for	IN	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

This	DT	O
therapy	NN	O
has	VBZ	O
iatrogenic	JJ	O
complications	NNS	O
,	,	O
such	JJ	O
as	IN	O
osteoporosis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
neridronate	NN	O
,	,	O
a	DT	O
relatively	RB	O
new	JJ	O
bisphosphonate	NN	O
,	,	O
to	TO	O
prevent	VB	O
bone	JJ	O
loss	NN	O
during	IN	O
androgen	JJ	O
ablation	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty-eight	NNP	O
osteoporotic	JJ	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
,	,	O
treated	VBN	O
with	IN	O
3-month	JJ	O
depot	NN	O
triptorelina	NN	O
,	,	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
different	JJ	O
treatment	NN	O
groups	NNS	O
:	:	O
group	NN	O
A	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
was	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
daily	JJ	O
calcium	NN	O
and	CC	O
cholecalciferol	NN	O
supplement	NN	O
(	(	O
500	CD	O
mg	NN	O
of	IN	O
elemental	JJ	O
calcium	NN	O
and	CC	O
400	CD	O
IU	NNP	O
cholecalciferol	NN	O
)	)	O
,	,	O
and	CC	O
group	NN	O
B	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
received	VBN	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
same	JJ	O
daily	JJ	O
calcium	NN	O
and	CC	O
cholecalciferol	NN	O
supplement	NN	O
,	,	O
25	CD	O
mg	NN	O
of	IN	O
neridronate	JJ	O
given	VBN	O
intramuscularly	RB	O
every	DT	O
month	NN	O
.	.	O

All	DT	O
patients	NNS	O
also	RB	O
received	VBD	O
bicalutamide	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Lumbar	NNP	Physical
and	CC	Physical
femoral	JJ	Physical
BMD	NNP	Physical
was	VBD	O
evaluated	VBN	O
by	IN	O
DXA	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
1	CD	O
year	NN	O
of	IN	O
therapy	NN	O
;	:	O
moreover	CC	O
,	,	O
deoxypyridinoline	NN	Physical
(	(	Physical
DPD	NNP	Physical
)	)	Physical
and	CC	Physical
bone	$	Physical
alkaline	JJ	Physical
phosphatase	NN	Physical
(	(	Physical
BALP	NNP	Physical
)	)	Physical
were	VBD	O
determined	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
,	,	O
midway	RB	O
through	IN	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
,	,	O
whereas	JJ	O
patients	NNS	O
treated	VBD	O
only	RB	O
with	IN	O
calcium	NN	O
and	CC	O
cholecalciferol	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
showed	VBD	O
a	DT	O
marked	JJ	Physical
bone	NN	Physical
loss	NN	Physical
,	,	O
with	IN	O
increased	JJ	Physical
levels	NNS	Physical
of	IN	Physical
DPD	NNP	Physical
and	CC	Physical
BALP	NNP	Physical
compared	VBN	O
with	IN	O
baseline	NN	O
values	NNS	O
,	,	O
patients	NNS	O
treated	VBD	O
also	RB	O
with	IN	O
neridronate	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
had	VBD	O
substantially	RB	O
unchanged	JJ	O
levels	NNS	O
of	IN	O
these	DT	O
markers	NNS	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
,	,	O
lumbar	NN	Physical
and	CC	Physical
total	JJ	Physical
hip	NN	Physical
BMD	NNP	Physical
decreased	VBD	Physical
significantly	RB	Physical
in	IN	O
patients	NNS	O
treated	VBN	O
only	RB	O
with	IN	O
calcium	NN	O
and	CC	O
cholecalciferol	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
,	,	O
whereas	IN	O
it	PRP	O
did	VBD	O
not	RB	O
change	VB	Others
significantly	RB	Others
at	IN	O
any	DT	O
skeletal	JJ	O
site	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
also	RB	O
with	IN	O
neridronate	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

No	DT	O
relevant	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
during	IN	O
our	PRP$	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Neridronate	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
in	IN	O
preventing	VBG	O
bone	NN	Physical
loss	NN	Physical
in	IN	O
the	DT	O
hip	NN	O
and	CC	O
lumbar	NN	O
spine	NN	O
in	IN	O
men	NNS	O
receiving	VBG	O
ADT	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

Randomized	VBN	O
placebo	NN	O
controlled	VBN	O
human	JJ	O
volunteer	NN	O
trial	NN	O
of	IN	O
a	DT	O
live	JJ	O
oral	JJ	O
cholera	NN	O
vaccine	NN	O
VA1.3	NNP	O
for	IN	O
safety	NN	Others
and	CC	O
immune	JJ	O
response	NN	O
.	.	O

A	DT	O
live	JJ	O
oral	JJ	O
cholera	NN	O
vaccine	NN	O
developed	VBN	O
from	IN	O
a	DT	O
non-toxigenic	JJ	O
Vibrio	NNP	O
cholerae	NN	O
O1	NNP	O
El	NNP	O
Tor	NNP	O
strain	NN	O
VA1.3	NNP	O
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
placebo	NN	O
controlled	VBD	O
study	NN	O
for	IN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
in	IN	O
304	CD	O
men	NNS	O
aged	VBN	O
between	IN	O
16	CD	O
and	CC	O
50	CD	O
years	NNS	O
from	IN	O
Kolkata	NNP	O
,	,	O
India	NNP	O
.	.	O

A	NNP	O
dose	NN	O
of	IN	O
5	CD	O
x	NNS	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU	NNP	O
(	(	O
n=186	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
n=116	JJ	O
)	)	O
containing	VBG	O
the	DT	O
diluent	NN	O
buffer	NN	O
was	VBD	O
administered	VBN	O
.	.	O

The	DT	O
vaccine	NN	O
did	VBD	O
not	RB	O
elicit	JJ	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
except	IN	O
in	IN	O
two	CD	O
vaccine	NN	O
recipients	NNS	O
with	IN	O
mild	JJ	Adverseeffect
diarrhoea	NN	Adverseeffect
and	CC	Adverseeffect
vomiting	NN	Adverseeffect
.	.	O

None	NN	O
excreted	VBD	O
the	DT	O
vaccine	NN	O
strain	NN	O
.	.	O

Vibriocidal	NNP	Physical
antibody	NN	Physical
response	NN	Physical
developed	VBD	O
in	IN	O
105/186	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
and	CC	O
5/116	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
in	IN	O
vaccine	NN	O
and	CC	O
placebo	NN	O
recipients	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
,	,	O
anti-CT	JJ	Physical
antibody	NN	Physical
rose	VBD	Physical
(	(	O
>	JJ	O
or	CC	O
=2-folds	NNS	O
)	)	O
in	IN	O
23/30	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
and	CC	O
6/19	CD	O
(	(	O
32	CD	O
%	NN	O
)	)	O
in	IN	O
vaccine	NN	O
and	CC	O
placebo	NN	O
recipients	NNS	O
,	,	O
respectively	RB	O
.	.	O

These	DT	O
studies	NNS	O
demonstrate	VBP	O
that	IN	O
VA1.3	NNP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
5	CD	O
x	NNS	O
10	CD	O
(	(	O
9	CD	O
)	)	O
is	VBZ	O
safe	JJ	Others
and	CC	Others
immunogenic	JJ	Others
in	IN	O
adults	NNS	O
from	IN	O
a	DT	O
cholera	NN	O
endemic	JJ	O
region	NN	O
.	.	O

Treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
virus	NN	O
infection	NN	O
in	IN	O
severely	RB	O
immunocompromised	JJ	O
patients	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
acyclovir	NN	O
and	CC	O
vidarabine	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
intravenous	JJ	O
acyclovir	NNS	O
and	CC	O
vidarabine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
virus	NN	O
infection	NN	O
in	IN	O
severely	RB	O
immunocompromised	JJ	O
patients	NNS	O
who	WP	O
presented	VBD	O
within	IN	O
72	CD	O
hours	NNS	O
of	IN	O
onset	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Cutaneous	JJ	Physical
dissemination	NN	Physical
of	IN	Physical
infection	NN	Physical
occurred	VBD	O
in	IN	O
none	NN	O
of	IN	O
the	DT	O
10	CD	O
acyclovir	NN	O
recipients	NNS	O
and	CC	O
in	IN	O
5	CD	O
of	IN	O
the	DT	O
10	CD	O
vidarabine	NN	O
recipients	NNS	O
who	WP	O
had	VBD	O
presented	VBN	O
with	IN	O
localized	JJ	O
dermatomal	JJ	O
disease	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.016	CD	O
)	)	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
vidarabine	NN	O
,	,	O
acyclovir	JJ	O
treatment	NN	O
shortened	VBD	O
the	DT	O
median	JJ	Physical
periods	NNS	Physical
during	IN	Physical
which	WDT	Physical
cultures	NNS	Physical
were	VBD	Physical
positive	JJ	Physical
for	IN	Physical
the	DT	Physical
virus	NN	Physical
(	(	O
four	CD	O
vs.	FW	O
seven	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
new	JJ	Physical
lesions	NNS	Physical
formed	VBN	O
(	(	O
three	CD	O
vs.	IN	O
six	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Acyclovir	NNP	O
also	RB	O
shortened	VBD	O
the	DT	O
median	JJ	O
interval	NN	Pain
until	IN	Pain
the	DT	Pain
first	JJ	Pain
decrease	NN	Pain
in	IN	Pain
pain	NN	Pain
(	(	O
4	CD	O
vs.	FW	O
7	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
the	DT	O
pustulation	NN	Physical
of	IN	Physical
all	DT	Physical
lesions	NNS	Physical
(	(	O
4	CD	O
vs.	FW	O
7	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0004	CD	O
)	)	O
,	,	O
the	DT	O
crusting	NN	Physical
of	IN	Physical
all	DT	Physical
lesions	NNS	Physical
(	(	O
7	CD	O
vs.	FW	O
17	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
complete	JJ	O
healing	NN	O
of	IN	O
lesions	NNS	O
(	(	O
17	CD	O
vs.	FW	O
28	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
acyclovir	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
fever	NN	Physical
(	(	O
two	CD	O
vs.	FW	O
eight	CD	O
patients	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
acyclovir	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
vidarabine	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
infection	NN	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
.	.	O

Moclobemide	NNP	O
,	,	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depression	NN	Physical
.	.	O

Moclobemide	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
episodes	NNS	O
in	IN	O
75	CD	O
outpatients	NNS	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
moclobemide	NN	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
was	VBD	O
300	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
increased	VBN	O
to	TO	O
600	CD	O
mg.	NNS	O
Imipramine	NNP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
was	VBD	O
given	VBN	O
in	IN	O
a	DT	O
dosage	NN	O
starting	VBG	O
with	IN	O
33	CD	O
mg	NNS	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
100	CD	O
mg/day	NN	O
in	IN	O
the	DT	O
first	JJ	O
5	CD	O
days	NNS	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
further	RB	O
increased	VBN	O
;	:	O
25	CD	O
patients	NNS	O
received	VBD	O
placebo	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	Physical
Rating	NNP	Physical
Scale	NNP	Physical
for	IN	Physical
Depression	NNP	Physical
,	,	O
the	DT	O
overall	JJ	O
assessment	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
the	DT	O
Zung	NNP	Others
Self-rating	NNP	Others
Scale	NNP	Others
,	,	O
and	CC	O
clearly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
active	JJ	O
drugs	NNS	O
.	.	O

Moclobemide	NNP	O
was	VBD	O
better	RBR	Others
tolerated	VBN	Others
than	IN	O
imipramine	NN	O
,	,	O
and	CC	O
was	VBD	O
almost	RB	O
comparable	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
this	DT	O
respect	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
faropenem	JJ	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	Physical
bacterial	JJ	Physical
maxillary	JJ	Physical
sinusitis	NN	Physical
in	IN	O
adults	NNS	O
.	.	O

In	IN	O
this	DT	O
multicentre	NN	O
,	,	O
multinational	JJ	O
,	,	O
comparative	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
outpatients	NNS	O
with	IN	O
both	DT	O
clinical	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
and	CC	O
radiographic	JJ	O
evidence	NN	O
of	IN	O
acute	JJ	O
sinusitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
for	IN	O
7	CD	O
days	NNS	O
either	CC	O
a	DT	O
twice-daily	JJ	O
oral	JJ	O
regimen	NNS	O
of	IN	O
faropenem	JJ	O
daloxate	NN	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
twice	JJ	O
daily	JJ	O
oral	JJ	O
regimen	NNS	O
of	IN	O
cefuroxime	NN	O
axetil	NN	O
(	(	O
250	CD	O
mg	NN	O
)	)	O
.	.	O

Among	IN	O
452	CD	O
patients	NNS	O
considered	VBN	O
valid	JJ	O
for	IN	O
clinical	JJ	O
efficacy	NN	O
,	,	O
faropenem	JJ	O
daloxate	NN	O
treatment	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
statistically	RB	O
equivalent	JJ	O
to	TO	O
cefuroxime	VB	O
axetil	NN	O
(	(	O
89.0	CD	O
%	NN	O
vs.	FW	O
88.4	CD	O
%	NN	O
-95	CD	O
%	NN	O
CI=-5.2	NNP	O
%	NN	O
;	:	O
+6.4	CD	O
%	NN	O
)	)	O
at	IN	O
the	DT	O
7-16	JJ	O
days	NNS	O
post-therapy	JJ	O
assessment	NN	O
.	.	O

At	IN	O
28-35	JJ	O
days	NNS	O
post-therapy	NN	O
,	,	O
the	DT	O
continued	JJ	O
clinical	JJ	Others
cure	NN	Others
rate	NN	Others
in	IN	O
the	DT	O
faropenem	JJ	O
daloxate	NN	O
group	NN	O
was	VBD	O
92.6	CD	O
%	NN	O
and	CC	O
that	IN	O
for	IN	O
the	DT	O
cefuroxime	NN	O
axetil	NN	O
group	NN	O
was	VBD	O
94.9	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-6.8	CD	O
%	NN	O
;	:	O
+1.2	CD	O
%	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
148	CD	O
organisms	NNS	O
was	VBD	O
obtained	VBN	O
in	IN	O
136	CD	O
microbiologically	RB	O
valid	JJ	O
patients	NNS	O
(	(	O
30.1	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
predominant	JJ	O
causative	JJ	O
organisms	NNS	O
were	VBD	O
Streptococcus	NNP	O
pneumoniae	NN	O
(	(	O
47.1	CD	O
%	NN	O
)	)	O
,	,	O
Haemophilus	NNP	O
influenzae	NN	O
(	(	O
30.1	CD	O
%	NN	O
)	)	O
,	,	O
Staphylococcus	NNP	O
aureus	NN	O
(	(	O
14.7	CD	O
%	NN	O
)	)	O
and	CC	O
Moraxella	NNP	O
catarrhalis	NN	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
bacteriological	JJ	Others
success	NN	Others
rate	NN	Others
at	IN	O
the	DT	O
7-16	JJ	O
days	NNS	O
post-therapy	JJ	O
evaluation	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
:	:	O
91.5	CD	O
%	NN	O
and	CC	O
90.8	CD	O
%	NN	O
in	IN	O
the	DT	O
faropenem	NN	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
95	CD	O
%	NN	O
CI=-9.2	NNP	O
%	NN	O
;	:	O
+9.5	CD	O
%	NN	O
)	)	O
.	.	O

Eradication	NN	Others
or	CC	Others
presumed	VBN	Others
eradication	NN	Others
was	VBD	O
detected	VBN	O
for	IN	O
97.3	CD	O
%	NN	O
and	CC	O
96.3	CD	O
%	NN	O
of	IN	O
S.	NNP	O
pneumoniae	NN	O
,	,	O
85.0	CD	O
%	NN	O
and	CC	O
90.5	CD	O
%	NN	O
of	IN	O
H.	NNP	O
influenzae	NN	O
,	,	O
88.9	CD	O
%	NN	O
and	CC	O
90.9	CD	O
%	NN	O
of	IN	O
S.	NNP	O
aureus	NN	O
and	CC	O
100.0	CD	O
%	NN	O
and	CC	O
83.3	CD	O
%	NN	O
of	IN	O
M.	NNP	O
catarrhalis	NN	O
in	IN	O
faropenem	JJ	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
recipients	NNS	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
least	JJS	O
one	CD	O
drug-related	JJ	Adverseeffect
event	NN	Adverseeffect
was	VBD	O
reported	VBN	O
by	IN	O
9.5	CD	O
%	NN	O
of	IN	O
the	DT	O
faropenem	JJ	O
daloxate-treated	JJ	O
patients	NNS	O
and	CC	O
by	IN	O
10.3	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
cefuroxime	RB	O
axetil	JJ	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
drug-related	JJ	O
events	NNS	O
were	VBD	O
diarrhoea	NNS	Adverseeffect
(	(	O
2.2	CD	O
%	NN	O
versus	IN	O
2.9	CD	O
%	NN	O
)	)	O
,	,	O
nausea/vomiting	VBG	Adverseeffect
(	(	O
1.5	CD	O
%	NN	O
vs.	FW	O
0.7	CD	O
%	NN	O
)	)	O
,	,	O
abdominal	JJ	Adverseeffect
pain	NN	Adverseeffect
(	(	O
0.7	CD	O
%	NN	O
vs	JJ	O
1.5	CD	O
%	NN	O
)	)	O
and	CC	O
skin	JJ	Physical
reactions	NNS	Physical
(	(	O
1.5	CD	O
%	NN	O
vs.	FW	O
1.1	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
faropenem	JJ	O
daloxate	NN	O
was	VBD	O
at	IN	O
least	JJS	O
as	IN	O
effective	JJ	O
clinically	NN	Others
and	CC	Others
bacteriologically	RB	Others
as	IN	O
cefuroxime	NN	O
axetil	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
.	.	O

Two	CD	O
different	JJ	O
methods	NNS	O
for	IN	O
donor	JJ	O
hepatic	JJ	O
transection	NN	O
:	:	O
cavitron	NN	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
with	IN	O
bipolar	JJ	O
cautery	NN	O
versus	NN	O
cavitron	NN	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
with	IN	O
radiofrequency	NN	O
coagulator-A	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
Cavitron	NNP	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
(	(	O
CUSA	NNP	O
)	)	O
with	IN	O
bipolar	JJ	O
cautery	NN	O
(	(	O
BP	NNP	O
)	)	O
to	TO	O
CUSA	NNP	O
with	IN	O
a	DT	O
radiofrequency	NN	O
coagulator	NN	O
[	NN	O
TissueLink	NNP	O
(	(	O
TL	NNP	O
)	)	O
]	VBP	O
in	IN	O
terms	NNS	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
hepatic	JJ	O
transection	NN	O
in	IN	O
living	VBG	O
donor	NN	O
liver	JJ	O
transplantation	NN	O
.	.	O

Twenty-four	CD	O
living	NN	O
liver	NN	O
donors	NNS	O
(	(	O
n	JJ	O
=	VBP	O
12	CD	O
for	IN	O
each	DT	O
group	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
hepatic	JJ	O
transection	NN	O
using	VBG	O
CUSA	NNP	O
with	IN	O
BP	NNP	O
or	CC	O
CUSA	NNP	O
with	IN	O
TL	NNP	O
.	.	O

Blood	NNP	Physical
loss	NN	Physical
during	IN	Physical
parenchymal	JJ	Physical
transection	NN	Physical
and	CC	Physical
speed	NN	Physical
of	IN	Physical
transection	NN	Physical
were	VBD	O
the	DT	O
primary	JJ	O
endpoints	NNS	O
,	,	O
whereas	IN	O
the	DT	O
degree	NN	Physical
of	IN	Physical
postoperative	JJ	Physical
liver	JJ	Physical
injury	NN	Physical
and	CC	Physical
morbidity	NN	Physical
were	VBD	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

Median	JJ	Physical
blood	NN	Physical
loss	NN	Physical
during	IN	Physical
liver	JJ	Physical
transection	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
195.2	CD	O
+/-	JJ	O
84.5	CD	O
versus	NN	O
343.3	CD	O
+/-	JJ	O
198.4	CD	O
mL	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
,	,	O
and	CC	O
liver	JJS	Others
transection	NN	Others
was	VBD	O
significantly	RB	O
faster	RBR	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
0.7	CD	O
+/-	JJ	O
0.2	CD	O
versus	NN	O
0.5	CD	O
+/-	JJ	O
0.2	CD	O
cm	NN	O
(	(	O
2	CD	O
)	)	O
/minute	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
.	.	O

Significantly	RB	O
fewer	JJR	Physical
ties	NNS	Physical
were	VBD	O
required	VBN	O
during	IN	O
liver	JJ	O
transection	NN	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
15.8	CD	O
+/-	JJ	O
4.8	CD	O
versus	NN	O
22.8	CD	O
+/-	JJ	O
7.9	CD	O
ties	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

The	DT	O
morbidity	NN	Others
rates	NNS	Others
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
CUSA	NNP	O
with	IN	O
TL	NNP	O
is	VBZ	O
superior	JJ	O
to	TO	O
CUSA	NNP	O
with	IN	O
BP	NNP	O
for	IN	O
donor	JJ	O
hepatectomy	NN	O
in	IN	O
terms	NNS	O
of	IN	O
blood	NN	Physical
loss	NN	Physical
and	CC	O
speed	NN	Others
of	IN	Others
transection	NN	Others
with	IN	O
no	DT	O
increase	NN	O
in	IN	O
morbidity	NN	Physical
.	.	O

Randomised	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
beta-sitosterol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
.	.	O

Beta-sitosterol	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Medical	NNP	O
treatments	NNS	O
have	VBP	O
become	VBN	O
available	JJ	O
for	IN	O
benign	JJ	O
hypertrophy	NN	O
of	IN	O
the	DT	O
prostate	NN	O
,	,	O
including	VBG	O
alpha-receptor	JJ	O
blocking	NN	O
agents	NNS	O
and	CC	O
5-alpha-reductase	JJ	O
inhibitors	NNS	O
.	.	O

Drugs	NNS	O
derived	VBN	O
from	IN	O
plants	NNS	O
,	,	O
for	IN	O
which	WDT	O
no	DT	O
precise	NN	O
mechanism	NN	O
of	IN	O
action	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
,	,	O
are	VBP	O
widely	RB	O
used	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
in	IN	O
Europe	NNP	O
.	.	O

In	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
multicentre	NN	O
study	NN	O
,	,	O
200	CD	O
patients	NNS	O
(	(	O
recruited	VBN	O
between	IN	O
April	NNP	O
and	CC	O
October	NNP	O
1993	CD	O
)	)	O
with	IN	O
symptomatic	JJ	O
benign	NN	O
prostatic	JJ	O
hyperplasia	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
either	DT	O
20	CD	O
mg	NN	O
beta-sitosterol	NN	O
(	(	O
which	WDT	O
contains	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
phytosterols	NNS	O
)	)	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
or	CC	O
placebo	NN	O
.	.	O

Primary	JJ	O
end-point	NN	O
was	VBD	O
a	DT	O
difference	NN	O
of	IN	O
modified	JJ	O
Boyarsky	NNP	Others
score	NN	Others
between	IN	O
treatment	NN	O
groups	NNS	O
after	IN	O
6	CD	O
months	NNS	O
;	:	O
secondary	JJ	O
end-points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
International	NNP	Physical
Prostate	NNP	Physical
Symptom	NNP	Physical
Score	NNP	Physical
(	(	Physical
IPSS	NNP	Physical
)	)	Physical
,	,	Physical
urine	JJ	Physical
flow	NN	Physical
,	,	Physical
and	CC	Physical
prostate	NN	Physical
volume	NN	Physical
.	.	Physical

Modified	NNP	Physical
Boyarsky	NNP	Physical
score	NN	Physical
decreased	VBD	O
significantly	RB	O
with	IN	O
a	DT	O
mean	NN	O
of	IN	O
-6.7	NNP	O
(	(	O
SD	NNP	O
4.0	CD	O
)	)	O
points	NNS	O
in	IN	O
the	DT	O
beta-sitosterol-treated	JJ	O
group	NN	O
versus	NN	O
-2.1	NNP	O
(	(	O
3.2	CD	O
)	)	O
points	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
p	VBD	O
<	RB	O
0.01	CD	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
IPSS	NNP	Physical
(	(	O
-7.4	NNP	O
[	VBZ	O
3.8	CD	O
]	NN	O
points	NNS	O
in	IN	O
the	DT	O
beta-sitosterol-treated	JJ	O
group	NN	O
vs	NN	O
-2.1	NNP	O
[	VBZ	O
3.8	CD	O
]	NN	O
points	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
and	CC	O
changes	NNS	O
in	IN	O
urine	JJ	Physical
flow	NN	Physical
parameters	NNS	Physical
:	:	O
beta-sitosterol	NN	O
treatment	NN	O
resulted	VBD	O
in	IN	O
increasing	VBG	O
peak	NN	Physical
flow	NN	Physical
(	(	O
15.2	CD	O
[	RB	O
5.7	CD	O
]	JJ	O
mL/s	NN	O
from	IN	O
9.9	CD	O
[	$	O
2.5	CD	O
]	NNP	O
mL/s	NN	O
)	)	O
,	,	O
and	CC	O
decrease	NN	O
of	IN	O
mean	JJ	Physical
residual	JJ	Physical
urinary	JJ	Physical
volume	NN	Physical
(	(	O
30.4	CD	O
[	RB	O
39.9	CD	O
]	JJ	O
mL	NN	O
from	IN	O
65.8	CD	O
[	$	O
20.8	CD	O
]	NNP	O
mL	NN	O
)	)	O
.	.	O

These	DT	O
parameters	NNS	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
relevant	JJ	O
reduction	NN	O
of	IN	O
prostatic	JJ	Physical
volume	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Significant	JJ	O
improvement	NN	O
in	IN	O
symptoms	NNS	Physical
and	CC	Physical
urinary	JJ	Physical
flow	NN	Physical
parameters	NNS	Physical
show	VBP	O
the	DT	O
effectiveness	NN	O
of	IN	O
beta-sitosterol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
.	.	O

Atrial	JJ	O
fibrillation	NN	O
catheter	NN	O
ablation	NN	O
versus	NN	O
surgical	JJ	O
ablation	NN	O
treatment	NN	O
(	(	O
FAST	NNP	O
)	)	O
:	:	O
a	DT	O
2-center	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Catheter	NNP	O
ablation	NN	O
(	(	O
CA	NNP	O
)	)	O
and	CC	O
minimally	RB	O
invasive	JJ	O
surgical	JJ	O
ablation	NN	O
(	(	O
SA	NNP	O
)	)	O
have	VBP	O
become	VBN	O
accepted	JJ	O
therapy	NN	O
for	IN	O
antiarrhythmic	JJ	O
drug-refractory	JJ	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

This	DT	O
study	NN	O
describes	VBZ	O
the	DT	O
first	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
their	PRP$	O
efficacy	NN	O
and	CC	O
safety	NN	O
during	IN	O
a	DT	O
12-month	JJ	O
follow-up	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
One	CD	O
hundred	VBD	O
twenty-four	JJ	O
patients	NNS	O
with	IN	O
antiarrhythmic	JJ	O
drug-refractory	JJ	O
atrial	JJ	O
fibrillation	NN	O
with	IN	O
left	JJ	O
atrial	JJ	O
dilatation	NN	O
and	CC	O
hypertension	NN	O
(	(	O
42	CD	O
patients	NNS	O
,	,	O
33	CD	O
%	NN	O
)	)	O
or	CC	O
failed	VBN	O
prior	JJ	O
CA	NNP	O
(	(	O
82	CD	O
patients	NNS	O
,	,	O
67	CD	O
%	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
CA	NNP	O
(	(	O
63	CD	O
patients	NNS	O
)	)	O
or	CC	O
SA	NNP	O
(	(	O
61	CD	O
patients	NNS	O
)	)	O
.	.	O

CA	NNP	O
consisted	VBD	O
of	IN	O
linear	JJ	O
antral	JJ	O
pulmonary	JJ	O
vein	NN	O
isolation	NN	O
and	CC	O
optional	JJ	O
additional	JJ	O
lines	NNS	O
.	.	O

SA	NNP	O
consisted	VBD	O
of	IN	O
bipolar	JJ	O
radiofrequency	NN	O
isolation	NN	O
of	IN	O
the	DT	O
bilateral	JJ	O
pulmonary	JJ	O
vein	NN	O
,	,	O
ganglionated	VBD	O
plexi	JJ	O
ablation	NN	O
,	,	O
and	CC	O
left	VBD	O
atrial	JJ	O
appendage	NN	O
excision	NN	O
with	IN	O
optional	JJ	O
additional	JJ	O
lines	NNS	O
.	.	O

Follow-up	NN	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
was	VBD	O
performed	VBN	O
by	IN	O
ECG	NNP	O
and	CC	O
7-day	JJ	O
Holter	NNP	O
recording	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
freedom	NN	O
from	IN	O
left	VBN	O
atrial	JJ	O
arrhythmia	NN	O
>	VBD	O
30	CD	O
seconds	NNS	O
without	IN	O
antiarrhythmic	JJ	O
drugs	NNS	O
after	IN	O
12	CD	O
months	NNS	O
,	,	O
was	VBD	O
36.5	CD	O
%	NN	O
for	IN	O
CA	NNP	O
and	CC	O
65.6	CD	O
%	NN	O
for	IN	O
SA	NNP	O
(	(	O
P=0.0022	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
effect	NN	O
for	IN	O
subgroups	NNS	O
,	,	O
which	WDT	O
was	VBD	O
consistent	NN	O
at	IN	O
both	DT	O
sites	NNS	O
.	.	O

The	DT	O
primary	JJ	O
safety	NN	O
end	NN	O
point	NN	O
of	IN	O
significant	JJ	O
adverse	JJ	O
events	NNS	O
during	IN	O
the	DT	O
12-month	JJ	O
follow-up	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
SA	NNP	O
than	IN	O
for	IN	O
CA	NNP	O
(	(	O
n=21	JJ	O
[	RB	O
34.4	CD	O
%	NN	O
]	JJ	O
versus	NN	O
n=10	NN	O
[	VBD	O
15.9	CD	O
%	NN	O
]	NN	O
;	:	O
P=0.027	NNP	O
)	)	O
,	,	O
driven	VBN	O
mainly	RB	O
by	IN	O
procedural	JJ	O
complications	NNS	O
such	JJ	O
as	IN	O
pneumothorax	NN	O
,	,	O
major	JJ	O
bleeding	NN	O
,	,	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
pacemaker	NN	O
.	.	O

In	IN	O
the	DT	O
CA	NNP	O
group	NN	O
,	,	O
1	CD	O
patient	NN	O
died	VBD	O
at	IN	O
1	CD	O
month	NN	O
of	IN	O
subarachnoid	JJ	O
hemorrhage	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
atrial	JJ	O
fibrillation	NN	O
patients	NNS	O
with	IN	O
dilated	JJ	O
left	JJ	O
atrium	NN	O
and	CC	O
hypertension	NN	O
or	CC	O
failed	VBD	O
prior	RB	O
atrial	JJ	O
fibrillation	NN	O
CA	NNP	O
,	,	O
SA	NNP	O
is	VBZ	O
superior	JJ	O
to	TO	O
CA	NNP	O
in	IN	O
achieving	VBG	O
freedom	NN	O
from	IN	O
left	VBN	O
atrial	JJ	O
arrhythmias	NNS	O
after	IN	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
although	IN	O
the	DT	O
procedural	JJ	O
adverse	JJ	O
event	NN	O
rate	NN	O
is	VBZ	O
significantly	RB	O
higher	JJR	O
for	IN	O
SA	NNP	O
than	IN	O
for	IN	O
CA	NNP	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
http	NN	O
:	:	O
//clinicaltrials.gov	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
NCT00662701	NNP	O
.	.	O

Radiation-induced	JJ	O
brachial	JJ	O
plexopathy	NN	O
:	:	O
neurological	JJ	O
follow-up	NN	O
in	IN	O
161	CD	O
recurrence-free	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
was	VBD	O
to	TO	O
assess	VB	Physical
the	DT	Physical
incidence	NN	Physical
and	CC	Physical
clinical	JJ	Physical
manifestations	NNS	Physical
of	IN	O
radiation-induced	JJ	O
brachial	JJ	O
plexopathy	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
,	,	O
treated	VBD	O
according	VBG	O
to	TO	O
the	DT	O
Danish	JJ	O
Breast	NNP	O
Cancer	NNP	O
Cooperative	NNP	O
Group	NNP	O
protocols	VBZ	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
One	NNP	O
hundred	CD	O
and	CC	O
sixty-one	JJ	O
recurrence-free	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
were	VBD	O
examined	VBN	O
for	IN	O
radiation-induced	JJ	O
brachial	JJ	O
plexopathy	NN	O
after	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
50	CD	O
months	NNS	O
(	(	O
13-99	JJ	O
months	NNS	O
)	)	O
.	.	O

After	IN	O
total	JJ	O
mastectomy	NN	O
and	CC	O
axillary	JJ	O
node	NN	O
sampling	NN	O
,	,	O
high-risk	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
adjuvant	VB	O
therapy	NN	O
.	.	O

One	CD	O
hundred	VBD	O
twenty-eight	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
postoperative	JJ	O
radiotherapy	NN	O
with	IN	O
50	CD	O
Gy	NNP	O
in	IN	O
25	CD	O
daily	JJ	O
fractions	NNS	O
over	IN	O
5	CD	O
weeks	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
82	CD	O
of	IN	O
these	DT	O
patients	NNS	O
received	VBD	O
cytotoxic	JJ	O
therapy	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
methotrexate	NN	O
,	,	O
and	CC	O
5-fluorouracil	JJ	O
)	)	O
and	CC	O
46	CD	O
received	VBD	O
tamoxifen	NN	O
.	.	O

RESULTS	NNP	O
Five	CD	O
percent	NN	O
and	CC	O
9	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
had	VBD	O
disabling	NN	Physical
and	CC	Physical
mild	JJ	Physical
radiation-induced	JJ	Physical
brachial	NN	Physical
plexopathy	NN	Physical
,	,	O
respectively	RB	O
.	.	O

Radiation-induced	JJ	Physical
brachial	JJ	Physical
plexopathy	NN	Physical
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
cytotoxic	JJ	O
therapy	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
and	CC	O
in	IN	O
younger	JJR	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
manifestations	NNS	O
were	VBD	O
paraesthesia	JJ	Physical
(	(	O
100	CD	O
%	NN	O
)	)	O
,	,	O
hypaesthesia	NN	Physical
(	(	O
74	CD	O
%	NN	O
)	)	O
,	,	O
weakness	NN	Physical
(	(	O
58	CD	O
%	NN	O
)	)	O
,	,	O
decreased	VBN	Adverseeffect
muscle	NN	Adverseeffect
stretch	NN	Adverseeffect
reflexes	NNS	Adverseeffect
(	(	O
47	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
pain	NN	Pain
(	(	O
47	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
brachial	JJ	O
plexus	NN	O
is	VBZ	O
more	RBR	O
vulnerable	JJ	O
to	TO	O
large	JJ	O
fraction	NN	O
size	NN	O
.	.	O

Fractions	NNS	O
of	IN	O
2	CD	O
Gy	NNP	O
or	CC	O
less	JJR	O
are	VBP	O
advisable	JJ	O
.	.	O

Cytotoxic	NNP	O
therapy	NN	O
adds	VBZ	O
to	TO	O
the	DT	O
damaging	JJ	O
effect	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

Peripheral	JJ	O
nerves	NNS	O
in	IN	O
younger	JJR	O
patients	NNS	O
seems	VBZ	O
more	RBR	O
vulnerable	JJ	O
.	.	O

Radiation-induced	JJ	O
brachial	JJ	O
plexopathy	NN	O
occurs	VBZ	O
mainly	RB	O
as	IN	O
diffuse	NN	O
damage	NN	O
to	TO	O
the	DT	O
brachial	JJ	O
plexus	NN	O
.	.	O

Randomized	VBN	O
comparative	JJ	O
study	NN	O
of	IN	O
tegafur/uracil	NN	O
and	CC	O
oral	JJ	O
leucovorin	NN	O
versus	IN	O
parenteral	JJ	O
fluorouracil	NN	O
and	CC	O
leucovorin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	O
colorectal	NN	O
cancer	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
phase	NN	O
III	NNP	O
study	NN	O
compared	VBN	O
the	DT	O
time	NN	Others
to	TO	Others
progression	NN	Others
(	(	Others
TTP	NNP	Others
)	)	Others
of	IN	O
an	DT	O
oral	JJ	O
regimen	NNS	O
of	IN	O
dihydropyrimidine	JJ	O
dehydrogenase	NN	O
inhibitory	NN	O
fluoropyrimidine	NN	O
composed	VBN	O
of	IN	O
a	DT	O
fixed	JJ	O
combination	NN	O
of	IN	O
tegafur	NN	O
and	CC	O
uracil	NN	O
in	IN	O
a	DT	O
1:4	CD	O
molar	JJ	O
ratio	NN	O
(	(	O
UFT	NNP	O
)	)	O
and	CC	O
leucovorin	$	O
(	(	O
LV	NNP	O
)	)	O
to	TO	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
fluorouracil	NN	O
(	(	O
5-FU	JJ	O
)	)	O
and	CC	O
LV	NNP	O
in	IN	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	O
colorectal	NN	O
carcinoma	NN	O
(	(	O
CRC	NNP	O
)	)	O
patients	NNS	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
survival	JJ	Mortality
,	,	O
tumor	JJ	Physical
response	NN	Physical
,	,	O
safety	NN	Others
,	,	O
and	CC	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
May	NNP	O
1996	CD	O
and	CC	O
July	NNP	O
1997	CD	O
,	,	O
380	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
UFT	NNP	O
(	(	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
and	CC	O
LV	NNP	O
(	(	O
90	CD	O
mg/d	NN	O
)	)	O
,	,	O
administered	VBN	O
for	IN	O
28	CD	O
days	NNS	O
every	DT	O
35	CD	O
days	NNS	O
,	,	O
or	CC	O
5-FU	JJ	O
(	(	O
425	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
and	CC	O
LV	NNP	O
(	(	O
20	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
,	,	O
given	VBN	O
IV	NNP	O
for	IN	O
5	CD	O
days	NNS	O
every	DT	O
35	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
TTP	NNP	Physical
was	VBD	O
observed	VBN	O
between	IN	O
treatments	NNS	O
.	.	O

With	IN	O
320	CD	O
events	NNS	O
assessed	VBN	O
,	,	O
the	DT	O
median	JJ	O
TTP	NNP	Physical
was	VBD	O
3.4	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
Confidence	NNP	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
2.6	CD	O
to	TO	O
3.8	CD	O
)	)	O
on	IN	O
UFT/LV	NNP	O
and	CC	O
3.3	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
2.5	CD	O
to	TO	O
3.7	CD	O
)	)	O
on	IN	O
5-FU/LV	JJ	O
(	(	O
P	NNP	O
=.591	NNP	O
,	,	O
stratified	VBD	O
log-rank	JJ	O
test	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
survival	NN	Mortality
,	,	O
tumor	NN	Physical
response	NN	Physical
,	,	O
duration	NN	Physical
of	IN	Physical
response	NN	Physical
,	,	O
and	CC	O
time	NN	Physical
to	TO	Physical
response	NN	Physical
.	.	O

Substantial	NNP	O
safety	NN	Others
benefits	NNS	Others
were	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
UFT/LV	NNP	O
.	.	O

They	PRP	O
experienced	VBD	O
significantly	RB	O
less	JJR	O
stomatitis/mucositis	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
myelosuppression	NN	Physical
,	,	O
resulting	VBG	O
in	IN	O
fewer	JJR	O
episodes	NNS	O
of	IN	O
febrile	JJ	Physical
neutropenia	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
less	RBR	O
documented	JJ	Physical
infection	NN	Physical
(	(	O
P	NNP	O
=.04	NNP	O
)	)	O
.	.	O

Concomitant	JJ	O
medication	NN	O
usage	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
on	IN	O
5-FU/LV	JJ	O
(	(	O
P	NNP	O
=.010	NNP	O
)	)	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
quality	NN	Others
of	IN	Others
life	NN	Others
,	,	O
after	IN	O
correcting	VBG	O
for	IN	O
baseline	NN	O
imbalances	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatments	NNS	O
for	IN	O
any	DT	O
scale	NN	O
,	,	O
except	IN	O
diarrhea	NN	Adverseeffect
.	.	O

CONCLUSION	VB	O
The	DT	O
oral	JJ	O
UFT/LV	NNP	O
regimen	NNS	O
failed	VBD	O
to	TO	O
achieve	VB	O
improved	JJ	O
TTP	NNP	Physical
;	:	O
however	RB	O
,	,	O
the	DT	O
study	NN	O
confirms	VBZ	O
significant	JJ	O
safety	NN	O
improvements	NNS	O
compared	VBN	O
with	IN	O
bolus	JJ	O
IV	NNP	O
5-FU/LV	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
CRC	NNP	O
.	.	O

Therapeutic	JJ	O
recommendations	NNS	Others
in	IN	O
polycythemia	NN	O
vera	NN	O
based	VBN	O
on	IN	O
Polycythemia	NNP	O
Vera	NNP	O
Study	NNP	O
Group	NNP	O
protocols	VBZ	O
.	.	O

The	DT	O
PVSG	NNP	O
was	VBD	O
organized	VBN	O
in	IN	O
1967	CD	O
to	TO	O
establish	VB	O
effective	JJ	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
polycythemia	NN	O
vera	NN	O
,	,	O
to	TO	O
study	VB	O
the	DT	O
natural	JJ	O
history	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
to	TO	O
define	VB	O
the	DT	O
optimal	JJ	O
treatment	NN	O
.	.	O

Although	IN	O
polycythemia	NN	O
vera	NN	O
and	CC	O
the	DT	O
other	JJ	O
myeloproliferative	JJ	O
diseases	NNS	O
are	VBP	O
relatively	RB	O
uncommon	JJ	O
,	,	O
the	DT	O
PVSG	NNP	O
was	VBD	O
able	JJ	O
to	TO	O
accumulate	VB	O
well	RB	O
over	IN	O
1,000	CD	O
patients	NNS	O
with	IN	O
these	DT	O
various	JJ	O
disorders	NNS	O
and	CC	O
to	TO	O
study	VB	O
them	PRP	O
according	VBG	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
15	CD	O
different	JJ	O
protocols	NNS	O
.	.	O

PVSG-01	NNP	O
,	,	O
a	DT	O
long-term	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
phlebotomy	NN	O
alone	RB	O
compared	VBN	O
with	IN	O
the	DT	O
myelosuppressive	JJ	O
agents	NNS	O
,	,	O
32P	CD	O
or	CC	O
chlorambucil	NN	O
supplemented	VBN	O
by	IN	O
phlebotomy	NN	O
,	,	O
continues	VBZ	O
to	TO	O
receive	VB	O
follow-up	JJ	O
data	NNS	O
on	IN	O
93	CD	O
%	NN	O
of	IN	O
surviving	VBG	O
patients	NNS	O
18	CD	O
years	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

During	IN	O
its	PRP$	O
lifetime	NN	O
,	,	O
PVSG	NNP	O
has	VBZ	O
developed	VBN	O
a	DT	O
widely	RB	O
accepted	VBN	O
and	CC	O
highly	RB	O
effective	JJ	O
set	NN	O
of	IN	O
criteria	NNS	O
for	IN	O
the	DT	O
specific	JJ	O
diagnosis	NN	O
of	IN	O
polycythemia	NN	O
vera	NN	O
as	RB	O
well	RB	O
as	IN	O
useful	JJ	O
criteria	NNS	O
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
essential	JJ	O
thrombocythemia	NN	O
.	.	O

It	PRP	O
has	VBZ	O
gathered	VBN	O
an	DT	O
enormous	JJ	O
volume	NN	O
of	IN	O
data	NNS	O
on	IN	O
the	DT	O
natural	JJ	O
history	NN	O
of	IN	O
the	DT	O
myeloproliferative	JJ	O
diseases	NNS	O
and	CC	O
in	IN	O
particular	JJ	O
on	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
prevalent	JJ	O
complications	NNS	O
,	,	O
such	JJ	O
as	IN	O
thrombotic	JJ	O
events	NNS	O
and	CC	O
hematologic	NN	O
and	CC	O
nonhematologic	JJ	O
malignancies	NNS	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
the	DT	O
final	JJ	O
question	NN	O
,	,	O
the	DT	O
optimal	JJ	O
treatment	NN	O
for	IN	O
polycythemia	NN	O
vera	NN	O
,	,	O
it	PRP	O
is	VBZ	O
apparent	JJ	O
that	IN	O
the	DT	O
expectation	NN	O
of	IN	O
a	DT	O
single	JJ	O
optimal	JJ	O
therapy	NN	O
that	WDT	O
would	MD	O
apply	VB	O
to	TO	O
all	DT	O
patients	NNS	O
at	IN	O
all	DT	O
ages	NNS	O
and	CC	O
stages	NNS	O
of	IN	O
the	DT	O
disease	NN	O
was	VBD	O
naive	JJ	O
.	.	O

Nevertheless	NNP	O
considerable	JJ	O
progress	NN	O
has	VBZ	O
been	VBN	O
made	VBN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
group	NN	O
has	VBZ	O
defined	VBN	O
more	RBR	O
precisely	RB	O
than	IN	O
ever	RB	O
before	IN	O
the	DT	O
nature	NN	Physical
of	IN	Physical
the	DT	Physical
complications	NNS	Physical
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
the	DT	O
association	NN	O
of	IN	O
the	DT	O
risks	NNS	Physical
of	IN	Physical
specific	JJ	Adverseeffect
complications	NNS	Adverseeffect
with	IN	O
specific	JJ	O
forms	NNS	O
of	IN	O
therapy	NN	O
.	.	O

It	PRP	O
thus	RB	O
has	VBZ	O
made	VBN	O
it	PRP	O
possible	JJ	O
to	TO	O
pose	VB	O
the	DT	O
next	JJ	O
series	NN	O
of	IN	O
therapeutic	JJ	O
questions	NNS	O
that	WDT	O
must	MD	O
be	VB	O
addressed	VBN	O
in	IN	O
this	DT	O
disorder	NN	O
with	IN	O
a	DT	O
greater	JJR	O
degree	NN	O
of	IN	O
sophistication	NN	O
than	IN	O
was	VBD	O
previously	RB	O
possible	JJ	O
.	.	O

Long-term	JJ	O
effects	NNS	O
of	IN	O
choline	NN	O
on	IN	O
productive	JJ	Mental
performance	NN	Mental
and	CC	Mental
egg	NN	Mental
quality	NN	Mental
of	IN	O
brown-egg	NN	O
laying	NN	O
hens	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
five	CD	O
hundred	JJ	O
forty	NN	O
19-wk-old	JJ	O
HyLine	NNP	O
Brown	NNP	O
hens	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
study	VB	O
the	DT	O
long-term	JJ	O
effects	NNS	O
of	IN	O
increasing	VBG	O
choline	NN	O
with	IN	O
0	CD	O
(	(	O
control	NN	O
)	)	O
,	,	O
425	CD	O
,	,	O
850	CD	O
,	,	O
1,700	CD	O
,	,	O
3,400	CD	O
,	,	O
and	CC	O
6,800	CD	O
mg/kg	NN	O
of	IN	O
corn-soybean	JJ	O
meal-based	JJ	O
diets	NNS	O
on	IN	O
productive	JJ	Mental
performance	NN	Mental
and	CC	Mental
egg	NN	Mental
quality	NN	Mental
.	.	O

Phase	VB	O
1	CD	O
was	VBD	O
from	IN	O
19	CD	O
to	TO	O
58	CD	O
wk	NN	O
,	,	O
and	CC	O
phase	NN	O
2	CD	O
was	VBD	O
from	IN	O
59	CD	O
to	TO	O
68	CD	O
wk	NN	O
.	.	O

During	IN	O
the	DT	O
whole	JJ	O
experimental	JJ	O
period	NN	O
,	,	O
dietary	JJ	O
choline	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
feed	NN	Mental
intake	NN	Mental
,	,	Mental
egg	NN	Mental
weight	NN	Mental
,	,	Mental
and	CC	Mental
egg	NN	Mental
mass	NN	Mental
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

During	IN	O
phase	NN	O
1	CD	O
,	,	O
egg	NN	Mental
production	NN	Mental
decreased	VBD	O
linearly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
feed	JJ	Mental
conversion	NN	Mental
ratio	NN	Mental
(	(	Mental
FCR	NNP	Mental
)	)	Mental
tended	VBD	O
to	TO	O
increase	VB	O
linearly	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.057	CD	O
)	)	O
with	IN	O
increasing	VBG	O
choline	JJ	O
level	NN	O
in	IN	O
the	DT	O
diet	NN	O
.	.	O

Moreover	RB	O
,	,	O
BW	NNP	Mental
decreased	VBD	O
both	DT	O
linearly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
quadratically	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
as	IN	O
choline	NN	O
increased	VBN	O
from	IN	O
0	CD	O
to	TO	O
6,800	CD	O
mg/kg	NNS	O
.	.	O

No	DT	O
significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
shell	NN	Mental
thickness	NN	Mental
and	CC	Mental
shell	NN	Mental
strength	NN	Mental
of	IN	O
eggs	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
albumen	NNS	Mental
height	VBD	Mental
and	CC	Mental
Haugh	NNP	Mental
units	NNS	Mental
increased	VBD	O
linearly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
and	CC	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
respectively	RB	O
)	)	O
as	IN	O
choline	NN	O
increased	VBD	O
during	IN	O
phase	NN	O
2	CD	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
diets	NNS	O
supplemented	VBD	O
with	IN	O
425	CD	O
or	CC	O
850	CD	O
mg	NN	O
of	IN	O
choline/kg	NN	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
improved	VBN	O
yolk	JJ	Mental
color	NN	Mental
during	IN	O
phase	NN	O
1	CD	O
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
a	DT	O
dietary	JJ	O
choline	NN	O
level	NN	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
700	CD	O
mg/kg	NN	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
maintain	VB	O
egg	NN	O
production	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
choline	NN	O
on	IN	O
egg	NN	Mental
quality	NN	Mental
was	VBD	O
minimal	JJ	O
when	WRB	O
hens	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
corn-soybean	JJ	O
meal-based	JJ	O
diet	NN	O
from	IN	O
19	CD	O
to	TO	O
68	CD	O
wk	NN	O
of	IN	O
age	NN	O
.	.	O

Using	VBG	O
baby	NN	O
books	NNS	O
to	TO	O
increase	VB	O
new	JJ	Mental
mothers	NNS	Mental
'	POS	Mental
safety	NN	Mental
practices	NNS	Mental
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
educational	JJ	O
baby	NN	O
books	NNS	O
are	VBP	O
an	DT	O
effective	JJ	O
method	NN	O
for	IN	O
increasing	VBG	O
low-income	JJ	Mental
,	,	Mental
first-time	JJ	Mental
mothers	NNS	Mental
'	POS	Mental
safety	NN	Mental
practices	NNS	Mental
during	IN	O
their	PRP$	O
child	NN	O
's	POS	O
first	JJ	O
18	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
Primiparous	JJ	O
women	NNS	O
(	(	O
n	JJ	O
=	NNP	O
167	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
:	:	O
an	DT	O
educational	JJ	O
book	NN	O
group	NN	O
,	,	O
a	DT	O
noneducational	JJ	O
book	NN	O
group	NN	O
,	,	O
or	CC	O
a	DT	O
no-book	JJ	O
group	NN	O
.	.	O

Home	NNP	O
visits	NNS	O
and	CC	O
interviews	NNS	O
measured	VBN	O
safety	NN	Mental
practices	NNS	Mental
when	WRB	O
women	NNS	O
were	VBD	O
in	IN	O
their	PRP$	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
(	(	O
baseline	NN	O
)	)	O
and	CC	O
when	WRB	O
their	PRP$	O
children	NNS	O
were	VBD	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
in	IN	O
the	DT	O
educational	JJ	O
book	NN	O
group	NN	O
had	VBD	O
fewer	JJR	Mental
risks	NNS	Mental
in	IN	Mental
their	PRP$	Mental
homes	NNS	Mental
and	CC	O
exercised	VBD	O
more	JJR	O
safety	NN	Mental
practices	NNS	Mental
than	IN	O
the	DT	O
no-book	JJ	O
group	NN	O
(	(	O
-	:	O
20	CD	O
%	NN	O
risk	NN	O
reduction	NN	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
-.30	NNP	O
)	)	O
.	.	O

When	WRB	O
the	DT	O
safety	NN	O
practices	NNS	Mental
involved	VBN	O
little	JJ	Mental
time	NN	Mental
or	CC	Mental
expense	NN	Mental
(	(	O
eg	UH	O
,	,	O
putting	VBG	O
away	RB	O
sharp	JJ	O
objects	NNS	O
)	)	O
,	,	O
the	DT	O
educational	JJ	O
book	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
engage	VB	O
in	IN	O
these	DT	O
behaviors	NNS	O
than	IN	O
the	DT	O
no-book	JJ	O
group	NN	O
(	(	O
40	CD	O
%	NN	O
higher	JJR	O
practices	NNS	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
0.19	CD	O
)	)	O
or	CC	O
noneducational	JJ	O
book	NN	O
group	NN	O
(	(	O
27	CD	O
%	NN	O
higher	JJR	O
practices	NNS	O
;	:	O
effect	NN	O
size	NN	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
groups	NNS	O
for	IN	O
behaviors	NNS	O
that	WDT	O
required	VBD	O
high	JJ	O
effort	NN	O
in	IN	O
time	NN	O
,	,	O
money	NN	O
,	,	O
or	CC	O
hassle	NN	O
(	(	O
eg	JJ	O
,	,	O
installing	VBG	O
latches	NNS	O
on	IN	O
cabinets	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Educational	NNP	O
baby	NN	O
books	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
an	DT	O
easy	JJ	O
and	CC	O
low-cost	JJ	O
way	NN	O
to	TO	O
increase	VB	O
the	DT	O
safety	NN	O
practices	NNS	O
of	IN	O
new	JJ	O
mothers	NNS	O
,	,	O
especially	RB	O
if	IN	O
the	DT	O
practices	NNS	O
involve	VBP	O
little	JJ	O
to	TO	O
no	DT	O
time	NN	O
,	,	O
money	NN	O
,	,	O
or	CC	O
hassle	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
outcome	NN	O
of	IN	O
labetalol	NN	O
or	CC	O
hydralazine	JJ	O
therapy	NN	O
during	IN	O
hypertension	NN	O
in	IN	O
pregnancy	NN	O
in	IN	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
.	.	O

Ninety-seven	JJ	O
women	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
preeclampsia	NN	O
(	(	O
PE	NNP	O
)	)	O
were	VBD	O
allocated	VBN	O
at	IN	O
random	NN	O
to	TO	O
labetalol	VB	O
or	CC	O
hydralazine	VB	O
treatment	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
22	CD	O
women	NNS	O
with	IN	O
severe	JJ	O
PE	NNP	O
gave	VBD	O
birth	NN	O
to	TO	O
neonates	NNS	O
with	IN	O
VLBW	NNP	O
(	(	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
<	NN	O
or	CC	O
=	JJ	O
1500	CD	O
g	NN	O
)	)	O
.	.	O

Seven	VBN	O
were	VBD	O
allocated	VBN	O
to	TO	O
labetalol	VB	O
treatment	NN	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
,	,	O
eight	CD	O
to	TO	O
hydralazine	VB	O
treatment	NN	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
and	CC	O
seven	CD	O
women	NNS	O
received	VBD	O
both	DT	O
drugs	NNS	O
due	JJ	O
to	TO	O
poor	JJ	O
blood	NN	O
pressure	NN	O
control	NN	O
with	IN	O
a	DT	O
single	JJ	O
drug	NN	O
therapy	NN	O
(	(	O
Group	NNP	O
C	NNP	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
cesarean	JJ	Physical
section	NN	Physical
rate	NN	Physical
or	CC	O
in	IN	O
the	DT	O
indication	NN	Physical
for	IN	Physical
operative	JJ	Physical
delivery	NN	Physical
could	MD	O
be	VB	O
seen	VBN	O
.	.	O

Gestational	JJ	Physical
age	NN	Physical
was	VBD	O
29.9	CD	O
weeks	NNS	O
(	(	O
25.4-32.5	JJ	O
)	)	O
in	IN	O
Group	NNP	O
A	NNP	O
,	,	O
28.6	CD	O
weeks	NNS	O
(	(	O
26.6-33.4	JJ	O
)	)	O
in	IN	O
Group	NNP	O
B	NNP	O
and	CC	O
27.3	CD	O
weeks	NNS	O
(	(	O
26.7-31.1	JJ	O
)	)	O
in	IN	O
Group	NNP	O
C	NNP	O
(	(	O
median	JJ	O
and	CC	O
range	NN	O
)	)	O
.	.	O

Birth	NNP	Physical
weight	VBD	Physical
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
and	CC	O
13	CD	O
of	IN	O
the	DT	O
22	CD	O
infants	NNS	O
weighed	VBN	O
below	IN	O
1000	CD	O
g.	NN	O
There	EX	O
was	VBD	O
a	DT	O
tendency	NN	O
to	TO	O
lower	VB	O
Apgar	NNP	Physical
scores	NNS	Physical
at	IN	O
five	CD	O
minutes	NNS	O
in	IN	O
the	DT	O
hydralazine	NN	O
group	NN	O
.	.	O

Time	NNP	Others
spent	NN	Others
in	IN	Others
the	DT	Others
neonatal	JJ	Others
intensive	JJ	Others
care	NN	Others
unit	NN	Others
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
.	.	O

Five	CD	O
of	IN	O
the	DT	O
11	CD	O
neonates	NNS	O
with	IN	O
gestational	JJ	O
age	NN	O
(	(	O
GA	NNP	O
)	)	O
<	VBD	O
or	CC	O
=	$	O
28	CD	O
weeks	NNS	O
and	CC	O
three	CD	O
of	IN	O
the	DT	O
seven	CD	O
neonates	NNS	O
in	IN	O
GA	NNP	O
29-30	JJ	O
weeks	NNS	O
died	VBD	Mortality
.	.	O

Neither	CC	O
the	DT	O
number	NN	Others
of	IN	Others
infants	NNS	Others
requiring	VBG	Physical
intermittent	JJ	Physical
positive	JJ	Physical
pressure	NN	Physical
ventilation	NN	Physical
or	CC	O
duration	NN	Others
of	IN	Others
O2-	NNP	Others
treatment	NN	Others
,	,	O
nor	CC	O
number	NN	Physical
of	IN	Physical
infants	NNS	Physical
with	IN	Physical
respiratory	JJ	Physical
distress	JJ	Physical
syndrome	NN	Physical
differed	VBD	O
between	IN	O
groups	NNS	O
.	.	O

We	PRP	O
did	VBD	O
not	RB	O
find	VB	O
any	DT	O
difference	NN	O
in	IN	O
the	DT	O
outcome	NN	O
of	IN	O
the	DT	O
VLBW	NNP	O
infants	NNS	O
when	WRB	O
the	DT	O
hypertensive	NN	O
mother	NN	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
either	DT	O
hydralazine	NN	O
or	CC	O
labetalol	NN	O
.	.	O

PSK	NNP	O
may	MD	O
suppress	VB	O
CD57	NNP	O
(	(	O
+	NNP	O
)	)	O
T	NNP	O
cells	NNS	O
to	TO	O
improve	VB	O
survival	NN	O
of	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
A	NNP	O
recent	JJ	O
report	NN	O
showed	VBD	O
that	IN	O
oral	JJ	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
protein-bound	JJ	O
polysaccharide	NN	O
K	NNP	O
(	(	O
PSK	NNP	O
)	)	O
and	CC	O
tegafur/uracil	NN	O
(	(	O
UFT	NNP	O
)	)	O
for	IN	O
stage	NN	O
II	NNP	O
and	CC	O
III	NNP	O
colorectal	JJ	O
cancer	NN	O
improves	VBZ	O
overall	JJ	O
survival	NN	O
compared	VBN	O
with	IN	O
UFT	NNP	O
alone	RB	O
.	.	O

PSK	NNP	O
has	VBZ	O
been	VBN	O
supposed	VBN	O
to	TO	O
improve	VB	O
survival	NN	O
through	IN	O
immunological	JJ	O
mechanisms	NNS	O
such	JJ	O
as	IN	O
induction	NN	O
of	IN	O
cytokines	NNS	O
,	,	O
regulation	NN	O
of	IN	O
Th1/Th2	NNP	O
balance	NN	O
,	,	O
and	CC	O
inhibition	NN	O
of	IN	O
immunosuppressive	JJ	O
molecules	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
mechanisms	NNS	O
by	IN	O
which	WDT	O
PSK	NNP	O
influences	VBZ	O
immunological	JJ	Physical
parameters	NNS	Physical
such	JJ	O
as	IN	O
Th1	NNP	Physical
cells	NNS	Physical
(	(	Physical
IFN-gamma-positive	JJ	Physical
CD4	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
)	)	Physical
,	,	Physical
Th2	NNP	Physical
cells	NNS	Physical
(	(	Physical
IL-4-positive	JJ	Physical
CD4	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
)	)	Physical
,	,	Physical
Th1/Th2	NNP	Physical
ratio	NN	Physical
,	,	Physical
NKT	NNP	Physical
cells	NNS	Physical
(	(	Physical
CD56	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
and	CC	Physical
CD57	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
)	)	Physical
,	,	Physical
NK	NNP	Physical
cells	NNS	Physical
,	,	Physical
and	CC	Physical
CD25	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
CD4	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
in	IN	O
stage	NN	O
III	NNP	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
3	CD	O
g	NN	O
PSK	NNP	O
plus	CC	O
300	CD	O
mg	NN	O
UFT	NNP	O
(	(	O
PSK	NNP	O
group	NN	O
)	)	O
or	CC	O
300	CD	O
mg	JJ	O
UFT	NNP	O
alone	RB	O
(	(	O
control	NN	O
)	)	O
orally	RB	O
each	DT	O
day	NN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
year	NN	O
following	VBG	O
their	PRP$	O
operation	NN	O
.	.	O

RESULTS	NNP	O
Twenty-one	CD	O
registered	VBD	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
gastric	JJ	O
cancer	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
3-year	JJ	Mortality
overall	JJ	Mortality
survival	NN	Mortality
was	VBD	O
62.2	CD	O
%	NN	O
in	IN	O
the	DT	O
PSK	NNP	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
and	CC	O
12.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
.	.	O

Before	IN	O
operation	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
Th1	NNP	Physical
cells	NNS	Physical
,	,	Physical
Th2	NNP	Physical
cells	NNS	Physical
,	,	Physical
Th1/Th2	NNP	Physical
ratio	NN	Physical
,	,	Physical
CD56	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
,	,	Physical
CD57	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
,	,	Physical
NK	NNP	Physical
cells	NNS	Physical
,	,	Physical
and	CC	Physical
CD4	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
CD25	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	O
between	IN	O
PSK	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
after	IN	O
operation	NN	O
,	,	O
CD57	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
T	NNP	Physical
cells	NNS	Physical
decreased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
PSK	NNP	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0486	CD	O
)	)	O
.	.	O

When	WRB	O
all	DT	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
,	,	O
patients	NNS	O
with	IN	O
increased	JJ	O
proportion	NN	O
(	(	O
>	JJ	O
18	CD	O
%	NN	O
)	)	O
of	IN	O
CD57	NNP	O
(	(	O
+	NNP	O
)	)	O
T	NNP	O
cells	NNS	O
showed	VBD	O
worse	JJR	O
survival	NN	O
than	IN	O
those	DT	O
with	IN	O
lower	JJR	O
(	(	O
<	CD	O
or	CC	O
=	VB	O
18	CD	O
%	NN	O
)	)	O
CD57	NNP	O
(	(	O
+	NNP	O
)	)	O
T	NNP	O
cells	NNS	O
(	(	O
3-year	JJ	O
survival	NN	O
,	,	O
25.0	CD	O
and	CC	O
45.7	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.046	CD	O
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
our	PRP$	O
previous	JJ	O
report	NN	O
that	WDT	O
high	JJ	O
CD57	NNP	O
(	(	O
+	NNP	O
)	)	O
is	VBZ	O
an	DT	O
indicator	NN	O
of	IN	O
poor	JJ	O
prognosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
PSK	NNP	O
+	NNP	O
UFT	NNP	O
,	,	O
3-year	JJ	Mortality
survival	NN	Mortality
of	IN	O
CD57-high	JJ	O
patients	NNS	O
was	VBD	O
as	RB	O
great	JJ	O
as	IN	O
that	DT	O
of	IN	O
CD57-low	JJ	O
patients	NNS	O
(	(	O
66.7	CD	O
and	CC	O
51.4	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.67	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
PSK	NNP	O
improves	VBZ	O
overall	JJ	O
survival	NN	O
of	IN	O
stage	NN	O
III	NNP	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
partly	RB	O
by	IN	O
inhibiting	VBG	O
CD57	NNP	O
(	(	O
+	NNP	O
)	)	O
T	NNP	O
cells	NNS	O
,	,	O
a	DT	O
proven	JJ	O
poor	JJ	O
prognostic	JJ	O
factor	NN	O
in	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

Sulfasalazine	NNP	O
decreases	VBZ	O
acute	JJ	O
gastrointestinal	JJ	O
complications	NNS	O
due	JJ	O
to	TO	O
pelvic	JJ	O
radiotherapy	NN	O
.	.	O

BACKGROUND	NNP	O
Radiation-induced	NNP	O
gastrointestinal	JJ	O
toxicity	NN	O
is	VBZ	O
a	DT	O
significant	JJ	O
concern	NN	O
for	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
treated	VBN	O
with	IN	O
this	DT	O
modality	NN	O
for	IN	O
pelvic	JJ	O
malignancies	NNS	O
.	.	O

Eicosanoids	NNS	O
and	CC	O
free	JJ	O
radicals	NNS	O
are	VBP	O
thought	VBN	O
to	TO	O
be	VB	O
among	IN	O
the	DT	O
reasons	NNS	O
for	IN	O
this	DT	O
effect	NN	O
.	.	O

Sulfasalazine	NNP	O
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
their	PRP$	O
synthesis	NN	O
in	IN	O
the	DT	O
mucosa	NN	O
.	.	O

OBJECTlVE	NN	O
:	:	O
To	TO	O
determine	VB	O
whether	IN	O
sulfasalazine	NN	O
can	MD	O
reduce	VB	O
the	DT	O
radiation-induced	JJ	O
acute	JJ	O
gastrointestinal	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
,	,	O
31	CD	O
patients	NNS	O
receiving	VBG	O
pelvic	JJ	O
radiotherapy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
two	CD	O
sulfasalazine	JJ	O
500-mg	JJ	O
tablets	NNS	O
twice	JJ	O
daily	RB	O
or	CC	O
placebo	VB	O
,	,	O
administered	VBN	O
orally	RB	O
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
irradiation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	JJ	O
weekly	JJ	O
,	,	O
and	CC	O
gastrointestinal	JJ	Physical
toxicities	NNS	Physical
were	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Late	JJ	Physical
Effect	NNP	Physical
of	IN	Physical
Normal	NNP	Physical
Tissue-Subjective	NNP	Physical
Objective	NNP	Physical
Management	NNP	Physical
Analytic	NNP	Physical
(	(	Physical
LENT-SOMA	NNP	Physical
)	)	Physical
toxicity	NN	Physical
table	NN	Physical
during	IN	O
pelvic	JJ	O
radiotherapy	NN	O
.	.	O

On	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
week	NN	O
5	CD	O
,	,	O
the	DT	O
subjects	NNS	O
were	VBD	O
graded	VBN	O
endoscopically	RB	O
,	,	O
and	CC	O
biopsies	NNS	O
taken	VBN	O
from	IN	O
the	DT	O
rectum	NN	O
were	VBD	O
classified	VBN	O
histopathologically	RB	O
.	.	O

RESULTS	NNP	O
Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
tumor	NN	O
site	NN	O
,	,	O
or	CC	O
irradiation	NN	O
procedure	NN	O
.	.	O

During	IN	O
radiotherapy	NN	O
,	,	O
grade	VBD	Physical
2	CD	Physical
or	CC	Physical
higher	JJR	Physical
gastrointestinal	JJ	Physical
toxicity	NN	Physical
occurred	VBD	O
in	IN	O
20	CD	O
%	NN	O
(	(	O
3/15	CD	O
)	)	O
and	CC	O
63	CD	O
%	NN	O
(	(	O
10/16	CD	O
)	)	O
of	IN	O
the	DT	O
sulfasalazine	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

This	DT	O
difference	NN	Others
was	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
endoscopic	NN	O
and	CC	O
histopathologic	JJ	O
evaluations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Sulfasalazine	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
clinically	RB	O
acute	JJ	O
gastrointestinal	JJ	O
toxicities	NNS	O
.	.	O

Long-term	JJ	O
follow-up	JJ	O
with	IN	O
the	DT	O
subjects	NNS	O
will	MD	O
help	VB	O
to	TO	O
determine	VB	O
the	DT	O
net	JJ	O
effect	NN	O
of	IN	O
sulfasalazine	NN	O
on	IN	O
the	DT	O
radiation-induced	JJ	O
gastrointestinal	JJ	O
injuries	NNS	O
.	.	O

The	DT	O
injured	JJ	O
colon	NN	O
:	:	O
therapeutic	JJ	O
considerations	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
the	DT	O
Detroit	NNP	O
General	NNP	O
Hospital	NNP	O
over	IN	O
a	DT	O
two	CD	O
year	NN	O
period	NN	O
to	TO	O
evaluate	VB	O
methods	NNS	O
of	IN	O
management	NN	O
in	IN	O
165	CD	O
patients	NNS	O
with	IN	O
colonic	JJ	O
injuries	NNS	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
show	NN	O
that	IN	O
primary	JJ	O
closure	NN	O
is	VBZ	O
a	DT	O
safe	JJ	Others
and	CC	O
reiable	JJ	Others
method	NN	O
of	IN	O
management	NN	O
when	WRB	O
rigid	JJ	O
criteria	NNS	O
are	VBP	O
incorporated	VBN	O
in	IN	O
an	DT	O
ongoing	JJ	O
protocol	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
technic	NN	O
of	IN	O
exteriorization	NN	O
is	VBZ	O
a	DT	O
safe	JJ	Others
adjunct	NN	O
to	TO	O
management	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
any	DT	O
patient	NN	O
with	IN	O
a	DT	O
colonic	JJ	O
injury	NN	O
above	IN	O
18	CD	O
cm	NN	O
in	IN	O
which	WDT	O
one	CD	O
suture	NN	O
line	NN	O
is	VBZ	O
required	VBN	O
and	CC	O
in	IN	O
which	WDT	O
the	DT	O
additional	JJ	O
operating	NN	O
time	NN	O
of	IN	O
twenty	NN	O
minutes	NNS	O
will	MD	O
not	RB	O
compromise	VB	O
the	DT	O
management	NN	O
of	IN	O
secondary	JJ	O
injuries	NNS	O
.	.	O

Patients	NNS	O
not	RB	O
fulfilling	VBG	O
these	DT	O
criteria	NNS	O
should	MD	O
have	VB	O
primary	JJ	Physical
colostomy	NN	Physical
.	.	Physical

These	DT	O
principles	NNS	O
make	VBP	O
it	PRP	O
possible	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
primary	JJ	Physical
colostomy	NN	Physical
to	TO	O
approximately	RB	O
50	CD	O
per	IN	O
cent	NN	O
in	IN	O
a	DT	O
large	JJ	O
ongoing	VBG	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
colonic	JJ	O
injury	NN	O
.	.	O

Can	MD	O
a	DT	O
home-visit	JJ	O
invitation	NN	O
increase	NN	O
Pap	NNP	O
smear	JJ	O
screening	NN	O
in	IN	O
Samliem	NNP	O
,	,	O
Khon	NNP	O
Kaen	NNP	O
,	,	O
Thailand	NNP	O
?	.	O
Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
a	DT	O
home-visit	JJ	O
invitation	NN	O
aimed	VBN	O
to	TO	O
increase	VB	O
uptake	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
in	IN	O
women	NNS	O
between	IN	O
35	CD	O
and	CC	O
60	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

From	NN	O
May	NNP	O
,	,	O
2006	CD	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
quasi-randomized	JJ	O
trial	NN	O
to	TO	O
determine	VB	O
if	IN	O
an	DT	O
in-home	JJ	O
education	NN	O
and	CC	O
invitation	NN	O
intervention	NN	O
would	MD	O
increase	VB	O
uptake	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
.	.	O

We	PRP	O
randomly	RB	O
recruited	VBD	O
304	CD	O
women	NNS	O
from	IN	O
the	DT	O
Samliem	NNP	O
inner-city	NN	O
community	NN	O
,	,	O
Khon	NNP	O
Kaen	NNP	O
,	,	O
Northeast	NNP	O
Thailand	NNP	O
,	,	O
and	CC	O
assigned	VBD	O
participants	NNS	O
to	TO	O
either	VB	O
the	DT	O
intervention	NN	O
or	CC	O
control	VB	O
zone	NN	O
.	.	O

Baseline	NNP	O
screening	VBG	O
coverage	NN	O
interviews	NNS	O
were	VBD	O
then	RB	O
performed	VBN	O
:	:	O
58	CD	O
of	IN	O
158	CD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
and	CC	O
46	CD	O
of	IN	O
146	CD	O
in	IN	O
the	DT	O
control	NN	O
zone	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
having	VBG	O
had	VBD	O
a	DT	O
Pap	NNP	O
smear	NN	O
within	IN	O
5	CD	O
years	NNS	O
,	,	O
but	CC	O
these	DT	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
final	JJ	O
analysis	NN	O
.	.	O

First	NNP	O
,	,	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
were	VBD	O
visited	VBN	O
in	IN	O
their	PRP$	O
homes	NNS	O
by	IN	O
one	CD	O
of	IN	O
the	DT	O
researchers	NNS	O
,	,	O
who	WP	O
provided	VBD	O
culturally-sensitive	JJ	O
health	NN	O
education	NN	O
that	WDT	O
emphasized	VBD	O
the	DT	O
need	NN	O
for	IN	O
screening	VBG	O
.	.	O

Four	CD	O
months	NNS	O
later	RB	O
,	,	O
post-intervention	NN	O
,	,	O
screening-coverage	JJ	O
interviews	NNS	O
were	VBD	O
again	RB	O
performed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
same	JJ	O
health	NN	O
education	NN	O
for	IN	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
a	DT	O
comparison	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
baseline	NN	Others
Pap	NNP	Others
smear	JJ	Others
screening-coverage	NN	Others
rate	NN	Others
in	IN	O
the	DT	O
intervention	NN	O
vs.	FW	O
control	NN	O
zones	NNS	O
(	(	O
36.7	CD	O
vs.	FW	O
31.5	CD	O
%	NN	O
,	,	O
p=0.339	NN	O
)	)	O
.	.	O

One	CD	O
hundred	JJ	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
completed	VBD	O
the	DT	O
intervention	NN	O
interviews	NNS	O
and	CC	O
after	IN	O
four	CD	O
months	NNS	O
,	,	O
100	CD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
100	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
also	RB	O
completed	VBD	O
the	DT	O
post-intervention	NN	O
interviews	NNS	O
.	.	O

The	DT	O
increased	JJ	O
screening-coverage	NN	Others
rate	NN	Others
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
zone	NN	O
(	(	O
43.6	CD	O
vs.	FW	O
34.9	CD	O
%	NN	O
,	,	O
p=0.119	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
borderline	NN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
intervention	NN	O
zone	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
36.7	CD	O
to	TO	O
43.6	CD	O
%	NN	O
,	,	O
p=0.070	NN	O
)	)	O
.	.	O

Therefore	NNP	O
,	,	O
home	NN	O
visit	NN	O
education	NN	O
and	CC	O
invitation	NN	O
intervention	NN	O
produced	VBD	O
only	RB	O
a	DT	O
nominal	JJ	O
effect	NN	O
on	IN	O
increasing	VBG	O
Pap	NNP	O
smear	JJ	O
coverage	NN	O
within	IN	O
a	DT	O
4-month	JJ	O
study	NN	O
period	NN	O
.	.	O

Pharmacokinetic-pharmacodynamic	JJ	Others
modelling	NN	Others
of	IN	O
the	DT	O
antihistaminic	NN	O
(	(	O
H1	NNP	O
)	)	O
effect	NN	O
of	IN	O
bilastine	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
model	VB	O
the	DT	O
pharmacokinetic	JJ	Physical
and	CC	O
pharmacodynamic	JJ	Physical
relationship	NN	O
of	IN	O
bilastine	NN	O
,	,	O
a	DT	O
new	JJ	O
histamine	NN	O
H	NNP	O
(	(	O
1	CD	O
)	)	O
receptor	NN	O
antagonist	NN	O
,	,	O
from	IN	O
single-	JJ	O
and	CC	O
multiple-dose	JJ	O
studies	NNS	O
in	IN	O
healthy	JJ	O
adult	NN	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
pharmacokinetic	JJ	O
model	NN	O
was	VBD	O
developed	VBN	O
from	IN	O
different	JJ	O
single-dose	JJ	O
and	CC	O
multiple-dose	JJ	O
studies	NNS	O
.	.	O

In	IN	O
the	DT	O
single-dose	JJ	O
studies	NNS	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
183	CD	O
subjects	NNS	O
received	VBD	O
oral	JJ	O
doses	NNS	O
of	IN	O
bilastine	NN	O
2.5	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
50	CD	O
,	,	O
100	CD	O
,	,	O
120	CD	O
,	,	O
160	CD	O
,	,	O
200	CD	O
and	CC	O
220	CD	O
mg	NN	O
.	.	O

In	IN	O
the	DT	O
multiple-dose	JJ	O
studies	NNS	O
,	,	O
127	CD	O
healthy	JJ	O
subjects	NNS	O
received	VBD	O
bilastine	JJ	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
50	CD	O
,	,	O
80	CD	O
,	,	O
100	CD	O
,	,	O
140	CD	O
or	CC	O
200	CD	O
mg/day	NN	O
as	IN	O
multiple	JJ	O
doses	NNS	O
during	IN	O
a	DT	O
4-	JJ	O
,	,	O
7-	JJ	O
or	CC	O
14-day	JJ	O
period	NN	O
.	.	O

The	DT	O
pharmacokinetic	JJ	Others
profile	NN	Others
of	IN	O
bilastine	NN	O
was	VBD	O
investigated	VBN	O
using	VBG	O
a	DT	O
simultaneous	JJ	O
analysis	NN	O
of	IN	O
all	DT	O
concentration-time	JJ	Others
data	NNS	Others
by	IN	O
means	NNS	O
of	IN	O
nonlinear	JJ	O
mixed-effects	NNS	O
modelling	VBG	O
population	NN	O
pharmacokinetic	JJ	O
software	NN	O
NONMEM	NNP	O
version	NN	O
6.1	CD	O
.	.	O

Plasma	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
modelled	VBN	O
according	VBG	O
to	TO	O
a	DT	O
two-compartment	JJ	O
open	JJ	O
model	NN	O
with	IN	O
first-order	JJ	O
absorption	NN	O
and	CC	O
elimination	NN	O
.	.	O

For	IN	O
the	DT	O
pharmacodynamic	JJ	O
analysis	NN	O
,	,	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
bilastine	NN	O
(	(	O
inhibition	NN	O
of	IN	O
histamine-induced	JJ	O
wheal	NN	O
and	CC	O
flare	NN	O
)	)	O
was	VBD	O
assessed	VBN	O
on	IN	O
a	DT	O
preselected	JJ	O
time	NN	O
schedule	NN	O
,	,	O
and	CC	O
the	DT	O
predicted	JJ	O
typical	JJ	Others
pharmacokinetic	JJ	Others
profile	NN	Others
(	(	O
based	VBN	O
on	IN	O
the	DT	O
pharmacokinetic	JJ	O
model	NN	O
previously	RB	O
developed	VBN	O
)	)	O
was	VBD	O
used	VBN	O
.	.	O

An	DT	O
indirect	JJ	O
response	NN	O
model	NN	O
was	VBD	O
developed	VBN	O
to	TO	O
describe	VB	O
the	DT	O
pharmacodynamic	JJ	Others
relationships	NNS	Others
between	IN	O
flare	NN	O
or	CC	O
wheal	JJ	O
areas	NNS	O
and	CC	O
bilastine	NN	O
plasma	NN	O
concentrations	NNS	O
.	.	O

Finally	RB	O
,	,	O
once	RB	O
values	NNS	O
of	IN	O
the	DT	O
concentration	NN	Others
that	WDT	Others
produced	VBD	Others
50	CD	Others
%	NN	Others
inhibition	NN	Others
(	(	Others
IC	NNP	Others
(	(	Others
50	CD	Others
)	)	Others
)	)	Others
had	VBD	O
been	VBN	O
estimated	VBN	O
for	IN	O
wheal	NN	O
and	CC	O
flare	NN	O
effects	NNS	O
,	,	O
simulations	NNS	O
were	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
predict	VB	O
plasma	JJ	Physical
concentrations	NNS	Physical
for	IN	O
the	DT	O
doses	NNS	O
of	IN	O
bilastine	NN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
mg	NN	O
at	IN	O
steady	JJ	O
state	NN	O
(	(	O
72-96	JJ	O
hours	NNS	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
non-compartmental	JJ	O
analysis	NN	O
resulted	VBD	O
in	IN	O
linear	JJ	O
kinetics	NNS	O
of	IN	O
bilastine	NN	O
in	IN	O
the	DT	O
dose	JJ	O
range	NN	O
studied	VBN	O
.	.	O

Bilastine	NNP	O
was	VBD	O
characterized	VBN	O
by	IN	O
two-compartmental	JJ	O
kinetics	NNS	O
with	IN	O
a	DT	O
rapid-absorption	NN	O
phase	NN	O
(	(	O
first-order	JJ	O
absorption	NN	O
rate	NN	O
constant	JJ	O
=	NN	O
1.50	CD	O
h	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
,	,	O
plasma	JJ	Physical
peak	NN	Physical
concentrations	NNS	Physical
were	VBD	O
observed	VBN	O
at	IN	O
1	CD	O
hour	NN	O
following	VBG	O
administration	NN	O
and	CC	O
the	DT	O
maximal	JJ	Others
response	NN	Others
was	VBD	O
observed	VBN	O
at	IN	O
approximately	RB	O
4	CD	O
hours	NNS	O
or	CC	O
later	RB	O
.	.	O

Concerning	VBG	O
the	DT	O
selected	VBN	O
pharmacodynamic	JJ	O
model	NN	O
to	TO	O
fit	VB	O
the	DT	O
data	NN	O
(	(	O
type	NN	O
I	PRP	O
indirect	VBP	O
response	NN	O
model	NN	O
)	)	O
,	,	O
this	DT	O
selection	NN	O
is	VBZ	O
attributable	JJ	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
inhibitory	JJ	O
bilastine	NN	O
plasma	NN	O
concentrations	NNS	O
that	WDT	O
decrease	VBP	O
the	DT	O
input	NN	Others
response	NN	Others
function	NN	Others
,	,	O
i.e	NN	O
.	.	O

the	DT	O
production	NN	O
of	IN	O
the	DT	O
skin	JJ	O
reaction	NN	O
.	.	O

This	DT	O
model	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
best	JJS	O
fit	NN	O
of	IN	O
wheal	NN	O
and	CC	O
flare	NN	O
data	NNS	O
.	.	O

The	DT	O
estimates	NNS	O
(	(	O
with	IN	O
relative	JJ	O
standard	JJ	O
errors	NNS	O
expressed	VBD	O
in	IN	O
percentages	NNS	O
in	IN	O
parentheses	NNS	O
)	)	O
of	IN	O
the	DT	O
apparent	JJ	Physical
zero-order	NN	Physical
rate	NN	Physical
constant	NN	Physical
for	IN	Physical
flare	NN	Physical
or	CC	O
wheal	NN	Physical
spontaneous	JJ	Physical
appearance	NN	Physical
(	(	O
k	NN	O
(	(	O
in	IN	O
)	)	O
)	)	O
,	,	O
the	DT	O
first-order	JJ	Physical
rate	NN	Physical
constant	NN	Physical
for	IN	Physical
flare	NN	Physical
or	CC	O
wheal	JJ	Physical
disappearance	NN	Physical
(	(	O
k	NN	O
(	(	O
out	IN	O
)	)	O
)	)	O
and	CC	O
bilastine	JJ	Physical
IC	NNP	Physical
(	(	O
50	CD	O
)	)	O
values	NNS	O
were	VBD	O
0.44	CD	O
ng/mL/h	NNS	O
(	(	O
14.60	CD	O
%	NN	O
)	)	O
,	,	O
1.09	CD	O
h	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
15.14	CD	O
%	NN	O
)	)	O
and	CC	O
5.15	CD	O
ng/mL	NN	O
(	(	O
16.16	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
wheal	JJ	O
inhibition	NN	O
,	,	O
and	CC	O
11.10	CD	O
ng/mL/h	NN	O
(	(	O
8.48	CD	O
%	NN	O
)	)	O
,	,	O
1.03	CD	O
h	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
8.35	CD	O
%	NN	O
)	)	O
and	CC	O
1.25	CD	O
ng/mL	NN	O
(	(	O
14.56	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
flare	JJ	O
inhibition	NN	O
.	.	O

The	DT	O
simulation	NN	O
results	NNS	O
revealed	VBD	O
that	IN	O
bilastine	NN	Physical
plasma	NN	Physical
concentrations	NNS	Physical
do	VBP	O
not	RB	O
remain	VB	O
over	IN	O
the	DT	O
IC	NNP	O
(	(	O
50	CD	O
)	)	O
value	NN	O
throughout	IN	O
the	DT	O
inter-dose	JJ	O
period	NN	O
for	IN	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
.	.	O

However	RB	O
,	,	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
20	CD	O
mg	NN	O
of	IN	O
bilastine	NN	O
administered	VBN	O
every	DT	O
24	CD	O
hours	NNS	O
,	,	O
plasma	JJ	Others
concentrations	NNS	Others
remained	VBD	O
over	IN	O
the	DT	O
IC	NNP	O
(	(	O
50	CD	O
)	)	O
value	NN	O
during	IN	O
the	DT	O
considered	JJ	O
period	NN	O
for	IN	O
the	DT	O
flare	NN	O
effect	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
20	CD	O
hours	NNS	O
for	IN	O
the	DT	O
wheal	JJ	O
effect	NN	O
.	.	O

CONCLUSION	NNP	O
Pharmacokinetic	NNP	O
and	CC	O
pharmacodynamic	JJ	O
relationships	NNS	O
of	IN	O
bilastine	NN	O
were	VBD	O
reliably	RB	O
described	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
an	DT	O
indirect	JJ	O
response	NN	O
pharmacodynamic	JJ	O
model	NN	O
;	:	O
this	DT	O
led	VBD	O
to	TO	O
an	DT	O
accurate	JJ	O
prediction	NN	O
of	IN	O
the	DT	O
pharmacodynamic	JJ	O
activity	NN	O
of	IN	O
bilastine	NN	O
.	.	O

Benefit	NN	O
of	IN	O
FSH	NNP	O
priming	NN	O
of	IN	O
women	NNS	O
with	IN	O
PCOS	NNP	O
to	TO	O
the	DT	O
in	IN	O
vitro	JJ	O
maturation	NN	O
procedure	NN	O
and	CC	O
the	DT	O
outcome	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
rates	NNS	Physical
of	IN	Physical
in	IN	Physical
vitro	JJ	Physical
oocyte	JJ	Physical
maturation	NN	Physical
,	,	Physical
fertilization	NN	Physical
and	CC	Physical
cleavage	NN	Physical
,	,	O
as	RB	O
well	RB	O
as	IN	O
implantation	NN	Physical
rate	NN	Physical
and	CC	Physical
pregnancy	NN	Physical
rate	NN	Physical
,	,	O
could	MD	O
be	VB	O
improved	VBN	O
by	IN	O
low-dose	JJ	O
priming	NN	O
with	IN	O
FSH	NNP	O
in	IN	O
vivo	NN	O
before	IN	O
retrieval	NN	O
of	IN	O
immature	NN	O
oocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

From	IN	O
March	NNP	O
1998	CD	O
to	TO	O
June	NNP	O
2000	CD	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
28	CD	O
women	NNS	O
underwent	JJ	O
36	CD	O
completed	VBN	O
treatment	NN	O
cycles	NNS	O
,	,	O
randomized	VBN	O
sequentially	RB	O
in	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Women	NNP	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
n	JJ	O
=	$	O
12	CD	O
cycles	NNS	O
)	)	O
received	VBD	O
no	DT	O
stimulation	NN	O
and	CC	O
women	NNS	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
n	JJ	O
=	$	O
24	CD	O
cycles	NNS	O
)	)	O
received	VBD	O
150	CD	O
iu	NN	O
recombinant	JJ	O
FSH	NNP	O
day	NN	O
(	(	O
-1	NNP	O
)	)	O
for	IN	O
3	CD	O
days	NNS	O
,	,	O
initiated	VBN	O
on	IN	O
day	NN	O
3	CD	O
after	IN	O
menstruation	NN	O
.	.	O

Aspiration	NN	O
was	VBD	O
performed	VBN	O
transvaginally	RB	O
between	IN	O
day	NN	O
9	CD	O
and	CC	O
day	NN	O
17	CD	O
in	IN	O
the	DT	O
unstimulated	JJ	O
group	NN	O
and	CC	O
on	IN	O
day	NN	O
8	CD	O
or	CC	O
day	NN	O
9	CD	O
in	IN	O
the	DT	O
FSH-primed	NNP	O
group	NN	O
after	IN	O
FSH	NNP	O
deprivation	NN	O
for	IN	O
2	CD	O
or	CC	O
3	CD	O
days	NNS	O
.	.	O

All	DT	O
cumulus-enclosed	JJ	O
oocytes	NNS	O
of	IN	O
healthy	JJ	O
appearance	NN	O
were	VBD	O
matured	VBN	O
in	IN	O
culture	NN	O
medium	NN	O
(	(	O
TCM-199	NNP	O
)	)	O
in	IN	O
vitro	NN	O
for	IN	O
28-36	JJ	O
h	NN	O
before	IN	O
intracytoplasmic	JJ	O
sperm	NN	O
injection	NN	O
(	(	O
ICSI	NNP	O
)	)	O
.	.	O

After	IN	O
oocyte	JJ	O
retrieval	NN	O
the	DT	O
women	NNS	O
were	VBD	O
given	VBN	O
oestradiol	NNS	O
(	(	O
6	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
and	CC	O
progesterone	JJ	O
administration	NN	O
(	(	O
300	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
was	VBD	O
initiated	VBN	O
2	CD	O
days	NNS	O
later	RB	O
.	.	O

Suitable	JJ	O
embryos	NN	O
(	(	O
maximum	JJ	O
two	CD	O
embryos	NN	O
)	)	O
were	VBD	O
transferred	VBN	O
on	IN	O
day	NN	O
3	CD	O
after	IN	O
ICSI	NNP	O
.	.	O

The	DT	O
percentage	NN	Others
of	IN	Others
oocytes	NNS	Others
reaching	VBG	Others
metaphase	NN	Others
II	NNP	Others
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
FSH-primed	NNP	O
group	NN	O
(	(	O
59	CD	O
%	NN	O
,	,	O
92/156	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
non-primed	JJ	O
group	NN	O
(	(	O
44	CD	O
%	NN	O
,	,	O
36/81	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
rates	NNS	Others
of	IN	Others
oocyte	JJ	Others
fertilization	NN	Others
and	CC	Others
cleavage	NN	Others
between	IN	O
these	DT	O
groups	NNS	O
.	.	O

No	DT	O
pregnancies	NNS	Physical
were	VBD	O
obtained	VBN	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
0	CD	O
%	NN	O
,	,	O
0/12	CD	O
)	)	O
,	,	O
whereas	JJ	O
seven	CD	O
clinical	JJ	Others
pregnancies	NNS	Others
were	VBD	O
obtained	VBN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
29	CD	O
%	NN	O
,	,	O
7/24	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
group	NN	O
2	CD	O
,	,	O
37	CD	O
embryo	NN	O
transfers	NNS	O
resulted	VBD	O
in	IN	O
eight	CD	O
implantations	NNS	Physical
(	(	O
21.6	CD	O
%	NN	O
)	)	O
.	.	O

Three	CD	O
healthy	JJ	Physical
singleton	NN	Physical
children	NNS	Physical
have	VBP	O
been	VBN	O
born	VBN	Physical
at	IN	O
term	NN	O
;	:	O
the	DT	O
remaining	VBG	O
pregnancies	NNS	O
ended	VBN	O
with	IN	O
spontaneous	JJ	Adverseeffect
abortions	NNS	Adverseeffect
in	IN	O
the	DT	O
first	JJ	O
trimester	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
priming	VBG	O
with	IN	O
recombinant	JJ	O
FSH	NNP	O
before	IN	O
harvesting	NN	O
of	IN	O
immature	NN	O
oocytes	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
PCOS	NNP	O
may	MD	O
improve	VB	O
the	DT	O
maturational	JJ	Others
potential	NN	Others
of	IN	Others
the	DT	Others
oocytes	NNS	Others
and	CC	Others
the	DT	Others
implantation	NN	Others
rate	NN	Others
of	IN	Others
the	DT	Others
cleaved	JJ	Others
embryos	NN	Others
.	.	Physical

Divalproex	NNP	O
sodium	NN	O
vs	NN	O
placebo	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	Mental
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
are	VBP	O
neurodevelopmental	JJ	O
disorders	NNS	O
characterized	VBN	O
by	IN	O
social	JJ	O
and	CC	O
language	NN	O
deficits	NNS	O
and	CC	O
by	IN	O
repetitive	JJ	O
behaviors	NNS	O
and	CC	O
interests	NNS	O
.	.	O

Irritability/aggression	NN	O
is	VBZ	O
a	DT	O
significant	JJ	O
comorbid	NN	O
symptom	NN	O
in	IN	O
this	DT	O
population	NN	O
,	,	O
which	WDT	O
greatly	RB	O
impacts	VBZ	O
burden	NN	O
of	IN	O
care	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
divalproex	NN	O
sodium	NN	O
for	IN	O
irritability/aggression	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
12-week	JJ	O
randomized	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

All	DT	O
efficacy	NN	O
measures	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
evaluator	NN	O
blinded	VBD	O
to	TO	O
randomization	VB	O
condition	NN	O
and	CC	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
55	CD	O
subjects	NNS	O
gavetheir	JJ	O
consent	NN	O
and	CC	O
27	CD	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
1	CD	O
:	:	O
1	CD	O
manner	NN	O
(	(	O
mean	JJ	O
age	NN	O
9.46+/-2.46	CD	O
,	,	O
mean	FW	O
nonverbal	JJ	O
IQ	NNP	O
63.3+/-23.9	NN	O
)	)	O
.	.	O

Two	CD	O
subjects	NNS	O
from	IN	O
the	DT	O
active	JJ	O
group	NN	O
and	CC	O
one	CD	O
subject	NN	O
from	IN	O
the	DT	O
placebo	NN	O
group	NN	O
discontinued	VBD	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
either	CC	O
a	DT	O
lack	NN	O
of	IN	O
efficacy	NN	Others
or	CC	O
side	NN	O
effects	NNS	O
(	(	O
increased	JJ	O
irritability	NN	O
)	)	O
.	.	O

Primary	JJ	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist-Irritability	NNP	Mental
subscale	NN	Mental
and	CC	Mental
Clinical	JJ	Mental
Global	NNP	Mental
Impression-Improvement	NNP	Mental
,	,	O
which	WDT	O
focused	VBD	O
on	IN	O
irritability	NN	O
.	.	O

Overall	NNP	O
,	,	O
62.5	CD	O
%	NN	O
of	IN	O
divalproex	JJ	O
subjects	NNS	O
vs	VBP	O
9	CD	O
%	NN	O
of	IN	O
placebo	JJ	O
subjects	NNS	O
were	VBD	O
responders	NNS	Mental
(	(	O
CGI-irritability	NN	O
OR	NNP	O
:	:	O
16.7	CD	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
p=0.008	NN	O
)	)	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
on	IN	O
the	DT	O
ABC-Irritability	NNP	Mental
subscale	NN	Mental
(	(	O
p=0.048	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
responders	NNS	O
to	TO	O
have	VB	O
higher	JJR	O
valproate	NN	Physical
blood	NN	Physical
levels	NNS	Physical
compared	VBN	O
with	IN	O
nonresponders	NNS	O
.	.	O

This	DT	O
study	NN	O
suggests	VBZ	O
the	DT	O
efficacy	NN	Others
of	IN	O
divalproex	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	Mental
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Larger	NNP	O
sample	JJ	O
follow-up	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
.	.	O

Recurrence	NN	Physical
of	IN	Physical
condylomata	NNS	Physical
acuminata	NNS	Physical
following	VBG	O
cryotherapy	NN	O
is	VBZ	O
not	RB	O
prevented	VBN	O
by	IN	O
systemically	RB	O
administered	VBN	O
interferon	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
whether	IN	O
interferon	JJ	O
alpha-2a	NN	O
,	,	O
when	WRB	O
utilised	JJ	O
as	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
following	VBG	O
ablation	NN	O
of	IN	O
condylomata	NN	O
acuminata	NNS	O
(	(	O
genital	JJ	O
warts	NNS	O
)	)	O
by	IN	O
cryotherapy	NN	O
,	,	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrences	NNS	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
by	IN	O
2-tailed	JJ	O
Fisher	NNP	O
's	POS	O
Exact	NNP	O
Test	NNP	O
.	.	O

PATIENTS	CC	O
97	CD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NN	O
acuminata	NN	O
.	.	O

INTERVENTION	NNP	O
49	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
cryotherapy	NN	O
plus	CC	O
subcutaneously	RB	O
administered	VBN	O
interferon	NN	O
alpha-2a	NN	O
,	,	O
and	CC	O
48	CD	O
received	VBD	O
cryotherapy	NN	O
plus	CC	O
placebo	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
36	CD	O
and	CC	O
37	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
evaluable	JJ	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Clinical	NNP	Others
eradication	NN	Others
of	IN	Others
condylomata	NN	Others
for	IN	Others
six	CD	Others
months	NNS	Others
following	VBG	O
adjuvant	JJ	Others
chemotherapy	NN	Others
.	.	O

RESULTS	VBN	O
By	IN	O
completion	NN	O
of	IN	O
the	DT	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
10	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
interferon	NN	O
recipients	NNS	O
and	CC	O
16	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	O
recurrences	NNS	Physical
.	.	O

At	IN	O
six	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
25	CD	O
(	(	O
69	CD	O
%	NN	O
)	)	O
interferon	NN	O
and	CC	O
27	CD	O
(	(	O
73	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	Others
recurrences	NNS	Others
.	.	O

In	IN	O
the	DT	O
six	CD	O
months	NNS	O
following	VBG	O
interferon	NN	O
therapy	NN	O
,	,	O
only	RB	O
31	CD	O
%	NN	O
of	IN	O
interferon	NN	O
and	CC	O
27	CD	O
%	NN	O
of	IN	O
placebo	NN	O
recipients	NNS	O
remained	VBD	O
free	JJ	Physical
of	IN	Physical
recurrences	NNS	Physical
(	(	O
p	JJ	O
=	NNP	O
0.99	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Interferon	NNP	O
alpha-2a	NN	O
administered	VBD	O
subcutaneously	RB	O
offers	VBZ	O
no	DT	O
benefit	NN	O
as	IN	O
a	DT	O
chemotherapeutic	JJ	O
adjuvant	NN	O
to	TO	O
cryotherapy	VB	O
when	WRB	O
used	VBN	O
alone	RB	O
in	IN	O
the	DT	O
therapy	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NNS	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
method	NN	O
for	IN	O
the	DT	O
estimation	NN	Physical
of	IN	Physical
flunarizine	JJ	Physical
area	NN	Physical
under	IN	Physical
the	DT	Physical
curve	NN	Physical
(	(	Physical
AUC	NNP	Physical
)	)	Physical
and	CC	Physical
maximum	JJ	Physical
plasma	JJ	Physical
concentration	NN	Physical
(	(	Physical
Cmax	NNP	Physical
)	)	Physical
.	.	Physical

A	DT	O
limited	JJ	O
sampling	NN	O
model	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
flunarizine	NN	O
following	VBG	O
a	DT	O
30	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
in	IN	O
epileptic	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
receiving	VBG	O
phenytoin	NN	O
or	CC	O
carbamazepine	NN	O
or	CC	O
both	DT	O
,	,	O
to	TO	O
estimate	VB	Physical
the	DT	Physical
area	NN	Physical
under	IN	Physical
the	DT	Physical
curve	NN	Physical
(	(	Physical
AUC	NNP	Physical
)	)	Physical
and	CC	Physical
maximum	JJ	Physical
plasma	JJ	Physical
concentration	NN	Physical
(	(	Physical
Cmax	NNP	Physical
)	)	Physical
.	.	Physical

The	DT	O
model	NN	O
was	VBD	O
developed	VBN	O
using	VBG	O
training	VBG	O
data	NNS	O
sets	NNS	O
from	IN	O
30	CD	O
,	,	O
20	CD	O
,	,	O
15	CD	O
,	,	O
or	CC	O
10	CD	O
patients	NNS	O
at	IN	O
one	CD	O
or	CC	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

The	DT	O
equations	NNS	O
describing	VBG	O
the	DT	O
models	NNS	O
for	IN	O
AUC	NNP	O
using	VBG	O
two	CD	O
time	NN	O
points	NNS	O
(	(	O
3	CD	O
and	CC	O
24h	CD	O
)	)	O
and	CC	O
Cmax	NNP	O
for	IN	O
the	DT	O
training	NN	O
data	NNS	O
set	NN	O
of	IN	O
30	CD	O
subjects	NNS	O
were	VBD	O
AUCpredicted	NNP	O
=	NNP	O
11.1	CD	O
C3h	NNP	O
+	VBD	O
121.4	CD	O
C24h	NNP	O
-	:	O
157	CD	O
(	(	O
r	NN	O
=	RB	O
0.80	CD	O
)	)	O
Cmax	NNP	O
(	(	O
predicted	VBN	O
)	)	O
=	$	O
0.036	CD	O
AUC	NNP	O
+	$	O
42.9	CD	O
(	(	O
r	NN	O
=	RB	O
0.74	CD	O
)	)	O
The	DT	O
model	NN	O
was	VBD	O
validated	VBN	O
on	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
flunarizine	JJ	O
orally	RB	O
.	.	O

The	DT	O
model	NN	O
provided	VBD	O
reasonably	RB	O
good	JJ	O
estimates	NNS	Physical
for	IN	Physical
both	DT	Physical
AUC	NNP	Physical
and	CC	O
Cmax	NNP	Physical
.	.	O

The	DT	O
mean	NN	Physical
predicted	VBD	Physical
AUC	NNP	Physical
of	IN	Physical
flunarizine	NN	Physical
was	VBD	O
1230	CD	O
+/-	JJ	O
717	CD	O
ng	JJ	O
h	NN	O
mL-1	NN	O
,	,	O
whereas	IN	O
the	DT	O
observed	JJ	Physical
AUC	NNP	Physical
was	VBD	O
1203	CD	O
+/-	JJ	O
900	CD	O
ng	JJ	O
h	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	Others
of	IN	Others
the	DT	Others
prediction	NN	Others
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
precision	NN	O
was	VBD	O
28	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	Physical
Cmax	NNP	Physical
of	IN	Physical
flunarizine	NN	Physical
was	VBD	O
86	CD	O
+/-	JJ	O
32	CD	O
ng	JJ	O
mL-1	NN	O
as	IN	O
compared	VBN	O
to	TO	O
an	DT	O
observed	JJ	Physical
mean	NN	Physical
Cmax	NNP	Physical
of	IN	O
90	CD	O
+/-	JJ	O
42	CD	O
ng	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	Others
and	CC	Others
precision	NN	Others
of	IN	Others
the	DT	Others
prediction	NN	Others
were	VBD	O
4	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
method	NN	O
described	VBD	O
here	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
for	IN	O
flunarizine	NN	O
without	IN	O
detailed	JJ	O
pharmacokinetic	JJ	O
studies	NNS	O
.	.	O

Efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
recombinant	JJ	O
human	JJ	O
nerve	NN	O
growth	NN	O
factor	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
:	:	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

rhNGF	VB	O
Clinical	NNP	O
Investigator	NNP	O
Group	NNP	O
.	.	O

CONTEXT	NNP	O
Nerve	NNP	O
growth	NN	O
factor	NN	O
is	VBZ	O
a	DT	O
neurotrophic	JJ	O
factor	NN	O
that	WDT	O
promotes	VBZ	O
the	DT	O
survival	NN	O
of	IN	O
small	JJ	O
fiber	NNP	O
sensory	JJ	O
neurons	NNS	O
and	CC	O
sympathetic	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
nervous	JJ	O
system	NN	O
.	.	O

Recombinant	JJ	O
human	JJ	O
nerve	NN	O
growth	NN	O
factor	NN	O
(	(	O
rhNGF	NN	O
)	)	O
has	VBZ	O
demonstrated	VBN	O
efficacy	NN	O
as	IN	O
treatment	NN	O
for	IN	O
peripheral	JJ	O
neuropathy	NN	O
in	IN	O
experimental	JJ	O
models	NNS	O
and	CC	O
phase	VB	O
2	CD	O
clinical	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
a	DT	O
12-month	JJ	O
regimen	NN	O
of	IN	O
rhNGF	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
3	CD	O
trial	NN	O
conducted	VBN	O
from	IN	O
July	NNP	O
1997	CD	O
through	IN	O
May	NNP	O
1999	CD	O
.	.	O

SETTING	VB	O
Eighty-four	JJ	O
outpatient	NN	O
centers	NNS	O
throughout	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1019	CD	O
men	NNS	O
and	CC	O
women	NNS	O
aged	VBD	O
18	CD	O
to	TO	O
74	CD	O
years	NNS	O
with	IN	O
either	DT	O
type	NN	O
1	CD	O
or	CC	O
type	VB	O
2	CD	O
diabetes	NNS	O
and	CC	O
a	DT	O
sensory	JJ	O
polyneuropathy	NN	O
attributable	JJ	O
to	TO	O
diabetes	NNS	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
rhNGF	NN	O
,	,	O
0.1	CD	O
microg/kg	NN	O
(	(	O
n	JJ	O
=	NNP	O
504	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
515	CD	O
)	)	O
by	IN	O
subcutaneous	JJ	O
injection	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
,	,	O
12	CD	O
weeks	NNS	O
,	,	O
24	CD	O
weeks	NNS	O
,	,	O
and	CC	O
48	CD	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
a	DT	O
change	NN	Physical
in	IN	Physical
neuropathy	JJ	Physical
between	IN	Physical
baseline	NN	Physical
and	CC	Physical
week	NN	Physical
48	CD	Physical
,	,	Physical
demonstrated	VBN	Physical
by	IN	Physical
the	DT	Physical
Neuropathy	NNP	Physical
Impairment	NNP	Physical
Score	NNP	Physical
for	IN	O
the	DT	O
Lower	NNP	O
Limbs	NNP	O
,	,	O
compared	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
quantitative	JJ	Physical
sensory	NN	Physical
tests	NNS	Physical
using	VBG	Physical
the	DT	Physical
CASE	NNP	Physical
IV	NNP	Physical
System	NNP	Physical
,	,	Physical
the	DT	Physical
Neuropathy	NNP	Physical
Symptom	NNP	Physical
and	CC	Physical
Change	NNP	Physical
questionnaire	NN	Physical
,	,	Physical
the	DT	Physical
Patient	NNP	Physical
Benefit	NNP	Physical
Questionnaire	NNP	Physical
(	(	Physical
PBQ	NNP	Physical
)	)	Physical
,	,	Physical
and	CC	Physical
a	DT	Physical
global	JJ	Physical
symptom	NN	Physical
assessment	NN	Physical
,	,	Physical
as	RB	Physical
well	RB	Physical
as	IN	Physical
nerve	NN	Physical
conduction	NN	Physical
studies	NNS	Physical
and	CC	Physical
occurrence	NN	Physical
of	IN	Physical
new	JJ	Physical
plantar	JJ	Physical
foot	NN	Physical
ulcers	NNS	Physical
.	.	O

Patients	NNS	O
also	RB	O
were	VBD	O
evaluated	VBN	O
for	IN	O
presence	NN	O
of	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

RESULTS	NNP	O
Among	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
rhNGF	NN	O
,	,	O
418	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
regimen	NNS	O
compared	VBN	O
with	IN	O
461	CD	O
(	(	O
90	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
placebo	NN	O
.	.	O

Administration	NNP	O
of	IN	O
rhNGF	NN	O
was	VBD	O
safe	JJ	O
,	,	O
with	IN	O
few	JJ	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
attributed	VBD	O
to	TO	O
treatment	NN	O
apart	RB	O
from	IN	O
injection	NN	O
site	NN	Pain
pain/hyperalgesia	NN	Pain
and	CC	Pain
other	JJ	Pain
pain	NN	Pain
syndromes	NNS	Pain
.	.	O

However	RB	O
,	,	O
neither	CC	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
(	(	O
P	NNP	O
=.25	NNP	O
)	)	O
nor	CC	O
most	JJS	O
of	IN	O
the	DT	O
secondary	JJ	O
end	NN	O
points	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rhNGF	NN	O
.	.	O

Exceptions	NNS	O
were	VBD	O
the	DT	O
global	JJ	Physical
symptom	NN	Physical
assessment	NN	Physical
(	(	O
P	NNP	O
=.03	NNP	O
)	)	O
and	CC	O
2	CD	O
of	IN	O
32	CD	O
comparisons	NNS	O
within	IN	O
the	DT	O
PBQ	NNP	O
,	,	O
which	WDT	O
showed	VBD	O
a	DT	O
modest	JJ	O
but	CC	O
significant	JJ	O
benefit	NN	O
of	IN	O
rhNGF	NN	O
(	(	O
P	NNP	O
=.05	NNP	O
for	IN	O
severity	NN	O
of	IN	O
pain	NN	O
in	IN	O
the	DT	O
legs	NN	O
and	CC	O
P	NNP	O
=.003	NNP	O
for	IN	O
6-month	JJ	O
symptoms	NNS	O
in	IN	O
the	DT	O
feet	NNS	O
and	CC	O
legs	NNS	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Unlike	IN	O
previous	JJ	O
phase	NN	O
2	CD	O
trials	NNS	O
,	,	O
this	DT	O
phase	NN	O
3	CD	O
clinical	JJ	O
trial	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
beneficial	JJ	O
effect	NN	O
of	IN	O
rhNGF	NN	O
on	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
.	.	O

JAMA	NNP	O
.	.	O

2000	CD	O
;	:	O
284:2215-2221	JJ	O
.	.	O

Treatment	JJ	O
effects	NNS	O
of	IN	O
eptifibatide	NN	O
in	IN	O
planned	JJ	O
coronary	JJ	O
stent	NN	O
implantation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
ESPRIT	NNP	O
Trial	NNP	O
)	)	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
platelet	NN	O
glycoprotein	NN	O
IIb/IIIa	NNP	O
inhibitor	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
renal	JJ	O
impairment	NN	O
is	VBZ	O
not	RB	O
well	RB	O
characterized	VBN	O
.	.	O

Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
associations	NNS	Others
of	IN	Others
creatinine	JJ	Others
clearance	NN	Others
(	(	Others
CrCl	NNP	Others
)	)	Others
with	IN	O
outcomes	NNS	O
in	IN	O
a	DT	O
trial	NN	O
of	IN	O
eptifibatide	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
who	WP	O
underwent	VBP	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

We	PRP	O
analyzed	VBD	O
48-hour	CD	O
and	CC	O
30-day	JJ	O
outcomes	NNS	O
of	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Enhanced	NNP	O
Suppression	NNP	O
of	IN	O
the	DT	O
Platelet	NNP	O
IIb/IIIa	NNP	O
Receptor	NNP	O
with	IN	O
Integrilin	NNP	O
Therapy	NNP	O
(	(	O
ESPRIT	NNP	O
)	)	O
trial	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
eptifibatide	VB	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
stent	VB	O
implantation	NN	O
(	(	O
1,755	CD	O
with	IN	O
CrCl	NNP	O
>	NNP	O
or	CC	O
=60	NNP	O
ml/min	NN	O
and	CC	O
289	CD	O
with	IN	O
CrCl	NNP	O
<	NNP	O
60	CD	O
ml/min	NN	O
)	)	O
.	.	O

CrCl	NNP	Physical
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	Others
Cockcroft	NNP	Others
and	CC	Others
Gault	NNP	Others
formula	NN	Others
,	,	O
and	CC	O
the	DT	O
associations	NNS	O
of	IN	O
CrCl	NNP	Physical
with	IN	O
outcomes	NNS	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
logistic	JJ	Others
regression	NN	Others
models	NNS	Others
.	.	O

Patients	NNS	O
with	IN	O
CrCl	NNP	O
<	NNP	O
60	CD	O
ml/min	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
older	JJR	O
,	,	O
women	NNS	O
,	,	O
hypertensive	JJ	O
,	,	O
and	CC	O
have	VBP	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
.	.	O

The	DT	O
interaction	NN	O
of	IN	O
eptifibatide	NN	O
with	IN	O
CrCl	NNP	O
had	VBD	O
borderline	JJ	O
significance	NN	O
for	IN	O
the	DT	O
30-day	JJ	O
outcome	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.109	CD	O
)	)	O
.	.	O

Treatment	JJ	O
effect	NN	O
trended	VBD	O
toward	IN	O
a	DT	O
greater	JJR	O
magnitude	NN	O
in	IN	O
patients	NNS	O
with	IN	O
lower	JJR	O
CrCl	NNP	O
(	(	O
60	CD	O
ml/min	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.53	CD	O
,	,	O
confidence	NN	O
interval	NN	O
0.34	CD	O
to	TO	O
0.83	CD	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
higher	JJR	O
CrCl	NNP	O
(	(	O
90	CD	O
ml/min	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.68	CD	O
,	,	O
confidence	NN	O
interval	NN	O
0.49	CD	O
to	TO	O
0.94	CD	O
)	)	O
.	.	O

An	DT	O
accompanying	VBG	O
increase	NN	O
in	IN	O
bleeding	VBG	Adverseeffect
risk	NN	Adverseeffect
also	RB	O
was	VBD	O
not	RB	O
apparent	JJ	O
with	IN	O
lower	JJR	O
CrCl	NNP	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
eptifibatide	NN	O
is	VBZ	O
realized	VBN	O
regardless	RB	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
trends	VBZ	O
toward	IN	O
being	VBG	O
greater	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
renal	JJ	Physical
impairment	NN	Physical
.	.	O

Bronchodilator	NNP	O
effect	NN	O
of	IN	O
fenoterol	NN	O
and	CC	O
ipratropium	NN	O
bromide	NN	O
in	IN	O
infants	NNS	O
with	IN	O
acute	JJ	O
wheezing	NN	O
:	:	O
use	NN	O
of	IN	O
MDI	NNP	O
with	IN	O
a	DT	O
spacer	NN	O
device	NN	O
.	.	O

Twenty-eight	JJ	O
infants	NNS	O
admitted	VBN	O
to	TO	O
Exequiel	NNP	O
Gonz?lez	NNP	O
Cortes	NNP	O
Children	NNP	O
's	POS	O
Hospital	NNP	O
because	IN	O
of	IN	O
acute	NN	O
wheezing	NN	O
(	(	O
AW	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
study	NN	O
groups	NNS	O
.	.	O

Fenoterol	NNP	O
(	(	O
FNT	NNP	O
)	)	O
,	,	O
ipratropium	JJ	O
bromide	NN	O
(	(	O
IB	NNP	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
respectively	RB	O
to	TO	O
children	NNS	O
in	IN	O
the	DT	O
different	JJ	O
groups	NNS	O
by	IN	O
means	NNS	O
of	IN	O
metered	VBN	O
dose	JJ	O
inhalers	NNS	O
(	(	O
MDI	NNP	O
)	)	O
with	IN	O
spacers	NNS	O
,	,	O
using	VBG	O
doses	NNS	O
of	IN	O
3	CD	O
puffs	NNS	O
every	DT	O
hour	NN	O
,	,	O
for	IN	O
4	CD	O
hours	NNS	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
bronchial	JJ	O
obstruction	NN	O
was	VBD	O
assessed	VBN	O
clinically	RB	O
and	CC	O
scored	VBN	O
with	IN	O
the	DT	O
single-blind	JJ	O
method	NN	O
every	DT	O
hour	NN	O
prior	RB	O
to	TO	O
each	DT	O
treatment	NN	O
.	.	O

The	DT	O
criterion	NN	O
of	IN	O
a	DT	O
bronchodilator	NN	O
effect	NN	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
bronchial	JJ	O
obstruction	NN	O
at	IN	O
subsequent	JJ	O
scorings	NNS	O
.	.	O

The	DT	O
scores	NNS	O
of	IN	O
the	DT	O
three	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
using	VBG	O
the	DT	O
Student	NN	O
's	POS	O
t	JJ	O
test	NN	O
for	IN	O
matched	JJ	O
samples	NNS	O
.	.	O

The	DT	O
same	JJ	O
test	NN	O
was	VBD	O
also	RB	O
applied	VBN	O
to	TO	O
the	DT	O
independent	JJ	O
samples	NNS	O
for	IN	O
determining	VBG	O
the	DT	O
superiority	NN	O
of	IN	O
one	CD	O
treatment	NN	O
,	,	O
FNT	NNP	O
or	CC	O
IB	NNP	O
,	,	O
over	IN	O
the	DT	O
other	JJ	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
scores	NNS	O
of	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
FNT	NNP	O
and	CC	O
IB	NNP	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
;	:	O
this	DT	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
the	DT	O
group	NN	O
in	IN	O
which	WDT	O
placebo	NN	O
was	VBD	O
used	VBN	O
.	.	O

FNT	NNP	O
produced	VBD	O
a	DT	O
more	RBR	O
rapid	JJ	O
and	CC	O
sustained	VBD	O
effect	NN	O
than	IN	O
IB	NNP	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Significant	JJ	O
bronchodilator	NN	O
effect	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
infants	NNS	O
with	IN	O
AW	NNP	O
when	WRB	O
repeated	VBN	O
doses	NNS	O
of	IN	O
FNT	NNP	O
or	CC	O
IB	NNP	O
were	VBD	O
administered	VBN	O
with	IN	O
MDI	NNP	O
and	CC	O
spacers	NNS	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
FNT	NNP	O
.	.	O

Neuromuscular	JJ	O
excitability	NN	O
changes	NNS	O
in	IN	O
the	DT	O
vastus	NN	O
medialis	NN	O
following	VBG	O
anterior	JJ	O
cruciate	JJ	O
ligament	NN	O
reconstruction	NN	O
.	.	O

PURPOSE	NNP	O
Quadriceps	NNP	O
weakness	NN	O
following	VBG	O
anterior	JJ	O
cruciate	JJ	O
ligament	NN	O
reconstruction	NN	O
(	(	O
ACLR	NNP	O
)	)	O
is	VBZ	O
prevalent	JJ	O
despite	IN	O
intensive	JJ	O
rehabilitation	NN	O
.	.	O

Diminished	NNP	O
neuromuscular	JJ	O
excitability	NN	O
is	VBZ	O
one	CD	O
potential	JJ	O
factor	NN	O
that	WDT	O
may	MD	O
limit	VB	O
muscular	JJ	O
recovery	NN	O
following	VBG	O
injury	NN	O
or	CC	O
surgery	NN	O
.	.	O

The	DT	O
H-reflex	NNP	Physical
provides	VBZ	O
a	DT	O
measure	NN	O
of	IN	O
alpha	NN	O
motorneuron	NN	O
(	(	O
neuromuscular	JJ	O
)	)	O
excitability	NN	O
in	IN	O
the	DT	O
sensory-motor	JJ	O
pathway	NN	O
of	IN	O
the	DT	O
respective	JJ	O
muscle	NN	O
and	CC	O
nerve	NN	O
.	.	O

To	TO	O
date	NN	O
the	DT	O
vastus	NN	O
medialis	NN	O
(	(	O
VM	NNP	O
)	)	O
and	CC	O
soleus	NN	O
(	(	O
SOL	NNP	O
)	)	O
H-reflexes	NNP	O
have	VBP	O
been	VBN	O
examined	VBN	O
primarily	RB	O
in	IN	O
control	NN	O
subjects	NNS	O
with	IN	O
induced	JJ	O
knee	NNS	O
joint	JJ	O
effusion	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
evaluated	VBD	O
the	DT	O
affect	NN	O
of	IN	O
ACLR	NNP	O
,	,	O
utilizing	VBG	O
hamsting	NN	Physical
(	(	Physical
HS	NNP	Physical
)	)	Physical
or	CC	Physical
bone-patellar	JJ	Physical
tendon-bone	NN	Physical
(	(	Physical
BTB	NNP	Physical
)	)	Physical
autograft	NN	Physical
,	,	O
on	IN	O
VM	NNP	Physical
and	CC	Physical
SOL	NNP	Physical
H-reflex	NNP	Physical
latency	NN	Physical
and	CC	Physical
amplitude	NN	Physical
in	IN	O
twenty	JJ	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
Preoperatively	RB	O
bilateral	JJ	O
VM	NNP	O
and	CC	O
SOL	NNP	O
H-reflex	NNP	O
tests	NNS	O
were	VBD	O
conducted	VBN	O
.	.	O

VM	NNP	Physical
and	CC	Physical
SOL	NNP	Physical
H-reflexes	NNP	Physical
were	VBD	O
subsequently	RB	O
conducted	VBN	O
on	IN	O
the	DT	O
involved	VBN	O
lower	JJR	O
extremity	NN	O
at	IN	O
1	CD	O
and	CC	O
3	CD	O
months	NNS	O
post	VBN	O
surgery	NN	O
.	.	O

At	IN	O
each	DT	O
test	NN	O
session	NN	O
subjects	NNS	O
completed	VBN	O
visual	JJ	Others
analog	NN	Others
scales	NNS	Others
and	CC	O
knee	VB	Physical
girth	NN	Physical
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
VM	NNP	Physical
H-reflex	NNP	Physical
amplitude	NN	Physical
increased	VBD	O
in	IN	O
the	DT	O
HS	NNP	O
group	NN	O
at	IN	O
3	CD	O
months	NNS	O
compared	VBN	O
to	TO	O
1-month	JJ	O
post	NN	O
surgery	NN	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Significant	JJ	O
changes	NNS	O
over	IN	O
time	NN	O
were	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
the	DT	O
visual	JJ	Pain
analog	NN	Pain
pain	NN	Pain
and	CC	O
functional	JJ	Physical
scales	NNS	Physical
and	CC	Physical
the	DT	Physical
mid-patella	JJ	Physical
girth	NN	Physical
.	.	O

CONCLUSIONS	VB	O
The	DT	O
increased	JJ	O
VM	NNP	Physical
H-reflex	NNP	Physical
amplitude	NN	Physical
at	IN	O
3	CD	O
months	NNS	O
following	VBG	O
HS	NNP	O
autograft	NN	O
ACLR	NNP	O
demonstrates	VBZ	O
an	DT	O
increase	NN	O
in	IN	O
VM	NNP	Physical
neuromuscular	JJ	Physical
excitability	NN	Physical
.	.	O

Increased	VBN	O
VM	NNP	Physical
neuromuscular	JJ	Physical
excitability	NN	Physical
was	VBD	O
not	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
following	VBG	O
BTB	NNP	O
reconstruction	NN	O
.	.	O

The	DT	O
increased	JJ	O
neuromuscular	JJ	Physical
excitability	NN	Physical
,	,	O
observed	VBD	O
only	RB	O
in	IN	O
the	DT	O
HS	NNP	O
group	NN	O
,	,	O
warrants	NNS	O
consideration	NN	O
when	WRB	O
selecting	VBG	O
graft	NN	O
type	NN	O
for	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
preoperative	JJ	O
quadriceps	NNS	O
dysfunction	NN	O
.	.	O

Atrial	NNP	Physical
remodeling	NN	Physical
after	IN	O
mitral	JJ	O
valve	NN	O
surgery	NN	O
in	IN	O
patients	NNS	O
with	IN	O
permanent	JJ	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

BACKGROUND	NNP	O
Mitral	NNP	O
valve	NNP	O
pathology	NN	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
auricular	JJ	O
dilatation	NN	O
and	CC	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Mitral	JJ	O
surgery	NN	O
allows	VBZ	O
an	DT	O
immediate	JJ	O
surgical	JJ	O
auricular	NN	O
remodeling	NN	O
and	CC	O
besides	NNS	O
in	IN	O
those	DT	O
cases	NNS	O
in	IN	O
which	WDT	O
sinus	NN	O
rhythm	NN	O
is	VBZ	O
reached	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
late	JJ	O
remodeling	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
process	NN	O
of	IN	O
postoperative	JJ	O
auricular	JJ	O
remodeling	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
permanent	JJ	O
atrial	JJ	O
fibrillation	NN	O
undergoing	VBG	O
mitral	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
,	,	O
50	CD	O
patients	NNS	O
with	IN	O
permanent	JJ	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
dilated	VBD	O
left	JJ	O
atrium	NN	O
,	,	O
submitted	VBN	O
to	TO	O
surgical	JJ	O
mitral	JJ	O
repair	NN	O
,	,	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
I	PRP	O
contained	VBD	O
25	CD	O
patients	NNS	O
with	IN	O
left	JJ	O
auricular	JJ	O
reduction	NN	O
and	CC	O
mitral	JJ	O
surgery	NN	O
,	,	O
and	CC	O
Group	NNP	O
II	NNP	O
contained	VBD	O
25	CD	O
patients	NNS	O
with	IN	O
isolated	JJ	O
valve	NN	O
surgery	NN	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
considered	VBN	O
homogeneous	JJ	O
in	IN	O
the	DT	O
preoperative	JJ	O
assessment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
31	CD	O
months	NNS	O
,	,	O
46	CD	O
%	NN	O
of	IN	O
patients	NNS	O
included	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
versus	VBP	O
18	CD	O
%	NN	O
of	IN	O
patients	NNS	O
included	VBN	O
in	IN	O
Group	NNP	O
II	NNP	O
restarted	VBD	O
sinus	JJ	Physical
rhythm	NN	Physical
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

An	DT	O
auricular	JJ	Physical
remodeling	NN	Physical
with	IN	Physical
size	NN	Physical
regression	NN	Physical
occurred	VBD	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
recovered	VBD	O
from	IN	O
sinus	NN	O
rhythm	NN	O
,	,	O
worthy	NN	O
of	IN	O
remark	NN	O
in	IN	O
Group	NNP	O
II	NNP	O
(	(	O
-10.8	CD	O
%	NN	O
of	IN	O
left	JJ	O
auricular	JJ	O
volume	NN	O
reduction	NN	O
in	IN	O
Group	NNP	O
I	PRP	O
compared	VBN	O
to	TO	O
-21.5	VB	O
%	NN	O
in	IN	O
Group	NNP	O
II	NNP	O
;	:	O
p	CC	O
<	VB	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
new	JJ	Physical
atrial	JJ	Physical
enlargement	NN	Physical
took	VBD	O
place	NN	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
remained	VBD	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
+16.8	CD	O
%	NN	O
left	VBD	O
auricular	JJ	O
volume	NN	O
in	IN	O
Group	NNP	O
I	PRP	O
vs.	VBP	O
+8.4	CD	O
%	NN	O
in	IN	O
Group	NNP	O
II	NNP	O
;	:	O
p	CC	O
<	VB	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Mitral	NNP	O
surgery	NN	O
produces	VBZ	O
an	DT	O
atrial	JJ	O
postoperative	NN	O
volume	NN	O
that	IN	O
decrease	NN	O
especially	RB	O
when	WRB	O
reduction	NN	O
techniques	NNS	O
are	VBP	O
employed	VBN	O
.	.	O

Late	JJ	O
left	VBD	O
atrial	JJ	O
remodeling	VBG	O
depended	VBN	O
on	IN	O
the	DT	O
type	NN	O
of	IN	O
atrial	JJ	Physical
rhythm	NN	Physical
and	CC	O
postoperative	JJ	Physical
surgical	JJ	Physical
volume	NN	Physical
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
recombinant	JJ	O
alpha	JJ	O
2b-interferon	JJ	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
malignant	JJ	O
melanoma	NN	O
.	.	O

alpha-Interferon	NN	O
has	VBZ	O
antitumor	VBN	O
activity	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
malignancies	NNS	O
but	CC	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
unacceptable	JJ	O
toxic	JJ	Adverseeffect
side-effects	NNS	Adverseeffect
.	.	O

The	DT	O
routine	JJ	O
use	NN	O
of	IN	O
agents	NNS	O
potentially	RB	O
capable	JJ	O
of	IN	O
reducing	VBG	O
these	DT	O
side-effects	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
recommended	VBN	O
out	IN	O
of	IN	O
concern	NN	O
for	IN	O
possible	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
interferon	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
alpha-interferon	JJ	O
given	VBN	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
to	TO	O
determine	VB	O
what	WP	O
effect	NN	O
,	,	O
if	IN	O
any	DT	O
,	,	O
indomethacin	NN	O
might	MD	O
have	VB	O
on	IN	O
the	DT	O
toxic	NN	Adverseeffect
,	,	O
immunomodulatory	NN	Physical
,	,	O
and	CC	O
therapeutic	JJ	Physical
properties	NNS	Others
of	IN	O
interferon	NN	O
in	IN	O
this	DT	O
disease	NN	O
.	.	O

53	CD	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
performance	NN	O
status	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
alpha	JJ	O
2b-interferon	CD	O
,	,	O
20	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
i.v.	NN	O
,	,	O
5	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
10	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
s.c.	NN	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
either	RB	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NN	O
,	,	O
25	CD	O
mg	NN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

The	DT	O
overall	JJ	Others
major	JJ	Others
response	NN	Physical
rate	NN	Physical
was	VBD	O
13	CD	O
%	NN	O
(	(	O
three	CD	O
complete	JJ	O
responders	NNS	O
and	CC	O
three	CD	O
partial	JJ	O
responders	NNS	O
among	IN	O
47	CD	O
evaluable	JJ	O
patients	NNS	O
)	)	O
and	CC	O
was	VBD	O
the	DT	O
same	JJ	O
on	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
mean	JJ	Physical
maximal	JJ	Physical
temperature	NN	Physical
elevation	NN	Physical
induced	VBN	O
by	IN	O
interferon	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
from	IN	O
102.1	CD	O
to	TO	O
100.7	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
by	IN	O
indomethacin	NN	O
,	,	O
but	CC	O
the	DT	O
incidence	NN	Physical
and	CC	Physical
severity	NN	Physical
of	IN	Physical
interferon-related	JJ	Physical
fatigue	NN	Physical
,	,	O
reduction	NN	Physical
in	IN	Physical
performance	NN	Physical
status	NN	Physical
,	,	O
headache	NN	Physical
,	,	O
depression	NN	Mental
,	,	O
confusion	NN	Mental
,	,	O
elevations	NNS	Physical
in	IN	Physical
liver	JJ	Physical
function	NN	Physical
tests	NNS	Physical
,	,	O
and	CC	O
myelosuppression	NN	Physical
were	VBD	O
no	DT	O
different	JJ	O
in	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Indomethacin	NNP	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
frequency	NN	Adverseeffect
of	IN	Adverseeffect
dose	JJ	Adverseeffect
reductions	NNS	Adverseeffect
for	IN	Adverseeffect
toxic	JJ	Adverseeffect
side-effects	NNS	Adverseeffect
and	CC	O
did	VBD	O
not	RB	O
permit	VB	O
the	DT	O
administration	NN	Others
of	IN	Others
higher	JJR	Others
interferon	NN	Others
doses	NNS	Others
.	.	O

Peripheral	NNP	Physical
blood	VBD	Physical
natural	JJ	Physical
killer	NN	Physical
activity	NN	Physical
was	VBD	O
significantly	RB	O
enhanced	VBN	O
in	IN	O
patients	NNS	O
during	IN	O
maintenance	NN	O
therapy	NN	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
received	VBD	O
indomethacin	NN	O
.	.	O

Indomethacin	NNP	O
appeared	VBD	O
to	TO	O
inhibit	VB	O
augmentation	NN	Physical
of	IN	Physical
natural	JJ	Physical
killer	NN	Physical
activity	NN	Physical
during	IN	O
high	JJ	O
dose	JJ	O
induction	NN	O
therapy	NN	O
.	.	O

Immunological	JJ	Physical
changes	NNS	Physical
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
response	NN	O
status	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
indomethacin	NN	O
can	MD	O
reduce	VB	O
the	DT	O
fever	NN	Physical
associated	VBN	O
with	IN	O
interferon	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
its	PRP$	O
therapeutic	JJ	Physical
or	CC	Physical
chronic	JJ	Physical
immunomodulatory	NN	Physical
activities	NNS	Physical
.	.	O

Since	IN	O
fever	NN	Physical
is	VBZ	O
rarely	RB	O
the	DT	O
dose-limiting	JJ	O
toxicity	NN	O
of	IN	O
interferon	NN	O
,	,	O
indomethacin	NN	O
is	VBZ	O
of	IN	O
marginal	JJ	O
benefit	NN	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
receiving	VBG	O
interferon	NN	O
at	IN	O
the	DT	O
doses	NNS	O
outlined	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
multicenter	NN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
study	NN	O
of	IN	O
a	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
of	IN	O
Zostavax	NNP	O
.	.	O

The	DT	O
vaccine	NN	O
Zostavax	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
prevent	VB	O
herpes	NNS	O
zoster	NNP	O
(	(	O
HZ	NNP	O
)	)	O
and	CC	O
postherpetic	JJ	O
neuralgia	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
for	IN	O
individuals	NNS	O
>	CD	O
or	CC	O
=60	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
safety	NN	Others
and	CC	O
the	DT	O
immunogenicity	NN	Others
of	IN	O
a	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
(	(	O
Zostavax	NNP	O
refrigerated	VBD	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
current	JJ	O
formulation	NN	O
(	(	O
Zostavax	NNP	O
frozen	RB	O
)	)	O
in	IN	O
subjects	NNS	O
>	VBP	O
or	CC	O
=50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Subjects	VBZ	O
with	IN	O
a	DT	O
negative	JJ	O
history	NN	O
for	IN	O
HZ	NNP	O
were	VBD	O
randomized	VBN	O
1:1	CD	O
to	TO	O
receive	VB	O
one	CD	O
dose	NN	O
of	IN	O
either	DT	O
formulation	NN	O
.	.	O

Enrollment	NN	O
was	VBD	O
stratified	VBN	O
1:2	CD	O
by	IN	O
age	NN	O
(	(	O
50	CD	O
to	TO	O
59	CD	O
years	NNS	O
and	CC	O
>	NN	O
or	CC	O
=60	CD	O
years	NNS	O
)	)	O
.	.	O

Safety	NN	Others
was	VBD	O
evaluated	VBN	O
for	IN	O
28	CD	O
days	NNS	O
postvaccination	NN	O
.	.	O

Varicella-zoster	JJ	Physical
virus	NN	Physical
(	(	Physical
VZV	NNP	Physical
)	)	Physical
antibody	NN	Physical
responses	NNS	Physical
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
glycoprotein	JJ	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
gpELISA	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
were	VBD	O
the	DT	O
VZV	NNP	Physical
antibody	NN	Physical
geometric	JJ	Physical
mean	NN	Physical
titer	NN	Physical
(	(	Physical
GMT	NNP	Physical
;	:	Physical
day	NN	Physical
28	CD	Physical
)	)	Physical
,	,	O
the	DT	O
VZV	NNP	Physical
antibody	NN	Physical
geometric	JJ	Physical
mean	NN	Physical
rise	NN	Physical
(	(	Physical
GMR	NNP	Physical
;	:	Physical
days	NNS	Physical
1	CD	Physical
to	TO	Physical
28	CD	Physical
)	)	Physical
,	,	O
and	CC	O
the	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
vaccine-related	JJ	Adverseeffect
serious	JJ	Adverseeffect
adverse	JJ	Adverseeffect
experiences	NNS	Adverseeffect
(	(	Adverseeffect
AEs	NNP	Adverseeffect
)	)	Adverseeffect
over	IN	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
refrigerated	JJ	O
(	(	O
n	JJ	O
=	NNP	O
182	CD	O
)	)	O
and	CC	O
frozen	JJ	O
(	(	O
n	JJ	O
=	NNP	O
185	CD	O
)	)	O
formulations	NNS	O
induced	VBD	O
similar	JJ	O
GMTs	NNP	Physical
(	(	O
727.4	CD	O
and	CC	O
834.4	CD	O
gpELISA	NN	O
units/ml	NN	O
,	,	O
respectively	RB	O
)	)	O
;	:	O
the	DT	O
estimated	VBN	Physical
GMT	NNP	Physical
ratio	NN	Physical
(	(	Physical
refrigerated	VBN	Physical
formulation/frozen	RB	Physical
formulation	NN	Physical
)	)	Physical
was	VBD	O
0.87	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.71	CD	O
to	TO	O
1.07	CD	O
)	)	O
.	.	O

The	DT	O
GMRs	NNPS	Physical
were	VBD	O
2.6-	JJ	O
and	CC	O
2.9-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

No	DT	O
vaccine-related	JJ	Adverseeffect
serious	JJ	Adverseeffect
AEs	NNP	Adverseeffect
were	VBD	O
reported	VBN	O
in	IN	O
either	DT	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
safety	NN	Others
profiles	NNS	Others
of	IN	O
the	DT	O
formulations	NNS	O
were	VBD	O
generally	RB	O
similar	JJ	O
.	.	O

The	DT	O
frequencies	NNS	Adverseeffect
of	IN	Adverseeffect
injection-site	JJ	Adverseeffect
AEs	NNP	Adverseeffect
during	IN	O
follow-up	JJ	O
were	VBD	O
35.6	CD	O
%	NN	O
and	CC	O
46.4	CD	O
%	NN	O
in	IN	O
the	DT	O
refrigerated	JJ	O
and	CC	O
the	DT	O
frozen	JJ	O
formulation	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
were	VBD	O
generally	RB	O
mild	VBN	O
.	.	O

The	DT	O
frequencies	NNS	Adverseeffect
of	IN	Adverseeffect
systemic	JJ	Adverseeffect
AEs	NNP	Adverseeffect
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
those	DT	O
of	IN	O
vaccine-related	JJ	Adverseeffect
AEs	NNP	Adverseeffect
were	VBD	O
approximately	RB	O
6	CD	O
%	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
of	IN	O
Zostavax	NNP	O
has	VBZ	O
an	DT	O
acceptable	JJ	O
safety	NN	Others
profile	NN	Others
and	CC	O
is	VBZ	O
as	RB	O
immunogenic	JJ	Others
as	IN	O
the	DT	O
frozen	JJ	O
formulation	NN	O
;	:	O
thus	RB	O
,	,	O
the	DT	O
vaccine	NN	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
clinical	JJ	O
settings	NNS	O
where	WRB	O
freezer	NN	O
availability	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Intra-articular	JJ	O
hyaluronic	JJ	O
acid	NN	O
compared	VBN	O
to	TO	O
intra-articular	JJ	O
triamcinolone	NN	O
hexacetonide	NN	O
in	IN	O
inflammatory	JJ	O
knee	NN	O
osteoarthritis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
intra-articular	JJ	O
(	(	O
i/a	NN	O
)	)	O
triamcinolone	NN	O
.	.	O

hexacetonide	NN	O
(	(	O
TH	NNP	O
)	)	O
and	CC	O
i/a	JJ	O
hyaluronic	JJ	O
acid	NN	O
(	(	O
HA	NNP	O
)	)	O
in	IN	O
inflammatory	JJ	O
knee	NN	O
osteoarthritis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
comparative	JJ	O
trail	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
rheumatology	NN	O
outpatient	NN	O
department	NN	O
.	.	O

There	EX	O
were	VBD	O
63	CD	O
patients	NNS	O
(	(	O
24	CD	O
male	NN	O
,	,	O
39	CD	O
female	NN	O
,	,	O
mean	JJ	O
age	NN	O
70.5	CD	O
years	NNS	O
)	)	O
with	IN	O
bilateral	JJ	O
symptomatic	JJ	O
knee	NN	O
osteoarthritis	NN	O
with	IN	O
effusion	NN	O
.	.	O

Each	DT	O
was	VBD	O
given	VBN	O
five	CD	O
HA	NNP	O
injections	NNS	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
;	:	O
or	CC	O
20	CD	O
mg	NN	O
TH	NNP	O
followed	VBN	O
by	IN	O
four	CD	O
placebo	NN	O
(	(	O
saline	NN	O
)	)	O
injections	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
examined	JJ	O
weekly	JJ	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
and	CC	O
then	RB	O
at	IN	O
monthly	JJ	O
intervals	NNS	O
for	IN	O
a	DT	O
further	JJ	O
6	CD	O
months	NNS	O
.	.	O

Assessment	NNP	O
included	VBD	O
recording	NN	O
of	IN	O
:	:	O
visual	JJ	Pain
analog	NN	Pain
scores	NNS	Pain
(	(	Pain
VAS	NNP	Pain
)	)	Pain
for	IN	Pain
pain	NN	Pain
;	:	O
duration	NN	Physical
of	IN	Physical
stiffness	NN	Physical
;	:	O
range	NN	Physical
of	IN	Physical
movement	NN	Physical
;	:	O
joint	JJ	Physical
effusion	NN	Physical
;	:	O
local	JJ	Physical
heat	NN	Physical
;	:	O
synovial	JJ	Physical
thickening	NN	Physical
;	:	O
joint-line	JJ	Physical
and	CC	Physical
periarticular	JJ	Physical
tenderness	NN	Physical
.	.	O

The	DT	O
principal	JJ	O
outcome	JJ	O
measure	NN	O
was	VBD	O
pain	NN	Pain
on	IN	Pain
a	DT	Pain
self-selected	JJ	Pain
activity	NN	Pain
assessed	VBN	Pain
by	IN	Pain
Vas	NNP	Pain
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
entry	NN	O
and	CC	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
developed	VBD	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
high	JJ	O
drop-out	NN	O
rate	NN	O
and	CC	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

In	IN	O
patients	NNS	O
remaining	VBG	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
significantly	RB	O
less	JJR	O
pain	NN	Pain
was	VBD	O
experienced	VBN	O
by	IN	O
the	DT	O
HA	NNP	O
group	NN	O
during	IN	O
the	DT	O
6	CD	O
month	NN	O
follow-up	JJ	O
period	NN	O
.	.	O

Other	JJ	O
parameters	NNS	O
showed	VBD	O
a	DT	O
similar	JJ	O
trend	NN	O
in	IN	O
favor	NN	O
of	IN	O
experienced	VBN	O
by	IN	O
the	DT	O
HA	NNP	O
group	NN	O
during	IN	O
the	DT	O
6	CD	O
month	NN	O
follow-up	JJ	O
period	NN	O
.	.	O

Other	JJ	O
parameters	NNS	O
showed	VBD	O
a	DT	O
similar	JJ	O
trend	NN	O
in	IN	O
favor	NN	O
of	IN	O
HA	NNP	O
.	.	O

We	PRP	O
could	MD	O
not	RB	O
,	,	O
however	RB	O
,	,	O
demonstrate	JJ	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
placebo	NN	O
and	CC	O
active	JJ	O
treatments	NNS	O
.	.	O

HA	NNP	O
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
useful	JJ	O
additional	JJ	O
therapy	NN	O
for	IN	O
symptomatic	JJ	O
knee	NN	O
osteoarthritis	NN	O
and	CC	O
may	MD	O
have	VB	O
a	DT	O
long	JJ	O
duration	NN	O
of	IN	O
action	NN	O
.	.	O

Assisted	VBN	O
exercise	NN	O
and	CC	O
bone	NN	O
strength	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

Studies	NNS	O
have	VBP	O
previously	RB	O
demonstrated	VBN	O
that	IN	O
brief	NN	O
(	(	O
4	CD	O
weeks	NNS	O
)	)	O
passive	VBP	O
range-of-motion	NN	O
exercise	NN	O
is	VBZ	O
beneficial	JJ	O
for	IN	O
bone	NN	O
development	NN	O
in	IN	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
(	(	O
VLBW	NNP	O
)	)	O
preterm	NN	O
infants	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
exercise	NN	O
for	IN	O
bone	NN	O
development	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
is	VBZ	O
yet	RB	O
unknown	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
assisted	JJ	O
exercise	NN	O
on	IN	O
bone	NN	O
strength	NN	O
and	CC	O
metabolism	NN	O
in	IN	O
VLBW	NNP	O
premature	NN	O
infants	NNS	O
.	.	O

Sixteen	JJ	O
infants	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
error	NN	O
of	IN	O
the	DT	O
mean	JJ	O
birth	NN	O
weight	VBD	O
1,009	CD	O
+/-	JJ	O
55	CD	O
g	NN	O
and	CC	O
gestational	JJ	O
age	NN	O
27.3	CD	O
+/-	JJ	O
0.3	CD	O
weeks	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
exercise	NN	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
and	CC	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
groups	NNS	O
.	.	O

The	DT	O
intervention	NN	O
started	VBD	O
at	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
life	NN	O
and	CC	O
involved	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
daily	JJ	O
passive	JJ	O
extension	NN	O
and	CC	O
flexion	NN	O
range-of-motion	NN	O
exercise	NN	O
of	IN	O
the	DT	O
upper	JJ	O
and	CC	O
lower	JJR	O
extremities	NNS	O
.	.	O

Biochemical	JJ	Physical
markers	NNS	Physical
of	IN	Physical
bone	NN	Physical
turnover	NN	Physical
were	VBD	O
measured	VBN	O
at	IN	O
enrollment	NN	O
and	CC	O
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Bone	NNP	Physical
strength	NN	Physical
was	VBD	O
measured	VBN	O
weekly	JJ	O
by	IN	O
quantitative	JJ	O
ultrasound	JJ	O
measurement	NN	O
of	IN	O
tibial	JJ	Physical
bone	NN	Physical
speed	NN	Physical
of	IN	Physical
sound	NN	Physical
(	(	O
SOS	NNP	O
)	)	O
.	.	O

Bone	NNP	Physical
SOS	NNP	Physical
decreased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-108.1	JJ	O
+/-	JJ	O
33.7	CD	O
m/second	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
while	IN	O
remaining	VBG	O
stable	JJ	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
11.3	CD	O
+/-	JJ	O
22.8	CD	O
m/second	NN	O
)	)	O
.	.	O

The	DT	O
main	JJ	Physical
beneficial	JJ	Physical
effect	NN	Physical
of	IN	Physical
exercise	NN	Physical
occurred	VBN	O
in	IN	O
the	DT	O
first	JJ	O
4	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
bone	NN	Physical
turnover	NN	Physical
marker	NN	Physical
changes	NNS	Physical
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
significant	JJ	O
postnatal	JJ	Physical
decrease	NN	Physical
in	IN	Physical
bone	NN	Physical
SOS	NNP	Physical
in	IN	O
VLBW	NNP	O
preterm	NN	O
infants	NNS	O
.	.	O

Eight	NNP	O
weeks	NNS	O
of	IN	O
assisted	JJ	O
range-of-motion	NN	O
exercise	NN	O
attenuates	VBZ	O
the	DT	O
decrease	NN	O
in	IN	O
bone	NN	Physical
strength	NN	Physical
and	CC	O
may	MD	O
decrease	VB	O
the	DT	O
risk	NN	Physical
of	IN	Physical
osteopenia	NN	Physical
in	IN	O
premature	JJ	O
infants	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
intra-arterial	JJ	O
versus	NN	O
intravenous	JJ	O
heparin	NN	O
on	IN	O
radial	JJ	O
artery	NN	O
occlusion	NN	O
after	IN	O
transradial	JJ	O
catheterization	NN	O
.	.	O

Radial	JJ	O
artery	NN	O
occlusion	NN	O
(	(	O
RAO	NNP	O
)	)	O
is	VBZ	O
an	DT	O
infrequent	NN	O
,	,	O
asymptomatic	JJ	O
,	,	O
complication	NN	O
of	IN	O
transradial	JJ	O
catheterization	NN	O
and	CC	O
probably	RB	O
1	CD	O
of	IN	O
the	DT	O
few	JJ	O
.	.	O

Intravenous	JJ	O
heparin	NN	O
and	CC	O
patent	NN	O
hemostasis	NN	O
lower	RBR	O
its	PRP$	O
incidence	NN	O
.	.	O

A	DT	O
possible	JJ	O
local	JJ	O
effect	NN	O
of	IN	O
intra-arterially	RB	O
administered	VBN	O
heparin	NN	O
during	IN	O
transradial	JJ	O
procedures	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
500	CD	O
consecutive	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
an	DT	O
intravenous	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
250	CD	O
)	)	O
,	,	O
receiving	VBG	O
50	CD	O
U/kg	NNP	O
of	IN	O
unfractionated	JJ	O
heparin	NN	O
(	(	O
maximal	JJ	O
dose	VBP	O
5,000	CD	O
U	NNP	O
)	)	O
intravenously	RB	O
,	,	O
and	CC	O
an	DT	O
intra-arterial	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
250	CD	O
)	)	O
receiving	VBG	O
the	DT	O
same	JJ	O
dose	JJ	O
intra-arterially	RB	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
vasodilator	NN	O
cocktail	NN	O
intra-arterially	RB	O
and	CC	O
underwent	JJ	O
cardiac	JJ	O
catheterization	NN	O
using	VBG	O
a	DT	O
5F	CD	O
introducer	NN	O
sheath	NN	O
and	CC	O
catheters	NNS	O
.	.	O

The	DT	O
activated	JJ	Physical
clotting	NN	Physical
time	NN	Physical
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
hemostasis	NN	O
with	IN	O
a	DT	O
radial	JJ	O
compression	NN	O
device	NN	O
(	(	O
TR	NNP	O
Band	NNP	O
)	)	O
,	,	O
applied	VBN	O
after	IN	O
sheath	NN	O
removal	NN	O
,	,	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O

A	DT	O
plethysmographic	JJ	Physical
evaluation	NN	Physical
for	IN	Physical
RAO	NNP	Physical
was	VBD	O
performed	VBN	O
at	IN	O
24	CD	O
hours	NNS	O
and	CC	O
30	CD	O
days	NNS	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

Early	JJ	Mental
RAO	NNP	Mental
occurred	VBD	O
in	IN	O
5.6	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
of	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
and	CC	O
6	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
of	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
chi-square	JJ	O
=	NN	O
0.037	CD	O
,	,	O
p	NN	O
>	NNP	O
0.8	CD	O
)	)	O
.	.	O

Chronic	NNP	Mental
RAO	NNP	Mental
occurred	VBD	O
in	IN	O
3.2	CD	O
%	NN	O
,	,	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
of	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
4	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
of	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
chi-square	JJ	O
=	NN	O
0.231	CD	O
,	,	O
p	NN	O
>	NNP	O
0.6	CD	O
)	)	O
.	.	O

The	DT	O
activated	JJ	Physical
clotting	NN	Physical
time	NN	Physical
was	VBD	O
211	CD	O
+/-	JJ	O
16	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
and	CC	O
213	CD	O
+/-	JJ	O
17	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
,	,	O
a	DT	O
statistically	RB	O
insignificant	JJ	O
difference	NN	O
(	(	O
t	JJ	O
=	NNP	O
-1.095	NNP	O
,	,	O
p	NN	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
intra-arterial	JJ	O
and	CC	O
intravenous	JJ	O
heparin	NNS	O
administration	NN	O
provide	VBP	O
comparable	JJ	O
efficacy	NN	O
in	IN	O
preventing	VBG	O
RAO	NNP	O
,	,	O
favoring	VBG	O
a	DT	O
probable	JJ	O
systemically	RB	O
mediated	VBD	O
mechanism	NN	O
of	IN	O
action	NN	O
,	,	O
rather	RB	O
than	IN	O
a	DT	O
local	JJ	O
effect	NN	O
.	.	O

Leukocyte-depleted	JJ	O
reperfusion	NN	O
of	IN	O
transplanted	JJ	O
human	JJ	O
hearts	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Standard	NNP	O
methods	NNS	O
of	IN	O
myocardial	JJ	O
preservation	NN	O
for	IN	O
heart	NN	O
transplantation	NN	O
have	VBP	O
generally	RB	O
provided	VBN	O
good	JJ	O
results	NNS	O
.	.	O

Preservation	NNP	O
times	VBZ	O
beyond	IN	O
3	CD	O
hours	NNS	O
,	,	O
however	RB	O
,	,	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
decreased	JJ	O
survival	NN	Mortality
.	.	O

Leukocyte-mediated	JJ	O
reperfusion	NN	O
injury	NN	O
is	VBZ	O
partly	RB	O
responsible	JJ	O
for	IN	O
decreased	JJ	O
graft	NN	Physical
function	NN	Physical
after	IN	O
prolonged	JJ	O
graft	NN	O
ischemia	NN	O
.	.	O

Leukocyte-depleted	JJ	O
reperfusion	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
experimentally	RB	O
to	TO	O
improve	VB	O
cardiac	JJ	Physical
function	NN	Physical
after	IN	O
cold	JJ	O
ischemic	JJ	O
arrest	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
leukocyte-depleted	JJ	O
reperfusion	NN	O
,	,	O
20	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
be	VB	O
treated	VBN	O
with	IN	O
either	DT	O
warm	JJ	O
whole	NN	O
blood	NN	O
reperfusion	NN	O
(	(	O
group	NN	O
I	PRP	O
;	:	O
n	CC	O
=	VB	O
9	CD	O
)	)	O
or	CC	O
warm	JJ	O
leukocyte-depleted	JJ	O
blood	NN	O
reperfusion	NN	O
(	(	O
group	NN	O
II	NNP	O
;	:	O
n	CC	O
=	VB	O
11	CD	O
)	)	O
.	.	O

Reperfusion	NN	O
with	IN	O
leukocyte-depleted	JJ	O
blood	NN	O
or	CC	O
whole	JJ	O
blood	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
for	IN	O
10	CD	O
minutes	NNS	O
,	,	O
with	IN	O
enriched	JJ	O
cardioplegic	JJ	O
solution	NN	O
added	VBD	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
minutes	NNS	O
of	IN	O
reperfusion	NN	O
.	.	O

The	DT	O
mean	JJ	O
donor	NN	O
and	CC	O
recipient	JJ	O
age	NN	O
and	CC	O
the	DT	O
ischemic	JJ	Physical
time	NN	Physical
(	(	O
142	CD	O
versus	NN	O
153	CD	O
minutes	NNS	O
)	)	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Coronary	NNP	Physical
sinus	VBD	Physical
release	NN	Physical
of	IN	Physical
creatinine	JJ	Physical
phosphokinase-MB	JJ	Physical
5	CD	Physical
minutes	NNS	Physical
after	IN	Physical
reperfusion	NN	Physical
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
1.65	CD	O
EU/min	NNP	O
)	)	O
than	IN	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
3.83	CD	O
units/min	NN	O
;	:	O
p	CC	O
=	VB	O
0.05	CD	O
)	)	O
.	.	O

Thromboxane	NNP	Physical
B2	NNP	Physical
release	NN	Physical
was	VBD	O
also	RB	O
significantly	RB	O
less	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
33.6	CD	O
pg/min	NN	O
)	)	O
than	IN	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
67.0	CD	O
pg/min	NN	O
)	)	O
.	.	O

All	DT	O
hearts	NNS	Physical
functioned	VBD	Physical
adequately	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
duration	NN	Physical
of	IN	Physical
inotropic	JJ	Physical
support	NN	Physical
was	VBD	O
shorter	JJR	O
in	IN	O
group	NN	O
II	NNP	O
than	IN	O
in	IN	O
group	NN	O
I	PRP	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Postoperative	JJ	Adverseeffect
hemodynamics	NNS	Adverseeffect
,	,	Adverseeffect
rejection	NN	Adverseeffect
episodes	NNS	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
infectious	JJ	Adverseeffect
complications	NNS	Adverseeffect
were	VBD	O
also	RB	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
in	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
9	CD	O
months	NNS	O
.	.	O

Mean	NNP	Physical
ejection	NN	Physical
fraction	NN	Physical
1	CD	Physical
month	NN	Physical
after	IN	Physical
operation	NN	Physical
was	VBD	O
65	CD	O
%	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

One	CD	O
early	JJ	O
death	NN	Adverseeffect
occurred	VBD	O
at	IN	O
66	CD	O
days	NNS	O
secondary	JJ	O
to	TO	O
infection	NN	O
;	:	O
two	CD	O
late	JJ	O
deaths	NNS	Adverseeffect
occurred	VBD	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
both	DT	O
from	IN	O
rejection	NN	O
.	.	O

Leukocyte-depleted	JJ	O
reperfusion	NN	O
is	VBZ	O
safe	JJ	Others
and	CC	O
easily	RB	O
applied	VBN	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
.	.	O

Furthermore	CD	O
,	,	O
leukocyte-depleted	JJ	O
reperfusion	NN	O
decreases	VBZ	O
biochemical	JJ	Physical
evidence	NN	Physical
of	IN	O
reperfusion	NN	O
injury	NN	O
.	.	O

Although	IN	O
not	RB	O
influencing	VBG	O
postoperative	JJ	O
cardiac	JJ	Physical
function	NN	Physical
when	WRB	O
the	DT	O
ischemic	JJ	O
time	NN	O
is	VBZ	O
short	JJ	O
,	,	O
less	JJR	O
than	IN	O
3	CD	O
hours	NNS	O
,	,	O
leukocyte-depleted	JJ	O
reperfusion	NN	O
may	MD	O
prevent	VB	O
significant	JJ	O
reperfusion	NN	Physical
injury	NN	Physical
and	CC	O
improve	VB	O
posttransplantation	NN	Physical
graft	NN	Physical
function	NN	Physical
when	WRB	O
ischemic	JJ	Physical
times	NNS	Physical
are	VBP	O
long	JJ	O
.	.	O

Safe	JJ	O
extension	NN	O
of	IN	O
the	DT	O
ischemic	JJ	O
time	NN	O
would	MD	O
expand	VB	O
the	DT	O
donor	NN	O
pool	NN	O
and	CC	O
allow	VB	O
for	IN	O
better	JJR	O
crossmatching	NN	O
.	.	O

Anticholinergic	NNP	O
drugs	NNS	O
:	:	O
effects	NNS	O
on	IN	O
oxygen	NN	Physical
consumption	NN	Physical
and	CC	Physical
energy	NN	Physical
expenditure	NN	Physical
.	.	O

Premedication	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
affect	VB	O
both	DT	O
oxygen	NN	Physical
consumption	NN	Physical
(	(	O
VO2	NNP	O
)	)	O
and	CC	O
energy	NN	Physical
expenditure	NN	Physical
(	(	O
EE	NNP	O
)	)	O
.	.	O

The	DT	O
metabolic	JJ	O
responses	NNS	O
to	TO	O
anticholinergic	VB	O
drugs	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	JJ	O
drugs	NNS	O
on	IN	O
VO2	NNP	O
and	CC	O
EE	NNP	O
(	(	O
calculated	VBN	O
from	IN	O
the	DT	O
measured	VBN	O
rates	NNS	O
of	IN	O
VO2	NNP	O
and	CC	O
carbon	NN	O
dioxide	NN	O
production	NN	O
[	NNP	O
VCO2	NNP	O
]	NN	O
:	:	O
EE	NNP	O
[	NNP	O
kcal/d	NNP	O
]	NNP	O
=	VBD	O
3.581	CD	O
x	NNP	O
VO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
+	VBD	O
1.448	CD	O
x	NNP	O
VCO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
-	:	O
32.4	CD	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
six	CD	O
healthy	JJ	O
female	NN	O
volunteers	NNS	O
.	.	O

They	PRP	O
were	VBD	O
given	VBN	O
intramuscular	JJ	O
atropine	NN	O
(	(	O
15	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
glycopyrrolate	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
scopolamine	NN	O
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
in	IN	O
a	DT	O
random	JJ	O
double-blind	JJ	O
cross-over	NN	O
design	NN	O
.	.	O

The	DT	O
consecutive	JJ	O
sessions	NNS	O
were	VBD	O
at	IN	O
least	JJS	O
1	CD	O
wk	JJ	O
apart	RB	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

VO2	NNP	Physical
and	CC	Physical
EE	NNP	Physical
were	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
indirect	JJ	O
calorimetry	NN	O
(	(	O
Deltatrac	NNP	O
)	)	O
.	.	O

Cardiovascular	JJ	Physical
responses	NNS	Physical
were	VBD	O
assessed	VBN	O
using	VBG	O
standard	JJ	O
noninvasive	JJ	O
monitoring	NN	O
.	.	O

Plasma	NNP	Physical
drug	NN	Physical
concentrations	NNS	Physical
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
sensitive	JJ	O
modification	NN	O
of	IN	O
radioreceptor	NN	O
assay	NN	O
.	.	O

Subjective	JJ	O
responses	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
visual	JJ	Physical
analog	NN	Physical
scale	NN	Physical
(	(	Physical
VAS	NNP	Physical
)	)	Physical
.	.	O

Atropine	NNP	O
and	CC	O
glycopyrrolate	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
with	IN	O
a	DT	O
simultaneous	JJ	O
decrease	NN	O
in	IN	O
pressure	NN	Physical
rate	NN	Physical
quotient	NN	Physical
(	(	Physical
PRQ	NNP	Physical
)	)	Physical
,	,	O
while	IN	O
scopolamine	NN	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
with	IN	O
a	DT	O
simultaneous	JJ	O
increase	NN	Physical
in	IN	Physical
PRQ	NNP	Physical
.	.	O

Scopolamine	NNP	O
significantly	RB	O
decreased	VBD	O
both	DT	O
VO2	NNP	Physical
and	CC	Physical
EE	NNP	Physical
,	,	O
whereas	JJ	O
glycopyrrolate	NN	O
increased	VBD	O
VO2	NNP	Physical
.	.	O

Atropine	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
metabolic	JJ	Physical
variables	NNS	Physical
.	.	O

Only	RB	O
scopolamine	NN	O
induced	JJ	O
sedation	NN	Physical
in	IN	O
this	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
atropine	NN	O
,	,	O
glycopyrrolate	NN	O
,	,	O
and	CC	O
scopolamine	NN	O
differ	NN	O
not	RB	O
only	RB	O
in	IN	O
their	PRP$	O
cardiovascular	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
effects	NNS	O
,	,	O
but	CC	O
also	RB	O
in	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
metabolism	NN	O
.	.	O

The	DT	O
FLT3ITD	NNP	O
mRNA	NN	O
level	NN	O
has	VBZ	O
a	DT	O
high	JJ	O
prognostic	JJ	O
impact	NN	O
in	IN	O
NPM1	NNP	O
mutated	VBD	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
NPM1	NNP	O
unmutated	VBD	O
,	,	O
AML	NNP	O
with	IN	O
a	DT	O
normal	JJ	O
karyotype	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
FLT3-internal	JJ	O
tandem	NN	O
duplication	NN	O
(	(	O
FLT3ITD	NNP	O
)	)	O
on	IN	O
prognosis	NN	O
of	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
AML	NNP	O
)	)	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
ratio	NN	O
of	IN	O
mutated	VBN	O
to	TO	O
wild-type	JJ	O
allele	NN	O
.	.	O

In	IN	O
648	CD	O
normal	JJ	O
karyotype	NN	O
(	(	O
NK	NNP	O
)	)	O
AML	NNP	O
patients	NNS	O
,	,	O
we	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
independent	JJ	O
effect	NN	O
of	IN	O
the	DT	O
quantitative	JJ	Physical
FLT3ITD	NNP	Physical
mRNA	NN	Physical
level	NN	Physical
--	:	Physical
measured	VBN	Physical
as	IN	O
(	(	O
FLT3ITD/wtFLT3	NNP	O
)	)	O
/	NN	O
(	(	O
FLT3ITD/wtFLT3+1	NNP	O
)	)	O
--	:	O
on	IN	O
outcome	NN	O
.	.	O

Moreover	RB	O
,	,	O
this	DT	O
effect	NN	O
was	VBD	O
clearly	RB	O
seen	VBN	O
in	IN	O
329	CD	O
patients	NNS	O
with	IN	O
a	DT	O
mutated	VBN	O
NPM1	NNP	O
gene	NN	O
(	(	O
NPM1+	NNP	O
)	)	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
319	CD	O
patients	NNS	O
without	IN	O
a	DT	O
NPM1	NNP	O
mutation	NN	O
(	(	O
wtNPM1	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
multivariate	NN	O
Cox	NNP	O
regression	NN	O
model	NN	O
,	,	O
the	DT	O
quantitative	JJ	O
FLT3ITD	NNP	O
mRNA	NN	O
level	NN	O
showed	VBD	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
impact	NN	O
on	IN	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	O
OS	NNP	O
)	)	O
and	CC	O
relapse-free	JJ	Mortality
survival	NN	Mortality
(	(	O
RFS	NNP	O
)	)	O
only	RB	O
in	IN	O
the	DT	O
NPM1+	NNP	O
subgroup	NN	O
(	(	O
OS	NNP	O
:	:	O
hazard	NN	O
ratio	NN	O
,	,	O
5.9	CD	O
;	:	O
[	CC	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
3.1-11.2	JJ	O
]	NN	O
;	:	O
RFS	NNP	O
:	:	O
hazard	NN	O
ratio	NN	O
,	,	O
7.5	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
3.4-16.5	JJ	O
]	NN	O
)	)	O
.	.	O

The	DT	O
FLT3ITD	NNP	O
mRNA	MD	O
level	VB	O
contributes	NNS	O
to	TO	O
relapse	VB	O
risk	NN	O
stratification	NN	O
and	CC	O
might	MD	O
help	VB	O
to	TO	O
guide	VB	O
postremission	NN	O
therapy	NN	O
in	IN	O
NPM1-mutated	JJ	O
AML	NNP	O
.	.	O

Efficacy	NN	Others
and	CC	O
safety	NN	Others
relative	VBP	O
to	TO	O
placebo	VB	O
of	IN	O
an	DT	O
oral	JJ	O
formulation	NN	O
of	IN	O
cetirizine	NN	O
and	CC	O
sustained-release	JJ	O
pseudoephedrine	NN	O
in	IN	O
the	DT	O
management	NN	Physical
of	IN	Physical
nasal	JJ	Physical
congestion	NN	Physical
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
clinical	JJ	Others
efficacy	NN	Others
of	IN	O
an	DT	O
oral	JJ	O
formulation	NN	O
of	IN	O
cetirizine	NN	O
5	CD	O
mg	NN	O
with	IN	O
sustained-release	JJ	O
pseudoephedrine	NN	O
(	(	O
PSE	NNP	O
)	)	O
120	CD	O
mg	JJ	O
relative	NN	O
to	TO	O
placebo	VB	O
in	IN	O
patients	NNS	O
with	IN	O
nasal	JJ	Physical
congestion	NN	Physical
.	.	O

METHODS	NNP	O
Twenty-four	JJ	O
patients	NNS	O
with	IN	O
perennial	JJ	O
rhinitis	NN	O
due	JJ	O
to	TO	O
house-dust-mite	JJ	O
(	(	O
HDM	NNP	O
)	)	O
allergy	NN	O
were	VBD	O
recruited	VBN	O
in	IN	O
this	DT	O
crossover	NN	O
study	NN	O
.	.	O

A	DT	O
treatment	NN	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
,	,	O
in	IN	O
which	WDT	O
cetirizine/PSE	NN	O
was	VBD	O
administered	VBN	O
twice	RB	O
daily	RB	O
,	,	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
and	CC	O
a	DT	O
further	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
in	IN	O
which	WDT	O
the	DT	O
alternative	NN	O
treatment	NN	O
was	VBD	O
given	VBN	O
to	TO	O
each	DT	O
patient	NN	O
.	.	O

Immediately	RB	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
each	DT	O
medication	NN	O
(	(	O
day	NN	O
1	CD	O
)	)	O
,	,	O
nasal	JJ	Physical
congestion	NN	Physical
and	CC	O
related	VBN	Others
symptoms	NNS	Others
were	VBD	O
assessed	VBN	O
during	IN	O
a	DT	O
7-h	JJ	O
challenge	NN	O
with	IN	O
HDM	NNP	O
feces	NNS	O
,	,	O
with	IN	O
the	DT	O
Vienna	NNP	O
Challenge	NNP	O
Chamber	NNP	O
(	(	O
VCC	NNP	O
)	)	O
,	,	O
to	TO	O
investigate	VB	O
onset	NN	O
of	IN	O
action	NN	O
of	IN	O
the	DT	O
preparation	NN	O
.	.	O

A	DT	O
second	JJ	O
challenge	NN	O
of	IN	O
3-h	JJ	O
duration	NN	O
,	,	O
carried	VBD	O
out	RP	O
at	IN	O
least	JJS	O
12	CD	O
h	NN	O
after	IN	O
the	DT	O
final	JJ	O
dose	NN	O
,	,	O
was	VBD	O
undertaken	VBN	O
after	IN	O
1	CD	O
week	NN	O
(	(	O
mean	JJ	O
)	)	O
of	IN	O
twice-daily	JJ	O
treatment	NN	O
to	TO	O
assess	VB	O
residual	JJ	O
effects	NNS	Others
of	IN	O
the	DT	O
formulation	NN	O
after	IN	O
achievement	NN	O
of	IN	O
steady	JJ	O
state	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
oral	JJ	O
formulation	NN	O
of	IN	O
cetirizine/PSE	NN	O
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
superior	NN	O
to	TO	O
placebo	VB	O
in	IN	O
improving	VBG	O
nasal	JJ	Physical
obstruction	NN	Physical
during	IN	O
both	DT	O
challenges	NNS	O
.	.	O

The	DT	O
improvement	NN	Physical
in	IN	Physical
nasal	JJ	Physical
airflow	NN	Physical
and	CC	Physical
nasal	JJ	Physical
patency	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
with	IN	O
cetirizine/PSE	NN	O
than	IN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
subjective	JJ	O
assessment	NN	O
of	IN	O
nasal	NN	Physical
symptoms	NNS	Physical
showed	VBD	O
that	IN	O
cetirizine/PSE	NN	O
was	VBD	O
significantly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
both	DT	O
challenges	NNS	O
for	IN	O
the	DT	O
sum	NN	Physical
of	IN	Physical
nasal	JJ	Physical
obstruction	NN	Physical
scores	NNS	Physical
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Both	DT	O
medications	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	Others
,	,	O
and	CC	O
no	DT	O
serious	JJ	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
occurred	VBD	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
cetirizine/PSE	NN	O
relieved	VBD	O
nasal	JJ	Physical
congestion	NN	Physical
and	CC	O
other	JJ	O
objective	JJ	O
and	CC	O
subjective	JJ	O
symptoms	NNS	Others
to	TO	O
a	DT	O
significantly	RB	O
greater	JJR	O
extent	NN	O
than	IN	O
placebo	NN	O
.	.	O

No	DT	O
serious	JJ	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
occurred	VBD	O
,	,	O
and	CC	O
both	DT	O
regimens	NNS	O
were	VBD	O
equally	RB	O
well	RB	O
tolerated	VBN	Others
.	.	O

The	DT	O
reversibility	NN	O
of	IN	O
increased	JJ	O
airways	NNS	O
resistance	NN	O
in	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
measured	VBN	O
by	IN	O
impulse	JJ	O
oscillometry	NN	O
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
with	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
complain	NN	O
of	IN	O
breathlessness	NN	O
and	CC	O
fatigue	NN	O
on	IN	O
exercise	NN	O
.	.	O

Airways	NNS	O
resistance	NN	O
is	VBZ	O
increased	VBN	O
and	CC	O
lung	JJ	O
compliance	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
pulmonary	JJ	O
abnormalities	NNS	O
are	VBP	O
reversible	JJ	O
and	CC	O
whether	IN	O
any	DT	O
improvements	NNS	O
lead	VBP	O
to	TO	O
changes	NNS	O
to	TO	O
exercise	VB	O
capacity	NN	O
or	CC	O
symptoms	NNS	O
.	.	O

METHODS	NNP	O
Twelve	NNP	O
patients	NNS	O
with	IN	O
stable	JJ	O
chronic	JJ	O
heart	NN	O
failure	NN	O
and	CC	O
10	CD	O
matched	VBD	O
controls	NNS	O
underwent	JJ	O
repeated	VBD	O
assessment	NN	O
of	IN	O
airways	NNS	O
resistance	NN	O
using	VBG	O
impulse	JJ	O
oscillometry	NN	O
and	CC	O
peak	NN	O
exercise	NN	O
testing	VBG	O
with	IN	O
metabolic	NNP	O
gas	NN	O
exchange	NN	O
after	IN	O
receiving	VBG	O
nebulized	JJ	O
saline	NN	O
as	IN	O
placebo	NN	O
or	CC	O
combined	VBN	O
salbutamol	NNS	O
and	CC	O
ipratropium	NN	O
bromide	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
randomized	VBN	O
fashion	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
had	VBD	O
lower	JJR	O
peak	NN	Physical
oxygen	NN	Physical
consumption	NN	Physical
and	CC	O
a	DT	O
steeper	JJ	O
slope	NN	O
relating	VBG	O
ventilation	NN	O
to	TO	O
carbon	VB	O
dioxide	NN	O
production	NN	O
than	IN	O
controls	NNS	O
.	.	O

Bronchodilators	NNS	O
reduced	VBD	O
peripheral	JJ	O
airways	NNS	O
resistance	NN	O
in	IN	O
patients	NNS	O
(	(	O
0.53	CD	O
versus	NN	O
0.38	CD	O
,	,	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
and	CC	O
controls	NNS	O
(	(	O
0.21	CD	O
versus	NN	O
0.19	CD	O
,	,	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
and	CC	O
increased	JJ	O
measures	NNS	O
of	IN	O
compliance	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
peak	NN	Physical
oxygen	NN	Physical
consumption	NN	Physical
,	,	Physical
exercise	NN	Physical
time	NN	Physical
,	,	Physical
ventilation	NN	Physical
to	TO	Physical
carbon	VB	Physical
dioxide	NN	Physical
slope	NN	Physical
,	,	Physical
or	CC	Physical
anaerobic	JJ	Physical
threshold	NN	Physical
.	.	Physical

There	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
peak	JJ	Physical
tidal	JJ	Physical
volume	NN	Physical
(	(	Physical
VT	NNP	Physical
)	)	Physical
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
peak	JJ	Physical
ventilation	NN	Physical
.	.	Physical

The	DT	O
slope	NN	O
relating	VBG	O
symptoms	NNS	O
to	TO	O
ventilation	NN	Physical
(	(	O
ie	JJ	O
,	,	O
Borg/VE	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
patients	NNS	O
after	IN	O
bronchodilators	NNS	O
(	(	O
17	CD	O
%	NN	O
+/-8	JJ	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
improvement	NN	O
in	IN	O
VT	NNP	O
and	CC	O
reduction	NN	O
in	IN	O
gradient	NN	O
of	IN	O
the	DT	O
Borg/VE	NNP	Physical
slope	NN	Physical
was	VBD	O
significant	JJ	O
(	(	O
r=.40	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Nebulized	NNP	O
bronchodilators	NNS	O
improve	VBP	O
airways	NNS	Physical
resistance	NN	Physical
,	,	Physical
lung	NN	Physical
reactance	NN	Physical
,	,	O
and	CC	O
peak	JJ	Physical
tidal	JJ	Physical
volume	NN	Physical
during	IN	O
exercise	NN	O
in	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
but	CC	O
do	VBP	O
not	RB	O
increase	VB	O
peak	NN	O
exercise	NN	O
capacity	NN	O
.	.	O

They	PRP	O
do	VBP	O
,	,	O
however	RB	O
,	,	O
reduce	VB	O
the	DT	O
symptom	NN	Physical
of	IN	Physical
breathlessness	NN	Physical
.	.	Physical

Effects	NNS	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
on	IN	O
serum	NN	Physical
liver	NN	Physical
enzymes	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
hepatitis	JJ	O
C	NNP	O
virus-related	JJ	O
chronic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
(	(	O
UDCA	NNP	O
)	)	O
on	IN	O
serum	NN	Physical
liver	NN	Physical
enzyme	NN	Physical
levels	NNS	Physical
[	VBP	Physical
alanine	JJ	Physical
aminotransferase	NN	Physical
(	(	Physical
ALT	NNP	Physical
)	)	Physical
and	CC	Physical
gamma-glutamyl	JJ	Physical
transferase	NN	Physical
(	(	Physical
GGT	NNP	Physical
)	)	Physical
]	VBP	Physical
in	IN	O
101	CD	O
patients	NNS	O
with	IN	O
hepatitis	JJ	O
C	NNP	O
virus-related	JJ	O
chronic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
Forty-nine	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
UDCA	NNP	O
(	(	O
450	CD	O
mg/day	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
and	CC	O
52	CD	O
to	TO	O
receive	VB	O
no	DT	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
UDCA	NNP	O
group	NN	O
,	,	O
serum	NN	Physical
ALT	NNP	Physical
and	CC	Physical
GGT	NNP	Physical
levels	NNS	Physical
significantly	RB	O
improved	VBN	O
.	.	O

ALT	NNP	Physical
values	NNS	Physical
decreased	VBN	O
from	IN	O
pre-treatment	JJ	O
levels	NNS	O
of	IN	O
157.0	CD	O
+/-	JJ	O
62.6	CD	O
IU/l	NNP	O
to	TO	O
82.5	CD	O
+/-	JJ	O
46.4	CD	O
IU/l	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
GGT	NNP	O
fell	VBD	O
from	IN	O
141.3	CD	O
+/-	JJ	O
86.2	CD	O
IU/l	NNP	O
to	TO	O
66.0	CD	O
+/-	JJ	O
49.5	CD	O
IU/l	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
mean	JJ	Physical
ALT	NNP	Physical
and	CC	Physical
GGT	NNP	Physical
levels	NNS	Physical
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
our	PRP$	O
encouraging	JJ	O
preliminary	JJ	O
results	NNS	O
must	MD	O
be	VB	O
validated	VBN	O
by	IN	O
double-blind	JJ	O
histological	JJ	O
trials	NNS	O
,	,	O
UDCA	NNP	O
may	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
who	WP	O
fail	VBP	O
to	TO	O
respond	VB	O
to	TO	O
interferon	VB	O
therapy	NN	O
.	.	O

Variance	NN	O
in	IN	O
albumin	NN	O
loading	NN	O
in	IN	O
exchange	NN	O
transfusions	NNS	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
rationale	NN	O
of	IN	O
albumin	NN	O
priming	VBG	O
prior	RB	O
to	TO	O
exchange	NN	O
transfusions	NNS	O
,	,	O
42	CD	O
hyperbilirubinemic	JJ	O
infants	NNS	O
who	WP	O
required	VBD	O
exchange	NN	O
transfusions	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
consisted	VBD	O
of	IN	O
15	CD	O
infants	NNS	O
who	WP	O
were	VBD	O
given	VBN	O
intravenously	RB	O
1	CD	O
gm/kg	NN	O
of	IN	O
salt-poor	JJ	O
human	JJ	O
serum	NN	O
albumin	IN	O
one	CD	O
hour	NN	O
before	IN	O
the	DT	O
exchanges	NNS	O
.	.	O

Group	NNP	O
II	NNP	O
,	,	O
which	WDT	O
consisted	VBD	O
of	IN	O
27	CD	O
infants	NNS	O
,	,	O
received	VBD	O
simple	JJ	O
exchanges	NNS	O
.	.	O

No	DT	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
variations	NNS	O
in	IN	O
reserve	NN	O
albumin-binding	JJ	O
capacity	NN	O
,	,	O
bilirubin	NN	O
,	,	O
albumin	NN	O
,	,	O
or	CC	O
red	JJ	O
cell	NN	O
bilirubin	NN	O
at	IN	O
pre	NN	O
and	CC	O
one-hour	JJ	O
post	NN	O
albumin	NN	O
infusion	NN	O
in	IN	O
the	DT	O
primed	JJ	O
infants	NNS	O
.	.	O

The	DT	O
amount	NN	Physical
of	IN	Physical
bilirubin	NN	Physical
removed	VBN	Physical
per	IN	Physical
kilogram	NN	Physical
is	VBZ	O
directly	RB	O
correlated	VBN	O
to	TO	O
plasma	VB	Physical
bilirubin	JJ	Physical
concentration	NN	Physical
(	(	O
r=0.87	NN	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
efficiency	NN	Physical
on	IN	Physical
bilirubin	NN	Physical
removal	NN	Physical
was	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
albumin	JJ	O
therapy	NN	O
was	VBD	O
apparent	JJ	O
only	RB	O
in	IN	O
those	DT	O
infants	NNS	O
with	IN	O
low	JJ	O
RABC	NNP	O
as	IN	O
determined	VBN	O
by	IN	O
the	DT	O
sephadex	NN	O
gel	JJ	O
filtration	NN	O
technique	NN	O
.	.	O

Pulse	NNP	O
oximeter	NN	O
perfusion	NN	O
index	NN	O
as	IN	O
an	DT	O
early	JJ	O
indicator	NN	O
of	IN	O
sympathectomy	NN	O
after	IN	O
epidural	JJ	O
anesthesia	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
pulse	JJ	O
oximeter	NN	O
perfusion	NN	O
index	NN	O
(	(	O
PI	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
used	VBN	O
to	TO	O
indicate	VB	O
sympathectomy-induced	JJ	O
vasodilatation	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
pulse	JJ	O
oximeter	NN	O
PI	NNP	O
provides	VBZ	O
an	DT	O
earlier	JJR	O
and	CC	O
clearer	JJR	O
indication	NN	O
of	IN	O
sympathectomy	NN	O
following	VBG	O
epidural	JJ	O
anesthesia	NNS	O
than	IN	O
skin	JJ	O
temperature	NN	O
and	CC	O
arterial	JJ	O
pressure	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
patients	NNS	O
received	VBD	O
lumbar	JJ	O
epidural	JJ	O
catheters	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
10	CD	O
ml	VBD	O
0.5	CD	O
%	NN	O
bupivacaine	NN	O
or	CC	O
10	CD	O
ml	JJ	O
0.25	CD	O
%	NN	O
bupivacaine	NN	O
.	.	O

PI	NNP	Physical
in	IN	Physical
the	DT	Physical
toe	NN	Physical
,	,	Physical
mean	JJ	Physical
arterial	JJ	Physical
pressure	NN	Physical
(	(	Physical
MAP	NNP	Physical
)	)	Physical
and	CC	Physical
toe	JJ	Physical
temperature	NN	Physical
were	VBD	O
all	DT	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
min	NN	O
following	VBG	O
epidural	JJ	O
anesthesia	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
epidural	JJ	O
anesthesia	NN	O
over	IN	O
time	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
repeated	JJ	O
measures	NNS	Others
analysis	NN	Others
of	IN	Others
variance	NN	Others
.	.	Physical

Additionally	RB	O
,	,	O
we	PRP	O
defined	VBD	O
clinically	RB	Physical
evident	JJ	Physical
sympathectomy	NN	Physical
criteria	NNS	Physical
(	(	Physical
a	DT	Physical
100	CD	Physical
%	NN	Physical
increase	NN	Physical
in	IN	Physical
the	DT	Physical
PI	NNP	Physical
,	,	Physical
a	DT	Physical
15	CD	Physical
%	NN	Physical
decrease	NN	Physical
in	IN	Physical
MAP	NNP	Physical
and	CC	Physical
a	DT	Physical
1	CD	Physical
degrees	NNS	Physical
C	NNP	Physical
increase	NN	Physical
in	IN	Physical
toe	JJ	Physical
temperature	NN	Physical
)	)	Physical
.	.	Physical

The	DT	O
numbers	NNS	O
of	IN	O
patients	NNS	O
demonstrating	VBG	O
these	DT	O
changes	NNS	Physical
for	IN	O
each	DT	O
test	NN	O
were	VBD	O
compared	VBN	O
using	VBG	O
the	DT	O
McNemar	NNP	Others
test	NN	Others
for	IN	O
each	DT	O
time	NN	O
point	NN	O
.	.	O

RESULTS	NNP	O
Twenty-nine	JJ	O
subjects	NNS	O
had	VBD	O
photoplethysmography	NN	Physical
signals	NNS	Physical
that	WDT	O
met	VBD	O
a	DT	O
priori	JJ	O
signal	NN	O
quality	NN	O
criteria	NNS	O
for	IN	O
analysis	NN	O
.	.	O

By	IN	O
20	CD	O
min	NNS	O
,	,	O
PI	NNP	Physical
increased	VBN	O
by	IN	O
326	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
a	DT	O
10	CD	O
%	NN	O
decrease	NN	O
and	CC	O
a	DT	O
3	CD	O
%	NN	O
increase	NN	O
in	IN	O
MAP	NNP	Physical
and	CC	Physical
toe	JJ	Physical
temperature	NN	Physical
,	,	O
respectively	RB	O
.	.	O

For	IN	O
PI	NNP	O
15/29	CD	O
,	,	O
26/29	CD	O
and	CC	O
29/29	CD	O
of	IN	O
the	DT	O
subjects	NNS	O
met	VBD	O
the	DT	O
sympathectomy	NN	Physical
criteria	NNS	Physical
at	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
min	NN	O
,	,	O
respectively	RB	O
,	,	O
compared	VBN	O
with	IN	O
4/29	CD	O
,	,	O
6/29	CD	O
and	CC	O
18/29	CD	O
for	IN	O
MAP	NNP	Physical
changes	NNS	O
and	CC	O
3/29	CD	O
,	,	O
8/29	CD	O
and	CC	O
14/29	CD	O
for	IN	O
toe	NN	O
temperature	NN	Physical
changes	NNS	Physical
.	.	O

CONCLUSIONS	NNP	O
PI	NNP	O
was	VBD	O
an	DT	O
earlier	JJR	O
,	,	O
clearer	JJR	O
and	CC	O
more	RBR	O
sensitive	JJ	O
indicator	NN	O
of	IN	O
the	DT	O
development	NN	O
of	IN	O
epidural-induced	JJ	O
sympathectomy	NN	O
than	IN	O
either	DT	O
skin	JJ	Physical
temperature	NN	Physical
or	CC	O
MAP	NNP	Physical
.	.	O

Effects	NNS	O
of	IN	O
home	NN	O
strength	NN	O
training	NN	O
and	CC	O
stretching	VBG	O
versus	NN	O
stretching	VBG	O
alone	RB	O
after	IN	O
lumbar	JJ	O
disk	NN	O
surgery	NN	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
with	IN	O
a	DT	O
1-year	JJ	O
follow-up	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
adherence	NN	O
to	TO	O
and	CC	O
effects	NNS	O
of	IN	O
a	DT	O
12-month	JJ	O
combined	JJ	O
strength	NN	O
and	CC	O
stretching	NN	O
home	NN	O
exercise	NN	O
regimen	NNS	O
versus	IN	O
stretching	VBG	O
alone	RB	O
,	,	O
on	IN	O
patient	JJ	O
outcome	NN	O
after	IN	O
lumbar	NN	O
disk	NN	O
surgery	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
Departments	NNS	O
of	IN	O
physical	JJ	O
medicine	NN	O
and	CC	O
rehabilitation	NN	O
and	CC	O
orthopedics	NNS	O
at	IN	O
a	DT	O
Finnish	JJ	O
hospital	NN	O
.	.	O

PARTICIPANTS	JJ	O
Patients	NNPS	O
(	(	O
N=126	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
into	IN	O
either	CC	O
a	DT	O
combined	JJ	O
strength	NN	O
training	NN	O
and	CC	O
stretching	VBG	O
group	NN	O
(	(	O
STG	NNP	O
,	,	O
n=65	NN	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
CG	NNP	O
,	,	O
n=61	NN	O
)	)	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
STG	NNP	O
was	VBD	O
instructed	VBN	O
to	TO	O
perform	VB	O
strength	NN	O
training	NN	O
and	CC	O
both	DT	O
the	DT	O
STG	NNP	O
and	CC	O
CG	NNP	O
were	VBD	O
instructed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
stretching	NN	O
and	CC	O
stabilization	NN	O
exercises	NNS	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Pain	NNP	O
on	IN	O
the	DT	O
visual	JJ	Physical
analog	NN	Physical
scale	NN	Physical
(	(	Physical
VAS	NNP	Physical
)	)	Physical
,	,	Physical
the	DT	Physical
Oswestry	NNP	Physical
and	CC	Physical
the	DT	Physical
Million	NNP	Physical
disability	NN	Physical
indexes	NNS	Physical
,	,	Physical
isometric	JJ	Physical
and	CC	Physical
dynamic	JJ	Physical
trunk	NN	Physical
muscle	NN	Physical
strength	NN	Physical
,	,	Physical
mobility	NN	Physical
in	IN	Physical
the	DT	Physical
lumbar	NN	Physical
spine	NN	Physical
,	,	Physical
and	CC	Physical
straight-leg	JJ	Physical
raising	NN	Physical
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
trial	NN	O
was	VBD	O
completed	VBN	O
by	IN	O
71	CD	O
%	NN	O
and	CC	O
77	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
from	IN	O
the	DT	O
STG	NNP	O
and	CC	O
the	DT	O
CG	NNP	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	Physical
strength	NN	Physical
training	NN	Physical
frequency	NN	Physical
decreased	VBD	O
from	IN	O
1.5	CD	O
to	TO	O
0.6	CD	O
times	NNS	O
a	DT	O
week	NN	O
in	IN	O
the	DT	O
STG	NNP	O
during	IN	O
the	DT	O
intervention	NN	O
.	.	O

The	DT	O
mean	JJ	Physical
stretching	NN	Physical
frequency	NN	Physical
decreased	VBD	O
from	IN	O
3.7	CD	O
to	TO	O
1.6	CD	O
times	NNS	O
a	DT	O
week	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Median	JJ	Pain
back	RB	Pain
and	CC	Pain
leg	NN	Pain
pain	NN	Pain
varied	VBD	O
between	IN	O
17	CD	O
and	CC	O
23	CD	O
mm	NN	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Million	NNP	Physical
and	CC	Physical
Oswestry	NNP	Physical
indices	NNS	Physical
varied	VBD	O
between	IN	O
14	CD	O
and	CC	O
23	CD	O
points	NNS	O
2	CD	O
months	NNS	O
postoperatively	RB	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
took	VBD	O
place	NN	O
in	IN	O
these	DT	O
outcome	NN	O
measures	NNS	O
during	IN	O
the	DT	O
12-month	JJ	O
follow-up	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
isometric	JJ	Physical
trunk	NN	Physical
extension	NN	Physical
favored	VBD	O
the	DT	O
STG	NNP	O
(	(	O
P	NNP	O
=.016	NNP	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	O
months	NNS	O
.	.	O

However	RB	O
,	,	O
during	IN	O
the	DT	O
whole	JJ	O
12-month	JJ	O
training	NN	O
period	NN	O
,	,	O
both	DT	O
dynamic	JJ	Physical
and	CC	Physical
isometric	JJ	Physical
back	NN	Physical
extension	NN	Physical
and	CC	Physical
flexion	NN	Physical
strength	NN	Physical
,	,	O
as	RB	O
well	RB	O
as	IN	O
mobility	NN	Physical
of	IN	Physical
the	DT	Physical
spine	NN	Physical
and	CC	Physical
repetitive	JJ	Physical
squat-test	JJ	Physical
results	NNS	Physical
,	,	O
improved	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
physical	JJ	Physical
function	NN	Physical
parameters	NNS	Physical
between	IN	O
the	DT	O
STG	NNP	O
and	CC	O
CG	NNP	O
.	.	O

CONCLUSIONS	NNP	O
At	IN	O
the	DT	O
12-month	JJ	O
follow-up	NN	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
physical	JJ	Physical
function	NN	Physical
,	,	Pain
pain	NN	Pain
,	,	Physical
or	CC	Physical
disability	NN	Physical
measures	NNS	Physical
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
STG	NNP	O
,	,	O
training	VBG	O
adherence	NN	O
with	IN	O
regard	NN	O
to	TO	O
training	NN	O
frequency	NN	O
and	CC	O
intensity	NN	O
remained	VBD	O
too	RB	O
low	JJ	O
to	TO	O
lead	VB	O
to	TO	O
specific	JJ	O
training-induced	JJ	O
adaptations	NNS	O
in	IN	O
the	DT	O
neuromuscular	JJ	O
system	NN	O
.	.	O

Progressive	JJ	O
loading	NN	O
,	,	O
supervision	NN	O
of	IN	O
training	NN	O
,	,	O
and	CC	O
psychosocial	JJ	O
support	NN	O
is	VBZ	O
needed	VBN	O
in	IN	O
long-term	JJ	O
rehabilitation	NN	O
programs	NNS	O
to	TO	O
maintain	VB	O
patient	JJ	O
motivation	NN	O
.	.	O

A	DT	O
comparative	JJ	O
trial	NN	O
of	IN	O
fixed	JJ	O
ratio	NN	O
beta-adrenoceptor	NN	O
blocker	NN	O
and	CC	O
diuretic	JJ	O
combination	NN	O
products	NNS	O
in	IN	O
moderate	JJ	O
hypertension	NN	O
.	.	O

Two	CD	O
fixed	JJ	O
ratio	NN	O
combination	NN	O
tablets	NNS	O
,	,	O
10	CD	O
mg	NN	O
pindolol	NN	O
combined	VBN	O
with	IN	O
5	CD	O
mg	NNS	O
clopamide	NN	O
and	CC	O
100	CD	O
mg	NN	O
metoprolol	NN	O
combined	VBN	O
with	IN	O
12.5	CD	O
mg	NNS	O
hydrochlorothiazide	RB	O
,	,	O
were	VBD	O
compared	VBN	O
at	IN	O
two	CD	O
dose	JJ	O
levels	NNS	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
in	IN	O
10	CD	O
previously	RB	O
untreated	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
resting	VBG	Physical
blood	NN	Physical
pressure	NN	Physical
on	IN	O
the	DT	O
two	CD	O
combinations	NNS	O
at	IN	O
either	DT	O
dose	JJ	O
level	NN	O
.	.	O

Exercise	NNP	Physical
systolic	JJ	Physical
pressure	NN	Physical
was	VBD	O
lower	JJR	O
after	IN	O
the	DT	O
pindolol/clopamide	JJ	O
combination	NN	O
at	IN	O
low	JJ	O
dose	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
side-effects	NNS	Adverseeffect
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
high	JJ	O
but	CC	O
proper	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
two	CD	O
products	NNS	O
could	MD	O
not	RB	O
be	VB	O
made	VBN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
combination	NN	O
products	NNS	O
should	MD	O
be	VB	O
used	VBN	O
only	RB	O
after	IN	O
patients	NNS	O
have	VBP	O
failed	VBN	O
to	TO	O
respond	VB	O
adequately	RB	O
to	TO	O
a	DT	O
single	JJ	O
agent	NN	O
.	.	O

Effect	NN	O
of	IN	O
propranolol	NN	O
on	IN	O
word	NN	O
fluency	NN	O
in	IN	O
autism	NN	O
.	.	O

OBJECTIVE	NNP	O
AND	CC	O
BACKGROUND	NNP	O
Autism	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
repetitive	JJ	O
behaviors	NNS	O
and	CC	O
impaired	JJ	O
socialization	NN	O
and	CC	O
communication	NN	O
.	.	O

Preliminary	JJ	O
evidence	NN	O
showed	VBD	O
possible	JJ	O
language	NN	O
benefits	NNS	O
in	IN	O
autism	NN	O
from	IN	O
the	DT	O
?-adrenergic	JJ	O
antagonist	NN	O
propranolol	NN	O
.	.	O

Earlier	JJR	O
studies	NNS	O
in	IN	O
other	JJ	O
populations	NNS	O
suggested	VBD	O
propranolol	NN	O
might	MD	O
benefit	VB	O
performance	NN	O
on	IN	O
tasks	NNS	O
involving	VBG	O
a	DT	O
search	NN	O
of	IN	O
semantic	JJ	O
and	CC	O
associative	JJ	O
networks	NNS	O
under	IN	O
certain	JJ	O
conditions	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
wished	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
this	DT	O
benefit	NN	O
of	IN	O
propranolol	NN	O
includes	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
semantic	JJ	O
fluency	NN	O
in	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
sample	NN	O
of	IN	O
14	CD	O
high-functioning	JJ	O
adolescent	NN	O
and	CC	O
adult	NN	O
participants	NNS	O
with	IN	O
autism	NN	O
and	CC	O
14	CD	O
matched	VBN	O
controls	NNS	O
were	VBD	O
given	VBN	O
letter	NN	O
and	CC	O
category	NN	O
word	NN	O
fluency	NN	O
tasks	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
testing	NN	O
sessions	NNS	O
;	:	O
1	CD	O
test	NN	O
was	VBD	O
given	VBN	O
60	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
40	CD	O
mg	NNS	O
propranolol	JJ	O
orally	RB	O
,	,	O
and	CC	O
1	CD	O
test	NN	O
was	VBD	O
given	VBN	O
after	IN	O
placebo	NN	O
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
counterbalanced	JJ	O
manner	NN	O
.	.	O

RESULTS	JJ	O
Participants	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
significantly	RB	O
impaired	VBN	O
compared	VBN	O
with	IN	O
controls	NNS	O
on	IN	O
both	DT	O
fluency	NN	O
tasks	NNS	O
.	.	O

Propranolol	NNP	O
significantly	RB	O
improved	VBD	O
performance	NN	O
on	IN	O
category	NN	O
fluency	NN	O
,	,	O
but	CC	O
not	RB	O
letter	NN	O
fluency	NN	O
among	IN	O
autism	NN	O
participants	NNS	O
.	.	O

No	DT	O
drug	NN	O
effect	NN	O
was	VBD	O
observed	VBN	O
among	IN	O
controls	NNS	O
.	.	O

Expected	VBN	O
drug	NN	O
effects	NNS	O
on	IN	O
heart	NN	O
rate	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
both	CC	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Results	NNP	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
selective	JJ	O
beneficial	JJ	O
effect	NN	O
of	IN	O
propranolol	NN	O
on	IN	O
flexibility	NN	O
of	IN	O
access	NN	O
to	TO	O
semantic	JJ	O
and	CC	O
associative	JJ	O
networks	NNS	O
in	IN	O
autism	NN	O
,	,	O
with	IN	O
no	DT	O
observed	JJ	O
effect	NN	O
on	IN	O
phonological	JJ	O
networks	NNS	O
.	.	O

Further	NNP	O
study	NN	O
will	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
understand	VB	O
potential	JJ	O
clinical	JJ	O
implications	NNS	O
of	IN	O
this	DT	O
finding	NN	O
.	.	O

Treatment	NN	O
of	IN	O
severe	JJ	O
aplastic	JJ	O
anemia	NN	O
with	IN	O
antilymphocyte	JJ	O
globulin	NN	O
,	,	O
cyclosporine	NN	O
and	CC	O
two	CD	O
different	JJ	O
granulocyte	NNS	O
colony-stimulating	JJ	O
factor	NN	O
regimens	NNS	O
:	:	O
a	DT	O
GITMO	NNP	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
In	IN	O
a	DT	O
previous	JJ	O
study	NN	O
we	PRP	O
showed	VBD	O
that	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
aplastic	JJ	O
anemia	NN	O
(	(	O
SAA	NNP	O
)	)	O
treated	VBD	O
with	IN	O
anti-lymphocyte	JJ	O
globulin	NN	O
(	(	O
ALG	NNP	O
)	)	O
,	,	O
cyclosporin	NN	O
(	(	O
CyA	NNP	O
)	)	O
and	CC	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
5	CD	O
micro	NN	O
g/kg/day	NN	O
had	VBD	O
an	DT	O
encouraging	JJ	O
outcome	NN	O
.	.	O

However	RB	O
,	,	O
failure	NN	Others
to	TO	Others
respond	VB	Others
,	,	Others
delayed	JJ	Others
responses	NNS	Others
,	,	Others
partial	JJ	Others
responses	NNS	Others
,	,	Others
relapses	NNS	Others
and	CC	O
early	JJ	Mortality
deaths	NNS	Mortality
remain	VBP	O
significant	JJ	O
problems	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
whether	IN	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
G-CSF	NNP	O
(	(	O
10	CD	O
micro	NNS	O
g/kg/day	NN	O
)	)	O
would	MD	O
reduce	VB	Adverseeffect
these	DT	Adverseeffect
complications	NNS	Adverseeffect
.	.	Adverseeffect

DESIGN	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
multicenter	NN	O
prospective	JJ	O
trial	NN	O
in	IN	O
77	CD	O
SAA	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
horse	NN	O
ALG	NNP	O
(	(	O
15	CD	O
mg/kg/day	RB	O
day1-5	NN	O
)	)	O
and	CC	O
CyA	NNP	O
(	(	O
5	CD	O
mg/kg/day	RB	O
day	NN	O
1-180	JJ	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
G-CSF	NNP	O
5	CD	O
micro	NN	O
g/kg/day	NN	O
(	(	O
n=38	JJ	O
,	,	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
10	CD	O
micro	NNS	O
g/kg/day	NN	O
(	(	O
n=39	JJ	O
,	,	O
group	NN	O
B	NNP	O
)	)	O
from	IN	O
day	NN	O
+1	CD	O
to	TO	O
day	NN	O
+30	NNP	O
.	.	O

All	DT	O
patients	NNS	O
then	RB	O
received	VBD	O
G-CSF	NNP	O
5	CD	O
micro	NN	O
g/kg/day	NN	O
from	IN	O
day	NN	O
+31	CD	O
to	TO	O
day	NN	O
+90	NNP	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
response	NN	Others
at	IN	O
day	NN	O
+120	NNP	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
early	JJ	Mortality
deaths	NNS	Mortality
,	,	Mortality
blood	NN	Physical
counts	NNS	Physical
at	IN	O
day	NN	O
+120	NNP	O
,	,	O
and	CC	O
survival	NN	Mortality
.	.	Mortality

RESULTS	NNP	O
At	IN	O
day	NN	O
+120	JJ	O
responses	NNS	Others
were	VBD	O
classified	VBN	O
as	IN	O
absent	NN	Others
,	,	Others
partial	JJ	Others
,	,	O
and	CC	O
complete	JJ	Others
in	IN	O
12	CD	O
,	,	O
22	CD	O
,	,	O
and	CC	O
4	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
in	IN	O
23	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
9	CD	O
patients	NNS	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.001	NN	O
)	)	O
.	.	O

At	IN	O
last	JJ	O
follow-up	JJ	O
these	DT	O
figures	NNS	O
were	VBD	O
respectively	RB	O
9	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
17	CD	O
vs	NN	O
19	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
18	CD	O
(	(	O
p=0.004	NN	O
)	)	O
.	.	O

Thirteen	JJ	O
patients	NNS	O
(	(	O
5	CD	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
8	CD	O
in	IN	O
group	NN	O
B	NNP	O
)	)	O
died	VBD	Mortality
before	IN	O
day	NN	O
120	CD	O
(	(	O
p=0.3	NN	O
)	)	O
.	.	O

Median	JJ	O
peripheral	JJ	Physical
blood	NN	Physical
counts	NNS	Physical
on	IN	O
day	NN	O
120	CD	O
were	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
:	:	O
Hb	NNP	O
10.5	CD	O
and	CC	O
9.5	CD	O
g/dL	NN	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
p=0.6	NN	O
)	)	O
,	,	O
Neutrophil	NNP	Physical
counts	VBZ	Physical
were	VBD	O
2.4	CD	O
vs	NNS	O
1.9x10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
in	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
(	(	O
p=0.4	NN	O
)	)	O
and	CC	O
platelet	NN	Physical
counts	NNS	Physical
were	VBD	O
,	,	O
respectively	RB	O
,	,	O
42	CD	O
vs	NN	O
36x10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
(	(	O
p=0.3	NN	O
)	)	O
.	.	O

The	DT	O
actuarial	JJ	Mortality
survival	NN	Mortality
at	IN	O
4	CD	O
years	NNS	O
is	VBZ	O
72	CD	O
%	NN	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
67	CD	O
%	NN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.3	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
AND	CC	O
CONCLUSIONS	NNP	O
Increasing	VBG	O
the	DT	O
dose	NN	O
of	IN	O
G-CSF	NNP	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
reduce	VB	Mortality
early	JJ	Mortality
deaths	NNS	Mortality
,	,	O
does	VBZ	O
not	RB	O
improve	VB	O
peripheral	JJ	Physical
blood	NN	Physical
counts	NNS	Physical
nor	CC	O
survival	NN	Mortality
,	,	O
and	CC	O
may	MD	O
reduce	VB	O
the	DT	O
response	NN	Others
rate	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
SAA	NNP	O
receiving	VBG	O
ALG	NNP	O
and	CC	O
CyA	NNP	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
upper	JJ	O
lip	NN	O
bite	JJ	O
test	NN	O
(	(	O
a	DT	O
simple	JJ	O
new	JJ	O
technique	NN	O
)	)	O
with	IN	O
modified	VBN	O
Mallampati	NNP	O
classification	NN	O
in	IN	O
predicting	VBG	O
difficulty	NN	O
in	IN	O
endotracheal	JJ	Physical
intubation	NN	Physical
:	:	O
a	DT	O
prospective	JJ	O
blinded	VBN	O
study	NN	O
.	.	O

We	PRP	O
explored	VBD	O
the	DT	O
possibility	NN	O
that	IN	O
a	DT	O
simple	JJ	O
and	CC	O
single	JJ	O
test	NN	O
could	MD	O
replace	VB	O
the	DT	O
modified	JJ	O
Mallampati	NNP	Physical
score	NN	Physical
for	IN	O
either	CC	O
a	DT	O
difficult	JJ	O
or	CC	O
an	DT	O
unaccomplished	JJ	O
tracheal	NN	Physical
intubation	NN	Physical
in	IN	O
an	DT	O
impending	JJ	Physical
hypoxic	NN	Physical
patient	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
adult	NN	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
subjected	VBN	O
to	TO	O
the	DT	O
following	JJ	O
assessments	NNS	O
:	:	O
1	CD	O
)	)	O
oropharyngeal	NN	O
class	NN	O
according	VBG	O
to	TO	O
the	DT	O
modified	VBN	O
Mallampati	NNP	O
criteria	NNS	O
;	:	O
2	CD	O
)	)	O
the	DT	O
new	JJ	O
,	,	O
upper	JJ	O
lip	NN	O
bite	IN	O
criteria-class	NN	O
I	PRP	O
=	VBP	O
lower	JJR	O
incisors	NNS	O
can	MD	O
bite	VB	O
the	DT	O
upper	JJ	O
lip	NN	O
above	IN	O
the	DT	O
vermilion	NN	O
line	NN	O
,	,	O
class	NN	O
II	NNP	O
=	NNP	O
lower	JJR	O
incisors	NNS	O
can	MD	O
bite	VB	O
the	DT	O
upper	JJ	O
lip	NN	O
below	IN	O
the	DT	O
vermilion	NN	O
line	NN	O
,	,	O
and	CC	O
class	NN	O
III	NNP	O
=	NNP	O
lower	JJR	O
incisors	NNS	O
can	MD	O
not	RB	O
bite	VB	O
the	DT	O
upper	JJ	O
lip	NN	O
;	:	O
and	CC	O
3	CD	O
)	)	O
laryngeal	NN	O
view	NN	O
grading	VBG	O
according	VBG	O
to	TO	O
Cormack	NNP	Physical
's	POS	Physical
criteria	NNS	Physical
.	.	O

The	DT	O
incidence	NN	Physical
of	IN	Physical
difficult	JJ	Physical
intubation	NN	Physical
was	VBD	O
5.7	CD	O
%	NN	O
.	.	O

The	DT	O
upper	JJ	Others
lip	NN	Others
bite	NN	Others
test	NN	Others
showed	VBD	O
significantly	RB	O
higher	JJR	O
specificity	NN	Others
and	CC	Others
accuracy	NN	Others
than	IN	O
the	DT	O
modified	JJ	O
Mallampati	NNP	Physical
test	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Comparisons	NNS	O
of	IN	O
sensitivity	NN	Others
,	,	Others
positive	JJ	Others
and	CC	Others
negative	JJ	Others
predictive	NN	Others
values	NNS	Others
,	,	O
between	IN	O
the	DT	O
two	CD	O
tests	NNS	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
upper	JJ	O
lip	NN	O
bite	JJ	O
test	NN	O
is	VBZ	O
an	DT	O
acceptable	JJ	O
option	NN	O
for	IN	O
predicting	VBG	O
difficult	JJ	O
intubation	NN	O
as	IN	O
a	DT	O
simple	NN	O
,	,	O
single	JJ	O
test	NN	O
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
weighted	JJ	O
vests	NNS	O
.	.	O

OBJECTIVE	NN	O
In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
determined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
weighted	JJ	O
vest	NN	O
on	IN	O
attention	NN	O
to	TO	O
task	VB	O
for	IN	O
second-grade	JJ	O
general	JJ	O
education	NN	O
students	NNS	O
with	IN	O
difficulty	NN	O
attending	VBG	O
.	.	O

METHOD	NNP	O
We	PRP	O
used	VBD	O
an	DT	O
intervention	NN	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
an	DT	O
ABA	NNP	O
design	NN	O
to	TO	O
compare	VB	O
participants	NNS	O
'	POS	O
percentage	NN	O
of	IN	O
time	NN	O
on	IN	O
task	NN	O
with	IN	O
and	CC	O
without	IN	O
a	DT	O
vest	NN	O
.	.	O

Ten	CD	O
participants	NNS	O
from	IN	O
nine	CD	O
elementary	JJ	O
schools	NNS	O
in	IN	O
a	DT	O
suburban	JJ	O
Texas	NNP	O
school	NN	O
district	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Control	NNP	O
group	NN	O
participants	NNS	O
wore	VBD	O
a	DT	O
nonweighted	JJ	O
vest	NN	O
.	.	O

Participants	NNS	O
,	,	O
classroom	NN	O
teachers	NNS	O
,	,	O
and	CC	O
research	NN	O
assistants	NNS	O
who	WP	O
coded	VBD	O
the	DT	O
data	NNS	O
were	VBD	O
blind	RB	O
as	IN	O
to	TO	O
the	DT	O
group	NN	O
to	TO	O
which	WDT	O
the	DT	O
participants	NNS	O
were	VBD	O
assigned	VBN	O
.	.	O

RESULTS	VB	O
A	NNP	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
or	CC	O
between	IN	O
baseline	NN	O
,	,	O
intervention	NN	O
,	,	O
and	CC	O
withdrawal	NN	O
conditions	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
weighted	JJ	O
vests	NNS	O
were	VBD	O
not	RB	O
effective	JJ	O
in	IN	O
increasing	VBG	O
time	NN	Mental
on	IN	Mental
task	NN	Mental
.	.	O

These	DT	O
results	NNS	O
should	MD	O
be	VB	O
generalized	VBN	O
cautiously	RB	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
and	CC	O
participant	JJ	O
selection	NN	O
process	NN	O
.	.	O

Letrozole	NNP	O
in	IN	O
the	DT	O
neoadjuvant	JJ	O
setting	NN	O
:	:	O
the	DT	O
P024	NNP	O
trial	NN	O
.	.	O

Neoadjuvant	JJ	O
chemotherapy	NN	O
trials	NNS	O
have	VBP	O
consistently	RB	O
reported	VBN	O
lower	JJR	O
response	NN	Others
rates	NNS	Others
in	IN	O
hormone	NN	O
receptor-positive	JJ	O
(	(	O
HR+	NNP	O
)	)	O
breast	NN	O
cancer	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
HR-	NNP	O
cases	NNS	O
.	.	O

Preoperative	JJ	O
endocrine	NN	O
therapy	NN	O
has	VBZ	O
therefore	RB	O
become	VBN	O
a	DT	O
logical	JJ	O
alternative	NN	O
and	CC	O
has	VBZ	O
gained	VBN	O
considerable	JJ	O
momentum	NN	O
from	IN	O
the	DT	O
finding	NN	O
that	WDT	O
aromatase	NN	O
inhibitors	NNS	O
(	(	O
AIs	NNP	O
)	)	O
are	VBP	O
more	RBR	O
effective	JJ	O
than	IN	O
tamoxifen	NN	O
for	IN	O
HR+	NNP	O
breast	NN	O
cancer	NN	O
in	IN	O
both	CC	O
the	DT	O
neoadjuvant	NN	O
and	CC	O
adjuvant	JJ	O
settings	NNS	O
.	.	O

The	DT	O
most	RBS	O
convincing	JJ	O
neoadjuvant	JJ	O
trial	NN	O
to	TO	O
demonstrate	VB	O
the	DT	O
superiority	NN	O
of	IN	O
an	DT	O
AI	NNP	O
versus	NN	O
tamoxifen	NN	O
was	VBD	O
the	DT	O
P024	NNP	O
study	NN	O
,	,	O
a	DT	O
large	JJ	O
multinational	JJ	O
double-blind	JJ	O
trial	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
HR+	NNP	O
breast	NN	O
cancer	NN	O
ineligible	JJ	O
for	IN	O
breast-conserving	JJ	O
surgery	NN	O
.	.	O

The	DT	O
overall	JJ	Others
response	NN	Others
rate	NN	Others
(	(	Others
ORR	NNP	Others
)	)	Others
was	VBD	O
55	CD	O
%	NN	O
for	IN	O
letrozole	NN	O
and	CC	O
36	CD	O
%	NN	O
for	IN	O
tamoxifen	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significantly	RB	O
more	RBR	O
letrozole-treated	JJ	O
patients	NNS	O
underwent	JJ	Others
breast-conserving	JJ	Others
surgery	NN	Others
(	(	O
45	CD	O
vs.	FW	O
35	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P=0.022	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
ORR	NNP	Others
was	VBD	O
significantly	RB	O
higher	JJR	O
with	IN	O
letrozole	JJR	O
than	IN	O
tamoxifen	NN	O
in	IN	O
the	DT	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
HER1/HER2+	NNP	O
subgroup	NN	O
(	(	O
P=0.0004	NNP	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	Others
efficacy	NN	Others
of	IN	O
letrozole	NN	O
in	IN	O
HER2+	NNP	O
breast	NN	O
cancer	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
fluorescent	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
analysis	NN	O
and	CC	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
to	TO	O
that	DT	O
of	IN	O
HER2-	NNP	O
cases	NNS	O
(	(	O
ORR	NNP	O
71	CD	O
%	NN	O
in	IN	O
both	DT	O
subsets	NNS	O
)	)	O
.	.	O

Biomarker	NNP	Others
studies	NNS	Others
confirmed	VBD	O
the	DT	O
superiority	NN	O
of	IN	O
letrozole	NN	O
in	IN	O
centrally	RB	O
assessed	VBN	O
estrogen	NN	O
receptor-positive	JJ	O
(	(	O
ER+	NNP	O
)	)	O
tumors	NNS	O
and	CC	O
found	VBD	O
a	DT	O
strong	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
degree	NN	Others
of	IN	Others
ER	NNP	Others
positivity	NN	Others
for	IN	O
both	DT	O
agents	NNS	O
.	.	O

Interestingly	RB	O
,	,	O
letrozole	NN	O
was	VBD	O
effective	JJ	O
even	RB	O
in	IN	O
marginally	RB	O
ER+	NNP	O
tumors	NNS	O
and	CC	O
,	,	O
unlike	IN	O
tamoxifen	NN	O
,	,	O
consistently	RB	O
reduced	VBD	O
the	DT	O
expression	NN	Physical
from	IN	Physical
estrogen-regulated	JJ	Physical
genes	NNS	Physical
(	(	O
progesterone	NN	O
receptor	NN	O
and	CC	O
trefoil	NN	O
factor	NN	O
1	CD	O
)	)	O
.	.	O

Furthermore	RB	O
,	,	O
when	WRB	O
analyzed	VBN	O
by	IN	O
Ki67	NNP	O
immunohistochemistry	NN	O
,	,	O
letrozole	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
tamoxifen	NN	O
in	IN	O
reducing	VBG	O
tumor	NN	Physical
proliferation	NN	Physical
(	(	O
P=0.0009	NNP	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
neoadjuvant	JJ	O
letrozole	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
superior	JJ	O
to	TO	O
tamoxifen	VB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
HR+	NNP	O
locally	RB	O
advanced	VBD	O
breast	NN	O
cancer	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
epidural	JJ	O
tramadol-ropivacaine	JJ	O
and	CC	O
fentanyl-ropivacaine	JJ	O
for	IN	O
labor	NN	O
analgesia	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
5	CD	O
mg/mL	NN	O
tramadol	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
3	CD	O
?	.	O
g/mL	NN	O
fentanyl	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
0.125	CD	O
%	NN	O
ropivacaine	NN	O
in	IN	O
parturients	NNS	O
undergoing	VBG	O
labor	NN	O
during	IN	O
epidural	JJ	O
analgesia	NN	O
.	.	O

METHODS	NNP	O
Sixty-one	JJ	O
parturients	NNS	O
undergoing	VBG	O
labor	NN	O
selected	VBN	O
for	IN	O
delivery	NN	O
with	IN	O
epidural	JJ	O
analgesia	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
tramadol	VBD	O
(	(	O
0.125	CD	O
%	NN	O
ropivacaine	NN	O
plus	CC	O
tramadol	JJ	O
5	CD	O
mg/mL	NN	O
)	)	O
and	CC	O
Group	NNP	O
fentanyl	NNP	O
(	(	O
0.125	CD	O
%	NN	O
ropivacaine	NN	O
plus	CC	O
fentanyl	JJ	O
3	CD	O
ug/mL	NN	O
)	)	O
.	.	O

Hemodynamics	NNS	Physical
,	,	O
rate	NN	Others
of	IN	Others
cesarean	JJ	Others
delivery	NN	Others
,	,	O
sensory	JJ	Others
block	NN	Others
level	NN	Others
,	,	Others
Bromage	NNP	Physical
motor	NN	Physical
scale	NN	Physical
scores	NNS	Physical
,	,	O
instrument-assisted	JJ	Others
delivery	NN	Others
,	,	O
oxytocin	NN	Others
use	NN	Others
,	,	O
visual	JJ	Pain
analog	NN	Pain
scale	NN	Pain
(	(	Pain
VAS	NNP	Pain
)	)	Pain
scores	VBZ	Pain
,	,	O
Apgar	NNP	Physical
scores	VBZ	Physical
,	,	O
umbilical	JJ	Physical
cord	NN	Physical
artery	NN	Physical
gas	NN	O
analysis	NN	O
,	,	O
and	CC	O
maternal	JJ	Adverseeffect
side-effects	NNS	Adverseeffect
including	VBG	Adverseeffect
nausea	NN	Adverseeffect
,	,	Adverseeffect
vomiting	VBG	Adverseeffect
,	,	Adverseeffect
pruritus	NN	Adverseeffect
,	,	Adverseeffect
urinary	JJ	Adverseeffect
retention	NN	Adverseeffect
,	,	Adverseeffect
shivering	VBG	Adverseeffect
,	,	Adverseeffect
hypotension	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
respiratory	JJ	Adverseeffect
depression	NN	Adverseeffect
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
two	CD	O
groups	NNS	O
had	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
with	IN	O
respect	NN	O
to	TO	O
maternal	JJ	Physical
hemodynamics	NNS	Physical
,	,	O
neonatal	JJ	Physical
heart	NN	Physical
rate	NN	Physical
,	,	O
VAS	NNP	Pain
scores	VBZ	Pain
,	,	O
rate	NN	Others
of	IN	Others
cesarean	JJ	Others
delivery	NN	Others
,	,	O
sensory	JJ	Physical
block	NN	Physical
level	NN	Physical
,	,	O
Bromage	NNP	Physical
motor	NN	Physical
scale	NN	Physical
scores	NNS	Physical
,	,	O
instrument-assisted	JJ	Others
delivery	NN	Others
,	,	O
oxytocin	NN	Others
use	NN	Others
,	,	O
hypotension	NN	Adverseeffect
,	,	O
nausea	NN	Adverseeffect
,	,	O
vomiting	NN	Adverseeffect
,	,	O
and	CC	O
respiratory	JJ	Adverseeffect
depression	NN	Adverseeffect
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
pruritus	NN	Adverseeffect
,	,	Adverseeffect
shivering	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
urinary	JJ	Adverseeffect
retention	NN	Adverseeffect
were	VBD	O
more	JJR	O
commonly	RB	O
observed	VBN	O
in	IN	O
Group	NNP	O
fentanyl	VBD	O
despite	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Umbilical	JJ	Physical
artery	NN	Physical
pH	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
while	IN	O
PCO	NNP	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
higher	RBR	O
in	IN	O
Group	NNP	O
fentanyl	VBD	O
than	IN	O
Group	NNP	O
tramadol	NN	O
(	(	O
p	JJ	O
=	NN	O
0.003	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.026	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Birth-weight	NNP	Physical
,	,	O
umbilical	JJ	Physical
artery	NN	Physical
PO	NNP	Physical
(	(	Physical
2	CD	Physical
)	)	Physical
and	CC	Physical
base	NN	Physical
deficit	NN	Physical
,	,	O
and	CC	O
Apgar	NNP	Physical
scores	NNS	Physical
at	IN	O
1	CD	O
and	CC	O
5	CD	O
min	NNS	O
were	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
Our	PRP$	O
observations	NNS	O
suggest	VBP	O
that	IN	O
tramadol	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
for	IN	O
labor	NN	O
analgesia	NNS	O
due	JJ	O
to	TO	O
its	PRP$	O
similar	JJ	O
analgesic	JJ	O
efficacy	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	O
adenoassociated	VBN	O
vector	NN	O
containing	VBG	O
a	DT	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	IN	O
antagonist	JJ	O
gene	NN	O
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	Others
and	CC	Others
tolerability	NN	Others
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
,	,	O
an	DT	O
adenoassociated	JJ	O
virus	NN	O
serotype	NN	O
2	CD	O
vector	NN	O
containing	VBG	O
the	DT	O
cDNA	NN	O
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
(	(	O
14	CD	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
1	CD	O
with	IN	O
ankylosing	VBG	O
spondylitis	NN	O
)	)	O
not	RB	O
receiving	VBG	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	NN	O
(	(	O
TNFalpha	NNP	O
)	)	O
inhibitors	NNS	O
with	IN	O
persistent	JJ	O
moderate	NN	O
(	(	O
grade	JJ	O
2	CD	O
)	)	O
or	CC	O
severe	JJ	O
(	(	O
grade	JJ	O
3	CD	O
)	)	O
swelling	NN	O
in	IN	O
a	DT	O
target	NN	O
joint	NN	O
due	JJ	O
to	TO	O
inflammatory	JJ	O
arthritis	NN	O
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	Others
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	Physical
in	IN	Physical
injected	JJ	Physical
joint	NN	Physical
tenderness	NN	Physical
and	CC	Physical
swelling	VBG	Physical
scores	NNS	Physical
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	Physical
fluid	NN	Physical
TNFR	NNP	Physical
:	:	Physical
Fc	NNP	Physical
protein	NN	Physical
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	Physical
in	IN	Physical
swelling	VBG	Physical
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	Others
and	CC	Others
efficacy	NN	Others
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

Assessment	NN	O
of	IN	O
elementary	JJ	O
school	NN	O
students	NNS	O
'	POS	O
sun	NN	Physical
protection	NN	Physical
behaviors	NNS	Physical
.	.	Physical

BACKGROUND/OBJECTIVES	NNP	O
Studies	NNPS	O
suggest	VBP	O
that	IN	O
excessive	JJ	O
sun	NN	O
exposure	NN	O
in	IN	O
childhood	NN	O
contributes	NNS	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
skin	NN	O
cancer	NN	O
later	RBR	O
in	IN	O
life	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
explores	VBZ	O
4th	CD	O
grade	NN	O
student	NN	O
assessment	NN	O
of	IN	O
their	PRP$	O
sun	NN	O
protection	NN	O
behaviors	NNS	O
.	.	O

This	DT	O
study	NN	O
used	VBN	O
baseline	NN	O
data	NNS	O
collected	VBN	O
in	IN	O
the	DT	O
Fall	NN	O
of	IN	O
2006	CD	O
for	IN	O
the	DT	O
Sun	NNP	O
Protection	NNP	O
for	IN	O
Florida	NNP	O
's	POS	O
Children	NNP	O
(	(	O
SPF	NNP	O
)	)	O
project	NN	O
.	.	O

In	IN	O
brief	NN	O
,	,	O
the	DT	O
SPF	NNP	O
project	NN	O
is	VBZ	O
a	DT	O
group	NN	O
randomized	VBD	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
school	NN	O
based	VBN	O
intervention	NN	O
promoting	VBG	O
sun	JJ	O
protection	NN	O
in	IN	O
general	JJ	O
,	,	O
and	CC	O
hat	RB	O
use	NN	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
Hillsborough	NNP	O
County	NNP	O
Schools	NNP	O
,	,	O
Florida	NNP	O
.	.	O

The	DT	O
data	NN	O
reported	VBD	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
before	IN	O
any	DT	O
intervention	NN	O
activities	NNS	O
was	VBD	O
initiated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
self-reported	JJ	Mental
use	NN	Mental
of	IN	Mental
various	JJ	Mental
methods	NNS	Mental
of	IN	Mental
sun	NN	Mental
protection	NN	Mental
was	VBD	O
low	JJ	O
.	.	O

Only	RB	O
a	DT	O
small	JJ	O
percentage	NN	O
of	IN	O
students	NNS	O
wore	VBP	O
long	JJ	Physical
sleeves	NNS	Physical
or	CC	Physical
a	DT	Physical
hat	NN	Physical
with	IN	Physical
a	DT	Physical
brim	NN	Physical
before	IN	O
leaving	VBG	O
for	IN	O
school	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
few	JJ	O
students	NNS	O
wore	VBD	O
a	DT	O
hat	NN	Physical
with	IN	Physical
a	DT	Physical
wide	JJ	Physical
brim	NN	Physical
when	WRB	Physical
outside	NN	Physical
but	CC	O
not	RB	O
at	IN	O
school	NN	O
.	.	O

Students	NNS	O
spent	VBD	O
an	DT	O
average	NN	O
of	IN	O
59.1	CD	O
minutes	NNS	O
per	IN	O
week	NN	O
outdoors	NNS	O
while	IN	O
attending	VBG	O
school	NN	O
and	CC	O
35.5	CD	O
minutes	NNS	O
during	IN	O
peak	JJ	Physical
sun	NN	Physical
exposure	NN	Physical
.	.	Physical

CONCLUSION	NNP	O
Sun	NNP	O
exposure	NN	O
at	IN	O
school	NN	O
poses	NNS	O
a	DT	O
significant	JJ	O
risk	NN	O
to	TO	O
student	VB	O
health	NN	O
and	CC	O
more	JJR	O
needs	NNS	O
to	TO	O
be	VB	O
carried	VBN	O
out	IN	O
to	TO	O
promote	VB	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
wide-brimmed	JJ	O
hat	NN	O
and	CC	O
limiting	VBG	O
student	NN	Others
sun	NN	Others
exposure	NN	Others
.	.	Others

Improvement	NN	O
of	IN	O
pain	NN	O
related	VBN	O
self	JJ	O
management	NN	O
for	IN	O
oncologic	JJ	O
patients	NNS	O
through	IN	O
a	DT	O
trans	JJ	O
institutional	JJ	O
modular	JJ	O
nursing	NN	O
intervention	NN	O
:	:	O
protocol	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
multicenter	RB	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Pain	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
frequent	JJ	O
and	CC	O
distressing	VBG	O
symptoms	NNS	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

For	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
patients	NNS	O
,	,	O
sufficient	JJ	O
pain	NN	O
relief	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
if	IN	O
adequate	JJ	O
treatment	NN	O
is	VBZ	O
provided	VBN	O
.	.	O

However	RB	O
,	,	O
pain	NN	O
remains	NNS	O
often	RB	O
undertreated	VBD	O
due	JJ	O
to	TO	O
institutional	JJ	O
,	,	O
health	NN	O
care	NN	O
professional	JJ	O
and	CC	O
patient	JJ	O
related	JJ	O
barriers	NNS	O
.	.	O

Patients	NNS	O
self	JJ	O
management	NN	O
skills	NNS	O
are	VBP	O
affected	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
'	POS	O
knowledge	NN	O
,	,	O
activities	NNS	O
and	CC	O
attitude	NN	O
to	TO	O
pain	VB	O
management	NN	O
.	.	O

This	DT	O
trial	NN	O
protocol	NN	O
is	VBZ	O
aimed	VBN	O
to	TO	O
test	VB	O
the	DT	O
SCION-PAIN	JJ	O
program	NN	O
,	,	O
a	DT	O
multi	NN	O
modular	NN	O
structured	VBD	O
intervention	NN	O
to	TO	O
improve	VB	O
self	NN	O
management	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
pain	NN	O
.	.	O

METHODS	NNP	O
240	CD	O
patients	NNS	O
with	IN	O
diagnosed	JJ	O
malignancy	NN	O
and	CC	O
pain	NN	O
>	VBP	O
3	CD	O
days	NNS	O
and	CC	O
average	JJ	O
pain	NN	O
>	JJ	O
or=	NN	O
3/10	CD	O
will	MD	O
participate	VB	O
in	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
on	IN	O
18	CD	O
wards	NNS	O
in	IN	O
2	CD	O
German	JJ	O
university	NN	O
hospitals	NNS	O
.	.	O

Patients	NNS	O
from	IN	O
the	DT	O
intervention	NN	O
wards	NNS	O
will	MD	O
receive	VB	O
,	,	O
additionally	RB	O
to	TO	O
standard	VB	O
pain	NN	O
treatment	NN	O
,	,	O
the	DT	O
SCION-PAIN	JJ	O
program	NN	O
consisting	NN	O
of	IN	O
3	CD	O
modules	NNS	O
:	:	O
pharmacologic	NN	O
pain	NN	O
management	NN	O
,	,	O
nonpharmacologic	RB	O
pain	JJ	O
management	NN	O
and	CC	O
discharge	NN	O
management	NN	O
.	.	O

The	DT	O
intervention	NN	O
will	MD	O
be	VB	O
conducted	VBN	O
by	IN	O
specially	RB	O
trained	JJ	O
oncology	NN	O
nurses	NNS	O
and	CC	O
includes	VBZ	O
components	NNS	O
of	IN	O
patient	JJ	O
education	NN	O
,	,	O
skills	NNS	O
training	NN	O
and	CC	O
counseling	NN	O
to	TO	O
improve	VB	O
self	PRP	O
care	VB	O
regarding	VBG	O
pain	JJ	O
management	NN	O
beginning	VBG	O
with	IN	O
admission	NN	O
followed	VBN	O
by	IN	O
booster	NN	O
session	NN	O
every	DT	O
3rd	CD	O
day	NN	O
and	CC	O
one	CD	O
follow	VBP	O
up	RP	O
telephone	NN	O
counseling	NN	O
within	IN	O
2	CD	O
to	TO	O
3	CD	O
days	NNS	O
after	IN	O
discharge	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
will	MD	O
receive	VB	O
standard	NN	O
care	NN	O
.	.	O

Primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
group	NN	Mental
difference	NN	Mental
in	IN	Mental
patient	NN	Mental
related	JJ	Mental
barriers	NNS	Pain
to	TO	Pain
management	NN	Pain
of	IN	Pain
cancer	NN	Pain
pain	NN	Pain
(	(	O
BQII	NNP	O
)	)	O
,	,	O
7	CD	O
days	NNS	O
after	IN	O
discharge	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
are	VBP	O
:	:	O
pain	NN	Pain
intensity	NN	Pain
&	CC	O
interference	NN	Pain
,	,	O
adherence	NN	Pain
,	,	O
coping	VBG	Pain
and	CC	O
HRQoL	NNP	Pain
.	.	O

DISCUSSION	NNP	O
The	DT	O
study	NN	O
will	MD	O
determine	VB	O
if	IN	O
the	DT	O
acquired	VBN	O
self	NN	O
management	NN	O
skills	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
continue	VBP	O
to	TO	O
be	VB	O
used	VBN	O
after	IN	O
discharge	NN	O
from	IN	O
hospital	NN	O
.	.	O

It	PRP	O
is	VBZ	O
hypothesized	VBN	O
that	IN	O
patients	NNS	O
who	WP	O
receive	VBP	O
the	DT	O
multi	NN	O
modular	NN	O
structured	VBN	O
intervention	NN	O
will	MD	O
have	VB	O
less	RBR	O
patient	JJ	O
related	JJ	O
barriers	NNS	O
and	CC	O
a	DT	O
better	JJR	O
self	JJ	O
management	NN	O
of	IN	O
cancer	NN	Pain
pain	NN	Pain
.	.	Pain

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials	NNP	O
NCT00779597	NNP	O
.	.	O

[	JJ	O
Intravesical	NNP	O
instillation	NN	O
of	IN	O
doxorubicin	NN	O
or	CC	O
epirubicin	NN	O
for	IN	O
chemoprophylaxis	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
--	:	O
the	DT	O
fifth	JJ	O
study	NN	O
of	IN	O
the	DT	O
Japanese	JJ	O
Urological	JJ	O
Cancer	NNP	O
Research	NNP	O
Group	NNP	O
for	IN	O
Adriamycin/Farumorubicin	NNP	O
]	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
465	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
and	CC	O
multiple	JJ	O
or	CC	O
recurrent	NN	O
,	,	O
stages	VBZ	O
Ta	NNP	O
and	CC	O
T1	NNP	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
randomized	JJ	O
multicenter	NN	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
prophylactic	JJ	O
effect	NN	O
by	IN	O
17	CD	O
times	NNS	O
instillation	NN	O
of	IN	O
40	CD	O
mg	NNS	O
doxorubicin	VBD	O
or	CC	O
40	CD	O
mg	NNS	O
epirubicin	VBP	O
with	IN	O
no	DT	O
instillation	NN	O
after	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
tumor	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
first	JJ	Physical
recurrence	NN	Physical
after	IN	O
transurethral	JJ	O
resection	NN	O
.	.	O

Endoscopic	NNP	Others
examination	NN	Others
as	RB	O
well	RB	O
as	IN	O
urinary	JJ	Others
cytology	NN	Others
was	VBD	O
performed	VBN	O
in	IN	O
each	DT	O
case	NN	O
every	DT	O
three	CD	O
months	NNS	O
.	.	O

It	PRP	O
became	VBD	O
evident	JJ	O
that	IN	O
the	DT	O
recurrence	NN	Physical
rate	NN	Physical
in	IN	O
the	DT	O
doxorubicin	NN	O
or	CC	O
epirubicin	JJ	O
instillation	NN	O
arm	NN	O
was	VBD	O
lower	JJR	O
that	IN	O
in	IN	O
the	DT	O
no	DT	O
instillation	NN	O
arm	NN	O
.	.	O

Toxicity	NN	Adverseeffect
was	VBD	O
mainly	RB	O
restricted	VBN	O
to	TO	O
bladder	VB	Adverseeffect
irritation	NN	Adverseeffect
in	IN	O
about	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
instillation	NN	O
arm	NN	O
.	.	O

Treatment	NN	O
of	IN	O
acute	NN	O
otitis	NN	O
media	NNS	O
in	IN	O
children	NNS	O
under	IN	O
2	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

BACKGROUND	NNP	O
Recommendations	NNP	O
vary	VBP	O
regarding	VBG	O
immediate	JJ	O
antimicrobial	JJ	O
treatment	NN	O
versus	NN	O
watchful	JJ	O
waiting	VBG	O
for	IN	O
children	NNS	O
younger	JJR	O
than	IN	O
2	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
291	CD	O
children	NNS	O
6	CD	O
to	TO	O
23	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
diagnosed	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
stringent	NN	O
criteria	NNS	O
,	,	O
to	TO	O
receive	VB	O
amoxicillin-clavulanate	NN	O
or	CC	O
placebo	NN	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

We	PRP	O
measured	VBD	O
symptomatic	JJ	Physical
response	NN	Physical
and	CC	O
rates	NNS	Physical
of	IN	Physical
clinical	JJ	Physical
failure	NN	Physical
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
children	NNS	O
who	WP	O
received	VBD	O
amoxicillin-clavulanate	NN	O
,	,	O
35	CD	O
%	NN	O
had	VBD	O
initial	JJ	Physical
resolution	NN	Physical
of	IN	Physical
symptoms	NNS	Physical
by	IN	O
day	NN	O
2	CD	O
,	,	O
61	CD	O
%	NN	O
by	IN	O
day	NN	O
4	CD	O
,	,	O
and	CC	O
80	CD	O
%	NN	O
by	IN	O
day	NN	O
7	CD	O
;	:	O
among	IN	O
children	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
,	,	O
28	CD	O
%	NN	O
had	VBD	O
initial	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
by	IN	O
day	NN	O
2	CD	O
,	,	O
54	CD	O
%	NN	O
by	IN	O
day	NN	O
4	CD	O
,	,	O
and	CC	O
74	CD	O
%	NN	O
by	IN	O
day	NN	O
7	CD	O
(	(	O
P=0.14	NNP	O
for	IN	O
the	DT	O
overall	JJ	O
comparison	NN	O
)	)	O
.	.	O

For	IN	O
sustained	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
the	DT	O
corresponding	JJ	O
values	NNS	O
were	VBD	O
20	CD	O
%	NN	O
,	,	O
41	CD	O
%	NN	O
,	,	O
and	CC	O
67	CD	O
%	NN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
14	CD	O
%	NN	O
,	,	O
36	CD	O
%	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
with	IN	O
placebo	NN	O
(	(	O
P=0.04	NNP	O
for	IN	O
the	DT	O
overall	JJ	O
comparison	NN	O
)	)	O
.	.	O

Mean	JJ	Physical
symptom	NN	Physical
scores	NNS	Physical
over	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
the	DT	O
children	NNS	O
treated	VBN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
than	IN	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
clinical	JJ	Physical
failure	NN	Physical
--	:	Physical
defined	VBD	Physical
as	IN	O
the	DT	O
persistence	NN	O
of	IN	O
signs	NNS	O
of	IN	O
acute	JJ	Physical
infection	NN	Physical
on	IN	Physical
otoscopic	JJ	Physical
examination	NN	Physical
--	:	O
was	VBD	O
also	RB	O
lower	JJR	O
among	IN	O
the	DT	O
children	NNS	O
treated	VBN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
than	IN	O
among	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
:	:	O
4	CD	O
%	NN	O
versus	IN	O
23	CD	O
%	NN	O
at	IN	O
or	CC	O
before	IN	O
the	DT	O
visit	NN	O
on	IN	O
day	NN	O
4	CD	O
or	CC	O
5	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
16	CD	O
%	NN	O
versus	IN	O
51	CD	O
%	NN	O
at	IN	O
or	CC	O
before	IN	O
the	DT	O
visit	NN	O
on	IN	O
day	NN	O
10	CD	O
to	TO	O
12	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Mastoiditis	NNP	Adverseeffect
developed	VBD	O
in	IN	O
one	CD	O
child	NN	O
who	WP	O
received	VBD	O
placebo	NN	O
.	.	O

Diarrhea	NNP	Adverseeffect
and	CC	Adverseeffect
diaper-area	JJ	Adverseeffect
dermatitis	NN	Adverseeffect
were	VBD	O
more	JJR	O
common	JJ	O
among	IN	O
children	NNS	O
who	WP	O
received	VBD	O
amoxicillin-clavulanate	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
either	DT	O
group	NN	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
nasopharyngeal	JJ	Physical
colonization	NN	Physical
with	IN	O
nonsusceptible	JJ	O
Streptococcus	NNP	O
pneumoniae	NN	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
children	NNS	O
6	CD	O
to	TO	O
23	CD	O
months	NNS	O
of	IN	O
age	NN	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
,	,	O
treatment	NN	O
with	IN	O
amoxicillin-clavulanate	NN	O
for	IN	O
10	CD	O
days	NNS	O
tended	VBD	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
to	TO	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
reduced	VBD	O
the	DT	O
overall	JJ	O
symptom	NN	O
burden	NN	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
persistent	JJ	O
signs	NNS	O
of	IN	O
acute	JJ	O
infection	NN	O
on	IN	O
otoscopic	JJ	O
examination	NN	O
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Allergy	NNP	O
and	CC	O
Infectious	NNP	O
Diseases	NNP	O
;	:	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00377260	NNP	O
.	.	O

)	)	O
.	.	O

Effects	NNS	O
of	IN	O
supervised	JJ	O
exercise	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
Postoperative	NNP	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
has	VBZ	O
a	DT	O
number	NN	O
of	IN	O
associated	JJ	O
complications	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
could	MD	O
mitigate	VB	O
the	DT	O
complications	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
radiotherapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	O
women	NNS	O
were	VBD	O
randomized	VBN	O
before	IN	O
radiotherapy	NN	O
after	IN	O
various	JJ	O
operations	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
for	IN	O
50	CD	O
min	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Twenty-three	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
self-shoulder	JJ	O
stretching	VBG	O
exercise	NN	O
.	.	O

The	DT	O
World	NNP	Others
Health	NNP	Others
Organization	NNP	Others
Quality	NNP	Others
of	IN	Others
Life-BREF	NNP	Others
(	(	Others
WHOQOL-BREF	NNP	Others
)	)	Others
,	,	O
brief	JJ	Others
fatigue	JJ	Others
inventory	NN	Others
(	(	Others
BFI	NNP	Others
)	)	Others
,	,	O
range	NN	Physical
of	IN	Physical
motion	NN	Physical
(	(	Physical
ROM	NNP	Physical
)	)	Physical
of	IN	Physical
the	DT	Physical
shoulder	NN	Physical
,	,	O
and	CC	O
pain	NN	Pain
score	NN	Pain
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
noted	VBD	O
at	IN	O
baseline	NN	O
between	IN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
exercise	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	Others
and	CC	Others
shoulder	NN	Others
ROM	NNP	Others
and	CC	O
decrease	NN	Pain
in	IN	Pain
BFI	NNP	Pain
and	CC	Pain
pain	NN	Pain
score	NN	Pain
after	IN	O
radiotherapy	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
showed	VBD	O
decrease	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	Physical
and	CC	O
shoulder	NN	Physical
ROM	NNP	Physical
and	CC	O
increase	VB	Pain
in	IN	Pain
BFI	NNP	Pain
and	CC	Pain
pain	NN	Pain
score	NN	Pain
after	IN	O
radiotherapy	NN	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
WHOQOL	NNP	Physical
,	,	O
BFI	NNP	Physical
,	,	O
shoulder	NN	Physical
ROM	NNP	Physical
,	,	O
and	CC	O
pain	VB	Pain
score	NN	Pain
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
may	MD	O
benefit	VB	O
in	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
aspects	NNS	O
from	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
.	.	O

The	DT	O
effectiveness	NN	Others
and	CC	O
cost	NN	Others
of	IN	O
passive	JJ	Mental
warming	NN	Mental
in	IN	O
adult	NN	O
ambulatory	NN	O
surgery	NN	O
patients	NNS	O
.	.	O

Hypothermia	NNP	O
is	VBZ	O
a	DT	O
common	JJ	O
problem	NN	O
for	IN	O
surgical	JJ	O
patients	NNS	O
and	CC	O
can	MD	O
result	VB	O
in	IN	O
many	JJ	O
complications	NNS	O
.	.	O

Because	IN	O
few	JJ	O
studies	NNS	O
compare	VBP	O
methods	NNS	O
of	IN	O
passive	JJ	O
warming	NN	O
,	,	O
we	PRP	O
used	VBD	O
an	DT	O
unblinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
experimental	JJ	O
,	,	O
randomized	JJ	O
design	NN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
two	CD	O
passive	JJ	O
methods	NNS	O
of	IN	O
normothermia	JJ	O
management	NN	O
in	IN	O
the	DT	O
postanesthesia	NN	O
care	NN	O
unit	NN	O
(	(	O
PACU	NNP	O
)	)	O
.	.	O

We	PRP	O
assigned	VBD	O
a	DT	O
total	NN	O
of	IN	O
578	CD	O
adult	NN	O
ambulatory	NN	O
surgery	NN	O
patients	NNS	O
to	TO	O
either	VB	O
a	DT	O
control	NN	O
group	NN	O
that	WDT	O
was	VBD	O
given	VBN	O
two	CD	O
folded	JJ	O
,	,	O
warmed	JJ	O
cotton	NN	O
blankets	NNS	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
that	WDT	O
was	VBD	O
given	VBN	O
a	DT	O
warmed	NN	O
,	,	O
unfolded	JJ	O
cotton	NN	O
sheet	NN	O
and	CC	O
cotton	NN	O
blanket	NN	O
.	.	O

We	PRP	O
recorded	VBD	O
patients	NNS	Mental
'	POS	Mental
temperatures	NNS	Mental
on	IN	Mental
their	PRP$	Mental
arrival	NN	Mental
in	IN	Mental
the	DT	Mental
PACU	NNP	Mental
and	CC	Mental
at	IN	Mental
30	CD	Mental
minutes	NNS	Mental
after	IN	Mental
arrival	NN	Mental
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
temperatures	NNS	Physical
that	WDT	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
30	CD	O
minutes	NNS	O
after	IN	O
arrival	NN	O
in	IN	O
the	DT	O
PACU	NNP	O
,	,	O
and	CC	O
the	DT	O
treatment	NN	O
group	NN	O
experienced	VBD	O
a	DT	O
greater	JJR	O
change	NN	Physical
in	IN	Physical
temperature	NN	Physical
from	IN	O
baseline	NN	O
measurements	NNS	O
to	TO	O
those	DT	O
taken	VBN	O
at	IN	O
30	CD	O
minutes	NNS	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
also	RB	O
used	VBD	O
fewer	JJR	O
warmed	JJ	O
blankets	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
cost	NN	O
savings	NNS	O
for	IN	O
the	DT	O
PACU	NNP	O
.	.	O

Epinephrine-induced	JJ	O
panic	NN	O
attacks	NNS	O
and	CC	O
hyperventilation	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
epinephrine	NN	O
on	IN	O
ventilation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
in	IN	O
social	JJ	O
phobics	NNS	O
,	,	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
pooled	VBN	O
data	NNS	O
from	IN	O
two	CD	O
previous	JJ	O
infusion	NN	O
studies	NNS	O
.	.	O

Throughout	IN	O
the	DT	O
infusion	NN	O
,	,	O
changes	NNS	Physical
in	IN	Physical
transcutaneous	JJ	Physical
PCO2	NNP	Physical
(	(	Physical
tcPCO2	NN	Physical
)	)	Physical
,	,	O
subjective	JJ	Mental
anxiety	NN	Mental
,	,	O
heart	NN	Physical
rate	NN	Physical
and	CC	O
blood	NN	Physical
pressure	NN	Physical
were	VBD	O
recorded	VBN	O
continuously	RB	O
.	.	O

Twenty-nine	JJ	O
patients	NNS	O
received	VBD	O
epinephrine	JJ	O
,	,	O
ten	JJ	O
patients	NNS	O
received	VBD	O
placebo	NN	O
.	.	O

Thirteen	JJ	O
patients	NNS	O
(	(	O
45	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
panic	JJ	O
attack	NN	O
during	IN	O
epinephrine	NN	O
.	.	O

The	DT	O
fall	NN	Physical
in	IN	Physical
tcPCO2	NN	Physical
and	CC	O
the	DT	Physical
cardiovascular	JJ	Physical
response	NN	Physical
was	VBD	O
greater	JJR	O
in	IN	O
panicking	VBG	O
patients	NNS	O
than	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
panic	JJ	O
.	.	O

Although	IN	O
the	DT	O
fall	NN	O
in	IN	O
tcPCO2	NN	Physical
associated	VBN	O
with	IN	O
panic	NN	O
was	VBD	O
not	RB	O
substantial	JJ	O
and	CC	O
did	VBD	O
not	RB	O
indicate	VB	O
clinically	RB	O
significant	JJ	O
acute	JJ	Physical
hyperventilation	NN	Physical
,	,	O
it	PRP	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
sensitive	JJ	O
index	NN	O
for	IN	O
epinephrine-induced	JJ	O
panic	NN	O
.	.	O

The	DT	O
fall	NN	Physical
in	IN	Physical
tcPCO2	NN	Physical
was	VBD	O
predicted	VBN	O
rather	RB	O
by	IN	O
the	DT	O
frequency	NN	O
of	IN	O
occurrence	NN	Mental
of	IN	Mental
anxiety-related	JJ	Mental
somatic	NN	Mental
symptoms	NNS	Mental
than	IN	O
by	IN	O
the	DT	O
fear	NN	O
of	IN	O
these	DT	O
symptoms	NNS	O
.	.	O

These	DT	O
findings	NNS	O
further	RB	O
reduce	VB	O
a	DT	O
role	NN	O
for	IN	O
fear	NN	O
of	IN	O
bodily	JJ	O
sensations	NNS	O
in	IN	O
epinephrine-induced	JJ	O
panic	NN	O
attacks	NNS	O
and	CC	O
favor	VBP	O
a	DT	O
biological	JJ	O
sensitivity	NN	O
to	TO	O
sympathetic	JJ	O
stimulation	NN	O
.	.	O

A	DT	O
multi-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
parenteral	JJ	O
nutrition	NN	O
titrated	VBD	O
to	TO	O
resting	VBG	O
energy	NN	O
expenditure	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
PNTREE	NNP	O
)	)	O
:	:	O
rationale	NN	O
and	CC	O
design	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
undergoing	VBG	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
HSCT	NNP	O
)	)	O
frequently	RB	O
require	VBP	O
prolonged	JJ	O
courses	NNS	O
of	IN	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
PN	NNP	O
)	)	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
gastrointestinal	JJ	O
dysfunction	NN	O
related	VBN	O
to	TO	O
preparative	JJ	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
.	.	O

PN	NNP	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
shorter	JJR	O
engraftment	NN	O
time	NN	O
and	CC	O
decreased	JJ	O
mortality	NN	O
during	IN	O
HSCT	NNP	O
,	,	O
however	RB	O
,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
linked	VBN	O
with	IN	O
complications	NNS	O
,	,	O
including	VBG	O
infections	NNS	Physical
,	,	Adverseeffect
liver	RB	Physical
disease	NN	Physical
,	,	Adverseeffect
and	CC	Adverseeffect
metabolic	JJ	Physical
disturbances	NNS	Physical
.	.	Adverseeffect

Some	DT	O
of	IN	O
these	DT	O
complications	NNS	O
may	MD	O
be	VB	O
a	DT	O
result	NN	O
of	IN	O
providing	VBG	O
PN	NNP	O
in	IN	O
excess	NN	O
of	IN	O
nutrient	JJ	O
requirements	NNS	O
.	.	O

We	PRP	O
previously	RB	O
described	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
resting	VBG	O
energy	NN	O
expenditure	NN	O
(	(	O
REE	NNP	O
)	)	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
indirect	JJ	O
calorimetry	NN	O
,	,	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
HSCT	NNP	O
.	.	O

We	PRP	O
also	RB	O
documented	VBD	O
a	DT	O
decline	NN	O
in	IN	O
mid-arm	JJ	O
muscle	NN	O
area	NN	O
,	,	O
suggesting	VBG	O
depletion	NN	O
of	IN	O
muscle	NN	O
mass	NN	O
,	,	O
while	IN	O
triceps	NNS	O
skinfold	RB	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
fat	JJ	O
stores	NNS	O
,	,	O
was	VBD	O
unchanged	JJ	O
.	.	O

These	DT	O
results	NNS	O
suggested	VBD	O
the	DT	O
need	NN	O
for	IN	O
further	JJ	O
study	NN	O
of	IN	O
energy	NN	O
expenditure	NN	O
,	,	O
body	NN	O
composition	NN	O
and	CC	O
nutritional	JJ	O
intake	NN	O
in	IN	O
this	DT	O
group	NN	O
of	IN	O
high	JJ	O
risk	NN	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
AND	CC	O
HYPOTHESIS	NNP	O
We	PRP	O
hypothesize	VBP	O
that	IN	O
changes	NNS	O
in	IN	O
body	NN	O
composition	NN	O
affect	JJ	O
REE	NNP	O
during	IN	O
HSCT	NNP	O
,	,	O
and	CC	O
that	IN	O
standard	JJ	O
nutritional	JJ	O
support	NN	O
may	MD	O
lead	VB	O
to	TO	O
overfeeding	VBG	O
.	.	O

We	PRP	O
are	VBP	O
performing	VBG	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
parenteral	JJ	O
nutrition	NN	O
among	IN	O
children	NNS	O
undergoing	VBG	O
allogeneic	NN	O
HSCT	NNP	O
.	.	O

Subjects	NNS	O
are	VBP	O
randomized	VBN	O
to	TO	O
receive	VB	O
PN	NNP	O
designed	VBN	O
to	TO	O
provide	VB	O
100	CD	O
%	NN	O
of	IN	O
measured	JJ	O
REE	NNP	O
,	,	O
or	CC	O
standard	JJ	O
PN	NNP	O
,	,	O
i.e.	NN	O
,	,	O
140	CD	O
%	NN	O
of	IN	O
estimated	VBN	O
energy	NN	O
expenditure	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
is	VBZ	O
change	VBN	Physical
in	IN	Physical
percent	NN	Physical
body	NN	Physical
fat	JJ	Physical
.	.	Physical

Secondary	JJ	O
outcomes	NNS	O
include	VBP	O
glycemic	JJ	Physical
control	NN	Physical
and	CC	Physical
frequency	NN	Physical
of	IN	Physical
infections	NNS	Physical
,	,	Physical
changes	NNS	Physical
in	IN	Physical
REE	NNP	Physical
and	CC	Physical
body	NN	Physical
composition	NN	Physical
.	.	Physical

CONCLUSION	NNP	O
This	DT	O
study	NN	O
will	MD	O
provide	VB	O
unique	JJ	O
and	CC	O
comprehensive	JJ	O
nutritional	JJ	O
data	NNS	O
and	CC	O
its	PRP$	O
results	NNS	O
will	MD	O
guide	VB	O
nutritional	JJ	O
therapy	NN	O
for	IN	O
children	NNS	O
undergoing	VBG	O
HSCT	NNP	O
and	CC	O
possibly	RB	O
other	JJ	O
catabolic	JJ	O
patients	NNS	O
.	.	O

Alinidine	NNP	O
in	IN	O
chronic	JJ	O
stable	JJ	O
angina	NN	O
:	:	O
the	DT	O
effect	NN	O
on	IN	O
diastolic	JJ	Physical
perfusion	NN	Physical
time	NN	Physical
.	.	Physical

The	DT	O
present	JJ	O
study	NN	O
has	VBZ	O
been	VBN	O
performed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
alinidine	NN	O
on	IN	O
diastolic	JJ	O
duration	NN	O
during	IN	O
exercise	NN	O
in	IN	O
chronic	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Twelve	VB	O
male	NN	O
patients	NNS	O
with	IN	O
stable	JJ	O
effort	NN	O
angina	NN	O
and	CC	O
without	IN	O
previous	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
studied	VBN	O
.	.	O

They	PRP	O
received	VBD	O
alinidine	NN	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
crossover	NN	O
trial	NN	O
for	IN	O
3	CD	O
days	NNS	O
after	IN	O
a	DT	O
wash-out	JJ	O
period	NN	O
of	IN	O
4	CD	O
days	NNS	O
.	.	O

Alinidine	NNP	O
was	VBD	O
administered	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
30	CD	O
mg	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
treatment	NN	O
the	DT	O
patients	NNS	O
underwent	JJ	O
upright	JJ	O
bicycle	NN	O
exercise	NN	O
.	.	O

Left	NNP	O
ventricular	JJ	Physical
time	NN	O
intervals	NNS	O
were	VBD	O
obtained	VBN	Physical
by	IN	O
means	NNS	O
of	IN	O
carotid	NN	O
thermistor	NN	O
plethysmography	NN	O
.	.	O

Diastolic	NNP	Physical
duration	NN	Physical
was	VBD	O
calculated	VBN	Others
by	IN	Others
subtracting	VBG	Others
the	DT	Others
electromechanical	JJ	Others
systole	NN	Others
from	IN	Others
the	DT	Others
R-R	NNP	Others
interval	NN	Others
and	CC	Others
expressed	VBD	Others
as	IN	Others
a	DT	Others
percentage	NN	Others
of	IN	Others
the	DT	Others
cardiac	JJ	Others
cycle	NN	Others
(	(	Others
%	NN	Others
D	NNP	Others
)	)	Others
.	.	Others

Alinidine	NN	O
increased	VBD	O
both	DT	O
total	JJ	O
exercise	NN	O
duration	NN	O
from	IN	O
246.7	CD	O
+/-	JJ	O
120.7	CD	O
to	TO	O
346.6	CD	O
+/-	JJ	O
114.1	CD	O
s	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
and	CC	O
time	NN	O
to	TO	O
0.1-mV	JJ	O
ST	NNP	O
segment	NN	O
depression	NN	O
from	IN	O
98.3	CD	O
+/-	JJ	O
53	CD	O
to	TO	O
187.2	CD	O
+/-	JJ	O
105	CD	O
s	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Similarly	RB	O
the	DT	O
drug	NN	O
induced	VBD	Physical
a	DT	Physical
reduction	NN	Physical
of	IN	Physical
the	DT	Physical
rate-pressure	JJ	Physical
product	NN	Physical
and	CC	O
of	IN	O
the	DT	O
extent	NN	O
of	IN	O
ischemic	JJ	O
ST	NNP	O
segment	NN	O
depression	NN	O
during	IN	O
exercise	NN	O
.	.	O

%	NN	O
D	NNP	O
was	VBD	O
increased	VBN	O
by	IN	O
alinidine	JJ	O
both	DT	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
.	.	O

A	DT	O
direct	JJ	O
linear	JJ	Physical
regression	NN	Physical
between	IN	O
R-R	NNP	O
and	CC	O
%	NN	O
D	NNP	O
was	VBD	O
found	VBN	O
after	IN	O
both	DT	O
alinidine	NN	O
and	CC	O
placebo	NN	O
treatments	NNS	O
either	CC	O
at	IN	O
rest	NN	O
or	CC	O
during	IN	O
exercise	NN	O
.	.	O

Nevertheless	NNP	O
,	,	O
no	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
both	DT	O
slopes	NNS	O
and	CC	O
intercepts	NNS	O
.	.	O

Therefore	RB	O
,	,	O
since	IN	O
the	DT	O
relationship	NN	O
between	IN	O
R-R	NNP	O
interval	NN	O
and	CC	O
%	NN	O
D	NNP	O
was	VBD	O
unaffected	VBN	O
by	IN	O
alinidine	NN	O
,	,	O
it	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
hypothesize	VB	O
that	IN	O
the	DT	O
changes	NNS	O
in	IN	O
diastolic	JJ	Others
duration	NN	Others
were	VBD	O
due	JJ	O
only	RB	O
to	TO	O
the	DT	O
bradycardic	JJ	O
action	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Effect	NN	O
of	IN	O
whole-body	JJ	O
mild-cold	JJ	O
exposure	NN	O
on	IN	O
arterial	JJ	Physical
stiffness	NN	Physical
and	CC	O
central	JJ	Physical
haemodynamics	NNS	Physical
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
in	IN	O
healthy	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

Aortic	JJ	Physical
pulse	NN	Physical
wave	NN	Physical
velocity	NN	Physical
(	(	Physical
PWV	NNP	Physical
)	)	Physical
and	CC	O
augmentation	NN	Physical
index	NN	Physical
(	(	Physical
AIx	NNP	Physical
)	)	Physical
are	VBP	O
independent	JJ	O
predictors	NNS	O
of	IN	O
cardiovascular	JJ	Physical
risk	NN	Physical
and	CC	O
mortality	NN	Mortality
,	,	O
but	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
air	NN	O
temperature	NN	O
changes	NNS	O
on	IN	O
these	DT	O
variables	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
exposure	NN	O
to	TO	O
whole-body	JJ	O
mild-cold	JJ	O
on	IN	O
measures	NNS	O
of	IN	O
arterial	JJ	Physical
stiffness	NN	Physical
(	(	Physical
aortic	JJ	Physical
and	CC	Physical
brachial	JJ	Physical
PWV	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
on	IN	Physical
central	JJ	Physical
haemodynamics	NNS	Physical
[	VBP	Physical
including	VBG	Physical
augmented	VBN	Physical
pressure	NN	Physical
(	(	Physical
AP	NNP	Physical
)	)	Physical
,	,	Physical
AIx	NNP	Physical
]	NNP	Physical
,	,	O
and	CC	O
aortic	JJ	Physical
reservoir	NN	Physical
components	NNS	Physical
[	VBP	O
including	VBG	O
reservoir	NN	Physical
and	CC	Physical
excess	JJ	Physical
pressures	NNS	Physical
(	(	Physical
P	NNP	Physical
ex	NN	Physical
)	)	Physical
]	NN	O
.	.	O

Sixteen	NNP	O
healthy	JJ	O
volunteers	NNS	O
(	(	O
10	CD	O
men	NNS	O
,	,	O
age	NN	O
43	CD	O
?	.	O
19	CD	O
years	NNS	O
;	:	O
mean	VB	O
?	.	O
SD	NNP	O
)	)	O
were	VBD	O
randomised	VBN	O
to	TO	O
be	VB	O
studied	VBN	O
under	IN	O
conditions	NNS	O
of	IN	O
12	CD	O
?C	NNS	O
(	(	O
mild-cold	JJ	O
)	)	O
and	CC	O
21	CD	O
?C	NNP	O
(	(	O
control	NN	O
)	)	O
on	IN	O
separate	JJ	O
days	NNS	O
.	.	O

Supine	JJ	O
resting	VBG	O
measures	NNS	O
were	VBD	O
taken	VBN	O
at	IN	O
baseline	NN	O
(	(	O
ambient	JJ	O
temperature	NN	O
)	)	O
and	CC	O
after	IN	O
10	CD	O
,	,	O
30	CD	O
,	,	O
and	CC	O
60	CD	O
min	NN	O
exposure	NN	O
to	TO	O
each	DT	O
experimental	JJ	O
condition	NN	O
in	IN	O
a	DT	O
climate	JJ	O
chamber	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
brachial	JJ	O
blood	NN	O
pressure	NN	O
between	IN	O
mild-cold	JJ	O
and	CC	O
control	JJ	O
conditions	NNS	O
.	.	O

However	RB	O
,	,	O
compared	VBN	O
to	TO	O
control	VB	O
,	,	O
AP	NNP	O
[	NNP	O
+2	NNP	O
mmHg	NN	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.36-4.36	NN	O
;	:	O
p	CC	O
=	$	O
0.01	CD	O
]	NN	O
and	CC	O
AIx	NNP	O
(	(	O
+6	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.24-10.1	CD	O
;	:	O
p	CC	O
=	VB	O
0.02	CD	O
)	)	O
increased	VBN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
maximum	VB	O
P	NNP	O
ex	FW	O
(	(	O
a	DT	O
component	NN	O
of	IN	O
reservoir	NN	O
function	NN	O
related	VBN	O
to	TO	O
timing	NN	O
of	IN	O
peak	JJ	O
aortic	JJ	O
in-flow	NN	O
)	)	O
decreased	VBD	O
(	(	O
-7	JJ	O
ms	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-15.4	NNP	O
to	TO	O
2.03	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.01	CD	O
)	)	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

Yet	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
aortic	JJ	O
PWV	NNP	O
(	(	O
+0.04	NNP	O
m/s	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-0.47	NNP	O
to	TO	O
0.55	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.87	CD	O
)	)	O
or	CC	O
brachial	JJ	O
PWV	NNP	O
(	(	O
+0.36	NNP	O
m/s	NN	O
;	:	O
-0.41	VBZ	O
to	TO	O
1.12	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.35	CD	O
)	)	O
between	IN	O
conditions	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
mild-cold	JJ	O
exposure	NN	O
increases	VBZ	O
central	JJ	O
haemodynamic	JJ	O
stress	NN	O
and	CC	O
alters	NNS	O
timing	NN	O
of	IN	O
peak	JJ	O
aortic	JJ	O
in-flow	NN	O
without	IN	O
differentially	RB	O
affecting	VBG	O
arterial	JJ	O
stiffness	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
betamethasone	NN	O
on	IN	O
neuromuscular	JJ	Physical
blockade	NN	Physical
induced	VBN	O
by	IN	O
vecuronium	NN	O
in	IN	O
continuous	JJ	O
infusion	NN	O
]	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
a	DT	O
possible	JJ	O
interaction	NN	O
between	IN	O
a	DT	O
corticosteroid	NN	O
(	(	O
betamethasone	NN	O
)	)	O
and	CC	O
vecuronium	NN	O
,	,	O
a	DT	O
nondepolarizing	JJ	O
muscle	NN	O
relaxant	NN	O
.	.	O

The	DT	O
authors	NNS	O
studied	VBD	O
20	CD	O
patients	NNS	O
,	,	O
ASA	NNP	O
I-II	NNP	O
,	,	O
aged	VBD	O
20-54	JJ	O
,	,	O
both	DT	O
sexes	NNS	O
,	,	O
scheduled	VBN	O
for	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Mechanomyographic	NNP	Physical
and	CC	Physical
clinical	JJ	Physical
evaluation	NN	Physical
by	IN	Physical
single	JJ	Physical
twitch	NN	Physical
and	CC	O
TOF	NNP	Physical
stimulation	NN	Physical
of	IN	Physical
the	DT	Physical
ulnar	JJ	Physical
nerve	NN	Physical
at	IN	Physical
the	DT	Physical
wrist	NN	Physical
and	CC	O
measurement	NN	O
of	IN	O
the	DT	O
concomitant	JJ	Physical
abductor	NN	Physical
pollicis	NN	Physical
muscle	NN	Physical
was	VBD	O
applied	VBN	O
.	.	O

The	DT	O
onset	JJ	Others
time	NN	Others
of	IN	O
vecuronium	NN	O
after	IN	O
a	DT	O
single	JJ	O
bolus	NN	O
dose	NN	O
of	IN	O
0.08	CD	O
mg/kg	NN	O
,	,	O
duration	NN	Others
of	IN	Others
action	NN	Others
to	TO	O
10	CD	O
%	NN	O
single	JJ	Physical
twitch	NN	Physical
recovery	NN	Physical
,	,	O
duration	NN	O
of	IN	O
continuous	JJ	O
infusion	NN	O
of	IN	O
0.4-0.5	JJ	O
micrograms/kg/min	NN	O
of	IN	O
vecuronium	NN	O
started	VBN	O
at	IN	O
10	CD	O
%	NN	O
single	JJ	Physical
twitch	NN	Physical
recovery	NN	Physical
,	,	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
0.1	CD	O
mg/kg	NNS	O
betamethasone	CD	O
administration	NN	O
10	CD	O
min	NN	O
after	IN	O
continuous	JJ	O
infusion	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

The	DT	O
recovery	NN	Physical
rate	NN	Physical
of	IN	Physical
vecuronium	NN	Physical
after	IN	O
stopping	VBG	O
infusion	NN	O
at	IN	O
10	CD	O
%	NN	O
recovery	NN	O
was	VBD	O
also	RB	O
evaluated	VBN	O
.	.	O

Corticosteroids	NNS	O
may	MD	O
interact	VB	O
with	IN	O
non-depolarizing	JJ	O
muscle	NN	O
relaxants	NNS	O
both	DT	O
in	IN	O
prejunctional	NN	O
and	CC	O
postjunctional	JJ	O
acetylcholine	NN	O
receptors	NNS	O
by	IN	O
several	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
.	.	O

Post-laparoscopic	NNP	O
cholecystectomy	NN	O
pain	NN	O
:	:	O
effects	NNS	Others
of	IN	O
intraperitoneal	JJ	O
local	JJ	O
anesthetics	NNS	O
on	IN	O
pain	NN	O
control	NN	O
--	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
double-blinded	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Postoperative	NNP	O
pain	NN	O
after	IN	O
laparoscopic	NN	O
cholecystectomy	NN	O
(	(	O
LC	NNP	O
)	)	O
is	VBZ	O
generally	RB	O
less	JJR	O
than	IN	O
open	JJ	O
cholecystectomy	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
postoperative	JJ	O
shoulder	NN	O
and	CC	O
abdominal	JJ	O
pain	NN	O
experienced	VBN	O
by	IN	O
patients	NNS	O
still	RB	O
causes	VBZ	O
preventable	JJ	O
distress	NN	O
.	.	O

Intraperitoneal	NNP	O
irrigation	NN	O
of	IN	O
the	DT	O
diaphragmatic	JJ	O
surface	NN	O
and	CC	O
gallbladder	NN	O
fossa	NN	O
using	VBG	O
normal	JJ	O
saline	NN	O
,	,	O
bupivacaine	NN	O
,	,	O
or	CC	O
lignocaine	NN	O
may	MD	O
effectively	RB	O
control	VB	O
visceral	JJ	Pain
abdominal	JJ	Pain
pain	NN	Pain
after	IN	O
an	DT	O
LC	NNP	O
.	.	O

Two	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
similar	JJ	O
demographics	NNS	O
undergoing	JJ	O
elective	JJ	O
LC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
of	IN	O
50	CD	O
patients	NNS	O
each	DT	O
,	,	O
including	VBG	O
Group	NNP	O
A	NNP	O
placebo	NN	O
control	NN	O
,	,	O
Group	NNP	O
B	NNP	O
with	IN	O
isotonic	JJ	O
saline	NN	O
irrigation	NN	O
,	,	O
Group	NNP	O
C	NNP	O
with	IN	O
bupivacaine	JJ	O
irrigation	NN	O
,	,	O
and	CC	O
Group	NNP	O
D	NNP	O
with	IN	O
lignocaine	JJ	O
irrigation	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
preperitoneal	JJ	O
abdominal	JJ	O
wall	NN	O
infiltration	NN	O
with	IN	O
0.25	CD	O
per	IN	O
cent	NN	O
bupivacaine	NN	O
to	TO	O
control	VB	O
parietal	JJ	O
(	(	O
somatic	JJ	O
)	)	O
abdominal	JJ	O
pain	NN	O
.	.	O

The	DT	O
visual	JJ	Pain
analogue	NN	Pain
and	CC	Others
verbal	JJ	Pain
rating	NN	Pain
pain	NN	Pain
scores	NNS	Pain
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
hours	NNS	O
for	IN	O
both	DT	O
shoulder	NN	O
and	CC	O
abdominal	JJ	O
pain	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
double-blind	JJ	O
fashion	NN	O
at	IN	O
four	CD	O
points	NNS	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
postoperative	JJ	O
hours	NNS	O
.	.	O

Analgesia	NNP	Physical
requirements	NNS	Physical
,	,	Physical
vital	JJ	Physical
signs	NNS	Physical
,	,	Physical
blood	NN	Physical
glucose	NN	Physical
,	,	Physical
and	CC	Physical
incidence	NN	Physical
of	IN	Physical
nausea	NN	Physical
and	CC	Physical
vomiting	NN	Physical
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

Patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
visual	JJ	Pain
analogue	NN	Pain
and	CC	Pain
verbal	JJ	Pain
rating	NN	Pain
pain	NN	Pain
scores	NNS	Pain
and	CC	O
analgesic	JJ	Others
consumption	NN	Others
when	WRB	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Lignocaine	NNP	O
controlled	VBD	Pain
pain	NN	Pain
significantly	RB	O
better	JJR	O
than	IN	O
saline	NN	O
or	CC	O
bupivacaine	NN	O
.	.	O

Bowel	NNP	Physical
function	NN	Physical
recovery	NN	Physical
was	VBD	O
similar	JJ	O
in	IN	O
all	DT	O
patients	NNS	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
complications	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
intraperitoneal	JJ	O
irrigation	NN	O
with	IN	O
either	DT	O
saline	NN	O
,	,	O
bupivacaine	NN	O
,	,	O
or	CC	O
lignocaine	NN	O
can	MD	O
significantly	RB	O
reduce	VB	O
visceral	JJ	Pain
abdominal	NN	Pain
pain	NN	Pain
after	IN	O
LC	NNP	O
.	.	O

Lignocaine	NNP	O
was	VBD	O
the	DT	O
most	RBS	O
efficacious	JJ	O
local	JJ	O
anesthetic	NN	O
in	IN	O
this	DT	O
trial	NN	O
and	CC	O
has	VBZ	O
a	DT	O
high	JJ	O
safety	NN	O
profile	NN	O
when	WRB	O
used	VBN	O
at	IN	O
recommended	JJ	O
doses	NNS	O
.	.	O

[	JJ	O
Observation	NNP	O
on	IN	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
acupuncture	NN	O
on	IN	O
early	JJ	O
peripheral	JJ	O
facial	JJ	O
paralysis	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
acupuncture	NN	O
at	IN	O
different	JJ	O
opportunities	NNS	O
on	IN	O
peripheral	JJ	O
facial	JJ	O
paralysis	NN	O
.	.	O

METHODS	NNP	O
Fifty-two	JJ	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
treatment	NN	O
group	NN	O
(	(	O
n=28	CC	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n=24	RB	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
at	IN	O
the	DT	O
acute	JJ	O
stage	NN	O
(	(	O
1-10	JJ	O
days	NNS	O
)	)	O
were	VBD	O
treated	VBN	O
with	IN	O
acupuncture	NN	O
at	IN	O
Dicang	NNP	O
(	(	O
ST	NNP	O
4	CD	O
)	)	O
,	,	O
Jiache	NNP	O
(	(	O
ST	NNP	O
6	CD	O
)	)	O
,	,	O
Yangbai	NNP	O
(	(	O
GB	NNP	O
14	CD	O
)	)	O
,	,	O
etc.	FW	O
,	,	O
with	IN	O
less	JJR	O
than	IN	O
4	CD	O
points	NNS	O
selected	VBN	O
on	IN	O
the	DT	O
face	NN	O
and	CC	O
with	IN	O
shallow	JJ	O
puncture	NN	O
,	,	O
and	CC	O
10	CD	O
days	NNS	O
later	RB	O
electroacupuncture	VBP	O
were	VBD	O
added	VBN	O
at	IN	O
acupoints	NNS	O
selected	VBN	O
routinely	RB	O
;	:	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
same	JJ	O
methods	NNS	O
as	IN	O
the	DT	O
treatment	NN	O
group	NN	O
but	CC	O
acupuncture	NN	O
was	VBD	O
not	RB	O
given	VBN	O
at	IN	O
the	DT	O
acute	JJ	O
stage	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
cured	JJ	Others
rate	NN	Others
of	IN	O
78.6	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
50.0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Early	JJ	O
acupuncture	NN	O
is	VBZ	O
a	DT	O
key	NN	O
for	IN	O
achieving	VBG	O
the	DT	O
best	JJS	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
facial	JJ	O
paralysis	NN	O
.	.	O

Report	NN	O
on	IN	O
the	DT	O
second	JJ	O
myelomatosis	NN	O
trial	NN	O
after	IN	O
five	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Medical	NNP	O
Research	NNP	O
Council	NNP	O
's	POS	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	O
in	IN	O
Adults	NNP	O
.	.	O

Three	CD	O
hundred	VBD	O
and	CC	O
seventy-two	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
between	IN	O
3	CD	O
regimens	NNS	O
of	IN	O
chemotherapy	NN	O
:	:	O
cyclophosphamide	NN	O
,	,	O
intermittent	NN	O
melphalan	NN	O
,	,	O
and	CC	O
melphalan	NN	O
with	IN	O
prednisone	NN	O
,	,	O
and	CC	O
were	VBD	O
followed	VBN	O
up	RP	O
to	TO	O
death	NN	O
or	CC	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
years	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	Mortality
between	IN	O
the	DT	O
treatments	NNS	O
,	,	O
either	RB	O
overall	JJ	O
or	CC	O
in	IN	O
any	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
choice	NN	O
among	IN	O
these	DT	O
3	CD	O
treatments	NNS	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
comfort	NN	O
and	CC	O
convenience	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
prognostic	JJ	O
feature	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
the	DT	O
quality	NN	O
of	IN	O
renal	JJ	Physical
function	NN	Physical
.	.	O

It	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
define	VB	O
good	JJ	O
,	,	O
intermediate	JJ	O
and	CC	O
poor	JJ	O
renal-function	NN	O
groups	NNS	O
which	WDT	O
were	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
(	(	O
X2	NNP	O
for	IN	O
trend	NN	O
=	NNP	O
62.6	CD	O
)	)	O
.	.	O

The	DT	O
haemoglobin	JJ	Physical
level	NN	Physical
at	IN	O
presentation	NN	O
was	VBD	O
strongly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
good	JJ	O
renal-function	NN	O
group	NN	O
.	.	O

Among	IN	O
107	CD	O
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
good	JJ	O
renal	JJ	O
function	NN	O
and	CC	O
with	IN	O
haemoglobin	NNS	O
above	IN	O
100	CD	O
g/l	NN	O
,	,	O
the	DT	O
5-year	JJ	O
survival	NN	Mortality
was	VBD	O
43	CD	O
%	NN	O
.	.	O

Other	JJ	O
prognostic	JJ	O
features	NNS	O
were	VBD	O
much	RB	O
less	RBR	O
important	JJ	O
when	WRB	O
account	NN	O
was	VBD	O
taken	VBN	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
haemoglobin	JJ	O
level	NN	O
.	.	O

Erythema	JJ	O
migrans	NNS	O
:	:	O
comparison	NN	O
of	IN	O
treatment	NN	O
with	IN	O
azithromycin	NN	O
,	,	O
doxycycline	NN	O
and	CC	O
phenoxymethylpenicillin	NN	O
.	.	O

Azithromycin	NNP	O
,	,	O
doxycycline	NN	O
and	CC	O
phenoxymethylpenicillin	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
study	NN	O
of	IN	O
64	CD	O
patients	NNS	O
with	IN	O
typical	JJ	O
erythema	NN	O
migrans	NNS	O
.	.	O

Twenty	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
oral	JJ	O
azithromycin	NN	O
,	,	O
250	CD	O
mg	NN	O
bd	NN	O
for	IN	O
two	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
250	CD	O
mg	NNS	O
od	NN	O
for	IN	O
eight	CD	O
days	NNS	O
,	,	O
21	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
phenoxymethylpenicillin	$	O
1	CD	O
million	CD	O
IU	NNP	O
tds	NN	O
for	IN	O
14	CD	O
days	NNS	O
and	CC	O
23	CD	O
patients	NNS	O
received	JJ	O
doxycycline	NN	O
,	,	O
100	CD	O
mg	NN	O
bd	NN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
persistence	NN	O
of	IN	O
cutaneous	JJ	Physical
lesions	NNS	Physical
after	IN	O
starting	VBG	O
treatment	NN	O
;	:	O
the	DT	O
mean	JJ	Others
durations	NNS	Others
were	VBD	O
10.5	CD	O
days	NNS	O
in	IN	O
the	DT	O
penicillin	NN	O
group	NN	O
,	,	O
8.8	CD	O
days	NNS	O
in	IN	O
the	DT	O
doxycycline	NN	O
group	NN	O
and	CC	O
8.6	CD	O
days	NNS	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
resolution	NN	Physical
of	IN	Physical
associated	JJ	Physical
local	JJ	Physical
and/or	NN	Physical
systemic	NN	Physical
symptoms	NNS	Physical
.	.	Physical

The	DT	O
response	NN	Others
time	NN	Others
was	VBD	O
shortest	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
azithromycin	NN	O
.	.	O

Two	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
phenoxymethylpenicillin	NN	O
and	CC	O
two	CD	O
given	VBN	O
doxycycline	VBP	O
subsequently	RB	O
developed	VBN	O
major	JJ	O
manifestations	NNS	O
of	IN	O
Lyme	NNP	Physical
borreliosis	NN	Physical
;	:	O
these	DT	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
azithromycin	RB	O
.	.	O

Although	IN	O
azithromycin	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
erythema	NN	O
migrans	NNS	O
,	,	O
further	JJ	O
studies	NNS	O
will	MD	O
be	VB	O
needed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
dosage	NN	O
and	CC	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

Rotigotine	NNP	O
transdermal	JJ	O
patch	NN	O
enables	NNS	O
rapid	JJ	O
titration	NN	O
to	TO	O
effective	JJ	O
doses	NNS	O
in	IN	O
advanced-stage	JJ	O
idiopathic	JJ	O
Parkinson	NNP	O
disease	NN	O
:	:	O
subanalysis	NN	O
of	IN	O
a	DT	O
parallel	JJ	O
group	NN	O
,	,	O
open-label	JJ	O
,	,	O
dose-escalation	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Rotigotine	NNP	O
(	(	O
Neupro	NNP	O
)	)	O
is	VBZ	O
formulated	VBN	O
as	IN	O
a	DT	O
transdermal	JJ	O
delivery	NN	O
system	NN	O
designed	VBN	O
to	TO	O
provide	VB	O
a	DT	O
selective	JJ	O
,	,	O
non-ergot	JJ	O
D3/D2/D1	NNP	O
agonist	NN	O
to	TO	O
the	DT	O
systemic	JJ	O
blood	NN	O
flow	NN	O
over	IN	O
a	DT	O
24-hour	JJ	O
period	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
patches	NNS	O
were	VBD	O
applied	VBN	O
once	RB	O
daily	JJ	O
and	CC	O
uptitrated	JJ	O
to	TO	O
the	DT	O
individual	JJ	O
effective	JJ	O
dose	NN	O
in	IN	O
increments	NNS	O
of	IN	O
2	CD	O
mg/24	NNS	O
h	RB	O
every	DT	O
week	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
analysis	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	Others
of	IN	O
a	DT	O
more	RBR	O
rapid	JJ	O
titration	NN	O
of	IN	O
rotigotine	NN	O
by	IN	O
assessing	VBG	O
the	DT	O
tolerability	NN	O
of	IN	O
escalating	VBG	O
transdermal	JJ	O
doses	NNS	O
of	IN	O
rotigotine	NN	O
given	VBN	O
in	IN	O
2	CD	O
different	JJ	O
titration	NN	O
schemes	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
analyzed	VBD	O
the	DT	O
safety	NN	Others
of	IN	O
rotigotine	NN	O
in	IN	O
2	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
stage	NN	O
Parkinson	NNP	O
Disease	NNP	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
4	CD	O
mg/24	NN	O
h	NN	O
was	VBD	O
increased	VBN	O
every	DT	O
week	NN	O
by	IN	O
2	CD	O
mg/24	NNS	O
h	NN	O
in	IN	O
the	DT	O
slow-titration	NN	O
group	NN	O
and	CC	O
4	CD	O
mg/24	NN	O
h	NN	O
in	IN	O
the	DT	O
fast-titration	NN	O
group	NN	O
.	.	O

The	DT	O
primary	JJ	O
focus	NN	O
of	IN	O
this	DT	O
subanalysis	NN	O
was	VBD	O
the	DT	O
separate	JJ	O
tolerability	NN	Others
of	IN	Others
rotigotine	NN	Others
in	IN	O
each	DT	O
randomized	JJ	O
treatment	NN	O
arm	NN	O
,	,	O
during	IN	O
the	DT	O
dose-escalation	JJ	O
period	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
2	CD	O
titration	NN	O
schemes	NNS	O
were	VBD	O
also	RB	O
compared	VBN	O
with	IN	O
each	DT	O
other	JJ	O
.	.	O

RESULTS	VB	O
The	DT	O
dose	NN	O
of	IN	O
first	JJ	O
reported	VBD	O
nausea	JJ	Adverseeffect
and/or	NN	Adverseeffect
vomiting	NN	Adverseeffect
was	VBD	O
8	CD	O
mg/24	NN	O
h	NN	O
for	IN	O
the	DT	O
fast-titration	NN	O
group	NN	O
and	CC	O
4	CD	O
mg/	NN	O
24	CD	O
h	NN	O
for	IN	O
the	DT	O
slow-titration	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
remarkable	JJ	O
differences	NNS	O
concerning	VBG	O
the	DT	O
side-effect	JJ	Adverseeffect
profile	NN	Adverseeffect
between	IN	O
the	DT	O
2	CD	O
different	JJ	O
titration	NN	O
schemes	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
fast-titration	JJ	O
regimen	NNS	O
had	VBD	O
a	DT	O
similar	JJ	O
adverse	JJ	Adverseeffect
event	NN	Adverseeffect
profile	NN	Adverseeffect
to	TO	O
slower	JJR	O
titration	NN	O
,	,	O
and	CC	O
allowed	VBD	O
rotigotine	NN	O
to	TO	O
be	VB	O
introduced	VBN	O
quickly	RB	O
.	.	O

This	DT	O
subanalysis	NN	O
suggests	VBZ	O
that	IN	O
rotigotine	NN	O
may	MD	O
be	VB	O
uptitrated	VBN	O
more	RBR	O
rapidly	RB	O
.	.	O

[	JJ	O
Physical	NNP	O
performance	NN	O
and	CC	O
sedation	NN	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
benzodiazepine	NN	O
(	(	O
temazepam	NN	O
)	)	O
and	CC	O
of	IN	O
a	DT	O
non-benzodiazepine	JJ	O
hypnotic	NN	O
(	(	O
zolpidem	NN	O
)	)	O
]	NN	O
.	.	O

It	PRP	O
is	VBZ	O
well-known	JJ	O
that	IN	O
many	JJ	O
athletes	NNS	O
experience	VBP	O
some	DT	O
form	NN	O
of	IN	O
precompetition	NN	O
stress	NN	O
that	WDT	O
may	MD	O
result	VB	O
in	IN	O
insomnia	NN	O
during	IN	O
the	DT	O
night	NN	O
before	IN	O
their	PRP$	O
competition	NN	O
.	.	O

Yet	CC	O
,	,	O
sleep	VBP	O
withdrawal	NN	O
even	RB	O
if	IN	O
only	RB	O
partial	JJ	O
,	,	O
has	VBZ	O
a	DT	O
negative	JJ	O
influence	NN	O
on	IN	O
performance	NN	O
,	,	O
particularly	RB	O
when	WRB	O
the	DT	O
type	NN	O
of	IN	O
exercise	NN	O
requires	VBZ	O
good	JJ	O
psychomotor	NN	O
performance	NN	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
intake	NN	O
of	IN	O
a	DT	O
hypnotic	JJ	O
drug	NN	O
would	MD	O
have	VB	O
negative	JJ	O
effects	NNS	O
on	IN	O
physical	JJ	O
performance	NN	O
capacity	NN	O
.	.	O

The	DT	O
authors	NNS	O
have	VBP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
temazepam	NN	O
,	,	O
a	DT	O
medium	NN	O
half-life	JJ	O
benzodiazepine	NN	O
vs	IN	O
oral	JJ	O
zolpidem	NN	O
,	,	O
a	DT	O
short	JJ	O
half-life	JJ	O
non-benzodiazepine	JJ	O
drug	NN	O
,	,	O
vs	NN	O
placebo	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
trial	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
endurance	NN	Mental
,	,	Physical
resistance	NN	Mental
,	,	Physical
strength	NN	Mental
and	CC	Physical
coordination	NN	Physical
in	IN	O
26	CD	O
athletes	NNS	O
.	.	O

The	DT	O
results	NNS	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
differences	NNS	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
,	,	O
neither	CC	O
in	IN	O
physical	JJ	Mental
performance	NN	Mental
characteristic	JJ	Mental
nor	CC	Mental
in	IN	Mental
coordination	NN	Mental
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
as	IN	O
regards	NNS	O
the	DT	O
performance	NN	O
capacity	NN	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
risk	NN	O
for	IN	O
stressed	JJ	O
athletes	NNS	O
to	TO	O
use	VB	O
sleep	JJ	O
inducers	NNS	O
the	DT	O
night	NN	O
before	IN	O
their	PRP$	O
competition	NN	O
.	.	O

Clonidine	NNP	O
premedication	NN	O
improves	VBZ	O
metabolic	JJ	Physical
control	NN	Physical
in	IN	Physical
type	NN	Physical
2	CD	Physical
diabetic	JJ	Physical
patients	NNS	Physical
during	IN	O
ophthalmic	JJ	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
stressful	JJ	O
conditions	NNS	O
,	,	O
increasing	VBG	O
blood	NN	O
glucose	NN	O
concentrations	NNS	O
are	VBP	O
closely	RB	O
related	VBN	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
catecholamines	NNS	O
and	CC	O
cortisol	NN	O
release	NN	O
.	.	O

Clonidine	NNP	O
,	,	O
a	DT	O
centrally	RB	O
acting	VBG	O
alpha	NN	O
(	(	O
2	CD	O
)	)	O
-adrenoceptor	NN	O
agonist	NN	O
,	,	O
has	VBZ	O
neuroendocrine	JJ	O
effects	NNS	O
,	,	O
including	VBG	O
inhibition	NN	O
of	IN	O
sympathoadrenal	JJ	O
activity	NN	O
.	.	O

We	PRP	O
therefore	RB	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
clonidine	NN	O
on	IN	O
blood	NN	Physical
glucose	NN	Physical
control	NN	Physical
and	CC	O
insulin	NN	Physical
requirements	NNS	Physical
during	IN	O
ophthalmic	JJ	O
surgery	NN	O
when	WRB	O
given	VBN	O
as	IN	O
premedication	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
After	IN	O
randomization	NN	O
,	,	O
patients	NNS	O
were	VBD	O
premedicated	VBN	O
with	IN	O
clonidine	NN	O
or	CC	O
flunitrazepam	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

Patients	NNPS	O
were	VBD	O
given	VBN	O
insulin	NN	O
by	IN	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
to	TO	O
maintain	VB	O
blood	NN	O
glucose	NN	O
in	IN	O
the	DT	O
range	NN	O
5.5-11.1	JJ	O
mmol	NN	O
litre	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

Blood	NNP	Physical
glucose	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
measured	VBN	O
every	DT	O
15	CD	O
min	NN	O
during	IN	O
surgery	NN	O
,	,	O
and	CC	O
hourly	RB	O
for	IN	O
6	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

Plasma	NNP	Physical
C-peptide	JJ	Physical
and	CC	Physical
counter-regulatory	JJ	Physical
hormones	NNS	Physical
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
Glycaemia	NNP	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
clonidine	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
the	DT	O
median	JJ	Physical
amount	NN	Physical
of	IN	Physical
insulin	NN	Physical
administered	VBN	Physical
was	VBD	O
significantly	RB	O
reduced	VBN	O
:	:	O
clonidine	NN	O
group	NN	O
9.0	CD	O
(	(	O
interquartile	JJ	O
range	NN	O
5.1	CD	O
)	)	O
units	NNS	O
;	:	O
control	VB	O
18.6	CD	O
(	(	O
10.2	CD	O
)	)	O
units	NNS	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Plasma	NNP	Physical
catecholamine	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
given	VBN	O
clonidine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
cortisol	JJ	Physical
concentrations	NNS	Physical
.	.	Physical

CONCLUSION	NNP	O
Premedication	NNP	O
of	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
clonidine	JJ	O
90	CD	O
min	NN	O
before	IN	O
surgery	NN	O
improves	VBZ	O
blood	NN	Physical
glucose	VB	Physical
control	NN	Physical
and	CC	O
decreases	VBZ	O
insulin	NN	O
requirements	NNS	O
during	IN	O
ophthalmic	JJ	O
surgery	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
succinylcholine	NN	O
with	IN	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
using	VBG	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
monitoring	VBG	O
neuromuscular	JJ	Physical
block	NN	Physical
at	IN	O
the	DT	O
laryngeal	NN	O
muscles	NNS	O
by	IN	O
surface	NN	O
laryngeal	NN	O
electromyography	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
onset	NN	Physical
of	IN	Physical
neuromuscular	JJ	Physical
block	NN	Physical
with	IN	O
succinylcholine	NN	O
(	(	O
1	CD	O
mg	RB	O
kg-1	NN	O
)	)	O
and	CC	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	O
(	(	O
0.6	CD	O
and	CC	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
)	)	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
muscle	NN	O
using	VBG	O
electromyography	NN	O
(	(	O
EMG	NNP	O
)	)	O
and	CC	O
acceleromyography	NN	O
(	(	O
AMG	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
adductor	NN	O
laryngeal	NN	O
muscles	NNS	O
with	IN	O
a	DT	O
new	JJ	O
electromyographic	JJ	O
method	NN	O
using	VBG	O
a	DT	O
disposable	JJ	O
surface	NN	O
electrode	NN	O
attached	VBN	O
to	TO	O
the	DT	O
cuff	NN	O
of	IN	O
a	DT	O
tracheal	JJ	O
tube	NN	O
.	.	O

At	IN	O
the	DT	O
larynx	NN	O
,	,	O
the	DT	O
mean	NN	Physical
(	(	Physical
+/-	JJ	Physical
SD	NNP	Physical
)	)	Physical
time	NN	Physical
to	TO	Physical
90	CD	Physical
%	NN	Physical
block	NN	Physical
and	CC	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	Others
(	(	O
38	CD	O
+/-	JJ	O
15	CD	O
and	CC	O
47	CD	O
+/-	JJ	O
19	CD	O
s	NN	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
92	CD	O
+/-	JJ	O
42	CD	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
and	CC	O
rocuronium	$	O
0.9	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
52	CD	O
+/-	JJ	O
31	CD	O
and	CC	O
64	CD	O
+/-	JJ	O
30	CD	O
s	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
with	IN	O
comparable	JJ	O
degrees	NNS	O
of	IN	O
neuromuscular	JJ	Physical
block	NN	Physical
,	,	O
the	DT	O
onset	JJ	Others
time	NN	Others
of	IN	Others
succinylcholine	NN	Others
at	IN	Others
the	DT	Others
adductor	NN	Others
pollicis	NN	Others
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	O
0.6	CD	O
mg	NN	O
kg-1	NN	O
and	CC	O
0.9	CD	O
mg	NNS	O
kg-1	JJ	O
(	(	O
EMG	NNP	O
,	,	O
80	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
145	CD	O
+/-	JJ	O
48	CD	O
s	NN	O
and	CC	O
99	CD	O
+/-	JJ	O
31	CD	O
s	NN	O
;	:	O
AMG	NNP	O
,	,	O
90	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
124	CD	O
+/-	JJ	O
53	CD	O
s	NN	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
.	.	O

Clinical	JJ	Others
duration	NN	Others
at	IN	Others
the	DT	Others
adductor	NN	Others
pollicis	NN	Others
(	(	Others
AMG	NNP	Others
)	)	Others
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
for	IN	O
both	DT	O
rocuronium	NN	O
groups	NNS	O
than	IN	O
for	IN	O
succinylcholine	NN	O
(	(	O
T4	NNP	O
:	:	O
T1	NNP	O
=	VBZ	O
0.7	CD	O
,	,	O
54	CD	O
+/-	JJ	O
18	CD	O
and	CC	O
77	CD	O
+/-	JJ	O
21	CD	O
vs	JJ	O
8	CD	O
+/-	JJ	O
6	CD	O
min	NN	O
)	)	O
.	.	O

The	DT	O
surface	NN	O
laryngeal	JJ	O
electrode	NN	O
proved	VBD	O
non-invasive	JJ	O
,	,	O
easy	JJ	O
to	TO	O
use	VB	O
and	CC	O
reliable	VB	O
in	IN	O
measuring	VBG	O
onset	NN	Physical
of	IN	Physical
the	DT	Physical
neuromuscular	JJ	Physical
block	NN	Physical
at	IN	O
the	DT	O
larynx	NN	O
.	.	O

In-season	JJ	O
effect	NN	O
of	IN	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
programs	NNS	O
on	IN	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
in-season	JJ	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
protocols	NNS	O
on	IN	O
vertical	JJ	O
countermovement	NN	O
jump	NN	O
height	NN	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
arms	NNS	O
)	)	O
,	,	O
sprint	NN	O
(	(	O
Sprint-15m	NNP	O
)	)	O
speed	NN	O
,	,	O
and	CC	O
agility	NN	O
(	(	O
Agility-15m	NNP	O
)	)	O
speed	NN	O
in	IN	O
male	JJ	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

Twenty	NNP	O
highly	RB	O
trained	VBD	O
soccer	NN	O
players	NNS	O
(	(	O
age	NN	O
18.3	CD	O
+/-	JJ	O
0.6	CD	O
years	NNS	O
,	,	O
height	VBD	O
177	CD	O
+/-	JJ	O
4	CD	O
cm	NN	O
,	,	O
body	NN	O
mass	VBD	O
71.4	CD	O
+/-	JJ	O
6.9	CD	O
kg	NN	O
,	,	O
sum	NN	O
skinfolds	NNS	O
48.1	CD	O
+/-	JJ	O
11.4	CD	O
mm	NN	O
)	)	O
,	,	O
members	NNS	O
of	IN	O
a	DT	O
professional	JJ	O
soccer	NN	O
academy	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
CONTRAST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
SPRINT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
group	NN	O
.	.	O

The	DT	O
training	NN	O
intervention	NN	O
consisted	VBD	O
of	IN	O
6	CD	O
supervised	JJ	O
training	NN	O
sessions	NNS	O
over	IN	O
7	CD	O
weeks	NNS	O
,	,	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
the	DT	O
players	NNS	O
'	POS	O
speed	NN	Mental
and	CC	Mental
power	NN	Mental
.	.	Physical

CONTRAST	NNP	O
protocol	NN	O
consisted	VBD	O
of	IN	O
alternating	VBG	O
heavy-light	JJ	O
resistance	NN	O
(	(	O
15-50	CD	O
%	NN	O
body	NN	O
mass	NN	O
)	)	O
with	IN	O
soccer-specific	JJ	O
drills	NNS	O
(	(	O
small-sided	JJ	O
games	NNS	O
or	CC	O
technical	JJ	O
skills	NNS	O
)	)	O
.	.	O

SPRINT	NNP	O
training	NN	O
protocol	NN	O
used	VBN	O
line	NN	O
30-m	JJ	O
sprints	NNS	O
(	(	O
2-4	JJ	O
sets	NNS	O
of	IN	O
4	CD	O
x	JJ	O
30	CD	O
m	NN	O
with	IN	O
180	CD	O
and	CC	O
90	CD	O
seconds	NNS	O
of	IN	O
recovery	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

At	IN	O
baseline	JJ	O
no	DT	O
difference	NN	O
between	IN	O
physical	JJ	Physical
test	NN	Physical
performance	NN	Physical
was	VBD	O
evident	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
time	NN	O
x	VBZ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
vertical	JJ	Others
jump	NN	Others
and	CC	Others
Agility-15m	JJ	Others
variables	NNS	Others
(	(	Physical
p	JJ	Physical
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
time	NN	O
x	JJ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
Sprint-15m	JJ	O
performance	NN	O
with	IN	O
the	DT	O
CONTRAST	NNP	O
group	NN	O
showing	VBG	O
significantly	RB	O
better	JJR	O
scores	NNS	O
than	IN	O
the	DT	O
SPRINT	NNP	O
group	NN	O
(	(	O
7.23	CD	O
+/-	JJ	O
0.18	CD	O
vs.	FW	O
7.09	CD	O
+/-	JJ	O
0.20	CD	O
m.s	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
these	DT	O
findings	NNS	O
CONTRAST	NNP	O
training	NN	O
should	MD	O
be	VB	O
preferred	VBN	O
to	TO	O
line	NN	O
sprint	NN	O
training	NN	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
in	IN	O
young	JJ	O
elite	JJ	O
soccer	NN	O
players	NNS	O
when	WRB	O
the	DT	O
aim	NN	O
is	VBZ	O
to	TO	O
improve	VB	O
soccer-specific	JJ	Mental
sprint	NN	Mental
performance	NN	Mental
(	(	Physical
15	CD	Physical
m	NN	Physical
)	)	Physical
during	IN	O
the	DT	O
competitive	JJ	O
season	NN	O
.	.	O

Topiramate	NNP	O
improves	VBZ	O
health-related	JJ	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
when	WRB	O
used	VBN	O
to	TO	O
prevent	VB	O
migraine	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
changes	NNS	O
in	IN	O
health-related	JJ	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
(	(	Physical
HRQoL	NNP	Physical
)	)	Physical
measures	VBZ	Physical
among	IN	O
patients	NNS	O
receiving	VBG	O
topiramate	NN	O
(	(	O
TPM	NNP	O
)	)	O
100	CD	O
mg/d	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
for	IN	O
migraine	JJ	O
prevention	NN	O
in	IN	O
three	CD	O
randomized	NNS	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
26-week	JJ	O
trials	NNS	O
with	IN	O
similar	JJ	O
protocols	NNS	O
and	CC	O
study	NN	O
populations	NNS	O
.	.	O

BACKGROUND	NNP	O
Migraine	NNP	O
substantially	RB	O
impairs	VBZ	O
HRQoL	NNP	Physical
and	CC	O
work	NN	Others
productivity	NN	Others
before	IN	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
attacks	NNS	O
.	.	O

Approximately	RB	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
migraine	NN	O
could	MD	O
be	VB	O
recommended	VBN	O
for	IN	O
preventive	JJ	O
therapies	NNS	O
,	,	O
yet	RB	O
only	RB	O
3	CD	O
%	NN	O
to	TO	O
5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receive	VBP	O
them	PRP	O
.	.	O

TPM	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	Others
and	CC	Others
generally	RB	Others
well-tolerated	JJ	Others
migraine	NN	O
prophylactic	NN	O
(	(	O
preventive	JJ	O
)	)	O
therapy	NN	O
for	IN	O
adults	NNS	O
,	,	O
as	IN	O
demonstrated	VBN	O
in	IN	O
several	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
studies	NNS	O
of	IN	O
TPM	NNP	O
in	IN	O
migraine	JJ	O
prevention	NN	O
are	VBP	O
paresthesia	NN	Adverseeffect
,	,	Adverseeffect
fatigue	NN	Adverseeffect
,	,	Adverseeffect
anorexia	NN	Adverseeffect
,	,	Adverseeffect
nausea	NN	Adverseeffect
,	,	Adverseeffect
taste	NN	Adverseeffect
alteration	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
diarrhea	NN	Adverseeffect
.	.	O

DESIGN	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
Migraine-Specific	NNP	Physical
Questionnaire	NNP	Physical
(	(	Physical
MSQ	NNP	Physical
,	,	O
version	NN	O
2.1	CD	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
on	IN	O
the	DT	O
functionality	NN	O
and	CC	O
HRQoL	NNP	O
of	IN	O
randomized	VBN	O
intent-to-treat	NN	O
(	(	O
ITT	NNP	O
)	)	O
and	CC	O
study-completer	JJ	O
populations	NNS	O
pooled	VBD	O
from	IN	O
three	CD	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

MSQ	NNP	Physical
scores	NNS	Physical
(	(	O
0	CD	O
to	TO	O
100	CD	O
,	,	O
higher	JJR	O
score	NN	O
indicates	VBZ	O
better	RBR	O
functioning	VBG	O
)	)	O
were	VBD	O
assessed	VBN	O
for	IN	O
the	DT	O
following	JJ	O
three	CD	O
domains	NNS	O
:	:	O
role	NN	O
restriction	NN	O
(	(	O
examines	VBZ	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
performance	NN	O
of	IN	O
daily	JJ	O
activities	NNS	O
is	VBZ	O
limited	VBN	O
by	IN	O
migraine	NN	O
)	)	O
,	,	O
role	NN	O
prevention	NN	O
(	(	O
examines	VBZ	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
performance	NN	O
of	IN	O
daily	JJ	O
activities	NNS	O
is	VBZ	O
interrupted	VBN	O
by	IN	O
migraine	NN	O
)	)	O
,	,	O
and	CC	O
emotional	JJ	Mental
function	NN	Mental
(	(	O
examines	JJ	O
feelings	NNS	O
of	IN	O
frustration	NN	O
and	CC	O
helplessness	NN	O
due	JJ	O
to	TO	O
migraine	VB	O
)	)	O
.	.	O

Between-group	JJ	O
differences	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
mean	JJ	Physical
MSQ	NNP	Physical
domain	NN	Physical
scores	NNS	Physical
for	IN	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
compared	VBN	O
using	VBG	O
a	DT	O
mixed-effects	NNS	O
model	NN	O
with	IN	O
piecewise	NN	O
linear	JJ	O
regression	NN	O
.	.	O

Effect	JJ	O
sizes	NNS	O
were	VBD	O
calculated	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
magnitude	NN	O
of	IN	O
change	NN	O
in	IN	O
HRQoL	NNP	O
that	WDT	O
can	MD	O
be	VB	O
associated	VBN	O
with	IN	O
TPM	NNP	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
significantly	RB	O
improved	VBN	O
all	DT	Physical
three	CD	Physical
MSQ	NNP	Physical
domains	NNS	Physical
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
both	DT	O
the	DT	O
ITT	NNP	O
(	(	O
TPM	NNP	O
,	,	O
n	JJ	O
=	VBP	O
372	CD	O
;	:	O
placebo	NN	O
,	,	O
n	JJ	O
=	NNP	O
362	CD	O
)	)	O
and	CC	O
study-completer	NN	O
(	(	O
TPM	NNP	O
,	,	O
n	JJ	O
=	VBP	O
220	CD	O
;	:	O
placebo	NN	O
,	,	O
n	JJ	O
=	NNP	O
216	CD	O
)	)	O
populations	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
for	IN	O
all	DT	O
three	CD	O
domains	NNS	O
,	,	O
both	DT	O
populations	NNS	O
)	)	O
.	.	O

Effect	JJ	O
sizes	NN	O
for	IN	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
varied	VBD	O
from	IN	O
0.40	CD	O
to	TO	O
0.78	CD	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
changes	NNS	O
in	IN	O
MSQ	NNP	Physical
scores	NNS	Physical
for	IN	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
were	VBD	O
moderate	JJ	O
and	CC	O
may	MD	O
be	VB	O
clinically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
TPM	NNP	O
100	CD	O
mg/d	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
migraine	NN	Physical
headache	NN	Physical
in	IN	O
adults	NNS	O
.	.	O

As	IN	O
the	DT	O
MSQ	NNP	O
results	NNS	O
from	IN	O
the	DT	O
three	CD	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trials	NNS	O
indicate	VBP	O
,	,	O
HRQoL	NNP	Physical
is	VBZ	O
significantly	RB	O
improved	VBN	O
for	IN	O
up	RB	O
to	TO	O
6	CD	O
months	NNS	O
following	VBG	O
initiation	NN	O
of	IN	O
treatment	NN	O
.	.	O

Effect	NN	O
of	IN	O
chelation	NN	O
therapy	NN	O
on	IN	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
and	CC	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
previous	JJ	O
study	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	NN	O
burdens	VBZ	O
showed	VBD	O
that	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
slows	VBZ	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
during	IN	O
a	DT	O
12-month	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
longer	JJR	O
course	NN	O
of	IN	O
therapy	NN	O
on	IN	O
kidney	NN	O
function	NN	O
decrease	NN	O
over	IN	O
a	DT	O
longer	JJR	O
follow-up	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
12-month	JJ	O
run-in	JJ	O
phase	NN	O
,	,	O
then	RB	O
a	DT	O
randomized	VBN	O
single-blind	NN	O
study	NN	O
with	IN	O
a	DT	O
27-month	JJ	O
intervention	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
University	NNP	O
medical	JJ	O
center	NN	O
;	:	O
50	CD	O
patients	NNS	O
(	(	O
serum	JJ	O
creatinine	NN	O
,	,	O
1.5-3.9	JJ	O
mg/dL	NN	O
)	)	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burden	NN	O
(	(	O
?80-	JJ	O
<	NN	O
600	CD	O
?g	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
weekly	JJ	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
body	NN	O
lead	JJ	O
burden	NN	O
to	TO	O
<	VB	O
60	CD	O
?g	NNS	O
and	CC	O
then	RB	O
as	IN	O
needed	VBN	O
for	IN	O
24	CD	O
months	NNS	O
to	TO	O
maintain	VB	O
this	DT	O
level	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
and	CC	O
then	RB	O
weekly	VB	O
for	IN	O
5	CD	O
weeks	NNS	O
at	IN	O
6-month	JJ	O
intervals	NNS	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

OUTCOMES	IN	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
change	NN	O
in	IN	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
eGFR	NN	O
)	)	O
over	IN	O
time	NN	O
.	.	O

A	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
baseline	JJ	O
serum	NN	O
creatinine	NN	O
level	NN	O
or	CC	O
the	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
.	.	O

MEASUREMENTS	NNP	O
Body	NNP	O
lead	JJ	O
burdens	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
EDTA	NNP	O
mobilization	NN	O
tests	NNS	O
and	CC	O
eGFR	NN	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
equation	NN	O
for	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
eGFRs	NN	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
of	IN	O
chelation	NN	O
therapy	NN	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
eGFR	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
+1.0	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
differed	VBN	O
significantly	RB	O
from	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-1.5	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
subsequent	JJ	O
24-month	JJ	O
intervention	NN	O
,	,	O
the	DT	O
yearly	JJ	O
rate	NN	O
of	IN	O
decrease	NN	O
in	IN	O
eGFR	NN	O
(	(	O
5.6	CD	O
?	.	O
5.0	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
that	DT	O
(	(	O
9.2	CD	O
?	.	O
3.6	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

17	CD	O
(	(	O
68	CD	O
%	NN	O
)	)	O
control-group	NN	O
patients	NNS	O
and	CC	O
9	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
treatment-group	NN	O
patients	NNS	O
achieved	VBD	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
.	.	O

LIMITATIONS	NNP	O
Small	NNP	O
sample	NN	O
size	NN	O
,	,	O
not	RB	O
double	JJ	O
blind	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
27-month	JJ	O
course	NN	O
of	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
retards	VBZ	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

[	VB	O
A	DT	O
randomized	JJ	O
comparative	NN	O
study	NN	O
of	IN	O
surgical	JJ	O
adjuvant	NN	O
chemotherapy	NN	O
using	VBG	O
5-fluorouracil	JJ	O
and	CC	O
dl-leucovorin	JJ	O
with	IN	O
CDDP	NNP	O
5-FU	JJ	O
and	CC	O
dl-leucovorin	JJ	O
for	IN	O
colorectal	JJ	O
cancer	NN	O
]	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
comparative	NN	O
study	NN	O
of	IN	O
surgical	JJ	O
adjuvant	NN	O
chemotherapy	NN	O
using	VBG	O
dl-leucovorin	JJ	O
(	(	O
dl-LV	JJ	O
)	)	O
and	CC	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
(	(	O
FL-therapy	NNP	O
)	)	O
with	IN	O
CDDP	NNP	O
,	,	O
5-FU	JJ	O
,	,	O
and	CC	O
dl-LV	JJ	O
(	(	O
PFL-therapy	NNP	O
)	)	O
was	VBD	O
conducted	VBN	O
.	.	O

The	DT	O
following	VBG	O
were	VBD	O
the	DT	O
administration	NN	O
schedules	NNS	O
:	:	O
Arm	VB	O
A	DT	O
was	VBD	O
13	CD	O
mg/m2	NN	O
of	IN	O
CDDP	NNP	O
,	,	O
300	CD	O
mg/m2	NN	O
of	IN	O
5-FU	JJ	O
,	,	O
and	CC	O
30	CD	O
mg/body	NN	O
of	IN	O
dl-LV	NN	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
and	CC	O
arm	NN	O
B	NNP	O
was	VBD	O
300	CD	O
mg/m2	NN	O
of	IN	O
5-FU	JJ	O
and	CC	O
30	CD	O
mg/body	NN	O
of	IN	O
dl-LV	NN	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
followed	VBN	O
by	IN	O
biweekly	JJ	O
administration	NN	O
of	IN	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
dl-LV	JJ	O
and	CC	O
5-FU	JJ	O
in	IN	O
outpatients	NNS	O
.	.	O

Arm	VB	O
A	DT	O
was	VBD	O
started	VBN	O
at	IN	O
the	DT	O
26th	CD	O
postoperative	JJ	O
day	NN	O
and	CC	O
arm	NN	O
B	NNP	O
at	IN	O
the	DT	O
21st	CD	O
day	NN	O
on	IN	O
average	NN	O
.	.	O

Some	DT	O
26	CD	O
cases	NNS	O
composed	VBN	O
of	IN	O
11	CD	O
cases	NNS	O
of	IN	O
arm	NN	O
A	NNP	O
and	CC	O
15	CD	O
cases	NNS	O
of	IN	O
arm	NN	O
B	NNP	O
completed	VBD	O
the	DT	O
administration	NN	O
schedules	NNS	O
.	.	O

Only	RB	O
one	CD	O
case	NN	O
in	IN	O
arm	NN	O
A	NN	O
was	VBD	O
complicated	VBN	O
by	IN	O
local	JJ	Physical
recurrence	NN	Physical
around	IN	O
35	CD	O
months	NNS	O
after	IN	O
operation	NN	O
.	.	O

Major	JJ	O
toxicities	NNS	Physical
were	VBD	O
anorexia	JJ	Physical
and	CC	Physical
neutropenia	NN	Physical
.	.	Physical

Both	CC	O
toxicities	NNS	Physical
were	VBD	O
seen	VBN	O
more	RBR	O
in	IN	O
arm	NN	O
A	NN	O
than	IN	O
in	IN	O
arm	NN	O
B	NNP	O
,	,	O
showing	VBG	O
complete	JJ	O
recovery	NN	O
in	IN	O
all	DT	O
cases	NNS	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
PFL-therapy	NNP	O
and	CC	O
FL-therapy	NNP	O
seem	VBP	O
to	TO	O
be	VB	O
possible	JJ	O
and	CC	O
promising	JJ	O
surgical	JJ	O
adjuvant	NN	O
therapies	NNS	O
for	IN	O
advanced	JJ	Physical
colorectal	JJ	Physical
carcinoma	NN	Physical
.	.	Physical

The	DT	O
effects	NNS	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
on	IN	O
academic	JJ	O
engagement	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
participation	NN	O
in	IN	O
aerobic	JJ	O
exercise	NN	O
before	IN	O
classroom	NN	O
activities	NNS	O
improves	VBZ	O
academic	JJ	O
engagement	NN	O
and	CC	O
reduces	NNS	O
stereotypic	VBP	O
behaviors	NNS	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
employed	VBD	O
a	DT	O
within-subjects	NNS	O
crossover	NN	O
design	NN	O
,	,	O
using	VBG	O
a	DT	O
treatment	NN	O
condition	NN	O
(	(	O
aerobic	JJ	O
exercise	NN	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
condition	NN	O
,	,	O
across	IN	O
4	CD	O
classrooms	NNS	O
.	.	O

The	DT	O
treatment	NN	O
condition	NN	O
included	VBD	O
15	CD	O
minutes	NNS	O
of	IN	O
running/jogging	VBG	O
followed	VBN	O
by	IN	O
a	DT	O
classroom	NN	O
task	NN	O
.	.	O

The	DT	O
control	NN	O
condition	NN	O
included	VBD	O
a	DT	O
classroom	NN	O
task	NN	O
not	RB	O
preceded	VBN	O
by	IN	O
exercise	NN	O
.	.	O

The	DT	O
number	NN	Mental
of	IN	Mental
stereotypic	JJ	Mental
behaviors	NNS	Mental
,	,	Mental
percentage	NN	Mental
of	IN	Mental
on-task	JJ	Mental
behavior	NN	Mental
,	,	Mental
and	CC	Mental
correct/incorrect	JJ	Mental
responses	NNS	Mental
were	VBD	O
measured	VBN	O
.	.	O

The	DT	O
Wilcoxon	NNP	Mental
signed	VBD	Mental
rank	JJ	Mental
test	NN	Mental
was	VBD	Mental
used	VBN	Mental
to	TO	Mental
compare	VB	Mental
differences	NNS	Mental
between	IN	Mental
conditions	NNS	Mental
.	.	Mental

RESULTS	NNP	O
Statistically	NNP	O
significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
correct	JJ	O
responding	VBG	O
following	VBG	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
on-task	JJ	Mental
behavior	NN	Mental
or	CC	O
stereotypic	NN	Mental
behaviors	NNS	Mental
.	.	O

CONCLUSIONS	NNP	O
Consistent	NNP	O
with	IN	O
findings	NNS	O
in	IN	O
older	JJR	O
children	NNS	O
,	,	O
these	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
aerobic	JJ	O
exercise	NN	O
prior	RB	O
to	TO	O
classroom	VB	O
activities	NNS	O
may	MD	O
improve	VB	O
academic	JJ	O
responding	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
magnesium	NN	O
added	VBN	O
to	TO	O
levobupivacaine	VB	O
for	IN	O
femoral	JJ	O
nerve	NN	O
block	NN	O
on	IN	O
postoperative	JJ	O
analgesia	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
ACL	NNP	O
reconstruction	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
randomised	VBD	O
double-blind	NN	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
magnesium	NN	O
added	VBN	O
to	TO	O
local	JJ	O
anaesthetics	NNS	O
on	IN	O
postoperative	JJ	O
VAS	NNP	O
scores	NNS	O
,	,	O
total	JJ	O
opioid	JJ	O
consumption	NN	O
,	,	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
,	,	O
patient	JJ	O
satisfaction	NN	O
and	CC	O
rescue	NN	O
analgesic	JJ	O
requirements	NNS	O
in	IN	O
arthroscopic	JJ	O
ACL	NNP	O
reconstruction	NN	O
surgery	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
107	CD	O
American	JJ	O
Society	NNP	O
of	IN	O
Anaesthesiologists	NNP	O
physical	JJ	O
status	NN	O
grade	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
between	IN	O
18	CD	O
and	CC	O
65	CD	O
years	NNS	O
of	IN	O
age	NN	O
who	WP	O
were	VBD	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
elective	JJ	O
anterior	JJ	O
crucial	JJ	O
ligament	NN	O
(	(	O
ACL	NNP	O
)	)	O
reconstruction	NN	O
with	IN	O
hamstring	VBG	O
autografts	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
Groups	NNP	O
L	NNP	O
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
and	CC	O
LM	NNP	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
using	VBG	O
the	DT	O
closed-envelope	NN	O
method	NN	O
.	.	O

Group	NNP	O
LM	NNP	O
was	VBD	O
administered	VBN	O
19	CD	O
ml	NN	O
of	IN	O
0.25	CD	O
%	NN	O
levobupivacaine	NN	O
and	CC	O
1	CD	O
ml	NN	O
of	IN	O
15	CD	O
%	NN	O
magnesium	NN	O
sulphate	NN	O
,	,	O
while	IN	O
Group	NNP	O
L	NNP	O
was	VBD	O
administered	VBN	O
20	CD	O
ml	NN	O
of	IN	O
0.25	CD	O
%	NN	O
levobupivacaine	NN	O
for	IN	O
femoral	JJ	O
blockade	NN	O
.	.	O

General	NNP	O
anaesthesia	NN	O
was	VBD	O
administered	VBN	O
using	VBG	O
laryngeal	JJ	O
airway	RB	O
masks	NNS	O
following	VBG	O
neural	JJ	O
blockade	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
heart	NN	Physical
rate	NN	Physical
and	CC	Physical
mean	VB	Physical
arterial	JJ	Physical
pressure	NN	Physical
,	,	O
oxygen	NN	Physical
saturation	NN	Physical
,	,	O
visual	JJ	Physical
analogue	NN	Physical
score	NN	Physical
(	(	Physical
VAS	NNP	Physical
)	)	Physical
,	,	Physical
verbal	JJ	Physical
rating	NN	Physical
scale	NN	Physical
(	(	Physical
VRS	NNP	Physical
)	)	Physical
,	,	O
rescue	NN	Others
analgesic	JJ	Others
requirements	NNS	Others
,	,	O
total	JJ	Others
opioid	JJ	Others
consumption	NN	Others
,	,	O
side	NN	O
effects	NNS	O
and	CC	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
at	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
4th	CD	O
,	,	O
6th	CD	O
,	,	O
12th	CD	O
and	CC	O
24th	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
demographic	JJ	Physical
data	NNS	Physical
,	,	Physical
mean	JJ	Physical
arterial	JJ	Physical
pressure	NN	Physical
,	,	Physical
heart	NN	Physical
rate	NN	Physical
or	CC	Physical
oxygen	NN	Physical
saturation	NN	Physical
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
area	NN	Physical
under	IN	Physical
the	DT	Physical
curve	NN	Physical
VAS	NNP	Physical
and	CC	Physical
VRS	NNP	Physical
scores	NNS	Physical
were	VBD	O
lower	JJR	O
at	IN	O
4	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
h	NN	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.001	CD	O
,	,	O
p	NN	O
=	VBD	O
0.016	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
rescue	NN	Physical
analgesic	JJ	Physical
requirement	NN	Physical
and	CC	Physical
the	DT	Physical
total	JJ	Physical
opioid	JJ	Physical
consumption	NN	Physical
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.015	CD	O
,	,	O
p	NN	O
=	VBD	O
0.019	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
time	NN	Others
to	TO	Others
first	JJ	Others
mobilisation	NN	Others
and	CC	O
the	DT	O
Likert	NNP	O
score	NN	O
(	(	O
completely	RB	O
comfortable	JJ	O
;	:	O
quite	RB	O
comfortable	JJ	O
;	:	O
slight	JJ	O
discomfort	NN	O
;	:	O
painful	JJ	O
;	:	O
very	RB	O
painful	JJ	O
)	)	O
were	VBD	O
higher	JJR	O
,	,	O
and	CC	O
the	DT	O
block	NN	Others
onset	VBD	Others
time	NN	Others
was	VBD	O
lower	JJR	O
in	IN	O
Group	NNP	O
LM	NNP	O
(	(	O
p	JJ	O
=	NN	O
0.014	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.012	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
magnesium	NN	O
to	TO	O
levobupivacaine	VB	O
prolongs	NNS	O
the	DT	O
sensory	NN	O
and	CC	O
motor	NN	O
block	NN	O
duration	NN	O
without	IN	O
increasing	VBG	O
side	NN	O
effects	NNS	O
,	,	O
enhances	VBZ	O
the	DT	O
quality	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
and	CC	O
increases	VBZ	O
patient	JJ	O
satisfaction	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
magnesium	NN	O
delays	VBZ	O
the	DT	O
time	NN	O
to	TO	O
first	JJ	O
mobilisation	NN	O
and	CC	O
decreases	VBZ	O
rescue	NN	O
analgesic	JJ	O
requirements	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
fish	JJ	O
oil	NN	O
supplementation	NN	O
on	IN	O
markers	NNS	O
of	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
fish	JJ	O
oil	NN	O
affects	NNS	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
during	IN	O
the	DT	O
adolescent	JJ	O
growth	NN	O
spurt	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
78	CD	O
boys	NNS	O
age	NN	O
13-15	CD	O
years	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
body	NN	O
fat	JJ	O
percentage	NN	O
of	IN	O
30	CD	O
%	NN	O
+/-9	JJ	O
%	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
consume	VB	O
fish	JJ	O
oil	NN	O
(	(	O
providing	VBG	O
1.5	CD	O
g	NN	O
of	IN	O
n-3	JJ	O
long-chain	NN	O
polyunsaturated	VBD	O
fatty	JJ	O
acid/day	NN	O
)	)	O
or	CC	O
vegetable	JJ	O
oil	NN	O
(	(	O
control	NN	O
)	)	O
for	IN	O
16	CD	O
weeks	NNS	O
.	.	O

The	DT	O
oils	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
bread	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
intervention	NN	O
,	,	O
the	DT	O
red	JJ	Physical
blood	NN	Physical
cell	NN	Physical
(	(	Physical
RBC	NNP	Physical
)	)	Physical
content	NN	O
of	IN	O
eicosapentaenoic	JJ	Physical
acid	NN	Physical
(	(	Physical
EPA	NNP	Physical
)	)	Physical
and	CC	Physical
docosahexaenoic	JJ	Physical
acid	NN	Physical
(	(	Physical
DHA	NNP	Physical
)	)	Physical
were	VBD	O
1.2	CD	O
%	NN	O
+/-0.5	JJ	O
%	NN	O
and	CC	O
6.7	CD	O
%	NN	O
+/-1.6	JJ	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
those	DT	O
receiving	VBG	O
fish	JJ	O
oil	NN	O
(	(	O
FO	NNP	O
group	NN	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
0.6	CD	O
%	NN	O
+/-0.3	JJ	O
%	NN	O
and	CC	O
4.1	CD	O
%	NN	O
+/-0.9	JJ	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Systolic	NNP	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	Physical
SBP	NNP	Physical
)	)	Physical
was	VBD	O
3.8+/-1.4	JJ	O
mm	NN	O
Hg	NNP	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.006	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
was	VBD	O
2.6+/-1.1	JJ	O
mm	NN	O
Hg	NNP	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
in	IN	O
the	DT	O
FO	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Plasma	NNP	Physical
triacylglycerol	NN	Physical
(	(	Physical
TAG	NNP	Physical
)	)	Physical
concentration	NN	Physical
and	CC	O
insulin	JJ	Physical
sensitivity	NN	Physical
were	VBD	O
unaffected	VBN	O
by	IN	O
either	DT	O
of	IN	O
the	DT	O
treatments	NNS	O
.	.	O

Plasma	NNP	Physical
high-density	NN	Physical
lipoprotein	NN	Physical
(	(	Physical
HDL	NNP	Physical
)	)	Physical
and	CC	Physical
non-HDL	JJ	Physical
cholesterol	NN	Physical
were	VBD	O
increased	VBN	O
by	IN	O
5	CD	O
%	NN	O
and	CC	O
7	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
FO	NNP	O
group	NN	O
,	,	O
and	CC	O
by	IN	O
2	CD	O
%	NN	O
and	CC	O
0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01-.02	NN	O
)	)	O
.	.	O

The	DT	O
changes	NNS	Physical
in	IN	Physical
RBC	NNP	Physical
EPA	NNP	Physical
content	NN	Physical
were	VBD	O
inversely	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
changes	NNS	Physical
in	IN	Physical
SBP	NNP	Physical
and	CC	Physical
DBP	NNP	Physical
and	CC	O
directly	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
increases	NNS	O
in	IN	O
HDL	NNP	Physical
cholesterol	NN	Physical
and	CC	Physical
non-HDL	JJ	Physical
cholesterol	NN	Physical
concentrations	NNS	Physical
.	.	Physical

No	DT	O
association	NN	O
was	VBD	O
seen	VBN	O
between	IN	O
RBC	NNP	Physical
EPA	NNP	Physical
and	CC	Physical
plasma	VB	Physical
TAG	NNP	Physical
concentration	NN	Physical
or	CC	Physical
insulin	JJ	Physical
sensitivity	NN	Physical
.	.	Physical

CONCLUSION	NNP	O
Fish	NNP	O
oil	NN	O
improves	VBZ	O
BP	NNP	Physical
in	IN	O
normotensive	JJ	O
and	CC	O
normolipidemic	JJ	O
slightly	RB	O
overweight	JJ	O
adolescent	NN	O
boys	NNS	O
.	.	O

Pre-exposure	JJ	O
studies	NNS	O
with	IN	O
purified	JJ	O
chick	JJ	O
embryo	NN	O
cell	NN	O
culture	NN	O
rabies	VBZ	O
vaccine	NN	O
and	CC	O
human	JJ	O
diploid	NN	O
cell	NN	O
vaccine	NN	O
:	:	O
serological	JJ	O
and	CC	O
clinical	JJ	O
responses	NNS	O
in	IN	O
man	NN	O
.	.	O

Clinical	JJ	O
reactions	NNS	O
and	CC	O
neutralizing	VBG	O
antibody	NN	O
responses	NNS	O
to	TO	O
six	CD	O
pre-exposure	NN	O
regimens	NNS	O
of	IN	O
purified	JJ	O
chick	JJ	O
embryo	NN	O
cell	NN	O
culture	NN	O
rabies	VBZ	O
vaccine	NN	O
(	(	O
PCECV	NNP	O
)	)	O
and	CC	O
human	JJ	O
diploid	NN	O
cell	NN	O
strain	NN	O
rabies	NNS	O
vaccine	VBP	O
(	(	O
HDCSV	NNP	O
)	)	O
were	VBD	O
studied	VBN	O
in	IN	O
177	CD	O
volunteers	NNS	O
.	.	O

Antibody	NN	O
kinetics	NNS	O
,	,	O
height	NN	O
of	IN	O
the	DT	O
response	NN	Physical
and	CC	O
persistence	NN	Physical
of	IN	Physical
antibody	NN	Physical
over	IN	Physical
two	CD	Physical
years	NNS	Physical
were	VBD	O
virtually	RB	O
identical	JJ	O
after	IN	O
PCECV	NNP	O
and	CC	O
HDCSV	NNP	O
.	.	O

An	DT	O
antibody	NN	Mental
response	NN	Mental
was	VBD	O
detected	VBN	O
in	IN	O
all	DT	O
subjects	NNS	O
on	IN	O
day	NN	O
14	CD	O
when	WRB	O
the	DT	O
highest	JJS	O
titres	NNS	O
were	VBD	O
found	VBN	O
after	IN	O
two	CD	O
intramuscular	JJ	O
(	(	O
i.m	JJ	O
.	.	O

)	)	O
1.0	CD	O
ml	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
schedule	NN	O
of	IN	O
immunization	NN	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
7	CD	O
and	CC	O
21	CD	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
a	DT	O
schedule	NN	O
of	IN	O
immunization	NN	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
28	CD	O
and	CC	O
56	CD	O
ultimately	RB	O
evoked	VBD	O
the	DT	O
highest	JJS	O
titres	NNS	Physical
21	CD	Physical
days	NNS	Physical
after	IN	Physical
the	DT	Physical
final	JJ	Physical
injection	NN	Physical
,	,	O
but	CC	O
antibody	NN	O
persisted	VBD	O
equally	RB	O
well	RB	O
over	IN	O
two	CD	O
years	NNS	O
with	IN	O
either	DT	O
schedule	NN	O
.	.	O

Neutralizing	VBG	Physical
antibody	NN	Physical
titres	NNS	Physical
were	VBD	O
lower	JJR	O
after	IN	O
intradermal	JJ	O
(	(	O
i.d	JJ	O
.	.	O

)	)	O
vaccination	NN	O
with	IN	O
0.1	CD	O
ml	NNS	O
compared	VBN	O
to	TO	O
1.0	CD	O
ml	NN	O
i.m	NN	O
.	.	O

on	IN	O
days	NNS	O
0	CD	O
,	,	O
7	CD	O
and	CC	O
21	CD	O
,	,	O
but	CC	O
when	WRB	O
given	VBN	O
on	IN	O
days	NNS	O
0	CD	O
,	,	O
28	CD	O
and	CC	O
56	CD	O
the	DT	O
responses	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

Three	CD	O
subjects	NNS	O
with	IN	O
a	DT	O
personal	JJ	O
or	CC	O
family	NN	O
history	NN	O
of	IN	O
atopy	NN	O
developed	VBN	O
urticarial	JJ	Physical
lesions	NNS	Physical
after	IN	O
PCECV	NNP	O
.	.	O

Both	DT	O
vaccines	NNS	O
were	VBD	O
otherwise	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
secretin	NN	O
:	:	O
effects	NNS	O
on	IN	O
aberrant	JJ	Mental
behavior	NN	Mental
in	IN	Mental
children	NNS	Mental
with	IN	Mental
autism	NN	Mental
.	.	Mental

Secretin	NNP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
treatment	NN	O
alternative	NN	O
for	IN	O
autistic	JJ	Mental
spectrum	NN	Mental
disorders	NNS	Mental
,	,	O
but	CC	O
empirical	JJ	O
support	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
on	IN	O
aberrant	JJ	Mental
behavior	NN	Mental
.	.	Mental

Parent	NN	O
and	CC	O
teacher	NN	O
data	NNS	O
from	IN	O
the	DT	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
for	IN	O
eight	CD	O
male	JJ	O
children	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
reliable	JJ	O
change	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
replication	NN	O
series	NN	O
.	.	O

By	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
report	NN	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
change	NN	O
occurred	VBD	O
either	CC	O
on	IN	O
the	DT	O
placebo	NN	O
trial	NN	O
or	CC	O
reflected	VBN	O
deterioration	NN	O
subsequent	NN	O
to	TO	O
secretin	VB	O
infusion	NN	O
.	.	O

Repeated-measures	JJ	O
multivariate	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

Results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
other	JJ	O
studies	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
secretin	NN	O
may	MD	O
not	RB	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
.	.	O

Efficiency	NN	Others
of	IN	O
slush	NN	O
nitrogen	NN	O
vitrification	NN	O
of	IN	O
human	JJ	O
oocytes	NNS	O
vitrified	VBN	O
with	IN	O
or	CC	O
without	IN	O
cumulus	JJ	O
cells	NNS	O
in	IN	O
relation	NN	O
to	TO	O
survival	VB	Mortality
rate	NN	Mortality
and	CC	O
meiotic	JJ	Physical
spindle	NN	Physical
competence	NN	Physical
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	Others
of	IN	O
slush	NN	O
nitrogen	NN	O
vitrification	NN	O
of	IN	O
human	JJ	O
oocytes	NNS	O
with	IN	O
or	CC	O
without	IN	O
cumulus	JJ	O
cells	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
survival	NN	Mortality
rate	NN	Mortality
and	CC	O
maintenance	NN	Physical
of	IN	Physical
meiotic	JJ	Physical
spindle	NN	Physical
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
comparative	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Medical	NNP	O
center	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
total	NN	O
of	IN	O
274	CD	O
oocytes	NNS	O
obtained	VBN	O
from	IN	O
46	CD	O
couples	NNS	O
undergoing	JJ	O
infertility	NN	O
treatment	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Metaphase	NNP	O
II	NNP	O
oocytes	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
vitrified	VBD	O
with	IN	O
and	CC	O
without	IN	O
cumulus	JJ	O
cells	NNS	O
,	,	O
respectively	RB	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Survival	NNP	Mortality
rates	NNS	Mortality
and	CC	O
maintenance	NN	Others
of	IN	Others
meiotic	JJ	Others
spindle	NN	Others
observed	VBD	Others
immediately	RB	Others
after	IN	Others
warming	VBG	Others
and	CC	Others
3	CD	Others
hours	NNS	Others
after	IN	Others
incubation	NN	Others
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
survival	NN	Mortality
rate	NN	Mortality
,	,	O
but	CC	O
a	DT	O
significantly	RB	O
higher	JJR	O
percentage	NN	O
of	IN	O
detectable	JJ	Physical
spindle	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
completely	RB	O
denuded	VBN	O
oocytes	NNS	O
)	)	O
,	,	O
either	RB	O
immediately	RB	O
after	IN	O
warming	VBG	O
or	CC	O
3	CD	O
hours	NNS	O
after	IN	O
incubation	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
Complete	NNP	O
denudation	NN	O
of	IN	O
oocytes	NNS	O
before	IN	O
slush	JJ	O
nitrogen	NN	O
vitrification	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
survival	JJ	Mortality
rates	NNS	Mortality
but	CC	O
positively	RB	O
affects	VBZ	O
oocyte	JJ	O
meiotic	JJ	Physical
spindle	NN	Physical
competence	NN	Physical
.	.	O

These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
cumulus	VBZ	O
cells	NNS	O
during	IN	O
vitrification	NN	O
represent	VBP	O
an	DT	O
obstacle	NN	O
to	TO	O
cryoprotectant	VB	O
penetration	NN	O
more	JJR	O
than	IN	O
having	VBG	O
a	DT	O
protective	JJ	O
role	NN	O
for	IN	O
the	DT	O
oocyte	NN	O
.	.	O

Is	VBZ	O
Na+	NNP	O
modeling	VBG	O
necessary	JJ	O
in	IN	O
high	JJ	O
flux	NN	O
dialysis	NN	O
?	.	O
One	CD	O
important	JJ	O
pathogenic	JJ	O
factor	NN	O
in	IN	O
dialysis	NN	O
hypotension	NN	O
is	VBZ	O
the	DT	O
drop	NN	O
in	IN	O
plasma	JJ	O
osmolality	NN	O
.	.	O

Increasing	VBG	O
the	DT	O
dialysate	NN	O
Na+	NNP	O
concentration	NN	O
decreases	VBZ	O
hypotensive	JJ	O
episodes	NNS	O
.	.	O

The	DT	O
authors	NNS	O
studied	VBD	O
39	CD	O
patients	NNS	O
being	VBG	O
treated	VBN	O
with	IN	O
high	JJ	O
flux	JJ	O
dialysis	NN	O
.	.	O

During	IN	O
a	DT	O
9	CD	O
week	NN	O
period	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
on	IN	O
a	DT	O
standard	JJ	O
Na+	NNP	O
dialysate	NN	O
(	(	O
Na+	NNP	O
=	VBZ	O
140	CD	O
meq/L	NN	O
)	)	O
basal	NN	O
period	NN	O
(	(	O
B	NNP	O
)	)	O
;	:	O
9	CD	O
%	NN	O
(	(	O
Na+	NNP	O
=	VBZ	O
149	CD	O
meq/L	NN	O
)	)	O
linear	NN	O
(	(	O
L	NNP	O
)	)	O
;	:	O
step	VBN	O
drop	NN	O
(	(	O
S	NNP	O
)	)	O
;	:	O
and	CC	O
exponential	JJ	O
drop	NN	O
(	(	O
E	NNP	O
)	)	O
.	.	O

The	DT	O
Na+	NNP	O
program	NN	O
was	VBD	O
changed	VBN	O
weekly	RB	O
at	IN	O
random	NN	O
.	.	O

The	DT	O
results	NNS	O
obtained	VBD	O
with	IN	O
the	DT	O
three	CD	O
Na+	NNP	O
modeling	VBG	O
programs	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
periods	NNS	O
with	IN	O
and	CC	O
without	IN	O
Na+	NNP	O
modeling	NN	O
:	:	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
weight	NN	Physical
gained	VBN	Physical
interdialysis	NN	Physical
,	,	O
mean	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
predialysis	NN	Physical
and	CC	Physical
postdialysis	NN	Physical
,	,	O
and	CC	O
hemoconcentration	NN	Physical
.	.	O

Serum	NNP	Physical
Na+	NNP	Physical
levels	NNS	Physical
were	VBD	O
significantly	RB	O
higher	JJR	O
predialysis	NN	O
and	CC	O
postdialysis	NN	O
for	IN	O
those	DT	O
patients	NNS	O
on	IN	O
Na+	NNP	O
modeling	VBG	O
.	.	O

Hypotensive	NNP	Physical
episodes	NNS	Physical
and	CC	Physical
cramps	NNS	Physical
decreased	VBD	O
50	CD	O
%	NN	O
with	IN	O
Na+	NNP	O
modeling	VBG	O
.	.	O

The	DT	O
amount	NN	Physical
of	IN	Physical
hypertonic	JJ	Physical
and	CC	Physical
normal	JJ	Physical
saline	NN	Physical
given	VBN	O
during	IN	O
dialysis	NN	O
was	VBD	O
markedly	RB	O
reduced	VBN	O
.	.	O

Na+	NNP	O
modeling	VBG	O
should	MD	O
always	RB	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	O
being	VBG	O
maintained	VBN	O
on	IN	O
high	JJ	O
flux	JJ	O
dialysis	NN	O
.	.	O

Rett	NNP	O
syndrome	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
is	VBZ	O
a	DT	O
severe	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
occurring	VBG	O
almost	RB	O
exclusively	RB	O
in	IN	O
female	JJ	O
patients	NNS	O
.	.	O

The	DT	O
etiology	NN	O
and	CC	O
functional	JJ	O
significance	NN	O
of	IN	O
plasma	JJ	O
carnitine	NN	O
deficiency	NN	O
seen	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
L-carnitine	JJ	O
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
Rett	NNP	O
syndrome	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
has	VBZ	O
been	VBN	O
completed	VBN	O
in	IN	O
35	CD	O
subjects	NNS	O
.	.	O

Eight-week	JJ	O
treatment	NN	O
phases	NNS	O
were	VBD	O
completed	VBN	O
for	IN	O
both	DT	O
a	DT	O
placebo	NN	O
and	CC	O
L-carnitine	NNP	O
.	.	O

Outcome	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
parents/caregivers	NNS	O
and	CC	O
at	IN	O
medical	JJ	O
follow-up	NN	O
using	VBG	O
three	CD	O
established	VBN	O
tools	NNS	O
:	:	O
the	DT	Mental
Rett	NNP	Mental
Syndrome	NNP	Mental
Motor	NNP	Mental
Behavioral	NNP	Mental
Assessment	NNP	Mental
,	,	O
the	DT	Mental
Hand	NNP	Mental
Apraxia	NNP	Mental
Scale	NNP	Mental
,	,	O
and	CC	O
the	DT	Others
Patient	NNP	Mental
Well-Being	NNP	Mental
Index	NNP	Mental
.	.	O

Analysis	NNP	O
comparing	VBG	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
of	IN	O
treatment	NN	O
for	IN	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
placebo	NN	O
showed	VBD	O
that	IN	O
both	DT	O
parents/caregivers	NNS	O
and	CC	O
medical	JJ	O
follow-up	NN	O
detected	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
well-being	NN	Mental
.	.	O

In	IN	O
addition	NN	O
,	,	O
medical	JJ	O
review	NN	O
showed	VBD	O
an	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Hand	NNP	Mental
Apraxia	NNP	Mental
Scale	NNP	Mental
for	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
girls	NNS	O
on	IN	O
L-carnitine	NNP	O
.	.	O

Identification	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
improvement	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
by	IN	O
the	DT	O
power	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
is	VBZ	O
of	IN	O
benefit	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
.	.	O

While	IN	O
L-carnitine	NNP	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
major	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
ability	NN	O
,	,	O
the	DT	O
type	NN	O
of	IN	O
changes	NNS	O
reported	VBN	O
could	MD	O
still	RB	O
have	VB	O
a	DT	O
substantial	JJ	O
impact	NN	O
on	IN	O
the	DT	O
girls	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Information	NN	O
is	VBZ	O
still	RB	O
needed	VBN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
only	RB	O
subgroups	NNS	O
of	IN	O
girls	NNS	O
with	IN	O
the	DT	O
disorder	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

Effectiveness	NN	Others
of	IN	O
written	VBN	O
guidelines	NNS	O
on	IN	O
the	DT	O
appropriateness	NN	O
of	IN	O
thromboprophylaxis	JJ	O
prescriptions	NNS	O
for	IN	O
medical	JJ	O
patients	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
providing	VBG	O
doctors	NNS	O
with	IN	O
written	VBN	O
thromboprophylaxis	JJ	O
prescription	NN	O
aids	NNS	O
based	VBN	O
on	IN	O
current	JJ	O
recommendations	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
trial	NN	O
of	IN	O
specific	JJ	O
anticoagulant	JJ	O
prescription	NN	O
forms	NNS	O
:	:	O
a	DT	O
1-day	JJ	O
survey	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
in	IN	O
each	DT	O
centre	NN	O
.	.	O

SETTING	CC	O
30	CD	O
Internal	NNP	O
Medicine	NNP	O
departments	NNS	O
of	IN	O
Assistance	NNP	O
Publique-H?pitaux	NNP	O
de	IN	O
Paris	NNP	O
.	.	O

SUBJECTS	NNP	O
All	DT	O
inpatients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
except	IN	O
those	DT	O
who	WP	O
were	VBD	O
either	RB	O
admitted	VBN	O
or	CC	O
discharged	VBN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
survey	NN	O
,	,	O
and	CC	O
those	DT	O
receiving	VBG	O
curative	JJ	O
anticoagulant	JJ	O
treatment	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
study	NN	O
included	VBD	O
three	CD	O
parts	NNS	O
:	:	O
(	(	O
i	NN	O
)	)	O
a	DT	O
1-day	JJ	O
baseline	NN	O
survey	NN	O
;	:	O
(	(	O
ii	NN	O
)	)	O
over	IN	O
the	DT	O
following	JJ	O
3-month	JJ	O
period	NN	O
,	,	O
departments	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
all	DT	O
practitioners	NNS	O
in	IN	O
wards	NNS	O
allocated	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
group	NN	O
were	VBD	O
required	VBN	O
to	TO	O
systematically	RB	O
use	VB	O
specific	JJ	O
anticoagulant	JJ	O
prescription	NN	O
forms	NNS	O
,	,	O
whilst	NN	O
doctors	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
continued	VBD	O
prescribing	VBG	O
according	VBG	O
to	TO	O
their	PRP$	O
usual	JJ	O
practices	NNS	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
a	DT	O
1-day	JJ	O
postintervention	NN	O
survey	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
proportion	NN	O
of	IN	O
prescriptions	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
recommendations	NNS	O
.	.	O

RESULTS	VB	O
1,469	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
.	.	O

The	DT	O
intervention	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
over-prescriptions	NNS	O
,	,	O
from	IN	O
25	CD	O
%	NN	O
to	TO	O
14	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
meet	VB	O
the	DT	O
guideline	NN	O
criteria	NNS	O
(	(	O
adjusted	VBN	O
OR	NNP	O
:	:	O
0.3	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.1-0.8	NN	O
)	)	O
.	.	O

Using	VBG	O
specific	JJ	O
forms	NNS	O
did	VBD	O
not	RB	O
improve	VB	O
under-prescription	NN	O
of	IN	O
anticoagulants	NNS	O
.	.	O

A	DT	O
little	JJ	O
over	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
met	VBD	O
guideline	NN	O
criteria	NNS	O
for	IN	O
thromboprophylaxis	NN	O
were	VBD	O
prescribed	JJ	O
anticoagulants	NNS	O
in	IN	O
both	DT	O
intervention	NN	O
and	CC	O
control	NN	O
wards	NNS	O
,	,	O
either	RB	O
at	IN	O
baseline	NN	O
or	CC	O
after	IN	O
intervention	NN	O
.	.	O

CONCLUSIONS	NNP	O
Multitargeted	VBD	O
interventions	NNS	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
means	NNS	O
and	CC	O
strategies	NNS	O
should	MD	O
still	RB	O
be	VB	O
considered	VBN	O
to	TO	O
improve	VB	O
prescriptions	NNS	O
that	WDT	O
may	MD	O
have	VB	O
a	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
health	NN	O
expenses	NNS	O
and	CC	O
,	,	O
most	RBS	O
importantly	RB	O
,	,	O
on	IN	O
patients	NNS	O
outcomes	NNS	O
.	.	O

Prazosin	NNP	O
versus	NN	O
captopril	NN	O
as	IN	O
initial	JJ	O
therapy	NN	O
.	.	O

Effect	VB	O
on	IN	O
hypertension	NN	Physical
and	CC	Physical
lipid	JJ	Physical
levels	NNS	Physical
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
evaluated	VBD	O
the	DT	O
safety	NN	Others
,	,	Others
efficacy	NN	Others
,	,	Others
and	CC	Others
effect	NN	Others
of	IN	O
the	DT	O
alpha	NN	O
blocking	VBG	O
agent	JJ	O
prazosin	NN	O
and	CC	O
the	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
captopril	NN	O
on	IN	O
serum	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
hypertension	NN	O
.	.	O

Baseline	JJ	O
evaluations	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
31	CD	O
patients	NNS	O
after	IN	O
a	DT	O
four-week	JJ	O
placebo	NN	O
washout	IN	O
period	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
prazosin	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
captopril	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
.	.	O

Daily	JJ	O
doses	NNS	O
were	VBD	O
titrated	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
for	IN	O
prazosin	NN	O
,	,	O
1	CD	O
mg	NN	O
two	CD	O
times	NNS	O
daily	RB	O
to	TO	O
maximum	VB	O
of	IN	O
20	CD	O
mg	NNS	O
per	IN	O
day	NN	O
;	:	O
for	IN	O
captopril	NN	O
,	,	O
25	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
450	CD	O
mg	NNS	O
per	IN	O
day	NN	O
.	.	O

If	IN	O
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
was	VBD	O
not	RB	O
adequately	RB	O
controlled	VBN	O
(	(	O
less	JJR	O
than	IN	O
85	CD	O
mm	JJ	O
Hg	NNP	O
)	)	O
after	IN	O
four	CD	O
weeks	NNS	O
of	IN	O
monotherapy	NN	O
,	,	O
1	CD	O
mg	NN	O
of	IN	O
polythiazide	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
daily	JJ	O
regimen	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
drug	NN	O
groups	NNS	O
for	IN	O
the	DT	O
measured	JJ	O
variables	NNS	O
in	IN	O
either	CC	O
the	DT	O
parallel	NN	O
or	CC	O
crossover	JJ	O
phase	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Five	CD	O
of	IN	O
15	CD	O
prazosin-treated	JJ	O
patients	NNS	O
and	CC	O
six	CD	O
of	IN	O
16	CD	O
captopril-treated	JJ	O
patients	NNS	O
required	VBD	O
the	DT	O
addition	NN	O
of	IN	O
thiazide	NN	O
to	TO	O
achieve	VB	O
blood	NN	Physical
pressure	NN	Physical
control	NN	Physical
.	.	O

Oral	NNP	O
contraceptive	NN	O
use	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
cardiovascular	JJ	Physical
reactivity	NN	Physical
in	IN	O
nonsmokers	NNS	O
.	.	O

Women	NNS	O
who	WP	O
smoke	VBD	O
and	CC	O
take	VB	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OCs	NNP	O
)	)	O
have	VBP	O
significantly	RB	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
but	CC	O
the	DT	O
exact	JJ	O
mechanismsfor	VBZ	O
the	DT	O
increased	VBN	O
risk	NN	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

Cardiovascular	JJ	O
reactivity	NN	O
to	TO	O
psychological	JJ	O
stress	NN	O
may	MD	O
be	VB	O
one	CD	O
mechanism	NN	O
for	IN	O
the	DT	O
enhanced	JJ	O
risk	NN	O
,	,	O
but	CC	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
studies	NNS	O
examining	VBG	O
whether	IN	O
OC	NNP	O
users	NNS	O
who	WP	O
smoke	VBP	O
have	VBP	O
greater	JJR	O
reactivity	NN	Physical
have	VBP	O
produced	VBN	O
mixed	JJ	O
results	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
chronic	JJ	O
cigarette	NN	O
smoking	NN	O
,	,	O
acute	JJ	O
nicotine	JJ	O
administration	NN	O
,	,	O
and	CC	O
OC	NNP	O
use	VBP	O
on	IN	O
cardiovascular	NN	Physical
and	CC	Physical
lipid	JJ	Physical
reactivity	NN	Physical
.	.	O

Sixty	NNP	O
healthy	JJ	O
women	NNS	O
,	,	O
half	NN	O
of	IN	O
whom	WP	O
had	VBD	O
been	VBN	O
using	VBG	O
OCs	NNP	O
for	IN	O
at	IN	O
least	JJS	O
the	DT	O
previous	JJ	O
6	CD	O
months	NNS	O
,	,	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Approximately	RB	O
two	CD	O
thirds	NNS	O
were	VBD	O
smokers	NNS	O
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
be	VB	O
tested	VBN	O
after	IN	O
either	DT	O
a	DT	O
12-hr	JJ	O
nicotine	JJ	O
deprivation	NN	O
or	CC	O
administration	NN	O
of	IN	O
nicotine	JJ	O
gum	NN	O
.	.	O

One	CD	O
third	WDT	O
were	VBD	O
nonsmokers	NNS	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
,	,	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	Physical
and	CC	Physical
lipid	JJ	Physical
measures	NNS	Physical
were	VBD	O
taken	VBN	O
at	IN	O
rest	NN	O
,	,	O
during	IN	O
a	DT	O
videotaped	JJ	O
speech	NN	O
task	NN	O
,	,	O
and	CC	O
during	IN	O
recovery	NN	O
from	IN	O
the	DT	O
task	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
,	,	O
among	IN	O
OC	NNP	O
nonusers	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
smoking	VBG	O
status	NN	O
or	CC	O
nicotine	JJ	O
administration	NN	O
on	IN	O
cardiovascular	JJ	Physical
reactivity	NN	Physical
.	.	O

However	RB	O
,	,	O
among	IN	O
OC	NNP	O
users	NNS	O
,	,	O
nonsmokers	NNS	O
had	VBD	O
significantly	RB	O
greater	JJR	O
heart	NN	Physical
rate	NN	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
reactivity	NN	Physical
to	TO	Physical
stress	VB	Physical
.	.	O

These	DT	O
data	NNS	O
show	VBP	O
that	IN	O
acute	JJ	O
nicotine	JJ	O
administration	NN	O
,	,	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
nicotine	JJ	O
gum	NN	O
,	,	O
has	VBZ	O
no	DT	O
effect	NN	O
on	IN	O
cardiovascular	NN	Physical
or	CC	Physical
lipid	JJ	Physical
stress	NN	Physical
reactivity	NN	Physical
in	IN	O
women	NNS	O
.	.	O

However	RB	O
OC	NNP	O
use	NN	O
among	IN	O
nonsmoking	JJ	O
women	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
greater	JJR	O
cardiovascular	JJ	Physical
reactivity	NN	Physical
to	TO	Physical
stress	VB	Physical
.	.	O

Treatment	NN	O
of	IN	O
multiple	JJ	O
myeloma	NN	O
according	VBG	O
to	TO	O
the	DT	O
extension	NN	O
of	IN	O
the	DT	O
disease	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
comparing	VBG	O
a	DT	O
less	RBR	O
with	IN	O
a	DT	O
more	RBR	O
aggressive	JJ	O
cystostatic	JJ	O
policy	NN	O
.	.	O

Cooperative	NNP	O
Group	NNP	O
of	IN	O
Study	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Multiple	NNP	O
Myeloma	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
ascertain	VB	O
whether	IN	O
the	DT	O
prognostic	JJ	O
significance	NN	O
of	IN	O
staging	VBG	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
(	(	O
MM	NNP	O
)	)	O
is	VBZ	O
influenced	VBN	O
by	IN	O
the	DT	O
aggressiveness	NN	O
of	IN	O
effective	JJ	O
induction	NN	O
treatment	NN	O
and/or	NN	O
by	IN	O
continuing	VBG	O
or	CC	O
discontinuing	VBG	O
maintenance	NN	O
chemotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
untreated	JJ	O
stage	NN	O
I	PRP	O
MM	NNP	O
(	(	O
defined	VBN	O
according	VBG	O
to	TO	O
Durie	NNP	O
and	CC	O
Salmon	NNP	O
)	)	O
were	VBD	O
randomised	VBN	O
between	IN	O
being	VBG	O
followed	VBN	O
without	IN	O
cytostatics	NNS	O
until	IN	O
the	DT	O
disease	NN	O
progressed	VBD	O
and	CC	O
receiving	VBG	O
six	CD	O
courses	NNS	O
of	IN	O
melphalan	NN	O
and	CC	O
prednisone	NN	O
(	(	O
MP-P	NNP	O
)	)	O
just	RB	O
after	IN	O
diagnosis	NN	O
;	:	O
stage	NN	O
II	NNP	O
patients	NNS	O
were	VBD	O
uniformly	RB	O
treated	VBN	O
with	IN	O
MPH-P	NNP	O
and	CC	O
stage	NN	O
III	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
between	IN	O
MPH-P	NNP	O
and	CC	O
four	CD	O
courses	NNS	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
Peptichemio	NNP	O
,	,	O
vincristine	NN	O
and	CC	O
prednisone	NN	O
(	(	O
PTC-VCR-P	NNP	O
)	)	O
.	.	O

Within	IN	O
each	DT	O
stage	NN	O
,	,	O
responsive	JJ	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
between	IN	O
receiving	VBG	O
additional	JJ	O
therapy	NN	O
only	RB	O
until	IN	O
maximal	JJ	O
tumour	NNS	O
reduction	NN	O
was	VBD	O
reached	VBN	O
(	(	O
plateau	JJ	O
phase	NN	O
)	)	O
and	CC	O
continuing	VBG	O
induction	NN	O
therapy	NN	O
indefinitely	RB	O
until	IN	O
relapse	NN	O
.	.	O

With	IN	O
resistant	JJ	O
,	,	O
progressive	JJ	O
or	CC	O
relapsing	VBG	O
disease	NN	O
,	,	O
patients	NNS	O
originally	RB	O
treated	VBN	O
with	IN	O
MPH-P	NNP	O
for	IN	O
induction	NN	O
received	VBN	O
combination	NN	O
chemotherapy	NN	O
and	CC	O
vice	NN	O
versa	NN	O
.	.	O

The	DT	O
overall	JJ	Mental
first	JJ	Mental
response	NN	Mental
rate	NN	Mental
was	VBD	O
43.8	CD	O
%	NN	O
(	(	O
42.2	CD	O
%	NN	O
in	IN	O
206	CD	O
stage	NN	O
I	PRP	O
,	,	O
II	NNP	O
and	CC	O
III	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
MPH-P	NNP	O
and	CC	O
48.0	CD	O
%	NN	O
in	IN	O
75	CD	O
stage	NN	O
III	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
combination	NN	O
chemotherapy	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Combination	NNP	O
chemotherapy	NN	O
was	VBD	O
more	RBR	O
myelotoxic	JJ	Physical
than	IN	O
MPH-P	NNP	O
and	CC	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
caused	VBD	O
more	RBR	O
non-haematological	JJ	Adverseeffect
side-effects	NNS	Adverseeffect
.	.	O

Both	CC	O
the	DT	O
less	JJR	O
and	CC	O
the	DT	O
more	RBR	O
aggressive	JJ	O
induction	NN	O
policies	NNS	O
gave	VBD	O
the	DT	O
same	JJ	O
disease	NN	Others
control	NN	Others
.	.	O

Progression	NN	Physical
of	IN	Physical
disease	NN	Physical
was	VBD	O
statistically	RB	O
similar	JJ	O
in	IN	O
stage	NN	O
I	PRP	O
patients	NNS	O
who	WP	O
were	VBD	O
initially	RB	O
left	VBN	O
untreated	JJ	O
and	CC	O
in	IN	O
t	JJ	O
hose	NN	O
who	WP	O
received	VBD	O
MPH-P	NNP	O
just	RB	O
after	IN	O
diagnosis	NN	O
;	:	O
median	JJ	O
duration	NN	Others
of	IN	Others
first	JJ	Others
response	NN	Physical
was	VBD	O
similar	JJ	O
in	IN	O
stage	NN	O
III	NNP	O
patients	NNS	O
receiving	VBG	O
MPH-P	NNP	O
and	CC	O
in	IN	O
those	DT	O
on	IN	O
combination	NN	O
chemotherapy	NN	O
.	.	O

In	IN	O
all	DT	O
stages	NNS	O
,	,	O
discontinuing	VBG	O
or	CC	O
continuing	VBG	O
maintenance	NN	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
median	JJ	Others
duration	NN	Others
of	IN	Others
first	JJ	Others
response	NN	Physical
.	.	O

The	DT	O
overall	JJ	Others
second	JJ	Others
response	NN	Physical
rate	NN	Others
was	VBD	O
28.5	CD	O
%	NN	O
(	(	O
34.0	CD	O
%	NN	O
to	TO	O
MPH-P	NNP	O
and	CC	O
25.3	CD	O
%	NN	O
to	TO	O
combination	NN	O
chemotherapy	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Median	JJ	Others
survival	NN	Mortality
was	VBD	O
greater	JJR	O
than	IN	O
78	CD	O
months	NNS	O
in	IN	O
stage	NN	O
I	PRP	O
,	,	O
was	VBD	O
46.3	CD	O
months	NNS	O
in	IN	O
stage	NN	O
II	NNP	O
and	CC	O
was	VBD	O
24.3	CD	O
months	NNS	O
in	IN	O
stage	NN	O
III	NNP	O
patients	NNS	O
,	,	O
still	RB	O
independent	JJ	O
of	IN	O
both	DT	O
induction	NN	O
and	CC	O
post-induction	NN	O
policies	NNS	O
.	.	O

In	IN	O
MM	NNP	O
,	,	O
the	DT	O
significance	NN	O
of	IN	O
staging	VBG	O
for	IN	O
survival	NN	Mortality
is	VBZ	O
independent	JJ	O
of	IN	O
both	DT	O
the	DT	O
aggressiveness	NN	O
of	IN	O
induction	NN	O
and	CC	O
of	IN	O
continuing	VBG	O
or	CC	O
discontinuing	VBG	O
maintenance	NN	O
chemotherapy	NN	O
after	IN	O
the	DT	O
maximal	JJ	O
tumor	NN	O
reduction	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
.	.	O

Both	DT	O
MPH-P	NNP	O
and	CC	O
and	CC	O
the	DT	O
association	NN	O
of	IN	O
PTC	NNP	O
,	,	O
VCR	NNP	O
and	CC	O
P	NNP	O
are	VBP	O
effective	JJ	O
in	IN	O
inducing	VBG	O
first	JJ	Others
response	NN	Physical
and	CC	O
also	RB	O
second	JJ	Others
response	NN	Physical
in	IN	O
patients	NNS	O
failing	VBG	O
on	IN	O
the	DT	O
alternative	JJ	O
regimen	NNS	O
,	,	O
but	CC	O
PTC-VCR-P	NNP	O
causes	VBZ	O
more	JJR	O
side	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	Adverseeffect

Thus	RB	O
,	,	O
the	DT	O
overwhelming	JJ	O
majority	NN	O
of	IN	O
patients	NNS	O
with	IN	O
MM	NNP	O
can	MD	O
safely	RB	O
be	VB	O
given	VBN	O
MPH-P	NNP	O
as	IN	O
first	JJ	O
therapy	NN	O
,	,	O
and	CC	O
this	DT	O
treatment	NN	O
may	MD	O
be	VB	O
delayed	VBN	O
in	IN	O
early	JJ	O
diseases	NNS	O
.	.	O

Anti-inflammatory	JJ	Physical
effects	NNS	Physical
of	IN	O
inhaled	JJ	O
carbon	NN	O
monoxide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

In	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
carbon	NN	O
monoxide	NN	O
(	(	O
CO	NNP	O
)	)	O
has	VBZ	O
both	DT	O
anti-inflammatory	JJ	O
and	CC	O
anti-oxidant	JJ	O
capacities	NNS	O
.	.	O

Since	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
is	VBZ	O
characterised	VBN	O
by	IN	O
inflammation	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
,	,	O
low-dose	JJ	O
CO	NNP	O
could	MD	O
be	VB	O
of	IN	O
therapeutic	JJ	O
use	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
feasibility	NN	Physical
and	CC	Physical
anti-inflammatory	JJ	Physical
effects	NNS	Physical
of	IN	O
100-125	JJ	O
ppm	NN	O
CO	NNP	O
inhalation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
COPD	NNP	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
20	CD	O
ex-smoking	JJ	O
COPD	NNP	O
patients	NNS	O
with	IN	O
post-bronchodilator	NN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
>	$	O
1.20	CD	O
L	NNP	O
and	CC	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
/forced	VBD	O
vital	JJ	O
capacity	NN	O
<	VBP	O
70	CD	O
%	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Effects	NNS	Physical
on	IN	Physical
inflammation	NN	Physical
were	VBD	O
measured	VBN	O
in	IN	O
induced	JJ	Physical
sputum	NN	Physical
and	CC	Physical
blood	NN	Physical
.	.	O

CO	NNP	Physical
inhalation	NN	Physical
was	VBD	O
feasible	JJ	Others
and	CC	O
patients	NNS	Physical
'	POS	Physical
vital	JJ	Physical
signs	NNS	Physical
were	VBD	O
unaffected	VBN	O
;	:	O
2	CD	O
h.day	NN	O
(	(	O
-1	NNP	O
)	)	O
inhalation	NN	O
of	IN	O
low-dose	JJ	O
CO	NNP	O
on	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
led	VBD	O
to	TO	O
a	DT	O
maximal	JJ	O
individual	JJ	O
carboxyhaemoglobin	NN	Physical
level	NN	Physical
of	IN	O
4.5	CD	O
%	NN	O
.	.	O

Two	CD	O
exacerbations	NNS	Physical
occurred	VBD	O
in	IN	O
the	DT	O
CO	NNP	O
period	NN	O
.	.	O

CO	NNP	O
inhalation	NN	O
led	VBD	O
to	TO	O
trends	NNS	O
in	IN	O
reduced	JJ	Physical
sputum	NN	Physical
eosinophils	NNS	Physical
(	(	O
median	JJ	O
reduction	NN	O
0.25	CD	O
%	NN	O
point	NN	O
)	)	O
and	CC	O
improved	JJ	Physical
responsiveness	NN	Physical
to	TO	Physical
methacholine	VB	Physical
(	(	O
median	JJ	O
provocative	NN	O
concentration	NN	O
causing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
0.85	CD	O
versus	$	O
0.63	CD	O
mg.mL	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
.	.	O

Inhalation	NN	O
of	IN	O
100-125	JJ	O
ppm	NN	O
carbon	NN	O
monoxide	NN	O
by	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
in	IN	O
a	DT	O
stable	JJ	O
phase	NN	O
was	VBD	O
feasible	JJ	O
and	CC	O
led	VBD	O
to	TO	O
trends	NNS	O
in	IN	O
reduction	NN	O
of	IN	O
sputum	NN	O
eosinophils	NNS	O
and	CC	O
improvement	NN	Physical
of	IN	Physical
responsiveness	NN	Physical
to	TO	Physical
methacholine	VB	Physical
.	.	O

Further	NNP	O
studies	NNS	O
need	VBP	O
to	TO	O
confirm	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
efficacy	NN	Others
in	IN	O
inflammatory	JJ	O
lung	NN	O
diseases	NNS	O
.	.	O

Asthma	NNP	O
and	CC	O
the	DT	O
home	NN	O
environment	NN	O
of	IN	O
low-income	JJ	O
urban	JJ	O
children	NNS	O
:	:	O
preliminary	JJ	O
findings	NNS	O
from	IN	O
the	DT	O
Seattle-King	NNP	O
County	NNP	O
healthy	JJ	O
homes	NNS	O
project	NN	O
.	.	O

OBJECTIVES	NNP	O
Childhood	NNP	O
asthma	NN	O
is	VBZ	O
a	DT	O
growing	VBG	O
public	JJ	O
health	NN	O
concern	NN	O
in	IN	O
low-income	JJ	O
urban	JJ	O
communities	NNS	O
.	.	O

Indoor	NNP	O
exposure	NN	O
to	TO	O
asthma	VB	O
triggers	NNS	O
has	VBZ	O
emerged	VBN	O
as	IN	O
an	DT	O
important	JJ	O
cause	NN	O
of	IN	O
asthma	JJ	O
exacerbations	NNS	O
.	.	O

We	PRP	O
describe	VBP	O
indoor	JJ	O
environmental	JJ	O
conditions	NNS	O
related	VBN	O
to	TO	O
asthma	JJ	O
triggers	NNS	O
among	IN	O
a	DT	O
low-income	JJ	O
urban	JJ	O
population	NN	O
in	IN	O
Seattle/King	NNP	O
County	NNP	O
,	,	O
Washington	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
caregiver	NN	O
knowledge	NN	O
and	CC	O
resources	NNS	O
related	VBN	O
to	TO	O
control	VB	O
of	IN	O
these	DT	O
triggers	NNS	O
.	.	O

METHODS	NNP	O
Data	NNP	O
are	VBP	O
obtained	VBN	O
from	IN	O
in-person	JJ	O
,	,	O
structured	JJ	O
,	,	O
closed-end	JJ	O
interviews	NNS	O
with	IN	O
the	DT	O
caretakers	NNS	O
of	IN	O
children	NNS	O
aged	VBN	O
4-12	CD	O
years	NNS	O
with	IN	O
persistent	JJ	O
asthma	NN	O
living	NN	O
in	IN	O
households	NNS	O
with	IN	O
incomes	NNS	O
less	JJR	O
than	IN	O
200	CD	O
%	NN	O
of	IN	O
poverty	NN	O
.	.	O

Additional	JJ	O
information	NN	O
is	VBZ	O
collected	VBN	O
during	IN	O
a	DT	O
home	NN	O
inspection	NN	O
.	.	O

The	DT	O
children	NNS	O
and	CC	O
their	PRP$	O
caregivers	NNS	O
are	VBP	O
participants	NNS	O
in	IN	O
the	DT	O
ongoing	JJ	O
Seattle-King	JJ	O
County	NNP	O
Healthy	NNP	O
Homes	NNP	O
Project	NNP	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
intervention	NN	O
to	TO	O
empower	VB	O
low-income	JJ	O
families	NNS	O
to	TO	O
reduce	VB	O
exposure	NN	O
to	TO	O
indoor	VB	O
asthma	JJ	O
triggers	NNS	O
.	.	O

We	PRP	O
report	VBP	O
findings	NNS	O
on	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
the	DT	O
homes	NNS	O
prior	RB	O
to	TO	O
this	DT	O
intervention	NN	O
among	IN	O
the	DT	O
first	JJ	O
112	CD	O
enrolled	JJ	O
households	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
smoker	NN	O
was	VBD	O
present	JJ	O
in	IN	O
37.5	CD	O
%	NN	O
of	IN	O
homes	NNS	O
.	.	O

Mold	NNP	Others
was	VBD	Others
visible	JJ	Others
in	IN	O
26.8	CD	O
%	NN	O
of	IN	O
homes	NNS	O
,	,	O
water	NN	Others
damage	NN	Others
was	VBD	O
present	JJ	O
in	IN	O
18.6	CD	O
%	NN	O
of	IN	O
homes	NNS	O
,	,	O
and	CC	O
damp	JJ	Others
conditions	NNS	Others
occurred	VBD	O
in	IN	O
64.8	CD	O
%	NN	O
of	IN	O
households	NNS	O
,	,	O
while	IN	O
39.6	CD	O
%	NN	O
of	IN	O
caregivers	NNS	O
were	VBD	O
aware	JJ	O
that	IN	O
excessive	JJ	O
moisture	NN	O
can	MD	O
increase	VB	O
exposures	NNS	O
to	TO	O
allergens	NNS	O
.	.	O

Dust-trapping	JJ	Others
reservoirs	NNS	Others
were	VBD	O
common	JJ	O
;	:	O
76.8	CD	O
%	NN	O
of	IN	O
children	NNS	O
's	POS	O
bedrooms	NNS	O
had	VBD	O
carpeting	NN	O
.	.	O

Cockroach	NNP	Others
infestation	NN	Others
in	IN	Others
the	DT	Others
past	JJ	Others
3	CD	Others
months	NNS	Others
was	VBD	O
reported	VBN	O
by	IN	O
23.4	CD	O
%	NN	O
of	IN	O
caregivers	NNS	O
,	,	O
while	IN	O
57.1	CD	O
%	NN	O
were	VBD	O
unaware	JJ	O
of	IN	O
the	DT	O
association	NN	Others
of	IN	Others
roaches	NNS	Others
and	CC	Others
asthma	NN	Others
.	.	O

Only	RB	O
19.8	CD	O
%	NN	O
of	IN	O
the	DT	O
children	NNS	O
had	VBD	O
allergy-control	JJ	Others
mattress	NN	Others
covers	NNS	Others
.	.	Others

CONCLUSIONS	NNP	O
Many	JJ	O
low-income	JJ	O
urban	JJ	O
children	NNS	O
with	IN	O
asthma	NN	O
in	IN	O
King	NNP	O
County	NNP	O
live	VBP	O
in	IN	O
indoor	JJ	O
environments	NNS	O
that	WDT	O
place	VBP	O
them	PRP	O
at	IN	O
substantial	JJ	O
risk	NN	O
of	IN	O
ongoing	VBG	O
exposure	NN	O
to	TO	O
asthma	VB	O
triggers	NNS	O
.	.	O

Substandard	NNP	O
housing	NN	O
and	CC	O
lack	NN	O
of	IN	O
resources	NNS	O
often	RB	O
underlie	VBP	O
these	DT	O
exposures	NNS	O
.	.	O

Initiatives	VBZ	O
involving	VBG	O
health	NN	O
educators	NNS	O
,	,	O
outreach	NN	O
workers	NNS	O
,	,	O
medical	JJ	O
providers	NNS	O
,	,	O
health	NN	O
care	NN	O
insurers	NNS	O
,	,	O
housing	NN	O
agencies	NNS	O
,	,	O
and	CC	O
elected	VBN	O
officials	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
reduce	VB	O
these	DT	O
exposures	NNS	O
.	.	O

JobTIPS	NN	O
:	:	O
a	DT	O
transition	NN	O
to	TO	O
employment	NN	O
program	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effectiveness	NN	Others
of	IN	O
an	DT	O
internet	NN	Others
accessed	VBD	Others
training	VBG	Others
program	NN	Others
that	WDT	O
included	VBD	O
Theory	NNP	O
of	IN	O
Mind-based	JJ	O
guidance	NN	O
,	,	O
video	NN	O
models	NNS	O
,	,	O
visual	JJ	O
supports	NNS	O
,	,	O
and	CC	O
virtual	JJ	O
reality	NN	O
practice	NN	O
sessions	NNS	O
in	IN	O
teaching	VBG	O
appropriate	JJ	O
job	NN	O
interview	NN	O
skills	NNS	O
to	TO	O
individuals	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
,	,	O
twenty-two	JJ	O
youth	NN	O
,	,	O
ages	VBZ	O
16-19	JJ	O
,	,	O
were	VBD	O
evaluated	VBN	O
during	IN	O
two	CD	O
employment	NN	O
interviews	NNS	O
.	.	O

Half	NNP	O
received	VBD	O
a	DT	O
training	NN	O
intervention	NN	O
following	VBG	O
the	DT	O
initial	JJ	O
interview	NN	O
and	CC	O
the	DT	O
half	NN	O
who	WP	O
served	VBD	O
as	IN	O
a	DT	O
contrast	NN	O
group	NN	O
did	VBD	O
not	RB	O
.	.	O

Their	PRP$	O
performance	NN	O
pre	NN	O
and	CC	O
post	NN	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
four	CD	O
independent	JJ	O
raters	NNS	O
using	VBG	O
a	DT	O
scale	NN	O
that	WDT	O
included	VBD	O
evaluation	NN	O
of	IN	O
both	DT	O
Content	NNP	Others
and	CC	Others
Delivery	NNP	Others
.	.	O

Results	NNP	O
suggest	VBP	O
that	IN	O
youth	NN	O
who	WP	O
completed	VBD	O
the	DT	O
JobTIPS	NNP	O
employment	NN	O
program	NN	O
demonstrated	VBD	O
significantly	RB	Mental
more	RBR	Mental
effective	JJ	Mental
verbal	JJ	Mental
content	NN	Mental
skills	NNS	Mental
than	IN	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
lisinopril	NN	O
and	CC	O
nifedipine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
hypertension	NN	O
.	.	O

A	DT	O
multicentre	NN	O
study	NN	O
.	.	O

Lisinopril	NNP	O
has	VBZ	O
been	VBN	O
compared	VBN	O
with	IN	O
slow-release	JJ	O
nifedipine	NN	O
in	IN	O
a	DT	O
16-week	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
involving	VBG	O
102	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
hypertension	NN	O
.	.	O

Sitting	VBG	Physical
systolic	JJ	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressures	NNS	Physical
were	VBD	O
reduced	VBN	O
6	CD	O
and	CC	O
5	CD	O
mmHg	NNS	O
more	JJR	O
by	IN	O
lisinopril	JJR	O
than	IN	O
by	IN	O
nifedipine	NN	O
over	IN	O
12	CD	O
weeks	NNS	O
monotherapy	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	O
taking	VBG	O
lisinopril	NN	O
was	VBD	O
controlled	VBN	O
(	(	O
sitting	VBG	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
below	IN	O
95	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
than	IN	O
in	IN	O
those	DT	O
taking	VBG	O
nifedipine	JJ	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
17	CD	O
%	NN	O
of	IN	O
those	DT	O
taking	VBG	O
lisinopril	JJ	O
and	CC	O
38	CD	O
%	NN	O
of	IN	O
those	DT	O
taking	VBG	O
nifedipine	NN	O
required	VBN	O
additional	JJ	O
therapy	NN	O
with	IN	O
hydrochlorothiazide	NN	Physical
.	.	O

The	DT	O
addition	NN	O
of	IN	O
hydrochlorothiazide	NN	O
resulted	VBD	O
in	IN	O
similar	JJ	Others
response	NN	Others
rates	NNS	Others
in	IN	O
the	DT	O
lisinopril	NN	O
and	CC	O
nifedipine	JJ	O
groups	NNS	O
(	(	O
89	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
reporting	NN	O
of	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
considered	VBN	O
to	TO	O
be	VB	O
drug-related	JJ	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
withdrawals	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
treatments	NNS	O
.	.	O

Cough	NNP	Adverseeffect
was	VBD	O
more	RBR	O
often	RB	O
reported	VBN	O
with	IN	O
lisinopril	NN	O
and	CC	O
headache	NN	Adverseeffect
,	,	Adverseeffect
sweating	NN	Adverseeffect
,	,	O
and	CC	O
hot	JJ	Adverseeffect
flushes	NNS	Adverseeffect
with	IN	O
nifedipine	JJ	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
once-daily	RB	O
titrated	JJ	O
doses	NNS	O
of	IN	O
lisinopril	NN	O
produced	VBN	O
better	RBR	O
control	NN	O
of	IN	O
blood	NN	Physical
pressure	NN	Physical
than	IN	O
twice-daily	RB	O
titrated	JJ	O
doses	NNS	O
of	IN	O
nifedipine	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
application	NN	O
of	IN	O
irradiated	JJ	O
drug-containing	JJ	O
porcine-cornea	NN	O
to	TO	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
]	FW	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

METHODS	NNP	O
Fifty-five	JJ	O
cases	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
(	(	O
in	IN	O
88	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Thirty	NNP	O
cases	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
49	CD	O
eyes	NNS	O
were	VBD	O
transplanted	VBN	O
with	IN	O
irradiated	JJ	O
drug-containing	NN	O
(	(	O
ofloxacin	UH	O
,	,	O
acetyl	JJ	O
cysteine	NN	O
and	CC	O
reduced	JJ	O
glutathione	NN	O
)	)	O
porcine-cornea	NN	O
.	.	O

25	CD	O
cases	NNS	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
39	CD	O
eyes	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
routine	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Thirty-two	JJ	O
eyes	NNS	Others
were	VBD	Others
rescued	VBN	Others
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
65.3	CD	O
%	NN	O
.	.	O

But	CC	O
only	RB	O
17	CD	O
eyes	NNS	Others
were	VBD	Others
saved	VBN	Others
in	IN	O
control	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
43.59	CD	O
%	NN	O
,	,	O
indicating	VBG	O
significant	JJ	O
difference	NN	O
of	IN	O
the	DT	O
cure	NN	Others
rate	NN	Others
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiated	VBD	O
drug-containing	JJ	O
porcine-cornea	NN	O
might	MD	O
well	RB	O
be	VB	O
an	DT	O
ideal	JJ	O
therapeutic	JJ	O
material	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

Flow-cytometric	JJ	O
studies	NNS	O
with	IN	O
eleutherococcus	JJ	O
senticosus	NN	O
extract	NN	O
as	IN	O
an	DT	O
immunomodulatory	NN	O
agent	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
Eleutherococcus	NNP	O
senticosus	NN	O
extract	NN	O
(	(	O
Eleukokk	NNP	O
)	)	O
on	IN	O
the	DT	O
immune	NN	O
system	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
36	CD	O
healthy	JJ	O
volunteers	NNS	O
utilising	VBG	O
quantitative	JJ	O
multi-parameter	NN	O
flow	NN	O
cytometry	NN	O
with	IN	O
monoclonal	JJ	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
specific	JJ	O
surface	NN	O
markers	NNS	O
of	IN	O
human	JJ	O
lymphocyte	JJ	O
subsets	NNS	O
.	.	O

Volunteers	NNS	O
in	IN	O
the	DT	O
verum	NN	O
group	NN	O
received	VBD	O
10	CD	O
ml	NN	O
of	IN	O
an	DT	O
ethanolic	JJ	O
(	(	O
vincamine	JJ	O
free	JJ	O
)	)	O
eleutherococcus	VBP	O
senticosus	JJ	O
preparation	NN	O
,	,	O
3	CD	O
times	NNS	O
daily	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
,	,	O
the	DT	O
eleutherococcus	NN	O
extract	NN	O
was	VBD	O
substituted	VBN	O
by	IN	O
additional	JJ	O
wine	NN	O
,	,	O
resulting	VBG	O
in	IN	O
identical	JJ	O
final	JJ	O
concentrations	NNS	O
of	IN	O
ethanol	NN	O
in	IN	O
both	DT	O
preparations	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
double-blind	NN	O
study	NN	O
was	VBD	O
the	DT	O
demonstration	NN	O
of	IN	O
possible	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
cellular	JJ	Physical
immune	NN	Physical
status	NN	Physical
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
quantitative	JJ	Others
flow	NN	Others
cytometry	NN	Others
.	.	O

The	DT	O
most	RBS	O
salient	JJ	O
feature	NN	O
in	IN	O
the	DT	O
verum	NN	O
group	NN	O
was	VBD	O
a	DT	O
drastic	JJ	O
increase	NN	O
in	IN	O
the	DT	O
absolute	JJ	Physical
number	NN	Physical
of	IN	Physical
immunocompetent	JJ	Physical
cells	NNS	Physical
,	,	O
with	IN	O
an	DT	O
especially	RB	O
pronounced	JJ	O
effect	NN	O
on	IN	O
T	NNP	Physical
lymphocytes	NNS	Physical
,	,	O
predominantly	RB	O
of	IN	O
the	DT	O
helper/inducer	NN	Physical
type	NN	Physical
,	,	O
but	CC	O
also	RB	O
on	IN	O
cytotoxic	NN	Physical
and	CC	Physical
natural	JJ	Physical
killer	NN	Physical
cells	NNS	Physical
.	.	Physical

In	IN	O
addition	NN	O
,	,	O
a	DT	O
general	JJ	O
enhancement	NN	O
of	IN	O
the	DT	O
activation	NN	Physical
state	NN	Physical
of	IN	Physical
T	NNP	Physical
lymphocytes	NNS	Physical
was	VBD	O
observed	VBN	O
.	.	O

No	DT	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
trial	NN	O
or	CC	O
afterwards	NNS	O
(	(	O
observation	NN	O
period	NN	O
6	CD	O
months	NNS	O
)	)	O
.	.	O

[	RB	O
4	CD	O
years	NNS	O
'	POS	O
experience	NN	O
with	IN	O
a	DT	O
balloon-expandable	JJ	O
endoprosthesis	NN	O
.	.	O

Experimental	JJ	O
and	CC	O
clinical	JJ	O
application	NN	O
]	NNP	O
.	.	O

During	IN	O
a	DT	O
4-year	JJ	O
period	NN	O
of	IN	O
clinical	JJ	O
application	NN	O
of	IN	O
the	DT	O
balloon-expandable	JJ	O
Palmaz	NNP	O
stent	NN	O
,	,	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
stent	JJ	O
implantation	NN	O
and	CC	O
traditional	JJ	O
balloon	NN	O
angioplasty	NN	O
of	IN	O
iliac	JJ	O
arteries	NNS	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
was	VBD	O
started	VBN	O
.	.	O

The	DT	O
first	JJ	O
long-term	JJ	O
results	NNS	O
,	,	O
recorded	VBD	O
after	IN	O
2	CD	O
years	NNS	O
,	,	O
indicate	VBP	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
complication	NN	Adverseeffect
rate	NN	Adverseeffect
(	(	O
after	IN	O
stenting	VBG	O
2/62	CD	O
and	CC	O
after	IN	O
angioplasty	JJ	O
5/69	CD	O
)	)	O
and	CC	O
patency	NN	Others
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
70	CD	O
%	NN	O
of	IN	O
original	JJ	O
lumen	NNS	O
size	NN	O
upon	IN	O
stent	JJ	O
implantation	NN	O
or	CC	O
balloon	NN	O
inflation	NN	O
:	:	O
95	CD	O
%	NN	O
after	IN	O
stenting	VBG	O
and	CC	O
72	CD	O
%	NN	O
after	IN	O
angioplasty	NN	O
)	)	O
.	.	O

Clinical	JJ	Others
improvement	NN	Others
after	IN	Physical
2	CD	Physical
years	NNS	Physical
was	VBD	O
89	CD	O
%	NN	O
after	IN	O
stenting	VBG	O
and	CC	O
70	CD	O
%	NN	O
after	IN	O
angioplasty	NN	O
.	.	O

Parallel	NNP	O
to	TO	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
experimental	JJ	O
canine	NN	O
artery	NN	O
stenting	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
differences	NNS	O
in	IN	O
the	DT	O
long-term	JJ	O
patency	NN	O
of	IN	O
stents	NNS	O
exposed	VBN	O
to	TO	O
restricted	VBN	O
flow	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
neointimal	JJ	Physical
healing	NN	Physical
were	VBD	O
found	VBN	O
between	IN	O
normally	RB	O
perfused	VBN	O
stents	NNS	O
and	CC	O
stents	NNS	O
with	IN	O
artificially	RB	O
reduced	VBN	O
flow	NN	O
:	:	O
during	IN	O
the	DT	O
total	JJ	O
observation	NN	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
the	DT	O
neointimal	JJ	Physical
height	NN	Physical
was	VBD	O
up	RB	O
to	TO	O
200	CD	O
%	NN	O
higher	JJR	O
in	IN	O
flow-restricted	JJ	O
stents	NNS	O
,	,	O
while	IN	O
the	DT	O
histological	JJ	Physical
composition	NN	Physical
of	IN	Physical
the	DT	Physical
neointima	NN	Physical
was	VBD	O
the	DT	O
same	JJ	O
as	IN	O
with	IN	O
normally	RB	O
perfused	VBN	O
stents	NNS	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
enhance	VB	O
immune	JJ	O
function	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

OBJECTIVE	NNP	O
We	PRP	O
collected	VBD	O
preliminary	JJ	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	O
to	TO	O
improve	VB	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
persons	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
and	CC	O
acquired	VBD	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
in	IN	O
an	DT	O
academic	JJ	O
medical	JJ	O
center-based	JJ	O
infectious	JJ	O
disease	NN	O
clinic	NN	O
,	,	O
11	CD	O
clinically	RB	O
stable	JJ	O
,	,	O
HIV-infected	JJ	O
adults	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
highly	RB	O
active	JJ	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
had	VBD	O
HIV	NNP	O
plasma	NN	O
RNA	NNP	O
levels	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	O
000	CD	O
copies/mL	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
19.6	CD	O
g	NN	O
of	IN	O
arginine/d	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
for	IN	O
14	CD	O
d.	NN	O
Plasma	NNP	Physical
HIV	NNP	Physical
RNA	NNP	Physical
levels	NNS	Physical
,	,	O
neuropsychologic	RB	Physical
functioning	NN	Physical
,	,	Mental
and	CC	O
self-reported	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
analyzed	VBN	O
for	IN	O
safety	NN	O
of	IN	O
treatment	NN	O
.	.	O

Efficacy	NN	Others
was	VBD	O
measured	VBN	O
by	IN	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
.	.	O

RESULTS	NNP	O
None	NN	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
any	DT	O
adverse	JJ	Adverseeffect
clinical	NN	Adverseeffect
,	,	Adverseeffect
virologic	NN	Adverseeffect
,	,	Adverseeffect
or	CC	Adverseeffect
neuropsychologic	JJ	Adverseeffect
events	NNS	Adverseeffect
that	WDT	O
necessitated	VBD	O
withdrawal	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
arginine-supplemented	JJ	O
group	NN	O
showed	VBD	O
a	DT	O
mean	JJ	Physical
natural	JJ	Physical
killer	NN	Physical
cell	NN	Physical
cytotoxicity	NN	Physical
increase	NN	O
of	IN	O
18.9	CD	O
lytic	JJ	O
units	NNS	O
,	,	O
whereas	IN	O
the	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
0.3	CD	O
lytic	JJ	O
units	NNS	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.79	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
arginine	NN	O
supplementation	NN	O
is	VBZ	O
safe	JJ	O
for	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

Additional	NNP	O
studies	NNS	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
longer	JJR	O
periods	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
arginine	JJ	O
supplementation	NN	O
on	IN	O
other	JJ	O
indices	NNS	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
such	JJ	O
as	IN	O
intercurrent	JJ	O
illnesses	NNS	O
.	.	O

Fasting	VBG	O
and	CC	O
meal-stimulated	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
neurotensin	NN	O
in	IN	O
obese	JJ	O
patients	NNS	O
after	IN	O
jejunoileal	JJ	O
bypass	NN	O
with	IN	O
3:1	CD	O
or	CC	O
1:3	CD	O
jejunoileal	NN	O
ratio	NN	O
.	.	O

The	DT	O
functional	JJ	O
role	NN	O
of	IN	O
the	DT	O
jejunum	NN	O
and	CC	O
ileum	NN	O
with	IN	O
regard	NN	O
to	TO	O
peripheral	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
intact	JJ	O
neurotensin	JJ	O
and	CC	O
NH2-terminal	JJ	O
immunoreactivity	NN	O
of	IN	O
neurotensin	NN	O
was	VBD	O
studied	VBN	O
by	IN	O
using	VBG	O
jejunoileal	JJ	O
bypass	NN	O
as	IN	O
a	DT	O
model	NN	O
.	.	O

Plasma	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
before	IN	O
and	CC	O
after	IN	O
jejunoileal	JJ	O
bypass	NN	O
randomized	VBN	O
to	TO	O
different	JJ	O
jejunoileal	JJ	O
ratios	NNS	O
.	.	O

Seven	CD	O
patients	NNS	O
were	VBD	O
studied	VBN	O
before	IN	O
bypass	NN	O
surgery	NN	O
and	CC	O
28	CD	O
were	VBD	O
examined	VBN	O
after	IN	O
end-to-side	JJ	O
jejunoileal	JJ	O
bypass	NN	O
with	IN	O
50	CD	O
cm	NNS	O
intestine	NN	O
in	IN	O
continuity	NN	O
and	CC	O
a	DT	O
3:1	CD	O
or	CC	O
1:3	CD	O
ratio	NN	O
between	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
jejunal	NN	O
and	CC	O
ileal	JJ	O
segments	NNS	O
.	.	O

Fasting	VBG	Physical
levels	NNS	Physical
of	IN	Physical
intact	JJ	Physical
neurotensin	NNS	Physical
were	VBD	O
unchanged	JJ	O
by	IN	O
surgery	NN	O
,	,	O
whereas	JJ	O
levels	NNS	O
of	IN	O
NH2-terminal	JJ	Physical
immunoreactivity	NN	Physical
were	VBD	O
higher	JJR	O
in	IN	O
bypass	NN	O
patients	NNS	O
with	IN	O
a	DT	O
long	JJ	O
ileal	NN	O
segment	NN	O
(	(	O
37.5	CD	O
cm	NN	O
)	)	O
than	IN	O
in	IN	O
unoperated	JJ	O
patients	NNS	O
and	CC	O
in	IN	O
those	DT	O
with	IN	O
a	DT	O
short	JJ	O
ileal	NN	O
segment	NN	O
(	(	O
12.5	CD	O
cm	NN	O
)	)	O
.	.	O

Meal-stimulated	JJ	Physical
levels	NNS	Physical
of	IN	Physical
intact	JJ	Physical
neurotensin	NNS	Physical
were	VBD	O
higher	JJR	O
after	IN	O
1:3	CD	O
than	IN	O
3:1	CD	O
jejunoileal	JJ	O
bypass	NN	O
.	.	O

The	DT	O
levels	NNS	Physical
of	IN	Physical
NH2-terminal	JJ	Physical
immunoreactivity	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
short	JJ	O
ileal	NN	O
segment	NN	O
and	CC	O
in	IN	O
controls	NNS	O
were	VBD	O
lower	JJR	O
than	IN	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
long	JJ	O
ileal	NN	O
segment	NN	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
postprandial	JJ	Physical
levels	NNS	Physical
of	IN	Physical
both	DT	Physical
intact	JJ	Physical
neurotensin	NN	Physical
and	CC	Physical
NH2-terminal	JJ	Physical
immunoreactivity	NN	Physical
are	VBP	O
related	VBN	O
to	TO	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
functioning	NN	O
ileum	NN	O
and	CC	O
that	IN	O
even	RB	O
a	DT	O
difference	NN	O
in	IN	O
length	NN	O
of	IN	O
25	CD	O
cm	NN	O
is	VBZ	O
reflected	VBN	O
in	IN	O
the	DT	O
circulating	NN	O
levels	NNS	O
of	IN	O
neurotensin	NN	O
.	.	O

Neurophysiological	JJ	O
double-blind	JJ	O
trial	NN	O
of	IN	O
a	DT	O
botulinum	NN	O
neurotoxin	NN	O
type	IN	O
a	DT	O
free	JJ	O
of	IN	O
complexing	VBG	O
proteins	NNS	O
.	.	O

OBJECTIVE	NNP	O
Safety	NNP	Others
and	CC	O
efficacy	NN	Others
of	IN	O
botulinum	NN	O
neurotoxin	NN	O
type	NN	O
A	DT	O
preparation	NN	O
NT	NNP	O
201	CD	O
(	(	O
Xeomin	NNP	O
,	,	O
Merz	NNP	O
Pharmaceuticals	NNP	O
GmbH	NNP	O
,	,	O
Frankfurt	NNP	O
am	VBP	O
Main	NNP	O
,	,	O
Germany	NNP	O
)	)	O
were	VBD	O
investigated	VBN	O
over	IN	O
52	CD	O
weeks	NNS	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
with	IN	O
32	CD	O
male	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
Electroneurographic	JJ	Others
assessments	NNS	Physical
with	IN	O
surface	NN	O
electrodes	NNS	O
were	VBD	O
performed	VBN	O
after	IN	O
single	JJ	O
injections	NNS	O
of	IN	O
NT	NNP	O
201	CD	O
(	(	O
2	CD	O
,	,	O
4	CD	O
,	,	O
16	CD	O
,	,	O
or	CC	O
32	CD	O
units	NNS	O
)	)	O
into	IN	O
the	DT	O
extensor	NN	O
digitorum	NN	O
brevis	NN	O
(	(	O
EDB	NNP	O
)	)	O
muscle	NN	O
and	CC	O
the	DT	O
same	JJ	O
dose	NN	O
(	(	O
Botox	NNP	O
;	:	O
Allergan	NNP	O
Pharmaceuticals	NNP	O
(	(	O
Ireland	NNP	O
)	)	O
Ltd.	NNP	O
Westport	NNP	O
,	,	O
Ireland	NNP	O
)	)	O
into	IN	O
the	DT	O
contralateral	JJ	O
EDB	NNP	O
.	.	O

RESULTS	NNP	O
All	NNP	O
NT	NNP	O
201	CD	O
and	CC	O
BTXCo	NNP	O
doses	VBZ	O
achieved	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	Physical
of	IN	Physical
the	DT	Physical
compound	NN	Physical
muscle	NN	Physical
action	NN	Physical
potential	JJ	Physical
M-wave	NNP	Physical
amplitude	NN	Physical
in	IN	O
the	DT	O
EDB	NNP	O
muscle	NN	O
.	.	O

At	IN	O
week	NN	O
4	CD	O
,	,	O
the	DT	O
highest	JJS	O
dose	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
more	RBR	O
effective	JJ	Others
than	IN	O
the	DT	O
lowest	JJS	O
dose	NN	O
(	(	O
NT	NNP	O
201	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.019	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.195-1.370	JJ	O
;	:	O
and	CC	O
BTXCo	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.309-1.167	JJ	O
)	)	O
.	.	O

Duration	NN	Others
of	IN	Others
effect	NN	Others
was	VBD	O
dose	JJ	O
dependent	NN	O
.	.	O

The	DT	O
mean	JJ	Physical
values	NNS	Physical
of	IN	Physical
compound	NN	Physical
muscle	NN	Physical
action	NN	Physical
potential	JJ	Physical
M-wave	NNP	Physical
amplitudes	NNS	Physical
in	IN	Physical
the	DT	Physical
adjacent	JJ	Physical
muscles	NNS	Physical
(	(	O
abductor	NN	O
digiti	NN	O
quinti	NN	O
and	CC	O
abductor	NN	O
hallucis	NN	O
)	)	O
were	VBD	O
above	IN	O
the	DT	O
predefined	JJ	O
threshold	NN	O
of	IN	O
effect	NN	O
,	,	O
indicating	VBG	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
relevant	JJ	O
diffusion-induced	JJ	O
reduction	NN	O
of	IN	O
muscle	NN	Physical
activity	NN	Physical
.	.	O

NT	CC	O
201	CD	O
and	CC	O
BTXCo	NNP	O
were	VBD	O
well	RB	O
tolerated	VBN	Others
.	.	O

CONCLUSIONS	NNP	O
NT	NNP	O
201	CD	O
is	VBZ	O
effective	JJ	O
and	CC	O
safe	JJ	O
in	IN	O
inducing	VBG	O
the	DT	O
desired	VBN	O
paretic	JJ	O
effect	NN	O
.	.	O

Effects	NNS	O
of	IN	O
maternal	JJ	O
and	CC	O
dietary	JJ	O
selenium	NN	O
(	(	O
Se-enriched	NNP	O
yeast	NN	O
)	)	O
on	IN	O
the	DT	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
of	IN	O
germ	JJ	O
cells	NNS	O
of	IN	O
their	PRP$	O
offspring	NN	O
in	IN	O
goats	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
selenium	NN	O
on	IN	O
the	DT	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
(	(	O
two	CD	O
components	NNS	O
of	IN	O
MPF	NNP	O
regulating	VBG	O
cell	NN	O
cycle	NN	O
)	)	O
of	IN	O
germ	JJ	O
cells	NNS	O
of	IN	O
their	PRP$	O
offspring	NN	O
in	IN	O
goats	NNS	O
.	.	O

A	DT	O
herd	NN	O
of	IN	O
119	CD	O
Taihang	NNP	O
Black	NNP	O
Goats	NNP	O
,	,	O
which	WDT	O
was	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
treatments	NNS	O
,	,	O
received	VBD	O
experimental	JJ	O
diet	JJ	O
with	IN	O
different	JJ	O
Se	NNP	O
levels	NNS	O
(	(	O
from	IN	O
Se-enriched	NNP	O
yeast	NN	O
)	)	O
for	IN	O
174d	CD	O
.	.	O

The	DT	O
four	CD	O
treatments	NNS	O
,	,	O
fed	VBN	O
with	IN	O
a	DT	O
basal	NN	O
diet	JJ	O
,	,	O
were	VBD	O
supplemented	VBN	O
with	IN	O
0	CD	O
(	(	O
control	NN	O
)	)	O
,	,	O
0.5	CD	O
,	,	O
2	CD	O
and	CC	O
4	CD	O
mgkg??	NN	O
DM	NNP	O
Se	NNP	O
.	.	O

Testis	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
from	IN	O
the	DT	O
young	JJ	O
male	NN	O
goats	NNS	O
of	IN	O
each	DT	O
treatment	NN	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
30d	CD	O
after	IN	O
weaning	VBG	O
)	)	O
for	IN	O
mRNA	NN	O
expression	NN	O
using	VBG	O
real-time	JJ	O
PCR	NNP	O
and	CC	O
for	IN	O
protein	JJ	O
expression	NN	O
by	IN	O
immunohistochemistry	NN	O
assay	NN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
mRNA	JJ	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
in	IN	O
the	DT	O
testis	NN	O
of	IN	O
Se-deficient	NNP	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
and	CC	O
Se-excess	NNP	O
(	(	O
Group	NNP	O
4	CD	O
)	)	O
animals	NNS	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
Groups	NNP	O
2	CD	O
and	CC	O
3	CD	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
mRNA	JJ	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
between	IN	O
Se-deficient	NNP	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
and	CC	O
Se-excess	NNP	O
(	(	O
Group	NNP	O
4	CD	O
)	)	O
.	.	O

Also	RB	O
the	DT	O
immunohistochemistry	NN	O
assay	NN	O
detected	VBD	O
similar	JJ	O
results	NNS	O
of	IN	O
protein	JJ	O
expression	NN	O
of	IN	O
these	DT	O
two	CD	O
genes	NNS	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
,	,	O
that	DT	O
maternal	JJ	O
and	CC	O
dietary	JJ	O
Se-induced	NNP	O
oxidative	JJ	O
stress	NN	O
can	MD	O
modulate	VB	O
the	DT	O
mRNA	NN	O
and	CC	O
protein	JJ	O
expression	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
related	VBN	O
genes	NNS	O
(	(	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
)	)	O
in	IN	O
the	DT	O
testis	NN	O
of	IN	O
their	PRP$	O
offspring	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
Se	NNP	O
deficiency	NN	O
and	CC	O
Se	NNP	O
excess	NN	O
could	MD	O
prevent	VB	O
the	DT	O
completion	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
.	.	O

Naltrexone	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
naltrexone	NN	O
,	,	O
an	DT	O
opiate	NN	O
blocker	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Thirteen	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.4	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
(	(	O
mean	VB	O
5.4	CD	O
)	)	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
.	.	O

Naltrexone	NNP	O
,	,	O
1.0	CD	O
mg/kg	NN	O
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	Mental
Global	NNP	Mental
Impressions	NNP	Mental
(	(	Mental
CGI	NNP	Mental
)	)	Mental
,	,	O
Conners	NNPS	Mental
Rating	NNP	Mental
Scales	NNP	Mental
,	,	O
and	CC	O
Naltrexone	NNP	Others
Side-Effects	NNP	Others
(	(	Others
SE	NNP	Others
)	)	Others
Rating	NNP	Others
Scale	NNP	Others
;	:	O
laboratory	NN	Mental
CGI	NNP	Mental
,	,	O
movement	NN	Mental
actometer	NN	Mental
readings	NNS	Mental
,	,	O
and	CC	O
a	DT	Mental
10-second	JJ	Mental
interval	NN	Mental
recording	VBG	Mental
system	NN	Mental
analysis	NN	Mental
of	IN	Mental
on-task	NN	Mental
,	,	O
communication	NN	Mental
initiations	NNS	Mental
,	,	O
disruptive	JJ	Mental
behavior	NN	Mental
,	,	O
and	CC	O
self-stimulation	NN	Mental
.	.	O

RESULTS	NNP	O
Eight	NNP	O
of	IN	O
13	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
parent	NN	Mental
measures	NNS	Mental
(	(	Mental
CGI	NNP	Mental
,	,	O
Conners	NNP	Mental
Impulsivity-Hyperactivity	NNP	Mental
Factor	NNP	Mental
,	,	O
and	CC	O
SE-Restlessness	NNP	Mental
)	)	O
and	CC	O
Teacher	NNP	Mental
CGI	NNP	Mental
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Teacher	CC	Mental
SE-Restlessness	JJ	Mental
and	CC	O
initiation	NN	Mental
of	IN	Mental
communication	NN	Mental
in	IN	O
the	DT	O
clinic	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
.	.	O

Actometer	NNP	Physical
readings	NNS	Physical
improved	VBN	O
in	IN	O
two	CD	O
children	NNS	O
who	WP	O
were	VBD	O
very	RB	O
active	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Adverse	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
behavioral	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
transient	NN	O
.	.	O

Administering	VBG	O
the	DT	O
bitter	JJ	O
tablet	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	O
offers	VBZ	O
promise	RB	O
as	IN	O
an	DT	O
agent	NN	O
for	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	O
and	CC	O
social	JJ	Mental
communication	NN	Mental
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
measures	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
outpatient	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
change	NN	O
.	.	O

Prevention	NN	O
of	IN	O
premature	JJ	O
labor	NN	O
by	IN	O
17	CD	O
alpha-hydroxyprogesterone	JJ	O
caproate	NN	O
.	.	O

Eighty	NNP	O
pregnant	JJ	O
women	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
of	IN	O
giving	VBG	O
birth	NN	O
prematurely	RB	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
either	DT	O
17	CD	O
alpha-hydroxyprogesterone	NN	O
caproate	NN	O
,	,	O
250	CD	O
mg	NN	O
by	IN	O
intramuscular	JJ	O
injection	NN	O
once	RB	O
a	DT	O
week	NN	O
,	,	O
or	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
given	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
.	.	O

Imminent	JJ	O
premature	NN	O
labor	NN	O
occurred	VBD	O
in	IN	O
29.0	CD	O
%	NN	O
of	IN	O
the	DT	O
treated	VBN	O
group	NN	O
and	CC	O
in	IN	O
59.4	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
premature	NN	Physical
deliveries	NNS	Physical
was	VBD	O
also	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
(	(	O
16.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
37.82	CD	O
%	NN	O
)	)	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
cases	NNS	O
of	IN	O
perinatal	JJ	Mortality
death	NN	Mortality
or	CC	O
fetal	JJ	Adverseeffect
malformations	NNS	Adverseeffect
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
mean	JJ	Physical
birth	NN	Physical
weight	NN	Physical
of	IN	O
all	DT	O
infants	NNS	O
of	IN	O
the	DT	O
treated	JJ	O
group	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
in	IN	O
those	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
3111.9	CD	O
+/-	JJ	O
905	CD	O
gm	NN	O
versus	NN	O
2680	CD	O
+/-	JJ	O
813.4	CD	O
gm	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
support	VB	O
treatment	NN	O
with	IN	O
progesterone	NN	O
caproate	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
premature	JJ	O
labor	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
study	NN	O
of	IN	O
customized	JJ	O
preventive	JJ	O
medicine	NN	O
reminder	NN	O
letters	NNS	O
in	IN	O
a	DT	O
community	NN	O
practice	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
customized	JJ	O
,	,	O
family-oriented	JJ	O
reminder	NN	O
letters	NNS	O
in	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
seek	VB	O
appropriate	JJ	O
preventive	JJ	O
services	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
computer-generated	JJ	O
,	,	O
customized	JJ	O
letters	NNS	O
explaining	VBG	O
recommended	VBD	O
preventive	JJ	O
procedures	NNS	O
for	IN	O
each	DT	O
family	NN	O
member	NN	O
.	.	O

A	DT	O
second	JJ	O
group	NN	O
received	VBD	O
a	DT	O
form	JJ	O
letter	NN	O
listing	NN	O
recommendations	NNS	O
for	IN	O
all	DT	O
preventive	JJ	O
procedures	NNS	O
for	IN	O
all	DT	O
age	NN	O
and	CC	O
sex	NN	O
groups	NNS	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
received	VBD	O
no	DT	O
letters	NNS	O
.	.	O

SETTING	VBG	O
A	DT	O
private	JJ	O
medical	JJ	O
centre	NN	O
,	,	O
without	IN	O
university	NN	O
affiliation	NN	O
,	,	O
in	IN	O
rural	JJ	O
Quebec	NNP	O
.	.	O

PARTICIPANTS	NN	O
From	IN	O
8770	CD	O
patients	NNS	O
who	WP	O
met	VBD	O
study	NN	O
criteria	NNS	O
,	,	O
719	CD	O
families	NNS	O
were	VBD	O
randomly	RB	O
selected	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
1971	CD	O
of	IN	O
1998	CD	O
patients	NNS	O
in	IN	O
these	DT	O
families	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	Physical
Family	NNP	Physical
Received	NNP	Physical
Index	NNP	Physical
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
all	DT	O
procedures	NNS	O
for	IN	O
which	WDT	O
a	DT	O
family	NN	O
was	VBD	O
overdue	JJ	O
that	IN	O
they	PRP	O
received	VBD	O
.	.	O

The	DT	O
Family	JJ	Physical
End-of-study	NNP	Physical
Up-to-date	NNP	Physical
Index	NNP	Physical
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
procedures	NNS	O
for	IN	O
which	WDT	O
the	DT	O
family	NN	O
was	VBD	O
eligible	JJ	O
and	CC	O
for	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
up-to-date	JJ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
Family	NNP	Physical
Received	NNP	Physical
Index	NNP	Physical
for	IN	O
families	NNS	O
mailed	VBN	O
customized	JJ	O
letters	NNS	O
was	VBD	O
more	RBR	O
than	IN	O
double	RB	O
the	DT	O
index	NN	O
for	IN	O
patients	NNS	O
not	RB	O
mailed	VBN	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0139	NNP	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
Family	NNP	Physical
End-of-study	NNP	Physical
Up-to-date	NNP	Physical
indices	NNS	Physical
also	RB	O
demonstrated	VBD	O
that	IN	O
families	NNS	O
of	IN	O
patients	NNS	O
sent	JJ	O
customized	JJ	O
letters	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
up-to-date	JJ	O
than	IN	O
families	NNS	O
not	RB	O
sent	VBD	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0054	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
appeared	VBD	O
between	IN	O
the	DT	O
number	NN	O
of	IN	O
preventive	JJ	O
measures	NNS	O
received	VBN	O
by	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
form-letter	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
a	DT	O
clinically	RB	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
value	NN	O
to	TO	O
customizing	VBG	O
reminder	NN	O
letters	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
dietary	JJ	O
pyridoxine	NN	O
on	IN	O
haemato-immunological	JJ	Physical
responses	NNS	Physical
of	IN	O
Labeo	NNP	O
rohita	JJ	O
fingerlings	NNS	O
reared	VBD	O
at	IN	O
higher	JJR	O
water	NN	O
temperature	NN	O
.	.	O

A	DT	O
sixty-day	JJ	O
feeding	NN	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
elucidate	VB	O
the	DT	O
effect	NN	O
of	IN	O
dietary	JJ	O
pyridoxine	NN	O
(	(	O
PN	NNP	O
)	)	O
on	IN	O
hemato-immunological	JJ	Physical
parameters	NNS	Physical
in	IN	O
Labeo	NNP	O
rohita	VBP	O
fingerlings	NNS	O
exposed	VBN	O
to	TO	O
an	DT	O
elevated	JJ	O
temperature	NN	O
(	(	O
ET	NNP	O
)	)	O
of	IN	O
33	CD	O
?C	NNS	O
.	.	O

Two	CD	O
hundred	VBD	O
and	CC	O
seventy	JJ	O
fingerlings	NNS	O
(	(	O
6.71	CD	O
?	.	O
0.32	CD	O
g	NN	O
)	)	O
were	VBD	O
randomly	RB	O
distributed	VBN	O
into	IN	O
six	CD	O
treatments	NNS	O
in	IN	O
triplicates	NNS	O
(	(	O
15	CD	O
fish/tank	NN	O
)	)	O
.	.	O

Five	CD	O
iso-nitrogenous	JJ	O
(	(	O
356.3	CD	O
?	.	O
2.7	CD	O
g/kg	JJ	O
crude	NN	O
protein	NN	O
)	)	O
purified	VBD	O
diets	NNS	O
were	VBD	O
prepared	VBN	O
with	IN	O
graded	JJ	O
levels	NNS	O
(	(	O
0	CD	O
,	,	O
10	CD	O
,	,	O
50	CD	O
,	,	O
100	CD	O
and	CC	O
200	CD	O
mg/kg	NNS	O
diet	JJ	O
)	)	O
of	IN	O
PN	NNP	O
.	.	O

Six	NNP	O
treatment	NN	O
groups	NNS	O
were	VBD	O
P10T26	NNP	O
(	(	O
10	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ambient	JJ	O
temperature	NN	O
(	(	O
26	CD	O
?C	NN	O
)	)	O
,	,	O
P0T33	NNP	O
(	(	O
0	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ET	NNP	O
)	)	O
,	,	O
P10T33	NNP	O
(	(	O
10	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ET	NNP	O
)	)	O
,	,	O
P50T33	NNP	O
(	(	O
50	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ET	NNP	O
)	)	O
,	,	O
P100T33	NNP	O
(	(	O
100	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ET	NNP	O
)	)	O
and	CC	O
P200T33	NNP	O
(	(	O
200	CD	O
mg	NN	O
PN	NNP	O
+	NNP	O
ET	NNP	O
)	)	O
.	.	O

The	DT	O
responses	NNS	O
of	IN	O
L.	NNP	O
rohita	JJ	O
fingerlings	NNS	O
to	TO	O
dietary	JJ	O
PN	NNP	O
were	VBD	O
assessed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
growth	NN	O
and	CC	O
by	IN	O
analysing	VBG	O
some	DT	O
hemato-immunological	JJ	O
parameters	NNS	O
.	.	O

When	WRB	O
PN	NNP	O
supplementation	NN	O
increased	VBD	O
from	IN	O
10	CD	O
to	TO	O
200	CD	O
mg/kg	NNS	O
diet	JJ	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
weight	JJ	O
gain	NN	O
percentage	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Erythrocyte	NNP	O
(	(	O
RBC	NNP	O
)	)	O
count	NN	O
,	,	O
leucocyte	NN	O
(	(	O
WBC	NNP	O
)	)	O
count	NN	O
,	,	O
haemoglobin	NN	O
content	NN	O
and	CC	O
respiratory	JJ	O
burst	NN	O
activity	NN	O
were	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
in	IN	O
100	CD	O
mg	JJ	O
PN/kg	NNP	O
diet-fed	NN	O
group	NN	O
than	IN	O
their	PRP$	O
non-PN-fed	JJ	O
counterpart	NN	O
.	.	O

Also	RB	O
,	,	O
serum	JJ	Physical
albumin	NN	Physical
,	,	Physical
globulin	NN	Physical
and	CC	Physical
lysozyme	JJ	Physical
activity	NN	Physical
were	VBD	O
found	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
in	IN	O
PN-fed	NNP	O
groups	NNS	O
.	.	O

The	DT	O
overall	JJ	O
results	NNS	O
indicated	VBD	O
that	IN	O
dietary	JJ	O
PN	NNP	O
supplementation	NN	O
at	IN	O
100	CD	O
mg/kg	NNS	O
diet	JJ	O
may	MD	O
reverse	VB	O
the	DT	O
negative	JJ	O
effects	NNS	O
caused	VBN	O
by	IN	O
ET	NNP	O
and	CC	O
may	MD	O
protect	VB	O
the	DT	O
haemato-immunological	JJ	O
status	NN	O
of	IN	O
L.	NNP	O
rohita	JJ	O
fingerlings	NNS	O
reared	VBD	O
at	IN	O
higher	JJR	O
water	NN	O
temperature	NN	O
.	.	O

Torasemide	NNP	O
versus	NN	O
furosemide	NN	O
in	IN	O
cirrhosis	NN	O
:	:	O
a	DT	O
long-term	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
long-term	JJ	O
therapy	NN	O
(	(	O
70	CD	O
days	NNS	O
)	)	O
with	IN	O
torasemide	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
loop	NN	O
diuretic	JJ	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
furosemide	NN	O
(	(	O
50	CD	O
mg/day	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
administered	VBN	O
in	IN	O
association	NN	O
with	IN	O
spironolactone	NN	O
(	(	O
200	CD	O
mg/day	NN	O
)	)	O
in	IN	O
28	CD	O
nonazotemic	JJ	O
cirrhotic	JJ	O
patients	NNS	O
with	IN	O
controlled	JJ	O
ascites	NNS	O
.	.	O

The	DT	O
treatments	NNS	O
did	VBD	O
not	RB	O
modify	VB	O
creatinine	JJ	Physical
clearance	NN	Physical
and	CC	O
exhibited	VBD	O
a	DT	O
similar	JJ	O
effect	NN	O
on	IN	O
body	NN	Physical
weight	NN	Physical
,	,	Physical
urinary	JJ	Physical
volume	NN	Physical
,	,	O
and	CC	O
fractional	JJ	Physical
excretion	NN	Physical
of	IN	Physical
uric	JJ	Physical
acid	NN	Physical
,	,	Physical
sodium	NN	Physical
,	,	Physical
and	CC	Physical
chloride	NN	Physical
.	.	O

The	DT	O
effect	NN	O
of	IN	O
torasemide	NN	O
on	IN	O
fractional	JJ	Physical
potassium	NN	Physical
excretion	NN	Physical
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
furosemide	NN	O
.	.	O

Torasemide	VB	O
showed	VBD	O
higher	JJR	O
sparing	VBG	Others
effect	NN	Others
than	IN	O
furosemide	NN	O
on	IN	O
calcium	NN	Physical
,	,	Physical
inorganic	JJ	Physical
phosphate	NN	Physical
,	,	Physical
and	CC	Physical
magnesium	NN	Physical
excretion	NN	Physical
and	CC	O
stronger	JJR	O
action	NN	O
on	IN	O
free	JJ	Physical
water	NN	Physical
clearance	NN	Physical
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
serum	NN	Physical
parameters	NNS	Physical
were	VBD	O
induced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
.	.	O

Two	CD	O
episodes	NNS	O
of	IN	O
hepatic	JJ	Physical
encephalopathy	NN	Physical
occurred	VBD	O
in	IN	O
the	DT	O
torasemide	NN	O
group	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
its	PRP$	O
effects	NNS	Physical
on	IN	Physical
sodium	NN	Physical
and	CC	Physical
water	NN	Physical
excretion	NN	Physical
and	CC	O
on	IN	Physical
other	JJ	Physical
urinary	JJ	Physical
parameters	NNS	Physical
,	,	O
torasemide	NN	O
can	MD	O
represent	VB	O
an	DT	O
alternative	JJ	O
tool	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
ascites	NNS	O
.	.	O

[	JJ	O
Afala	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
BPH	NNP	O
:	:	O
efficacy	NN	O
and	CC	O
safety	NN	O
]	NN	O
.	.	O

The	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
94	CD	O
patients	NNS	O
has	VBZ	O
evaluated	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
domestic	JJ	O
preparation	NN	O
afala	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptoms	NNS	O
of	IN	O
I-II	NNP	O
stages	NNS	O
benign	VBP	O
prostatic	JJ	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
a	DT	O
6-month	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
afala	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
2	CD	O
tablets	NNS	O
4	CD	O
times	NNS	O
a	DT	O
day	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
severity	NN	O
of	IN	O
urinary	JJ	O
disorders	NNS	O
,	,	O
estimated	VBN	O
by	IN	O
total	JJ	O
IPSS	NNP	O
score	NN	O
,	,	O
relative	JJ	O
to	TO	O
baseline	VB	O
values	NNS	O
and	CC	O
compared	VBN	O
to	TO	O
placebo	VB	O
therapy	NN	O
.	.	O

The	DT	O
most	RBS	O
pronounced	JJ	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
were	VBD	O
registered	VBN	O
in	IN	O
respect	NN	O
of	IN	O
irritative	JJ	O
symptoms	NNS	O
of	IN	O
BPH	NNP	O
.	.	O

According	VBG	O
uroflowmetry	NN	O
,	,	O
peak	JJ	Physical
flow	NN	Physical
rate	NN	Physical
after	IN	Physical
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
.	.	O

Significant	JJ	O
clinical	JJ	O
benefit	NN	O
persisted	VBD	O
not	RB	O
only	RB	O
within	IN	O
the	DT	O
6-month	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
but	CC	O
3	CD	O
months	NNS	O
after	IN	O
.	.	O

Long-term	JJ	O
therapy	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
concentration	NN	Physical
of	IN	Physical
total	JJ	Physical
,	,	Physical
free	JJ	Physical
and	CC	Physical
complex	JJ	Physical
PSA	NNP	Physical
,	,	O
testosterone	NN	Physical
(	(	Physical
total	JJ	Physical
and	CC	Physical
free	JJ	Physical
)	)	Physical
,	,	Physical
dihydrotestosterone	NN	Physical
,	,	O
and	CC	O
prolactin	NN	Physical
in	IN	Physical
the	DT	Physical
blood	NN	Physical
.	.	Physical

Absence	NN	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
,	,	Adverseeffect
biochemical	JJ	Adverseeffect
abnormalities	NNS	Adverseeffect
,	,	Adverseeffect
changes	NNS	Adverseeffect
in	IN	Adverseeffect
clinical	JJ	Adverseeffect
blood	NN	Adverseeffect
and	CC	Adverseeffect
urine	NN	Adverseeffect
confirmed	VBD	O
the	DT	O
safety	NN	O
of	IN	O
6-month	JJ	O
therapy	NN	O
.	.	O

Ambulatory	NNP	O
blood	NN	Physical
pressure	NN	Physical
control	NN	O
with	IN	O
bedtime	JJ	O
aspirin	JJ	O
administration	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
prehypertension	NN	O
.	.	O

BACKGROUND	NNP	O
Aspirin	NNP	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
prevent	VB	O
angiotensin	JJ	O
II-induced	NNP	O
hypertension	NN	O
and	CC	O
to	TO	O
induce	VB	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
release	NN	O
from	IN	O
vascular	JJ	O
endothelium	NN	O
.	.	O

Low-dose	JJ	O
aspirin	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
blood	NN	Physical
pressure	NN	Physical
(	(	Physical
BP	NNP	Physical
)	)	Physical
when	WRB	O
administered	VBN	O
at	IN	O
bedtime	NN	O
,	,	O
as	IN	O
opposed	VBN	O
to	TO	O
upon	IN	O
awakening	VBG	O
,	,	O
in	IN	O
untreated	JJ	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
high-risk	JJ	O
pregnant	JJ	O
women	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
on	IN	O
ambulatory	JJ	Physical
BP	NNP	Physical
of	IN	O
aspirin	NN	O
administered	VBN	O
at	IN	O
different	JJ	O
times	NNS	O
of	IN	O
the	DT	O
day	NN	O
in	IN	O
prehypertension	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
244	CD	O
subjects	NNS	O
with	IN	O
prehypertension	NN	O
,	,	O
43.0	CD	O
+/-	JJ	O
13.0	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
randomly	RB	O
divided	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
:	:	O
nonpharmacological	JJ	O
hygienic-dietary	JJ	O
recommendations	NNS	O
;	:	O
the	DT	O
same	JJ	O
recommendations	NNS	O
and	CC	O
aspirin	NN	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
on	IN	O
awakening	VBG	O
;	:	O
or	CC	O
the	DT	O
same	JJ	O
recommendations	NNS	O
and	CC	O
aspirin	NN	O
at	IN	O
bedtime	NN	O
.	.	O

BP	NNP	Physical
was	VBD	O
measured	VBN	O
for	IN	O
48	CD	O
consecutive	JJ	O
hours	NNS	O
before	IN	O
and	CC	O
after	IN	O
3	CD	O
months	NNS	O
of	IN	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Ambulatory	NNP	Mental
BP	NNP	Mental
was	VBD	O
unchanged	JJ	O
in	IN	O
subjects	NNS	O
randomized	VBN	O
to	TO	O
either	DT	O
nonpharmacological	JJ	O
intervention	NN	O
or	CC	O
aspirin	NN	O
on	IN	O
awakening	VBG	O
.	.	O

A	DT	O
significant	JJ	O
ambulatory	NN	Others
BP	NNP	Others
reduction	NN	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
observed	VBN	O
in	IN	O
the	DT	O
subjects	NNS	O
who	WP	O
received	VBD	O
aspirin	NN	O
at	IN	O
bedtime	NN	O
(	(	O
decrease	NN	O
of	IN	O
6/3	CD	O
mm	NNS	O
Hg	NNP	O
in	IN	O
the	DT	O
24-h	JJ	O
mean	NN	O
of	IN	O
systolic	NN	Mental
(	(	Mental
SBP	NNP	Mental
)	)	Mental
/diastolic	VBP	Mental
BP	NNP	Mental
(	(	Mental
DBP	NNP	Mental
)	)	Mental
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
without	IN	O
changes	NNS	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
(	(	Physical
HR	NNP	Physical
)	)	Physical
from	IN	O
baseline	NN	O
.	.	O

BP	NNP	Others
was	VBD	O
homogeneously	RB	O
controlled	VBN	O
along	IN	O
the	DT	O
24	CD	O
h	NN	O
after	IN	O
bedtime	NN	O
aspirin	JJ	O
administration	NN	O
(	(	O
6/4	CD	O
mm	NN	O
Hg	NNP	O
reduction	NN	O
in	IN	O
activity	NN	O
mean	NN	O
of	IN	O
SBP/DBP	NNP	O
;	:	O
6/3	CD	O
mm	NN	O
Hg	NNP	O
reduction	NN	O
in	IN	O
sleep-time	JJ	O
mean	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
prospective	JJ	O
trial	NN	O
documents	NNS	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
BP	NNP	Others
of	IN	O
low	JJ	O
dose	NN	O
aspirin	NN	O
only	RB	O
when	WRB	O
ingested	VBN	O
at	IN	O
bedtime	NN	O
by	IN	O
prehypertensive	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
timed	JJ	O
administration	NN	O
of	IN	O
low-dose	JJ	O
aspirin	NN	O
could	MD	O
thus	RB	O
provide	VB	O
a	DT	O
valuable	JJ	O
and	CC	O
cost-effective	JJ	O
approach	NN	O
for	IN	O
BP	NNP	Physical
control	NN	Physical
in	IN	O
subjects	NNS	O
at	IN	O
elevated	JJ	O
risk	NN	O
of	IN	O
developing	VBG	O
hypertension	NN	O
.	.	O

Intermittent	NNP	O
recombinant	JJ	O
growth	NN	O
hormone	NN	O
treatment	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
:	:	O
four-year	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
different	JJ	O
treatment	NN	O
regimens	NNS	O
.	.	O

BACKGROUND	NNP	O
Treatment	NNP	O
of	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
SGA	NNP	O
with	IN	O
recombinant	JJ	O
human	JJ	O
growth	NN	O
hormone	VBD	O
r-hGH	JJ	O
increases	NNS	O
growth	NN	Physical
velocity	NN	Physical
during	IN	O
childhood	NN	O
.	.	O

As	IN	O
in	IN	O
other	JJ	O
indications	NNS	O
,	,	O
the	DT	O
growth	NN	Physical
velocity	NN	Physical
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
more	JJR	O
marked	JJ	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
treatment	NN	O
and	CC	O
then	RB	O
decreases	VBZ	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
different	JJ	O
r-hGH	JJ	O
treatment	NN	O
schedules	NNS	O
(	(	O
67	CD	O
microg/kg/day	NN	O
in	IN	O
a	DT	O
discontinuous	JJ	O
or	CC	O
continuous	JJ	O
regimen	NNS	O
)	)	O
during	IN	O
the	DT	O
second	JJ	O
year	NN	O
of	IN	O
r-hGH	JJ	O
treatment	NN	O
by	IN	O
comparing	VBG	O
height	JJ	Physical
velocity	NN	Physical
changes	NNS	O
and	CC	O
total	JJ	Physical
gain	NN	Physical
of	IN	Physical
height	NN	Physical
over	IN	O
a	DT	O
4-year	JJ	O
period	NN	O
.	.	O

METHODS	$	O
58	CD	O
growth-retarded	JJ	O
SGA	NNP	O
children	NNS	O
aged	VBN	O
2-5	CD	O
years	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
TOTO	NNP	O
regimen	NN	O
(	(	O
4	CD	O
years	NNS	O
alternating	VBG	O
treatment	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
observation	NN	O
(	(	O
O	NNP	O
)	)	O
,	,	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
TTOO	JJ	O
regimen	NN	O
(	(	O
2	CD	O
years	NNS	O
'	POS	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
years	NNS	O
'	POS	O
observation	NN	O
,	,	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
.	.	O

Height	NNP	Physical
velocity	NN	Physical
HV	NNP	Physical
and	CC	O
total	JJ	Physical
height	NN	Physical
gain	NN	Physical
were	VBD	O
assessed	VBN	O
during	IN	O
the	DT	O
4-year	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
groups	NNS	O
,	,	O
HV	NNP	Physical
and	CC	O
HV	NNP	Physical
standard	JJ	Physical
deviation	NN	Physical
score	VBD	Physical
HV-SDSCA	NNP	Physical
increased	VBD	O
during	IN	O
treatment	NN	O
and	CC	O
decreased	VBD	O
during	IN	O
observation	NN	O
periods	NNS	O
.	.	O

Interruption	NN	O
of	IN	O
treatment	NN	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
better	JJR	O
gain	NN	Physical
in	IN	Physical
height	JJ	Physical
standard	NN	Physical
deviation	NN	Physical
score	VBD	Physical
H-SDSCA	NNP	Physical
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
.	.	O

After	IN	O
4	CD	O
years	NNS	O
of	IN	O
study	NN	O
,	,	O
the	DT	O
gain	NN	Physical
in	IN	Physical
H-SDSCA	NNP	Physical
was	VBD	O
1.4	CD	O
+	NN	O
or	CC	O
-	:	O
01	CD	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
and	CC	O
1.6	CD	O
+	NN	O
or	CC	O
-	:	O
0.2	CD	O
in	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
leading	VBG	O
to	TO	O
a	DT	O
mean	JJ	O
height	NN	Physical
of	IN	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
1.0	CD	O
SDS	NNP	O
and	CC	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
0.8	CD	O
SDS	NNP	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
bone	NN	Physical
maturation	NN	Physical
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
TOTO	NNP	O
and	CC	O
TTOO	NNP	O
regimens	NNS	O
produced	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
growth	NN	Physical
during	IN	O
r-hGH	JJ	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
treatment	NN	O
interruption	NN	O
after	IN	O
1	CD	O
year	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
overall	JJ	Physical
gain	NN	Physical
in	IN	Physical
height	NN	Physical
SDS	NNP	Physical
when	WRB	O
compared	VBN	O
with	IN	O
2	CD	O
years	NNS	O
'	POS	O
continuous	JJ	O
treatment	NN	O
.	.	O

Risperidone	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
serious	JJ	O
behavioral	JJ	O
problems	NNS	O
.	.	O

BACKGROUND	NNP	O
Atypical	NNP	O
antipsychotic	JJ	O
agents	NNS	O
,	,	O
which	WDT	O
block	VBP	O
postsynaptic	JJ	O
dopamine	NN	O
and	CC	O
serotonin	NN	O
receptors	NNS	O
,	,	O
have	VBP	O
advantages	NNS	O
over	IN	O
traditional	JJ	O
antipsychotic	JJ	O
medications	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
schizophrenia	NN	O
and	CC	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
who	WP	O
have	VBP	O
serious	JJ	O
behavioral	JJ	O
disturbances	NNS	O
.	.	O

However	RB	O
,	,	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
children	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
old	JJ	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
score	NN	O
on	IN	O
the	DT	O
Irritability	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
and	CC	O
the	DT	O
rating	NN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
-	:	O
Improvement	NN	O
(	(	O
CGI-I	NNP	O
)	)	O
scale	NN	O
at	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
101	CD	O
children	NNS	O
(	(	O
82	CD	O
boys	NNS	O
and	CC	O
19	CD	O
girls	NNS	O
;	:	O
mean	VB	O
[	IN	O
+/-SD	JJ	O
]	NNP	O
age	NN	O
,	,	O
8.8+/-2.7	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
risperidone	NN	O
(	(	O
49	CD	O
children	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
52	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
risperidone	NN	O
for	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
dose	JJ	O
range	NN	O
,	,	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
56.9	CD	O
percent	NN	O
reduction	NN	O
in	IN	O
the	DT	O
Irritability	NNP	Mental
score	NN	Mental
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
a	DT	O
14.1	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
a	DT	O
positive	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
at	IN	O
least	JJS	O
a	DT	O
25	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
the	DT	O
Irritability	NNP	Mental
score	NN	Mental
and	CC	O
a	DT	O
rating	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
CGI-I	NNP	Mental
scale	NN	Mental
,	,	O
was	VBD	O
69	CD	O
percent	NN	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
(	(	O
34	CD	O
of	IN	O
49	CD	O
children	NNS	O
had	VBD	O
a	DT	O
positive	JJ	O
response	NN	O
)	)	O
and	CC	O
12	CD	O
percent	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
6	CD	O
of	IN	O
52	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Risperidone	NNP	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
average	JJ	Physical
weight	JJ	Physical
gain	NN	Physical
of	IN	O
2.7+/-2.9	JJ	O
kg	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
0.8+/-2.2	JJ	O
kg	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Increased	VBN	O
appetite	RB	Physical
,	,	Physical
fatigue	NN	Adverseeffect
,	,	Physical
drowsiness	NN	Adverseeffect
,	,	Physical
dizziness	NN	Adverseeffect
,	,	Physical
and	CC	Physical
drooling	VBG	Adverseeffect
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
each	DT	O
comparison	NN	O
)	)	O
.	.	O

In	IN	O
two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
children	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
response	NN	O
to	TO	O
risperidone	VB	O
at	IN	O
eight	CD	O
weeks	NNS	O
(	(	O
23	CD	O
of	IN	O
34	CD	O
)	)	O
,	,	O
the	DT	O
benefit	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Risperidone	NNP	O
was	VBD	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

The	DT	O
short	JJ	O
period	NN	O
of	IN	O
this	DT	O
trial	NN	O
limits	VBZ	O
inferences	NNS	O
about	IN	O
adverse	JJ	O
effects	NNS	O
such	JJ	O
as	IN	O
tardive	JJ	O
dyskinesia	NN	O
.	.	O

Efficacy	NN	Others
screening	VBG	O
trials	NNS	O
of	IN	O
paroxetine	NN	O
,	,	O
pentoxifylline	NN	O
,	,	O
riluzole	NN	O
,	,	O
pramipexole	NN	O
and	CC	O
venlafaxine	NN	O
in	IN	O
cocaine	NN	O
dependence	NN	O
.	.	O

AIMS	CC	O
The	DT	O
two	CD	O
studies	NNS	O
presented	VBN	O
here	RB	O
were	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
paroxetine	NN	O
,	,	O
pentoxifylline	NN	O
,	,	O
riluzole	NN	O
,	,	O
venlafaxine	NN	O
and	CC	O
pramipexole	NN	O
as	IN	O
medications	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cocaine	NN	O
dependence	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
multi-arm	NN	O
,	,	O
modified	VBN	O
blinded	VBD	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
was	VBD	O
used	VBN	O
.	.	O

SETTING	VBG	O
The	DT	O
studies	NNS	O
were	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Boston	NNP	O
VA	NNP	O
Healthcare	NNP	O
System	NNP	O
and	CC	O
the	DT	O
Boston	NNP	O
University	NNP	O
School	NNP	O
of	IN	O
Medicine	NNP	O
Medication	NNP	O
Development	NNP	O
Research	NNP	O
Unit	NNP	O
(	(	O
MDRU	NNP	O
)	)	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
met	VBD	O
criteria	NNS	O
for	IN	O
cocaine	NN	O
dependence	NN	O
during	IN	O
a	DT	O
2-week	JJ	O
screening	NN	O
period	NN	O
.	.	O

INTERVENTION	NNP	O
Following	VBG	O
random	JJ	O
assignment	NN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
subjects	NNS	O
received	VBD	O
active	JJ	O
medication	NN	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
in	IN	O
combination	NN	O
with	IN	O
cognitive	JJ	O
behavioral	JJ	O
counseling	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
the	DT	O
efficacy	NN	Others
of	IN	O
the	DT	O
antidepressant	JJ	O
paroxetine	NN	O
(	(	O
20	CD	O
mg	NNS	O
daily	RB	O
)	)	O
,	,	O
the	DT	O
phosphodiesterase	NN	O
inhibitor	NN	O
pentoxifylline	NN	O
(	(	O
1200	CD	O
mg	FW	O
daily	RB	O
)	)	O
and	CC	O
the	DT	O
glutamate	NN	O
release	NN	O
inhibitor	NN	O
riluzole	NN	O
(	(	O
100	CD	O
mg	NNS	O
daily	RB	O
)	)	O
was	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
antidepressant	JJ	O
venlafaxine	NN	O
(	(	O
150	CD	O
mg	NNS	O
daily	RB	O
)	)	O
and	CC	O
the	DT	O
dopamine	JJ	O
agonist	NN	O
pramipexole	NN	O
(	(	O
1.5	CD	O
mg	NNS	O
daily	RB	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
the	DT	O
second	JJ	O
study	NN	O
.	.	O

MEASUREMENTS	NNP	O
Urine	NNP	Physical
benzoylecgonine	NN	Physical
(	(	Physical
BE	NNP	Physical
)	)	Physical
concentrations	NNS	Physical
,	,	O
self-report	NN	Mental
of	IN	Mental
cocaine	NN	Mental
use	NN	Mental
and	CC	O
global	JJ	Physical
impression	NN	Physical
scores	NNS	Physical
served	VBD	O
as	IN	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
assessments	NNS	Mental
of	IN	Mental
cocaine	NN	Mental
craving	NN	Mental
and	CC	O
psychiatric	JJ	Mental
functioning	NN	Mental
.	.	O

Adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
monitored	VBN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

FINDINGS	NNP	O
None	NN	O
of	IN	O
the	DT	O
active	JJ	O
medications	NNS	O
produced	VBD	O
greater	JJR	O
reductions	NNS	O
in	IN	O
urine	JJ	Physical
BE	NNP	Physical
concentrations	NNS	Physical
over	IN	O
the	DT	O
treatment	NN	O
period	NN	O
than	IN	O
did	VBD	O
placebo	NN	O
.	.	O

There	EX	O
were	VBD	O
trends	NNS	O
for	IN	O
BE	NNP	Physical
levels	NNS	Physical
to	TO	O
become	VB	O
reduced	VBN	O
in	IN	O
the	DT	O
pentoxifylline	NN	O
group	NN	O
during	IN	O
the	DT	O
first	JJ	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
for	IN	O
Addiction	NNP	Physical
Severity	NNP	Physical
Index	NNP	Physical
(	(	Physical
ASI	NNP	Physical
)	)	Physical
drug	NN	O
composite	JJ	O
scores	NNS	O
to	TO	O
be	VB	O
lower	JJR	O
in	IN	O
the	DT	O
pentoxyfylline	NN	O
group	NN	O
at	IN	O
end-point	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Significant	JJ	O
within-group	JJ	O
reductions	NNS	O
in	IN	O
reported	JJ	O
cocaine	NN	Mental
use	NN	Mental
and	CC	Mental
craving	NN	Mental
were	VBD	O
found	VBN	O
for	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
but	CC	O
none	NN	O
of	IN	O
the	DT	O
active	JJ	O
medications	NNS	O
were	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
on	IN	O
these	DT	O
measures	NNS	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
self-reported	JJ	Mental
cocaine	NN	Mental
use	NN	Mental
declined	VBD	O
over	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Overall	JJ	O
,	,	O
the	DT	O
active	JJ	O
medications	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	Others
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
does	VBZ	O
not	RB	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
paroxetine	NN	O
,	,	O
pentoxifylline	NN	O
,	,	O
riluzole	NN	O
,	,	O
venlafaxine	NN	O
or	CC	O
pramipexole	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cocaine	NN	O
dependence	NN	O
.	.	O

However	RB	O
,	,	O
these	DT	O
results	NNS	O
need	VBP	O
to	TO	O
be	VB	O
interpreted	VBN	O
with	IN	O
caution	NN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
size	NN	O
and	CC	O
lack	NN	O
of	IN	O
homogeneity	NN	O
of	IN	O
the	DT	O
experimental	JJ	O
groups	NNS	O
.	.	O

Minimal	NNP	O
clinically	RB	O
important	JJ	O
change	NN	O
for	IN	O
pain	NN	Pain
intensity	NN	Pain
,	,	O
functional	JJ	Mental
status	NN	Mental
,	,	O
and	CC	O
general	JJ	O
health	NN	Physical
status	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
nonspecific	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Cohort	NNP	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
estimate	VB	O
the	DT	O
Minimal	NNP	Physical
Clinically	NNP	Physical
Important	NNP	Physical
Change	NNP	Physical
(	(	Physical
MCIC	NNP	Physical
)	)	Physical
of	IN	O
the	DT	O
pain	NN	Pain
intensity	NN	Pain
numerical	JJ	Pain
rating	NN	Pain
scale	NN	Pain
(	(	Pain
PI-NRS	NNP	Pain
)	)	Pain
,	,	O
the	DT	O
Quebec	NNP	Mental
Back	NNP	Mental
Pain	NNP	Mental
Disability	NNP	Mental
Scale	NNP	Mental
(	(	Mental
QBPDS	NNP	Mental
)	)	Physical
,	,	O
and	CC	O
the	DT	O
Euroqol	NNP	Physical
(	(	Physical
EQ	NNP	Physical
)	)	Physical
in	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
MCIC	NNP	O
can	MD	O
provide	VB	O
valuable	JJ	O
information	NN	O
for	IN	O
researchers	NNS	O
,	,	O
healthcare	NN	O
providers	NNS	O
,	,	O
and	CC	O
policymakers	NNS	O
.	.	O

METHODS	NNP	O
Data	NNP	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
442	CD	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
MCIC	NNP	O
was	VBD	O
estimated	VBN	O
over	IN	O
a	DT	O
12-week	JJ	O
period	NN	O
,	,	O
and	CC	O
three	CD	O
different	JJ	O
methods	NNS	O
were	VBD	O
used	VBN	O
:	:	O
1	CD	O
)	)	O
mean	NN	O
change	NN	O
scores	NNS	O
,	,	O
2	CD	O
)	)	O
minimal	NN	O
detectable	JJ	O
change	NN	O
,	,	O
and	CC	O
3	CD	O
)	)	O
optimal	VBD	O
cutoff	NN	O
point	NN	O
in	IN	O
receiver	NN	O
operant	JJ	O
curves	NNS	O
.	.	O

The	DT	O
global	JJ	O
perceived	JJ	O
effect	NN	O
scale	NN	O
(	(	O
GPE	NNP	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
an	DT	O
external	JJ	O
criterion	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
initial	JJ	O
scores	NNS	O
on	IN	O
the	DT	O
MCIC	NNP	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
MCIC	NNP	Physical
of	IN	O
the	DT	O
PI-NRS	NNP	O
ranged	VBD	O
from	IN	O
3.5	CD	O
to	TO	O
4.7	CD	O
points	NNS	O
in	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
patients	NNS	O
and	CC	O
2.5	CD	O
to	TO	O
4.5	CD	O
points	NNS	O
in	IN	O
chronic	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
MCIC	NNP	Mental
of	IN	Mental
the	DT	Mental
QBPDS	NNP	Mental
was	VBD	O
estimated	VBN	O
between	IN	O
17.5	CD	O
to	TO	O
32.9	CD	O
points	NNS	O
and	CC	O
8.5	CD	O
to	TO	O
24.6	CD	O
points	NNS	O
for	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
and	CC	O
chronic	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
MCIC	NNP	Physical
for	IN	Physical
the	DT	Physical
EQ	NNP	Physical
ranged	VBD	O
from	IN	O
0.07	CD	O
to	TO	O
0.58	CD	O
in	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
patients	NNS	O
and	CC	O
0.09	CD	O
to	TO	O
0.28	CD	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

CONCLUSION	NNP	O
Reporting	VBG	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
made	VBN	O
a	DT	O
MCIC	NNP	O
adds	VBZ	O
to	TO	O
the	DT	O
interpretability	NN	O
of	IN	O
study	NN	O
results	NNS	O
.	.	O

We	PRP	O
present	VBD	O
a	DT	O
range	NN	O
of	IN	O
MCIC	NNP	O
values	NNS	O
and	CC	O
advocate	VB	O
the	DT	O
choice	NN	O
of	IN	O
a	DT	O
single	JJ	O
MCIC	NNP	O
value	NN	O
according	VBG	O
to	TO	O
the	DT	O
specific	JJ	O
context	NN	O
.	.	O

Successful	JJ	O
production	NN	Others
of	IN	O
piglets	NNS	O
derived	VBN	O
from	IN	O
expanded	JJ	O
blastocysts	NNS	O
vitrified	VBD	O
using	VBG	O
a	DT	O
micro	NN	O
volume	NN	O
air	NN	O
cooling	VBG	O
method	NN	O
without	IN	O
direct	JJ	O
exposure	NN	O
to	TO	O
liquid	VB	O
nitrogen	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
newly	RB	O
developed	VBN	O
vitrification	NN	O
techniques	NNS	O
for	IN	O
porcine	NN	O
embryos	NN	O
using	VBG	O
the	DT	O
micro	NN	O
volume	NN	O
air	NN	O
cooling	VBG	O
(	(	O
MVAC	NNP	O
)	)	O
method	NN	O
without	IN	O
direct	JJ	O
contact	NN	O
with	IN	O
liquid	JJ	O
nitrogen	NN	O
(	(	O
LN?	NNP	O
)	)	O
.	.	O

Expanded	VBN	O
blastocysts	NNS	O
were	VBD	O
vitrified	VBN	O
in	IN	O
a	DT	O
solution	NN	O
containing	VBG	O
6	CD	O
M	NNP	O
ethylene	NN	O
glycol	NN	O
,	,	O
0.6	CD	O
M	NNP	O
trehalose	NN	O
and	CC	O
2	CD	O
%	NN	O
(	(	O
wt/vol	NN	O
)	)	O
polyethylene	NN	O
glycol	NN	O
in	IN	O
10	CD	O
%	NN	O
HEPES-buffered	JJ	O
PZM-5	NNP	O
.	.	O

The	DT	O
blastocysts	NNS	O
were	VBD	O
collected	VBN	O
from	IN	O
gilts	NNS	O
and	CC	O
vitrified	VBD	O
using	VBG	O
the	DT	O
new	JJ	O
device	NN	O
(	(	O
MVAC	NNP	O
)	)	O
or	CC	O
a	DT	O
Cryotop	NNP	O
(	(	O
CT	NNP	O
)	)	O
.	.	O

Blastocysts	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
LN?	NNP	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
.	.	O

After	IN	O
warming	VBG	O
,	,	O
cryoprotective	JJ	O
agents	NNS	O
were	VBD	O
removed	VBN	O
using	VBG	O
a	DT	O
single	JJ	O
step	NN	O
.	.	O

Survival	NN	O
of	IN	O
the	DT	O
embryos	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
in	IN	O
vitro	JJ	O
culture	NN	O
(	(	O
Experiment	NNP	O
1	CD	O
)	)	O
and	CC	O
by	IN	O
embryo	NN	O
transfer	NN	O
to	TO	O
recipients	NNS	O
(	(	O
Experiment	NNP	O
2	CD	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
the	DT	O
embryos	NN	O
vitrified	VBN	O
by	IN	O
the	DT	O
MVAC	NNP	O
or	CC	O
CT	NNP	O
and	CC	O
fresh	JJ	O
embryos	NN	O
without	IN	O
vitrification	NN	O
(	(	O
Control	NNP	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
survival	JJ	O
rates	NNS	O
of	IN	O
embryos	NN	O
in	IN	O
the	DT	O
MVAC	NNP	O
,	,	O
CT	NNP	O
and	CC	O
Control	NNP	O
groups	NNS	O
were	VBD	O
88.9	CD	O
%	NN	O
(	(	O
32/36	CD	O
)	)	O
,	,	O
91.7	CD	O
%	NN	O
(	(	O
33/36	CD	O
)	)	O
and	CC	O
100	CD	O
%	NN	O
(	(	O
34/34	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
after	IN	O
48	CD	O
h	JJ	O
culture	NN	O
,	,	O
and	CC	O
the	DT	O
hatching	VBG	Others
rates	NNS	Others
of	IN	Others
embryos	NN	Others
after	IN	Others
48	CD	Others
h	JJ	Others
incubation	NN	Others
were	VBD	O
69.4	CD	O
%	NN	O
(	(	O
25/36	CD	O
)	)	O
,	,	O
63.9	CD	O
%	NN	O
(	(	O
23/36	CD	O
)	)	O
and	CC	O
94.1	CD	O
%	NN	O
(	(	O
32/34	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
64	CD	O
vitrified	VBD	O
embryos	NN	O
were	VBD	O
transferred	VBN	O
to	TO	O
5	CD	O
recipient	NN	O
gilts	NNS	O
,	,	O
and	CC	O
8	CD	O
healthy	JJ	O
piglets	NNS	O
were	VBD	O
produced	VBN	O
from	IN	O
3	CD	O
recipients	NNS	O
in	IN	O
the	DT	O
MVAC	NNP	O
group	NN	O
.	.	O

Similarly	RB	O
,	,	O
66	CD	O
vitrified	VBD	O
embryos	NN	O
were	VBD	O
transferred	VBN	O
to	TO	O
5	CD	O
recipient	NN	O
gilts	NNS	O
,	,	O
and	CC	O
9	CD	O
healthy	JJ	O
piglets	NNS	O
were	VBD	O
produced	VBN	O
from	IN	O
2	CD	O
recipients	NNS	O
in	IN	O
the	DT	O
CT	NNP	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
porcine	NN	O
expanded	VBN	O
blastocysts	NNS	O
can	MD	O
be	VB	O
cryopreserved	VBN	O
using	VBG	O
the	DT	O
MVAC	NNP	O
method	NN	O
without	IN	O
potential	JJ	O
pathogen	NN	O
contamination	NN	O
from	IN	O
LN?	NNP	O
.	.	O

Oral	NNP	O
amoxicillin	NN	O
vs.	FW	O
oral	JJ	O
erythromycin	NN	O
in	IN	O
the	DT	O
treatment	NN	Physical
of	IN	Physical
pyoderma	NN	Physical
in	IN	O
Bamako	NNP	O
,	,	O
Mali	NNP	O
:	:	O
an	DT	O
open	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Pyoderma	NNP	O
(	(	O
bacterial	JJ	O
superficial	NN	O
skin	NN	O
infection	NN	O
)	)	O
is	VBZ	O
an	DT	O
extremely	RB	O
common	JJ	O
disorder	NN	O
in	IN	O
tropical	JJ	O
developing	VBG	O
countries	NNS	O
.	.	O

In	IN	O
these	DT	O
settings	NNS	O
,	,	O
Streptococcus	NNP	O
pyogenes	NNS	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
the	DT	O
main	JJ	O
etiological	JJ	O
agent	NN	O
.	.	O

Apart	RB	O
from	IN	O
epidemics	NNS	O
of	IN	O
poststreptococcal	JJ	O
glomerulonephritis	NN	O
where	WRB	O
mass	NN	O
treatment	NN	O
with	IN	O
intramuscular	JJ	O
benzathine-penicillin	NN	O
is	VBZ	O
recommended	VBN	O
,	,	O
no	DT	O
recommendation	NN	O
exists	VBZ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pyoderma	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
oral	JJ	O
amoxicillin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pyoderma	NN	O
in	IN	O
Mali	NNP	O
,	,	O
by	IN	O
comparison	NN	O
with	IN	O
oral	JJ	O
erythromycin	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
Bamako	NNP	O
,	,	O
132	CD	O
patients	NNS	O
with	IN	O
pyoderma	NN	O
,	,	O
diagnosed	VBN	O
and	CC	O
graded	VBN	O
as	IN	O
severe	JJ	O
on	IN	O
clinical	JJ	O
grounds	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
oral	JJ	O
treatment	NN	O
by	IN	O
either	DT	O
amoxicillin	NN	O
(	(	O
50	CD	O
mg/kg	NNS	O
per	IN	O
day	NN	O
)	)	O
or	CC	O
erythromycin	$	O
;	:	O
infections	NNS	O
of	IN	O
the	DT	O
follicular	JJ	O
appendage	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
topical	JJ	O
application	NN	O
of	IN	O
povidone	NN	O
iodine	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
openly	RB	O
at	IN	O
the	DT	O
seventh	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
for	IN	O
cure	NN	O
or	CC	O
marked	JJ	O
improvement	NN	O
of	IN	O
the	DT	O
clinical	JJ	Others
features	NNS	Others
,	,	O
indicating	VBG	O
successful	JJ	Others
treatment	NN	Others
.	.	O

RESULTS	NNP	O
Three	CD	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	JJ	O
.	.	O

Treatment	NN	Others
was	VBD	Others
successful	JJ	Others
in	IN	O
57	CD	O
of	IN	O
64	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
amoxicillin	NN	O
vs.	FW	O
58	CD	O
of	IN	O
65	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
erythromycin	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.00	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Amoxicillin	NNP	Others
was	VBD	Others
as	RB	Others
efficacious	JJ	Others
as	IN	O
erythromycin	NN	O
in	IN	O
the	DT	O
treatment	NN	Physical
of	IN	Physical
severe	JJ	Physical
pyoderma	NN	Physical
in	IN	O
Mali	NNP	O
.	.	O

Owing	VBG	O
to	TO	O
its	PRP$	O
efficacy	NN	O
,	,	O
added	VBD	O
to	TO	O
high	JJ	O
availability	NN	O
and	CC	O
low	JJ	O
cost	NN	O
,	,	O
this	DT	O
compound	NN	O
should	MD	O
be	VB	O
considered	VBN	O
a	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
disorder	NN	O
in	IN	O
this	DT	O
country	NN	O
,	,	O
and	CC	O
perhaps	RB	O
in	IN	O
other	JJ	O
countries	NNS	O
where	WRB	O
this	DT	O
condition	NN	O
presents	VBZ	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
.	.	O

Osteocalcin	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

A	DT	O
one-year	JJ	O
followup	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
analyze	VB	O
clinical	JJ	O
,	,	O
radiological	JJ	O
,	,	O
and	CC	O
drug	NN	O
(	(	O
disease	NN	O
modifying	VBG	O
antirheumatic	JJ	O
drug	NN	O
,	,	O
DMARD	NNP	O
)	)	O
dependent	NN	O
factors	NNS	O
influencing	VBG	O
bone	NN	O
turnover	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
in	IN	O
a	DT	O
one-year	JJ	O
double	JJ	O
blind	NN	O
randomized	VBD	O
study	NN	O
comparing	VBG	O
intramuscular	JJ	O
(	(	O
im	NN	O
)	)	O
gold	NN	O
with	IN	O
im	JJ	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
,	,	O
whether	IN	O
the	DT	O
variation	NN	O
of	IN	O
inflammatory	JJ	Physical
activity	NN	Physical
or	CC	O
functional	JJ	Physical
capacity	NN	Physical
,	,	O
the	DT	O
ascending	VBG	O
anatomic	JJ	O
stage	NN	O
,	,	O
or	CC	O
DMARD	NNP	O
treatments	NNS	O
have	VBP	O
an	DT	O
influence	NN	O
on	IN	O
bone	NN	O
formation	NN	O
(	(	O
osteocalcin	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
enrolled	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
our	PRP$	O
study	NN	O
had	VBD	O
significantly	RB	O
increased	VBN	O
osteocalcin	NN	Others
levels	NNS	Others
(	(	O
3.45	CD	O
+/-	JJ	O
0.93	CD	O
--	:	O
>	JJ	O
4.42	CD	O
+/-	JJ	O
1.39	CD	O
ng/ml	JJ	O
p	NN	O
<	NNP	O
0.02	CD	O
)	)	O
after	IN	O
one	CD	O
year	NN	O
if	IN	O
inflammatory	JJ	Physical
activity	NN	Physical
decreased	VBN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
SD	NNP	O
:	:	O
erythrocyte	JJ	Physical
sedimentation	NN	Physical
rate	NN	Physical
(	(	Physical
ESR	NNP	Physical
)	)	Physical
26.4	CD	O
mm/h	NN	O
,	,	O
C-reactive	JJ	Physical
protein	NN	Physical
(	(	Physical
CRP	NNP	Physical
)	)	Physical
3.8	CD	O
mg/dl	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
negative	JJ	O
correlation	NN	O
of	IN	O
the	DT	O
one-year	JJ	O
CRP-	NNP	Physical
(	(	O
r	NN	O
=	NNP	O
-0.44	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
or	CC	O
ESR	NNP	Physical
differences	NNS	Others
(	(	O
r	NN	O
=	NNP	O
-0.45	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
the	DT	O
corresponding	JJ	O
osteocalcin	NN	O
differences	NNS	O
.	.	O

This	DT	O
was	VBD	O
also	RB	O
evident	JJ	O
if	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
pooled	VBN	O
with	IN	O
15	CD	O
patients	NNS	O
excluded	VBN	O
from	IN	O
the	DT	O
double	JJ	O
blind	NN	O
study	NN	O
as	IN	O
already	RB	O
receiving	VBG	O
DMARD	NNP	O
treatment	NN	O
(	(	O
n	JJ	O
=	VBZ	O
63	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.01	CD	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
impaired	JJ	O
functional	JJ	Physical
capacity	NN	Physical
also	RB	O
had	VBD	O
significantly	RB	O
reduced	VBN	O
osteocalcin	NN	Physical
levels	NNS	Physical
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
cases	NNS	O
,	,	O
alkaline	JJ	Others
phosphatase	NN	Others
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
.	.	O

CONCLUSIONS	VB	O
Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
osteocalcin	NN	O
,	,	O
a	DT	O
useful	JJ	O
followup	NN	O
variable	NN	O
of	IN	O
bone	NN	Physical
turnover	NN	Physical
,	,	O
is	VBZ	O
changed	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
regarding	VBG	O
inflammatory	JJ	Physical
activity	NN	Physical
and	CC	O
functional	JJ	Physical
capacity	NN	Physical
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
alkaline	VB	Others
phosphatase	NN	Others
,	,	O
a	DT	O
fall	NN	O
in	IN	O
inflammatory	JJ	O
activity	NN	O
stimulated	VBN	O
and	CC	O
impairment	NN	O
of	IN	O
functional	JJ	Physical
capacity	NN	Physical
significantly	RB	O
decreased	VBD	O
osteocalcin	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
.	.	O

Functional	JJ	O
outcome	NN	O
following	VBG	O
intramedullary	JJ	O
nailing	NN	O
of	IN	O
the	DT	O
femur	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
of	IN	O
piriformis	NN	O
fossa	NN	O
and	CC	O
greater	JJR	O
trochanteric	JJ	O
entry	NN	O
portals	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
compare	VB	O
the	DT	O
functional	JJ	O
outcome	NN	O
of	IN	O
intramedullary	JJ	O
nailing	NN	O
of	IN	O
the	DT	O
femur	NN	O
performed	VBD	O
with	IN	O
use	NN	O
of	IN	O
a	DT	O
trochanteric	NN	O
and	CC	O
a	DT	O
piriformis	NN	O
fossa	NN	O
entry	NN	O
portal	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
ten	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
femoral	JJ	O
shaft	NN	O
fracture	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
Group	NNP	O
A	NNP	O
(	(	O
piriformis	JJ	O
fossa	NN	O
portal	NN	O
)	)	O
and	CC	O
fifty-six	JJ	O
to	TO	O
Group	NNP	O
B	NNP	O
(	(	O
trochanteric	JJ	O
portal	NN	O
)	)	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
Osteoarthritis	NNP	O
Index	NNP	O
hip	NN	O
function	NN	O
score	NN	O
,	,	O
pain	NN	O
,	,	O
and	CC	O
blinded	VBD	O
functional	JJ	O
evaluation	NN	O
by	IN	O
a	DT	O
physical	JJ	O
therapist	NN	O
.	.	O

RESULTS	NNP	O
Most	JJS	O
measures	NNS	O
of	IN	O
hip	NN	O
function	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
WOMAC	NNP	Physical
score	NN	Physical
at	IN	O
three	CD	O
,	,	O
six	CD	O
,	,	O
and	CC	O
twelve	JJ	O
months	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
and	CC	O
trochanteric	JJ	O
nailing	NN	O
groups	NNS	O
.	.	O

Functional	JJ	O
tests	NNS	O
included	VBD	O
the	DT	O
chair	NN	O
stand	VBP	O
test	NN	O
and	CC	O
the	DT	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
test	NN	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
B	NNP	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
chair	NN	Others
stand	VBP	Others
test	NN	Others
(	(	O
13.3	CD	O
compared	VBN	O
with	IN	O
11.1	CD	O
in	IN	O
Group	NNP	O
A	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
at	IN	O
six	CD	O
months	NNS	O
postoperatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
at	IN	O
twelve	JJ	O
months	NNS	O
(	(	O
14.0	CD	O
compared	VBN	O
with	IN	O
13.6	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
on	IN	O
the	DT	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
test	NN	O
at	IN	O
either	DT	O
six	CD	O
or	CC	O
twelve	VB	O
months	NNS	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
the	DT	O
muscle	NN	Physical
strength	NN	Physical
testing	VBG	Physical
.	.	O

Intraoperative	JJ	O
parameters	NNS	O
differed	VBD	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
with	IN	O
respect	NN	Others
to	TO	Others
operative	JJ	Others
time	NN	Others
,	,	O
fluoroscopy	JJ	Others
time	NN	Others
,	,	O
and	CC	O
incision	NN	Others
length	NN	Others
,	,	O
with	IN	O
the	DT	O
difference	NN	O
favoring	VBG	O
Group	NNP	O
B	NNP	O
for	IN	O
each	DT	O
parameter	NN	O
.	.	O

Analog	NNP	O
pain	VBP	O
scale	JJ	O
values	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
Group	NNP	O
A	NNP	O
(	(	O
2.49	CD	O
)	)	O
and	CC	O
Group	NNP	O
B	NNP	O
(	(	O
2.15	CD	O
)	)	O
at	IN	O
twelve	JJ	O
months	NNS	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
in	IN	O
our	PRP$	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
trochanteric	JJ	O
nailing	VBG	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
hip	NN	Physical
function	NN	Physical
at	IN	O
one	CD	O
year	NN	O
postoperatively	RB	O
compared	VBN	O
with	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
intramedullary	JJ	O
nailing	VBG	O
through	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
.	.	O

The	DT	O
values	NNS	O
of	IN	O
several	JJ	O
intraoperative	JJ	O
parameters	NNS	O
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
trochanteric	JJ	O
nailing	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
functional	JJ	O
hip	NN	O
outcome	NN	O
of	IN	O
femoral	JJ	O
intramedullary	JJ	O
nailing	NN	O
performed	VBN	O
through	IN	O
the	DT	O
greater	JJR	O
trochanter	NN	O
is	VBZ	O
equal	JJ	O
to	TO	O
that	DT	O
of	IN	O
intramedullary	JJ	O
nailing	NN	O
performed	VBN	O
through	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
.	.	O

Resistance	NNP	O
training	NN	O
increases	NNS	O
basal	VBP	O
limb	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
aging	VBG	O
humans	NNS	O
.	.	O

Age-related	JJ	O
reductions	NNS	O
in	IN	O
basal	NN	O
limb	NN	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
,	,	O
functional	JJ	O
impairments	NNS	O
,	,	O
and	CC	O
osteoporosis	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
strength	NN	O
training	NN	O
program	NN	O
would	MD	O
increase	VB	O
basal	JJ	Physical
femoral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
in	IN	O
aging	VBG	O
adults	NNS	O
.	.	O

Twenty-six	JJ	O
sedentary	JJ	O
but	CC	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
a	DT	O
whole	JJ	O
body	NN	O
strength	NN	O
training	VBG	O
intervention	NN	O
group	NN	O
(	(	O
52	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
3	CD	O
men	NNS	O
,	,	O
10	CD	O
women	NNS	O
)	)	O
who	WP	O
underwent	VBD	O
three	CD	O
supervised	VBN	O
resistance	NN	O
training	NN	O
sessions	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
wk	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
53	CD	O
+/-	JJ	O
2	CD	O
yr	NN	O
,	,	O
4	CD	O
men	NNS	O
,	,	O
9	CD	O
women	NNS	O
)	)	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
supervised	JJ	O
stretching	NN	O
program	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
blood	NN	Physical
pressure	NN	Physical
,	,	O
cardiac	JJ	Physical
output	NN	Physical
,	,	O
basal	JJ	Physical
femoral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
(	(	Physical
via	IN	Physical
Doppler	NNP	Physical
ultrasound	NN	Physical
)	)	Physical
,	,	O
vascular	JJ	Physical
conductance	NN	Physical
,	,	O
and	CC	O
vascular	JJ	Physical
resistance	NN	Physical
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
strength	NN	O
training	VBG	O
group	NN	O
increased	VBD	O
maximal	JJ	Physical
strength	NN	Physical
in	IN	O
all	PDT	O
the	DT	O
major	JJ	O
muscle	NN	O
groups	NNS	O
tested	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Whole	JJ	Physical
body	NN	Physical
lean	JJ	Physical
body	NN	Physical
mass	NN	Physical
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
strength	NN	O
training	NN	O
,	,	O
but	CC	O
leg	VBZ	Physical
fat-free	JJ	Physical
mass	NN	Physical
did	VBD	O
not	RB	O
.	.	O

Basal	NNP	Physical
femoral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	Physical
vascular	JJ	Physical
conductance	NN	Physical
increased	VBN	O
by	IN	O
55-60	CD	O
%	NN	O
after	IN	O
strength	NN	O
training	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
such	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
brachial	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	O
plasma	JJ	Physical
endothelin-1	NN	Physical
and	CC	Physical
angiotensin	NN	Physical
II	NNP	Physical
concentrations	NNS	Physical
,	,	O
femoral	JJ	Physical
artery	NN	Physical
wall	NN	Physical
thickness	NN	Physical
,	,	O
cardiac	JJ	Physical
output	NN	Physical
,	,	O
and	CC	O
systemic	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
.	.	O

Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	IN	O
short-term	JJ	O
strength	NN	O
training	NN	O
increases	NNS	O
basal	VBP	O
femoral	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
vascular	JJ	O
conductance	NN	O
in	IN	O
healthy	JJ	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

Use	NNP	O
of	IN	O
activated	JJ	O
charcoal	NN	O
in	IN	O
a	DT	O
simulated	JJ	O
poisoning	NN	O
with	IN	O
acetaminophen	NN	O
:	:	O
a	DT	O
new	JJ	O
loading	NN	O
dose	NN	O
for	IN	O
N-acetylcysteine	NNP	O
?	.	O
STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
ability	NN	O
of	IN	O
a	DT	O
supranormal	JJ	O
dose	NN	O
of	IN	O
N-acetylcysteine	NNP	O
to	TO	O
overcome	VB	O
the	DT	O
effects	NNS	O
of	IN	O
activated	JJ	O
charcoal	NN	O
on	IN	O
N-acetylcysteine	NNP	O
bioavailability	NN	O
and	CC	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
activated	JJ	O
charcoal	NN	O
on	IN	O
serum	NN	O
acetaminophen	NN	O
levels	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Ten	NNP	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
controlled	JJ	O
cross-over	JJ	O
experiment	NN	O
.	.	O

During	IN	O
phase	NN	O
I	PRP	O
(	(	O
control	NN	O
)	)	O
,	,	O
subjects	VBZ	O
ingested	JJ	O
3	CD	O
g	NN	O
acetaminophen	NN	O
,	,	O
followed	VBD	O
one	CD	O
hour	NN	O
later	RB	O
by	IN	O
the	DT	O
normal	JJ	O
loading	VBG	O
dose	NN	O
of	IN	O
N-acetylcysteine	NNP	O
(	(	O
140	CD	O
mg/kg	NN	O
)	)	O
.	.	O

During	IN	O
phase	NN	O
II	NNP	O
(	(	O
charcoal	NN	O
)	)	O
,	,	O
subjects	VBZ	O
ingested	JJ	O
3	CD	O
g	NN	O
acetaminophen	NN	O
,	,	O
followed	VBD	O
one	CD	O
hour	NN	O
later	RB	O
by	IN	O
60	CD	O
g	NNS	O
activated	VBN	O
charcoal	NN	O
and	CC	O
a	DT	O
supranormal	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
N-acetylcysteine	NNP	O
(	(	O
235	CD	O
mg/kg	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Serum	NNP	Physical
levels	NNS	Physical
of	IN	Physical
N-acetylcysteine	NNP	Physical
were	VBD	O
measured	VBN	O
every	DT	O
30	CD	O
minutes	NNS	O
for	IN	O
six	CD	O
hours	NNS	O
.	.	O

A	DT	O
serum	NN	Physical
acetaminophen	NN	Physical
level	NN	Physical
was	VBD	O
measured	VBN	O
at	IN	O
four	CD	O
hours	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
for	IN	O
N-acetylcysteine	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
phase	NN	O
II	NNP	O
than	IN	O
phase	NN	O
I	PRP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
,	,	O
two-tailed	JJ	O
paired	VBD	O
t-test	NN	O
)	)	O
.	.	O

Peak	VB	Physical
N-acetylcysteine	JJ	Physical
and	CC	O
time	NN	Physical
to	TO	Physical
peak	VB	Physical
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

The	DT	O
four-hour	JJ	Physical
serum	NN	Physical
acetaminophen	NN	Physical
level	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
phase	NN	O
II	NNP	O
than	IN	O
phase	NN	O
I	PRP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
,	,	O
two-tailed	JJ	O
paired	VBD	O
t-test	NN	O
)	)	O
.	.	O

Diarrhea	NNP	Adverseeffect
occurred	VBD	O
during	IN	O
both	DT	O
phases	NNS	O
,	,	O
but	CC	O
N-acetylcysteine	NNP	O
was	VBD	O
otherwise	RB	O
well	RB	O
tolerated	VBN	Others
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
activated	JJ	O
charcoal	NN	O
can	MD	O
be	VB	O
used	VBN	O
safely	RB	O
for	IN	O
victims	NNS	O
of	IN	O
acetaminophen	NN	O
overdose	NN	O
.	.	O

A	DT	O
beneficial	JJ	O
effect	NN	O
in	IN	O
preventing	VBG	O
acetaminophen	JJ	O
absorption	NN	O
can	MD	O
be	VB	O
expected	VBN	O
if	IN	O
it	PRP	O
is	VBZ	O
given	VBN	O
within	IN	O
one	CD	O
hour	NN	O
after	IN	O
ingestion	NN	O
.	.	O

If	IN	O
N-acetylcysteine	NNP	O
is	VBZ	O
needed	VBN	O
because	IN	O
of	IN	O
a	DT	O
toxic	JJ	O
serum	NN	O
acetaminophen	NN	O
level	NN	O
,	,	O
bioavailability	NN	O
can	MD	O
be	VB	O
ensured	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
N-acetylcysteine	JJ	O
loading	NN	O
dose	NN	O
from	IN	O
140	CD	O
mg/kg	NNS	O
to	TO	O
235	CD	O
mg/kg	NNS	O
.	.	O

Simplified	NNP	O
subjective	JJ	O
workload	NN	O
assessment	NN	O
technique	NN	O
.	.	O

Although	IN	O
the	DT	O
subjective	JJ	Others
workload	NN	Others
assessment	NN	Others
technique	NN	Others
(	(	O
SWAT	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
widely	RB	O
used	VBN	O
,	,	O
it	PRP	O
has	VBZ	O
two	CD	O
main	JJ	O
problems	NNS	O
:	:	O
it	PRP	O
is	VBZ	O
not	RB	O
very	RB	O
sensitive	JJ	O
for	IN	O
low	JJ	O
mental	JJ	O
workloads	NNS	O
and	CC	O
it	PRP	O
requires	VBZ	O
a	DT	O
time-consuming	JJ	O
card	NN	O
sorting	VBG	O
pretask	JJ	O
procedure	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
are	VBP	O
presented	VBN	O
five	CD	O
variations	NNS	O
of	IN	O
SWAT	NNP	O
in	IN	O
an	DT	O
effort	NN	O
to	TO	O
overcome	VB	O
the	DT	O
limitations	NNS	O
.	.	O

Four	CD	O
of	IN	O
the	DT	O
variants	NNS	O
used	VBD	O
the	DT	O
continuous	JJ	O
SWAT	NNP	O
subscales	NNS	O
while	IN	O
one	CD	O
used	VBD	O
the	DT	O
discrete	JJ	O
SWAT	NNP	O
subscale	NN	O
.	.	O

Fifteen	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
experiment	NN	O
.	.	O

The	DT	O
scales	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
original	JJ	O
SWAT	NNP	O
scale	NN	O
in	IN	O
terms	NNS	O
of	IN	O
sensitivity	NN	Others
and	CC	O
pretask	NN	O
procedure	NN	O
completion	NN	O
time	NN	O
when	WRB	O
performing	VBG	O
arithmetic	JJ	O
tasks	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
all	DT	O
four	CD	O
variants	NNS	O
are	VBP	O
more	RBR	O
sensitive	JJ	Others
than	IN	O
the	DT	O
conventional	JJ	Others
SWAT	NNP	Others
scale	NN	Others
and	CC	O
that	IN	O
the	DT	O
pairwise	NN	O
comparison	NN	O
procedure	NN	O
takes	VBZ	O
significantly	RB	O
less	JJR	O
pretask	JJ	Others
completion	NN	Others
time	NN	Others
compared	VBN	O
with	IN	O
the	DT	O
original	JJ	O
SWAT	NNP	O
scale	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
conventional	JJ	O
pretask	JJ	O
procedure	NN	O
can	MD	O
be	VB	O
replaced	VBN	O
by	IN	O
a	DT	O
simple	JJ	O
unweighted	JJ	O
averaging	VBG	O
to	TO	O
yield	VB	O
a	DT	O
scale	NN	O
of	IN	O
high	JJ	O
sensitivity	NN	O
.	.	O

Face	NNP	O
composite	JJ	O
effects	NNS	O
reveal	VBP	O
abnormal	JJ	O
face	NN	O
processing	NN	O
in	IN	O
Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Although	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
individuals	NNS	O
with	IN	O
an	DT	O
Autism	NNP	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
process	NN	O
faces	VBZ	O
less	RBR	O
holistically	RB	O
than	IN	O
typically	RB	O
developing	VBG	O
controls	NNS	O
,	,	O
there	EX	O
are	VBP	O
few	JJ	O
direct	JJ	O
investigations	NNS	O
of	IN	O
this	DT	O
hypothesis	NN	O
.	.	O

This	DT	O
question	NN	O
was	VBD	O
addressed	VBN	O
before	IN	O
using	VBG	O
the	DT	O
composite	JJ	O
paradigm	NN	O
(	(	O
Teunisse	NNP	O
,	,	O
J.	NNP	O
P.	NNP	O
,	,	O
&	CC	O
de	FW	O
Gelder	NNP	O
,	,	O
B	NNP	O
.	.	O

(	(	O
2003	CD	O
)	)	O
.	.	O

Face	NN	O
processing	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
The	DT	O
inversion	NN	O
and	CC	O
composite	JJ	O
effects	NNS	O
.	.	O

Brain	NNP	O
Cognition	NNP	O
,	,	O
52	CD	O
(	(	O
3	CD	O
)	)	O
,	,	O
285-294.	JJ	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
had	VBD	O
revealed	VBN	O
that	IN	O
adolescents	NNS	O
with	IN	O
ASDs	NNP	O
were	VBD	O
less	RBR	O
sensitive	JJ	O
than	IN	O
controls	NNS	O
to	TO	O
the	DT	O
misalignment	NN	O
of	IN	O
face	NN	O
parts	NNS	O
and	CC	O
it	PRP	O
was	VBD	O
concluded	VBN	O
their	PRP$	O
face	NN	O
processing	NN	O
was	VBD	O
less	RBR	O
holistic	JJ	O
.	.	O

However	RB	O
,	,	O
because	IN	O
of	IN	O
shortcomings	NNS	O
of	IN	O
the	DT	O
design	NN	O
,	,	O
it	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
distinguish	VB	O
whether	IN	O
individuals	NNS	O
with	IN	O
Autism	NNP	O
processed	VBD	O
both	DT	O
aligned	VBN	O
and	CC	O
misaligned	VBN	O
composites	NNS	O
in	IN	O
a	DT	O
part-based	JJ	O
fashion	NN	O
,	,	O
or	CC	O
both	DT	O
in	IN	O
a	DT	O
holistic	JJ	O
fashion	NN	O
.	.	O

We	PRP	O
compared	VBN	O
adolescents	NNS	O
with	IN	O
ASDs	NNP	O
to	TO	O
controls	VB	O
matched	VBN	O
on	IN	O
sex	NN	O
,	,	O
age	NN	O
and	CC	O
IQ	NNP	O
on	IN	O
a	DT	O
more	RBR	O
complete	JJ	O
version	NN	O
of	IN	O
the	DT	O
composite	JJ	O
paradigm	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
individuals	NNS	O
with	IN	O
ASDs	NNP	O
,	,	O
like	IN	O
controls	NNS	O
,	,	O
experience	NN	Mental
interference	NN	Mental
from	IN	O
facial	JJ	O
features	NNS	O
that	IN	O
they	PRP	O
are	VBP	O
told	VBN	O
to	TO	O
ignore	VB	O
.	.	O

However	RB	O
,	,	O
while	IN	O
such	JJ	O
interference	NN	O
is	VBZ	O
released	VBN	O
for	IN	O
controls	NNS	O
if	IN	O
parts	NNS	O
of	IN	O
face	NN	O
composites	NNS	O
are	VBP	O
misaligned	VBN	O
,	,	O
individuals	NNS	O
with	IN	O
ASDs	NNP	O
show	VBP	O
comparable	JJ	Mental
interference	NN	Mental
from	IN	O
irrelevant	JJ	O
parts	NNS	O
regardless	RB	O
of	IN	O
alignment	NN	O
.	.	O

Two	CD	O
different	JJ	O
interpretations	NNS	O
are	VBP	O
discussed	VBN	O
,	,	O
both	DT	O
compatible	JJ	O
with	IN	O
the	DT	O
idea	NN	O
that	WDT	O
perceptual	JJ	O
and	CC	O
or	CC	O
attentional	JJ	O
abnormalities	NNS	O
in	IN	O
ASDs	NNP	O
result	NN	O
in	IN	O
a	DT	O
diminished	JJ	O
level	NN	O
of	IN	O
expertise	NN	O
for	IN	O
faces	VBZ	O
.	.	O

Comparison	NNP	O
of	IN	O
inhaled	JJ	O
albuterol	NN	O
powder	NN	O
and	CC	O
aerosol	NN	O
in	IN	O
asthma	NN	O
.	.	O

In	IN	O
this	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
aerosolized	JJ	O
albuterol	NN	O
with	IN	O
the	DT	O
dry	JJ	O
powder	NN	O
formulation	NN	O
,	,	O
231	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
reversible	JJ	O
obstructive	JJ	O
airway	NN	O
disease	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
albuterol	NN	O
aerosol	NN	O
followed	VBD	O
immediately	RB	O
by	IN	O
active	JJ	O
albuterol	NN	O
powder	NN	O
(	(	O
200	CD	O
micrograms	NNS	O
)	)	O
or	CC	O
active	JJ	O
albuterol	NN	O
aerosol	NN	O
(	(	O
two	CD	O
puffs	NNS	O
,	,	O
180	CD	O
micrograms	NNS	O
)	)	O
followed	VBD	O
immediately	RB	O
by	IN	O
placebo	NN	O
lactose	JJ	O
powder	NN	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
powder	NN	O
and	CC	O
aerosol	JJ	O
formulations	NNS	O
with	IN	O
respect	NN	O
to	TO	O
pulmonary	JJ	Physical
function	NN	Physical
,	,	O
length	NN	Physical
of	IN	Physical
time	NN	Physical
mean	JJ	Physical
FEV1	NNP	Physical
remained	VBD	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
15	CD	O
%	NN	O
above	IN	O
baseline	NN	O
,	,	O
physicians	NNS	Physical
'	POS	Physical
assessments	NNS	Physical
of	IN	Physical
patients	NNS	Physical
'	POS	Physical
clinical	JJ	Physical
response	NN	Physical
,	,	O
or	CC	O
patients	NNS	Others
'	POS	Others
subjective	JJ	Others
symptom	NN	Others
scores	NNS	Others
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
cardiovascular	JJ	Physical
effects	NNS	Physical
,	,	O
laboratory	NN	Physical
values	NNS	Physical
,	,	O
or	CC	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	O

Among	IN	O
patients	NNS	O
who	WP	O
expressed	VBD	O
a	DT	O
preference	NN	Others
for	IN	Others
one	CD	Others
of	IN	Others
the	DT	Others
delivery	NN	Others
systems	NNS	Others
,	,	O
half	NN	O
preferred	VBD	O
using	VBG	O
the	DT	O
powder	NN	O
.	.	O

Results	NNS	O
of	IN	O
this	DT	O
study	NN	O
demonstrate	NN	O
that	IN	O
200	CD	O
micrograms	NNS	O
of	IN	O
albuterol	NN	O
powder	NN	O
is	VBZ	O
as	IN	O
safe	JJ	O
and	CC	O
effective	JJ	O
as	IN	O
180	CD	O
micrograms	NNS	O
of	IN	O
albuterol	NN	O
aerosol	NN	O
.	.	O

Early	JJ	O
treatment	NN	O
of	IN	O
cold	JJ	O
sores	NNS	O
with	IN	O
topical	JJ	O
ME-609	NNP	O
decreases	VBZ	O
the	DT	O
frequency	NN	Physical
of	IN	Physical
ulcerative	JJ	Physical
lesions	NNS	Physical
:	:	Physical
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
patient-initiated	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Prior	NNP	O
pilot	NN	O
studies	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
antiviral	JJ	O
medications	NNS	O
with	IN	O
topical	JJ	O
corticosteroids	NNS	O
for	IN	O
herpes	NNS	O
simplex	JJ	O
labialis	NN	O
(	(	O
HSL	NNP	O
)	)	O
.	.	O

ME-609	NNP	O
(	(	O
Xerese	JJ	O
,	,	O
Xerclear	NNP	O
)	)	O
is	VBZ	O
a	DT	O
combination	NN	O
of	IN	O
5	CD	O
%	NN	O
acyclovir	NN	O
and	CC	O
1	CD	O
%	NN	O
hydrocortisone	NN	O
developed	VBD	O
for	IN	O
the	DT	O
topical	JJ	O
treatment	NN	O
of	IN	O
HSL	NNP	O
.	.	O

OBJECTIVES	NNP	O
The	DT	O
primary	NN	O
study	VBD	O
end	JJ	O
point	NN	O
was	VBD	O
the	DT	O
prevention	NN	O
of	IN	O
ulcerative	JJ	Physical
HSL	NNP	Physical
lesions	NNS	Physical
.	.	Physical

METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
2437	CD	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
HSL	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
self-initiate	JJ	O
treatment	NN	O
with	IN	O
ME-609	NNP	O
,	,	O
5	CD	O
%	NN	O
acyclovir	NN	O
in	IN	O
ME-609	NNP	O
vehicle	NN	O
,	,	O
or	CC	O
ME-609	JJ	O
vehicle	NN	O
(	(	O
placebo	NN	O
)	)	O
at	IN	O
the	DT	O
earliest	JJS	O
sign	NN	O
of	IN	O
a	DT	O
cold	JJ	O
sore	NN	O
recurrence	NN	O
.	.	O

Cream	NNP	O
was	VBD	O
applied	VBN	O
5	CD	O
times/d	NN	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1443	CD	O
patients	NNS	O
experienced	VBD	O
a	DT	Physical
recurrence	NN	Physical
and	CC	O
initiated	JJ	O
treatment	NN	O
with	IN	O
ME-609	NNP	O
(	(	O
n	JJ	O
=	NNP	O
601	CD	O
)	)	O
,	,	O
acyclovir	FW	O
(	(	O
n	JJ	O
=	NNP	O
610	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
patients	NNS	O
receiving	VBG	O
ME-609	NNP	O
,	,	O
42	CD	O
%	NN	O
did	VBD	O
not	RB	O
develop	VB	O
an	DT	O
ulcerative	JJ	Physical
lesion	NN	Physical
compared	VBN	O
with	IN	O
35	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
acyclovir	NN	O
in	IN	O
ME-609	NNP	O
vehicle	NN	O
(	(	O
P	NNP	O
=	NNP	O
.014	NNP	O
)	)	O
and	CC	O
26	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
ulcerative	JJ	O
lesions	NNS	O
,	,	O
healing	VBG	Others
times	NNS	Others
were	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
ME-609	NNP	O
and	CC	O
acyclovir	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
for	IN	O
both	DT	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	Physical
lesion	NN	Physical
area	NN	Physical
for	IN	O
all	DT	O
lesions	NNS	O
was	VBD	O
reduced	VBN	O
50	CD	O
%	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ME-609	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
positive	JJ	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
cultures	NNS	O
.	.	O

The	DT	O
side-effect	JJ	Adverseeffect
profile	NN	Adverseeffect
was	VBD	O
similar	JJ	O
among	IN	O
treatments	NNS	O
.	.	O

LIMITATIONS	VB	O
The	DT	O
study	NN	O
did	VBD	O
not	RB	O
contain	VB	O
a	DT	O
group	NN	O
treated	VBD	O
with	IN	O
a	DT	O
topical	JJ	O
corticosteroid	NN	O
alone	RB	O
.	.	O

CONCLUSIONS	NNP	O
ME-609	NNP	O
prevented	VBD	O
progression	NN	O
of	IN	O
cold	JJ	Physical
sores	NNS	Physical
to	TO	O
ulcerative	JJ	Physical
lesions	NNS	Physical
and	CC	O
significantly	RB	O
reduced	VBD	O
the	DT	O
cumulative	JJ	Physical
lesion	NN	Physical
area	NN	Physical
compared	VBN	O
with	IN	O
acyclovir	NN	O
and	CC	O
placebo	NN	O
.	.	O

ME-609	NNP	O
treatment	NN	O
offers	NNS	O
additional	JJ	O
therapeutic	JJ	O
benefit	NN	O
compared	VBN	O
with	IN	O
therapy	NN	O
with	IN	O
topical	JJ	O
acyclovir	NN	O
alone	RB	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
social	JJ	Mental
functioning	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Imitation	NNP	O
is	VBZ	O
an	DT	O
early	JJ	O
skill	NN	O
thought	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
social	JJ	O
development	NN	O
,	,	O
leading	VBG	O
some	DT	O
to	TO	O
suggest	VB	O
that	IN	O
teaching	VBG	O
imitation	NN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
should	MD	O
lead	VB	O
to	TO	O
improvements	NNS	O
in	IN	O
social	JJ	Mental
functioning	NN	Mental
.	.	O

This	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	O
imitation	NN	O
intervention	NN	O
on	IN	O
initiation	NN	O
of	IN	O
joint	JJ	Mental
attention	NN	Mental
and	CC	O
social-emotional	JJ	Mental
functioning	NN	Mental
in	IN	O
27	CD	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
more	RBR	O
gains	NNS	O
in	IN	O
joint	JJ	Mental
attention	NN	Mental
initiations	NNS	Mental
at	IN	O
post-treatment	JJ	O
and	CC	O
follow-up	JJ	O
and	CC	O
social-emotional	JJ	Mental
functioning	NN	Mental
at	IN	O
follow-up	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Although	IN	O
gains	NNS	Mental
in	IN	Mental
social	JJ	Mental
functioning	NN	Mental
were	VBD	O
associated	VBN	O
with	IN	O
treatment	NN	O
,	,	O
a	DT	O
mediation	NN	O
analysis	NN	O
did	VBD	O
not	RB	O
support	VB	O
imitation	NN	O
as	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
the	DT	O
intervention	NN	O
improves	VBZ	O
social	JJ	Mental
functioning	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Histamine	NNP	O
intolerance-like	NN	O
symptoms	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
after	IN	O
oral	JJ	O
provocation	NN	O
with	IN	O
liquid	JJ	O
histamine	NN	O
.	.	O

Histamine	NNP	O
in	IN	O
food	NN	O
at	IN	O
non-toxic	JJ	O
doses	NNS	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
causing	NN	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
,	,	O
hypotension	NN	O
,	,	O
headache	NN	O
,	,	O
pruritus	NN	O
and	CC	O
flush	NN	O
(	(	O
histamine	JJ	O
intolerance	NN	O
)	)	O
.	.	O

Histamine-rich	JJ	O
foods	NNS	O
such	JJ	O
as	IN	O
cheese	NN	O
,	,	O
sausages	NNS	O
,	,	O
sauerkraut	NN	O
,	,	O
tuna	NN	O
,	,	O
tomatoes	NNS	O
,	,	O
and	CC	O
alcoholic	JJ	O
beverages	NNS	O
may	MD	O
contain	VB	O
histamine	VB	O
up	IN	O
to	TO	O
500	CD	O
mg/kg	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
10	CD	O
healthy	JJ	O
females	NNS	O
(	(	O
age	NN	O
range	NN	O
22-36	CD	O
years	NNS	O
,	,	O
mean	JJ	O
29.1	CD	O
+/-	JJ	O
5.4	CD	O
)	)	O
who	WP	O
were	VBD	O
hospitalized	VBN	O
and	CC	O
challenged	VBN	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
with	IN	O
placebo	NN	O
(	(	O
peppermint	JJ	O
tea	NN	O
)	)	O
or	CC	O
75	CD	O
mg	NN	O
of	IN	O
pure	JJ	O
histamine	NN	O
(	(	O
equaling	VBG	O
124	CD	O
mg	JJ	O
histamine	NN	O
dihydrochloride	NN	O
,	,	O
dissolved	VBN	O
in	IN	O
peppermint	NN	O
tea	NN	O
)	)	O
.	.	O

Objective	JJ	O
parameters	NNS	O
(	(	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
temperature	NN	O
,	,	O
peak	VB	O
flow	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
total	JJ	O
clinical	JJ	O
symptom	NN	O
score	NN	O
using	VBG	O
a	DT	O
standardized	VBN	O
protocol	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
received	VBD	O
a	DT	O
histamine-free	JJ	O
diet	NN	O
also	RB	O
low	JJ	O
in	IN	O
allergen	NN	O
24	CD	O
hours	NNS	O
before	IN	O
hospitalization	NN	O
and	CC	O
over	IN	O
the	DT	O
whole	JJ	O
observation	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
histamine	NN	O
and	CC	O
the	DT	O
histamine-degrading	JJ	O
enzyme	NN	O
diamine	NN	O
oxidase	NN	O
(	(	O
DAO	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

After	IN	O
histamine	JJ	O
challenge	NN	O
,	,	O
5	CD	O
of	IN	O
10	CD	O
subjects	NNS	O
showed	VBD	O
no	DT	Physical
reaction	NN	Physical
.	.	O

One	CD	O
individual	NN	O
experienced	VBD	O
tachycardia	NN	Physical
,	,	O
mild	JJ	Physical
hypotension	NN	Physical
after	IN	Physical
20	CD	Physical
minutes	NNS	Physical
,	,	O
sneezing	VBG	Physical
,	,	O
itching	NN	Physical
of	IN	Physical
the	DT	Physical
nose	NN	Physical
,	,	O
and	CC	O
rhinorrhea	NN	Physical
after	IN	Physical
60	CD	Physical
minutes	NNS	Physical
.	.	O

Four	CD	O
subjects	NNS	O
experienced	VBD	O
delayed	JJ	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	Physical
(	(	Physical
4x	CD	Physical
)	)	Physical
,	,	O
flatulence	NN	Physical
(	(	Physical
3x	CD	Physical
)	)	Physical
,	,	O
headache	NN	Physical
(	(	Physical
3x	CD	Physical
)	)	Physical
,	,	O
pruritus	NN	Physical
(	(	Physical
2x	CD	Physical
)	)	Physical
and	CC	O
ocular	JJ	Physical
symptoms	NNS	Physical
(	(	O
1x	CD	O
)	)	O
starting	VBG	O
3	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
provocation	NN	O
.	.	O

No	DT	O
subject	NN	O
reacted	VBD	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
histamine	NN	Physical
and	CC	Physical
DAO	NNP	Physical
levels	NNS	Physical
within	IN	O
the	DT	O
first	JJ	O
80	CD	O
minutes	NNS	O
in	IN	O
non-reactors	NNS	O
as	RB	O
well	RB	O
as	IN	O
reactors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
challenge	NN	O
with	IN	O
histamine	JJ	O
versus	NN	O
challenge	NN	O
with	IN	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
75	CD	O
mg	NN	O
of	IN	O
pure	NN	O
liquid	JJ	O
oral	JJ	O
histamine	NN	O
--	:	O
a	DT	O
dose	JJ	O
found	VBN	O
in	IN	O
normal	JJ	O
meals	NNS	O
--	:	O
can	MD	O
provoke	VB	O
immediate	JJ	O
as	RB	O
well	RB	O
as	IN	O
delayed	VBN	O
symptoms	NNS	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
healthy	JJ	O
females	NNS	O
without	IN	O
a	DT	O
history	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
.	.	O

Soluble	JJ	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
in	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
:	:	O
effect	NN	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
and	CC	O
immunosuppressive	JJ	O
therapy	NN	O
.	.	O

OBJECTIVES	NNP	O
Soluble	JJ	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
(	(	O
sICAM-1	JJ	O
)	)	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
released	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
cells	NNS	O
at	IN	O
sites	NNS	O
of	IN	O
inflammation	NN	O
,	,	O
and	CC	O
their	PRP$	O
serum	NN	O
levels	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
as	IN	O
markers	NNS	O
of	IN	O
inflammatory	NN	O
and	CC	O
immune	JJ	O
activity	NN	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
therapy	NN	O
with	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
azathioprine	NN	O
and	CC	O
prednisone	NN	O
on	IN	O
serum	JJ	Physical
sICAM-1	JJ	Physical
levels	NNS	Physical
in	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
.	.	O

DESIGN/METHODS	NNP	O
Twenty-four	JJ	O
patients	NNS	O
with	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
and	CC	O
17	CD	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
patients	NNS	O
received	VBD	O
ursodeoxycholic	JJ	O
acid	NN	O
for	IN	O
12	CD	O
months	NNS	O
and	CC	O
were	VBD	O
then	RB	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
to	TO	O
receive	VB	O
prednisone	NN	O
and	CC	O
azathioprine	NN	O
,	,	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
ursodeoxycholic	JJ	O
acid	NN	O
.	.	O

RESULTS	NNP	O
sICAM-1	JJ	Physical
levels	NNS	Physical
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
patients	NNS	O
than	IN	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
fell	VBD	O
by	IN	O
a	DT	O
median	NN	O
of	IN	O
20	CD	O
%	NN	O
after	IN	O
12	CD	O
months	NNS	O
'	POS	O
therapy	NN	O
with	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0004	CD	O
)	)	O
.	.	O

Addition	NN	O
of	IN	O
azathioprine	NN	O
and	CC	O
prednisone	NN	O
to	TO	O
ursodeoxycholic	JJ	O
acid	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
further	JJ	O
reduction	NN	O
of	IN	O
sICAM-1	JJ	Physical
levels	NNS	Physical
by	IN	O
a	DT	O
median	NN	O
of	IN	O
25	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Reductions	NNPS	O
in	IN	O
sICAM-1	JJ	Physical
were	VBD	O
accompanied	VBN	O
by	IN	O
improvement	NN	O
in	IN	O
liver	JJ	Physical
function	NN	Physical
tests	NNS	Physical
but	CC	O
not	RB	O
in	IN	O
the	DT	O
lymphocyte	JJ	Physical
activation	NN	Physical
marker	NN	Physical
,	,	Physical
soluble	JJ	Physical
interleukin-2	JJ	Physical
receptor	NN	Physical
.	.	O

CONCLUSION	NNP	O
sICAM-1	JJ	Physical
levels	NNS	Physical
in	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
are	VBP	O
reduced	VBN	O
by	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
.	.	O

Further	JJ	O
reductions	NNS	O
were	VBD	O
achieved	VBN	O
by	IN	O
adding	VBG	O
prednisone	NN	O
and	CC	O
azathioprine	NN	O
.	.	O

These	DT	O
reductions	NNS	O
probably	RB	O
reflect	VBP	O
an	DT	O
improvement	NN	O
in	IN	O
hepatobiliary	JJ	Physical
excretion	NN	Physical
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
cellular	JJ	Physical
production	NN	Physical
of	IN	Physical
sICAM-1	NN	Physical
.	.	Physical

Using	VBG	O
a	DT	O
population-based	JJ	O
cancer	NN	O
registry	NN	O
for	IN	O
recruitment	NN	O
in	IN	O
a	DT	O
pilot	NN	O
cancer	NN	O
control	NN	O
study	NN	O
.	.	O

Cancer	NNP	O
control	NN	O
investigations	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
rarely	RB	O
use	VBP	O
population-based	JJ	O
registries	NNS	O
as	IN	O
a	DT	O
resource	NN	O
for	IN	O
recruitment	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
toxicity	NN	O
trial	NN	O
of	IN	O
tamoxifen	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
node	JJ	O
negative	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

To	TO	O
achieve	VB	O
the	DT	O
accrual	JJ	O
goal	NN	O
of	IN	O
140	CD	O
subjects	NNS	O
in	IN	O
this	DT	O
single	JJ	O
institution	NN	O
study	NN	O
,	,	O
the	DT	O
Wisconsin	NNP	Physical
Cancer	NNP	Physical
Reporting	NNP	Physical
System	NNP	Physical
(	(	Physical
WCRS	NNP	Physical
)	)	Physical
,	,	O
a	DT	O
population-based	JJ	O
cancer	NN	O
registry	NN	O
,	,	O
was	VBD	O
used	VBN	O
.	.	O

Registry	VB	O
information	NN	O
from	IN	O
the	DT	O
last	JJ	O
9	CD	O
years	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
3,585	CD	O
women	NNS	O
who	WP	O
met	VBD	O
the	DT	O
study	NN	O
criteria	NNS	O
with	IN	O
respect	NN	O
to	TO	O
age	NN	O
,	,	O
stage	NN	O
,	,	O
and	CC	O
previous	JJ	O
therapy	NN	O
.	.	O

The	DT	O
vital	JJ	O
status	NN	O
of	IN	O
identified	JJ	O
women	NNS	O
was	VBD	O
confirmed	VBN	O
using	VBG	O
Wisconsin	NNP	O
state	NN	O
death	NN	O
records	NNS	O
.	.	O

For	IN	O
identified	JJ	O
cases	NNS	O
,	,	O
rosters	NNS	O
were	VBD	O
prepared	JJ	O
and	CC	O
sent	VBD	O
to	TO	O
the	DT	O
physician	NN	O
with	IN	O
a	DT	O
cover	NN	O
letter	NN	O
and	CC	O
study	NN	O
description	NN	O
.	.	O

The	DT	O
physicians	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
update	VB	O
the	DT	O
list	NN	O
and	CC	O
,	,	O
if	IN	O
appropriate	JJ	O
,	,	O
to	TO	O
sign	VB	O
letters	NNS	O
to	TO	O
potentially	RB	O
eligible	JJ	O
and	CC	O
interested	JJ	O
women	NNS	O
.	.	O

Thirty-eight	JJ	O
percent	NN	O
of	IN	O
women	NNS	O
receiving	VBG	O
a	DT	O
letter	NN	O
and	CC	O
study	NN	O
information	NN	O
from	IN	O
their	PRP$	O
physicians	NNS	O
contacted	VBN	O
the	DT	O
study	NN	O
office	NN	O
about	IN	O
participation	NN	O
.	.	O

Eighteen	JJ	O
months	NNS	O
from	IN	O
its	PRP$	O
initiation	NN	O
,	,	O
140	CD	O
women	NNS	O
were	VBD	O
entered	VBN	O
on	IN	O
study	NN	O
.	.	O

This	DT	O
successful	JJ	O
use	NN	O
of	IN	O
a	DT	O
population-based	JJ	Others
cancer	NN	Others
registry	NN	Others
illustrates	VBZ	O
an	DT	O
efficient	JJ	Others
recruitment	NN	Others
method	NN	Others
which	WDT	O
could	MD	O
be	VB	O
modified	VBN	O
for	IN	O
other	JJ	O
cancer	NN	O
control/chemoprevention	NN	O
trials	NNS	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
of	IN	O
the	DT	O
Stockholm	NNP	O
randomized	VBD	O
trials	NNS	O
of	IN	O
postoperative	JJ	O
radiation	NN	O
therapy	NN	O
versus	NN	O
adjuvant	JJ	O
chemotherapy	NN	O
among	IN	O
'high	JJ	O
risk	NN	O
'	POS	O
pre-	NN	O
and	CC	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

For	IN	O
many	JJ	O
years	NNS	O
,	,	O
loco-regional	JJ	O
radiotherapy	NN	O
was	VBD	O
the	DT	O
standard	JJ	O
postoperative	JJ	O
treatment	NN	O
for	IN	O
node	JJ	O
positive	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
in	IN	O
Sweden	NNP	O
.	.	O

Because	IN	O
of	IN	O
encouraging	VBG	O
results	NNS	O
from	IN	O
trials	NNS	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
in	IN	O
the	DT	O
mid	NN	O
1970s	CD	O
,	,	O
the	DT	O
Stockholm	NNP	O
Breast	NNP	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
decided	VBD	O
to	TO	O
directly	RB	O
compare	VB	O
postoperative	JJ	O
radiation	NN	O
(	(	O
RT	NNP	O
)	)	O
with	IN	O
adjuvant	JJ	O
CMF-type	JJ	O
chemotherapy	NN	O
(	(	O
CT	NNP	O
)	)	O
.	.	O

Long-term	JJ	O
results	NNS	O
are	VBP	O
presented	VBN	O
from	IN	O
two	CD	O
randomized	JJ	O
trials	NNS	O
of	IN	O
RT	NNP	O
versus	NN	O
CT	NNP	O
in	IN	O
pre-	NN	O
(	(	O
n	JJ	O
=	NNP	O
547	CD	O
)	)	O
and	CC	O
postmenopausal	NN	O
(	(	O
n	JJ	O
=	NNP	O
679	CD	O
)	)	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
node	JJ	O
positive	JJ	O
disease	NN	O
or	CC	O
a	DT	O
tumour	JJ	O
diameter	NN	O
>	VBD	O
30	CD	O
mm	NN	O
.	.	O

RT	NNP	O
substantially	RB	O
reduced	VBD	O
loco-regional	JJ	Physical
recurrences	NNS	Physical
among	IN	O
both	DT	O
pre-	JJ	O
and	CC	O
postmenopausal	JJ	O
patients	NNS	O
(	(	O
relative	JJ	O
hazard	NN	O
RT	NNP	O
versus	NN	O
CT	NNP	O
:	:	O
0.67	CD	O
and	CC	O
0.43	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Among	IN	O
premenopausal	JJ	O
patients	NNS	O
distant	JJ	Physical
metastases	NNS	Physical
occurred	VBD	O
less	RBR	O
frequently	RB	O
in	IN	O
the	DT	O
CT	NNP	O
group	NN	O
(	(	O
relative	JJ	O
hazard	NN	O
:	:	O
1.68	CD	O
,	,	O
p	NN	O
>	NNP	O
0.001	CD	O
)	)	O
resulting	VBG	O
in	IN	O
an	DT	O
improved	JJ	O
recurrence-free	JJ	Mortality
survival	NN	Mortality
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Overall	JJ	Mortality
survival	NN	Mortality
was	VBD	O
also	RB	O
better	RB	O
with	IN	O
CT	NNP	O
(	(	O
cumulative	JJ	O
survival	NN	O
at	IN	O
15	CD	O
years	NNS	O
:	:	O
50	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
in	IN	O
the	DT	O
CT	NNP	O
and	CC	O
RT	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Among	IN	O
the	DT	O
postmenopausal	NN	O
patients	NNS	O
there	EX	O
were	VBD	O
no	DT	O
substantial	JJ	O
differences	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
recurrence-free	NN	Mortality
or	CC	Mortality
overall	JJ	Mortality
survival	NN	Mortality
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
risk	NN	Physical
of	IN	Physical
a	DT	Physical
second	JJ	Physical
primary	JJ	Physical
malignancy	NN	Physical
,	,	O
however	RB	O
,	,	O
was	VBD	O
doubled	VBN	O
in	IN	O
the	DT	O
RT	NNP	O
group	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
pronounced	JJ	O
excess	NN	O
concerned	JJ	O
second	JJ	Physical
lung	NN	Physical
cancers	NNS	Physical
occurring	VBG	O
after	IN	O
10	CD	O
years	NNS	O
.	.	O

The	DT	O
cumulative	JJ	Physical
incidence	NN	Physical
at	IN	Physical
20	CD	Physical
years	NNS	Physical
was	VBD	O
estimated	VBN	O
at	IN	O
0.3	CD	O
%	NN	O
and	CC	O
3.7	CD	O
%	NN	O
in	IN	O
the	DT	O
CT	NNP	O
and	CC	O
RT	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
trials	NNS	O
illustrate	VBP	O
the	DT	O
role	NN	O
of	IN	O
radiotherapy	NN	O
in	IN	O
preventing	VBG	O
loco-regional	JJ	Physical
recurrences	NNS	Physical
among	IN	O
high-risk	JJ	O
patients	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
need	NN	O
for	IN	O
systemic	JJ	O
treatment	NN	O
to	TO	O
control	VB	O
the	DT	O
disease	NN	O
systemically	RB	O
.	.	O

Impact	NN	O
of	IN	O
preinduced	JJ	O
quadriceps	NNS	O
fatigue	VBP	O
on	IN	O
exercise	NN	O
response	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
and	CC	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Exercise	NN	O
intolerance	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
results	NNS	O
from	IN	O
a	DT	O
complex	JJ	O
interaction	NN	O
between	IN	O
central	JJ	O
(	(	O
ventilatory	NN	O
)	)	O
and	CC	O
peripheral	JJ	O
(	(	O
limb	JJ	O
muscles	NNS	O
)	)	O
components	NNS	O
of	IN	O
exercise	NN	O
limitation	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
quadriceps	NNS	O
muscle	VBP	O
fatigue	NN	O
on	IN	O
exercise	NN	O
tolerance	NN	O
and	CC	O
ventilatory	JJ	O
response	NN	O
during	IN	O
constant-workrate	JJ	O
cycling	NN	O
exercise	NN	O
testing	NN	O
(	(	O
CWT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
and	CC	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
with	IN	O
COPD	NNP	O
and	CC	O
nine	CD	O
age-matched	JJ	O
healthy	JJ	O
subjects	NNS	O
performed	VBN	O
,	,	O
7	CD	O
days	NNS	O
apart	RB	O
,	,	O
two	CD	O
CWTs	NNP	O
up	RB	O
to	TO	O
exhaustion	NN	O
at	IN	O
80	CD	O
%	NN	O
of	IN	O
their	PRP$	O
predetermined	VBN	O
maximal	JJ	O
work	NN	O
capacity	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
one	CD	O
test	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
preinduced	JJ	O
quadriceps	NNS	O
fatigue	NN	O
and	CC	O
the	DT	O
other	JJ	O
in	IN	O
a	DT	O
fresh	JJ	O
state	NN	O
.	.	O

Quadriceps	NNP	O
fatigue	NN	O
was	VBD	O
produced	VBN	O
by	IN	O
electrostimulation-induced	JJ	O
contractions	NNS	O
and	CC	O
quantified	VBN	O
by	IN	O
maximal	JJ	Physical
voluntary	JJ	Physical
contraction	NN	Physical
and	CC	O
potentiated	VBD	Others
twitch	NN	Others
force	NN	Others
(	(	Others
TwQ	NNP	Others
(	(	Others
pot	NN	Others
)	)	Others
)	)	Physical
.	.	O

Endurance	NN	Others
time	NN	Others
and	CC	Physical
ventilatory	JJ	Others
response	NN	Others
during	IN	O
CWT	NNP	O
were	VBD	O
compared	VBN	O
between	IN	O
fatigued	VBN	O
and	CC	O
fresh	JJ	O
state	NN	O
.	.	O

Endurance	NN	Others
time	NN	Others
significantly	RB	O
decreased	VBN	O
in	IN	O
the	DT	O
fatigued	JJ	O
state	NN	O
compared	VBN	O
with	IN	O
the	DT	O
fresh	JJ	O
condition	NN	O
in	IN	O
COPD	NNP	O
(	(	O
356	CD	O
+/-	JJ	O
69	CD	O
s	NN	O
vs.	FW	O
294	CD	O
+/-	JJ	O
45	CD	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
controls	NNS	O
(	(	O
450	CD	O
+/-	JJ	O
74	CD	O
s	NN	O
vs.	FW	O
340	CD	O
+/-	JJ	O
45	CD	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Controls	NNP	O
showed	VBD	O
significantly	RB	O
higher	JJR	O
ventilation	NN	Others
and	CC	Others
end-exercise	JJ	Others
dyspnea	NN	Others
scores	NNS	Others
in	IN	O
the	DT	O
fatigued	JJ	O
condition	NN	O
,	,	O
whereas	NNS	O
,	,	O
in	IN	O
COPD	NNP	O
,	,	O
fatigue	NN	O
did	VBD	O
not	RB	O
influence	VB	O
ventilation	NN	O
or	CC	O
dyspnea	NN	O
during	IN	O
exercise	NN	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
ventilatory	NN	Others
limitation	NN	Others
,	,	O
as	IN	O
expressed	VBN	O
by	IN	O
the	DT	O
Ve/maximum	NNP	Physical
voluntary	JJ	Physical
ventilation	NN	Physical
ratio	NN	Physical
,	,	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
conditions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
induce	VB	O
quadriceps	NNS	O
fatigue	VBN	O
by	IN	O
local	JJ	O
electrostimulation-induced	JJ	O
contractions	NNS	O
.	.	O

Our	PRP$	O
findings	NNS	O
demonstrate	VBP	O
that	IN	O
peripheral	JJ	O
muscle	NN	O
fatigue	NN	O
is	VBZ	O
an	DT	O
additional	JJ	O
important	JJ	O
factor	NN	O
,	,	O
besides	IN	O
intense	JJ	O
dyspnea	NN	O
,	,	O
that	IN	O
limits	NNS	O
exercise	VBP	O
tolerance	NN	O
in	IN	O
COPD	NNP	O
.	.	O

Regular	JJ	O
replacement	NN	O
of	IN	O
extended	VBN	O
wear	NN	O
rigid	JJ	O
gas	NN	O
permeable	JJ	O
contact	NN	O
lenses	NNS	O
.	.	O

PURPOSE	NNP	O
While	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
planned	JJ	O
replacement	NN	O
of	IN	O
soft	JJ	O
contact	NN	O
lenses	NNS	O
have	VBP	O
been	VBN	O
investigated	VBN	O
,	,	O
the	DT	O
question	NN	O
of	IN	O
whether	IN	O
there	EX	O
are	VBP	O
any	DT	O
clinical	JJ	O
benefits	NNS	O
to	TO	O
planned	VBN	O
replacement	NN	O
of	IN	O
rigid	JJ	O
gas	NN	O
permeable	NN	O
(	(	O
RGP	NNP	O
)	)	O
lenses	VBZ	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
have	VB	O
been	VBN	O
addressed	VBN	O
experimentally	RB	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
the	DT	O
benefits	NNS	O
of	IN	O
regular	JJ	O
replacement	NN	O
of	IN	O
extended	VBN	O
wear	NN	O
RGP	NNP	O
contact	NN	O
lenses	VBZ	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
single-center	JJ	O
,	,	O
controlled	VBN	O
,	,	O
double-masked	JJ	O
study	NN	O
of	IN	O
39	CD	O
RGP	NNP	O
lens	VBZ	O
wearers	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
and	CC	O
wore	NN	O
extended	VBD	O
wear	JJ	O
Quantum	NNP	O
2	CD	O
lenses	NNS	O
(	(	O
Dk	NNP	O
=	NNP	O
120	CD	O
)	)	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
Group	NNP	O
I	PRP	O
replaced	VBD	O
lenses	NNS	O
every	DT	O
3	CD	O
months	NNS	O
,	,	O
whereas	VBP	O
those	DT	O
in	IN	O
Group	NNP	O
II	NNP	O
were	VBD	O
not	RB	O
scheduled	VBN	O
to	TO	O
replace	VB	O
their	PRP$	O
lenses	NNS	O
.	.	O

The	DT	O
integrity	NN	Others
of	IN	Others
the	DT	Others
lenses	NNS	Others
and	CC	O
the	DT	O
ocular	JJ	Physical
responses	NNS	Physical
to	TO	O
lens	NNS	O
wear	WDT	O
were	VBD	O
monitored	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
every	DT	O
three	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
to	TO	O
lenses	NNS	O
worn	VBN	O
by	IN	O
subjects	NNS	O
in	IN	O
Group	NNP	O
I	PRP	O
,	,	O
lenses	VBZ	O
worn	VBN	O
by	IN	O
Group	NNP	O
II	NNP	O
subjects	VBZ	O
showed	VBD	O
significantly	RB	O
more	RBR	O
mucous	JJ	Physical
coating	NN	Physical
,	,	O
lens	VBZ	Physical
binding	NN	Physical
,	,	O
and	CC	O
corneal	NN	Physical
staining	NN	Physical
over	IN	O
time	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
;	:	O
ANCOVA	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
microcystic	JJ	Physical
or	CC	Physical
tarsal	JJ	Physical
conjunctiva	JJ	Physical
response	NN	Physical
,	,	O
lens	VBZ	Physical
comfort	NN	Physical
,	,	O
refractive	JJ	Physical
change	NN	Physical
,	,	O
or	CC	O
visual	JJ	Physical
acuity	NN	Physical
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
advocate	VBP	O
that	DT	O
to	TO	O
maintain	VB	O
optimal	JJ	Physical
lens	NNS	Physical
integrity	NN	Physical
and	CC	O
ocular	JJ	Physical
health	NN	Physical
,	,	O
RGP	NNP	O
lenses	VBZ	O
used	VBN	O
for	IN	O
extended	JJ	O
wear	NN	O
should	MD	O
be	VB	O
replaced	VBN	O
every	DT	O
3	CD	O
to	TO	O
6	CD	O
months	NNS	O
.	.	O

Clinical	JJ	O
trial	NN	O
:	:	O
exposure	NN	O
to	TO	O
ribavirin	VB	O
predicts	NNS	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
infection	NN	O
treated	VBN	O
with	IN	O
peginterferon	NN	O
alpha-2a	JJ	O
plus	CC	O
ribavirin	JJ	O
.	.	O

BACKGROUND	VB	O
The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	O
drug	NN	O
exposure	NN	O
on	IN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
in	IN	O
routine	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

AIM	NNP	O
To	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
exposure	NN	O
to	TO	O
peginterferon	VB	O
alpha-2a	JJ	O
and	CC	O
ribavirin	VB	O
on	IN	O
early	JJ	O
virological	JJ	O
response	NN	O
(	(	O
EVR	NNP	O
)	)	O
and	CC	O
sustained	VBD	O
virological	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
with	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
infection	NN	O
enrolled	VBN	O
in	IN	O
a	DT	O
large	JJ	O
expanded	JJ	O
access	NN	O
programme	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
hundred	VBD	O
and	CC	O
ninety-one	JJ	O
patients	NNS	O
treated	VBD	O
for	IN	O
48	CD	O
weeks	NNS	O
with	IN	O
an	DT	O
initial	JJ	O
ribavirin	NN	O
dose	NN	O
of	IN	O
800	CD	O
or	CC	O
1000/1200	CD	O
mg/day	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Ribavirin	JJ	O
1000	CD	O
mg/day	NN	O
(	(	O
<	JJ	O
75	CD	O
kg	NN	O
)	)	O
or	CC	O
1200	CD	O
mg/day	NN	O
(	(	O
>	JJ	O
or=75	RB	O
kg	NN	O
)	)	O
and	CC	O
peginterferon	VB	O
alpha-2a	JJ	O
180	CD	O
microg/week	NN	O
were	VBD	O
considered	VBN	O
optimal	JJ	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	Physical
drug	NN	Physical
exposure	NN	Physical
(	(	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
optimal	NN	O
)	)	O
on	IN	O
EVR	NNP	Physical
and	CC	O
SVR	NNP	Physical
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	Others
ribavirin	NN	Others
exposure	NN	Others
in	IN	O
week	NN	O
0-12	NN	O
was	VBD	O
70	CD	O
%	NN	O
and	CC	O
96	CD	O
%	NN	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
and	CC	O
1000/1200	CD	O
mg/day	NN	O
,	,	O
respectively	RB	O
.	.	O

EVR	NNP	Physical
and	CC	O
SVR	NNP	Physical
rates	NNS	Physical
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
than	IN	O
1000/1200	CD	O
mg/day	NN	O
(	(	O
EVR	NNP	O
,	,	O
75	CD	O
%	NN	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
SVR	NNP	O
,	,	O
45	CD	O
%	NN	O
vs.	FW	O
54	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

Furthermore	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
achievement	NN	O
of	IN	O
EVR	NNP	Physical
and	CC	O
SVR	NNP	Physical
and	CC	O
ribavirin	VB	O
dose	NN	O
over	IN	O
the	DT	O
first	JJ	O
12	CD	O
weeks	NNS	O
expressed	VBD	O
either	CC	O
as	IN	O
absolute	JJ	O
dose	NN	O
or	CC	O
proportion	NN	O
of	IN	O
optimal	JJ	O
dose	NN	O
received	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Ribavirin	NNP	O
exposure	NN	O
to	TO	O
week	NN	O
12	CD	O
is	VBZ	O
significantly	RB	O
associated	VBN	O
with	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
genotype	JJ	O
1	CD	O
patients	NNS	O
.	.	O

Maintenance	NNP	O
of	IN	O
an	DT	O
optimal	JJ	O
ribavirin	NN	O
dose	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
important	JJ	O
modifiable	JJ	O
factor	NN	O
during	IN	O
combination	NN	O
therapy	NN	O
for	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
.	.	O

Bevacizumab-augmented	JJ	O
retinal	JJ	O
laser	NN	O
photocoagulation	NN	O
in	IN	O
proliferative	JJ	O
diabetic	JJ	O
retinopathy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
double-masked	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
additional	JJ	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
single	JJ	O
intravitreal	NN	O
bevacizumab	NN	O
injection	NN	O
on	IN	O
standard	JJ	O
laser	NN	O
treatment	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
proliferative	JJ	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
fellow-eye	JJ	O
sham	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
80	CD	O
eyes	NNS	O
of	IN	O
40	CD	O
high-risk	JJ	O
characteristic	JJ	O
proliferative	JJ	O
diabetic	JJ	O
retinopathy	NN	O
type	NN	O
II	NNP	O
diabetics	NNS	O
.	.	O

All	DT	O
cases	NNS	O
received	VBN	O
standard	JJ	O
laser	NN	O
treatment	NN	O
according	VBG	O
to	TO	O
Early	NNP	O
Treatment	NNP	O
Diabetic	NNP	O
Retinopathy	NNP	O
Study	NNP	O
protocol	NN	O
.	.	O

Avastin-assigned	JJ	O
eyes	NNS	O
received	VBD	O
1.25	CD	O
mg	NNS	O
intravitreal	JJ	O
bevacizumab	NN	O
(	(	O
Genentech	NNP	O
Inc.	NNP	O
,	,	O
San	NNP	O
Francisco	NNP	O
,	,	O
CA	NNP	O
)	)	O
on	IN	O
the	DT	O
first	JJ	O
session	NN	O
of	IN	O
their	PRP$	O
laser	NN	O
treatments	NNS	O
.	.	O

Fluorescein	NNP	O
angiography	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
weeks	NNS	O
6	CD	O
and	CC	O
16	CD	O
,	,	O
and	CC	O
proliferative	JJ	O
diabetic	JJ	O
retinopathy	NN	O
regression	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
masked	JJ	O
fashion	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
age	NN	O
was	VBD	O
52	CD	O
years	NNS	O
(	(	O
range	NN	O
:	:	O
39-68	JJ	O
)	)	O
and	CC	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
participants	NNS	O
were	VBD	O
male	JJ	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
16	CD	O
weeks	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
87.5	CD	O
%	NN	O
of	IN	O
Avastin-injected	JJ	O
eyes	NNS	O
and	CC	O
25	CD	O
%	NN	O
of	IN	O
sham	NN	O
group	NN	O
showed	VBD	O
complete	JJ	Physical
regression	NN	Physical
at	IN	O
week	NN	O
6	CD	O
of	IN	O
follow-up	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
at	IN	O
week	NN	O
16	CD	O
,	,	O
PDR	NNP	Physical
recurred	VBD	O
in	IN	O
a	DT	O
sizable	JJ	O
number	NN	O
of	IN	O
the	DT	O
Avastin-treated	JJ	O
eyes	NNS	O
,	,	O
and	CC	O
the	DT	O
complete	JJ	Physical
regression	NN	Physical
rate	NN	Physical
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
became	VBD	O
identical	JJ	O
(	(	O
25	CD	O
%	NN	O
;	:	O
p=1.000	NN	O
)	)	O
;	:	O
partial	JJ	O
regression	NN	O
rates	NNS	O
were	VBD	O
70	CD	O
%	NN	O
vs	JJ	O
65	CD	O
%	NN	O
.	.	O

In	IN	O
the	DT	O
subgroup	NN	O
of	IN	O
Avastin-treated	JJ	O
eyes	NNS	O
,	,	O
multivariate	NN	O
analysis	NN	O
identified	VBN	O
hemoglobin	JJ	O
A1c	NNP	O
as	IN	O
the	DT	O
strongest	JJS	O
predictor	NN	O
of	IN	O
proliferative	JJ	Physical
diabetic	JJ	Physical
retinopathy	NN	Physical
recurrence	NN	Physical
(	(	O
p=0.033	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Intravitreal	NNP	O
bevacizumab	NN	O
remarkably	RB	O
augmented	VBD	O
the	DT	O
short-term	JJ	O
response	NN	O
to	TO	O
scatter	VB	O
panretinal	JJ	O
laser	NN	O
photocoagulation	NN	O
in	IN	O
high-risk	JJ	O
characteristic	JJ	O
proliferative	JJ	O
diabetic	JJ	O
retinopathy	NN	O
but	CC	O
the	DT	O
effect	NN	O
was	VBD	O
short-lived	JJ	O
,	,	O
as	IN	O
many	JJ	O
of	IN	O
the	DT	O
eyes	NNS	O
showed	VBD	O
rapid	JJ	Physical
recurrence	NN	Physical
.	.	O

Alternative	JJ	O
dosing	NN	O
(	(	O
multiple	JJ	O
and/or	NN	O
periodic	JJ	O
intravitreal	NN	O
Avastin	NNP	O
injections	NNS	O
)	)	O
is	VBZ	O
recommended	VBN	O
for	IN	O
further	JJ	O
evaluation	NN	O
.	.	O

Resisting	VBG	O
good	JJ	O
news	NN	O
:	:	O
reactions	NNS	O
to	TO	O
breast	VB	O
cancer	NN	O
risk	NN	O
communication	NN	O
.	.	O

Many	JJ	O
women	NNS	O
overestimate	VBP	O
their	PRP$	O
percentage	NN	O
risk	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
,	,	O
even	RB	O
after	IN	O
they	PRP	O
have	VBP	O
received	VBN	O
careful	JJ	O
estimates	NNS	O
from	IN	O
health	NN	O
professionals	NNS	O
.	.	O

In	IN	O
2	CD	O
experiments	NNS	O
with	IN	O
134	CD	O
young	JJ	O
adult	NN	O
women	NNS	O
,	,	O
6	CD	O
variables	NNS	O
were	VBD	O
explored	VBN	O
that	IN	O
might	MD	O
influence	VB	O
such	JJ	O
risk	NN	Mental
perception	NN	Mental
persistence	NN	O
.	.	O

In	IN	O
Study	NNP	O
1	CD	O
,	,	O
each	DT	O
of	IN	O
the	DT	O
following	JJ	O
explanations	NNS	O
was	VBD	O
unrelated	JJ	O
to	TO	O
persistence	VB	Mental
:	:	Mental
public	JJ	O
commitment	NN	O
,	,	O
self-consistency	NN	O
,	,	O
and	CC	O
unique	JJ	O
causal	NN	O
risk	NN	O
models	NNS	O
.	.	O

In	IN	O
Study	NNP	O
2	CD	O
,	,	O
two	CD	O
individual	JJ	O
difference	NN	O
measures	NNS	O
,	,	O
pessimism	NN	O
and	CC	O
differences	NNS	O
in	IN	O
understanding	JJ	O
percentages	NNS	O
,	,	O
were	VBD	O
unrelated	JJ	O
to	TO	O
risk	VB	Mental
perception	NN	Mental
persistence	NN	Mental
.	.	Mental

However	RB	O
,	,	O
providing	VBG	O
a	DT	O
risk	NN	O
anchor	NN	O
based	VBN	O
on	IN	O
downward	JJ	O
social	JJ	O
comparison	NN	O
processes	NNS	O
resulted	VBD	O
in	IN	O
better	JJR	O
risk	NN	Mental
acceptance	NN	Mental
at	IN	O
posttest	JJS	O
that	IN	O
persisted	VBD	O
at	IN	O
a	DT	O
2-week	JJ	O
follow-up	JJ	O
assessment	NN	O
.	.	O

This	DT	O
article	NN	O
discusses	VBZ	O
why	WRB	O
comparison	NN	O
anchors	NNS	O
might	MD	O
be	VB	O
important	JJ	O
in	IN	O
risk	NN	O
feedback	NN	O
situations	NNS	O
and	CC	O
concludes	NNS	O
with	IN	O
recommendations	NNS	O
for	IN	O
professionals	NNS	O
who	WP	O
wish	VBP	O
to	TO	O
provide	VB	O
accurate	NN	O
risk	NN	O
information	NN	O
and	CC	O
have	VBP	O
patients	NNS	O
adopt	VB	O
that	DT	O
information	NN	O
.	.	O

Ambulatory	JJ	Physical
activity	NN	Physical
of	IN	O
children	NNS	O
with	IN	O
cerebral	JJ	O
palsy	NN	O
:	:	O
which	WDT	O
characteristics	NNS	O
are	VBP	O
important	JJ	O
?	.	O
AIM	NNP	O
To	TO	O
assess	VB	O
ambulatory	JJ	Physical
activity	NN	Physical
of	IN	O
children	NNS	O
with	IN	O
cerebral	JJ	O
palsy	NN	O
(	(	O
CP	NNP	O
)	)	O
,	,	O
aged	VBD	O
7	CD	O
to	TO	O
13	CD	O
years	NNS	O
,	,	O
and	CC	O
identify	VB	O
associated	VBN	O
characteristics	NNS	O
.	.	O

METHOD	NNP	O
Sixty-two	JJ	O
children	NNS	O
with	IN	O
spastic	JJ	O
CP	NNP	O
(	(	O
39	CD	O
males	NNS	O
,	,	O
23	CD	O
females	NNS	O
;	:	O
mean	JJ	O
age	NN	O
10y	CD	O
1mo	CD	O
,	,	O
SD	NNP	O
1y	CD	O
8mo	CD	O
;	:	O
age	NN	O
range	NN	O
7-13y	NNP	O
)	)	O
,	,	O
classified	VBD	O
as	IN	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Classification	NNP	O
System	NNP	O
(	(	O
GMFCS	NNP	O
)	)	O
levels	NNS	O
I	PRP	O
to	TO	O
III	NNP	O
,	,	O
participated	VBD	O
.	.	O

Ambulatory	NNP	O
activity	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
1	CD	O
week	NN	O
with	IN	O
a	DT	O
StepWatch	NNP	O
activity	NN	O
monitor	NN	O
as	IN	O
steps	NNS	O
per	IN	O
day	NN	O
,	,	O
and	CC	O
time	NN	O
spent	VBN	O
at	IN	O
medium	NN	O
and	CC	O
high	JJ	O
step	NN	O
rates	NNS	O
.	.	O

Multiple	JJ	O
linear	JJ	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
following	VBG	O
a	DT	O
backward	JJ	O
selection	NN	O
procedure	NN	O
until	IN	O
only	RB	O
independent	JJ	O
variables	NNS	O
with	IN	O
p	JJ	O
<	$	O
0.05	CD	O
remained	VBN	O
in	IN	O
the	DT	O
model	NN	O
.	.	O

Ambulatory	JJ	O
activity	NN	O
outcome	NN	O
parameters	NNS	O
served	VBD	O
as	IN	O
dependent	JJ	O
variables	NNS	O
,	,	O
and	CC	O
disease	NN	O
,	,	O
personal	JJ	O
,	,	O
and	CC	O
environmental	JJ	O
characteristics	NNS	O
as	IN	O
independent	JJ	O
variables	NNS	O
.	.	O

Ambulatory	NNP	O
activity	NN	O
was	VBD	O
corrected	VBN	O
for	IN	O
body	NN	O
height	NN	O
.	.	O

RESULTS	NNP	O
Children	NNP	O
took	VBD	O
more	RBR	O
steps	NNS	O
during	IN	O
school	NN	O
days	NNS	O
(	(	O
5169	CD	O
steps	NNS	O
,	,	O
SD	NNP	O
1641	CD	O
)	)	O
than	IN	O
during	IN	O
weekend	NN	O
days	NNS	O
(	(	O
4158	CD	O
steps	NNS	O
,	,	O
SD	NNP	O
2048	CD	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
.	.	O

Higher	JJR	O
GMFCS	NNP	O
level	NN	O
,	,	O
bilateral	JJ	O
CP	NNP	O
,	,	O
and	CC	O
higher	JJR	O
age	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
ambulatory	NN	O
activity	NN	O
on	IN	O
school	NN	O
days	NNS	O
(	(	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
ranged	VBD	O
from	IN	O
43-53	CD	O
%	NN	O
)	)	O
,	,	O
whereas	JJ	O
bilateral	JJ	O
CP	NNP	O
,	,	O
higher	JJR	O
age	NN	O
,	,	O
and	CC	O
no	DT	O
sport	NN	O
club	NN	O
participation	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
ambulatory	NN	O
activity	NN	O
in	IN	O
the	DT	O
weekend	NN	O
(	(	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
ranged	VBD	O
from	IN	O
21-42	CD	O
%	NN	O
)	)	O
.	.	O

Correcting	VBG	O
for	IN	O
body	NN	O
height	NN	O
decreased	VBD	O
the	DT	O
association	NN	O
with	IN	O
age	NN	O
.	.	O

INTERPRETATION	NNP	O
Interventions	NNP	O
should	MD	O
focus	VB	O
at	IN	O
increasing	VBG	O
physical	JJ	O
activity	NN	O
at	IN	O
the	DT	O
weekend	NN	O
for	IN	O
children	NNS	O
with	IN	O
bilateral	JJ	O
spastic	JJ	O
CP	NNP	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
levofloxacin	NN	O
,	,	O
omeprazole	NN	O
,	,	O
nitazoxanide	RB	O
,	,	O
and	CC	O
doxycycline	VB	O
versus	NN	O
triple	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	Physical
pylori	NN	Physical
.	.	O

OBJECTIVES	NNP	O
Resistance	NNP	O
to	TO	O
standard	VB	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
HP	NNP	O
)	)	O
treatment	NN	O
regimens	VBZ	O
has	VBZ	O
led	VBN	O
to	TO	O
unsatisfactory	JJ	O
cure	NN	O
rates	NNS	O
in	IN	O
HP-infected	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
a	DT	O
novel	JJ	O
four-drug	JJ	O
regimen	NNS	O
(	(	O
three	CD	O
antibiotics	NNS	O
and	CC	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
)	)	O
for	IN	O
eradication	NN	O
of	IN	O
HP	NNP	O
infection	NN	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
HP	NNP	O
gastritis	NN	O
or	CC	O
peptic	JJ	O
ulcer	JJ	O
disease	NN	O
confirmed	VBD	O
using	VBG	O
endoscopy	NN	O
and	CC	O
stool	NN	O
antigen	NN	O
testing	VBG	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
any	DT	O
prior	JJ	O
antibiotic	JJ	O
or	CC	O
PPI	JJ	O
usage	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomized	VBN	O
to	TO	O
either	DT	O
levofloxacin	NN	O
,	,	O
omeprazole	NN	O
,	,	O
nitazoxanide	RB	O
,	,	O
and	CC	O
doxycycline	NN	O
(	(	O
LOAD	NNP	O
)	)	O
therapy	NN	O
for	IN	O
7	CD	O
days	NNS	O
(	(	O
LOAD-7	NNP	O
)	)	O
or	CC	O
10	CD	O
days	NNS	O
(	(	O
LOAD-10	NNP	O
)	)	O
,	,	O
including	VBG	O
levofloxacin	JJ	O
250	CD	O
mg	NN	O
with	IN	O
breakfast	NN	O
,	,	O
omeprazole	JJ	O
40	CD	O
mg	NN	O
before	IN	O
breakfast	NN	O
,	,	O
nitazoxanide	RB	O
(	(	O
Alina	NNP	O
)	)	O
500	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
with	IN	O
meals	NNS	O
and	CC	O
doxycycline	VB	O
100	CD	O
mg	NN	O
at	IN	O
dinner	NN	O
,	,	O
or	CC	O
lansoprozole	NN	O
,	,	O
amoxicillin	NN	O
,	,	O
and	CC	O
clarithromycin	NN	O
(	(	O
LAC	NNP	O
)	)	O
therapy	NN	O
for	IN	O
10	CD	O
days	NNS	O
,	,	O
which	WDT	O
included	VBD	O
lansoprozole	JJ	O
30	CD	O
mg	NN	O
,	,	O
amoxicillin	VBZ	O
1	CD	O
g	NN	O
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
,	,	O
and	CC	O
clarithromycin	VBZ	O
500	CD	O
mg	NN	O
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

HP	NNP	O
eradication	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
stool	NN	Physical
antigen	NN	Physical
testing	VBG	Physical
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
Intention-to-treat	JJ	Others
analysis	NN	Others
revealed	VBD	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
respective	JJ	O
eradication	NN	Physical
rates	NNS	Physical
of	IN	Physical
the	DT	Physical
LOAD	NNP	Physical
therapies	NNS	Physical
(	(	O
88.9	CD	O
%	NN	O
(	(	O
80/90	CD	O
)	)	O
LOAD-10	NNP	O
,	,	O
90	CD	O
%	NN	O
(	(	O
81/90	CD	O
)	)	O
LOAD-7	NNP	O
,	,	O
89.4	CD	O
%	NN	O
(	(	O
161/180	CD	O
)	)	O
for	IN	O
combined	VBN	O
LOAD	NNP	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
LAC	NNP	Physical
,	,	O
73.3	CD	O
%	NN	O
(	(	O
66/90	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
open-label	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
demonstrates	VBZ	O
that	IN	O
LOAD	NNP	Physical
is	VBZ	O
a	DT	O
highly	RB	O
active	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HP	NNP	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

A	DT	O
large	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
further	RBR	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
this	DT	O
regimen	NNS	O
.	.	O

Comorbidity	NN	Physical
,	,	Physical
age	NN	Physical
and	CC	O
overall	JJ	Mortality
survival	NN	Mortality
in	IN	O
cetuximab-treated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
(	(	O
ACRC	NNP	O
)	)	O
--	:	O
results	NNS	O
from	IN	O
NCIC	NNP	O
CTG	NNP	O
CO.17	NNP	O
:	:	O
a	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
of	IN	O
cetuximab	NN	O
versus	NN	O
best	RBS	O
supportive	JJ	O
care	NN	O
.	.	O

BACKGROUND	IN	O
the	DT	O
interplay	NN	O
between	IN	O
comorbidity	NN	Physical
,	,	Physical
age	NN	Physical
and	CC	O
performance	NN	Physical
status	NN	Physical
(	(	Physical
PS	NNP	Physical
)	)	Physical
as	IN	O
predictors	NNS	O
of	IN	O
outcome	NN	O
in	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
(	(	O
ACRC	NNP	O
)	)	O
is	VBZ	O
poorly	JJ	O
understood	NN	O
.	.	O

We	PRP	O
examined	VBD	O
these	DT	O
factors	NNS	O
as	IN	O
predictors	NNS	O
of	IN	O
treatment	NN	O
toxicity	NN	Physical
and	CC	O
outcome	NN	O
in	IN	O
cetuximab-treated	JJ	O
patients	NNS	O
with	IN	O
ACRC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
comorbidity	NN	O
was	VBD	O
independently	RB	O
evaluated	VBN	O
using	VBG	O
the	DT	O
Charlson	NNP	Physical
Comorbidity	NNP	Physical
Index	NNP	Physical
(	(	Physical
CCI	NNP	Physical
)	)	Physical
,	,	O
a	DT	O
validated	JJ	O
measure	NN	O
of	IN	O
comorbidity	NN	Physical
based	VBN	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
medical	JJ	O
conditions	NNS	O
weighted	VBD	O
according	VBG	O
to	TO	O
their	PRP$	O
effect	NN	O
on	IN	O
mortality	NN	O
.	.	O

CCI	NNP	Physical
score	NN	Physical
was	VBD	O
correlated	VBN	O
with	IN	O
clinical	JJ	O
and	CC	O
outcome	JJ	O
data	NNS	O
.	.	O

RESULTS	NNP	O
five	CD	O
hundred	VBD	O
and	CC	O
seventy-two	JJ	O
patients	NNS	O
were	VBD	O
included	VBN	O
;	:	O
41	CD	O
%	NN	O
were	VBD	O
?	.	O
65	CD	O
years	NNS	O
and	CC	O
25	CD	O
%	NN	O
had	VBD	O
comorbidities	NNS	O
at	IN	O
randomization	NN	O
.	.	O

In	IN	O
multivariate	JJ	O
analysis	NN	O
(	(	O
MVA	NNP	O
)	)	O
of	IN	O
all	DT	O
covariates	NNS	O
,	,	O
only	RB	O
older	JJR	O
age	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
comorbidity	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

Overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
better	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
greater	JJR	O
comorbidity	NN	O
in	IN	O
univariate	JJ	O
analysis	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.047	CD	O
)	)	O
.	.	O

Conversely	RB	O
,	,	O
better	JJR	O
PS	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
better	JJR	O
OS	NNP	O
in	IN	O
MVA	NNP	O
(	(	O
hazard	JJ	O
ratio	NN	O
1.92	CD	O
for	IN	O
PS	NNP	O
=	NNP	O
2	CD	O
versus	NN	O
PS	NNP	O
=	NNP	O
0	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Age	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
OS	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

Elderly	JJ	O
patients	NNS	O
had	VBD	O
significantly	RB	O
less	JJR	O
grade	NN	O
?	.	O
3	CD	O
vomiting	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.034	CD	O
)	)	O
but	CC	O
more	JJR	O
dyspnea	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
greater	JJR	O
comorbidity	NN	O
had	VBD	O
significantly	RB	O
less	JJR	O
grade	NN	O
?	.	O
3	CD	O
vomiting	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
but	CC	O
more	JJR	O
non-neutropenic	JJ	O
fever	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
better	JJR	O
PS	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
OS	NNP	O
.	.	O

For	IN	O
patients	NNS	O
with	IN	O
good	JJ	O
PS	NNP	O
,	,	O
restricting	VBG	O
cetuximab	NN	O
use	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
significant	JJ	O
comorbidity	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
justified	VBN	O
.	.	O

Modest	NNP	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
epanolol	NN	O
,	,	O
a	DT	O
beta	NN	O
1-selective	JJ	O
receptor	NN	O
blocker	NN	O
with	IN	O
beta	NN	O
1	CD	O
agonist	NN	O
activity	NN	O
:	:	O
an	DT	O
acute	NN	O
and	CC	O
long-term	JJ	O
hemodynamic	NN	O
study	NN	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
and	CC	O
double	JJ	O
crossover	NN	O
comparison	NN	O
with	IN	O
atenolol	NN	O
on	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Beta-blockers	NNS	O
with	IN	O
less	JJR	O
cardiodepressive	JJ	O
effect	NN	O
than	IN	O
traditional	JJ	O
nonselective	JJ	O
beta	NN	O
(	(	O
1+2	CD	O
)	)	O
-blocking	VBG	O
agents	NNS	O
could	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
provided	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
was	VBD	O
satisfactory	JJ	O
.	.	O

Epanolol	NNP	O
,	,	O
a	DT	O
selective	JJ	O
beta	NN	O
1-receptor	JJ	O
blocker	NN	O
with	IN	O
intrinsic	JJ	O
sympathomimetic	JJ	O
activity	NN	O
,	,	O
induced	VBD	O
a	DT	O
fall	NN	O
in	IN	O
intraarterial	JJ	Physical
pressure	NN	Physical
of	IN	O
8	CD	O
%	NN	O
at	IN	O
rest	NN	O
sitting	VBG	O
and	CC	O
11	CD	O
%	NN	O
during	IN	O
100	CD	O
W	NNP	O
bicycle	NN	O
exercise	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
,	,	Physical
stroke	VBD	Physical
index	NN	Physical
,	,	Physical
and	CC	Physical
cardiac	JJ	Physical
index	NN	Physical
initially	RB	O
fell	VBD	O
by	IN	O
14	CD	O
%	NN	O
,	,	O
11	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
total	JJ	Physical
peripheral	JJ	Physical
resistance	NN	Physical
index	NN	Physical
increased	VBD	O
by	IN	O
21	CD	O
%	NN	O
after	IN	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
then	RB	O
reverted	VBD	O
towards	IN	O
the	DT	O
pretreatment	NN	O
level	NN	O
.	.	O

After	IN	O
10	CD	O
months	NNS	O
of	IN	O
epanolol	JJ	O
treatment	NN	O
(	(	O
mean	JJ	O
300	CD	O
mg/day	NN	O
)	)	O
,	,	O
the	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	Physical
pressure	NN	Physical
was	VBD	O
5	CD	O
%	NN	O
at	IN	O
rest	NN	O
and	CC	O
10	CD	O
%	NN	O
during	IN	O
exercise	NN	O
.	.	O

Cardiac	NNP	Physical
index	NN	Physical
and	CC	Physical
heart	NN	Physical
rate	NN	Physical
were	VBD	O
still	RB	O
reduced	VBN	O
14-21	CD	O
%	NN	O
,	,	O
while	IN	O
total	JJ	Physical
peripheral	JJ	Physical
resistance	NN	Physical
was	VBD	O
unchanged	JJ	O
or	CC	O
slightly	RB	O
increased	VBN	O
(	(	O
2-10	CD	O
%	NN	O
)	)	O
.	.	O

Twenty-four	JJ	Physical
hour	NN	Physical
ambulatory	NN	Physical
blood	NN	Physical
pressure	NN	Physical
was	VBD	O
higher	JJR	O
on	IN	O
epanolol	NN	O
(	(	O
300	CD	O
mg/day	NN	O
)	)	O
than	IN	O
on	IN	O
atenolol	NN	O
(	(	O
150	CD	O
mg/day	NN	O
)	)	O
treatment	NN	O
(	(	O
137/97	CD	O
vs.	FW	O
128/91	CD	O
mmHg	NN	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
achieved	VBN	O
blood	NN	Physical
pressure	NN	Physical
reduction	NN	O
induced	VBN	O
by	IN	O
epanolol	NN	O
was	VBD	O
moderate	JJ	O
,	,	O
while	IN	O
other	JJ	O
characteristics	NNS	O
of	IN	O
beta-receptor	NN	O
blockade	NN	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
heart	NN	Physical
rate	NN	Physical
and	CC	Physical
cardiac	JJ	Physical
output	NN	Physical
,	,	O
were	VBD	O
maintained	VBN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
compound	NN	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
other	JJ	O
cardiovascular	JJ	O
disorders	NNS	O
,	,	O
e.g.	NN	O
,	,	O
angina	JJ	O
pectoris	NN	O
in	IN	O
patients	NNS	O
without	IN	O
hypertension	NN	O
or	CC	O
cardiac	JJ	O
arrhythmia	NN	O
.	.	O

Intraoperative	JJ	O
microscopy	NN	O
of	IN	O
bile	NN	O
--	:	O
is	VBZ	O
it	PRP	O
useful	JJ	O
?	.	O
Direct	JJ	O
microscopy	NN	O
of	IN	O
the	DT	O
bile	NN	O
was	VBD	O
performed	VBN	O
during	IN	O
cholecystectomy	NN	O
in	IN	O
111	CD	O
patients	NNS	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
identify	VB	O
those	DT	O
with	IN	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
wound	JJ	O
infection	NN	O
.	.	O

Bacteria	NNP	O
were	VBD	O
identified	VBN	O
in	IN	O
23	CD	O
patients	NNS	O
,	,	O
11	CD	O
of	IN	O
83	CD	O
undergoing	JJ	O
cholecystectomy	NN	O
alone	RB	O
and	CC	O
12	CD	O
of	IN	O
28	CD	O
undergoing	JJ	O
exploration	NN	O
of	IN	O
the	DT	O
common	JJ	O
bile	NN	O
duct	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
23	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
an	DT	O
antibiotic	JJ	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
;	:	O
there	EX	O
was	VBD	O
one	CD	O
wound	NN	O
infection	NN	O
in	IN	O
the	DT	O
antibiotic	JJ	O
group	NN	O
and	CC	O
two	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
14	CD	O
patients	NNS	O
developed	VBD	O
wound	JJ	Physical
sepsis	NN	Physical
.	.	Physical

Infection	NN	Physical
was	VBD	O
more	RBR	O
likely	JJ	O
if	IN	O
the	DT	O
common	JJ	O
bile	NN	O
duct	NN	O
was	VBD	O
explored	VBN	O
(	(	O
6	CD	O
of	IN	O
28	CD	O
)	)	O
rather	RB	O
than	IN	O
cholecystectomy	VB	O
alone	JJ	O
(	(	O
8	CD	O
of	IN	O
83	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
microscopy	NN	O
and	CC	O
culture	NN	O
of	IN	O
the	DT	O
bile	NN	O
for	IN	O
bacteria	NNS	Adverseeffect
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
sepsis	NN	Physical
when	WRB	O
bacteria	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
microscopy	NN	O
.	.	O

We	PRP	O
were	VBD	O
not	RB	O
able	JJ	O
to	TO	O
identify	VB	O
a	DT	O
high	JJ	O
risk	NN	O
group	NN	O
of	IN	O
patients	NNS	O
by	IN	O
intraoperative	JJ	O
microscopy	NN	O
of	IN	O
bile	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
heart	NN	O
disease	NN	O
:	:	O
breast	NN	O
cancer	NN	O
prevention	NN	O
trial	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
overall	JJ	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
which	WDT	O
include	VBP	O
preventing	VBG	Physical
breast	NN	Physical
cancer	NN	Physical
and	CC	O
altering	VBG	O
cardiovascular	JJ	Physical
risk	NN	Physical
.	.	O

In	IN	O
a	DT	O
recent	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
postmenopausal	JJ	O
estrogen-progestin	JJ	O
therapy	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
early	JJ	Physical
cardiovascular	JJ	Physical
events	NNS	Physical
among	IN	O
women	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	Adverseeffect
effects	NNS	Adverseeffect
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

The	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
(	(	O
BCPT	NNP	O
)	)	O
is	VBZ	O
the	DT	O
only	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
provides	VBZ	O
data	NNS	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	JJ	Adverseeffect
effects	NNS	Adverseeffect
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
13	CD	O
388	CD	O
women	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
the	DT	O
BCPT	NNP	O
to	TO	O
receive	VB	O
either	DT	O
tamoxifen	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Cardiovascular	JJ	O
follow-up	NN	O
was	VBD	O
available	JJ	O
for	IN	O
13	CD	O
194	CD	O
women	NNS	O
,	,	O
1048	CD	O
of	IN	O
whom	WP	O
had	VBD	O
prior	RB	O
clinical	JJ	O
CHD	NNP	O
.	.	O

Fatal	NNP	Physical
and	CC	Physical
nonfatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
,	,	O
unstable	JJ	Physical
angina	NN	Physical
,	,	Physical
and	CC	Physical
severe	JJ	Physical
angina	NN	Physical
were	VBD	O
tabulated	VBN	O
(	(	O
mean	JJ	O
follow-up	NN	O
:	:	O
49	CD	O
months	NNS	O
)	)	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	NNP	O
Cardiovascular	JJ	Others
event	NN	Others
rates	NNS	Others
were	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
women	NNS	O
assigned	VBN	O
to	TO	O
receive	VB	O
tamoxifen	NN	O
and	CC	O
those	DT	O
assigned	VBN	O
to	TO	O
receive	VB	O
placebo	NN	O
,	,	O
independent	JJ	O
of	IN	O
pre-existing	JJ	O
CHD	NNP	O
.	.	O

Among	IN	O
women	NNS	O
without	IN	O
CHD	NNP	O
(	(	O
6074	CD	O
on	IN	O
tamoxifen	NN	O
versus	NN	O
6072	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
CIs	NNP	O
]	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
1.75	CD	O
(	(	O
0.44	CD	O
to	TO	O
8.13	CD	O
)	)	O
for	IN	O
fatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
,	,	O
1.11	CD	O
(	(	O
0.55	CD	O
to	TO	O
2.28	CD	O
)	)	O
for	IN	O
nonfatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
,	,	O
0.69	CD	O
(	(	O
0.29	CD	O
to	TO	O
1.57	CD	O
)	)	O
for	IN	O
unstable	JJ	Physical
angina	NN	Physical
,	,	O
and	CC	O
0.83	CD	O
(	(	O
0.32	CD	O
to	TO	O
2.10	CD	O
)	)	O
for	IN	O
severe	JJ	Physical
angina	NN	Physical
.	.	O

In	IN	O
women	NNS	O
with	IN	O
CHD	NNP	O
(	(	O
516	CD	O
on	IN	O
tamoxifen	NNS	O
versus	$	O
532	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	Others
ratios	NNS	Others
(	(	O
95	CD	O
%	NN	O
CIs	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
0.00	CD	O
(	(	O
0	CD	O
to	TO	O
1.58	CD	O
)	)	O
for	IN	O
fatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
,	,	O
1.25	CD	O
(	(	O
0.32	CD	O
to	TO	O
5.18	CD	O
)	)	O
for	IN	O
nonfatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
,	,	O
2.26	CD	O
(	(	O
0.87	CD	O
to	TO	O
6.55	CD	O
)	)	O
for	IN	O
unstable	JJ	Physical
angina	NN	Physical
,	,	O
and	CC	O
1.39	CD	O
(	(	O
0.23	CD	O
to	TO	O
9.47	CD	O
)	)	O
for	IN	O
severe	JJ	Physical
angina	NN	Physical
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
lack	NN	O
of	IN	O
association	NN	O
between	IN	O
tamoxifen	NN	O
and	CC	O
cardiovascular	JJ	Physical
events	NNS	Physical
was	VBD	O
related	VBN	O
to	TO	O
an	DT	O
early	JJ	O
increase	NN	Physical
in	IN	Physical
risk	NN	Physical
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
offset	VBN	O
by	IN	O
a	DT	O
late	JJ	O
decrease	NN	O
in	IN	O
risk	NN	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
used	VBN	O
for	IN	O
breast	NN	O
cancer	NN	O
prevention	NN	O
in	IN	O
women	NNS	O
with	IN	O
or	CC	O
without	IN	O
heart	NN	O
disease	NN	O
,	,	O
tamoxifen	NN	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
beneficial	JJ	O
or	CC	O
adverse	JJ	O
cardiovascular	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

Parecoxib	NNP	O
for	IN	O
analgesia	NN	O
after	IN	O
craniotomy	NN	O
.	.	O

BACKGROUND	NNP	O
Pain	NNP	Physical
after	IN	O
craniotomy	NN	O
is	VBZ	O
often	RB	O
under-treated	JJ	O
.	.	O

Opiates	VBZ	O
carry	VBP	O
distinct	JJ	O
disadvantages	NNS	O
.	.	O

Non-steroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
have	VBP	O
an	DT	O
anti-platelet	JJ	O
action	NN	O
and	CC	O
carry	VBP	O
a	DT	O
bleeding	NN	O
risk	NN	O
.	.	O

Cyclo-oxygenase	JJ	O
2	CD	O
inhibitors	NNS	O
such	JJ	O
as	IN	O
parecoxib	NNS	O
are	VBP	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
bleeding	NN	O
risk	NN	O
and	CC	O
would	MD	O
be	VB	O
welcome	JJ	O
analgesics	NNS	O
if	IN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
parecoxib	NN	O
40	CD	O
mg	NN	O
given	VBN	O
at	IN	O
dural	JJ	O
closure	NN	O
in	IN	O
82	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
craniotomies	NNS	O
.	.	O

Remifentanil	NNP	O
was	VBD	O
used	VBN	O
intraoperatively	RB	O
,	,	O
and	CC	O
i.v	NN	O
.	.	O

morphine	NN	O
was	VBD	O
titrated	VBN	O
to	TO	O
the	DT	O
requirement	NN	O
in	IN	O
the	DT	O
post-anaesthetic	JJ	O
unit	NN	O
.	.	O

On	IN	O
the	DT	O
ward	NN	O
,	,	O
i.m	NN	O
.	.	O

morphine	VB	O
5	CD	O
mg	NNS	O
as	IN	O
required	VBN	O
and	CC	O
regular	JJ	O
acetaminophen	NN	O
was	VBD	O
prescribed	VBN	O
.	.	O

Morphine	NNP	O
use	NN	O
and	CC	O
visual	JJ	Adverseeffect
analogue	NN	Adverseeffect
pain	NN	Adverseeffect
scores	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
at	IN	O
1	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
Parecoxib	NNP	O
reduced	VBD	Mental
pain	NN	Mental
scores	NNS	Mental
at	IN	O
6	CD	O
h	NN	O
and	CC	O
morphine	NN	O
use	NN	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
h	NN	O
after	IN	O
operation	NN	O
.	.	O

However	RB	O
,	,	O
overall	JJ	O
,	,	O
it	PRP	O
had	VBD	O
only	RB	O
minimal	JJ	O
impact	NN	O
on	IN	O
postoperative	JJ	Others
analgesia	NN	Others
.	.	Others

We	PRP	O
found	VBD	O
a	DT	O
wide	JJ	O
variability	NN	O
in	IN	O
analgesic	JJ	O
requirements	NNS	O
where	WRB	O
11	CD	O
%	NN	O
of	IN	O
patients	NNS	O
required	VBN	O
no	DT	O
opioids	NNS	O
and	CC	O
16	CD	O
%	NN	O
required	VBN	O
more	JJR	O
than	IN	O
15	CD	O
mg	JJ	O
i.v	NN	O
.	.	O

morphine	VB	O
1	CD	O
h	NN	O
after	IN	O
the	DT	O
surgery	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
only	RB	O
limited	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
parecoxib	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
after	IN	O
craniotomy	NN	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
glucagon	NN	O
and	CC	O
hyoscine	VB	O
N-butyl	NNP	O
bromide	NN	O
before	IN	O
endoscopic	NN	O
retrograde	NN	O
cholangiopancreatography	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
tried	VBD	O
to	TO	O
resolve	VB	O
whether	IN	O
glucagon	NN	O
is	VBZ	O
a	DT	O
better	JJR	O
premedication	NN	O
for	IN	O
endoscopic	NN	Physical
retrograde	NN	Physical
cholangiopancreatography	NN	Physical
(	(	Physical
ERCP	NNP	Physical
)	)	Physical
.	.	O

METHODS	NNP	O
We	PRP	O
first	RB	O
measured	VBD	O
the	DT	O
basal	NN	Physical
blood	NN	Physical
sugar	NN	Physical
and	CC	Physical
amylase	NN	Physical
levels	NNS	Physical
.	.	Physical

Then	RB	O
an	DT	O
endoscope	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
duodenum	NN	O
without	IN	O
premedication	NN	O
,	,	O
and	CC	O
basal	NN	Physical
pulse	NN	Physical
and	CC	Physical
duodenal	JJ	Physical
peristaltic	JJ	Physical
rates	NNS	Physical
were	VBD	O
measured	VBN	O
.	.	O

ERCP	NNP	O
began	VBD	O
after	IN	O
studied	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
premedicated	VBN	O
with	IN	O
either	DT	O
1	CD	O
mg	NN	O
glucagon	NN	O
(	(	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
or	CC	O
40	CD	O
mg	JJ	O
hyoscine	NN	O
N-butyl	NNP	O
bromide	NN	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
intravenously	RB	O
.	.	O

Ten	CD	O
minutes	NNS	O
later	RB	O
the	DT	O
variables	NNS	O
were	VBD	O
measured	VBN	O
again	RB	O
.	.	O

RESULTS	NNP	O
Glucagon	NNP	O
elicited	VBD	O
hyperglycemia	NN	Physical
whereas	NNS	O
hyoscine	VBP	O
N-butyl	NNP	O
bromide	NN	O
manifested	VBD	O
an	DT	O
anticholinergic	JJ	Physical
effect	NN	Physical
.	.	Physical

No	DT	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
these	DT	O
two	CD	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
necessary	JJ	Others
interval	NN	Others
for	IN	Others
ERCP	NNP	Others
(	(	O
20.6	CD	O
+/-	JJ	O
14.1	CD	O
min	NN	O
versus	NN	O
21.4	CD	O
+/-	JJ	O
14.7	CD	O
min	NN	O
;	:	O
NS	NNP	O
)	)	O
or	CC	O
the	DT	O
success	NN	Others
rate	NN	Others
for	IN	Others
cholangiopancreatography	NN	Others
(	(	O
92.1	CD	O
%	NN	O
versus	IN	O
91.7	CD	O
%	NN	O
;	:	O
NS	NNP	O
)	)	O
.	.	O

Neither	CC	O
hyperamylasemia	JJ	Physical
nor	CC	Physical
pancreatitis	NN	Physical
was	VBD	O
preventable	JJ	O
when	WRB	O
glucagon	NN	O
was	VBD	O
used	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
two	CD	O
premedications	NNS	O
appear	VBP	O
equally	RB	O
effective	JJ	O
in	IN	O
the	DT	O
performance	NN	Others
of	IN	Others
ERCP	NNP	Others
.	.	O

Comparison	NNP	O
of	IN	O
nicardipine	NN	O
and	CC	O
propranolol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild	NN	O
and	CC	O
moderate	JJ	O
hypertension	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
controlled	VBN	O
trial	NN	O
22	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
or	CC	O
moderate	JJ	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
nicardipine	JJ	O
30	CD	O
mg	NN	O
t.d.s	NN	O
.	.	O

and	CC	O
19	CD	O
patients	NNS	O
with	IN	O
propranolol	JJ	O
80	CD	O
mg	NN	O
t.d.s	NN	O
.	.	O

as	IN	O
monotherapy	NN	O
for	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Blood	NNP	Physical
pressure	NN	Physical
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
trial	NN	O
was	VBD	O
equally	RB	O
and	CC	O
significantly	RB	O
reduced	VBN	O
;	:	O
systolic	JJ	O
pressure	NN	O
22.2	CD	O
mmHg	NN	O
and	CC	O
diastolic	JJ	O
pressure	NN	O
15.5	CD	O
mmHg	NN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
,	,	O
and	CC	O
24.4	CD	O
mmHg	NN	O
and	CC	O
18.4	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
standing	VBG	O
position	NN	O
in	IN	O
those	DT	O
on	IN	O
nicardipine	NN	O
,	,	O
and	CC	O
by	IN	O
23.7	CD	O
and	CC	O
16.2	CD	O
mmHg	NN	O
and	CC	O
28.0	CD	O
and	CC	O
19.2	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
an	DT	O
initial	JJ	O
increase	NN	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
in	IN	O
the	DT	O
nicardipine	NN	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
rise	NN	O
was	VBD	O
only	RB	O
moderate	JJ	O
(	(	O
3	CD	O
beats/min	NN	O
supine	NN	O
p	NN	O
=	VBD	O
0.3219	CD	O
,	,	O
and	CC	O
7	CD	O
beats/min	NN	O
standing	NN	O
,	,	O
p	VBP	O
=	RB	O
0.0203	CD	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
24	CD	O
weeks	NNS	O
.	.	O

In	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
heart	NN	Physical
rate	NN	Physical
was	VBD	O
reduced	VBN	O
markedly	RB	O
.	.	O

Adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
occurred	VBD	O
in	IN	O
77	CD	O
%	NN	O
of	IN	O
patients	NNS	O
on	IN	O
nicardipine	NN	O
and	CC	O
in	IN	O
63	CD	O
%	NN	O
of	IN	O
those	DT	O
on	IN	O
propranolol	NN	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
unexpected	JJ	O
findings	NNS	O
.	.	O

The	DT	O
effects	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
did	VBD	O
not	RB	O
lead	VB	O
any	DT	O
patient	NN	O
to	TO	O
stop	VB	O
medication	NN	O
.	.	O

One	CD	O
patient	NN	O
on	IN	O
propranolol	NN	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
trial	NN	O
because	IN	O
of	IN	O
poor	JJ	O
blood	NN	Physical
pressure	NN	Physical
control	NN	Physical
and	CC	O
suspected	VBD	Physical
angina	NNS	Physical
pectoris	VBP	Physical
after	IN	O
5	CD	O
weeks	NNS	O
on	IN	O
active	JJ	O
medication	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
blood	NN	Physical
chemistry	NN	Physical
,	,	O
including	VBG	O
lipoprotein	NN	Physical
classes	NNS	Physical
.	.	O

Overall	JJ	O
,	,	O
in	IN	O
comparison	NN	O
with	IN	O
propranolol	NN	O
,	,	O
nicardipine	NN	O
was	VBD	O
effective	JJ	O
,	,	O
well-tolerated	JJ	O
and	CC	O
safe	JJ	O
to	TO	O
use	VB	O
in	IN	O
the	DT	O
monotherapy	NN	O
of	IN	O
mild	NN	O
or	CC	O
moderate	JJ	O
essential	JJ	O
hypertension	NN	O
.	.	O

Plasma	NNP	O
pH	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
maximal	JJ	O
whole	JJ	O
body	NN	O
exercise	NN	O
.	.	O

Exercise	NN	O
lowers	VBZ	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
of	IN	O
O2	NNP	O
to	TO	O
carbohydrate	VB	O
(	(	O
glucose+1/2	JJ	O
lactate	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
appears	VBZ	O
to	TO	O
promote	VB	Others
cerebral	JJ	Others
lactate	JJ	Others
uptake	NN	Others
.	.	O

However	RB	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
pH	NN	O
on	IN	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
and	CC	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
on	IN	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
exercise	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Sodium	NN	O
bicarbonate	NN	O
(	(	O
Bicarb	NNP	O
,	,	O
1	CD	O
M	NNP	O
;	:	O
350-500	CD	O
ml	NN	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
normal	JJ	O
saline	NN	O
(	(	O
Sal	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
constant	JJ	O
rate	NN	O
during	IN	O
a	DT	O
'2000	CD	O
m	NN	O
'	''	O
maximal	JJ	O
ergometer	NN	O
row	NN	O
in	IN	O
six	CD	O
male	JJ	O
oarsmen	NNS	O
(	(	O
23?2	CD	O
years	NNS	O
;	:	O
mean?S.D.	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
Sal	NNP	O
trial	NN	O
,	,	O
pH	NN	O
decreased	VBD	O
from	IN	O
7.41?0.01	CD	O
at	IN	O
rest	NN	O
to	TO	O
7.02?0.02	CD	O
but	CC	O
only	RB	O
to	TO	O
7.36?0.02	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
during	IN	O
the	DT	O
Bicarb	NNP	O
trial	NN	O
.	.	O

Arterial	JJ	O
lactate	NN	O
increased	VBD	O
to	TO	O
21.4?0.8	CD	O
and	CC	O
32.7?2.3	CD	O
mM	NN	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
arterial-jugular	JJ	O
venous	JJ	O
lactate	NN	O
difference	NN	O
increased	VBD	O
from-0.03?0.01	JJ	O
mM	NN	O
at	IN	O
rest	NN	O
to	TO	O
3.2?0.9	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
3.4?1.4	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
following	VBG	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
cerebral	JJ	Physical
metabolic	NN	Physical
ratio	NN	Physical
decreased	VBD	O
equally	RB	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
:	:	O
from	IN	O
5.8?0.6	CD	O
at	IN	O
rest	NN	O
to	TO	O
1.7?0.1	CD	O
and	CC	O
1.8?0.2	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
enlarged	JJ	O
blood-buffering	NN	O
capacity	NN	O
after	IN	O
infusion	NN	O
of	IN	O
Bicarb	NNP	O
eliminated	VBD	O
metabolic	JJ	O
acidosis	NN	O
during	IN	O
maximal	JJ	O
exercise	NN	O
but	CC	O
that	DT	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
lactate	NN	O
uptake	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
dose	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
Adjuvant	NNP	O
locoregional	JJ	O
chemotherapy	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
to	TO	O
prevent	VB	O
recurrence	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
(	(	O
HCC	NNP	O
)	)	O
in	IN	O
some	DT	O
retrospective	JJ	O
studies	NNS	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
dose	JJ	O
effect	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tumor	NN	O
recurrence	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
HCC	NNP	O
;	:	O
they	PRP	O
were	VBD	O
given	VBN	O
either	DT	O
one	CD	O
intra-arterial	JJ	O
dose	NN	O
of	IN	O
cisplatin/lipiodol	NN	O
,	,	O
or	CC	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
once	RB	O
every	DT	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
rates	NNS	Physical
of	IN	Physical
recurrence	NN	Physical
,	,	O
disease-free	JJ	Mortality
and	CC	O
overall	JJ	Mortality
survival	NN	Mortality
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
During	IN	O
a	DT	O
median	JJ	O
follow	NN	O
up	IN	O
of	IN	O
818	CD	O
days	NNS	O
,	,	O
21	CD	O
patients	NNS	O
received	VBD	O
one	CD	O
dose	NN	O
and	CC	O
19	CD	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
with	IN	O
10	CD	O
(	(	O
47.6	CD	O
%	NN	O
)	)	O
and	CC	O
eight	CD	O
(	(	O
42.1	CD	O
%	NN	O
)	)	O
recurrences	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
1-year	JJ	Mortality
,	,	Mortality
2-year	JJ	Mortality
and	CC	Mortality
3-year	JJ	Mortality
disease-free	JJ	Mortality
survival	NN	Mortality
rates	NNS	Mortality
were	VBD	O
71	CD	O
%	NN	O
,	,	O
54	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
for	IN	O
the	DT	O
one-dose	JJ	O
group	NN	O
and	CC	O
74	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
the	DT	O
four-dose	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.78	CD	O
)	)	O
.	.	O

The	DT	O
respective	JJ	O
overall	JJ	Mortality
survival	NN	Mortality
rates	NNS	Mortality
were	VBD	O
85	CD	O
%	NN	O
,	,	O
74	CD	O
%	NN	O
,	,	O
55	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
,	,	O
71	CD	O
%	NN	O
,	,	O
40	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.64	CD	O
)	)	O
.	.	O

The	DT	O
only	JJ	O
prognostic	JJ	O
factor	NN	O
was	VBD	O
presence	NN	Physical
of	IN	Physical
vascular	JJ	Physical
permeation	NN	Physical
.	.	O

The	DT	O
side-effects	NNS	Adverseeffect
were	VBD	O
mild	JJ	O
and	CC	O
tolerable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
survival	NN	Mortality
rates	NNS	Mortality
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Adjuvant	NNP	O
chemotherapy	NN	O
may	MD	O
not	RB	O
be	VB	O
useful	JJ	O
.	.	O

Radiotherapy	NNP	O
and	CC	O
CCNU	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
high-grade	JJ	O
supratentorial	JJ	O
astrocytomas	NN	O
.	.	O

Forty-one	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
supratentorial	JJ	O
primary	JJ	O
brain	NN	O
tumors	NNS	O
(	(	O
38	CD	O
Grade	NNP	O
III	NNP	O
and	CC	O
IV	NNP	O
astrocytomas	RB	O
,	,	O
one	CD	O
giant-cell	NN	O
astrocytoma	NN	O
,	,	O
and	CC	O
two	CD	O
cases	NNS	O
with	IN	O
insufficient	JJ	O
tissue	NN	O
for	IN	O
diagnosis	NN	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
within	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
surgery	NN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
therapeutic	JJ	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
(	(	O
15	CD	O
patients	NNS	O
)	)	O
received	VBD	O
radiation	NN	O
therapy	NN	O
totaling	VBG	O
4000	CD	O
to	TO	O
4500	CD	O
rads	NNS	O
in	IN	O
4	CD	O
to	TO	O
5	CD	O
weeks	NNS	O
.	.	O

Group	NNP	O
2	CD	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
received	VBD	O
1-	JJ	O
(	(	O
2-chloroethyl	JJ	O
)	)	O
-3-cyclohexyl-1-nitrosourea	FW	O
CCNU	NNP	O
)	)	O
130	CD	O
mg/sq	JJ	O
m	NNS	O
orally	RB	O
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

Group	NNP	O
3	CD	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
received	VBD	O
radiation	NN	O
therapy	NN	O
plus	CC	O
CCNU	NNP	O
as	IN	O
for	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
.	.	O

When	WRB	O
the	DT	O
disease	NN	O
progressed	VBD	O
,	,	O
patients	NNS	O
in	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
receive	VB	O
CCNU	NNP	O
and	CC	O
irradiation	NN	O
respectively	RB	O
.	.	O

The	DT	O
median	JJ	Mortality
survival	NN	Mortality
time	NN	Mortality
in	IN	O
these	DT	O
groups	NNS	O
was	VBD	O
188	CD	O
,	,	O
259	CD	O
,	,	O
and	CC	O
252	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
survival	NN	Mortality
263	CD	O
,	,	O
262	CD	O
,	,	O
and	CC	O
329	CD	O
days	NNS	O
.	.	O

The	DT	O
median	JJ	Physical
time	NN	Physical
from	IN	Physical
diagnosis	NN	Physical
to	TO	Physical
crossover	VB	Physical
(	(	Physical
Groups	NNP	Physical
1	CD	Physical
and	CC	Physical
2	CD	Physical
)	)	Physical
or	CC	Physical
to	TO	Physical
progression	NN	Physical
(	(	O
Group	NNP	O
3	CD	O
)	)	O
was	VBD	O
163	CD	O
,	,	O
99	CD	O
,	,	O
and	CC	O
220	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
time	NN	O
was	VBD	O
172	CD	O
,	,	O
108	CD	O
,	,	O
and	CC	O
231	CD	O
days	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
means	NNS	Others
or	CC	Others
medians	NNS	Others
in	IN	O
any	DT	O
of	IN	O
these	DT	O
situations	NNS	O
.	.	O

Cholesterol-lowering	JJ	O
therapy	NN	O
may	MD	O
retard	VB	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

There	EX	O
is	VBZ	O
experimental	JJ	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
hypercholesterolaemia	NN	O
may	MD	O
play	VB	O
a	DT	O
pathogenetic	JJ	O
role	NN	O
in	IN	O
progressive	JJ	O
glomerular	JJ	O
injury	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
cholesterol-lowering	JJ	O
therapy	NN	O
on	IN	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
34	CD	O
patients	NNS	O
with	IN	O
non-insulin-dependent	JJ	O
diabetes	NNS	O
mellitus	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
single-blind	JJ	O
fashion	NN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
lovastatin	NN	O
,	,	O
an	DT	O
HMG	NNP	O
CoA	NNP	O
reductase	NN	O
inhibitor	NN	O
(	(	O
n	JJ	O
=	VBZ	O
16	CD	O
;	:	O
mean	VB	O
dose	JJ	O
30.0	CD	O
+/-	JJ	O
12.6	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

Renal	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
serially	RB	O
measuring	VBG	O
the	DT	O
serum	NN	O
creatinine	NN	O
,	,	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
using	VBG	O
Cr51-EDTA	NNP	O
)	)	O
,	,	O
and	CC	O
24-h	JJ	O
urinary	JJ	O
protein	NN	O
excretion	NN	O
.	.	O

Lovastatin	NNP	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
LDL-cholesterol	NNP	Physical
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
apo	JJ	Physical
B	NNP	Physical
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
reductions	NNS	O
at	IN	O
24	CD	O
months	NNS	O
being	VBG	O
26	CD	O
,	,	O
30	CD	O
and	CC	O
18	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
on	IN	O
serum	NN	Physical
triglyceride	NN	Physical
,	,	O
HDL-cholesterol	NNP	Physical
and	CC	O
apo	VB	Physical
A1	NNP	Physical
levels	NNS	Physical
were	VBD	O
also	RB	O
observed	VBN	O
.	.	O

Lp	NNP	Physical
(	(	Physical
a	DT	Physical
)	)	Physical
showed	VBD	O
no	DT	Others
significant	JJ	Others
change	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Glomerular	JJ	Others
filtration	NN	Others
rate	NN	Others
deteriorated	VBN	Others
significantly	RB	Others
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
after	IN	O
24	CD	O
months	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.025	CD	O
)	)	O
but	CC	O
showed	VBD	O
no	DT	Others
significant	JJ	Others
change	NN	Others
in	IN	O
the	DT	O
lovastatin-treated	JJ	O
patients	NNS	O
.	.	O

The	DT	O
increase	NN	Physical
in	IN	Physical
serum	JJ	Physical
creatinine	NN	Physical
was	VBD	O
statistically	RB	Others
significant	JJ	Others
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
in	IN	O
placebo-treated	JJ	O
patients	NNS	O
at	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
lovastatin	NN	O
group	NN	O
after	IN	O
24	CD	O
months	NNS	O
.	.	O

Twenty-four	CD	O
hour	NN	O
urinary	JJ	Physical
protein	NN	Physical
excretion	NN	Physical
increased	VBN	Physical
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Lovastatin	NNP	O
treatment	NN	O
was	VBD	O
not	RB	Others
associated	VBN	Others
with	IN	O
significant	JJ	Physical
elevations	NNS	Physical
in	IN	O
liver	NN	Physical
or	CC	Physical
muscle	NN	Physical
enzymes	NNS	Physical
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
effective	JJ	O
normalisation	NN	O
of	IN	O
hypercholesterolaemia	NN	Physical
may	MD	O
retard	VB	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	Physical
nephropathy	NN	Physical
.	.	O

Scaling	VBG	O
clinical	JJ	O
judgments	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
psychophysiological	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

Summing	VBG	O
scores	NNS	O
across	IN	O
heterogeneous	JJ	O
symptom	NN	O
items	NNS	O
without	IN	O
consideration	NN	O
of	IN	O
their	PRP$	O
differing	JJ	O
psychopathological	JJ	O
significance	NN	O
has	VBZ	O
been	VBN	O
criticized	VBN	O
as	IN	O
producing	VBG	O
an	DT	O
inadequate	JJ	O
picture	NN	O
of	IN	O
an	DT	O
individual	NN	O
's	POS	O
clinical	JJ	O
status	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
derive	JJ	O
symptom	JJ	O
item	NN	O
weights	NNS	O
representing	VBG	O
clinically	RB	O
judged	VBN	O
seriousness	NN	O
of	IN	O
each	DT	O
symptom	NN	O
through	IN	O
the	DT	O
application	NN	O
of	IN	O
Steven	NNP	O
's	POS	O
psychophysical	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

A	DT	O
nationwide	JJ	O
sample	NN	O
of	IN	O
129	CD	O
clinicians	NNS	O
rated	VBD	O
the	DT	O
pathological	JJ	O
significance	NN	O
of	IN	O
221	CD	O
symptom	JJ	O
items	NNS	O
in	IN	O
a	DT	O
design	NN	O
such	JJ	O
that	IN	O
every	DT	O
rater	NN	O
rated	VBD	O
121	CD	O
items	NNS	O
,	,	O
21	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
by	IN	O
all	DT	O
raters	NNS	O
and	CC	O
100	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
only	RB	O
by	IN	O
the	DT	O
A	NNP	O
or	CC	O
B	NNP	O
subgroup	NN	O
to	TO	O
which	WDT	O
each	DT	O
rater	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

Each	DT	O
item	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
to	TO	O
the	DT	O
seriousness	NN	O
of	IN	O
the	DT	O
pathology	NN	O
it	PRP	O
would	MD	O
represent	VB	O
if	IN	O
manifested	VBN	O
by	IN	O
either	CC	O
a	DT	O
boy	NN	O
child	NN	O
,	,	O
girl	JJ	O
child	NN	O
,	,	O
boy	JJ	O
adolescent	NN	O
,	,	O
or	CC	O
girl	JJ	O
adolescent	NN	O
,	,	O
with	IN	O
one-fourth	NN	O
of	IN	O
the	DT	O
raters	NNS	O
assigned	VBD	O
to	TO	O
each	DT	O
condition	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
211	CD	O
two-way	JJ	O
analyses	NNS	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
age	NN	O
and	CC	O
age	NN	Mental
and	CC	Mental
sex	NN	Mental
in	IN	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
sex	VB	O
alone	RB	O
,	,	O
significantly	RB	O
influenced	VBD	O
the	DT	O
clinical	JJ	O
ratings	NNS	O
.	.	O

The	DT	O
resulting	VBG	O
magnitude	JJ	Mental
estimation	NN	Mental
ratings	NNS	Mental
of	IN	Mental
symptom	JJ	Mental
pathology	NN	Mental
ranged	VBD	O
from	IN	O
1.0	CD	O
to	TO	O
9.9	CD	O
.	.	O

They	PRP	O
were	VBD	O
demonstrated	VBN	O
to	TO	O
have	VB	O
satisfactoy	VBN	O
reliability	NN	O
and	CC	O
convergent	NN	O
validity	NN	O
and	CC	O
to	TO	O
have	VB	O
the	DT	O
psychophysical	JJ	O
characteristics	NNS	O
of	IN	O
a	DT	O
prothetic	JJ	O
continuum	NN	O
.	.	O

The	DT	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	JJ	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
number	NN	Physical
and	CC	Physical
function	NN	Physical
of	IN	Physical
endothelial	JJ	Physical
progenitor	NN	Physical
cells	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	CC	O
Peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	NN	O
(	(	O
PPAR	NNP	O
gamma	NN	O
)	)	O
agonists	VBZ	O
(	(	O
thiazolidinediones	NNS	O
[	NNP	O
TZDs	NNP	O
]	NNP	O
)	)	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Bone	CD	O
marrow-derived	JJ	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
(	(	O
EPCs	NNP	O
)	)	O
improve	VB	O
vascular	JJ	Physical
function	NN	Physical
and	CC	O
predict	NN	O
cardiovascular	NN	Physical
risk	NN	Physical
.	.	Physical

The	DT	O
effect	NN	O
of	IN	O
pioglitazone	NN	O
therapy	NN	O
on	IN	O
EPCs	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
patients	NNS	O
with	IN	O
documented	JJ	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

Of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
fasting	VBG	O
glucose	JJ	O
levels	NNS	O
,	,	O
18	CD	O
showed	VBD	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
36	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
30-day	JJ	O
treatment	NN	O
with	IN	O
pioglitazone	NN	O
(	(	O
45	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
optimal	VB	O
medical	JJ	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
TZD	NNP	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
adiponectin	JJ	Physical
levels	NNS	Physical
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
compliance	NN	O
(	(	O
11.4	CD	O
+/-	JJ	O
1.1	CD	O
to	TO	O
36.8	CD	O
+/-	JJ	O
2.1	CD	O
microg/ml	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TZD	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
decreased	VBN	O
mean	JJ	Physical
high-sensitivity	NN	Physical
C-reactive	JJ	Physical
protein	NN	Physical
to	TO	O
43	CD	O
+/-	JJ	O
19	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Pioglitazone	NN	O
increased	VBD	O
CD34	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
/kinase	NN	Physical
insert	JJ	Physical
domain	NN	Physical
receptor	NN	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
EPCs	NNP	Physical
to	TO	O
142	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
and	CC	O
cultured	VBD	Physical
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	Physical
acetylated	JJ	Physical
LDL	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
/lectin	NN	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
EPCs	NNP	Physical
to	TO	O
180	CD	O
+/-	JJ	O
3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

EPC	JJ	Physical
numbers	NNS	Physical
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

TZD	NNP	O
increased	VBD	O
the	DT	O
SDF-1-induced	NNP	Physical
migratory	NN	Physical
capacity	NN	Physical
to	TO	O
146	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
per	IN	O
EPC	NNP	O
number	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
upregulated	VBD	O
the	DT	O
clonogenic	JJ	Physical
potential	NN	Physical
of	IN	Physical
EPCs	NNP	Physical
,	,	O
increasing	VBG	O
the	DT	Physical
colony-forming	JJ	Physical
units	NNS	Physical
to	TO	O
172	CD	O
+/-	JJ	O
12	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
cultured	JJ	O
human	JJ	O
EPCs	NNP	O
,	,	O
TZD	NNP	O
increased	VBD	O
EPC	NNP	Physical
numbers	NNS	Physical
and	CC	Physical
migration	NN	Physical
and	CC	Physical
reduced	JJ	Physical
NADPH-oxidase	NNP	Physical
activity	NN	Physical
.	.	Physical

The	DT	O
TZD	NNP	O
effect	NN	O
was	VBD	O
reversed	VBN	O
by	IN	O
the	DT	O
PPAR	NNP	O
gamma	NN	O
antagonist	NN	O
GW9662	NNP	O
and	CC	O
mimicked	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
adiponectin	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
PPAR	NNP	O
gamma	NN	O
agonist	NN	O
pioglitazone	NN	O
increases	VBZ	O
the	DT	O
number	NN	Physical
and	CC	Physical
function	NN	Physical
of	IN	Physical
EPCs	NNP	Physical
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
regenerative	NN	O
mechanism	NN	O
in	IN	O
atherosclerosis	NN	O
and	CC	O
is	VBZ	O
observed	VBN	O
in	IN	O
normoglycemic	JJ	O
individuals	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Airway	NNP	Others
management	NN	Others
training	NN	O
using	VBG	O
the	DT	O
laryngeal	NN	O
mask	NN	O
airway	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
two	CD	O
different	JJ	O
training	VBG	O
programmes	NNS	O
.	.	O

Nurses	NNS	O
without	IN	O
prior	JJ	O
experience	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
(	(	O
LMA	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
to	TO	O
be	VB	O
trained	VBN	O
in	IN	O
the	DT	O
emergency	NN	O
technique	NN	O
of	IN	O
insertion	NN	O
of	IN	O
an	DT	O
LMA	NNP	O
.	.	O

Group	NNP	O
A	NNP	O
(	(	O
32	CD	O
nurses	NNS	O
)	)	O
were	VBD	O
trained	VBN	O
only	RB	O
on	IN	O
a	DT	O
manikin	NN	O
and	CC	O
group	NN	O
B	NNP	O
(	(	O
20	CD	O
nurses	NNS	O
)	)	O
were	VBD	O
trained	VBN	O
on	IN	O
a	DT	O
manikin	NN	O
and	CC	O
with	IN	O
live	JJ	O
anaesthetised	VBN	O
patient	JJ	O
practice	NN	O
in	IN	O
theatre	NN	O
(	(	O
five	CD	O
successful	JJ	O
insertions	NNS	O
)	)	O
.	.	O

Without	IN	O
further	JJ	O
practice	NN	O
,	,	O
both	DT	O
groups	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
insert	VB	O
an	DT	O
LMA	NNP	O
in	IN	O
a	DT	O
live	JJ	O
patient	NN	O
in	IN	O
theatre	JJ	O
3	CD	O
months	NNS	O
after	IN	O
initial	JJ	O
training	NN	O
.	.	O

Three	CD	O
attempts	NNS	O
per	IN	O
nurse	NN	O
were	VBD	O
allowed	VBN	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
75	CD	O
%	NN	O
passed	VBD	O
the	DT	O
LMA	NNP	Others
successfully	RB	Others
at	IN	O
the	DT	O
first	JJ	O
attempt	NN	O
,	,	O
22	CD	O
%	NN	O
at	IN	O
the	DT	O
second	JJ	O
attempt	NN	O
and	CC	O
3	CD	O
%	NN	O
(	(	O
one	CD	O
nurse	NN	O
)	)	O
at	IN	O
the	DT	O
third	JJ	O
attempt	NN	O
.	.	O

In	IN	O
group	NN	O
B	NNP	O
,	,	O
80	CD	O
%	NN	O
were	VBD	O
successful	JJ	Mental
at	IN	O
first	JJ	O
attempt	NN	O
and	CC	O
20	CD	O
%	NN	O
at	IN	O
the	DT	O
second	JJ	O
attempt	NN	O
.	.	O

Skill	NNP	Mental
performance	NN	Mental
and	CC	Mental
retention	NN	Mental
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
high	JJ	O
following	VBG	O
either	CC	O
training	VBG	O
method	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
performance	NN	Mental
of	IN	O
either	DT	O
group	NN	O
(	(	O
chi	JJ	O
2	CD	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
shown	VBN	O
that	IN	O
manikin-only	JJ	O
training	NN	O
in	IN	O
the	DT	O
emergency	NN	O
technique	NN	O
for	IN	O
LMA	NNP	O
insertion	NN	O
is	VBZ	O
as	RB	O
effective	JJ	Others
as	IN	O
live	JJ	O
patient	NN	O
training	NN	O
.	.	O

It	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
manikin	JJ	O
training	VBG	O
alone	NN	O
may	MD	O
be	VB	O
adopted	VBN	O
as	IN	O
a	DT	O
future	JJ	O
training	NN	O
modality	NN	O
if	IN	O
,	,	O
as	IN	O
is	VBZ	O
expected	VBN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
LMA	NNP	O
in	IN	O
resuscitation	NN	O
becomes	NNS	O
more	RBR	O
commonplace	NN	O
.	.	O

Rehabilitation	NN	O
of	IN	O
therapy-related	JJ	O
cognitive	JJ	O
deficits	NNS	O
in	IN	O
patients	NNS	O
after	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
.	.	O

Neuropsychological	JJ	O
deficits	NNS	O
are	VBP	O
potential	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
therapy	NN	O
(	(	O
HSCT	NNP	O
)	)	O
.	.	O

Systematic	JJ	O
data	NNS	O
on	IN	O
the	DT	O
long-term	JJ	O
course	NN	O
of	IN	O
and	CC	O
therapeutic	JJ	O
options	NNS	O
for	IN	O
these	DT	O
consequences	NNS	O
are	VBP	O
limited	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
fifty-seven	JJ	O
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
cognitive	JJ	O
deficits	NNS	O
following	VBG	O
HSCT	NNP	O
for	IN	O
malignant	JJ	O
diseases	NNS	O
at	IN	O
an	DT	O
in-patient	JJ	O
oncologic	NN	O
rehabilitation	NN	O
clinic	NN	O
.	.	O

Patients	NNS	O
showing	VBG	O
evidence	NN	O
of	IN	O
impairment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
training	VBG	O
groups	NNS	O
:	:	O
individualized	VBN	O
PC-supported	JJ	O
training	NN	O
or	CC	O
neuropsychological	JJ	O
group	NN	O
therapy	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
no	DT	O
specific	JJ	O
training	NN	O
.	.	O

During	IN	O
in-patient	JJ	O
rehabilitation	NN	O
,	,	O
the	DT	O
results	NNS	Mental
of	IN	Mental
a	DT	Mental
comprehensive	JJ	Mental
neuropsychological	JJ	Mental
test	NN	Mental
battery	NN	Mental
improved	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
no	DT	O
specific	JJ	O
intervention	NN	O
effects	NNS	O
were	VBD	O
identified	VBN	O
.	.	O

Neuropsychological	JJ	Mental
deficits	NNS	Mental
were	VBD	O
still	RB	O
evident	JJ	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Correlation	NN	Mental
between	IN	Mental
neuropsychological	JJ	Mental
testing	NN	Mental
and	CC	Mental
patients	NNS	Mental
'	POS	Mental
self-evaluation	NN	Mental
of	IN	Mental
cognitive	JJ	Mental
functioning	NN	Mental
in	IN	Mental
daily	JJ	Mental
life	NN	Mental
was	VBD	O
generally	RB	O
low	JJ	O
.	.	O

Sustained	VBN	Mental
attention	NN	Mental
and	CC	O
verbal-semantic	JJ	Mental
memory	NN	Mental
played	VBD	O
the	DT	O
main	JJ	O
role	NN	O
for	IN	O
self-appraisal	JJ	O
and	CC	O
in	IN	O
the	DT	O
designation	NN	O
as	IN	O
'neuropsychologically	RB	O
impaired	VBN	O
'	''	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
a	DT	O
substantial	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
revealed	JJ	O
evidence	NN	O
of	IN	O
cognitive	JJ	O
deficits	NNS	O
a	DT	O
long	JJ	O
time	NN	O
after	IN	O
HSCT	NNP	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
need	NN	O
for	IN	O
more	JJR	O
studies	NNS	O
and	CC	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
differentiated	JJ	O
rehabilitative	JJ	O
measures	NNS	O
for	IN	O
such	JJ	O
therapeutic	JJ	O
consequences	NNS	O
.	.	O

Atypical	JJ	O
recruitment	NN	O
of	IN	O
medial	JJ	O
prefrontal	JJ	O
cortex	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
an	DT	O
fMRI	NN	O
study	NN	O
of	IN	O
two	CD	O
executive	NN	O
function	NN	O
tasks	NNS	O
.	.	O

Recent	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
an	DT	O
uneven	JJ	O
profile	NN	O
of	IN	O
executive	JJ	O
dysfunction	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

For	IN	O
example	NN	O
,	,	O
some	DT	O
authors	NNS	O
have	VBP	O
reported	VBN	O
deficits	NNS	O
on	IN	O
newly	RB	O
developed	VBN	O
tests	NNS	O
of	IN	O
executive	NN	O
function	NN	O
sensitive	JJ	O
to	TO	O
rostral	JJ	O
prefrontal	JJ	O
function	NN	O
,	,	O
despite	IN	O
spared	VBN	O
,	,	O
or	CC	O
even	RB	O
superior	JJ	O
,	,	O
performance	NN	O
on	IN	O
other	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
performance	NN	O
of	IN	O
a	DT	O
group	NN	O
of	IN	O
high-functioning	JJ	O
participants	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
N=15	NNP	O
)	)	O
and	CC	O
an	DT	O
age-	JJ	O
and	CC	O
IQ-matched	JJ	O
control	NN	O
group	NN	O
(	(	O
N=18	NNP	O
)	)	O
on	IN	O
two	CD	O
executive	NN	O
function	NN	O
tests	NNS	O
,	,	O
whilst	VBP	O
undergoing	JJ	O
functional	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
fMRI	NN	O
)	)	O
.	.	O

Behaviourally	NNP	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
a	DT	O
classical	JJ	O
test	NN	O
of	IN	O
executive	NN	O
function	NN	O
(	(	O
random	JJ	O
response	NN	O
generation	NN	O
)	)	O
,	,	O
BOLD	NNP	Physical
signal	NN	Physical
differed	VBD	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
cerebellum	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
frontal	JJ	O
lobes	NN	O
.	.	O

However	RB	O
,	,	O
on	IN	O
a	DT	O
new	JJ	O
test	NN	O
of	IN	O
executive	NN	O
function	NN	O
(	(	O
selection	NN	O
between	IN	O
stimulus-oriented	JJ	O
and	CC	O
stimulus-independent	JJ	O
thought	NN	O
)	)	O
,	,	O
the	DT	O
ASD	NNP	O
group	NN	O
exhibited	VBD	O
significantly	RB	O
greater	JJR	O
signal-change	NN	Physical
in	IN	Physical
medial	JJ	Physical
rostral	JJ	Physical
prefrontal	NN	Physical
cortex	NN	Physical
(	(	Physical
especially	RB	Physical
Brodmann	NNP	Physical
Area	NNP	Physical
10	CD	Physical
)	)	Physical
in	IN	O
the	DT	O
comparison	NN	O
of	IN	O
stimulus-oriented	JJ	O
versus	NN	O
stimulus-independent	JJ	O
attention	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
new	JJ	O
test	NN	O
(	(	O
but	CC	O
not	RB	O
the	DT	O
classical	JJ	O
test	NN	O
)	)	O
provided	VBD	O
evidence	NN	O
for	IN	O
abnormal	JJ	Physical
functional	JJ	Physical
organisation	NN	Physical
of	IN	Physical
medial	JJ	Physical
prefrontal	JJ	Physical
cortex	NN	Physical
in	IN	Physical
ASD	NNP	Physical
.	.	O

These	DT	O
results	NNS	O
underline	VBP	O
the	DT	O
heterogeneity	NN	O
of	IN	O
different	JJ	O
tests	NNS	O
of	IN	O
executive	NN	O
function	NN	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
executive	NN	O
functioning	NN	O
in	IN	O
ASD	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
task-specific	JJ	O
functional	JJ	O
change	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
adult	NN	O
intervention	NN	O
on	IN	O
infants	NNS	Mental
'	POS	Mental
level	NN	Mental
of	IN	Mental
attention	NN	Mental
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
adult	NN	O
intervention	NN	O
on	IN	O
infants	NNS	O
'	POS	O
level	NN	Mental
of	IN	Mental
attention	NN	Mental
to	TO	O
objects	NNS	O
were	VBD	O
studied	VBN	O
with	IN	O
10-month-old	JJ	O
infants	NNS	O
.	.	O

After	IN	O
a	DT	O
baseline	JJ	O
measure	NN	O
of	IN	O
spontaneous	JJ	O
attention	NN	O
was	VBD	O
obtained	VBN	O
,	,	O
infants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
4	CD	O
conditions	NNS	O
(	(	O
low	JJ	O
,	,	O
medium	NN	O
,	,	O
high	JJ	O
intervention	NN	O
,	,	O
or	CC	O
no-intervention	JJ	O
control	NN	O
)	)	O
.	.	O

Level	NN	O
of	IN	O
intervention	NN	O
was	VBD	O
controlled	VBN	O
by	IN	O
systematically	RB	O
varying	VBG	O
the	DT	O
manner	NN	O
and	CC	O
frequency	NN	O
with	IN	O
which	WDT	O
objects	NNS	O
were	VBD	O
presented	VBN	O
,	,	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
the	DT	O
experimenter	NN	O
talked	VBD	O
to	TO	O
the	DT	O
infant	NN	O
,	,	O
and	CC	O
physical	JJ	O
proximity	NN	O
.	.	O

Infant	JJ	O
attention	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
duration	NN	Mental
of	IN	Mental
time	NN	Mental
spent	VBN	Mental
examining	VBG	Mental
objects	NNS	Mental
.	.	O

The	DT	O
overall	JJ	Mental
duration	NN	Mental
of	IN	Mental
infant	JJ	Mental
attention	NN	Mental
increased	VBD	O
during	IN	O
medium	NN	O
intervention	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Baseline	NNP	O
attention	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
separate	VB	O
low	JJ	O
and	CC	O
high	JJ	O
attenders	NNS	O
.	.	O

Low	JJ	O
attending	VBG	O
infants	NNS	O
attended	VBD	Mental
more	RBR	O
in	IN	O
medium	NN	O
and	CC	O
high	JJ	O
intervention	NN	O
than	IN	O
in	IN	O
the	DT	O
low	JJ	O
condition	NN	O
,	,	O
while	IN	O
high	JJ	O
attending	VBG	O
infants	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
intervention	NN	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
level	NN	O
of	IN	O
intervention	NN	O
interacts	NNS	O
with	IN	O
the	DT	O
child	NN	Mental
's	POS	Mental
spontaneous	JJ	Mental
tendency	NN	Mental
to	TO	Mental
focus	VB	Mental
attention	NN	Mental
on	IN	O
objects	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
acupuncture	NN	O
with	IN	O
advice	NN	O
and	CC	O
exercises	NNS	O
on	IN	O
the	DT	O
symptomatic	JJ	Physical
treatment	NN	Physical
of	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
hip	NN	O
--	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

Acupuncture	NN	O
is	VBZ	O
becoming	VBG	O
a	DT	O
common	JJ	O
technique	NN	O
within	IN	O
the	DT	O
physiotherapy	NN	O
profession	NN	O
as	IN	O
a	DT	O
treatment	NN	O
modality	NN	O
for	IN	O
pain	NN	Pain
relief	NN	Pain
;	:	O
however	RB	O
,	,	O
few	JJ	O
randomised	VBD	O
controlled	VBN	O
trials	NNS	O
have	VBP	O
been	VBN	O
undertaken	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
acupuncture	NN	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
of	IN	O
the	DT	O
hip	NN	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
randomised	JJ	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
acupuncture	NN	O
with	IN	O
advice	NN	O
and	CC	O
exercises	NNS	O
on	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
OA	NNP	O
of	IN	O
the	DT	O
hip	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

Thirty-two	JJ	O
patients	NNS	O
awaiting	VBG	O
a	DT	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	CC	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
(	(	O
A	DT	O
)	)	O
,	,	O
to	TO	O
have	VB	O
six	CD	O
sessions	NNS	O
of	IN	O
acupuncture	NN	O
each	DT	O
lasting	VBG	O
up	RP	O
to	TO	O
25	CD	O
minutes	NNS	O
,	,	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
(	(	O
B	NNP	O
)	)	O
,	,	O
to	TO	O
be	VB	O
given	VBN	O
advice	NN	O
and	CC	O
exercises	NNS	O
for	IN	O
their	PRP$	O
hip	NN	O
over	IN	O
a	DT	O
six	CD	O
week	NN	O
period	NN	O
.	.	O

Group	NNP	O
A	NNP	O
consisted	VBD	O
of	IN	O
three	CD	O
men	NNS	O
and	CC	O
13	CD	O
women	NNS	O
,	,	O
and	CC	O
group	NN	O
B	NNP	O
consisted	VBD	O
of	IN	O
four	CD	O
men	NNS	O
and	CC	O
eight	CD	O
women	NNS	O
.	.	O

The	DT	O
average	JJ	O
age	NN	O
in	IN	O
group	NN	O
A	NNP	O
was	VBD	O
66	CD	O
years	NNS	O
and	CC	O
in	IN	O
group	NN	O
B	NNP	O
it	PRP	O
was	VBD	O
68	CD	O
years	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
pain	NN	O
and	CC	O
functional	JJ	O
ability	NN	O
,	,	O
using	VBG	O
a	DT	O
modified	JJ	O
version	NN	O
of	IN	O
the	DT	O
WOMAC	NNP	Others
questionnaire	NN	Others
,	,	O
pre-treatment	JJ	O
,	,	O
immediately	RB	O
post-treatment	JJ	O
and	CC	O
at	IN	O
eight	CD	O
weeks	NNS	O
post-treatment	JJ	O
.	.	O

The	DT	O
pre-treatment	JJ	O
WOMAC	NNP	Others
scores	NNS	Others
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
(	(	O
p=0.85	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
decrease	NN	O
in	IN	O
WOMAC	NNP	Others
score	NN	Others
)	)	O
immediately	RB	O
post-treatment	JJ	O
(	(	O
p=0.002	NN	O
)	)	O
and	CC	O
this	DT	O
was	VBD	O
maintained	VBN	O
at	IN	O
the	DT	O
eight-week	JJ	O
follow-up	NN	O
(	(	O
p=0.03	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
group	NN	O
B	NNP	O
.	.	O

When	WRB	O
the	DT	O
changes	NNS	O
in	IN	O
WOMAC	NNP	Others
scores	NNS	Others
were	VBD	O
compared	VBN	O
between	IN	O
groups	NNS	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
was	VBD	O
found	VBN	O
between	IN	O
pre-treatment	JJ	O
and	CC	O
immediately	RB	O
post-treatment	JJ	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
compared	VBN	O
with	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.02	NN	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
between	IN	O
pre-treatment	NN	O
and	CC	O
the	DT	O
eight-week	JJ	O
follow-up	NN	O
also	RB	O
showed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
group	NN	O
A	NNP	O
compared	VBN	O
with	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.03	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
this	DT	O
trial	NN	O
supports	VBZ	O
the	DT	O
hypothesis	NN	O
that	IN	O
acupuncture	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	Others
than	IN	O
advice	NN	O
and	CC	O
exercises	NNS	O
in	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
OA	NNP	O
of	IN	O
the	DT	O
hip	NN	O
.	.	O

Iron	NNP	O
intake	NN	O
and	CC	O
iron	NN	O
nutritional	JJ	O
status	NN	O
of	IN	O
infants	NNS	O
fed	VBN	O
iron-fortified	JJ	O
beikost	NN	O
with	IN	O
meat	NN	O
.	.	O

We	PRP	O
compared	VBN	O
iron	NNS	O
intake	NN	O
and	CC	O
iron	NN	O
nutritional	JJ	O
status	NN	O
of	IN	O
two	CD	O
groups	NNS	O
of	IN	O
healthy	JJ	O
term	NN	O
infants	NNS	O
who	WP	O
received	VBD	O
meat-containing	JJ	O
baby	NN	O
foods	NNS	O
fortified	VBN	O
with	IN	O
ferrous	JJ	O
sulphate	NN	O
(	(	O
2	CD	O
mg	NN	O
Fe/100	NNP	O
g	NN	O
)	)	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
an	DT	O
Fe-fortified	JJ	O
formula	NN	O
(	(	O
1.6	CD	O
mg	NN	O
Fe/100	NNP	O
kcal	NN	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
a	DT	O
nonfortified	JJ	O
formula	NN	O
.	.	O

Fe	NNP	O
intake	NN	O
of	IN	O
the	DT	O
group	NN	O
fed	VBD	O
the	DT	O
nonfortified	JJ	O
formula	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

These	DT	O
infants	NNS	O
received	VBD	O
Fe	NNP	O
mainly	RB	O
from	IN	O
fortification	NN	O
Fe	NNP	O
with	IN	O
beikost	NN	O
(	(	O
75-86	CD	O
%	NN	O
)	)	O
and	CC	O
less	JJR	O
than	IN	O
10	CD	O
%	NN	O
met	VBD	O
the	DT	O
recommended	JJ	O
intake	NN	O
of	IN	O
1	CD	O
mg.kg-1.d-1	NN	O
;	:	O
whereas	CC	O
80-85	CD	O
%	NN	O
of	IN	O
the	DT	O
infants	NNS	O
fed	VBD	O
the	DT	O
Fe-fortified	NNP	O
formula	NN	O
did	VBD	O
.	.	O

Hb	NNP	Physical
,	,	Physical
Hct	NNP	Physical
,	,	Physical
FEP	NNP	Physical
,	,	Physical
and	CC	Physical
ferritin	NNS	Physical
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
lower	JJR	O
ferritin	NN	O
values	NNS	O
at	IN	O
age	NN	O
365	CD	O
d	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
fed	VBD	O
the	DT	O
nonfortified	JJ	O
formula	NN	O
.	.	O

No	DT	O
infant	NN	O
had	VBD	O
hemoglobin	NN	Physical
less	JJR	O
than	IN	O
100	CD	O
g/L	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
regular	JJ	O
consumption	NN	O
of	IN	O
commercially	RB	O
prepared	JJ	O
Fe-fortified	JJ	O
beikost	NN	O
with	IN	O
meat	NN	O
prevents	NNS	O
most	RBS	O
healthy	JJ	O
term	NN	O
infants	NNS	O
from	IN	O
Fe	NNP	O
deficiency	NN	O
even	RB	O
if	IN	O
Fe	NNP	O
intake	NN	O
is	VBZ	O
substantially	RB	O
below	IN	O
the	DT	O
recommended	JJ	O
intake	NN	O
.	.	O

Seven-star	NNP	O
needle	JJ	O
stimulation	NN	O
improves	VBZ	O
language	NN	Mental
and	CC	Mental
social	JJ	Mental
interaction	NN	Mental
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
that	WDT	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
treatment	NN	O
on	IN	O
children	NNS	O
with	IN	O
Autistic	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirty-two	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	VBD	O
30	CD	O
sessions	NNS	O
of	IN	O
stimulation	NN	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
while	IN	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
on	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
treatment	NN	O
during	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

Intervention	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
treatment	NN	O
regime	NN	O
comprising	NN	O
of	IN	O
30	CD	O
sessions	NNS	O
of	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
,	,	O
delivered	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Each	DT	O
session	NN	O
lasted	VBD	O
5	CD	O
to	TO	O
10	CD	O
min	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
stimulated	VBN	O
at	IN	O
the	DT	O
front	NN	O
and	CC	O
back	RB	O
sides	NNS	O
of	IN	O
their	PRP$	O
body	NN	O
and	CC	O
the	DT	O
head	NN	O
by	IN	O
using	VBG	O
Seven-star	JJ	O
Needles	NNP	O
.	.	O

The	DT	O
change	NN	O
in	IN	O
the	DT	O
children	NNS	Mental
's	POS	Mental
behavior	NN	Mental
was	VBD	O
evaluated	VBN	O
using	VBG	O
parents	NNS	O
'	POS	O
report	NN	O
and	CC	O
neurophysiological	JJ	O
changes	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
EEG	NNP	O
(	(	O
qEEG	NN	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
language	NN	Mental
and	CC	Mental
social	JJ	Mental
interaction	NN	Mental
,	,	O
but	CC	O
not	RB	O
in	IN	O
stereotyped	JJ	Mental
behavior	NN	Mental
or	CC	Mental
motor	NN	Mental
function	NN	Mental
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

qEEG	JJ	Physical
spectral	JJ	Physical
amplitudes	NNS	Physical
in	IN	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
were	VBD	O
also	RB	O
reduced	VBN	O
significantly	RB	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
Seven-star	NNP	O
Needle	NNP	O
Stimulation	NNP	O
might	MD	O
be	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
improve	VB	O
language	NN	Mental
and	CC	Mental
social	JJ	Mental
functioning	NN	Mental
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
:	:	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
conduct	VB	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBD	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
the	DT	O
Early	JJ	O
Start	NNP	O
Denver	NNP	O
Model	NNP	O
(	(	O
ESDM	NNP	O
)	)	O
,	,	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
,	,	O
for	IN	O
improving	VBG	O
outcomes	NNS	O
of	IN	O
toddlers	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Forty-eight	JJ	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
ASD	NNP	O
between	IN	O
18	CD	O
and	CC	O
30	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
ESDM	NNP	O
intervention	NN	O
,	,	O
which	WDT	O
is	VBZ	O
based	VBN	O
on	IN	O
developmental	JJ	O
and	CC	O
applied	JJ	O
behavioral	JJ	O
analytic	JJ	O
principles	NNS	O
and	CC	O
delivered	VBN	O
by	IN	O
trained	JJ	O
therapists	NNS	O
and	CC	O
parents	NNS	O
for	IN	O
2	CD	O
years	NNS	O
;	:	O
or	CC	O
(	(	O
2	CD	O
)	)	O
referral	NN	O
to	TO	O
community	NN	O
providers	NNS	O
for	IN	O
intervention	NN	O
commonly	RB	O
available	JJ	O
in	IN	O
the	DT	O
community	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
children	NNS	O
who	WP	O
received	VBD	O
community-intervention	NN	O
,	,	O
children	NNS	O
who	WP	O
received	VBD	O
ESDM	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
IQ	NNP	Physical
,	,	Physical
adaptive	JJ	Physical
behavior	NN	Physical
,	,	Physical
and	CC	Physical
autism	NN	Physical
diagnosis	NN	Physical
.	.	Physical

Two	CD	O
years	NNS	O
after	IN	O
entering	VBG	O
intervention	NN	O
,	,	O
the	DT	O
ESDM	NNP	O
group	NN	O
on	IN	O
average	NN	O
improved	VBD	O
17.6	CD	O
standard	NN	O
score	NN	O
points	NNS	O
(	(	O
1	CD	O
SD	NNP	O
:	:	O
15	CD	O
points	NNS	O
)	)	O
compared	VBN	O
with	IN	O
7.0	CD	O
points	NNS	O
in	IN	O
the	DT	O
comparison	NN	O
group	NN	O
relative	VBP	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

The	DT	O
ESDM	NNP	O
group	NN	O
maintained	VBD	O
its	PRP$	O
rate	NN	Physical
of	IN	Physical
growth	NN	Physical
in	IN	Physical
adaptive	JJ	Physical
behavior	NN	Physical
compared	VBN	O
with	IN	O
a	DT	O
normative	JJ	O
sample	NN	O
of	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
over	IN	O
the	DT	O
2-year	JJ	O
span	NN	O
,	,	O
the	DT	O
comparison	NN	O
group	NN	O
showed	VBD	O
greater	JJR	O
delays	NNS	O
in	IN	O
adaptive	JJ	O
behavior	NN	O
.	.	O

Children	NNP	O
who	WP	O
received	VBD	O
ESDM	NNP	O
also	RB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
a	DT	O
change	NN	Physical
in	IN	Physical
diagnosis	NN	Physical
from	IN	O
autism	NN	O
to	TO	O
pervasive	VB	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
than	IN	O
the	DT	O
comparison	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
demonstrate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
comprehensive	JJ	O
developmental	JJ	O
behavioral	JJ	O
intervention	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
ASD	NNP	O
for	IN	O
improving	VBG	O
cognitive	JJ	O
and	CC	O
adaptive	JJ	O
behavior	NN	O
and	CC	O
reducing	VBG	O
severity	NN	O
of	IN	O
ASD	NNP	O
diagnosis	NN	O
.	.	O

Results	NNS	O
of	IN	O
this	DT	O
study	NN	O
underscore	VBD	O
the	DT	O
importance	NN	O
of	IN	O
early	JJ	O
detection	NN	O
of	IN	O
and	CC	O
intervention	NN	O
in	IN	O
autism	NN	O
.	.	O

Phase	NNP	O
III	NNP	O
,	,	O
randomised	VBD	O
,	,	O
multicentre	JJ	O
trial	NN	O
of	IN	O
maintenance	NN	O
immunotherapy	NN	O
with	IN	O
low-dose	JJ	O
interleukin-2	JJ	O
and	CC	O
interferon-alpha	JJ	O
for	IN	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
cancer	NN	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
phase	NN	O
III	NNP	O
randomised	VBD	O
trial	NN	O
to	TO	O
evaluate	VB	O
maintenance	NN	O
immunotherapy	NN	O
in	IN	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
cancer	NN	O
(	(	O
mRCC	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
4-week	JJ	O
cycle	NN	O
of	IN	O
subcutaneous	JJ	O
low	JJ	O
doses	NNS	O
IL-2	NNP	O
+	NNP	O
IFN	NNP	O
in	IN	O
months	NNS	O
1	CD	O
,	,	O
3	CD	O
and	CC	O
5	CD	O
,	,	O
and	CC	O
then	RB	O
every	DT	O
3	CD	O
months	NNS	O
until	IN	O
the	DT	O
first	JJ	O
documented	JJ	O
disease	NN	O
progression	NN	O
(	(	O
arm	NN	O
A	NNP	O
,	,	O
suspension	NN	O
)	)	O
,	,	O
or	CC	O
the	DT	O
same	JJ	O
regimen	NNS	O
,	,	O
with	IN	O
chronic	JJ	O
maintenance	NN	O
of	IN	O
immunotherapy	NN	O
,	,	O
regardless	RB	O
of	IN	O
tumour	JJ	O
response	NN	O
,	,	O
until	IN	O
death	NN	O
or	CC	O
intolerable	JJ	O
toxicity	NN	O
(	(	O
arm	NN	O
B	NNP	O
,	,	O
maintenance	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
;	:	Mortality
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
time	NN	Mortality
from	IN	Mortality
first	JJ	Mortality
progression	NN	Mortality
to	TO	Mortality
death	NN	Mortality
(	(	Mortality
TFPTD	NNP	Mortality
)	)	Mortality
and	CC	O
tolerability	NN	Mortality
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eighty-three	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
between	IN	O
January	NNP	O
1998	CD	O
and	CC	O
November	NNP	O
2003	CD	O
.	.	O

After	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
53.9	CD	O
months	NNS	O
,	,	O
response	NN	Mortality
rate	NN	Mortality
,	,	O
median	JJ	Mortality
OS	NNP	Mortality
and	CC	O
median	JJ	Mortality
TFPTD	NNP	Mortality
were	VBD	O
14.7	CD	O
%	NN	O
(	(	O
6.3	CD	O
%	NN	O
CR	NNP	O
)	)	O
versus	VBP	O
11.3	CD	O
%	NN	O
(	(	O
5.5	CD	O
%	NN	O
CR	NNP	O
)	)	O
,	,	O
14	CD	O
versus	NN	O
14	CD	O
months	NNS	O
,	,	O
6	CD	O
versus	NN	O
5	CD	O
months	NNS	O
,	,	O
in	IN	O
arms	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
with	IN	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Cox	NNP	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
chemotherapy	NN	O
after	IN	O
first	JJ	O
progression	NN	O
(	(	O
HR	NNP	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.35-0.86	CD	O
;	:	O
p	CC	O
=	VB	O
0.008	CD	O
)	)	O
,	,	O
PS	NNP	O
=	VBZ	O
0	CD	O
(	(	O
HR	NNP	O
0.53	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.35-0.81	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
and	CC	O
female	JJ	O
gender	NN	O
(	(	O
HR	NNP	O
0.63	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.41-0.98	CD	O
;	:	O
p	CC	O
=	VB	O
0.038	CD	O
)	)	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
a	DT	O
longer	RBR	O
TFPTD	NNP	Mortality
;	:	O
treatment	NN	O
arm	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
(	(	O
HR	NNP	O
0.88	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.60-1.31	CD	O
;	:	O
p	CC	O
=	VB	O
0.54	CD	O
)	)	O
.	.	O

Toxicity	NN	Adverseeffect
was	VBD	O
mainly	RB	O
limited	JJ	O
to	TO	O
WHO	NNP	O
grades	VBZ	O
1	CD	O
or	CC	O
2	CD	O
.	.	O

Chronic	JJ	O
maintenance	NN	O
immunotherapy	NN	O
after	IN	O
disease	NN	O
progression	NN	O
is	VBZ	O
feasible	JJ	O
,	,	O
but	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
increase	VB	O
OS	NNP	Mortality
or	CC	O
the	DT	O
TFPTD	NNP	Mortality
.	.	O

[	IN	O
The	DT	O
effects	NNS	O
of	IN	O
mexicor	NN	O
on	IN	O
thrombocyte	JJ	Physical
aggregation	NN	Physical
,	,	O
blood	NN	Physical
viscosity	NN	Physical
,	,	O
hemodynamics	NNS	Physical
,	,	O
and	CC	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
]	NNP	O
.	.	O

The	DT	O
authors	NNS	O
analyze	VBP	O
their	PRP$	O
experience	NN	O
in	IN	O
the	DT	O
application	NN	O
of	IN	O
mexicor	NN	O
,	,	O
a	DT	O
Russian	JJ	O
cytoprotector	NN	O
,	,	O
in	IN	O
50patients	CD	O
with	IN	O
chronic	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
and	CC	O
51	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
.	.	O

In	IN	O
additional	JJ	O
to	TO	O
cytoprotective	JJ	O
action	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
mexidor	NN	O
in	IN	O
complex	JJ	O
therapy	NN	O
of	IN	O
CAD	NNP	O
lowers	VBZ	O
the	DT	O
functional	JJ	Physical
activity	NN	Physical
of	IN	Physical
thrombocytes	NNS	Physical
,	,	O
eliminates	VBZ	O
high	JJ	Physical
blood	NN	Physical
viscosity	NN	Physical
syndrome	NN	Physical
,	,	O
and	CC	O
lowers	NNS	O
low	JJ	Physical
density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
level	NN	Physical
.	.	O

These	DT	O
favorable	JJ	O
changes	NNS	O
in	IN	O
hemorheological	JJ	O
parameters	NNS	O
improves	VBZ	O
myocardial	JJ	Physical
perfusion	NN	Physical
,	,	O
lowers	VBZ	O
the	DT	O
strength	NN	Physical
and	CC	Physical
frequency	NN	Physical
of	IN	Physical
coronary	JJ	Physical
pain	NN	Physical
attacks	NNS	Physical
,	,	O
retards	NNS	O
postinfarction	NN	Physical
left	VBD	Physical
ventricular	JJ	Physical
remodeling	NN	Physical
,	,	O
and	CC	O
increases	VBZ	O
the	DT	O
quality	NN	Others
of	IN	Others
life	NN	Others
of	IN	Others
patients	NNS	Others
with	IN	O
various	JJ	O
CAD	NNP	O
forms	NNS	O
.	.	O

Pretreatment	NN	O
and	CC	O
co-administration	NN	O
of	IN	O
oral	JJ	O
anti-diabetic	JJ	O
agent	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
or	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

AIM	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
result	NN	O
of	IN	O
pretreatment	NN	O
and	CC	O
concomitant	NN	O
use	NN	O
of	IN	O
metformin	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
(	(	O
CC	NNP	O
)	)	O
and	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
in	IN	O
the	DT	O
Dhaka	NNP	O
Medical	NNP	O
College	NNP	O
and	CC	O
Hospital	NNP	O
and	CC	O
the	DT	O
Infertility	NNP	O
Care	NNP	O
and	CC	O
Research	NNP	O
Centre	NNP	O
,	,	O
Dhaka	NNP	O
,	,	O
Bangladesh	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
165	CD	O
infertile	JJ	O
patients	NNS	O
with	IN	O
CC-resistant	JJ	O
PCOS	NNP	O
who	WP	O
attended	VBD	O
for	IN	O
treatment	NN	O
were	VBD	O
the	DT	O
target	NN	O
population	NN	O
for	IN	O
this	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
groups	NNS	O
A	DT	O
and	CC	O
B	NNP	O
were	VBD	O
given	VBN	O
metformin	NNS	O
and	CC	O
group	NN	O
C	NNP	O
was	VBD	O
the	DT	O
control	NN	O
.	.	O

Along	IN	O
with	IN	O
metformin	NN	O
,	,	O
group	NN	O
A	NNP	O
received	VBD	O
CC	NNP	O
and	CC	O
group	NN	O
B	NNP	O
received	VBD	O
rFSH	NN	O
.	.	O

Group	NNP	O
C	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
only	RB	O
rFSH	NN	O
.	.	O

Metformin	NNP	O
was	VBD	O
given	VBN	O
1500	CD	O
mg	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
CC	NNP	O
or	CC	O
rFSH	VB	O
were	VBD	O
added	VBN	O
for	IN	O
induction	NN	O
of	IN	O
ovulation	NN	O
along	IN	O
with	IN	O
metformin	NN	O
.	.	O

Six	NNP	O
ovulatory	JJ	O
cycles	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

Treatment	NNP	O
was	VBD	O
terminated	VBN	O
when	WRB	O
there	EX	O
was	VBD	O
no	DT	O
response	NN	O
with	IN	O
maximum	JJ	O
dose	NN	O
of	IN	O
CC	NNP	O
and	CC	O
rFSH	NN	O
or	CC	O
after	IN	O
six	CD	O
ovulatory	JJ	O
cycles	NNS	O
without	IN	O
pregnancy	NN	O
or	CC	O
after	IN	O
achieving	VBG	O
pregnancy	NN	O
.	.	O

A	DT	O
P-value	NNP	O
of	IN	O
<	NNP	O
0.5	CD	O
was	VBD	O
considered	VBN	O
as	IN	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Ovulation	NNP	O
(	(	O
89.09	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
54.55	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
B.	NNP	O
Ovulation	NNP	O
(	(	O
74.55	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
29.09	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
also	RB	O
satisfactory	JJ	O
in	IN	O
group	NN	O
C	NNP	O
but	CC	O
a	DT	O
dose	NN	O
of	IN	O
rFSH	JJ	O
requirement	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
both	DT	O
ovulation	NN	O
and	CC	O
pregnancy	NN	Physical
rate	NN	Physical
were	VBD	O
much	RB	O
lower	JJR	O
than	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
27.27	CD	O
%	NN	O
and	CC	O
12.73	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
metformin	NN	O
increases	VBZ	O
the	DT	O
response	NN	O
of	IN	O
ovulation-inducing	JJ	O
agents	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
safely	RB	O
in	IN	O
PCOS	NNP	O
.	.	O

Assessment	NN	O
of	IN	O
therapeutic	JJ	Others
response	NN	O
of	IN	O
Plasmodium	NNP	O
falciparum	NN	O
to	TO	O
chloroquine	VB	O
and	CC	O
sulfadoxine-pyrimethamine	VB	O
in	IN	O
an	DT	O
area	NN	O
of	IN	O
low	JJ	O
malaria	NNS	O
transmission	NN	O
in	IN	O
Colombia	NNP	O
.	.	O

Although	IN	O
chloroquine	NN	O
(	(	O
CQ	NNP	O
)	)	O
resistance	NN	O
was	VBD	O
first	RB	O
reported	VBN	O
in	IN	O
Colombia	NNP	O
in	IN	O
1961	CD	O
and	CC	O
sulfadoxine-pyrimethamine	JJ	O
(	(	O
SP	NNP	O
)	)	O
resistance	NN	O
in	IN	O
1981	CD	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
to	TO	O
these	DT	O
drugs	NNS	O
in	IN	O
Colombia	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

A	DT	O
modified	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
14-day	JJ	O
in	IN	O
vivo	JJ	O
drug	NN	O
efficacy	NN	O
test	NN	O
for	IN	O
uncomplicated	JJ	O
Plasmodium	NNP	O
falciparum	NN	O
malaria	NN	O
in	IN	O
areas	NNS	O
with	IN	O
intense	JJ	O
malaria	NNS	O
transmission	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
epidemiologic	JJ	O
features	NNS	O
of	IN	O
a	DT	O
low-intensity	JJ	O
malaria	NN	O
transmission	NN	O
area	NN	O
in	IN	O
the	DT	O
Pacific	NNP	O
Coast	NNP	O
Region	NNP	O
of	IN	O
Colombia	NNP	O
.	.	O

Patients	NNPS	O
>	JJ	O
or	CC	O
=1	JJ	O
year	NN	O
of	IN	O
age	NN	O
with	IN	O
a	DT	O
parasite	JJ	O
density	NN	O
>	NN	O
or	CC	O
=1,000	CD	O
asexual	JJ	O
parasites	NNS	O
per	IN	O
microliter	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Forty-four	CD	O
percent	NN	O
(	(	O
24	CD	O
of	IN	O
54	CD	O
)	)	O
of	IN	O
the	DT	O
CQ-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	Others
failures	NNS	Others
,	,	O
including	VBG	O
7	CD	O
early	JJ	Others
treatment	NN	Others
failures	NNS	Others
(	(	Others
ETFs	NNP	Others
)	)	Physical
and	CC	O
17	CD	O
late	JJ	Others
treatment	NN	Others
failures	NNS	Others
(	(	Physical
LTFs	NNP	Physical
)	)	Physical
.	.	Physical

Four	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
67	CD	O
SP-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	Others
failures	NNS	Others
(	(	O
2	CD	O
ETFs	NNP	O
and	CC	O
2	CD	O
LTFs	NNP	O
)	)	O
.	.	O

Therapeutic	JJ	Others
failure	NN	Others
in	IN	O
the	DT	O
CQ-treated	JJ	O
group	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
age	NN	O
<	VBD	O
15	CD	O
years	NNS	O
old	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
initial	JJ	O
parasite	JJ	O
density	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
CQ	NNP	O
or	CC	O
sulfa-containing	JJ	O
drugs	NNS	O
in	IN	O
urine	NN	O
,	,	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
malaria	NN	O
.	.	O

The	DT	O
high	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	Others
failures	NNS	Others
to	TO	O
CQ	NNP	O
detected	VBN	O
in	IN	O
this	DT	O
study	NN	O
underscores	VBZ	O
the	DT	O
need	NN	O
and	CC	O
importance	NN	O
of	IN	O
drug	NN	O
efficacy	NN	Others
evaluation	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
rational	JJ	O
national	JJ	O
antimalarial	JJ	O
drug	NN	O
policy	NN	O
.	.	O

The	DT	O
relatively	RB	O
low	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	Others
failures	NNS	Others
to	TO	O
SP	NNP	O
compared	VBN	O
with	IN	O
other	JJ	O
South	JJ	O
American	JJ	O
countries	NNS	O
raises	VBZ	O
further	JJ	O
questions	NNS	O
regarding	VBG	O
factors	NNS	O
that	WDT	O
might	MD	O
have	VB	O
prevented	VBN	O
the	DT	O
rapid	JJ	O
development	NN	O
of	IN	O
in	IN	O
vivo	NN	O
resistance	NN	O
to	TO	O
this	DT	O
drug	NN	O
combination	NN	O
.	.	O

Predictors	NNS	O
of	IN	O
recruited	JJ	O
melanoma	NN	O
families	NNS	O
into	IN	O
a	DT	O
behavioral	JJ	O
intervention	NN	O
project	NN	O
.	.	O

BACKGROUND	NNP	O
Examination	NNP	O
of	IN	O
families	NNS	O
represents	VBZ	O
an	DT	O
important	JJ	O
priority	NN	O
in	IN	O
health	NN	O
research	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
we	PRP	O
report	VBP	Others
on	IN	O
individual	JJ	Mental
and	CC	Mental
family-level	JJ	Mental
factors	NNS	Mental
associated	VBN	O
with	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
cancer	NN	O
prevention	NN	O
research	NN	O
project	NN	O
.	.	O

We	PRP	O
approached	VBD	O
families	NNS	O
affected	VBN	O
by	IN	O
melanoma	NN	O
for	IN	O
possible	JJ	O
participation	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
a	DT	O
web-based	JJ	O
communication	NN	O
and	CC	O
support	NN	O
intervention	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
recruited	VBD	O
three	CD	O
family	NN	O
members	NNS	O
per	IN	O
family	NN	O
for	IN	O
assessment	NN	O
-	:	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
a	DT	O
first-degree	JJ	O
relative	NN	O
(	(	O
FDR	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
relative	NN	O
who	WP	O
is	VBZ	O
a	DT	O
parent	NN	O
of	IN	O
a	DT	O
child	JJ	O
age	NN	O
18	CD	O
or	CC	O
younger	JJR	O
.	.	O

Recruitment	NNP	O
involved	VBD	O
three	CD	O
steps	NNS	O
:	:	O
requesting	VBG	O
the	DT	O
physician	NN	O
's	POS	O
consent	NN	O
to	TO	O
approach	VB	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
approaching	VBG	O
the	DT	O
case	NN	O
to	TO	O
request	VB	O
their	PRP$	O
participation	NN	O
and	CC	O
family	NN	O
contact	NN	O
information	NN	O
,	,	O
and	CC	O
they	PRP	O
approaching	VBG	O
the	DT	O
FDRs	NNP	O
and	CC	O
parents	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1380	CD	O
families	NNS	O
approached	VBD	O
,	,	O
313	CD	O
were	VBD	O
enrolled	VBN	O
,	,	O
263	CD	O
were	VBD	O
excluded	VBN	O
because	IN	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
or	CC	O
contact	VB	O
a	DT	O
family	NN	O
member	NN	O
(	(	O
FDR	CD	O
or	CC	O
parent	NN	O
)	)	O
,	,	O
331	CD	O
did	VBD	O
not	RB	O
have	VB	O
eligible	JJ	O
family	NN	O
members	NNS	O
,	,	O
and	CC	O
473	CD	O
refused	VBD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
noted	VBD	O
reason	NN	O
for	IN	O
refusal	NN	Others
was	VBD	O
being	VBG	O
too	RB	O
busy	JJ	O
or	CC	O
having	VBG	O
no	DT	O
time	NN	O
.	.	O

The	DT	O
primary	JJ	O
predictors	NNS	O
of	IN	O
participation	NN	O
for	IN	O
cases	NNS	O
(	(	O
OR=1.6	NNP	O
;	:	O
CI=1.01-2.51	NNP	O
)	)	O
and	CC	O
FDRs	NNP	O
(	(	O
OR=2.15	NNP	O
;	:	O
CI=1.11-4.13	NNP	O
)	)	O
included	VBD	O
higher	JJR	Mental
educational	JJ	Mental
attainment	NN	Mental
.	.	Mental

FDRs	NNP	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
they	PRP	O
were	VBD	O
female	JJ	O
(	(	O
OR=1.77	NNP	O
;	:	O
CI=1.1-.85	NNP	O
)	)	O
and	CC	O
parents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
the	DT	O
case	NN	O
had	VBD	O
been	VBN	O
diagnosed	VBN	Physical
more	RBR	Physical
recently	RB	Physical
(	(	O
OR=3.3	NNP	O
;	:	O
CI=1.9-5.93	NNP	O
)	)	O
,	,	O
if	IN	O
the	DT	O
parent	NN	Others
was	VBD	Others
partnered	VBN	Others
(	(	O
OR=4.37	NNP	O
;	:	O
CI=1.86-10.26	NNP	O
)	)	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
parent	NN	Mental
lived	VBD	Mental
in	IN	Mental
the	DT	Mental
same	JJ	Mental
city	NN	Mental
as	IN	Mental
the	DT	Mental
case	NN	Mental
(	(	O
OR=2.88	NNP	O
;	:	O
CI=1.08-7.68	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
can	MD	O
provide	VB	O
information	NN	O
on	IN	O
potential	JJ	O
directions	NNS	O
for	IN	O
future	JJ	O
family	NN	O
recruitment	NN	O
.	.	O

Effect	NN	O
of	IN	O
acebutolol	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
performance	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
acebutolol	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
performance	NN	O
was	VBD	O
examined	VBN	O
by	IN	O
various	JJ	O
noninvasive	JJ	O
means	NNS	O
in	IN	O
three	CD	O
studies	NNS	O
.	.	O

M-mode	NNP	O
echocardiographic	JJ	O
measurements	NNS	O
were	VBD	O
made	VBN	O
in	IN	O
21	CD	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
who	WP	O
were	VBD	O
receiving	VBG	O
placebo	NN	O
,	,	O
acebutolol	NN	O
,	,	O
and	CC	O
propranolol	NN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

In	IN	O
these	DT	O
patients	NNS	O
with	IN	O
normal	JJ	O
or	CC	O
near-normal	JJ	O
resting	NN	O
left	VBD	O
ventricular	JJ	O
function	NN	O
,	,	O
neither	CC	O
drug	NN	O
induced	JJ	O
depression	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
function	NN	O
.	.	O

In	IN	O
26	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
angina	NNS	O
pectoris	VBP	O
receiving	VBG	O
acebutolol	NN	O
under	IN	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
conditions	NNS	O
,	,	O
gated	VBN	O
(	(	O
equilibrium	NN	O
)	)	O
myocardial	NN	O
blood	NN	O
pool	NN	O
imaging	VBG	O
using	VBG	O
red	JJ	O
blood	NN	O
cells	NNS	O
labeled	VBN	O
with	IN	O
technetium	NN	O
99m	CD	O
showed	VBD	O
acebutolol	NN	O
to	TO	O
have	VB	O
no	DT	O
clinically	RB	O
significant	JJ	O
negative	JJ	O
effect	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
performance	NN	O
at	IN	O
rest	NN	O
or	CC	O
during	IN	O
supine	JJ	O
bicycle	NN	O
exercise	NN	O
.	.	O

Acebutolol	NNP	O
at	IN	O
effective	JJ	O
antianginal	JJ	O
doses	NNS	O
modestly	RB	O
improved	VBN	O
resting	NN	Physical
global	JJ	Physical
and	CC	Physical
regional	JJ	Physical
myocardial	JJ	Physical
function	NN	Physical
.	.	Physical

In	IN	O
13	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NNS	O
pectoris	VBP	O
,	,	O
single-pass	JJ	O
studies	NNS	O
of	IN	O
left	JJ	O
ventricular	JJ	O
function	NN	O
with	IN	O
indium	NN	O
113	CD	O
under	IN	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
conditions	NNS	O
similarly	RB	O
showed	VBD	O
acebutolol	NN	O
to	TO	O
have	VB	O
no	DT	O
clinically	RB	O
significant	JJ	O
negative	JJ	O
inotropic	NN	O
effects	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
acebutolol	NN	O
is	VBZ	O
safe	JJ	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
disease	NN	O
and	CC	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
ejection	NN	O
fractions	NNS	O
but	CC	O
,	,	O
as	IN	O
with	IN	O
all	DT	O
beta	NN	O
blockers	NNS	O
,	,	O
should	MD	O
be	VB	O
used	VBN	O
cautiously	RB	O
in	IN	O
patients	NNS	O
with	IN	O
markedly	RB	O
reduced	VBN	O
resting	NN	O
left	VBD	O
ventricular	JJ	O
function	NN	O
.	.	O

Angiotensin-converting	JJ	O
enzyme	JJ	O
inhibition	NN	O
does	VBZ	O
not	RB	O
suppress	VB	O
plasma	NN	O
angiotensin	NN	O
II	NNP	O
increase	NN	O
during	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Physical	JJ	O
effort	NN	O
stimulates	VBZ	O
the	DT	O
reninangiotensin	NN	O
system	NN	O
(	(	O
RAS	NNP	O
)	)	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
(	(	O
ACE	NNP	O
inhibitor	NN	O
)	)	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
on	IN	O
eight	CD	O
volunteers	NNS	O
undergoing	VBG	O
physical	JJ	O
stress	NN	O
on	IN	O
an	DT	O
ergometric	JJ	O
bicycle	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
captopril	NN	O
(	(	O
C	NNP	O
)	)	O
(	(	O
50	CD	O
mg	NN	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
3	CD	O
days	NNS	O
)	)	O
on	IN	O
arterial	JJ	Physical
pressure	NN	Physical
(	(	Physical
AP	NNP	Physical
)	)	Physical
,	,	Physical
O2	NNP	Physical
consumption	NN	Physical
(	(	Physical
VO2	NNP	Physical
)	)	Physical
,	,	Physical
variations	NNS	Physical
in	IN	Physical
auricular	JJ	Physical
natriuretic	JJ	Physical
factor	NN	Physical
(	(	Physical
ANF	NNP	Physical
)	)	Physical
,	,	Physical
renin	NN	Physical
,	,	Physical
angiotensin	NN	Physical
II	NNP	Physical
(	(	Physical
AII	NNP	Physical
)	)	Physical
plasma	NN	Physical
levels	NNS	Physical
,	,	Physical
as	RB	Physical
well	RB	Physical
as	IN	Physical
glomerular	JJ	Physical
filtration	NN	Physical
rate	NN	Physical
(	(	Physical
GFR	NNP	Physical
)	)	Physical
and	CC	Physical
microalbuminuria	$	Physical
(	(	Physical
MA	NNP	Physical
)	)	Physical
were	VBD	O
evaluated	VBN	O
.	.	O

The	DT	O
different	JJ	O
parameters	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
.	.	O

The	DT	O
pressure	NN	O
profile	NN	O
and	CC	O
VO2	NNP	O
were	VBD	O
not	RB	O
modified	VBN	O
by	IN	O
ACE	NNP	O
inhibitor	NN	O
.	.	O

Exercise	NN	O
stimulates	VBZ	O
release	NN	O
of	IN	O
renin	NN	O
;	:	O
this	DT	O
action	NN	O
was	VBD	O
greater	JJR	O
with	IN	O
captopril	JJ	O
administration	NN	O
(	(	O
treatment	NN	O
effect	NN	O
:	:	O
p	NN	O
<	VBZ	O
10	CD	O
(	(	O
-4	NN	O
)	)	O
,	,	O
indicating	VBG	O
blockade	NN	O
of	IN	O
the	DT	O
RAS	NNP	O
.	.	O

This	DT	O
inhibition	NN	O
was	VBD	O
incomplete	JJ	O
because	IN	O
AII	NNP	O
levels	NNS	O
increased	VBD	O
markedly	RB	O
when	WRB	O
captopril	NN	O
was	VBD	O
given	VBN	O
(	(	O
no	DT	O
treatment	NN	O
effect	NN	O
:	:	O
p	NN	O
<	VBZ	O
0.37	CD	O
)	)	O
.	.	O

Finally	RB	O
,	,	O
ACE	NNP	O
inhibitor	NN	O
resulted	VBD	O
in	IN	O
decreased	JJ	O
GFR	NNP	Physical
(	(	O
p	JJ	O
=	$	O
115	CD	O
+/-	JJ	O
5.8	CD	O
ml/mn-1	NN	O
,	,	O
C	NNP	O
=	VBD	O
91.1	CD	O
+/-	JJ	O
4	CD	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
exercise	NN	O
without	IN	O
modification	NN	O
of	IN	O
MA	NNP	O
.	.	O

ACE	NNP	O
inhibitor	JJ	O
administration	NN	O
does	VBZ	O
not	RB	O
modify	VB	O
the	DT	O
physical	JJ	O
performance	NN	O
of	IN	O
nonathletic	JJ	O
subjects	NNS	O
;	:	O
AII	NNP	O
is	VBZ	O
significantly	RB	O
increased	VBN	O
with	IN	O
exercise	NN	O
despite	IN	O
captopril	JJ	O
treatment	NN	O
;	:	O
ACE	NNP	O
inhibitor	NN	O
decreases	VBZ	O
GFR	NNP	Physical
significantly	RB	O
but	CC	O
does	VBZ	O
not	RB	O
influence	VB	O
MA	NNP	O
with	IN	O
prolonged	JJ	O
physical	JJ	O
effort	NN	O
.	.	O

Outcome	NN	O
of	IN	O
CNS	NNP	O
disease	NN	O
at	IN	O
diagnosis	NN	O
in	IN	O
disseminated	JJ	O
small	JJ	O
noncleaved-cell	JJ	O
lymphoma	NN	O
and	CC	O
B-cell	NNP	O
leukemia	NN	O
:	:	O
a	DT	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Group	NNP	O
study	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
initial	JJ	O
CNS	NNP	O
involvement	NN	O
on	IN	O
outcome	NN	O
and	CC	O
patterns	NNS	O
of	IN	O
failure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
disseminated	JJ	O
small	JJ	O
noncleaved-cell	JJ	O
lymphoma	NN	O
and	CC	O
B-cell	NNP	O
leukemia	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
in	IN	O
four	CD	O
successive	JJ	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Group	NNP	O
trials	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Of	IN	O
462	CD	O
patients	NNS	O
with	IN	O
disseminated	JJ	O
disease	NN	O
,	,	O
49	CD	O
(	(	O
10.6	CD	O
%	NN	O
)	)	O
had	VBD	O
CNS	NNP	O
disease	NN	O
at	IN	O
diagnosis	NN	O
(	(	O
CNS+	NNP	O
)	)	O
.	.	O

CNS	NNP	O
disease	NN	O
included	VBD	O
meningeal	JJ	O
disease	NN	O
or	CC	O
CNS	NNP	O
parenchymal	JJ	O
masses	NNS	O
with	IN	O
or	CC	O
without	IN	O
cranial	JJ	O
neuropathies	NNS	O
(	(	O
CSF+/Mass	NNP	O
;	:	O
CNPs	NNP	O
)	)	O
in	IN	O
36	CD	O
patients	NNS	O
and	CC	O
isolated	JJ	O
CNPs	NNP	O
in	IN	O
13	CD	O
.	.	O

Of	IN	O
the	DT	O
CNS+	NNP	O
patients	NNS	O
,	,	O
28	CD	O
had	VBD	O
M2	NNP	O
(	(	O
5	CD	O
%	NN	O
to	TO	O
25	CD	O
%	NN	O
blasts	NNS	O
)	)	O
or	CC	O
M3	NNP	O
(	(	O
>	VB	O
25	CD	O
%	NN	O
blasts	NNS	O
)	)	O
bone	NN	O
marrow	JJ	O
involvement	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
protocol-based	JJ	O
systemic	JJ	O
and	CC	O
intrathecal	JJ	O
chemotherapy	NN	O
.	.	O

Thirty-six	JJ	O
patients	NNS	O
also	RB	O
received	VBD	O
CNS	NNP	O
irradiation	NN	O
.	.	O

RESULTS	NNP	O
Relapses	NNPS	Physical
occurred	VBD	O
in	IN	O
21	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
of	IN	O
49	CD	O
patients	NNS	O
,	,	O
predominantly	RB	O
in	IN	O
the	DT	O
CNS	NNP	O
(	(	O
71	CD	O
%	NN	O
)	)	O
and	CC	O
bone	NN	O
marrow	NN	O
(	(	O
52	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
3-year	JJ	Mortality
event-free	JJ	Mortality
survival	NN	Mortality
+/-	JJ	O
SE	NNP	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
CNS+	NNP	O
disease	NN	O
was	VBD	O
45	CD	O
%	NN	O
+/-	JJ	O
7	CD	O
%	NN	O
.	.	O

Patients	NNS	O
with	IN	O
CSF+/Mass	NNP	O
had	VBD	O
a	DT	O
nominally	RB	O
higher	JJR	Others
treatment	NN	Others
failure	NN	Others
rate	NN	Others
compared	VBN	O
with	IN	O
patients	NNS	O
with	IN	O
CNS-	NNP	O
after	IN	O
adjusting	VBG	O
for	IN	O
marrow	NN	O
status	NN	O
and	CC	O
lactate	VB	O
dehydrogenase	NN	O
(	(	O
LDH	NNP	O
)	)	O
diagnosis	NN	O
,	,	O
with	IN	O
a	DT	O
relative	JJ	Physical
failure	NN	Physical
rate	NN	Physical
(	(	Physical
RFR	NNP	Physical
)	)	Physical
of	IN	O
1.52	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.88	CD	O
to	TO	O
2.6	CD	O
;	:	O
P	NNP	O
=.15	NNP	O
)	)	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
the	DT	O
RFRs	NNP	Physical
for	IN	O
patients	NNS	O
with	IN	O
M2	NNP	O
or	CC	O
M3	NNP	O
marrow	NN	O
and	CC	O
for	IN	O
those	DT	O
with	IN	O
LDH	NNP	O
levels	NNS	O
greater	JJR	O
than	IN	O
500	CD	O
IU/L	NNP	O
after	IN	O
adjusting	VBG	O
for	IN	O
CNS	NNP	Physical
disease	NN	Physical
were	VBD	O
1.4	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.96	CD	O
to	TO	O
2.0	CD	O
;	:	O
P	NNP	O
=.029	NNP	O
)	)	O
and	CC	O
2.2	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.5	CD	O
to	TO	O
3.0	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
RFR	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
CNPs	NNP	O
was	VBD	O
0.87	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.36	CD	O
to	TO	O
2.1	CD	O
;	:	O
P	NNP	O
=.76	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
with	IN	O
the	DT	O
treatments	NNS	O
used	VBN	O
during	IN	O
the	DT	O
period	NN	O
covered	VBN	O
by	IN	O
these	DT	O
studies	NNS	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
CSF+/Mass	NNP	O
CNS	NNP	O
disease	NN	O
at	IN	O
diagnosis	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
nominally	RB	Others
worse	JJR	Others
outcome	JJ	Others
independent	JJ	O
of	IN	O
initial	JJ	O
bone	NN	O
marrow	NN	O
status	NN	O
and	CC	O
LDH	NNP	O
level	NN	O
,	,	O
but	CC	O
the	DT	O
effect	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
.	.	O

Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
relative	JJ	O
efficacies	NNS	O
of	IN	O
various	JJ	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
are	VBP	O
not	RB	O
well	RB	O
known	VBN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
imipramine	NN	O
,	,	O
mexiletine	NN	O
,	,	O
pirmenol	NN	O
,	,	O
procainamide	NN	O
,	,	O
propafenone	NN	O
,	,	O
quinidine	NN	O
,	,	O
and	CC	O
sotalol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
serial	JJ	O
testing	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
strategies	NNS	O
:	:	O
electrophysiologic	NN	O
study	NN	O
or	CC	O
Holter	NNP	O
monitoring	VBG	O
together	RB	O
with	IN	O
exercise	NN	O
testing	NN	O
.	.	O

The	DT	O
seven	CD	O
drugs	NNS	O
were	VBD	O
then	RB	O
tested	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
random	JJ	O
order	NN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
eligible	JJ	O
to	TO	O
receive	VB	O
them	PRP	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
and	CC	O
of	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
the	DT	O
initial	JJ	O
drug	NN	O
titration	NN	O
were	VBD	O
tabulated	VBN	O
for	IN	O
all	DT	O
486	CD	O
randomized	VBN	O
subjects	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
long-term	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
first	JJ	O
antiarrhythmic	JJ	O
drug	NN	O
that	WDT	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
drug	NN	O
testing	NN	O
.	.	O

Recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
,	,	O
deaths	NNS	O
,	,	O
and	CC	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
long-term	JJ	O
follow-up	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
296	CD	O
patients	NNS	O
in	IN	O
whom	WP	O
an	DT	O
antiarrhythmic	JJ	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
electrophysiologic-study	JJ	O
group	NN	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
predictions	NNS	O
of	IN	O
drug	NN	Mental
efficacy	NN	Mental
was	VBD	O
higher	JJR	Mental
with	IN	O
sotalol	NN	O
(	(	O
35	CD	O
percent	NN	O
)	)	O
than	IN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
16	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	Mental
significant	JJ	Mental
difference	NN	Mental
among	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
the	DT	O
Holter-monitoring	NNP	O
group	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	Mental
with	IN	Mental
adverse	JJ	Mental
drug	NN	Mental
effects	NNS	Mental
was	VBD	O
lowest	JJS	Mental
among	IN	O
those	DT	O
receiving	VBG	O
sotalol	NN	O
.	.	O

The	DT	O
actuarial	JJ	Mental
probability	NN	Mental
of	IN	Mental
a	DT	Mental
recurrence	NN	Mental
of	IN	Mental
arrhythmia	NN	Mental
after	IN	O
a	DT	O
prediction	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
by	IN	O
either	DT	O
strategy	NN	O
was	VBD	O
significantly	RB	Others
lower	JJR	Others
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
sotalol	NN	O
than	IN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.29	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

With	IN	O
sotalol	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
combined	VBN	O
,	,	O
there	EX	O
were	VBD	O
lower	JJR	Others
risks	NNS	Others
of	IN	Others
death	NN	Others
from	IN	O
any	DT	O
cause	NN	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.50	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.30	CD	O
to	TO	O
0.80	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
death	NN	O
from	IN	O
cardiac	JJ	O
causes	NNS	O
,	,	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
death	NN	Others
from	IN	Others
arrhythmia	NN	Others
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
a	DT	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
in	IN	O
whom	WP	O
it	PRP	O
remained	VBD	O
effective	JJ	O
and	CC	O
tolerated	VBD	O
was	VBD	O
higher	JJR	O
for	IN	O
sotalol	JJR	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Sotalol	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
other	JJ	O
six	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
preventing	VBG	O
death	NN	O
and	CC	O
recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
.	.	O

In	IN	O
patients	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
if	IN	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
to	TO	O
prevent	VB	O
recurrences	NNS	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
,	,	O
treatment	NN	O
with	IN	O
sotalol	NN	O
and	CC	O
assessment	NN	O
of	IN	O
its	PRP$	O
potential	JJ	O
efficacy	NN	O
by	IN	O
Holter	NNP	O
monitoring	NN	O
are	VBP	O
a	DT	O
reasonable	JJ	O
initial	JJ	O
strategy	NN	O
.	.	O

[	JJ	O
Supplementary	NNP	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
of	IN	O
female	JJ	O
patients	NNS	O
undergoing	VBG	O
curative	JJ	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
breast	NN	O
cancer	NN	O
]	NNP	O
.	.	O

1	CD	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
supposed	VBN	O
to	TO	O
investigate	VB	O
a	DT	O
possible	JJ	O
prevention	NN	Physical
or	CC	Physical
reduction	NN	Physical
of	IN	Physical
the	DT	Physical
toxicity	NN	Physical
of	IN	O
radiotherapy	NN	O
by	IN	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
.	.	O

This	DT	O
question	NN	O
arose	VBD	O
when	WRB	O
performing	VBG	O
an	DT	O
investigation	NN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
in	IN	O
a	DT	O
combined	JJ	O
chemo-radiotherapy	NN	O
.	.	O

Whereas	IN	O
the	DT	O
latter	JJ	O
induces	NNS	O
above	IN	O
all	PDT	O
a	DT	O
systemic	JJ	O
damage	NN	O
to	TO	O
the	DT	O
hemopoietic	JJ	O
system	NN	O
,	,	O
radiotherapy	NN	O
is	VBZ	O
a	DT	O
regional	JJ	O
noxa	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
present	JJ	O
prospective	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
50	CD	O
patients	NNS	O
submitted	VBN	O
to	TO	O
curative	VB	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
surgery	NN	O
for	IN	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

The	DT	O
radiotherapy	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
irradiations	NNS	O
of	IN	O
the	DT	O
thoracic	NN	O
wall	NN	O
and	CC	O
the	DT	O
regional	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
were	VBD	O
built	VBN	O
by	IN	O
randomization	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
received	VBD	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
receive	VB	O
an	DT	O
additional	JJ	O
treatment	NN	O
.	.	O

3	CD	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
no	DT	O
protective	JJ	O
influence	NN	O
of	IN	O
Esberitox	NNP	O
could	MD	O
be	VB	O
demonstrated	VBN	O
.	.	O

The	DT	O
parameters	NNS	O
investigated	VBN	O
were	VBD	O
the	DT	O
peripheral	JJ	Physical
blood	NN	Physical
count	NN	Physical
(	(	Physical
leucocytes	NNS	Physical
,	,	Physical
granulocytes	NNS	Physical
,	,	Physical
lymphocytes	NNS	Physical
,	,	Physical
monocytes	NNS	Physical
,	,	Physical
thrombocytes	NNS	Physical
,	,	Physical
hemoglobin	NN	Physical
,	,	Physical
hematocrit	NN	Physical
)	)	Physical
and	CC	Physical
the	DT	Physical
incidence	NN	Physical
of	IN	Physical
infections	NNS	Physical
.	.	O

4	CD	O
.	.	O

This	DT	O
result	NN	O
diverging	VBG	O
from	IN	O
literature	NN	O
is	VBZ	O
discussed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
probably	RB	O
affected	VBN	O
by	IN	O
volume	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
injury	NN	O
induced	VBN	O
by	IN	O
a	DT	O
hematotoxic	NN	O
noxa	NN	O
and	CC	O
furthermore	NN	O
by	IN	O
the	DT	O
ability	NN	O
of	IN	O
regeneration	NN	O
.	.	O

If	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
exhausted	VBN	O
,	,	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
can	MD	O
act	VB	O
no	DT	O
longer	JJR	O
.	.	O

Therefore	VB	O
the	DT	O
essential	JJ	O
factor	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
duration	NN	O
of	IN	O
exposure	NN	O
to	TO	O
the	DT	O
noxa	NN	O
.	.	O

Esberitox	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
case	NN	O
of	IN	O
a	DT	O
short	JJ	O
toxicity	NN	O
,	,	O
it	PRP	O
was	VBD	O
ineffective	JJ	O
in	IN	O
case	NN	O
of	IN	O
prolonged	JJ	O
toxicity	NN	O
,	,	O
if	IN	O
the	DT	O
treatment	NN	O
continuity	NN	O
(	(	O
noxa	JJ	O
)	)	O
was	VBD	O
not	RB	O
broken	VBN	O
up	RP	O
by	IN	O
some	DT	O
regeneration	NN	O
intervals	NNS	O
.	.	O

The	DT	O
radiotherapy	NN	O
studied	VBN	O
in	IN	O
this	DT	O
trial	NN	O
had	VBD	O
a	DT	O
duration	NN	O
of	IN	O
50	CD	O
days	NNS	O
,	,	O
and	CC	O
its	PRP$	O
effect	NN	O
was	VBD	O
that	IN	O
of	IN	O
a	DT	O
longterm	JJ	O
injury	NN	O
.	.	O

Safety	NN	Others
and	CC	O
efficacy	NN	Others
of	IN	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
Logiparin	NNP	O
)	)	O
versus	NN	O
dextran	NN	O
as	IN	O
prophylaxis	NN	O
against	IN	O
thrombosis	NN	O
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
study	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
factor	NN	O
XaI	NNP	O
and	CC	O
IIaI	NNP	O
activity	NN	O
an	DT	O
enzymatically	RB	O
depolymerized	VBN	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMW-heparin	NNP	O
;	:	O
Logiparin	NNP	O
)	)	O
was	VBD	O
given	VBN	O
s.c.	NN	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
for	IN	O
7	CD	O
days	NNS	O
to	TO	O
10	CD	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
(	(	O
THR	NNP	O
)	)	O
in	IN	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
XaI	NN	O
activity	NN	O
was	VBD	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.24	CD	O
XaI	NNP	O
units/ml	NN	O
and	CC	O
the	DT	O
IIaI	NNP	O
activity	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.043	CD	O
IIaI	NNP	O
mu/ml	NN	O
.	.	O

No	DT	O
accumulation	NN	O
of	IN	O
the	DT	O
activities	NNS	O
were	VBD	O
seen	VBN	O
.	.	O

No	DT	O
phlebographically	RB	Physical
verified	VBN	Physical
thrombi	NN	Physical
or	CC	O
any	DT	O
bleeding	JJ	Physical
complications	NNS	Physical
were	VBD	O
registered	VBN	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
given	VBN	O
dose	NN	O
of	IN	O
Logiparin	NNP	O
was	VBD	O
safe	JJ	O
with	IN	O
regard	NN	O
to	TO	O
bleeding	VBG	O
complications	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
,	,	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
was	VBD	O
started	VBN	O
.	.	O

In	IN	O
this	DT	O
main	JJ	O
study	NN	O
the	DT	O
thromboprophylactic	JJ	Physical
effect	NN	Physical
of	IN	O
the	DT	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
dextran	NN	O
70	CD	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
THR	NNP	O
.	.	O

100	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

The	DT	O
over-all	JJ	Others
thrombosis	NN	Others
rate	NN	Others
was	VBD	O
28	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
LMW-heparin	NNP	O
and	CC	O
39	CD	O
%	NN	O
in	IN	O
those	DT	O
given	VBN	O
dextran	NN	O
,	,	O
a	DT	O
non-significant	JJ	O
difference	NN	O
.	.	O

No	UH	O
bleeding	VBG	Adverseeffect
complications	NNS	Adverseeffect
,	,	O
deaths	NNS	Mortality
or	CC	O
pulmonary	JJ	Physical
embolism	NN	Physical
were	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Peroperative	JJ	Physical
blood	NN	Physical
loss	NN	Physical
and	CC	Physical
transfusion	NN	Physical
requirements	NNS	Physical
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
investigated	JJ	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
thromboembolism	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
,	,	O
but	CC	O
the	DT	O
dosage	NN	O
can	MD	O
probably	RB	O
be	VB	O
optimized	VBN	O
.	.	O

Rapid-sequence	JJ	O
intubation	NN	O
of	IN	O
head	NN	O
trauma	NN	O
patients	NNS	O
:	:	O
prevention	NN	O
of	IN	O
fasciculations	NNS	Physical
with	IN	O
pancuronium	NN	O
versus	NN	O
minidose	JJ	O
succinylcholine	NN	O
.	.	O

INTRODUCTION	NNP	O
Fasciculations	NNP	Physical
during	IN	O
rapid-sequence	JJ	O
intubation	NN	O
may	MD	O
lead	VB	O
to	TO	O
increased	VBN	O
intracranial	JJ	O
pressure	NN	O
and	CC	O
emesis	NN	Physical
with	IN	O
aspiration	NN	O
.	.	O

Standard	NNP	O
rapid-sequence	NN	O
intubation	NN	O
requires	VBZ	O
a	DT	O
nondepolarizing	JJ	O
blocking	NN	O
agent	NN	O
before	IN	O
succinylcholine	JJ	O
administration	NN	O
.	.	O

HYPOTHESIS	NNP	O
Prevention	NNP	O
of	IN	O
fasciculations	NNS	Physical
during	IN	O
rapid-sequence	JJ	O
intubation	NN	O
of	IN	O
head	NN	O
trauma	IN	O
patients	NNS	O
can	MD	O
be	VB	O
accomplished	VBN	O
as	IN	O
safely	RB	O
and	CC	O
effectively	RB	O
with	IN	O
minidose	JJ	O
succinylcholine	NN	O
as	IN	O
with	IN	O
a	DT	O
defasciculating	VBG	O
dose	NN	O
of	IN	O
pancuronium	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

SETTING	VBG	O
An	DT	O
inner-city	JJ	O
county	NN	O
trauma	NN	O
center	NN	O
with	IN	O
70,000	CD	O
patient	JJ	O
visits	NNS	O
per	IN	O
year	NN	O
.	.	O

PARTICIPANTS	NNP	O
Sequential	NNP	O
adult	NN	O
head	NN	O
trauma	NN	O
patients	NNS	O
requiring	VBG	O
rapid-sequence	JJ	O
intubation	NN	O
who	WP	O
had	VBD	O
no	DT	O
contraindications	NNS	O
to	TO	O
succinylcholine	VB	O
or	CC	O
pancuronium	VB	O
.	.	O

INTERVENTIONS	NNP	O
Each	DT	O
head	NN	O
trauma	NN	O
patient	JJ	O
requiring	VBG	O
rapid-sequence	NN	O
intubation	NN	O
who	WP	O
met	VBD	O
the	DT	O
inclusion	NN	O
criteria	NNS	O
received	VBD	O
standard	JJ	O
rapid-sequence	NN	O
intubation	NN	O
maneuvers	NNS	O
and	CC	O
lidocaine	NN	O
(	(	O
1	CD	O
mg/kg	NN	O
)	)	O
IV	NNP	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
minidose	JJ	O
succinylcholine	NN	O
(	(	O
0.1	CD	O
mg/kg	NN	O
)	)	O
or	CC	O
pancuronium	NN	O
(	(	O
0.03	CD	O
mg/kg	NN	O
)	)	O
IV	NNP	O
one	CD	O
minute	NN	O
prior	RB	O
to	TO	O
the	DT	O
full	JJ	O
paralytic	JJ	O
dose	NN	O
of	IN	O
succinylcholine	NN	O
(	(	O
1.5	CD	O
mg/kg	NN	O
)	)	O
IV	NNP	O
.	.	O

Fasciculations	NNS	Physical
were	VBD	O
recorded	VBN	O
using	VBG	O
a	DT	O
graded	JJ	Others
visual	JJ	Others
scale	NN	Others
.	.	O

RESULTS	NNP	O
Of	IN	O
46	CD	O
patients	NNS	O
,	,	O
eight	CD	O
of	IN	O
19	CD	O
(	(	O
42	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
pancuronium	NN	O
group	NN	O
and	CC	O
six	CD	O
of	IN	O
27	CD	O
(	(	O
22	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
succinylcholine	NN	O
group	NN	O
experienced	VBD	O
fasciculations	NNS	Physical
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
fasciculations	NNS	Physical
was	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
using	VBG	O
chi	JJ	O
2	CD	O
analysis	NN	O
.	.	O

Complete	JJ	Physical
relaxation	NN	Physical
of	IN	Physical
the	DT	Physical
cords	NNS	Physical
was	VBD	O
present	JJ	O
in	IN	O
all	DT	O
but	CC	O
two	CD	O
patients	NNS	O
,	,	O
one	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

No	DT	O
patient	NN	O
in	IN	O
either	DT	O
group	NN	O
experienced	VBD	O
emesis	NN	Physical
or	CC	O
significant	JJ	Physical
dysrhythmias	NN	Physical
.	.	O

CONCLUSION	NNP	O
Pretreatment	NNP	O
with	IN	O
minidose	JJ	O
succinylcholine	JJ	O
causes	VBZ	O
no	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
fasciculations	NNS	Physical
than	IN	O
pancuronium	NN	O
in	IN	O
rapid-sequence	JJ	O
intubation	NN	O
of	IN	O
head	NN	O
trauma	NN	O
patients	NNS	O
in	IN	O
an	DT	O
ED	NNP	O
setting	NN	O
.	.	O

Thus	NNP	O
succinylcholine	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
the	DT	O
sole	JJ	O
paralytic	JJ	O
agent	NN	O
in	IN	O
rapid-sequence	JJ	O
intubation	NN	O
of	IN	O
head	NN	O
trauma	NN	O
patients	NNS	O
.	.	O

Efficacy	NN	Others
of	IN	O
intravenous	JJ	O
acetaminophen	NN	O
and	CC	O
lidocaine	NN	O
on	IN	O
propofol	NN	O
injection	NN	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
Different	NNP	O
methods	NNS	O
and	CC	O
propofol	NN	O
formulations	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
decrease	VB	O
propofol	JJ	Pain
injection	NN	Pain
pain	NN	Pain
,	,	O
but	CC	O
it	PRP	O
remains	VBZ	O
an	DT	O
unresolved	JJ	O
problem	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
i.v	NN	O
.	.	O

acetaminophen	JJ	O
pretreatment	NN	O
on	IN	O
the	DT	O
propofol	NN	O
injection	NN	Pain
pain	NN	Pain
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
fifty	JJ	O
ASA	NNP	O
I-II	NNP	O
patients	NNS	O
undergoing	VBG	O
general	JJ	O
anaesthesia	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
.	.	O

A	DT	O
20-gauge	JJ	O
catheter	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
a	DT	O
superficial	JJ	O
radial	JJ	O
vein	NN	O
of	IN	O
the	DT	O
left	JJ	O
hand	NN	O
,	,	O
and	CC	O
after	IN	O
the	DT	O
occlusion	NN	O
of	IN	O
venous	JJ	O
drainage	NN	O
,	,	O
Groups	NNP	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
and	CC	O
III	NNP	O
were	VBD	O
pretreated	VBN	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
lidocaine	NN	O
in	IN	O
saline	NN	O
,	,	O
50	CD	O
mg	NN	O
of	IN	O
i.v	NN	O
.	.	O

acetaminophen	NN	O
,	,	O
and	CC	O
5	CD	O
ml	NN	O
of	IN	O
saline	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
occlusion	NN	O
was	VBD	O
released	VBN	O
after	IN	O
2	CD	O
min	NN	O
and	CC	O
one-fourth	NN	O
of	IN	O
the	DT	O
total	JJ	O
propofol	NN	O
dose	NN	O
was	VBD	O
injected	VBN	O
into	IN	O
the	DT	O
vein	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
5	CD	O
s.	NN	O
During	IN	O
the	DT	O
injection	NN	O
of	IN	O
both	DT	O
pretreatment	JJ	O
solution	NN	O
and	CC	O
propofol	NN	O
,	,	O
patients	NNS	O
'	POS	O
pain	NN	Pain
was	VBD	O
assessed	VBN	O
and	CC	O
recorded	VBN	O
as	IN	O
0-3	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
no	DT	O
,	,	O
mild	RB	O
,	,	O
moderate	JJ	O
or	CC	O
severe	JJ	O
pain	NN	O
,	,	O
respectively	RB	O
.	.	O

Chi2	NNP	O
and	CC	O
Kruskal-Wallis	NNP	O
tests	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
the	DT	O
statistical	JJ	O
analysis	NN	O
.	.	O

For	IN	O
all	DT	O
analyses	NNS	O
,	,	O
differences	NNS	O
were	VBD	O
considered	VBN	O
to	TO	O
be	VB	O
significant	JJ	O
at	IN	O
P	NNP	O
<	NNP	O
0.05	CD	O
.	.	O

RESULTS	NNP	O
Patient	JJ	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

Incidence	NN	Pain
of	IN	Pain
pain	NN	Pain
on	IN	Pain
injection	NN	Pain
of	IN	O
propofol	NN	O
in	IN	O
control	NN	O
,	,	O
i.v	NN	O
.	.	O

acetaminophen	NN	O
,	,	O
and	CC	O
lidocaine	NN	O
groups	NNS	O
was	VBD	O
64	CD	O
%	NN	O
,	,	O
22	CD	O
%	NN	O
and	CC	O
8	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Pretreatment	NNP	O
with	IN	O
i.v	NN	O
.	.	O

acetaminophen	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
attenuating	VBG	O
pain	NN	Pain
during	IN	O
i.v	NN	O
.	.	O

injection	NN	O
of	IN	O
propofol	NN	O
.	.	O

Teaching	VBG	O
children	NNS	O
with	IN	O
autism	NN	O
to	TO	O
seek	VB	O
information	NN	O
:	:	O
acquisition	NN	O
of	IN	O
novel	JJ	O
information	NN	O
and	CC	O
generalization	NN	O
of	IN	O
responding	VBG	O
.	.	O

A	DT	O
time	NN	O
delay	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
teach	VB	O
3	CD	O
children	NNS	O
with	IN	O
autism	NN	O
to	TO	O
ask	VB	O
the	DT	O
question	NN	O
What	WP	O
's	VBZ	O
that	DT	O
?	.	O
when	WRB	O
novel	JJ	O
stimuli	NNS	O
were	VBD	O
presented	VBN	O
during	IN	O
an	DT	O
instructional	JJ	O
task	NN	O
.	.	O

Once	IN	O
the	DT	O
ability	NN	O
to	TO	O
ask	VB	O
the	DT	O
question	NN	O
was	VBD	O
acquired	VBN	O
,	,	O
the	DT	O
children	NNS	O
's	POS	O
ability	NN	O
to	TO	O
learn	VB	O
novel	JJ	O
information	NN	O
by	IN	O
asking	VBG	O
the	DT	O
question	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
then	RB	O
taught	VBN	O
to	TO	O
ask	VB	O
the	DT	O
question	NN	O
within	IN	O
a	DT	O
less	RBR	O
structured	JJ	O
context	NN	O
.	.	O

All	DT	O
three	CD	O
studies	NNS	O
used	VBD	O
a	DT	O
multiple	JJ	O
baseline	NN	O
across	IN	O
participants	NNS	O
.	.	O

Generalization	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
different	JJ	O
room	NN	O
,	,	O
to	TO	O
a	DT	O
new	JJ	O
person	NN	O
,	,	O
and	CC	O
to	TO	O
novel	VB	O
stimuli	NNS	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
children	NNS	O
learned	VBD	O
to	TO	O
ask	VB	O
the	DT	O
question	NN	O
within	IN	O
the	DT	O
instructional	JJ	O
context	NN	O
,	,	O
while	IN	O
on	IN	O
a	DT	O
walk	NN	O
in	IN	O
the	DT	O
school	NN	O
building	NN	O
,	,	O
and	CC	O
to	TO	O
request	VB	O
information	NN	O
about	IN	O
three-dimensional	JJ	O
objects	NNS	O
.	.	O

The	DT	O
acquisition	NN	Mental
of	IN	Mental
novel	JJ	Mental
information	NN	Mental
was	VBD	O
consistent	JJ	O
for	IN	O
receptive	JJ	O
and	CC	O
expressive	JJ	O
tests	NNS	O
for	IN	O
2	CD	O
of	IN	O
the	DT	O
children	NNS	O
,	,	O
with	IN	O
varied	JJ	O
results	NNS	O
for	IN	O
the	DT	O
3rd	CD	O
.	.	O

These	DT	O
studies	NNS	O
indicate	VBP	O
that	IN	O
children	NNS	O
with	IN	O
autism	NN	O
can	MD	O
be	VB	O
taught	VBN	O
to	TO	O
ask	VB	O
questions	NNS	O
that	WDT	O
lead	VBP	O
to	TO	O
the	DT	O
acquisition	NN	O
of	IN	O
new	JJ	O
information	NN	O
.	.	O

Intravenous	JJ	O
aflibercept	NN	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
irinotecan	JJ	O
,	,	O
5-fluorouracil	JJ	O
and	CC	O
leucovorin	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
solid	JJ	O
tumours	NNS	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
expansion	NN	O
cohort	NN	O
of	IN	O
a	DT	O
phase	NN	O
I	PRP	O
study	VBP	O
.	.	O

BACKGROUND	NNP	O
Following	VBG	O
the	DT	O
dose-escalation	NN	O
stage	NN	O
,	,	O
this	DT	O
double-blind	JJ	O
expansion	NN	O
stage	NN	O
of	IN	O
the	DT	O
phase	NN	O
I	PRP	O
study	VBP	O
evaluated	VBD	O
the	DT	O
safety	NN	O
,	,	O
pharmacodynamics	NNS	O
,	,	O
pharmacokinetics	NNS	O
,	,	O
anti-vascular	JJ	O
effects	NNS	O
and	CC	O
antitumour	JJ	O
activity	NN	O
of	IN	O
aflibercept	$	O
4	CD	O
mg/kg	NN	O
with	IN	O
irinotecan	JJ	O
,	,	O
5-fluorouracil	JJ	O
and	CC	O
leucovorin	JJ	O
(	(	O
LV5FU2	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNP	O
with	IN	O
advanced	JJ	O
solid	JJ	O
tumours	NNS	O
were	VBD	O
randomised	VBN	O
at	IN	O
cycle-1	NN	O
to	TO	O
placebo	VB	O
or	CC	O
aflibercept	VB	O
(	(	O
4	CD	O
mg/kg	NN	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
then	RB	O
irinotecan-LV5FU2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
2	CD	O
.	.	O

Subsequently	RB	O
,	,	O
all	DT	O
patients	NNS	O
received	VBD	O
aflibercept	JJ	O
with	IN	O
irinotecan-LV5FU2	JJ	O
every	DT	O
2	CD	O
weeks	NNS	O
.	.	O

Anti-vascular	JJ	O
effects	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
dynamic	JJ	O
contrast-enhanced	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
DCE-MRI	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Twenty-seven	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
;	:	O
14	CD	O
received	VBD	O
placebo	NN	O
in	IN	O
cycle-1	NN	O
followed	VBN	O
by	IN	O
aflibercept	NN	O
in	IN	O
later	JJ	O
cycles	NNS	O
and	CC	O
13	CD	O
received	VBD	O
aflibercept	JJ	O
4	CD	O
mg/kg	NN	O
upfront	NN	O
.	.	O

The	DT	O
median	JJ	Physical
number	NN	Physical
of	IN	Physical
aflibercept	JJ	Physical
cycles	NNS	Physical
was	VBD	O
16	CD	O
(	(	O
range	VB	O
1-44	CD	O
)	)	O
,	,	O
12	CD	O
patients	NNS	O
received	VBD	O
?20	JJ	O
cycles	NNS	O
.	.	O

Most	JJS	O
frequent	JJ	O
grade	NN	O
3/4	CD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
neutropenia	RB	O
(	(	O
37	CD	O
%	NN	O
)	)	O
,	,	O
fatigue	NN	O
(	(	O
33	CD	O
%	NN	O
)	)	O
and	CC	O
hypertension	NN	O
(	(	O
30	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
anti-aflibercept	JJ	O
antibodies	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

Four	CD	O
patients	NNS	O
achieved	VBN	O
partial	JJ	O
responses	NNS	O
and	CC	O
17	CD	O
had	VBD	O
stable	JJ	O
disease	NN	O
,	,	O
lasting	VBG	O
>	JJ	O
3	CD	O
months	NNS	O
in	IN	O
14	CD	O
patients	NNS	O
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
free	JJ	O
over	IN	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor-bound	JJ	O
aflibercept	NN	O
were	VBD	O
adequate	JJ	O
,	,	O
with	IN	O
steady-state	JJ	O
achieved	VBN	O
from	IN	O
cycle-3	NN	O
.	.	O

Exploratory	JJ	O
DCE-MRI	NNP	O
showed	VBD	O
no	DT	O
significant	JJ	O
perfusion	NN	O
changes	NNS	O
with	IN	O
aflibercept	NN	O
.	.	O

CONCLUSION	NNP	O
Aflibercept	IN	O
4	CD	O
mg/kg	JJ	O
plus	CC	O
irinotecan-LV5FU2	JJ	O
every	DT	O
2	CD	O
weeks	NNS	O
had	VBD	O
acceptable	JJ	O
toxicity	NN	O
and	CC	O
pharmacokinetics	NNS	O
,	,	O
and	CC	O
showed	VBD	O
promising	JJ	O
antitumour	JJ	O
activity	NN	O
.	.	O

Prenatal	JJ	O
depression	NN	O
predicts	VBZ	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
low-income	JJ	O
Latina	NNP	O
mothers	NNS	O
with	IN	O
infants	NNS	O
.	.	O

Although	IN	O
maternal	JJ	O
attachment	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
infant	JJ	O
attachment	JJ	O
security	NN	O
and	CC	O
other	JJ	O
developmental	JJ	O
outcomes	NNS	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
formation	NN	O
of	IN	O
maternal	JJ	O
attachment	NN	O
in	IN	O
the	DT	O
first	JJ	O
few	JJ	O
months	NNS	O
of	IN	O
the	DT	O
infant	NN	O
's	POS	O
life	NN	O
,	,	O
particularly	RB	O
among	IN	O
ethnic	JJ	O
minority	NN	O
mothers	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
predictors	NNS	O
of	IN	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
217	CD	O
Latina	NNP	O
women	NNS	O
enrolled	VBD	O
in	IN	O
a	DT	O
perinatal	JJ	O
depression	NN	O
prevention	NN	O
trial	NN	O
.	.	O

Mothers	NNS	O
'	POS	O
attachment	NN	O
to	TO	O
their	PRP$	O
infants	NNS	O
was	VBD	O
measured	VBN	O
at	IN	O
6-8	JJ	O
weeks	NNS	O
postpartum	NN	O
using	VBG	O
the	DT	O
Maternal	NNP	Mental
Postnatal	NNP	Mental
Attachment	NNP	Mental
Scale	NNP	Mental
.	.	O

A	NNP	O
variety	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
early	JJ	O
attachment	NN	O
were	VBD	O
explored	VBN	O
including	VBG	O
:	:	O
depressive	JJ	Mental
symptoms	NNS	Mental
during	IN	Mental
pregnancy	NN	Mental
,	,	Mental
pregnancy	NN	Mental
intention	NN	Mental
,	,	Mental
feelings	NNS	Mental
about	IN	Mental
the	DT	Mental
pregnancy	NN	Mental
,	,	Mental
and	CC	Mental
the	DT	Mental
quality	NN	Mental
of	IN	Mental
the	DT	Mental
partner	NN	Mental
relationship	NN	Mental
.	.	O

The	DT	O
strongest	JJS	O
predictor	NN	O
of	IN	O
lower	JJR	Others
maternal	JJ	Others
attachment	NN	Others
was	VBD	O
depressive	JJ	Mental
symptoms	NNS	Mental
late	RB	O
in	IN	O
pregnancy	NN	O
;	:	O
pregnancy	NN	O
intention	NN	O
was	VBD	O
marginally	RB	O
predictive	JJ	O
of	IN	O
attachment	NN	Mental
,	,	O
with	IN	O
lower	JJR	O
scores	NNS	O
being	VBG	O
associated	VBN	O
with	IN	O
unwanted	JJ	O
pregnancies	NNS	O
.	.	O

The	DT	O
study	NN	O
fills	VBZ	O
a	DT	O
critical	JJ	O
gap	NN	O
in	IN	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
role	NN	O
of	IN	O
depressive	JJ	O
symptoms	NNS	O
during	IN	O
pregnancy	NN	O
in	IN	O
shaping	VBG	O
mothers	NNS	O
'	POS	O
early	JJ	O
attachment	NN	O
to	TO	O
their	PRP$	O
infants	NNS	O
.	.	O

Postoperative	JJ	Pain
pain	NN	Pain
control	NN	Pain
for	IN	O
outpatient	JJ	O
oral	JJ	O
surgery	NN	O
.	.	O

16	CD	O
healthy	JJ	O
patients	NNS	O
requiring	VBG	O
removal	NN	O
of	IN	O
bilateral	JJ	O
symmetrically-impacted	JJ	O
mandibular	JJ	O
third	JJ	O
molars	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
double-blind	NN	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	Pain
of	IN	Pain
postoperative	JJ	Pain
pain	NN	Pain
control	NN	Pain
using	VBG	O
a	DT	O
long-acting	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
(	(	O
diflunisal	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
long-acting	JJ	O
local	JJ	O
anaesthetic	JJ	O
agent	NN	O
(	(	O
bupivacaine	NN	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
more	RBR	O
traditional	JJ	O
method	NN	O
of	IN	O
using	VBG	O
an	DT	O
oral	JJ	O
analgesic	NN	O
with	IN	O
shorter	JJR	O
duration	NN	O
of	IN	O
action	NN	O
(	(	O
paracetamol	NN	O
with	IN	O
codeine	NN	O
)	)	O
with	IN	O
lignocaine	NN	O
as	IN	O
the	DT	O
local	JJ	O
anaesthetic	NN	O
.	.	O

Using	VBG	O
a	DT	O
visual	JJ	Pain
analogue	NN	Pain
pain	NN	Pain
scale	NN	Pain
,	,	O
patients	NNS	O
reported	VBD	O
that	IN	O
significantly	RB	O
reduced	VBN	O
pain	NN	Pain
was	VBD	O
experienced	VBN	O
over	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
postoperatively	RB	O
with	IN	O
the	DT	O
diflunisal/bupivacaine	NN	O
treatment	NN	O
and	CC	O
patient	JJ	Pain
preference	NN	Pain
for	IN	O
this	DT	O
treatment	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
.	.	O

This	DT	O
report	NN	O
represents	VBZ	O
the	DT	O
first	JJ	O
such	JJ	O
study	NN	O
of	IN	O
diflunisal	NN	O
used	VBN	O
for	IN	O
an	DT	O
extended	JJ	O
course	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
pain	NN	Pain
assessment	NN	O
over	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
side-effects	NNS	Adverseeffect
or	CC	Adverseeffect
adverse	JJ	Adverseeffect
reactions	NNS	Adverseeffect
were	VBD	O
encountered	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
dual-axis	JJ	O
rotational	JJ	O
coronary	NN	O
angiography	NN	O
(	(	O
XPERSWING	NN	O
)	)	O
versus	IN	O
conventional	JJ	O
technique	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
.	.	O

INTRODUCTION	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Coronary	NNP	O
angiography	NN	O
is	VBZ	O
the	DT	O
gold	JJ	O
standard	NN	O
for	IN	O
the	DT	O
study	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

This	DT	O
technique	NN	O
requires	VBZ	O
several	JJ	O
orthogonal	JJ	O
projections	NNS	O
.	.	O

Rotational	JJ	O
angiography	NN	O
is	VBZ	O
a	DT	O
new	JJ	O
technique	NN	O
which	WDT	O
involves	VBZ	O
pre-set	JJ	O
rotation	NN	O
of	IN	O
the	DT	O
X-ray	JJ	O
tube	NN	O
around	IN	O
the	DT	O
patient	NN	O
and	CC	O
allows	VBZ	O
visualization	NN	O
of	IN	O
each	DT	O
coronary	JJ	O
artery	NN	O
in	IN	O
different	JJ	O
views	NNS	O
,	,	O
using	VBG	O
a	DT	O
single	JJ	O
contrast	NN	O
injection	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
conventional	JJ	O
coronary	JJ	O
angiography	NN	O
(	(	O
A	DT	O
)	)	O
vs	FW	O
rotational	JJ	O
angiography	NN	O
(	(	O
B	NNP	O
)	)	O
,	,	O
focusing	VBG	O
on	IN	O
radiation	NN	O
dose	NN	O
,	,	O
amount	NN	O
of	IN	O
contrast	NN	O
administered	VBN	O
,	,	O
and	CC	O
total	JJ	O
procedure	NN	O
time	NN	O
for	IN	O
both	DT	O
diagnostic	JJ	O
and	CC	O
therapeutic	JJ	O
percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
.	.	O

METHODS	NNP	O
Prospective	NNP	O
study	NN	O
of	IN	O
104	CD	O
consecutive	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
angiography	NN	O
who	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
these	DT	O
techniques	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
amount	NN	Others
of	IN	Others
contrast	NN	Others
administered	VBN	Others
(	(	O
A	DT	O
vs	NN	O
B	NNP	O
,	,	O
93.1	CD	O
[	NN	O
41.7	CD	O
]	NNP	O
vs	NN	O
50.9	CD	O
[	NN	O
14.7	CD	O
]	NNP	O
mL	NN	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
and	CC	O
radiation	NN	Others
exposure	NN	Others
(	(	O
27.6	CD	O
[	RB	O
11.5	CD	O
]	JJ	O
vs	NN	O
18	CD	O
[	NN	O
6.4	CD	O
]	NN	O
mGycm	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
total	JJ	Others
procedure	NN	Others
time	NN	Others
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
rotational	JJ	O
angiography	NN	O
arm	NN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
only	RB	O
the	DT	O
last	JJ	O
50	CD	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
,	,	O
we	PRP	O
found	VBD	O
no	DT	O
difference	NN	O
in	IN	O
procedure	NN	Others
time	NN	Others
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
probably	RB	O
related	VBN	O
to	TO	O
the	DT	O
learning	VBG	O
curve	NN	O
of	IN	O
the	DT	O
operators	NNS	O
.	.	O

Angioplasty	NNP	Physical
was	VBD	O
performed	VBN	O
in	IN	O
29	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
28	CD	O
patients	NNS	O
in	IN	O
group	NN	O
B	NNP	O
.	.	O

Contrast	NNP	Others
reduction	NN	Others
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
rotational	JJ	O
angiography	NN	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
conventional	JJ	O
technique	NN	O
(	(	O
A	NNP	O
vs	NN	O
B	NNP	O
,	,	O
335.1	CD	O
[	NN	O
192.1	CD	O
]	NNP	O
vs	NN	O
238.5	CD	O
[	NN	O
114.4	CD	O
]	NNP	O
mL	NN	O
;	:	O
P=.02	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
rotational	JJ	O
angiography	NN	O
technique	NN	O
leads	VBZ	O
to	TO	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
radiation	NN	Physical
exposure	NN	Physical
and	CC	O
contrast	NN	Others
dose	NN	Others
administered	VBN	O
for	IN	O
diagnostic	JJ	O
procedures	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
conventional	JJ	O
coronary	JJ	O
angiography	NN	O
.	.	O

In	IN	O
patients	NNS	O
who	WP	O
undergo	VBP	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
contrast	NN	O
reduction	NN	O
remains	VBZ	O
significant	JJ	O
.	.	O

Relationship	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
to	TO	O
gastrointestinal	VB	Physical
symptoms	NNS	Physical
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
Gastrointestinal	NNP	O
(	(	O
GI	NNP	O
)	)	O
symptoms	NNS	O
and	CC	O
abnormalities	NNS	O
in	IN	O
stool	NN	O
consistency	NN	O
are	VBP	O
frequently	RB	O
reported	VBN	O
by	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
1	CD	O
)	)	O
describe	NN	O
dietary	JJ	O
intake	NN	O
of	IN	O
a	DT	O
cohort	NN	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
compared	VBN	O
with	IN	O
normative	JJ	O
data	NNS	O
and	CC	O
2	CD	O
)	)	O
determine	NN	O
whether	IN	O
GI	NNP	O
symptoms	NNS	O
and	CC	O
stool	JJ	O
consistency	NN	O
are	VBP	O
related	VBN	O
to	TO	O
dietary	JJ	O
intake	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
from	IN	O
diet	JJ	O
diaries	NNS	O
of	IN	O
children	NNS	O
(	(	O
3-8	CD	O
years	NNS	O
)	)	O
with	IN	O
ASD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
62	CD	O
)	)	O
were	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
registered	JJ	O
pediatric	JJ	O
dietician	NN	O
to	TO	O
compare	VB	O
to	TO	O
RDA	NNP	O
standards	NNS	O
for	IN	O
total	JJ	O
calories	NNS	O
,	,	O
protein	NN	O
,	,	O
carbohydrate	NN	O
,	,	O
and	CC	O
fat	NN	O
.	.	O

Dietary	NNP	O
intake	NN	O
was	VBD	O
correlated	VBN	O
with	IN	O
descriptors	NNS	O
of	IN	O
stool	NN	O
consistency	NN	O
using	VBG	O
cumulative	JJ	O
logistic	JJ	O
regression	NN	O
methods	NNS	O
.	.	O

RESULTS	NNP	O
Intake	NNP	O
of	IN	O
calories	NNS	O
,	,	O
carbohydrates	NNS	O
,	,	O
and	CC	O
fat	NN	O
were	VBD	O
in	IN	O
the	DT	O
average	JJ	O
range	NN	O
;	:	O
protein	CC	O
intake	VB	O
was	VBD	O
increased	VBN	O
(	(	O
211	CD	O
%	NN	O
of	IN	O
RDA	NNP	O
)	)	O
.	.	O

Reported	VBN	O
frequency	NN	Physical
of	IN	Physical
GI	NNP	Physical
abnormalities	NNS	Physical
,	,	O
including	VBG	O
abnormal	JJ	Physical
stool	NN	Physical
consistency	NN	Physical
(	(	O
e.g.	JJ	O
,	,	O
bulky	NN	Physical
or	CC	O
loose	JJ	Physical
)	)	O
,	,	O
was	VBD	O
increased	VBN	O
(	(	O
54	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
relationships	NNS	O
between	IN	O
stool	NN	O
consistency	NN	O
and	CC	O
dietary	JJ	O
intake	NN	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
sample	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
reported	VBN	O
gastrointestinal	JJ	Physical
symptoms	NNS	Physical
,	,	O
despite	IN	O
lack	NN	O
of	IN	O
medical	JJ	O
causes	NNS	O
.	.	O

Intake	NNP	O
was	VBD	O
adequate	JJ	O
for	IN	O
calories	NNS	O
and	CC	O
carbohydrates	NNS	O
and	CC	O
increased	VBD	O
for	IN	O
protein	NN	O
.	.	O

The	DT	O
children	NNS	O
did	VBD	O
not	RB	O
exhibit	VB	O
excessive	JJ	O
carbohydrate	NN	O
intake	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
association	NN	O
of	IN	O
nutrient	JJ	O
intake	NN	O
to	TO	O
changes	NNS	O
in	IN	O
stool	NN	O
consistency	NN	O
.	.	O

Stepwise	NNP	O
assessment	JJ	O
tool	NN	O
of	IN	O
operative	JJ	O
skills	NNS	O
(	(	O
SATOS	NNP	O
)	)	O
:	:	O
validity	NN	O
testing	VBG	O
on	IN	O
a	DT	O
porcine	JJ	O
training	NN	O
model	NN	O
of	IN	O
open	JJ	O
gastrectomy	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
operative	JJ	O
performance	NN	O
and	CC	O
technical	JJ	O
improvement	NN	O
of	IN	O
surgical	JJ	O
trainees	NNS	O
learning	VBG	O
open	JJ	O
gastrectomy	NN	O
using	VBG	O
an	DT	O
objective	JJ	O
structured	JJ	O
stepwise	NN	O
assessment	JJ	O
tool	NN	O
of	IN	O
operative	JJ	O
skills	NNS	O
(	(	O
SATOS	NNP	O
)	)	O
previously	RB	O
validated	VBN	O
for	IN	O
open	JJ	O
surgery	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Thirty	NNP	O
residents	NNS	O
in	IN	O
general	JJ	O
surgery	NN	O
performed	VBD	O
2	CD	O
open	JJ	O
partial	JJ	O
gastrectomy	NN	O
training	VBG	O
events	NNS	O
on	IN	O
a	DT	O
porcine	JJ	O
model	NN	O
.	.	O

Earlier	JJR	O
instruction	NN	O
was	VBD	O
provided	VBN	O
for	IN	O
the	DT	O
critical	JJ	O
operative	JJ	O
steps	NNS	O
,	,	O
with	IN	O
additional	JJ	O
intraoperative	JJ	O
instruction	NN	O
when	WRB	O
required	VBN	O
.	.	O

Performance	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
postgraduate	JJ	Others
year	NN	Others
(	(	Others
PGY	NNP	Others
)	)	Others
according	VBG	O
to	TO	O
operative	JJ	Others
time	NN	Others
,	,	O
technical	JJ	Mental
skills	NNS	Mental
using	VBG	O
a	DT	O
23-step	JJ	Others
objective	NN	Others
structured	VBD	Others
tool	NN	Others
,	,	Others
and	CC	Others
error	NN	Others
rate	NN	Others
.	.	Others

RESULTS	CC	O
There	EX	O
were	VBD	O
11	CD	O
PGY-3	NNP	O
,	,	O
11	CD	O
PGY-4	NN	O
,	,	O
and	CC	O
8	CD	O
PGY-5	JJ	O
residents	NNS	O
.	.	O

At	IN	O
the	DT	O
initial	JJ	O
assessment	NN	O
,	,	O
performance	NN	O
significantly	RB	O
differentiated	VBD	O
the	DT	O
3	CD	O
PGY	NNP	O
grades	NNS	O
according	VBG	O
to	TO	O
technical	JJ	Others
skills	NNS	Others
and	CC	Others
error	NN	Others
rate	NN	Others
.	.	Others

At	IN	O
the	DT	O
second	JJ	O
assessment	NN	O
,	,	O
all	DT	O
3	CD	O
PGY	NNP	O
classes	NNS	O
were	VBD	O
still	RB	O
significantly	RB	O
differentiable	JJ	O
by	IN	O
technical	JJ	Others
skills	NNS	Others
,	,	Others
with	IN	Others
no	DT	Others
difference	NN	Others
in	IN	Others
error	NN	Others
rate	NN	Others
.	.	Others

Comparing	NNP	O
performances	NNS	O
,	,	O
residents	NNS	O
improved	VBD	O
operative	JJ	Others
time	NN	Others
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
technical	JJ	Others
skills	NNS	Others
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
error	NN	Others
rate	NN	Others
(	(	O
p	JJ	O
=	NNP	O
0.019	CD	O
)	)	O
over	IN	O
the	DT	O
2	CD	O
training	NN	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
SATOS	NNP	O
demonstrated	VBD	O
relevant	JJ	Others
and	CC	Others
accurate	JJ	Others
objective	JJ	Others
assessment	NN	Others
of	IN	O
trainees	NNS	O
'	POS	O
operative	JJ	Others
skills	NNS	Others
and	CC	Others
improvement	NN	Others
for	IN	O
open	JJ	O
gastrectomy	NN	O
in	IN	O
a	DT	O
porcine	JJ	O
model	NN	O
.	.	O

This	DT	O
tool	NN	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
standardize	VB	O
instruction	NN	O
,	,	O
to	TO	O
expose	VB	O
weaknesses	NNS	O
of	IN	O
trainees	NNS	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
minimal	JJ	O
technical	JJ	O
standards	NNS	O
in	IN	O
residency	NN	O
programs	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
guided	JJ	O
imagery	NN	O
with	IN	O
relaxation	NN	O
training	NN	O
on	IN	O
anxiety	NN	Mental
and	CC	O
quality	NN	Mental
of	IN	Mental
life	NN	Mental
among	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
Inflammatory	NNP	O
Bowel	NNP	O
Disease	NNP	O
(	(	O
IBD	NNP	O
)	)	O
impacts	VBZ	O
quality	NN	Others
of	IN	Others
life	NN	Others
(	(	O
QoL	NNP	O
)	)	O
.	.	O

Psychological	JJ	O
factors	NNS	O
influence	VBP	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
should	MD	O
be	VB	O
targeted	VBN	O
for	IN	O
intervention	NN	O
.	.	O

METHODS	NNP	O
Our	PRP$	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
control	NN	O
trial	NN	O
.	.	O

Fifty-six	JJ	O
outpatients	NNS	O
were	VBD	O
randomly	RB	O
chosen	VBN	O
and	CC	O
allocated	VBN	O
to	TO	O
a	DT	O
treatment	NN	O
group	NN	O
or	CC	O
a	DT	O
waiting-list	JJ	O
control	NN	O
group	NN	O
.	.	O

Treatment	NNP	O
group	NN	O
patients	NNS	O
attended	VBD	O
three	CD	O
relaxation-training	JJ	O
sessions	NNS	O
and	CC	O
received	VBD	O
an	DT	O
audio	JJ	O
disc	NN	O
for	IN	O
home	NN	O
practice	NN	O
.	.	O

Evaluations	NNS	O
performed	VBD	O
pre	JJ	O
and	CC	O
post-treatment	JJ	O
:	:	O
state	NN	Mental
anxiety	NN	Mental
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
State-Trait	NNP	Mental
Anxiety	NNP	Mental
Inventory	NNP	Mental
,	,	Mental
QoL	NNP	Mental
with	IN	Mental
the	DT	Mental
IBD	NNP	Mental
Questionnaire	NNP	Mental
.	.	O

The	DT	O
Visual	NNP	Others
Analogue	NNP	Others
Scale	NNP	Others
assessed	VBD	O
pain	NN	Pain
,	,	O
depression	NN	Mental
,	,	O
stress	NN	Mental
and	CC	O
mood	NN	Mental
.	.	O

Patients	NNS	O
completed	VBD	O
a	DT	O
symptom	JJ	O
monitoring	NN	O
diary	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
's	POS	O
symptoms	NNS	O
were	VBD	O
monitored	VBN	O
without	IN	O
study-related	JJ	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Thirty-nine	JJ	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
data	NN	O
analysis	NN	O
.	.	O

Following	VBG	O
the	DT	O
relaxation-training	JJ	O
intervention	NN	O
,	,	O
the	DT	O
treatment	NN	O
group	NN	O
's	POS	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
measured	VBN	O
results	NNS	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
(	(	O
time	NN	O
by	IN	O
treatment	NN	O
interaction	NN	O
)	)	O
:	:	O
anxiety	NN	O
levels	NNS	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
QoL	NNP	O
and	CC	O
mood	NN	O
improved	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
while	IN	O
levels	NNS	O
of	IN	O
pain	NN	O
and	CC	O
stress	NN	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Findings	NNP	O
indicate	VBP	O
IBD	NNP	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
relaxation	NN	O
training	NN	O
in	IN	O
their	PRP$	O
holistic	JJ	O
care	NN	O
.	.	O

New	NNP	O
studies	NNS	O
as	RB	O
well	RB	O
as	IN	O
further	JJ	O
investigation	NN	O
of	IN	O
the	DT	O
subject	NN	O
are	VBP	O
warranted	VBN	O
.	.	O

Prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
of	IN	O
transperitoneal	JJ	O
versus	NN	O
retroperitoneal	NN	O
laparoscopic	JJ	O
adrenalectomy	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
report	VBP	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
of	IN	O
transperitoneal	JJ	O
laparoscopic	JJ	O
adrenalectomy	NN	O
(	(	O
TLA	NNP	O
)	)	O
vs	FW	O
retroperitoneal	JJ	O
laparoscopic	NN	O
adrenalectomy	NN	O
(	(	O
RLA	NNP	O
)	)	O
for	IN	O
adrenal	JJ	O
lesions	NNS	O
with	IN	O
long-term	JJ	O
followup	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
December	NNP	O
1997	CD	O
and	CC	O
November	NNP	O
1999	CD	O
,	,	O
57	CD	O
consecutive	JJ	O
eligible	JJ	O
patients	NNS	O
with	IN	O
surgical	JJ	O
adrenal	JJ	O
disease	NN	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
undergo	VB	O
TLA	NNP	O
(	(	O
25	CD	O
)	)	O
or	CC	O
RLA	NNP	O
(	(	O
32	CD	O
)	)	O
.	.	O

Study	NNP	O
exclusion	NN	O
criteria	NNS	O
were	VBD	O
patient	JJ	O
age	NN	O
greater	JJR	O
than	IN	O
80	CD	O
years	NNS	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
greater	JJR	O
than	IN	O
40	CD	O
,	,	O
bilateral	JJ	O
adrenalectomy	NN	O
and	CC	O
significant	JJ	O
prior	JJ	O
abdominal	JJ	O
surgery	NN	O
in	IN	O
the	DT	O
quadrant	NN	O
of	IN	O
interest	NN	O
.	.	O

Mean	NNP	O
followup	NN	O
was	VBD	O
5.96	CD	O
years	NNS	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
were	VBD	O
matched	VBN	O
in	IN	O
regard	NN	O
to	TO	O
patient	JJ	O
age	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.84	CD	O
)	)	O
,	,	O
body	JJ	O
mass	NN	O
index	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.43	CD	O
)	)	O
,	,	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
class	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.81	CD	O
)	)	O
and	CC	O
laterality	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.12	CD	O
)	)	O
.	.	O

Median	JJ	O
adrenal	JJ	Physical
mass	NN	Physical
size	NN	Physical
was	VBD	O
2.7	CD	O
cm	NN	O
(	(	O
range	VB	O
1	CD	O
to	TO	O
9	CD	O
)	)	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
and	CC	O
2.6	CD	O
cm	NN	O
(	(	O
range	VB	O
0.5	CD	O
to	TO	O
6	CD	O
)	)	O
in	IN	O
the	DT	O
RLA	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.83	CD	O
)	)	O
.	.	O

TLA	NNP	O
was	VBD	O
comparable	JJ	O
to	TO	O
RLA	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
operative	JJ	Others
time	NN	Others
(	(	O
130	CD	O
vs	NN	O
126.5	CD	O
minutes	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.64	CD	O
)	)	O
,	,	O
estimated	VBN	Physical
blood	NN	Physical
loss	NN	Physical
(	(	O
p	JJ	O
=	NNP	O
0.92	CD	O
)	)	O
,	,	O
specimen	NNS	Physical
weight	VBD	Physical
(	(	O
p	JJ	O
=	NNP	O
0.81	CD	O
)	)	O
,	,	O
analgesic	JJ	Pain
requirements	NNS	Pain
(	(	O
p	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
,	,	O
hospital	JJ	Others
stay	NN	Others
(	(	O
p	JJ	O
=	NNP	O
0.56	CD	O
)	)	O
and	CC	O
the	DT	O
complication	NN	Adverseeffect
rate	NN	Adverseeffect
(	(	O
p	JJ	O
=	NNP	O
0.58	CD	O
)	)	O
.	.	O

One	CD	O
case	NN	O
per	IN	O
group	NN	O
was	VBD	O
electively	RB	O
converted	VBN	O
to	TO	O
open	VB	O
surgery	NN	O
.	.	O

Pathology	NNP	O
data	NNS	O
on	IN	O
the	DT	O
intact	JJ	O
extracted	JJ	O
specimens	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Averaged	VBD	O
convalescence	NN	Others
was	VBD	O
4.7	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
and	CC	O
2.3	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
RLA	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

During	IN	O
a	DT	O
mean	JJ	O
followup	NN	O
of	IN	O
6	CD	O
years	NNS	O
2	CD	O
patients	NNS	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
had	VBD	O
a	DT	O
late	JJ	Adverseeffect
complication	NN	Adverseeffect
(	(	Adverseeffect
port	JJ	Adverseeffect
site	NN	Adverseeffect
hernia	NN	Adverseeffect
)	)	Adverseeffect
.	.	O

Mortality	NN	Mortality
occurred	VBD	O
in	IN	O
5	CD	O
patients	NNS	O
,	,	O
including	VBG	O
1	CD	O
with	IN	O
TLA	NNP	O
and	CC	O
4	CD	O
with	IN	O
RLA	NNP	O
,	,	O
during	IN	O
the	DT	O
6-year	JJ	O
followup	NN	O
.	.	O

CONCLUSIONS	NNP	O
For	IN	O
most	JJS	O
benign	JJ	O
adrenal	JJ	O
lesions	NNS	O
requiring	VBG	O
surgery	NN	O
laparoscopic	NN	O
adrenalectomy	NN	O
can	MD	O
be	VB	O
performed	VBN	O
safely	RB	Others
and	CC	O
effectively	RB	Others
by	IN	O
the	DT	O
transperitoneal	NN	O
or	CC	O
the	DT	O
retroperitoneal	JJ	O
approach	NN	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	JJ	O
versus	NN	O
procainamide	NN	O
for	IN	O
enhancing	VBG	O
termination	NN	O
of	IN	O
atrial	JJ	O
flutter	NN	O
by	IN	O
atrial	JJ	O
overdrive	JJ	O
pacing	NN	O
.	.	O

This	DT	O
study	NN	O
compares	VBZ	O
the	DT	O
influence	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	NN	O
,	,	O
a	DT	O
class	NN	O
III	NNP	O
antiarrhythmic	JJ	O
agent	NN	O
,	,	O
with	IN	O
procainamide	NN	O
,	,	O
a	DT	O
class	NN	O
IA	NNP	O
antiarrhythmic	JJ	O
agent	NN	O
,	,	O
and	CC	O
with	IN	O
placebo	NN	O
on	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
terminate	VB	O
atrial	JJ	O
flutter	NN	O
using	VBG	O
rapid	JJ	O
atrial	JJ	O
pacing	NN	O
.	.	O

Fifty-nine	NNP	O
episodes	NNS	O
of	IN	O
atrial	JJ	O
flutter	NN	O
in	IN	O
54	CD	O
patients	NNS	O
who	WP	O
failed	VBD	O
to	TO	O
terminate	VB	O
with	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
ibutilide	NN	O
,	,	O
procainamide	NN	O
,	,	O
or	CC	O
placebo	VB	O
alone	JJ	O
underwent	JJ	O
attempts	NNS	O
at	IN	O
pacing	VBG	O
termination	NN	O
using	VBG	O
a	DT	O
standard	JJ	O
protocol	NN	O
of	IN	O
burst	JJ	O
atrial	JJ	O
overdrive	JJ	O
pacing	NN	O
.	.	O

Atrial	JJ	O
flutter	NN	O
cycle	NN	O
length	NN	O
and	CC	O
atrial	JJ	O
monophasic	JJ	O
action	NN	O
potential	JJ	O
duration	NN	O
recorded	VBN	O
from	IN	O
the	DT	O
right	JJ	O
atrium	NN	O
during	IN	O
atrial	JJ	O
flutter	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
following	VBG	O
infusion	NN	O
of	IN	O
ibutilide	NN	O
,	,	O
procainamide	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Both	DT	O
ibutilide	JJ	O
and	CC	O
procainamide	JJ	O
significantly	RB	O
enhanced	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
pacing-induced	JJ	Others
termination	NN	Others
of	IN	Others
atrial	JJ	Others
flutter	NN	Others
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Pacing	VBG	O
converted	VBD	O
2	CD	O
of	IN	O
11	CD	O
patients	NNS	O
(	(	O
18	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
placebo	NN	O
,	,	O
13	CD	O
of	IN	O
15	CD	O
patients	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
ibutilide	RB	O
,	,	O
and	CC	O
29	CD	O
of	IN	O
33	CD	O
patients	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
procainamide	RB	O
to	TO	O
sinus	VB	Physical
rhythm	NN	Physical
.	.	Physical

Ibutilide	NNP	O
and	CC	O
procainamide	RB	O
compared	VBN	O
with	IN	O
placebo	NN	O
markedly	RB	O
reduced	VBD	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
pacing-induced	JJ	Physical
atrial	JJ	Physical
fibrillation	NN	Physical
.	.	Physical

The	DT	Physical
atrial	JJ	Physical
flutter	NN	Physical
cycle	NN	Physical
length	NN	Physical
was	VBD	O
prolonged	VBN	O
significantly	RB	O
less	RBR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
atrial	JJ	Physical
monophasic	JJ	Physical
action	NN	Physical
potential	JJ	Physical
duration	NN	Physical
was	VBD	O
increased	VBN	O
significantly	RB	O
more	RBR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
by	IN	O
ibutilide	NN	O
than	IN	O
by	IN	O
procainamide	NN	O
.	.	O

Although	IN	O
the	DT	O
electrophysiologic	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
these	DT	O
antiarrhythmic	JJ	O
agents	NNS	O
contributed	VBD	O
to	TO	O
facilitating	VBG	O
pacing-induced	JJ	O
termination	NN	O
,	,	O
neither	CC	O
tachycardia	JJ	Physical
cycle	NN	Physical
length	NN	Physical
nor	CC	Physical
action	NN	Physical
potential	JJ	Physical
duration	NN	Physical
were	VBD	O
useful	JJ	O
predictors	NNS	O
of	IN	O
the	DT	O
ability	NN	O
of	IN	O
pacing	VBG	O
to	TO	O
terminate	VB	O
atrial	JJ	O
flutter	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
despite	IN	O
differing	VBG	O
electrophysiologic	JJ	O
effects	NNS	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	NN	O
or	CC	O
procainamide	NN	O
enhances	VBZ	O
the	DT	O
termination	NN	Physical
of	IN	Physical
atrial	JJ	Physical
flutter	NN	Physical
by	IN	Physical
atrial	JJ	Physical
overdrive	JJ	Physical
pacing	NN	Physical
.	.	Physical

Conduit	NNP	O
artery	NN	O
structure	NN	O
and	CC	O
function	NN	O
in	IN	O
lowlanders	NNS	O
and	CC	O
native	JJ	O
highlanders	NNS	O
:	:	O
relationships	NNS	O
with	IN	O
oxidative	JJ	O
stress	NN	O
and	CC	O
role	NN	O
of	IN	O
sympathoexcitation	NN	O
.	.	O

Research	NNP	O
detailing	VBG	O
the	DT	O
normal	JJ	O
vascular	JJ	O
adaptions	NNS	O
to	TO	O
high	JJ	O
altitude	NN	O
is	VBZ	O
minimal	JJ	O
and	CC	O
often	RB	O
confounded	VBN	O
by	IN	O
pathology	NN	O
(	(	O
e.g.	JJ	O
,	,	O
chronic	JJ	O
mountain	NN	O
sickness	NN	O
)	)	O
and	CC	O
methodological	JJ	O
issues	NNS	O
.	.	O

We	PRP	O
examined	VBD	O
vascular	JJ	O
function	NN	O
and	CC	O
structure	NN	O
in	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
healthy	JJ	O
lowlanders	NNS	O
during	IN	O
acute	JJ	O
hypoxia	NN	O
and	CC	O
prolonged	JJ	O
(	(	O
?2	JJ	O
weeks	NNS	O
)	)	O
exposure	NN	O
to	TO	O
high	JJ	O
altitude	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
high-altitude	NN	O
natives	NNS	O
at	IN	O
5050	CD	O
m	NN	O
(	(	O
highlanders	NNS	O
)	)	O
.	.	O

In	IN	O
12	CD	O
healthy	JJ	O
lowlanders	NNS	O
(	(	O
aged	VBN	O
32	CD	O
?	.	O
7	CD	O
years	NNS	O
)	)	O
and	CC	O
12	CD	O
highlanders	NNS	O
(	(	O
Sherpa	NNP	O
;	:	O
33	CD	O
?	.	O
14	CD	O
years	NNS	O
)	)	O
we	PRP	O
assessed	VBD	O
brachial	JJ	O
endothelium-dependent	JJ	O
flow-mediated	JJ	O
dilatation	NN	O
(	(	O
FMD	NNP	O
)	)	O
,	,	O
endothelium-independent	JJ	O
dilatation	NN	O
(	(	O
via	IN	O
glyceryl	NN	O
trinitrate	NN	O
;	:	O
GTN	NNP	O
)	)	O
,	,	O
common	JJ	O
carotid	NN	O
intima-media	JJ	O
thickness	NN	O
(	(	O
CIMT	NNP	O
)	)	O
and	CC	O
diameter	NN	O
(	(	O
ultrasound	JJ	O
)	)	O
,	,	O
and	CC	O
arterial	JJ	O
stiffness	NN	O
via	IN	O
pulse	JJ	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
;	:	O
applanation	NN	O
tonometry	NN	O
)	)	O
.	.	O

Cephalic	NNP	O
venous	JJ	O
biomarkers	NNS	O
of	IN	O
free	JJ	O
radical-mediated	JJ	O
lipid	JJ	O
peroxidation	NN	O
(	(	O
lipid	JJ	O
hydroperoxides	NNS	O
,	,	O
LOOH	NNP	O
)	)	O
,	,	O
nitrite	JJ	O
(	(	O
NO2-	NNP	O
)	)	O
and	CC	O
lipid	JJ	O
soluble	JJ	O
antioxidants	NNS	O
were	VBD	O
also	RB	O
obtained	VBN	O
at	IN	O
rest	NN	O
.	.	O

In	IN	O
lowlanders	NNS	O
,	,	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
sea	NN	O
level	NN	O
(	(	O
334	CD	O
m	NN	O
)	)	O
and	CC	O
between	IN	O
days	NNS	O
3-4	NNP	O
(	(	O
acute	JJ	O
high	JJ	O
altitude	NN	O
)	)	O
and	CC	O
12-14	JJ	O
(	(	O
chronic	JJ	O
high	JJ	O
altitude	NN	O
)	)	O
following	VBG	O
arrival	NN	O
to	TO	O
5050	CD	O
m.	NN	O
Highlanders	NNP	O
were	VBD	O
assessed	VBN	O
once	RB	O
at	IN	O
5050	CD	O
m.	NN	O
Compared	NNP	O
with	IN	O
sea	NN	O
level	NN	O
,	,	O
acute	JJ	O
high	JJ	O
altitude	NN	O
reduced	VBD	O
lowlanders	NNS	O
'	POS	O
FMD	NNP	O
(	(	O
7.9	CD	O
?	.	O
0.4	CD	O
vs.	IN	O
6.8	CD	O
?	.	O
0.4	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
GTN-induced	JJ	O
dilatation	NN	O
(	(	O
16.6	CD	O
?	.	O
0.9	CD	O
vs.	IN	O
14.5	CD	O
?	.	O
0.8	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
and	CC	O
raised	VBD	O
central	JJ	O
PWV	NNP	O
(	(	O
6.0	CD	O
?	.	O
0.2	CD	O
vs.	IN	O
6.6	CD	O
?	.	O
0.3	CD	O
m	NN	O
s	NN	O
(	(	O
-1	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

These	DT	O
changes	NNS	O
persisted	VBD	O
at	IN	O
days	NNS	O
12-14	CD	O
,	,	O
and	CC	O
after	IN	O
allometrically	RB	O
scaling	VBG	O
FMD	NNP	O
to	TO	O
adjust	VB	O
for	IN	O
altered	JJ	O
baseline	NN	O
diameter	NN	O
.	.	O

Compared	VBN	O
to	TO	O
lowlanders	NNS	O
at	IN	O
sea	NN	O
level	NN	O
and	CC	O
high	JJ	O
altitude	NN	O
,	,	O
highlanders	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
carotid	NN	Physical
wall	NN	Physical
:	:	Physical
lumen	NNS	Physical
ratio	VBP	Physical
(	(	O
?19	CD	O
%	NN	O
,	,	O
P	NNP	O
?	.	O
0.04	CD	O
)	)	O
,	,	O
attributable	JJ	O
to	TO	O
a	DT	O
narrower	JJR	O
CIMT	NNP	O
and	CC	O
wider	JJR	O
lumen	NNS	O
.	.	O

Although	IN	O
both	DT	O
LOOH	NNP	Physical
and	CC	O
NO2-	NNP	Physical
increased	VBD	O
with	IN	O
high	JJ	O
altitude	NN	O
in	IN	O
lowlanders	NNS	O
,	,	O
only	RB	O
LOOH	NNP	O
correlated	VBD	O
with	IN	O
the	DT	O
reduction	NN	O
in	IN	O
GTN-induced	NNP	O
dilatation	NN	O
evident	NN	O
during	IN	O
acute	NN	O
(	(	O
n	JJ	O
=	NN	O
11	CD	O
,	,	O
r	NN	O
=	NNP	O
-0.53	NNP	O
)	)	O
and	CC	O
chronic	JJ	O
(	(	O
n	JJ	O
=	NN	O
7	CD	O
,	,	O
r	NN	O
=	NNP	O
-0.69	NNP	O
;	:	O
P	NNP	O
?	.	O
0.01	CD	O
)	)	O
exposure	NN	O
to	TO	O
5050	CD	O
m.	NN	O
In	IN	O
a	DT	O
follow-up	JJ	O
,	,	O
placebo-controlled	JJ	O
experiment	NN	O
(	(	O
n	JJ	O
=	$	O
11	CD	O
healthy	JJ	O
lowlanders	NNS	O
)	)	O
conducted	VBN	O
in	IN	O
a	DT	O
normobaric	JJ	O
hypoxic	NN	O
chamber	NN	O
(	(	O
inspired	JJ	O
O2	NNP	O
fraction	NN	O
(	(	O
F	NNP	O
IO	NNP	O
2	CD	O
)	)	O
=	NN	O
0.11	CD	O
;	:	O
6	CD	O
h	NN	O
)	)	O
,	,	O
a	DT	O
sustained	JJ	O
reduction	NN	O
in	IN	O
FMD	NNP	O
was	VBD	O
evident	JJ	O
within	IN	O
1	CD	O
h	NN	O
of	IN	O
hypoxic	NN	O
exposure	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
normoxic	VB	O
baseline	NN	O
(	(	O
5.7	CD	O
?	.	O
1.6	CD	O
vs.	IN	O
8.0	CD	O
?1.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
this	DT	O
decline	NN	O
in	IN	O
FMD	NNP	O
was	VBD	O
largely	RB	O
reversed	JJ	O
following	VBG	O
?1-adrenoreceptor	NN	O
blockade	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
high-altitude	JJ	O
exposure	NN	O
in	IN	O
lowlanders	NNS	O
caused	VBD	O
persistent	JJ	O
impairment	NN	O
in	IN	O
vascular	JJ	O
function	NN	O
,	,	O
which	WDT	O
was	VBD	O
mediated	VBN	O
partially	RB	O
via	IN	O
oxidative	JJ	O
stress	NN	O
and	CC	O
sympathoexcitation	NN	O
.	.	O

Although	IN	O
a	DT	O
lifetime	NN	O
of	IN	O
high-altitude	JJ	O
exposure	NN	O
neither	CC	O
intensifies	NNS	O
nor	CC	O
attenuates	VBZ	O
the	DT	O
impairments	NNS	O
seen	VBN	O
with	IN	O
short-term	JJ	O
exposure	NN	O
,	,	O
chronic	JJ	O
high-altitude	NN	O
exposure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
arterial	JJ	O
remodelling	NN	O
.	.	O

Randomised	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
fluticasone	NN	O
propionate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
:	:	O
the	DT	O
ISOLDE	NNP	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
long	JJ	O
term	NN	O
inhaled	VBN	O
corticosteroids	NNS	O
on	IN	O
lung	NN	Physical
function	NN	Physical
,	,	Physical
exacerbations	NNS	Physical
,	,	Physical
and	CC	Physical
health	NN	Physical
status	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

DESIGN	NNP	O
Double	NNP	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Eighteen	NNP	O
UK	NNP	O
hospitals	NNS	O
.	.	O

PARTICIPANTS	VB	O
751	CD	O
men	NNS	O
and	CC	O
women	NNS	O
aged	VBD	O
between	IN	O
40	CD	O
and	CC	O
75	CD	O
years	NNS	O
with	IN	O
mean	NN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
50	CD	O
%	NN	O
of	IN	O
predicted	VBN	O
normal	JJ	O
.	.	O

INTERVENTIONS	NNP	O
Inhaled	VBD	O
fluticasone	NN	O
propionate	NN	O
500	CD	O
microgram	NN	O
twice	RB	O
daily	RB	O
from	IN	O
a	DT	O
metered	VBN	O
dose	JJ	O
inhaler	NN	O
or	CC	O
identical	JJ	O
placebo	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Efficacy	NNP	Others
measures	NNS	O
:	:	O
rate	NN	Physical
of	IN	Physical
decline	NN	Physical
in	IN	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
after	IN	Physical
the	DT	Physical
bronchodilator	NN	Physical
and	CC	Physical
in	IN	Physical
health	NN	Physical
status	NN	Physical
,	,	Physical
frequency	NN	Physical
of	IN	Physical
exacerbations	NNS	Physical
,	,	O
respiratory	JJ	Physical
withdrawals	NNS	Physical
.	.	O

Safety	NN	O
measures	NNS	O
:	:	O
morning	NN	Physical
serum	NN	Physical
cortisol	NN	Physical
concentration	NN	Physical
,	,	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	Physical
significant	JJ	Physical
difference	NN	Physical
in	IN	O
the	DT	O
annual	JJ	Physical
rate	NN	Physical
of	IN	Physical
decline	NN	Physical
in	IN	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
(	(	Physical
P=0.16	NNP	Physical
)	)	Physical
.	.	O

Mean	JJ	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
after	IN	O
bronchodilator	NN	O
remained	VBD	O
significantly	RB	Physical
higher	JJR	Physical
throughout	IN	O
the	DT	O
study	NN	O
with	IN	O
fluticasone	NN	O
propionate	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Median	JJ	Physical
exacerbation	NN	Physical
rate	NN	Physical
was	VBD	O
reduced	VBN	O
by	IN	O
25	CD	O
%	NN	O
from	IN	O
1.32	CD	O
a	DT	O
year	NN	O
on	IN	O
placebo	NN	O
to	TO	O
0.99	CD	O
a	DT	O
year	NN	O
on	IN	O
with	IN	O
fluticasone	NN	O
propionate	NN	O
(	(	O
P=0.026	NNP	O
)	)	O
.	.	O

Health	NNP	Physical
status	NN	Physical
deteriorated	VBN	Physical
by	IN	O
3.2	CD	O
units	NNS	O
a	DT	O
year	NN	O
on	IN	O
placebo	NN	O
and	CC	O
2.0	CD	O
units	NNS	O
a	DT	O
year	NN	O
on	IN	O
fluticasone	NN	O
propionate	NN	O
(	(	O
P=0.0043	NNP	O
)	)	O
.	.	O

Withdrawals	NNS	Others
because	IN	O
of	IN	O
respiratory	NN	O
disease	NN	O
not	RB	O
related	VBN	O
to	TO	O
malignancy	NN	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
25	CD	O
%	NN	O
v	JJ	O
19	CD	O
%	NN	O
,	,	O
P=0.034	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Fluticasone	NNP	O
propionate	NN	O
500	CD	O
microgram	NN	O
twice	RB	O
daily	RB	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
rate	NN	Physical
of	IN	Physical
decline	NN	Physical
in	IN	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
but	CC	O
did	VBD	O
produce	VB	Physical
a	DT	Physical
small	JJ	Physical
increase	NN	Physical
in	IN	Physical
FEV	NNP	Physical
(	(	Physical
1	CD	Physical
)	)	Physical
.	.	Physical

Patients	NNS	O
on	IN	O
fluticasone	NN	O
propionate	NN	O
had	VBD	O
fewer	JJR	O
exacerbations	NNS	Physical
and	CC	O
a	DT	O
slower	JJR	Physical
decline	NN	Physical
in	IN	Physical
health	NN	Physical
status	NN	Physical
.	.	O

These	DT	O
improvements	NNS	O
in	IN	O
clinical	JJ	O
outcomes	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

Can	MD	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
(	(	O
statins	NNS	O
)	)	O
slow	VBP	O
the	DT	O
progression	NN	O
of	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
?	.	O
The	DT	O
age-related	JJ	O
maculopathy	NN	O
statin	NN	O
study	NN	O
(	(	O
ARMSS	NNP	O
)	)	O
.	.	O

Age-related	JJ	O
macular	JJ	O
degeneration	NN	O
(	(	O
AMD	NNP	O
)	)	O
is	VBZ	O
responsible	JJ	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
visual	JJ	O
impairment	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
cholesterol-lowering	JJ	O
medications	NNS	O
,	,	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
or	CC	O
statins	NNS	O
,	,	O
in	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
AMD	NNP	O
or	CC	O
of	IN	O
delaying	VBG	O
its	PRP$	O
progression	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
fully	RB	O
investigated	VBN	O
.	.	O

A	DT	O
3-year	JJ	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
40	CD	O
mg	NN	O
simvastatin	NN	O
per	IN	O
day	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
subjects	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
of	IN	O
AMD	NNP	O
progression	NN	O
is	VBZ	O
described	VBN	O
.	.	O

This	DT	O
paper	NN	O
outlines	VBZ	O
the	DT	O
primary	JJ	O
aims	NNS	O
of	IN	O
the	DT	O
Age-Related	NNP	O
Maculopathy	NNP	O
Statin	NNP	O
Study	NNP	O
(	(	O
ARMSS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
methodology	NN	O
involved	VBN	O
.	.	O

Standardized	NNP	O
clinical	JJ	O
grading	NN	O
of	IN	O
macular	JJ	O
photographs	NN	O
and	CC	O
comparison	NN	O
of	IN	O
serial	JJ	O
macular	JJ	O
digital	NN	O
photographs	NN	O
,	,	O
using	VBG	O
the	DT	O
International	NNP	O
grading	NN	O
scheme	NN	O
,	,	O
form	VB	O
the	DT	O
basis	NN	O
for	IN	O
assessment	NN	O
of	IN	O
primary	JJ	O
study	NN	O
outcomes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
macular	JJ	O
function	NN	O
is	VBZ	O
assessed	VBN	O
at	IN	O
each	DT	O
visit	NN	O
with	IN	O
detailed	JJ	O
psychophysical	JJ	O
measurements	NNS	O
of	IN	O
rod	NN	O
and	CC	O
cone	NN	O
function	NN	O
.	.	O

Information	NN	O
collected	VBN	O
in	IN	O
this	DT	O
study	NN	O
will	MD	O
assist	VB	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
the	DT	O
potential	JJ	O
value	NN	O
of	IN	O
HMG	NNP	O
Co-A	NNP	O
reductase	NN	O
inhibitors	NNS	O
(	(	O
statins	NNS	O
)	)	O
in	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
AMD	NNP	O
progression	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
laparoscopically	RB	O
assisted	VBN	O
and	CC	O
open	JJ	O
colectomy	NN	O
for	IN	O
colon	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Minimally	NNP	O
invasive	JJ	O
,	,	O
laparoscopically	RB	O
assisted	VBN	O
surgery	NN	O
was	VBD	O
first	RB	O
considered	VBN	O
in	IN	O
1990	CD	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
colectomy	NN	O
for	IN	O
cancer	NN	O
.	.	O

Concern	VB	O
that	IN	O
this	DT	O
approach	NN	O
would	MD	O
compromise	VB	O
survival	NN	O
by	IN	O
failing	VBG	O
to	TO	O
achieve	VB	O
a	DT	O
proper	JJ	O
oncologic	JJ	O
resection	NN	O
or	CC	O
adequate	JJ	O
staging	NN	O
or	CC	O
by	IN	O
altering	VBG	O
patterns	NNS	O
of	IN	O
recurrence	NN	O
(	(	O
based	VBN	O
on	IN	O
frequent	JJ	O
reports	NNS	O
of	IN	O
tumor	NN	O
recurrences	NNS	O
within	IN	O
surgical	JJ	O
wounds	NNS	O
)	)	O
prompted	VBD	O
a	DT	O
controlled	VBN	O
trial	NN	O
evaluation	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
noninferiority	NN	O
trial	NN	O
at	IN	O
48	CD	O
institutions	NNS	O
and	CC	O
randomly	RB	O
assigned	VBD	O
872	CD	O
patients	NNS	O
with	IN	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
colon	NN	O
to	TO	O
undergo	VB	O
open	JJ	O
or	CC	O
laparoscopically	RB	O
assisted	VBN	O
colectomy	NN	O
performed	VBN	O
by	IN	O
credentialed	JJ	O
surgeons	NNS	O
.	.	O

The	DT	O
median	JJ	O
follow-up	NN	O
was	VBD	O
4.4	CD	O
years	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
time	NN	Others
to	TO	Others
tumor	VB	Others
recurrence	NN	Others
.	.	Others

RESULTS	NN	O
At	IN	O
three	CD	O
years	NNS	O
,	,	O
the	DT	O
rates	NNS	Others
of	IN	Others
recurrence	NN	Others
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
--	:	O
16	CD	O
percent	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
underwent	JJ	O
laparoscopically	RB	O
assisted	VBN	O
surgery	NN	O
and	CC	O
18	CD	O
percent	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
open-colectomy	JJ	O
group	NN	O
(	(	O
two-sided	JJ	O
P=0.32	NNP	O
;	:	O
hazard	PRP$	O
ratio	NN	O
for	IN	O
recurrence	NN	O
,	,	O
0.86	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.63	CD	O
to	TO	O
1.17	CD	O
)	)	O
.	.	O

Recurrence	NN	Others
rates	NNS	Others
in	IN	Others
surgical	JJ	Others
wounds	NNS	Others
were	VBD	O
less	JJR	O
than	IN	O
1	CD	O
percent	NN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
P=0.50	NNP	O
)	)	O
.	.	O

The	DT	O
overall	JJ	Mortality
survival	NN	Mortality
rate	NN	Mortality
at	IN	O
three	CD	O
years	NNS	O
was	VBD	O
also	RB	O
very	RB	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
86	CD	O
percent	NN	O
in	IN	O
the	DT	O
laparoscopic-surgery	JJ	O
group	NN	O
and	CC	O
85	CD	O
percent	NN	O
in	IN	O
the	DT	O
open-colectomy	JJ	O
group	NN	O
;	:	O
P=0.51	NNP	O
;	:	O
hazard	PRP$	Mortality
ratio	NN	Mortality
for	IN	Mortality
death	NN	Mortality
in	IN	O
the	DT	O
laparoscopic-surgery	JJ	O
group	NN	O
,	,	O
0.91	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.68	CD	O
to	TO	O
1.21	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
time	NN	Others
to	TO	Others
recurrence	VB	Others
or	CC	O
overall	JJ	Mortality
survival	NN	Mortality
for	IN	O
patients	NNS	O
with	IN	O
any	DT	O
stage	NN	O
of	IN	O
cancer	NN	O
.	.	O

Perioperative	JJ	Physical
recovery	NN	Physical
was	VBD	O
faster	RBR	O
in	IN	O
the	DT	O
laparoscopic-surgery	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
open-colectomy	JJ	O
group	NN	O
,	,	O
as	IN	O
reflected	VBN	O
by	IN	O
a	DT	O
shorter	NN	O
median	JJ	Others
hospital	NN	Others
stay	NN	Others
(	(	O
five	CD	O
days	NNS	O
vs.	FW	O
six	CD	O
days	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
briefer	VBP	O
use	NN	O
of	IN	O
parenteral	JJ	O
narcotics	NNS	O
(	(	O
three	CD	O
days	NNS	O
vs.	FW	O
four	CD	O
days	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
oral	JJ	O
analgesics	NNS	O
(	(	O
one	CD	O
day	NN	O
vs.	FW	O
two	CD	O
days	NNS	O
,	,	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
rates	NNS	O
of	IN	O
intraoperative	JJ	Adverseeffect
complications	NNS	Adverseeffect
,	,	O
30-day	JJ	Mortality
postoperative	JJ	Mortality
mortality	NN	Mortality
,	,	O
complications	NNS	Adverseeffect
at	IN	Adverseeffect
discharge	NN	Adverseeffect
and	CC	Adverseeffect
60	CD	Adverseeffect
days	NNS	Adverseeffect
,	,	O
hospital	JJ	Others
readmission	NN	Others
,	,	Others
and	CC	Others
reoperation	NN	Others
were	VBD	O
very	RB	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
multi-institutional	JJ	O
study	NN	O
,	,	O
the	DT	O
rates	NNS	Others
of	IN	Others
recurrent	JJ	Others
cancer	NN	Others
were	VBD	O
similar	JJ	O
after	IN	O
laparoscopically	RB	O
assisted	VBN	O
colectomy	NN	O
and	CC	O
open	JJ	O
colectomy	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
laparoscopic	NN	O
approach	NN	O
is	VBZ	O
an	DT	O
acceptable	JJ	O
alternative	NN	O
to	TO	O
open	VB	O
surgery	NN	O
for	IN	O
colon	NN	O
cancer	NN	O
.	.	O

Effect	NN	O
of	IN	O
medical	JJ	O
ozone	NN	O
therapy	NN	O
on	IN	O
renal	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	Physical
renal	JJ	Physical
function	NN	Physical
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
severe	JJ	O
hepatitis	NN	O
.	.	O

BACKGROUND	NNP	O
Medical	NNP	O
ozone	NN	O
therapy	NN	O
system	NN	O
was	VBD	O
reported	VBN	O
to	TO	O
have	VB	O
certain	JJ	O
effects	NNS	Others
on	IN	Others
the	DT	Others
treatment	NN	Others
of	IN	Others
severe	JJ	Others
hepatitis	NN	Others
,	,	O
but	CC	O
its	PRP$	O
mechanism	NN	O
is	VBZ	O
not	RB	O
very	RB	O
clear	JJ	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
causes	NNS	O
of	IN	O
death	NN	O
of	IN	O
severe	JJ	O
hepatitis	NN	O
is	VBZ	O
complication	NN	Physical
of	IN	Physical
renal	JJ	Physical
damage	NN	Physical
or	CC	O
hepatorenal	JJ	Adverseeffect
syndrome	NN	Adverseeffect
.	.	Adverseeffect

The	DT	O
present	JJ	O
study	NN	O
aimed	VBN	O
to	TO	O
observe	VB	O
effects	NNS	O
of	IN	O
medical	JJ	O
ozone	NN	O
therapy	NN	O
system	NN	O
on	IN	O
plasma	JJ	Physical
renin	NN	Physical
activity	NN	Physical
(	(	Physical
PRA	NNP	Physical
)	)	Physical
,	,	Physical
angiotensin	JJ	Physical
II	NNP	Physical
(	(	Physical
AII	NNP	Physical
)	)	Physical
,	,	Physical
aldosterone	NN	Physical
(	(	Physical
ALD	NNP	Physical
)	)	Physical
,	,	Physical
renal	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	Physical
renal	JJ	Physical
function	NN	Physical
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
severe	JJ	O
hepatitis	NN	O
and	CC	O
explore	VB	O
mechanisms	NNS	O
of	IN	O
medical	JJ	O
ozone	NN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
hepatitis	NN	O
.	.	O

METHODS	NNP	O
Eighty-five	JJ	O
cases	NNS	O
with	IN	O
chronic	JJ	O
severe	JJ	O
hepatitis	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
ozone	NN	O
therapy	NN	O
group	NN	O
(	(	O
43	CD	O
cases	NNS	O
)	)	O
and	CC	O
control	NN	O
group	NN	O
(	(	O
42	CD	O
cases	NNS	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
the	DT	O
ozone	NN	O
therapy	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
basic	JJ	O
treatments	NNS	O
plus	CC	O
ozone	NN	O
therapy	NN	O
system	NN	O
.	.	O

Basic	JJ	Others
autohemotherapy	NN	Others
was	VBD	O
used	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
milliliter	RBR	O
venous	JJ	O
blood	NN	O
was	VBD	O
drawn	VBN	O
from	IN	O
each	DT	O
patient	NN	O
,	,	O
and	CC	O
was	VBD	O
mixed	JJ	O
with	IN	O
100	CD	O
ml	NNS	O
(	(	O
35	CD	O
?g/ml	NN	O
)	)	O
medical	JJ	O
ozone	NN	O
and	CC	O
then	RB	O
was	VBD	O
returned	VBN	O
the	DT	O
blood	NN	O
to	TO	O
the	DT	O
patient	NN	O
intravenously	RB	O
,	,	O
once	RB	O
every	DT	O
other	JJ	O
day	NN	O
for	IN	O
20	CD	O
days	NNS	O
.	.	O

Only	RB	O
the	DT	O
basic	JJ	O
treatments	NNS	O
were	VBD	O
given	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

PRA	NNP	O
,	,	O
AII	NNP	O
,	,	O
ALD	NNP	O
,	,	O
renal	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
damage	NN	O
to	TO	O
renal	JJ	O
function	NN	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
before	IN	O
treatment	NN	O
and	CC	O
20	CD	O
days	NNS	O
after	IN	O
treatment	NN	O
were	VBD	O
compared	VBN	O
.	.	O

Survival	JJ	O
rates	NNS	O
were	VBD	O
also	RB	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Twenty	NNP	O
days	NNS	O
after	IN	O
the	DT	O
treatment	NN	O
,	,	O
in	IN	O
ozone	NN	O
therapy	NN	O
group	NN	O
,	,	O
PRA	NNP	O
was	VBD	O
(	(	O
1.31	CD	O
?	.	O
0.12	CD	O
)	)	O
ng?ml???h??	NN	O
,	,	O
AII	NNP	O
(	(	O
111.25	CD	O
?	.	O
17.35	CD	O
)	)	O
pg/ml	NN	O
,	,	O
ALD	NNP	O
(	(	O
251.31	CD	O
?	.	O
22.60	CD	O
)	)	O
pg/ml	NN	O
,	,	O
which	WDT	O
decreased	VBD	O
significantly	RB	O
compared	VBN	O
with	IN	O
those	DT	O
before	IN	O
treatment	NN	O
(	(	O
PRA	NNP	O
(	(	O
2.23	CD	O
?	.	O
0.13	CD	O
)	)	O
ng?ml???h??	NN	O
,	,	O
AII	NNP	O
(	(	O
155.18	CD	O
?	.	O
19.13	CD	O
)	)	O
pg/ml	NN	O
,	,	O
ALD	NNP	O
(	(	O
405.31	CD	O
?	.	O
29.88	CD	O
)	)	O
pg/ml	NN	O
,	,	O
t	EX	O
=	$	O
4.67	CD	O
-	:	O
14.23	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
also	RB	O
lower	JJR	O
than	IN	O
those	DT	O
of	IN	O
control	NN	O
group	NN	O
20	CD	O
days	NNS	O
after	IN	O
the	DT	O
treatment	NN	O
(	(	O
PRA	NNP	O
(	(	O
2.02	CD	O
?	.	O
0.11	CD	O
)	)	O
ng?ml???h??	NN	O
,	,	O
AII	NNP	O
(	(	O
162.21	CD	O
?	.	O
15.32	CD	O
)	)	O
pg/ml	NN	O
,	,	O
ALD	NNP	O
(	(	O
401.20	CD	O
?	.	O
35.02	CD	O
)	)	O
pg/ml	NN	O
,	,	O
t	EX	O
=	$	O
4.97	CD	O
-	:	O
15.61	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
renal	JJ	O
blood	NN	O
flow	NN	O
was	VBD	O
(	(	O
175.15	CD	O
?	.	O
28.20	CD	O
)	)	O
ml/min	NN	O
,	,	O
which	WDT	O
increased	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
before	IN	O
the	DT	O
treatment	NN	O
(	(	O
(	(	O
125.68	CD	O
?	.	O
21.25	CD	O
)	)	O
ml/min	NN	O
)	)	O
and	CC	O
was	VBD	O
higher	JJR	O
than	IN	O
that	DT	O
of	IN	O
control	NN	O
group	NN	O
20	CD	O
days	NNS	O
after	IN	O
the	DT	O
treatment	NN	O
(	(	O
(	(	O
128.59	CD	O
?	.	O
23.15	CD	O
)	)	O
ml/min	NN	O
,	,	O
t	EX	O
=	JJ	O
4.78	CD	O
,	,	O
4.61	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Renal	JJ	O
damage	NN	O
occurred	VBD	O
in	IN	O
2	CD	O
cases	NNS	O
(	(	O
5	CD	O
%	NN	O
)	)	O
in	IN	O
ozone	NN	O
therapy	NN	O
group	NN	O
,	,	O
less	JJR	O
than	IN	O
that	DT	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
9	CD	O
cases	NNS	O
,	,	O
21	CD	O
%	NN	O
)	)	O
(	(	O
??	JJ	O
=	NN	O
5.295	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thirty-three	JJ	O
cases	NNS	O
(	(	O
77	CD	O
%	NN	O
)	)	O
in	IN	O
ozone	NN	O
therapy	NN	O
group	NN	O
vs.	FW	O
16	CD	O
cases	NNS	O
(	(	O
38	CD	O
%	NN	O
)	)	O
in	IN	O
control	NN	O
group	NN	O
survived	VBD	O
(	(	O
??	JJ	O
=	NN	O
12.993	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Basic	NNP	O
treatment	NN	O
plus	CC	O
medical	JJ	O
ozone	NN	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
severe	JJ	O
hepatitis	NN	O
could	MD	O
decrease	VB	O
PRA	NNP	O
,	,	O
AII	NNP	O
and	CC	O
ALD	NNP	O
levels	NNS	O
significantly	RB	O
increase	VBP	O
renal	JJ	O
blood	NN	O
flow	NN	O
,	,	O
prevent	JJ	O
renal	JJ	O
damage	NN	O
to	TO	O
certain	JJ	O
extent	NN	O
and	CC	O
improve	VB	O
survival	NN	O
rate	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Once-daily	JJ	O
versus	NN	O
twice-daily	RB	O
lamivudine	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
zidovudine	NN	O
and	CC	O
efavirenz	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antiretroviral-naive	JJ	O
adults	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
:	:	O
a	DT	O
randomized	JJ	O
equivalence	NN	Others
trial	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
controlled	VBN	O
,	,	O
multicenter	RBR	O
trial	NN	O
was	VBD	O
conducted	VBN	O
that	IN	O
involved	VBD	O
554	CD	O
antiretroviral-naive	JJ	O
human	JJ	O
immunodeficiency	NN	O
virus-infected	JJ	O
adults	NNS	O
(	(	O
plasma	JJ	O
HIV	NNP	O
type	NN	O
1	CD	O
[	JJ	O
HIV-1	NNP	O
]	NNP	O
RNA	NNP	O
level	NN	O
,	,	O
>	NNP	O
or=400	VBZ	O
copies/mL	NN	O
;	:	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
cell	NN	O
count	NN	O
,	,	O
>	VBZ	O
100	CD	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
)	)	O
and	CC	O
compared	VBN	O
a	DT	O
300-mg	JJ	O
once-daily	JJ	O
(	(	O
q.d	JJ	O
.	.	O

)	)	O
regimen	NNS	O
of	IN	O
lamivudine	NN	O
(	(	O
3TC	CD	O
)	)	O
versus	NN	O
a	DT	O
150-mg	JJ	O
twice-daily	JJ	O
(	(	O
b.i.d	NN	O
.	.	O

)	)	O
regimen	NNS	O
of	IN	O
3TC	CD	O
,	,	O
combined	VBN	O
with	IN	O
zidovudine	NN	O
(	(	O
300	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

)	)	O
and	CC	O
efavirenz	$	O
(	(	O
600	CD	O
mg	NN	O
q.d	NN	O
.	.	O

)	)	O
,	,	O
during	IN	O
a	DT	O
48-week	JJ	O
period	NN	O
.	.	O

Treatments	NNS	O
were	VBD	O
considered	VBN	O
equivalent	JJ	Others
if	IN	O
the	DT	O
95	CD	Physical
%	NN	Physical
confidence	NN	Physical
interval	NN	Physical
(	(	Physical
CI	NNP	Physical
)	)	Physical
for	IN	O
the	DT	O
difference	NN	O
in	IN	O
proportions	NNS	Physical
of	IN	Physical
patients	NNS	Physical
achieving	VBG	Physical
an	DT	Physical
HIV-1	JJ	Others
RNA	NNP	Others
level	NN	Others
of	IN	Others
<	$	Others
400	CD	Others
copies/mL	NN	Others
was	VBD	O
within	IN	O
the	DT	O
bound	NN	O
of	IN	O
-12	NN	O
%	NN	O
to	TO	O
12	CD	O
%	NN	O
.	.	O

At	IN	O
week	NN	O
48	CD	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
an	DT	O
intent-to-treat	JJ	O
analysis	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
with	IN	O
missing	VBG	O
data	NNS	O
were	VBD	O
considered	VBN	O
to	TO	O
have	VB	O
experienced	VBN	O
treatment	NN	O
failure	NN	Others
showed	VBD	O
that	IN	O
the	DT	O
3TC	CD	O
q.d	NN	O
.	.	O

and	CC	O
3TC	CD	O
b.i.d	NN	O
.	.	O

regimens	NNS	O
were	VBD	O
equivalent	JJ	O
(	(	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
<	VBD	O
400	CD	O
copies/mL	NN	O
,	,	O
178	CD	O
[	JJ	O
64	CD	O
%	NN	O
]	NN	O
of	IN	O
278	CD	O
vs.	FW	O
174	CD	O
[	$	O
63	CD	O
%	NN	O
]	NN	O
of	IN	O
276	CD	O
;	:	O
treatment	NN	O
difference	NN	O
,	,	O
1	CD	O
%	NN	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-7.1	NNP	O
%	NN	O
to	TO	O
8.9	CD	O
%	NN	O
]	NN	O
;	:	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
<	VBD	O
50	CD	O
copies/mL	NN	O
,	,	O
165	CD	O
[	JJ	O
59	CD	O
%	NN	O
]	NN	O
of	IN	O
278	CD	O
vs.	FW	O
168	CD	O
[	$	O
61	CD	O
%	NN	O
]	NN	O
of	IN	O
276	CD	O
;	:	O
treatment	NN	O
difference	NN	O
,	,	O
1.7	CD	O
%	NN	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-9.7	NNP	O
%	NN	O
to	TO	O
6.6	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

Median	JJ	Physical
increase	NN	Physical
above	IN	Physical
baseline	NN	Physical
in	IN	Physical
CD4	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
cell	NN	Physical
count	NN	Physical
was	VBD	O
similar	JJ	O
(	(	O
q.d	JJ	O
.	.	O

group	NN	O
,	,	O
+144	NNP	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
;	:	O
b.i.d	NN	O
.	.	O

group	NN	O
,	,	O
+146	NNP	O
cells/mm	NN	O
(	(	O
3	CD	O
)	)	O
)	)	O
,	,	O
and	CC	O
the	DT	O
incidences	NNS	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
,	,	Adverseeffect
disease	NN	Adverseeffect
progression	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
HIV-associated	JJ	Adverseeffect
conditions	NNS	Adverseeffect
were	VBD	O
comparable	JJ	O
.	.	O

Dalteparin	NNP	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMWH	NNP	O
)	)	O
in	IN	O
ovarian	JJ	O
cancer	NN	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Low	NNP	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
(	(	O
VTE	NNP	O
)	)	O
and	CC	O
may	MD	O
have	VB	O
antineoplastic	JJ	O
effects	NNS	O
by	IN	O
interfering	VBG	O
with	IN	O
angiogenesis	NN	O
and	CC	O
with	IN	O
tumor	NN	O
growth	NN	O
and	CC	O
metastasis	NN	O
.	.	O

A	DT	O
multicentre	JJ	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
was	VBD	O
done	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
antineoplastic	JJ	O
potential	NN	O
of	IN	O
dalteparin	NN	O
in	IN	O
ovarian	JJ	O
cancer	NN	O
(	(	O
OC	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Women	NNP	O
with	IN	O
newly-diagnosed	JJ	O
epithelial	JJ	O
OC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
standard	JJ	O
chemotherapy	NN	O
(	(	O
CT	NNP	O
)	)	O
and	CC	O
one	CD	O
of	IN	O
3	CD	O
doses	NNS	O
of	IN	O
dalteparin	NN	O
(	(	O
50	CD	O
IU/kg	NNP	O
,	,	O
100	CD	O
IU/kg	NNP	O
,	,	O
or	CC	O
150	CD	O
IU/kg	NNP	O
)	)	O
subcutaneously	RB	O
once	RB	O
daily	JJ	O
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
of	IN	O
6	CD	O
cycles	NNS	O
of	IN	O
3-weekly	JJ	O
CT	NNP	O
.	.	O

Blood	NNP	O
was	VBD	O
drawn	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
cycle	NN	O
for	IN	O
CA125	NNP	O
and	CC	O
,	,	O
in	IN	O
a	DT	O
substudy	NN	O
of	IN	O
randomized	JJ	O
patients	NNS	O
,	,	O
for	IN	O
markers	NNS	O
of	IN	O
coagulation	NN	O
activation	NN	O
and	CC	O
angiogenesis	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
tumor	JJ	O
response	NN	O
defined	VBN	O
by	IN	O
?	.	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
serum	NN	O
CA125	NNP	O
from	IN	O
baseline	NN	O
sustained	VBN	O
for	IN	O
at	IN	O
least	JJS	O
28	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
until	IN	O
the	DT	O
end	NN	O
of	IN	O
CT	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
early	RB	O
due	JJ	O
to	TO	O
poor	JJ	O
recruitment	NN	O
.	.	O

Seventy-seven	JJ	O
women	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

A	DT	O
50	CD	O
%	NN	O
drop	NN	O
in	IN	O
CA125	NNP	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
cycle	NN	O
3	CD	O
was	VBD	O
seen	VBN	O
in	IN	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
50	CD	O
IU/kg	NNP	O
group	NN	O
,	,	O
92	CD	O
%	NN	O
of	IN	O
the	DT	O
100	CD	O
IU/kg	NNP	O
group	NN	O
,	,	O
and	CC	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
150	CD	O
IU/kg	NNP	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
symptomatic	JJ	O
VTE	NNP	O
or	CC	O
major	JJ	O
bleeding	VBG	O
events	NNS	O
while	IN	O
on	IN	O
dalteparin	NN	O
.	.	O

Two	CD	O
patients	NNS	O
experienced	VBD	O
VTE	NNP	O
several	JJ	O
days	NNS	O
after	IN	O
discontinuing	VBG	O
study	JJ	O
drug	NN	O
.	.	O

Women	NNS	O
on	IN	O
dalteparin	NN	O
had	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
D-dimer	NNP	O
and	CC	O
thrombin-antithrombin	NN	O
,	,	O
and	CC	O
higher	JJR	O
levels	NNS	O
of	IN	O
tissue	NN	O
factor	NN	O
pathway	NN	O
inhibitor	NN	O
,	,	O
relative	JJ	O
to	TO	O
baseline	VB	O
.	.	O

CONCLUSION	NNP	O
Dalteparin	NNP	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
women	NNS	O
receiving	VBG	O
CT	NNP	O
for	IN	O
newly-diagnosed	JJ	O
epithelial	JJ	O
OC	NNP	O
.	.	O

A	DT	O
dose-response	JJ	O
effect	NN	O
was	VBD	O
not	RB	O
identified	VBN	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
control	NN	O
group	NN	O
precluded	VBD	O
any	DT	O
inference	NN	O
on	IN	O
the	DT	O
antineoplastic	JJ	O
effect	NN	O
of	IN	O
dalteparin	NN	O
.	.	O

Oral	JJ	O
desensitization	NN	O
in	IN	O
papular	JJ	O
urticaria	NN	O
in	IN	O
children	NNS	O
.	.	O

Papular	JJ	O
urticaria	NN	O
(	(	O
PU	NNP	O
)	)	O
is	VBZ	O
among	IN	O
the	DT	O
commonest	JJS	O
skin	NN	O
ailments	NNS	O
in	IN	O
children	NNS	O
.	.	O

Induced	NNP	O
specific	JJ	O
desensitization	NN	O
to	TO	O
insect	VB	O
bites	NNS	O
is	VBZ	O
theoretically	RB	O
an	DT	O
effective	JJ	O
means	NNS	O
of	IN	O
prevention	NN	O
of	IN	O
PU	NNP	O
.	.	O

In	IN	O
this	DT	O
double	JJ	O
blind	NN	O
placebo	NN	O
controlled	VBD	O
study	NN	O
,	,	O
an	DT	O
oral	JJ	O
vaccine	NN	O
prepared	VBN	O
from	IN	O
insect	JJ	O
saliva	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
stable	JJ	O
vaccine	NN	O
solvent	NN	O
)	)	O
.	.	O

Vaccine	NNP	O
and	CC	O
placebo	NN	O
effectiveness	NN	O
were	VBD	O
tested	VBN	O
by	IN	O
counting	VBG	Physical
active	JJ	Physical
PU	NNP	Physical
lesions	NNS	Physical
,	,	O
serum	NN	Physical
eosinophils	NNS	Physical
,	,	O
and	CC	O
IgE	NNP	Physical
,	,	O
before	IN	O
and	CC	O
after	IN	O
4	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
oral	JJ	O
vaccine	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
or	CC	O
the	DT	O
immunological	JJ	O
variables	NNS	O
tested	VBN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
although	IN	O
a	DT	O
lack	NN	O
of	IN	O
oral	JJ	O
vaccine	NN	O
efficacy	NN	O
was	VBD	O
suspected	VBN	O
,	,	O
larger	JJR	O
study	NN	O
samples	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
strengthen	VB	O
our	PRP$	O
conclusion	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
multi-component	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
on	IN	O
adolescent	JJ	O
boys	NNS	O
.	.	O

A	DT	O
six-session	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
incorporating	NN	O
descriptive	NN	O
,	,	O
explanatory	NN	O
and	CC	O
directive	JJ	O
information	NN	O
was	VBD	O
delivered	VBN	O
to	TO	O
adolescent	VB	O
boys	NNS	O
and	CC	O
the	DT	O
impact	NN	O
upon	IN	O
knowledge	NN	Mental
,	,	Mental
attitudes	NNS	Mental
and	CC	Mental
behavioural	JJ	Mental
intentions	NNS	Mental
towards	NNS	O
peers	NNS	O
with	IN	O
autism	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
seventh-	JJ	O
,	,	O
eighth-	JJ	O
and	CC	O
ninth-grade	JJ	O
students	NNS	O
(	(	O
N	NNP	O
=	NNP	O
395	CD	O
)	)	O
from	IN	O
regular	JJ	O
classes	NNS	O
in	IN	O
a	DT	O
mainstream	JJ	O
school	NN	O
.	.	O

Two-eighth-grade	JJ	O
classes	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
condition	NN	O
and	CC	O
all	DT	O
remaining	VBG	O
students	NNS	O
were	VBD	O
either	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
no-intervention	JJ	O
peer	NN	O
or	CC	O
no-intervention	JJ	O
non-peer	JJ	O
condition	NN	O
.	.	O

The	DT	O
anti-stigma	JJ	O
program	NN	O
improved	VBD	O
the	DT	O
knowledge	NN	O
and	CC	O
attitudes	NNS	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
behavioural	JJ	O
intentions	NNS	O
of	IN	O
participants	NNS	O
towards	VBP	O
their	PRP$	O
peers	NNS	O
with	IN	O
autism	NN	O
.	.	O

Knowledge	NNP	O
and	CC	O
attitudinal	JJ	O
changes	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
follow-up	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
spill-over	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
program	NN	O
to	TO	O
non-targeted	JJ	O
students	NNS	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
some	DT	O
preliminary	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
multi-session	NN	O
anti-stigma	JJ	O
programs	NNS	O
incorporating	VBG	O
combined	VBN	O
information	NN	O
for	IN	O
adolescent	NN	O
students	NNS	O
in	IN	O
inclusive	JJ	O
educational	JJ	O
environments	NNS	O
.	.	O

RESPECT-PTSD	JJ	O
:	:	O
re-engineering	JJ	O
systems	NNS	O
for	IN	O
the	DT	O
primary	JJ	O
care	NN	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
collaborative	JJ	O
care	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
depression	NN	O
and	CC	O
other	JJ	O
mental	JJ	O
disorders	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
randomized	JJ	O
trials	NNS	O
of	IN	O
collaborative	JJ	O
care	NN	O
specifically	RB	O
for	IN	O
patients	NNS	O
with	IN	O
Posttraumatic	NNP	O
stress	NN	O
disorder	NN	O
(	(	O
PTSD	NNP	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
a	DT	O
collaborative	JJ	O
approach	NN	O
,	,	O
the	DT	O
Three	NNP	O
Component	NNP	O
Model	NNP	O
(	(	O
3CM	CD	O
)	)	O
,	,	O
with	IN	O
usual	JJ	O
care	NN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
two-arm	JJ	O
,	,	O
parallel	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

PTSD	JJ	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
five	CD	O
primary	JJ	O
care	NN	O
clinics	NNS	O
at	IN	O
four	CD	O
Veterans	NNS	O
Affairs	NNP	O
healthcare	NN	O
facilities	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
usual	JJ	O
care	NN	O
or	CC	O
usual	JJ	O
care	NN	O
plus	CC	O
3CM	CD	O
.	.	O

Blinded	VBN	O
assessors	NNS	O
collected	VBD	O
data	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-month	JJ	O
and	CC	O
6-month	JJ	O
follow-up	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
were	VBD	O
195	CD	O
Veterans	NNPS	O
.	.	O

Their	PRP$	O
average	JJ	O
age	NN	O
was	VBD	O
45	CD	O
years	NNS	O
,	,	O
91	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
58	CD	O
%	NN	O
were	VBD	O
white	JJ	O
,	,	O
40	CD	O
%	NN	O
served	VBN	O
in	IN	O
Iraq	NNP	O
or	CC	O
Afghanistan	NNP	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
served	VBD	O
in	IN	O
Vietnam	NNP	O
.	.	O

INTERVENTION	NNP	O
All	NNP	O
participants	NNS	O
received	VBD	O
usual	JJ	O
care	NN	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
also	RB	O
received	VBD	O
telephone	NN	O
care	NN	O
management	NN	O
.	.	O

Care	NN	O
managers	NNS	O
received	VBD	O
supervision	NN	O
from	IN	O
a	DT	O
psychiatrist	NN	O
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
PTSD	NNP	Physical
symptom	NN	Physical
severity	NN	Physical
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

Depression	NNP	Physical
,	,	Mental
functioning	NN	Physical
,	,	O
perceived	VBD	Physical
quality	NN	Physical
of	IN	Physical
care	NN	Physical
,	,	Others
utilization	NN	Others
,	,	O
and	CC	O
costs	NNS	Others
were	VBD	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

KEY	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
3CM	CD	O
and	CC	O
usual	JJ	O
care	NN	O
in	IN	O
symptoms	NNS	O
or	CC	O
functioning	VBG	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
mental	JJ	Mental
health	NN	Mental
visit	NN	Mental
,	,	O
fill	VB	Others
an	DT	Others
antidepressant	JJ	Others
prescription	NN	Others
,	,	O
and	CC	O
have	VBP	Others
adequate	VBN	Others
antidepressant	JJ	Others
refills	NNS	Others
.	.	Others

3CM	CD	O
participants	NNS	O
also	RB	O
had	VBD	O
more	RBR	O
mental	JJ	Mental
health	NN	Mental
visits	NNS	Mental
and	CC	O
higher	JJR	O
outpatient	NN	Others
pharmacy	NN	Others
costs	NNS	Others
.	.	Others

CONCLUSIONS	NNP	O
Results	NNP	O
suggest	VBP	O
the	DT	O
need	NN	O
for	IN	O
careful	JJ	O
examination	NN	O
of	IN	O
the	DT	O
way	NN	O
that	IN	O
collaborative	JJ	O
care	NN	O
models	NNS	O
are	VBP	O
implemented	VBN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
,	,	O
and	CC	O
for	IN	O
additional	JJ	O
supports	NNS	O
to	TO	O
encourage	VB	O
primary	JJ	O
care	NN	O
providers	NNS	O
to	TO	O
manage	VB	O
PTSD	NNP	O
.	.	O

Comparative	JJ	O
trial	NN	O
of	IN	O
carbenicillin	NN	O
and	CC	O
ampicillin	NN	O
therapy	NN	O
for	IN	O
purulent	NN	O
meningitis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
therapeutic	JJ	O
trial	NN	O
of	IN	O
carbenicillin	NN	O
(	(	O
CB	NNP	O
)	)	O
or	CC	O
ampicillin	NN	O
(	(	O
AMP	NNP	O
)	)	O
in	IN	O
purulent	NN	O
meningitis	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
86	CD	O
pediatric	JJ	O
and	CC	O
adult	NN	O
patients	NNS	O
(	(	O
41	CD	O
Haemophilus	NNP	O
influenzae	NN	O
,	,	O
22	CD	O
Streptococcus	NNP	O
pneumoniae	NN	O
,	,	O
13	CD	O
Neisseria	NNP	O
meningitidis	NN	O
,	,	O
and	CC	O
10	CD	O
of	IN	O
unknown	JJ	O
etiology	NN	O
)	)	O
.	.	O

All	DT	O
isolates	NNS	O
,	,	O
incuding	VBG	O
H.	NNP	O
influenzae	NN	O
,	,	O
were	VBD	O
susceptible	JJ	O
to	TO	O
CB	NNP	O
and	CC	O
AMP	NNP	O
.	.	O

Median	JJ	O
cerebrospinal	JJ	Physical
fluid	NN	Physical
(	(	Physical
CSF	NNP	Physical
)	)	Physical
antibiotic	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
0.85	CD	O
and	CC	O
1.60	CD	O
mug/ml	NN	O
for	IN	O
CB	NNP	O
and	CC	O
AMP	NNP	O
,	,	O
respectively	RB	O
,	,	O
during	IN	O
administration	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
400	CD	O
mg/kg	NNS	O
and	CC	O
0.65	CD	O
and	CC	O
0.45	CD	O
mug/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
on	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
200	CD	O
mg/kg	NN	O
.	.	O

Higher	JJR	Physical
CSF	NNP	Physical
concentrations	NNS	Physical
,	,	O
up	RB	O
to	TO	O
a	DT	O
median	JJ	O
concentration	NN	O
of	IN	O
4.5	CD	O
mug/ml	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSF	NNP	O
protein	NN	O
concentrations	NNS	O
>	VBP	O
/=75	JJ	O
mg/100	NN	O
ml	NN	O
.	.	O

Clinical	JJ	Physical
responses	NNS	Physical
were	VBD	O
equivalent	JJ	O
on	IN	O
either	CC	O
antibiotic	JJ	O
regimen	NNS	O
.	.	O

Among	IN	O
AMP	JJ	O
patients	NNS	O
(	(	O
45	CD	O
)	)	O
,	,	O
8	CD	O
had	VBD	Adverseeffect
significant	JJ	Adverseeffect
residua	NN	Adverseeffect
and	CC	O
3	CD	O
died	VBD	Mortality
;	:	Mortality
among	IN	O
CB	NNP	O
patients	NNS	O
(	(	O
41	CD	O
)	)	O
,	,	O
5	CD	O
had	VBD	O
residua	NN	O
and	CC	O
none	NN	O
died	VBD	O
.	.	O

However	RB	O
,	,	O
38	CD	O
%	NN	O
of	IN	O
H.	NNP	O
influenzae	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
CB	NNP	O
had	VBD	O
positive	JJ	Physical
CSF	NNP	Physical
cultures	NNS	Physical
on	IN	O
day	NN	O
1	CD	O
follow-up	JJ	O
lumbar	NN	O
punctures	NNS	O
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
5.8	CD	O
%	NN	O
of	IN	O
AMP	NNP	O
patients	NNS	O
with	IN	O
H.	NNP	O
influenzae	NN	O
.	.	O

The	DT	O
significance	NN	O
of	IN	O
a	DT	O
delay	NN	Physical
of	IN	Physical
CSF	NNP	Physical
sterilization	NN	Physical
among	IN	O
CB-treated	JJ	O
patients	NNS	O
is	VBZ	O
unknown	JJ	O
,	,	O
since	IN	O
there	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
persistence	NN	O
of	IN	O
hemophilus	JJ	O
organisms	NNS	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
adverse	JJ	O
outcome	NN	O
.	.	O

AMP	NNP	O
and	CC	O
CB	NNP	O
are	VBP	O
equivalent	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacterial	JJ	O
meningitis	NN	O
due	JJ	O
to	TO	O
susceptible	JJ	O
organisms	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
selected	VBN	O
fitness	NN	Physical
parameters	NNS	Physical
following	VBG	O
six	CD	O
weeks	NNS	O
of	IN	O
snowshoe	JJ	O
training	NN	O
.	.	O

BACKGROUND	NNP	O
Recently	RB	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
an	DT	O
increase	NN	O
in	IN	O
popularity	NN	O
and	CC	O
participation	NN	O
in	IN	O
the	DT	O
sport	NN	O
of	IN	O
snowshoeing	VBG	O
.	.	O

While	IN	O
the	DT	O
sport	NN	O
has	VBZ	O
gained	VBN	O
considerable	JJ	O
recognition	NN	O
,	,	O
to	TO	O
date	NN	O
there	EX	O
is	VBZ	O
little	JJ	O
or	CC	O
no	DT	O
scientific	JJ	O
research	NN	O
regarding	VBG	O
training	NN	Others
responses	NNS	Others
to	TO	O
snowshoeing	VBG	O
as	IN	O
a	DT	O
form	NN	O
of	IN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
snowshoe	JJ	O
training	NN	O
could	MD	O
improve	VB	O
fitness	NN	Physical
measures	NNS	Physical
.	.	Physical

A	DT	O
further	JJ	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	O
responses	NNS	O
from	IN	O
a	DT	O
snowshoe	JJ	O
training	NN	O
program	NN	O
to	TO	O
a	DT	O
similarly	RB	O
designed	VBN	O
run	RP	O
training	VBG	O
program	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
prospective	JJ	O
,	,	O
comparative	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
healthy	JJ	O
males	NNS	O
and	CC	O
females	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
19	CD	O
and	CC	O
24	CD	O
.	.	O

These	DT	O
subjects	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
the	DT	O
University	NNP	O
of	IN	O
Vermont	NNP	O
population	NN	O
and	CC	O
surrounding	VBG	O
community	NN	O
.	.	O

Following	VBG	O
baseline	NN	O
measurements	NNS	O
in	IN	O
VO2max	NNP	Physical
,	,	Physical
running	VBG	Others
time	NN	Others
to	TO	Others
exhaustion	NN	Others
(	(	Others
RTE	NNP	Others
)	)	Others
,	,	Physical
and	CC	Physical
anthropometry	NN	Physical
,	,	O
17	CD	O
subjects	NNS	O
(	(	O
10	CD	O
snowshoers	NNS	O
and	CC	O
7	CD	O
runners	NNS	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
six	CD	O
week	NN	O
conditioning	VBG	O
program	NN	O
.	.	O

Both	DT	O
groups	NNS	O
exercised	VBD	O
for	IN	O
30	CD	O
min	NNS	O
at	IN	O
75-85	CD	O
%	NN	O
age	NN	O
predicted	VBD	O
maximum	JJ	O
heart	NN	O
rate	NN	O
,	,	O
3-4	JJ	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
18	CD	O
sessions	NNS	O
.	.	O

RESULTS	NNP	O
VO2max	NNP	Physical
improved	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
running	NN	O
and	CC	O
snowshoeing	VBG	O
groups	NNS	O
,	,	O
6.3	CD	O
and	CC	O
8.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Run	VB	Physical
time	NN	Physical
to	TO	Physical
exhaustion	NN	Physical
also	RB	O
improved	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
23.3	CD	O
and	CC	O
33.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
changes	NNS	O
in	IN	O
anthropometry	NN	Physical
for	IN	O
either	DT	O
group	NN	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
RTE	NNP	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
any	DT	O
other	JJ	O
measurements	NNS	O
at	IN	O
baseline	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
support	VBD	O
the	DT	O
acceptability	NN	O
of	IN	O
snowshoeing	VBG	O
as	IN	O
a	DT	O
valid	JJ	O
means	NN	O
to	TO	O
improve	VB	O
or	CC	O
maintain	VB	O
cardiovascular	JJ	Physical
endurance	NN	Physical
.	.	Physical

Parent	NN	O
satisfaction	NN	O
in	IN	O
a	DT	O
multi-site	JJ	O
acute	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
social	JJ	O
validity	NN	O
study	NN	O
.	.	O

RATIONALE	NNP	O
Subjects	NNPS	O
who	WP	O
view	VBP	O
experimental	JJ	O
procedures	NNS	O
as	IN	O
worthwhile	NN	O
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
participate	VB	O
in	IN	O
clinical	JJ	O
trials	NNS	O
and	CC	O
comply	NN	O
with	IN	O
study	NN	O
procedures	NNS	O
.	.	O

Designing	VBG	O
studies	NNS	O
that	WDT	O
consider	VBP	O
the	DT	O
consumer	NN	O
's	POS	O
perspective	NN	O
will	MD	O
help	VB	O
to	TO	O
forge	VB	O
a	DT	O
better	JJR	O
alliance	NN	O
between	IN	O
participants	NNS	O
and	CC	O
researchers	NNS	O
.	.	O

OBJECTIVE	NNP	O
Participant	NNP	O
satisfaction	NN	O
is	VBZ	O
seldom	RB	O
assessed	VBN	O
in	IN	O
pharmacological	JJ	O
research	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
,	,	O
we	PRP	O
report	VBP	O
on	IN	O
parent	NN	O
satisfaction	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
and	CC	O
severely	RB	O
disruptive	JJ	O
behavior	NN	O
.	.	O

METHOD	NNP	O
Parents	NNP	O
of	IN	O
101	CD	O
children	NNS	O
with	IN	O
autism	NN	O
who	WP	O
had	VBD	O
participated	VBN	O
in	IN	O
a	DT	O
multi-site	JJ	O
8-week	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
were	VBD	O
given	VBN	O
a	DT	O
questionnaire	NN	O
at	IN	O
the	DT	O
end	NN	O
to	TO	O
elicit	VB	O
their	PRP$	O
perceptions	NNS	O
of	IN	O
the	DT	O
appropriateness	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
clinical	JJ	O
trial	NN	O
procedures	NNS	O
.	.	O

RESULTS	VB	O
Ninety-six	NNP	O
(	(	O
95.0	CD	O
%	NN	O
)	)	O
parents	NNS	O
returned	VBD	O
the	DT	O
questionnaire	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
80.0	CD	O
to	TO	O
96.8	CD	O
%	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
question	NN	O
,	,	O
expressed	VBN	O
satisfaction	NN	O
with	IN	O
their	PRP$	O
child	NN	O
's	POS	O
research	NN	O
participation	NN	O
regardless	NN	O
of	IN	O
treatment	NN	O
outcome	NN	O
or	CC	O
assignment	NN	O
to	TO	O
active	JJ	O
drug	NN	O
or	CC	O
placebo	NN	O
.	.	O

In	IN	O
all	DT	O
,	,	O
90.5	CD	O
%	NN	O
of	IN	O
parents	NNS	O
indicated	VBN	O
that	IN	O
they	PRP	O
would	MD	O
definitely	RB	O
recommend	VB	O
the	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
other	JJ	O
families	NNS	O
with	IN	O
similar	JJ	O
children	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
92.7	CD	O
%	NN	O
indicated	VBD	O
that	IN	O
they	PRP	O
would	MD	O
rejoin	VB	O
the	DT	O
clinical	JJ	O
trial	NN	O
if	IN	O
they	PRP	O
had	VBD	O
to	TO	O
do	VB	O
it	PRP	O
all	DT	O
over	RB	O
again	RB	O
.	.	O

Ethnic	JJ	O
minority	NN	O
subjects	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
than	IN	O
white	JJ	O
participants	NNS	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
learning	VBG	O
tests	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Parents	NNPS	O
of	IN	O
children	NNS	O
participating	VBG	O
in	IN	O
this	DT	O
trial	NN	O
were	VBD	O
highly	RB	Others
satisfied	JJ	Others
and	CC	Others
supportive	JJ	Others
of	IN	Others
the	DT	Others
clinical	JJ	Others
trial	NN	Others
procedures	NNS	Others
.	.	O

Random	NNP	O
assignment	NN	O
to	TO	O
drug	NN	O
or	CC	O
placebo	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
response	NN	O
of	IN	O
their	PRP$	O
children	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
influence	VB	O
their	PRP$	O
views	NNS	O
.	.	O

Further	JJ	O
satisfaction	NN	O
studies	NNS	O
of	IN	O
this	DT	O
sort	NN	O
are	VBP	O
encouraged	VBN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
EICESS-92	NNP	O
Study	NNP	O
:	:	O
two	CD	O
randomized	JJ	O
trials	NNS	O
of	IN	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
treatment	NN	O
--	:	O
cyclophosphamide	NN	O
compared	VBN	O
with	IN	O
ifosfamide	NN	O
in	IN	O
standard-risk	JJ	O
patients	NNS	O
and	CC	O
assessment	NN	O
of	IN	O
benefit	NN	O
of	IN	O
etoposide	NN	O
added	VBD	O
to	TO	O
standard	VB	O
treatment	NN	O
in	IN	O
high-risk	JJ	O
patients	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
European	NNP	O
Intergroup	NNP	O
Cooperative	NNP	O
Ewing	NNP	O
's	POS	O
Sarcoma	NNP	O
Study	NNP	O
investigated	VBD	O
whether	IN	O
cyclophosphamide	NN	O
has	VBZ	O
a	DT	O
similar	JJ	O
efficacy	NN	O
as	IN	O
ifosfamide	NN	O
in	IN	O
standard-risk	JJ	O
(	(	O
SR	NNP	O
)	)	O
patients	NNS	O
and	CC	O
whether	IN	O
the	DT	O
addition	NN	O
of	IN	O
etoposide	JJ	O
improves	NNS	O
survival	VBP	Mortality
in	IN	O
high-risk	NN	O
(	(	O
HR	NNP	O
)	)	O
patients	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
SR	NNP	O
patients	NNS	O
(	(	O
localized	JJ	O
tumors	NNS	O
,	,	O
volume	NN	O
<	VBD	O
100	CD	O
mL	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
four	CD	O
courses	NNS	O
of	IN	O
vincristine	NN	O
,	,	O
dactinomycin	NN	O
,	,	O
ifosfamide	NN	O
,	,	O
and	CC	O
doxorubicin	NN	O
(	(	O
VAIA	NNP	O
)	)	O
induction	NN	O
therapy	NN	O
followed	VBN	O
by	IN	O
10	CD	O
courses	NNS	O
of	IN	O
either	DT	O
VAIA	NNP	O
or	CC	O
vincristine	NN	O
,	,	O
dactinomycin	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
and	CC	O
doxorubicin	NN	O
(	(	O
VACA	NNP	O
;	:	O
cyclophosphamide	NN	O
replacing	VBG	O
ifosfamide	NN	O
)	)	O
.	.	O

HR	$	O
patients	NNS	O
(	(	O
volume	NN	O
>	NNP	O
or=100	VBZ	O
mL	NN	O
or	CC	O
metastases	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
14	CD	O
courses	NNS	O
of	IN	O
either	DT	O
VAIA	NNP	O
or	CC	O
VAIA	NNP	O
plus	CC	O
etoposide	NN	O
(	(	O
EVAIA	NNP	O
)	)	O
.	.	O

Outcome	JJ	O
measures	NNS	O
were	VBD	O
event-free	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
EFS	NNP	Mortality
;	:	O
defined	VBD	O
as	IN	O
the	DT	O
time	NN	O
to	TO	O
first	JJ	O
recurrence	NN	O
,	,	O
progression	NN	O
,	,	O
second	JJ	O
malignancy	NN	O
,	,	O
or	CC	O
death	NN	O
)	)	O
and	CC	O
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
.	.	Mortality

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
647	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
:	:	O
79	CD	O
SR	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
VAIA	NNP	O
,	,	O
76	CD	O
SR	NN	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
VACA	NNP	O
,	,	O
240	CD	O
HR	NNP	O
were	VBD	O
assigned	VBN	O
to	TO	O
VAIA	NNP	O
,	,	O
and	CC	O
252	CD	O
HR	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
EVAIA	NNP	O
.	.	O

The	DT	O
median	JJ	O
follow-up	NN	O
was	VBD	O
8.5	CD	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
SR	NNP	O
group	NN	O
,	,	O
the	DT	O
hazard	NN	Physical
ratios	NNS	Physical
(	(	O
VACA	NNP	O
v	NNP	O
VAIA	NNP	O
)	)	O
for	IN	O
EFS	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
0.91	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.55	CD	O
to	TO	O
1.53	CD	O
)	)	O
and	CC	O
1.08	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.58	CD	O
to	TO	O
2.03	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
hematologic	JJ	Physical
toxicities	NNS	Physical
in	IN	O
the	DT	O
VACA	NNP	O
arm	NN	O
.	.	O

In	IN	O
the	DT	O
HR	NNP	O
group	NN	O
,	,	O
the	DT	O
EFS	NNP	Physical
and	CC	Physical
OS	NNP	Physical
hazard	NN	Physical
ratios	NNS	Physical
(	(	O
EVAIA	NNP	O
v	NNP	O
VAIA	NNP	O
)	)	O
indicated	VBD	O
a	DT	O
17	CD	O
%	NN	O
reduction	NN	O
in	IN	O
the	DT	O
risk	NN	O
of	IN	O
an	DT	O
event	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-35	NNP	O
%	NN	O
to	TO	O
5	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.12	NNP	O
)	)	O
and	CC	O
15	CD	O
%	NN	O
reduction	NN	O
in	IN	O
dying	VBG	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-34	NNP	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
effect	NN	O
seemed	VBD	O
greater	JJR	O
among	IN	O
patients	NNS	O
without	IN	O
metastases	NNS	O
(	(	O
hazard	NN	O
ratio	NN	O
=	VBZ	O
0.79	CD	O
;	:	O
P	NNP	O
=	NNP	O
.16	NNP	O
)	)	O
than	IN	O
among	IN	O
those	DT	O
with	IN	O
metastases	NNS	O
(	(	O
hazard	NN	O
ratio	NN	O
=	VBZ	O
0.96	CD	O
;	:	O
P	NNP	O
=	NNP	O
.84	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Cyclophosphamide	NNP	O
seemed	VBD	O
to	TO	O
have	VB	O
a	DT	O
similar	JJ	O
effect	NN	O
on	IN	O
EFS	NNP	Physical
and	CC	Physical
OS	NNP	Physical
as	IN	O
ifosfamide	NN	O
in	IN	O
SR	NNP	O
patients	NNS	O
but	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
toxicity	NN	Physical
.	.	O

In	IN	O
HR	NNP	O
patients	NNS	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
etoposide	NN	O
seemed	VBD	O
to	TO	O
be	VB	O
beneficial	JJ	O
.	.	O

A	DT	O
cluster	NN	O
randomised	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
a	DT	O
physical	JJ	O
activity	NN	O
intervention	NN	O
among	IN	O
3-5	JJ	O
year	NN	O
old	JJ	O
children	NNS	O
attending	VBG	O
long	RB	O
day	NN	O
care	NN	O
services	NNS	O
:	:	O
study	NN	O
protocol	NN	O
.	.	O

BACKGROUND	NNP	O
Young	NNP	O
children	NNS	O
are	VBP	O
not	RB	O
participating	VBG	O
in	IN	O
recommended	JJ	O
levels	NNS	O
of	IN	O
physical	JJ	O
activity	NN	O
and	CC	O
exhibit	NN	O
high	JJ	O
levels	NNS	O
of	IN	O
sedentary	JJ	O
behaviour	NN	O
.	.	O

Childcare	NNP	O
services	NNS	O
provide	RB	O
access	NN	O
to	TO	O
large	JJ	O
numbers	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
for	IN	O
prolonged	JJ	O
periods	NNS	O
,	,	O
yet	RB	O
there	EX	O
is	VBZ	O
limited	JJ	O
experimental	JJ	O
evidence	NN	O
regarding	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
physical	JJ	O
activity	NN	O
interventions	NNS	O
implemented	VBN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
a	DT	O
multi-component	JJ	O
physical	JJ	O
activity	NN	O
intervention	NN	O
,	,	O
delivered	VBN	O
by	IN	O
childcare	NN	O
service	NN	O
staff	NN	O
,	,	O
in	IN	O
increasing	VBG	O
the	DT	O
physical	JJ	O
activity	NN	O
levels	NNS	O
of	IN	O
children	NNS	O
attending	VBG	O
long	RB	O
day	NN	O
care	NN	O
services	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
study	NN	O
will	MD	O
employ	VB	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
design	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
children	NNS	O
aged	VBN	O
between	IN	O
3-5	CD	O
years	NNS	O
from	IN	O
twenty	NN	O
randomly	RB	O
selected	VBN	O
long	RB	O
day	NN	O
care	NN	O
services	NNS	O
in	IN	O
the	DT	O
Hunter	NNP	O
Region	NNP	O
of	IN	O
New	NNP	O
South	NNP	O
Wales	NNP	O
,	,	O
Australia	NNP	O
will	MD	O
be	VB	O
invited	VBN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
trial	NN	O
.	.	O

Ten	CD	O
of	IN	O
the	DT	O
20	CD	O
long	JJ	O
day	NN	O
care	NN	O
services	NNS	O
will	MD	O
be	VB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
deliver	VB	O
the	DT	O
intervention	NN	O
with	IN	O
the	DT	O
remaining	VBG	O
ten	NN	O
services	NNS	O
allocated	VBN	O
to	TO	O
a	DT	O
wait	JJ	O
list	NN	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
physical	JJ	O
activity	NN	O
intervention	NN	O
will	MD	O
consist	VB	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
strategies	NNS	O
including	VBG	O
:	:	O
delivering	NN	O
structured	VBD	O
fundamental	JJ	O
movement	NN	O
skill	NN	O
activities	NNS	O
,	,	O
increasing	VBG	O
physical	JJ	O
activity	NN	O
opportunities	NNS	O
,	,	O
increasing	VBG	O
staff	NN	O
role	NN	O
modelling	NN	O
,	,	O
providing	VBG	O
children	NNS	O
with	IN	O
a	DT	O
physical	JJ	O
activity	NN	O
promoting	VBG	O
indoor	NN	O
and	CC	O
outdoor	JJ	O
environment	NN	O
and	CC	O
limiting	VBG	O
children	NNS	O
's	POS	O
small	JJ	O
screen	JJ	O
recreation	NN	O
and	CC	O
sedentary	JJ	O
behaviours	NNS	O
.	.	O

Intervention	NNP	O
effectiveness	NN	O
will	MD	O
be	VB	O
measured	VBN	O
via	IN	O
child	JJ	Physical
physical	JJ	Physical
activity	NN	Physical
levels	NNS	Physical
during	IN	Mental
attendance	NN	Mental
at	IN	Mental
long	RB	Mental
day	NN	Mental
care	NN	Mental
.	.	O

The	DT	O
study	NN	O
also	RB	O
seeks	VBZ	O
to	TO	O
determine	VB	O
the	DT	O
acceptability	NN	Others
and	CC	Others
extent	NN	Others
of	IN	Others
implementation	NN	Others
of	IN	Others
the	DT	Others
intervention	NN	Others
by	IN	Others
services	NNS	Others
and	CC	O
their	PRP$	O
staff	NN	O
participating	VBG	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

DISCUSSION	NNP	O
The	DT	O
trial	NN	O
will	MD	O
address	VB	O
current	JJ	O
gaps	NNS	O
in	IN	O
the	DT	O
research	NN	O
evidence	NN	O
base	NN	O
and	CC	O
contribute	NN	O
to	TO	O
the	DT	O
design	NN	O
and	CC	O
delivery	NN	O
of	IN	O
future	JJ	O
interventions	NNS	O
promoting	VBG	O
physical	JJ	O
activity	NN	O
for	IN	O
young	JJ	O
children	NNS	O
in	IN	O
long	JJ	O
day	NN	O
care	NN	O
settings	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Australian	NNP	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
ACTRN12610000087055	NNP	O
.	.	O

Behavioral	NNP	O
and	CC	O
physiological	JJ	O
effects	NNS	O
of	IN	O
deep	JJ	O
pressure	NN	O
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
evaluating	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
Grandin	NNP	O
's	POS	O
Hug	NNP	O
Machine	NNP	O
.	.	O

OBJECTIVE	NNP	O
One	CD	O
symptom	NN	O
common	JJ	O
to	TO	O
many	JJ	O
persons	NNS	O
with	IN	O
autism	NN	O
is	VBZ	O
a	DT	O
high	JJ	O
arousal	NN	O
or	CC	O
anxiety	NN	O
level	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
deep	JJ	O
pressure	NN	O
on	IN	O
arousal	NN	O
and	CC	O
anxiety	NN	O
reduction	NN	O
in	IN	O
autism	NN	O
with	IN	O
Grandin	NNP	O
's	POS	O
Hug	NNP	O
Machine	NNP	O
,	,	O
a	DT	O
device	NN	O
that	WDT	O
allows	VBZ	O
self-administration	NN	O
of	IN	O
lateral	JJ	O
body	NN	O
pressure	NN	O
.	.	O

METHOD	NNP	O
Twelve	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	O
group	NN	O
(	(	O
receiving	VBG	O
deep	JJ	O
pressure	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
group	NN	O
(	(	O
not	RB	O
receiving	VBG	O
deep	JJ	O
pressure	NN	O
but	CC	O
in	IN	O
the	DT	O
disengaged	JJ	O
Hug	NNP	O
Machine	NNP	O
)	)	O
.	.	O

All	DT	O
children	NNS	O
received	VBD	O
two	CD	O
20-min	JJ	O
sessions	NNS	O
a	DT	O
week	NN	O
over	IN	O
a	DT	O
6-week	JJ	O
period	NN	O
.	.	O

Arousal	NNP	Mental
was	VBD	O
measured	VBN	O
behaviorally	RB	O
with	IN	O
the	DT	O
Conners	NNPS	Mental
Parent	NNP	Mental
Rating	NNP	Mental
Scale	NNP	Mental
and	CC	Mental
physiologically	RB	Mental
with	IN	Mental
galvanic	JJ	Mental
skin	NN	Mental
response	NN	Mental
(	(	Mental
GSR	NNP	Mental
)	)	Mental
readings	NNS	Mental
.	.	O

RESULTS	NNP	O
Behavioral	NNP	O
results	NNS	O
indicated	VBD	O
a	DT	O
significant	JJ	Mental
reduction	NN	Mental
in	IN	Mental
tension	NN	Mental
and	CC	Mental
a	DT	Mental
marginally	RB	Mental
significant	JJ	Mental
reduction	NN	Mental
in	IN	Mental
anxiety	NN	Mental
for	IN	O
children	NNS	O
who	WP	O
received	VBD	O
the	DT	O
deep	JJ	O
pressure	NN	O
compared	VBN	O
with	IN	O
the	DT	O
children	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

Additionally	RB	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
whose	WP$	O
GSR	NNP	Mental
measures	NNS	Mental
decreased	VBD	O
,	,	O
on	IN	O
average	NN	O
,	,	O
after	IN	O
deep	JJ	O
pressure	NN	O
,	,	O
were	VBD	O
somewhat	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
higher	JJR	O
GSR	NNP	Mental
arousal	VBZ	Mental
a	DT	O
priori	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
preliminary	JJ	O
findings	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	WDT	O
deep	JJ	O
pressure	NN	O
may	MD	O
have	VB	O
a	DT	O
calming	JJ	O
effect	NN	O
for	IN	O
persons	NNS	O
with	IN	O
autism	NN	O
,	,	O
especially	RB	O
those	DT	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
arousal	NN	O
or	CC	O
anxiety	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
health	NN	O
care	NN	O
program	NN	O
for	IN	O
first-time	JJ	O
adolescent	NN	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
special	JJ	O
health	NN	O
care	NN	O
program	NN	O
for	IN	O
adolescent	JJ	O
mothers	NNS	O
(	(	O
17	CD	O
years	NNS	O
old	JJ	O
or	CC	O
younger	JJR	O
)	)	O
and	CC	O
their	PRP$	O
infants	NNS	O
,	,	O
243	CD	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
unwed	JJ	O
,	,	O
on	IN	O
Medicaid	NNP	O
,	,	O
and	CC	O
black	JJ	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
routine	JJ	O
well-baby	NN	O
care	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
routine	JJ	O
care	NN	O
and	CC	O
services	NNS	O
that	WDT	O
included	VBD	O
rigorous	JJ	O
follow-up	NN	O
,	,	O
discussions	NNS	O
with	IN	O
the	DT	O
mother	NN	O
about	IN	O
her	PRP$	O
plans	NNS	O
for	IN	O
return	NN	O
to	TO	O
school	NN	O
and	CC	O
use	NN	O
of	IN	O
family	NN	O
planning	NN	O
methods	NNS	O
,	,	O
and	CC	O
extra	JJ	O
health	NN	O
teaching	NN	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
60	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
less	JJR	O
after	IN	O
18	CD	O
months	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
high	JJ	O
dropout	NN	O
rate	NN	O
,	,	O
91	CD	O
%	NN	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
located	VBN	O
for	IN	O
the	DT	O
18	CD	O
month	NN	O
follow-up	JJ	O
interview	NN	O
.	.	O

The	DT	O
repeat	JJ	Physical
pregnancy	NN	Physical
rate	NN	Physical
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
12	CD	O
%	NN	O
after	IN	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
28	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	Mental
returning	VBG	Mental
to	TO	Mental
school	NN	Mental
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
fully	RB	Physical
immunized	VBN	Physical
(	(	O
33	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mothers	NNS	O
in	IN	O
the	DT	O
special	JJ	O
care	NN	O
program	NN	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
clinic	NN	O
used	VBN	Others
the	DT	Others
emergency	NN	Others
room	NN	Others
less	JJR	Others
than	IN	O
the	DT	O
mothers	NNS	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
comprehensive	JJ	O
health	NN	O
care	NN	O
program	NN	O
is	VBZ	O
one	CD	O
way	NN	O
to	TO	O
bring	VB	O
about	RP	O
better	JJR	O
outcomes	NNS	O
for	IN	O
both	DT	O
adolescent	JJ	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
clinical	JJ	Others
effectiveness	NN	Others
of	IN	O
acupuncture	NN	O
and	CC	O
a	DT	O
Western	JJ	O
drug	NN	O
on	IN	O
allergic	JJ	O
rhinitis	NN	O
:	:	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
acupuncture	NN	O
regimen	NN	O
for	IN	O
persistent	JJ	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
PER	NNP	O
)	)	O
,	,	O
aimed	VBN	O
at	IN	O
improving	VBG	O
a	DT	O
patient	NN	O
's	POS	O
mind	NN	O
or	CC	O
Shen	NNP	O
in	IN	O
Traditional	NNP	O
Chinese	NNP	O
Medicine	NNP	O
,	,	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
second-generation	JJ	O
Hi-receptor	NNP	O
antagonist	NN	O
,	,	O
cetirizine	JJ	O
hydrochloride	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
on	IN	O
PER	NNP	O
will	MD	O
be	VB	O
conducted	VBN	O
at	IN	O
three	CD	O
institutions	NNS	O
in	IN	O
China	NNP	O
.	.	O

The	DT	O
total	JJ	O
study	NN	O
period	NN	O
will	MD	O
be	VB	O
9	CD	O
weeks	NNS	O
.	.	O

After	IN	O
a	DT	O
1-week	JJ	O
preparatory	NN	O
screening	VBG	O
period	NN	O
,	,	O
240	CD	O
eligible	JJ	O
participants	NNS	O
with	IN	O
PER	NNP	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
receive	VB	O
acupuncture	NN	O
or	CC	O
pharmacotherapy	NN	O
(	(	O
1:1	CD	O
)	)	O
for	IN	O
4	CD	O
weeks	NNS	O
with	IN	O
a	DT	O
4-week	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
will	MD	O
be	VB	O
changes	NNS	O
in	IN	O
7-day	JJ	Others
average	JJ	Others
total	JJ	Others
nasal	JJ	Others
symptom	NN	Others
score	NN	Others
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
include	VBP	O
rhinoconjunctivitis	JJ	Others
quality	NN	Others
of	IN	Others
life	NN	Others
questionnaire	NN	Others
score	NN	Others
and	CC	Physical
total	JJ	Others
non-nasal	JJ	Others
symptom	NN	Others
score	NN	Others
.	.	O

RESULTS	VB	O
The	DT	O
presence	NN	O
and	CC	O
seriousness	NN	O
of	IN	O
psychological	JJ	O
and	CC	O
emotional	JJ	O
impairments	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
therapeutic	JJ	O
programs	NNS	O
for	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

No	DT	O
clinical	JJ	O
trial	NN	O
for	IN	O
treating	VBG	O
allergic	JJ	O
rhinitis	NN	O
via	IN	O
acupuncture	NN	O
regulation	NN	O
of	IN	O
psychological	JJ	O
and	CC	O
emotional	JJ	O
activities	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
findings	NNS	O
of	IN	O
the	DT	O
trial	NN	O
will	MD	O
allow	VB	O
us	PRP	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
mind	NN	O
(	(	O
Shen	NNP	O
)	)	O
-regulation	NN	O
treatment	NN	O
approach	NN	O
.	.	O

We	PRP	O
will	MD	O
also	RB	O
be	VB	O
able	JJ	O
to	TO	O
confirm	VB	O
if	IN	O
the	DT	O
effects	NNS	O
of	IN	O
acupuncture	NN	O
are	VBP	O
equivalent	JJ	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
conventional	JJ	O
drug	NN	O
cetirizine	NN	O
hydrochloride	NN	O
.	.	O

[	NN	O
Using	VBG	O
gaviscon	JJ	O
preparation	NN	O
for	IN	O
relief	NN	O
of	IN	O
esophageal	NN	O
,	,	O
extraesophageal	JJ	O
syndromes	NNS	O
and	CC	O
functional	JJ	O
dyspepsia	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
GERD	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
alginate	JJ	O
drug	NN	O
Geviskon	NNP	O
and	CC	O
aluminum-magnesium	JJ	O
antacids	NNS	O
to	TO	O
relieve	VB	O
symptoms	NNS	O
of	IN	O
esophageal	NN	O
,	,	O
extraesophageal	JJ	O
syndrome	NN	O
and	CC	O
functional	JJ	O
dyspepsia	NN	O
at	IN	O
3	CD	O
and	CC	O
7	CD	O
days	NNS	O
of	IN	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
GERD	NNP	O
elderly	RB	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
An	DT	O
open	JJ	O
,	,	O
longitudinal	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	NN	O
.	.	O

The	DT	O
study	NN	O
included	VBD	O
60	CD	O
patients	NNS	O
with	IN	O
A	NNP	O
degree	NN	O
of	IN	O
ERD	NNP	O
,	,	O
consistently	RB	O
received	VBN	O
in-patient	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
Municipal	NNP	O
KGVV	NNP	O
,	,	O
mean	JJ	O
age	NN	O
79.0	CD	O
+/-	JJ	O
6.8	CD	O
years	NNS	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
12	CD	O
hours	NNS	O
of	IN	O
hospital	NN	O
stay	NN	O
by	IN	O
sealed	JJ	O
envelopes	NNS	O
them	PRP	O
randomly	RB	O
divided	VBD	O
into	IN	O
equal	JJ	O
groups	NNS	O
of	IN	O
comparison	NN	O
,	,	O
given	VBN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
:	:	O
alginate	JJ	O
product	NN	O
--	:	O
Geviskon	NNP	O
forte	VBP	O
dose	NN	O
of	IN	O
10	CD	O
ml	NNS	O
and	CC	O
aluminum-magnesium	JJ	O
antacid	JJ	O
drug	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
sachet	NN	O
.	.	O

Assess	IN	O
the	DT	O
frequency	NN	Physical
and	CC	O
severity	NN	Physical
of	IN	Physical
esophageal	NN	Physical
symptoms	NNS	Physical
,	,	Physical
extraesophageal	JJ	Physical
syndrome	NN	Physical
,	,	Physical
functional	JJ	Physical
dyspepsia	NN	Physical
at	IN	O
3	CD	O
and	CC	O
7	CD	O
days	NNS	O
of	IN	O
study	NN	O
on	IN	O
5-point	JJ	O
scale	NN	O
Likert	NNP	O
.	.	O

The	DT	O
degree	NN	Physical
of	IN	Physical
esophageal	NN	Physical
mucosal	JJ	Physical
injury	NN	Physical
was	VBD	O
determined	VBN	O
during	IN	O
endoscopy	NN	O
before	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
technique	NN	O
of	IN	O
alginate	NN	O
compared	VBN	O
with	IN	O
antacids	NNS	O
provided	VBN	O
significantly	RB	O
more	RBR	O
complete	JJ	O
and	CC	O
earlier	RBR	O
effect	NN	O
on	IN	O
the	DT	O
relief	NN	Physical
of	IN	Physical
heartburn	NN	Physical
,	,	Physical
regurgitation	NN	Physical
,	,	Physical
chronic	JJ	Physical
cough	NN	Physical
,	,	Physical
sore	RB	Physical
throat	NN	Physical
,	,	Physical
and	CC	Physical
EBS	NNP	Physical
.	.	Physical

Only	RB	O
Geviskon	NNP	O
influenced	VBD	O
the	DT	O
symptoms	NNS	O
of	IN	O
PPD	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
GERD	NNP	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
clinical	JJ	O
features	NNS	O
Geviskon	VBP	O
the	DT	O
frequency	NN	O
and	CC	O
timing	NN	O
of	IN	O
relief	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
esophageal	NN	Physical
,	,	O
extraesophageal	JJ	Physical
syndrome	NN	Physical
,	,	O
functional	JJ	Physical
dyspepsia	NN	Physical
with	IN	O
GERD	NNP	O
in	IN	O
the	DT	O
older	JJR	O
age	NN	O
groups	NNS	O
is	VBZ	O
higher	JJR	O
than	IN	O
that	DT	O
of	IN	O
antacids	NNS	O
.	.	O

Suspension	NNP	O
Geviskon	NNP	O
may	MD	O
be	VB	O
recommended	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
middle	JJ	O
and	CC	O
old	JJ	O
age	NN	O
as	IN	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
symptomatic	JJ	O
funds	NNS	O
in	IN	O
the	DT	O
first	JJ	O
days	NNS	O
of	IN	O
exchange	NN	O
rate	NN	O
earlier	RBR	O
generations	NNS	O
of	IN	O
PPI	NNP	O
therapy	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monotherapy	NN	O
--	:	O
to	TO	O
maintain	VB	O
remission	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
autologous	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
with	IN	O
sequential	JJ	O
chemotherapy	NN	O
for	IN	O
intermediate-grade	JJ	O
and	CC	O
high-grade	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
in	IN	O
first	JJ	O
complete	JJ	Physical
remission	NN	Physical
:	:	Physical
a	DT	O
study	NN	O
of	IN	O
464	CD	O
patients	NNS	O
.	.	O

Groupe	NNP	O
d'Etude	NN	O
des	NNS	O
Lymphomes	NNP	O
de	IN	O
l'Adulte	FW	O
.	.	O

PURPOSE	NNP	O
Intensive	NNP	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
autotransplantation	NN	O
has	VBZ	O
given	VBN	O
promising	VBG	O
results	NNS	O
in	IN	O
partially	RB	O
responding	VBG	O
or	CC	O
sensitive	JJ	O
relapsed	JJ	O
patients	NNS	O
with	IN	O
aggressive	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
.	.	O

In	IN	O
1987	CD	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
randomized	VBN	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
potential	JJ	O
benefit	NN	Physical
of	IN	O
a	DT	O
high-dose	JJ	O
regimen	NN	O
containing	VBG	O
cyclophosphamide	NN	O
,	,	O
carmustine	NN	O
,	,	O
and	CC	O
etoposide	RB	O
(	(	O
CBV	NNP	O
)	)	O
followed	VBN	O
by	IN	O
autotransplantation	NN	O
over	IN	O
a	DT	O
consolidative	JJ	O
sequential	JJ	O
chemotherapy	NN	O
(	(	O
ifosfamide	JJ	O
,	,	O
etoposide	RB	O
,	,	O
asparaginase	NN	O
,	,	O
and	CC	O
cytarabine	NN	O
)	)	O
in	IN	O
patients	NNS	O
in	IN	O
first	JJ	O
complete	JJ	O
remission	NN	O
with	IN	O
intermediate-	JJ	O
and	CC	O
high-grade	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
younger	JJR	O
than	IN	O
55	CD	O
years	NNS	O
and	CC	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
adverse	JJ	O
prognostic	JJ	O
factor	NN	O
.	.	O

Induction	NNP	O
treatment	NN	O
was	VBD	O
that	IN	O
of	IN	O
the	DT	O
LNH84	NNP	O
protocol	NN	O
with	IN	O
an	DT	O
open	JJ	O
randomization	NN	O
on	IN	O
the	DT	O
anthracycline	NN	O
.	.	O

Patients	NNS	O
in	IN	O
complete	JJ	Physical
remission	NN	Physical
were	VBD	O
further	JJ	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
consolidation	NN	O
procedure	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
induction	NN	O
treatment	NN	O
,	,	O
464	CD	O
patients	NNS	O
were	VBD	O
assessable	JJ	O
for	IN	O
the	DT	O
consolidation	NN	O
phase	NN	O
.	.	O

With	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
duration	NN	O
of	IN	O
28	CD	O
months	NNS	O
,	,	O
the	DT	O
3-year	JJ	Mortality
disease-free	JJ	Mortality
survival	NN	Mortality
rate	NN	Mortality
was	VBD	O
52	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
45	CD	O
%	NN	O
to	TO	O
59	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
sequential	JJ	O
chemotherapy	NN	O
arm	NN	O
and	CC	O
59	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
52	CD	O
%	NN	O
to	TO	O
66	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
autologous	JJ	O
transplant	NN	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
.46	NNP	O
,	,	O
relative	JJ	O
risk	NN	O
=	NNP	O
0.90	CD	O
)	)	O
.	.	O

The	DT	O
3-year	JJ	Mortality
survival	NN	Mortality
rate	NN	Mortality
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
sequential	JJ	O
chemotherapy	NN	O
and	CC	O
autotransplantation	NN	O
,	,	O
at	IN	O
71	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
64	CD	O
%	NN	O
to	TO	O
78	CD	O
%	NN	O
)	)	O
and	CC	O
69	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
62	CD	O
%	NN	O
to	TO	O
76	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.60	NNP	O
,	,	O
relative	JJ	O
risk	NN	O
=	NNP	O
1.11	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
For	IN	O
such	JJ	O
a	DT	O
subset	NN	O
of	IN	O
patients	NNS	O
,	,	O
consolidation	NN	O
with	IN	O
the	DT	O
CBV	NNP	O
regimen	NNS	O
followed	VBN	O
by	IN	O
autologous	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
is	VBZ	O
not	RB	O
superior	JJ	Others
to	TO	O
sequential	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
trandolapril	NN	O
and	CC	O
its	PRP$	O
fixed-dose	JJ	O
combination	NN	O
with	IN	O
verapamil	NN	O
on	IN	O
circulating	VBG	O
adhesion	NN	O
molecules	NNS	O
levels	NNS	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
Endothelial	NNP	O
dysfunction	NN	O
in	IN	O
hypertensive	JJ	O
type-2	JJ	O
diabetic	JJ	O
patients	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
circulating	VBG	O
soluble	JJ	Physical
adhesion	NN	Physical
molecules	NNS	Physical
(	(	Physical
SAM	NNP	Physical
)	)	Physical
.	.	O

SAM	NNP	O
participate	VB	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
diabetic	JJ	O
macroangiopathy	NN	O
and	CC	O
microangiopathy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
trandolapril	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
its	PRP$	O
fixed-dose	JJ	O
combination	NN	O
with	IN	O
verapamil	NN	O
(	(	O
FDTV	NNP	O
)	)	O
on	IN	O
SAM	NNP	O
levels	NNS	O
in	IN	O
hypertensive	JJ	O
type-2	JJ	O
diabetic	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
type-2	JJ	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
never-treated	JJ	O
hypertension	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
(	(	O
FDTV	NNP	O
)	)	O
received	VBD	O
2/180	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
;	:	O
the	DT	O
other	JJ	O
group	NN	O
received	VBD	O
T	NNP	O
2	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
.	.	O

Study	NNP	O
drugs	NNS	O
were	VBD	O
administered	VBN	O
for	IN	O
three	CD	O
months	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

VCAM-1	NNP	Physical
,	,	O
ICAM	NNP	Physical
,	,	O
and	CC	O
E-selectin	NNP	Physical
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
monthly	RB	O
for	IN	O
blood	NN	O
pressure	NN	O
,	,	O
fasting	VBG	O
serum	NN	O
glucose	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
ANOVA	NNP	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
therapeutics	NNS	O
regimens	NNS	O
reduced	VBD	O
significantly	RB	O
the	DT	O
levels	NNS	Physical
of	IN	Physical
the	DT	Physical
SAM	NNP	Physical
tested	VBD	Physical
.	.	O

When	WRB	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
we	PRP	O
did	VBD	O
not	RB	O
find	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
ICAM	NNP	Physical
and	CC	O
E-selectin	NNP	Physical
reduction	NN	Physical
.	.	O

However	RB	O
,	,	O
VCAM-1	NNP	Physical
presented	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.022	CD	O
)	)	O
in	IN	O
the	DT	O
trandolapril-verapamil	JJ	O
group	NN	O
.	.	O

No	DT	O
patient	NN	O
suffered	VBD	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
FDTV	NNP	O
produces	VBZ	O
a	DT	O
greater	JJR	O
reduction	NN	O
of	IN	O
VCAM-1	NNP	O
circulating	NN	O
levels	NNS	O
than	IN	O
trandolapril	NN	O
alone	RB	O
.	.	O

This	DT	O
may	MD	O
explain	VB	O
some	DT	O
of	IN	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
fixed	VBN	O
dosed	JJ	O
combination	NN	O
that	WDT	O
are	VBP	O
non-related	JJ	O
to	TO	O
its	PRP$	O
antihypertensive	JJ	O
effects	NNS	O
.	.	O

Relation	NN	O
between	IN	O
early	JJ	O
mitral	JJ	O
regurgitation	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
thrombus	NN	O
formation	NN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
GISSI-3	NNP	O
echo	NN	O
substudy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
prevalence	NN	O
and	CC	O
correlates	NNS	O
of	IN	O
left	JJ	O
ventricular	JJ	O
thrombosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
whether	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
early	JJ	O
mitral	JJ	O
regurgitation	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
the	DT	O
formation	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
thrombus	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
SETTING	NNP	O
Multicentre	NNP	O
clinical	JJ	O
trial	NN	O
carried	VBD	O
out	IN	O
in	IN	O
47	CD	O
Italian	JJ	O
coronary	JJ	O
care	NN	O
units	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
757	CD	O
patients	NNS	O
from	IN	O
the	DT	O
GISSI-3	NNP	O
echo	NN	O
substudy	NN	O
population	NN	O
with	IN	O
their	PRP$	O
first	JJ	O
acute	JJ	O
myocardial	JJ	O
infarct	NN	O
were	VBD	O
studied	VBN	O
by	IN	O
echocardiography	NN	O
at	IN	O
24-48	JJ	O
hours	NNS	O
from	IN	O
symptom	JJ	O
onset	NN	O
(	(	O
S1	NNP	O
)	)	O
,	,	O
at	IN	O
discharge	NN	O
(	(	O
S2	NNP	O
)	)	O
,	,	O
at	IN	O
six	CD	O
weeks	NNS	O
(	(	O
S3	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
six	CD	O
months	NNS	O
(	(	O
S4	NNP	O
)	)	O
.	.	O

The	DT	O
diagnosis	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
thrombosis	NN	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
detection	NN	O
of	IN	O
an	DT	O
echo	JJ	O
dense	NN	O
mass	NN	O
with	IN	O
defined	JJ	O
margins	NNS	O
visible	JJ	O
throughout	IN	O
the	DT	O
cardiac	JJ	O
cycle	NN	O
in	IN	O
at	IN	O
least	JJS	O
two	CD	O
orthogonal	JJ	O
views	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
64	CD	O
patients	NNS	O
(	(	O
8	CD	O
%	NN	O
)	)	O
,	,	O
left	VBD	Physical
ventricular	JJ	Physical
thrombosis	NN	Physical
was	VBD	O
detected	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
examinations	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
remaining	VBG	O
693	CD	O
patients	NNS	O
,	,	O
subjects	NNS	O
with	IN	O
left	JJ	Physical
ventricular	JJ	Physical
thrombosis	NN	Physical
were	VBD	O
older	JJR	O
(	(	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
age	NN	O
:	:	O
64.6	CD	O
(	(	O
13.0	CD	O
)	)	O
v	NN	O
59.8	CD	O
(	(	O
11.7	CD	O
)	)	O
years	NNS	O
,	,	O
p	NN	O
<	NNP	O
0.005	CD	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
larger	JJR	Physical
infarcts	NNS	Physical
(	(	O
extent	NN	O
of	IN	O
wall	NN	O
motion	NN	O
asynergy	NN	O
:	:	O
40.9	CD	O
(	(	O
11.5	CD	O
)	)	O
%	NN	O
v	JJ	O
24.9	CD	O
(	(	O
14	CD	O
)	)	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
greater	JJR	O
depression	NN	Physical
of	IN	Physical
left	JJ	Physical
ventricular	JJ	Physical
ejection	NN	Physical
fraction	NN	Physical
at	IN	Physical
S1	NNP	Physical
(	(	O
43.3	CD	O
(	(	O
6.9	CD	O
)	)	O
%	NN	O
v	JJ	O
48.1	CD	O
(	(	O
6.8	CD	O
)	)	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
greater	JJR	O
left	VBD	Physical
ventricular	JJ	Physical
volumes	NNS	Physical
at	IN	Physical
S1	NNP	Physical
(	(	O
end	VB	O
diastolic	NN	O
volume	NN	O
:	:	O
87	CD	O
(	(	O
22	CD	O
)	)	O
v	NN	O
78	CD	O
(	(	O
18	CD	O
)	)	O
ml/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
p	JJ	O
<	VBP	O
0.001	CD	O
;	:	O
end	VB	O
systolic	JJ	O
volume	NN	O
:	:	O
50	CD	O
(	(	O
17	CD	O
)	)	O
v	NN	O
41	CD	O
(	(	O
14	CD	O
)	)	O
ml/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
prevalence	NN	Physical
of	IN	Physical
moderate	JJ	Physical
to	TO	Physical
severe	VB	Physical
mitral	JJ	Physical
regurgitation	NN	Physical
on	IN	Physical
colour	NN	Physical
Doppler	NNP	Physical
at	IN	Physical
S1	NNP	Physical
was	VBD	O
greater	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
left	VBN	Physical
ventricular	JJ	Physical
thrombosis	NN	Physical
at	IN	O
any	DT	O
time	NN	O
(	(	O
10.2	CD	O
%	NN	O
v	JJ	O
4.2	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

On	IN	O
stepwise	NN	O
multiple	JJ	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
the	DT	O
only	JJ	O
independent	JJ	O
variables	NNS	O
related	VBN	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
left	JJ	Physical
ventricular	JJ	Physical
thrombosis	NN	Physical
were	VBD	O
the	DT	O
extent	NN	O
of	IN	O
wall	NN	O
motion	NN	O
asynergy	NN	O
and	CC	O
anterior	JJ	O
site	NN	O
of	IN	O
infarction	NN	O
.	.	O

CONCLUSIONS	NNP	O
Left	NNP	Physical
ventricular	JJ	Physical
thrombosis	NN	Physical
is	VBZ	O
not	RB	O
reduced	VBN	O
,	,	O
and	CC	O
may	MD	O
even	RB	O
be	VB	O
increased	VBN	O
,	,	O
by	IN	O
early	JJ	O
moderate	NN	O
to	TO	O
severe	VB	O
mitral	JJ	O
regurgitation	NN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

The	DT	O
only	JJ	O
independent	JJ	O
determinant	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
thrombosis	NN	O
is	VBZ	O
the	DT	O
extent	NN	O
of	IN	O
the	DT	O
akinetic-dyskinetic	JJ	O
area	NN	O
detected	VBN	O
on	IN	O
echocardiography	NN	O
between	IN	O
24-48	JJ	O
hours	NNS	O
from	IN	O
symptom	JJ	O
onset	NN	O
.	.	O

Twice-a-day	JJ	O
versus	NN	O
four-times-a-day	JJ	O
ofloxacin	JJ	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
infection	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	Others
of	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
when	WRB	O
given	VBN	O
twice-a-day	JJ	O
(	(	O
BID	NNP	O
)	)	O
versus	IN	O
four-times-a-day	JJ	O
(	(	O
QID	NNP	O
)	)	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Fifty	NNP	O
patients	NNS	O
with	IN	O
blepharitis	NN	O
,	,	O
conjuctivitis	NN	O
,	,	O
or	CC	O
blepharoconjunctivitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
BID	NNP	O
or	CC	O
QID	NNP	O
,	,	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

Signs	NNP	O
,	,	O
symptoms	NNS	O
,	,	O
and	CC	O
cultures	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
clinical	JJ	O
outcome	NN	O
was	VBD	O
virtually	RB	O
identical	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	Others
scores	NNS	Others
in	IN	O
the	DT	O
BID	NNP	O
and	CC	O
QID	NNP	O
groups	NNS	O
by	IN	O
days	NNS	O
3	CD	O
to	TO	O
5	CD	O
(	(	O
2.6-3.0	JJ	O
points	NNS	O
)	)	O
and	CC	O
a	DT	O
further	JJ	O
decrease	NN	O
by	IN	O
day	NN	O
11	CD	O
(	(	O
4.3-5.0	JJ	O
points	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
at	IN	O
any	DT	O
time	NN	O
interval	NN	O
.	.	O

Microbiologic	NNP	O
studies	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
colony-forming	JJ	Physical
units	NNS	Physical
in	IN	O
87	CD	O
%	NN	O
of	IN	O
the	DT	O
BID	NNP	O
group	NN	O
and	CC	O
in	IN	O
80	CD	O
%	NN	O
of	IN	O
the	DT	O
QID	NNP	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
external	JJ	Physical
ocular	JJ	Physical
disease	NN	Physical
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	Others
eyedrops	NN	Others
was	VBD	Others
equally	RB	Others
effective	JJ	Others
when	WRB	Others
given	VBN	Others
BID	NNP	Others
or	CC	Others
QID	NNP	Others
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
an	DT	O
aqueous	JJ	O
and	CC	O
a	DT	O
pressurized	JJ	O
nasal	NN	O
spray	NN	O
of	IN	O
beclomethasone	NN	O
dipropionate	NN	O
in	IN	O
the	DT	O
management	NN	Physical
of	IN	Physical
seasonal	JJ	Physical
rhinitis	NN	Physical
.	.	O

A	DT	O
multi-centre	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
38	CD	O
patients	NNS	O
with	IN	O
seasonal	JJ	O
rhinitis	NN	O
to	TO	O
compare	VB	O
a	DT	O
new	JJ	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
of	IN	O
beclomethasone	NN	O
dipropionate	NN	O
with	IN	O
the	DT	O
conventional	JJ	O
pressurized	JJ	O
nasal	NN	O
spray	NN	O
.	.	O

Beclomethasone	NNP	O
dipropionate	NN	O
(	(	O
200	CD	O
micrograms	NNS	O
)	)	O
was	VBD	O
administered	VBN	O
twice	RB	O
daily	RB	O
for	IN	O
a	DT	O
treatment	NN	O
period	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Both	DT	O
treatments	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
equally	RB	O
effective	JJ	Others
and	CC	Others
well	RB	Others
tolerated	VBN	Others
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
,	,	O
therefore	RB	O
,	,	O
that	IN	O
the	DT	O
new	JJ	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
provides	VBZ	O
an	DT	O
alternative	JJ	O
method	NN	O
of	IN	O
intranasal	JJ	O
administration	NN	O
of	IN	O
the	DT	O
steroid	NN	O
for	IN	O
patients	NNS	O
who	WP	O
may	MD	O
prefer	VB	O
an	DT	O
aqueous	JJ	O
product	NN	O
.	.	O

[	JJ	O
Comparison	NNP	O
of	IN	O
three	CD	O
analgesic	JJ	O
methods	NNS	O
for	IN	O
postoperative	JJ	O
pain	NN	O
relief	NN	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
plasma	JJ	Physical
interleukin-6	JJ	Physical
concentration	NN	Physical
following	VBG	O
radical	JJ	O
surgery	NN	O
for	IN	O
gastric	JJ	O
carcinoma	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
preemptive	JJ	O
epidural	JJ	O
analgesia	NN	O
combined	VBN	O
with	IN	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
,	,	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
alone	RB	O
and	CC	O
intravenous	JJ	O
analgesia	NN	O
for	IN	O
postoperative	JJ	Pain
pain	NN	Pain
relief	NN	Pain
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
plasma	JJ	Physical
interleukin-6	JJ	Physical
(	(	Physical
IL-6	NNP	Physical
)	)	Physical
concentration	NN	Physical
following	VBG	O
radical	JJ	O
surgery	NN	O
for	IN	O
gastric	JJ	O
carcinoma	NN	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	O
patients	NNS	O
with	IN	O
gastric	JJ	O
carcinoma	NN	O
scheduled	VBN	O
for	IN	O
gastrectomy	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
,	,	O
namely	RB	O
group	NN	O
P	NNP	O
(	(	O
n=22	NN	O
)	)	O
,	,	O
group	NN	O
E	NNP	O
(	(	O
n=22	NN	O
)	)	O
and	CC	O
group	NN	O
V	NNP	O
(	(	O
n=22	NN	O
)	)	O
,	,	O
to	TO	O
receive	VB	O
preemptive	JJ	O
epidural	JJ	O
analgesia	NN	O
combined	VBN	O
with	IN	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
,	,	O
exclusive	JJ	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
,	,	O
and	CC	O
exclusive	JJ	O
postoperative	NN	O
intravenous	JJ	O
analgesia	NN	O
,	,	O
respectively	RB	O
.	.	O

Hemodynamic	NNP	Physical
data	NNS	Physical
were	VBD	O
recorded	VBN	O
for	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
during	IN	O
the	DT	O
operation	NN	O
,	,	O
and	CC	O
visual	JJ	Others
analogue	NN	Others
scale	NN	Others
(	(	Others
VAS	NNP	Others
)	)	Others
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
pain	NN	Pain
intensity	NN	Pain
at	IN	O
4	CD	O
,	,	O
8	CD	O
,	,	O
16	CD	O
,	,	O
24	CD	O
,	,	O
48	CD	O
and	CC	O
72	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

Plasma	NNP	Physical
IL-6	JJ	Physical
concentration	NN	Physical
was	VBD	O
determined	VBN	O
before	IN	O
surgery	NN	O
and	CC	O
at	IN	O
24	CD	O
,	,	O
48	CD	O
,	,	O
72	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
changes	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
hemodynamics	NNS	O
during	IN	O
the	DT	O
preoperative	JJ	O
periods	NNS	O
.	.	O

VAS	NNP	Others
and	CC	O
IL-6	NNP	Physical
were	VBD	O
lower	JJR	O
in	IN	O
group	NN	O
P	NNP	O
than	IN	O
in	IN	O
group	NN	O
E	NNP	O
and	CC	O
V	NNP	O
,	,	O
and	CC	O
group	NN	O
E	NNP	O
had	VBD	O
lower	JJR	O
measurement	NN	O
than	IN	O
group	NN	O
V	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Preemptive	NNP	O
epidural	JJ	O
analgesia	NN	O
combined	VBN	O
with	IN	O
postoperative	JJ	O
epidural	JJ	O
analgesia	NN	O
provides	VBZ	O
more	RBR	O
satisfactory	JJ	O
pain	NN	Pain
relief	NN	Pain
and	CC	O
more	RBR	O
effectively	RB	O
prevents	VBZ	O
IL-6	JJ	Physical
increment	NN	Physical
than	IN	O
exclusive	JJ	O
epidural	JJ	O
analgesia	NN	O
or	CC	O
intravenous	JJ	O
analgesia	NN	O
after	IN	O
gastrectomy	NN	O
for	IN	O
gastric	JJ	O
carcinoma	NN	O
.	.	O

Age-related	JJ	Physical
response	NN	Physical
to	TO	O
two	CD	O
Haemophilus	NNP	O
influenzae	NN	O
type	NN	O
b	NN	O
vaccines	NNS	O
.	.	O

Two	CD	O
types	NNS	O
of	IN	O
Hib	NNP	O
vaccines	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
in	IN	O
71	CD	O
normal	JJ	O
children	NNS	O
in	IN	O
three	CD	O
age	NN	O
groups	NNS	O
:	:	O
36	CD	O
to	TO	O
72	CD	O
months	NNS	O
,	,	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
6	CD	O
to	TO	O
8	CD	O
months	NNS	O
.	.	O

One	CD	O
vaccine	NN	O
contained	VBD	O
the	DT	O
Hib-specific	NNP	O
capsular	JJ	O
polysaccharide	NN	O
,	,	O
PRP	NNP	O
;	:	O
the	DT	O
second	JJ	O
vaccine	NN	O
contained	VBN	O
PRP	NNP	O
combined	VBN	O
with	IN	O
pertussis	NN	O
vaccine	NN	O
,	,	O
PRP-P.	NNP	O
A	NNP	O
third	JJ	O
vaccine	NN	O
,	,	O
DTP	NNP	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
for	IN	O
each	DT	O
age	NN	O
.	.	O

Anti-PRP	NNP	Physical
antibody	NN	Physical
levels	NNS	Physical
were	VBD	O
greater	JJR	O
after	IN	O
vaccination	NN	O
with	IN	O
PRP-P	NNP	O
than	IN	O
after	IN	O
PRP	NNP	O
in	IN	O
all	DT	O
three	CD	O
age	NN	O
groups	NNS	O
.	.	O

Immunoresponsiveness	NN	Physical
to	TO	O
both	DT	O
vaccines	NNS	O
increased	VBD	O
with	IN	O
age	NN	O
.	.	O

A	DT	O
lower	JJR	Adverseeffect
incidence	NN	Adverseeffect
of	IN	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
was	VBD	O
seen	VBN	O
with	IN	O
both	DT	O
PRP	NNP	O
(	(	O
15	CD	O
%	NN	O
)	)	O
and	CC	O
PRP-P	NNP	O
(	(	O
20	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
DTP	NNP	O
(	(	O
56	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
PRP-P	NNP	O
is	VBZ	O
both	DT	O
well	RB	Others
tolerated	VBN	Others
clinically	RB	Others
and	CC	Others
has	VBZ	Others
greater	JJR	Others
immunogenicity	NN	Others
than	IN	O
PRP	NNP	O
.	.	O

Stepwise	NNP	O
hook	NN	O
extension	NN	O
technique	NN	O
for	IN	O
radiofrequency	NN	O
ablation	NN	O
therapy	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stepwise	NN	O
hook	NN	O
extension	NN	O
technique	NN	O
for	IN	O
radiofrequency	NN	O
ablation	NN	O
(	(	O
RFA	NNP	O
)	)	O
therapy	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
.	.	O

METHOD	NNP	O
Twenty	NNP	O
patients	NNS	O
with	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
measuring	VBG	O
<	$	O
25	CD	O
mm	NN	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
equal	JJ	O
groups	NNS	O
.	.	O

RFA	NNP	O
was	VBD	O
applied	VBN	O
using	VBG	O
our	PRP$	O
new	JJ	O
stepwise	NN	O
hook	NN	O
extension	NN	O
technique	NN	O
in	IN	O
patients	NNS	O
of	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
the	DT	O
full	JJ	O
extension	NN	O
method	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

The	DT	O
10-hook	JJ	O
electrode	NN	O
of	IN	O
LeVeen	NNP	O
needle	NN	O
was	VBD	O
deployed	VBN	O
in	IN	O
four	CD	O
steps	NNS	O
to	TO	O
full	JJ	O
extension	NN	O
during	IN	O
ablation	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
full	JJ	O
extension	NN	O
at	IN	O
start	NN	O
of	IN	O
treatment	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

RESULTS	VB	O
Roll-off	NNP	Physical
was	VBD	O
achieved	VBN	O
in	IN	O
all	DT	O
10	CD	O
patients	NNS	O
of	IN	O
group	NN	O
1	CD	O
,	,	O
indicative	NN	O
of	IN	O
sufficient	JJ	O
tumor	NN	O
coagulation	NN	O
,	,	O
but	CC	O
only	RB	O
in	IN	O
3	CD	O
of	IN	O
10	CD	O
patients	NNS	O
of	IN	O
group	NN	O
2	CD	O
.	.	O

The	DT	O
median	JJ	Others
time	NN	Others
to	TO	Others
completion	NN	Others
of	IN	Others
treatment	NN	Others
was	VBD	O
6	CD	O
min	NN	O
and	CC	O
55	CD	O
s	NN	O
(	(	O
range	VB	O
3	CD	O
min	NN	O
to	TO	O
14	CD	O
min	NNS	O
and	CC	O
3	CD	O
s	NN	O
)	)	O
and	CC	O
15	CD	O
min	NN	O
(	(	O
6-15	JJ	O
min	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
total	JJ	Others
power	NN	Others
output	NN	Others
used	VBN	O
for	IN	O
RF	NNP	O
was	VBD	O
lower	JJR	O
in	IN	O
group	NN	O
1	CD	O
than	IN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
median	JJ	O
271	CD	O
vs.	FW	O
1,045	CD	O
W.m	NNP	O
)	)	O
.	.	O

The	DT	O
diameters	NNS	Physical
of	IN	Physical
RFA-induced	JJ	Physical
lesions	NNS	Physical
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
group	NN	O
1	CD	O
:	:	O
27	CD	O
,	,	O
range	NN	O
23-37	JJ	O
mm	NN	O
;	:	O
group	NN	O
2	CD	O
:	:	O
23	CD	O
,	,	O
0-42	JJ	O
mm	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Application	NNP	O
of	IN	O
RFA	NNP	O
using	VBG	O
stepwise	NN	O
hook	NN	O
extension	NN	O
technique	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
the	DT	O
full	JJ	O
extension	NN	O
method	NN	O
since	IN	O
it	PRP	O
produces	VBZ	O
the	DT	O
same	JJ	Others
therapeutic	JJ	Others
effects	NNS	Others
within	IN	O
a	DT	O
short	JJ	O
period	NN	O
using	VBG	O
a	DT	O
lower	JJR	O
energy	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
ebrotidine	NN	O
and	CC	O
ranitidine	NN	O
combined	VBN	O
with	IN	O
amoxicillin	NN	O
and	CC	O
metronidazole	NN	O
in	IN	O
the	DT	O
eradication	NN	Others
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
in	IN	O
patients	NNS	O
with	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

This	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
phase	VB	O
III	NNP	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
two	CD	O
parallel	JJ	O
groups	NNS	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
ebrotidine	NN	O
(	(	O
N-	JJ	O
[	NN	O
(	(	O
E	NNP	O
)	)	O
-	:	O
[	JJ	O
[	JJ	O
2-	JJ	O
[	NN	O
[	NNP	O
[	NNP	O
2-	JJ	O
[	NNP	O
(	(	O
diaminomethylene	NN	O
)	)	O
amino	NN	O
]	JJ	O
-4-thiazolyl	NNP	O
]	NNP	O
methyl	NN	O
]	NNP	O
thio	NN	O
]	NNP	O
ethyl	VBZ	O
]	NNP	O
amino	NN	O
]	NNP	O
methylene	NN	O
]	NNP	O
-4-bromo-benzenesulfonamide	NNP	O
,	,	O
CAS	NNP	O
100981-43-9	CD	O
,	,	O
FI-3542	NNP	O
)	)	O
400	CD	O
mg	NN	O
and	CC	O
ranitidine	VB	O
300	CD	O
mg	NN	O
given	VBN	O
in	IN	O
single	JJ	O
evening	NN	O
dose	NN	O
,	,	O
combined	VBN	O
with	IN	O
amoxicillin	JJ	O
750	CD	O
mg	NN	O
and	CC	O
metronidazole	$	O
500	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
,	,	O
in	IN	O
the	DT	O
eradication	NN	Physical
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
in	IN	O
patients	NNS	O
with	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

Thirty	JJ	O
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
of	IN	O
15	CD	O
,	,	O
to	TO	O
whom	WP	O
one	CD	O
of	IN	O
the	DT	O
study	NN	O
therapies	NNS	O
was	VBD	O
administered	VBN	O
based	VBN	O
on	IN	O
a	DT	O
randomization	NN	O
code	NN	O
.	.	O

Clinical	JJ	O
and	CC	O
endoscopic	JJ	O
controls	NNS	O
were	VBD	O
performed	VBN	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
demographic	JJ	Physical
parameters	NNS	Physical
and	CC	O
clinical	JJ	Physical
histories	NNS	Physical
.	.	O

They	PRP	O
were	VBD	O
both	DT	O
perfectly	RB	O
homogeneous	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
eradication	NN	Physical
of	IN	O
both	DT	O
therapies	NNS	O
in	IN	O
both	DT	O
the	DT	O
antrum	NN	O
and	CC	O
gastric	JJ	O
body	NN	O
samples	NNS	O
(	(	O
over	IN	O
80	CD	O
%	NN	O
eradication	NN	O
)	)	O
,	,	O
allowing	VBG	O
the	DT	O
results	NNS	O
to	TO	O
be	VB	O
classified	VBN	O
as	IN	O
satisfactory	NN	O
.	.	O

Moreover	RB	O
,	,	O
perfect	JJ	O
control	NN	O
was	VBD	O
achieved	VBN	O
through	IN	O
the	DT	O
study	NN	O
of	IN	O
clinical	JJ	Physical
symptoms	NNS	Physical
,	,	O
which	WDT	O
even	RB	O
disappeared	VBD	O
in	IN	O
some	DT	O
cases	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
healing	VBG	Physical
rate	NN	Physical
of	IN	O
the	DT	O
duodenal	JJ	O
ulcer	NN	O
after	IN	O
four	CD	O
weeks	NNS	O
,	,	O
86.7	CD	O
%	NN	O
being	VBG	O
achieved	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Omega-3/omega-6	NNP	O
fatty	JJ	O
acids	NNS	O
for	IN	O
attention	NN	Mental
deficit	NN	Mental
hyperactivity	NN	Mental
disorder	NN	Mental
:	:	Mental
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
omega	JJ	O
3/6	CD	O
fatty	JJ	O
acids	NNS	O
(	(	O
eye	NN	O
q	NN	O
)	)	O
in	IN	O
attention	NN	Mental
deficit	NN	Mental
hyperactivity	NN	Mental
disorder	NN	Mental
(	(	Mental
ADHD	NNP	Mental
)	)	Mental
.	.	Mental

METHOD	PDT	O
The	DT	O
study	NN	O
included	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
3-month	JJ	O
,	,	O
omega	JJ	O
3/6	CD	O
placebo-controlled	JJ	O
,	,	O
one-way	JJ	O
crossover	NN	O
trial	NN	O
with	IN	O
75	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
8-18	CD	O
years	NNS	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
with	IN	O
omega	JJ	O
3/6	CD	O
for	IN	O
all	DT	O
.	.	O

Investigator-rated	JJ	Mental
ADHD	NNP	Mental
Rating	NNP	Mental
Scale-IV	NNP	Mental
and	CC	Mental
Clinical	NNP	Mental
Global	NNP	Mental
Impression	NNP	Mental
(	(	Mental
CGI	NNP	Mental
)	)	Mental
scale	NN	Mental
were	VBD	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
majority	NN	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
omega	VB	O
3/6	CD	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subgroup	NN	O
of	IN	O
26	CD	O
%	NN	O
responded	VBD	O
with	IN	O
more	JJR	O
than	IN	O
25	CD	O
%	NN	O
reduction	NN	Mental
of	IN	Mental
ADHD	NNP	Mental
symptoms	NNS	Mental
and	CC	O
a	DT	O
drop	NN	Mental
of	IN	Mental
CGI	NNP	Mental
scores	NNS	Mental
to	TO	O
the	DT	O
near-normal	JJ	O
range	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
47	CD	O
%	NN	O
of	IN	O
all	DT	O
showed	VBD	O
such	JJ	O
improvement	NN	O
.	.	O

Responders	NNS	O
tended	VBD	O
to	TO	O
have	VB	O
ADHD	NNP	Mental
inattentive	JJ	O
subtype	NN	O
and	CC	O
comorbid	NN	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

CONCLUSION	VB	O
A	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ADHD	NNP	Mental
,	,	O
characterized	VBN	O
by	IN	O
inattention	NN	O
and	CC	O
associated	VBN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
treated	VBN	O
with	IN	O
omega	JJ	O
3/6	CD	O
fatty	JJ	O
acids	NNS	O
for	IN	O
6	CD	O
months	NNS	O
responded	VBN	O
with	IN	O
meaningful	JJ	O
reduction	NN	Mental
of	IN	Mental
ADHD	NNP	Mental
symptoms	NNS	Mental
.	.	Mental

[	IN	O
The	DT	O
somatostatin	NN	O
infusion	NN	O
test	NN	O
for	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
glucose	JJ	Physical
utilization	NN	Physical
in	IN	O
bezafibrate	JJ	O
medication	NN	O
]	NN	O
.	.	O

The	DT	O
utilisation	NN	O
of	IN	O
blood	NN	Physical
glucose	NN	Physical
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
definition	NN	O
of	IN	O
insulin	NN	O
resistance	NN	O
in	IN	O
type	NN	O
II	NNP	O
diabetes	VBZ	O
mellitus	NN	O
.	.	O

To	TO	O
evaluate	VB	O
this	DT	O
possibility	NN	O
we	PRP	O
adapted	VBD	O
an	DT	O
infusion	NN	O
test	NN	O
of	IN	O
somatostatin	NN	O
in	IN	O
10	CD	O
normal	JJ	O
persons	NNS	O
(	(	O
age	NN	O
26	CD	O
+/-	JJ	O
3	CD	O
years	NNS	O
,	,	O
relative	JJ	O
body	NN	O
weight	VBD	O
26	CD	O
+/-	JJ	O
10	CD	O
%	NN	O
according	VBG	O
to	TO	O
Broca	NNP	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
cross-over	NN	O
therapy	NN	O
with	IN	O
bezafibrate	NN	O
(	(	O
3	CD	O
X	RB	O
200	CD	O
mg/die	NN	O
)	)	O
.	.	O

As	IN	O
the	DT	O
coefficient	NN	O
of	IN	O
variation	NN	O
(	(	O
VC	NNP	O
)	)	O
of	IN	O
measured	VBN	O
blood	NN	Physical
glucose	NN	Physical
continuously	RB	O
increased	VBD	O
the	DT	O
best	JJS	O
time	NN	O
of	IN	O
a	DT	O
steady	JJ	O
state	NN	O
was	VBD	O
between	IN	O
90	CD	O
and	CC	O
130	CD	O
min	NN	O
after	IN	O
beginning	VBG	O
the	DT	O
infusion	NN	O
(	(	O
mean	JJ	O
VC	NNP	O
8.9	CD	O
%	NN	O
)	)	O
.	.	O

While	IN	O
insulin	NN	Physical
remained	VBD	O
nearly	RB	O
constant	JJ	O
(	(	O
41	CD	O
(	(	O
45	CD	O
;	:	O
38	CD	O
)	)	O
microU/ml	NN	O
)	)	O
blood	NN	Physical
glucose	NN	Physical
dropped	VBN	O
by	IN	O
about	IN	O
14	CD	O
%	NN	O
and	CC	O
reached	VBD	O
a	DT	O
steady	JJ	O
state	NN	O
of	IN	O
89	CD	O
(	(	O
134	CD	O
;	:	O
45	CD	O
)	)	O
mg/dl	NN	O
.	.	O

During	IN	O
the	DT	O
therapy	NN	O
of	IN	O
bezafibrate	NN	O
blood	NN	Physical
glucose	NN	Physical
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
36	CD	O
%	NN	O
130	CD	O
min	NN	O
after	IN	O
beginning	VBG	O
the	DT	O
infusion	NN	O
.	.	O

Although	IN	O
the	DT	O
effect	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
during	IN	O
the	DT	O
whole	JJ	O
time	NN	O
of	IN	O
the	DT	O
steady	JJ	O
state	NN	O
it	PRP	O
became	VBD	O
evident	JJ	O
by	IN	O
a	DT	O
negative	JJ	O
correlation	NN	O
with	IN	O
lactate	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.687	NNP	O
)	)	O
and	CC	O
pyruvate	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.843	NNP	O
)	)	O
.	.	O

A	DT	O
correlation	NN	O
with	IN	O
a	DT	O
concomitant	JJ	O
decrease	NN	O
of	IN	O
triglyceride	NN	Physical
and	CC	O
cholesterol	NN	Physical
also	RB	O
induced	VBN	O
by	IN	O
bezafibrate	NN	O
could	MD	O
not	RB	O
be	VB	O
proven	RB	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
infusion	NN	O
test	NN	O
of	IN	O
somatostatin	NN	O
is	VBZ	O
fitted	VBN	O
to	TO	O
measure	VB	O
a	DT	O
steady	JJ	O
state	NN	O
of	IN	O
blood	NN	Physical
glucose	NN	Physical
and	CC	O
insulin	NN	Physical
and	CC	O
that	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
by	IN	O
this	DT	O
technique	NN	O
to	TO	O
quantify	VB	O
a	DT	O
changed	JJ	O
utilisation	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
induced	VBN	O
by	IN	O
specific	JJ	O
therapy	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
auditory	JJ	O
integrative	JJ	O
training	NN	O
on	IN	O
autistic	JJ	O
children	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
short-term	JJ	O
treatment	NN	O
effect	NN	O
of	IN	O
the	DT	O
auditory	JJ	O
integrative	JJ	O
training	NN	O
on	IN	O
autistic	JJ	O
children	NNS	O
and	CC	O
provide	VB	O
them	PRP	O
with	IN	O
clinical	JJ	O
support	NN	O
for	IN	O
rehabilitative	JJ	O
treatment	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
81	CD	O
cases	NNS	O
of	IN	O
autistic	JJ	O
children	NNS	O
were	VBD	O
selected	VBN	O
through	IN	O
the	DT	O
standard	NN	O
of	IN	O
DSM-4	NNP	O
and	CC	O
clinical	JJ	O
case	NN	O
study	NN	O
was	VBD	O
used	VBN	O
.	.	O

They	PRP	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
experimental	JJ	O
group	NN	O
and	CC	O
control	VB	O
one	CD	O
,	,	O
and	CC	O
respectively	RB	O
received	VBD	O
auditory	JJ	O
integrative	JJ	O
training	NN	O
and	CC	O
no	DT	O
training	NN	O
based	VBN	O
on	IN	O
the	DT	O
multiple	JJ	O
therapies	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
investigated	VBN	O
using	VBG	O
clinical	JJ	Physical
manifestation	NN	Physical
and	CC	O
Autism	NNP	Others
Behavior	NNP	Others
Checklist	NNP	Others
(	(	Others
ABC	NNP	Others
)	)	Others
and	CC	O
intelligence	NN	Others
quotient	NN	Others
(	(	Others
IQ	NNP	Others
)	)	Others
before	IN	O
and	CC	O
after	IN	O
six	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
evaluated	VBN	O
through	IN	O
the	DT	O
changes	NNS	O
of	IN	O
clinical	JJ	O
manifestations	NNS	O
and	CC	O
scores	NNS	O
of	IN	O
ABC	NNP	Adverseeffect
and	CC	O
IQ	NNP	Others
.	.	Others

The	DT	O
changes	NNS	O
of	IN	O
scores	NNS	O
of	IN	O
IQ	NNP	Others
were	VBD	O
determined	VBN	O
with	IN	O
Gesell	NNP	O
and	CC	O
WPPSI	NNP	O
or	CC	O
WISC-R	NNP	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
40	CD	O
patients	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
after	IN	O
the	DT	O
six	CD	O
months	NNS	O
of	IN	O
the	DT	O
auditory	JJ	O
integrative	JJ	O
training	NN	O
,	,	O
41	CD	O
of	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
had	VBD	O
greatly	RB	Others
improved	VBN	Others
in	IN	O
many	JJ	O
aspects	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
disorders	NNS	Others
of	IN	Others
their	PRP$	Others
language	NN	Others
,	,	Others
social	JJ	Others
interactions	NNS	Others
and	CC	Others
typical	JJ	Others
behavior	NN	Others
symptoms	NNS	Others
while	IN	O
they	PRP	O
had	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
their	PRP$	O
abnormal	JJ	Others
behaviors	NNS	Others
.	.	Others

The	DT	O
scores	NNS	Others
of	IN	Others
IQ	NNP	Others
or	CC	Others
DQ	NNP	Others
had	VBD	Others
increased	VBN	Others
and	CC	O
scores	NNS	O
of	IN	O
ABC	NNP	Others
had	VBD	Others
dropped	VBN	Others
.	.	Others

The	DT	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
greatly	RB	O
significant	JJ	O
in	IN	O
statistics	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
decreasing	VBG	Others
level	NN	Others
of	IN	Others
both	DT	Others
ABC	NNP	Others
scores	NNS	Others
and	CC	Others
the	DT	Others
increasing	VBG	Others
level	NN	Others
of	IN	Others
the	DT	Others
IQ	NNP	Others
scores	NNS	Others
were	VBD	O
negatively	RB	O
correlated	VBN	O
with	IN	O
age	NN	O
,	,	O
and	CC	O
the	DT	O
decreasing	VBG	Others
level	NN	Others
of	IN	Others
ABC	NNP	Others
scores	NNS	Others
was	VBD	O
in	IN	O
line	NN	O
regression	NN	O
(	(	O
positive	JJ	O
correlation	NN	O
)	)	O
with	IN	O
base	NN	O
IQ	NNP	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
auditory	JJ	O
integrative	JJ	O
training	NN	O
(	(	O
AIT	NNP	O
)	)	O
could	MD	O
greatly	RB	O
improve	VB	O
on	IN	O
language	NN	Others
disorders	NNS	Others
,	,	O
the	DT	O
difficulties	NNS	Physical
of	IN	Physical
social	JJ	Physical
interactions	NNS	Physical
,	,	Physical
typical	JJ	Physical
behavior	NN	Physical
symptoms	NNS	Physical
and	CC	O
developmental	JJ	Others
levels	NNS	Others
,	,	O
therefore	IN	O
it	PRP	O
is	VBZ	O
positive	JJ	O
to	TO	O
the	DT	O
autistic	JJ	O
children	NNS	O
in	IN	O
its	PRP$	O
short-term	JJ	O
treatment	NN	O
effect	NN	O
.	.	O

Arginine	NNP	O
vasopressin	NN	O
dissociates	VBZ	O
the	DT	O
diuresis	NN	Physical
and	CC	Physical
natriuresis	NN	Physical
due	JJ	O
to	TO	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
in	IN	O
man	NN	O
.	.	O

The	DT	O
possible	JJ	O
interaction	NN	O
between	IN	O
arginine	JJ	O
vasopressin	NN	O
(	(	O
AVP	NNP	O
)	)	O
and	CC	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
(	(	O
ANF	NNP	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
urinary	JJ	O
sodium	NN	O
and	CC	O
water	NN	O
excretion	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
man	NN	O
.	.	O

Nine	NNP	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
undergoing	VBG	O
stable	JJ	O
maximal	JJ	O
water	NN	O
diuresis	NN	O
were	VBD	O
studied	VBN	O
on	IN	O
four	CD	O
separate	JJ	O
occasions	NNS	O
.	.	O

Atrial	NNP	O
natriuretic	JJ	O
factor	NN	O
15	CD	O
pmol	JJ	O
kg-1	JJ	O
min-1	NN	O
or	CC	O
placebo	NN	O
(	(	O
P	NNP	O
)	)	O
was	VBD	O
concomitantly	RB	O
administered	VBN	O
against	IN	O
a	DT	O
background	JJ	O
infusion	NN	O
of	IN	O
either	DT	O
AVP	NNP	O
0.003	CD	O
pmol	JJ	O
kg-1	JJ	O
min-1	NN	O
or	CC	O
P	NNP	O
;	:	O
thus	RB	O
the	DT	O
combinations	NNS	O
P	NNP	O
+	NNP	O
P	NNP	O
,	,	O
AVP	NNP	O
+	NNP	O
P	NNP	O
,	,	O
P	NNP	O
+	NNP	O
ANF	NNP	O
and	CC	O
AVP	NNP	O
+	NNP	O
ANF	NNP	O
were	VBD	O
studied	VBN	O
.	.	O

Atrial	NNP	O
natriuretic	JJ	O
factor	NN	O
caused	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
sodium	JJ	Physical
excretion	NN	Physical
(	(	Physical
UNaV	NNP	Physical
)	)	Physical
[	VBP	O
+56	CD	O
%	NN	O
]	NN	O
,	,	O
urinary	JJ	Physical
flow	NN	Physical
rate	NN	Physical
(	(	Physical
V	NNP	Physical
)	)	Physical
[	VBP	O
+17	CD	O
%	NN	O
]	NN	O
and	CC	O
free	JJ	Physical
water	NN	Physical
clearance	NN	Physical
(	(	Physical
CH2O	NNP	Physical
)	)	Physical
[	VBP	O
+23	CD	O
%	NN	O
]	NN	O
;	:	O
creatinine	JJ	Physical
clearance	NN	Physical
(	(	Physical
Ccr	NNP	Physical
)	)	Physical
did	VBD	O
not	RB	O
change	NN	O
.	.	O

Arginine	NNP	O
vasopressin	NN	O
reduced	VBD	O
V	NNP	Physical
(	(	O
-58	NNP	O
%	NN	O
)	)	O
and	CC	O
CH2O	NNP	Physical
(	(	O
-68	CD	O
%	NN	O
)	)	O
but	CC	O
did	VBD	O
not	RB	O
alter	VB	O
UNaV	NNP	Physical
or	CC	Physical
Ccr	NNP	Physical
.	.	O

On	IN	O
the	DT	O
AVP	NNP	O
+	NNP	O
ANF	NNP	O
study	NN	O
day	NN	O
,	,	O
UNaV	NNP	Physical
increased	VBD	O
(	(	O
+64	CD	O
%	NN	O
)	)	O
as	IN	O
with	IN	O
P	NNP	Physical
+	NNP	Physical
ANF	NNP	Physical
,	,	O
but	CC	O
V	NNP	Physical
(	(	O
-44	NNP	O
%	NN	O
)	)	O
and	CC	O
CH2O	NNP	Physical
(	(	O
-52	NNP	O
%	NN	O
)	)	O
continued	VBD	O
to	TO	O
decrease	VB	O
below	IN	O
baseline	NN	O
levels	NNS	O
;	:	O
analysis	NN	O
of	IN	O
variance	NN	O
showed	VBD	O
this	DT	O
antidiuresis	NN	O
reflected	VBD	O
the	DT	O
prevalent	JJ	O
effect	NN	O
of	IN	O
AVP	NNP	O
rather	RB	O
than	IN	O
any	DT	O
specific	JJ	O
interaction	NN	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
AVP	NNP	O
is	VBZ	O
able	JJ	O
to	TO	O
dissociate	VB	O
the	DT	O
natriuretic	JJ	Physical
and	CC	Physical
diuretic	JJ	Physical
effects	NNS	Physical
of	IN	O
ANF	NNP	O
.	.	O

Virtual	JJ	O
reality	NN	O
exposure	NN	O
therapy	NN	O
and	CC	O
standard	NN	O
(	(	O
in	IN	O
vivo	NN	O
)	)	O
exposure	NN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
fear	NN	O
of	IN	O
flying	VBG	O
.	.	O

This	DT	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
tested	VBD	O
virtual	JJ	O
reality	NN	O
exposure	NN	O
(	(	O
VRE	NNP	O
)	)	O
therapy	NN	O
for	IN	O
the	DT	O
fear	NN	O
of	IN	O
flying	VBG	O
(	(	O
FOF	NNP	O
)	)	O
,	,	O
a	DT	O
relatively	RB	O
new	JJ	O
and	CC	O
innovative	JJ	O
way	NN	O
to	TO	O
do	VB	O
exposure	NN	O
therapy	NN	O
,	,	O
and	CC	O
compared	VBN	O
it	PRP	O
to	TO	O
standard	VB	O
(	(	O
in	IN	O
vivo	NN	O
)	)	O
exposure	NN	O
therapy	NN	O
(	(	O
SE	NNP	O
)	)	O
and	CC	O
a	DT	O
wait	JJ	O
list	NN	O
(	(	O
WL	NNP	O
)	)	O
control	NN	O
with	IN	O
a	DT	O
6-	JJ	O
and	CC	O
12-month	JJ	O
follow-up	NN	O
.	.	O

Eighty-three	JJ	O
participants	NNS	O
with	IN	O
FOF	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
VRE	NNP	O
,	,	O
SE	NNP	O
,	,	O
or	CC	O
WL	NNP	O
.	.	O

Seventy-five	JJ	O
participants	NNS	O
,	,	O
25	CD	O
per	IN	O
group	NN	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Twenty-three	JJ	O
WL	JJ	O
participants	NNS	O
completed	VBD	O
randomly	RB	O
assigned	VBN	O
treatment	NN	O
following	VBG	O
the	DT	O
waiting	VBG	O
period	NN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
anxiety	NN	O
management	NN	O
training	NN	O
followed	VBD	O
either	CC	O
by	IN	O
exposure	NN	O
to	TO	O
a	DT	O
virtual	JJ	O
airplane	NN	O
(	(	O
VRE	NNP	O
)	)	O
or	CC	O
an	DT	O
actual	JJ	O
airplane	NN	O
at	IN	O
the	DT	O
airport	NN	O
(	(	O
SE	NNP	O
)	)	O
conducted	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
VRE	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
WL	VB	O
on	IN	O
all	DT	O
measures	NNS	O
,	,	O
including	VBG	O
willingness	NN	Mental
to	TO	Mental
fly	VB	Mental
on	IN	Mental
the	DT	Mental
posttreatment	NN	Mental
flight	NN	Mental
(	(	O
76	CD	O
%	NN	O
for	IN	O
VRE	NNP	O
and	CC	O
SE	NNP	O
;	:	O
20	CD	O
%	NN	O
for	IN	O
WL	NNP	O
)	)	O
.	.	O

VRE	NNP	O
and	CC	O
SE	NNP	O
were	VBD	O
essentially	RB	O
equivalent	JJ	O
on	IN	O
standardized	JJ	Others
questionnaires	NNS	Others
,	,	O
willingness	NN	Mental
to	TO	Mental
fly	VB	Mental
,	,	O
anxiety	NN	Mental
ratings	NNS	Mental
during	IN	Mental
the	DT	Mental
flight	NN	Mental
,	,	O
self-ratings	NNS	Mental
of	IN	Mental
improvement	NN	Mental
,	,	O
and	CC	O
patient	JJ	Mental
satisfaction	NN	Mental
with	IN	Mental
treatment	NN	Mental
.	.	O

Follow-up	JJ	O
assessments	NNS	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
indicated	VBD	O
that	IN	O
treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
,	,	O
with	IN	O
more	JJR	O
than	IN	O
70	CD	O
%	NN	O
of	IN	O
respondents	NNS	O
from	IN	O
both	DT	O
groups	NNS	O
reporting	VBG	O
continued	VBD	O
flying	VBG	O
at	IN	O
follow-up	NN	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
findings	NNS	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
VRE	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
FOF	NNP	O
was	VBD	O
supported	VBN	O
in	IN	O
this	DT	O
controlled	VBN	O
study	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
experiences	NNS	O
in	IN	O
the	DT	O
virtual	JJ	O
world	NN	O
can	MD	O
change	VB	O
experiences	NNS	O
in	IN	O
the	DT	O
real	JJ	O
world	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
on	IN	O
deep	JJ	Physical
cervical	JJ	Physical
flexor	NN	Physical
endurance	NN	Physical
:	:	Physical
implications	NNS	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	Physical
headache	NN	Physical
and	CC	O
mechanical	JJ	Physical
neck	NN	Physical
pain	NN	Physical
.	.	O

The	DT	O
convergence	NN	O
of	IN	O
cervical	JJ	O
and	CC	O
trigeminal	JJ	O
afferents	NNS	O
on	IN	O
second-order	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
trigeminocervical	JJ	O
nucleus	NN	O
may	MD	O
refer	VB	O
pain	NN	O
from	IN	O
the	DT	O
upper	JJ	O
cervical	JJ	O
spine	NN	O
into	IN	O
the	DT	O
head	NN	O
and	CC	O
face	NN	O
.	.	O

Furthermore	RB	O
,	,	O
bi-directional	JJ	O
interactions	NNS	O
between	IN	O
trigeminal	JJ	O
and	CC	O
upper	JJ	O
cervical	JJ	O
afferents	NNS	O
may	MD	O
also	RB	O
explain	VB	O
neck	NN	O
symptoms	NNS	O
of	IN	O
trigeminal	JJ	O
origin	NN	O
(	(	O
e.g.	JJ	O
,	,	O
migraine	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
cervicogenic	JJ	O
headache	NN	O
sufferers	NNS	O
present	JJ	O
with	IN	O
several	JJ	O
musculoskeletal	JJ	O
changes	NNS	O
including	VBG	O
poor	JJ	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscles	NNS	O
.	.	O

These	DT	O
intrinsic	JJ	O
muscles	NNS	O
of	IN	O
the	DT	O
neck	NN	O
contribute	NN	O
to	TO	O
stabilization	NN	O
and	CC	O
protection	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
and	CC	O
are	VBP	O
critical	JJ	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
intervertebral	JJ	O
motion	NN	O
and	CC	O
the	DT	O
cervical	JJ	O
lordosis	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	O
(	(	O
SomatoCentric	NNP	O
Systems	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Toronto	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
)	)	O
,	,	O
a	DT	O
posture	NN	O
support	NN	O
and	CC	O
exercise	NN	O
jacket	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
deep	JJ	Physical
cervical	JJ	Physical
muscle	NN	Physical
endurance	NN	Physical
.	.	O

Forty-five	JJ	O
(	(	O
45	CD	O
)	)	O
female	NN	O
subjects	NNS	O
,	,	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
18	CD	O
and	CC	O
40	CD	O
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
consisting	VBG	O
of	IN	O
the	DT	O
no-treatment	JJ	O
control	NN	O
,	,	O
the	DT	O
treatment-control	NN	O
(	(	O
table	JJ	O
stabilization	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
experimental	JJ	O
(	(	O
PostureJac	NNP	O
)	)	O
group	NN	O
.	.	O

The	DT	O
outcome	JJ	O
measure	NN	O
of	IN	O
deep	JJ	Physical
cervical	JJ	Physical
flexor	NN	Physical
muscle	NN	Physical
endurance	NN	Physical
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
Flexor	NNP	Physical
Endurance	NNP	Physical
Test	NNP	Physical
and	CC	O
was	VBD	O
recorded	VBN	O
in	IN	O
seconds	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
PostureJac	NNP	O
group	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
no-treatment	JJ	O
control	NN	O
(	(	O
p=.001	NN	O
)	)	O
and	CC	O
the	DT	O
treatment-control	NN	O
(	(	O
p=.004	NN	O
)	)	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
increasing	VBG	O
endurance	NN	Physical
of	IN	Physical
the	DT	Physical
deep	JJ	Physical
cervical	JJ	Physical
flexors	NNS	Physical
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
PostureJac	NNP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
therapeutic	JJ	O
tool	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	Physical
headache	NN	Physical
and	CC	O
mechanical	JJ	Physical
neck	NN	Physical
pain	NN	Physical
.	.	O

Middle	NNP	Physical
cerebral	JJ	Physical
arterial	JJ	Physical
blood	NN	Physical
flow	NN	Physical
velocity	NN	Physical
and	CC	Physical
hemodynamics	NNS	Physical
in	IN	O
heart	NN	O
surgery	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
propofol	NN	O
,	,	O
isoflurane	NN	O
,	,	O
and	CC	O
sevoflurane	NN	O
on	IN	O
middle	JJ	Physical
cerebral	JJ	Physical
arterial	JJ	Physical
blood	NN	Physical
flow	NN	Physical
velocity	NN	Physical
during	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
relationship	NN	O
between	IN	O
these	DT	O
effects	NNS	O
and	CC	O
hemodynamic	JJ	O
parameters	NNS	O
.	.	O

Fifty-two	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
on	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
3	CD	O
groups	NNS	O
:	:	O
the	DT	O
first	JJ	O
group	NN	O
received	VBD	O
100	CD	O
microg	NNS	O
x	JJ	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
propofol	NN	O
,	,	O
the	DT	O
other	JJ	O
groups	NNS	O
received	VBD	O
one	CD	O
minimum	NN	O
alveolar	JJ	O
concentration	NN	O
of	IN	O
sevoflurane	NN	O
or	CC	O
isoflurane	NN	O
for	IN	O
anesthesia	JJ	O
maintenance	NN	O
.	.	O

Middle	NNP	Physical
cerebral	JJ	Physical
arterial	JJ	Physical
blood	NN	Physical
flow	NN	Physical
velocities	NNS	Physical
were	VBD	O
measured	VBN	O
by	IN	O
transcranial	JJ	O
Doppler	NNP	O
,	,	O
and	CC	O
hemodynamics	NNS	Physical
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
thermodilution	NN	O
technique	NN	O
.	.	O

Middle	NNP	Physical
cerebral	JJ	Physical
arterial	JJ	Physical
blood	NN	Physical
flow	NN	Physical
velocities	NNS	Physical
decreased	VBN	O
significantly	RB	O
after	IN	O
administration	NN	O
of	IN	O
isoflurane	NN	O
and	CC	O
propofol	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
weaning	VBG	O
from	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
,	,	O
cerebral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
increased	VBD	Physical
and	CC	O
came	VBD	O
close	RB	O
to	TO	O
the	DT	O
value	NN	O
after	IN	O
induction	NN	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

The	DT	O
pulsatility	NN	Physical
index	NN	Physical
and	CC	Physical
resistivity	NN	Physical
index	NN	Physical
increased	VBD	O
significantly	RB	O
only	RB	O
after	IN	O
the	DT	O
propofol	NN	O
infusion	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
pre-	NN	O
and	CC	O
intraoperative	JJ	O
positioning	NN	O
of	IN	O
the	DT	O
condyle	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
on	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
in	IN	O
orthognathic	JJ	O
surgery	NN	O
.	.	O

A	NNP	O
magnetic	JJ	O
resonance	NN	O
study	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
investigated	VBD	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	O
joint	NN	O
(	(	O
TMJ	NNP	O
)	)	O
after	IN	O
bilateral	JJ	O
sagittal	JJ	O
split	NN	O
osteotomy	NN	O
of	IN	O
the	DT	O
mandible	JJ	O
for	IN	O
orthognathic	JJ	O
surgery	NN	O
and	CC	O
the	DT	O
influence	NN	O
of	IN	O
positioning	NN	O
of	IN	O
the	DT	O
condylar	JJ	O
process	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
operation	NN	O
for	IN	O
preventing	VBG	O
changes	NNS	O
in	IN	O
the	DT	O
TMJ	NNP	O
postoperatively	RB	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
28	CD	O
patients	NNS	O
with	IN	O
mandibular	JJ	O
retrognathism	NN	O
had	VBD	O
bilateral	JJ	O
sagittal	JJ	O
split	NN	O
osteotomies	NNS	O
for	IN	O
mandibular	JJ	O
advancement	NN	O
.	.	O

In	IN	O
one	CD	O
group	NN	O
of	IN	O
14	CD	O
patients	NNS	O
(	(	O
28	CD	O
TMJ	NNP	O
)	)	O
,	,	O
the	DT	O
condyles	NNS	O
were	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
operation	NN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
other	JJ	O
group	NN	O
they	PRP	O
were	VBD	O
not	RB	O
.	.	O

Differences	NNS	Others
on	IN	Others
magnetic	JJ	Others
resonance	NN	Others
imaging	NN	Others
(	(	Others
MRI	NNP	Others
)	)	Others
were	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
results	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
main	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
at	IN	O
maximal	JJ	Physical
mouth	NN	Physical
opening	NN	Physical
.	.	O

15/28	CD	O
TMJs	NNP	O
(	(	O
54	CD	O
%	NN	O
)	)	O
that	WDT	O
had	VBD	O
not	RB	O
been	VBN	O
positioned	VBN	O
changed	VBD	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
from	IN	O
physiological	JJ	O
to	TO	O
anterior	VB	O
disc	JJ	O
derangement	NN	O
with	IN	O
and	CC	O
without	IN	O
reduction	NN	O
postoperatively	RB	O
.	.	O

In	IN	O
the	DT	O
28	CD	O
that	WDT	O
had	VBD	O
been	VBN	O
positioned	VBN	O
,	,	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
only	RB	O
3	CD	O
TMJs	NNP	Physical
(	(	O
11	CD	O
%	NN	O
)	)	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Fixing	VBG	O
the	DT	O
condylar	JJ	O
process	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
intraoperatively	RB	O
before	IN	O
bilateral	JJ	O
sagittal	JJ	O
split	NN	O
osteotomy	NN	O
is	VBZ	O
a	DT	O
factor	NN	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
structural	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	O
joint	NN	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
itraconazole	JJ	O
versus	NN	O
fluconazole	NN	O
for	IN	O
the	DT	O
prevention	NN	Physical
of	IN	Physical
fungal	JJ	Physical
infections	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
haematological	JJ	O
malignancies	NNS	O
.	.	O

U.K.	NNP	O
Multicentre	NNP	O
Antifungal	NNP	O
Prophylaxis	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Fluconazole	NNP	O
is	VBZ	O
widely	RB	O
used	VBN	O
as	IN	O
antifungal	JJ	Physical
prophylaxis	NN	Physical
but	CC	O
it	PRP	O
is	VBZ	O
ineffective	JJ	O
against	IN	O
Aspergillus	NNP	O
.	.	O

Itraconazole	NNP	O
has	VBZ	O
a	DT	O
broader	JJR	O
spectrum	NN	O
of	IN	O
activity	NN	O
but	CC	O
the	DT	O
capsules	NNS	O
give	VBP	O
erratic	JJ	O
bioavailability	NN	O
in	IN	O
neutropenic	JJ	O
patients	NNS	O
.	.	O

We	PRP	O
compared	VBN	O
itraconazole	JJ	O
oral	JJ	O
solution	NN	O
(	(	O
which	WDT	O
has	VBZ	O
an	DT	O
improved	VBN	O
pharmacokinetic	JJ	O
profile	NN	O
)	)	O
with	IN	O
fluconazole	NN	O
for	IN	O
antifungal	JJ	O
prophylaxis	NN	O
.	.	O

Adults	NNS	O
with	IN	O
haematological	JJ	O
malignancies	NNS	O
receiving	VBG	O
chemotherapy	NN	O
or	CC	O
bone	NN	O
marrow	NN	O
transplants	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
5	CD	O
mg/kg/d	JJ	O
itraconazole	NN	O
(	(	O
itra	JJ	O
)	)	O
solution	NN	O
(	(	O
288	CD	O
episodes	NNS	O
)	)	O
or	CC	O
100	CD	O
mg	JJ	O
fluconazole	JJ	O
suspension	NN	O
(	(	O
flu	NN	O
)	)	O
(	(	O
293	CD	O
episodes	NNS	O
)	)	O
from	IN	O
before	IN	O
the	DT	O
onset	NN	O
of	IN	O
neutropenia	NN	O
until	IN	O
neutrophil	JJ	O
recovery	NN	O
or	CC	O
suspected	VBN	O
fungal	JJ	O
infection	NN	O
.	.	O

Outcomes	CC	O
were	VBD	O
assessed	VBN	O
by	IN	O
independent	JJ	O
reviewers	NNS	O
unaware	NN	O
of	IN	O
the	DT	O
prophylaxis	JJ	O
allocation	NN	O
.	.	O

More	JJR	O
proven	JJ	Physical
systemic	JJ	Physical
fungal	JJ	Physical
infections	NNS	Physical
occurred	VBD	O
in	IN	O
flu	NN	O
(	(	O
Aspergillus	NNP	O
four	CD	O
,	,	O
Candida	NNP	O
tropicalis	VBZ	O
one	CD	O
,	,	O
C.	NNP	O
krusei	NNP	O
one	NN	O
)	)	O
than	IN	O
itra	NN	O
(	(	O
C.	NNP	O
albicans	VBZ	O
one	CD	O
)	)	O
and	CC	O
more	JJR	O
of	IN	O
these	DT	O
were	VBD	O
fatal	JJ	O
(	(	O
four	CD	O
versus	NN	O
nil	NN	O
)	)	O
.	.	O

This	DT	O
difference	NN	O
reached	VBD	O
statistical	JJ	O
significance	NN	O
when	WRB	O
first	RB	O
study	VB	O
episodes	NNS	O
were	VBD	O
considered	VBN	O
separately	RB	O
(	(	O
six	CD	O
flu	NN	O
versus	NN	O
nil	JJ	O
itra	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Significantly	RB	O
more	RBR	O
deaths	NNS	Mortality
of	IN	Mortality
presumed	JJ	Mortality
fungal	JJ	Mortality
origin	NN	Mortality
occurred	VBD	O
in	IN	O
flu	NN	O
than	IN	O
itra	JJ	O
(	(	O
seven	CD	O
versus	NN	O
nil	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.024	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
cases	NNS	O
of	IN	O
proven	JJ	O
aspergillosis	NN	Physical
in	IN	O
flu	NN	O
than	IN	O
itra	JJ	O
(	(	O
six	CD	O
versus	NN	O
nil	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.038	CD	O
,	,	O
5/6	CD	O
cases	NNS	O
were	VBD	O
fatal	JJ	O
)	)	O
if	IN	O
those	DT	O
occurring	VBG	O
outside	IN	O
the	DT	O
study	NN	O
period	NN	O
are	VBP	O
included	VBN	O
.	.	O

Significantly	RB	O
more	RBR	O
patients	NNS	O
receiving	VBG	O
flu	NN	O
required	VBN	O
amphotericin	NN	O
B	NNP	O
(	(	O
58	CD	O
v	NN	O
39	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
but	CC	O
this	DT	O
may	MD	O
have	VB	O
been	VBN	O
affected	VBN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
the	DT	O
study	NN	O
was	VBD	O
not	RB	O
blinded	VBN	O
.	.	O

There	EX	O
were	VBD	O
11	CD	O
proven	JJ	O
mucosal	NN	Physical
candidal	JJ	Physical
infections	NNS	Physical
in	IN	O
flu	NN	O
and	CC	O
four	CD	O
in	IN	O
itra	NN	O
.	.	O

Itraconazole	NNP	O
solution	NN	O
and	CC	O
fluconazole	JJ	O
provide	NN	O
effective	JJ	O
prophylaxis	NN	O
against	IN	O
Candida	NNP	O
but	CC	O
itraconazole	JJ	O
affords	NNS	O
greater	JJR	O
protection	NN	O
against	IN	O
fatal	JJ	O
aspergillosis	NN	Mortality
.	.	Mortality

Hyperinsulinemia	NNP	O
fails	VBZ	O
to	TO	O
augment	VB	O
ET-1	JJ	O
action	NN	O
in	IN	O
the	DT	O
skeletal	JJ	O
muscle	NN	O
vascular	JJ	O
bed	NN	O
in	IN	O
vivo	NN	O
in	IN	O
humans	NNS	O
.	.	O

Endogenous	JJ	O
endothelin	JJ	O
action	NN	O
is	VBZ	O
augmented	VBN	O
in	IN	O
human	JJ	O
obesity	NN	O
and	CC	O
type	NN	O
2	CD	O
diabetes	NNS	O
and	CC	O
contributes	NNS	O
to	TO	O
endothelial	JJ	O
dysfunction	NN	O
and	CC	O
impairs	VB	O
insulin-mediated	JJ	O
vasodilation	NN	O
in	IN	O
humans	NNS	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
insulin	JJ	O
resistance-associated	JJ	O
hyperinsulinemia	NN	O
could	MD	O
preferentially	RB	O
drive	VB	O
endothelin-mediated	JJ	Physical
vasoconstriction	NN	Physical
.	.	O

We	PRP	O
applied	VBD	O
hyperinsulinemic-euglycemic	JJ	O
clamps	NNS	O
with	IN	O
higher	JJR	O
insulin	NN	O
dosing	VBG	O
in	IN	O
obese	JJ	O
subjects	NNS	O
than	IN	O
lean	JJ	O
subjects	NNS	O
(	(	O
30	CD	O
vs.	FW	O
10	CD	O
mU.m	NN	O
(	(	O
-2	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
with	IN	O
the	DT	O
goal	NN	O
of	IN	O
matching	VBG	O
insulin	NN	O
's	POS	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
-mediated	VBD	O
vascular	JJ	O
effects	NNS	O
.	.	O

We	PRP	O
predicted	VBD	O
that	IN	O
,	,	O
under	IN	O
these	DT	O
circumstances	NNS	O
,	,	O
insulin-stimulated	JJ	O
endothelin-1	JJ	O
(	(	O
ET-1	NNP	O
)	)	O
action	NN	O
(	(	O
assessed	VBN	O
with	IN	O
the	DT	O
type	NN	O
A	NNP	O
endothelin	NN	O
receptor	NN	O
antagonist	IN	O
BQ-123	NNP	O
)	)	O
would	MD	O
be	VB	O
augmented	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
hyperinsulinemia	VB	O
.	.	O

NO	DT	Physical
bioactivity	NN	Physical
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibitor	NN	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-l-arginine	NN	O
.	.	O

Insulin-mediated	JJ	Physical
vasodilation	NN	Physical
and	CC	O
insulin-stimulated	JJ	Physical
NO	NNP	Physical
bioavailability	NN	Physical
were	VBD	O
well	RB	O
matched	VBN	O
across	IN	O
groups	NNS	O
by	IN	O
this	DT	O
approach	NN	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
steady-state	JJ	Physical
insulin	NN	Physical
levels	NNS	Physical
were	VBD	O
approximately	RB	O
threefold	JJ	O
higher	JJR	O
in	IN	O
obese	JJ	O
than	IN	O
lean	JJ	O
subjects	NNS	O
(	(	O
109.2	CD	O
+/-	JJ	O
10.2	CD	O
pmol/l	NN	O
vs.	FW	O
518.4	CD	O
+/-	JJ	O
84.0	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Despite	IN	O
this	DT	O
,	,	O
the	DT	O
augmentation	NN	O
of	IN	O
insulin-mediated	JJ	Physical
vasodilation	NN	Physical
by	IN	O
BQ-123	NNP	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
.	.	O

ET-1	JJ	Physical
flux	NN	Physical
across	IN	O
the	DT	O
leg	NN	O
was	VBD	O
not	RB	O
augmented	VBN	O
by	IN	O
insulin	NN	O
alone	RB	O
but	CC	O
was	VBD	O
increased	VBN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
BQ-123	NNP	O
to	TO	O
insulin	VB	O
(	(	O
P	NNP	O
=	VBZ	O
0.01	CD	O
BQ-123	JJ	O
effect	NN	O
,	,	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
comparing	VBG	O
groups	NNS	O
)	)	O
.	.	O

Endothelin	NNP	O
antagonism	NN	O
augmented	VBD	O
insulin-stimulated	JJ	Physical
NO	NNP	Physical
bioavailability	NN	Physical
and	CC	O
NOx	NNP	Physical
flux	NN	Physical
,	,	O
but	CC	O
not	RB	O
differently	RB	O
between	IN	O
groups	NNS	O
and	CC	O
not	RB	O
proportional	JJ	O
to	TO	O
hyperinsulinemia	VB	O
.	.	O

These	DT	O
findings	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
insulin	VBZ	O
resistance-associated	JJ	O
hyperinsulinemia	NN	O
preferentially	RB	O
drives	VBZ	O
endothelin-mediated	JJ	Physical
vasoconstriction	NN	Physical
.	.	O

Carpal	NNP	O
tunnel	NN	O
release	NN	O
by	IN	O
limited	JJ	O
palmar	NN	O
incision	NN	O
vs	IN	O
traditional	JJ	O
open	JJ	O
technique	NN	O
:	:	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
a	DT	O
limited	JJ	O
palmar	NN	O
incision	NN	O
for	IN	O
carpal	JJ	O
tunnel	NN	O
release	NN	O
(	(	O
CTR	NNP	O
)	)	O
with	IN	O
a	DT	O
traditional	JJ	O
open	JJ	O
technique	NN	O
,	,	O
which	WDT	O
is	VBZ	O
still	RB	O
considered	VBN	O
the	DT	O
gold	JJ	O
standard	NN	O
.	.	O

METHODS	NNP	O
Seventy-two	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
carpal	JJ	O
tunnel	NN	O
syndrome	NN	O
were	VBD	O
individually	RB	O
randomized	VBN	O
into	IN	O
the	DT	O
trial	NN	O
(	(	O
limited	JJ	O
incision	NN	O
CTR	NNP	O
)	)	O
(	(	O
n=36	JJ	O
)	)	O
and	CC	O
control	NN	O
group	NN	O
(	(	O
traditional	JJ	O
technique	NN	O
CTR	NNP	O
)	)	O
(	(	O
n=36	JJ	O
)	)	O
.	.	O

In	IN	O
the	DT	O
trial	NN	O
group	NN	O
,	,	O
skin	FW	O
incision	NN	O
parallel	NN	O
to	TO	O
the	DT	O
thenar	NN	O
crease	NN	O
was	VBD	O
made	VBN	O
up	RP	O
to	TO	O
2.5	CD	O
cm	NN	O
in	IN	O
length	NN	O
,	,	O
under	IN	O
an	DT	O
operating	NN	O
microscope	NN	O
and	CC	O
endoscopic	JJ	O
transillumination	NN	O
.	.	O

Skin	NNP	O
incision	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
began	VBD	O
at	IN	O
the	DT	O
distal	JJ	O
border	NN	O
of	IN	O
the	DT	O
carpal	JJ	O
ligament	NN	O
,	,	O
followed	VBD	O
the	DT	O
longitudinal	JJ	O
crease	NN	O
of	IN	O
the	DT	O
palm	NN	O
,	,	O
and	CC	O
crossed	VBD	O
the	DT	O
base	NN	O
of	IN	O
the	DT	O
palm	NN	O
in	IN	O
a	DT	O
zigzag	JJ	O
fashion	NN	O
.	.	O

Three	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
asked	VBN	O
about	IN	O
symptomatic	JJ	Physical
relief	NN	Physical
and	CC	Physical
intervals	NNS	Physical
between	IN	Physical
the	DT	Physical
operation	NN	Physical
and	CC	Physical
return	NN	Physical
to	TO	Physical
their	PRP$	Physical
daily	JJ	Physical
activities	NNS	Physical
and	CC	Physical
work	NN	Physical
,	,	Physical
and	CC	Physical
examined	VBD	Physical
for	IN	Physical
scar	NN	Physical
tenderness	NN	Physical
and	CC	Physical
esthetic	JJ	Physical
outcome	NN	Physical
.	.	Physical

Distal	NNP	Physical
motor	NN	Physical
latency	NN	Physical
,	,	Physical
conduction	NN	Physical
velocity	NN	Physical
,	,	Physical
scar	NN	Physical
length	NN	Physical
,	,	Physical
scar	NN	Physical
width	NN	Physical
,	,	Physical
and	CC	Physical
operation	NN	Physical
time	NN	Physical
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
symptomatic	JJ	Physical
relief	NN	Physical
and	CC	Physical
electrophysiological	JJ	Physical
parameters	NNS	Physical
.	.	Physical

Intervals	NNS	Physical
between	IN	Physical
the	DT	Physical
operation	NN	Physical
and	CC	Physical
return	NN	Physical
to	TO	Physical
daily	JJ	Physical
activities	NNS	Physical
(	(	O
median	JJ	O
5	CD	O
days	NNS	O
,	,	O
range	VBP	O
2-15	JJ	O
)	)	O
were	VBD	O
shorter	JJR	O
in	IN	O
the	DT	O
trial	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
median	JJ	O
10	CD	O
days	NNS	O
,	,	O
range	VBP	O
2-21	JJ	O
;	:	O
p	VB	O
<	$	O
0.001	CD	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
intervals	NNS	Physical
between	IN	Physical
the	DT	Physical
operation	NN	Physical
and	CC	Physical
return	NN	Physical
to	TO	Physical
work	VB	Physical
(	(	O
median	JJ	O
15	CD	O
days	NNS	O
,	,	O
range	VBP	O
5-45	JJ	O
vs	NN	O
median	JJ	O
30	CD	O
days	NNS	O
,	,	O
range	VBP	O
10-60	JJ	O
;	:	O
p	VB	O
<	$	O
0.001	CD	O
)	)	O
.	.	O

Scar/pillar	JJ	Physical
tenderness	NN	Physical
,	,	Physical
scar	NN	Physical
length	NN	Physical
and	CC	Physical
width	NN	Physical
,	,	Physical
esthetic	JJ	Physical
outcome	NN	Physical
,	,	Physical
and	CC	Physical
operation	NN	Physical
time	NN	Physical
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
trial	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Limited	NNP	O
palmar	NN	O
incision	NN	O
CTR	NNP	O
is	VBZ	O
as	IN	O
effective	JJ	O
and	CC	O
safe	JJ	O
as	IN	O
traditional	JJ	O
CTR	NNP	O
technique	NN	O
,	,	O
but	CC	O
with	IN	O
better	JJR	O
postoperative	JJ	O
recovery	NN	O
and	CC	O
cosmetic	JJ	O
results	NNS	O
.	.	O

Systemic	NNP	Physical
hemodynamic	NN	Physical
,	,	Physical
neurohormonal	JJ	Physical
,	,	Physical
and	CC	Physical
renal	JJ	Physical
effects	NNS	Physical
of	IN	O
a	DT	O
steady-state	JJ	O
infusion	NN	O
of	IN	O
human	JJ	O
brain	NN	O
natriuretic	JJ	O
peptide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hemodynamically	RB	O
decompensated	VBN	O
heart	NN	O
failure	NN	O
.	.	O

BACKGROUND	NNP	O
Human	NNP	O
brain	NN	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
hBNP	NN	O
)	)	O
is	VBZ	O
a	DT	O
promising	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
decompensated	JJ	O
cardiac	JJ	O
failure	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
systemic	JJ	Physical
hemodynamic	NN	Physical
,	,	O
neurohormonal	JJ	Physical
,	,	O
and	CC	O
renal	JJ	Physical
effects	NNS	Physical
of	IN	O
hBNP	NNS	O
have	VBP	O
been	VBN	O
incompletely	RB	O
studied	VBN	O
in	IN	O
human	JJ	O
heart	NN	O
failure	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
continuous	JJ	O
4-hour	JJ	O
infusion	NN	O
of	IN	O
hBNP	NN	O
were	VBD	O
determined	VBN	O
in	IN	O
16	CD	O
decompensated	JJ	O
heart	NN	O
failure	NN	O
patients	NNS	O
in	IN	O
an	DT	O
invasive	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
during	IN	O
three	CD	O
4-hour	JJ	O
study	NN	O
periods	NNS	O
:	:	O
baseline	NN	O
,	,	O
treatment	NN	O
(	(	O
placebo	JJ	O
[	NNP	O
n	NN	O
=	VBD	O
4	CD	O
]	NNP	O
versus	NN	O
hBNP	NN	O
0.025	CD	O
or	CC	O
0.05	CD	O
microgram/kg/min	NNS	O
[	JJ	O
n	JJ	O
=	NN	O
12	CD	O
]	NN	O
)	)	O
,	,	O
and	CC	O
post-treatment	NN	O
.	.	O

Urinary	JJ	O
volume	NN	O
losses	NNS	O
were	VBD	O
replaced	VBN	O
hourly	RB	O
to	TO	O
separate	VB	O
the	DT	O
vasodilatory	NN	O
and	CC	O
diuretic	JJ	O
effects	NNS	O
of	IN	O
hBNP	NN	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
hBNP	NN	O
group	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
analysis	NN	O
because	IN	O
of	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

hBNP	NN	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
reduced	VBD	O
right	JJ	Physical
atrial	JJ	Physical
pressure	NN	Physical
and	CC	Physical
pulmonary	JJ	Physical
capillary	JJ	Physical
wedge	NN	Physical
pressure	NN	Physical
by	IN	O
approximately	RB	O
30	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

hBNP	NN	O
also	RB	O
significantly	RB	O
lowered	VBN	O
systemic	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
from	IN	O
1722	CD	O
+/-	JJ	O
139	CD	O
to	TO	O
1101	CD	O
+/-	JJ	O
83	CD	O
dynes.s.cm-5	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

These	DT	O
unloading	JJ	O
effects	NNS	O
of	IN	O
hBNP	NN	O
produced	VBD	O
a	DT	O
28	CD	O
%	NN	O
increase	NN	O
in	IN	O
cardiac	JJ	Physical
index	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
.	.	Physical

Compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
hBNP	VB	O
decreased	VBN	O
plasma	JJ	Physical
norepinephrine	NN	Physical
and	CC	Physical
aldosterone	NN	Physical
.	.	Physical

Renal	JJ	Physical
hemodynamics	NNS	Physical
were	VBD	O
unaffected	VBN	O
by	IN	O
hBNP	NN	O
;	:	O
however	RB	O
,	,	O
most	JJS	O
patients	NNS	O
were	VBD	O
resistant	JJ	O
to	TO	O
its	PRP$	O
natriuretic	JJ	Physical
effect	NN	Physical
.	.	Physical

CONCLUSIONS	NNP	O
1	CD	O
)	)	O
The	DT	O
predominant	JJ	O
hemodynamic	JJ	Physical
effects	NNS	Physical
of	IN	O
hBNP	NN	O
were	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	Physical
preload	NN	Physical
and	CC	Physical
systemic	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
.	.	Physical

2	CD	O
)	)	O
hBNP	NN	O
also	RB	O
improved	VBD	O
cardiac	JJ	Physical
output	NN	Physical
without	IN	O
increasing	VBG	O
heart	NN	Physical
rate	NN	Physical
.	.	Physical

3	CD	O
)	)	O
Plasma	NNP	Physical
norepinephrine	NN	Physical
and	CC	Physical
aldosterone	NN	Physical
levels	NNS	Physical
decreased	VBN	O
during	IN	O
hBNP	JJ	O
infusion	NN	O
.	.	O

4	CD	O
)	)	O
hBNP	NN	O
is	VBZ	O
pharmacologically	RB	O
active	JJ	O
and	CC	O
has	VBZ	O
potential	VBN	O
in	IN	O
the	DT	O
therapy	NN	O
for	IN	O
decompensated	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Movement-related	JJ	O
potentials	NNS	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Presence	NNP	O
and	CC	O
predictability	NN	O
of	IN	O
temporal	JJ	O
and	CC	O
spatial	JJ	O
cues	NNS	O
.	.	O

Activity	NN	O
of	IN	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
may	MD	O
be	VB	O
inferred	VBN	O
from	IN	O
movement-related	JJ	O
potentials	NNS	O
(	(	O
MRPs	NNP	O
)	)	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
the	DT	O
preparation	NN	O
and	CC	O
execution	NN	O
of	IN	O
voluntary	JJ	O
,	,	O
or	CC	O
internally	RB	O
determined	JJ	O
movements	NNS	O
.	.	O

Supplementary	NNP	O
motor	NN	O
area	NN	O
activity	NN	O
may	MD	O
be	VB	O
abnormal	JJ	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
since	IN	O
its	PRP$	O
major	JJ	O
input	NN	O
from	IN	O
the	DT	O
basal	NN	O
ganglia	NN	O
is	VBZ	O
disrupted	VBN	O
.	.	O

Investigation	NN	O
of	IN	O
the	DT	O
abnormalities	NNS	O
in	IN	O
supplementary	JJ	O
motor	NN	O
area	NN	O
activity	NN	O
associated	VBN	O
with	IN	O
movement	NN	O
deficits	NNS	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
may	MD	O
therefore	VB	O
reveal	JJ	O
functions	NNS	O
of	IN	O
the	DT	O
basal	NN	O
ganglia	NN	O
and	CC	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
.	.	O

Movement-related	JJ	O
potentials	NNS	O
associated	VBN	O
with	IN	O
sequential	JJ	O
movements	NNS	O
were	VBD	O
investigated	VBN	O
under	IN	O
various	JJ	O
cueing	VBG	O
conditions	NNS	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
subjects	NNS	O
and	CC	O
age-matched	JJ	O
controls	NNS	O
.	.	O

In	IN	O
controls	NNS	O
,	,	O
MRPs	NNP	O
revealed	VBD	O
involvement	NN	O
of	IN	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
in	IN	O
movements	NNS	O
which	WDT	O
can	MD	O
be	VB	O
internally	RB	O
determined	VBN	O
(	(	O
non-cued	JJ	O
and	CC	O
externally	RB	O
cued	VBN	O
,	,	O
predictable	JJ	O
movements	NNS	O
,	,	O
but	CC	O
not	RB	O
unpredictable	JJ	O
movements	NNS	O
)	)	O
.	.	O

In	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
however	RB	O
,	,	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
was	VBD	O
only	RB	O
involved	VBN	O
in	IN	O
movements	NNS	O
which	WDT	O
must	MD	O
be	VB	O
internally	RB	O
determined	VBN	O
(	(	O
non-cued	JJ	O
movements	NNS	O
,	,	O
but	CC	O
not	RB	O
externally	RB	O
cued	VBN	O
movements	NNS	O
)	)	O
;	:	O
therefore	RB	O
impaired	VBD	O
internal	JJ	O
control	NN	O
mechanisms	NNS	O
,	,	O
operating	VBG	O
via	IN	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
,	,	O
are	VBP	O
bypassed	VBN	O
when	WRB	O
external	JJ	O
cues	NNS	O
are	VBP	O
given	VBN	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
patients	NNS	O
are	VBP	O
more	RBR	O
reliant	JJ	O
on	IN	O
external	JJ	O
cues	NNS	O
and	CC	O
are	VBP	O
unable	JJ	O
to	TO	O
use	VB	O
predictive	JJ	O
models	NNS	O
to	TO	O
internally	RB	O
guide	VB	O
movement	NN	O
.	.	O

Supplementary	NNP	O
motor	NN	O
area	NN	O
involvement	NN	O
also	RB	O
relied	VBD	O
on	IN	O
the	DT	O
predictability	NN	O
(	(	O
in	IN	O
controls	NNS	O
)	)	O
or	CC	O
presence	NN	O
(	(	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
)	)	O
of	IN	O
timing	VBG	O
cues	NNS	O
and	CC	O
not	RB	O
spatial	JJ	O
cues	NNS	O
,	,	O
indicating	VBG	O
a	DT	O
role	NN	O
of	IN	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
and	CC	O
basal	NN	O
ganglia	NNS	O
in	IN	O
the	DT	O
temporal	JJ	O
organizations	NNS	O
of	IN	O
sequential	JJ	O
movement	NN	O
rather	RB	O
than	IN	O
the	DT	O
programming	NN	O
of	IN	O
specific	JJ	O
movements	NNS	O
.	.	O

For	IN	O
non-cued	JJ	O
movements	NNS	O
,	,	O
abnormalities	NNS	O
in	IN	O
MRPs	NNP	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
subjects	VBZ	O
consisted	VBN	O
of	IN	O
delayed	JJ	Physical
MRP	NNP	Physical
onset	NN	Physical
and	CC	O
peak	NN	Others
times	NNS	Others
,	,	O
and	CC	O
prolonged	VBD	O
cortical	JJ	O
activity	NN	O
following	VBG	O
movement	NN	O
.	.	O

These	DT	O
observations	NNS	O
led	VBD	O
to	TO	O
a	DT	O
proposed	VBN	O
model	NN	O
of	IN	O
the	DT	O
interaction	NN	O
between	IN	O
the	DT	O
basal	NN	O
ganglia	NN	O
and	CC	O
the	DT	O
supplementary	JJ	O
motor	NN	O
area	NN	O
,	,	O
involving	VBG	O
the	DT	O
temporal	JJ	O
organization	NN	O
of	IN	O
voluntary	JJ	O
and	CC	O
internally	RB	O
determined	VBD	O
sequential	JJ	O
movements	NNS	O
.	.	O

Relationship	NN	O
between	IN	O
biliary	NN	O
and	CC	O
serum	NN	O
bile	NN	O
acids	NNS	O
and	CC	O
response	NN	O
to	TO	O
ursodeoxycholic	JJ	O
acid	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
.	.	O

OBJECTIVE	NNP	O
Ursodeoxycholic	NNP	O
acid	NN	O
(	(	O
UDCA	NNP	O
)	)	O
improves	VBZ	O
liver	JJ	Physical
biochemistries	NNS	Physical
and	CC	O
enriches	VBZ	Physical
the	DT	Physical
bile	NN	Physical
with	IN	Physical
UDCA	NNP	Physical
in	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
degree	NN	O
of	IN	O
enrichment	NN	O
of	IN	O
bile	NN	O
correlated	VBN	O
with	IN	O
that	DT	O
of	IN	O
serum	NN	O
and	CC	O
whether	IN	O
either	DT	O
of	IN	O
these	DT	O
measures	NNS	O
correlated	VBD	O
with	IN	O
improvement	NN	O
in	IN	O
measures	NNS	O
of	IN	O
liver	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
,	,	O
biliary	JJ	O
and	CC	O
serum	JJ	O
bile	NN	O
acid	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
entry	NN	O
and	CC	O
after	IN	O
2	CD	O
yr	NN	O
of	IN	O
UDCA	NNP	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
percentage	NN	Physical
of	IN	Physical
ursodeoxycholic	JJ	Physical
acid	NN	Physical
in	IN	Physical
bile	NN	Physical
increased	VBN	O
by	IN	O
42	CD	O
%	NN	O
in	IN	O
the	DT	O
UDCA	NNP	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
61	CD	O
)	)	O
compared	VBN	O
with	IN	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
57	CD	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Measurement	NN	Physical
of	IN	Physical
serum	NN	Physical
bile	NN	Physical
acids	NNS	Physical
in	IN	O
32	CD	O
patients	NNS	O
(	(	O
18	CD	O
ursodeoxycholic	JJ	O
acid	NN	O
,	,	O
14	CD	O
placebo	NN	O
)	)	O
indicated	VBD	O
that	IN	O
at	IN	O
2	CD	O
yr	NN	O
,	,	O
ursodeoxycholic	JJ	O
acid	NN	O
comprised	VBD	O
65	CD	O
%	NN	O
of	IN	O
serum	NN	O
bile	NN	O
acids	NNS	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
and	CC	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Agreement	NNP	O
between	IN	O
bile	NN	O
and	CC	O
serum	NN	O
was	VBD	O
fair	JJ	O
(	(	O
r	JJ	O
=	NN	O
0.75	CD	O
,	,	O
p	NN	O
<	NN	O
or	CC	O
=	VB	O
0.00002	CD	O
)	)	O
because	IN	O
in	IN	O
some	DT	O
patients	NNS	O
,	,	O
plasma	NNS	O
but	CC	O
not	RB	O
biliary	JJ	O
bile	NN	O
acids	NNS	O
were	VBD	O
enriched	VBN	O
with	IN	O
UDCA	NNP	O
.	.	O

Changes	NNS	Physical
in	IN	Physical
biliary	JJ	Physical
ursodeoxycholic	JJ	Physical
acid	NN	Physical
correlated	VBN	O
significantly	RB	O
but	CC	O
weakly	RB	O
with	IN	O
the	DT	O
changes	NNS	O
in	IN	O
serum	NN	Physical
alkaline	NN	Physical
phosphatase	NN	Physical
,	,	Physical
AST	NNP	Physical
,	,	Physical
bilirubin	NN	Physical
,	,	Physical
and	CC	Physical
in	IN	Physical
Mayo	NNP	Physical
risk	NN	Physical
score	NN	Physical
.	.	O

Correlations	NNS	O
between	IN	O
changes	NNS	O
in	IN	O
serum	NN	Physical
bile	NN	Physical
acid	JJ	Physical
composition	NN	Physical
and	CC	O
biochemical	JJ	Physical
measures	NNS	Physical
of	IN	Physical
disease	NN	Physical
activity	NN	Physical
were	VBD	O
even	RB	O
weaker	JJR	O
.	.	O

CONCLUSION	VB	O
The	DT	O
measurement	NN	O
of	IN	O
biliary	JJ	O
bile	NN	O
acids	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
that	DT	O
of	IN	O
serum	NN	O
bile	NN	O
acids	NNS	O
for	IN	O
assessing	VBG	O
the	DT	O
compliance	NN	O
and	CC	O
changes	NNS	O
in	IN	O
the	DT	O
circulating	NN	O
bile	JJ	O
acids	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ursodeoxycholic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	Physical
biliary	JJ	Physical
cirrhosis	NN	Physical
.	.	O

Furthermore	NNP	O
,	,	O
measures	VBZ	O
to	TO	O
further	JJ	O
increase	VB	O
the	DT	O
proportion	NN	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
in	IN	O
circulating	VBG	O
bile	JJ	O
acids	NNS	O
should	MD	O
be	VB	O
explored	VBN	O
.	.	O

Cognitive	JJ	O
effects	NNS	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
irritable	JJ	O
behavior	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
research	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	O
on	IN	O
cognitive	JJ	Mental
processes	NNS	Mental
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
irritable	JJ	O
behavior	NN	O
.	.	O

METHOD	NNP	O
Thirty-eight	JJ	O
children	NNS	O
,	,	O
ages	VBZ	O
5-17	CD	O
years	NNS	O
with	IN	O
autism	NN	O
and	CC	O
severe	JJ	O
behavioral	JJ	O
disturbance	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
risperidone	VB	O
(	(	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

This	DT	O
sample	NN	O
of	IN	O
38	CD	O
was	VBD	O
a	DT	O
subset	NN	O
of	IN	O
101	CD	O
subjects	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
;	:	O
63	CD	O
were	VBD	O
unable	JJ	O
to	TO	O
perform	VB	O
the	DT	O
cognitive	JJ	O
tasks	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
parallel	NN	O
groups	NNS	O
design	NN	O
was	VBD	O
used	VBN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
tests	NNS	Physical
of	IN	Physical
sustained	JJ	Physical
attention	NN	Physical
,	,	O
verbal	JJ	Physical
learning	NN	Physical
,	,	O
hand-eye	JJ	Physical
coordination	NN	Physical
,	,	O
and	CC	O
spatial	JJ	Physical
memory	NN	Physical
assessed	VBN	Physical
before	IN	Physical
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
the	DT	Physical
8-week	JJ	Physical
treatment	NN	Physical
.	.	O

Changes	NNS	O
in	IN	O
performance	NN	O
were	VBD	O
compared	VBN	O
by	IN	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	Mental
.	.	O

RESULTS	NNP	O
Twenty-nine	JJ	O
boys	NNS	O
and	CC	O
9	CD	O
girls	NNS	O
with	IN	O
autism	NN	O
and	CC	O
severe	JJ	O
behavioral	JJ	O
disturbance	NN	O
and	CC	O
a	DT	O
mental	JJ	O
age	NN	O
>	NNP	O
or=18	JJ	O
months	NNS	O
completed	VBN	O
the	DT	O
cognitive	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
decline	NN	O
in	IN	O
performance	NN	O
occurred	VBD	O
with	IN	O
risperidone	NN	O
.	.	O

Performance	NN	O
on	IN	O
a	DT	O
cancellation	NN	Mental
task	NN	Mental
(	(	Mental
number	NN	Mental
of	IN	Mental
correct	JJ	Mental
detections	NNS	Mental
)	)	Others
and	CC	O
a	DT	O
verbal	JJ	Mental
learning	NN	Mental
task	NN	Mental
(	(	Mental
word	NN	Mental
recognition	NN	Mental
)	)	Mental
was	VBD	O
better	RBR	O
on	IN	O
risperidone	NN	O
than	IN	O
on	IN	O
placebo	NN	O
(	(	O
without	IN	O
correction	NN	O
for	IN	O
multiplicity	NN	O
)	)	O
.	.	O

Equivocal	JJ	Physical
improvement	NN	Physical
also	RB	O
occurred	VBD	O
on	IN	O
a	DT	O
spatial	JJ	Mental
memory	NN	Mental
task	NN	Mental
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
conditions	NNS	O
on	IN	O
the	DT	O
Purdue	NNP	Mental
Pegboard	NNP	Mental
(	(	Mental
hand-eye	JJ	Mental
coordination	NN	Mental
)	)	Mental
task	NN	O
or	CC	O
the	DT	O
Analog	NNP	Mental
Classroom	NNP	Mental
Task	NNP	Mental
(	(	Mental
timed	VBN	Mental
math	RB	Mental
test	NN	Mental
)	)	Others
.	.	O

CONCLUSION	NNP	O
Risperidone	NNP	O
given	VBN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
at	IN	O
doses	VBZ	O
up	RB	O
to	TO	O
3.5	CD	O
mg	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
appears	VBZ	O
to	TO	O
have	VB	O
no	DT	O
detrimental	JJ	O
effect	NN	O
on	IN	O
cognitive	JJ	Mental
performance	NN	Mental
.	.	O

Clinical	JJ	O
effects	NNS	O
of	IN	O
naltrexone	NN	O
on	IN	O
autistic	JJ	O
behavior	NN	O
.	.	O

Eight	NNP	O
young	JJ	O
adults	NNS	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
were	VBD	O
given	VBN	O
the	DT	O
opiate	JJ	O
antagonist	NN	O
naltrexone	NN	O
to	TO	O
control	VB	O
self-injurious	JJ	O
behavior	NN	O
and	CC	O
maladaptive	JJ	O
idiosyncratic	JJ	O
mannerisms	NNS	O
.	.	O

The	DT	O
drug	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
over	IN	O
17	CD	O
weeks	NNS	O
.	.	O

Although	IN	O
one	CD	O
subject	NN	O
appeared	VBD	O
to	TO	O
have	VB	O
partial	JJ	Mental
decreases	NNS	Mental
in	IN	Mental
maladaptive	JJ	Mental
behaviors	NNS	Mental
associated	VBN	O
with	IN	O
naltrexone	NN	O
use	NN	O
,	,	O
the	DT	O
drugs	NNS	O
,	,	O
as	IN	O
administered	VBN	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
did	VBD	O
not	RB	O
reduce	VB	Mental
the	DT	Mental
self-injurious	JJ	Mental
and	CC	Mental
other	JJ	Mental
maladaptive	JJ	Mental
behaviors	NNS	Mental
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

Bronchoscopic	NNP	Physical
findings	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
complete	JJ	O
radiographic	JJ	O
regression	NN	O
of	IN	O
small	JJ	Physical
cell	NN	Physical
bronchogenic	JJ	Physical
carcinoma	NN	Physical
.	.	Physical

Fibre-optic	JJ	O
bronchoscopy	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
21	CD	O
patients	NNS	O
with	IN	O
small	JJ	Physical
cell	NN	Physical
bronchogenic	JJ	Physical
carcinoma	NN	Physical
who	WP	O
demonstrated	VBD	O
a	DT	O
complete	JJ	O
radiographic	JJ	O
regression	NN	O
of	IN	O
their	PRP$	O
chest	JJS	O
lesions	NNS	O
after	IN	O
3-4	JJ	O
months	NNS	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
showed	VBD	O
abnormalities	NNS	Physical
at	IN	O
the	DT	O
site	NN	Physical
of	IN	O
the	DT	O
original	JJ	O
tumour	NN	Physical
consisting	NN	O
of	IN	O
nodular	JJ	Physical
elevations	NNS	Physical
,	,	Physical
narrowing	VBG	Physical
of	IN	Physical
bronchi	NN	Physical
and/or	VBP	Physical
fibrous	JJ	Physical
strands	NNS	Physical
or	CC	Physical
membranes	NNS	Physical
.	.	Physical

Microscopic	NNP	O
evidence	NN	O
of	IN	O
residual	JJ	O
cancer	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
3	CD	O
cases	NNS	O
.	.	O

In	IN	O
3	CD	O
out	IN	O
of	IN	O
8	CD	O
patients	NNS	O
who	WP	O
underwent	VBP	O
a	DT	O
further	JJ	O
bronchoscopy	NN	Physical
after	IN	O
18	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
disappearance	NN	O
of	IN	O
nodules	NNS	Physical
was	VBD	O
noted	VBN	O
at	IN	O
the	DT	O
later	JJ	O
examination	NN	O
.	.	O

Persistent	JJ	Physical
bronchial	JJ	Physical
narrowing	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
became	VBD	O
disease-free	JJ	O
2-yr	JJ	O
survivors	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
tumour	JJ	O
regression	NN	O
may	MD	O
be	VB	O
accompanied	VBN	O
by	IN	O
scar	NN	Physical
formation	NN	Physical
,	,	O
which	WDT	O
complicate	VBP	O
the	DT	O
interpretation	NN	O
of	IN	O
post-treatment	JJ	Physical
abnormalities	NNS	Physical
,	,	O
and	CC	O
that	IN	O
further	JJ	O
regression	NN	O
of	IN	O
intrabronchial	JJ	O
lesions	NNS	O
may	MD	O
occur	VB	O
beyond	IN	O
3-4	JJ	O
months	NNS	O
.	.	O

Clinic	JJ	O
visit	NN	O
and	CC	O
waiting	NN	O
:	:	O
patient	JJ	Mental
education	NN	Mental
and	CC	Others
satisfaction	NN	Others
.	.	O

Patients	NNS	O
who	WP	O
were	VBD	O
taught	VBN	O
about	IN	O
their	PRP$	O
health	NN	O
problems	NNS	O
while	IN	O
waiting	VBG	O
in	IN	O
the	DT	O
clinic	NN	O
(	(	O
n	JJ	O
=	NNP	O
104	CD	O
)	)	O
were	VBD	O
significantly	RB	O
more	RBR	O
satisfied	JJ	Others
with	IN	Others
the	DT	Others
education	NN	Others
received	VBD	O
during	IN	O
that	DT	O
visit	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
101	CD	O
)	)	O
.	.	O

The	DT	O
longer	JJR	O
patients	NNS	O
waited	VBD	O
in	IN	O
the	DT	O
clinic	NN	O
to	TO	O
see	VB	O
their	PRP$	O
providers	NNS	O
,	,	O
the	DT	O
less	JJR	O
satisfied	JJ	Others
they	PRP	O
were	VBD	O
with	IN	O
the	DT	O
clinic	JJ	O
visit	NN	O
.	.	O

Prospective	JJ	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
comparing	VBG	O
plasmakinetic	JJ	O
vaporesection	NN	O
and	CC	O
conventional	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

OBJECTIVE	NNP	O
Plasmakinetic	NNP	O
vaporesection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
(	(	O
PKVP	NNP	O
)	)	O
using	VBG	O
normal	JJ	O
saline	JJ	O
irrigation	NN	O
has	VBZ	O
the	DT	O
theoretical	JJ	O
advantage	NN	O
of	IN	O
avoiding	VBG	O
transurethral	JJ	O
resection	NN	O
syndrome	NN	O
and	CC	O
minimizing	VBG	O
blood	NN	O
loss	NN	O
.	.	O

It	PRP	O
may	MD	O
also	RB	O
shorten	VB	O
the	DT	O
operative	JJ	O
time	NN	O
since	IN	O
tissue	NN	O
is	VBZ	O
resected	VBN	O
instead	RB	O
of	IN	O
just	RB	O
vaporized	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	Others
,	,	O
safety	NN	Others
and	CC	O
advantages	NNS	Others
of	IN	O
PKVP	NNP	O
compared	VBN	O
with	IN	O
standard	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
(	(	O
TURP	NNP	O
)	)	O
at	IN	O
a	DT	O
regional	JJ	O
acute	NN	O
hospital	NN	O
.	.	O

METHODS	CC	O
A	DT	O
total	NN	O
of	IN	O
60	CD	O
consecutive	JJ	O
men	NNS	O
admitted	VBN	O
from	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
for	IN	O
surgery	NN	O
for	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
either	DT	O
PKVP	NNP	O
or	CC	O
TURP	NNP	O
.	.	O

Peri-	NNP	O
and	CC	O
postoperative	JJ	O
outcome	NN	O
data	NNS	O
at	IN	O
3	CD	O
months	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
PKVP	NNP	O
loop	NN	O
achieved	VBD	O
a	DT	O
fast	JJ	O
and	CC	O
sharp	JJ	O
cutting	VBG	O
action	NN	O
similar	JJ	O
to	TO	O
that	DT	O
with	IN	O
the	DT	O
traditional	JJ	O
TURP	NNP	O
loop	NN	O
.	.	O

Data	NNP	O
analysis	NN	O
was	VBD	O
based	VBN	O
on	IN	O
51	CD	O
patients	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
methods	NNS	O
in	IN	O
resection	NN	Others
time	NN	Others
,	,	O
postoperative	JJ	Others
catheterization	NN	Others
time	NN	Others
and	CC	O
hospital	NN	Others
stay	NN	Others
.	.	O

The	DT	O
mean	JJ	Physical
reductions	NNS	Physical
in	IN	Physical
serum	NN	Physical
sodium	NN	Physical
2	CD	O
hours	NNS	O
after	IN	O
PKVP	NNP	O
and	CC	O
on	IN	O
postoperative	JJ	O
day	NN	O
1	CD	O
were	VBD	O
0.52	CD	O
mmol/L	NNS	O
and	CC	O
3.35	CD	O
mmol/L	NN	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
mean	JJ	O
reductions	NNS	O
in	IN	O
haemoglobin	NN	O
were	VBD	O
0.36	CD	O
g/dL	NN	O
and	CC	O
0.24	CD	O
g/dL	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
haemoglobin	JJ	Physical
reductions	NNS	Physical
between	IN	O
PKVP	NNP	O
and	CC	O
TURP	NNP	O
(	(	O
p	JJ	O
=	RB	O
0.326	CD	O
at	IN	O
2	CD	O
hours	NNS	O
;	:	O
p	VB	O
=	$	O
0.192	CD	O
on	IN	O
day	NN	O
1	CD	O
)	)	O
and	CC	O
serum	JJ	O
sodium	NN	O
(	(	O
p	JJ	O
=	RB	O
0.757	CD	O
at	IN	O
2	CD	O
hours	NNS	O
;	:	O
p	VB	O
=	$	O
0.888	CD	O
on	IN	O
day	NN	O
1	CD	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
achieved	VBD	O
comparable	JJ	O
improvement	NN	O
in	IN	O
International	NNP	Others
Prostate	NNP	Others
Symptom	NNP	Others
Score	NNP	Others
(	(	O
p	JJ	O
=	NNP	O
0.862	CD	O
)	)	O
,	,	O
quality-of-life	JJ	O
score	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.169	CD	O
)	)	O
and	CC	O
peak	JJ	O
flow	NN	O
rate	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.96	CD	O
)	)	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSION	NNP	O
PKVP	NNP	O
achieved	VBD	O
comparable	JJ	O
results	NNS	O
to	TO	O
traditional	JJ	O
TURP	NNP	O
and	CC	O
was	VBD	O
an	DT	O
effective	JJ	Others
and	CC	Others
safe	JJ	Others
procedure	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
did	VBD	O
not	RB	O
demonstrate	VB	O
obvious	JJ	O
advantages	NNS	O
over	IN	O
TURP	NNP	O
in	IN	O
this	DT	O
acute	JJ	O
regional	JJ	O
hospital	NN	O
regular	JJ	O
TURP	NNP	O
list	NN	O
setting	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
levetiracetam	NN	O
on	IN	O
essential	JJ	Physical
tremor	NN	Physical
.	.	Physical

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
1,000	CD	O
mg	NN	O
of	IN	O
levetiracetam	NN	O
on	IN	O
essential	JJ	O
tremor	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
hand	NN	Physical
tremor	NN	Physical
for	IN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
accelerometry	NN	O
and	CC	O
functional	JJ	O
tests	NNS	O
.	.	O

Acute	NNP	O
intravenous	JJ	O
L-arginine	JJ	O
infusion	NN	O
decreases	VBZ	O
endothelin-1	JJ	Physical
levels	NNS	Physical
and	CC	O
improves	VBZ	O
endothelial	JJ	Physical
function	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
angina	JJ	O
pectoris	NN	O
and	CC	O
normal	JJ	O
coronary	JJ	O
arteriograms	NNS	O
:	:	O
correlation	NN	O
with	IN	O
asymmetric	JJ	O
dimethylarginine	NN	Physical
levels	NNS	Physical
.	.	Physical

BACKGROUND	NNP	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
asymmetric	JJ	Physical
dimethylarginine	NN	Physical
(	(	Physical
ADMA	NNP	Physical
)	)	Physical
levels	NNS	Physical
could	MD	O
be	VB	O
elevated	VBN	O
and	CC	O
influence	VB	O
endothelin-1	JJ	Physical
and	CC	O
nitric	JJ	Physical
oxide	NN	Physical
release	NN	Physical
and	CC	Physical
action	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	O
syndrome	NN	O
X	NNP	O
(	(	O
CSX	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
whether	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
would	MD	O
improve	VB	O
endothelial	JJ	Physical
function	NN	Physical
in	IN	O
these	DT	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Nine	NNP	O
patients	NNS	O
with	IN	O
CSX	NNP	O
and	CC	O
14	CD	O
control	NN	O
subjects	NNS	O
underwent	VBD	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
L-arginine	NNP	O
(	(	O
0.125	CD	O
g/min	NN	O
)	)	O
or	CC	O
saline	NN	O
for	IN	O
120	CD	O
minutes	NNS	O
.	.	O

Sixty	NNP	O
minutes	NNS	O
after	IN	O
L-arginine	NNP	O
or	CC	O
saline	JJ	O
infusions	NNS	O
,	,	O
an	DT	O
intravenous	JJ	O
insulin	NN	O
bolus	NN	O
(	(	O
0.1	CD	O
U/kg	NNP	O
)	)	O
combined	VBD	O
with	IN	O
a	DT	O
euglycemic	JJ	O
clamp	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Basal	NNP	Physical
ADMA	NNP	Physical
and	CC	O
endothelin-1	JJ	Physical
levels	NNS	Physical
were	VBD	O
higher	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
infusion	NN	O
,	,	O
compared	VBN	O
with	IN	O
saline	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
increased	VBD	O
basal	JJ	Physical
forearm	NN	Physical
blood	NN	Physical
flow	NN	Physical
,	,	O
nitrite	JJ	Physical
and	CC	Physical
nitrate	JJ	Physical
(	(	Physical
NOx	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
forearm	NN	Physical
cGMP	NN	Physical
release	NN	O
and	CC	O
decreased	VBD	O
endothelin-1	NN	Physical
.	.	O

After	IN	O
insulin	NN	O
bolus	NN	O
,	,	O
during	IN	O
saline	NN	O
,	,	O
insulin-induced	JJ	Physical
NOx	NNP	Physical
,	,	O
endothelin-1	JJ	Physical
,	,	O
and	CC	O
forearm	NN	Physical
cGMP	NN	Physical
release	NN	O
was	VBD	O
almost	RB	O
abolished	VBN	O
.	.	O

Conversely	RB	O
,	,	O
L-arginine	NNP	O
restored	VBD	O
a	DT	O
physiological	JJ	O
profile	NN	O
of	IN	O
all	DT	O
endothelial	JJ	Others
variables	NNS	Others
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
.	.	O

In	IN	O
control	NN	O
subjects	NNS	O
,	,	O
compared	VBN	O
with	IN	O
saline	JJ	O
infusion	NN	O
,	,	O
L-arginine	JJ	O
infusion	NN	O
did	VBD	O
not	RB	O
modify	VB	O
any	DT	O
parameter	NN	O
.	.	O

ADMA	NNP	Physical
levels	NNS	Physical
were	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
basal	JJ	O
endothelin-1	JJ	Physical
levels	NNS	Physical
and	CC	O
negatively	RB	O
correlated	VBN	O
with	IN	O
insulin-induced	JJ	Mental
incremental	JJ	Mental
levels	NNS	Physical
of	IN	Physical
NOx	NNP	Physical
and	CC	Mental
forearm	NN	Physical
cGMP	NN	Physical
release	NN	Mental
.	.	O

CONCLUSIONS	NNP	O
Plasma	NNP	Physical
ADMA	NNP	Physical
levels	NNS	Physical
are	VBP	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
,	,	O
and	CC	O
they	PRP	O
are	VBP	O
correlated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
endothelin-1	JJ	Physical
and	CC	O
reductions	NNS	O
in	IN	O
insulin-induced	JJ	O
increments	NNS	O
in	IN	O
plasma	NN	Physical
NOx	NNP	Physical
and	CC	Physical
cGMP	NN	Physical
,	,	O
effects	NNS	O
that	WDT	O
are	VBP	O
reversed	VBN	O
by	IN	O
intravenous	JJ	O
L-arginine	NNP	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
increased	VBD	O
ADMA	NNP	Physical
levels	NNS	Physical
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
abnormal	JJ	O
vascular	JJ	O
reactivity	NN	O
that	WDT	O
is	VBZ	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
.	.	O

Clozapine	NNP	O
versus	NN	O
placebo	NN	O
in	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
comparative	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
clozapine	NN	O
on	IN	O
chorea	NN	O
,	,	O
voluntary	JJ	O
motor	NN	O
performance	NN	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
three	CD	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
participated	VBD	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

A	DT	O
maximum	NN	O
of	IN	O
150	CD	O
mg/day	JJ	O
clozapine	NN	O
or	CC	O
placebo	NN	O
equivalent	NN	O
was	VBD	O
given	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
31	CD	O
days	NNS	O
.	.	O

Assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
and	CC	O
at	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Chorea	NNP	O
was	VBD	O
scored	VBN	O
using	VBG	O
the	DT	O
abnormal	JJ	O
involuntary	JJ	O
movement	NN	O
scale	NN	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
the	DT	O
chorea	NN	O
score	NN	O
of	IN	O
the	DT	O
unified	JJ	O
Huntington	NNP	O
's	POS	O
disease	NN	O
rating	NN	O
scale	NN	O
(	(	O
UHDRS	NNP	O
)	)	O
,	,	O
and	CC	O
judgement	NN	O
of	IN	O
video	JJ	O
recordings	NNS	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
UHDRS	NNP	O
motor	NN	O
scale	NN	O
.	.	O

Patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	O
regarding	VBG	O
functional	JJ	O
disability	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
already	RB	O
used	VBD	O
other	JJ	O
neuroleptic	JJ	O
medication	NN	O
,	,	O
which	WDT	O
was	VBD	O
kept	FW	O
unchanged	JJ	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
.	.	O

Results	NNS	O
of	IN	O
neuroleptic	JJ	O
naive	JJ	O
and	CC	O
neuroleptic	JJ	O
treated	JJ	O
patients	NNS	O
were	VBD	O
analysed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
Clozapine	NNP	O
tended	VBD	O
to	TO	O
reduce	VB	O
chorea	NN	Physical
in	IN	O
neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
only	RB	O
(	(	O
AIMS	NNP	O
)	)	O
;	:	O
improvement	NN	O
seemed	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
higher	JJR	O
doses	NNS	O
of	IN	O
clozapine	NN	O
.	.	O

Other	JJ	O
measures	NNS	Physical
of	IN	Physical
chorea	NN	Physical
(	(	Physical
UHDRS	NNP	Physical
chorea	NN	Physical
score	NN	Physical
,	,	Physical
video	JJ	Physical
ratings	NNS	Physical
)	)	Physical
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Clozapine	NNP	O
had	VBD	O
no	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
chorea	NN	Physical
in	IN	O
patients	NNS	O
already	RB	O
receiving	VBG	O
neuroleptic	JJ	O
medication	NN	O
.	.	O

Voluntary	JJ	Physical
motor	NN	Physical
performance	NN	Physical
did	VBD	O
not	RB	O
improve	VB	O
with	IN	O
clozapine	NN	O
.	.	O

Neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
reported	VBN	O
aggravation	NN	O
of	IN	O
functional	JJ	Physical
disability	NN	Physical
,	,	O
possibly	RB	O
reflecting	VBG	O
the	DT	O
frequent	JJ	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Adverse	JJ	O
reactions	NNS	O
forced	VBD	O
trial	NN	O
termination	NN	O
in	IN	O
six	CD	O
patients	NNS	O
and	CC	O
dose	JJ	O
reduction	NN	O
in	IN	O
another	DT	O
eight	CD	O
,	,	O
and	CC	O
consisted	VBD	O
mainly	RB	O
of	IN	O
drowsiness	NN	Adverseeffect
,	,	Adverseeffect
fatigue	NN	Adverseeffect
,	,	Adverseeffect
anticholinergic	NN	Adverseeffect
symptoms	NNS	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
walking	VBG	Adverseeffect
difficulties	NNS	Adverseeffect
.	.	O

CONCLUSIONS	NNP	O
Clozapine	NNP	O
has	VBZ	O
little	JJ	O
beneficial	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
tolerate	VB	O
doses	NNS	O
high	JJ	O
enough	RB	O
to	TO	O
reduce	VB	O
chorea	NN	O
.	.	O

Because	IN	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
often	RB	O
encountered	VBN	O
,	,	O
clozapine	NN	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
restraint	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

Short-term	JJ	O
fluoxetine	NN	O
monotherapy	NN	O
for	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
or	CC	O
bipolar	JJ	O
NOS	NNP	O
major	JJ	O
depression	NN	O
-	:	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
.	.	O

OBJECTIVES	CC	O
Current	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
(	(	O
BP	NNP	O
II	NNP	O
)	)	O
major	JJ	O
depressive	JJ	O
episode	NN	O
(	(	O
MDE	NNP	O
)	)	O
recommend	VBP	O
using	VBG	O
either	CC	O
a	DT	O
mood	NN	O
stabilizer	NN	O
alone	RB	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
mood	NN	O
stabilizer	NN	O
plus	CC	O
a	DT	O
selective	JJ	O
serotonin	NN	O
re-uptake	NN	O
inhibitor	NN	O
(	(	O
SSRI	NNP	O
)	)	O
.	.	O

This	DT	O
recommendation	NN	O
is	VBZ	O
the	DT	O
result	NN	O
of	IN	O
concern	NN	O
over	IN	O
antidepressant-induced	JJ	O
manic	JJ	O
switch	NN	O
episodes	NNS	O
.	.	O

However	RB	O
,	,	O
recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
manic	JJ	O
switch	NN	O
rate	NN	O
may	MD	O
be	VB	O
low	JJ	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
during	IN	O
SSRI	NNP	O
therapy	NN	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
relapse-prevention	NN	O
study	NN	O
of	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
37	CD	O
patients	NNS	O
received	VBD	O
open-label	JJ	O
fluoxetine	NN	O
20	CD	O
mg	NN	O
every	DT	O
day	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
(	(	O
HAM-D	NNP	O
17	CD	O
)	)	O
rating	NN	O
and	CC	O
the	DT	O
Young	NNP	O
Mania	NNP	O
Rating	NNP	O
(	(	O
YMR	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
)	)	O
who	WP	O
completed	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
fluoxetine	NN	O
treatment	NN	O
showed	VBD	O
a	DT	O
HAM-D	JJ	Physical
17	CD	Physical
reduction	NN	Physical
of	IN	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
,	,	O
while	IN	O
14	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
treated	JJ	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
baseline	JJ	O
HAM-D	JJ	O
17	CD	O
score	NN	O
.	.	O

Using	VBG	O
a	DT	O
conservative	JJ	O
YMR	NNP	Physical
score	NN	Physical
of	IN	Physical
>	NN	Physical
or	CC	Physical
=8	VB	Physical
to	TO	O
identify	VB	O
hypomanic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
patients	NNS	O
with	IN	O
YMR	NNP	O
score	NN	O
>	NN	O
or	CC	O
=8	NN	O
during	IN	O
fluoxetine	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
seen	VBN	O
during	IN	O
the	DT	O
screen	NN	O
and	CC	O
baseline	JJ	O
period	NN	O
.	.	O

Only	RB	O
three	CD	O
patients	NNS	O
(	(	O
7.3	CD	O
%	NN	O
)	)	O
had	VBD	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
hypomania	NN	Physical
,	,	O
and	CC	O
only	RB	O
one	CD	O
patient	NN	O
stopped	VBD	O
treatment	NN	O
because	IN	O
of	IN	O
a	DT	O
rapid	JJ	Mental
mood	NN	Mental
swing	VBG	Mental
into	IN	Mental
depression	NN	Mental
.	.	O

LIMITATIONS	NNP	O
Fluoxetine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mg	NNS	O
everyday	JJ	O
.	.	O

Fluoxetine	NNP	O
was	VBD	O
prescribed	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
manner	NN	O
,	,	O
and	CC	O
the	DT	O
sample	NN	O
size	NN	O
was	VBD	O
limited	VBN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
observations	NNS	O
support	VBP	O
the	DT	O
findings	NNS	O
of	IN	O
a	DT	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
during	IN	O
SSRI	NNP	O
monotherapy	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
may	MD	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
initial	JJ	O
treatment	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
.	.	O

A	DT	O
single	JJ	O
nasal	NN	O
allergen	NN	O
challenge	NN	O
increases	NNS	O
induced	VBD	O
sputum	JJ	Physical
inflammatory	JJ	Physical
markers	NNS	Physical
in	IN	O
non-asthmatic	JJ	O
subjects	NNS	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
:	:	O
correlation	NN	O
with	IN	O
plasma	JJ	O
interleukin-5	JJ	O
.	.	O

BACKGROUND	NNP	O
Seasonal	NNP	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
SAR	NNP	O
)	)	O
is	VBZ	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
asthma	NN	O
in	IN	O
affected	JJ	O
individuals	NNS	O
.	.	O

Nasal	NNP	O
allergic	JJ	O
inflammation	NN	O
enhances	VBZ	O
bone-marrow	JJ	O
eosinophil	NN	O
production	NN	O
,	,	O
mainly	RB	O
via	IN	O
IL-5	NNP	O
,	,	O
and	CC	O
rhinitis	NN	O
patients	NNS	O
have	VBP	O
increased	VBN	O
airway	JJ	O
inflammation	NN	O
during	IN	O
the	DT	O
pollen	NN	O
season	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
nasal	NN	O
allergy	NN	O
on	IN	O
sputum	NN	Physical
inflammatory	NN	Physical
markers	NNS	Physical
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open-labelled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
with	IN	O
16	CD	O
non-asthmatic	JJ	O
SAR	NNP	O
patients	NNS	O
(	(	O
median	JJ	O
age	NN	O
25	CD	O
years	NNS	O
,	,	O
56	CD	O
%	NN	O
males	NNS	O
)	)	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
nasal	NN	O
allergen	NN	O
challenge	NN	O
performed	VBD	O
out	IN	O
of	IN	O
season	NN	O
on	IN	O
induced	JJ	O
sputum	NN	Physical
inflammatory	NN	Physical
parameters	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

SAR	JJ	O
patients	NNS	O
were	VBD	O
identified	VBN	O
by	IN	O
history	NN	O
,	,	O
skin-prick	JJ	O
test	NN	O
and	CC	O
specific	JJ	O
IgE	NNP	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
normal	JJ	O
lung	JJ	O
function/bronchial	JJ	O
hyper-responsiveness	NN	O
out	IN	O
of	IN	O
season	NN	O
and	CC	O
a	DT	O
negative	JJ	O
asthma/wheezing	NN	O
history	NN	O
.	.	O

Sputum	NNP	Physical
cells	NNS	Physical
and	CC	Physical
supernatant	JJ	Physical
levels	NNS	Physical
of	IN	Physical
ECP	NNP	Physical
,	,	O
sICAM	NN	Physical
,	,	O
IL-5	NNP	Physical
and	CC	Physical
IL-10	NNP	Physical
,	,	O
and	CC	O
plasma	NN	Physical
levels	NNS	Physical
of	IN	Physical
IL-5	NNP	Physical
and	CC	Physical
ECP	NNP	Physical
,	,	O
were	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
nasal	JJ	O
allergen	NN	O
challenge	NN	O
.	.	O

After	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
,	,	O
the	DT	O
procedure	NN	O
was	VBD	O
repeated	VBN	O
with	IN	O
placebo	NN	O
challenge	NN	O
(	(	O
diluent	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Nasal	NNP	O
allergen	VBZ	O
challenge	NN	O
led	VBD	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
sputum	JJ	Physical
ECP	NNP	Physical
(	(	O
pre	JJ	O
=	$	O
60	CD	O
+/-	JJ	O
12	CD	O
,	,	O
post	NN	O
=	VBD	O
212	CD	O
+/-	JJ	O
63	CD	O
micro	NN	O
g/L	NN	O
,	,	O
P	NNP	O
=	VBZ	O
0.02	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
,	,	O
and	CC	O
sICAM	NN	Physical
(	(	O
4.8	CD	O
+/-	JJ	O
2.7	CD	O
to	TO	O
6.5	CD	O
+/-	JJ	O
2.9	CD	O
ng/mL	NN	O
,	,	O
P	NNP	O
=	VBZ	O
0.02	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
,	,	O
whereas	JJ	O
IL-10	NNP	Physical
decreased	VBD	O
after	IN	O
provocation	NN	O
(	(	O
44	CD	O
+/-	JJ	O
11	CD	O
to	TO	O
29	CD	O
+/-	JJ	O
6	CD	O
pg/mL	NN	O
,	,	O
P	NNP	O
=	VBZ	O
0.06	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Sputum	NNP	Physical
IL-5	NNP	Physical
was	VBD	O
undetectable	JJ	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

The	DT	O
absolute	JJ	O
number	NN	O
of	IN	O
blood	NN	Physical
and	CC	Physical
sputum	NN	Physical
eosinophils	NNS	Physical
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
after	IN	O
allergen	NN	O
or	CC	O
placebo	NN	O
challenge	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.07	CD	O
,	,	O
both	DT	O
comparisons	NNS	O
)	)	O
.	.	O

Plasma	NNP	Physical
levels	NNS	Physical
of	IN	Physical
IL-5	NNP	Physical
increased	VBD	O
after	IN	O
allergen	NN	O
challenge	NN	O
(	(	O
8.7	CD	O
+/-	JJ	O
2.9	CD	O
to	TO	O
14.5	CD	O
+/-	JJ	O
3.9	CD	O
pg/mL	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
IL-5	NNP	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
rise	NN	O
in	IN	O
sputum	NN	Physical
ECP	NNP	Physical
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
'responders	NNS	O
'	POS	O
(	(	O
n	JJ	O
=	NN	O
12	CD	O
,	,	O
r	NN	O
=	VBD	O
0.71	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
single	JJ	O
nasal	NN	O
allergen	NN	O
challenge	NN	O
in	IN	O
SAR	NNP	O
patients	NNS	O
increased	VBD	O
markers	NNS	O
of	IN	O
allergic	JJ	Physical
inflammation	NN	Physical
in	IN	O
the	DT	O
lower	JJR	O
respiratory	NN	O
tract	NN	O
,	,	O
possibly	RB	O
via	IN	O
pronounced	JJ	O
activation	NN	O
of	IN	O
inflammatory	NN	O
cells	NNS	O
through	IN	O
circulating	VBG	O
immediate-type	JJ	O
reaction	NN	O
cytokines	NNS	O
like	IN	O
IL-5	NNP	O
.	.	O

These	DT	O
findings	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
explanatory	NN	O
data	NNS	O
for	IN	O
the	DT	O
high	JJ	O
susceptibility	NN	O
of	IN	O
SAR	NNP	O
patients	NNS	O
to	TO	O
incident	VB	O
asthma	NN	O
.	.	O

Secretin	NNP	O
and	CC	O
autism	NN	O
:	:	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
investigation	NN	O
.	.	O

Recent	JJ	O
anecdotal	JJ	O
reports	NNS	O
have	VBP	O
touted	VBN	O
the	DT	O
gastrointestinal	NN	O
(	(	O
GI	NNP	O
)	)	O
hormone	NN	O
secretin	NN	O
as	IN	O
a	DT	O
treatment	NN	O
modality	NN	O
for	IN	O
autism	NN	O
,	,	O
though	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
clinical	JJ	O
evidence	NN	O
or	CC	O
literature	NN	O
to	TO	O
support	VB	O
its	PRP$	O
viability	NN	O
.	.	O

We	PRP	O
undertook	VBD	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
these	DT	O
claims	NNS	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
(	(	O
49	CD	O
boys	NNS	O
,	,	O
7	CD	O
girls	NNS	O
,	,	O
mean	JJ	O
age	NN	O
=	VBD	O
6.4	CD	O
years	NNS	O
,	,	O
SD	NNP	O
=	NNP	O
2.7	CD	O
)	)	O
enrolled	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
trial	NN	O
of	IN	O
secretin	NN	O
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
one	CD	O
injection	NN	O
of	IN	O
the	DT	O
hormone	NN	O
(	(	O
2	CD	O
IU/kg	NNP	O
)	)	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
their	PRP$	O
parents	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	JJ	O
visits	NNS	O
(	(	O
3-6	JJ	O
weeks	NNS	O
later	RB	O
,	,	O
M	NNP	O
=	NNP	O
3.7	CD	O
,	,	O
SD	NNP	O
=	VBZ	O
1.4	CD	O
weeks	NNS	O
)	)	O
with	IN	O
Childhood	NNP	Mental
Autism	NNP	Mental
Rating	NNP	Mental
Scales	NNP	Mental
(	(	Mental
CARS	NNP	Mental
)	)	Mental
.	.	O

Thirty-four	JJ	O
patients	NNS	O
were	VBD	O
labeled	VBN	O
with	IN	O
Pervasive	NNP	O
Developmental	NNP	O
Disorder	NNP	O
Not	RB	O
Otherwise	NNP	O
Specified	NNP	O
,	,	O
and	CC	O
22	CD	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
Autistic	JJ	O
Disorder	NNP	O
.	.	O

Forty-five	JJ	O
patients	NNS	O
were	VBD	O
concurrently	RB	O
on	IN	O
other	JJ	O
drug	NN	O
treatments	NNS	O
.	.	O

At	IN	O
follow-up	NN	O
,	,	O
some	DT	O
reported	VBD	O
minimal	JJ	O
but	CC	O
potentially	RB	O
significant	JJ	O
improvements	NNS	O
including	VBG	O
changes	NNS	Physical
in	IN	Physical
GI	NNP	Physical
symptoms	NNS	Physical
,	,	O
expressive	JJ	Mental
and/or	NN	Mental
receptive	JJ	Mental
language	NN	Mental
function	NN	Mental
,	,	Mental
and	CC	Mental
improved	JJ	Mental
awareness	NN	Mental
and	CC	Mental
social	JJ	Mental
interactions	NNS	Mental
.	.	O

No	DT	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
reported	VBN	O
or	CC	O
observed	VBN	O
.	.	O

Subsequently	NNP	O
,	,	O
17	CD	O
of	IN	O
the	DT	O
most	RBS	O
responsive	JJ	O
patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
began	VBD	O
a	DT	O
double-blind	JJ	O
trial	NN	O
that	WDT	O
also	RB	O
included	VBD	O
8	CD	O
newly	RB	O
enrolled	VBN	O
patients	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
this	DT	O
second	JJ	O
study	NN	O
were	VBD	O
alternatively	RB	O
entered	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
and	CC	O
received	VBD	O
injections	NNS	O
of	IN	O
secretin	NN	O
or	CC	O
placebo	NN	O
with	IN	O
crossover	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
entered	VBD	O
into	IN	O
Study	NNP	O
2	CD	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
6.5	CD	O
(	(	O
SD	NNP	O
=	NNP	O
0.8	CD	O
)	)	O
weeks	NNS	O
after	IN	O
beginning	VBG	O
Study	NNP	O
1	CD	O
.	.	O

Results	NNS	O
of	IN	O
both	DT	O
inquiries	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
treatment	NN	O
with	IN	O
secretin	NN	O
was	VBD	O
reported	VBN	O
to	TO	O
cause	VB	O
transient	JJ	Mental
changes	NNS	Mental
in	IN	Mental
speech	NN	Mental
and	CC	Mental
behavior	NN	Mental
in	IN	O
some	DT	O
children	NNS	O
,	,	O
overall	JJ	O
it	PRP	O
produced	VBD	O
few	JJ	O
clinically	RB	O
meaningful	JJ	O
changes	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
children	NNS	O
given	VBN	O
placebo	JJ	O
injections	NNS	O
.	.	O

Reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
:	:	O
evidence	NN	O
from	IN	O
the	DT	O
Scandinavian	JJ	O
Simvastatin	NNP	O
Survival	NNP	O
Study	NNP	O
(	(	O
4S	CD	O
)	)	O
.	.	O

The	DT	O
Scandinavian	JJ	O
Simvastatin	NNP	O
Survival	NNP	O
Study	NNP	O
(	(	O
4S	CD	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
cholesterol	NN	O
reduction	NN	O
with	IN	O
simvastatin	NN	O
on	IN	O
mortality	NN	Mortality
and	CC	O
morbidity	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
4,444	CD	O
patients	NNS	O
with	IN	O
angina	JJ	O
pectoris	NN	O
or	CC	O
previous	JJ	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
serum	VB	O
cholesterol	NN	O
levels	NNS	O
of	IN	O
213-310	JJ	O
mg/dl	NN	O
(	(	O
5.5-8.0	JJ	O
mmol/liter	NN	O
)	)	O
while	IN	O
treated	VBN	O
with	IN	O
a	DT	O
lipid-lowering	JJ	O
diet	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
.	.	O

Over	IN	O
the	DT	O
5.4	CD	O
years	NNS	O
of	IN	O
median	JJ	O
follow-up	NN	O
,	,	O
simvastatin	NN	O
produced	VBD	O
changes	NNS	O
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
,	,	Physical
low	JJ	Physical
density	NN	Physical
lipoprotein	NN	Physical
(	(	Physical
LDL	NNP	Physical
)	)	Physical
cholesterol	NN	Physical
,	,	O
and	CC	O
high	JJ	Physical
density	NN	Physical
lipoprotein	NN	Physical
(	(	Physical
HDL	NNP	Physical
)	)	Physical
cholesterol	NN	Physical
of	IN	O
-25	NNP	O
%	NN	O
,	,	O
-35	CD	O
%	NN	O
,	,	O
and	CC	O
+8	NNP	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
minimal	JJ	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	Adverseeffect

A	DT	O
total	NN	O
of	IN	O
256	CD	O
patients	NNS	O
(	(	O
12	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	Mortality
compared	VBN	O
with	IN	O
182	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
30	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0003	CD	O
)	)	O
attributable	NN	O
to	TO	O
a	DT	O
42	CD	O
%	NN	O
reduction	NN	O
in	IN	O
the	DT	O
risk	NN	O
of	IN	O
coronary	JJ	O
death	NN	O
.	.	O

Noncardiovascular	JJ	Adverseeffect
causes	NNS	Adverseeffect
accounted	VBD	O
for	IN	O
49	CD	O
and	CC	O
46	CD	O
deaths	NNS	Mortality
in	IN	O
the	DT	O
placebo	NN	O
and	CC	O
simvastatin	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Major	JJ	Physical
coronary	JJ	Physical
events	NNS	Physical
were	VBD	O
experienced	VBN	O
by	IN	O
622	CD	O
patients	NNS	O
(	(	O
28	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
431	CD	O
patients	NNS	O
(	(	O
19	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
a	DT	O
risk	NN	Physical
reduction	NN	Physical
of	IN	O
34	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.00001	CD	O
)	)	O
.	.	O

This	DT	O
risk	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
reduced	VBN	O
in	IN	O
subgroups	NNS	O
consisting	VBG	O
of	IN	O
women	NNS	O
and	CC	O
patients	NNS	O
of	IN	O
both	DT	O
sexes	NNS	O
aged	VBN	O
>	CD	O
or	CC	O
=	$	O
60	CD	O
years	NNS	O
.	.	O

Other	JJ	O
benefits	NNS	O
of	IN	O
treatment	NN	O
included	VBD	O
a	DT	O
37	CD	O
%	NN	O
reduction	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.00001	CD	O
)	)	O
in	IN	O
the	DT	O
risk	NN	Physical
of	IN	Physical
undergoing	VBG	Physical
myocardial	JJ	Physical
revascularization	NN	Physical
procedures	NNS	Physical
.	.	Physical

Simvastatin	NNP	O
was	VBD	O
beneficial	JJ	O
regardless	NN	O
of	IN	O
whether	IN	O
patients	NNS	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
whether	IN	O
they	PRP	O
were	VBD	O
smokers	NNS	O
or	CC	O
had	VBD	O
hypertension	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
The	DT	O
SNRI	NNP	O
venlafaxine	NN	O
improves	VBZ	O
emotional	JJ	Mental
unawareness	NN	Mental
in	IN	O
patients	NNS	O
with	IN	O
post-stroke	JJ	O
depression	NN	O
.	.	O

OBJECTIVE	CC	O
Patients	NNPS	O
with	IN	O
stroke	NNS	O
have	VBP	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
depression	NN	O
and	CC	O
unawareness	NN	O
of	IN	O
emotions	NNS	O
or	CC	O
alexithymia	NN	Mental
.	.	Mental

Here	RB	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
serotoninergic	NN	O
and	CC	O
noradrenergic	JJ	O
reuptake	NN	O
inhibitor	NN	O
(	(	O
SNRI	NNP	O
)	)	O
venlafaxine	NN	O
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
SSRI	NNP	O
fluoxetine	NN	O
on	IN	O
alexithymia	NN	Mental
severity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
DSM-IV	NNP	O
post-stroke	JJ	O
major	JJ	O
depressive-like	JJ	O
episode	NN	O
(	(	O
PSD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
inpatients	NNS	O
with	IN	O
first-ever	JJ	O
stroke	NN	O
and	CC	O
PSD	NNP	O
were	VBD	O
consecutively	RB	O
enrolled	VBN	O
in	IN	O
this	DT	O
randomized	JJ	O
open-label	NN	O
study	NN	O
.	.	O

Twenty-five	JJ	O
were	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
SNRI	NNP	O
venlafaxine	NN	O
SR	NNP	O
(	(	O
75-150	JJ	O
mg/die	NN	O
)	)	O
,	,	O
and	CC	O
25	CD	O
with	IN	O
the	DT	O
SSRI	NNP	O
fluoxetine	NN	O
(	(	O
20-40	JJ	O
mg/die	NN	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
day	NN	O
0	CD	O
,	,	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
8	CD	O
weeks	NNS	O
,	,	O
using	VBG	O
the	DT	O
Mini-Mental	JJ	Mental
State	NNP	Mental
Examination	NNP	Mental
,	,	Mental
the	DT	Mental
Hamilton	NNP	Mental
Depression	NNP	Mental
Rating	NNP	Mental
Scale	NNP	Mental
,	,	Mental
and	CC	Mental
the	DT	Mental
Toronto	NNP	Mental
Alexithymia	NNP	Mental
Scale	NNP	Mental
(	(	O
TAS-20	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
treated	VBN	O
with	IN	O
fluoxetine	NN	O
and	CC	O
those	DT	O
treated	VBN	O
with	IN	O
venlafaxine	NN	O
showed	VBD	O
similar	JJ	O
improvement	NN	O
in	IN	O
depressive	JJ	Mental
symptoms	NNS	Mental
.	.	Mental

However	RB	O
,	,	O
patients	NNS	O
treated	VBD	O
with	IN	O
venlafaxine	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
improvement	NN	O
on	IN	O
alexithymia	NN	Mental
severity	NN	Mental
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
fluoxetine	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
venlafaxine	NN	O
on	IN	O
unawareness	NN	Mental
of	IN	Mental
emotions	NNS	Mental
was	VBD	O
evident	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
alexithymia	NN	O
(	(	O
TAS-20	NNP	O
>	NNP	O
or=	IN	O
61	CD	O
)	)	O
at	IN	O
the	DT	O
baseline	NN	O
and	CC	O
in	IN	O
those	DT	O
without	IN	O
alexithymia	NN	O
(	(	O
TAS-20	NNP	O
<	NNP	O
61	CD	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Antidepressants	NNPS	O
acting	VBG	O
on	IN	O
both	CC	O
the	DT	O
serotoninergic	NN	O
and	CC	O
noradrenergic	JJ	O
systems	NNS	O
might	MD	O
represent	VB	O
a	DT	O
valid	JJ	O
resource	NN	O
not	RB	O
only	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
but	CC	O
also	RB	O
for	IN	O
improving	VBG	O
emotional	JJ	Mental
unawareness	NN	Mental
in	IN	O
stroke	NN	O
patients	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
sequential	JJ	O
annual	JJ	O
vaccination	NN	O
and	CC	O
of	IN	O
DHEA	NNP	O
administration	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
repeated	VBN	O
vaccination	NN	O
and	CC	O
of	IN	O
dehydroepiandrosterone	NN	O
(	(	O
DHEA	NNP	O
)	)	O
treatment	NN	O
on	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Seventy-one	CD	O
elderly	JJ	O
volunteers	NNS	O
,	,	O
aged	VBN	O
61-89	CD	O
years	NNS	O
,	,	O
enrolled	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
DHEA	NNP	O
(	(	O
50	CD	O
mg	NN	O
qd	NN	O
p.o	NN	O
.	.	O

for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
starting	VBG	O
2	CD	O
days	NNS	O
before	IN	O
immunization	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Antibody	NNP	O
response	NN	O
against	IN	O
the	DT	O
three	CD	O
strains	NNS	O
of	IN	O
vaccine	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
previously	RB	O
vaccinated	VBN	O
and	CC	O
non-vaccinated	JJ	O
subjects	NNS	O
.	.	O

DHEA	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
enhance	VB	O
established	VBN	Physical
immunity	NN	Physical
.	.	Physical

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
attainment	NN	O
of	IN	O
protective	JJ	Others
antibody	NN	Others
titer	NN	Others
(	(	O
titer	NN	O
of	IN	O
1:40	CD	O
or	CC	O
greater	JJR	O
)	)	O
against	IN	O
A/Texas	NNP	O
in	IN	O
subjects	NNS	O
with	IN	O
non-protective	JJ	O
baseline	NN	O
antibody	NN	O
titer	NN	O
was	VBD	O
recorded	VBN	O
following	VBG	O
DHEA	NNP	O
treatment	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
52	CD	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Post-immunization	NN	Others
titers	NNS	Others
against	IN	O
influenza	VBP	O
A	DT	O
strains	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
immunized	VBN	O
before	RB	O
.	.	O

Additionally	RB	O
,	,	O
post-vaccination	JJ	Others
protective	JJ	Others
titers	NNS	Others
against	IN	O
the	DT	O
A/Johannesburg	NNP	O
strain	NN	O
were	VBD	O
more	RBR	O
prevalent	JJ	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
vaccinated	VBN	O
before	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
not	RB	O
the	DT	O
same	JJ	O
for	IN	O
anti-B/Harbin	JJ	O
antibodies-repeated	JJ	O
vaccination	NN	O
caused	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
HI	NNP	O
titer	NN	O
in	IN	O
previously	RB	O
vaccinated	VBN	O
subjects	NNS	O
.	.	O

Low	JJ	O
power	NN	O
Ga-Al-As	NNP	O
laser	NN	O
treatment	NN	O
of	IN	O
painful	JJ	Pain
osteoarthritis	NN	Pain
of	IN	O
the	DT	O
knee	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
double-blind	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
low	JJ	O
power	NN	O
Ga-Al-As	NNP	O
laser	NN	O
treatment	NN	O
on	IN	O
chronic	JJ	Pain
pain	NN	Pain
related	VBN	O
to	TO	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
with	IN	O
periarticular	JJ	O
tender	NN	O
points	NNS	O
.	.	O

Twenty-nine	JJ	O
out-patients	NNS	O
with	IN	O
uni-	JJ	O
or	CC	O
bilateral	JJ	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
were	VBD	O
included	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
laser	NN	O
or	CC	O
placebo	NN	O
laser	NN	O
.	.	O

Fourteen	JJ	O
patients	NNS	O
received	VBD	O
active	JJ	O
laser	NN	O
treatment	NN	O
and	CC	O
all	DT	O
patients	NNS	O
included	VBD	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
effect	NN	O
variables	NNS	O
were	VBD	O
daily	JJ	Physical
levels	NNS	Physical
of	IN	Physical
pain	NN	Physical
,	,	Physical
analgesic	JJ	Pain
requirements	NNS	Pain
,	,	Physical
palpation	NN	Physical
tenderness	NN	Physical
and	CC	Physical
isokinetic	JJ	Physical
quadriceps	NNS	Physical
strength	NN	Physical
.	.	O

Each	DT	O
patient	NN	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
for	IN	O
9	CD	O
weeks	NNS	O
and	CC	O
registered	VBD	O
daily	JJ	Pain
level	NN	Pain
of	IN	Pain
pain	NN	Pain
and	CC	O
consumption	NN	Physical
of	IN	Physical
analgesics	NNS	Physical
.	.	O

In	IN	O
weeks	NNS	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
6	CD	O
the	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
total	NN	O
of	IN	O
nine	CD	O
treatments	NNS	O
,	,	O
each	DT	O
of	IN	O
15	CD	O
min	NNS	O
and	CC	O
administered	VBN	O
to	TO	O
periarticular	VB	O
tender	NN	O
points	NNS	O
.	.	O

The	DT	O
dose	JJ	O
per	IN	O
treatment	NN	O
was	VBD	O
22.5	CD	O
joule	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
effect	NN	O
variables	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
before	IN	O
,	,	O
during	IN	O
or	CC	O
after	IN	O
treatment	NN	O
.	.	O

With	IN	O
regard	NN	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
overall	JJ	O
assessment	NN	O
there	EX	O
was	VBD	O
a	DT	O
clearly	RB	O
demonstrable	JJ	O
positive	JJ	O
effect	NN	O
of	IN	O
treatment	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

This	DT	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
a	DT	O
placebo	NN	O
effect	NN	O
.	.	O

Cemented	VBN	O
CeraOne	NNP	O
and	CC	O
porcelain	NN	O
fused	VBD	O
to	TO	O
TiAdapt	NNP	O
abutment	JJ	O
single-implant	JJ	O
crown	JJ	O
restorations	NNS	O
:	:	O
a	DT	O
10-year	JJ	O
comparative	JJ	O
follow-up	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Long-term	NNP	O
data	NNS	O
comparing	NN	O
cemented	VBN	O
and	CC	O
noncemented	VBN	O
single-implant	JJ	O
restorations	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
reported	VBN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
clinical	JJ	Physical
and	CC	Physical
radiographic	JJ	Others
performance	NN	Others
of	IN	O
single-implant	JJ	O
crown	NN	O
restorations	NNS	O
made	VBN	O
by	IN	O
either	DT	O
directly	RB	O
baked	VBN	O
porcelain	NN	O
to	TO	O
custom-made	JJ	O
TiAdapt	NNP	O
titanium	NN	O
abutments	NNS	O
(	(	O
Nobel	NNP	O
Biocare	NNP	O
AB	NNP	O
,	,	O
G?teborg	NNP	O
,	,	O
Sweden	NNP	O
)	)	O
(	(	O
test	NN	O
)	)	O
or	CC	O
cement	JJ	O
crowns	NNS	O
onto	IN	O
CeraOne	NNP	O
(	(	O
Nobel	NNP	O
Biocare	NNP	O
AB	NNP	O
)	)	O
abutments	NNS	O
(	(	O
control	NN	O
)	)	O
after	IN	O
10	CD	O
years	NNS	O
in	IN	O
function	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Altogether	NNP	O
,	,	O
35	CD	O
consecutive	JJ	O
patients	NNS	O
were	VBD	O
provided	VBN	O
with	IN	O
41	CD	O
turned	VBD	O
single	JJ	O
Br?nemark	NNP	O
System	NNP	O
implants	NNS	O
(	(	O
Nobel	NNP	O
Biocare	NNP	O
AB	NNP	O
)	)	O
in	IN	O
the	DT	O
partially	RB	O
edentulous	JJ	O
upper	JJ	O
jaw	NN	O
.	.	O

By	IN	O
random	NN	O
,	,	O
15	CD	O
and	CC	O
20	CD	O
patients	NNS	O
were	VBD	O
provided	VBN	O
with	IN	O
18	CD	O
test	NN	O
and	CC	O
23	CD	O
control	NN	O
implant	JJ	O
crowns	NNS	O
,	,	O
respectively	RB	O
.	.	O

Thereafter	NNP	O
,	,	O
clinical	JJ	O
and	CC	O
radiographic	JJ	O
data	NNS	O
were	VBD	O
collected	VBN	O
and	CC	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
None	NN	O
of	IN	O
the	DT	O
implants	NNS	O
were	VBD	O
found	VBN	O
loose	RB	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
(	(	O
100	CD	O
%	NN	O
)	)	O
.	.	O

Few	JJ	O
clinical	JJ	O
problems	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
and	CC	O
the	DT	O
overall	JJ	O
average	JJ	O
marginal	JJ	O
bone	NN	O
loss	NN	O
was	VBD	O
0.26	CD	O
mm	NN	O
(	(	O
SD	NNP	O
0.64	CD	O
)	)	O
during	IN	O
10	CD	O
years	NNS	O
in	IN	O
function	NN	O
.	.	O

After	IN	O
the	DT	O
final	JJ	O
tightening	NN	O
of	IN	O
the	DT	O
crowns	NNS	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
test	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
head	NN	O
of	IN	O
the	DT	O
implants	NNS	O
was	VBD	O
placed	VBN	O
on	IN	O
an	DT	O
average	JJ	O
6.3	CD	O
mm	NN	O
(	(	O
SD	NNP	O
2.24	CD	O
)	)	O
below	IN	O
the	DT	O
cement/enamel	JJ	O
junction	NN	O
of	IN	O
the	DT	O
adjacent	JJ	O
teeth	NN	O
(	(	O
range	JJ	O
2.5-10.0	JJ	O
mm	NN	O
)	)	O
.	.	O

Implants	NNS	O
with	IN	O
reported	JJ	O
mechanical	JJ	O
and/or	NN	O
mucosal	NN	O
problems	NNS	O
or	CC	O
placed	VBD	O
more	JJR	O
apically	RB	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
adjacent	JJ	O
teeth	NN	O
did	VBD	O
not	RB	O
present	VB	O
more	JJR	O
bone	JJ	O
loss	NN	O
as	IN	O
compared	VBN	O
with	IN	O
implants	NNS	O
with	IN	O
no	DT	O
problems	NNS	O
or	CC	O
placed	VBD	O
more	RBR	O
coronally	RB	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
seems	VBZ	O
to	TO	O
be	VB	O
no	DT	O
obvious	JJ	O
clinical	JJ	O
or	CC	O
radiographic	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
test	NN	O
and	CC	O
control	VB	O
single-implant	JJ	O
restorations	NNS	O
during	IN	O
10	CD	O
years	NNS	O
of	IN	O
follow-up	JJ	O
.	.	O

Occasionally	NNP	O
,	,	O
some	DT	O
restorations	NNS	O
presented	VBD	O
loose	JJ	O
abutment	JJ	O
screws	NNS	O
and/or	VBP	O
fistulas	NNS	O
during	IN	O
follow-up	JJ	O
.	.	O

This	DT	O
implies	VBZ	O
a	DT	O
certain	JJ	O
need	NN	O
for	IN	O
maintenance	NN	O
where	WRB	O
a	DT	O
one-piece	JJ	O
single-implant	JJ	O
protocol	NN	O
(	(	O
test	NN	O
)	)	O
allows	VBZ	O
both	DT	O
for	IN	O
a	DT	O
simple	JJ	O
clinical	JJ	O
procedure	NN	O
at	IN	O
placement	NN	O
without	IN	O
cementation	NN	O
problems	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
an	DT	O
easy	JJ	O
and	CC	O
simple	JJ	O
maintenance	NN	O
of	IN	O
installed	JJ	O
single	JJ	O
implant	NN	O
crowns	NNS	O
in	IN	O
long-term	JJ	O
function	NN	O
.	.	O

Global	JJ	O
contour	NN	O
saliency	NN	O
and	CC	O
local	JJ	O
colinear	NN	O
interactions	NNS	O
.	.	O

Our	PRP$	O
visual	JJ	O
system	NN	O
can	MD	O
link	VB	O
components	NNS	O
of	IN	O
contours	NNS	O
and	CC	O
segregate	JJ	O
contours	NNS	O
from	IN	O
complex	JJ	O
backgrounds	NNS	O
based	VBN	O
on	IN	O
geometric	JJ	O
grouping	NN	O
rules	NNS	O
.	.	O

This	DT	O
is	VBZ	O
an	DT	O
important	JJ	O
intermediate	JJ	O
step	NN	O
in	IN	O
object	JJ	Physical
recognition	NN	Physical
.	.	Physical

The	DT	O
substrate	NN	O
for	IN	O
contour	JJ	O
integration	NN	O
may	MD	O
be	VB	O
based	VBN	O
on	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
intrinsic	JJ	O
horizontal	NN	O
connections	NNS	O
seen	VBN	O
in	IN	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
(	(	O
V1	NNP	O
)	)	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
perceptual	JJ	O
rules	NNS	O
governing	VBG	O
contour	NN	O
saliency	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
spatial	JJ	O
extents	NNS	O
of	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
horizontal	JJ	O
connections	NNS	O
match	VBP	O
those	DT	O
mediating	JJ	O
saliency	NN	O
.	.	O

To	TO	O
quantify	VB	O
these	DT	O
rules	NNS	O
,	,	O
we	PRP	O
used	VBD	O
stimuli	NNS	O
composed	VBN	O
of	IN	O
randomly	RB	O
oriented	VBN	O
nonoverlapping	JJ	O
line	NN	O
segments	NNS	O
.	.	O

Salient	NN	O
contours	NN	O
within	IN	O
this	DT	O
complex	JJ	O
background	NN	O
were	VBD	O
formed	VBN	O
by	IN	O
colinear	JJ	O
alignment	NN	O
of	IN	O
nearby	JJ	O
segments	NNS	O
.	.	O

Contour	NNP	Physical
detectability	NN	Physical
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
2-interval-forced-choice	JJ	O
design	NN	O
.	.	O

Contour	NNP	Others
detectability	NN	Others
deteriorated	VBN	O
with	IN	O
increasing	VBG	O
spacing	VBG	Physical
between	IN	O
contour	JJ	O
elements	NNS	O
and	CC	O
improved	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
line	NN	O
elements	NNS	O
was	VBD	O
increased	VBN	O
.	.	O

At	IN	O
short	JJ	O
contour	NN	O
spacing	NN	O
,	,	O
the	DT	O
detectability	NN	O
reached	VBD	O
a	DT	O
plateau	NN	O
with	IN	O
alignment	NN	O
of	IN	O
a	DT	O
few	JJ	O
line	NN	O
segments	NNS	O
that	IN	O
together	RB	O
formed	VBD	O
a	DT	O
contour	NN	O
subtending	VBG	O
several	JJ	O
visual	JJ	O
degrees	NNS	O
.	.	O

At	IN	O
intermediate	JJ	O
spacing	NN	O
,	,	O
saliency	NN	Physical
built	VBD	O
up	RP	O
progressively	RB	O
with	IN	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
,	,	O
extending	VBG	O
up	RP	O
to	TO	O
30	CD	O
degrees	NNS	O
.	.	O

When	WRB	O
contour	NN	O
spacing	NN	O
was	VBD	O
beyond	IN	O
a	DT	O
critical	JJ	O
range	NN	O
(	(	O
about	IN	O
2	CD	O
degrees	NNS	O
)	)	O
,	,	O
however	RB	O
,	,	O
the	DT	O
detectability	NN	Others
dropped	VBD	O
to	TO	O
chance	NN	O
levels	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
.	.	O

Contour	NNP	Others
detectability	NN	Others
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
function	NN	O
not	RB	O
only	RB	O
of	IN	O
the	DT	O
relative	JJ	O
spacing	NN	O
of	IN	O
contour	JJ	O
elements	NNS	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
noise	NN	O
elements	NNS	O
but	CC	O
also	RB	O
of	IN	O
the	DT	O
average	JJ	O
density	NN	O
of	IN	O
the	DT	O
overall	JJ	O
pattern	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
training	VBG	O
significantly	RB	O
improved	VBN	O
contour	JJ	Mental
detection	NN	Mental
,	,	O
increasing	VBG	O
the	DT	O
critical	JJ	Physical
spacing	NN	Physical
of	IN	O
line	NN	O
elements	NNS	O
beyond	IN	O
which	WDT	O
contours	NNS	O
were	VBD	O
no	RB	O
longer	RBR	O
detectable	JJ	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
global	JJ	Others
contour	NN	Others
integration	NN	Others
is	VBZ	O
based	VBN	O
on	IN	O
mechanisms	NNS	O
of	IN	O
limited	JJ	O
spatial	JJ	O
extent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
the	DT	O
interactions	NNS	O
observed	VBD	O
in	IN	O
V1	NNP	O
.	.	O

These	DT	O
interactions	NNS	O
can	MD	O
cascade	VB	O
over	IN	O
larger	JJR	O
distances	NNS	O
provided	VBD	O
the	DT	O
spacing	NN	O
of	IN	O
stimulus	JJ	O
elements	NNS	O
is	VBZ	O
kept	VBN	O
within	IN	O
a	DT	O
limited	JJ	O
range	NN	O
.	.	O

Induction	NNP	O
versus	NN	O
noninduction	NN	O
in	IN	O
renal	JJ	O
transplant	NN	O
recipients	NNS	O
with	IN	O
tacrolimus-based	JJ	O
immunosuppression	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
induction	NN	O
treatment	NN	O
with	IN	O
antithymocyte	NN	O
globulins	NNS	O
(	(	O
ATG	NNP	O
)	)	O
followed	VBN	O
by	IN	O
tacrolimus	JJ	O
therapy	NN	O
with	IN	O
immediate	JJ	O
tacrolimus	NNS	O
therapy	NN	O
in	IN	O
renal	JJ	O
transplant	NN	O
recipients	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
12-month	JJ	O
,	,	O
open	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
15	CD	O
centers	NNS	O
in	IN	O
France	NNP	O
and	CC	O
1	CD	O
center	NN	O
in	IN	O
Belgium	NNP	O
;	:	O
309	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
induction	NN	O
therapy	NN	O
with	IN	O
ATG	NNP	O
(	(	O
n=151	NN	O
)	)	O
followed	VBN	O
by	IN	O
initiation	NN	O
of	IN	O
tacrolimus	NN	O
on	IN	O
day	NN	O
9	CD	O
or	CC	O
immediate	JJ	O
tacrolimus-based	JJ	O
triple	NN	O
therapy	NN	O
(	(	O
n=158	JJ	O
)	)	O
.	.	O

In	IN	O
both	DT	O
study	NN	O
arms	NNS	O
,	,	O
the	DT	O
initial	JJ	O
daily	JJ	O
tacrolimus	NN	O
dose	NN	O
was	VBD	O
0.2	CD	O
mg/kg	NN	O
.	.	O

Steroid	JJ	O
boluses	NNS	O
were	VBD	O
given	VBN	O
in	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
and	CC	O
tapered	JJ	O
thereafter	NN	O
from	IN	O
20	CD	O
mg/day	NN	O
to	TO	O
5	CD	O
mg/day	NN	O
.	.	O

Azathioprine	NNP	O
was	VBD	O
administered	VBN	O
at	IN	O
1-2	JJ	O
mg/kg	NNS	O
per	IN	O
day	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
month	NN	O
12	CD	O
,	,	O
biopsy-confirmed	JJ	Physical
acute	NN	Physical
rejections	NNS	Physical
were	VBD	O
reported	VBN	O
for	IN	O
15.2	CD	O
%	NN	O
(	(	O
induction	NN	O
)	)	O
and	CC	O
30.4	CD	O
%	NN	O
(	(	O
noninduction	NN	O
)	)	O
of	IN	O
patients	NNS	O
(	(	O
P=0.001	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	Physical
of	IN	Physical
steroid-sensitive	JJ	Physical
acute	JJ	Physical
rejections	NNS	Physical
was	VBD	O
7.9	CD	O
%	NN	O
(	(	O
induction	NN	O
)	)	O
and	CC	O
22.2	CD	O
%	NN	O
(	(	O
noninduction	NN	O
)	)	O
(	(	O
P=0.001	NNP	O
)	)	O
.	.	O

Steroid-resistant	JJ	Physical
acute	JJ	Physical
rejections	NNS	Physical
were	VBD	O
reported	VBN	O
for	IN	O
8.6	CD	O
%	NN	O
(	(	O
induction	NN	O
)	)	O
and	CC	O
8.9	CD	O
%	NN	O
(	(	O
noninduction	NN	O
)	)	O
of	IN	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
nine	CD	O
patients	NNS	O
died	VBD	Mortality
.	.	Mortality

Patient	NNP	Mortality
survival	NN	Mortality
and	CC	Mortality
graft	NN	Mortality
survival	NN	Mortality
at	IN	O
month	NN	O
12	CD	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
97.4	CD	O
%	NN	O
vs.	FW	O
96.8	CD	O
%	NN	O
and	CC	O
92.1	CD	O
%	NN	O
vs.	FW	O
91.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
found	VBN	O
for	IN	O
cytomegalovirus	NN	Adverseeffect
(	(	Adverseeffect
CMV	NNP	Adverseeffect
)	)	Adverseeffect
infection	NN	Adverseeffect
(	(	O
induction	NN	O
,	,	O
32.5	CD	O
%	NN	O
vs.	FW	O
noninduction	NN	O
,	,	O
19.0	CD	O
%	NN	O
,	,	O
P=0.009	NNP	O
)	)	O
,	,	O
leukopenia	NN	Physical
(	(	O
37.3	CD	O
%	NN	O
vs.	FW	O
9.5	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
fever	RB	Physical
(	(	O
25.2	CD	O
%	NN	O
vs.	FW	O
10.1	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
herpes	VBZ	Adverseeffect
simplex	JJ	Adverseeffect
(	(	O
17.9	CD	O
%	NN	O
vs.	FW	O
5.7	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
and	CC	O
thrombocytopenia	NN	Physical
(	(	O
11.3	CD	O
%	NN	O
vs.	FW	O
3.2	CD	O
%	NN	O
,	,	O
P=0.007	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
induction	NN	O
group	NN	O
,	,	O
serum	NN	Physical
sickness	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
10.6	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
new	JJ	Physical
onset	NN	Physical
diabetes	NNS	Physical
mellitus	NN	Physical
was	VBD	O
3.4	CD	O
%	NN	O
(	(	O
induction	NN	O
)	)	O
and	CC	O
4.5	CD	O
%	NN	O
(	(	O
noninduction	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Low	NNP	O
incidences	NNS	O
of	IN	O
acute	JJ	Physical
rejection	NN	Physical
were	VBD	O
found	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
.	.	O

Induction	NNP	O
treatment	NN	O
with	IN	O
ATG	NNP	O
has	VBZ	O
the	DT	O
advantage	NN	O
of	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
acute	JJ	O
rejection	NN	O
,	,	O
but	CC	O
it	PRP	O
significantly	RB	O
increases	VBZ	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
,	,	O
particularly	RB	O
CMV	NNP	O
infection	NN	O
.	.	O

Cost-effectiveness	NN	Others
of	IN	O
collaborative	JJ	O
care	NN	O
including	VBG	O
PST	NNP	O
and	CC	O
an	DT	O
antidepressant	JJ	O
treatment	NN	O
algorithm	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
in	IN	O
primary	JJ	O
care	NN	O
;	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Depressive	NNP	O
disorder	NN	O
is	VBZ	O
currently	RB	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
burdensome	JJ	O
disorders	NNS	O
worldwide	VBP	O
.	.	O

Evidence-based	JJ	O
treatments	NNS	O
for	IN	O
depressive	JJ	O
disorder	NN	O
are	VBP	O
already	RB	O
available	JJ	O
,	,	O
but	CC	O
these	DT	O
are	VBP	O
used	VBN	O
insufficiently	RB	O
,	,	O
and	CC	O
with	IN	O
less	JJR	O
positive	JJ	O
results	NNS	O
than	IN	O
possible	JJ	O
.	.	O

Earlier	RBR	O
research	NN	O
in	IN	O
the	DT	O
USA	NNP	O
has	VBZ	O
shown	VBN	O
good	JJ	O
results	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depressive	JJ	O
disorder	NN	O
based	VBN	O
on	IN	O
a	DT	O
collaborative	JJ	O
care	NN	O
approach	NN	O
with	IN	O
Problem	NNP	Physical
Solving	NNP	Physical
Treatment	NNP	Physical
and	CC	O
an	DT	O
antidepressant	JJ	O
treatment	NN	O
algorithm	NN	O
,	,	O
and	CC	O
research	NN	O
in	IN	O
the	DT	O
UK	NNP	O
has	VBZ	O
also	RB	O
shown	VBN	O
good	JJ	O
results	NNS	O
with	IN	O
Problem	NNP	O
Solving	VBG	O
Treatment	NNP	O
.	.	O

These	DT	O
treatment	NN	O
strategies	NNS	O
may	MD	O
also	RB	O
work	VB	O
very	RB	O
well	RB	O
in	IN	O
the	DT	O
Netherlands	NNP	O
too	RB	O
,	,	O
even	RB	O
though	IN	O
health	NN	O
care	NN	O
systems	NNS	O
differ	VBP	O
between	IN	O
countries	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
two-armed	JJ	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
with	IN	O
randomization	NN	O
on	IN	O
patient-level	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
trial	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
treatment	NN	Mental
of	IN	O
depressive	JJ	O
disorder	NN	O
in	IN	O
primary	JJ	O
care	NN	O
in	IN	O
the	DT	O
Netherlands	NNP	O
by	IN	O
means	NNS	O
of	IN	O
an	DT	O
adapted	JJ	O
collaborative	NN	O
care	NN	O
framework	NN	O
,	,	O
including	VBG	O
contracting	NN	O
and	CC	O
adherence-improving	JJ	O
strategies	NNS	O
,	,	O
combined	VBN	O
with	IN	O
Problem	NNP	O
Solving	NNP	O
Treatment	NNP	O
and	CC	O
antidepressant	JJ	O
medication	NN	O
according	VBG	O
to	TO	O
a	DT	O
treatment	NN	O
algorithm	NN	O
.	.	O

Forty	NNP	O
general	JJ	O
practices	NNS	O
will	MD	O
be	VB	O
randomised	VBN	O
to	TO	O
either	CC	O
the	DT	O
intervention	NN	O
group	NN	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Included	VBN	O
will	MD	O
be	VB	O
patients	NNS	O
who	WP	O
are	VBP	O
diagnosed	VBN	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	JJ	O
depression	NN	O
,	,	O
based	VBN	O
on	IN	O
DSM-IV	NNP	O
criteria	NNS	O
,	,	O
and	CC	O
stratified	VBD	O
according	VBG	O
to	TO	O
comorbid	VB	O
chronic	JJ	O
physical	JJ	O
illness	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
will	MD	O
receive	VB	O
treatment	NN	O
based	VBN	O
on	IN	O
the	DT	O
collaborative	JJ	O
care	NN	O
approach	NN	O
,	,	O
and	CC	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
will	MD	O
receive	VB	O
care	NN	O
as	IN	O
usual	JJ	O
.	.	O

Baseline	NN	O
measurements	NNS	O
and	CC	O
follow	VB	O
up	RP	O
measures	NNS	O
(	(	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
and	CC	O
12	CD	O
months	NNS	O
)	)	O
are	VBP	O
assessed	VBN	O
using	VBG	O
questionnaires	NNS	O
and	CC	O
an	DT	O
interview	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
is	VBZ	O
severity	NN	Mental
of	IN	Mental
depressive	JJ	Mental
symptoms	NNS	Mental
,	,	O
according	VBG	O
to	TO	O
the	DT	O
PHQ9	NNP	Physical
.	.	O

Secondary	NNP	O
outcome	NN	O
measures	NNS	O
are	VBP	O
remission	NN	Physical
as	IN	Physical
measured	VBN	Physical
with	IN	Physical
the	DT	Physical
PHQ9	NNP	Physical
and	CC	Physical
the	DT	Physical
IDS-SR	NNP	Physical
,	,	Physical
and	CC	O
cost-effectiveness	NN	Others
measured	VBN	O
with	IN	O
the	DT	Others
TiC-P	NNP	Others
,	,	O
the	DT	Others
EQ-5D	NNP	Others
and	CC	O
the	DT	Others
SF-36	NNP	Others
.	.	O

DISCUSSION	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
an	DT	O
American	JJ	O
model	NN	O
to	TO	O
enhance	VB	O
care	NN	O
for	IN	O
patients	NNS	O
with	IN	O
a	DT	O
depressive	JJ	O
disorder	NN	O
,	,	O
the	DT	O
collaborative	JJ	O
care	NN	O
model	NN	O
,	,	O
will	MD	O
be	VB	O
evaluated	VBN	O
for	IN	O
effectiveness	NN	O
in	IN	O
the	DT	O
primary	JJ	O
care	NN	O
setting	VBG	O
.	.	O

If	IN	O
effective	JJ	O
across	IN	O
the	DT	O
Atlantic	NNP	O
and	CC	O
across	IN	O
different	JJ	O
health	NN	O
care	NN	O
systems	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
likely	JJ	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
strategy	NN	O
to	TO	O
implement	VB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
in	IN	O
the	DT	O
Netherlands	NNP	O
.	.	O

Early	JJ	O
combination	NN	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drug	NN	O
therapy	NN	O
and	CC	O
tight	JJ	O
disease	NN	O
control	NN	O
improve	VB	O
long-term	JJ	Others
radiologic	JJ	Others
outcome	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
the	DT	O
11-year	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Finnish	NNP	O
Rheumatoid	NNP	O
Arthritis	NNP	O
Combination	NNP	O
Therapy	NNP	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Early	NNP	O
treatment	NN	O
of	IN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
retard	VB	O
the	DT	O
development	NN	Physical
of	IN	Physical
joint	JJ	Physical
damage	NN	Physical
for	IN	O
a	DT	O
period	NN	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	Others
the	DT	Others
radiologic	JJ	Others
progression	NN	Others
beyond	IN	O
that	DT	O
time	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
RA	NNP	O
initially	RB	O
treated	VBD	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
three	CD	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drugs	NNS	O
(	(	O
DMARDs	NNP	O
)	)	O
or	CC	O
a	DT	O
single	JJ	O
DMARD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
199	CD	O
patients	NNS	O
with	IN	O
early	JJ	O
active	JJ	O
RA	NNP	O
were	VBD	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
methotrexate	NN	O
,	,	O
sulfasalazine	NN	O
,	,	O
and	CC	O
hydroxychloroquine	NN	O
with	IN	O
prednisolone	NN	O
(	(	O
FIN-RACo	NNP	O
)	)	O
,	,	O
or	CC	O
treatment	NN	O
with	IN	O
a	DT	O
single	JJ	O
DMARD	NNP	O
(	(	O
initially	RB	O
,	,	O
sulfasalazine	NN	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
prednisolone	NN	O
(	(	O
SINGLE	NNP	O
)	)	O
.	.	O

After	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
drug-treatment	JJ	O
strategy	NN	O
became	VBD	O
unrestricted	JJ	O
,	,	O
but	CC	O
still	RB	O
targeted	VBN	O
remission	NN	O
.	.	O

The	DT	O
radiographs	NN	Others
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
were	VBD	O
analyzed	VBN	Physical
by	IN	Physical
using	VBG	Physical
the	DT	Physical
Larsen	NNP	Physical
score	NN	Physical
at	IN	O
baseline	NN	O
,	,	O
2	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
11	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
radiographs	NN	O
of	IN	O
large	JJ	O
joints	NNS	O
,	,	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Sixty-five	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
65	CD	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
had	VBD	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
available	JJ	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
11	CD	O
years	NNS	O
in	IN	O
Larsen	NNP	Physical
score	NN	Physical
was	VBD	O
17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
to	TO	O
26	CD	O
)	)	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
group	NN	O
and	CC	O
27	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
22	CD	O
to	TO	O
33	CD	O
)	)	O
in	IN	O
the	DT	O
SINGLE	NNP	O
group	NN	O
(	(	O
P=0.037	NNP	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
87	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
74	CD	O
to	TO	O
94	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
58	CD	O
to	TO	O
84	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
the	DT	O
SINGLE	NNP	O
treatment	NN	O
arms	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
no	DT	O
erosive	JJ	Physical
changes	NNS	Physical
in	IN	O
large	JJ	O
joints	NNS	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Targeting	VBG	O
to	TO	O
remission	NN	O
with	IN	O
tight	JJ	O
clinical	JJ	O
controls	NNS	O
results	NNS	O
in	IN	O
low	JJ	O
radiologic	JJ	Others
progression	NN	Others
in	IN	O
most	JJS	O
RA	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
DMARDs	NNP	O
have	VBP	O
less	RBR	O
long-term	JJ	Others
radiologic	NN	Others
damage	NN	Others
than	IN	O
do	VBP	O
those	DT	O
treated	VBN	O
initially	RB	O
with	IN	O
DMARD	NNP	O
monotherapy	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN18445519	NNP	O
.	.	O

Adenosinergic	NNP	O
mechanisms	NNS	O
contribute	VBP	O
to	TO	O
individual	JJ	O
differences	NNS	O
in	IN	O
sleep	JJ	O
deprivation-induced	JJ	O
changes	NNS	O
in	IN	O
neurobehavioral	JJ	O
function	NN	O
and	CC	O
brain	NN	O
rhythmic	JJ	O
activity	NN	O
.	.	O

Large	JJ	O
individual	JJ	O
differences	NNS	O
characterize	VBP	O
the	DT	O
changes	NNS	O
induced	VBN	O
by	IN	O
sleep	JJ	O
deprivation	NN	O
on	IN	O
neurobehavioral	JJ	O
functions	NNS	O
and	CC	O
rhythmic	JJ	O
brain	NN	O
activity	NN	O
.	.	O

To	TO	O
investigate	VB	O
adenosinergic	JJ	O
mechanisms	NNS	O
in	IN	O
these	DT	O
differences	NNS	O
,	,	O
we	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
prolonged	JJ	O
waking	NN	O
and	CC	O
the	DT	O
adenosine	NN	O
receptor	NN	O
antagonist	JJ	O
caffeine	NN	O
on	IN	O
sustained	VBN	O
vigilant	JJ	O
attention	NN	O
and	CC	O
regional	JJ	O
electroencephalogram	NN	O
(	(	O
EEG	NNP	O
)	)	O
power	NN	O
in	IN	O
the	DT	O
ranges	NNS	O
of	IN	O
theta	NN	O
activity	NN	O
(	(	O
6.25-8.25	JJ	O
Hz	NNP	O
)	)	O
in	IN	O
waking	VBG	O
and	CC	O
the	DT	O
slow	JJ	O
oscillation	NN	O
(	(	O
<	JJ	O
1	CD	O
Hz	NNP	O
)	)	O
in	IN	O
sleep	NN	O
.	.	O

Activity	NN	O
in	IN	O
these	DT	O
frequencies	NNS	O
is	VBZ	O
functionally	RB	O
related	VBN	O
to	TO	O
sleep	VB	O
deprivation	NN	O
.	.	O

In	IN	O
12	CD	O
subjectively	RB	O
caffeine-sensitive	JJ	O
and	CC	O
10	CD	O
-insensitive	JJ	O
young	JJ	O
men	NNS	O
,	,	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
(	(	O
PVT	NNP	O
)	)	O
performance	NN	O
and	CC	O
EEG	NNP	O
were	VBD	O
assessed	VBN	O
at	IN	O
3	CD	O
h	NN	O
intervals	NNS	O
before	IN	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
one	CD	O
night	NN	O
without	IN	O
sleep	NN	O
.	.	O

After	IN	O
11	CD	O
and	CC	O
23	CD	O
h	NN	O
waking	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
200	CD	O
mg	JJ	O
caffeine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
manner	NN	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
condition	NN	O
,	,	O
sleep	JJ	O
deprivation	NN	O
impaired	VBD	O
PVT	NNP	O
speed	VBD	O
more	RBR	O
in	IN	O
caffeine-sensitive	JJ	O
than	IN	O
in	IN	O
caffeine-insensitive	JJ	O
men	NNS	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
counteracted	VBN	O
by	IN	O
caffeine	NN	O
.	.	O

Theta	NNP	Physical
power	NN	Physical
in	IN	Physical
waking	VBG	Physical
increased	VBD	O
more	RBR	O
in	IN	O
a	DT	O
frontal	JJ	O
EEG	NNP	O
derivation	NN	O
than	IN	O
in	IN	O
a	DT	O
posterior	JJ	O
derivation	NN	O
.	.	O

Caffeine	NNP	O
attenuated	VBD	O
this	DT	O
power	NN	O
gradient	NN	O
in	IN	O
caffeine	JJ	O
sensitive	JJ	O
subjects	NNS	O
.	.	O

Sleep	NNP	Physical
loss	NN	Physical
also	RB	O
differently	RB	O
affected	VBD	O
the	DT	O
power	NN	O
distribution	NN	O
<	VBD	O
1	CD	O
Hz	NNP	O
in	IN	O
non-rapid	JJ	Physical
eye	NN	Physical
movement	NN	Physical
sleep	NN	Physical
between	IN	O
caffeine	NN	O
sensitive	JJ	O
and	CC	O
insensitive	JJ	O
subjects	NNS	O
.	.	O

Also	RB	O
,	,	O
this	DT	O
difference	NN	O
was	VBD	O
mirrored	VBN	O
by	IN	O
the	DT	O
action	NN	O
of	IN	O
caffeine	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
sleep	JJ	Physical
deprivation	NN	Physical
and	CC	O
caffeine	NN	O
on	IN	O
sustained	JJ	O
attention	NN	O
and	CC	O
regional	JJ	O
EEG	NNP	O
power	NN	O
in	IN	O
waking	NN	Physical
and	CC	Physical
sleep	NN	Physical
were	VBD	O
inversely	RB	O
related	VBN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
adenosinergic	JJ	O
mechanisms	NNS	O
contribute	VBP	O
to	TO	O
individual	JJ	O
differences	NNS	O
in	IN	O
waking-induced	JJ	Physical
impairment	NN	Physical
of	IN	Physical
neurobehavioral	JJ	Physical
performance	NN	Physical
and	CC	O
functional	JJ	O
aspects	NNS	O
of	IN	O
EEG	NNP	O
topography	NN	O
associated	VBN	O
with	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
acellular	JJ	O
diphtheria	NN	O
,	,	O
pertussis	NN	O
and	CC	O
tetanus	NN	O
vaccines	NNS	Others
in	IN	O
southern	JJ	O
Ghana	NNP	O
.	.	O

A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
acellular	JJ	O
diphtheria/pertussis/tetanus	NN	O
(	(	O
ADPT	NNP	O
)	)	O
freeze-dried	JJ	O
and	CC	O
liquid	JJ	O
vaccines	NNS	O
in	IN	O
infants	NNS	O
was	VBD	O
conducted	VBN	O
in	IN	O
a	DT	O
peri-urban	JJ	O
community	NN	O
(	(	O
Ashaiman	NNP	O
)	)	O
in	IN	O
southern	JJ	O
Ghana	NNP	O
.	.	O

Immunogenicity	NNP	Physical
of	IN	O
the	DT	O
acellular	JJ	O
vaccines	NNS	O
,	,	O
persistence	NN	O
of	IN	O
antibodies	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
achieved	VBN	O
with	IN	O
a	DT	O
whole-cell	JJ	O
diphtheria-pertussis-tetanus	NN	O
(	(	O
DPT	NNP	O
)	)	O
vaccine	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
pertussis	NN	O
in	IN	O
the	DT	O
vaccine	NN	O
groups	NNS	O
and	CC	O
prevalence	NN	O
of	IN	O
pertussis	NN	O
in	IN	O
children	NNS	O
under	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
in	IN	O
the	DT	O
study	NN	O
area	NN	O
were	VBD	O
also	RB	O
determined	VBN	O
.	.	O

The	DT	O
acellular	JJ	O
vaccines	NNS	O
produced	VBN	O
significantly	RB	O
fewer	JJR	O
local	JJ	Adverseeffect
and	CC	Adverseeffect
systemic	JJ	Adverseeffect
reactions	NNS	Adverseeffect
.	.	Adverseeffect

Local	JJ	Physical
reactions	NNS	Physical
such	JJ	O
as	IN	O
swelling	VBG	Adverseeffect
and	CC	Adverseeffect
redness	NN	Adverseeffect
were	VBD	O
observed	VBN	O
in	IN	O
2	CD	O
%	NN	O
(	(	O
8/399	CD	O
)	)	O
to	TO	O
2.3	CD	O
%	NN	O
(	(	O
9/385	CD	O
)	)	O
of	IN	O
the	DT	O
acellular	JJ	O
vaccine	NN	O
recipients	NNS	O
as	IN	O
against	IN	O
31	CD	O
%	NN	O
(	(	O
122/394	CD	O
)	)	O
in	IN	O
the	DT	O
whole-cell	JJ	O
vaccine	NN	O
group	NN	O
.	.	O

Fever	NNP	Adverseeffect
(	(	O
>	CD	O
or	CC	O
=	VB	O
37.5	CD	O
degrees	NNS	O
C	NNP	O
)	)	O
occurred	VBD	O
in	IN	O
7.27	CD	O
%	NN	O
(	(	O
29/399	CD	O
)	)	O
to	TO	O
9.8	CD	O
%	NN	O
(	(	O
38/385	CD	O
)	)	O
in	IN	O
the	DT	O
acellular	JJ	O
vaccine	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
36.6	CD	O
%	NN	O
(	(	O
145/394	CD	O
)	)	O
in	IN	O
the	DT	O
whole-cell	JJ	O
vaccine	NN	O
group	NN	O
.	.	O

Geometric	NNP	Physical
mean	JJ	Physical
titres	NNS	Physical
(	(	Physical
GMTs	NNP	Physical
)	)	Physical
,	,	O
measured	VBN	O
by	IN	O
ELISA	NNP	Others
,	,	O
to	TO	O
pertussis	VB	Physical
toxin	NN	Physical
(	(	Physical
PT	NNP	Physical
)	)	Physical
and	CC	Physical
filamentous	JJ	Physical
haemagglutinin	NN	Physical
(	(	Physical
FHA	NNP	Physical
)	)	Physical
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
acellular	JJ	O
vaccine	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
whole-cell	JJ	O
DPT	NNP	O
(	(	O
WCDPT	NNP	O
)	)	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
GMTs	NNP	Physical
of	IN	Physical
tetanus	NN	Physical
and	CC	Physical
diphtheria	NN	Physical
antitoxins	NNS	Physical
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
after	IN	O
each	DT	O
vaccination	NN	O
.	.	O

Twelve	NNP	O
months	NNS	O
after	IN	O
primary	JJ	O
vaccination	NN	O
,	,	O
GMTs	NNP	Physical
to	TO	Physical
PT	NNP	Physical
in	IN	O
the	DT	O
freeze-dried	JJ	O
,	,	O
liquid	JJ	O
ADPT	NNP	O
groups	NNS	O
and	CC	O
the	DT	O
WCDPT	NNP	O
group	NN	O
have	VBP	O
fallen	VBN	O
from	IN	O
56.23	CD	O
,	,	O
62.63	CD	O
and	CC	O
44.97	CD	O
ELISA	NNP	O
U/ml	NNP	O
to	TO	O
6.08	CD	O
,	,	O
6.18	CD	O
and	CC	O
11.30	CD	O
ELISA	NNP	O
U/ml	NNP	O
,	,	O
respectively	RB	O
.	.	O

GMTs	NNP	Physical
to	TO	Physical
FHA	NNP	Physical
in	IN	O
all	PDT	O
the	DT	O
vaccine	NN	O
groups	NNS	O
also	RB	O
dropped	VBD	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
from	IN	O
49.94	CD	O
,	,	O
41.73	CD	O
and	CC	O
20.74	CD	O
ELISA	NNP	O
U/ml	NNP	O
to	TO	O
7.26	CD	O
,	,	O
7.72	CD	O
and	CC	O
5.91	CD	O
ELISA	NNP	O
U/ml	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
this	DT	O
comparative	NN	O
controlled	VBD	O
trial	NN	O
,	,	O
the	DT	O
ADPT	NNP	O
vaccines	NNS	O
were	VBD	O
more	JJR	O
immunogenic	JJ	Physical
,	,	O
with	IN	O
less	JJR	Physical
local	JJ	Physical
and	CC	Physical
systemic	JJ	Physical
reactions	NNS	Physical
,	,	O
than	IN	O
the	DT	O
WCDPT	NNP	O
vaccine	NN	O
but	CC	O
there	EX	O
was	VBD	O
a	DT	O
considerable	JJ	O
drop	NN	O
in	IN	O
antibody	NN	Physical
titres	NNS	Physical
in	IN	O
all	PDT	O
the	DT	O
vaccine	NN	O
groups	NNS	O
12	CD	O
months	NNS	O
after	IN	O
primary	JJ	O
vaccination	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
titres	NNS	O
of	IN	O
anti-PT	JJ	Physical
and	CC	Physical
anti-FHA	JJ	Physical
antibodies	NNS	Physical
in	IN	O
all	PDT	O
the	DT	O
three	CD	O
vaccines	NNS	O
that	WDT	O
confer	VBP	O
protection	NN	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
provide	VB	O
this	DT	O
information	NN	O
in	IN	O
order	NN	O
to	TO	O
assess	VB	O
the	DT	O
need	NN	O
for	IN	O
subsequent	JJ	O
booster	NN	O
doses	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
with	IN	O
both	DT	O
ADPT	NNP	O
and	CC	O
WCDPT	NNP	O
vaccines	NNS	O
.	.	O

Teaching	VBG	O
young	JJ	O
nonverbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
useful	JJ	O
speech	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
Denver	NNP	O
Model	NNP	O
and	CC	O
PROMPT	NNP	O
interventions	NNS	O
.	.	O

This	DT	O
single	JJ	O
subject	NN	O
design	NN	O
study	NN	O
examined	VBD	O
two	CD	O
models	NNS	O
of	IN	O
intervention	NN	O
:	:	O
Denver	NNP	O
Model	NNP	O
(	(	O
which	WDT	O
merges	VBZ	O
behavioral	JJ	O
,	,	O
developmental	JJ	O
,	,	O
and	CC	O
relationship-oriented	JJ	O
intervention	NN	O
)	)	O
,	,	O
and	CC	O
PROMPT	NNP	O
(	(	O
a	DT	O
neuro-developmental	JJ	O
approach	NN	O
for	IN	O
speech	JJ	O
production	NN	O
disorders	NNS	O
)	)	O
.	.	O

Ten	CD	O
young	JJ	O
,	,	O
nonverbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
matched	VBN	O
in	IN	O
pairs	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
treatment	NN	O
.	.	O

They	PRP	O
received	VBD	O
12	CD	O
1-h	JJ	O
weekly	JJ	O
sessions	NNS	O
of	IN	O
therapy	NN	O
and	CC	O
daily	JJ	O
1-h	JJ	O
home	NN	O
intervention	NN	O
delivered	VBN	O
by	IN	O
parents	NNS	O
.	.	O

Fidelity	NNP	O
criteria	NNS	O
were	VBD	O
maintained	VBN	O
throughout	IN	O
.	.	O

Eight	NNP	O
of	IN	O
the	DT	O
ten	JJ	O
children	NNS	O
used	VBN	O
five	CD	O
or	CC	O
more	JJR	O
novel	JJ	O
,	,	O
functional	JJ	Mental
words	NNS	O
spontaneously	RB	O
and	CC	O
spoke	VBD	O
multiple	JJ	Mental
times	NNS	Mental
per	IN	Mental
hour	NN	Mental
by	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
acquired	VBN	Mental
language	NN	Mental
skills	NNS	Mental
by	IN	O
intervention	NN	O
group	NN	O
.	.	O

Initial	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
best	JJS	O
responders	NNS	O
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
of	IN	O
autism	NN	O
,	,	O
better	JJR	O
motor	NN	Mental
imitation	NN	Mental
skills	NNS	Mental
,	,	Mental
and	CC	Mental
emerging	VBG	Mental
joint	JJ	Mental
attention	NN	Mental
skills	NNS	Mental
.	.	O

[	IN	O
The	DT	O
effects	NNS	O
of	IN	O
early	JJ	O
enteral	JJ	O
nutrition	NN	O
with	IN	O
addition	NN	O
of	IN	O
probiotics	NNS	O
on	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
acute	NN	O
pancreatitis	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
curative	JJ	O
effect	NN	O
of	IN	O
early	JJ	O
enteral	JJ	O
nutrition	NN	O
(	(	O
EN	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
probiotics	NNS	O
(	(	O
bifidobacterium	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
acute	NN	O
pancreatitis	NN	O
(	(	O
ASP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Seventy	NNP	O
SAP	NNP	O
cases	NNS	O
admitted	VBD	O
from	IN	O
January	NNP	O
2005	CD	O
to	TO	O
October	NNP	O
2012	CD	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
PN	NNP	O
)	)	O
group	NN	O
(	(	O
n=22	NN	O
)	)	O
,	,	O
EN	NNP	O
group	NN	O
(	(	O
n=25	CC	O
)	)	O
and	CC	O
bifidobacterium	NN	O
added	VBD	O
EN	NNP	O
(	(	O
P+EN	NNP	O
)	)	O
group	NN	O
(	(	O
n=23	RB	O
)	)	O
.	.	O

In	IN	O
P+EN	NNP	O
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
given	VBN	O
their	PRP$	O
nutrition	NN	O
the	DT	O
same	JJ	O
as	IN	O
that	DT	O
of	IN	O
EN	NNP	O
,	,	O
and	CC	O
also	RB	O
probiotics	NNS	O
(	(	O
bifidobacterium	NN	O
,	,	O
4	CD	O
capsules	NNS	O
every	DT	O
12	CD	O
hours	NNS	O
,	,	O
given	VBN	O
through	IN	O
nasal	JJ	O
gastric	JJ	O
tube	NN	O
,	,	O
each	DT	O
capsule	NN	O
weighing	VBG	O
210	CD	O
mg	NN	O
)	)	O
.	.	O

The	DT	O
routine	JJ	O
treatment	NN	O
including	VBG	O
anti-infection	NN	O
and	CC	O
anti-acid	JJ	O
agents	NNS	O
,	,	O
and	CC	O
that	IN	O
of	IN	O
inhibition	NN	O
of	IN	O
pancreatic	JJ	O
secretion	NN	O
were	VBD	O
given	VBN	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
different	JJ	O
nutritional	JJ	O
interventions	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

The	DT	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
for	IN	O
e	NN	O
same	JJ	O
measurements	NNS	O
of	IN	O
interleukin-8	JJ	O
(	(	O
IL-8	NNP	O
)	)	O
and	CC	O
tumor	JJ	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF-?	NNP	O
)	)	O
by	IN	O
enzyme	NN	O
linked	VBN	O
immunosorbent	JJ	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
,	,	O
and	CC	O
for	IN	O
the	DT	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
lactic	JJ	O
acid	NN	O
dehydrogenase	NN	O
(	(	O
LDH	NNP	O
)	)	O
,	,	O
white	JJ	O
blood	NN	O
cell	NN	O
(	(	O
WBC	NNP	O
)	)	O
count	NN	O
,	,	O
amylase	NN	O
and	CC	O
lipase	NN	O
by	IN	O
biochemistry	NN	O
assay	VBP	O
1	CD	O
day	NN	O
before	IN	O
intervention	NN	O
of	IN	O
nutrition	NN	O
,	,	O
and	CC	O
7	CD	O
days	NNS	O
and	CC	O
14	CD	O
days	NNS	O
after	IN	O
intervention	NN	O
.	.	O

Changes	NNS	O
in	IN	O
organ	JJ	O
function	NN	O
and	CC	O
outcome	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
points	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
plasma	JJ	Physical
levels	NNS	Physical
of	IN	O
IL-8	NNP	O
,	,	O
TNF-?	NNP	O
,	,	O
CRP	NNP	O
,	,	O
LDH	NNP	O
,	,	O
WBC	NNP	O
count	NN	O
,	,	O
amylase	NN	O
and	CC	O
lipase	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
nutritional	JJ	O
intervention	NN	O
compared	VBN	O
with	IN	O
their	PRP$	O
levels	NNS	O
on	IN	O
day	NN	O
1	CD	O
before	IN	O
intervention	NN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
.	.	O

The	DT	O
plasma	JJ	O
IL-8	NNP	O
,	,	O
TNF-?	NNP	O
,	,	O
CRP	NNP	O
,	,	O
lipase	NN	O
,	,	O
LDH	NNP	O
at	IN	O
14	CD	O
days	NNS	O
after	IN	O
intervention	NN	O
of	IN	O
nutrition	NN	O
in	IN	O
P+EN	NNP	O
group	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
PN	NNP	O
group	NN	O
and	CC	O
EN	NNP	O
group	NN	O
(	(	O
IL-8	NNP	O
:	:	O
21.00	CD	O
?	.	O
7.07	CD	O
?g/L	NN	O
vs.	FW	O
48.00	CD	O
?	.	O
10.32	CD	O
?g/L	NN	O
,	,	O
32.00	CD	O
?	.	O
9.30	CD	O
?g/L	NN	O
;	:	O
TNF-?	JJ	O
:	:	O
44.3	CD	O
?	.	O
10.9	CD	O
ng/L	JJ	O
vs.	FW	O
132.1	CD	O
?	.	O
34.1	CD	O
ng/L	NN	O
,	,	O
67.8	CD	O
?	.	O
22.3	CD	O
ng/L	NN	O
;	:	O
CRP	NNP	O
:	:	O
35.0	CD	O
?	.	O
12.4	CD	O
mg/L	NN	O
vs.	FW	O
103.2	CD	O
?	.	O
49.2	CD	O
mg/L	NN	O
,	,	O
63.0	CD	O
?	.	O
29.2	CD	O
mg/L	NN	O
;	:	O
lipase	NN	O
:	:	O
269	CD	O
?	.	O
79	CD	O
U/L	NNP	O
vs.	FW	O
670	CD	O
?	.	O
145	CD	O
U/L	NNP	O
,	,	O
310	CD	O
?	.	O
78	CD	O
U/L	NNP	O
;	:	O
LDH	NNP	O
:	:	O
21.8	CD	O
?	.	O
10.3	CD	O
U/L	NNP	O
vs.	FW	O
78.1	CD	O
?	.	O
37.4	CD	O
U/L	NNP	O
,	,	O
37.9	CD	O
?	.	O
25.1	CD	O
U/L	NNP	O
,	,	O
P	NNP	O
<	VBZ	O
0.05	CD	O
or	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
WBC	NNP	O
count	NN	O
in	IN	O
P+EN	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
PN	NNP	O
group	NN	O
(	(	O
5.9	CD	O
?	.	O
3.0	CD	O
?	.	O
10?/L	CD	O
,	,	O
6.3	CD	O
?	.	O
3.2	CD	O
?	.	O
10?/L	CD	O
vs.	IN	O
9.6	CD	O
?	.	O
3.0	CD	O
?10?/L	NN	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
amylase	NN	O
between	IN	O
P+EN	NNP	O
group	NN	O
and	CC	O
PN	NNP	O
group	NN	O
(	(	O
211	CD	O
?	.	O
49	CD	O
U/L	NNP	O
,	,	O
236	CD	O
?	.	O
52	CD	O
U/L	NNP	O
vs.	FW	O
298	CD	O
?	.	O
71	CD	O
U/L	NNP	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
gastrointestinal	JJ	O
dysfunction	NN	O
score	NN	O
in	IN	O
P+EN	NNP	O
,	,	O
EN	NNP	O
,	,	O
PN	NNP	O
groups	NNS	O
14	CD	O
days	NNS	O
after	IN	O
nutritional	JJ	O
intervention	NN	O
was	VBD	O
0.28	CD	O
?	.	O
0.05	CD	O
,	,	O
0.43	CD	O
?	.	O
0.09	CD	O
,	,	O
0.71	CD	O
?	.	O
0.11	CD	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
PN	NNP	O
and	CC	O
EN	NNP	O
groups	NNS	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
upper	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
(	(	O
1	CD	O
vs.	FW	O
9	CD	O
,	,	O
2	CD	O
)	)	O
,	,	O
infection	NN	O
and	CC	O
abscess	NN	O
(	(	O
2	CD	O
vs.	FW	O
12	CD	O
,	,	O
5	CD	O
)	)	O
was	VBD	O
lower	JJR	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
hospital	JJ	O
day	NN	O
was	VBD	O
significantly	RB	O
shortened	VBN	O
in	IN	O
P+EN	NNP	O
group	NN	O
(	(	O
10.4	CD	O
?	.	O
3.9	CD	O
days	NNS	O
vs.	FW	O
25.8	CD	O
?	.	O
6.4	CD	O
days	NNS	O
,	,	O
13.4	CD	O
?	.	O
5.2	CD	O
days	NNS	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
in	IN	O
mortality	NN	O
rate	NN	O
among	IN	O
three	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
early	JJ	O
EN	NNP	O
with	IN	O
addition	NN	O
of	IN	O
probiotics	NNS	O
(	(	O
bifidobacterium	NN	O
)	)	O
resulted	VBD	O
in	IN	O
significant	JJ	O
lowering	NN	O
of	IN	O
the	DT	O
level	NN	O
of	IN	O
pro-inflammatory	JJ	O
cytokines	NNS	O
,	,	O
earlier	JJR	O
restoration	NN	O
of	IN	O
gastrointestinal	JJ	O
function	NN	O
,	,	O
decrease	NN	O
of	IN	O
complications	NNS	O
such	JJ	O
as	IN	O
infection	NN	O
,	,	O
and	CC	O
shortening	NN	O
of	IN	O
hospital	JJ	O
day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SAP	NNP	O
.	.	O

Effect	NN	O
of	IN	O
fats	NNS	O
high	JJ	O
in	IN	O
individual	JJ	O
saturated	VBD	O
fatty	JJ	O
acids	NNS	O
on	IN	O
plasma	NN	Physical
lipoprotein	NN	Physical
[	VBZ	Physical
a	DT	Physical
]	NN	Physical
levels	NNS	Physical
in	IN	O
young	JJ	O
healthy	JJ	O
men	NNS	O
.	.	O

Plasma	NNP	Physical
lipoprotein	VBZ	Physical
[	VBZ	Physical
a	DT	Physical
]	NN	Physical
(	(	Physical
Lp	NNP	Physical
[	VBZ	Physical
a	DT	Physical
]	NN	Physical
)	)	Physical
is	VBZ	O
associated	VBN	O
with	IN	O
atherogenesis	NN	O
and	CC	O
thrombogenesis	NN	O
.	.	O

We	PRP	O
examined	VBD	O
how	WRB	O
plasma	JJ	O
Lp	NNP	O
[	VBZ	O
a	DT	O
]	NN	O
in	IN	O
healthy	JJ	O
young	JJ	O
men	NNS	O
was	VBD	O
affected	VBN	O
by	IN	O
fats	NNS	O
high	JJ	O
in	IN	O
stearic	JJ	O
(	(	O
C18	NNP	O
)	)	O
,	,	O
palmitic	JJ	O
(	(	O
C16	NNP	O
)	)	O
,	,	O
and	CC	O
lauric+myristic	JJ	O
(	(	O
C12+	NNP	O
C14	NNP	O
)	)	O
acid	NN	O
(	(	O
experiment	JJ	O
I	PRP	O
,	,	O
15	CD	O
subjects	NNS	O
)	)	O
,	,	O
and	CC	O
by	IN	O
fats	NNS	O
high	JJ	O
in	IN	O
myristic	JJ	O
(	(	O
C14	NNP	O
)	)	O
and	CC	O
palmitic	JJ	O
(	(	O
C16	NNP	O
)	)	O
acid	NN	O
(	(	O
experiment	JJ	O
II	NNP	O
,	,	O
12	CD	O
subjects	NNS	O
)	)	O
.	.	O

Strictly	RB	O
controlled	VBN	O
isocaloric	JJ	O
diets	NNS	O
with	IN	O
36	CD	O
%	NN	O
of	IN	O
energy	NN	O
from	IN	O
test	NN	O
fats	NNS	O
were	VBD	O
served	VBN	O
in	IN	O
random	JJ	O
order	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
separated	VBN	O
by	IN	O
wash-out	JJ	O
period	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O

Diets	NNS	O
high	JJ	O
in	IN	O
C18	NNP	O
gave	VBD	O
significantly	RB	O
higher	JJR	O
levels	NNS	Physical
of	IN	Physical
Lp	NNP	Physical
[	NNP	Physical
a	DT	Physical
]	NNP	Physical
(	(	O
51	CD	O
(	(	O
12-560	JJ	O
)	)	O
mg/L	NN	O
)	)	O
than	IN	O
diets	NNS	O
high	JJ	O
in	IN	O
C16	NNP	O
(	(	O
38	CD	O
(	(	O
12-533	JJ	O
mg/L	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.020	CD	O
)	)	O
and	CC	O
C12	NNP	O
+	NNP	O
C14	NNP	O
(	(	O
34	CD	O
(	(	O
12-534	JJ	O
)	)	O
mg/L	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

These	DT	O
differences	NNS	Physical
were	VBD	O
observed	VBN	O
in	IN	O
several	JJ	O
of	IN	O
the	DT	O
subjects	NNS	O
in	IN	O
experiment	NN	O
I	PRP	O
.	.	O

In	IN	O
experiment	JJ	O
II	NNP	O
we	PRP	O
saw	VBD	O
no	DT	O
difference	NN	O
in	IN	O
plasma	NN	Physical
Lp	NNP	Physical
[	VBZ	Physical
a	DT	Physical
]	NN	Physical
after	IN	O
diets	NNS	O
high	JJ	O
in	IN	O
C16	NNP	O
and	CC	O
C14	NNP	O
.	.	O

Our	PRP$	O
observations	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
fat	JJ	O
high	NN	O
in	IN	O
stearic	JJ	O
acid	NN	O
might	MD	O
affect	VB	O
Lp	NNP	Physical
[	VB	Physical
a	DT	Physical
]	NN	Physical
in	IN	O
a	DT	O
different	JJ	O
way	NN	O
than	IN	O
fats	NNS	O
high	JJ	O
in	IN	O
palmitic	JJ	O
and	CC	O
myristic+lauric	JJ	O
acid	NN	O
.	.	O

Lp	NNP	Physical
[	VBD	Physical
a	DT	Physical
]	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
not	RB	O
associate	JJ	O
with	IN	O
changes	NNS	O
in	IN	O
tissue-plasminogen	NN	Physical
activator	NN	Physical
(	(	Physical
t-PA	JJ	Physical
)	)	Physical
activity	NN	Physical
,	,	O
factor	NN	Physical
VII	NNP	Physical
coagualant	NN	Physical
activity	NN	Physical
,	,	O
or	CC	O
plasma	NN	Physical
LDL	NNP	Physical
cholesterol	NN	Physical
.	.	O

Acupuncture	NNP	O
versus	NN	O
venlafaxine	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
vasomotor	NN	Physical
symptoms	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
hormone	JJ	O
receptor-positive	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Vasomotor	NNP	Physical
symptoms	NNS	Physical
are	VBP	O
common	JJ	O
adverse	JJ	O
effects	NNS	O
of	IN	O
antiestrogen	NN	O
hormone	NN	O
treatment	NN	O
in	IN	O
conventional	JJ	O
breast	NN	O
cancer	NN	O
care	NN	O
.	.	O

Hormone	CD	O
replacement	NN	O
therapy	NN	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
.	.	O

Venlafaxine	NNP	O
(	(	O
Effexor	NNP	O
)	)	O
,	,	O
the	DT	O
therapy	NN	O
of	IN	O
choice	NN	O
for	IN	O
these	DT	O
symptoms	NNS	O
,	,	O
has	VBZ	O
numerous	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
acupuncture	NN	O
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
vasomotor	NN	Physical
symptoms	NNS	Physical
in	IN	O
menopausal	JJ	O
women	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
tested	VBD	O
whether	IN	O
acupuncture	NN	O
reduces	NNS	O
vasomotor	NN	Physical
symptoms	NNS	Physical
and	CC	O
produces	VBZ	O
fewer	JJR	O
adverse	JJ	O
effects	NNS	O
than	IN	O
venlafaxine	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Fifty	NNP	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
12	CD	O
weeks	NNS	O
of	IN	O
acupuncture	NN	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
or	CC	O
venlafaxine	NN	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
treatment	NN	O
.	.	O

Health	NNP	Physical
outcomes	NNS	Physical
were	VBD	O
measured	VBN	O
for	IN	O
up	RB	O
to	TO	O
1	CD	O
year	NN	O
post-treatment	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
exhibited	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
hot	JJ	Physical
flashes	NNS	Physical
,	,	Physical
depressive	NN	Physical
symptoms	NNS	Physical
,	,	Physical
and	CC	Physical
other	JJ	Physical
quality-of-life	NN	Physical
symptoms	NNS	Physical
,	,	O
including	VBG	O
significant	JJ	O
improvements	NNS	O
in	IN	O
mental	JJ	Mental
health	NN	Mental
from	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
.	.	O

These	DT	O
changes	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
acupuncture	NN	O
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
venlafaxine	NN	O
.	.	O

By	IN	O
2	CD	O
weeks	NNS	O
post-treatment	JJ	O
,	,	O
the	DT	O
venlafaxine	NN	O
group	NN	O
experienced	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
hot	JJ	Physical
flashes	NNS	Physical
,	,	O
whereas	NNS	O
hot	JJ	O
flashes	NNS	O
in	IN	O
the	DT	O
acupuncture	NN	O
group	NN	O
remained	VBD	O
at	IN	O
low	JJ	O
levels	NNS	O
.	.	O

The	DT	O
venlafaxine	NN	O
group	NN	O
experienced	VBD	O
18	CD	O
incidences	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
(	(	O
eg	NN	O
,	,	O
nausea	NN	Physical
,	,	Physical
dry	JJ	Physical
mouth	NN	Physical
,	,	Physical
dizziness	NN	Physical
,	,	Physical
anxiety	NN	Physical
)	)	O
,	,	O
whereas	IN	O
the	DT	O
acupuncture	NN	O
group	NN	O
experienced	VBD	O
no	DT	O
negative	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

Acupuncture	NN	O
had	VBD	O
the	DT	O
additional	JJ	O
benefit	NN	O
of	IN	O
increased	JJ	O
sex	NN	Physical
drive	NN	Physical
in	IN	O
some	DT	O
women	NNS	O
,	,	O
and	CC	O
most	JJS	O
reported	VBD	O
an	DT	O
improvement	NN	O
in	IN	O
their	PRP$	O
energy	NN	Mental
,	,	Mental
clarity	NN	Mental
of	IN	Mental
thought	NN	Mental
,	,	Mental
and	CC	Mental
sense	NN	Mental
of	IN	Mental
well-being	NN	Mental
.	.	O

CONCLUSION	NNP	O
Acupuncture	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
equivalent	JJ	O
to	TO	O
drug	NN	O
therapy	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
a	DT	O
safe	JJ	O
,	,	O
effective	JJ	O
and	CC	O
durable	JJ	O
treatment	NN	O
for	IN	O
vasomotor	NN	O
symptoms	NNS	O
secondary	JJ	O
to	TO	O
long-term	JJ	O
antiestrogen	NN	O
hormone	NN	O
use	NN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
.	.	O

Using	VBG	O
the	DT	O
demand-control	JJ	O
model	NN	O
of	IN	O
job	NN	O
strain	NN	O
to	TO	O
predict	VB	O
caregiver	NN	Others
burden	NN	Others
and	CC	O
caregiver	JJ	Others
satisfaction	NN	Others
in	IN	O
the	DT	O
informal	JJ	O
caregivers	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
demand-control	NN	O
(	(	O
D-C	NNP	O
)	)	O
model	NN	O
of	IN	O
job	NN	O
strain	NN	O
has	VBZ	O
generated	VBN	O
a	DT	O
considerable	JJ	O
body	NN	O
of	IN	O
empirical	JJ	O
support	NN	O
in	IN	O
predicting	VBG	O
psychological	JJ	O
health	NN	O
outcomes	NNS	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
work	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
extend	VB	O
previous	JJ	O
work	NN	O
using	VBG	O
the	DT	O
D-C	NNP	O
model	NN	O
of	IN	O
job	NN	O
strain	NN	O
to	TO	O
predict	VB	O
caregiver	NN	O
burden	NN	O
and	CC	O
satisfaction	NN	O
in	IN	O
the	DT	O
informal	JJ	O
caregivers	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Data	NNP	O
were	VBD	O
gathered	VBN	O
from	IN	O
60	CD	O
caregiver/patient	NN	O
dyads	NNS	O
in	IN	O
a	DT	O
cross-sectional	JJ	O
design	NN	O
.	.	O

Patients	NNS	O
with	IN	O
chronic	JJ	O
stable	JJ	O
heart	NN	O
failure	NN	O
were	VBD	O
recruited	VBN	O
from	IN	O
out-patient	JJ	O
clinics	NNS	O
.	.	O

The	DT	O
dependent	JJ	O
variables	NNS	O
were	VBD	O
caregiver	JJ	Others
burden	NN	Others
and	CC	O
satisfaction	NN	Others
.	.	O

Demand	NNP	Others
and	CC	Others
control	VB	Others
were	VBD	O
measured	VBN	O
using	VBG	O
both	DT	O
patient-	JJ	Others
and	CC	Others
caregiver-derived	JJ	Others
measures	NNS	Others
.	.	Others

RESULTS	VB	O
The	DT	O
D-C	NNP	O
model	NN	O
accounted	VBD	O
for	IN	O
15	CD	O
and	CC	O
19	CD	O
%	NN	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
caregiver	NN	Others
burden	NN	Others
,	,	O
after	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
and	CC	O
relationship	NN	O
to	TO	O
the	DT	O
patient	NN	O
.	.	O

Lower	JJR	O
control	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
burden	NN	O
.	.	O

The	DT	O
D-C	JJ	O
model	NN	O
did	VBD	O
not	RB	O
predict	VB	O
caregiver	NN	Others
satisfaction	NN	Others
.	.	O

CONCLUSION	VB	O
The	DT	O
D-C	NNP	O
model	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
caregiver	NN	O
burden	NN	O
,	,	O
but	CC	O
not	RB	O
satisfaction	NN	O
in	IN	O
caregivers	NNS	O
,	,	O
with	IN	O
control	NN	O
being	VBG	O
the	DT	O
dominant	JJ	O
predictor	NN	O
.	.	O

Research	NNP	O
linking	VBG	O
the	DT	O
theory	NN	O
and	CC	O
findings	NNS	O
from	IN	O
job	NN	O
strain	NN	O
and	CC	O
informal	JJ	O
caregiving	VBG	O
studies	NNS	O
may	MD	O
elucidate	VB	O
both	DT	O
fields	NNS	O
of	IN	O
research	NN	O
.	.	O

Using	VBG	O
the	DT	O
demand-control	JJ	O
model	NN	O
of	IN	O
job	NN	O
strain	NN	O
to	TO	O
predict	VB	O
caregiver	NN	Others
burden	NN	Others
and	CC	O
caregiver	JJ	O
satisfaction	NN	O
in	IN	O
the	DT	O
informal	JJ	O
caregivers	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

Assessment	NN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	Physical
disorder	NN	Physical
:	:	Physical
the	DT	O
Autism	NNP	O
RUPP	NNP	O
Network	NNP	O
.	.	O

Research	NNP	O
Units	VBZ	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
.	.	O

Assessment	NNP	O
of	IN	O
autistic	JJ	Physical
disorder	NN	Physical
(	(	Physical
autism	NN	Physical
)	)	Physical
symptoms	NNS	Physical
,	,	Physical
primary	JJ	Physical
and	CC	Physical
secondary	JJ	Physical
,	,	O
poses	VBZ	O
more	RBR	O
challenging	JJ	O
problems	NNS	O
than	IN	O
ordinarily	RB	O
found	VBN	O
in	IN	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessments	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
subjects	NNS	O
may	MD	O
be	VB	O
uncommunicative	JJ	O
and	CC	O
extremely	RB	O
heterogeneous	JJ	O
in	IN	O
problem	NN	O
presentation	NN	O
,	,	O
and	CC	O
current	JJ	O
pharmacological	JJ	O
treatments	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
alter	VB	O
most	JJS	O
core	NN	O
features	NNS	O
of	IN	O
autism	NN	O
.	.	O

The	DT	O
Autism	NNP	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
Autism	NNP	O
Network	NNP	O
)	)	O
resolved	VBD	O
some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
during	IN	O
the	DT	O
design	NN	O
of	IN	O
a	DT	O
risperidone	NN	O
RCT	NNP	O
in	IN	O
children/adolescents	NNS	O
.	.	O

The	DT	O
inappropriateness	NN	O
of	IN	O
the	DT	O
usual	JJ	O
anchors	NNS	O
for	IN	O
a	DT	O
Clinical	JJ	O
Global	NNP	O
Impression	NNP	O
of	IN	O
Severity	NNP	O
(	(	O
CGI-S	NNP	O
)	)	O
was	VBD	O
resolved	VBN	O
by	IN	O
defining	VBG	O
uncomplicated	JJ	O
autism	NN	O
without	IN	O
secondary	JJ	O
symptoms	NNS	O
as	IN	O
a	DT	O
CGI-S	NNP	O
of	IN	O
3	CD	O
,	,	O
mildly	RB	O
ill	JJ	O
.	.	O

The	DT	O
communication	NN	Physical
problems	NNS	Physical
,	,	O
compromising	VBG	O
use	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	IN	O
an	DT	O
informant	NN	O
,	,	O
were	VBD	O
addressed	VBN	O
by	IN	O
several	JJ	O
strategies	NNS	O
,	,	O
including	VBG	O
careful	JJ	Physical
questioning	NN	Physical
of	IN	Physical
care	NN	Physical
providers	NNS	Physical
,	,	Physical
rating	NN	Others
scales	NNS	Others
,	,	Physical
laboratory	NN	Others
tests	NNS	Others
,	,	O
and	CC	O
physical	JJ	Others
exams	NN	Others
.	.	Others

The	DT	O
broad	JJ	O
subject	JJ	O
heterogeneity	NN	O
requires	VBZ	O
outcome	JJ	O
measures	NNS	O
sensitive	JJ	O
to	TO	O
individual	JJ	O
change	NN	O
over	IN	O
a	DT	O
wide	JJ	O
spectrum	NN	O
of	IN	O
treatment	NN	O
response	NN	Others
and	CC	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
.	.	Adverseeffect

The	DT	O
problems	NNS	O
of	IN	O
neuropsychologically	RB	O
testing	VBG	O
nonverbal	JJ	O
,	,	O
lower	JJR	O
functioning	NN	O
,	,	O
sometimes	RB	O
noncompliant	JJ	O
subjects	NNS	O
requires	VBZ	O
careful	JJ	O
instrument	JJ	O
selection/adaptation	NN	O
and	CC	O
flexible	JJ	O
administration	NN	O
techniques	NNS	O
.	.	O

The	DT	O
problems	NNS	O
of	IN	O
assessing	VBG	O
low-end	JJ	Physical
IQs	NNP	Physical
,	,	O
neglected	VBN	O
by	IN	O
most	JJS	O
standardized	JJ	O
test	NN	O
developers	NNS	O
,	,	O
was	VBD	O
resolved	VBN	O
by	IN	O
an	DT	O
algorithm	NN	O
of	IN	O
test	NN	O
hierarchy	NN	O
.	.	O

Scarcity	NN	O
of	IN	O
other	JJ	O
autism-adapted	JJ	O
cognitive	NN	O
and	CC	O
neuropsychological	JJ	O
tests	NNS	O
and	CC	O
lack	NN	O
of	IN	O
standardization	NN	O
required	VBN	O
development	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
specially	RB	O
adapted	VBN	O
battery	NN	O
.	.	O

Reliability	NN	O
on	IN	O
the	DT	O
Autism	NNP	Physical
Diagnostic	NNP	Physical
Interview	NNP	Physical
(	(	O
currently	RB	O
the	DT	O
most	RBS	O
valid	JJ	O
diagnostic	JJ	O
instrument	NN	O
)	)	O
and	CC	O
other	JJ	O
clinician	JJ	O
instruments	NNS	O
required	VBN	O
extensive	JJ	O
cross-site	JJ	O
training	NN	O
(	(	O
in-person	JJ	O
,	,	O
videotape	NN	O
,	,	O
and	CC	O
teleconference	NN	O
sessions	NNS	O
)	)	O
.	.	O

Definition	NN	O
of	IN	O
a	DT	O
treatment	NN	O
responder	NN	O
required	VBN	O
focus	NN	O
on	IN	O
individually	RB	O
relevant	JJ	O
target	NN	O
symptoms	NNS	O
,	,	O
synthesis	NN	O
of	IN	O
possible	JJ	O
modest	JJ	O
improvements	NNS	O
in	IN	O
many	JJ	O
domains	NNS	O
,	,	O
and	CC	O
acceptance	NN	O
of	IN	O
attainable	JJ	O
though	IN	O
imperfect	JJ	O
goals	NNS	O
.	.	O

The	DT	O
assessment	NN	O
strategy	NN	O
developed	VBD	O
is	VBZ	O
implemented	VBN	O
in	IN	O
a	DT	O
RCT	NNP	O
of	IN	O
risperidone	NN	O
(	(	O
McDougle	NNP	O
et	RB	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
for	IN	O
which	WDT	O
the	DT	O
design	NN	O
and	CC	O
other	JJ	O
methodological	JJ	O
challenges	NNS	O
are	VBP	O
described	VBN	O
elsewhere	RB	O
(	(	O
Scahill	NNP	O
et	VBZ	O
al.	RB	O
,	,	O
2000	CD	O
)	)	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
problems	NNS	O
and	CC	O
solutions	NNS	O
are	VBP	O
partially	RB	O
shared	VBN	O
with	IN	O
RCTs	NNP	O
of	IN	O
other	JJ	O
treatments	NNS	O
and	CC	O
other	JJ	O
disorders	NNS	O
.	.	O

Intravenous	JJ	O
hyperimmune	NN	O
globulin	NN	O
prophylaxis	NN	O
against	IN	O
cytomegalovirus	JJ	O
interstitial	JJ	O
pneumonitis	NN	O
after	IN	O
allogenic	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
.	.	O

In	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
lethal	JJ	O
cytomegalovirus	NN	Physical
(	(	Physical
CMV	NNP	Physical
)	)	Physical
interstitial	NN	Physical
pneumonitis	NN	Physical
after	IN	O
allogenic	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
49	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
controlled	VBN	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
CMV-hyperimmune	NNP	O
globulin	NN	O
or	CC	O
a	DT	O
control	NN	O
immune	JJ	O
globulin	NN	O
with	IN	O
low	JJ	O
anticytomegalovirus	NN	O
titer	NN	O
.	.	O

Immune	NNP	O
globulin	NN	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
6	CD	O
times	NNS	O
with	IN	O
20	CD	O
days	NNS	O
interval	NN	O
,	,	O
starting	VBG	O
on	IN	O
day	NN	O
7	CD	O
before	IN	O
transplantation	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
CMV	NNP	O
hyperimmune	NN	O
globulin	NN	O
or	CC	O
control	NN	O
immune	JJ	O
globulin	NNS	O
were	VBD	O
comparable	JJ	O
with	IN	O
regard	NN	O
to	TO	O
age	NN	O
,	,	O
diagnosis	NN	O
,	,	O
pretransplant	JJ	O
anti-CMV	JJ	O
titer	NN	O
,	,	O
incidence	NN	O
of	IN	O
graft-versus-host	JJ	O
disease	NN	O
and	CC	O
transfusions	NNS	O
.	.	O

In	IN	O
each	DT	O
group	NN	O
,	,	O
the	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
histologically	RB	Adverseeffect
proven	VBN	Adverseeffect
CMV	NNP	Adverseeffect
interstitial	JJ	Adverseeffect
pneumonitis	NN	Adverseeffect
during	IN	O
the	DT	O
first	JJ	O
110	CD	O
days	NNS	O
post	RB	O
BMT	NNP	O
was	VBD	O
recorded	VBN	O
.	.	O

Six	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
versus	VBD	O
1	CD	O
of	IN	O
26	CD	O
in	IN	O
the	DT	O
CMV	NNP	O
hyperimmune	NNP	O
globulin	NN	O
group	NN	O
died	VBD	Mortality
of	IN	Mortality
CMV	NNP	Mortality
interstitial	JJ	Mortality
pneumonitis	NN	Mortality
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
idiopathic	JJ	Mortality
pneumonitis	NN	Mortality
or	CC	O
survival	NN	Mortality
was	VBD	O
observed	VBN	O
.	.	O

[	JJ	O
Results	NNP	O
of	IN	O
three-year	JJ	O
clinical	JJ	O
study	NN	O
of	IN	O
prostamol	NN	O
uno	JJ	O
efficacy	NN	Others
and	CC	O
safety	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
initial	JJ	O
symptoms	NNS	O
of	IN	O
prostatic	JJ	O
adenoma	NN	O
and	CC	O
risk	NN	O
of	IN	O
its	PRP$	O
progression	NN	O
]	NN	O
.	.	O

Prostamol	NNP	O
Uno	NNP	O
(	(	O
PU	NNP	O
)	)	O
efficacy	NN	Others
and	CC	O
safety	NN	Others
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
open-population	NN	O
,	,	O
randomized	VBN	O
and	CC	O
comparative	JJ	O
trial	NN	O
.	.	O

PU	NNP	O
was	VBD	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	O
daily	JJ	O
dose	VB	O
320	CD	O
mg	NN	O
for	IN	O
36	CD	O
months	NNS	O
to	TO	O
50	CD	O
patients	NNS	O
with	IN	O
initial	JJ	O
symptoms	NNS	O
of	IN	O
prostatic	JJ	O
adenoma	NN	O
(	(	O
PA	NNP	O
)	)	O
in	IN	O
comparison	NN	O
with	IN	O
50	CD	O
matched	JJ	O
controls	NNS	O
.	.	O

The	DT	O
trial	NN	O
evaluated	VBD	O
PU	NNP	O
action	NN	O
on	IN	O
the	DT	O
symptoms	NNS	Physical
progression	NN	Physical
and	CC	O
quality	NN	Others
of	IN	Others
life	NN	Others
with	IN	O
application	NN	O
of	IN	O
questionnaires	NNS	Physical
IPSS	NNP	Physical
and	CC	Physical
QoL	NNP	Others
(	(	Others
BS	NNP	Others
)	)	Others
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
PU	NNP	O
treatment	NN	O
relieved	VBD	O
PA	NNP	O
symptoms	NNS	O
by	IN	O
IPSS	NNP	O
,	,	O
while	IN	O
these	DT	O
symptoms	NNS	O
progressed	VBD	O
in	IN	O
the	DT	O
controls	NNS	O
.	.	O

QoL	NNP	Physical
improved	VBD	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
and	CC	O
deteriorated	VBN	O
in	IN	O
the	DT	O
control	NN	O
one	CD	O
.	.	O

Administration	NN	O
of	IN	O
PU	NNP	O
significantly	RB	O
increased	VBD	O
urinary	JJ	Physical
flow	NN	Physical
rate	NN	Physical
though	IN	O
in	IN	O
the	DT	O
controls	NNS	O
urinary	JJ	Physical
flow	NN	Physical
rate	NN	Physical
decreased	VBN	O
,	,	O
size	NN	Physical
of	IN	Physical
the	DT	Physical
prostate	NN	Physical
diminished	VBD	O
and	CC	O
increased	VBD	O
,	,	O
respectively	RB	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
PSA	NNP	Physical
were	VBD	O
not	RB	O
seen	VBN	O
and	CC	O
were	VBD	O
insignificant	JJ	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
study	NN	O
say	VBP	O
that	IN	O
prostamol	NN	O
Uno	NNP	O
in	IN	O
a	DT	O
dose	JJ	O
320	CD	O
mg/day	NN	O
can	MD	O
prevent	VB	O
PA	NNP	O
progression	NN	O
without	IN	O
side	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

Relationship	NN	O
between	IN	O
subjective	JJ	O
effects	NNS	O
and	CC	O
drug	NN	O
preferences	NNS	O
:	:	O
ethanol	NN	O
and	CC	O
diazepam	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
subjective	JJ	O
effects	NNS	O
and	CC	O
drug	NN	O
preferences	NNS	O
in	IN	O
normal	JJ	O
volunteers	NNS	O
was	VBD	O
explored	VBN	O
in	IN	O
a	DT	O
meta-analysis	NN	O
of	IN	O
several	JJ	O
previously	RB	O
published	VBN	O
studies	NNS	O
.	.	O

Subjective	JJ	O
effects	NNS	O
of	IN	O
,	,	O
and	CC	O
preference	NN	O
for	IN	O
,	,	O
ethanol	NN	O
and	CC	O
diazepam	NN	O
vs.	FW	O
placebo	NN	O
were	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
choice	NN	O
procedure	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
grouped	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
drug	NN	O
choices	NNS	O
:	:	O
'non-choosers	NNS	O
'	POS	O
never	RB	O
chose	JJ	O
drug	NN	O
,	,	O
whereas	IN	O
'choosers	NNS	O
'	POS	O
always	RB	O
chose	JJ	O
drug	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
on	IN	O
their	PRP$	O
subjective	JJ	O
responses	NNS	O
to	TO	O
drug	NN	O
and	CC	O
on	IN	O
demographic	JJ	O
variables	NNS	O
.	.	O

Ethanol	NNP	O
decreased	VBD	Mental
Arousal	NNP	Mental
,	,	Mental
Elation	NNP	Mental
,	,	Mental
Positive	NNP	Mental
Mood	NNP	Mental
and	CC	Mental
Vigor	NNP	Mental
,	,	O
and	CC	O
increased	VBD	Mental
Anxiety	NNP	Mental
,	,	Mental
Depression	NNP	Mental
and	CC	Physical
Fatigue	NNP	Physical
in	IN	O
the	DT	O
non-choosers	NNS	O
,	,	O
whereas	IN	O
it	PRP	O
increased	VBD	Mental
Arousal	NNP	Mental
and	CC	O
Vigor	NNP	Mental
in	IN	O
the	DT	O
choosers	NNS	O
.	.	O

Ethanol	JJ	O
choosers	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
likely	JJ	Others
to	TO	Others
be	VB	Others
males	NNS	Others
and/or	IN	Others
full-time	JJ	Others
students	NNS	Others
than	IN	O
non-choosers	NNS	O
.	.	O

Diazepam	NNP	O
produced	VBD	O
sedative-like	JJ	Adverseeffect
effects	NNS	Adverseeffect
in	IN	O
both	DT	O
choosers	NNS	O
and	CC	O
non-choosers	NNS	O
,	,	O
but	CC	O
markedly	RB	O
decreased	VBD	Mental
Anxiety	NNP	Mental
and	CC	Mental
increased	VBD	Mental
Friendliness	NNP	Mental
in	IN	O
choosers	NNS	O
only	RB	O
.	.	O

Diazepam	NNP	O
choice	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
more	RBR	Others
frequent	JJ	Others
recreational	JJ	Others
use	NN	Others
of	IN	Others
marijuana	NN	Others
and	CC	Others
stimulants	NNS	Others
.	.	Others

Thus	RB	O
,	,	O
both	DT	O
demographic	JJ	Adverseeffect
variables	NNS	Adverseeffect
and	CC	Adverseeffect
subjective	JJ	Adverseeffect
drug	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
related	VBN	O
to	TO	O
drug	NN	O
preference	NN	O
.	.	O

Superior	JJ	O
visual	JJ	O
search	NN	O
in	IN	O
adults	NNS	O
with	IN	O
autism	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
children	NNS	O
with	IN	O
autism	NN	O
perform	NN	O
better	RBR	O
than	IN	O
matched	VBN	O
controls	NNS	O
on	IN	O
visual	JJ	O
search	NN	O
tasks	NNS	O
and	CC	O
that	IN	O
this	DT	O
stems	VBZ	O
from	IN	O
a	DT	O
superior	JJ	O
visual	JJ	Mental
discrimination	NN	Mental
ability	NN	Mental
.	.	Mental

This	DT	O
study	NN	O
assessed	VBD	O
whether	IN	O
these	DT	O
findings	NNS	O
generalize	VBP	O
from	IN	O
children	NNS	O
to	TO	O
adults	NNS	O
with	IN	O
autism	NN	O
.	.	O

Experiments	NNS	O
1	CD	O
and	CC	O
2	CD	O
showed	VBD	O
that	IN	O
,	,	O
like	IN	O
children	NNS	O
,	,	O
adults	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
superior	JJ	O
to	TO	O
controls	NNS	O
at	IN	O
searching	VBG	Mental
for	IN	Mental
targets	NNS	Mental
.	.	Mental

Experiment	NN	O
3	CD	O
showed	VBD	O
that	IN	O
increases	NNS	O
in	IN	O
target-distractor	JJ	Mental
similarity	NN	Mental
slowed	VBD	Mental
the	DT	Mental
visual	JJ	Mental
search	NN	Mental
performance	NN	Mental
of	IN	O
the	DT	O
control	NN	O
group	NN	O
significantly	RB	O
more	RBR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
autism	NN	O
group	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
adults	NNS	O
with	IN	O
autism	NN	O
have	VBP	O
a	DT	O
superior	JJ	Physical
visual	JJ	Physical
discrimination	NN	Physical
ability	NN	Physical
.	.	Physical

Thus	RB	O
,	,	O
these	DT	O
experiments	NNS	O
replicate	VBP	O
in	IN	O
adults	NNS	O
previous	JJ	O
findings	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Superior	NNP	O
unique	JJ	Mental
item	NN	Mental
detection	NN	Mental
in	IN	O
adults	NNS	O
with	IN	O
autism	NN	O
,	,	O
stemming	VBG	O
from	IN	O
enhanced	VBN	O
discrimination	NN	O
,	,	O
is	VBZ	O
discussed	VBN	O
in	IN	O
the	DT	O
light	NN	O
of	IN	O
the	DT	O
possible	JJ	O
role	NN	O
of	IN	O
stimulus	JJ	O
processing	NN	O
disturbances	NNS	O
in	IN	O
the	DT	O
disorder	NN	O
in	IN	O
general	JJ	O
.	.	O

Efficacy	NN	Others
,	,	Others
safety	NN	Others
,	,	Others
and	CC	Others
steady-state	JJ	Others
pharmacokinetics	NNS	Others
of	IN	O
once-a-day	JJ	O
controlled-release	JJ	O
morphine	NN	O
(	(	O
MS	NNP	O
Contin	NNP	O
XL	NNP	O
)	)	O
in	IN	O
cancer	NN	O
pain	NN	O
.	.	O

The	DT	O
efficacy	NN	Others
,	,	Others
safety	NN	Others
,	,	Others
and	CC	Others
pharmacokinetics	NNS	Others
of	IN	O
a	DT	O
novel	JJ	O
once-daily	JJ	O
morphine	NN	O
formulation	NN	O
(	(	O
OAD	NNP	O
morphine	NN	O
)	)	O
and	CC	O
a	DT	O
12-hourly	JJ	O
formulation	NN	O
(	(	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
)	)	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
multi-centered	JJ	O
crossover	NN	O
study	NN	O
.	.	O

Chronic	NNP	O
cancer	NN	O
pain	NN	O
patients	NNS	O
(	(	O
n=25	JJ	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
OAD	NNP	O
morphine	NN	O
(	(	O
mean	JJ	O
238	CD	O
+/-	JJ	O
319	CD	O
mg	NN	O
q24h	NN	O
)	)	O
or	CC	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
(	(	O
mean	JJ	O
119	CD	O
+/-	JJ	O
159	CD	O
mg	NN	O
q12h	NN	O
)	)	O
for	IN	O
one	CD	O
week	NN	O
.	.	O

They	PRP	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
the	DT	O
alternate	JJ	O
drug	NN	O
,	,	O
which	WDT	O
also	RB	O
was	VBD	O
taken	VBN	O
for	IN	O
one	CD	O
week	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatments	NNS	O
for	IN	O
evaluations	NNS	O
of	IN	O
overall	JJ	Pain
pain	NN	Pain
intensity	NN	Pain
,	,	O
analgesic	JJ	Others
efficacy	NN	Others
,	,	O
or	CC	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	O

However	RB	O
,	,	O
whereas	JJ	O
pain	NN	Pain
scores	NNS	Pain
increased	VBD	O
during	IN	O
the	DT	O
day	NN	O
on	IN	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
(	(	O
P=0.0108	NNP	O
)	)	O
,	,	O
they	PRP	O
remained	VBD	O
stable	JJ	O
on	IN	O
OAD	NNP	O
morphine	NN	O
.	.	O

Most	JJS	O
patients	NNS	O
(	(	O
68	CD	O
%	NN	O
)	)	O
chose	VBD	O
once-daily	JJ	O
dosing	NN	O
for	IN	O
continuing	VBG	O
pain	JJ	Pain
management	NN	Pain
(	(	O
P=0.015	NNP	O
)	)	O
.	.	O

The	DT	O
AUC	NNP	Others
ratio	NN	Others
was	VBD	O
100.3	CD	O
%	NN	O
,	,	O
indicating	VBG	O
equivalent	JJ	O
absorption	NN	O
.	.	O

Fluctuation	NN	Others
indices	NNS	Others
were	VBD	O
93.5	CD	O
+/-	JJ	O
28.8	CD	O
%	NN	O
and	CC	O
179.3	CD	O
+/-	JJ	O
41.3	CD	O
%	NN	O
(	(	O
P=0.0001	NNP	O
)	)	O
for	IN	O
OAD	NNP	O
morphine	NN	O
and	CC	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
,	,	O
respectively	RB	O
.	.	O

OAD	NNP	O
morphine	NN	O
provides	VBZ	O
analgesia	RB	O
similar	JJ	O
to	TO	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
with	IN	O
reduced	JJ	O
fluctuation	NN	Physical
in	IN	Physical
plasma	JJ	Physical
morphine	NN	Physical
concentration	NN	Physical
and	CC	O
more	RBR	O
stable	JJ	O
pain	NN	Pain
control	NN	Pain
.	.	O

Complementary	JJ	O
feeding	NN	O
with	IN	O
fortified	JJ	O
spread	NN	O
and	CC	O
incidence	NN	O
of	IN	O
severe	JJ	Physical
stunting	VBG	Physical
in	IN	O
6-	JJ	O
to	TO	O
18-month-old	JJ	O
rural	JJ	O
Malawians	NNPS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
growth	NN	Others
and	CC	O
incidence	NN	O
of	IN	O
malnutrition	NN	Physical
in	IN	O
infants	NNS	O
receiving	VBG	O
long-term	JJ	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
ready-to-use	NN	O
fortified	VBN	O
spread	NN	O
(	(	O
FS	NNP	O
)	)	O
or	CC	O
micronutrient-fortified	JJ	O
maize-soy	JJ	O
flour	NN	O
(	(	O
likuni	JJ	O
phala	NN	O
[	NNP	O
LP	NNP	O
]	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
single-blind	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Rural	JJ	O
Malawi	NNP	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
six-month-old	JJ	O
infants	NNS	O
.	.	O

INTERVENTION	NN	O
Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
year	NN	O
of	IN	O
daily	JJ	O
supplementation	NN	O
with	IN	O
71	CD	O
g	NN	O
of	IN	O
LP	NNP	O
(	(	O
282	CD	O
kcal	NN	O
)	)	O
,	,	O
50	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS50	NNP	O
)	)	O
(	(	O
256	CD	O
kcal	NN	O
)	)	O
,	,	O
or	CC	O
25	CD	O
g	NN	O
of	IN	O
FS	NNP	O
(	(	O
FS25	NNP	O
)	)	O
(	(	O
130	CD	O
[	RB	O
corrected	VBN	O
]	NNP	O
kcal	JJ	O
)	)	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Weight	NNP	Physical
and	CC	Physical
length	NN	Physical
gains	NNS	Physical
and	CC	O
the	DT	O
incidences	NNS	Physical
of	IN	Physical
severe	JJ	Physical
stunting	NN	Physical
,	,	O
underweight	JJ	Physical
,	,	O
and	CC	O
wasting	VBG	Physical
.	.	O

RESULTS	NNP	O
Mean	NNP	Physical
weight	NN	Physical
and	CC	Physical
length	NN	Physical
gains	NNS	Physical
in	IN	O
the	DT	O
LP	NNP	O
,	,	O
FS50	NNP	O
,	,	O
and	CC	O
FS25	NNP	O
groups	NNS	O
were	VBD	O
2.37	CD	O
,	,	O
2.47	CD	O
,	,	O
and	CC	O
2.37	CD	O
kg	NN	O
(	(	O
P	NNP	O
=	NNP	O
.66	NNP	O
)	)	O
and	CC	O
12.7	CD	O
,	,	O
13.5	CD	O
,	,	O
and	CC	O
13.2	CD	O
cm	NN	O
(	(	O
P	NNP	O
=	NNP	O
.23	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
groups	NNS	O
,	,	O
the	DT	O
cumulative	JJ	O
12-month	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	Physical
stunting	NN	Physical
was	VBD	O
13.3	CD	O
%	NN	O
,	,	O
0.0	CD	O
%	NN	O
,	,	O
and	CC	O
3.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
of	IN	O
severe	JJ	O
underweight	NN	Physical
was	VBD	O
15.0	CD	O
%	NN	O
,	,	O
22.5	CD	O
%	NN	O
,	,	O
and	CC	O
16.9	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.71	NNP	O
)	)	O
,	,	O
and	CC	O
of	IN	O
severe	JJ	Physical
wasting	NN	Physical
was	VBD	O
1.8	CD	O
%	NN	O
,	,	O
1.9	CD	O
%	NN	O
,	,	O
and	CC	O
1.8	CD	O
%	NN	O
(	(	O
P	NNP	O
>	NNP	O
.99	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
LP-supplemented	JJ	O
infants	NNS	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
100	CD	O
g	NNS	O
more	JJR	O
weight	NN	Physical
and	CC	O
0.8	CD	O
cm	NN	O
more	JJR	O
length	NN	Physical
.	.	Physical

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
baseline	NN	O
length	NN	O
and	CC	O
intervention	NN	O
(	(	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
;	:	O
in	IN	O
children	NNS	O
with	IN	O
below-median	JJ	O
length	NN	O
at	IN	O
enrollment	NN	O
,	,	O
those	DT	O
given	VBN	O
FS50	NNP	O
gained	VBD	O
a	DT	O
mean	NN	O
of	IN	O
1.9	CD	O
cm	NNS	O
more	JJR	O
than	IN	O
individuals	NNS	O
receiving	VBG	O
LP	NNP	O
.	.	O

CONCLUSION	NNP	O
One-year-long	JJ	O
complementary	JJ	O
feeding	NN	O
with	IN	O
FS	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
a	DT	O
significantly	RB	O
larger	JJR	O
effect	NN	O
than	IN	O
LP	NNP	O
on	IN	O
mean	JJ	Physical
weight	NN	Physical
gain	NN	Physical
in	IN	O
all	DT	O
infants	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
likely	JJ	O
to	TO	O
boost	VB	O
linear	JJ	Physical
growth	NN	Physical
in	IN	O
the	DT	O
most	RBS	O
disadvantaged	JJ	O
individuals	NNS	O
and	CC	O
,	,	O
hence	RB	O
,	,	O
decrease	VB	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
severe	JJ	Physical
stunting	NN	Physical
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
on	IN	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
in	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	O
intervention	NN	O
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
and	CC	O
behaviour	NN	Mental
of	IN	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

36	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	O
intervention	NN	O
(	(	O
weekly	JJ	O
cognitive	VBP	O
individual	JJ	O
psychotherapy	NN	O
and	CC	O
bimonthly	JJ	O
family	NN	O
counselling	VBG	O
)	)	O
or	CC	O
standard	JJ	O
follow-up	NN	O
.	.	O

Personality	NNP	Mental
(	(	Mental
16-PF	JJ	Mental
and	CC	Mental
IIQ	NNP	Mental
)	)	Mental
,	,	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
(	(	Physical
FLIC	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
depression	NN	Mental
(	(	Mental
BDI	NNP	Mental
)	)	Mental
scores	NNS	Mental
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	Mental
and	CC	O
quality	NN	Physical
of	IN	Physical
life	NN	Physical
indexes	NNS	Physical
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	Mental
coping	NN	Mental
behaviours	NNS	Mental
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

Weighted	VBN	O
blankets	NNS	O
and	CC	O
sleep	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
--	:	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
weighted-blanket	JJ	O
intervention	NN	O
in	IN	O
treating	VBG	O
severe	JJ	O
sleep	NN	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
aged	VBN	O
between	IN	O
5	CD	O
years	NNS	O
and	CC	O
16	CD	O
years	NNS	O
10	CD	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
confirmed	JJ	O
ASD	NNP	O
diagnosis	NN	O
and	CC	O
severe	JJ	O
sleep	NN	O
problems	NNS	O
,	,	O
refractory	NN	O
to	TO	O
community-based	JJ	O
interventions	NNS	O
.	.	O

The	DT	O
interventions	NNS	O
were	VBD	O
either	RB	O
a	DT	O
commercially	RB	O
available	JJ	O
weighted	JJ	O
blanket	NN	O
or	CC	O
otherwise	RB	O
identical	JJ	O
usual	JJ	O
weight	NN	O
blanket	NN	O
(	(	O
control	NN	O
)	)	O
,	,	O
introduced	VBN	O
at	IN	O
bedtime	NN	O
;	:	O
each	DT	O
was	VBD	O
used	VBN	O
for	IN	O
a	DT	O
2-week	JJ	O
period	NN	O
before	IN	O
crossover	NN	O
to	TO	O
the	DT	O
other	JJ	O
blanket	NN	O
.	.	O

Primary	JJ	O
outcome	NN	O
was	VBD	O
total	JJ	Mental
sleep	JJ	Mental
time	NN	Mental
(	(	Physical
TST	NNP	Physical
)	)	Physical
recorded	VBN	O
by	IN	O
actigraphy	NN	O
over	IN	O
each	DT	O
2-week	JJ	O
period	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
actigraphically	RB	Physical
recorded	VBN	Physical
sleep-onset	JJ	Physical
latency	NN	Physical
,	,	Mental
sleep	JJ	Others
efficiency	NN	Others
,	,	O
assessments	NNS	Mental
of	IN	Mental
child	NN	Mental
behavior	NN	Mental
,	,	O
family	NN	Mental
functioning	NN	Mental
,	,	O
and	CC	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	O

Sleep	NNP	O
was	VBD	O
also	RB	O
measured	VBN	O
by	IN	O
using	VBG	O
parent-report	JJ	O
diaries	NNS	O
.	.	O

RESULTS	NNP	O
Seventy-three	JJ	O
children	NNS	O
were	VBD	O
randomized	VBN	O
and	CC	O
analysis	NN	O
conducted	VBN	O
on	IN	O
67	CD	O
children	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Using	VBG	O
objective	JJ	O
measures	NNS	O
,	,	O
the	DT	O
weighted	JJ	O
blanket	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
blanket	NN	O
,	,	O
did	VBD	O
not	RB	O
increase	VB	O
TST	NNP	Mental
as	IN	O
measured	VBN	O
by	IN	O
actigraphy	NN	O
and	CC	O
adjusted	VBN	O
for	IN	O
baseline	NN	O
TST	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	NNS	O
in	IN	O
any	DT	O
other	JJ	O
objective	NN	Others
or	CC	Others
subjective	JJ	Others
measure	NN	Others
of	IN	Others
sleep	NN	Others
,	,	O
including	VBG	O
behavioral	JJ	O
outcomes	NNS	O
.	.	O

On	IN	O
subjective	JJ	O
preference	NN	O
measures	NNS	O
,	,	O
parents	NNS	O
and	CC	O
children	NNS	O
favored	VBD	O
the	DT	O
weighted	JJ	O
blanket	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
a	DT	O
weighted	JJ	O
blanket	NN	O
did	VBD	O
not	RB	O
help	VB	O
children	NNS	O
with	IN	O
ASD	NNP	O
sleep	NN	O
for	IN	O
a	DT	O
longer	JJR	O
period	NN	O
of	IN	O
time	NN	O
,	,	O
fall	VB	O
asleep	RB	O
significantly	RB	O
faster	RBR	O
,	,	O
or	CC	O
wake	VB	O
less	JJR	O
often	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
weighted	JJ	O
blanket	NN	O
was	VBD	O
favored	VBN	O
by	IN	O
children	NNS	O
and	CC	O
parents	NNS	O
,	,	O
and	CC	O
blankets	NNS	O
were	VBD	O
well	RB	Others
tolerated	VBN	Others
over	IN	O
this	DT	O
period	NN	O
.	.	O

Deficiency	NN	Physical
of	IN	Physical
serum	NN	Physical
ionized	JJ	Physical
magnesium	NN	Physical
in	IN	O
patients	NNS	O
receiving	VBG	O
hemodialysis	NN	O
or	CC	O
peritoneal	JJ	O
dialysis	NN	O
.	.	O

Serum	NNP	O
total	JJ	O
magnesium	NN	O
(	(	O
TMg	NNP	O
)	)	O
measurements	NNS	O
in	IN	O
dialysis	NN	O
patients	NNS	O
are	VBP	O
variable	JJ	O
,	,	O
with	IN	O
some	DT	O
groups	NNS	O
reporting	VBG	O
hypermagnesemia	NN	O
and	CC	O
some	DT	O
hypomagnesemia	NN	O
.	.	O

It	PRP	O
had	VBD	O
not	RB	O
been	VBN	O
possible	JJ	O
to	TO	O
measure	VB	O
the	DT	O
biologically	RB	O
active	JJ	O
fraction	NN	O
,	,	O
ionized	JJ	O
magnesium	NN	O
(	(	O
IMg2+	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
utilized	VBD	O
an	DT	O
ion-selective	JJ	O
electrode	NN	O
to	TO	O
measure	VB	O
IMg	NNP	Physical
in	IN	O
26	CD	O
hemodialysis	NN	O
patients	NNS	O
and	CC	O
10	CD	O
peritoneal	JJ	O
dialysis	NN	O
(	(	O
CAPD	NNP	O
)	)	O
patients	NNS	O
and	CC	O
compared	VBN	O
the	DT	O
results	NNS	O
with	IN	O
those	DT	O
from	IN	O
66	CD	O
age	NN	O
matched	VBD	O
control	NN	O
subjects	NNS	O
.	.	O

Dialysate	NNP	O
magnesium	NN	O
was	VBD	O
0.375	CD	O
mM/L	NN	O
for	IN	O
the	DT	O
hemodialysis	NN	O
and	CC	O
0.25	CD	O
mM/L	NN	O
for	IN	O
the	DT	O
CAPD	NNP	O
patients	NNS	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
,	,	O
both	DT	O
hemodialysis	NN	O
and	CC	O
CAPD	NNP	O
patients	NNS	O
had	VBD	O
significantly	RB	O
lower	JJR	O
IMg2+	NNP	Physical
(	(	O
0.55	CD	O
+/-	JJ	O
0.02	CD	O
and	CC	O
0.50	CD	O
+/-	JJ	O
0.02	CD	O
vs.	FW	O
0.60	CD	O
+/-	JJ	O
0.004	CD	O
mM/L	NN	O
;	:	O
p	CC	O
<	VB	O
0.05	CD	O
)	)	O
and	CC	O
greater	JJR	Physical
or	CC	Physical
normal	JJ	Physical
TMg	NNP	Physical
values	NNS	Physical
(	(	O
0.99	CD	O
+/-	JJ	O
0.04	CD	O
,	,	O
different	JJ	O
at	IN	O
the	DT	O
p	NN	O
<	VBZ	O
0.001	CD	O
level	NN	O
,	,	O
and	CC	O
0.85	CD	O
+/-	JJ	O
0.04	CD	O
vs.	FW	O
0.84	CD	O
+/-	JJ	O
0.008	CD	O
)	)	O
.	.	O

Ionized	VBN	Physical
calcium	NN	Physical
(	(	Physical
ICa2+	NNP	Physical
)	)	Physical
values	NNS	Physical
were	VBD	O
similar	JJ	O
for	IN	O
all	DT	O
three	CD	O
groups	NNS	O
(	(	O
1.15	CD	O
+/-	JJ	O
0.02	CD	O
and	CC	O
1.21	CD	O
+/-	JJ	O
0.04	CD	O
vs.	FW	O
1.17	CD	O
+/-	JJ	O
0.01	CD	O
)	)	O
,	,	O
resulting	VBG	O
in	IN	O
increased	VBN	O
mean	NN	O
ICa2+/IMg2+	NNP	Physical
ratios	NNS	Physical
(	(	O
2.14	CD	O
+/-	JJ	O
0.07	CD	O
and	CC	O
2.42	CD	O
+/-	JJ	O
0.06	CD	O
vs.	FW	O
1.95	CD	O
+/-	JJ	O
0.02	CD	O
for	IN	O
the	DT	O
control	NN	O
subjects	VBZ	O
;	:	O
p	VB	O
<	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
percent	NN	O
of	IN	O
total	JJ	O
magnesium	NN	O
that	WDT	O
was	VBD	O
ionized	VBN	Physical
(	(	Physical
%	NN	Physical
IMg2+	NNP	Physical
)	)	Physical
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
the	DT	O
hemodialysis	NN	O
and	CC	O
CAPD	NNP	O
patients	NNS	O
(	(	O
55.6	CD	O
+/-	JJ	O
0.93	CD	O
and	CC	O
59.2	CD	O
+/-	JJ	O
1.05	CD	O
)	)	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
control	NN	O
subjects	NNS	O
(	(	O
72	CD	O
+/-	JJ	O
0.61	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.05	CD	O
)	)	O
.	.	O

IMg2+	NNP	O
values	NNS	O
correlated	VBN	O
with	IN	O
TMg	NNP	O
values	NNS	O
in	IN	O
both	DT	O
hemodialysis	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.93	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
and	CC	O
CAPD	NNP	O
(	(	O
r	VB	O
=	RB	O
0.92	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
patients	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
age	NN	O
,	,	O
time	NN	O
on	IN	O
dialysis	NN	O
,	,	O
weight	NN	O
,	,	O
fasting	VBG	O
cholesterol	NN	O
or	CC	O
triglyceride	NN	O
,	,	O
albumin	NN	O
,	,	O
blood	NN	O
urea	JJ	O
nitrogen	NN	O
(	(	O
BUN	NNP	O
)	)	O
,	,	O
creatinine	NN	O
,	,	O
hematocrit	NN	O
,	,	O
phosphate	NN	O
,	,	O
or	CC	O
PTH	NNP	O
values	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Low	JJ	O
body	NN	O
mass	NN	O
index	NN	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
linked	VBN	O
to	TO	O
elevated	VBN	O
plasma	NN	O
fibroblast	NN	O
growth	NN	O
factor	NN	O
23	CD	O
.	.	O

BACKGROUND	NNP	O
Fibroblast	NNP	O
growth	NN	O
factor	NN	O
23	CD	O
(	(	O
FGF23	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
death	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

Since	IN	O
FGF23	NNP	O
shares	NNS	O
structural	JJ	O
features	NNS	O
with	IN	O
FGF19	NNP	O
subfamily	RB	O
members	NNS	O
that	IN	O
exert	JJ	O
hormonal	JJ	O
control	NN	O
of	IN	O
fat	JJ	O
mass	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	DT	O
high	JJ	O
circulating	NN	O
FGF23	NNP	O
concentrations	NNS	O
would	MD	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
uremic	JJ	O
lipid	NN	O
profile	NN	O
and	CC	O
lower	JJR	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
654	CD	O
patients	NNS	O
receiving	VBG	O
chronic	JJ	O
hemodialysis	NN	O
.	.	O

C-terminal	JJ	Physical
FGF23	NNP	Physical
concentrations	NNS	Physical
were	VBD	O
measured	VBN	O
in	IN	O
stored	JJ	O
plasma	NN	O
samples	NNS	O
.	.	O

Linear	JJ	O
regression	NN	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
cross-sectional	JJ	O
associations	NNS	O
of	IN	O
plasma	NN	Physical
FGF23	NNP	Physical
concentrations	NNS	Physical
with	IN	Physical
BMI	NNP	Physical
,	,	Physical
total	JJ	Physical
cholesterol	NN	Physical
(	(	Physical
TC	NNP	Physical
)	)	Physical
,	,	Physical
low-density	JJ	Physical
lipoprotein-cholesterol	NN	Physical
(	(	Physical
LDL-C	NNP	Physical
)	)	Physical
,	,	Physical
high-density	JJ	Physical
lipoprotein-cholesterol	NN	Physical
(	(	Physical
HDL-C	NNP	Physical
)	)	Physical
and	CC	Physical
triglycerides	NNS	Physical
.	.	Physical

Cox	NNP	O
proportional	JJ	O
hazard	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
concentrations	NNS	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
.	.	O

RESULTS	JJ	O
Participants	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60	CD	O
?	.	O
11	CD	O
years	NNS	O
and	CC	O
a	DT	O
median	JJ	O
(	(	O
IQR	NNP	O
)	)	O
FGF23	NNP	O
concentration	NN	O
of	IN	O
4,212	CD	O
(	(	O
1,411-13,816	JJ	O
)	)	O
RU/ml	NNP	O
.	.	O

An	DT	O
increase	NN	O
per	IN	O
SD	NNP	O
in	IN	O
log10	JJ	O
FGF23	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
?	.	O
=	NNP	O
-1.11	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.008	CD	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
?	.	O
=	NNP	O
-6.46	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.02	CD	O
)	)	O
,	,	O
LDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-4.73	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.04	CD	O
)	)	O
and	CC	O
HDL-C	NNP	O
(	(	O
?	.	O
=	NNP	O
-2.14	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.03	CD	O
)	)	O
;	:	O
after	IN	O
adjusting	VBG	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
race	NN	O
,	,	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
serum	NN	O
albumin	NN	O
,	,	O
markers	NNS	O
of	IN	O
mineral	JJ	O
metabolism	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
lipid-lowering	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
association	NN	O
of	IN	O
FGF23	NNP	O
with	IN	O
death	NN	O
was	VBD	O
attenuated	VBN	O
after	IN	O
adjustment	NN	O
for	IN	O
HDL-C	NNP	O
(	(	O
HR	NNP	O
of	IN	O
highest	JJS	O
quartile	NN	O
1.53	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.06-2.20	CD	O
compared	VBN	O
to	TO	O
lowest	VB	O
quartile	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
higher	JJR	O
plasma	NN	O
FGF23	NNP	O
levels	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
and	CC	O
dyslipidemia	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
association	NN	O
between	IN	O
FGF23	NNP	O
and	CC	O
death	NN	O
may	MD	O
be	VB	O
mediated	VBN	O
through	IN	O
unexplored	JJ	O
metabolic	JJ	O
risk	NN	O
factors	NNS	O
unrelated	VBD	O
to	TO	O
mineral	JJ	O
metabolism	NN	O
.	.	O

Combination	NNP	O
therapy	NN	O
with	IN	O
methotrexate	NN	O
and	CC	O
hydroxychloroquine	NN	O
for	IN	O
rheumatoid	JJ	O
arthritis	NN	O
increases	NNS	O
exposure	VBP	O
to	TO	O
methotrexate	VB	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
hydroxychloroquine	NN	O
(	(	O
HCQ	NNP	O
)	)	O
,	,	O
and	CC	O
vice	NN	O
versa	NN	O
,	,	O
to	TO	O
determine	VB	O
a	DT	O
possible	JJ	O
pharmacokinetic	JJ	O
explanation	NN	O
for	IN	O
the	DT	O
observation	NN	O
that	IN	O
combination	NN	O
treatment	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
with	IN	O
MTX	NNP	O
and	CC	O
HCQ	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
,	,	O
clinically	RB	O
,	,	O
to	TO	O
be	VB	O
more	RBR	O
potent	JJ	O
than	IN	O
MTX	NNP	O
used	VBD	O
alone	RB	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
10	CD	O
healthy	JJ	O
subjects	NNS	O
received	VBN	O
,	,	O
on	IN	O
each	DT	O
of	IN	O
5	CD	O
dosing	VBG	O
occasions	NNS	O
,	,	O
MTX	NNP	O
alone	RB	O
as	IN	O
tablets	NNS	O
or	CC	O
intravenous	JJ	O
solution	NN	O
,	,	O
HCQ	NNP	O
alone	RB	O
as	IN	O
a	DT	O
tablet	NN	O
or	CC	O
oral	JJ	O
solution	NN	O
,	,	O
or	CC	O
a	DT	O
coadministered	JJ	O
dose	NN	O
of	IN	O
MTX	NNP	O
tablets	NNS	O
with	IN	O
an	DT	O
HCQ	NNP	O
tablet	NN	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	Others
curve	NN	Others
(	(	Others
AUC	NNP	Others
)	)	Others
was	VBD	O
determined	VBN	O
for	IN	O
each	DT	O
subject	NN	O
,	,	O
on	IN	O
each	DT	O
dosing	VBG	O
occasion	NN	O
,	,	O
for	IN	O
each	DT	O
compound	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	Others
AUC	NNP	Others
for	IN	Others
MTX	NNP	Others
was	VBD	O
increased	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
and	CC	O
the	DT	O
maximum	JJ	Others
MTX	NNP	Others
concentration	NN	Others
(	(	Others
Cmax	NNP	Others
)	)	Others
decreased	VBD	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
when	WRB	O
MTX	NNP	O
was	VBD	O
coadministered	VBN	O
with	IN	O
HCQ	NNP	O
,	,	O
compared	VBN	O
to	TO	O
MTX	NNP	O
administered	VBD	O
alone	RB	O
.	.	O

The	DT	O
time	NN	Others
to	TO	Others
reach	VB	Others
Cmax	NNP	Others
for	IN	Others
MTX	NNP	Others
administration	NN	Others
,	,	Others
tmax	NN	Others
,	,	O
was	VBD	O
also	RB	O
increased	VBN	O
during	IN	O
the	DT	O
coadministration	NN	O
with	IN	O
HCQ	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.072	CD	O
)	)	O
.	.	O

The	DT	O
AUC	NNP	O
of	IN	O
HCQ	NNP	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.957	CD	O
)	)	O
between	IN	O
any	DT	O
of	IN	O
the	DT	O
dosing	NN	O
occasions	NNS	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
may	MD	O
explain	VB	O
the	DT	O
increased	JJ	O
potency	NN	O
of	IN	O
the	DT	O
MTX-HCQ	NNP	O
combination	NN	O
over	RB	O
MTX	NNP	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
and	CC	O
also	RB	O
the	DT	O
sustained	JJ	O
effects	NNS	O
of	IN	O
MTX	NNP	O
when	WRB	O
administered	VBN	O
with	IN	O
HCQ	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
reduced	JJ	O
Cmax	NNP	O
of	IN	O
MTX	NNP	O
observed	VBD	O
during	IN	O
the	DT	O
coadministration	NN	O
may	MD	O
explain	VB	O
diminution	NN	O
of	IN	O
acute	JJ	O
liver	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

Extra	NNP	O
vigilance	NN	O
for	IN	O
MTX	NNP	O
adverse	JJ	O
effects	NNS	O
during	IN	O
combination	NN	O
therapy	NN	O
with	IN	O
HCQ	NNP	O
is	VBZ	O
recommended	VBN	O
,	,	O
especially	RB	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
decreased	VBN	O
.	.	O

A	DT	O
multi-component	JJ	O
social	JJ	O
skills	NNS	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
:	:	O
the	DT	O
Junior	NNP	O
Detective	NNP	O
Training	NNP	O
Program	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
study	NN	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
a	DT	O
new	JJ	O
multi-component	JJ	O
social	JJ	O
skills	NNS	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
(	(	O
AS	IN	O
)	)	O
:	:	O
The	DT	O
Junior	NNP	O
Detective	NNP	O
Training	NNP	O
Program	NNP	O
.	.	O

This	DT	O
7-week	JJ	O
program	NN	O
included	VBD	O
a	DT	O
computer	NN	O
game	NN	O
,	,	O
small	JJ	O
group	NN	O
sessions	NNS	O
,	,	O
parent	NN	O
training	NN	O
sessions	NNS	O
and	CC	O
teacher	NN	O
handouts	NNS	O
.	.	O

METHOD	NNP	O
Forty-nine	JJ	O
children	NNS	O
with	IN	O
AS	NNP	O
were	VBD	O
recruited	VBN	O
to	TO	O
participate	VB	O
and	CC	O
randomly	VB	O
assigned	VBN	O
to	TO	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
or	CC	O
wait-list	JJ	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
23	CD	O
)	)	O
conditions	NNS	O
.	.	O

RESULTS	NNP	O
Relative	NNP	O
to	TO	O
children	NNS	O
in	IN	O
the	DT	O
wait-list	JJ	O
group	NN	O
,	,	O
program	NN	O
participants	NNS	O
showed	VBD	O
greater	JJR	O
improvements	NNS	Mental
in	IN	Mental
social	JJ	Mental
skills	NNS	Mental
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
parent-report	JJ	O
measures	NNS	O
.	.	O

Teacher-report	NNP	O
data	NNS	O
also	RB	O
confirmed	VBD	O
that	IN	O
children	NNS	O
receiving	VBG	O
the	DT	O
intervention	NN	O
made	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
social	JJ	Mental
functioning	NN	Mental
from	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
.	.	O

Treatment	NNP	O
group	NN	O
participants	NNS	O
were	VBD	O
better	RBR	O
able	JJ	O
to	TO	O
suggest	VB	O
appropriate	JJ	O
emotion-management	JJ	Mental
strategies	NNS	Mental
for	IN	O
story	NN	O
characters	NNS	O
at	IN	O
post-intervention	NN	O
than	IN	O
at	IN	O
pre-intervention	NN	O
,	,	O
whereas	NNS	O
control	VBP	O
participants	NNS	O
were	VBD	O
not	RB	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
improvements	NNS	O
made	VBN	O
by	IN	O
children	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
conditions	NNS	O
on	IN	O
facial	JJ	Mental
expression	NN	Mental
and	CC	O
body-posture	NN	Mental
recognition	NN	Mental
measures	NNS	Mental
.	.	O

Follow-up	NNP	O
data	NN	O
suggested	VBD	O
that	IN	O
treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
by	IN	O
children	NNS	O
at	IN	O
5-months	JJ	O
post-intervention	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Junior	NNP	O
Detective	NNP	O
Training	NNP	O
Program	NNP	O
appeared	VBD	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
the	DT	O
social	JJ	Mental
skills	NNS	Mental
and	CC	O
emotional	JJ	Mental
understanding	NN	Mental
of	IN	O
children	NNS	O
with	IN	O
AS	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
suggestions	NNS	O
for	IN	O
future	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Small-dose	JJ	O
selective	JJ	O
spinal	NN	O
anesthesia	NN	O
for	IN	O
short-duration	JJ	O
outpatient	JJ	O
laparoscopy	NN	O
:	:	O
recovery	NN	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
desflurane	NN	O
anesthesia	NN	O
.	.	O

UNLABELLED	IN	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
recovery	NN	O
characteristics	NNS	O
of	IN	O
selective	JJ	O
spinal	JJ	O
anesthesia	NN	O
(	(	O
SSA	NNP	O
)	)	O
and	CC	O
desflurane	JJ	O
anesthesia	NN	O
(	(	O
DES	NNP	O
)	)	O
in	IN	O
outpatient	JJ	O
gynecological	JJ	O
laparoscopy	NN	O
.	.	O

Twenty	NNP	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
patients	NNS	O
undergoing	VBG	O
gynecological	JJ	O
laparoscopy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
SSA	NNP	O
with	IN	O
lidocaine	JJ	O
10	CD	O
mg	NN	O
+	NNP	O
sufentanil	VBD	O
10	CD	O
microg	NN	O
or	CC	O
general	JJ	O
anesthesia	NN	O
with	IN	O
DES	NNP	O
and	CC	O
N	NNP	O
(	(	O
2	CD	O
)	)	O
O.	NNP	O
Intraoperative	NNP	Physical
conditions	NNS	Physical
,	,	Physical
recovery	NN	Physical
times	NNS	Physical
,	,	Physical
postanesthesia	JJ	Physical
recovery	NN	Physical
scores	NNS	Physical
,	,	Physical
and	CC	Physical
postoperative	JJ	Physical
outcomes	NNS	Physical
were	VBD	O
recorded	VBN	O
.	.	O

Intraoperative	JJ	O
conditions	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
SSA	NNP	O
group	NN	O
were	VBD	O
awake	RB	O
and	CC	O
oriented	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
,	,	O
whereas	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
DES	NNP	O
group	NN	O
required	VBD	O
7	CD	O
+/-	JJ	O
2	CD	O
min	NN	O
for	IN	O
extubation	NN	O
and	CC	O
orientation	NN	O
.	.	O

SSA	NNP	O
patients	NNS	O
had	VBD	O
a	DT	O
significantly	RB	O
shorter	JJR	Physical
time	NN	Physical
to	TO	Physical
straight	VB	Physical
leg	NN	Physical
raising	VBG	Physical
(	(	O
3	CD	O
+/-	JJ	O
1	CD	O
min	NN	O
versus	NN	O
9	CD	O
+/-	JJ	O
4	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
to	TO	O
ambulation	NN	Physical
(	(	O
3	CD	O
+/-	JJ	O
0.9	CD	O
min	NN	O
versus	NN	O
59	CD	O
+/-	JJ	O
16	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
DES	NNP	O
group	NN	O
.	.	O

SSA	NNP	O
patients	NNS	O
had	VBD	O
significantly	RB	O
less	RBR	O
postoperative	JJ	Pain
pain	NN	Pain
than	IN	O
DES	NNP	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

We	PRP	O
concluded	VBD	O
that	IN	O
SSA	NNP	O
was	VBD	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
DES	NNP	O
for	IN	O
outpatient	JJ	O
gynecological	JJ	O
laparoscopy	NN	O
.	.	O

IMPLICATIONS	NNP	O
This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
desflurane	NN	O
general	JJ	O
anesthetic	JJ	O
to	TO	O
a	DT	O
small-dose	JJ	O
spinal	JJ	O
anesthetic	NN	O
in	IN	O
ambulatory	JJ	O
gynecological	JJ	O
laparoscopy	NN	O
.	.	O

Using	VBG	O
the	DT	O
spinal	JJ	O
technique	NN	O
,	,	O
patients	NNS	O
can	MD	O
walk	VB	O
from	IN	O
the	DT	O
operating	NN	O
room	NN	O
table	NN	O
to	TO	O
a	DT	O
stretcher	NN	O
on	IN	O
completion	NN	O
of	IN	O
surgery	NN	O
.	.	O

Their	PRP$	O
recovery	NN	Others
time	NN	Others
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
desflurane	NN	O
group	NN	O
.	.	O

Design	NN	O
of	IN	O
the	DT	O
DEFINE	NNP	O
trial	NN	O
:	:	O
determining	VBG	O
the	DT	O
EFficacy	NNP	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
CETP	NNP	O
INhibition	NNP	O
with	IN	O
AnacEtrapib	NNP	O
.	.	O

BACKGROUND	NNP	O
Residual	NNP	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
risk	NN	O
often	RB	O
remains	VBZ	O
high	JJ	O
despite	IN	O
statin	JJ	O
therapy	NN	O
to	TO	O
lower	VB	O
low-density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
LDL-C	NNP	Physical
)	)	Physical
.	.	O

New	NNP	O
therapies	NNS	O
to	TO	O
raise	VB	O
high-density	NN	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
HDL-C	NNP	Physical
)	)	Physical
are	VBP	O
currently	RB	O
being	VBG	O
investigated	VBN	O
.	.	O

Anacetrapib	NNP	O
is	VBZ	O
a	DT	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
inhibitor	NN	O
that	WDT	O
raises	VBZ	O
HDL-C	NNP	O
and	CC	O
reduces	NNS	O
LDL-C	NNP	Physical
when	WRB	O
administered	VBN	O
alone	RB	O
or	CC	O
with	IN	O
a	DT	O
statin	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
on	IN	O
blood	NN	O
pressure	NN	O
,	,	O
electrolytes	VBZ	O
,	,	O
and	CC	O
aldosterone	NN	O
levels	NNS	O
,	,	O
seen	VBN	O
with	IN	O
another	DT	O
drug	NN	O
in	IN	O
this	DT	O
class	NN	O
,	,	O
have	VBP	O
not	RB	O
been	VBN	O
noted	VBN	O
in	IN	O
studies	NNS	O
of	IN	O
anacetrapib	NN	O
to	TO	O
date	NN	O
.	.	O

METHODS	NNP	O
Determining	VBG	O
the	DT	O
EFficacy	NNP	O
and	CC	O
Tolerability	NNP	O
of	IN	O
CETP	NNP	O
INhibition	NNP	O
with	IN	O
AnacEtrapib	NNP	O
(	(	O
DEFINE	NNP	O
)	)	O
is	VBZ	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
profile	NN	Others
of	IN	O
anacetrapib	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
or	CC	O
CHD	NNP	O
risk	NN	O
equivalents	NNS	O
(	(	O
clinical	JJ	O
trials.gov	NN	O
NCT00685776	NNP	O
)	)	O
.	.	O

Eligible	JJ	O
patients	NNS	O
at	IN	O
National	NNP	O
Cholesterol	NNP	O
Education	NNP	O
Program-Adult	NNP	O
Treatment	NNP	O
Panel	NNP	O
III	NNP	O
LDL-C	NNP	Physical
treatment	NN	O
goal	NN	O
on	IN	O
a	DT	O
statin	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
other	JJ	O
lipid-modifying	JJ	O
medications	NNS	O
,	,	O
are	VBP	O
treated	VBN	O
with	IN	O
anacetrapib	NN	O
,	,	O
100	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	O
for	IN	O
18	CD	O
months	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
3-month	JJ	O
,	,	O
poststudy	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
are	VBP	O
percent	JJ	Others
change	NN	Others
from	IN	Others
baseline	NN	Physical
in	IN	Physical
LDL-C	NNP	Physical
and	CC	O
the	DT	O
safety	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
anacetrapib	NN	O
.	.	O

Comprehensive	NNP	O
preplanned	VBD	O
interim	JJ	O
safety	NN	O
analyses	NNS	O
will	MD	O
be	VB	O
performed	VBN	O
at	IN	O
the	DT	O
6-	JJ	O
and	CC	O
12-month	JJ	O
time	NN	O
points	NNS	O
to	TO	O
examine	VB	O
treatment	NN	O
effects	NNS	O
on	IN	O
key	JJ	O
safety	NN	O
end	NN	O
points	NNS	O
,	,	O
including	VBG	O
blood	NN	Physical
pressure	NN	Physical
and	CC	O
electrolytes	NNS	Physical
.	.	O

A	DT	O
preplanned	JJ	O
Bayesian	JJ	O
analysis	NN	O
will	MD	O
be	VB	O
performed	VBN	O
to	TO	O
interpret	VB	O
the	DT	O
CV	NNP	O
event	NN	O
distribution	NN	O
,	,	O
given	VBN	O
the	DT	O
limited	JJ	O
number	NN	O
of	IN	O
events	NNS	O
expected	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,757	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
at	IN	O
153	CD	O
centers	NNS	O
in	IN	O
20	CD	O
countries	NNS	O
,	,	O
and	CC	O
1,623	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
the	DT	O
trial	NN	O
.	.	O

Lipid	JJ	Physical
results	NNS	Physical
,	,	O
clinical	JJ	Physical
CV	NNP	Physical
events	NNS	Physical
,	,	O
and	CC	O
safety	NN	Others
outcomes	RB	Others
from	IN	O
this	DT	O
trial	NN	O
are	VBP	O
anticipated	VBN	O
in	IN	O
2010	CD	O
.	.	O

Placebo-controlled	JJ	O
pilot	NN	O
trial	NN	O
of	IN	O
mecamylamine	NN	O
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	Mental
spectrum	NN	Mental
disorders	NNS	Mental
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
possible	JJ	O
benefits	NNS	O
of	IN	O
a	DT	O
nicotinic	JJ	O
acetylcholine	NN	O
receptor	NN	O
(	(	O
nAChR	JJ	O
)	)	O
agent	NN	O
for	IN	O
autistic	JJ	Mental
symptoms	NNS	Mental
based	VBN	O
on	IN	O
postmortem	NN	O
observation	NN	O
of	IN	O
nAChR	JJ	O
abnormalities	NNS	O
(	(	O
deficient	JJ	O
?4?2	NN	O
nAChRs	NN	O
,	,	O
excess	JJ	O
?7	NNP	O
nAChRs	NN	O
)	)	O
in	IN	O
brains	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Mecamylamine	NNP	O
,	,	O
because	IN	O
of	IN	O
its	PRP$	O
safety	NN	O
record	NN	O
in	IN	O
children	NNS	O
with	IN	O
other	JJ	O
disorders	NNS	O
,	,	O
was	VBD	O
chosen	VBN	O
for	IN	O
this	DT	O
first	JJ	O
exploration	NN	O
.	.	O

Twenty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
age	NN	O
4-12	CD	O
years	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
14	CD	O
weeks	NNS	O
to	TO	O
placebo	VB	O
(	(	O
n=8	NN	O
)	)	O
or	CC	O
mecamylamine	NN	O
(	(	O
n=12	JJ	O
)	)	O
in	IN	O
ascending	VBG	O
fixed	JJ	O
doses	NNS	O
:	:	O
0.5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
2.5	CD	O
mg	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
then	RB	O
5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Improvement	NNP	O
was	VBD	O
rated	VBN	O
by	IN	O
a	DT	O
blinded	JJ	O
independent	JJ	O
evaluator	NN	O
.	.	O

Because	IN	O
of	IN	O
small	JJ	O
sample	NN	O
,	,	O
data	NNS	O
analysis	NN	O
was	VBD	O
descriptive	JJ	O
.	.	O

RESULTS	NNP	O
Eighteen	JJ	O
participants	NNS	O
(	(	O
10	CD	O
mecamylamine	NN	O
,	,	O
8	CD	O
placebo	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
doses	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
the	DT	O
only	JJ	O
side	NN	O
effect	NN	O
of	IN	O
note	NN	O
was	VBD	O
constipation	NN	Adverseeffect
(	(	O
50	CD	O
%	NN	O
compared	VBN	O
with	IN	O
25	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

Three	CD	O
children	NNS	O
had	VBD	O
clinically	RB	O
nonsignificant	JJ	O
electrocardiographic	JJ	O
QT	NNP	O
prolongation	NN	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
modest	JJ	O
to	TO	O
moderate	VB	O
improvement	NN	O
,	,	O
but	CC	O
differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
negligible	JJ	O
.	.	O

On	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
the	DT	O
Ohio	NNP	Mental
Autism	NNP	Mental
Clinical	NNP	Mental
Impressions	NNP	Mental
Scale	NNP	Mental
,	,	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
showed	VBD	O
improvement	NN	O
at	IN	O
some	DT	O
point	NN	O
(	(	O
but	CC	O
only	RB	O
40	CD	O
%	NN	O
sustained	VBD	O
it	PRP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
62	CD	O
%	NN	O
on	IN	O
placebo	NN	O
.	.	O

Of	IN	O
the	DT	O
four	CD	O
in	IN	O
active	JJ	O
treatment	NN	O
that	WDT	O
sustained	VBD	O
improvement	NN	O
,	,	O
three	CD	O
had	VBD	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
0.13-0.15	JJ	O
mg/kg/day	NN	O
,	,	O
while	IN	O
those	DT	O
who	WP	O
regressed	VBD	O
had	VBD	O
doses	NNS	O
?0.18	JJ	O
mg/kg/day	NN	O
.	.	O

Graphed	VBN	O
means	NNS	O
suggested	VBD	O
better	RBR	O
outcome	NN	O
with	IN	O
lower	JJR	O
mg/kg	NN	O
and	CC	O
longer	JJR	O
medication	NN	O
duration	NN	O
.	.	O

Four	CD	O
parents	NNS	O
spontaneously	RB	O
reported	VBD	O
reduced	JJ	O
hyperactivity	NN	Mental
and	CC	Mental
irritability	NN	Mental
and	CC	O
better	JJR	O
verbalization	NN	Mental
and	CC	O
continued	JJ	O
mecamylamine	NN	O
at	IN	O
their	PRP$	O
own	JJ	O
expense	NN	O
.	.	O

CONCLUSION	NNP	O
Mecamylamine	NNP	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
but	CC	O
not	RB	O
very	RB	O
effective	JJ	O
in	IN	O
autism	NN	O
.	.	O

The	DT	O
suggestion	NN	O
of	IN	O
better	JJR	O
results	NNS	O
at	IN	O
lower	JJR	O
doses	NNS	O
and	CC	O
longer	JJR	O
exposure	NN	O
warrants	NNS	O
consideration	NN	O
for	IN	O
future	JJ	O
trials	NNS	O
.	.	O

The	DT	O
next	JJ	O
step	NN	O
would	MD	O
be	VB	O
exploration	NN	O
of	IN	O
a	DT	O
more	RBR	O
specific	JJ	O
?4?2	NNP	O
nAChR	JJ	O
agonist	NN	O
,	,	O
such	JJ	O
as	IN	O
varenicline	NN	O
.	.	O

Naltrexone	NN	O
,	,	O
an	DT	O
opiate	JJ	O
antagonist	NN	O
,	,	O
fails	VBZ	O
to	TO	O
modify	VB	O
motor	NN	Physical
symptoms	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

One	CD	O
month	NN	O
of	IN	O
adjunct	JJ	O
treatment	NN	O
with	IN	O
naltrexone	NN	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
was	VBD	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
design	NN	O
in	IN	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

The	DT	O
first	JJ	O
group	NN	O
was	VBD	O
composed	VBN	O
of	IN	O
10	CD	O
patients	NNS	O
with	IN	O
a	DT	O
moderate	JJ	O
motor	NN	Physical
impairment	NN	Physical
insufficiently	RB	O
controlled	VBN	O
by	IN	O
monotherapy	NN	O
with	IN	O
bromocriptine	NN	O
.	.	O

The	DT	O
second	JJ	O
group	NN	O
was	VBD	O
composed	VBN	O
of	IN	O
eight	CD	O
patients	NNS	O
with	IN	O
L-dopa-induced	JJ	O
peak-dose	JJ	O
dyskinesia	NN	O
.	.	O

Naltrexone	CC	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
did	VBD	O
not	RB	O
demonstrate	VB	O
any	DT	O
significant	JJ	O
change	NN	O
in	IN	O
motor	NN	Physical
function	NN	Physical
in	IN	O
either	DT	O
group	NN	O
.	.	O

These	DT	O
negative	JJ	O
clinical	JJ	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
a	DT	O
significant	JJ	O
role	NN	O
of	IN	O
endogenous	JJ	O
opioid	JJ	O
systems	NNS	O
in	IN	O
the	DT	O
pathophysiology	NN	O
of	IN	O
motor	NN	Physical
impairment	NN	Physical
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Nasal	NNP	Physical
eosinophilia	NNS	Physical
and	CC	O
serum	NN	Physical
soluble	JJ	Physical
intercellular	JJ	Physical
adhesion	NN	Physical
molecule	NN	Physical
1	CD	Physical
in	IN	O
patients	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
treated	VBN	O
with	IN	O
montelukast	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
desloratadine	NN	O
or	CC	O
levocetirizine	NN	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule	NN	O
(	(	O
ICAM	NNP	O
)	)	O
1	CD	O
and	CC	O
recruitment	NN	O
of	IN	O
eosinophils	NNS	O
are	VBP	O
crucial	JJ	O
in	IN	O
supporting	VBG	O
allergic	JJ	O
inflammation	NN	O
,	,	O
their	PRP$	O
down-regulation	NN	O
may	MD	O
bring	VB	O
additional	JJ	O
benefits	NNS	O
in	IN	O
patients	NNS	O
'	POS	O
recovery	NN	O
.	.	O

We	PRP	O
have	VBP	O
assessed	VBN	O
nasal	JJ	Physical
eosinophilia	NNS	Physical
and	CC	O
serum	NN	Physical
soluble	JJ	Physical
ICAM-1	NNP	Physical
(	(	Physical
sICAM-1	JJ	Physical
)	)	Physical
concentrations	NNS	Physical
in	IN	O
relation	NN	O
to	TO	O
nasal	VB	Physical
symptoms	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
persistent	JJ	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
AR	NNP	O
)	)	O
treated	VBD	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
either	DT	O
desloratadine	NN	O
,	,	O
levocetirizine	NN	O
,	,	O
montelukast	NN	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
single-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
,	,	O
two-arm	JJ	O
study	NN	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
persistent	JJ	O
AR	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
montelukast	NN	O
and/or	JJ	O
levocetirizine	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
montelukast	NN	O
and/or	JJ	O
desloratadine	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
.	.	O

Nasal	NNP	Physical
eosinophilia	JJ	Physical
and	CC	O
concentration	NN	Physical
of	IN	Physical
sICAM-1	NN	Physical
in	IN	Physical
peripheral	JJ	Physical
blood	NN	Physical
were	VBD	O
assessed	VBN	O
before	RB	O
and	CC	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
active	JJ	O
treatments	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
of	IN	O
the	DT	O
study	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
decrease	NN	O
of	IN	O
sICAM-1	JJ	Physical
and	CC	O
nasal	JJ	Physical
eosinophilia	NN	Physical
,	,	O
which	WDT	O
correlated	VBD	O
with	IN	O
the	DT	O
severity	NN	Physical
of	IN	Physical
nasal	NN	Physical
symptoms	NNS	Physical
.	.	O

In	IN	O
the	DT	O
montelukast/levocetirizine	NN	O
arm	NN	O
,	,	O
montelukast	NN	O
decreased	VBD	O
nasal	JJ	Physical
eosinophilia	RB	Physical
more	RBR	O
significantly	RB	O
than	IN	O
levocetirizine	NN	O
,	,	O
whereas	NNS	O
in	IN	O
reduction	NN	O
of	IN	O
sICAM-1	JJ	Physical
all	DT	O
active	JJ	O
treatment	NN	O
options	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
desloratadine/montelukast	NN	O
arm	NN	O
,	,	O
the	DT	O
resulting	VBG	O
improvement	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
of	IN	O
sICAM-1	NN	Physical
and	CC	O
the	DT	O
influx	NN	Physical
of	IN	Physical
eosinophils	NNS	Physical
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	VB	O
The	DT	O
improvement	NN	O
of	IN	O
nasal	NN	Physical
symptoms	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
AR	NNP	O
treated	VBD	O
with	IN	O
antihistamines	NNS	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
montelukast	JJS	O
,	,	O
may	MD	O
additionally	RB	O
result	VB	O
from	IN	O
the	DT	O
reduction	NN	O
of	IN	O
sICAM-1	NN	Physical
and	CC	O
nasal	JJ	Physical
eosinophilia	NN	Physical
.	.	O

Because	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
may	MD	O
bring	VB	O
inconclusive	JJ	O
benefits	NNS	O
in	IN	O
this	DT	O
area	NN	O
there	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
need	NN	O
of	IN	O
further	JJ	O
studies	NNS	O
to	TO	O
find	VB	O
mechanisms	NN	O
that	IN	O
favor	NN	O
combination	NN	O
therapy	NN	O
.	.	O

Does	VBZ	O
a	DT	O
first	JJ	O
trimester	NN	O
dating	VBG	O
scan	JJ	O
using	VBG	O
crown	JJ	O
rump	NN	O
length	NN	O
measurement	NN	O
reduce	VB	O
the	DT	O
rate	NN	Physical
of	IN	Physical
induction	NN	Physical
of	IN	Physical
labour	NN	Physical
for	IN	O
prolonged	JJ	Physical
pregnancy	NN	Physical
?	.	O
An	DT	O
uncompleted	JJ	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
463	CD	O
women	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	IN	O
dating	VBG	O
scan	JJ	O
on	IN	O
the	DT	O
rate	NN	Others
of	IN	Others
induction	NN	Physical
of	IN	Physical
labour	NN	Physical
for	IN	O
prolonged	JJ	Physical
pregnancy	NN	Physical
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
to	TO	O
include	VB	O
400	CD	O
women	NNS	O
in	IN	O
each	DT	O
arm	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

SETTING	NN	O
Participating	VBG	O
general	JJ	O
practices	NNS	O
and	CC	O
a	DT	O
district	NN	O
general	JJ	O
teaching	NN	O
hospital	NN	O
.	.	O

POPULATION	NNP	O
Women	NNP	O
attending	VBG	O
their	PRP$	O
general	JJ	O
practitioner	NN	O
in	IN	O
the	DT	O
first	JJ	O
trimester	NN	O
to	TO	O
confirm	VB	O
pregnancy	NN	O
,	,	O
in	IN	O
whom	WP	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	JJ	O
scan	NN	O
was	VBD	O
not	RB	O
indicated	VBN	O
.	.	O

METHODS	NNP	O
Women	NNP	O
randomised	VBD	O
to	TO	O
the	DT	O
study	NN	O
group	NN	O
(	(	O
scan	JJ	O
group	NN	O
)	)	O
underwent	VBD	O
an	DT	O
ultrasound	JJ	O
dating	NN	O
scan	NN	O
between	IN	O
8	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
,	,	O
measuring	VBG	O
crown-rump	JJ	O
length	NN	O
.	.	O

The	DT	O
estimated	JJ	O
date	NN	O
of	IN	O
delivery	NN	O
(	(	O
EDD	NNP	O
)	)	O
was	VBD	O
changed	VBN	O
if	IN	O
there	EX	O
was	VBD	O
a	DT	O
discrepancy	NN	O
of	IN	O
more	JJR	O
than	IN	O
5	CD	O
days	NNS	O
from	IN	O
the	DT	O
gestation	NN	O
,	,	O
calculated	VBN	O
from	IN	O
the	DT	O
last	JJ	O
menstrual	JJ	O
period	NN	O
(	(	O
LMP	NNP	O
)	)	O
.	.	O

For	IN	O
the	DT	O
remaining	VBG	O
women	NNS	O
(	(	O
no-scan	JJ	O
group	NN	O
)	)	O
,	,	O
gestation	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
the	DT	O
LMP	NNP	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	Others
rate	NN	Others
of	IN	Others
induction	NN	Physical
of	IN	Physical
labour	NN	Physical
for	IN	Others
prolonged	JJ	Physical
pregnancy	NN	Physical
.	.	O

RESULTS	NNP	O
Due	NNP	O
to	TO	O
circumstances	NNS	O
beyond	IN	O
the	DT	O
researchers	NNS	O
'	POS	O
control	NN	O
,	,	O
recruitment	NN	O
was	VBD	O
abandoned	VBN	O
when	WRB	O
463	CD	O
women	NNS	O
had	VBD	O
been	VBN	O
enrolled	VBN	O
.	.	O

The	DT	O
EDD	NNP	O
was	VBD	O
adjusted	VBN	O
in	IN	O
13	CD	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
women	NNS	O
in	IN	O
the	DT	O
scan	JJ	O
group	NN	O
and	CC	O
in	IN	O
2	CD	O
(	(	O
0.9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
no-scan	JJ	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	Physical
of	IN	Physical
induction	NN	Physical
for	IN	O
prolonged	JJ	Physical
pregnancy	NN	Physical
between	IN	O
the	DT	O
scan	JJ	O
(	(	O
19	CD	O
[	RB	O
8.2	CD	O
%	NN	O
]	NN	O
)	)	O
and	CC	O
the	DT	O
no-scan	JJ	O
(	(	O
17	CD	O
[	RB	O
7.4	CD	O
%	NN	O
]	NN	O
)	)	O
groups	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
1.10	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.59-2.07	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Acknowledging	VBG	O
the	DT	O
reduced	JJ	O
numbers	NNS	O
recruited	VBN	O
for	IN	O
study	NN	O
,	,	O
it	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
that	IN	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	IN	O
dating	VBG	O
scan	JJ	O
reduces	NNS	O
the	DT	O
rate	NN	Others
of	IN	Others
induction	NN	Others
of	IN	Others
labour	NN	Others
for	IN	O
prolonged	JJ	Physical
pregnancy	NN	Physical
and	CC	O
may	MD	O
result	VB	O
in	IN	O
a	DT	O
more	RBR	O
expensive	JJ	O
healthcare	NN	O
strategy	NN	O
.	.	O

Analysis	NN	O
of	IN	O
multiple-dose	JJ	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

In	IN	O
multiple-dose	JJ	O
bioequivalence	NN	O
studies	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
at	IN	O
steady	JJ	O
state	NN	O
to	TO	O
take	VB	O
repeated	JJ	O
measurements	NNS	O
of	IN	O
pharmacokinetic	JJ	Others
variables	NNS	Others
,	,	O
such	JJ	O
as	IN	O
area	NN	Others
under	IN	Others
the	DT	Others
curve	NN	Others
(	(	Others
AUC	NNP	Others
)	)	Others
and	CC	O
the	DT	O
maximum	JJ	Others
concentration	NN	Others
(	(	Others
CMAX	NNP	Others
)	)	Others
of	IN	O
the	DT	O
blood	NN	O
concentration-time	NN	O
profile	NN	O
,	,	O
within	IN	O
each	DT	O
period	NN	O
of	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

We	PRP	O
develop	VBP	O
a	DT	O
bivariate	NN	Physical
random	NN	Physical
effects	NNS	Physical
model	NN	Physical
for	IN	O
such	JJ	O
a	DT	O
situation	NN	O
in	IN	O
a	DT	O
2	CD	O
x	NN	O
2	CD	O
crossover	NN	O
design	NN	O
using	VBG	O
the	DT	O
natural	JJ	Others
log	NN	Others
scale	NN	Others
for	IN	Others
AUC	NNP	Others
and	CC	Others
CMAX	NNP	Others
that	WDT	O
assumes	VBZ	O
no	DT	O
differential	JJ	O
carryover	NN	O
effects	NNS	O
and	CC	O
includes	VBZ	O
components	NNS	O
for	IN	O
inter-	JJ	O
and	CC	O
intrasubject	JJ	O
variability	NN	O
with	IN	O
respect	NN	O
to	TO	O
both	DT	O
formulations	NNS	O
.	.	O

We	PRP	O
derive	VBP	O
the	DT	O
uniformly	JJ	O
minimum	JJ	O
variance	NN	O
unbiased	JJ	O
estimators	NNS	O
,	,	O
which	WDT	O
also	RB	O
happen	VBP	O
to	TO	O
be	VB	O
restricted	VBN	O
maximum	JJ	O
likelihood	NN	O
estimators	NNS	O
,	,	O
and	CC	O
we	PRP	O
provide	VBP	O
a	DT	O
sample	NN	O
size	NN	O
formula	NN	O
.	.	O

[	JJ	O
Complaints	NNS	O
in	IN	O
the	DT	O
postoperative	JJ	O
phase	NN	O
related	VBN	O
to	TO	O
anesthetics	NNS	O
]	NNP	O
.	.	O

In	IN	O
two	CD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
studies	NNS	O
the	DT	O
frequency	NN	Adverseeffect
of	IN	Adverseeffect
headache	NN	Adverseeffect
,	,	Adverseeffect
nausea	NN	Adverseeffect
,	,	Adverseeffect
vomiting	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
analgesic	JJ	Adverseeffect
requirement	NN	Adverseeffect
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
h	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
order	NN	O
to	TO	O
study	VB	O
differences	NNS	O
between	IN	O
the	DT	O
sexes	NNS	O
and	CC	O
the	DT	O
inhalation	NN	O
anesthetics	NNS	O
halothane	NN	O
,	,	O
enflurane	NN	O
,	,	O
isoflurane	NN	O
,	,	O
or	CC	O
balanced	VBD	O
anesthesia	NNS	O
with	IN	O
enflurane/alfentanil	NN	O
.	.	O

Nausea	NN	Adverseeffect
and	CC	Adverseeffect
vomiting	NN	Adverseeffect
were	VBD	O
more	RBR	O
frequent	JJ	O
after	IN	O
enflurane	NN	O
than	IN	O
after	IN	O
halothane	NN	O
or	CC	O
isoflurane	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
anesthetics	NNS	O
and	CC	O
frequency	NN	Adverseeffect
of	IN	Adverseeffect
headache	NN	Adverseeffect
,	,	O
but	CC	O
there	EX	O
were	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
postoperative	JJ	Others
analgesic	NN	Others
requirements	NNS	Others
which	WDT	O
were	VBD	O
highest	JJS	O
after	IN	O
halothane	NN	O
and	CC	O
lowest	JJS	O
after	IN	O
isoflurane	NN	O
.	.	O

Postoperative	JJ	Adverseeffect
complaints	NNS	Adverseeffect
were	VBD	O
always	RB	O
significantly	RB	O
greater	JJR	O
among	IN	O
women	NNS	O
than	IN	O
among	IN	O
men	NNS	O
.	.	O

The	DT	O
second	JJ	O
study	NN	O
indicated	VBD	O
that	IN	O
balanced	VBD	O
anesthesia	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
analgesic	JJ	Others
requirement	NN	Others
compared	VBN	O
to	TO	O
enflurane	VB	O
without	IN	O
alfentanil	NN	O
,	,	O
but	CC	O
lead	VBP	O
to	TO	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
vomiting	VBG	Adverseeffect
.	.	O

After	IN	O
premedication	NN	O
with	IN	O
flunitrazepam	NN	O
and	CC	O
atropine	NN	O
and	CC	O
combined	VBN	O
with	IN	O
70	CD	O
%	NN	O
N2O/30	NNP	O
%	NN	O
O2	NNP	O
,	,	O
isoflurane	NN	O
was	VBD	O
the	DT	O
most	RBS	O
favorable	JJ	O
anesthetic	JJ	O
agent	NN	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
parameters	NNS	O
studied	VBN	O
.	.	O

Balanced	NNP	O
anesthesia	NN	O
with	IN	O
enflurane/alfentanil	NN	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
advantages	NNS	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
postoperative	JJ	O
phase	NN	O
under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
.	.	O

Absence	NN	O
of	IN	O
central	JJ	Physical
effects	NNS	Physical
in	IN	O
man	NN	O
of	IN	O
the	DT	O
benzodiazepine	JJ	O
antagonist	NN	O
Ro	NNP	O
15-1788	JJ	O
.	.	O

The	DT	O
benzodiazepines	NNS	O
are	VBP	O
typified	VBN	O
by	IN	O
a	DT	O
profile	NN	O
of	IN	O
side	NN	O
effects	NNS	O
which	WDT	O
includes	VBZ	O
drowsiness	NN	Physical
,	,	O
ataxia	NN	Physical
and	CC	O
incoordination	NN	Physical
.	.	O

Ro	NNP	O
15-1788	JJ	O
,	,	O
an	DT	O
imidazodiazepine	JJ	O
derivative	NN	O
,	,	O
exhibits	VBZ	O
marked	JJ	O
antagonism	NN	O
of	IN	O
the	DT	O
behavioural	JJ	O
and	CC	O
biochemical	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
benzodiazepines	NNS	O
in	IN	O
animals	NNS	O
and	CC	O
man	NN	O
.	.	O

It	PRP	O
is	VBZ	O
devoid	JJ	O
of	IN	O
any	DT	O
behavioural	JJ	O
activity	NN	O
in	IN	O
animals	NNS	O
,	,	O
except	IN	O
at	IN	O
very	RB	O
high	JJ	O
doses	NNS	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
the	DT	O
effects	NNS	O
of	IN	O
single	JJ	O
rising	VBG	O
oral	JJ	O
doses	NNS	O
of	IN	O
Ro	NNP	O
15-1788	JJ	O
on	IN	O
cognitive	NN	Mental
,	,	O
psychomotor	NN	Mental
and	CC	O
subjective	JJ	Mental
function	NN	Mental
in	IN	O
man	NN	O
have	VBP	O
been	VBN	O
assessed	VBN	O
using	VBG	O
a	DT	O
battery	NN	O
of	IN	O
psychometric	JJ	Mental
tests	NNS	Mental
designed	VBN	O
to	TO	O
identify	VB	O
the	DT	O
sedative	JJ	Mental
action	NN	Mental
of	IN	O
the	DT	O
benzodiazepines	NNS	O
.	.	O

At	IN	O
all	DT	O
doses	VBZ	O
up	RP	O
to	TO	O
600	CD	O
mg	NNS	O
,	,	O
Ro	NNP	O
15-1788	CD	O
demonstrated	VBD	O
none	NN	O
of	IN	O
the	DT	O
classical	JJ	O
behavioural	JJ	Mental
effects	NNS	Mental
of	IN	O
the	DT	O
benzodiazepines	NNS	O
.	.	O

The	DT	O
home	NN	O
TEACCHing	NNP	O
program	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
a	DT	O
parent	NN	O
training	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
based	VBN	O
on	IN	O
the	DT	O
TEACCH	NNP	O
model	NN	O
.	.	O

Twenty	JJ	O
families	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
or	CC	O
waitlist	NN	O
group	NN	O
.	.	O

All	DT	O
families	NNS	O
were	VBD	O
compared	VBN	O
at	IN	O
pre-	JJ	O
and	CC	O
post-treatment	JJ	O
on	IN	O
formal	JJ	O
dependent	NN	O
measures	NNS	O
.	.	O

Direct	JJ	O
measures	NNS	Mental
of	IN	Mental
behavior	NN	Mental
were	VBD	O
compared	VBN	O
across	IN	O
six	CD	O
matched	VBD	O
pairs	NNS	O
using	VBG	O
a	DT	O
multiple	JJ	O
baseline	NN	O
probe	NN	O
design	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
multiple	JJ	O
baseline	NN	O
design	NN	O
showed	VBD	O
robust	JJ	O
support	NN	O
for	IN	O
improvement	NN	Physical
in	IN	Physical
child	NN	Physical
and	CC	Physical
parent	NN	Physical
behavior	NN	Physical
.	.	Physical

Due	NNP	O
to	TO	O
the	DT	O
sample	NN	O
size	NN	O
and	CC	O
short	JJ	O
time	NN	O
frame	NN	O
,	,	O
results	NNS	O
of	IN	O
a	DT	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
did	VBD	O
not	RB	O
reach	VB	O
significance	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
calcium	NN	O
supplementation	NN	O
on	IN	O
bone	NN	O
density	NN	O
in	IN	O
premenarcheal	JJ	O
females	NNS	O
:	:	O
a	DT	O
co-twin	JJ	O
approach	NN	O
.	.	O

The	DT	O
age	NN	O
and	CC	O
developmental	JJ	O
stage	NN	O
at	IN	O
which	WDT	O
calcium	NN	O
supplementation	NN	O
produces	VBZ	O
the	DT	O
greatest	JJS	O
bone	NN	O
effects	NNS	O
remain	VBP	O
controversial	JJ	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
calcium	NN	O
supplementation	NN	O
may	MD	O
improve	VB	O
bone	NN	Physical
accrual	JJ	Physical
in	IN	O
premenarcheal	JJ	O
females	NNS	O
.	.	O

Fifty-one	CD	O
pairs	NNS	O
of	IN	O
premenarcheal	JJ	O
female	NN	O
twins	NNS	O
(	(	O
27	CD	O
monozygotic	NN	O
and	CC	O
24	CD	O
dizygotic	JJ	O
;	:	O
mean	JJ	O
+/-	JJ	O
sd	NN	O
age	NN	O
,	,	O
10.3	CD	O
+/-	JJ	O
1.5	CD	O
yr	NN	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
with	IN	O
one	CD	O
twin	NN	O
of	IN	O
each	DT	O
pair	NN	O
receiving	VBG	O
a	DT	O
1200-mg	JJ	O
calcium	NN	O
carbonate	NN	O
(	(	O
Caltrate	NNP	O
)	)	O
supplement	NN	O
.	.	O

Areal	NNP	Physical
bone	JJ	Physical
mineral	NN	Physical
density	NN	Physical
(	(	Physical
aBMD	NN	Physical
)	)	Physical
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
,	,	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
within-pair	JJ	O
differences	NNS	O
in	IN	O
height	NN	O
,	,	O
weight	NN	O
,	,	O
or	CC	O
calcium	NN	O
intake	NN	O
at	IN	O
baseline	NN	O
.	.	O

Calcium	NNP	O
supplementation	NN	O
was	VBD	O
associated	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
increased	VBN	O
aBMD	NNS	Physical
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
adjusted	VBN	O
for	IN	O
age	NN	O
,	,	O
height	NN	O
,	,	O
and	CC	O
weight	NN	O
at	IN	O
the	DT	O
following	JJ	O
time	NN	O
points	NNS	O
from	IN	O
baseline	NN	O
:	:	O
total	JJ	O
hip	NN	O
,	,	O
6	CD	O
months	NNS	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
1.6	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
(	(	O
2.4	CD	O
%	NN	O
)	)	O
;	:	O
lumbar	CC	O
spine	NN	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
1.0	CD	O
%	NN	O
)	)	O
;	:	O
femoral	JJ	O
neck	NN	O
,	,	O
6	CD	O
months	NNS	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
.	.	O

Adjusted	VBN	Physical
total	JJ	Physical
body	NN	Physical
bone	JJ	Physical
mineral	JJ	Physical
content	NN	Physical
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
calcium	NN	O
group	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
2.0	CD	O
%	NN	O
)	)	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
2.5	CD	O
%	NN	O
)	)	O
,	,	O
18	CD	O
months	NNS	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
24	CD	O
months	NNS	O
(	(	O
3.7	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Calcium	NNP	O
supplementation	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
increasing	VBG	O
aBMD	NN	Physical
at	IN	O
regional	JJ	O
sites	NNS	O
over	IN	O
the	DT	O
first	JJ	O
12-18	JJ	O
months	NNS	O
,	,	O
but	CC	O
these	DT	O
gains	NNS	O
were	VBD	O
not	RB	O
maintained	VBN	O
to	TO	O
24	CD	O
months	NNS	O
.	.	O

Differential	JJ	O
effects	NNS	O
on	IN	O
bone	NN	Physical
density	NN	Physical
of	IN	O
progestogen-only	JJ	O
methods	NNS	O
for	IN	O
contraception	NN	O
in	IN	O
premenopausal	JJ	O
women	NNS	O
.	.	O

The	DT	O
question	NN	O
of	IN	O
differential	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
density	NN	O
by	IN	O
two	CD	O
different	JJ	O
types	NNS	O
of	IN	O
progestogen-only	JJ	O
methods	NNS	O
for	IN	O
contraception	NN	O
in	IN	O
premenopausal	JJ	O
women	NNS	O
was	VBD	O
addressed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
among	IN	O
22	CD	O
premenopausal	JJ	O
women	NNS	O
,	,	O
age	NN	O
32.6	CD	O
(	(	O
range	JJ	O
20-45	CD	O
years	NNS	O
)	)	O
,	,	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
of	IN	O
two	CD	O
treatments	NNS	O
with	IN	O
continuous	JJ	O
progestogens	NNS	O
for	IN	O
contraception	NN	O
were	VBD	O
analyzed	VBN	O
;	:	O
depot-medroxyprogesterone	JJ	O
acetate	NN	O
(	(	O
DMPA	NNP	O
)	)	O
or	CC	O
continuous	JJ	O
levonorgestrel	NN	O
treatment	NN	O
with	IN	O
subdermal	JJ	O
implants	NNS	O
(	(	O
Norplant	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Forearm	NNP	Physical
bone	NN	Physical
density	NN	Physical
(	(	Physical
BMDprox	NNP	Physical
)	)	Physical
increased	VBD	O
with	IN	O
2.94	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
in	IN	O
women	NNS	O
who	WP	O
were	VBD	O
prescribed	VBN	O
levonorgestrel	NN	O
,	,	O
which	WDT	O
was	VBD	O
in	IN	O
contrast	NN	O
to	TO	O
stable	JJ	O
values	NNS	O
in	IN	O
those	DT	O
prescribed	JJ	O
depot-medroxy-progesterone	JJ	O
acetate	NN	O
;	:	O
group	NN	O
difference	NN	O
at	IN	O
6	CD	O
months	NNS	O
for	IN	O
BMDprox	NNP	Physical
3.4	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.3	CD	O
,	,	O
5.5	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.025	CD	O
)	)	O
and	CC	O
BMDdist	$	Physical
4.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-	:	O
1.3	CD	O
,	,	O
9.6	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.077	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
bone	NN	Physical
density	NN	Physical
were	VBD	O
consistent	JJ	O
with	IN	O
the	DT	O
changes	NNS	O
in	IN	O
biochemical	JJ	Physical
indices	NNS	Physical
for	IN	Physical
bone	NN	Physical
metabolism	NN	Physical
;	:	O
DMPA	NNP	O
users	NNS	O
showed	VBD	O
signs	NNS	O
of	IN	O
increased	VBN	O
bone	NN	Physical
turnover	NN	Physical
and	CC	O
users	NNS	O
of	IN	O
levonorgestrel	NN	O
showed	VBD	O
increased	JJ	Physical
bone	NN	Physical
formation	NN	Physical
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
both	DT	O
alkaline	JJ	O
phosphatase	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
osteocalcin	$	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
an	DT	O
increase	NN	O
in	IN	O
bone	JJ	Physical
density	NN	Physical
during	IN	O
treatment	NN	O
with	IN	O
levonorgestrel	NN	O
and	CC	O
stable	JJ	O
values	NNS	O
during	IN	O
short-term	JJ	O
administration	NN	O
of	IN	O
DMPA	NNP	O
,	,	O
in	IN	O
standard	JJ	O
clinical	JJ	O
doses	NNS	O
for	IN	O
contraception	NN	O
.	.	O

A	DT	O
controlled	VBN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
supplement	NN	O
of	IN	O
cocoa	NN	O
husk	NN	O
that	WDT	O
is	VBZ	O
rich	JJ	O
in	IN	O
dietary	JJ	O
fiber	NN	O
on	IN	O
colonic	JJ	Physical
transit	NN	Physical
in	IN	O
constipated	JJ	O
pediatric	JJ	O
patients	NNS	O
.	.	O

OBJECTIVE	NNP	O
Although	IN	O
a	DT	O
diet	JJ	O
that	WDT	O
is	VBZ	O
rich	JJ	O
in	IN	O
fiber	NN	O
is	VBZ	O
widely	RB	O
recommended	VBN	O
for	IN	O
preventing	VBG	O
and	CC	O
treating	VBG	O
constipation	NN	O
,	,	O
the	DT	O
efficacy	NN	O
of	IN	O
fiber	NN	O
supplements	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
tested	VBN	O
sufficiently	RB	O
in	IN	O
children	NNS	O
.	.	O

Our	PRP$	O
aim	NN	O
with	IN	O
this	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
if	IN	O
fiber	JJ	O
supplementation	NN	O
is	VBZ	O
beneficial	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
idiopathic	JJ	Physical
chronic	JJ	Physical
constipation	NN	Physical
.	.	O

METHODS	NNP	O
Using	VBG	O
a	DT	O
parallel	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
an	DT	O
interventional	JJ	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
supplement	NN	O
of	IN	O
cocoa	NN	O
husk	NN	O
rich	JJ	O
in	IN	O
dietary	JJ	O
fiber	NN	O
on	IN	O
intestinal	JJ	O
transit	NN	O
time	NN	O
and	CC	O
other	JJ	O
indices	NNS	O
of	IN	O
constipation	NN	Physical
in	IN	O
children	NNS	O
with	IN	O
constipation	NN	O
.	.	O

After	IN	O
screening	VBG	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
,	,	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
4	CD	O
weeks	NNS	O
,	,	O
either	CC	O
a	DT	O
cocoa	NN	O
husk	NN	O
supplement	NN	O
or	CC	O
placebo	NN	O
plus	CC	O
standardized	JJ	O
toilet	NN	O
training	NN	O
procedures	NNS	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
we	PRP	O
(	(	O
1	CD	O
)	)	O
performed	VBD	O
anthropometry	NN	O
,	,	O
a	DT	O
physical	JJ	O
examination	NN	O
,	,	O
and	CC	O
routine	JJ	O
laboratory	NN	O
measurements	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
determined	VBN	O
total	JJ	O
and	CC	O
segmental	JJ	O
colonic	JJ	O
transit	NN	O
time	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
evaluated	VBD	O
bowel	JJ	O
movement	NN	O
habits	NNS	O
and	CC	O
stool	NN	O
consistency	NN	O
using	VBG	O
a	DT	O
diary	JJ	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
received	VBD	O
a	DT	O
subjective	JJ	O
evaluation	NN	O
from	IN	O
the	DT	O
parents	NNS	O
regarding	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
main	JJ	O
variable	NN	O
for	IN	O
verifying	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
treatment	NN	O
was	VBD	O
the	DT	O
total	JJ	Physical
colonic	JJ	Physical
transit	NN	Physical
time	NN	Physical
.	.	O

RESULTS	VB	O
Fifty-six	NNP	O
chronically	RB	O
constipated	VBD	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
but	CC	O
only	RB	O
48	CD	O
children	NNS	O
completed	VBD	O
it	PRP	O
.	.	O

These	DT	O
children	NNS	O
,	,	O
who	WP	O
were	VBD	O
aged	VBN	O
between	IN	O
3	CD	O
and	CC	O
10	CD	O
years	NNS	O
,	,	O
had	VBD	O
a	DT	O
diagnosis	NN	O
of	IN	O
chronic	JJ	O
idiopathic	JJ	O
constipation	NN	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
total	JJ	Physical
,	,	Physical
partial	JJ	Physical
colon	NN	Physical
,	,	Physical
and	CC	Physical
rectum	VB	Physical
transit	NN	Physical
time	NN	Physical
,	,	O
there	EX	O
seemed	VBN	O
to	TO	O
be	VB	O
a	DT	O
trend	NN	O
,	,	O
although	IN	O
statistically	RB	O
nonsignificant	JJ	O
,	,	O
toward	IN	O
faster	JJR	O
transit	NN	Physical
times	NNS	Physical
in	IN	O
the	DT	O
cocoa	NN	O
husk	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

When	WRB	O
we	PRP	O
analyzed	VBD	O
the	DT	O
evolution	NN	O
of	IN	O
the	DT	O
intestinal	JJ	Physical
transit	NN	Physical
time	NN	O
throughout	IN	O
the	DT	O
study	NN	O
of	IN	O
children	NNS	O
whose	WP$	O
total	JJ	O
basal	JJ	Physical
intestinal	JJ	Physical
transit	NN	Physical
time	NN	Physical
was	VBD	O
>	JJ	O
50th	JJ	O
percentile	NN	O
,	,	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
total	JJ	Physical
transit	NN	Physical
time	NN	Physical
decreased	VBN	O
by	IN	O
45.4	CD	O
+/-	JJ	O
38.4	CD	O
hours	NNS	O
in	IN	O
the	DT	O
cocoa	NN	O
husk	NN	O
group	NN	O
and	CC	O
by	IN	O
8.7	CD	O
+/-	JJ	O
28.9	CD	O
hours	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
-38.1	NNP	O
hours	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
the	DT	O
right	JJ	O
colon	NN	O
,	,	O
changes	NNS	Physical
in	IN	Physical
transit	NN	Physical
time	NN	Physical
also	RB	O
were	VBD	O
significant	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Mean	NNP	Physical
changes	NNS	Physical
tended	VBD	O
toward	IN	O
faster	RBR	O
transit	NN	O
times	NNS	O
in	IN	O
the	DT	O
left	NN	O
colon	NN	O
and	CC	O
the	DT	O
rectum	NN	O
,	,	O
although	IN	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

The	DT	O
children	NNS	O
who	WP	O
received	VBD	O
cocoa	NN	O
husk	NN	O
supplements	NNS	O
tended	VBD	O
to	TO	O
increase	VB	O
the	DT	O
number	NN	Physical
of	IN	Physical
bowel	NN	Physical
movements	NNS	Physical
by	IN	O
more	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
children	NNS	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

We	PRP	O
also	RB	O
observed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
reported	VBD	O
hard	JJ	O
stools	NNS	O
(	(	O
hard	JJ	Physical
scybalous	JJ	Physical
or	CC	Physical
pebble-like	JJ	Physical
stools	NNS	Physical
)	)	O
,	,	O
although	IN	O
this	DT	O
reduction	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
cocoa	NN	O
husk	NN	O
group	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
41.7	CD	O
%	NN	O
and	CC	O
75.0	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
cocoa	NN	O
husk	NN	O
supplementation	NN	O
or	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
,	,	O
reported	VBD	Physical
having	VBG	Physical
hard	JJ	Physical
stools	NNS	Physical
.	.	O

Moreover	RB	O
,	,	O
a	DT	O
significantly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
children	NNS	O
(	(	O
or	CC	O
their	PRP$	O
parents	NNS	O
)	)	O
reported	VBD	O
a	DT	O
subjective	JJ	O
improvement	NN	Physical
in	IN	Physical
stool	JJ	Physical
consistency	NN	Physical
.	.	O

No	DT	Adverseeffect
significant	JJ	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
reported	VBN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
a	DT	O
supplement	NN	O
of	IN	O
cocoa	NN	O
husk	NN	O
that	WDT	O
is	VBZ	O
rich	JJ	O
in	IN	O
dietary	JJ	O
fiber	NN	O
on	IN	O
chronic	JJ	Physical
idiopathic	JJ	Physical
constipation	NN	Physical
in	IN	O
children	NNS	O
.	.	O

These	DT	O
benefits	NNS	O
seem	VBP	O
to	TO	O
be	VB	O
more	RBR	O
evident	JJ	O
in	IN	O
pediatric	JJ	O
constipated	JJ	O
patients	NNS	O
with	IN	O
slow	JJ	O
colonic	JJ	O
transit	NN	O
time	NN	O
.	.	O

A	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
of	IN	O
bumetanide	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
in	IN	O
children	NNS	O
.	.	O

Gamma	NNP	O
aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-mediated	VBD	O
synapses	NNS	O
and	CC	O
the	DT	O
oscillations	NNS	O
they	PRP	O
orchestrate	VBP	O
are	VBP	O
altered	VBN	O
in	IN	O
autism	NN	O
.	.	O

GABA-acting	JJ	O
benzodiazepines	NNS	O
exert	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
autism	NN	O
paradoxical	JJ	O
effects	NNS	Others
,	,	O
raising	VBG	O
the	DT	O
possibility	NN	O
that	IN	O
like	IN	O
in	IN	O
epilepsies	NNS	O
,	,	O
GABA	NNP	O
excites	VBZ	O
neurons	NNS	O
because	IN	O
of	IN	O
elevated	JJ	O
intracellular	JJ	O
concentrations	NNS	O
of	IN	O
chloride	NN	O
.	.	O

Following	VBG	O
a	DT	O
successful	JJ	O
pilot	NN	O
study	NN	O
,	,	O
(	(	O
1	CD	O
)	)	O
we	PRP	O
have	VBP	O
now	RB	O
performed	VBN	O
a	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
using	VBG	O
the	DT	O
diuretic	JJ	O
,	,	O
chloride-importer	JJ	O
antagonist	NN	O
bumetanide	IN	O
that	DT	O
reduces	VBZ	O
intracellular	JJ	O
chloride	NN	O
reinforcing	VBG	O
GABAergic	NNP	O
inhibition	NN	O
.	.	O

Sixty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
(	(	O
3-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
received	VBD	O
for	IN	O
3	CD	O
months	NNS	O
placebo	NN	O
or	CC	O
bumetanide	NN	O
(	(	O
1	CD	O
mg	NNS	O
daily	RB	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1-month	JJ	O
wash	NN	O
out	IN	O
.	.	O

Determination	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
autism	NN	O
was	VBD	O
made	VBN	O
with	IN	O
video	JJ	O
films	NNS	O
at	IN	O
day	NN	O
0	CD	O
(	(	O
D0	NNP	O
)	)	O
and	CC	O
D90	NNP	O
by	IN	O
blind	NN	O
,	,	O
independent	JJ	O
evaluators	NNS	O
.	.	O

Bumetanide	NNP	O
reduced	VBD	O
significantly	RB	O
the	DT	O
Childhood	NNP	Physical
Autism	NNP	Physical
Rating	NNP	Physical
Scale	NNP	Physical
(	(	Physical
CARS	NNP	Physical
)	)	Physical
(	(	O
D90-D0	NNP	O
;	:	O
P	NNP	O
<	VBD	O
0.004	CD	O
treated	JJ	O
vs	NN	O
placebo	NN	O
)	)	O
,	,	O
Clinical	JJ	Mental
Global	NNP	Mental
Impressions	NNP	Mental
(	(	O
P	NNP	O
<	VBZ	O
0.017	CD	O
treated	JJ	O
vs	NN	O
placebo	NN	O
)	)	O
and	CC	O
Autism	NNP	Physical
Diagnostic	NNP	Physical
Observation	NNP	Physical
Schedule	NNP	Physical
values	NNS	Physical
when	WRB	O
the	DT	O
most	RBS	O
severe	JJ	O
cases	NNS	O
(	(	O
CARS	NNPS	O
values	NNS	O
above	IN	O
the	DT	O
mean	NN	O
?	.	O
s.d	NN	O
.	.	O

;	:	O
n=9	CC	O
)	)	O
were	VBD	O
removed	VBN	O
(	(	O
Wilcoxon	JJ	O
test	NN	O
:	:	O
P-value=0.031	NN	O
;	:	O
Student	NNP	O
's	POS	O
t-test	NN	O
:	:	O
P-value=0.017	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
restricted	VBN	O
to	TO	O
an	DT	O
occasional	JJ	O
mild	NN	O
hypokalaemia	NN	O
(	(	O
3.0-3.5	JJ	O
mM	NN	O
l	NN	O
(	(	O
-1	NNP	O
)	)	O
K	NNP	O
(	(	O
+	NNP	O
)	)	O
)	)	O
that	WDT	O
was	VBD	O
treated	VBN	O
with	IN	O
supplemental	JJ	O
potassium	NN	O
.	.	O

In	IN	O
a	DT	O
companion	NN	O
study	NN	O
,	,	O
chronic	JJ	O
bumetanide	NN	O
treatment	NN	O
significantly	RB	O
improved	VBN	O
accuracy	NN	O
in	IN	O
facial	JJ	O
emotional	JJ	O
labelling	NN	O
,	,	O
and	CC	O
increased	VBD	O
brain	NN	O
activation	NN	O
in	IN	O
areas	NNS	O
involved	VBN	O
in	IN	O
social	JJ	O
and	CC	O
emotional	JJ	O
perception	NN	O
(	(	O
Hadjikhani	NNP	O
et	RB	O
al.	RB	O
,	,	O
submitted	VBN	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
bumetanide	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
novel	NN	O
therapeutic	JJ	O
agent	NN	O
to	TO	O
treat	VB	O
autism	NN	O
.	.	O

Larger	JJR	O
trials	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
better	RBR	O
determine	VB	O
the	DT	O
population	NN	O
best	RB	O
suited	VBN	O
for	IN	O
this	DT	O
treatment	NN	O
.	.	O

Local	JJ	O
immunotherapy	NN	O
by	IN	O
inhalation	NN	O
of	IN	O
a	DT	O
powder	NN	O
extract	NN	O
in	IN	O
asthma	NN	O
due	JJ	O
to	TO	O
house	NN	O
dust	NN	O
mite	NN	O
Dermatophagoides	NNP	O
pteronyssinus	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
comparison	NN	O
with	IN	O
parenteral	JJ	O
immunotherapy	NN	O
.	.	O

To	TO	O
verify	VB	O
the	DT	O
efficacy	NN	Others
and	CC	O
the	DT	O
tolerability	NN	Others
of	IN	O
local	JJ	O
immunotherapy	NN	O
(	(	O
LI	NNP	O
)	)	O
by	IN	O
inhalation	NN	O
of	IN	O
a	DT	O
powder	NN	O
extract	NN	O
of	IN	O
house	NN	O
dust	NN	O
mite	NN	O
(	(	O
HDM	NNP	O
)	)	O
,	,	O
in	IN	O
comparison	NN	O
with	IN	O
parenteral	JJ	O
immunotherapy	NN	O
(	(	O
PI	NNP	O
)	)	O
by	IN	O
injection	NN	O
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
HDM	NNP	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
blind	JJ	O
fashion	NN	O
.	.	O

5	CD	O
patients	NNS	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
underwent	NN	O
LI	NNP	O
and	CC	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
placebo	NN	O
,	,	O
5	CD	O
patients	NNS	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
underwent	NN	O
PI	NNP	O
and	CC	O
inhalation	NN	O
of	IN	O
lactose	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
each	DT	O
inhalation	NN	O
was	VBD	O
preceded	VBN	O
by	IN	O
premedication	NN	O
with	IN	O
disodium	NN	O
cromoglycate	NN	O
(	(	O
DSCG	NNP	O
)	)	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
.	.	O

In	IN	O
Group	NNP	O
A	NNP	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
symptoms	NNS	Physical
score	NN	Physical
and	CC	O
in	IN	O
peak	JJ	Physical
expiratory	NN	Physical
flow	NN	Physical
(	(	Physical
PEF	NNP	Physical
)	)	Physical
-derived	VBD	Physical
parameters	NNS	Physical
was	VBD	O
observed	VBN	O
already	RB	O
after	IN	O
3	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
2	CD	O
patients	NNS	O
lost	VBD	O
the	DT	O
late	JJ	Physical
component	NN	Physical
of	IN	Physical
the	DT	Physical
bronchial	JJ	Physical
response	NN	Physical
to	TO	Physical
the	DT	Physical
challenge	NN	Physical
with	IN	Physical
HDM	NNP	Physical
.	.	Physical

No	NNP	O
significant	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
bronchial	JJ	Physical
responsiveness	NN	Physical
to	TO	Physical
methacholine	VB	Physical
and	CC	Physical
ultrasonically	RB	Physical
nebulized	VBN	Physical
distilled	JJ	Physical
water	NN	Physical
(	(	Physical
UNDW	NNP	Physical
)	)	Physical
and	CC	Physical
in	IN	Physical
immunologic	JJ	Physical
humoral	JJ	Physical
and	CC	Physical
cellular	JJ	Physical
parameters	NNS	Physical
in	IN	Physical
peripheral	JJ	Physical
blood	NN	Physical
after	IN	O
treatment	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

No	DT	O
local	JJ	Adverseeffect
important	JJ	Adverseeffect
adverse	JJ	Adverseeffect
reactions	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
in	IN	O
Group	NNP	O
A	NNP	O
and	CC	O
no	DT	O
systemic	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
LI	NNP	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
PI	NNP	O
,	,	O
but	CC	O
more	RBR	O
rapid	JJ	O
in	IN	O
its	PRP$	O
action	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
HDM	NNP	O
.	.	O

Moreover	RB	O
,	,	O
LI	NNP	O
is	VBZ	O
locally	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
providing	VBG	O
DSCG	NNP	O
is	VBZ	O
inhaled	VBN	O
before	IN	O
each	DT	O
therapeutic	JJ	O
inhalation	NN	O
,	,	O
and	CC	O
does	VBZ	O
not	RB	O
induce	VB	O
systemic	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
standard	NN	O
wound	NN	O
care	NN	O
with	IN	O
adjunctive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
(	(	O
HBOT	NNP	O
)	)	O
to	TO	O
standard	VB	O
wound	NN	O
care	NN	O
only	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	Physical
,	,	Physical
non-healing	JJ	Physical
ulcers	NNS	Physical
of	IN	O
the	DT	O
lower	JJR	O
limb	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
:	:	O
a	DT	O
study	NN	O
protocol	NN	O
.	.	O

BACKGROUND	NNP	O
It	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
adjunctive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
improves	VBZ	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	Physical
foot	NN	Physical
ulcers	NNS	Physical
,	,	O
and	CC	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
lower	JJR	Physical
extremity	NN	Physical
amputations	NNS	Physical
.	.	O

A	DT	O
limited	JJ	O
number	NN	O
of	IN	O
studies	NNS	O
have	VBP	O
used	VBN	O
a	DT	O
double	JJ	O
blind	NN	O
approach	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetic	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
plus	CC	O
standard	NN	O
wound	NN	O
care	NN	O
compared	VBN	O
with	IN	O
standard	NN	O
wound	NN	O
care	NN	O
alone	RB	O
in	IN	O
preventing	VBG	O
the	DT	O
need	NN	O
for	IN	O
major	JJ	Others
amputation	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
and	CC	O
chronic	JJ	O
ulcers	NNS	O
of	IN	O
the	DT	O
lower	JJR	O
limb	NN	O
.	.	O

METHODS/DESIGN	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
eighteen	JJ	O
(	(	O
59	CD	O
patients	NNS	O
per	IN	O
arm	NN	O
)	)	O
patients	NNS	O
with	IN	O
non-healing	JJ	O
diabetic	JJ	O
ulcers	NNS	O
of	IN	O
the	DT	O
lower	JJR	O
limb	NN	O
,	,	O
referred	VBD	O
to	TO	O
the	DT	O
Judy	NNP	O
Dan	NNP	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
Centre	NNP	O
are	VBP	O
being	VBG	O
recruited	VBN	O
if	IN	O
they	PRP	O
are	VBP	O
at	IN	O
least	JJS	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
have	VBP	O
either	DT	O
Type	NNP	O
1	CD	O
or	CC	O
2	CD	O
diabetes	NNS	O
with	IN	O
a	DT	O
Wagner	NNP	O
grading	NN	O
of	IN	O
foot	NN	O
lesions	NNS	O
2	CD	O
,	,	O
3	CD	O
or	CC	O
4	CD	O
on	IN	O
lower	JJR	O
limb	NN	O
not	RB	O
healing	VBG	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
receive	JJ	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
every	DT	O
day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
during	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
and	CC	O
are	VBP	O
provided	VBN	O
ongoing	VBG	O
wound	NN	O
care	NN	O
and	CC	O
weekly	JJ	O
assessments	NNS	O
.	.	O

Patients	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
return	VB	O
to	TO	O
the	DT	O
study	NN	O
centre	NN	O
every	DT	O
week	NN	O
for	IN	O
an	DT	O
additional	JJ	O
6	CD	O
weeks	NNS	O
of	IN	O
follow-up	NN	O
for	IN	O
wound	JJ	O
evaluation	NN	O
and	CC	O
management	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
is	VBZ	O
freedom	RB	Physical
from	IN	Physical
having	VBG	Physical
,	,	Physical
or	CC	Physical
meeting	VBG	Physical
the	DT	Physical
criteria	NN	Physical
for	IN	Physical
,	,	Physical
a	DT	Physical
major	JJ	Physical
amputation	NN	Physical
(	(	Physical
below	IN	Physical
knee	NN	Physical
amputation	NN	Physical
,	,	Physical
or	CC	Physical
metatarsal	VB	Physical
level	NN	Physical
)	)	Physical
up	RB	O
to	TO	O
12	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
decision	NN	O
to	TO	O
amputate	VB	O
is	VBZ	O
made	VBN	O
by	IN	O
a	DT	O
vascular	JJ	O
surgeon	NN	O
.	.	O

Other	JJ	O
outcomes	NNS	O
include	VBP	O
wound	IN	Physical
healing	NN	Physical
,	,	O
effectiveness	NN	Others
,	,	O
safety	NN	Others
,	,	O
healthcare	JJ	Others
resource	NN	Others
utilization	NN	Others
,	,	O
quality	NN	Mental
of	IN	Mental
life	NN	Mental
,	,	Physical
and	CC	O
cost-effectiveness	NN	Physical
.	.	O

The	DT	O
study	NN	O
will	MD	O
run	VB	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
about	IN	O
3	CD	O
years	NNS	O
.	.	O

DISCUSSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
will	MD	O
provide	VB	O
detailed	JJ	O
information	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
non-healing	JJ	O
ulcers	NNS	O
of	IN	O
the	DT	O
lower	JJR	O
limb	NN	O
.	.	O

This	DT	O
will	MD	O
be	VB	O
the	DT	O
first	JJ	O
double-blind	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
for	IN	O
this	DT	O
health	NN	O
technology	NN	O
which	WDT	O
evaluates	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
hyperbaric	JJ	O
oxygen	NN	O
therapy	NN	O
in	IN	O
prevention	NN	O
of	IN	O
amputations	NNS	Adverseeffect
in	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00621608	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
for	IN	O
monitoring	VBG	O
human	JJ	O
cytomegalovirus	NN	O
infection	NN	O
reduces	VBZ	O
the	DT	O
number	NN	Others
of	IN	Others
preemptively	RB	Others
treated	VBN	Others
children	NNS	Others
and	CC	O
young	JJ	O
adults	NNS	O
receiving	VBG	O
hematopoietic	JJ	O
stem-cell	JJ	O
transplantation	NN	O
compared	VBN	O
with	IN	O
qualitative	JJ	O
pp65	NN	O
antigenemia	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
the	DT	O
use	NN	O
of	IN	O
quantitative	JJ	O
DNAemia	NNP	O
versus	NN	O
positive	JJ	O
antigenemia	NN	O
for	IN	O
starting	VBG	O
preemptive	JJ	O
antihuman	NN	O
cytomegalovirus	NN	O
(	(	O
HCMV	NNP	O
)	)	O
therapy	NN	O
in	IN	O
hematopoietic	JJ	O
stem-cell	JJ	O
transplantation	NN	O
(	(	O
HSCT	NNP	O
)	)	O
recipients	NNS	O
.	.	O

In	IN	O
the	DT	O
DNAemia	NNP	O
arm	NN	O
,	,	O
antiviral	JJ	O
therapy	NN	O
was	VBD	O
initiated	VBN	O
on	IN	O
reaching	VBG	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
of	IN	O
10	CD	O
000	CD	O
DNA	NNP	O
copies/mL	NN	O
of	IN	O
whole	JJ	O
blood	NN	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
antigenemia	NN	O
arm	NN	O
,	,	O
therapy	NN	O
was	VBD	O
started	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
positive	JJ	O
antigenemia	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
in	IN	O
the	DT	O
2	CD	O
arms	NNS	O
.	.	O

On	IN	O
the	DT	O
whole	NN	O
,	,	O
178	CD	O
patients	NNS	O
(	(	O
89	CD	O
in	IN	O
each	DT	O
arm	NN	O
)	)	O
,	,	O
receiving	VBG	O
unmanipulated	JJ	O
HSCT	NNP	O
from	IN	O
either	CC	O
a	DT	O
relative	NN	O
or	CC	O
an	DT	O
unrelated	JJ	O
donor	NN	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
HCMV	NNP	Physical
infection	NN	Physical
was	VBD	O
comparable	JJ	O
in	IN	O
DNAemia	NNP	O
and	CC	O
antigenemia	NN	O
arms	NNS	O
(	(	O
34	CD	O
%	NN	O
vs	JJ	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
.259	NNP	O
)	)	O
,	,	O
the	DT	O
number	NN	Others
of	IN	Others
patients	NNS	Others
treated	VBN	Others
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
DNAemia	NNP	O
arm	NN	O
(	(	O
18	CD	O
%	NN	O
vs	JJ	O
31	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.026	NNP	O
)	)	O
.	.	O

No	DT	O
patient	NN	O
developed	VBD	O
HCMV	NNP	Physical
disease	NN	Physical
.	.	O

The	DT	O
use	NN	O
of	IN	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
avoids	NNS	O
unnecessary	JJ	O
antiviral	JJ	O
treatment	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
haloperidol	NN	O
on	IN	O
discrimination	NN	Mental
learning	NN	Mental
and	CC	Mental
behavioral	JJ	Mental
symptoms	NNS	Mental
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
three	CD	O
objectives	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
to	TO	O
replicate	VB	O
earlier	JJR	O
findings	NNS	O
that	IN	O
haloperidol	JJ	O
administration	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
behavioral	JJ	Mental
symptoms	NNS	Mental
;	:	O
(	(	O
b	NN	O
)	)	O
to	TO	O
further	JJ	O
assess	NN	O
its	PRP$	O
safety	NN	Others
when	WRB	O
given	VBN	O
on	IN	O
a	DT	O
short-term	JJ	O
basis	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
to	TO	O
assess	VB	O
whether	IN	O
it	PRP	O
has	VBZ	O
an	DT	O
effect	NN	Mental
on	IN	Mental
discrimination	NN	Mental
learning	NN	Mental
.	.	O

Forty-five	JJ	O
children	NNS	O
,	,	O
2.02	CD	O
to	TO	O
7.58	CD	O
years	NNS	O
old	JJ	O
(	(	O
M	NNP	O
=	NNP	O
4.49	CD	O
)	)	O
,	,	O
completed	VBD	O
this	DT	O
crossover	NN	O
design	NN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
treatment	NN	O
sequences	NNS	O
.	.	O

Haloperidol	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
powerful	JJ	O
therapeutic	JJ	O
agent	NN	O
when	WRB	O
administered	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
free	JJ	O
of	IN	O
side	JJ	Adverseeffect
effects	NNS	Adverseeffect
;	:	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25	CD	O
to	TO	O
4.0	CD	O
mg/day	NN	O
(	(	O
M	NNP	O
=	NNP	O
0.844	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
variety	NN	Mental
of	IN	Mental
symptoms	NNS	Mental
.	.	O

Under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
,	,	O
the	DT	O
children	NNS	O
failed	VBD	O
to	TO	O
learn	VB	O
on	IN	O
either	DT	O
haloperidol	NN	O
or	CC	O
placebo	NN	O
.	.	O

Placebo-controlled	JJ	O
study	NN	O
of	IN	O
oral	JJ	O
enoximone	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
with	IN	O
initial	JJ	Others
and	CC	Others
final	JJ	Others
intravenous	JJ	Others
hemodynamic	JJ	Others
evaluation	NN	Others
.	.	O

Seventeen	JJ	O
patients	NNS	O
with	IN	O
stable	JJ	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
class	NN	O
II	NNP	O
and	CC	O
III	NNP	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
)	)	O
received	VBD	O
intravenous	JJ	O
and	CC	O
oral	JJ	O
enoximone	NN	O
in	IN	O
a	DT	O
2-part	JJ	O
study	NN	O
.	.	O

Hemodynamic	NNP	Others
data	NNS	Others
were	VBD	O
first	RB	O
obtained	VBN	O
after	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
0.75	CD	O
mg/kg	NN	O
of	IN	O
enoximone	NN	O
;	:	O
data	NNS	O
were	VBD	O
again	RB	O
obtained	VBN	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
either	DT	O
oral	JJ	O
enoximone	NN	O
(	(	O
150	CD	O
mg	RB	O
3	CD	O
times	NNS	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
enoximone	NN	O
were	VBD	O
also	RB	O
studied	VBN	O
in	IN	O
a	DT	O
12-week	JJ	O
,	,	O
double-blind	JJ	O
randomized	JJ	O
format	NN	O
.	.	O

In	IN	O
the	DT	O
intravenous	JJ	O
study	NN	O
,	,	O
enoximone	NN	O
was	VBD	O
delivered	VBN	O
over	IN	O
5	CD	O
minutes	NNS	O
and	CC	O
hemodynamic	JJ	O
data	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
up	RB	O
to	TO	O
12	CD	O
hours	NNS	O
after	IN	O
.	.	O

Cardiac	NNP	Physical
index	NN	Physical
increased	VBD	O
2.76	CD	O
+/-	JJ	O
0.63	CD	O
to	TO	O
3.42	CD	O
+/-	JJ	O
0.72	CD	O
liters/min/m2	NN	O
)	)	O
,	,	O
pulmonary	JJ	Physical
wedge	NN	Physical
pressure	NN	Physical
decreased	VBN	O
(	(	O
19.5	CD	O
+/-	JJ	O
8.8	CD	O
to	TO	O
14.6	CD	O
+/-	JJ	O
8.0	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
as	IN	O
did	VBD	O
mean	VB	Physical
arterial	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	O
101	CD	O
+/-	JJ	O
14.8	CD	O
to	TO	O
85	CD	O
+/-	JJ	O
13.7	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
and	CC	O
systemic	JJ	Physical
vascular	NN	Physical
resistance	NN	Physical
(	(	O
1,880	CD	O
+/-	JJ	O
573	CD	O
to	TO	O
1,254	CD	O
+/-	JJ	O
383	CD	O
dynes	NNS	O
s	RB	O
cm-5	NN	O
)	)	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
increased	VBD	O
slightly	RB	O
(	(	O
82	CD	O
+/-	JJ	O
17	CD	O
to	TO	O
86	CD	O
+/-	JJ	O
14	CD	O
beats/min	NN	O
)	)	O
.	.	O

All	PDT	O
these	DT	O
changes	NNS	O
were	VBD	O
maximal	JJ	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
after	IN	O
infusion	NN	O
and	CC	O
lasted	VBD	O
8	CD	O
hours	NNS	O
at	IN	O
least	JJS	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomized	VBN	O
double-blind	NN	O
to	TO	O
oral	JJ	O
treatment	NN	O
.	.	O

Baseline	NNP	O
values	VBZ	O
showed	VBD	O
that	IN	O
the	DT	O
7	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
had	VBD	O
more	RBR	O
severe	JJ	O
CHF	NNP	Physical
.	.	O

Therefore	NNP	O
,	,	O
comparison	NN	O
might	MD	O
be	VB	O
biased	VBN	O
.	.	O

Patient	NNP	O
overall	JJ	O
assessment	NN	O
showed	VBD	O
a	DT	O
continuous	JJ	O
benefit	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Ejection	NNP	O
fraction	NN	O
improved	VBD	O
from	IN	O
30.1	CD	O
+/-	JJ	O
6.8	CD	O
%	NN	O
to	TO	O
33.9	CD	O
+/-	JJ	O
9.9	CD	O
%	NN	O
in	IN	O
the	DT	O
enoximone	NN	O
group	NN	O
while	IN	O
it	PRP	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
placebo	NN	O
(	(	O
23.4	CD	O
+/-	JJ	O
6.5	CD	O
%	NN	O
to	TO	O
23.4	CD	O
+/-	JJ	O
1.5	CD	O
%	NN	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
graded	JJ	O
exercise	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	Physical
fatigue	NN	Physical
syndrome	NN	Physical
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
graded	JJ	O
aerobic	JJ	O
exercise	NN	O
programme	NN	O
in	IN	O
the	DT	O
chronic	JJ	Physical
fatigue	NN	Physical
syndrome	NN	Physical
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
with	IN	O
control	NN	O
treatment	NN	O
crossover	NN	O
after	IN	O
the	DT	O
first	JJ	O
follow	VB	O
up	RP	O
examination	NN	O
.	.	O

SETTING	NN	O
Chronic	NNP	O
fatigue	NN	O
clinic	NN	O
in	IN	O
a	DT	O
general	JJ	O
hospital	NN	O
department	NN	O
of	IN	O
psychiatry	NN	O
.	.	O

SUBJECTS	NNP	O
66	CD	O
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
who	WP	O
had	VBD	O
neither	CC	O
a	DT	O
psychiatric	JJ	O
disorder	NN	O
nor	CC	O
appreciable	JJ	O
sleep	JJ	O
disturbance	NN	O
.	.	O

INTERVENTIONS	NNP	O
Random	NNP	O
allocation	NN	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
either	DT	O
graded	VBN	O
aerobic	NN	O
exercise	NN	O
or	CC	O
flexibility	NN	O
exercises	NNS	O
and	CC	O
relaxation	NN	O
therapy	NN	O
.	.	O

Patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
flexibility	NN	O
programme	NN	O
were	VBD	O
invited	VBN	O
to	TO	O
cross	VB	O
over	IN	O
to	TO	O
the	DT	O
exercise	NN	O
programme	NN	O
afterwards	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	Others
self	NN	Others
rated	VBN	Others
clinical	JJ	Others
global	JJ	Others
impression	NN	Others
change	NN	Others
score	NN	Others
,	,	Others
very	RB	Others
much	JJ	Others
better	RBR	Others
or	CC	Others
much	RB	Others
better	JJR	Others
being	VBG	Others
considered	VBN	Others
as	IN	Others
clinically	RB	Others
important	JJ	Others
.	.	O

RESULTS	VB	O
Four	CD	O
patients	NNS	O
receiving	VBG	O
exercise	NN	O
and	CC	O
three	CD	O
receiving	VBG	O
flexibility	NN	O
treatment	NN	O
dropped	VBD	O
out	RP	O
before	IN	O
completion	NN	O
.	.	O

15	CD	O
of	IN	O
29	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
after	IN	O
completing	VBG	O
exercise	NN	O
treatment	NN	O
compared	VBN	O
with	IN	O
eight	CD	O
of	IN	O
30	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
flexibility	NN	O
treatment	NN	O
.	.	O

Analysis	NN	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
gave	VBD	O
similar	JJ	O
results	NNS	O
(	(	O
17/33	CD	O
v	RB	O
9/33	CD	O
patients	NNS	O
better	RBR	O
)	)	O
.	.	O

Fatigue	NNP	Physical
,	,	O
functional	JJ	Physical
capacity	NN	Physical
,	,	O
and	CC	O
fitness	NN	Physical
were	VBD	O
significantly	RB	O
better	RBR	O
after	IN	O
exercise	NN	O
than	IN	O
after	IN	O
flexibility	NN	O
treatment	NN	O
.	.	O

12	CD	O
of	IN	O
22	CD	O
patients	NNS	O
who	WP	O
crossed	VBD	O
over	IN	O
to	TO	O
exercise	VB	O
after	IN	O
flexibility	NN	O
treatment	NN	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
after	IN	O
completing	VBG	O
exercise	NN	O
treatment	NN	O
32	CD	O
of	IN	O
47	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
three	CD	O
months	NNS	O
after	IN	O
completing	VBG	O
supervised	JJ	O
exercise	NN	O
treatment	NN	O
35	CD	O
of	IN	O
47	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	Others
one	CD	O
year	NN	O
after	IN	O
completing	VBG	O
supervised	JJ	O
exercise	NN	O
treatment	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
appropriately	RB	O
prescribed	VBN	O
graded	VBN	O
aerobic	JJ	O
exercise	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
.	.	O

Effect	NN	O
of	IN	O
flurbiprofen	JJ	O
sodium	NN	O
on	IN	O
pupillary	JJ	Physical
dilatation	NN	Physical
during	IN	O
scleral	JJ	O
buckling	NN	O
surgery	NN	O
.	.	O

Maintenance	NN	O
of	IN	O
pupillary	JJ	Physical
dilatation	NN	Physical
is	VBZ	O
necessary	JJ	O
for	IN	O
success	NN	O
of	IN	O
scleral	JJ	O
buckling	NN	O
procedures	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
0.03	CD	O
%	NN	O
flurbiprofen	NN	O
in	IN	O
preventing	VBG	O
intraoperative	JJ	O
miosis	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
controlled	VBD	O
trial	NN	O
of	IN	O
60	CD	O
patients	NNS	O
.	.	O

Thirty	JJ	O
patients	NNS	O
received	VBD	O
0.03	CD	O
%	NN	O
flurbiprofen	NN	O
6	CD	O
times	NNS	O
at	IN	O
15	CD	O
minute	NN	O
intervals	NNS	O
90	CD	O
minutes	NNS	O
preoperatively	RB	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
routine	JJ	O
dilation	NN	O
regimen	NNS	O
.	.	O

The	DT	O
treated	JJ	O
group	NN	O
had	VBD	O
a	DT	O
mean	JJ	Physical
pupillary	JJ	Physical
decrease	NN	Physical
of	IN	O
1.88	CD	O
mm	NNS	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
a	DT	O
decrease	NN	O
of	IN	O
1.57	CD	O
mm	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Flurbiprofen	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
pupillary	JJ	Physical
size	NN	Physical
at	IN	O
any	DT	O
step	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Factors	NNS	O
such	JJ	O
as	IN	O
age	NN	Mental
of	IN	Mental
the	DT	Mental
patient	NN	Mental
,	,	O
lens	VBZ	Physical
status	NN	Physical
,	,	O
number	NN	Physical
of	IN	Physical
cryo	NN	Physical
applications	NNS	Physical
,	,	O
duration	NN	Others
of	IN	Others
surgery	NN	Others
,	,	O
and	CC	O
the	DT	O
size	NN	Others
and	CC	Others
extent	NN	Others
of	IN	Others
buckle	NN	Others
were	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
flurbiprofen	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
mean	JJ	Physical
pupillary	JJ	Physical
change	NN	Physical
for	IN	O
any	DT	O
of	IN	O
these	DT	O
groups	NNS	O
.	.	O

Preoperative	NNP	O
use	NN	O
of	IN	O
flurbiprofen	NN	O
does	VBZ	O
not	RB	O
significantly	RB	O
decrease	VB	O
intraoperative	JJ	Physical
miosis	NN	Physical
during	IN	Physical
scleral	JJ	Physical
buckling	NN	Physical
procedures	NNS	Physical
.	.	O

[	NN	O
Erythropoietin	NNP	O
therapy	NN	O
during	IN	O
frequent	JJ	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
.	.	O

Dose-finding	NN	O
study	NN	O
]	NNP	O
.	.	O

Avoidance	NN	O
of	IN	O
homologous	JJ	O
blood	NN	O
products	NNS	O
and	CC	O
patients	NNS	O
'	POS	O
demand	NN	O
for	IN	O
preoperative	JJ	O
autologous	JJ	O
blood	NN	O
donation	NN	O
programs	NNS	O
are	VBP	O
increasing	VBG	O
.	.	O

As	IN	O
many	JJ	O
of	IN	O
these	DT	O
patients	NNS	O
are	VBP	O
older	JJR	O
,	,	O
with	IN	O
a	DT	O
compromised	VBN	O
cardiovascular	NN	O
system	NN	O
and	CC	O
a	DT	O
slow	JJ	O
response	NN	O
of	IN	O
the	DT	O
erythropoietic	JJ	O
system	NN	O
when	WRB	O
anemia	NN	O
occurs	VBZ	O
,	,	O
the	DT	O
feasibility	NN	O
and	CC	O
benefit	NN	O
of	IN	O
autologous	JJ	O
blood	NN	O
donation	NN	O
is	VBZ	O
often	RB	O
limited	JJ	O
.	.	O

Augmentation	NN	O
of	IN	O
preoperative	JJ	O
blood	NN	O
donation	NN	O
by	IN	O
therapy	NN	O
with	IN	O
recombinant	JJ	O
human	JJ	O
erythropoietin	NN	O
(	(	O
rHuEPO	NN	O
)	)	O
has	VBZ	O
been	VBN	O
described	VBN	O
in	IN	O
animal	JJ	O
models	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
.	.	O

In	IN	O
a	DT	O
multicenter	NN	O
,	,	O
controlled	VBN	O
,	,	O
randomized	VBN	O
trial	NN	O
,	,	O
49	CD	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
orthopaedic	JJ	O
or	CC	O
vascular	JJ	O
surgery	NN	O
received	VBD	O
0	CD	O
(	(	O
control	NN	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
9	CD	O
)	)	O
,	,	O
200	CD	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
300	CD	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
400	CD	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
500	CD	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
U/kg	NNP	O
rHuEPO	NN	O
(	(	O
Erypo	NNP	O
,	,	O
Cilag	NNP	O
,	,	O
Sulzbach	NNP	O
,	,	O
distributor	NN	O
Fresenius	NNP	O
,	,	O
Oberursel	NNP	O
,	,	O
Germany	NNP	O
)	)	O
subcutaneously	RB	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
while	IN	O
every	DT	O
week	NN	O
450	CD	O
ml	NN	O
blood	NN	O
was	VBD	O
collected	VBN	O
.	.	O

Iron	NNP	O
sulphate	NN	O
100	CD	O
mg	NN	O
was	VBD	O
prescribed	VBN	O
orally	RB	O
twice	RB	O
a	DT	O
day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ineligible	JJ	O
if	IN	O
they	PRP	O
had	VBD	O
uncontrolled	VBN	O
hypertension	NN	O
,	,	O
recent	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
haematological	JJ	O
disorders	NNS	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
seizures	NNS	O
.	.	O

Blood	NNP	O
donation	NN	O
had	VBD	O
to	TO	O
be	VB	O
cancelled	VBN	O
if	IN	O
the	DT	O
haematocrit	NN	O
was	VBD	O
below	IN	O
30	CD	O
%	NN	O
.	.	O

RESULTS	NNP	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
ANOVA	NNP	O
)	)	O
drop	NN	O
of	IN	O
the	DT	O
haematocrit	NN	Others
value	NN	Others
only	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
end-point	NN	Others
values	NNS	Others
for	IN	Others
haematocrit	NN	Others
and	CC	Others
haemoglobin	NN	Others
were	VBD	O
significantly	RB	O
elevated	VBN	O
in	IN	O
the	DT	O
400	CD	O
and	CC	O
500	CD	O
U/kg	NNP	O
groups	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
Table	NNP	O
9	CD	O
)	)	O
.	.	O

DISCUSSION	NNP	O
.	.	O

The	DT	O
erythropoietic	JJ	O
stimulus	NN	O
of	IN	O
phlebotomy	NN	O
for	IN	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
is	VBZ	O
often	RB	O
not	RB	O
efficient	JJ	O
enough	RB	O
to	TO	O
guarantee	VB	O
a	DT	O
constant	JJ	O
haematocrit	NN	Physical
.	.	O

Lowering	VBG	O
of	IN	O
the	DT	O
preoperative	JJ	O
haematocrit	NN	Physical
jeopardizes	VBZ	O
the	DT	O
aim	NN	O
of	IN	O
avoidance	NN	O
of	IN	O
homologous	JJ	O
blood	NN	O
transfusions	NNS	O
.	.	O

rHuEPO	NN	O
increased	VBD	O
the	DT	O
efficiency	NN	Others
of	IN	O
autologous	JJ	O
blood	NN	O
collections	NNS	O
,	,	O
as	IN	O
predonation	NN	O
haematocrit	NN	O
values	NNS	O
could	MD	O
be	VB	O
preserved	VBN	O
in	IN	O
the	DT	O
high-dosage	NN	O
groups	NNS	O
.	.	O

As	IN	O
a	DT	O
consequence	NN	O
,	,	O
homologous	JJ	O
transfusions	NNS	O
could	MD	O
be	VB	O
avoided	VBN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
broad	JJ	O
interindividual	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
erythropoietic	JJ	Physical
response	NN	Physical
,	,	O
possibly	RB	O
due	JJ	O
to	TO	O
limitations	NNS	O
in	IN	O
iron	NN	O
availability	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
of	IN	O
rHuEPO	NN	O
therapy	NN	O
,	,	O
such	JJ	O
as	IN	O
hypertension	NN	Adverseeffect
,	,	O
thrombosis	NN	Adverseeffect
or	CC	O
neurologic	JJ	Adverseeffect
disorders	NNS	Adverseeffect
,	,	O
are	VBP	O
mostly	RB	O
reported	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
terminal	JJ	Physical
kidney	NN	Physical
failure	NN	Physical
.	.	Physical

No	DT	O
such	JJ	O
disturbances	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

CONCLUSION	NNP	O
.	.	O

rHuEPO	NN	O
ameliorates	VBZ	Physical
the	DT	O
preoperative	JJ	O
decrease	NN	O
of	IN	O
haemoglobin	NN	Physical
and	CC	Physical
haematocrit	NN	Physical
values	NNS	Physical
due	JJ	O
to	TO	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
in	IN	O
a	DT	O
dose-related	JJ	O
fashion	NN	O
.	.	O

The	DT	O
individually	RB	O
adjusted	VBN	O
dosage	NN	O
of	IN	O
rHuEPO	NN	O
and	CC	O
iron	NN	O
supplementation	NN	O
merits	NNS	O
further	JJ	O
investigation	NN	O
.	.	O

Equivalence	NNP	O
study	NN	O
of	IN	O
a	DT	O
topical	JJ	O
diclofenac	NN	O
solution	NN	O
(	(	O
pennsaid	NN	O
)	)	O
compared	VBN	O
with	IN	O
oral	JJ	O
diclofenac	NN	O
in	IN	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
efficacy	NN	Others
of	IN	O
a	DT	O
topical	JJ	O
diclofenac	NN	O
solution	NN	O
versus	IN	O
oral	JJ	O
diclofenac	NN	O
in	IN	O
relieving	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
primary	JJ	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
of	IN	O
the	DT	O
knee	NN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
equivalence	NN	O
trial	NN	O
.	.	O

METHODS	VB	O
A	DT	O
total	NN	O
of	IN	O
622	CD	O
men	NNS	O
and	CC	O
women	NNS	O
with	IN	O
radiological	JJ	O
evidence	NN	O
of	IN	O
primary	JJ	O
knee	NN	O
OA	NNP	O
and	CC	O
mild	VB	O
to	TO	O
severe	VB	O
symptoms	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
a	DT	O
topical	JJ	O
diclofenac	NN	O
solution	NN	O
plus	CC	O
placebo	JJ	O
oral	JJ	O
capsules	NNS	O
,	,	O
or	CC	O
placebo	VB	O
topical	JJ	O
solution	NN	O
plus	CC	O
oral	JJ	O
diclofenac	NN	O
(	(	O
50	CD	O
mg	NN	O
)	)	O
capsules	NNS	O
.	.	O

Patients	NNS	O
applied	VBD	O
50	CD	O
drops	NNS	O
of	IN	O
study	NN	O
solution	NN	O
and	CC	O
took	VBD	O
1	CD	O
study	NN	O
capsule	NN	O
3	CD	O
times	NNS	O
daily	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Efficacy	NN	O
variables	NNS	O
were	VBD	O
pain	NN	O
and	CC	O
physical	JJ	O
function	NN	O
,	,	O
measured	VBN	O
by	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
VA	NNP	O
3.1	CD	O
OA	NNP	O
Index	NNP	O
,	,	O
and	CC	O
patient	JJ	O
global	JJ	O
assessment	NN	O
(	(	O
PGA	NNP	O
)	)	O
.	.	O

Equivalence	NN	O
in	IN	O
the	DT	O
per-protocol	JJ	O
group	NN	O
was	VBD	O
based	VBN	O
on	IN	O
previously	RB	O
defined	VBN	O
ranges	NNS	O
of	IN	O
clinically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

Safety	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
evaluation	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
vital	JJ	O
signs	NNS	O
,	,	O
and	CC	O
laboratory	NN	O
data	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
difference	NN	O
in	IN	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
change	NN	O
scores	NNS	O
(	(	O
final	JJ	O
minus	NN	O
baseline	NN	O
)	)	O
between	IN	O
treatments	NNS	O
was	VBD	O
13.3	CD	O
mm	NN	O
(	(	O
-8.6	UH	O
to	TO	O
35.2	CD	O
)	)	O
for	IN	O
pain	NN	O
(	(	O
total	JJ	O
scale	NN	O
500	CD	O
mm	NN	O
)	)	O
,	,	O
71.0	CD	O
mm	NN	O
(	(	O
-2.4	UH	O
to	TO	O
144.5	CD	O
)	)	O
for	IN	O
physical	JJ	O
function	NN	O
(	(	O
total	JJ	O
scale	NN	O
1700	CD	O
mm	NN	O
)	)	O
,	,	O
and	CC	O
4.3	CD	O
mm	NN	O
(	(	O
-1.2	UH	O
to	TO	O
9.8	CD	O
)	)	O
for	IN	O
PGA	NNP	O
(	(	O
total	JJ	O
scale	NN	O
100	CD	O
mm	NN	O
)	)	O
.	.	O

The	DT	O
CI	NNP	O
for	IN	O
each	DT	O
efficacy	NN	O
variable	NN	O
fell	VBD	O
within	IN	O
the	DT	O
predefined	JJ	O
equivalence	NN	O
ranges	NNS	O
(	(	O
pain	NN	O
,	,	O
+/-	JJ	O
75	CD	O
mm	NN	O
;	:	O
physical	JJ	O
function	NN	O
,	,	O
+/-	JJ	O
255	CD	O
mm	NN	O
;	:	O
PGA	NNP	O
,	,	O
+/-	JJ	O
20	CD	O
mm	NN	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
no	DT	O
clinically	RB	O
relevant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
2	CD	O
treatment	NN	O
arms	NNS	O
.	.	O

Safety	NN	Others
analyses	NNS	Others
of	IN	O
patients	NNS	O
applying	VBG	O
topical	JJ	O
diclofenac	NN	O
solution	NN	O
revealed	VBD	O
some	DT	O
minor	JJ	Adverseeffect
skin	NN	Adverseeffect
irritation	NN	Adverseeffect
at	IN	Adverseeffect
the	DT	Adverseeffect
application	NN	Adverseeffect
site	NN	Adverseeffect
--	:	Adverseeffect
mostly	RB	Adverseeffect
skin	JJ	O
dryness	NN	O
in	IN	O
83/311	CD	O
(	(	O
27	CD	O
%	NN	O
)	)	O
patients	NNS	O
--	:	O
but	CC	O
a	DT	O
significantly	RB	O
reduced	VBN	O
incidence	NN	O
,	,	O
relative	JJ	O
to	TO	O
oral	JJ	O
diclofenac	NN	O
,	,	O
of	IN	O
total	JJ	Adverseeffect
and	CC	Adverseeffect
severe	JJ	Adverseeffect
gastrointestinal	NN	Adverseeffect
(	(	Adverseeffect
GI	NNP	Adverseeffect
)	)	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
,	,	O
including	VBG	O
dyspepsia	NN	Adverseeffect
,	,	O
abdominal	JJ	Physical
pain	NN	Physical
,	,	O
diarrhea	NN	Adverseeffect
,	,	O
and	CC	O
nausea	NN	Adverseeffect
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
developing	VBG	O
abnormal	JJ	O
liver	NN	O
function	NN	O
tests	NNS	O
(	(	O
including	VBG	O
clinically	RB	O
significant	JJ	O
elevation	NN	O
)	)	O
,	,	O
hemoglobin	UH	O
,	,	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
oral	JJ	O
diclofenac	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Application	NNP	O
of	IN	O
this	DT	O
topical	JJ	O
diclofenac	NN	O
solution	NN	O
to	TO	O
the	DT	O
knee	NN	O
of	IN	O
patients	NNS	O
with	IN	O
OA	NNP	O
produced	VBD	O
relief	NN	Physical
of	IN	Physical
symptoms	NNS	Physical
equivalent	JJ	O
to	TO	O
oral	JJ	O
diclofenac	NN	O
,	,	O
with	IN	O
minor	JJ	O
local	JJ	O
skin	NN	O
irritation	NN	O
,	,	O
but	CC	O
significantly	RB	O
reduced	VBD	O
incidence	NN	Physical
of	IN	Physical
diclofenac-related	JJ	Physical
GI	NNP	Physical
complaints	NNS	Physical
and	CC	O
abnormal	JJ	Physical
laboratory	NN	Physical
values	NNS	Physical
.	.	O

Optimum	JJ	O
frequency	NN	O
of	IN	O
exercise	NN	O
for	IN	O
bone	NN	Physical
health	NN	Physical
:	:	O
randomised	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
a	DT	O
high-impact	JJ	O
unilateral	JJ	O
intervention	NN	O
.	.	O

INTRODUCTION	NNP	O
Exercise	NNP	O
can	MD	O
increase	VB	O
bone	NN	Physical
strength	NN	Physical
,	,	O
but	CC	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
fracture	NN	Adverseeffect
risk	NN	Adverseeffect
,	,	O
exercise	NN	O
must	MD	O
be	VB	O
feasible	JJ	O
enough	JJ	O
to	TO	O
be	VB	O
adopted	VBN	O
into	IN	O
daily	JJ	O
life	NN	O
and	CC	O
influence	NN	O
potentially	RB	O
vulnerable	JJ	O
skeletal	JJ	O
sites	NNS	O
such	JJ	O
as	IN	O
the	DT	O
superolateral	JJ	O
cortex	NN	O
of	IN	O
the	DT	O
femoral	JJ	O
neck	NN	O
,	,	O
where	WRB	O
thinning	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
fracture	NN	Adverseeffect
risk	NN	Adverseeffect
.	.	O

Brief	NNP	O
,	,	O
high-impact	JJ	O
exercise	NN	O
increases	VBZ	O
femoral	JJ	Physical
neck	NN	Physical
bone	NN	Physical
density	NN	Physical
but	CC	O
the	DT	O
optimal	JJ	O
frequency	NN	O
of	IN	O
such	JJ	O
exercise	NN	O
and	CC	O
the	DT	O
location	NN	O
of	IN	O
bone	NN	O
accrual	JJ	O
is	VBZ	O
unknown	JJ	O
.	.	O

This	DT	O
study	NN	O
thus	RB	O
examined	VBN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
weekly	JJ	O
frequencies	NNS	O
of	IN	O
exercise	NN	O
on	IN	O
femoral	JJ	Physical
neck	NN	Physical
BMD	NNP	Physical
and	CC	O
(	(	O
2	CD	O
)	)	O
whether	IN	Physical
BMD	NNP	Physical
change	NN	Physical
differed	VBD	Physical
between	IN	Physical
hip	NN	Physical
sites	NNS	Physical
using	VBG	O
a	DT	O
high-impact	JJ	O
,	,	O
unilateral	JJ	O
intervention	NN	O
.	.	O

METHODS	NNP	O
Healthy	NNP	O
premenopausal	NN	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
exercise	VB	O
0	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
or	CC	O
7	CD	O
days/week	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
exercise	NN	O
intervention	NN	O
incorporated	VBD	O
50	CD	O
multidirectional	JJ	O
hops	NNS	O
on	IN	O
one	CD	O
randomly	NN	O
selected	VBN	O
leg	NN	O
.	.	O

BMD	NNP	Physical
was	VBD	O
measured	VBN	O
by	IN	O
DXA	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
exercise	NN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
leg	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
groups	NNS	O
using	VBG	O
ANCOVA	NNP	O
,	,	O
with	IN	O
change	NN	O
in	IN	O
the	DT	O
control	NN	O
leg	NN	O
and	CC	O
baseline	NN	O
BMD	NNP	O
as	IN	O
covariates	NNS	O
.	.	O

RM-MANOVA	NNP	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
bone	NN	Physical
changes	NNS	Physical
from	IN	O
exercise	NN	O
differed	VBN	O
between	IN	O
hip	NN	O
sites	NNS	O
.	.	O

RESULTS	NNP	O
61	CD	O
women	NNS	O
(	(	O
age	NN	O
33.6+/-11.1	CD	O
years	NNS	O
)	)	O
completed	VBD	O
the	DT	O
intervention	NN	O
.	.	O

Compliance	NNP	O
amongst	JJ	O
exercisers	NNS	O
was	VBD	O
86.7+/-10.6	CD	O
%	NN	O
.	.	O

Peak	NNP	Physical
ground	NN	Physical
reaction	NN	Physical
forces	NNS	Physical
during	IN	O
exercise	NN	O
increased	VBN	O
from	IN	O
2.5	CD	O
to	TO	O
2.8	CD	O
times	NNS	O
body	JJ	O
weight	NN	O
.	.	O

The	DT	O
change	NN	Physical
in	IN	Physical
femoral	JJ	Physical
neck	NN	Physical
BMD	NNP	Physical
in	IN	O
the	DT	O
exercise	NN	O
limb	NN	O
(	(	O
adjusted	VBN	O
for	IN	O
change	NN	O
in	IN	O
the	DT	O
control	NN	O
limb	NN	O
and	CC	O
baseline	VB	O
BMD	NNP	O
)	)	O
differed	VBD	O
between	IN	O
groups	NNS	O
(	(	O
p=0.015	NN	O
)	)	O
,	,	O
being	VBG	O
-0.3	CD	O
%	NN	O
(	(	O
-1.2	CD	O
to	TO	O
0.6	CD	O
)	)	O
,	,	O
0.0	CD	O
%	NN	O
(	(	O
-1.0	CD	O
to	TO	O
1.0	CD	O
)	)	O
,	,	O
0.9	CD	O
%	NN	O
(	(	O
-0.1	CD	O
to	TO	O
2.0	CD	O
)	)	O
and	CC	O
1.8	CD	O
%	NN	O
(	(	O
0.8	CD	O
to	TO	O
2.8	CD	O
)	)	O
in	IN	O
those	DT	O
exercising	VBG	O
0	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
7	CD	O
days	NNS	O
per	IN	O
week	NN	O
,	,	O
respectively	RB	O
.	.	O

When	WRB	O
BMD	NNP	Physical
changes	NNS	Physical
at	IN	Physical
upper	JJ	Physical
neck	NN	Physical
,	,	Physical
lower	JJR	Physical
neck	NN	Physical
and	CC	Physical
trochanter	NN	Physical
were	VBD	O
compared	VBN	O
using	VBG	O
RM-MANOVA	NNP	O
,	,	O
a	DT	O
significant	JJ	O
exercise	NN	O
effect	NN	O
was	VBD	O
observed	VBN	O
(	(	O
p=0.048	NN	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
sites	NNS	O
(	(	O
p=0.439	NN	O
)	)	O
despite	IN	O
greatest	JJS	O
mean	NN	O
increases	NNS	O
at	IN	O
the	DT	O
upper	JJ	O
femoral	JJ	O
neck	NN	O
.	.	O

CONCLUSIONS	NNP	O
Brief	NNP	O
,	,	O
daily	RB	O
hopping	VBG	O
exercises	NNS	O
increased	VBD	O
femoral	JJ	Physical
neck	NN	Physical
BMD	NNP	Physical
in	IN	O
premenopausal	JJ	O
women	NNS	O
but	CC	O
less	JJR	O
frequent	JJ	O
exercise	NN	O
was	VBD	O
not	RB	O
effective	JJ	O
.	.	O

Brief	JJ	O
high-impact	JJ	O
exercise	NN	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
reducing	VBG	O
hip	NN	Physical
fragility	NN	Physical
,	,	O
but	CC	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
performed	VBN	O
frequently	RB	O
for	IN	O
optimal	JJ	O
response	NN	O
.	.	O

Analysis	NN	O
of	IN	O
prevention	NN	O
program	NN	O
effectiveness	NN	O
with	IN	O
clustered	VBN	O
data	NNS	O
using	VBG	O
generalized	JJ	O
estimating	NN	O
equations	NNS	O
.	.	O

Experimental	JJ	O
studies	NNS	O
of	IN	O
prevention	NN	O
programs	NNS	O
often	RB	O
randomize	VBP	O
clusters	NNS	O
of	IN	O
individuals	NNS	O
rather	RB	O
than	IN	O
individuals	NNS	O
to	TO	O
treatment	NN	O
conditions	NNS	O
.	.	O

When	WRB	O
the	DT	O
correlation	NN	O
among	IN	O
individuals	NNS	O
within	IN	O
clusters	NNS	O
is	VBZ	O
not	RB	O
accounted	VBN	O
for	IN	O
in	IN	O
statistical	JJ	O
analysis	NN	O
,	,	O
the	DT	O
standard	JJ	O
errors	NNS	O
are	VBP	O
biased	VBN	O
,	,	O
potentially	RB	O
resulting	VBG	O
in	IN	O
misleading	VBG	O
conclusions	NNS	O
about	IN	O
the	DT	O
significance	NN	O
of	IN	O
treatment	NN	O
effects	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
the	DT	O
generalized	JJ	O
estimating	NN	O
equations	NNS	O
(	(	O
GEE	NNP	O
)	)	O
method	NN	O
,	,	O
focusing	VBG	O
specifically	RB	O
on	IN	O
the	DT	O
GEE-independent	NNP	O
method	NN	O
,	,	O
to	TO	O
control	VB	O
for	IN	O
within-cluster	JJ	O
correlation	NN	O
in	IN	O
regression	NN	O
models	NNS	O
with	IN	O
either	DT	O
continuous	JJ	Others
or	CC	O
binary	JJ	Others
outcomes	NNS	Others
.	.	Others

The	DT	O
GEE-independent	JJ	O
method	NN	O
yields	NNS	O
consistent	JJ	Others
and	CC	O
robust	JJ	Others
variance	NN	Others
estimates	NNS	Others
.	.	Others

Data	NNS	O
from	IN	O
project	NN	O
DARE	NNP	O
,	,	O
a	DT	O
youth	NN	O
substance	NN	O
abuse	NN	O
prevention	NN	O
program	NN	O
,	,	O
are	VBP	O
used	VBN	O
for	IN	O
illustration	NN	O
.	.	O

Competitive	JJ	O
memory	NN	O
training	NN	O
(	(	O
COMET	NNP	O
)	)	O
for	IN	O
treating	VBG	O
low	JJ	Mental
self-esteem	NNS	Mental
in	IN	O
patients	NNS	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Self-esteem	NNP	O
is	VBZ	O
a	DT	O
major	JJ	O
concern	NN	O
in	IN	O
mood	NN	O
disorders	NNS	O
.	.	O

Low	JJ	Mental
self-esteem	NN	Mental
is	VBZ	O
a	DT	O
symptom	NN	O
of	IN	O
depressive	JJ	O
disorders	NNS	O
and	CC	O
is	VBZ	O
considered	VBN	O
by	IN	O
some	DT	O
to	TO	O
be	VB	O
a	DT	O
predictor	NN	O
for	IN	O
relapse	NN	O
,	,	O
whereas	JJ	O
high	JJ	O
self-esteem	NN	O
seems	VBZ	O
to	TO	O
buffer	VB	O
against	IN	O
depression	NN	O
.	.	O

Recently	RB	O
,	,	O
Competitive	NNP	Mental
Memory	NNP	Mental
Training	NNP	Mental
(	(	Mental
COMET	NNP	Mental
)	)	Mental
has	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
for	IN	O
the	DT	O
enhancement	NN	O
of	IN	O
self-esteem	NN	O
in	IN	O
several	JJ	O
psychopathological	JJ	O
conditions	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
assesses	VBZ	O
whether	IN	O
COMET	NNP	O
is	VBZ	O
also	RB	O
an	DT	O
effective	JJ	O
intervention	NN	O
for	IN	O
patients	NNS	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
Sixty-one	JJ	O
patients	NNS	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
who	WP	O
were	VBD	O
already	RB	O
in	IN	O
therapy	NN	O
in	IN	O
an	DT	O
outpatient	JJ	O
mental	JJ	O
health	NN	O
institution	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
eight	CD	O
group	NN	O
sessions	NNS	O
of	IN	O
COMET	NNP	O
in	IN	O
addition	NN	O
to	TO	O
their	PRP$	O
regular	JJ	O
therapy	NN	O
(	(	O
COMET	NNP	O
+	NNP	O
therapy	NN	O
as	IN	O
usual	JJ	O
[	NNP	O
TAU	NNP	O
]	NN	O
:	:	O
the	DT	O
experimental	JJ	O
group	NN	O
)	)	O
or	CC	O
to	TO	O
8	CD	O
weeks	NNS	O
of	IN	O
ongoing	VBG	O
regular	JJ	O
therapy	NN	O
(	(	O
TAU	NNP	O
only	RB	O
:	:	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
.	.	O

These	DT	O
latter	JJ	O
(	(	O
control	NN	O
)	)	O
patients	NNS	O
received	VBD	O
COMET	NNP	O
after	IN	O
their	PRP$	O
TAU	NNP	O
only	RB	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
that	WDT	O
completed	VBD	O
COMET	NNP	O
were	VBD	O
contacted	VBN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
later	RB	O
to	TO	O
assess	VB	O
whether	IN	O
the	DT	O
effects	NNS	Mental
of	IN	Mental
COMET	NNP	Mental
had	VBD	O
remained	VBN	O
stable	JJ	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
to	TO	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
TAU	NNP	O
only	RB	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
COMET	NNP	O
+	NNP	O
TAU	NNP	O
condition	NN	O
showed	VBD	O
significant	JJ	Others
improvement	NN	Others
with	IN	O
large	JJ	Mental
effect	NN	Mental
sizes	VBZ	Mental
on	IN	Mental
indices	NNS	Mental
of	IN	Mental
self-esteem	JJ	Mental
,	,	Mental
depression	NN	Mental
,	,	Mental
and	CC	Mental
depressive	JJ	Mental
rumination	NN	Mental
.	.	Mental

The	DT	O
therapeutic	JJ	Mental
effects	NNS	Mental
of	IN	O
COMET	NNP	O
+	NNP	O
TAU	NNP	O
remained	VBD	O
stable	JJ	Mental
after	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
on	IN	O
all	DT	O
outcome	NN	O
measures	NNS	O
or	CC	O
improved	VBN	O
even	RB	O
further	RBR	O
.	.	O

CONCLUSION	NNP	O
COMET	NNP	O
for	IN	O
low	JJ	O
self-esteem	JJ	O
seems	VBZ	O
to	TO	O
be	VB	O
an	DT	O
efficacious	JJ	O
trans-diagnostic	JJ	O
intervention	NN	O
that	WDT	O
can	MD	O
relatively	RB	O
easily	RB	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
regular	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
.	.	O

Unpacking	VBG	O
attitude	JJ	O
certainty	NN	O
:	:	O
attitude	NN	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
.	.	O

Attitude	NNP	O
certainty	NN	O
has	VBZ	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
considerable	JJ	O
attention	NN	O
in	IN	O
the	DT	O
attitudes	NNS	O
and	CC	O
persuasion	NN	O
literature	NN	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
identifies	VBZ	O
2	CD	O
aspects	NNS	O
of	IN	O
attitude	NN	O
certainty	NN	O
and	CC	O
provides	VBZ	O
evidence	NN	O
for	IN	O
the	DT	O
distinctness	NN	O
of	IN	O
the	DT	O
constructs	NNS	O
.	.	O

Specifically	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
attitude	JJ	O
certainty	NN	O
can	MD	O
be	VB	O
conceptualized	VBN	O
,	,	O
and	CC	O
empirically	RB	O
separated	VBN	O
,	,	O
in	IN	O
terms	NNS	O
of	IN	O
attitude	NN	O
clarity	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	WDT	O
one	CD	O
knows	VBZ	O
what	WP	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
)	)	O
and	CC	O
attitude	JJ	O
correctness	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	IN	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
correct	JJ	O
or	CC	O
valid	JJ	O
)	)	O
.	.	O

Experiment	JJ	O
1	CD	O
uses	NNS	O
factor	NN	O
analysis	NN	O
and	CC	O
correlational	JJ	O
data	NNS	O
to	TO	O
provide	VB	O
evidence	NN	O
for	IN	O
viewing	VBG	O
attitude	JJ	Mental
clarity	NN	Mental
and	CC	O
attitude	NN	Mental
correctness	NN	Mental
as	IN	O
separate	JJ	O
constructs	NNS	O
.	.	O

Experiments	NNS	O
2	CD	O
and	CC	O
3	CD	O
demonstrate	NN	O
that	WDT	O
attitude	VBP	Mental
clarity	NN	Mental
and	CC	O
attitude	NN	Mental
correctness	NN	Mental
can	MD	O
have	VB	O
distinct	JJ	O
antecedents	NNS	O
(	(	O
repeated	VBN	O
expression	NN	O
and	CC	O
consensus	NN	O
feedback	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Experiment	JJ	O
4	CD	O
reveals	NNS	O
that	IN	O
these	DT	O
constructs	NNS	O
each	DT	O
play	VBP	Mental
an	DT	Mental
independent	JJ	Mental
role	NN	Mental
in	IN	Mental
persuasion	NN	Mental
and	CC	Mental
resistance	NN	Mental
situations	NNS	Mental
.	.	O

As	IN	O
clarity	NN	O
and	CC	O
correctness	JJ	O
increase	NN	O
,	,	O
attitudes	VBZ	Mental
become	VBP	Mental
more	RBR	Mental
resistant	JJ	Mental
to	TO	O
counterattitudinal	JJ	O
persuasive	JJ	O
messages	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
existing	VBG	O
attitude	NN	O
strength	NN	O
literature	NN	O
.	.	O

Validity	NNP	Others
and	CC	Others
reliability	NN	Others
assessment	NN	O
of	IN	O
the	DT	O
Siriraj	NNP	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
present	JJ	O
study	NN	O
assessed	VBD	O
the	DT	O
validity	NN	Others
and	CC	O
reliability	NN	Others
of	IN	O
the	DT	O
Siriraj	NNP	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
in	IN	O
Asthma	NNP	O
Clinic	NNP	O
,	,	O
Siriraj	NNP	O
Hospital	NNP	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
The	DT	O
data	NN	O
of	IN	O
the	DT	O
questionnaire	NN	O
responses	NNS	O
and	CC	O
spirometric	JJ	O
results	NNS	O
from	IN	O
20	CD	O
randomized	JJ	O
asthmatic	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
clinic	NN	O
including	VBG	O
the	DT	O
record	NN	O
of	IN	O
3	CD	O
visits	NNS	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

The	DT	O
validation	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
Kruskal-Wallis	NNP	O
test	NN	O
comparing	VBG	O
the	DT	O
scores	NNS	O
with	IN	O
the	DT	O
level	NN	O
of	IN	O
asthma	NNS	O
control	NN	O
determined	VBN	O
by	IN	O
physicians	NNS	O
according	VBG	O
to	TO	O
GINA	NNP	O
guideline	NN	O
.	.	O

Internal	NNP	O
consistency	NN	O
reliability	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
questionnaires	VBZ	O
from	IN	O
20	CD	O
patients	NNS	O
with	IN	O
age	NN	O
29-73	CD	O
years	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

There	EX	O
were	VBD	O
40	CD	O
controlled	VBN	O
,	,	O
7	CD	O
partly	RB	O
controlled	VBN	O
and	CC	O
13	CD	O
uncontrolled	JJ	O
visits	NNS	O
.	.	O

The	DT	O
scores	NNS	Physical
from	IN	Physical
5-items	JJ	Physical
questionnaires	NNS	Physical
and	CC	Physical
6-items	JJ	Physical
clinical	JJ	Physical
score	NN	Physical
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
the	DT	O
physician-diagnosed	JJ	O
groups	NNS	O
(	(	O
i.e.	FW	O
,	,	O
controlled	VBD	O
,	,	O
partly	RB	O
controlled	VBN	O
and	CC	O
uncontrolled	JJ	O
groups	NNS	O
)	)	O
.	.	O

Median	JJ	Physical
scores	NNS	Physical
(	(	Physical
min	NN	Physical
,	,	Physical
max	NN	Physical
)	)	Physical
were	VBD	O
0	CD	O
(	(	O
0	CD	O
,	,	O
5	CD	O
)	)	O
,	,	O
2	CD	O
(	(	O
0	CD	O
,	,	O
6	CD	O
)	)	O
,	,	O
4	CD	O
(	(	O
0	CD	O
,	,	O
12	CD	O
)	)	O
respectively	RB	O
,	,	O
(	(	O
5-items	CD	O
,	,	O
p	VBZ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
2	CD	O
(	(	O
0	CD	O
,	,	O
7	CD	O
)	)	O
,	,	O
3	CD	O
(	(	O
1	CD	O
,	,	O
7	CD	O
)	)	O
,	,	O
6	CD	O
(	(	O
2,15	CD	O
)	)	O
respectively	RB	O
,	,	O
(	(	O
6-items	CD	O
,	,	O
p	VBZ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Internal	NNP	Others
consistency	NN	Others
reliability	NN	Others
of	IN	O
both	DT	O
5-items	JJ	O
questionnaire	NN	O
and	CC	O
6-items	JJ	O
clinical	JJ	O
score	NN	O
were	VBD	O
within	IN	O
the	DT	O
acceptable	JJ	O
range	NN	O
(	(	O
0.829	CD	O
and	CC	O
0.708	CD	O
respectively	RB	O
)	)	O
.	.	O

5-items	JJ	Others
questionnaire	NN	Others
is	VBZ	O
more	RBR	O
associated	JJ	O
with	IN	O
the	DT	O
physician	NN	O
diagnosed	VBN	O
group	NN	O
and	CC	O
more	JJR	O
consistent	JJ	Others
than	IN	O
6-items	JJ	Physical
clinical	JJ	Physical
score	NN	Physical
.	.	Physical

Further	JJ	O
analysis	NN	O
revealed	VBD	O
cutoff	NN	O
point	NN	O
at	IN	O
2.5	CD	O
to	TO	O
separate	VB	O
uncontrolled	JJ	O
from	IN	O
controlled	VBN	O
or	CC	O
partly	RB	O
controlled	VBN	O
patient	NN	O
with	IN	O
sensitivity	NN	Others
76.9	CD	O
%	NN	O
and	CC	O
specificity	NN	Others
89.4	CD	O
%	NN	O
and	CC	O
cutoff	NN	Others
point	NN	Others
at	IN	O
1.5	CD	O
to	TO	O
separate	VB	O
uncontrolled	JJ	O
or	CC	O
partly	RB	O
controlled	VBN	O
from	IN	O
controlled	VBN	O
patient	NN	O
with	IN	O
sensitivity	NN	Others
70.0	CD	O
%	NN	O
and	CC	O
specificity	NN	Others
85.0	CD	O
%	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
validity	NN	Others
and	CC	Others
reliability	NN	Others
of	IN	O
Siriraj	NNP	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
is	VBZ	O
acceptable	JJ	O
and	CC	O
might	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
practice	NN	O
and	CC	O
research	NN	O
in	IN	O
Thai	NNP	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Cardiac	JJ	O
failure	NN	O
:	:	O
symptoms	NNS	O
and	CC	O
functional	JJ	O
status	NN	O
.	.	O

The	DT	O
associations	NNS	O
between	IN	O
exercise	NN	O
capacity	NN	O
,	,	O
symptoms	NNS	O
and	CC	O
specific	JJ	O
aspects	NNS	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
were	VBD	O
examined	VBN	O
in	IN	O
subjects	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
trial	NN	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
heart	NN	O
failure	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
entry	NN	O
and	CC	O
after	IN	O
three	CD	O
months	NNS	O
treatment	NN	O
.	.	O

The	DT	O
principle	NN	O
symptoms	NNS	O
were	VBD	O
fatigue	JJ	O
,	,	O
breathlessness	NN	O
and	CC	O
chest	NN	O
pain	NN	O
.	.	O

These	DT	O
limited	VBD	O
the	DT	O
extent	NN	O
and	CC	O
speed	NN	O
of	IN	O
physical	JJ	O
activities	NNS	O
,	,	O
restricted	VBN	O
social	JJ	O
,	,	O
leisure	NN	O
and	CC	O
family	NN	O
life	NN	O
and	CC	O
were	VBD	O
associated	VBN	O
with	IN	O
emotional	JJ	O
distress	NN	O
.	.	O

There	EX	O
were	VBD	O
associations	NNS	O
between	IN	O
baseline	NN	Others
exercise	NN	Others
capacity	NN	Others
and	CC	O
measures	NNS	Others
of	IN	Others
quality	NN	Others
of	IN	Others
life	NN	Others
.	.	O

Change	NNP	O
in	IN	O
exercise	NN	O
capacity	NN	O
during	IN	O
three	CD	O
months	NNS	O
treatment	NN	O
was	VBD	O
correlated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
measures	NNS	Others
of	IN	Others
symptoms	NNS	Others
,	,	O
limitation	NN	Others
of	IN	Others
activity	NN	Others
and	CC	Others
quality	NN	Others
of	IN	Others
life	NN	Others
.	.	O

The	DT	O
findings	NNS	O
confirm	VBP	O
the	DT	O
value	NN	O
of	IN	O
change	NN	O
in	IN	O
exercise	NN	Others
capacity	NN	Others
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
functional	JJ	O
status	NN	O
and	CC	O
suggest	VBP	O
that	IN	O
it	PRP	O
should	MD	O
be	VB	O
supported	VBN	O
by	IN	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
specific	JJ	O
measures	NNS	O
of	IN	O
quality	NN	Others
of	IN	Others
life	NN	Others
.	.	O

Effect	NN	O
of	IN	O
CX516	NNP	O
,	,	O
an	DT	O
AMPA-modulating	JJ	O
compound	NN	O
,	,	O
on	IN	O
cognition	NN	Mental
and	CC	Physical
behavior	NN	Mental
in	IN	O
fragile	JJ	O
X	JJ	O
syndrome	NN	O
:	:	O
a	DT	O
controlled	JJ	O
trial	NN	O
.	.	O

A	DT	O
Phase	NNP	O
II	NNP	O
,	,	O
4-week	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
efficacy	NN	Others
of	IN	O
the	DT	O
Ampakine	NNP	O
compound	NN	O
CX516	NNP	O
as	IN	O
a	DT	O
potential	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
underlying	JJ	O
disorder	NN	O
in	IN	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
(	(	O
FXS	NNP	O
)	)	O
.	.	O

After	IN	O
baseline	NN	O
screening	NN	O
,	,	O
subjects	VBZ	O
with	IN	O
FXS	NNP	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
underwent	NN	O
a	DT	O
1-week	JJ	O
placebo	NN	O
lead-in	NN	O
and	CC	O
then	RB	O
were	VBD	O
randomized	VBN	O
to	TO	O
study	VB	O
drug	NN	O
or	CC	O
placebo	NN	O
for	IN	O
a	DT	O
4-week	JJ	O
period	NN	O
.	.	O

Cognitive	JJ	Mental
and	CC	Mental
behavioral	JJ	Mental
outcome	NN	O
measures	NNS	O
were	VBD	O
administered	VBN	O
prior	RB	O
to	TO	O
treatment	NN	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
2	CD	O
weeks	NNS	O
posttreatment	NN	O
.	.	O

There	EX	O
were	VBD	O
minimal	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
,	,	O
no	DT	O
significant	JJ	Others
changes	NNS	Others
in	IN	Others
safety	NN	Others
parameters	NNS	Others
,	,	O
and	CC	O
no	DT	Adverseeffect
serious	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

There	EX	O
was	VBD	O
a	DT	O
12.5	CD	O
%	NN	O
frequency	NN	O
of	IN	O
allergic	JJ	Physical
rash	NN	Physical
in	IN	O
the	DT	O
CX516	NNP	O
group	NN	O
and	CC	O
1	CD	O
subject	NN	O
developed	VBD	O
a	DT	O
substantial	JJ	Adverseeffect
rash	NN	Adverseeffect
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	Mental
improvement	NN	Mental
in	IN	O
memory	NN	Mental
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
or	CC	O
in	IN	O
secondary	JJ	O
measures	NNS	O
of	IN	O
language	NN	Mental
,	,	Mental
attention/executive	JJ	Mental
function	NN	Mental
,	,	Mental
behavior	NN	Mental
,	,	Mental
and	CC	Mental
overall	JJ	Mental
functioning	NN	Mental
in	IN	O
CX516-treated	JJ	O
subjects	NNS	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

This	DT	O
study	NN	O
did	VBD	O
demonstrate	VB	O
that	IN	O
many	JJ	O
outcome	JJ	O
measures	NNS	Others
were	VBD	O
reproducible	JJ	O
in	IN	O
this	DT	O
test-retest	JJ	O
setting	NN	O
for	IN	O
the	DT	O
FXS	NNP	O
population	NN	O
,	,	O
yet	CC	O
some	DT	O
were	VBD	O
too	RB	O
difficult	JJ	O
or	CC	O
variable	JJ	O
.	.	O

Adult	NNP	O
subjects	VBZ	O
with	IN	O
FXS	NNP	O
were	VBD	O
able	JJ	O
to	TO	O
complete	VB	O
an	DT	O
intensive	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
and	CC	O
some	DT	O
valid	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
identified	VBN	O
for	IN	O
future	JJ	O
FXS	NNP	O
trial	NN	O
design	NN	O
.	.	O

Problems	VBZ	O
with	IN	O
potency	NN	O
of	IN	O
CX516	NNP	O
in	IN	O
other	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
dosing	NN	O
may	MD	O
have	VB	O
been	VBN	O
inadequate	JJ	O
for	IN	O
therapeutic	JJ	O
effect	NN	O
and	CC	O
thus	RB	O
it	PRP	O
remains	VBZ	O
unclear	JJ	O
whether	IN	O
modulation	NN	O
of	IN	O
AMPA-mediated	JJ	O
neurotransmission	NN	O
is	VBZ	O
a	DT	O
viable	JJ	Others
therapeutic	JJ	Others
strategy	NN	Others
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
FXS	NNP	O
.	.	O

Custom	NNP	O
tray	JJ	O
application	NN	O
of	IN	O
peroxide	JJ	O
gel	NN	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
scaling	NN	O
and	CC	O
root	NN	O
planing	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
periodontitis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
after	IN	O
six	CD	O
months	NNS	O
.	.	O

OBJECTIVE	NNP	O
Scaling	NNP	O
and	CC	O
root	NN	O
planing	NN	O
(	(	O
SRP	NNP	O
)	)	O
is	VBZ	O
the	DT	O
primary	JJ	O
non-surgical	JJ	O
treatment	NN	O
for	IN	O
periodontitis	NN	O
,	,	O
but	CC	O
its	PRP$	O
effectiveness	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Consequently	RB	O
,	,	O
various	JJ	O
adjunctive	JJ	O
therapies	NNS	O
have	VBP	O
been	VBN	O
investigated	VBN	O
to	TO	O
improve	VB	O
clinical	JJ	O
outcome	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
clinical	JJ	O
effects	NNS	O
of	IN	O
one	CD	O
SRP	NNP	O
procedure	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
local	JJ	O
administration	NN	O
of	IN	O
hydrogen	NN	O
peroxide	NN	O
gel	NN	O
using	VBG	O
customized	JJ	O
trays	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
periodontitis	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
six	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
An	DT	O
examiner-blind	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
30	CD	O
subjects	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
advanced	JJ	O
periodontitis	NN	O
who	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
SRP	VB	O
alone	RB	O
or	CC	O
SRP	NNP	O
combined	VBN	O
with	IN	O
prescription	NN	O
custom-tray	JJ	O
application	NN	O
(	(	O
Perio	NNP	O
Tray	NNP	O
)	)	O
of	IN	O
1.7	CD	O
%	NN	O
hydrogen	NN	O
peroxide	NN	O
gel	NN	O
(	(	O
Perio	NNP	O
Gel	NNP	O
)	)	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
three	CD	O
months	NNS	O
,	,	O
then	RB	O
extended	VBD	O
to	TO	O
six	CD	O
months	NNS	O
.	.	O

Following	VBG	O
impressions	NNS	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
,	,	O
all	DT	O
subjects	NNS	O
brushed	VBN	O
twice	RB	O
daily	RB	O
with	IN	O
a	DT	O
regular	JJ	O
dentifrice	NN	O
and	CC	O
toothbrush	NN	O
for	IN	O
a	DT	O
four-week	JJ	O
acclimation	NN	O
phase	NN	O
to	TO	O
standardize	VB	O
oral	JJ	O
conditions	NNS	O
(	(	O
while	IN	O
trays	NNS	O
were	VBD	O
fabricated	VBN	O
)	)	O
prior	RB	O
to	TO	O
initiating	VBG	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

SRP	NNP	O
was	VBD	O
performed	VBN	O
three	CD	O
weeks	NNS	O
after	IN	O
baseline	NN	O
,	,	O
and	CC	O
clinical	JJ	O
assessments	NNS	O
,	,	O
i.e.	FW	O
,	,	O
pocket	NN	Physical
probing	VBG	Physical
depth	NN	Physical
(	(	Physical
PPD	NNP	Physical
)	)	Physical
and	CC	Physical
bleeding	VBG	Physical
index	NN	Physical
(	(	Physical
BI	NNP	Physical
)	)	Physical
,	,	O
were	VBD	O
conducted	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
two	CD	O
,	,	O
five	CD	O
,	,	O
13	CD	O
,	,	O
and	CC	O
26	CD	O
weeks	NNS	O
of	IN	O
peroxide	JJ	O
gel	NN	O
applications	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
ANCOVA	NNP	O
and	CC	O
paired	VBD	O
t-tests	NNS	O
after	IN	O
each	DT	O
treatment	NN	O
interval	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
13	CD	O
test	NN	O
and	CC	O
15	CD	O
control	NN	O
subjects	NNS	O
completed	VBD	O
the	DT	O
original	JJ	O
three-month	JJ	O
trial	NN	O
,	,	O
of	IN	O
whom	WP	O
10	CD	O
test	NN	O
and	CC	O
13	CD	O
control	NN	O
subjects	NNS	O
finished	VBD	O
the	DT	O
three-month	JJ	O
extension	NN	O
.	.	O

After	IN	O
two	CD	O
weeks	NNS	O
of	IN	O
peroxide	NN	O
gel	NN	O
use	NN	O
prior	RB	O
to	TO	O
SRP	NNP	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
for	IN	O
the	DT	O
test	NN	O
group	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
baseline	NN	O
by	IN	O
0.21	CD	O
mm	NNS	O
and	CC	O
mean	JJ	Physical
BI	NNP	Physical
significantly	RB	O
dropped	VBD	O
by	IN	O
0.14	CD	O
;	:	O
clinical	JJ	O
parameters	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
unchanged	JJ	O
.	.	O

Two	CD	O
weeks	NNS	O
following	VBG	O
SRP	NNP	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
significantly	RB	O
decreased	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
0.65	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.17	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
;	:	O
mean	CC	O
BI	NNP	O
significantly	RB	O
dropped	VBD	O
by	IN	O
0.17	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.05	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Ten	CD	O
weeks	NNS	O
following	VBG	O
SRP	NNP	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
decreases	NNS	O
were	VBD	O
0.77	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.13	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
mean	JJ	Physical
BI	NNP	Physical
reductions	NNS	O
were	VBD	O
0.14	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.00	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

For	IN	O
subjects	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
three-month	JJ	O
extension	NN	O
(	(	O
i.e.	JJ	O
,	,	O
23	CD	O
weeks	NNS	O
post-SRP	NN	O
)	)	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
decreases	NNS	O
were	VBD	O
0.72	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.13	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
mean	JJ	Physical
BI	NNP	Physical
reductions	NNS	O
were	VBD	O
0.05	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.01	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Analysis	NN	O
of	IN	O
deeper	JJR	O
pockets	NNS	O
(	(	O
i.e.	NN	O
,	,	O
>	VBZ	O
5	CD	O
mm	NN	O
at	IN	O
baseline	NN	O
)	)	O
showed	VBD	O
the	DT	O
same	JJ	O
relationship	NN	O
for	IN	O
PPD	NNP	O
,	,	O
but	CC	O
with	IN	O
larger	JJR	O
differences	NNS	O
between	IN	O
groups	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
after	IN	O
two	CD	O
weeks	NNS	O
of	IN	O
peroxide	NN	O
gel	NN	O
use	NN	O
prior	RB	O
to	TO	O
SRP	NNP	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
decreased	VBN	O
by	IN	O
0.48	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
compared	VBN	O
to	TO	O
0.04	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Two	CD	O
weeks	NNS	O
after	IN	O
SRP	NNP	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
decreased	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
1.40	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.60	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
10	CD	O
weeks	NNS	O
after	IN	O
SRP	NNP	O
by	IN	O
1.57	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.58	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

After	IN	O
the	DT	O
extension	NN	O
(	(	O
i.e.	JJ	O
,	,	O
23	CD	O
weeks	NNS	O
post-SRP	NN	O
)	)	O
,	,	O
mean	JJ	Physical
PPD	NNP	Physical
changed	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
1.50	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.55	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
BI	NNP	O
at	IN	O
23	CD	O
weeks	NNS	O
post-SRP	JJ	O
,	,	O
all	DT	O
reductions	NNS	O
cited	VBN	O
above	IN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
were	VBD	O
statistically	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
both	DT	O
PPD	NNP	O
and	CC	O
BI	NNP	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
compared	VBN	O
with	IN	O
SRP	NNP	O
alone	RB	O
,	,	O
clinical	JJ	O
improvements	NNS	O
in	IN	O
PPD	NNP	O
(	(	O
e.g.	NN	O
,	,	O
-1.0	NNP	O
mm	NN	O
for	IN	O
pockets	NNS	O
>	VBP	O
5	CD	O
mm	NN	O
at	IN	O
baseline	NN	O
)	)	O
were	VBD	O
maintained	VBN	O
for	IN	O
up	IN	O
to	TO	O
six	CD	O
months	NNS	O
after	IN	O
SRP	NNP	O
with	IN	O
adjunctive	JJ	O
use	NN	O
of	IN	O
1.7	CD	O
%	NN	O
hydrogen	NN	O
peroxide	NN	O
gel	NN	O
,	,	O
locally	RB	O
administered	VBN	O
using	VBG	O
prescription	NN	O
customized	VBD	O
trays	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
advanced	JJ	O
periodontitis	NN	O
.	.	O

Effects	NNS	O
of	IN	O
nifedipine	NN	O
on	IN	O
gastric	JJ	Physical
acid	JJ	Physical
secretion	NN	Physical
and	CC	O
gastrin	NN	Physical
release	NN	Physical
in	IN	O
man	NN	O
.	.	O

As	IN	O
calcium	NN	O
is	VBZ	O
important	JJ	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
gastric	JJ	O
acid	JJ	O
secretion	NN	O
and	CC	O
gastrin	NN	O
release	NN	O
,	,	O
we	PRP	O
have	VBP	O
examined	VBN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
calcium	NN	O
antagonist	NN	O
nifedipine	NN	O
on	IN	O
these	DT	O
processes	NNS	O
in	IN	O
man	NN	O
.	.	O

Nifedipine	CC	O
30	CD	O
mg	NNS	O
orally	RB	O
inhibited	VBN	O
basal	NN	O
acid	NN	O
output	NN	O
by	IN	O
37	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
and	CC	O
that	IN	O
stimulated	VBN	O
by	IN	O
low	JJ	O
infusion	NN	O
rates	NNS	O
of	IN	O
pentagastrin	NN	O
--	:	O
that	WDT	O
is	VBZ	O
,	,	O
0.031	CD	O
and	CC	O
0.062	CD	O
microgram/kg/h	NN	O
by	IN	O
44	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
and	CC	O
39	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
respectively	RB	O
.	.	O

On	IN	O
increasing	VBG	O
the	DT	O
pentagastrin	JJ	O
infusion	NN	O
rate	NN	O
the	DT	O
inhibition	NN	O
was	VBD	O
surmounted	VBN	O
suggesting	VBG	O
it	PRP	O
was	VBD	O
competitive	JJ	O
in	IN	O
type	NN	O
.	.	O

Nifedipine	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
basal	NN	Physical
or	CC	Physical
Oxo	NNP	Physical
meal	NN	Physical
stimulated	VBD	Physical
gastrin	JJ	Physical
concentrations	NNS	Physical
in	IN	O
normal	JJ	O
volunteers	NNS	O
nor	CC	O
did	VBD	O
it	PRP	O
affect	VB	O
resting	VBG	Physical
serum	JJ	Physical
gastrin	NN	Physical
or	CC	O
calcium	NN	Physical
stimulated	JJ	Physical
increase	NN	Physical
in	IN	Physical
gastrin	NN	Physical
in	IN	O
a	DT	O
single	JJ	O
patient	NN	O
with	IN	O
Zollinger-Ellison	NNP	O
syndrome	NN	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
transmembrane	NN	O
flux	NN	O
of	IN	O
calcium	NN	O
ions	NNS	O
being	VBG	O
involved	VBN	O
in	IN	O
basal	NN	O
and	CC	O
pentagastrin	NN	O
stimulated	VBD	O
acid	JJ	O
secretion	NN	O
in	IN	O
man	NN	O
.	.	O

Aspirin	NNP	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
noncardiac	JJ	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
substantial	JJ	O
variability	NN	O
in	IN	O
the	DT	O
perioperative	JJ	O
administration	NN	O
of	IN	O
aspirin	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
noncardiac	JJ	O
surgery	NN	O
,	,	O
both	DT	O
among	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
already	RB	O
on	IN	O
an	DT	O
aspirin	JJ	O
regimen	NNS	O
and	CC	O
among	IN	O
those	DT	O
who	WP	O
are	VBP	O
not	RB	O
.	.	O

METHODS	NNP	O
Using	VBG	O
a	DT	O
2-by-2	JJ	O
factorial	JJ	O
trial	NN	O
design	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	VBD	O
10,010	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
preparing	VBG	O
to	TO	O
undergo	VB	O
noncardiac	JJ	O
surgery	NN	O
and	CC	O
were	VBD	O
at	IN	O
risk	NN	O
for	IN	O
vascular	JJ	O
complications	NNS	O
to	TO	O
receive	VB	O
aspirin	NN	O
or	CC	O
placebo	NN	O
and	CC	O
clonidine	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
aspirin	JJ	O
trial	NN	O
are	VBP	O
reported	VBN	O
here	RB	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
they	PRP	O
had	VBD	O
not	RB	O
been	VBN	O
taking	VBG	O
aspirin	NN	O
before	IN	O
the	DT	O
study	NN	O
(	(	O
initiation	NN	O
stratum	NN	O
,	,	O
with	IN	O
5628	CD	O
patients	NNS	O
)	)	O
or	CC	O
they	PRP	O
were	VBD	O
already	RB	O
on	IN	O
an	DT	O
aspirin	JJ	O
regimen	NNS	O
(	(	O
continuation	NN	O
stratum	NN	O
,	,	O
with	IN	O
4382	CD	O
patients	NNS	O
)	)	O
.	.	O

Patients	NNS	O
started	VBD	O
taking	VBG	O
aspirin	NN	O
(	(	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
200	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	VB	O
just	RB	O
before	RB	O
surgery	NN	O
and	CC	O
continued	VBD	O
it	PRP	O
daily	RB	O
(	(	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
100	CD	O
mg	NNS	O
)	)	O
for	IN	O
30	CD	O
days	NNS	O
in	IN	O
the	DT	O
initiation	NN	O
stratum	NN	O
and	CC	O
for	IN	O
7	CD	O
days	NNS	O
in	IN	O
the	DT	O
continuation	NN	O
stratum	NN	O
,	,	O
after	IN	O
which	WDT	O
patients	NNS	O
resumed	VBD	O
their	PRP$	O
regular	JJ	O
aspirin	JJ	O
regimen	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
a	DT	O
composite	JJ	Mortality
of	IN	Mortality
death	NN	Mortality
or	CC	O
nonfatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
at	IN	Physical
30	CD	Physical
days	NNS	Physical
.	.	O

RESULTS	VB	O
The	DT	O
primary	JJ	O
outcome	NN	O
occurred	VBD	O
in	IN	O
351	CD	O
of	IN	O
4998	CD	O
patients	NNS	O
(	(	O
7.0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
and	CC	O
in	IN	O
355	CD	O
of	IN	O
5012	CD	O
patients	NNS	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
,	,	O
0.99	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.86	CD	O
to	TO	O
1.15	CD	O
;	:	O
P=0.92	NNP	O
)	)	O
.	.	O

Major	JJ	Physical
bleeding	NN	Physical
was	VBD	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
230	CD	O
patients	NNS	O
[	JJ	O
4.6	CD	O
%	NN	O
]	NNP	O
vs.	IN	O
188	CD	O
patients	NNS	O
[	JJ	O
3.8	CD	O
%	NN	O
]	NN	O
;	:	O
hazard	CC	O
ratio	NN	O
,	,	O
1.23	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01	CD	O
,	,	O
to	TO	O
1.49	CD	O
;	:	O
P=0.04	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcome	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
aspirin	NN	O
strata	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
aspirin	NN	O
before	IN	O
surgery	NN	O
and	CC	O
throughout	IN	O
the	DT	O
early	JJ	O
postsurgical	JJ	O
period	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
rate	NN	Mortality
of	IN	Mortality
a	DT	Mortality
composite	NN	Mortality
of	IN	Mortality
death	NN	Mortality
or	CC	O
nonfatal	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
but	CC	O
increased	VBD	O
the	DT	O
risk	NN	Physical
of	IN	Physical
major	JJ	Physical
bleeding	NN	Physical
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
the	DT	O
Canadian	NNP	O
Institutes	NNPS	O
of	IN	O
Health	NNP	O
Research	NNP	O
and	CC	O
others	NNS	O
;	:	O
POISE-2	NNP	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT01082874	NNP	O
.	.	O

)	)	O
.	.	O

Transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
for	IN	O
postoperative	JJ	O
pain	NN	O
relief	NN	O
after	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

Transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
(	(	O
TENS	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
used	VBN	O
to	TO	O
treat	VB	O
chronic	JJ	O
pain	NN	O
syndromes	NNS	O
and	CC	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
of	IN	O
some	DT	O
utility	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postsurgical	JJ	O
pain	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
blinded	VBD	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
utility	NN	O
of	IN	O
TENS	NNP	O
after	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
enrolled	VBN	O
into	IN	O
patient-controlled	JJ	O
anesthesia	NN	O
(	(	O
PCA	NNP	O
)	)	O
alone	RB	O
,	,	O
PCA	NNP	O
plus	CC	O
TENS	NNP	O
,	,	O
or	CC	O
PCA	NNP	O
plus	CC	O
sham	JJ	O
TENS	NNP	O
.	.	O

The	DT	O
cumulative	JJ	Physical
dose	NN	Physical
of	IN	Physical
morphine	NN	Physical
by	IN	O
PCA	NNP	O
for	IN	O
each	DT	O
group	NN	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
end-point	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
requirement	NN	Pain
for	IN	Pain
patient-controlled	JJ	Pain
analgesia	NN	Pain
with	IN	O
or	CC	O
without	IN	O
TENS	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
utility	NN	O
for	IN	O
TENS	NNP	O
in	IN	O
the	DT	O
postoperative	JJ	O
management	NN	O
of	IN	O
pain	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

In	IN	O
vivo	JJ	O
effect	NN	O
of	IN	O
clarithromycin	NN	O
on	IN	O
multiple	JJ	O
cytochrome	NN	O
P450s	NNP	O
.	.	O

The	DT	O
in	IN	O
vivo	JJ	O
effects	NNS	O
of	IN	O
oral	JJ	O
clarithromycin	JJ	O
administration	NN	O
on	IN	O
the	DT	O
in	IN	O
vivo	JJ	O
activity	NN	O
of	IN	O
cytochrome	NN	O
P450	NNP	O
1A2	CD	O
,	,	O
2C9	CD	O
,	,	O
and	CC	O
2D6	CD	O
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
cytochrome	JJ	O
P450	NNP	O
probes	NNS	O
caffeine	NN	O
(	(	O
CYP1A2	NNP	O
)	)	O
,	,	O
tolbutamide	RB	O
(	(	O
CYP2C9	NNP	O
)	)	O
,	,	O
and	CC	O
dextromethorphan	NN	O
(	(	O
CYP2D6	NNP	O
)	)	O
were	VBD	O
administered	VBN	O
as	IN	O
an	DT	O
oral	JJ	O
cocktail	NN	O
prior	NN	O
to	TO	O
and	CC	O
7	CD	O
days	NNS	O
after	IN	O
oral	JJ	O
clarithromycin	NN	O
(	(	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
administration	NN	O
to	TO	O
12	CD	O
healthy	JJ	O
male	JJ	O
subjects	NNS	O
.	.	O

Blood	NN	Physical
and	CC	Physical
urine	JJ	Physical
samples	NNS	Physical
were	VBD	O
collected	VBN	O
and	CC	O
assayed	VBN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
compounds	NNS	O
and	CC	O
their	PRP$	O
metabolites	NNS	O
using	VBG	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

The	DT	O
CYP1A2	NNP	Physical
indices	NNS	Physical
,	,	O
oral	JJ	Physical
caffeine	NN	Physical
clearance	NN	Physical
(	(	O
6.2	CD	O
+/-	JJ	O
3.3	CD	O
l/h	NN	O
before	IN	O
and	CC	O
5.7	CD	O
+/-	JJ	O
4.2	CD	O
l/h	NN	O
after	IN	O
,	,	O
p	VBD	O
>	RB	O
0.05	CD	O
)	)	O
and	CC	O
the	DT	O
6-h	JJ	Physical
paraxanthine	NN	Physical
to	TO	Physical
caffeine	VB	Physical
serum	JJ	Physical
concentration	NN	Physical
ratio	NN	Physical
(	(	O
0.49	CD	O
+/-	JJ	O
0.3	CD	O
before	IN	O
and	CC	O
0.44	CD	O
+/-	JJ	O
0.3	CD	O
after	IN	O
,	,	O
p	VBD	O
>	RB	O
0.05	CD	O
)	)	O
,	,	O
were	VBD	O
unchanged	JJ	O
following	VBG	O
clarithromycin	NN	O
dosing	VBG	O
.	.	O

Neither	CC	O
the	DT	O
tolbutamide	JJ	Physical
oral	JJ	Physical
clearance	NN	Physical
(	(	O
0.77	CD	O
+/-	JJ	O
0.28	CD	O
l/h	NN	O
before	IN	O
and	CC	O
0.72	CD	O
+/-0.24	JJ	O
l/h	NN	O
after	IN	O
,	,	O
p	VBD	O
>	RB	O
0.05	CD	O
)	)	O
nor	CC	O
the	DT	O
tolbutamide	JJ	Physical
urinary	JJ	Physical
metabolic	NN	Physical
ratio	NN	Physical
(	(	O
779	CD	O
+/-	JJ	O
294	CD	O
before	IN	O
and	CC	O
681	CD	O
+/-	JJ	O
416	CD	O
after	IN	O
,	,	O
p	VBD	O
>	RB	O
0.05	CD	O
)	)	O
indices	NNS	O
of	IN	O
CYP2C9	NNP	O
were	VBD	O
altered	VBN	O
by	IN	O
clarithromycin	JJ	O
administration	NN	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
CYP2D6	NNP	O
,	,	O
the	DT	O
dextromethorphan	NN	Physical
to	TO	O
dextrorphan	VB	Physical
urinary	JJ	Physical
ratio	NN	Physical
was	VBD	O
not	RB	O
significantly	RB	Others
different	JJ	Others
before	IN	O
(	(	O
0.021	CD	O
+/-	JJ	O
0.04	CD	O
)	)	O
and	CC	O
after	IN	O
(	(	O
0.024	CD	O
+/-	JJ	O
0.06	CD	O
)	)	O
clarithromycin	NN	O
dosing	VBG	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
clarithromycin	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
alter	VB	O
the	DT	O
in	IN	O
vivo	JJ	Physical
catalytic	JJ	Physical
activity	NN	Physical
of	IN	O
CYP1A2	NNP	O
,	,	O
CYP2C9	NNP	O
,	,	O
and	CC	O
CYP2D6	NNP	O
in	IN	O
healthy	JJ	O
individuals	NNS	O
as	IN	O
assessed	VBN	O
by	IN	O
caffeine	NN	O
,	,	O
tolbutamide	NN	O
,	,	O
and	CC	O
dextromethorphan	NN	O
,	,	O
respectively	RB	O
.	.	O

Cardiovascular	JJ	Physical
risk	NN	Physical
markers	NNS	Physical
during	IN	O
treatment	NN	O
with	IN	O
estradiol	NN	O
and	CC	O
trimegestone	NN	O
or	CC	O
dydrogesterone	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
cardiovascular	JJ	Physical
risk	NN	Physical
markers	NNS	Physical
in	IN	O
women	NNS	O
taking	VBG	O
estradiol/trimegestone	NN	O
or	CC	O
estradiol/dydrogesterone	NN	O
.	.	O

DESIGN	NNP	O
Multicenter	NNP	O
,	,	O
randomized	VBD	O
,	,	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
184	CD	O
healthy	JJ	O
post-menopausal	JJ	O
women	NNS	O
randomized	VBD	O
to	TO	O
6	CD	O
cycles	NNS	O
of	IN	O
either	DT	O
estradiol	NN	O
(	(	O
2mg	CD	O
)	)	O
+trimegestone	NN	O
(	(	O
0.5mg	CD	O
)	)	O
(	(	O
T-group	NNP	O
)	)	O
or	CC	O
estradiol	NN	O
(	(	O
2mg	CD	O
)	)	O
+dydrogesterone	NN	O
(	(	O
10mg	CD	O
)	)	O
(	(	O
DYDR	NNP	O
group	NN	O
)	)	O
.	.	O

Cardiovascular	JJ	Others
risk	NN	Others
markers	NNS	Others
were	VBD	O
measured	VBN	O
before	IN	O
,	,	O
after	IN	O
cycle	NN	O
1	CD	O
,	,	O
3	CD	O
and	CC	O
6	CD	O
and	CC	O
at	IN	O
4	CD	O
weeks	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Fibrinogen	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
more	JJR	O
markedly	RB	O
in	IN	O
the	DT	O
DYDR	NNP	O
group	NN	O
.	.	O

Factor	NNP	O
VIIc	NNP	O
activity	NN	O
levels	NNS	O
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
with	IN	O
a	DT	O
greater	JJR	O
change	NN	O
in	IN	O
the	DT	O
T-group	NNP	O
.	.	O

Factor	NNP	Physical
VII	NNP	Physical
antigen	NN	Physical
was	VBD	O
increased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
with	IN	O
a	DT	O
greater	JJR	O
increase	NN	O
in	IN	O
the	DT	O
DYDR	NNP	O
group	NN	O
.	.	O

Factor	NNP	O
VIIa	NNP	O
was	VBD	O
increased	VBN	O
in	IN	O
the	DT	O
DYDR	NNP	O
group	NN	O
only	RB	O
.	.	O

Plasminogen	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
increased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
with	IN	O
a	DT	O
greater	JJR	O
increase	NN	O
in	IN	O
the	DT	O
T-group	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
lipid	JJ	Others
variables	NNS	Others
between	IN	O
the	DT	O
different	JJ	O
regimens	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
and	CC	Physical
LDL	NNP	Physical
cholesterol	NN	Physical
were	VBD	O
correlated	VBN	O
positively	RB	O
with	IN	O
changes	NNS	O
in	IN	O
factor	NN	Physical
VIIc	NNP	Physical
in	IN	O
the	DT	O
DYDR	NNP	O
group	NN	O
and	CC	O
negatively	RB	O
with	IN	O
changes	NNS	O
in	IN	O
factor	NN	Physical
VIIc	NNP	Physical
in	IN	O
the	DT	O
T-group	NNP	O
.	.	O

Trigemestone	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
better	JJR	O
bleeding	NN	O
pattern	NN	O
.	.	O

CONCLUSIONS	NNP	O
Trimegestone	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
less	RBR	O
procoagulant	JJ	O
changes	NNS	O
in	IN	O
factor	NN	O
VIIa	NNP	O
and	CC	O
factor	NN	O
VIIc	NNP	O
activity	NN	O
and	CC	O
larger	JJR	O
decrease	NN	O
in	IN	O
PAI-1	NNP	O
activity	NN	O
compared	VBN	O
with	IN	O
the	DT	O
dydrogesterone	NN	O
preparation	NN	O
.	.	O

These	DT	O
results	NNS	O
reflect	VBP	O
less	JJR	O
androgenic	JJ	Others
properties	NNS	Others
of	IN	O
the	DT	O
trimegestone	NN	O
preparation	NN	O
.	.	O

The	DT	O
fibrinogen	NN	O
level	NN	O
and	CC	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
were	VBD	O
more	JJR	O
decreased	JJ	O
during	IN	O
dydrogesterone	NN	O
treatment	NN	O
.	.	O

Further	JJ	O
investigation	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
beneficial	JJ	O
effects	NNS	O
with	IN	O
respect	NN	O
to	TO	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

Effect	NN	O
of	IN	O
cerivastatin	NN	O
on	IN	O
proteinuria	NNS	O
and	CC	O
urinary	JJ	O
podocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
glomerulonephritis	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
previously	RB	O
reported	VBD	O
urinary	JJ	O
podocytes	NNS	O
to	TO	O
be	VB	O
a	DT	O
marker	NN	O
of	IN	O
glomerular	JJ	O
injury	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
cerivastatin	NN	O
,	,	O
a	DT	O
newly	RB	O
developed	VBN	O
,	,	O
potent	JJ	O
synthetic	JJ	O
statin	NN	O
,	,	O
affects	VBZ	O
proteinuria	NNS	O
and	CC	O
urinary	JJ	O
podocyte	NN	O
excretion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
glomerulonephritis	NN	O
(	(	O
CGN	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
40	CD	O
normotensive	JJ	O
hypercholesterolemic	JJ	O
patients	NNS	O
with	IN	O
CGN	NNP	O
to	TO	O
receive	VB	O
either	DT	O
cerivastatin	NN	O
0.15	CD	O
mg/day	NN	O
(	(	O
n=20	JJ	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=20	JJ	O
)	)	O
.	.	O

Subjects	NNS	O
comprised	VBD	O
24	CD	O
men	NNS	O
and	CC	O
16	CD	O
women	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
40.8+/-14.4	JJ	O
years	NNS	O
;	:	O
27	CD	O
had	VBD	O
IgA	NNP	O
nephropathy	JJ	O
and	CC	O
13	CD	O
had	VBD	O
non-IgA	JJ	O
proliferative	JJ	O
glomerulonephritis	NN	O
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Plasma	NNP	Physical
total	JJ	Physical
cholesterol	NN	Physical
,	,	O
HDL-cholesterol	NNP	Physical
,	,	O
LDL-cholesterol	NNP	Physical
and	CC	Physical
triglycerides	NNS	Physical
,	,	O
urinary	JJ	Physical
protein	NN	Physical
excretion	NN	Physical
and	CC	O
the	DT	O
number	NN	Physical
of	IN	Physical
podocytes	NNS	Physical
were	VBD	O
measured	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
LDL-cholesterol	NNP	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
triglycerides	NNS	Physical
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	Physical
in	IN	Physical
HDL-cholesterol	NNP	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
cerivastatin	NN	O
.	.	O

Urinary	JJ	Physical
protein	NN	Physical
excretion	NN	Physical
decreased	VBN	O
from	IN	O
1.8+/-0.6	JJ	O
to	TO	O
0.8+/-0.4	JJ	O
g/day	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
this	DT	O
group	NN	O
,	,	O
and	CC	O
urinary	JJ	Physical
podocyte	NN	Physical
excretion	NN	Physical
decreased	VBN	O
from	IN	O
1.6+/-0.6	JJ	O
to	TO	O
0.9+/-0.4	JJ	O
cells/ml	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
placebo	NN	O
showed	VBD	O
little	JJ	O
effect	NN	O
on	IN	O
these	DT	O
lipid	JJ	Physical
levels	NNS	Physical
,	,	O
urinary	JJ	Physical
protein	NN	Physical
excretion	NN	Physical
and	CC	O
urinary	JJ	Physical
podocyte	NN	Physical
excretion	NN	Physical
.	.	O

The	DT	O
differences	NNS	O
between	IN	O
the	DT	O
cerivastatin	NN	O
group	NN	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
significant	JJ	O
(	(	O
cholesterol	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
LDL-cholesterol	NNP	Physical
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
triglycerides	NNS	Physical
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
;	:	O
HDL-cholesterol	NNP	Physical
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
urinary	JJ	Physical
protein	NN	Physical
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
;	:	O
and	CC	O
urinary	JJ	Physical
podocytes	NNS	Physical
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Statins	NNP	O
such	JJ	O
as	IN	O
cerivastatin	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
for	IN	O
restoration	NN	O
of	IN	O
injured	JJ	O
podocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CGN	NNP	O
and	CC	O
hypercholesterolaemia	NN	O
.	.	O

West	NNP	O
Midlands	NNP	O
Oncology	NNP	O
Association	NNP	O
trials	NNS	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
in	IN	O
operable	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
after	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
7	CD	O
years	NNS	O
.	.	O

I	PRP	O
.	.	O

Patients	NNS	O
with	IN	O
involved	JJ	O
axillary	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
regimen	NNS	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
known	VBN	O
to	TO	O
be	VB	O
active	JJ	O
in	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
when	WRB	O
given	VBN	O
as	IN	O
an	DT	O
adjuvant	JJ	O
treatment	NN	O
after	IN	O
mastectomy	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
569	CD	O
patients	NNS	O
with	IN	O
cancer	NN	O
of	IN	O
the	DT	O
breast	NN	O
and	CC	O
involvement	NN	O
of	IN	O
axillary	JJ	O
lymph	NN	O
nodes	NNS	O
were	VBD	O
randomised	VBN	O
,	,	O
after	IN	O
simple	JJ	O
mastectomy	NN	O
with	IN	O
axillary	JJ	O
sampling	NN	O
,	,	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
adjuvant	JJ	O
treatment	NN	O
or	CC	O
intravenous	JJ	O
adriamycin	NNS	O
50	CD	O
mg	NN	O
,	,	O
vincristine	VBP	O
1	CD	O
mg	NN	O
,	,	O
cyclophosphamide	RB	O
250	CD	O
mg	NN	O
,	,	O
methotrexate	VB	O
150	CD	O
mg	NN	O
and	CC	O
fluorouracil	NN	O
250	CD	O
mg	NN	O
(	(	O
AVCMF	NNP	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
for	IN	O
eight	CD	O
cycles	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
menopausal	NN	O
status	NN	O
and	CC	O
tumour	NN	O
size	NN	O
.	.	O

Treatment	NN	O
was	VBD	O
started	VBN	O
within	IN	O
14	CD	O
days	NNS	O
of	IN	O
surgery	NN	O
in	IN	O
94	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Eighty-eight	JJ	O
per	IN	O
cent	NN	O
of	IN	O
patients	NNS	O
received	VBN	O
at	IN	O
least	JJS	O
seven	CD	O
cycles	NNS	O
of	IN	O
chemotherapy	NN	O
with	IN	O
no	DT	O
dose	JJ	O
reduction	NN	O
.	.	O

The	DT	O
median	JJ	Mortality
relapse-free	JJ	Mortality
survival	NN	Mortality
was	VBD	O
prolonged	VBN	O
by	IN	O
14	CD	O
months	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
AVCMF	NNP	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
11.7	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.0006	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
premenopausal	NN	O
group	NN	O
this	DT	O
period	NN	O
was	VBD	O
17	CD	O
months	NNS	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
8.8	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
compared	VBN	O
with	IN	O
8	CD	O
months	NNS	O
in	IN	O
the	DT	O
post-menopausal	JJ	O
group	NN	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
3.3	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

Neither	CC	O
overall	JJ	Mortality
survival	NN	Mortality
nor	CC	Mortality
survival	NN	Mortality
in	IN	O
these	DT	O
subgroups	NNS	O
was	VBD	O
significantly	RB	O
influenced	VBN	O
by	IN	O
treatment	NN	O
.	.	O

Trial	NN	O
of	IN	O
(	(	O
+	NNP	O
)	)	O
-cyanidanol-3	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hepatitis	NN	O
B	NNP	O
chronic	NN	O
liver	NN	O
disease	NN	O
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
12	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
(	(	O
+	NN	O
)	)	O
-cyanidanol-3	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
26	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
liver	NN	O
disease	NN	O
.	.	O

Treatment	NN	O
did	VBD	O
not	RB	O
improve	VB	O
liver	RB	Physical
blood	NN	Physical
tests	NNS	Physical
nor	CC	Physical
histological	JJ	Physical
appearances	NNS	Physical
of	IN	Physical
the	DT	Physical
liver	NN	Physical
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
trend	NN	O
towards	IN	O
reduction	NN	O
of	IN	O
serum	NN	Physical
titres	NNS	Physical
of	IN	Physical
hepatitis	NN	Physical
B	NNP	Physical
surface	NN	Physical
antigen	NN	Physical
.	.	Physical

Effect	NN	O
of	IN	O
chronic	JJ	O
aerobic	JJ	O
exercise	NN	O
and	CC	O
progressive	JJ	O
relaxation	NN	O
on	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
following	VBG	O
acute	JJ	O
stress	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
10-week	JJ	O
aerobic	JJ	O
exercise	NN	O
and	CC	O
progressive	JJ	O
relaxation	NN	O
training	VBG	O
program	NN	O
on	IN	O
somatic	JJ	O
,	,	O
emotional	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
responses	NNS	O
to	TO	O
acute	VB	O
stress	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
quality	NN	O
of	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
,	,	O
were	VBD	O
examined	VBN	O
.	.	O

The	DT	O
participants	NNS	O
consisted	VBD	O
of	IN	O
60	CD	O
unfit	JJ	O
male	NN	O
university	NN	O
undergraduate	JJ	O
students	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
training	NN	O
in	IN	O
stress	JJ	O
management	NN	O
who	WP	O
were	VBD	O
randomly	RB	O
and	CC	O
evenly	RB	O
assigned	VBD	O
to	TO	O
engage	VB	O
in	IN	O
one	CD	O
of	IN	O
four	CD	O
treatments	NNS	O
over	IN	O
10	CD	O
weeks	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
moderate	NN	O
aerobic	JJ	O
exercise	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
progressive	NN	O
relaxation	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
a	DT	O
placebo	NN	O
group	NN	O
that	WDT	O
engaged	VBD	O
in	IN	O
group	NN	O
discussion	NN	O
but	CC	O
did	VBD	O
experience	VB	O
acute	NN	O
stress	NN	O
,	,	O
and	CC	O
(	(	O
d	NN	O
)	)	O
a	DT	O
nonintervention	NN	O
control	NN	O
group	NN	O
that	WDT	O
did	VBD	O
not	RB	O
experience	VB	O
stress	NN	O
while	IN	O
performing	VBG	O
the	DT	O
motor	NN	O
task	NN	O
.	.	O

Acute	NNP	O
stress	NN	O
consisted	VBD	O
of	IN	O
losing	VBG	O
against	IN	O
a	DT	O
competitor	NN	O
of	IN	O
the	DT	O
opposite	JJ	O
sex	NN	O
on	IN	O
the	DT	O
criterion	NN	O
motor	NN	O
task	NN	O
while	IN	O
receiving	VBG	O
unpleasant	JJ	O
information	NN	O
about	IN	O
their	PRP$	O
performance	NN	O
over	IN	O
30	CD	O
preintervention	NN	O
and	CC	O
30	CD	O
postintervention	NN	O
trials	NNS	O
.	.	O

Analyses	NNS	O
indicated	VBD	O
that	IN	O
aerobic	JJ	O
exercisers	NNS	O
,	,	O
in	IN	O
comparisons	NNS	O
with	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
,	,	O
responded	VBD	O
to	TO	O
acute	VB	O
stress	NN	O
with	IN	O
more	RBR	O
positive	JJ	O
affect	NN	O
,	,	O
lower	JJR	Physical
stressor	NN	Physical
task	JJ	Physical
heart	NN	Physical
rate	NN	Physical
,	,	Physical
reduced	VBN	Physical
systolic	JJ	Physical
(	(	Physical
but	CC	Physical
not	RB	Physical
diastolic	JJ	Physical
)	)	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	O
and	CC	O
superior	JJ	O
motor	NN	Mental
performance	NN	Mental
.	.	O

Progressive	JJ	O
relaxation	NN	O
markedly	RB	O
reduced	VBD	O
systolic	JJ	Mental
blood	NN	Mental
pressure	NN	Mental
but	CC	O
did	VBD	O
not	RB	O
favorably	RB	O
influence	JJ	O
performance	NN	O
or	CC	O
affect	VB	O
in	IN	O
response	NN	O
to	TO	O
acute	VB	O
stress	NN	O
.	.	O

Placebo	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
statistically	RB	O
similar	JJ	O
on	IN	O
all	DT	O
measures	NNS	O
.	.	O

The	DT	O
findings	NNS	O
indicated	VBD	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
chronic	JJ	O
aerobic	JJ	O
exercise	NN	O
as	IN	O
a	DT	O
strategy	NN	O
for	IN	O
improved	JJ	O
coping	NN	O
with	IN	O
acute	JJ	O
stress	NN	O
.	.	O

Secondary	JJ	O
caries	NNS	O
formation	NN	O
in	IN	O
vitro	NN	O
around	IN	O
glass	NN	O
ionomer-lined	JJ	O
amalgam	NN	O
and	CC	O
composite	JJ	O
restorations	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
in	IN	O
vitro	JJ	O
secondary	JJ	O
caries	NNS	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
glass-ionomer	JJ	O
liner	NN	O
's	POS	O
effect	NN	O
on	IN	O
wall-lesion	NN	O
inhibition	NN	O
when	WRB	O
a	DT	O
conventional	JJ	O
and	CC	O
a	DT	O
light-cured	JJ	O
glass	NN	O
ionomer	NN	O
liner	NN	O
was	VBD	O
placed	VBN	O
under	IN	O
amalgam	NN	O
and	CC	O
composite	JJ	O
resin	NN	O
restorations	NNS	O
.	.	O

Class	NNP	O
V	NNP	O
preparations	NNS	O
in	IN	O
extracted	JJ	O
upper	JJ	O
premolars	NNS	O
were	VBD	O
used	VBN	O
and	CC	O
ten	JJ	O
restorations	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
following	JJ	O
groups	NNS	O
:	:	O
(	(	O
i	NN	O
)	)	O
two	CD	O
layers	NNS	O
of	IN	O
copal	JJ	O
varnish	JJ	O
and	CC	O
amalgam	NN	O
;	:	O
(	(	O
ii	NN	O
)	)	O
conventional	JJ	O
glass-ionomer	JJ	O
and	CC	O
amalgam	NN	O
;	:	O
(	(	O
iii	NN	O
)	)	O
light-cured	JJ	O
glass-ionomer	NN	O
and	CC	O
amalgam	NN	O
;	:	O
(	(	O
iv	NN	O
)	)	O
bonding	NN	O
agent	NN	O
and	CC	O
light-cured	JJ	O
composite	JJ	O
resin	NN	O
;	:	O
(	(	O
v	NN	O
)	)	O
conventional	JJ	O
glass-ionomer	JJ	O
,	,	O
bonding	JJ	O
agent	NN	O
and	CC	O
light-cured	JJ	O
composite	JJ	O
resin	NN	O
;	:	O
(	(	O
vi	NN	O
)	)	O
light-cured	JJ	O
glass-ionomer	NN	O
,	,	O
extended	VBD	O
0.3	CD	O
mm	NN	O
short	NN	O
of	IN	O
the	DT	O
enamel	JJ	O
margin	NN	O
bonding	VBG	O
agent	NN	O
and	CC	O
light-cured	JJ	O
composite	JJ	O
resin	NN	O
;	:	O
and	CC	O
(	(	O
vii	NN	O
)	)	O
light-cured	JJ	O
glass-ionomer	NN	O
,	,	O
extended	VBD	O
1	CD	O
mm	NN	O
short	NN	O
of	IN	O
the	DT	O
enamel	NN	O
margin	NN	O
,	,	O
bonding	VBG	O
agent	NN	O
and	CC	O
light-cured	JJ	O
composite	JJ	O
resin	NN	O
.	.	O

The	DT	O
teeth	NNS	O
were	VBD	O
thermocycled	VBN	O
and	CC	O
artificial	JJ	O
caries	NNS	O
were	VBD	O
created	VBN	O
using	VBG	O
an	DT	O
acid-gel	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
showed	VBD	O
that	IN	O
artificial	JJ	Physical
recurrent	NN	Physical
caries	NNS	Physical
can	MD	O
be	VB	O
reduced	VBN	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
a	DT	O
glass-ionomer	JJ	O
liner	NN	O
under	IN	O
amalgam	JJ	O
restorations	NNS	O
.	.	O

The	DT	O
results	NNS	O
also	RB	O
showed	VBD	O
that	IN	O
when	WRB	O
the	DT	O
light-cured	JJ	O
glass-ionomer	JJ	O
liner	NN	O
was	VBD	O
placed	VBN	O
0.3	CD	O
mm	NN	O
from	IN	O
the	DT	O
cavosurface	NN	O
margin	NN	O
under	IN	O
composite	JJ	O
resin	NN	O
restoration	NN	O
,	,	O
the	DT	O
artificial	JJ	Physical
recurrent	NN	Physical
caries	NNS	Physical
reduced	VBN	Physical
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Lack	NN	O
of	IN	O
benefit	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Secretin	NNP	O
is	VBZ	O
a	DT	O
peptide	JJ	O
hormone	NN	O
that	WDT	O
stimulates	VBZ	O
pancreatic	JJ	O
secretion	NN	O
.	.	O

After	IN	O
recent	JJ	O
publicity	NN	O
about	IN	O
a	DT	O
child	NN	O
with	IN	O
autism	NN	O
whose	WP$	O
condition	NN	O
markedly	RB	O
improved	VBN	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
secretin	NN	O
,	,	O
thousands	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
may	MD	O
have	VB	O
received	VBN	O
secretin	JJ	O
injections	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
in	IN	O
60	CD	O
children	NNS	O
(	(	O
age	NN	O
,	,	O
3	CD	O
to	TO	O
14	CD	O
years	NNS	O
)	)	O
with	IN	O
autism	NN	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
(	(	O
0.4	CD	O
microg	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
or	CC	O
saline	JJ	O
placebo	NN	O
.	.	O

We	PRP	O
used	VBD	O
standardized	JJ	O
behavioral	JJ	O
measures	NNS	O
of	IN	O
the	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
features	NNS	O
of	IN	O
autism	NN	O
,	,	O
including	VBG	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
to	TO	O
assess	VB	O
the	DT	O
degree	NN	O
of	IN	O
impairment	NN	O
at	IN	O
base	NN	O
line	NN	O
and	CC	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
a	DT	O
four-week	JJ	O
period	NN	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
children	NNS	O
,	,	O
4	CD	O
could	MD	O
not	RB	O
be	VB	O
evaluated	VBN	O
-	:	O
2	CD	O
received	VBD	O
secretin	NN	O
outside	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
2	CD	O
did	VBD	O
not	RB	O
return	VB	O
for	IN	O
follow-up	JJ	O
.	.	O

Thus	NNP	O
,	,	O
56	CD	O
children	NNS	O
(	(	O
28	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
secretin	FW	O
treatment	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	Others
improvements	NNS	Others
in	IN	Others
any	DT	Others
of	IN	Others
the	DT	Others
outcome	NN	Others
measures	NNS	Others
.	.	O

Among	IN	O
the	DT	O
children	NNS	O
in	IN	O
the	DT	O
secretin	NN	O
group	NN	O
,	,	O
the	DT	O
mean	JJ	Mental
total	NN	Mental
score	NN	Mental
on	IN	Mental
the	DT	Mental
Autism	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
at	IN	O
base	NN	O
line	NN	O
was	VBD	O
59.0	CD	O
(	(	O
range	NN	O
of	IN	O
possible	JJ	O
values	NNS	O
,	,	O
0	CD	O
to	TO	O
158	CD	O
,	,	O
with	IN	O
a	DT	O
larger	JJR	O
value	NN	O
corresponding	VBG	O
to	TO	O
greater	JJR	O
impairment	NN	O
)	)	O
,	,	O
and	CC	O
among	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
it	PRP	O
was	VBD	O
63.2	CD	O
.	.	O

The	DT	O
mean	JJ	Others
decreases	NNS	Others
in	IN	Others
scores	NNS	Mental
over	IN	O
the	DT	O
four-week	JJ	O
period	NN	O
were	VBD	O
8.9	CD	O
in	IN	O
the	DT	O
secretin	NN	O
group	NN	O
and	CC	O
17.8	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
-8.9	NNP	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-19.4	VBP	O
to	TO	O
1.6	CD	O
;	:	O
P=0.11	NNP	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
children	NNS	O
had	VBD	O
treatment-limiting	JJ	Adverseeffect
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

After	IN	O
they	PRP	O
were	VBD	O
told	VBN	O
the	DT	O
results	NNS	O
,	,	O
69	CD	O
percent	NN	O
of	IN	O
the	DT	O
parents	NNS	O
of	IN	O
the	DT	O
children	NNS	O
in	IN	O
this	DT	O
study	NN	O
said	VBD	O
they	PRP	O
remained	VBD	O
interested	JJ	O
in	IN	O
secretin	NN	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
their	PRP$	O
children	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
is	VBZ	O
not	RB	Others
an	DT	Others
effective	JJ	Others
treatment	NN	Others
for	IN	O
autism	NN	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
with	IN	O
implantable	JJ	O
defibrillators	NNS	O
in	IN	O
patients	NNS	O
resuscitated	VBN	O
from	IN	O
near-fatal	JJ	O
ventricular	JJ	O
arrhythmias	NN	O
.	.	O

The	DT	O
Antiarrhythmics	NNPS	O
versus	NN	O
Implantable	JJ	O
Defibrillators	NNS	O
(	(	O
AVID	NNP	O
)	)	O
Investigators	NNPS	O
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
who	WP	O
survive	VBP	O
life-threatening	JJ	O
ventricular	JJ	O
arrhythmias	NNS	O
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
recurrent	NN	O
arrhythmias	NN	O
.	.	O

They	PRP	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
either	DT	O
an	DT	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
or	CC	O
antiarrhythmic	JJ	O
drugs	NNS	O
,	,	O
but	CC	O
the	DT	O
relative	JJ	O
efficacy	NN	O
of	IN	O
these	DT	O
two	CD	O
treatment	NN	O
strategies	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
To	TO	O
address	VB	O
this	DT	O
issue	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
these	DT	O
two	CD	O
treatment	NN	O
strategies	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
resuscitated	VBN	O
from	IN	O
near-fatal	JJ	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
who	WP	O
had	VBD	O
undergone	JJ	O
cardioversion	NN	O
from	IN	O
sustained	VBN	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Patients	NNS	O
with	IN	O
ventricular	JJ	O
tachycardia	NN	O
also	RB	O
had	VBD	O
either	CC	O
syncope	NN	O
or	CC	O
other	JJ	O
serious	JJ	O
cardiac	NN	O
symptoms	NNS	O
,	,	O
along	IN	O
with	IN	O
a	DT	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
of	IN	O
0.40	CD	O
or	CC	O
less	JJR	O
.	.	O

One	CD	O
group	NN	O
of	IN	O
patients	NNS	O
was	VBD	O
treated	VBN	O
with	IN	O
implantation	NN	O
of	IN	O
a	DT	O
cardioverter-defibrillator	NN	O
;	:	O
the	DT	O
other	JJ	O
received	JJ	O
class	NN	O
III	NNP	O
antiarrhythmic	JJ	O
drugs	NNS	O
,	,	O
primarily	RB	O
amiodarone	NN	O
at	IN	O
empirically	RB	O
determined	VBN	O
doses	NNS	O
.	.	O

Fifty-six	NNP	O
clinical	JJ	O
centers	NNS	O
screened	VBD	O
all	DT	O
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
ventricular	JJ	O
tachycardia	NN	O
or	CC	O
ventricular	JJ	O
fibrillation	NN	O
during	IN	O
a	DT	O
period	NN	O
of	IN	O
nearly	RB	O
four	CD	O
years	NNS	O
.	.	O

Of	IN	O
1016	CD	O
patients	NNS	O
(	(	O
45	CD	O
percent	NN	O
of	IN	O
whom	WP	O
had	VBD	O
ventricular	JJ	O
fibrillation	NN	O
,	,	O
and	CC	O
55	CD	O
percent	NN	O
ventricular	JJ	O
tachycardia	NN	O
)	)	O
,	,	O
507	CD	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
implantable	JJ	O
cardioverter-defibrillators	NNS	O
and	CC	O
509	CD	O
to	TO	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
overall	JJ	Mortality
mortality	NN	Mortality
.	.	Mortality

RESULTS	NNP	O
Follow-up	NNP	O
was	VBD	O
complete	JJ	O
for	IN	O
1013	CD	O
patients	NNS	O
(	(	O
99.7	CD	O
percent	NN	O
)	)	O
.	.	O

Overall	JJ	O
survival	NN	Mortality
was	VBD	O
greater	JJR	O
with	IN	O
the	DT	O
implantable	JJ	O
defibrillator	NN	O
,	,	O
with	IN	O
unadjusted	JJ	O
estimates	NNS	O
of	IN	O
89.3	CD	O
percent	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
82.3	CD	O
percent	NN	O
in	IN	O
the	DT	O
antiarrhythmic-drug	JJ	O
group	NN	O
at	IN	O
one	CD	O
year	NN	O
,	,	O
81.6	CD	O
percent	NN	O
versus	NN	O
74.7	CD	O
percent	NN	O
at	IN	O
two	CD	O
years	NNS	O
,	,	O
and	CC	O
75.4	CD	O
percent	NN	O
versus	NN	O
64.1	CD	O
percent	NN	O
at	IN	O
three	CD	O
years	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	O
reductions	NNS	O
in	IN	O
mortality	NN	Mortality
(	(	O
with	IN	O
95	CD	O
percent	NN	O
confidence	NN	O
limits	NNS	O
)	)	O
with	IN	O
the	DT	O
implantable	JJ	O
defibrillator	NN	O
were	VBD	O
39+/-20	JJ	O
percent	NN	O
,	,	O
27+/-21	JJ	O
percent	NN	O
,	,	O
and	CC	O
31+/-21	JJ	O
percent	NN	O
CONCLUSIONS	NNP	O
Among	IN	O
survivors	NNS	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
sustained	VBN	O
ventricular	JJ	O
tachycardia	NN	O
causing	VBG	O
severe	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
antiarrhythmic	VB	O
drugs	NNS	O
for	IN	O
increasing	VBG	O
overall	JJ	O
survival	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
for	IN	O
behaviorally	RB	O
disordered	VBN	O
mentally	RB	O
handicapped	JJ	O
patients	NNS	O
on	IN	O
staff	NN	O
personnel	NNS	O
in	IN	O
residential	JJ	O
care	NN	O
]	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
designed	VBN	O
for	IN	O
mentally	RB	O
handicapped	JJ	O
persons	NNS	O
with	IN	O
severely	RB	O
disturbed	VBN	O
or	CC	O
autistic	JJ	O
behavior	NN	O
on	IN	O
their	PRP$	O
staff	NN	O
personal	JJ	O
which	WDT	O
had	VBD	O
an	DT	O
active	JJ	O
role	NN	O
in	IN	O
the	DT	O
program	NN	O
.	.	O

The	DT	O
staff	NN	O
members	NNS	O
rated	VBD	O
their	PRP$	O
professional	JJ	O
competence	NN	O
,	,	O
quality	NN	O
of	IN	O
interaction	NN	O
with	IN	O
the	DT	O
client	NN	O
,	,	O
team	JJ	O
culture	NN	O
and	CC	O
work	NN	O
satisfaction	NN	O
before	IN	O
and	CC	O
after	IN	O
being	VBG	O
engaged	VBN	O
in	IN	O
the	DT	O
program	NN	O
,	,	O
with	IN	O
additional	JJ	O
ratings	NNS	O
of	IN	O
their	PRP$	O
personal	JJ	O
aims	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
program	NN	O
.	.	O

Three	NNP	O
sets	NNS	O
of	IN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
the	DT	O
program	NN	O
being	VBG	O
conducted	VBN	O
three	CD	O
times	NNS	O
in	IN	O
a	DT	O
row	NN	O
.	.	O

The	DT	O
testings	NNS	O
of	IN	O
the	DT	O
related	VBN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
independent	JJ	O
samples	NNS	O
show	VBP	O
differentiated	JJ	O
program	NN	O
effects	NNS	O
.	.	O

The	DT	O
main	JJ	O
effect	NN	O
is	VBZ	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
professional	JJ	Others
competence	NN	Others
and	CC	Others
quality	NN	Others
of	IN	Others
interaction	NN	Others
,	,	O
especially	RB	O
by	IN	O
the	DT	O
qualified	JJ	O
staff	NN	O
members	NNS	O
.	.	O

Trainees	NNP	O
put	VBD	O
emphasis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
their	PRP$	O
personal	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
client	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
impact	NN	O
of	IN	O
learning	VBG	O
processes	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
roles	NNS	O
of	IN	O
the	DT	O
staff	NN	O
members	NNS	O
and	CC	O
motivational	JJ	O
factors	NNS	O
on	IN	O
learning	NN	O
and	CC	O
therapy	NN	O
outcome	NN	O
,	,	O
along	IN	O
with	IN	O
institutional	JJ	O
conditions	NNS	O
influencing	VBG	O
successful	JJ	O
learning	NN	O
.	.	O

Thus	VB	O
the	DT	O
program	NN	O
facilitates	VBZ	O
the	DT	O
professional	JJ	O
and	CC	O
interpersonal	JJ	O
learning	NN	O
process	NN	O
of	IN	O
staff	NN	O
members	NNS	O
in	IN	O
a	DT	O
specific	JJ	O
way	NN	O
with	IN	O
success	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
limitations	NNS	O
.	.	O

[	VB	O
A	NNP	O
randomized	JJ	O
study	NN	O
of	IN	O
prophylactic	JJ	O
intravesical	JJ	O
instillation	NN	O
of	IN	O
pirarubicin	NN	O
(	(	O
THP	NNP	O
)	)	O
prior	RB	O
to	TO	O
transurethral	JJ	O
resection	NN	O
of	IN	O
superficial	JJ	Physical
bladder	NN	Physical
cancer	NN	Physical
]	NNP	O
.	.	O

A	NNP	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
intravesical	JJ	O
instillation	NN	O
of	IN	O
pirarubicin	NN	O
(	(	O
THP	NNP	O
)	)	O
prior	RB	O
to	TO	O
transurethral	JJ	Physical
resection	NN	Physical
(	(	Physical
TUR	NNP	Physical
)	)	Physical
of	IN	Physical
superficial	JJ	Physical
bladder	NN	Physical
cancer	NN	Physical
.	.	Others

A	DT	O
total	NN	O
of	IN	O
63	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
the	DT	O
THP	NNP	O
group	NN	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
THP	NNP	O
group	NN	O
,	,	O
30	CD	O
mg	NN	O
of	IN	O
THP	NNP	O
dissolved	VBD	O
in	IN	O
50	CD	O
ml	NNS	O
saline	NN	O
was	VBD	O
administered	VBN	O
4	CD	O
times	NNS	O
intravesically	RB	O
for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
before	IN	O
TUR	NNP	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
no	DT	O
instillation	NN	O
was	VBD	O
performed	VBN	O
before	IN	O
TUR	NNP	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
by	IN	O
cystoscopy	NN	O
and	CC	O
urinary	JJ	O
cytology	NN	O
every	DT	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
non-recurrence	JJ	Others
rates	NNS	Others
in	IN	O
the	DT	O
THP	NNP	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
were	VBD	O
54.1	CD	O
%	NN	O
versus	IN	O
37.6	CD	O
%	NN	O
at	IN	O
1	CD	O
year	NN	O
and	CC	O
40.4	CD	O
%	NN	O
versus	IN	O
26.8	CD	O
%	NN	O
at	IN	O
2	CD	O
years	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.086	CD	O
)	)	O
.	.	O

Time	NN	Physical
to	TO	Physical
recurrence	VB	Physical
for	IN	Physical
tumors	NNS	Physical
larger	JJR	Physical
than	IN	Physical
1	CD	Physical
cm	NN	Physical
was	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
the	DT	O
THP	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0137	CD	O
)	)	O
.	.	O

Time	NN	Physical
to	TO	Physical
recurrence	VB	Physical
for	IN	Physical
single	JJ	Physical
and	CC	Physical
grade	VBD	Physical
1+2	CD	Physical
tumors	NNS	Physical
tended	VBD	O
to	TO	O
be	VB	O
longer	RBR	O
in	IN	O
the	DT	O
THP	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.09	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.079	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
patient	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
intravesical	JJ	O
THP	NNP	O
instillation	NN	O
prior	RB	O
to	TO	O
TUR	NNP	O
would	MD	O
be	VB	O
effective	JJ	Others
for	IN	O
patients	NNS	O
with	IN	O
single	JJ	Physical
,	,	Physical
low	JJ	Physical
grade	NN	Physical
lesions	NNS	Physical
larger	JJR	Physical
than	IN	Physical
1	CD	Physical
cm	NN	Physical
of	IN	O
superficial	JJ	Physical
bladder	NN	Physical
cancer	NN	Physical
.	.	O

Preoperative	JJ	O
irradiation	NN	O
versus	IN	O
the	DT	O
use	NN	O
of	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	JJ	Physical
ossification	NN	Physical
following	VBG	O
total	JJ	O
hip	JJ	O
replacement	NN	O
:	:	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Previous	JJ	O
studies	NNS	O
showed	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
early	JJ	O
preoperative	NN	O
(	(	O
4	CD	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
irradiation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	Physical
ossification	NN	Physical
(	(	Physical
HO	NNP	Physical
)	)	Physical
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

This	DT	O
procedure	NN	O
can	MD	O
result	VB	O
in	IN	O
logistic	JJ	O
problems	NNS	O
,	,	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
great	JJ	O
distance	NN	O
between	IN	O
the	DT	O
department	NN	O
of	IN	O
radiotherapy	NN	O
and	CC	O
the	DT	O
orthopedic	JJ	O
clinic	NN	O
.	.	O

To	TO	O
avoid	VB	O
these	DT	O
organizational	JJ	O
problems	NNS	O
a	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	Others
preoperative	JJ	Others
irradiation	NN	Others
on	IN	O
the	DT	O
day	NN	O
preceding	VBG	O
surgery	NN	O
(	(	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Between	NNP	O
1995	CD	O
and	CC	O
1996	CD	O
,	,	O
100	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
prophylactic	JJ	O
therapy	NN	O
for	IN	O
prevention	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
.	.	O

Forty-six	JJ	O
patients	NNS	O
were	VBD	O
irradiated	VBN	O
with	IN	O
7	CD	O
Gy	NNP	O
single	JJ	O
dose	NN	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
(	(	O
Voltaren	NNP	O
resinat	VBZ	O
2	CD	O
x	NN	O
75	CD	O
mg/day	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
)	)	O
.	.	O

Heterotopic	NNP	Physical
ossification	NN	Physical
was	VBD	O
scored	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Brooker	NNP	Others
Grading	NNP	Others
system	NN	Others
.	.	Others

One	CD	O
hundred	VBD	O
patients	NNS	O
receiving	VBG	O
no	DT	O
prophylactic	JJ	O
therapy	NN	O
after	IN	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
between	IN	O
1988	CD	O
and	CC	O
1992	CD	O
were	VBD	O
analyzed	VBN	O
and	CC	O
defined	VBN	O
as	IN	O
the	DT	O
historical	JJ	O
control	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
Incidence	NNP	O
of	IN	O
heterotopic	NN	Physical
ossification	NN	Physical
was	VBD	O
47.8	CD	O
%	NN	O
in	IN	O
the	DT	O
7	CD	O
Gy	NNP	O
preoperative	JJ	O
group	NN	O
(	(	O
Brooker	NNP	Others
Score	NNP	Others
I	PRP	O
:	:	O
36.9	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
8.7	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
2.2	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
11.1	CD	O
%	NN	O
in	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
(	(	O
Brooker	NNP	Others
Score	NNP	Others
I	PRP	O
:	:	O
9.3	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
1.8	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
0	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
0	CD	O
%	NN	O
)	)	O
.	.	O

Regarding	VBG	O
overall	JJ	O
heterotopic	NN	Physical
ossification	NN	Physical
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
NSAID	NNP	O
group	NN	O
and	CC	O
the	DT	O
7	CD	O
Gy	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Analyzing	VBG	O
the	DT	O
clinically	RB	O
significant	JJ	O
heterotopic	NN	Physical
ossification	NN	Physical
(	(	Physical
Brooker	NNP	Others
Score	NNP	Others
III	NNP	Others
and	CC	Others
IV	NNP	Others
)	)	Physical
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
untreated	JJ	O
historical	JJ	O
control	NN	O
group	NN	O
the	DT	O
incidence	NN	O
of	IN	O
heterotopic	NN	Physical
ossification	NN	Physical
was	VBD	O
65	CD	O
%	NN	O
(	(	O
Brooker	NNP	Others
Score	NNP	Others
I	PRP	O
:	:	O
26	CD	O
%	NN	O
;	:	O
II	NNP	O
:	:	O
15	CD	O
%	NN	O
;	:	O
III	NNP	O
:	:	O
19	CD	O
%	NN	O
;	:	O
IV	NNP	O
:	:	O
5	CD	O
%	NN	O
)	)	O
.	.	O

Referring	VBG	O
to	TO	O
overall	JJ	O
and	CC	O
to	TO	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	Physical
ossification	NN	Physical
the	DT	O
incidence	NN	O
of	IN	O
HO	NNP	Physical
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
prophylactically	RB	O
treated	VBN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiation	NNP	O
within	IN	O
16-20	JJ	O
h	NN	O
before	IN	O
operation	NN	O
and	CC	O
use	NN	O
of	IN	O
NSAID	NNP	O
(	(	O
Voltaren	NNP	O
resinat	NN	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
clinically	RB	O
relevant	JJ	O
heterotopic	NN	Physical
ossification	NN	Physical
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

Psychological	JJ	O
well-being	NN	O
correlates	NNS	O
with	IN	O
free	JJ	O
thyroxine	NN	O
but	CC	O
not	RB	O
free	JJ	O
3,5,3'-triiodothyronine	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
on	IN	O
thyroid	JJ	O
hormone	NN	O
replacement	NN	O
.	.	O

CONTEXT	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
An	DT	O
association	NN	O
between	IN	O
mood	NN	O
disorders	NNS	O
and	CC	O
overt	JJ	O
thyroid	JJ	O
dysfunction	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
on	IN	O
the	DT	O
potential	NN	O
for	IN	O
thyroid	JJ	O
hormone	NN	O
levels	NNS	O
closer	RBR	O
to	TO	O
the	DT	O
reference	NN	O
range	NN	O
to	TO	O
correlate	VB	O
with	IN	O
psychological	JJ	O
well-being	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
analyzed	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
psychological	JJ	O
well-being	NN	O
and	CC	O
free	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
(	(	O
fT4	NN	O
)	)	O
,	,	O
free	JJ	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
(	(	O
fT3	NN	O
)	)	O
,	,	O
TSH	NNP	O
,	,	O
and	CC	O
total	JJ	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
in	IN	O
697	CD	O
patients	NNS	O
on	IN	O
thyroid	JJ	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
at	IN	O
entry	NN	O
to	TO	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
combined	JJ	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
replacement	NN	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
on	IN	O
100	CD	O
mug	NN	O
or	CC	O
more	JJR	O
T	NNP	O
(	(	O
4	CD	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
AND	CC	O
MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Psychological	NNP	Mental
well-being	NN	Mental
was	VBD	O
assessed	VBN	O
with	IN	O
General	NNP	Mental
Health	NNP	Mental
Questionnaire-12	NNP	Mental
(	(	Mental
GHQ-12	NNP	Mental
)	)	Mental
,	,	O
Thyroid	NNP	Mental
Symptom	NNP	Mental
Questionnaire	NNP	Mental
,	,	O
and	CC	O
Hospital	NNP	Mental
Anxiety	NNP	Mental
and	CC	Mental
Depression	NNP	Mental
Scale	NNP	Mental
.	.	O

RESULTS	NNP	O
fT	NN	O
(	(	O
4	CD	O
)	)	O
and	CC	O
TSH	NNP	O
showed	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
with	IN	O
GHQ-12	NNP	O
scores	NNS	O
(	(	O
fT4	SYM	O
-	:	O
b	NN	O
:	:	O
-0.16	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
;	:	O
TSH	NNP	O
-	:	O
b	NN	O
:	:	O
0.663	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

No	UH	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
GHQ	NNP	O
scores	NNS	O
and	CC	O
fT3	NN	O
(	(	O
b	NN	O
:	:	O
0.318	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.275	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
(	(	O
b	NN	O
:	:	O
0.095	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.95	CD	O
)	)	O
,	,	O
rT	NN	O
(	(	O
3	CD	O
)	)	O
to	TO	O
fT4	VB	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
71.83	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.09	CD	O
)	)	O
or	CC	O
fT3	VBN	O
to	TO	O
rT	VB	O
(	(	O
3	CD	O
)	)	O
ratio	NN	O
(	(	O
b	NN	O
:	:	O
0.05	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.32	CD	O
)	)	O
.	.	O

The	DT	O
correlations	NNS	O
remained	VBD	O
when	WRB	O
the	DT	O
data	NN	O
set	NN	O
was	VBD	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
TSH	NNP	O
in	IN	O
the	DT	O
range	NN	O
0.3-4.0	JJ	O
mIU/liter	NN	O
.	.	O

Similar	JJ	O
correlations	NNS	O
were	VBD	O
seen	VBN	O
with	IN	O
the	DT	O
Thyroid	NNP	Physical
Symptom	NNP	Physical
Questionnaire	NNP	Physical
,	,	O
although	IN	O
not	RB	O
with	IN	O
the	DT	O
Hospital	NNP	Physical
Anxiety	NNP	Physical
and	CC	Physical
Depression	NNP	Physical
Scale	NNP	Physical
scores	NNS	Physical
.	.	O

CONCLUSIONS	NNP	O
Differences	NNPS	O
in	IN	O
fT4	NN	O
and	CC	O
TSH	NNP	O
concentration	NN	O
,	,	O
even	RB	O
within	IN	O
the	DT	O
reference	NN	O
range	NN	O
,	,	O
may	MD	O
be	VB	O
a	DT	O
determinant	NN	O
of	IN	O
psychological	JJ	O
well-being	NN	O
in	IN	O
treated	JJ	O
hypothyroid	NN	O
patients	NNS	O
although	IN	O
not	RB	O
necessarily	RB	O
with	IN	O
symptoms	NNS	O
typical	JJ	O
of	IN	O
anxiety	NN	O
or	CC	O
depression	NN	O
.	.	O

B-vitamins	NNS	O
reduce	VB	O
plasma	NN	Physical
levels	NNS	Physical
of	IN	O
beta	NN	O
amyloid	NN	O
.	.	O

Elevated	VBN	O
plasma	JJ	O
homocysteine	NN	O
(	(	O
tHcy	NN	O
)	)	O
is	VBZ	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
AD	NNP	O
)	)	O
,	,	O
and	CC	O
thus	RB	O
B	NNP	O
vitamins	NNS	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
AD	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
tHcy	JJ	O
lowering	NN	O
vitamins	NNS	O
decrease	VBP	O
the	DT	O
circulating	NN	Physical
levels	NNS	Physical
of	IN	Physical
A-beta	NNP	Physical
protein	NN	Physical
1-40	JJ	Physical
(	(	Physical
A	NNP	Physical
beta	RB	Physical
40	CD	Physical
)	)	Physical
.	.	O

We	PRP	O
randomized	VBD	O
299	CD	O
older	JJR	O
men	NNS	O
to	TO	O
treatment	NN	O
with	IN	O
2mg	CD	O
of	IN	O
folate	NN	O
,	,	O
plus	CC	O
25mg	CD	O
of	IN	O
B6	NNP	O
and	CC	O
400	CD	O
microg	NN	O
of	IN	O
B12	NNP	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

After	IN	O
2	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
the	DT	O
mean	NN	Physical
(	(	Physical
S.E	NNP	Physical
.	.	Physical

)	)	Physical
increase	NN	Physical
of	IN	Physical
A	NNP	Physical
beta	NN	Physical
40	CD	Physical
was	VBD	O
7.0	CD	O
pg/ml	NN	O
(	(	O
8.4	CD	O
)	)	O
in	IN	O
the	DT	O
vitamin	NN	O
group	NN	O
(	(	O
4.9	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
26.8	CD	O
pg/ml	NN	O
(	(	O
7.7	CD	O
)	)	O
(	(	O
18.5	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
B	NNP	O
vitamins	NNS	O
may	MD	O
decrease	VB	O
the	DT	Physical
plasma	JJ	Physical
level	NN	Physical
of	IN	Physical
A	NNP	Physical
beta	NN	Physical
40	CD	Physical
and	CC	O
have	VBP	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
AD	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
vacuum-compression	NN	Physical
therapy	NN	Physical
on	IN	O
healing	NN	O
of	IN	O
diabetic	JJ	Physical
foot	NN	Physical
ulcers	NNS	Physical
:	:	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
vacuum-compression	NN	Physical
therapy	NN	Physical
(	(	Physical
VCT	NNP	Physical
)	)	Physical
for	IN	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	Physical
foot	NN	Physical
ulcers	NNS	Physical
.	.	O

Eighteen	NNP	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
foot	JJ	Physical
ulcers	NNS	Physical
were	VBD	O
recruited	VBN	O
through	IN	O
simple	JJ	O
nonprobability	NN	O
sampling	VBG	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
the	DT	O
foot	NN	Physical
ulcer	JJ	Physical
surface	NN	Physical
area	NN	Physical
was	VBD	O
estimated	VBN	O
stereologically	RB	O
,	,	O
based	VBN	O
on	IN	O
Cavalieri	NNP	O
's	POS	O
principle	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
VCT	NNP	Others
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	Physical
therapy	NN	Physical
for	IN	O
10	CD	O
sessions	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
only	RB	O
conventional	JJ	Others
therapy	NN	Others
,	,	O
including	VBG	O
debridement	NN	Others
,	,	Others
blood	NN	Others
glucose	NNS	Others
control	NN	Others
agents	NNS	Others
,	,	O
systemic	JJ	Others
antibiotics	NNS	Others
,	,	O
wound	IN	Others
cleaning	VBG	Others
with	IN	Others
normal	JJ	Others
saline	NN	Others
,	,	O
offloading	VBG	Others
(	(	O
pressure	NN	O
relief	NN	O
)	)	O
,	,	O
and	CC	O
daily	RB	Physical
wound	JJ	Physical
dressings	NNS	Physical
.	.	O

The	DT	O
mean	JJ	O
foot	NN	Physical
ulcer	JJ	Physical
surface	NN	Physical
area	NN	Physical
decreased	VBD	O
from	IN	O
46.88	CD	O
+/-	JJ	O
9.28	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
35.09	CD	O
+/-	JJ	O
4.09	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
from	IN	O
46.62	CD	O
+/-	JJ	O
10.03	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
42.89	CD	O
+/-	JJ	O
8.1	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
experimental	JJ	O
group	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
measures	NNS	Physical
of	IN	Physical
foot	NN	Physical
ulcer	JJ	Physical
surface	NN	Physical
area	NN	Physical
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.024	CD	O
)	)	O
.	.	O

VCT	NNP	Others
enhances	VBZ	O
diabetic	JJ	Physical
foot	NN	Physical
ulcer	NN	Physical
healing	VBG	Physical
when	WRB	O
combined	VBN	O
with	IN	O
appropriate	JJ	O
wound	NN	O
care	NN	O
.	.	O

Walking	VBG	O
trials	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
effect	NN	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
on	IN	O
aerobic	JJ	Physical
fitness	NN	Physical
.	.	Physical

We	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
of	IN	O
walking	VBG	O
on	IN	O
aerobic	JJ	Physical
fitness	NN	Physical
and	CC	O
body	NN	Physical
composition	NN	Physical
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
thirty-four	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
exercise	NN	O
groups	NNS	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
130	CD	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
walked	VBD	O
5	CD	O
d/week	NN	O
for	IN	O
15	CD	O
weeks	NNS	O
at	IN	O
65	CD	O
%	NN	O
of	IN	O
their	PRP$	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
expending	VBG	O
300	CD	O
kcal	JJ	O
(	(	O
1255	CD	O
kJ	NN	O
)	)	O
in	IN	O
exercise	NN	O
in	IN	O
one	CD	O
(	(	O
Group	NNP	O
S1	NNP	O
)	)	O
or	CC	O
two	CD	O
daily	JJ	O
sessions	NNS	O
(	(	O
Group	NNP	O
S2	NNP	O
)	)	O
.	.	O

VO	NNP	Physical
(	(	Physical
2max	CD	Physical
)	)	Physical
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
direct	JJ	O
maximal	NN	O
treadmill	NN	O
test	NN	O
.	.	O

Body	NNP	Physical
mass	NN	Physical
index	NN	Physical
(	(	Physical
BMI	NNP	Physical
)	)	Physical
was	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
body	NN	O
fat	NN	O
(	(	O
fat	JJ	O
%	NN	O
)	)	O
estimated	VBN	O
using	VBG	O
skinfold	JJ	O
measurements	NNS	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
the	DT	O
VO	NNP	Physical
(	(	Physical
2max	CD	Physical
)	)	Physical
was	VBD	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	Physical
change	NN	Physical
in	IN	Physical
body	NN	Physical
mass	NN	Physical
was	VBD	O
-1.2	JJ	O
kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.9	NNP	O
,	,	O
-0.5	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.1	NNP	O
kg	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.8	NNP	O
,	,	O
-0.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	Physical
fat	NN	Physical
%	NN	Physical
change	NN	Physical
was	VBD	O
-2.1	JJ	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.7	NNP	O
,	,	O
-1.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.7	NNP	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.3	NNP	O
,	,	O
-1.0	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

Exercise	NN	O
improved	VBD	O
the	DT	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
and	CC	O
body	NN	O
composition	NN	O
equally	RB	O
when	WRB	O
walking	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
one	CD	O
or	CC	O
two	CD	O
daily	JJ	O
bouts	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
on	IN	O
cutaneous	JJ	Physical
vasodilation	NN	Physical
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
mechanism	NN	O
of	IN	O
cutaneous	JJ	O
vasodilation	NN	O
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
by	IN	O
investigating	VBG	O
the	DT	O
roles	NNS	O
of	IN	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
and	CC	O
axon	$	O
reflex	JJ	O
vasodilation	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
subjects	NNS	O
were	VBD	O
17	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
NO	NNP	O
was	VBD	O
investigated	VBN	O
by	IN	O
administering	VBG	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-nitro-l-arginine	VBP	O
methyl	JJ	O
ester	NN	O
hydrochloride	NN	O
(	(	O
L-NAME	NNP	O
,	,	O
20	CD	O
mM	NN	O
)	)	O
,	,	O
an	DT	O
NO	NNP	O
synthase	NN	O
inhibitor	NN	O
or	CC	O
Ringer	NNP	O
's	POS	O
solution	NN	O
(	(	O
control	VB	O
site	NN	O
)	)	O
,	,	O
via	IN	O
intradermal	JJ	O
microdialysis	NN	O
(	(	O
protocol	JJ	O
1	CD	O
;	:	O
n=7	NN	O
)	)	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
axon	JJ	O
reflex	JJ	O
vasodilation	NN	O
by	IN	O
local	JJ	O
sensory	NN	O
neurones	NNS	O
was	VBD	O
investigated	VBN	O
by	IN	O
comparing	VBG	O
vasodilation	NN	O
at	IN	O
sites	NNS	O
treated	VBN	O
with	IN	O
'eutectic	JJ	O
mixture	NN	O
of	IN	O
local	JJ	O
anaesthetics	NNS	O
'	POS	O
(	(	O
EMLA	NNP	O
)	)	O
cream	NN	O
(	(	O
2.5	CD	O
%	NN	O
lidocaine	NN	O
and	CC	O
2.5	CD	O
%	NN	O
prilocaine	NN	O
)	)	O
with	IN	O
untreated	JJ	O
sites	NNS	O
(	(	O
control	VB	O
site	NN	O
)	)	O
(	(	O
protocol	JJ	O
2	CD	O
;	:	O
n=10	NN	O
)	)	O
.	.	O

After	IN	O
5	CD	O
min	NN	O
of	IN	O
baseline	NN	O
recording	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
PC4	NNP	O
and	CC	O
a	DT	O
control	NN	O
site	NN	O
in	IN	O
proximity	NN	O
to	TO	O
PC4	NNP	O
for	IN	O
10	CD	O
min	NNS	O
and	CC	O
scanning	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
60	CD	O
min	NN	O
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
.	.	O

Skin	NNP	Physical
blood	NN	Physical
flow	NN	Physical
(	(	Physical
SkBF	NNP	Physical
)	)	Physical
was	VBD	O
evaluated	VBN	O
by	IN	O
laser	NN	O
Doppler	NNP	Others
perfusion	NN	Others
imaging	VBG	Others
.	.	O

Cutaneous	JJ	Physical
vascular	JJ	Physical
conductance	NN	Physical
(	(	Physical
CVC	NNP	Physical
)	)	Physical
was	VBD	O
calculated	VBN	O
from	IN	O
the	DT	O
ratio	NN	O
of	IN	O
SkBF	NNP	O
to	TO	O
mean	VB	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
first	JJ	O
protocol	NN	O
,	,	O
sites	NNS	O
administered	VBD	O
L-NAME	NNP	O
showed	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
CVC	NNP	Physical
responses	NNS	Physical
following	VBG	O
acupuncture	NN	O
stimulation	NN	O
compared	VBN	O
to	TO	O
control	VB	O
sites	NNS	O
(	(	O
administered	VBN	O
Ringer	NNP	O
's	POS	O
solution	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
protocol	NN	O
,	,	O
changes	NNS	Physical
in	IN	Physical
CVC	NNP	Physical
responses	NNS	Physical
after	IN	O
acupuncture	JJ	O
stimulation	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
treated	VBN	O
sites	NNS	O
with	IN	O
EMLA	NNP	O
cream	NN	O
and	CC	O
untreated	JJ	O
sites	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
cutaneous	JJ	O
vasodilation	NN	O
in	IN	O
response	NN	O
to	TO	O
acupuncture	VB	O
stimulation	NN	O
may	MD	O
not	RB	O
occur	VB	O
through	IN	O
an	DT	O
axon	JJ	O
reflex	NN	O
as	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Rather	NNP	O
,	,	O
NO	NNP	O
mechanisms	NN	O
appear	VBP	O
to	TO	O
contribute	VB	O
to	TO	O
the	DT	O
vasodilator	NN	O
response	NN	O
.	.	O

Modulation	NN	Physical
of	IN	Physical
human	JJ	Physical
motor	NN	Physical
cortex	NN	Physical
excitability	NN	Physical
by	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
amantadine	NN	O
.	.	O

Amantadine-sulfate	NNP	O
has	VBZ	O
been	VBN	O
used	VBN	O
for	IN	O
several	JJ	O
decades	NNS	O
to	TO	O
treat	VB	O
acute	JJ	O
influenza	NN	O
A	NNP	O
,	,	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
and	CC	O
acute	NN	O
or	CC	O
chronic	JJ	O
drug-induced	JJ	O
dyskinesia	NN	O
.	.	O

Several	JJ	O
mechanisms	NNS	O
of	IN	O
actions	NNS	O
detected	VBN	O
in	IN	O
vivo/in	JJ	O
vitro	JJ	O
including	VBG	O
N-methyl-D-aspartate	NNP	Physical
(	(	O
NMDA	NNP	O
)	)	O
-receptor	NN	O
antagonism	NN	Mental
,	,	O
blockage	NN	O
of	IN	O
potassium	NN	O
channels	NNS	O
,	,	O
dopamine	JJ	O
receptor	NN	O
agonism	NN	O
,	,	O
enhancement	NN	O
of	IN	O
noradrenergic	JJ	O
release	NN	O
,	,	O
and	CC	O
anticholinergic	JJ	O
effects	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
.	.	O

We	PRP	O
used	VBD	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
TMS	NNP	O
)	)	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
amantadine	NN	O
on	IN	O
human	JJ	O
motor	NN	O
cortex	NN	Physical
excitability	NN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
.	.	O

Using	VBG	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
design	NN	O
,	,	O
motor	NN	O
thresholds	NNS	O
,	,	O
recruitment	NN	O
curves	NNS	O
,	,	O
cortical	JJ	O
stimulation-induced	JJ	O
silent	JJ	O
period	NN	O
(	(	O
CSP	NNP	O
)	)	O
,	,	O
short	JJ	O
intracortical	JJ	O
inhibition	NN	O
(	(	O
ICI	NNP	O
)	)	O
,	,	O
intracortical	JJ	O
facilitation	NN	O
(	(	O
ICF	NNP	O
)	)	O
,	,	O
and	CC	O
late	JJ	O
inhibition	NN	O
(	(	O
L-ICI	NNP	O
)	)	O
in	IN	O
14	CD	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
investigated	VBN	O
after	IN	O
oral	JJ	O
doses	NNS	O
of	IN	O
50	CD	O
and	CC	O
100	CD	O
mg	NNS	O
amantadine	VBP	O
with	IN	O
single	JJ	O
and	CC	O
paired	JJ	O
pulse	NN	O
TMS	NNP	O
paradigms	NN	O
.	.	O

Spinal	NNP	Physical
cord	NN	Physical
excitability	NN	Physical
was	VBD	O
investigated	VBN	O
by	IN	O
distal	JJ	O
latencies	NNS	O
and	CC	O
M-amplitudes	NNS	Physical
of	IN	O
the	DT	O
abductor	NN	O
digiti	NN	O
minimi	NN	O
muscle	NN	O
.	.	O

After	IN	O
intake	NN	O
of	IN	O
amantadine	NN	O
,	,	O
a	DT	O
significant	JJ	O
dose-dependent	JJ	O
decrease	NN	O
of	IN	O
ICF	NNP	Physical
was	VBD	O
noticed	VBN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
L-ICI	NNP	Physical
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
on	IN	O
ICF	NNP	Physical
and	CC	O
L-ICI	NNP	Physical
significantly	RB	O
correlated	VBD	O
with	IN	O
amantadine	JJ	O
serum	NN	O
levels	NNS	O
.	.	O

ICI	NNP	Physical
was	VBD	O
slightly	RB	O
increased	VBN	O
after	IN	O
amantadine	JJ	O
intake	NN	O
,	,	O
but	CC	O
the	DT	O
effect	NN	O
failed	VBD	O
to	TO	O
be	VB	O
significant	JJ	O
.	.	O

Furthermore	RB	O
,	,	O
amantadine	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
motor	NN	Physical
thresholds	NNS	Physical
,	,	O
MEP	NNP	Physical
recruitment	NN	Physical
curves	NNS	Physical
,	,	O
CSP	NNP	Physical
,	,	O
or	CC	O
peripheral	JJ	Physical
excitability	NN	Physical
.	.	Physical

In	IN	O
conclusion	NN	O
,	,	O
a	DT	O
low	JJ	O
dose	NN	O
of	IN	O
amantadine	NN	O
is	VBZ	O
sufficient	JJ	O
in	IN	O
modulating	VBG	Physical
human	JJ	Physical
motor	NN	Physical
cortex	NN	Physical
excitability	NN	Physical
.	.	O

The	DT	O
decrease	NN	O
of	IN	O
ICF	NNP	Physical
and	CC	O
increase	NN	O
of	IN	O
L-ICI	NNP	Physical
may	MD	O
reflect	VB	O
glutamatergic	JJ	O
modulation	NN	O
or	CC	O
a	DT	O
polysynaptic	JJ	O
interaction	NN	O
of	IN	O
glutamatergic	NN	O
and	CC	O
GABA-ergic	JJ	O
circuits	NNS	O
.	.	O

Although	IN	O
amantadine	NN	O
has	VBZ	O
several	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
,	,	O
the	DT	O
NMDA-receptor	NNP	O
antagonism	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
relevant	JJ	O
effect	NN	O
on	IN	O
cortical	JJ	Physical
excitability	NN	Physical
.	.	O

As	IN	O
L-ICI	JJ	Physical
can	MD	O
be	VB	O
influenced	VBN	O
by	IN	O
this	DT	O
type	NN	O
of	IN	O
drug	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
an	DT	O
interesting	JJ	O
parameter	NN	O
for	IN	O
studies	NNS	O
of	IN	O
motor	NN	O
learning	NN	O
and	CC	O
use-dependent	JJ	O
plasticity	NN	O
.	.	O

Promoting	VBG	O
social	JJ	O
skill	NN	O
development	NN	O
in	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorders	NNS	O
:	:	O
a	DT	O
feasibility	NN	O
and	CC	O
efficacy	NN	O
study	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
design	NN	O
was	VBD	O
employed	VBN	O
to	TO	O
evaluate	VB	O
a	DT	O
social	JJ	O
skills	NNS	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

Aims	NNP	O
included	VBD	O
evaluating	VBG	O
the	DT	O
acceptability	NN	O
of	IN	O
the	DT	O
program	NN	O
and	CC	O
gathering	VBG	O
preliminary	JJ	O
evidence	NN	O
on	IN	O
efficacy	NN	O
.	.	O

Forty-four	JJ	O
children	NNS	O
,	,	O
ages	VBZ	O
8-11	CD	O
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
or	CC	O
wait	JJ	O
list	NN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
16-week	JJ	O
group	NN	O
intervention	NN	O
designed	VBN	O
to	TO	O
teach	VB	O
appropriate	JJ	O
social	JJ	O
behavior	NN	O
.	.	O

Between	NNP	O
group	NN	O
comparisons	NNS	O
showed	VBD	O
that	IN	O
children	NNS	O
in	IN	O
treatment	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
improved	VBN	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
(	(	O
unblinded	JJ	Mental
parent	NN	Mental
report	NN	Mental
)	)	O
,	,	O
but	CC	O
not	RB	O
on	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
a	DT	O
parent	NN	Mental
questionnaire	NN	Mental
.	.	O

Parents	NNS	O
reported	VBD	O
a	DT	O
high	JJ	O
level	NN	Others
of	IN	Others
satisfaction	NN	Others
with	IN	O
the	DT	O
intervention	NN	O
.	.	O

The	DT	O
study	NN	O
supports	VBZ	O
the	DT	O
feasibility	NN	O
of	IN	O
this	DT	O
intervention	NN	O
to	TO	O
families	NNS	O
and	CC	O
highlights	NNS	O
challenges	NNS	O
for	IN	O
future	JJ	O
research	NN	O
in	IN	O
social	JJ	O
skills	NNS	O
intervention	NN	O
.	.	O

Sun	NNP	O
protection	NN	O
counseling	VBG	O
for	IN	O
children	NNS	O
:	:	O
primary	NN	O
care	NN	O
practice	NN	O
patterns	NNS	O
and	CC	O
effect	NN	O
of	IN	O
an	DT	O
intervention	NN	O
on	IN	O
clinicians	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
describe	VB	O
current	JJ	O
primary	JJ	O
care	NN	O
sun	NN	O
protection	NN	O
advice	NN	O
for	IN	O
children	NNS	O
and	CC	O
assess	VB	O
the	DT	O
effect	NN	Others
on	IN	Others
clinicians	NNS	Others
of	IN	O
an	DT	O
intervention	NN	O
to	TO	O
enhance	VB	O
their	PRP$	O
sun	NN	Others
protection	NN	Others
advocacy	NN	Others
.	.	Others

SETTING	NN	O
Primary	NNP	O
care	NN	O
practices	NNS	O
caring	VBG	O
for	IN	O
children	NNS	O
in	IN	O
New	NNP	O
Hampshire	NNP	O
with	IN	O
special	JJ	O
attention	NN	O
to	TO	O
clinicians	NNS	O
serving	VBG	O
10	CD	O
towns	NNS	O
that	WDT	O
were	VBD	O
involved	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
multicomponent	NN	O
SunSafe	NNP	O
intervention	NN	O
involving	VBG	O
schools	NNS	O
,	,	O
recreation	NN	O
areas	NNS	O
,	,	O
and	CC	O
primary	JJ	O
care	NN	O
practices	NNS	O
.	.	O

DESIGN/INTERVENTION	VB	O
A	NNP	O
statewide	JJ	O
survey	NN	O
of	IN	O
all	DT	O
primary	JJ	O
care	NN	O
clinicians	NNS	O
serving	VBG	O
children	NNS	O
addressed	VBD	O
their	PRP$	O
self-reported	JJ	O
sun	NN	Others
protection	NN	Others
advocacy	NN	Others
practices	NNS	Others
.	.	Others

Clinicians	NNPS	O
in	IN	O
10	CD	O
systematically	RB	O
selected	VBN	O
rural	JJ	O
towns	NNS	O
were	VBD	O
involved	VBN	O
in	IN	O
the	DT	O
subsequent	JJ	O
intervention	NN	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
care	NN	O
intervention	NN	O
provided	VBD	O
assistance	NN	O
to	TO	O
practices	NNS	O
in	IN	O
establishing	VBG	O
an	DT	O
office	NN	O
system	NN	O
that	WDT	O
promoted	VBD	O
sun	JJ	O
protection	NN	O
advice	NN	O
to	TO	O
children	NNS	O
and	CC	O
their	PRP$	O
parents	NNS	O
during	IN	O
office	NN	O
visits	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Sun	NNP	Others
protection	NN	Others
promotion	NN	Others
activities	NNS	Others
of	IN	O
primary	JJ	O
care	NN	O
clinicians	NNS	O
as	IN	O
determined	VBN	O
by	IN	O
their	PRP$	O
self	JJ	O
report	NN	O
,	,	O
research	NN	O
assistant	NN	O
observation	NN	O
,	,	O
and	CC	O
parent	NN	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
261	CD	O
eligible	JJ	O
clinicians	NNS	O
responding	VBG	O
to	TO	O
the	DT	O
statewide	NN	O
survey	NN	O
,	,	O
about	IN	O
half	PDT	O
provide	JJ	Others
sun	NN	Others
protection	NN	Others
counseling	VBG	Others
most	JJS	Others
of	IN	Others
the	DT	Others
time	NN	Others
or	CC	Others
almost	RB	Others
always	RB	Others
during	IN	O
summer	NN	O
well	RB	O
care	VB	O
visits	NNS	O
.	.	O

Pediatricians	NNPS	O
do	VBP	O
so	RB	O
more	RBR	O
often	RB	O
than	IN	O
family	NN	O
physicians	NNS	O
.	.	O

Clinicians	NNPS	O
involved	VBN	O
in	IN	O
the	DT	O
intervention	NN	O
increased	VBD	O
their	PRP$	O
use	NN	Others
of	IN	Others
handouts	NNS	Others
,	,	Others
waiting	VBG	Others
room	NN	Others
educational	JJ	Others
materials	NNS	Others
,	,	Others
and	CC	Others
sunscreen	JJ	Others
samples	NNS	Others
.	.	Others

Compared	VBN	O
with	IN	O
control	NN	O
town	NN	O
parents	NNS	O
,	,	O
parents	NNS	O
in	IN	O
intervention	NN	O
towns	NNS	O
reported	VBD	O
an	DT	O
increase	NN	O
in	IN	O
clinician	JJ	Others
sun	NN	Others
protection	NN	Others
advice	NN	Others
.	.	O

CONCLUSIONS	VB	O
The	DT	O
SunSafe	NNP	O
primary	JJ	O
care	NN	O
intervention	NN	O
increased	VBD	O
sun	JJ	Others
protection	NN	Others
counseling	VBG	Others
activities	NNS	Others
of	IN	O
participating	VBG	O
clinicians	NNS	O
.	.	O

A	DT	O
single-focus	JJ	O
preventive	JJ	O
service	NN	O
office	NN	O
system	NN	O
is	VBZ	O
feasible	JJ	Others
to	TO	O
include	VB	O
in	IN	O
community	NN	O
interventions	NNS	O
to	TO	O
promote	VB	O
sun	NN	Others
protection	NN	Others
.	.	O

Oral	JJ	O
ciprofloxacin	NN	O
vs.	FW	O
intramuscular	JJ	O
ceftriaxone	NN	O
as	IN	O
empiric	JJ	O
treatment	NN	O
of	IN	O
acute	JJ	O
invasive	JJ	O
diarrhea	NN	O
in	IN	O
children	NNS	O
.	.	O

BACKGROUND	NNP	O
Acute	NNP	O
invasive	JJ	O
diarrhea	NN	O
is	VBZ	O
a	DT	O
potentially	RB	O
serious	JJ	O
condition	NN	O
in	IN	O
children	NNS	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
resistance	NN	O
of	IN	O
enteric	JJ	O
pathogens	NNS	O
to	TO	O
commonly	RB	O
used	JJ	O
oral	JJ	O
antibiotics	NNS	O
,	,	O
intramuscular	JJ	O
ceftriaxone	NN	O
has	VBZ	O
become	VBN	O
the	DT	O
routine	JJ	O
drug	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
invasive	JJ	O
diarrhea	NN	O
requiring	VBG	O
an	DT	O
emergency	NN	O
visit	NN	O
in	IN	O
southern	JJ	O
Israel	NNP	O
.	.	O

The	DT	O
inconvenience	NN	O
of	IN	O
this	DT	O
parenteral	JJ	O
regimen	NNS	O
created	VBD	O
an	DT	O
increased	VBN	O
need	NN	O
for	IN	O
oral	JJ	O
pediatric	JJ	O
formulations	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
invasive	JJ	O
diarrhea	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
a	DT	O
suspension	NN	O
formulation	NN	O
of	IN	O
ciprofloxacin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
invasive	JJ	O
diarrhea	NN	O
in	IN	O
infants	NNS	O
and	CC	O
children	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
July	NNP	O
1996	CD	O
through	IN	O
December	NNP	O
1997	CD	O
,	,	O
201	CD	O
evaluable	JJ	O
children	NNS	O
ages	VBZ	O
6	CD	O
months	NNS	O
to	TO	O
10	CD	O
years	NNS	O
(	(	O
35	CD	O
%	NN	O
<	CC	O
1	CD	O
year	NN	O
;	:	O
70	CD	O
%	NN	O
<	JJ	O
3	CD	O
years	NNS	O
)	)	O
presenting	VBG	O
with	IN	O
acute	JJ	O
invasive	JJ	O
diarrhea	NN	O
at	IN	O
the	DT	O
Pediatric	NNP	O
Emergency	NNP	O
Room	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ciprofloxacin	NN	O
suspension	NN	O
(	(	O
10	CD	O
mg/kg	NN	O
twice	RB	O
a	DT	O
day	NN	O
+	NNP	O
im	NN	O
placebo	NN	O
;	:	O
n	CC	O
=	VB	O
95	CD	O
)	)	O
or	CC	O
im	VB	O
ceftriaxone	NN	O
(	(	O
50	CD	O
mg/kg/day	NN	O
+	NNP	O
placebo	NN	O
suspension	NN	O
;	:	O
n	CC	O
=	VB	O
106	CD	O
)	)	O
for	IN	O
3	CD	O
days	NNS	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
manner	NN	O
.	.	O

Stool	NNP	Physical
cultures	NNS	Physical
for	IN	Physical
Shigella	NNP	Physical
,	,	O
Salmonella	NNP	Physical
,	,	O
Campylobacter	NNP	Physical
spp	NN	Physical
.	.	O

and	CC	O
diarrheagenic	JJ	Physical
Escherichia	NNP	Physical
coli	NNS	Physical
were	VBD	O
obtained	VBN	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
to	TO	O
5	CD	O
and	CC	O
21	CD	O
+/-	JJ	O
5	CD	O
.	.	O

Clinical	JJ	Others
response	NN	Others
and	CC	Others
safety	NN	Others
were	VBD	O
assessed	VBN	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
to	TO	O
5	CD	O
and	CC	O
21	CD	O
+/-	JJ	O
5	CD	O
.	.	O

RESULTS	NNP	O
We	PRP	O
isolated	VBD	O
127	CD	O
pathogens	NNS	O
from	IN	O
121	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
:	:	O
73	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
Shigella	NNP	Physical
;	:	O
23	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
Salmonella	NNP	Physical
;	:	O
18	CD	O
(	(	O
14	CD	O
%	NN	O
)	)	O
E.	NNP	Physical
coli	NNS	Physical
;	:	O
and	CC	O
13	CD	O
(	(	O
10	CD	O
%	NN	O
)	)	O
Campylobacter	NNP	Physical
.	.	O

Overall	NNP	Physical
bacteriologic	JJ	Physical
eradication	NN	Physical
on	IN	O
Day	NNP	O
4	CD	O
to	TO	O
5	CD	O
was	VBD	O
99	CD	O
%	NN	O
for	IN	O
Shigella	NNP	O
,	,	O
77	CD	O
%	NN	O
for	IN	O
Salmonella	NNP	O
and	CC	O
77	CD	O
%	NN	O
for	IN	O
Campylobacter	NNP	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Clinical	JJ	Others
cure	NN	Others
or	CC	Others
improvement	NN	Others
was	VBD	O
observed	VBN	O
in	IN	O
100	CD	O
and	CC	O
99	CD	O
%	NN	O
of	IN	O
the	DT	O
ciprofloxacin	NN	O
and	CC	O
ceftriaxone	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Serum	NNP	Physical
ciprofloxacin	NN	Physical
values	NNS	Physical
determined	VBN	O
on	IN	O
Day	NNP	O
3	CD	O
of	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
than	IN	O
were	VBD	O
the	DT	O
MIC50	NNP	Physical
and	CC	O
MIC90	NNP	Physical
values	NNS	Physical
for	IN	O
the	DT	O
Shigella	NNP	Physical
and	CC	O
Salmonella	NNP	Physical
spp	NN	Physical
.	.	O

isolated	VBN	O
.	.	O

Possible	JJ	Adverseeffect
drug-related	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
occurred	VBD	O
in	IN	O
13	CD	O
patients	NNS	O
[	JJ	O
ciprofloxacin	NN	O
,	,	O
8	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
;	:	O
ceftriaxone	NN	O
,	,	O
5	CD	O
(	(	O
4.7	CD	O
%	NN	O
)	)	O
]	NN	O
and	CC	O
were	VBD	O
mild	NNS	O
and	CC	O
transient	NN	O
.	.	O

Joint	JJ	Physical
examination	NN	Physical
was	VBD	O
normal	JJ	O
during	IN	O
and	CC	O
after	IN	O
completion	NN	O
of	IN	O
therapy	NN	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

CONCLUSION	NNP	O
Oral	NNP	O
ciprofloxacin	NN	O
was	VBD	O
as	IN	O
safe	JJ	Others
and	CC	O
effective	JJ	Others
as	IN	O
intramuscular	JJ	O
ceftriaxone	NN	O
for	IN	O
the	DT	O
empiric	JJ	O
treatment	NN	O
of	IN	O
acute	JJ	O
invasive	JJ	O
diarrhea	NN	O
in	IN	O
ambulatory	JJ	O
pediatric	JJ	O
patients	NNS	O
requiring	VBG	O
an	DT	O
emergency	NN	O
room	NN	O
visit	NN	O
.	.	O

Cost-effectiveness	JJ	O
analysis	NN	O
of	IN	O
serum	NN	O
vancomycin	NN	O
concentration	NN	O
monitoring	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hematologic	JJ	O
malignancies	NNS	O
.	.	O

OBJECTIVE	VB	O
This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
cost-effectiveness	NN	O
of	IN	O
vancomycin	NN	O
serum	NN	O
concentration	NN	O
monitoring	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hematologic	JJ	O
malignancies	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

Seventy	NNP	O
immunocompromised	VBD	O
febrile	JJ	O
patients	NNS	O
with	IN	O
hematologic	JJ	O
malignancies	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
vancomycin	JJ	O
therapeutic	JJ	O
drug	NN	O
monitoring	NN	O
group	NN	O
(	(	O
TDM	NNP	O
group	NN	O
;	:	O
n	CC	O
=	VB	O
37	CD	O
)	)	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
.	.	O

Intervention	NN	O
in	IN	O
the	DT	O
TDM	NNP	O
group	NN	O
involved	VBD	O
patient	JJ	O
follow-up	NN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
to	TO	O
obtain	VB	O
and	CC	O
pharmacokinetically	RB	O
interpret	JJ	O
serum	NN	O
vancomycin	NN	O
concentrations	NNS	O
for	IN	O
dosage	NN	O
individualization	NN	O
.	.	O

RESULTS	NNP	O
Evaluation	NNP	O
of	IN	O
all	DT	O
patients	NNS	O
included	VBD	O
global	JJ	Physical
clinical	JJ	Physical
response	NN	Physical
and	CC	O
nephrotoxicity	NN	Physical
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
economic	JJ	Others
costs	NNS	Others
and	CC	Others
effectiveness	JJ	Others
derived	VBN	O
from	IN	O
the	DT	O
vancomycin	JJ	O
monitoring	NN	O
program	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
TDM	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
in	IN	O
the	DT	O
outcome	NN	O
measures	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
nephrotoxicity	NN	Physical
:	:	Physical
the	DT	Physical
rates	NNS	Physical
of	IN	Physical
minor	JJ	Physical
nephrotoxicity	NN	Physical
were	VBD	O
33.3	CD	O
%	NN	O
and	CC	O
13.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
TDM	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
corresponding	JJ	O
figures	NNS	O
for	IN	O
moderate	JJ	Physical
nephrotoxicity	NN	Physical
were	VBD	O
9.1	CD	O
%	NN	O
and	CC	O
0	CD	O
%	NN	O
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
confirmed	VBD	O
that	IN	O
TDM	NNP	O
independently	RB	O
reduced	VBD	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
nephrotoxicity	NN	Physical
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
this	DT	O
reduced	JJ	O
nephrotoxicity	NN	Physical
,	,	O
a	DT	O
incremental	JJ	Others
cost	NN	Others
of	IN	O
$	$	O
435	CD	O
per	IN	O
case	NN	O
of	IN	O
nephrotoxicity	NN	O
prevented	VBN	O
was	VBD	O
found	VBN	O
for	IN	O
vancomycin	NN	O
serum	NN	O
concentration	NN	O
monitoring	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
decreased	JJ	Physical
incidence	NN	Physical
of	IN	Physical
nephrotoxicity	NN	Physical
provides	VBZ	O
evidence	NN	O
of	IN	O
a	DT	O
real	JJ	O
clinical	JJ	O
benefit	NN	O
to	TO	O
patient	VB	O
management	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hematologic	JJ	O
malignancies	NNS	O
.	.	O

The	DT	O
TDM	NNP	O
for	IN	O
vancomycin	NN	O
therapy	NN	O
in	IN	O
this	DT	O
high-risk	JJ	O
population	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
cost-effective	JJ	O
procedure	NN	O
.	.	O

An	DT	O
emergency	NN	O
clinical	JJ	O
pathway	NN	O
for	IN	O
stroke	NN	O
patients	NNS	O
--	:	O
results	NNS	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
trial	NN	O
(	(	O
isrctn41456865	NN	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Emergency	NNP	O
Clinical	NNP	O
Pathways	NNP	O
(	(	O
ECP	NNP	O
)	)	O
for	IN	O
stroke	NN	O
have	VBP	O
never	RB	O
been	VBN	O
tested	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
an	DT	O
ECP	NNP	O
for	IN	O
stroke	NN	O
patients	NNS	O
in	IN	O
Latium	NNP	O
(	(	O
Italy	NNP	O
)	)	O
emergency	NN	O
system	NN	O
.	.	O

METHODS	NNP	O
cluster-RCT	NN	O
designed	VBN	O
to	TO	O
compare	VB	O
stroke	JJ	O
patient	JJ	O
referrals	NNS	O
by	IN	O
Emergency	NNP	O
Medical	NNP	O
Service	NNP	O
(	(	O
EMS	NNP	O
)	)	O
and	CC	O
Emergency	NNP	O
Room	NNP	O
(	(	O
ER	NNP	O
)	)	O
health	NN	O
professionals	NNS	O
trained	VBN	O
in	IN	O
the	DT	O
ECP	NNP	O
,	,	O
with	IN	O
those	DT	O
of	IN	O
non-trained	JJ	O
EMS	NNP	O
and	CC	O
ER	NNP	O
controls	NNS	O
.	.	O

Primary	NNP	O
outcome	JJ	O
measure	NN	O
was	VBD	O
the	DT	O
proportion	NN	Others
of	IN	Others
eligible	JJ	Others
(	(	Others
aged	VBN	Others
<	NNP	Others
/=	$	Others
80	CD	Others
and	CC	Others
symptom	JJ	Others
onset	NN	Others
<	NNP	Others
/=	VBZ	Others
6	CD	Others
hours	NNS	Others
)	)	Others
stroke	VBD	Others
patients	NNS	Others
referred	VBN	Others
to	TO	Others
a	DT	Others
stroke	NN	Others
unit	NN	Others
(	(	Others
SU	NNP	Others
)	)	Others
.	.	O

Intention	NN	Others
to	TO	Others
treat	VB	Others
(	(	Others
ITT	NNP	Others
)	)	Others
and	CC	O
per-protocol	JJ	Others
(	(	Others
PP	NNP	Others
)	)	Others
analyses	NNS	Others
were	VBD	O
performed	VBN	O
,	,	O
and	CC	O
risk	NN	O
ratios	NNS	O
(	(	O
RR	NNP	O
)	)	O
adjusted	VBN	O
by	IN	O
age	NN	O
,	,	O
gender	NN	O
and	CC	O
area	NN	O
,	,	O
were	VBD	O
calculated	VBN	O
.	.	O

RESULTS	JJ	O
2656	CD	O
patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
arm	NN	O
and	CC	O
2239	CD	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
required	VBN	O
assistance	NN	Physical
;	:	O
78.3	CD	O
%	NN	O
of	IN	O
the	DT	O
former	JJ	O
and	CC	O
80.6	CD	O
%	NN	O
of	IN	O
the	DT	O
latter	NN	O
were	VBD	O
admitted	VBN	Others
to	TO	Others
hospitals	NNS	Others
,	,	O
and	CC	O
respectively	RB	O
74.8	CD	O
%	NN	O
and	CC	O
78.3	CD	O
%	NN	O
were	VBD	O
confirmed	VBN	Physical
strokes	NNS	Physical
.	.	O

Of	IN	O
the	DT	O
eligible	JJ	O
confirmed	JJ	Physical
strokes	NNS	Physical
,	,	O
106/434	CD	O
(	(	O
24.4	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
intervention	NN	O
arm	NN	O
and	CC	O
43/328	CD	O
(	(	O
13.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
were	VBD	O
referred	VBN	O
to	TO	O
the	DT	O
SU	NNP	Others
in	IN	O
the	DT	O
ITT	NNP	O
analysis	NN	O
(	(	O
RR	NNP	O
=	NNP	O
2.01	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.79-4.00	NN	O
)	)	O
,	,	O
and	CC	O
respectively	RB	O
105/243	CD	O
(	(	O
43.2	CD	O
%	NN	O
)	)	O
and	CC	O
43/311	CD	O
(	(	O
13.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PP	NNP	O
analysis	NN	O
(	(	O
RR	NNP	O
=	NNP	O
3.21	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.62-4.98	JJ	O
)	)	O
.	.	O

Of	IN	O
patients	NNS	O
suitable	JJ	O
for	IN	O
i.v	NN	O
.	.	O

thrombolysis	NN	O
,	,	O
15/175	CD	O
(	(	O
8.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
intervention	NN	O
arm	NN	O
and	CC	O
2/115	CD	O
(	(	O
1.7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
received	VBN	O
thrombolysis	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
in	IN	O
the	DT	O
ITT	NNP	O
analysis	NN	O
,	,	O
and	CC	O
respectively	RB	O
15/99	CD	O
(	(	O
15.1	CD	O
%	NN	O
)	)	O
and	CC	O
2/107	CD	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
in	IN	O
the	DT	O
PP	NNP	O
analysis	NN	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
data	NNS	O
suggest	VBP	O
potenti	JJ	O
efficiency	NN	Others
and	CC	Others
feasibility	NN	Others
of	IN	O
an	DT	O
ECP	NNP	O
.	.	O

The	DT	O
integration	NN	O
of	IN	O
EMS	NNP	O
and	CC	O
ERs	NNP	O
with	IN	O
SU	NNP	O
networks	NNS	O
for	IN	O
organised	JJ	O
acute	NN	O
stroke	NN	O
care	NN	O
is	VBZ	O
feasible	JJ	O
and	CC	O
may	MD	O
ameliorate	VB	O
the	DT	O
quality	NN	Others
of	IN	Others
care	NN	Others
for	IN	O
stroke	NN	O
patients	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
(	(	O
ISRCTN41456865	NNP	O
)	)	O
.	.	O

Efficacy	NN	Others
and	CC	O
safety	NN	Others
of	IN	O
a	DT	O
fixed	JJ	O
low-dose	JJ	O
perindopril/indapamide	NN	O
combination	NN	O
in	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

A	DT	O
randomised	JJ	O
controlled	VBN	O
study	NN	O
.	.	O

This	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Others
and	CC	O
the	DT	O
safety	NN	Others
of	IN	O
fixed	JJ	O
low	JJ	O
dose	NN	O
combination	NN	O
perindopril	VBD	O
2	CD	O
mg/indapamide	RB	O
0.625	CD	O
mg	NN	O
(	(	O
Per/Ind	NNP	O
)	)	O
versus	NN	O
atenolol	$	O
50	CD	O
mg	NN	O
(	(	O
Ate	NNP	O
)	)	O
.	.	O

After	IN	O
a	DT	O
4-week	JJ	O
placebo	NN	O
run-in	NN	O
,	,	O
446	CD	O
hypertensive	JJ	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
55.8	CD	O
+/-	JJ	O
11.0	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
Per/Ind	NNP	O
or	CC	O
Ate	NNP	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
changes	NNS	Physical
in	IN	Physical
trough	JJ	Physical
supine	NN	Physical
systolic	NN	Physical
and	CC	Physical
diastolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	Physical
sSBP	NN	Physical
,	,	Physical
sDBP	NN	Physical
)	)	Physical
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
last	JJ	O
observation	NN	O
.	.	O

Equivalence	NN	Physical
was	VBD	O
assessed	VBN	O
in	IN	O
an	DT	O
intention-to-treat	JJ	O
analysis	NN	O
using	VBG	O
a	DT	O
two	CD	O
one-sided	JJ	O
tests	NNS	O
procedure	NN	O
.	.	O

Per/Ind	NNP	O
and	CC	O
Ate	NNP	O
decreased	VBD	Physical
sSBP	NN	Physical
by	IN	O
-20.5	NNP	O
mmHg	NN	O
and	CC	O
-20.1	NNP	O
mmHg	NN	O
,	,	O
respectively	RB	O
;	:	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	Physical
interval	NN	Physical
[	NNP	O
-2.3	NNP	O
;	:	O
1.5	CD	O
]	NN	O
of	IN	O
the	DT	O
intertreatment	NN	O
difference	NN	O
(	(	O
-0.4	JJ	O
mmHg	NN	O
)	)	O
fell	VBD	O
within	IN	O
the	DT	O
predefined	JJ	Physical
equivalence	NN	Physical
interval	NN	Physical
[	NNP	O
-8	NNP	O
;	:	O
+8	NNP	O
mmHg	FW	O
]	NNP	O
.	.	O

Similarly	RB	O
,	,	O
the	DT	O
sDBP	NN	Physical
decreased	VBN	Physical
by	IN	O
-15.1	NNP	O
mmHg	NN	O
(	(	O
Per/Ind	NNP	O
)	)	O
and	CC	O
-16.2	$	O
mmHg	NN	O
(	(	O
Ate	NNP	O
)	)	O
with	IN	O
an	DT	O
intertreatment	JJ	O
difference	NN	O
of	IN	O
1.1	CD	O
mmHg	NNS	O
whose	WP$	O
90	CD	O
%	NN	O
confidence	NN	Others
interval	NN	Others
[	NNP	O
-0.1	NNP	O
;	:	O
2.2	CD	O
mmHg	NN	O
]	NN	O
fell	VBD	O
within	IN	O
the	DT	O
predefined	JJ	O
equivalence	NN	Physical
interval	NN	Physical
[	NNP	O
-4	NNP	O
;	:	O
+4	NNP	O
mmHg	VBZ	O
]	NNP	O
;	:	O
thus	RB	O
antihypertensive	JJ	Others
efficacy	NN	Others
of	IN	O
Per/Ind	NNP	O
and	CC	O
Ate	NNP	O
were	VBD	O
equivalent	JJ	Physical
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
older	JJR	O
than	IN	O
65	CD	O
,	,	O
Per/Ind	NNP	O
induces	VBZ	O
a	DT	O
statistically	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
sSBP	NN	Physical
than	IN	O
Ate	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Per/Ind	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
.	.	O

Further	RBR	O
controlled	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
confirm	VB	O
these	DT	O
results	NNS	O
on	IN	O
a	DT	O
long-term	JJ	O
period	NN	O
.	.	O

Reversal	NNP	O
of	IN	O
skeletal	JJ	O
effects	NNS	Others
of	IN	O
endocrine	NN	O
treatments	NNS	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
.	.	O

The	DT	O
adjuvant	JJ	O
use	NN	O
of	IN	O
aromatase	NN	O
inhibitors	NNS	O
in	IN	O
breast	NN	O
cancer	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
health	NN	O
.	.	O

We	PRP	O
previously	RB	O
reported	VBD	O
a	DT	O
decline	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
following	VBG	O
the	DT	O
switch	NN	O
from	IN	O
tamoxifen	NN	O
to	TO	O
exemestane	VB	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
(	(	O
IES	NNP	O
)	)	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
effects	NNS	O
of	IN	O
endocrine	JJ	O
treatment	NN	O
withdrawal	NN	O
on	IN	O
BMD	NNP	O
,	,	O
bone	NN	O
turnover	NN	O
markers	NNS	O
(	(	O
BTM	NNP	O
)	)	O
and	CC	O
fracture	JJ	O
rates	NNS	O
.	.	O

4,724	CD	O
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
IES	NNP	O
,	,	O
and	CC	O
206	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
bone	NN	O
sub-study	NN	O
.	.	O

BMD	NNP	O
and	CC	O
BTM	NNP	O
were	VBD	O
assessed	VBN	O
pre-randomization	NN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
EOT	NNP	O
)	)	O
.	.	O

To	TO	O
evaluate	VB	O
treatment	NN	O
withdrawal	NN	O
effects	NNS	O
,	,	O
12-	JJ	O
and	CC	O
24-month	JJ	O
post	NN	O
EOT	NNP	O
BMD	NNP	O
results	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
122	CD	O
and	CC	O
126	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

Similar	JJ	O
patient	NN	O
numbers	NNS	O
had	VBD	O
BTM	NNP	O
measured	VBD	O
post	NN	O
EOT	NNP	O
.	.	O

Following	VBG	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
differences	NNS	O
in	IN	O
BMD	NNP	O
observed	VBD	O
between	IN	O
the	DT	O
two	CD	O
endocrine	NN	O
strategies	NNS	O
were	VBD	O
partially	RB	O
reversed	VBN	O
.	.	O

At	IN	O
24	CD	O
months	NNS	O
from	IN	O
EOT	NNP	O
,	,	O
spine	JJ	Physical
BMD	NNP	Physical
increased	VBN	O
by	IN	O
1.53	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.63-2.43	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
after	IN	O
stopping	VBG	O
exemestane	NN	O
and	CC	O
fell	VBD	O
by	IN	O
1.93	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2.91	NNP	O
to	TO	O
0.95	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.0002	CD	O
)	)	O
following	VBG	O
tamoxifen	NN	O
withdrawal	NN	O
.	.	O

A	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
hip	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
post	RB	O
EOT	NNP	O
,	,	O
BMD	NNP	Physical
changes	NNS	Physical
from	IN	O
baseline	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
treatment	NN	O
strategies	NNS	O
.	.	O

Corresponding	VBG	O
inverse	JJ	Physical
changes	NNS	Physical
in	IN	Physical
BTM	NNP	Physical
were	VBD	O
seen	VBN	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
following	VBG	O
tamoxifen	JJ	O
withdrawal	NN	O
and	CC	O
a	DT	O
reduction	NN	O
after	IN	O
exemestane	NN	O
.	.	O

A	DT	O
higher	JJR	O
number	NN	Physical
of	IN	Physical
fractures	NNS	Physical
occurred	VBD	Physical
during	IN	O
exemestane	NN	O
treatment	NN	O
,	,	O
but	CC	O
fracture	NN	Physical
rates	NNS	Physical
were	VBD	O
similar	JJ	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
.	.	O

With	IN	O
the	DT	O
switch	NN	O
strategy	NN	O
used	VBN	O
in	IN	O
IES	NNP	O
,	,	O
the	DT	O
on	IN	O
treatment	NN	O
adverse	JJ	Adverseeffect
bone	NN	Adverseeffect
effects	NNS	Adverseeffect
of	IN	O
exemestane	NN	O
are	VBP	O
reversed	VBN	O
.	.	O

Ongoing	VBG	O
monitoring	NN	O
of	IN	O
BMD	NNP	O
is	VBZ	O
therefore	RB	O
not	RB	O
routinely	RB	O
required	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
placebo	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
of	IN	O
N-Acetylcysteine	NNP	O
added	VBD	O
to	TO	O
risperidone	VB	O
for	IN	O
treating	VBG	O
autistic	JJ	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
N-acetylcysteine	NNP	O
(	(	O
NAC	NNP	O
)	)	O
augmentation	NN	O
for	IN	O
treating	VBG	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
and	CC	O
adolescents	NNS	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
ASD	NNP	O
according	VBG	O
to	TO	O
DSM-IV	NNP	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
into	IN	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
NAC	NNP	O
(	(	O
1200	CD	O
mg/day	NN	O
)	)	O
+risperidone	NN	O
or	CC	O
placebo+risperidone	NN	O
.	.	O

NAC	NNP	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
effervescent	NN	O
and	CC	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Irritability	NNP	O
subscale	JJ	O
score	NN	O
of	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
was	VBD	O
considered	VBN	O
as	IN	O
the	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
were	VBD	O
also	RB	O
checked	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
score	NN	O
of	IN	O
irritability	NN	O
in	IN	O
the	DT	O
NAC+risperidone	NNP	O
and	CC	O
placebo+risperidone	NN	O
groups	NNS	O
at	IN	O
baseline	NN	O
was	VBD	O
13.2	CD	O
(	(	O
5.3	CD	O
)	)	O
and	CC	O
16.7	CD	O
(	(	O
7.8	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
scores	NNS	O
after	IN	O
8	CD	O
weeks	NNS	O
were	VBD	O
9.7	CD	O
(	(	O
4.1	CD	O
)	)	O
and	CC	O
15.1	CD	O
(	(	O
7.8	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Repeated	VBN	O
measures	NNS	O
of	IN	O
ANOVA	NNP	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
NAC+risperidone	NNP	O
group	NN	O
were	VBD	O
constipation	NN	O
(	(	O
16.1	CD	O
%	NN	O
)	)	O
,	,	O
increased	VBN	O
appetite	NN	O
(	(	O
16.1	CD	O
%	NN	O
)	)	O
,	,	O
fatigue	NN	O
(	(	O
12.9	CD	O
%	NN	O
)	)	O
,	,	O
nervousness	RB	O
(	(	O
12.9	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
daytime	JJ	O
drowsiness	NN	O
(	(	O
12.9	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
fatal	JJ	O
adverse	JJ	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Risperidone	NNP	O
plus	CC	O
NAC	NNP	O
more	JJR	O
than	IN	O
risperidone	NN	O
plus	CC	O
placebo	NN	O
decreased	JJ	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Meanwhile	RB	O
,	,	O
it	PRP	O
did	VBD	O
not	RB	O
change	VB	O
the	DT	O
core	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
were	VBD	O
not	RB	O
common	JJ	O
and	CC	O
NAC	NNP	O
was	VBD	O
generally	RB	O
tolerated	VBN	O
well	RB	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
This	DT	O
trial	NN	O
was	VBD	O
registered	VBN	O
at	IN	O
http	NN	O
:	:	O
//www.irct.ir	NN	O
.	.	O

The	DT	O
registration	NN	O
number	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
IRCT201106103930N6	NNP	O
.	.	O

Excimer	NNP	O
laser	NN	O
trabeculotomy	NN	O
vs	NN	O
180	CD	O
degrees	NNS	O
selective	JJ	O
laser	NN	O
trabeculoplasty	NN	O
in	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
.	.	O

A	DT	O
2-year	JJ	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
excimer	FW	O
laser	NN	O
trabeculotomy	NN	O
(	(	O
ELT	NNP	O
)	)	O
ab	VBP	O
interno	JJ	O
vs	NN	O
selective	JJ	O
laser	NN	O
trabeculoplasty	NN	O
(	(	O
SLT	NNP	O
)	)	O
over	IN	O
24	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
(	(	O
POAG	NNP	O
)	)	O
refractory	NN	O
to	TO	O
medical	JJ	O
therapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
included	VBD	O
30	CD	O
consecutive	JJ	O
eyes	NNS	O
assigned	VBD	O
randomly	RB	O
to	TO	O
either	DT	O
ELT	NNP	O
or	CC	O
SLT	NNP	O
group	NN	O
.	.	O

ELT	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
a	DT	O
XeCl	JJ	O
Excimer	NNP	O
Laser	NNP	O
with	IN	O
an	DT	O
emission	NN	O
wavelength	NN	O
of	IN	O
308	CD	O
nm	NN	O
.	.	O

Eight	JJ	O
spots	NNS	O
were	VBD	O
equally	RB	O
distributed	VBN	O
at	IN	O
a	DT	O
distance	NN	O
of	IN	O
500	CD	O
microm	NN	O
from	IN	O
one	CD	O
another	DT	O
over	IN	O
the	DT	O
anterior	JJ	O
trabeculum	NN	O
.	.	O

The	DT	O
SLT	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
frequency-doubled	JJ	O
q-switched	JJ	O
neodymium	NN	O
:	:	O
yytrium-aluminum-garnet	JJ	O
laser	NN	O
(	(	O
wavelength	JJ	O
532	CD	O
nm	NN	O
)	)	O
.	.	O

Approximately	RB	O
50	CD	O
adjacent	JJ	O
,	,	O
but	CC	O
not	RB	O
overlapping	JJ	O
,	,	O
laser	JJ	O
spots	NNS	O
were	VBD	O
distributed	VBN	O
over	IN	O
180	CD	O
degrees	NNS	O
of	IN	O
the	DT	O
trabecular	JJ	O
meshwork	NN	O
,	,	O
using	VBG	O
an	DT	O
energy	NN	O
level	NN	O
ranging	VBG	O
from	IN	O
0.7	CD	O
to	TO	O
1.0	CD	O
mJ	NNS	O
per	IN	O
pulse	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
intraocular	JJ	Physical
pressure	NN	Physical
(	(	Physical
IOP	NNP	Physical
)	)	Physical
lowering	NN	Physical
after	IN	Physical
ELT	NNP	Physical
and	CC	Physical
SLT	NNP	Physical
.	.	Physical

Success	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
>	JJ	O
or=20	CD	O
%	NN	O
reduction	NN	Physical
in	IN	Physical
IOP	NNP	Physical
without	IN	O
further	JJ	O
glaucoma	NN	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
24	CD	O
months	NNS	O
,	,	O
complete	JJ	O
success	NN	Physical
rates	NNS	Physical
were	VBD	O
53.3	CD	O
%	NN	O
for	IN	O
the	DT	O
ELT	NNP	O
group	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
the	DT	O
SLT	NNP	O
group	NN	O
(	(	O
P=0.35	NNP	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
)	)	O
;	:	O
qualified	VBN	Physical
success	NN	Physical
rates	NNS	Physical
were	VBD	O
33.3	CD	O
%	NN	O
for	IN	O
the	DT	O
ELT	NNP	O
and	CC	O
26.6	CD	O
%	NN	O
for	IN	O
the	DT	O
SLT	NNP	O
group	NN	O
(	(	O
P=0.5	NNP	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	Physical
)	)	Physical
.Mean	VBP	Physical
IOP	NNP	Physical
decreased	VBD	Physical
from	IN	O
25.0+/-1.9	JJ	O
to	TO	O
17.6+/-2.2	JJ	O
mmHg	NN	O
(	(	O
-29.6	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
ELT	NNP	O
group	NN	O
and	CC	O
from	IN	O
23.9+/-0.9	JJ	O
to	TO	O
19.1+/-1.8	JJ	O
mmHg	NN	O
(	(	O
-21	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
SLT	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
ELT	NNP	O
and	CC	O
SLT	NNP	O
proved	VBD	O
to	TO	O
be	VB	O
effective	JJ	O
techniques	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
POAG	NNP	O
refractory	NN	O
to	TO	O
medical	JJ	O
therapy	NN	O
.	.	O

Epidural	JJ	O
morphine	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
after	IN	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
epidurally	RB	O
administered	VBN	O
morphine	NN	O
in	IN	O
the	DT	O
relief	NN	Pain
of	IN	Pain
pain	NN	Pain
after	IN	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
controlled	VBN	O
study	NN	O
involving	VBG	O
20	CD	O
patients	NNS	O
aged	VBD	O
61	CD	O
to	TO	O
78	CD	O
years	NNS	O
.	.	O

Analgesia	NNP	Mental
provided	VBN	O
by	IN	O
epidural	JJ	O
morphine	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
that	DT	O
obtained	VBN	O
in	IN	O
matched	JJ	O
patients	NNS	O
given	VBN	O
an	DT	O
intramuscular	JJ	O
regime	NN	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
required	VBN	O
by	IN	O
the	DT	O
epidural	JJ	O
route	NN	O
was	VBD	O
less	JJR	O
than	IN	O
one-fifth	JJ	O
that	IN	O
required	VBD	O
intramuscularly	RB	O
,	,	O
and	CC	O
sedation	NN	O
was	VBD	O
correspondingly	RB	O
reduced	VBN	O
.	.	O

Postoperative	JJ	Mortality
respiratory	NN	Mortality
mechanics	NNS	Mortality
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
significantly	RB	O
improved	VBN	O
and	CC	O
delayed	VBN	Mental
respiratory	NN	Mental
depression	NN	Mental
was	VBD	O
observed	VBN	O
in	IN	O
one	CD	O
patient	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
undergoing	VBG	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
the	DT	O
risks	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
morphine	NN	O
by	IN	O
the	DT	O
epidural	JJ	O
route	NN	O
outweigh	VBP	O
the	DT	O
marginal	JJ	O
advantages	NNS	O
it	PRP	O
may	MD	O
offer	VB	O
over	IN	O
conventional	JJ	O
analgesic	JJ	O
techniques	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
maternal	JJ	O
glucose	JJ	O
infusion	NN	O
on	IN	O
fetal	JJ	O
acid-base	JJ	O
status	NN	O
in	IN	O
human	JJ	O
pregnancy	NN	O
.	.	O

The	DT	O
maternal	JJ	O
and	CC	O
fetal	JJ	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
three	CD	O
commonly	NNS	O
used	VBD	O
intravenous	JJ	O
fluids	NNS	O
administered	VBD	O
before	IN	O
regional	JJ	O
anesthesia	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
32	CD	O
gravid	JJ	O
women	NNS	O
undergoing	VBG	O
elective	JJ	O
cesarean	JJ	O
section	NN	O
at	IN	O
term	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
1	CD	O
L	NNP	O
of	IN	O
either	RB	O
5	CD	O
%	NN	O
dextrose	NN	O
(	(	O
50	CD	O
gm	NN	O
of	IN	O
glucose	NN	O
)	)	O
or	CC	O
Ringer	NNP	O
's	POS	O
lactate	NN	O
or	CC	O
isotonic	JJ	O
saline	JJ	O
solution	NN	O
before	IN	O
epidural	JJ	O
anesthesia	NN	O
.	.	O

Acute	NNP	Physical
glucose	JJ	Physical
infusion	NN	Physical
resulted	VBD	O
in	IN	O
maternal	JJ	Adverseeffect
hyperglycemia	NN	Adverseeffect
,	,	O
hyperinsulinemia	NN	Physical
,	,	O
and	CC	O
an	DT	O
increase	NN	Physical
in	IN	Physical
the	DT	Physical
blood	NN	Physical
lactate	NN	Physical
level	NN	Physical
.	.	O

Cord	NNP	O
blood	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
,	,	O
and	CC	O
lactate	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
increased	VBN	O
in	IN	O
this	DT	O
group	NN	O
.	.	O

The	DT	O
key	JJ	O
finding	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
the	DT	O
significant	JJ	Physical
lowering	NN	Physical
of	IN	Physical
pH	NN	Physical
in	IN	Physical
the	DT	Physical
umbilical	JJ	Physical
cord	NN	Physical
vein	NN	Physical
(	(	O
7.31	CD	O
+/-	JJ	O
0.04	CD	O
)	)	O
and	CC	O
artery	NN	Physical
(	(	O
7.21	CD	O
+/-	JJ	O
0.06	CD	O
)	)	O
in	IN	O
the	DT	O
glucose-infused	JJ	O
group	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
non-glucose	JJ	Physical
infusion	NN	Physical
groups	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Confounding	VBG	O
perinatal	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
maternal	JJ	Physical
position	NN	Physical
,	,	O
maternal	JJ	Physical
hypotension	NN	Physical
,	,	O
and	CC	O
prolonged	VBD	Physical
time	NN	Physical
of	IN	Physical
surgery	NN	Physical
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
fetal	JJ	O
acid-base	JJ	O
status	NN	O
.	.	O

Thus	RB	O
acute	JJ	O
maternal	JJ	Physical
glucose	NN	Physical
infusion	NN	Physical
in	IN	O
normal	JJ	O
patients	NNS	O
can	MD	O
cause	VB	O
fetal	JJ	Physical
hyperglycemia	NN	Physical
,	,	O
metabolic	JJ	Physical
acidosis	NN	Physical
,	,	O
and	CC	O
neonatal	JJ	Physical
hypoglycemia	NN	Physical
.	.	O

These	DT	O
findings	NNS	O
may	MD	O
be	VB	O
of	IN	O
particular	JJ	O
clinical	JJ	O
importance	NN	O
when	WRB	O
fetal	JJ	Physical
distress	NN	Physical
or	CC	O
fetal	JJ	Physical
hypoxemia	NN	Physical
is	VBZ	O
due	JJ	O
to	TO	O
other	JJ	O
perinatal	JJ	O
events	NNS	O
.	.	O

Under	IN	O
these	DT	O
circumstances	NNS	O
,	,	O
acute	JJ	Physical
maternal	JJ	Physical
glucose	JJ	Physical
infusion	NN	Physical
may	MD	O
further	RB	O
contribute	VB	O
to	TO	O
fetal	JJ	Physical
metabolic	JJ	Physical
acidosis	NN	Physical
.	.	O

Comparison	NNP	O
of	IN	O
warfarin	NN	O
and	CC	O
aspirin	NN	O
for	IN	O
symptomatic	JJ	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
.	.	O

BACKGROUND	NNP	O
Atherosclerotic	NNP	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
cause	NN	O
of	IN	O
stroke	NN	O
.	.	O

Warfarin	NNP	O
is	VBZ	O
commonly	RB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
aspirin	VB	O
for	IN	O
this	DT	O
disorder	NN	O
,	,	O
but	CC	O
these	DT	O
therapies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
patients	NNS	O
with	IN	O
transient	JJ	O
ischemic	JJ	O
attack	NN	O
or	CC	O
stroke	NN	O
caused	VBN	O
by	IN	O
angiographically	RB	O
verified	VBN	O
50	CD	O
to	TO	O
99	CD	O
percent	NN	O
stenosis	NN	O
of	IN	O
a	DT	O
major	JJ	O
intracranial	JJ	O
artery	NN	O
to	TO	O
receive	VB	O
warfarin	NN	O
(	(	O
target	VB	O
international	JJ	O
normalized	JJ	O
ratio	NN	O
,	,	O
2.0	CD	O
to	TO	O
3.0	CD	O
)	)	O
or	CC	O
aspirin	NN	O
(	(	O
1300	CD	O
mg	NN	O
per	IN	O
day	NN	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
multicenter	RB	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
ischemic	JJ	Physical
stroke	NN	Physical
,	,	O
brain	NN	Physical
hemorrhage	NN	Physical
,	,	O
or	CC	O
death	NN	Mortality
from	IN	O
vascular	JJ	O
causes	NNS	O
other	JJ	O
than	IN	O
stroke	NN	Physical
.	.	O

RESULTS	NNP	O
After	IN	O
569	CD	O
patients	NNS	O
had	VBD	O
undergone	JJ	O
randomization	NN	O
,	,	O
enrollment	NN	O
was	VBD	O
stopped	VBN	O
because	IN	O
of	IN	O
concerns	NNS	O
about	IN	O
the	DT	O
safety	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
assigned	VBN	O
to	TO	O
receive	VB	O
warfarin	NN	O
.	.	O

During	IN	O
a	DT	O
mean	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
1.8	CD	O
years	NNS	O
,	,	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
included	VBD	O
death	NN	Mortality
(	(	O
4.3	CD	O
percent	NN	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
vs.	FW	O
9.7	CD	O
percent	NN	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
;	:	O
hazard	CC	O
ratio	NN	O
for	IN	O
aspirin	JJ	O
relative	JJ	O
to	TO	O
warfarin	VB	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.23	CD	O
to	TO	O
0.90	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
,	,	O
major	JJ	Physical
hemorrhage	NN	Physical
(	(	O
3.2	CD	O
percent	NN	O
vs.	FW	O
8.3	CD	O
percent	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	NN	O
ratio	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.18	CD	O
to	TO	O
0.84	CD	O
;	:	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
myocardial	JJ	Physical
infarction	NN	Physical
or	CC	O
sudden	JJ	Mortality
death	NN	Mortality
(	(	O
2.9	CD	O
percent	NN	O
vs.	FW	O
7.3	CD	O
percent	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	NN	O
ratio	NN	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.18	CD	O
to	TO	O
0.91	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	Mortality
of	IN	Mortality
death	NN	Mortality
from	IN	O
vascular	JJ	O
causes	NNS	O
was	VBD	O
3.2	CD	O
percent	NN	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
and	CC	O
5.9	CD	O
percent	NN	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
;	:	O
the	DT	O
rate	NN	Mortality
of	IN	Mortality
death	NN	Mortality
from	IN	O
nonvascular	JJ	O
causes	NNS	O
was	VBD	O
1.1	CD	O
percent	NN	O
and	CC	O
3.8	CD	O
percent	NN	O
,	,	O
respectively	RB	O
(	(	O
P=0.05	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
occurred	VBD	O
in	IN	O
22.1	CD	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
and	CC	O
21.8	CD	O
percent	NN	O
of	IN	O
those	DT	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
1.04	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.73	CD	O
to	TO	O
1.48	CD	O
;	:	O
P=0.83	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Warfarin	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
provided	VBD	O
no	DT	O
benefit	NN	O
over	IN	O
aspirin	NN	O
in	IN	O
this	DT	O
trial	NN	O
.	.	O

Aspirin	NNP	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
warfarin	VB	O
for	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
.	.	O

In	IN	O
school-aged	JJ	O
children	NNS	O
a	DT	O
combination	NN	O
of	IN	O
galacto-oligosaccharides	NNS	O
and	CC	O
Lactobacillus	NNP	O
GG	NNP	O
increases	VBZ	O
bifidobacteria	RB	O
more	JJR	O
than	IN	O
Lactobacillus	NNP	O
GG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
combination	NN	O
of	IN	O
Lactobacillus	NNP	O
GG	NNP	O
(	(	O
LGG	NNP	O
)	)	O
and	CC	O
galacto-oligosaccharides	NNS	O
(	(	O
GOS	NNP	O
)	)	O
with	IN	O
LGG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
,	,	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
intestinal	JJ	O
microbiota	NN	O
in	IN	O
school-aged	JJ	O
children	NNS	O
.	.	O

The	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
crossover	NN	O
study	NN	O
comprised	VBD	O
30	CD	O
healthy	JJ	O
children	NNS	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
3-week	JJ	O
study	NN	O
periods	NNS	O
with	IN	O
a	DT	O
4-week	JJ	O
wash-out	JJ	O
period	NN	O
in	IN	O
between	IN	O
.	.	O

The	DT	O
children	NNS	O
ingested	VBD	O
daily	RB	O
65	CD	O
ml	NN	O
of	IN	O
milk-based	JJ	O
fruit	NN	O
juice	NN	O
containing	VBG	O
either	CC	O
LGG	NNP	O
alone	RB	O
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU	NNP	O
)	)	O
or	CC	O
LGG	NNP	O
plus	CC	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
.	.	O

Symptom	NNP	O
diaries	NNS	O
were	VBD	O
filled	VBN	O
during	IN	O
the	DT	O
study	NN	O
periods	NNS	O
.	.	O

Fecal	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
,	,	O
the	DT	O
amount	NN	Physical
of	IN	Physical
bifidobacteria	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
after	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
LGG	NNP	O
+	NNP	O
GOS	NNP	O
compared	VBN	O
with	IN	O
LGG	NNP	O
alone	RB	O
(	(	O
geometric	JJ	O
mean	VBP	O
9.33	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
vs.	FW	O
4.28	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU/g	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
amount	NN	Physical
of	IN	Physical
lactobacilli	NN	Physical
or	CC	Physical
LGG	NNP	Physical
,	,	O
nor	CC	O
did	VBD	O
gastrointestinal	JJ	Physical
symptoms	NNS	Physical
,	,	Physical
defecation	NN	Physical
frequency	NN	Physical
,	,	Physical
consistency	NN	Physical
of	IN	Physical
stools	NNS	Physical
or	CC	Physical
ease	NN	Physical
of	IN	Physical
defecation	NN	Physical
differ	NN	O
between	IN	O
the	DT	O
two	CD	O
study	NN	O
periods	NNS	O
.	.	O

Ingestion	NN	O
of	IN	O
LGG	NNP	O
combined	VBD	O
with	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
increased	VBD	O
the	DT	O
bifidobacteria	NN	Physical
more	JJR	O
than	IN	O
LGG	NNP	O
on	IN	O
its	PRP$	O
own	JJ	O
and	CC	O
thus	RB	O
GOS	NNP	O
clearly	RB	O
has	VBZ	O
a	DT	O
prebiotic	JJ	O
effect	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
children	NNS	O
tolerated	VBN	O
well	RB	O
a	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	O
.	.	O

Warfarin	NNP	O
versus	NN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
thromboembolism	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
II	NNP	O
Study	NNP	O
.	.	O

Warfarin	NNP	O
is	VBZ	O
an	DT	O
established	JJ	O
treatment	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
value	NN	O
of	IN	O
this	DT	O
agent	JJ	O
relative	NN	O
to	TO	O
aspirin	VB	O
in	IN	O
unclear	JJ	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
(	(	O
SPAF-I	NNP	O
)	)	O
study	NN	O
,	,	O
direct	JJ	O
comparison	NN	O
of	IN	O
warfarin	NN	O
with	IN	O
aspirin	NN	O
was	VBD	O
limited	VBN	O
by	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
thromboembolic	JJ	O
events	NNS	O
.	.	O

SPAF-II	JJ	O
aims	NNS	O
to	TO	O
address	VB	O
this	DT	O
issue	NN	O
and	CC	O
also	RB	O
to	TO	O
assess	VB	O
the	DT	O
differential	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
according	VBG	O
to	TO	O
age	NN	O
.	.	O

We	PRP	O
compared	VBN	O
warfarin	NN	O
(	(	O
prothrombin	JJ	O
time	NN	O
ratio	JJ	O
1.3-1.8	JJ	O
,	,	O
international	JJ	O
normalised	JJ	O
ratio	NN	O
2.0-4.5	JJ	O
)	)	O
with	IN	O
aspirin	$	O
325	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
and	CC	O
systemic	JJ	O
embolism	NN	O
(	(	O
primary	JJ	O
events	NNS	O
)	)	O
in	IN	O
two	CD	O
parallel	NNS	O
randomised	VBD	O
trials	NNS	O
involving	VBG	O
715	CD	O
patients	NNS	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
and	CC	O
385	CD	O
patients	NNS	O
older	JJR	O
than	IN	O
75	CD	O
;	:	O
we	PRP	O
sought	VBD	O
reductions	NNS	O
in	IN	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
warfarin	NNS	O
compared	VBN	O
with	IN	O
aspirin	NN	O
of	IN	O
2	CD	O
%	NN	O
per	IN	O
year	NN	O
and	CC	O
4	CD	O
%	NN	O
per	IN	O
year	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
younger	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	Physical
rate	NN	Physical
of	IN	Physical
primary	JJ	Physical
events	NNS	Physical
by	IN	O
0.7	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-0.4	NNP	O
to	TO	O
1.7	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	Physical
event	NN	Physical
rate	NN	Physical
per	IN	Physical
year	NN	Physical
was	VBD	O
1.3	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
1.9	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
0.67	CD	O
,	,	O
p	NN	O
=	NNP	O
0.24	CD	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
in	IN	O
low-risk	JJ	O
younger	NN	O
patients	NNS	O
(	(	O
without	IN	O
hypertension	NN	O
,	,	O
recent	JJ	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
previous	JJ	O
thromboembolism	NN	O
)	)	O
on	IN	O
aspirin	NN	O
was	VBD	O
0.5	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.1	CD	O
to	TO	O
1.9	CD	O
)	)	O
.	.	O

Among	IN	O
older	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	O
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
1.2	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.7	NNP	O
to	TO	O
4.1	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
3.6	CD	O
%	NN	O
with	IN	O
warfarin	NN	O
and	CC	O
4.8	CD	O
%	NN	O
with	IN	O
aspirin	NN	O
(	(	O
RR	NNP	O
0.73	CD	O
,	,	O
p	NN	O
=	NNP	O
0.39	CD	O
)	)	O
.	.	O

In	IN	O
this	DT	O
older	JJR	O
group	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
all	DT	O
stroke	NN	O
with	IN	O
residual	JJ	O
deficit	NN	O
(	(	O
ischaemic	JJ	O
or	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
4.3	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
aspirin	NN	O
and	CC	O
4.6	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
warfarin	NN	O
(	(	O
RR	NNP	O
1.1	CD	O
)	)	O
.	.	O

Warfarin	NNP	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
absolute	JJ	O
reduction	NN	O
in	IN	O
stroke	NN	O
rate	NN	O
by	IN	O
warfarin	NN	O
is	VBZ	O
small	JJ	O
.	.	O

Younger	JJR	O
patients	NNS	O
without	IN	O
risk	NN	O
factors	NNS	O
had	VBD	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
stroke	NN	O
when	WRB	O
treated	VBN	O
with	IN	O
aspirin	NN	O
.	.	O

In	IN	O
older	JJR	O
patients	NNS	O
the	DT	O
rate	NN	O
of	IN	O
stroke	NN	O
(	(	O
ischaemic	JJ	O
and	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
substantial	JJ	O
,	,	O
irrespective	NN	O
of	IN	O
which	WDT	O
agent	NN	O
was	VBD	O
given	VBN	O
.	.	O

Patient	JJ	O
age	NN	O
and	CC	O
the	DT	O
inherent	JJ	O
risk	NN	O
of	IN	O
thromboembolism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
choice	NN	O
of	IN	O
antithrombotic	JJ	O
prophylaxis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Nicotine	NNP	O
infusion	NN	O
acutely	RB	O
impairs	JJ	O
insulin	NN	O
sensitivity	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
but	CC	O
not	RB	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
if	IN	O
an	DT	O
acute	JJ	O
nicotine	NN	O
infusion	NN	O
alters	NNS	O
insulin	VBP	O
sensitivity	NN	O
to	TO	O
a	DT	O
similar	JJ	O
degree	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
as	IN	O
in	IN	O
healthy	JJ	O
control	NN	O
subjects	NNS	O
.	.	O

DESIGN	NNP	O
.	.	O

Double-blind	NNP	O
,	,	O
cross-over	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
experimental	NN	O
study	NN	O
.	.	O

Nicotine	NNP	O
0.3	CD	O
microg	NN	O
kg-1	JJ	O
min	NN	O
(	(	O
-1	JJ	O
)	)	O
or	CC	O
NaCl	NNP	O
was	VBD	O
infused	VBN	O
(	(	O
2	CD	O
h	NN	O
)	)	O
during	IN	O
a	DT	O
euglycaemic	JJ	O
hyperinsulinaemic	NN	O
clamp	NN	O
(	(	O
4	CD	O
h	NN	O
)	)	O
to	TO	O
assess	VB	O
insulin	JJ	O
sensitivity	NN	O
.	.	O

SETTING	NNP	O
University	NNP	O
research	NN	O
laboratory	NN	O
.	.	O

SUBJECTS	NNP	O
Six	NNP	O
male	NN	O
and	CC	O
female	JJ	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
[	JJ	O
DM2	NNP	O
;	:	O
age	NN	O
54	CD	O
+/-	JJ	O
10	CD	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
years	NNS	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
25.6	CD	O
+/-	JJ	O
2.9	CD	O
kg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
]	NN	O
treated	VBN	O
with	IN	O
diet	JJ	O
or	CC	O
one	CD	O
oral	JJ	O
hypoglycaemic	JJ	O
agent	NN	O
and	CC	O
six	CD	O
age-	JJ	O
and	CC	O
BMI-matched	JJ	O
control	NN	O
subjects	NNS	O
(	(	O
Ctr	NNP	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Insulin	NNP	Others
sensitivity	NN	Others
(	(	Others
rate	NN	Others
of	IN	Others
glucose	JJ	Others
infusion	NN	Others
per	IN	Others
kg	NN	Others
fat	JJ	Others
free	JJ	Others
body	NN	Others
mass	NN	Others
and	CC	Others
minute	NN	Others
)	)	Others
,	,	Others
nicotine	JJ	Physical
and	CC	Physical
free	JJ	Physical
fatty	NN	Physical
acid	NN	Physical
(	(	Physical
FFA	NNP	Physical
)	)	Physical
levels	NNS	Physical
,	,	O
pulse	NN	Physical
rate	NN	Physical
and	CC	O
blood	NN	Physical
pressure	NN	Physical
.	.	O

RESULTS	VB	O
The	DT	O
infusions	NNS	O
produced	VBD	O
similar	JJ	O
nicotine	NN	O
levels	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
nicotine	NN	O
,	,	O
DM2	NNP	O
were	VBD	O
more	JJR	O
insulin	NN	Physical
resistant	NN	Physical
than	IN	O
Ctr	NNP	O
(	(	O
6.7	CD	O
+/-	JJ	O
0.4	CD	O
vs.	FW	O
10.9	CD	O
+/-	JJ	O
0.3	CD	O
mg	JJ	O
kg-1	JJ	O
LBM	NNP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

This	DT	O
insulin	NN	Physical
resistance	NN	Physical
was	VBD	O
further	RBR	O
aggravated	VBN	O
by	IN	O
the	DT	O
nicotine	JJ	O
infusion	NN	O
in	IN	O
DM2	NNP	O
but	CC	O
not	RB	O
in	IN	O
Ctr	NNP	O
(	(	O
4.6	CD	O
+/-	JJ	O
0.3	CD	O
vs.	FW	O
10.9	CD	O
+/-	JJ	O
0.3	CD	O
mg	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
LBM	NNP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Only	RB	O
minor	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
FFA	NNP	Physical
levels	NNS	Physical
,	,	O
pulse	NN	Physical
rates	NNS	Physical
and	CC	O
blood	NN	Physical
pressure	NN	Physical
.	.	O

CONCLUSIONS	NN	O
At	IN	O
this	DT	O
low	JJ	O
infusion	NN	O
rate	NN	O
,	,	O
nicotine	NN	O
aggravated	VBD	O
the	DT	O
insulin	NN	Physical
resistance	NN	Physical
in	IN	O
DM2	NNP	O
but	CC	O
not	RB	O
in	IN	O
Ctr	NNP	O
.	.	O

This	DT	O
finding	NN	O
may	MD	O
be	VB	O
because	IN	O
of	IN	O
the	DT	O
(	(	O
dysmetabolic	JJ	O
)	)	O
diabetic	JJ	O
state	NN	O
per	IN	O
se	NN	O
or	CC	O
to	TO	O
an	DT	O
increased	VBN	O
sensitivity	NN	O
to	TO	O
environmental	JJ	O
factors	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
genetic	JJ	O
predisposition	NN	O
for	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
diabetic	JJ	O
subjects	NNS	O
are	VBP	O
particularly	RB	O
susceptible	JJ	O
to	TO	O
the	DT	O
detrimental	JJ	O
effects	NNS	O
of	IN	O
nicotine	NN	O
.	.	O

An	DT	O
open-label	JJ	O
extension	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
treating	VBG	O
irritability	NN	Physical
and	CC	O
related	JJ	O
behaviors	NNS	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
6	CD	O
month	NN	O
(	(	O
26	CD	O
week	NN	O
)	)	O
open-label	NN	O
extension	NN	O
(	(	O
OLE	NNP	O
)	)	O
study	NN	O
,	,	O
patients	NNS	O
(	(	O
5-17	JJ	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
who	WP	O
completed	VBD	O
the	DT	O
previous	JJ	O
fixed-dose	JJ	O
,	,	O
6	CD	O
week	NN	O
,	,	O
double-blind	JJ	O
[	NNP	O
DB	NNP	O
]	NNP	O
phase	NN	O
)	)	O
were	VBD	O
flexibly	RB	O
dosed	VBN	O
with	IN	O
risperidone	NN	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
maximum	JJ	O
allowed	VBD	O
dose	NN	O
was	VBD	O
1.25	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
20	CD	O
to	TO	O
<	VB	O
45	CD	O
kg	NN	O
,	,	O
and	CC	O
1.75	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
?	.	O
45	CD	O
kg	NN	O
.	.	O

The	DT	O
study	NN	O
primarily	RB	O
assessed	VBD	O
risperidone	NN	O
's	POS	O
safety	NN	O
;	:	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
as	IN	O
a	DT	O
secondary	JJ	O
end-point	NN	O
.	.	O

RESULTS	VB	O
Fifty-six	NNP	O
(	(	O
71	CD	O
%	NN	O
)	)	O
out	IN	O
of	IN	O
79	CD	O
enrolled	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
OLE	NNP	O
;	:	O
the	DT	O
most	RBS	O
common	JJ	O
discontinuations	NNS	O
were	VBD	O
for	IN	O
insufficient	JJ	O
response	NN	O
(	(	O
7	CD	O
[	RB	O
9	CD	O
%	NN	O
]	NN	O
)	)	O
or	CC	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
(	(	O
5	CD	O
[	RB	O
6	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
(	(	O
?	.	O
5	CD	O
%	NN	O
frequency	NN	O
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
)	)	O
AEs	NNP	O
were	VBD	O
increased	VBN	O
appetite	RB	O
(	(	O
11	CD	O
%	NN	O
[	JJ	O
n=9	JJ	O
]	NN	O
)	)	O
;	:	O
increased	VBN	O
weight	NN	O
and	CC	O
vomiting	NN	O
(	(	O
9	CD	O
%	NN	O
[	JJ	O
n=7	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
sedation	NN	O
,	,	O
pyrexia	NN	O
,	,	O
and	CC	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infection	NN	O
(	(	O
8	CD	O
%	NN	O
[	JJ	O
n=6	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
nasopharyngitis	NN	O
(	(	O
6	CD	O
%	NN	O
[	JJ	O
n=5	JJ	O
]	NN	O
)	)	O
;	:	O
and	CC	O
somnolence	NN	O
and	CC	O
fatigue	NN	O
(	(	O
5	CD	O
%	NN	O
[	JJ	O
n=4	JJ	O
]	NNP	O
each	DT	O
)	)	O
.	.	O

Extrapyramidal	JJ	O
AEs	NNP	O
were	VBD	O
reported	VBN	O
in	IN	O
6	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Increase	NNP	O
in	IN	O
mean	JJ	O
weight	NN	O
(	(	O
11-15	CD	O
%	NN	O
)	)	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
5-10	CD	O
%	NN	O
)	)	O
occurred	VBD	O
;	:	O
one	CD	O
patient	NN	O
discontinued	VBN	O
because	IN	O
of	IN	O
weight	JJ	O
increase	NN	O
.	.	O

One	CD	O
potentially	RB	O
prolactin-related	JJ	O
AE	NNP	O
(	(	O
irregular	JJ	O
menstruation	NN	O
)	)	O
was	VBD	O
reported	VBN	O
.	.	O

The	DT	O
risperidone	NN	O
high-dose	JJ	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
mean	JJ	O
improvement	NN	O
in	IN	O
sleep	JJ	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
24.6	CD	O
)	)	O
.	.	O

All	DT	O
groups	NNS	O
showed	VBD	O
additional	JJ	O
improvement	NN	O
in	IN	O
efficacy	NN	O
scale	JJ	O
scores	NNS	O
during	IN	O
the	DT	O
OLE	NNP	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
this	DT	O
OLE	NNP	O
,	,	O
safety	NN	O
findings	NNS	O
with	IN	O
risperidone	NN	O
treatment	NN	O
(	(	O
maximum	JJ	O
weight-based	JJ	O
dose	NN	O
of	IN	O
1.25	CD	O
mg/day	NN	O
or	CC	O
1.75	CD	O
mg/day	NN	O
)	)	O
were	VBD	O
consistent	JJ	O
with	IN	O
those	DT	O
observed	VBN	O
in	IN	O
the	DT	O
DB	NNP	O
phase	NN	O
,	,	O
and	CC	O
with	IN	O
the	DT	O
current	JJ	O
safety	NN	O
information	NN	O
for	IN	O
risperidone	NN	O
in	IN	O
autistic	JJ	O
,	,	O
psychiatric	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
disorders	NNS	O
.	.	O

Patients	NNS	O
experienced	VBD	O
some	DT	O
additional	JJ	O
improvement	NN	O
in	IN	O
irritability	NN	O
and	CC	O
related	JJ	O
behaviors	NNS	O
.	.	O

CLINICAL	JJ	O
TRIALS	NNP	O
REGISTRY	NNP	O
This	DT	O
phase-4	JJ	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
(	(	O
NCT00576732	NNP	O
)	)	O
.	.	O

Individual	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
short	JJ	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Having	VBG	O
a	DT	O
'theory	NN	O
of	IN	O
mind	NN	O
'	''	O
,	,	O
or	CC	O
having	VBG	O
the	DT	O
ability	NN	O
to	TO	O
attribute	VB	O
mental	JJ	O
states	NNS	O
to	TO	O
oneself	VB	O
or	CC	O
others	NNS	O
,	,	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
central	JJ	O
domains	NNS	O
of	IN	O
impairment	NN	O
among	IN	O
children	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Many	JJ	O
interventions	NNS	O
focus	VBP	O
on	IN	O
improving	VBG	O
theory	NN	O
of	IN	O
mind	NN	O
skills	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Nonetheless	NNP	O
,	,	O
the	DT	O
empirical	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
these	DT	O
interventions	NNS	O
is	VBZ	O
limited	JJ	O
.	.	O

The	DT	O
main	JJ	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
short	JJ	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

A	DT	O
second	JJ	O
objective	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
which	WDT	O
subgroups	NNS	O
within	IN	O
the	DT	O
autism	NN	O
spectrum	JJ	O
profit	NN	O
most	JJS	O
from	IN	O
the	DT	O
intervention	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

One	CD	O
hundred	VBD	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
aged	VBD	O
7	CD	O
to	TO	O
12	CD	O
years	NNS	O
will	MD	O
be	VB	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
or	CC	O
a	DT	O
waiting	JJ	O
list	NN	O
control	NN	O
group	NN	O
.	.	O

Outcome	NNP	O
measures	VBZ	O
include	VBP	O
the	DT	O
completion	NN	Mental
of	IN	Mental
theory	NN	Mental
of	IN	Mental
mind	NN	Mental
and	CC	Mental
emotion	NN	Mental
understanding	NN	Mental
tasks	NNS	Mental
,	,	O
and	CC	O
parent	NN	Mental
and	CC	Mental
teacher	NN	Mental
questionnaires	NNS	Mental
on	IN	Mental
children	NNS	Mental
's	POS	Mental
social	JJ	Mental
skills	NNS	Mental
.	.	O

Follow-up	NNP	O
data	NN	O
for	IN	O
the	DT	O
intervention	NN	O
group	NN	O
will	MD	O
be	VB	O
collected	VBN	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
interventions	NNS	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
efficacy	NN	Others
of	IN	O
a	DT	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Hypotheses	NNP	Others
,	,	O
strengths	NNS	Others
,	,	O
and	CC	O
limitations	NNS	Others
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Netherlands	NNP	O
Trial	NNP	O
Register	NNP	O
NTR2327	NNP	O
.	.	O

Effect	NN	O
of	IN	O
ranitidine	NN	O
and	CC	O
amoxicillin	JJ	O
plus	CC	O
metronidazole	JJ	O
on	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
and	CC	O
the	DT	O
recurrence	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

BACKGROUND	NNP	O
Persistent	NNP	O
infection	NN	O
with	IN	O
Helicobacter	NNP	O
pylori	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
recurrence	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

Whether	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
bismuth	NN	O
therapy	NN	O
in	IN	O
reducing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
recurrence	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
its	PRP$	O
antimicrobial	JJ	O
effects	NNS	O
on	IN	O
H.	NNP	O
pylori	NN	O
or	CC	O
to	TO	O
a	DT	O
direct	JJ	O
protective	JJ	O
action	NN	O
on	IN	O
the	DT	O
mucosa	NN	O
is	VBZ	O
still	RB	O
a	DT	O
matter	NN	O
of	IN	O
debate	NN	O
.	.	O

METHODS	NNP	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
eradication	NN	O
of	IN	O
H.	NNP	O
pylori	NN	Physical
on	IN	O
the	DT	O
recurrence	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
,	,	O
we	PRP	O
treated	VBD	O
104	CD	O
patients	NNS	O
with	IN	O
H.	NNP	O
pylori	FW	O
infection	NN	O
and	CC	O
recurrent	JJ	O
duodenal	JJ	O
ulcer	NN	O
with	IN	O
either	DT	O
amoxicillin	NN	O
(	(	O
750	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
plus	CC	O
metronidazole	JJ	O
(	(	O
500	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
or	CC	O
identical-appearing	JJ	O
placebos	NN	O
,	,	O
given	VBN	O
orally	RB	O
for	IN	O
12	CD	O
days	NNS	O
.	.	O

All	DT	O
patients	NNS	O
also	RB	O
received	VBD	O
ranitidine	NN	O
(	(	O
300	CD	O
mg	RB	O
each	DT	O
night	NN	O
)	)	O
for	IN	O
6	CD	O
or	CC	O
10	CD	O
weeks	NNS	O
.	.	O

Endoscopy	NNP	O
was	VBD	O
performed	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
periodically	RB	O
during	IN	O
follow-up	NN	O
for	IN	O
up	IN	O
to	TO	O
12	CD	O
months	NNS	O
after	IN	O
healing	VBG	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
52	CD	O
patients	NNS	O
given	VBN	O
antibiotics	NNS	O
,	,	O
H.	NNP	O
pylori	NN	O
was	VBD	O
eradicated	VBN	Others
in	IN	O
46	CD	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
1	CD	O
of	IN	O
the	DT	O
52	CD	O
given	VBN	O
placebo	NN	O
(	(	O
89	CD	O
percent	NN	O
vs.	FW	O
2	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

After	IN	O
six	CD	O
weeks	NNS	O
,	,	O
the	DT	O
ulcers	NNS	Physical
were	VBD	O
healed	VBN	Others
in	IN	O
48	CD	O
patients	NNS	O
given	VBN	O
antibiotics	NNS	O
and	CC	O
39	CD	O
given	VBN	O
placebo	NN	O
(	(	O
92	CD	O
percent	NN	O
vs.	FW	O
75	CD	O
percent	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
,	,	O
mainly	RB	O
diarrhea	NN	Adverseeffect
,	,	O
occurred	VBD	O
in	IN	O
15	CD	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
given	VBN	O
antibiotics	NNS	O
.	.	O

Among	IN	O
the	DT	O
patients	NNS	O
followed	VBD	O
up	RP	O
for	IN	O
12	CD	O
months	NNS	O
,	,	O
duodenal	JJ	Physical
ulcers	NNS	Physical
recurred	VBD	Physical
in	IN	O
4	CD	O
of	IN	O
50	CD	O
patients	NNS	O
given	VBN	O
antibiotics	NNS	O
and	CC	O
42	CD	O
of	IN	O
49	CD	O
given	VBN	O
placebo	NN	O
(	(	O
8	CD	O
percent	NN	O
vs.	FW	O
86	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Ulcers	NNS	Physical
recurred	VBD	Physical
in	IN	O
1	CD	O
of	IN	O
46	CD	O
patients	NNS	O
in	IN	O
whom	WP	O
H.	NNP	O
pylori	NN	O
had	VBD	O
been	VBN	O
eradicated	VBN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
45	CD	O
of	IN	O
53	CD	O
in	IN	O
whom	WP	O
H.	NNP	O
pylori	NN	O
persisted	VBD	O
(	(	O
2	CD	O
percent	NN	O
vs.	FW	O
85	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
duodenal	JJ	O
ulcer	NN	O
,	,	O
eradication	NN	Others
of	IN	Physical
H.	NNP	Physical
pylori	NN	O
by	IN	O
a	DT	O
regimen	NNS	O
that	WDT	O
does	VBZ	O
not	RB	O
have	VB	O
any	DT	O
direct	JJ	O
action	NN	O
on	IN	O
the	DT	O
mucosa	NN	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
marked	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
recurrence	NN	O
,	,	O
suggesting	VBG	O
a	DT	O
causal	JJ	O
role	NN	O
for	IN	O
H.	NNP	O
pylori	NN	O
in	IN	O
recurrent	JJ	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

Emotional	JJ	Mental
reactivity	NN	Mental
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
among	IN	O
persons	NNS	O
with	IN	O
borderline	JJ	O
personality	NN	O
features	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
emotional	JJ	Mental
reactivity	NN	Mental
of	IN	O
persons	NNS	O
with	IN	O
heightened	JJ	O
borderline	NN	O
personality	NN	O
(	(	O
BP	NNP	O
)	)	O
features	VBZ	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
and	CC	O
controls	NNS	O
with	IN	O
low	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
writing	NN	Mental
(	(	O
negative	JJ	O
evaluation/academic	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
personal	JJ	Mental
characteristics	NNS	Mental
as	RB	O
well	RB	O
as	IN	O
social	JJ	Mental
rejection	NN	Mental
(	(	Mental
negative	JJ	Mental
evaluation/social	JJ	Mental
rejection	NN	Mental
)	)	Mental
.	.	O

Hypothesis	$	O
1	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
,	,	O
but	CC	O
not	RB	O
low-BP	JJ	O
controls	NNS	O
,	,	O
would	MD	O
show	VB	O
greater	JJR	O
emotional	JJ	Mental
reactivity	NN	Mental
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
(	(	O
writing	VBG	O
)	)	O
stressor	NN	O
.	.	O

Hypothesis	$	O
2	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
would	MD	O
specifically	RB	O
show	VB	O
greater	JJR	O
reactivity	NN	Mental
of	IN	Mental
shame-	JJ	Mental
and	CC	Mental
anger-related	JJ	Mental
emotions	NNS	Mental
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
stressor	NN	O
.	.	O

Findings	NNS	O
indicated	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
showed	VBD	O
heightened	VBN	Mental
emotional	JJ	Mental
reactivity	NN	Mental
to	TO	O
the	DT	O
social	JJ	O
rejection	NN	O
stressor	NN	O
but	CC	O
not	RB	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation	NN	O
stressor	NN	O
,	,	O
but	CC	O
the	DT	O
opposite	JJ	O
pattern	NN	O
occurred	VBD	O
for	IN	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
evidence	NN	O
for	IN	O
heightened	JJ	Mental
reactivity	NN	Mental
of	IN	Mental
irritability	NN	Mental
,	,	Mental
distress	NN	Mental
,	,	Mental
and	CC	Mental
shame	NN	Mental
for	IN	O
the	DT	O
high-BP	JJ	O
group	NN	O
,	,	O
specifically	RB	O
in	IN	O
the	DT	O
social	JJ	O
rejection	NN	O
condition	NN	O
.	.	O

Treatment	NNP	O
outcome	NN	O
of	IN	O
appliance	NN	O
therapy	NN	O
in	IN	O
temporomandibular	JJ	O
disorder	NN	O
patients	NNS	O
with	IN	O
myofascial	JJ	Pain
pain	NN	Pain
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
long-term	JJ	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
a	DT	O
stabilization	NN	O
appliance	NN	O
(	(	O
group	NN	O
T	NNP	O
)	)	O
and	CC	O
treatment	NN	O
with	IN	O
a	DT	O
control	NN	O
appliance	NN	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
in	IN	O
temporomandibular	JJ	O
disorder	NN	O
(	(	O
TMD	NNP	O
)	)	O
patients	NNS	O
with	IN	O
myofascial	JJ	O
pain	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
controlled	JJ	O
trial	NN	O
,	,	O
60	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
29	CD	O
years	NNS	O
)	)	O
with	IN	O
myofascial	JJ	O
pain	NN	O
were	VBD	O
evaluated	VBN	O
after	IN	O
10	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
either	CC	O
a	DT	O
stabilization	NN	O
appliance	NN	O
or	CC	O
a	DT	O
control	JJ	O
appliance	NN	O
.	.	O

All	DT	O
60	CD	O
patients	NNS	O
were	VBD	O
then	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
according	VBG	O
to	TO	O
demand	NN	O
for	IN	O
treatment	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
from	IN	O
group	NN	O
C	NNP	O
requested	VBD	O
another	DT	O
appliance	NN	O
and	CC	O
were	VBD	O
given	VBN	O
a	DT	O
stabilization	NN	O
appliance	NN	O
,	,	O
thus	RB	O
creating	VBG	O
a	DT	O
mixed	JJ	O
group	NN	O
(	(	O
group	NN	O
M	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
improvement	NN	Physical
of	IN	Physical
overall	JJ	Physical
subjective	JJ	Physical
symptoms	NNS	Physical
in	IN	O
an	DT	O
intent-to-treat	JJ	O
analysis	NN	O
between	IN	O
groups	NNS	O
T	NNP	O
and	CC	O
C	NNP	O
was	VBD	O
found	VBN	O
at	IN	O
the	DT	O
follow-ups	NNS	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	O
analysis	NN	O
of	IN	O
treatment	NN	O
compliance	NN	O
,	,	O
a	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
groups	NNS	O
T	NNP	O
and	CC	O
C.	NNP	O
At	IN	O
the	DT	O
6-	JJ	O
and	CC	O
12-month	JJ	O
follow-ups	NNS	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
myofascial	JJ	Pain
pain	NN	O
,	,	O
as	IN	O
measured	VBN	O
on	IN	O
a	DT	O
visual	JJ	Physical
analog	NN	Physical
scale	NN	Physical
,	,	O
was	VBD	O
found	VBN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
frequency	NN	Pain
and	CC	Pain
intensity	NN	Pain
of	IN	Pain
myofascial	JJ	Pain
pain	NN	Pain
was	VBD	O
found	VBN	O
in	IN	O
group	NN	O
T	NNP	O
at	IN	O
the	DT	O
follow-ups	NNS	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
number	NN	Physical
of	IN	Physical
tender	NN	Physical
sites	NNS	Physical
on	IN	Physical
the	DT	Physical
masticatory	NN	Physical
muscles	NNS	Physical
was	VBD	O
found	VBN	O
in	IN	O
group	NN	O
T	NNP	O
at	IN	O
the	DT	O
follow-ups	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
support	VBD	O
the	DT	O
conclusion	NN	O
that	IN	O
the	DT	O
positive	JJ	O
treatment	NN	O
outcome	NN	O
obtained	VBN	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
stabilization	NN	O
appliance	NN	O
to	TO	O
alleviate	VB	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
myofascial	JJ	O
pain	NN	O
persisted	VBD	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Most	JJS	O
patients	NNS	O
in	IN	O
groups	NNS	O
T	NNP	O
and	CC	O
M	NNP	O
reported	VBD	O
positive	JJ	O
changes	NNS	O
in	IN	O
overall	JJ	Physical
subjective	JJ	Physical
symptoms	NNS	Physical
in	IN	O
this	DT	O
trial	NN	O
.	.	O

We	PRP	O
therefore	VBP	O
recommend	JJ	O
use	NN	O
of	IN	O
the	DT	O
stabilization	NN	O
appliance	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
TMD	NNP	O
patients	NNS	O
with	IN	O
myofascial	JJ	Pain
pain	NN	Pain
.	.	Pain

Venlafaxine	NNP	O
versus	NN	O
clonidine	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hot	JJ	Physical
flashes	NNS	Physical
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
cross-over	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Breast	NNP	O
cancer	NN	O
patients	NNS	O
with	IN	O
treatment-induced	JJ	O
menopause	NN	O
experience	NN	O
frequent	NN	O
and	CC	O
severe	JJ	Physical
hot	JJ	Physical
flashes	NNS	Physical
(	(	Physical
HF	NNP	Physical
)	)	Physical
.	.	O

We	PRP	O
compared	VBN	O
venlafaxine	NN	O
and	CC	O
clonidine	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HF	NNP	O
with	IN	O
regard	NN	O
to	TO	O
side	VB	Adverseeffect
effects	NNS	Adverseeffect
,	,	O
efficacy	NN	Others
,	,	O
quality	NN	Others
of	IN	Others
life	NN	Others
and	CC	O
sexual	JJ	Physical
functioning	NN	Physical
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
study	NN	O
,	,	O
60	CD	O
breast	NN	O
cancer	NN	O
patients	NNS	O
experiencing	VBG	O
HF	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
8	CD	O
weeks	NNS	O
venlafaxine	NN	O
followed	VBN	O
by	IN	O
2	CD	O
weeks	NNS	O
wash-out	RB	O
,	,	O
and	CC	O
8	CD	O
weeks	NNS	O
clonidine	NN	O
or	CC	O
vice	NN	O
versa	NN	O
.	.	O

HF	NNP	Physical
frequency	NN	Physical
and	CC	Physical
severity	NN	Physical
,	,	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
,	,	Adverseeffect
quality	NN	Physical
of	IN	Physical
life	NN	Physical
and	CC	Adverseeffect
sexuality	NN	Physical
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Thirty	NNP	O
patients	NNS	O
started	VBD	O
with	IN	O
venlafaxine	NN	O
and	CC	O
30	CD	O
with	IN	O
clonidine	NN	O
.	.	O

Premature	JJ	O
discontinuation	NN	O
for	IN	O
toxicity	NN	Physical
occurred	VBD	O
in	IN	O
14/59	CD	O
during	IN	O
venlafaxine	NN	O
and	CC	O
5/53	CD	O
during	IN	O
clonidine	NN	O
(	(	O
P	NNP	O
=	NNP	O
.038	NNP	O
)	)	O
.	.	O

Venlafaxine	NNP	O
induced	VBD	O
more	JJR	O
side	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

Median	JJ	Physical
reduction	NN	Physical
in	IN	Physical
HF	NNP	Physical
score	NN	Physical
was	VBD	O
49	CD	O
%	NN	O
for	IN	O
venlafaxine	NN	O
and	CC	O
55	CD	O
%	NN	O
for	IN	O
clonidine	NN	O
(	(	O
ns	JJ	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Venlafaxine	NNP	O
and	CC	O
clonidine	NN	O
are	VBP	O
equally	RB	O
,	,	O
but	CC	O
moderately	RB	O
effective	JJ	O
in	IN	O
HF	NNP	Physical
reduction	NN	Physical
.	.	O

Side	NN	Adverseeffect
effects	NNS	Adverseeffect
are	VBP	O
the	DT	O
main	JJ	O
reason	NN	O
for	IN	O
drug	NN	O
discontinuation	NN	O
,	,	O
occurring	VBG	O
more	RBR	O
often	RB	O
with	IN	O
venlafaxine	NN	O
.	.	O

Sustained	JJ	O
effect	NN	O
of	IN	O
SQ-standardized	NNP	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
on	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
prevalence	NN	O
of	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
has	VBZ	O
increased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
past	JJ	O
decades	NNS	O
with	IN	O
grass	NN	O
pollen	NN	O
being	VBG	O
a	DT	O
common	JJ	O
trigger	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
allergy	NN	O
on	IN	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
substantial	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
sustained	JJ	O
effect	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
during	IN	O
the	DT	O
grass	NN	O
pollen	NN	O
season	NN	O
1	CD	O
year	NN	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
SQ-standardized	JJ	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
(	(	O
AIT	NNP	O
)	)	O
,	,	O
Graza	NNP	O
(	(	O
Phleum	NNP	O
pratense	VBZ	O
75,000	CD	O
SQ-T/2800	JJ	O
BAU	NNP	O
;	:	O
ALK	NNP	O
,	,	O
Denmark	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
adult	NN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
moderate-severe	JJ	O
grass	NN	O
pollen	NN	O
induced	VBD	O
rhinoconjunctivitis	NN	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
.	.	O

Subjects	NNS	O
received	VBD	O
3	CD	O
years	NNS	O
of	IN	O
grass	NN	O
AIT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
157	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
126	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Quality	NN	Others
of	IN	Others
life	NN	Others
assessments	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
standardized	JJ	Others
rhinoconjunctivitis	NN	Others
quality	NN	Others
of	IN	Others
life	NN	Others
questionnaire	NN	Others
(	(	Others
RQLQ	NNP	Others
(	(	Others
S	NNP	Others
)	)	Others
)	)	Others
;	:	Others
completed	VBN	O
weekly	JJ	O
during	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
follow-up	JJ	O
,	,	O
the	DT	O
overall	JJ	O
RQLQ	NNP	Others
(	(	Others
S	NNP	Others
)	)	Others
score	NN	Others
for	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
relative	JJ	O
difference	NN	O
to	TO	O
placebo	VB	O
:	:	O
23	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
was	VBD	O
higher	JJR	O
during	IN	O
the	DT	O
peak	NN	O
pollen	NN	O
season	NN	O
(	(	O
28	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
grass	NN	O
AIT	NNP	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
and	CC	O
the	DT	O
previous	JJ	O
three	CD	O
treatment	NN	O
years	NNS	O
was	VBD	O
similar	JJ	O
.	.	O

Improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
all	DT	O
seven	CD	O
RQLQ	NNP	Others
(	(	Others
S	NNP	Others
)	)	Others
domains	VBZ	Others
.	.	O

The	DT	O
RQLQ	NNP	Others
(	(	Others
S	NNP	Others
)	)	Others
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
weekly	JJ	O
average	NN	O
pollen	NN	O
counts	VBZ	O
showed	VBD	O
a	DT	O
clear	JJ	O
separation	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
subjects	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
,	,	O
grass	NN	O
AIT	NNP	O
provided	VBD	O
sustained	VBN	O
and	CC	O
clinically	RB	O
relevant	JJ	O
improvements	NNS	O
in	IN	O
rhinoconjunctivitis	NN	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
grass	NN	O
pollen	NN	O
exposure	NN	O
.	.	O

Randomized	VBN	O
comparative	JJ	O
study	NN	O
of	IN	O
group	NN	O
versus	FW	O
individual	JJ	O
cognitive	JJ	O
behavioural	JJ	O
therapy	NN	O
for	IN	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
group	NN	O
and	CC	O
individual	JJ	O
cognitive	JJ	O
behaviour	NN	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
for	IN	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
(	(	O
OCD	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
ten	VB	O
out-patients	NNS	O
with	IN	O
OCD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
15	CD	O
sessions	NNS	O
of	IN	O
either	DT	O
group	NN	O
CBT	NNP	O
or	CC	O
individual	JJ	O
CBT	NNP	O
.	.	O

Outcome	NNP	O
measures	NNS	O
were	VBD	O
administered	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
at	IN	O
6-	JJ	O
and	CC	O
12-month	JJ	O
follow-ups	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
supplemented	VBN	O
by	IN	O
a	DT	O
meta-analysis	NN	O
of	IN	O
accomplished	JJ	O
comparative	JJ	O
studies	NNS	O
of	IN	O
group	NN	O
vs.	FW	O
individual	JJ	O
CBT	NNP	O
for	IN	O
OCD	NNP	O
.	.	O

RESULTS	NNP	O
Large	NNP	O
and	CC	O
stable	JJ	O
pre-post	JJ	O
effect	NN	Others
sizes	NNS	Others
were	VBD	O
found	VBN	O
for	IN	O
both	DT	O
treatment	NN	O
conditions	NNS	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
d	JJ	O
=	NNP	O
1.06-1.24	NN	O
on	IN	O
the	DT	O
Yale-Brown	JJ	Others
Obsessive	NNP	Others
Compulsive	NNP	Others
Scale	NNP	Others
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
in	IN	O
outcome	NN	O
at	IN	O
any	DT	O
data	NNS	O
point	NN	O
(	(	O
ds=	JJ	O
-0.13	NN	O
to	TO	O
0.15	CD	O
)	)	O
.	.	O

The	DT	O
meta-analysis	NN	O
of	IN	O
four	CD	O
accomplished	JJ	O
comparative	NN	O
studies	NNS	O
(	(	O
including	VBG	O
the	DT	O
present	JJ	O
one	NN	O
)	)	O
found	VBD	O
a	DT	O
between-group	JJ	O
mean	JJ	O
effect	NN	O
size	NN	O
of	IN	O
(	(	O
d=	JJ	O
0.15	CD	O
favouring	VBG	O
individual	JJ	O
over	IN	O
group	NN	O
CBT	NNP	O
at	IN	O
posttreatment	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-0.12	NNP	O
,	,	O
0.42	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
OCD	NNP	O
can	MD	O
be	VB	O
treated	VBN	O
effectively	RB	Others
with	IN	O
a	DT	O
group	NN	O
format	NN	O
of	IN	O
CBT	NNP	O
,	,	O
thus	RB	O
sparing	VBG	O
some	DT	O
therapist	JJ	O
resources	NNS	O
,	,	O
although	IN	O
the	DT	O
four	CD	O
accomplished	VBD	O
comparative	JJ	O
studies	NNS	O
do	VBP	O
not	RB	O
rule	VB	O
out	IN	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
small	JJ	O
superiority	NN	O
of	IN	O
individually	RB	O
conducted	VBN	O
CBT	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
an	DT	O
Internet-based	JJ	O
intervention	NN	O
on	IN	O
plasma	NNS	Physical
glucose	JJ	Physical
levels	NNS	Physical
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

This	DT	O
study	NN	O
applied	VBD	O
a	DT	O
12-week	JJ	O
educational	JJ	O
intervention	NN	O
that	WDT	O
used	VBD	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
to	TO	O
send	VB	O
short	JJ	O
message	NN	O
service	NN	O
.	.	O

Forty-two	NNP	O
diabetic	JJ	O
patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
access	NN	O
a	DT	O
Web	NNP	O
site	NN	O
by	IN	O
using	VBG	O
a	DT	O
cellular	JJ	O
phone	NN	O
or	CC	O
wire	NN	O
Internet	NNP	O
and	CC	O
input	VB	O
their	PRP$	O
blood	NN	Physical
glucose	NN	Physical
levels	NNS	Physical
every	DT	O
day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
sent	VBN	O
the	DT	O
optimal	JJ	O
recommendations	NNS	O
by	IN	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
28.6	CD	O
mg/dL	NNS	O
in	IN	O
fasting	VBG	Physical
plasma	NN	Physical
glucose	NN	Physical
and	CC	O
78.4	CD	O
mg/dL	NN	O
in	IN	O
2-hour	JJ	Physical
postprandial	JJ	Physical
blood	NN	Physical
sugar	NN	Physical
levels	NNS	Physical
and	CC	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
the	DT	O
care	NN	Others
satisfaction	NN	Others
score	NN	Others
.	.	O

Effect	NN	O
of	IN	O
explicit	JJ	O
instruction	NN	O
on	IN	O
Japanese	JJ	O
Verbal	NNP	O
Learning	NNP	O
Test	NNP	O
in	IN	O
schizophrenia	NN	O
patients	NNS	O
.	.	O

After	IN	O
random	JJ	O
assignment	NN	O
of	IN	O
20	CD	O
schizophrenia	NN	O
patients	NNS	O
to	TO	O
either	DT	O
an	DT	O
explicit	NN	O
or	CC	O
normal	JJ	O
instruction	NN	O
group	NN	O
,	,	O
the	DT	O
Japanese	JJ	O
Verbal	NNP	O
Learning	NNP	O
Test	NNP	O
was	VBD	O
administered	VBN	O
to	TO	O
them	PRP	O
.	.	O

Results	VB	O
reveal	NN	O
that	IN	O
explicit	JJ	O
instruction	NN	O
group	NN	O
patients	NNS	O
demonstrated	VBD	O
more	RBR	O
improved	JJ	Mental
memory	NN	Mental
performance	NN	Mental
using	VBG	O
semantic	JJ	O
clustering	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
explicit	NN	O
and	CC	O
direct	JJ	O
teaching	NN	O
facilitates	VBZ	O
patients	NNS	O
'	POS	O
learning	NN	O
of	IN	O
information	NN	O
.	.	O

Syncope	NNP	O
Evaluation	NNP	O
in	IN	O
the	DT	O
Emergency	NNP	O
Department	NNP	O
Study	NNP	O
(	(	O
SEEDS	NNP	O
)	)	O
:	:	O
a	DT	O
multidisciplinary	JJ	O
approach	NN	O
to	TO	O
syncope	VB	O
management	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
primary	JJ	O
aim	NN	O
and	CC	O
central	JJ	O
hypothesis	NN	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
that	IN	O
a	DT	O
designated	VBN	O
syncope	NN	O
unit	NN	O
in	IN	O
the	DT	O
emergency	NN	O
department	NN	O
improves	VBZ	O
diagnostic	JJ	O
yield	NN	O
and	CC	O
reduces	NNS	O
hospital	JJ	O
admission	NN	O
for	IN	O
patients	NNS	O
with	IN	O
syncope	NN	O
who	WP	O
are	VBP	O
at	IN	O
intermediate	JJ	O
risk	NN	O
for	IN	O
an	DT	O
adverse	JJ	O
cardiovascular	JJ	O
outcome	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
single-center	JJ	O
study	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
2	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
syncope	NN	O
unit	NN	O
evaluation	NN	O
and	CC	O
standard	NN	O
care	NN	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
chi2	JJ	O
test	NN	O
for	IN	O
independence	NN	O
of	IN	O
categorical	JJ	O
variables	NNS	O
.	.	O

Wilcoxon	NNP	O
rank	VBD	O
sum	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
for	IN	O
continuous	JJ	O
variables	NNS	O
.	.	O

Survival	NNP	Mortality
was	VBD	O
estimated	VBN	O
with	IN	O
the	DT	O
Kaplan-Meier	NNP	O
method	NN	O
.	.	O

One	CD	O
hundred	VBD	O
three	CD	O
consecutive	JJ	O
patients	NNS	O
(	(	O
53	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
64+/-17	CD	O
years	NNS	O
)	)	O
entered	VBD	O
the	DT	O
study	NN	O
.	.	O

Fifty-one	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
syncope	NN	O
unit	NN	O
.	.	O

For	IN	O
the	DT	O
syncope	NN	O
unit	NN	O
and	CC	O
standard	JJ	O
care	NN	O
patients	NNS	O
,	,	O
the	DT	O
presumptive	JJ	Others
diagnosis	NN	Others
was	VBD	O
established	VBN	O
in	IN	O
34	CD	O
(	(	O
67	CD	O
%	NN	O
)	)	O
and	CC	O
5	CD	O
(	(	O
10	CD	O
%	NN	O
)	)	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
hospital	JJ	Others
admission	NN	Others
was	VBD	O
required	VBN	O
for	IN	O
22	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
and	CC	O
51	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
total	JJ	Others
patient-hospital	JJ	Others
days	NNS	Others
were	VBD	O
reduced	VBN	O
from	IN	O
140	CD	O
to	TO	O
64	CD	O
.	.	O

Actuarial	JJ	Mortality
survival	NN	Mortality
was	VBD	O
97	CD	O
%	NN	O
and	CC	O
90	CD	O
%	NN	O
(	(	O
P=0.30	NNP	O
)	)	O
,	,	O
and	CC	O
survival	JJ	Mortality
free	JJ	Mortality
from	IN	Mortality
recurrent	JJ	Mortality
syncope	NN	Mortality
was	VBD	O
88	CD	O
%	NN	O
and	CC	O
89	CD	O
%	NN	O
(	(	O
P=0.72	NNP	O
)	)	O
at	IN	O
2	CD	O
years	NNS	O
for	IN	O
the	DT	O
syncope	NN	O
unit	NN	O
and	CC	O
standard	JJ	O
care	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
novel	JJ	O
syncope	NN	O
unit	NN	O
designed	VBN	O
for	IN	O
this	DT	O
study	NN	O
significantly	RB	O
improved	VBN	O
diagnostic	JJ	Others
yield	NN	Others
in	IN	O
the	DT	O
emergency	NN	O
department	NN	O
and	CC	O
reduced	JJ	O
hospital	NN	Others
admission	NN	Others
and	CC	O
total	JJ	Others
length	NN	Others
of	IN	Others
hospital	NN	Others
stay	NN	Others
without	IN	O
affecting	VBG	O
recurrent	NN	O
syncope	NN	O
and	CC	O
all-cause	JJ	O
mortality	NN	Mortality
among	IN	O
intermediate-risk	JJ	O
patients	NNS	O
.	.	O

Observations	NNS	O
from	IN	O
the	DT	O
present	JJ	O
study	NN	O
provide	VBP	O
benchmark	NN	O
data	NNS	O
for	IN	O
improving	VBG	O
patient	NN	O
care	NN	O
and	CC	O
effectively	RB	O
utilizing	JJ	O
healthcare	JJ	O
resources	NNS	O
.	.	O

ACE	NNP	O
inhibitors	NNS	O
or	CC	O
AT-1	JJ	O
antagonists	NNS	O
-	:	O
which	WDT	O
is	VBZ	O
OPTIMAAL	NNP	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
?	.	O
OPTIMAAL	NNP	O
(	(	O
Optimal	NNP	O
Trial	NNP	O
in	IN	O
Myocardial	NNP	O
Infarction	NNP	O
with	IN	O
the	DT	O
Angiotensin	NNP	O
II	NNP	O
Antagonist	NNP	O
Losartan	NNP	O
)	)	O
is	VBZ	O
the	DT	O
first	JJ	O
major	JJ	O
study	NN	O
to	TO	O
compare	VB	O
an	DT	O
angiotensin	NN	O
II	NNP	O
Type	NNP	O
1	CD	O
antagonist	NN	O
losartan	NN	O
(	(	O
Cozaar	NNP	O
trade	NN	O
mark	NN	O
,	,	O
Merck	NNP	O
)	)	O
with	IN	O
an	DT	O
ACE	NNP	O
inhibitor	NN	O
captonpril	NN	O
(	(	O
Capoten	NNP	O
trade	NN	O
mark	NN	O
,	,	O
Elan	NNP	O
)	)	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
losartan	JJ	O
50	CD	O
mg/day	NN	O
and	CC	O
captopril	NN	O
50	CD	O
mg	NN	O
t.i.d.	NN	O
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
all-cause	JJ	Mortality
mortality	NN	Mortality
and	CC	O
there	EX	O
were	VBD	O
499	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
and	CC	O
447	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
deaths	NNS	Mortality
in	IN	O
the	DT	O
losartan	NN	O
and	CC	O
captopril	NN	O
group	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
cardiovascular	JJ	Physical
deaths	NNS	Physical
with	IN	O
losartan	NN	O
(	(	O
420	CD	O
,	,	O
15	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
captopril	NN	O
(	(	O
363	CD	O
,	,	O
13	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.03	CD	O
)	)	O
.	.	O

Losartan	NNP	O
was	VBD	O
better	RBR	O
tolerated	VBN	Others
than	IN	O
captopril	NN	O
with	IN	O
fewer	JJR	O
patients	NNS	Mental
discontinuing	VBG	Mental
medication	NN	Mental
(	(	O
17	CD	O
versus	RB	O
23	CD	O
%	NN	O
for	IN	O
losartan	NN	O
and	CC	O
captopril	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
if	IN	O
tolerated	VBN	O
,	,	O
captopril	NN	O
should	MD	O
remain	VB	O
the	DT	O
preferred	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
after	IN	O
complicated	VBN	O
acute	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
.	.	O

[	JJ	O
Rapidity	NNP	Pain
of	IN	Pain
pain	NN	Pain
relief	NN	Pain
,	,	O
medication	NN	Others
requirement	NN	Others
and	CC	O
patient	JJ	Others
satisfaction	NN	Others
with	IN	O
reflux	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
]	NN	O
.	.	O

Treatment	NN	O
of	IN	O
gastroesophageal	NN	Physical
reflux	NN	Physical
disease	NN	Physical
(	(	Physical
GERD	NNP	Physical
)	)	Physical
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
three	CD	O
controlled	VBD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
open	JJ	O
studies	NNS	O
.	.	O

Lansoprazole	NNP	O
,	,	O
omeprazole	JJ	O
MUPS	NNP	O
and	CC	O
esomeprazole	NN	O
were	VBD	O
compared	VBN	O
under	IN	O
doctor	NN	O
's	POS	O
office	NN	O
conditions	NNS	O
.	.	O

The	DT	O
outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
the	DT	O
rapidity	NN	Pain
of	IN	Pain
pain	NN	Pain
relief	NN	Pain
achieved	VBN	O
with	IN	O
a	DT	O
single	JJ	Others
dose	NN	Others
,	,	O
effectiveness	NN	Others
and	CC	O
patient	JJ	Others
satisfaction	NN	Others
with	IN	O
on	IN	O
demand	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
180	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
and	CC	O
prolonged	JJ	O
episodes	NNS	O
of	IN	O
reflux	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Time	NN	O
to	TO	O
pain	VB	Pain
relief	NN	Pain
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
was	VBD	O
1.1	CD	O
+/-	JJ	O
0.8	CD	O
hours	NNS	O
with	IN	O
30	CD	O
mg	NNS	O
lansoprazole	JJ	O
,	,	O
3.0	CD	O
+/-	JJ	O
2.5	CD	O
hours	NNS	O
with	IN	O
20	CD	O
mgomeprazole	JJ	O
MUPS	NNP	O
and	CC	O
2.1	CD	O
+/-	JJ	O
1.2	CD	O
hours	NNS	O
with	IN	O
40	CD	O
mg	NNS	O
esomeprazole	JJ	O
.	.	O

Studies	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
designed	VBN	O
as	IN	O
cross-over	NN	O
studies	NNS	O
intended	VBN	O
to	TO	O
investigate	VB	O
drug	NN	Physical
consumption	NN	Physical
.	.	O

In	IN	O
study	NN	O
2	CD	O
,	,	O
the	DT	O
amount	NN	Others
of	IN	Others
lansoprazole	NN	Others
consumed	VBN	Others
was	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
less	JJR	O
than	IN	O
that	DT	O
of	IN	O
omeprazole	NN	O
,	,	O
and	CC	O
this	DT	O
translated	VBN	O
to	TO	O
81	CD	O
%	NN	O
patient	JJ	Others
satisfaction	NN	Others
with	IN	O
lansoprazole	JJ	O
compared	VBN	O
with	IN	O
only	RB	O
9.5	CD	O
%	NN	O
for	IN	O
omeprazole	NN	O
.	.	O

In	IN	O
study	NN	O
3	CD	O
comparing	VBG	O
lansoprazole	NN	O
and	CC	O
esomeprazole	NN	O
,	,	O
consumption	NN	Others
of	IN	O
the	DT	O
former	JJ	O
was	VBD	O
85	CD	O
%	NN	O
that	WDT	O
of	IN	O
the	DT	O
latter	NN	O
.	.	O

58	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
opted	VBD	O
to	TO	O
continuetreatment	VB	Others
with	IN	O
lansoprazole	NN	O
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
esomeprazole	NN	O
.	.	O

The	DT	O
appreciably	RB	O
greater	JJR	O
patient	JJ	Others
satisfaction	NN	Others
with	IN	O
lansoprazole	NN	O
was	VBD	O
due	JJ	O
tothe	NN	O
faster	RBR	Pain
pain	NN	Pain
relief	NN	Pain
achieved	VBN	O
with	IN	O
this	DT	O
drug	NN	O
.	.	O

Human	JJ	O
achaete-scute	JJ	O
homologue	NN	O
(	(	O
hASH1	NN	O
)	)	O
mRNA	NN	O
level	NN	O
as	IN	O
a	DT	O
diagnostic	JJ	O
marker	NN	O
to	TO	O
distinguish	VB	O
esthesioneuroblastoma	NN	O
from	IN	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
arising	VBG	O
in	IN	O
the	DT	O
sinonasal	NN	O
tract	NN	O
.	.	O

Distinction	NN	O
of	IN	O
high-grade	JJ	O
esthesioneuroblastomas	NN	O
from	IN	O
other	JJ	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
arising	VBG	O
in	IN	O
the	DT	O
nasal	JJ	O
cavity	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
diagnostic	JJ	O
challenge	NN	O
because	IN	O
it	PRP	O
determines	VBZ	O
patient	JJ	O
management	NN	O
and	CC	O
prognosis	NN	O
.	.	O

The	DT	O
human	JJ	O
achaete-scute	JJ	O
homologue	NN	O
(	(	O
hASH1	NN	O
)	)	O
gene	NN	O
is	VBZ	O
critical	JJ	O
in	IN	O
olfactory	JJ	O
neuronal	JJ	O
differentiation	NN	O
and	CC	O
is	VBZ	O
expressed	VBN	O
in	IN	O
immature	NN	O
olfactory	NN	O
cells	NNS	O
;	:	O
therefore	RB	O
,	,	O
it	PRP	O
could	MD	O
have	VB	O
potential	JJ	O
use	NN	O
as	IN	O
a	DT	O
diagnostic	JJ	O
marker	NN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
hASH1	JJ	O
messenger	NN	O
RNA	NNP	O
(	(	O
mRNA	NN	O
)	)	O
levels	NNS	O
in	IN	O
differentiating	VBG	O
esthesioneuroblastoma	NN	O
from	IN	O
other	JJ	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
.	.	O

A	DT	O
real-time	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
assay	NN	O
was	VBD	O
developed	VBN	O
,	,	O
permitting	VBG	O
the	DT	O
comparative	JJ	O
determination	NN	O
of	IN	O
hASH1	NN	Physical
mRNA	NN	Physical
levels	NNS	Physical
in	IN	O
triplicate	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
pilot	NN	O
study	NN	O
including	VBG	O
24	CD	O
frozen	JJ	O
cases	NNS	O
of	IN	O
esthesioneuroblastoma	NN	O
and	CC	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
.	.	O

All	DT	O
4	CD	O
positive	JJ	O
cases	NNS	O
were	VBD	O
esthesioneuroblastomas	JJ	Physical
,	,	O
and	CC	O
all	DT	O
19	CD	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
were	VBD	O
negative	JJ	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
inverse	JJ	O
association	NN	O
between	IN	O
the	DT	O
grade	NN	Physical
of	IN	Physical
esthesioneuroblastomas	NN	Physical
and	CC	O
hASH1	NN	O
mRNA	NN	O
levels	NNS	O
.	.	O

The	DT	O
hASH1	NN	O
mRNA	FW	O
level	NN	O
might	MD	O
represent	VB	O
a	DT	O
useful	JJ	O
tool	NN	O
for	IN	O
distinguishing	VBG	O
esthesioneuroblastoma	NN	O
from	IN	O
poorly	RB	O
differentiated	VBN	O
tumors	NNS	O
of	IN	O
the	DT	O
sinonasal	JJ	O
region	NN	O
.	.	O

Treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
:	:	O
do	VB	O
the	DT	O
specifics	NNS	O
of	IN	O
the	DT	O
regimen	NNS	O
matter	NN	O
?	.	O
:	:	O
Results	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Induction	NNP	O
therapy	NN	O
for	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
is	VBZ	O
similar	JJ	O
across	IN	O
essentially	RB	O
all	DT	O
regimens	NNS	O
,	,	O
comprised	VBN	O
of	IN	O
vincristine	NN	O
,	,	O
corticosteroids	NNS	O
,	,	O
and	CC	O
anthracyclines	NNS	O
intensified	VBN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
asparaginase	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

Given	VBN	O
the	DT	O
lack	NN	O
of	IN	O
randomized	VBN	O
data	NNS	O
,	,	O
to	TO	O
date	NN	O
,	,	O
no	DT	O
regimen	NN	O
has	VBZ	O
emerged	VBN	O
as	IN	O
standard	NN	O
.	.	O

The	DT	O
authors	NNS	O
previously	RB	O
evaluated	VBD	O
cytarabine	JJ	O
3	CD	O
g/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
with	IN	O
mitoxantrone	NN	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
)	)	O
as	IN	O
a	DT	O
novel	JJ	O
induction	NN	O
regimen	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
historic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
ALL-2	NNP	O
regimen	NN	O
was	VBD	O
superior	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
incidence	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
,	,	O
failure	NN	O
with	IN	O
resistant	JJ	O
disease	NN	O
,	,	O
and	CC	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Philadelphia	NNP	O
chromosome	NN	O
(	(	O
Ph	NNP	O
)	)	O
-positive	VBP	O
ALL	NNP	O
.	.	O

METHODS	NNP	O
The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
standard	JJ	O
4-drug	JJ	O
induction	NN	O
(	(	O
the	DT	O
L-20	NNP	O
regimen	NNS	O
)	)	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
consolidation	NN	O
,	,	O
maintenance	NN	O
therapy	NN	O
,	,	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
.	.	O

The	DT	O
trial	NN	O
accrued	VBD	O
patients	NNS	O
from	IN	O
August	NNP	O
1996	CD	O
to	TO	O
October	NNP	O
2004	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	Mortality
follow-up	NN	Mortality
for	IN	Mortality
survivors	NNS	Mortality
was	VBD	O
7	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
patient	NN	O
age	NN	O
was	VBD	O
43	CD	O
years	NNS	O
.	.	O

Responses	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
164	CD	O
patients	NNS	O
.	.	O

The	DT	O
treatment	NN	O
arms	NNS	O
were	VBD	O
balanced	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
pretreatment	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
frequency	NN	Physical
of	IN	Physical
complete	JJ	Physical
remission	NN	Physical
for	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
versus	IN	O
the	DT	O
L-20	JJ	O
regimen	NN	O
was	VBD	O
83	CD	O
%	NN	O
versus	IN	O
71	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.06	NNP	O
)	)	O
.	.	O

More	JJR	O
patients	NNS	O
on	IN	O
the	DT	O
L-20	NNP	O
arm	NN	O
failed	VBD	O
with	IN	O
resistant	JJ	Physical
disease	NN	Physical
(	(	O
21	CD	O
%	NN	O
vs	JJ	O
8	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

Induction	NNP	Mortality
deaths	NNS	Mortality
were	VBD	O
comparable	JJ	O
at	IN	O
9	CD	O
%	NN	O
(	(	O
ALL-2	NNP	O
)	)	O
versus	VBD	O
7	CD	O
%	NN	O
(	(	O
L-20	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	Mortality
survival	NN	Mortality
was	VBD	O
similar	JJ	O
;	:	O
and	CC	O
,	,	O
at	IN	O
5	CD	O
years	NNS	O
,	,	O
the	DT	O
survival	NN	Mortality
rate	NN	Mortality
was	VBD	O
33	CD	O
%	NN	O
alive	JJ	O
on	IN	O
the	DT	O
ALL-2	NNP	O
arm	NN	O
versus	NN	O
27	CD	O
%	NN	O
on	IN	O
the	DT	O
L-20	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
superior	JJ	O
results	NNS	O
of	IN	O
induction	NN	O
therapy	NN	O
with	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
,	,	O
this	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
improve	VB	O
long-term	JJ	Others
outcomes	NNS	Others
.	.	O

When	WRB	O
coupled	VBN	O
to	TO	O
the	DT	O
reported	VBN	O
experience	NN	O
of	IN	O
other	JJ	O
studies	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
ALL	NNP	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
randomized	VBN	O
trial	NN	O
raise	NN	O
the	DT	O
possibility	NN	O
that	WDT	O
ultimate	JJ	O
outcomes	NNS	O
in	IN	O
adult	NN	O
ALL	NNP	O
may	MD	O
be	VB	O
independent	JJ	O
of	IN	O
the	DT	O
specific	JJ	O
regimen	NNS	O
chosen	VBN	O
.	.	O

Cancer	NN	O
2013	CD	O
.	.	O

?	.	O
2012	CD	O
American	JJ	O
Cancer	NNP	O
Society	NNP	O
.	.	O

Long	JJ	O
term	NN	O
follow	VBP	O
up	IN	O
of	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
Helicobacter	NNP	Physical
pylori	JJ	Physical
infection	NN	Physical
.	.	Physical

BACKGROUND	NNP	O
Helicobacter	NNP	O
pylori	POS	O
infection	NN	O
induces	NNS	O
progressive	JJ	O
inflammatory	JJ	Physical
changes	NNS	Physical
in	IN	O
the	DT	O
gastric	JJ	O
mucosa	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
gastric	JJ	O
cancer	NN	O
.	.	O

Understanding	VBG	O
long	JJ	O
term	NN	O
effects	NNS	O
resulting	VBG	O
from	IN	O
the	DT	O
cure	NN	O
of	IN	O
this	DT	O
infection	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
design	VB	O
cancer	NN	O
prevention	NN	O
strategies	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
795	CD	O
adults	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
was	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
and/or	JJ	O
antioxidants	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
six	CD	O
years	NNS	O
of	IN	O
intervention	NN	O
,	,	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
were	VBD	O
offered	VBN	O
it	PRP	O
.	.	O

Gastric	JJ	O
biopsies	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
years	NNS	O
.	.	O

A	DT	O
histopathology	NN	Physical
score	NN	Physical
was	VBD	O
utilised	VBN	O
to	TO	O
document	VB	O
changes	NNS	O
in	IN	O
gastric	JJ	Physical
lesions	NNS	Physical
.	.	Physical

Non-linear	JJ	O
mixed	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
cumulative	JJ	O
effect	NN	O
of	IN	O
H	NNP	O
pylori	JJ	O
clearance	NN	O
on	IN	O
histopathology	NN	Physical
scores	NNS	Physical
adjusted	VBN	O
for	IN	O
follow	VB	O
up	RP	O
time	NN	O
,	,	O
interventions	NNS	O
,	,	O
and	CC	O
confounders	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
seven	CD	O
per	IN	O
cent	NN	O
of	IN	O
subjects	NNS	O
were	VBD	O
H	NNP	Physical
pylori	JJ	Physical
positive	JJ	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
.	.	O

Subjects	NNS	O
accumulated	JJ	O
1703	CD	O
person	NN	O
years	NNS	O
free	JJ	Physical
of	IN	Physical
infection	NN	Physical
.	.	Physical

A	DT	O
multivariate	NN	O
model	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
regression	NN	Physical
in	IN	Physical
histopathology	NN	Physical
score	NN	Physical
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
square	NN	O
of	IN	O
H	NNP	Physical
pylori	FW	Physical
negative	JJ	Physical
time	NN	Physical
.	.	Physical

Subjects	NNS	O
who	WP	O
were	VBD	O
H	NNP	Physical
pylori	JJ	Physical
negative	JJ	O
had	VBD	O
14.8	CD	O
%	NN	O
more	JJR	O
regression	NN	Physical
and	CC	O
13.7	CD	O
%	NN	O
less	JJR	O
progression	NN	Physical
than	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	Physical
of	IN	Physical
healing	NN	Physical
of	IN	Physical
gastric	JJ	Physical
lesions	NNS	Physical
occurred	VBD	O
more	RBR	O
rapidly	RB	O
as	IN	O
years	NNS	Adverseeffect
free	JJ	Adverseeffect
of	IN	Adverseeffect
infection	NN	Adverseeffect
accumulated	VBN	O
,	,	O
and	CC	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
less	RBR	O
advanced	JJ	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Preneoplastic	NNP	Physical
gastric	JJ	Physical
lesions	NNS	Physical
regress	NN	O
at	IN	O
a	DT	O
rate	NN	O
equal	JJ	O
to	TO	O
the	DT	O
square	NN	O
of	IN	O
time	NN	O
in	IN	O
patients	NNS	O
rendered	JJ	O
free	JJ	O
of	IN	O
H	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
and	CC	O
cured	VBN	O
of	IN	O
their	PRP$	O
H	NNP	O
pylori	NN	O
infection	NN	O
.	.	O

Fine	NNP	O
needle	JJ	O
aspiration	NN	O
coupled	VBN	O
with	IN	O
real-time	JJ	O
PCR	NNP	O
:	:	O
a	DT	O
painless	JJ	O
methodology	NN	O
to	TO	O
study	VB	O
adaptive	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
skeletal	JJ	O
muscle	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
In	IN	O
this	DT	O
study	NN	O
we	PRP	O
developed	VBD	O
a	DT	O
new	JJ	O
methodology	NN	O
for	IN	O
obtaining	VBG	O
human	JJ	O
skeletal	JJ	O
muscle	NN	O
samples	NNS	O
to	TO	O
evaluate	VB	O
gene	NN	O
expression	NN	O
.	.	O

This	DT	O
approach	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
a	DT	O
fine	JJ	O
needle	JJ	O
aspiration	NN	O
technique	NN	O
,	,	O
which	WDT	O
allows	VBZ	O
us	PRP	O
to	TO	O
extract	VB	O
a	DT	O
small	JJ	O
tissue	NN	O
sample	NN	O
in	IN	O
a	DT	O
significantly	RB	O
less	RBR	O
invasive	JJ	O
manner	NN	O
than	IN	O
with	IN	O
classic	JJ	O
biopsy	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Multiplex	NNP	O
tandem	VBD	O
RT-PCR	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
mRNA	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
ATP	NNP	O
production	NN	O
and	CC	O
mitochondrial	JJ	O
biogenesis	NN	O
in	IN	O
muscle	NN	O
tissue	NN	O
.	.	O

Samples	NNS	O
of	IN	O
vastus	NN	O
lateralis	NNS	O
muscle	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
21	CD	O
healthy	JJ	O
subjects	NNS	O
with	IN	O
different	JJ	O
fitness	NN	O
levels	NNS	O
.	.	O

The	DT	O
principal	JJ	O
findings	NNS	O
in	IN	O
our	PRP$	O
study	NN	O
show	VB	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
PGC-1alpha	NNP	Physical
and	CC	Physical
COX5B	NNP	Physical
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
between	IN	O
PGC-1alpha	NNP	Physical
and	CC	Physical
MT-CO2	NNP	Physical
(	(	O
p=0.017	NN	O
)	)	O
expression	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
a	DT	O
significant	JJ	O
positive	JJ	O
correlation	NN	O
between	IN	O
mtDNA	NN	O
content	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
MHCI	NNP	O
present	NN	O
in	IN	O
the	DT	O
aspired	JJ	O
samples	NNS	O
were	VBD	O
found	VBN	O
(	(	O
p=0.028	NN	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
are	VBP	O
in	IN	O
agreement	NN	O
with	IN	O
current	JJ	O
knowledge	NN	O
on	IN	O
skeletal	JJ	O
muscle	NN	O
physiology	NN	O
and	CC	O
show	VB	O
the	DT	O
reliability	NN	O
of	IN	O
the	DT	O
proposed	VBN	O
method	NN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
painless	JJ	O
methodology	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
investigate	VB	O
,	,	O
in	IN	O
vivo	NN	O
,	,	O
human	JJ	O
muscle	NN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
adaptations	NNS	O
in	IN	O
response	NN	O
to	TO	O
either	DT	O
physiological	JJ	O
and/or	NN	O
pharmacological	JJ	O
stimuli	NN	O
.	.	O

This	DT	O
method	NN	O
has	VBZ	O
major	JJ	O
clinical	JJ	O
relevance	NN	O
,	,	O
such	JJ	O
as	IN	O
its	PRP$	O
application	NN	O
in	IN	O
clarifying	VBG	O
the	DT	O
mechanisms	NN	O
underling	VBG	O
metabolic	JJ	O
and	CC	O
systemic	JJ	O
disorders	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
perioperative	JJ	O
indomethacin	NN	O
on	IN	O
intracranial	JJ	Physical
pressure	NN	Physical
,	,	O
cerebral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
,	,	O
and	CC	O
cerebral	JJ	Physical
metabolism	NN	Physical
in	IN	O
patients	NNS	O
subjected	VBN	O
to	TO	O
craniotomy	VB	O
for	IN	O
cerebral	JJ	O
tumors	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	Others
of	IN	O
perioperative	JJ	O
indomethacin	NN	O
on	IN	O
intracranial	JJ	Physical
pressure	NN	Physical
(	(	Physical
ICP	NNP	Physical
)	)	Physical
,	,	O
cerebral	JJ	Physical
blood	NN	Physical
flow	NN	Physical
(	(	Physical
CBF	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
cerebral	JJ	Physical
metabolism	NN	Physical
.	.	O

Twenty	CD	O
patients	NNS	O
subjected	VBN	O
to	TO	O
craniotomy	VB	O
for	IN	O
supratentorial	JJ	O
cerebral	JJ	O
tumors	NNS	O
were	VBD	O
anesthetized	VBN	O
with	IN	O
thiopental	JJ	O
,	,	O
fentanyl	JJ	O
,	,	O
nitrous	JJ	O
oxide	NN	O
,	,	O
and	CC	O
isoflurane	NN	O
.	.	O

A	DT	O
PaCO2	NNP	O
level	NN	O
averaging	VBG	O
4.8	CD	O
kPa	NN	O
(	(	O
median	JJ	O
)	)	O
was	VBD	O
achieved	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
intravenous	JJ	O
indomethacin	JJ	O
50	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
administrated	VBN	O
after	IN	O
exposure	NN	O
of	IN	O
the	DT	O
dura	NN	O
.	.	O

ICP	NNP	Physical
was	VBD	O
measured	VBN	O
continuously	RB	O
subdurally	RB	O
with	IN	O
a	DT	O
22-gauge	JJ	O
canula	NN	O
connected	VBN	O
to	TO	O
a	DT	O
transducer	NN	O
.	.	O

CBF	NNP	Physical
and	CC	O
the	DT	O
arteriovenous	JJ	Physical
difference	NN	Physical
of	IN	Physical
oxygen	NN	Physical
(	(	O
AVDO2	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
twice	RB	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
indomethacin/placebo	JJ	O
administration	NN	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
ICP	NNP	Physical
from	IN	O
6.5	CD	O
to	TO	O
1.5	CD	O
mm	NNS	O
Hg	NNP	O
(	(	O
median	JJ	O
)	)	O
was	VBD	O
found	VBN	O
after	IN	O
indomethacin	JJ	O
administration	NN	O
.	.	O

This	DT	O
decrease	NN	O
was	VBD	O
caused	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
CBF	NNP	Physical
associated	VBD	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
AVDO2	NNP	Physical
.	.	O

Indomethacin	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	Physical
metabolic	JJ	Physical
rate	NN	Physical
of	IN	Physical
oxygen	NN	Physical
,	,	O
the	DT	Physical
arteriovenous	JJ	Physical
difference	NN	Physical
of	IN	Physical
lactate	NN	Physical
,	,	Physical
or	CC	O
the	DT	O
lactate/oxygen	NN	Physical
index	NN	Physical
,	,	O
suggesting	VBG	O
that	IN	O
indomethacin	NN	O
did	VBD	O
not	RB	O
provoke	VB	O
global	JJ	O
cerebral	JJ	O
ischemia	NN	O
.	.	O

In	IN	O
the	DT	O
indomethacin	NN	O
group	NN	O
,	,	O
dura	NN	Physical
was	VBD	O
sufficiently	RB	O
relaxed	VBN	O
in	IN	O
eight	CD	O
of	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
dura	NN	Physical
was	VBD	O
opened	VBN	O
without	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
cerebral	JJ	Physical
swelling	VBG	Physical
.	.	O

In	IN	O
one	CD	O
patient	NN	O
,	,	O
mannitol	FW	O
treatment	NN	O
was	VBD	O
necessary	JJ	O
to	TO	O
prevent	VB	O
dural	JJ	Physical
tightness	NN	Physical
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
mannitol	RB	O
supplemented	VBN	O
with	IN	O
hypocapnia	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
five	CD	O
patients	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
perioperative	JJ	O
treatment	NN	O
with	IN	O
indomethacin	NN	O
is	VBZ	O
an	DT	O
excellent	JJ	O
treatment	NN	O
of	IN	O
intracranial	JJ	O
hypertension	NN	O
during	IN	O
normocapnic	JJ	O
isoflurane	NN	O
anesthesia	NN	O
for	IN	O
craniotomy	NN	O
.	.	O

Pre-transplant	JJ	O
pharmacokinetic	JJ	O
profiling	NN	O
and	CC	O
tacrolimus	NN	Physical
requirements	NNS	Physical
post-transplant	JJ	Physical
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
achieving	VBG	O
tacrolimus	JJ	Physical
whole-blood	JJ	Physical
concentrations	NNS	Physical
of	IN	O
?10	NNP	O
ng/mL	NN	O
within	IN	O
3	CD	O
days	NNS	O
of	IN	O
kidney	NN	O
transplantation	NN	O
,	,	O
after	IN	O
randomization	NN	O
either	RB	O
to	TO	O
standard	VB	O
dosing	VBG	O
(	(	O
control	VB	O
group	NN	O
)	)	O
or	CC	O
post-transplantation	NN	O
dosing	NN	O
guided	VBN	O
by	IN	O
a	DT	O
2-hour	JJ	O
(	(	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
level	NN	O
following	VBG	O
a	DT	O
preoperative	JJ	O
tacrolimus	NN	O
dose	NN	O
(	(	O
T2	NNP	O
group	NN	O
)	)	O
.	.	O

METHODS	NNP	O
The	DT	O
first	JJ	O
postoperative	JJ	O
tacrolimus	NN	O
dose	NN	O
was	VBD	O
given	VBN	O
either	RB	O
according	VBG	O
to	TO	O
standard	NN	O
care	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
or	CC	O
0.15	CD	O
mg/kg	JJ	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
pre-transplant	JJ	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
?20	JJ	O
ng/mL	RB	O
,	,	O
0.1	CD	O
mg/kg	NN	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
21-59	JJ	O
ng/mL	NN	O
or	CC	O
0.05	CD	O
mg/kg	JJ	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
?60	JJ	O
ng/mL	NN	O
(	(	O
T2	NNP	O
group	NN	O
)	)	O
.	.	O

Subsequent	JJ	O
dosing	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
based	VBN	O
upon	IN	O
tacrolimus	JJ	O
trough	IN	O
level	NN	O
monitoring	NN	O
.	.	O

Participants	NNS	O
received	VBD	O
concomitant	JJ	O
mycophenolate	NN	O
mofetil	NN	O
and	CC	O
steroids	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
,	,	O
of	IN	O
which	WDT	O
84	CD	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
(	(	O
control	NN	O
group	NN	O
n=43	VBD	O
;	:	O
T2	NNP	O
group	NN	O
n=41	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
achieving	VBG	O
tacrolimus	JJ	O
trough	NN	O
levels	NNS	O
?10	VBP	O
ng/mL	RB	O
(	(	O
82.9	CD	O
%	NN	O
Control	NNP	O
vs	VBZ	O
93.0	CD	O
%	NN	O
T2	NNP	O
;	:	O
P=0.19	NNP	O
)	)	O
or	CC	O
between	IN	O
10	CD	O
and	CC	O
15	CD	O
ng/mL	NN	O
(	(	O
41.5	CD	O
%	NN	O
Control	NNP	O
vs	VBZ	O
41.9	CD	O
%	NN	O
T2	NNP	O
;	:	O
P=0.97	NNP	O
)	)	O
at	IN	O
day	NN	O
3	CD	O
post	NN	O
transplant	NN	O
.	.	O

The	DT	O
T2	NNP	O
group	NN	O
achieved	VBD	O
tacrolimus	RB	O
trough	JJ	O
levels	NNS	O
of	IN	O
?10	NNP	O
ng/mL	FW	O
significantly	RB	O
faster	RBR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
100	CD	O
%	NN	O
achievement	NN	O
in	IN	O
14	CD	O
days	NNS	O
(	(	O
Control	NNP	O
)	)	O
versus	VBP	O
4	CD	O
days	NNS	O
(	(	O
T2	NNP	O
)	)	O
;	:	O
P=0.01	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Performing	VBG	O
a	DT	O
pre-transplant	JJ	O
tacrolimus	NN	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
does	VBZ	O
not	RB	O
significantly	RB	O
increase	VB	O
the	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
subjects	NNS	O
achieving	VBG	O
10	CD	O
ng/mL	JJ	O
tacrolimus	NN	O
concentrations	NNS	O
by	IN	O
day	NN	O
3	CD	O
using	VBG	O
routine	JJ	O
protocols	NNS	O
.	.	O

However	RB	O
,	,	O
compared	VBN	O
with	IN	O
standard	JJ	O
care	NN	O
,	,	O
performing	VBG	O
a	DT	O
pre-transplant	JJ	O
tacrolimus	NN	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
does	VBZ	O
lead	JJ	O
to	TO	O
patients	NNS	O
achieving	VBG	O
a	DT	O
whole-blood	JJ	O
concentration	NN	O
of	IN	O
?10	NNP	O
ng/mL	JJ	O
sooner	NN	O
.	.	O

Evaluation	NN	Others
of	IN	O
a	DT	O
device	NN	O
to	TO	O
facilitate	VB	O
female	JJ	O
urethral	JJ	O
catheterization	NN	O
.	.	O

Urethral	JJ	O
catheterization	NN	O
is	VBZ	O
a	DT	O
skilled	JJ	O
procedure	NN	O
that	WDT	O
nurses	VBZ	O
in	IN	O
hospital	JJ	O
settings	NNS	O
perform	VBP	O
routinely	RB	O
.	.	O

The	DT	O
opening	NN	O
of	IN	O
the	DT	O
female	JJ	O
urethra	NN	O
is	VBZ	O
located	VBN	O
within	IN	O
the	DT	O
vulvar	NN	O
vestibule	NN	O
,	,	O
making	VBG	O
insertion	NN	O
of	IN	O
urinary	JJ	O
catheters	NNS	O
into	IN	O
females	NNS	O
a	DT	O
greater	JJR	O
technical	JJ	O
challenge	NN	O
than	IN	O
in	IN	O
males	NNS	O
.	.	O

Researchers	NNS	O
evaluated	VBD	O
whether	IN	O
a	DT	O
new	JJ	O
device	NN	O
might	MD	O
decrease	VB	O
the	DT	O
time	NN	Others
required	VBN	Others
for	IN	Others
catheter	NN	Others
insertion	NN	Others
,	,	O
increase	VB	Others
the	DT	Others
likelihood	NN	Others
of	IN	Others
inserting	VBG	Others
the	DT	Others
catheter	NN	Others
on	IN	Others
the	DT	Others
first	JJ	Others
attempt	NN	Others
(	(	Others
improved	VBN	Others
accuracy	NN	Others
)	)	Others
,	,	O
and	CC	O
reduce	VB	Others
patient	JJ	Others
discomfort	NN	Others
.	.	O

Comments	NNS	O
about	IN	O
the	DT	O
device	NN	O
from	IN	O
both	DT	O
patients	NNS	O
and	CC	O
nurses	NNS	O
also	RB	O
are	VBP	O
reported	VBN	O
.	.	O

Serum	NNP	O
selenium	NN	O
concentration	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

AIM	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
chemo	NN	O
and	CC	O
radio	NN	O
therapies	NNS	O
on	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
content	NN	O
and	CC	O
antioxidant	JJ	Physical
activity	NN	Physical
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

METHODS	NNP	O
Among	IN	O
104	CD	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
selected	VBN	O
for	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
54	CD	O
and	CC	O
50	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
chemo-	JJ	O
and	CC	O
radiotherapy	NN	O
respectively	RB	O
.	.	O

Plasma	NNP	O
Se	NNP	O
,	,	O
Zn	NNP	O
,	,	O
Cu	NNP	O
and	CC	O
some	DT	O
enzymatic	JJ	O
antioxidants	NNS	O
activities	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
serum	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decreased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	Physical
trace	NN	Physical
elements	NNS	Physical
,	,	O
glutathione	NN	Physical
peroxidase	NN	Physical
activity	NN	Physical
and	CC	Physical
total	JJ	Physical
antioxidant	JJ	Physical
capacity	NN	Physical
,	,	O
and	CC	O
increased	VBD	O
malondialdehyde	NN	Physical
,	,	Physical
glutathion	NN	Physical
reductase	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
healthy	JJ	O
controls	NNS	O
.	.	O

The	DT	O
increased	JJ	O
concentration	NN	Physical
of	IN	Physical
serum	NN	Physical
Se	NNP	Physical
,	,	Physical
Zn	NNP	Physical
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
.	.	O

Simultaneously	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
increase	NN	O
in	IN	O
glutathione	JJ	Physical
peroxidase	NN	Physical
and	CC	Physical
total	JJ	Physical
antioxidant	JJ	Physical
capacity	NN	Physical
,	,	O
and	CC	O
significant	JJ	O
decrease	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
malondialdehyde	NN	Physical
and	CC	Physical
glutathion	NN	Physical
reductase	NN	Physical
levels	NNS	Physical
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
compared	VBN	O
to	TO	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
chemotherapy	NN	O
but	CC	O
not	RB	O
radiotherapy	JJ	O
results	NNS	O
in	IN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
trace	NN	Physical
elements	NNS	Physical
levels	NNS	Physical
and	CC	Physical
antioxidant	JJ	Physical
activities	NNS	Physical
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

Effect	NN	O
of	IN	O
camel	NN	O
milk	NN	O
on	IN	O
thymus	NN	O
and	CC	O
activation-regulated	JJ	O
chemokine	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
:	:	O
double-blind	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
camel	NN	O
milk	NN	O
(	(	O
CM	NNP	O
)	)	O
(	(	O
raw	JJ	O
and	CC	O
boiled	VBN	O
)	)	O
on	IN	O
thymus	NN	Physical
and	CC	Physical
activation-regulated	JJ	Physical
chemokine	NN	Physical
(	(	Physical
TARC	NNP	Physical
)	)	Physical
serum	NN	Physical
levels	NNS	Physical
and	CC	O
childhood	NN	Mental
autism	NN	Mental
rating	NN	Mental
scale	NN	Mental
(	(	Mental
CARS	NNP	Mental
)	)	Mental
score	NN	Mental
in	IN	O
subjects	NNS	O
with	IN	O
autism	NN	O
and	CC	O
compared	VBN	O
to	TO	O
placebo	VB	O
group	NN	O
(	(	O
cow	JJ	O
milk	NN	O
)	)	O
.	.	O

METHODS	NNP	O
Forty-five	JJ	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
boiled	VBN	O
CM	NNP	O
for	IN	O
group	NN	O
I	PRP	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
,	,	O
raw	JJ	O
CM	NNP	O
for	IN	O
group	NN	O
II	NNP	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
for	IN	O
group	NN	O
III	NNP	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
for	IN	O
2	CD	O
wk	NN	O
.	.	O

Measures	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
professionally	RB	O
completed	VBN	O
CARS	NNP	O
score	NN	O
and	CC	O
blood	NN	Physical
samples	NNS	Physical
for	IN	Physical
TARC	NNP	Physical
serum	NN	Physical
level	NN	Physical
were	VBD	O
taken	VBN	O
before	RB	O
and	CC	O
after	IN	O
milk	NN	O
consumption	NN	O
of	IN	O
500	CD	O
ml	NNS	O
per	IN	O
day	NN	O
in	IN	O
children	NNS	O
's	POS	O
regular	JJ	O
daily	JJ	O
diet	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
serum	NN	Physical
levels	NNS	Physical
of	IN	Physical
TARC	NNP	Physical
decreased	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
in	IN	O
boiled	VBN	O
CM	NNP	O
and	CC	O
in	IN	O
raw	JJ	O
CM	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
too	RB	O
,	,	O
but	CC	O
no	DT	O
effect	NN	O
was	VBD	O
observed	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.68	CD	O
)	)	O
in	IN	O
placebo	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
CARS	NNP	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
raw	JJ	O
CM	NNP	O
group	NN	O
only	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
relationships	NNS	O
between	IN	O
the	DT	O
serum	NN	O
of	IN	O
TARC	NNP	Physical
level	NN	Physical
and	CC	O
the	DT	O
CARS	NNP	O
score	NN	O
,	,	O
age	NN	O
,	,	O
or	CC	O
gender	VB	O
for	IN	O
any	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
CM	NNP	O
administered	VBD	O
for	IN	O
2	CD	O
wk	NNS	O
significantly	RB	O
improved	VBN	O
clinical	JJ	O
measurements	NNS	O
of	IN	O
autism	NN	O
severity	NN	O
and	CC	O
decreased	VBD	O
serum	JJR	O
level	NN	O
of	IN	O
TARC	NNP	O
in	IN	O
autistic	JJ	O
children	NNS	O
,	,	O
but	CC	O
subsequent	JJ	O
studies	NNS	O
are	VBP	O
recommended	VBN	O
.	.	O

Reduction	NN	O
of	IN	O
isoflurane	NN	O
MAC	NNP	O
by	IN	O
fentanyl	NN	O
or	CC	O
remifentanil	NN	O
in	IN	O
rats	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
main	JJ	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
three	CD	O
different	JJ	O
infusion	NN	O
rates	NNS	O
of	IN	O
fentanyl	NN	O
and	CC	O
remifentanil	NN	O
on	IN	O
the	DT	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
(	(	O
MAC	NNP	O
)	)	O
of	IN	O
isoflurane	NN	O
in	IN	O
the	DT	O
rat	NN	O
.	.	O

A	DT	O
secondary	JJ	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	NN	O
and	CC	O
respiratory	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
opioid	JJ	O
drugs	NNS	O
.	.	O

ANIMAL	NNP	O
POPULATION	NNP	O
Thirty-seven	NNP	O
male	NN	O
Wistar	NNP	O
rats	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
six	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
For	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
anaesthesia	NN	O
was	VBD	O
induced	VBN	O
with	IN	O
5	CD	O
%	NN	O
isoflurane	NN	O
in	IN	O
oxygen	NN	O
using	VBG	O
an	DT	O
induction	NN	O
chamber	NN	O
.	.	O

A	DT	O
14-gauge	JJ	O
catheter	NN	O
was	VBD	O
used	VBN	O
for	IN	O
endotracheal	JJ	O
intubation	NN	O
,	,	O
and	CC	O
anaesthesia	NN	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
delivered	VBN	O
in	IN	O
oxygen	NN	O
via	IN	O
a	DT	O
T-piece	NNP	O
breathing	NN	O
system	NN	O
.	.	O

A	DT	O
baseline	JJ	O
determination	NN	O
of	IN	O
the	DT	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
of	IN	O
isoflurane	NN	O
(	(	O
MACISO	NNP	O
)	)	O
was	VBD	O
made	VBN	O
for	IN	O
each	DT	O
animal	NN	O
.	.	O

Fentanyl	NNP	O
(	(	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
or	CC	O
remifentanil	NN	O
(	(	O
60	CD	O
,	,	O
120	CD	O
,	,	O
240	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
were	VBD	O
infused	VBN	O
intravenously	RB	O
into	IN	O
a	DT	O
previously	RB	O
cannulated	VBN	O
tail	NN	O
vein	NN	O
.	.	O

Thirty	NNP	O
minutes	NNS	O
after	IN	O
the	DT	O
infusion	NN	O
started	VBD	O
,	,	O
a	DT	O
second	JJ	O
MACISO	NNP	O
(	(	O
MACISO+drug	NNP	O
)	)	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
carotid	NN	O
artery	NN	O
was	VBD	O
cannulated	VBN	O
to	TO	O
monitor	VB	O
the	DT	O
arterial	JJ	Physical
pressure	NN	Physical
and	CC	O
to	TO	O
take	VB	O
samples	NNS	O
for	IN	O
arterial	JJ	Physical
gas	NN	Physical
measurements	NNS	Physical
.	.	Physical

Cardiovascular	NNP	Physical
(	(	Physical
heart	NN	Physical
rate	NN	Physical
and	CC	Physical
arterial	JJ	Physical
pressure	NN	Physical
)	)	Physical
and	CC	O
respiratory	NN	Physical
(	(	Physical
respiratory	JJ	Physical
rate	NN	Physical
and	CC	Physical
presence/absence	NN	Physical
of	IN	Physical
apnoea	NN	Physical
)	)	Physical
effects	NNS	Physical
after	IN	O
opioid	JJ	O
infusion	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Fentanyl	NNP	O
(	(	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
and	CC	O
remifentanil	NN	O
(	(	O
60	CD	O
,	,	O
120	CD	O
,	,	O
240	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
similarly	RB	O
reduced	VBN	O
isoflurane	NN	O
MAC	NNP	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
fashion	NN	O
:	:	O
by	IN	O
10	CD	O
%	NN	O
at	IN	O
lower	JJR	O
doses	NNS	O
,	,	O
25	CD	O
%	NN	O
at	IN	O
medium	NN	O
doses	NNS	O
and	CC	O
by	IN	O
60	CD	O
%	NN	O
at	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
both	DT	O
the	DT	O
drugs	NNS	O
.	.	O

Both	DT	O
opioids	NNS	O
reduced	VBD	O
the	DT	O
respiratory	NN	O
rate	NN	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
for	IN	O
all	DT	O
doses	NNS	O
tested	VBN	O
.	.	O

No	DT	O
episodes	NNS	O
of	IN	O
apnoea	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
the	DT	O
remifentanil	NN	O
groups	NNS	O
,	,	O
while	IN	O
administration	NN	O
of	IN	O
fentanyl	NN	O
resulted	VBN	O
in	IN	O
apnoea	NN	O
in	IN	O
three	CD	O
animals	NNS	O
(	(	O
one	CD	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
on	IN	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
drugs	NNS	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
intraoperative	JJ	O
use	NN	O
of	IN	O
remifentanil	NN	O
in	IN	O
the	DT	O
rat	NN	O
reduces	VBZ	O
the	DT	O
MAC	NNP	O
of	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
that	IN	O
this	DT	O
anaesthetic	JJ	O
sparing	NN	O
effect	NN	O
is	VBZ	O
dose-dependent	JJ	O
and	CC	O
similar	JJ	O
to	TO	O
that	DT	O
produced	VBN	O
by	IN	O
fentanyl	NN	O
at	IN	O
the	DT	O
doses	NNS	O
tested	VBN	O
.	.	O

CLINICAL	JJ	O
RELEVANCE	NNP	O
The	DT	O
use	NN	O
of	IN	O
remifentanil	NN	O
during	IN	O
inhalant	JJ	O
anaesthesia	NN	O
in	IN	O
the	DT	O
rat	NN	O
can	MD	O
be	VB	O
considered	VBN	O
an	DT	O
intravenous	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
,	,	O
providing	VBG	O
similar	JJ	O
reduction	NN	O
in	IN	O
isoflurane	NN	O
requirements	NNS	O
.	.	O

Due	NNP	O
to	TO	O
its	PRP$	O
rapid	JJ	O
offset	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
alternative	JJ	O
pain	NN	O
relief	NN	O
be	VB	O
instituted	VBN	O
before	IN	O
it	PRP	O
is	VBZ	O
discontinued	VBN	O
.	.	O

Denosumab	NNP	O
compared	VBN	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	O
metastases	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
randomized	VBN	O
study	NN	O
compared	VBN	O
denosumab	NN	O
,	,	O
a	DT	O
fully	RB	O
human	JJ	O
monoclonal	JJ	O
antibody	NN	O
against	IN	O
receptor	NN	O
activator	NN	O
of	IN	O
nuclear	JJ	O
factor	NN	O
?	.	O
B	NNP	O
(	(	O
RANK	NNP	O
)	)	O
ligand	NN	O
,	,	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
skeletal-related	JJ	O
events	NNS	O
(	(	O
SREs	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
with	IN	O
bone	NN	O
metastases	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
subcutaneous	JJ	O
denosumab	NN	O
120	CD	O
mg	NN	O
and	CC	O
intravenous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,026	CD	O
)	)	O
or	CC	O
intravenous	JJ	O
zoledronic	JJ	O
acid	NN	O
4	CD	O
mg	NN	O
adjusted	VBN	O
for	IN	O
creatinine	JJ	O
clearance	NN	O
and	CC	O
subcutaneous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,020	CD	O
)	)	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
strongly	RB	O
recommended	VBN	O
to	TO	O
take	VB	O
daily	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
time	NN	O
to	TO	O
first	VB	O
on-study	JJ	O
SRE	NNP	O
(	(	O
defined	VBN	O
as	IN	O
pathologic	JJ	O
fracture	NN	O
,	,	O
radiation	NN	O
or	CC	O
surgery	NN	O
to	TO	O
bone	VB	O
,	,	O
or	CC	O
spinal	JJ	O
cord	NN	O
compression	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	Physical
time	NN	Physical
to	TO	Physical
first	VB	Physical
on-study	JJ	Physical
SRE	NNP	Physical
(	(	O
hazard	NN	O
ratio	NN	O
,	,	O
0.82	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.71	CD	O
to	TO	O
0.95	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
superiority	NN	O
)	)	O
and	CC	O
time	NN	Physical
to	TO	Physical
first	RB	Physical
and	CC	Physical
subsequent	JJ	Physical
(	(	Physical
multiple	JJ	Physical
)	)	Physical
on-study	NN	Physical
SREs	NNP	Physical
(	(	O
rate	NN	O
ratio	NN	O
,	,	O
0.77	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.66	CD	O
to	TO	O
0.89	CD	O
;	:	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
bone	NN	O
turnover	NN	O
markers	NNS	O
was	VBD	O
greater	JJR	O
with	IN	O
denosumab	NN	O
.	.	O

Overall	JJ	O
survival	NN	O
,	,	O
disease	NN	Physical
progression	NN	Physical
,	,	O
and	CC	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
and	CC	O
serious	JJ	O
AEs	NNP	O
were	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

An	DT	O
excess	NN	O
of	IN	O
renal	JJ	O
AEs	NNP	O
and	CC	O
acute-phase	JJ	O
reactions	NNS	O
occurred	VBD	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
;	:	O
hypocalcemia	NN	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
with	IN	O
denosumab	NN	O
.	.	O

Osteonecrosis	NN	O
of	IN	O
the	DT	O
jaw	NN	O
occurred	VBD	O
infrequently	RB	O
(	(	O
2.0	CD	O
%	NN	O
,	,	O
denosumab	NN	O
;	:	O
1.4	CD	O
%	NN	O
,	,	O
zoledronic	JJ	O
acid	NN	O
;	:	O
P	NNP	O
=	NNP	O
.39	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
SREs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
metastatic	NN	O
to	TO	O
bone	NN	O
and	CC	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

With	IN	O
the	DT	O
convenience	NN	O
of	IN	O
a	DT	O
subcutaneous	JJ	O
injection	NN	O
and	CC	O
no	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
monitoring	NN	O
,	,	O
denosumab	JJ	O
represents	VBZ	O
a	DT	O
potential	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
patients	NNS	O
with	IN	O
bone	NN	O
metastases	NNS	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
treatment	NN	O
fidelity	NN	O
on	IN	O
outcomes	NNS	O
during	IN	O
a	DT	O
randomized	JJ	O
field	NN	O
trial	NN	O
of	IN	O
an	DT	O
autism	NN	O
intervention	NN	O
.	.	O

This	DT	O
randomized	JJ	O
field	NN	O
trial	NN	O
comparing	VBG	O
Strategies	NNS	O
for	IN	O
Teaching	VBG	O
based	VBN	O
on	IN	O
Autism	NNP	O
Research	NNP	O
and	CC	O
Structured	NNP	O
Teaching	NNP	O
enrolled	VBD	O
educators	NNS	O
in	IN	O
33	CD	O
kindergarten-through-second-grade	JJ	O
autism	NN	O
support	NN	O
classrooms	NNS	O
and	CC	O
119	CD	O
students	NNS	O
,	,	O
aged	VBN	O
5-8	CD	O
years	NNS	O
in	IN	O
the	DT	O
School	NNP	O
District	NNP	O
of	IN	O
Philadelphia	NNP	O
.	.	O

Students	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
academic	JJ	O
year	NN	O
using	VBG	O
the	DT	O
Differential	NNP	O
Ability	NNP	O
Scales	NNP	O
.	.	O

Program	NNP	Mental
fidelity	NN	Mental
was	VBD	O
measured	VBN	O
through	IN	O
video	NN	O
coding	NN	O
and	CC	O
use	NN	O
of	IN	O
a	DT	O
checklist	NN	O
.	.	O

Outcomes	CC	O
were	VBD	O
assessed	VBN	O
using	VBG	O
linear	JJ	O
regression	NN	O
with	IN	O
random	JJ	O
effects	NNS	O
for	IN	O
classroom	NN	O
and	CC	O
student	NN	O
.	.	O

Average	JJ	Physical
fidelity	NN	Physical
was	VBD	O
57	CD	O
%	NN	O
in	IN	O
Strategies	NNP	O
for	IN	O
Teaching	NNP	O
based	VBN	O
on	IN	O
Autism	NNP	O
Research	NNP	O
classrooms	NNS	O
and	CC	O
48	CD	O
%	NN	O
in	IN	O
Structured	NNP	O
Teaching	NNP	O
classrooms	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
9.2-point	JJ	O
(	(	O
standard	JJ	O
deviation	NN	O
=	NNP	O
9.6	CD	O
)	)	O
increase	NN	O
in	IN	O
Differential	NNP	Physical
Ability	NNP	Physical
Scales	NNP	Physical
score	RB	Physical
over	IN	O
the	DT	O
8-month	JJ	O
study	NN	O
period	NN	O
,	,	O
but	CC	O
no	DT	O
main	JJ	O
effect	NN	O
of	IN	O
program	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
fidelity	NN	O
and	CC	O
group	NN	O
.	.	O

In	IN	O
classrooms	NNS	O
with	IN	O
either	DT	O
low	JJ	O
or	CC	O
high	JJ	O
program	NN	O
fidelity	NN	O
,	,	O
students	NNS	O
in	IN	O
Strategies	NNP	O
for	IN	O
Teaching	NNP	O
based	VBN	O
on	IN	O
Autism	NNP	O
Research	NNP	O
experienced	VBD	O
a	DT	O
greater	JJR	O
gain	NN	O
in	IN	O
Differential	NNP	Mental
Ability	NNP	Mental
Scales	NNP	Mental
score	RB	Mental
than	IN	O
students	NNS	O
in	IN	O
Structured	NNP	O
Teaching	NNP	O
(	(	O
11.2	CD	O
vs.	RB	O
5.5	CD	O
points	NNS	O
and	CC	O
11.3	CD	O
vs.	FW	O
8.9	CD	O
points	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
classrooms	NNS	O
with	IN	O
moderate	JJ	O
fidelity	NN	Physical
,	,	O
students	NNS	Others
in	IN	Others
Structured	NNP	Others
Teaching	NNP	Others
experienced	VBD	Others
a	DT	O
greater	JJR	O
gain	NN	O
than	IN	O
students	NNS	O
in	IN	O
Strategies	NNP	Others
for	IN	Others
Teaching	NNP	Others
based	VBN	Others
on	IN	Others
Autism	NNP	Others
Research	NNP	Others
(	(	O
10.1	CD	O
vs.	RB	O
4.4	CD	O
points	NNS	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
significant	JJ	O
variability	NN	O
in	IN	O
implementation	NN	O
of	IN	O
evidence-based	JJ	O
practices	NNS	O
,	,	O
even	RB	O
with	IN	O
supports	NNS	O
,	,	O
and	CC	O
also	RB	O
suggest	VBP	O
the	DT	O
need	NN	O
to	TO	O
address	VB	O
challenging	VBG	O
issues	NNS	O
related	VBN	O
to	TO	O
implementation	VB	O
measurement	NN	O
in	IN	O
community	NN	O
settings	NNS	O
.	.	O

Intraperitoneal	NNP	O
application	NN	O
of	IN	O
bupivacaine	NN	O
plus	CC	O
morphine	NN	O
for	IN	O
pain	NN	Pain
relief	NN	Pain
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Intraperitoneal	NNP	O
administration	NN	O
of	IN	O
a	DT	O
local	JJ	O
anaesthetic	NN	O
in	IN	O
combination	NN	O
with	IN	O
an	DT	O
opioid	NN	O
,	,	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
postoperative	JJ	Pain
pain	NN	Pain
,	,	O
has	VBZ	O
already	RB	O
been	VBN	O
reported	VBN	O
except	IN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
bupivacaine	NN	O
and	CC	O
morphine	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

METHODS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	JJ	O
manner	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
injections	NNS	O
was	VBD	O
given	VBN	O
intraperitoneally	RB	O
.	.	O

There	EX	O
were	VBD	O
30	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
:	:	O
Group	NNP	O
1	CD	O
,	,	O
physiological	JJ	O
saline	NN	O
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
2	CD	O
,	,	O
bupivacaine	VBP	O
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
3	CD	O
,	,	O
bupivacaine	VBP	O
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
plus	CC	O
morphine	JJ	O
2	CD	O
mg	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
Group	NNP	O
2	CD	O
received	VBD	O
2	CD	O
mg	NNS	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
morphine	NN	O
in	IN	O
2	CD	O
mL	NNS	O
saline	NN	O
,	,	O
and	CC	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
2	CD	O
mL	NN	O
saline	NN	O
intravenously	RB	O
.	.	O

Patients	NNS	O
'	POS	O
postoperative	JJ	Pain
pain	NN	Pain
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	Others
analogue	NN	Others
scale	NN	Others
and	CC	O
a	DT	O
verbal	JJ	Mental
rating	NN	Mental
score	NN	Mental
.	.	O

The	DT	O
postoperative	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
metamizol	NN	Physical
administered	VBN	O
by	IN	O
an	DT	O
i.v	NN	O
.	.	O

patient-controlled	JJ	Others
analgesia	NN	Others
(	(	Others
PCA	NNP	Others
)	)	Others
device	NN	O
.	.	O

Pain	NNP	Pain
,	,	O
vital	JJ	Physical
signs	NNS	Physical
,	,	O
supplemental	JJ	Physical
analgesic	JJ	Physical
consumption	NN	Physical
and	CC	O
side-effects	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
for	IN	O
24	CD	O
h.	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
pain	NN	Pain
scores	NNS	Pain
(	(	O
at	IN	O
rest	NN	O
and	CC	O
coughing	VBG	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
except	IN	O
in	IN	O
the	DT	O
first	JJ	O
2	CD	O
h	NN	O
,	,	O
when	WRB	O
scores	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
patients	NNS	O
receiving	VBG	O
intraperitoneal	JJ	O
bupivacaine	NN	O
plus	CC	O
i.v	NN	O
.	.	O

morphine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Supplemental	JJ	Physical
consumption	NN	Physical
of	IN	Physical
metamizol	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
Group	NNP	O
3	CD	O
than	IN	O
in	IN	O
Group	NNP	O
1	CD	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cumulative	JJ	Others
doses	NNS	Others
of	IN	O
metamizol	NN	O
were	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
Group	NNP	O
2	CD	O
than	IN	O
in	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
(	(	O
2025	CD	O
+/-	NN	O
1044	CD	O
mg	NN	O
vs.	FW	O
4925	CD	O
+/-	JJ	O
1238	CD	O
and	CC	O
4125	CD	O
+/-	JJ	O
1276mg	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
morphine	JJ	O
plus	CC	O
bupivacaine	JJ	O
0.25	CD	O
%	NN	O
reduced	VBD	O
the	DT	O
analgesic	JJ	Physical
requirements	NNS	Physical
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
postoperative	JJ	O
hours	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
intraperitoneal	JJ	O
bupivacaine	JJ	O
0.25	CD	O
%	NN	O
and	CC	O
i.v	NN	O
.	.	O

morphine	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
pain	NN	Pain
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

Phase	NNP	O
II	NNP	O
multi-institutional	JJ	O
prospective	NN	O
randomised	VBN	O
trial	NN	O
comparing	VBG	O
S-1+paclitaxel	JJ	O
with	IN	O
S-1+cisplatin	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
and/or	JJ	O
recurrent	NN	O
advanced	VBD	O
gastric	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
combination	NN	O
of	IN	O
S-1	NNP	O
and	CC	O
cisplatin	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
with	IN	O
acceptable	JJ	O
safety	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
far-advanced	JJ	O
gastric	JJ	O
cancer	NN	O
in	IN	O
Japan	NNP	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
randomised	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
to	TO	O
compare	VB	O
S-1+paclitaxel	JJ	O
with	IN	O
S-1+cisplatin	NNP	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
unresectable	JJ	O
and/or	JJ	O
recurrent	NN	O
advanced	VBD	O
gastric	JJ	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
regimens	NNS	O
:	:	O
S-1	NNP	O
(	(	O
40	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
twice	RB	O
daily	RB	O
)	)	O
on	IN	O
days	NNS	O
1-14	JJ	O
plus	JJ	O
paclitaxel	NN	O
(	(	O
60	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
a	DT	O
4-week	JJ	O
cycle	NN	O
(	(	O
S-1+paclitaxel	NNP	O
)	)	O
or	CC	O
S-1	NNP	O
(	(	O
40	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
twice	RB	O
daily	RB	O
)	)	O
on	IN	O
days	NNS	O
1-21	JJ	O
plus	JJ	O
cisplatin	NN	O
(	(	O
60	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
on	IN	O
day	NN	O
8	CD	O
of	IN	O
a	DT	O
5-week	JJ	O
cycle	NN	O
(	(	O
S-1+cisplatin	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
response	NN	Others
rate	NN	Others
(	(	Others
RR	NNP	Others
)	)	Others
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
progression-free	JJ	Others
survival	NN	Others
(	(	Others
PFS	NNP	Others
)	)	Others
,	,	O
overall	JJ	Others
survival	NN	Others
(	(	Others
OS	NNP	Others
)	)	Others
,	,	O
and	CC	O
safety	NN	Others
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
83	CD	O
patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
analyses	NNS	O
.	.	O

In	IN	O
the	DT	O
S-1+paclitaxel	NNP	O
and	CC	O
S-1+cisplatin	NNP	O
groups	NNS	O
,	,	O
RRs	NNP	Others
(	(	O
52.3	CD	O
%	NN	O
vs	JJ	O
48.7	CD	O
%	NN	O
;	:	O
P=0.74	NNP	O
)	)	O
and	CC	O
median	JJ	O
PFS	NNP	O
(	(	O
9	CD	O
vs	RB	O
6	CD	O
months	NNS	O
;	:	O
P=0.50	NNP	O
)	)	O
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
median	JJ	Others
OS	NNP	Others
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
S-1+paclitaxel	NNP	O
and	CC	O
S-1+cisplatin	NNP	O
groups	NNS	O
(	(	O
16	CD	O
vs	RB	O
17	CD	O
months	NNS	O
;	:	O
P=0.84	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	Physical
of	IN	Physical
grade	NN	Physical
3	CD	Physical
or	CC	Physical
higher	JJR	Physical
haematological	JJ	Physical
toxicity	NN	Physical
was	VBD	O
19.0	CD	O
%	NN	O
with	IN	O
S-1+paclitaxel	NNP	O
and	CC	O
19.5	CD	O
%	NN	O
with	IN	O
S-1+cisplatin	NNP	O
.	.	O

The	DT	O
incidence	NN	Adverseeffect
of	IN	Adverseeffect
grade	NN	Adverseeffect
3	CD	Adverseeffect
or	CC	Adverseeffect
higher	JJR	Adverseeffect
non-haematological	JJ	Adverseeffect
toxicity	NN	Adverseeffect
was	VBD	O
14.2	CD	O
%	NN	O
with	IN	O
S-1+paclitaxel	NNP	O
and	CC	O
17.1	CD	O
%	NN	O
with	IN	O
S-1+cisplatin	NNP	O
.	.	O

CONCLUSION	NNP	O
S-1+paclitaxel	NNP	O
was	VBD	O
suggested	VBN	O
to	TO	O
be	VB	O
a	DT	O
feasible	JJ	O
and	CC	O
effective	JJ	O
non-platinum-based	JJ	O
regimen	NNS	O
for	IN	O
chemotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
should	MD	O
be	VB	O
confirmed	VBN	O
in	IN	O
multicenter	NN	O
,	,	O
phase	VB	O
III-controlled	NNP	O
clinical	JJ	O
trials	NNS	O
.	.	O

Multisite	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
in	IN	O
autism	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
examine	VB	O
the	DT	O
efficacy	NN	Others
of	IN	O
intravenous	JJ	O
porcine	NN	O
secretin	NN	O
for	IN	O
the	DT	O
treatment	NN	Others
of	IN	O
autistic	JJ	Physical
disorder	NN	Physical
.	.	O

METHOD	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
.	.	O

Fifty-six	JJ	O
subjects	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
received	VBD	O
either	CC	O
a	DT	O
secretin	NN	O
or	CC	O
placebo	NN	O
infusion	NN	O
at	IN	O
baseline	NN	O
and	CC	O
the	DT	O
other	JJ	O
substance	NN	O
at	IN	O
week	NN	O
4	CD	O
.	.	O

Subjects	NNS	O
were	VBD	O
given	VBN	O
the	DT	O
Autism	NNP	Mental
Diagnostic	NNP	Mental
Observation	NNP	Mental
Schedule	NNP	Mental
(	(	Mental
ADOS	NNP	Mental
)	)	Mental
and	CC	O
other	JJ	O
pertinent	JJ	Mental
developmental	JJ	Mental
measures	NNS	Mental
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
weeks	NNS	O
4	CD	O
and	CC	O
8	CD	O
to	TO	O
assess	VB	O
drug	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
,	,	O
change	NN	O
of	IN	O
ADOS	NNP	Mental
social-communication	NN	Mental
total	JJ	Mental
score	NN	Mental
from	IN	O
week	NN	O
0	CD	O
to	TO	O
week	NN	O
4	CD	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
obtained	VBN	O
between	IN	O
placebo	NN	O
(	(	O
-0.8	JJ	O
+/-	JJ	O
2.9	CD	O
)	)	O
and	CC	O
secretin	JJ	O
groups	NNS	O
(	(	O
-0.6	JJ	O
+/-	JJ	O
1.4	CD	O
;	:	O
t54	NN	O
=	VBZ	O
0.346	CD	O
,	,	O
p	NN	O
<	NNP	O
.73	NNP	O
)	)	O
.	.	O

The	DT	O
other	JJ	O
measures	NNS	O
showed	VBD	O
no	DT	O
treatment	NN	Physical
effect	NN	Physical
for	IN	O
secretin	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
for	IN	O
efficacy	NN	Others
of	IN	O
secretin	NN	O
in	IN	O
this	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

Effect	NN	O
of	IN	O
clinical	JJ	O
context	NN	O
on	IN	O
simulator-based	JJ	O
assessment	NN	O
of	IN	O
blood	NN	Physical
pressure	NN	Physical
taking	VBG	O
-	:	O
a	DT	O
pilot	NN	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Blood	NNP	O
pressure	NN	O
measurement	NN	O
is	VBZ	O
an	DT	O
essential	JJ	O
clinical	JJ	O
skill	NN	O
that	WDT	O
can	MD	O
readily	RB	O
be	VB	O
assessed	VBN	O
in	IN	O
objective	JJ	O
structured	JJ	O
clinical	JJ	O
examination	NN	O
(	(	O
OSCE	NNP	O
)	)	O
.	.	O

While	IN	O
the	DT	O
use	NN	O
of	IN	O
simulators	NNS	O
can	MD	O
enhance	VB	O
test	NN	O
validity	NN	O
and	CC	O
reliability	NN	O
,	,	O
the	DT	O
given	VBN	O
clinical	JJ	O
context	NN	O
may	MD	O
also	RB	O
affect	VB	O
student	NN	O
performance	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
impact	NN	O
of	IN	O
variations	NNS	O
in	IN	O
clinical	JJ	O
context	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
measurement	NN	O
in	IN	O
a	DT	O
simulator-based	JJ	O
OSCE	NNP	O
.	.	O

METHOD	NNP	O
We	PRP	O
randomized	VBD	O
162	CD	O
first-year	JJ	O
medical	JJ	O
students	NNS	O
into	IN	O
four	CD	O
groups	NNS	O
that	WDT	O
received	VBD	O
different	JJ	O
lead-in	JJ	O
statements	NNS	O
before	IN	O
measuring	VBG	O
blood	NN	Physical
pressure	NN	Physical
on	IN	O
a	DT	O
manikin	JJ	O
simulator	NN	O
.	.	O

These	DT	O
statements	NNS	O
described	VBD	O
hypothetical	JJ	O
patients	NNS	O
with	IN	O
different	JJ	O
likelihoods	NNS	O
of	IN	O
having	VBG	O
systemic	JJ	Physical
hypertension	NN	Physical
.	.	O

RESULTS	VB	O
The	DT	O
lead-in	JJ	O
that	WDT	O
described	VBD	O
the	DT	O
highest	JJS	O
likelihood	NN	Physical
of	IN	Physical
hypertension	NN	Physical
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
reported	VBD	Others
readings	NNS	Others
and	CC	Others
lower	JJR	Others
accuracy	NN	Others
.	.	O

The	DT	O
lead-in	NN	O
that	WDT	O
suggested	VBD	O
normality	NN	O
yielded	VBN	O
the	DT	O
best	JJS	O
performance	NN	O
.	.	O

CONCLUSION	NNP	O
Student	NNP	O
performance	NN	O
in	IN	O
simulator-based	JJ	O
OSCE	NNP	O
may	MD	O
be	VB	O
affected	VBN	O
by	IN	O
the	DT	O
clinical	JJ	O
context	NN	O
provided	VBN	O
.	.	O

However	RB	O
,	,	O
we	PRP	O
argue	VBP	O
that	IN	O
construct	NN	O
validity	NN	O
should	MD	O
be	VB	O
viewed	VBN	O
in	IN	O
light	NN	O
of	IN	O
the	DT	O
application	NN	O
of	IN	O
a	DT	O
test	NN	O
,	,	O
in	IN	O
that	DT	O
patients	NNS	O
may	MD	O
also	RB	O
present	VB	O
with	IN	O
different	JJ	O
cues	NNS	O
and	CC	O
likelihoods	NNS	O
of	IN	O
having	VBG	O
hypertension	NN	O
.	.	O

Variations	NNS	O
in	IN	O
construct	NN	O
design	NN	O
should	MD	O
be	VB	O
further	RB	O
explored	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
training	NN	O
and	CC	O
assessment	NN	O
of	IN	O
clinical	JJ	O
competence	NN	O
that	WDT	O
reflects	VBZ	O
the	DT	O
unpredictability	NN	O
encountered	VBN	O
in	IN	O
daily	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

Getting	VBG	O
a	DT	O
high	JJ	O
response	NN	O
rate	NN	O
of	IN	O
sexual	JJ	O
behavior	JJ	O
survey	NN	O
among	IN	O
the	DT	O
general	JJ	O
population	NN	O
in	IN	O
Japan	NNP	O
:	:	O
three	CD	O
different	JJ	O
methods	NNS	O
of	IN	O
survey	NN	O
on	IN	O
sexual	JJ	O
behavior	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
specify	VB	O
the	DT	O
most	RBS	O
accurate	JJ	O
,	,	O
reliable	JJ	O
and	CC	O
valid	JJ	O
technique	NN	O
for	IN	O
a	DT	O
general	JJ	O
sexual	JJ	O
behavioral	JJ	O
survey	NN	O
in	IN	O
Japan	NNP	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assure	VB	O
a	DT	O
high	JJ	O
response	NN	O
rate	NN	O
and	CC	O
to	TO	O
keep	VB	O
respondents	NNS	O
'	POS	O
privacy	NN	O
confidential	NN	O
by	IN	O
using	VBG	O
an	DT	O
anonymous	JJ	O
questionnaire	NN	O
survey	NN	O
technique	NN	O
.	.	O

The	DT	O
sample	NN	O
(	(	O
360	CD	O
potential	JJ	O
respondents	NNS	O
)	)	O
was	VBD	O
selected	VBN	O
randomly	RB	O
from	IN	O
basic	JJ	O
resident	NN	O
registers	NNS	O
in	IN	O
two	CD	O
geographically	RB	O
different	JJ	O
areas	NNS	O
.	.	O

From	IN	O
the	DT	O
registries	NNS	O
,	,	O
90	CD	O
residents	NNS	O
,	,	O
aged	VBD	O
20	CD	O
to	TO	O
49	CD	O
years	NNS	O
old	JJ	O
,	,	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
represent	VB	O
each	DT	O
sex	NN	O
from	IN	O
each	DT	O
area	NN	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
each	DT	O
having	VBG	O
a	DT	O
different	JJ	O
procedure	NN	O
of	IN	O
requesting	VBG	O
the	DT	O
completion	NN	O
of	IN	O
the	DT	O
survey	NN	O
and	CC	O
providing	VBG	O
the	DT	O
questionnaires	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Postal	NNP	O
Group	NNP	O
,	,	O
(	(	O
2	CD	O
)	)	O
Telephone	CD	O
Group	NNP	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
Face-to-face	NN	O
Group	NNP	O
.	.	O

The	DT	O
survey	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
from	IN	O
October	NNP	O
1995	CD	O
to	TO	O
February	NNP	O
1996	CD	O
.	.	O

Effective	JJ	Others
response	NN	Others
rates	NNS	Others
for	IN	O
the	DT	O
above	NN	O
mentioned	VBD	O
three	CD	O
groups	NNS	O
were	VBD	O
69.2	CD	O
%	NN	O
,	,	O
69.2	CD	O
%	NN	O
and	CC	O
55.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
difficult	JJ	O
to	TO	O
determine	VB	O
the	DT	O
best	JJS	O
method	NN	O
when	WRB	O
only	RB	O
considering	VBG	O
the	DT	O
effective	JJ	Others
response	NN	Others
rates	NNS	Others
.	.	Physical

However	RB	O
,	,	O
judging	VBG	O
from	IN	O
our	PRP$	O
effort	NN	O
and	CC	O
expense	NN	O
,	,	O
the	DT	O
mail	NN	O
survey	NN	O
is	VBZ	O
the	DT	O
best	JJS	O
possible	JJ	O
procedure	NN	O
and	CC	O
would	MD	O
be	VB	O
a	DT	O
reasonable	JJ	O
method	NN	O
for	IN	O
a	DT	O
national	JJ	O
sexual	JJ	O
behavior	NN	O
survey	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
17	CD	O
beta-oestradiol	JJ	O
and	CC	O
progesterone	NN	O
on	IN	O
finger	NN	Physical
skin	JJ	Physical
circulation	NN	Physical
in	IN	O
healthy	JJ	O
women	NNS	O
and	CC	O
in	IN	O
women	NNS	O
with	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
sex	NN	O
,	,	O
the	DT	O
menstrual	JJ	O
cycle	NN	O
,	,	O
oral	JJ	O
contraceptives	NNS	O
,	,	O
pregnancy	NN	O
,	,	O
and	CC	O
the	DT	O
menopause	NN	O
on	IN	O
skin	JJ	O
perfusion	NN	O
in	IN	O
healthy	JJ	O
women	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
with	IN	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
suggest	VBP	O
a	DT	O
role	NN	O
of	IN	O
female	JJ	O
sex	NN	O
hormones	NNS	O
.	.	O

However	RB	O
,	,	O
no	DT	O
clear	JJ	O
relation	NN	O
between	IN	O
skin	JJ	Physical
blood	NN	Physical
flow	NN	Physical
and	CC	O
circulating	VBG	O
concentrations	NNS	O
of	IN	O
oestrogens	NNS	O
or	CC	O
progestogens	NNS	O
has	VBZ	O
yet	RB	O
been	VBN	O
found	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
orally	RB	O
administered	VBN	O
17	CD	O
beta-oestradiol	JJ	O
and	CC	O
progesterone	NN	O
on	IN	O
finger	NN	Physical
skin	NN	Physical
blood	NN	Physical
flow	NN	Physical
before	IN	O
and	CC	O
during	IN	O
heat	NN	O
and	CC	O
cold	JJ	O
challenge	NN	O
in	IN	O
17	CD	O
healthy	JJ	O
normotensive	JJ	O
women	NNS	O
and	CC	O
in	IN	O
12	CD	O
women	NNS	O
with	IN	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
.	.	O

In	IN	O
each	DT	O
subject	NN	O
standardized	VBN	O
finger	NN	O
heating	NN	O
(	(	O
45	CD	O
degrees	NNS	O
C	NNP	O
water	NN	O
bath	NN	O
,	,	O
10	CD	O
min	NN	O
)	)	O
and	CC	O
cooling	VBG	O
tests	NNS	O
(	(	O
15	CD	O
degrees	NNS	O
C	NNP	O
water	NN	O
bath	NN	O
,	,	O
5	CD	O
min	NN	O
and	CC	O
20	CD	O
min	JJ	O
recovery	NN	O
)	)	O
were	VBD	O
performed	VBN	O
twice	RB	O
on	IN	O
the	DT	O
second	JJ	O
(	(	O
or	CC	O
third	JJ	O
)	)	O
day	NN	O
of	IN	O
two	CD	O
consecutive	JJ	O
menstrual	JJ	O
cycles	NNS	O
.	.	O

17	CD	O
beta-Oestradiol	JJ	O
(	(	O
9	CD	O
mg	NN	O
)	)	O
or	CC	O
progesterone	NN	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
were	VBD	O
given	VBN	O
before	IN	O
the	DT	O
second	JJ	O
test	NN	O
,	,	O
after	IN	O
a	DT	O
first	JJ	O
test	NN	O
with	IN	O
placebo	NN	O
.	.	O

Both	DT	O
hormonal	JJ	O
doses	NNS	O
resulted	VBN	O
in	IN	O
(	(	O
high	JJ	O
)	)	O
physiological	JJ	Physical
concentrations	NNS	Physical
.	.	O

Fingertip	NNP	Physical
skin	JJ	Physical
temperature	NN	Physical
and	CC	O
laser	NN	Physical
Doppler	NNP	Physical
flux	NN	Physical
were	VBD	O
measured	VBN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
test	NN	Physical
results	NNS	Physical
after	IN	O
placebo	NN	O
and	CC	O
after	IN	O
progesterone	NN	O
.	.	O

Although	IN	O
values	NNS	O
of	IN	O
fingertip	NN	O
skin	NN	O
temperature	NN	O
and	CC	O
laser	NN	O
Doppler	NNP	O
flux	NN	O
after	IN	O
17	CD	O
beta-oestradiol	NN	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
only	RB	O
the	DT	O
precooling	NN	O
values	NNS	O
in	IN	O
the	DT	O
healthy	JJ	O
subjects	NNS	O
reached	VBD	O
significance	NN	O
:	:	O
fingertip	NN	O
skin	NN	O
temperature	NN	O
respectively	RB	O
with	IN	O
placebo	NN	O
and	CC	O
with	IN	O
oestradiol	NN	O
(	(	O
mean	JJ	O
(	(	O
SD	NNP	O
)	)	O
)	)	O
:	:	O
32.7	CD	O
(	(	O
1.0	CD	O
)	)	O
and	CC	O
33.1	CD	O
(	(	O
0.8	CD	O
)	)	O
degrees	NNS	O
C	NNP	O
;	:	O
laser	JJR	O
Doppler	NNP	O
flux	NN	O
with	IN	O
placebo	NN	O
and	CC	O
with	IN	O
oestradiol	NN	O
:	:	O
33.6	CD	O
(	(	O
11.7	CD	O
)	)	O
and	CC	O
42.2	CD	O
(	(	O
9.5	CD	O
)	)	O
perfusion	NN	O
units	NNS	O
;	:	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Reflexive	JJ	O
orienting	VBG	O
in	IN	O
response	NN	O
to	TO	O
eye	NN	O
gaze	NN	O
and	CC	O
an	DT	O
arrow	NN	O
in	IN	O
children	NNS	O
with	IN	O
and	CC	O
without	IN	O
autism	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
investigated	VBD	O
whether	IN	O
another	DT	O
person	NN	O
's	POS	O
social	JJ	O
attention	NN	Mental
,	,	O
specifically	RB	O
the	DT	O
direction	NN	O
of	IN	O
their	PRP$	O
eye	NN	O
gaze	NN	O
,	,	O
and	CC	O
a	DT	O
non-social	JJ	O
directional	JJ	O
cue	NN	O
,	,	O
an	DT	O
arrow	NN	O
,	,	O
triggered	VBD	O
reflexive	JJ	Mental
orienting	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
and	CC	O
without	IN	O
autism	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
situation	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
and	CC	O
typically	RB	O
developed	JJ	O
children	NNS	O
participated	VBN	O
in	IN	O
one	CD	O
of	IN	O
two	CD	O
experiments	NNS	O
.	.	O

Both	DT	O
experiments	NNS	O
involved	VBD	O
the	DT	O
localization	NN	O
of	IN	O
a	DT	O
target	NN	O
that	WDT	O
appeared	VBD	O
to	TO	O
the	DT	O
left	NN	O
or	CC	O
right	NN	O
of	IN	O
the	DT	O
fixation	NN	O
point	NN	O
.	.	O

Before	IN	O
the	DT	O
target	NN	O
appeared	VBD	O
,	,	O
the	DT	O
participant	NN	O
's	POS	O
attention	NN	O
was	VBD	O
cued	VBN	O
to	TO	O
the	DT	O
left	NN	O
or	CC	O
right	NN	O
by	IN	O
either	DT	O
an	DT	O
arrow	NN	O
or	CC	O
the	DT	O
direction	NN	O
of	IN	O
eye	NN	O
gaze	NN	O
on	IN	O
a	DT	O
computerized	JJ	O
face	NN	O
.	.	O

RESULTS	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
were	VBD	O
slower	JJR	Mental
to	TO	Mental
respond	VB	Mental
,	,	O
which	WDT	O
suggests	VBZ	O
a	DT	O
slight	JJ	O
difference	NN	O
in	IN	O
the	DT	O
general	JJ	O
cognitive	JJ	Mental
ability	NN	Mental
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
although	IN	O
the	DT	O
participants	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
disregard	VB	O
the	DT	O
cue	NN	O
and	CC	O
the	DT	O
target	NN	O
was	VBD	O
correctly	RB	O
cued	VBN	O
in	IN	O
only	RB	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
trials	NNS	O
,	,	O
both	DT	O
groups	NNS	O
of	IN	O
children	NNS	O
responded	VBD	Physical
significantly	RB	O
faster	RBR	O
to	TO	O
cued	VB	O
targets	NNS	O
than	IN	O
to	TO	O
uncued	JJ	O
targets	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
cue	NN	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
children	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
attend	VB	O
to	TO	O
the	DT	O
direction	NN	O
opposite	IN	O
that	DT	O
of	IN	O
the	DT	O
cues	NNS	O
and	CC	O
the	DT	O
target	NN	O
was	VBD	O
correctly	RB	O
cued	VBN	O
in	IN	O
only	RB	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
trials	NNS	O
.	.	O

Typically	RB	O
developed	JJ	O
children	NNS	O
located	VBN	Mental
targets	NNS	Mental
cued	VBN	Mental
by	IN	Mental
eye	NN	Mental
gaze	NNS	Mental
more	RBR	O
quickly	RB	O
,	,	O
while	IN	O
the	DT	O
arrow	NN	O
cue	NN	O
did	VBD	O
not	RB	O
trigger	VB	O
such	JJ	O
reflexive	JJ	Mental
orienting	NN	Mental
in	IN	O
these	DT	O
children	NNS	O
.	.	O

However	RB	O
,	,	O
both	DT	O
social	JJ	O
and	CC	O
non-social	JJ	O
cues	NNS	O
shifted	VBD	O
attention	NN	Mental
to	TO	O
the	DT	O
cued	VBN	O
location	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
eye	NN	O
gaze	NN	O
attracted	VBD	O
attention	NN	Physical
more	RBR	O
effectively	RB	O
than	IN	O
the	DT	O
arrow	NN	O
in	IN	O
typically	RB	O
developed	JJ	O
children	NNS	O
,	,	O
while	IN	O
children	NNS	O
with	IN	O
autism	NN	O
shifted	VBN	O
their	PRP$	O
attention	NN	O
equally	RB	O
in	IN	O
response	NN	O
to	TO	O
eye	NN	O
gaze	NN	O
and	CC	O
arrow	JJ	O
direction	NN	O
,	,	O
failing	VBG	O
to	TO	O
show	VB	O
preferential	JJ	O
sensitivity	NN	Mental
to	TO	O
the	DT	O
social	JJ	O
cue	NN	O
.	.	O

Difficulty	NN	O
in	IN	O
shifting	VBG	O
controlled	JJ	O
attention	NN	Physical
to	TO	O
the	DT	O
instructed	JJ	O
side	NN	O
was	VBD	O
also	RB	O
found	VBN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

A	DT	O
community-based	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
praziquantel	NN	O
to	TO	O
control	VB	O
schistosomiasis	NN	O
morbidity	NN	O
in	IN	O
schoolchildren	NN	O
in	IN	O
Zambia	NNP	O
.	.	O

A	DT	O
community-based	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
praziquantel	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
an	DT	O
area	NN	O
of	IN	O
Zambia	NNP	O
endemic	FW	O
for	IN	O
schistosomiasis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
treatment	NN	O
on	IN	O
Schistosoma	NNP	O
mansoni	NNP	O
morbidity	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
377	CD	O
infected	JJ	O
children	NNS	O
,	,	O
aged	VBD	O
seven	CD	O
to	TO	O
19	CD	O
years	NNS	O
,	,	O
was	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
one	CD	O
of	IN	O
190	CD	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
one	CD	O
of	IN	O
187	CD	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

All	DT	O
children	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
40	CD	O
mg	NNS	O
praziquantel/kg	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Six	CD	O
months	NNS	O
later	RB	O
,	,	O
the	DT	O
children	NNS	O
in	IN	O
group	NN	O
A	NNP	O
were	VBD	O
re-treated	JJ	O
with	IN	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
praziquantel	NN	O
,	,	O
while	IN	O
the	DT	O
children	NNS	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
given	VBN	O
placebos	NNS	O
.	.	O

All	DT	O
children	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
three	CD	O
,	,	O
six	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
,	,	O
morbidity	NN	Physical
being	VBG	O
clinically	RB	O
evaluated	VBN	O
at	IN	O
the	DT	O
six-	JJ	O
and	CC	O
12-month	JJ	O
follow-ups	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
,	,	O
in	IN	O
both	DT	O
groups	NNS	O
of	IN	O
children	NNS	O
,	,	O
there	EX	O
were	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
splenomegaly	NN	Physical
,	,	Physical
hepatomegaly	NN	Physical
,	,	Physical
and	CC	Physical
subjective	JJ	Physical
symptoms	NNS	Physical
of	IN	Physical
morbidity	NN	Physical
six	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
initial	JJ	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
,	,	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
in	IN	O
the	DT	O
prevalences	NNS	O
of	IN	O
these	DT	O
symptoms	NNS	O
of	IN	O
morbidity	NN	Physical
.	.	O

It	PRP	O
therefore	RB	O
appears	VBZ	O
that	IN	O
once-yearly	JJ	O
treatment	NN	O
of	IN	O
children	NNS	O
,	,	O
in	IN	O
this	DT	O
and	CC	O
similar	JJ	O
endemic	JJ	O
areas	NNS	O
,	,	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
reduce	VB	O
schistosomiasis	NN	O
morbidity	NN	O
to	TO	O
,	,	O
and	CC	O
maintain	VB	O
it	PRP	O
at	IN	O
,	,	O
a	DT	O
tolerable	JJ	O
level	NN	O
.	.	O

Tramadol	NNP	O
suppository	NN	O
versus	NN	O
placebo	NN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
perineal	NN	Pain
pain	NN	Pain
after	IN	O
perineorrhaphy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
randomized	JJ	O
double-blinded	JJ	O
control	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Others
of	IN	O
tramodol	NN	O
and	CC	O
placebo	NN	O
rectal	JJ	O
suppository	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postpartum	NN	Pain
perineal	NN	Pain
pain	NN	Pain
after	IN	O
perineorrhaphy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
One	NNP	O
hundred	VBD	O
women	NNS	O
who	WP	O
gave	VBD	O
birth	NN	O
vaginally	RB	O
with	IN	O
episiotomy	NN	O
and	CC	O
a	DT	O
second-	JJ	O
or	CC	O
third-degree	JJ	O
tear	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assign	VBN	O
to	TO	O
receive	VB	O
two	CD	O
tablets	NNS	O
oftramadol	VBP	O
50	CD	O
mg	NNS	O
or	CC	O
two	CD	O
tablets	NNS	O
ofplacebo	RB	O
,	,	O
the	DT	O
pill	NN	O
were	VBD	O
physically	RB	O
similar	JJ	O
to	TO	O
the	DT	O
real	JJ	O
drug	NN	O
.	.	O

Pain	VB	Pain
ratings	NNS	Pain
were	VBD	O
recorded	VBN	O
immediately	RB	O
after	IN	O
perineorrhaphy	NN	O
,	,	O
30	CD	O
minutes	NNS	O
,	,	O
and	CC	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
dose	NN	O
on	IN	O
a	DT	O
10-cm	JJ	O
visual	JJ	Physical
analogue	NN	Physical
scale	NN	Physical
.	.	Physical

Side	JJ	Adverseeffect
effects	NNS	Adverseeffect
and	CC	Adverseeffect
overall	JJ	Adverseeffect
opinion	NN	Adverseeffect
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
had	VBD	O
no	DT	O
statistical	JJ	O
significances	NNS	O
in	IN	O
analgesic	JJ	Pain
properties	NNS	Pain
,	,	O
assessed	VBN	O
by	IN	O
the	DT	O
means	NNS	O
of	IN	O
pain	NN	Pain
rating	NN	Pain
at	IN	O
the	DT	O
different	JJ	O
time	NN	O
intervals	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	Adverseeffect
serious	JJ	Adverseeffect
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
between	IN	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
in	IN	O
relief	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
A	DT	O
comparison	NN	O
of	IN	O
three	CD	O
highly	RB	O
active	JJ	O
antiretroviral	JJ	O
treatment	NN	O
strategies	NNS	O
consisting	VBG	O
of	IN	O
non-nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitors	NNS	O
,	,	O
protease	NN	O
inhibitors	NNS	O
,	,	O
or	CC	O
both	DT	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitors	NNS	O
as	IN	O
initial	JJ	O
therapy	NN	O
(	(	O
CPCRA	NNP	O
058	CD	O
FIRST	NNP	O
Study	NNP	O
)	)	O
:	:	O
a	DT	O
long-term	JJ	O
randomised	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Long-term	NNP	O
data	NNS	O
from	IN	O
randomised	VBN	O
trials	NNS	O
on	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
a	DT	O
protease	NN	O
inhibitor	NN	O
(	(	O
PI	NNP	O
)	)	O
,	,	O
non-nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitor	NN	O
(	(	O
NNRTI	NNP	O
)	)	O
,	,	O
or	CC	O
both	DT	O
are	VBP	O
lacking	VBG	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
report	VBP	O
results	NNS	O
from	IN	O
the	DT	O
FIRST	NNP	O
trial	NN	O
,	,	O
which	WDT	O
compared	VBN	O
initial	JJ	O
treatment	NN	O
strategies	NNS	O
for	IN	O
clinical	JJ	O
,	,	O
immunological	JJ	O
,	,	O
and	CC	O
virological	JJ	O
outcomes	NNS	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1999	CD	O
and	CC	O
2002	CD	O
,	,	O
1397	CD	O
antiretroviral-treatment-naive	JJ	O
patients	NNS	O
,	,	O
presenting	VBG	O
at	IN	O
18	CD	O
clinical	JJ	O
trial	NN	O
units	NNS	O
with	IN	O
80	CD	O
research	NN	O
sites	NNS	O
in	IN	O
the	DT	O
USA	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
ratio	NN	O
of	IN	O
1:1:1	CD	O
to	TO	O
a	DT	O
protease	NN	O
inhibitor	NN	O
(	(	O
PI	NNP	O
)	)	O
strategy	NN	O
(	(	O
PI	NNP	O
plus	CC	O
nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitor	NN	O
[	NNP	O
NRTI	NNP	O
]	NNP	O
;	:	O
n=470	NN	O
)	)	O
,	,	O
a	DT	O
non-nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitor	NN	O
(	(	O
NNRTI	NNP	O
)	)	O
strategy	NN	O
(	(	O
NNRTI	NNP	O
plus	CC	O
NRTI	NNP	O
;	:	O
n=463	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
three-class	JJ	O
strategy	NN	O
(	(	O
PI	NNP	O
plus	CC	O
NNRTI	NNP	O
plus	CC	O
NRTI	NNP	O
;	:	O
n=464	NN	O
)	)	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
were	VBD	O
a	DT	O
composite	NN	O
of	IN	O
an	DT	O
AIDS-defining	JJ	Physical
event	NN	Physical
,	,	O
death	NN	Mortality
,	,	O
or	CC	O
CD4	NNP	Physical
cell	VBP	Physical
count	NN	Physical
decline	NN	Physical
to	TO	O
less	JJR	O
than	IN	O
200	CD	O
cells	NNS	O
per	IN	O
mm3	NN	O
for	IN	O
the	DT	O
PI	NNP	O
versus	NN	O
NNRTI	NNP	O
comparison	NN	O
,	,	O
and	CC	O
average	JJ	O
change	NN	Physical
in	IN	Physical
CD4	NNP	Physical
cell	NN	Physical
count	NN	Physical
at	IN	O
or	CC	O
after	IN	O
32	CD	O
months	NNS	O
for	IN	O
the	DT	O
three-class	JJ	O
versus	NN	O
combined	VBD	O
two-class	JJ	O
comparison	NN	O
.	.	O

Analyses	NNS	O
were	VBD	O
by	IN	O
intention-to-treat	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00000922	NNP	O
.	.	O

FINDINGS	NNP	O
1397	CD	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
the	DT	O
composite	JJ	O
endpoint	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
388	CD	O
participants	NNS	O
developed	VBD	O
the	DT	O
composite	JJ	Others
endpoint	NN	Others
,	,	O
302	CD	O
developed	VBD	O
AIDS	NNP	O
or	CC	O
died	VBN	O
,	,	O
and	CC	O
188	CD	O
died	VBD	O
.	.	O

NNRTI	NNP	O
versus	NN	O
PI	NNP	O
hazard	NN	Others
ratios	NNS	Others
(	(	O
HRs	NNP	O
)	)	O
for	IN	O
the	DT	O
composite	JJ	O
endpoint	NN	O
,	,	O
for	IN	O
AIDS	NNP	Mortality
or	CC	Mortality
death	NN	Mortality
,	,	O
for	IN	O
death	NN	Mortality
,	,	O
and	CC	O
for	IN	O
virological	JJ	Physical
failure	NN	Physical
were	VBD	O
1.02	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.79-1.31	NN	O
)	)	O
,	,	O
1.07	CD	O
(	(	O
0.80-1.41	NN	O
)	)	O
,	,	O
0.95	CD	O
(	(	O
0.66-1.37	NN	O
)	)	O
,	,	O
and	CC	O
0.66	CD	O
(	(	O
0.56-0.78	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

1196	CD	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
the	DT	O
three-class	JJ	O
versus	NN	O
combined	VBN	O
two-class	JJ	O
primary	JJ	O
endpoint	NN	O
.	.	O

Mean	JJ	Physical
change	NN	Physical
in	IN	Physical
CD4	NNP	Physical
cell	NN	Physical
count	NN	Physical
at	IN	O
or	CC	O
after	IN	O
32	CD	O
months	NNS	O
was	VBD	O
+234	JJ	O
cells	NNS	O
per	IN	O
mm3	NN	O
and	CC	O
+227	NNP	O
cells	NNS	O
per	IN	O
mm3	NN	O
for	IN	O
the	DT	O
three-class	NN	O
and	CC	O
the	DT	O
combined	JJ	O
two-class	NN	O
strategies	NNS	O
(	(	O
p=0.62	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

HRs	NNP	Others
(	(	O
three-class	JJ	O
vs	NN	O
combined	VBN	O
two-class	NN	O
)	)	O
for	IN	O
AIDS	NNP	Mortality
or	CC	Mortality
death	NN	Mortality
and	CC	O
virological	JJ	Physical
failure	NN	Physical
were	VBD	O
1.15	CD	O
(	(	O
0.91-1.45	NN	O
)	)	O
and	CC	O
0.87	CD	O
(	(	O
0.75-1.00	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

HRs	NNP	Others
(	(	O
three-class	JJ	O
vs	NN	O
combined	VBN	O
two-class	NN	O
)	)	O
for	IN	O
AIDS	NNP	Mortality
or	CC	Mortality
death	NN	Mortality
were	VBD	O
similar	JJ	O
for	IN	O
participants	NNS	O
with	IN	O
baseline	NN	O
CD4	NNP	O
cell	NN	O
counts	NNS	O
of	IN	O
200	CD	O
cells	NNS	O
per	IN	O
mm3	NN	O
or	CC	O
less	JJR	O
and	CC	O
of	IN	O
more	JJR	O
than	IN	O
200	CD	O
cells	NNS	O
per	IN	O
mm3	NN	O
(	(	O
p=0.38	NN	O
for	IN	O
interaction	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
participants	NNS	O
with	IN	O
baseline	NN	O
HIV	NNP	O
RNA	NNP	O
concentrations	NNS	O
less	JJR	O
than	IN	O
100	CD	O
000	CD	O
copies	NNS	O
per	IN	O
mL	NN	O
and	CC	O
100,000	CD	O
copies	NNS	O
per	IN	O
mL	NN	O
or	CC	O
more	JJR	O
(	(	O
p=0.26	NN	O
for	IN	O
interaction	NN	O
)	)	O
.	.	O

Participants	NNS	O
assigned	VBD	O
the	DT	O
three-class	NN	O
strategy	NN	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
discontinue	VB	Others
treatment	NN	Others
because	IN	O
of	IN	O
toxic	NN	Adverseeffect
effects	NNS	Adverseeffect
than	IN	O
were	VBD	O
those	DT	O
assigned	VBN	O
to	TO	O
the	DT	O
two-class	NN	O
strategies	NNS	O
(	(	O
HR	NNP	O
1.58	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Initial	NNP	O
treatment	NN	O
with	IN	O
either	DT	O
an	DT	O
NNRTI-based	JJ	O
regimen	NNS	O
or	CC	O
a	DT	O
PI-based	JJ	O
regimen	NN	O
,	,	O
but	CC	O
not	RB	O
both	DT	O
together	RB	O
,	,	O
is	VBZ	O
a	DT	O
good	JJ	O
strategy	NN	O
for	IN	O
long-term	JJ	O
antiretroviral	JJ	O
management	NN	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
with	IN	O
HIV	NNP	O
.	.	O

Dietary	NNP	O
patterns	NNS	O
differ	VBP	O
between	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
older	JJR	O
,	,	O
long-term	JJ	O
survivors	NNS	O
of	IN	O
breast	NN	O
,	,	O
prostate	NN	O
,	,	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

BACKGROUND	NNP	O
Older	NNP	O
adult	NN	O
cancer	NN	O
survivors	NNS	O
are	VBP	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
cancer	NN	Physical
recurrence	NN	Physical
and	CC	O
other	JJ	O
comorbidities	NNS	Physical
that	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
through	IN	O
improved	VBN	O
diet	JJ	O
and	CC	O
weight	JJ	O
management	NN	O
.	.	O

The	DT	O
tertiary	JJ	O
prevention	NN	O
needs	NNS	O
of	IN	O
rural-dwelling	JJ	O
survivors	NNS	O
can	MD	O
be	VB	O
even	RB	O
greater	JJR	O
,	,	O
yet	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
rural	JJ	O
and	CC	O
urban	JJ	O
differences	NNS	O
in	IN	O
lifestyle	JJ	O
factors	NNS	O
among	IN	O
this	DT	O
high-risk	JJ	O
population	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
dietary	JJ	O
patterns	NNS	O
of	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
cancer	NN	O
survivors	NNS	O
and	CC	O
to	TO	O
examine	VB	O
associations	NNS	O
of	IN	O
dietary	JJ	Others
patterns	NNS	Others
with	IN	O
body	NN	Physical
mass	NN	Physical
index	NN	Physical
(	(	Physical
BMI	NNP	Physical
)	)	Physical
.	.	Physical

DESIGN	VB	O
A	DT	O
secondary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
of	IN	O
baseline	NN	O
data	NNS	O
from	IN	O
the	DT	O
Reach	NNP	Physical
Out	NNP	Physical
to	TO	Physical
Enhance	VB	Physical
Wellness	NNP	Physical
(	(	O
RENEW	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
intervention	NN	O
among	IN	O
overweight	JJ	O
,	,	O
long-term	JJ	O
(	(	O
?5	CD	O
years	NNS	O
)	)	O
,	,	O
older	JJR	O
survivors	NNS	O
of	IN	O
colorectal	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
prostate	NN	O
cancer	NN	O
.	.	O

Survivors	NNS	O
in	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
(	(	O
n=729	JJ	O
)	)	O
underwent	JJ	O
two	CD	O
45-	JJ	O
to	TO	O
60-minute	JJ	O
telephone	NN	O
surveys	NNS	O
,	,	O
which	WDT	O
included	VBD	O
two	CD	O
24-hour	JJ	O
dietary	JJ	O
recalls	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
and	CC	O
multivariable	JJ	O
general	JJ	O
linear	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
to	TO	O
evaluate	VB	O
associations	NNS	O
between	IN	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
BMI	NNP	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	VB	O
Principal	JJ	O
components	NNS	O
analysis	NN	O
identified	VBD	O
three	CD	O
primary	JJ	O
dietary	JJ	O
patterns	NNS	O
among	IN	O
rural	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
sweets	NNS	O
and	CC	O
starches	NNS	O
,	,	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
,	,	O
and	CC	O
mixed	JJ	O
)	)	O
and	CC	O
three	CD	O
among	IN	O
urban	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
,	,	O
high	JJ	O
meat	NN	O
and	CC	O
refined	VBD	O
grains	NNS	O
,	,	O
and	CC	O
high	JJ	O
sugar-sweetened	JJ	O
beverages	NNS	O
)	)	O
.	.	O

Among	IN	O
rural	JJ	O
survivors	NNS	O
,	,	O
greater	JJR	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
pattern	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
whereas	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
mixed	JJ	O
pattern	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Greater	NNP	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
pattern	VBP	O
among	IN	O
urban	JJ	O
survivors	NNS	O
was	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Urban	NNP	O
and	CC	O
rural	JJ	O
differences	NNS	O
in	IN	O
dietary	JJ	O
intake	NN	O
behavior	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
designing	VBG	O
public	JJ	O
health	NN	O
interventions	NNS	O
among	IN	O
the	DT	O
increasing	VBG	O
population	NN	O
of	IN	O
older	JJR	O
cancer	NN	O
survivors	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
targeting	VBG	O
overall	JJ	O
dietary	JJ	O
patterns	NNS	O
might	MD	O
be	VB	O
one	CD	O
approach	NN	O
to	TO	O
help	VB	O
reduce	VB	O
the	DT	O
burden	NN	O
of	IN	O
obesity	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Monotherapy	NNP	O
of	IN	O
mild	JJ	O
hypertension	NN	Physical
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
effectiveness	NN	Others
of	IN	O
nifedipine	JJ	O
as	IN	O
first-line	JJ	O
monotherapy	NN	O
for	IN	O
mild	JJ	O
diastolic	JJ	Physical
hypertension	NN	Physical
(	(	O
range	NN	O
:	:	O
95	CD	O
to	TO	O
105	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
,	,	O
after	IN	O
titration	NN	O
of	IN	O
the	DT	O
placebo	NN	O
or	CC	O
active	JJ	O
drug	NN	O
,	,	O
they	PRP	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Significant	JJ	O
declines	NNS	O
in	IN	O
the	DT	O
sitting	VBG	O
systolic	JJ	Physical
and	CC	Physical
diastolic	JJ	Physical
pressures	NNS	Physical
of	IN	O
-19	JJ	O
+/-	JJ	O
4	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
standard	JJ	O
error	NN	O
)	)	O
and	CC	O
-13	$	O
+/-	JJ	O
2	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
observed	VBN	O
during	IN	O
this	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

Overall	JJ	O
,	,	O
75	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
drug	NN	O
had	VBD	O
diastolic	JJ	Physical
pressures	NNS	Physical
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
90	CD	O
mm	NNS	O
Hg	NNP	O
at	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
visit	NN	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
was	VBD	O
not	RB	O
significantly	RB	O
changed	VBN	O
in	IN	O
the	DT	O
sitting	VBG	O
position	NN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
(	(	O
75	CD	O
percent	NN	O
)	)	O
showed	VBD	O
a	DT	O
response	NN	O
to	TO	O
nifedipine	JJ	O
doses	NNS	O
of	IN	O
10	CD	O
or	CC	O
20	CD	O
mg	NNS	O
orally	RB	O
three	CD	O
times	NNS	O
daily	RB	O
in	IN	O
the	DT	O
capsule	NN	O
form	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
the	DT	O
systolic	NN	Physical
and	CC	O
diastolic	JJ	Physical
pressures	NNS	Physical
at	IN	O
entry	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
nifedipine	NN	O
required	VBN	O
for	IN	O
effective	JJ	Others
blood	NN	Others
pressure	NN	Others
control	NN	O
.	.	O

Acute	NNP	O
intervention	NN	O
studies	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
myocardial	JJ	O
infarction	NN	O
using	VBG	O
atenolol	NN	O
,	,	O
propranolol	NN	O
,	,	O
oxprenolol	NN	O
and	CC	O
disopyramide	JJ	O
phosphate	NN	O
.	.	O

The	DT	O
value	NN	O
of	IN	O
beta-blockade	JJ	O
and	CC	O
of	IN	O
disopyramide	JJ	O
phosphate	NN	O
in	IN	O
the	DT	O
immediate	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
suspected	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
two	CD	O
placebo	NN	O
controlled	VBD	O
trials	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
388	CD	O
patients	NNS	O
with	IN	O
suspected	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
propranolol	NN	O
,	,	O
atenolol	NN	O
,	,	O
or	CC	O
placebo	NN	O
,	,	O
and	CC	O
when	WRB	O
analysed	VBN	O
on	IN	O
an	DT	O
initial	JJ	O
intention	NN	O
to	TO	O
treat	VB	O
basis	NN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
in	IN	O
respect	NN	O
of	IN	O
the	DT	O
mortality	NN	Mortality
at	IN	O
one	CD	O
year	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
either	DT	O
atenolol	NN	O
,	,	O
or	CC	O
propranolol	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	Physical
'serious	JJ	Physical
'	POS	Physical
ventricular	JJ	Physical
arrhythmias	NNS	Physical
in	IN	O
the	DT	O
coronary	JJ	O
care	NN	O
unit	NN	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
study	NN	O
473	CD	O
patients	NNS	O
with	IN	O
suspected	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
oxprenolol	NN	O
,	,	O
disopyramide	JJ	O
phosphate	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Again	NNP	O
no	DT	Mortality
significant	JJ	Mortality
differences	NNS	Mortality
were	VBD	O
seen	VBN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
mortality	NN	Mortality
at	IN	O
six	CD	O
weeks	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significantly	RB	O
increased	VBN	O
incidence	NN	Physical
of	IN	Physical
heart	NN	Physical
failure	NN	Physical
in	IN	O
the	DT	O
group	NN	O
which	WDT	O
received	VBD	O
disopyramide	JJ	O
phosphate	NN	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
this	DT	O
drug	NN	O
also	RB	O
showed	VBD	O
a	DT	O
reduced	JJ	O
number	NN	Physical
of	IN	Physical
dysrhythmic	JJ	Physical
episodes	NNS	Physical
on	IN	Physical
24-hour	JJ	Physical
ECG	NNP	Physical
recordings	NNS	Physical
,	,	O
but	CC	O
this	DT	O
trend	NN	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
none	NN	O
of	IN	O
the	DT	O
three	CD	O
beta-blockers	NNS	O
tested	VBN	O
nor	CC	O
disopyramide	JJ	O
phosphate	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
reduce	VB	Mortality
the	DT	Mortality
mortality	NN	Mortality
from	IN	Mortality
acute	JJ	Mortality
myocardial	JJ	Mortality
infarction	NN	Mortality
when	WRB	O
given	VBN	O
prophylactically	RB	O
,	,	O
although	IN	O
disopyramide	JJ	O
phosphate	NN	O
does	VBZ	O
reduce	VB	Physical
the	DT	Physical
incidence	NN	Physical
of	IN	Physical
'serious	JJ	Physical
'	POS	Physical
ventriicular	JJ	Physical
arrhythmias	NNS	Physical
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
live	JJ	O
and	CC	O
videotape	JJ	O
ratings	NNS	O
:	:	O
clomipramine	NN	O
and	CC	O
haloperidol	NN	O
in	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
live	JJ	O
ratings	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
and	CC	O
compared	VBN	O
response	NN	O
to	TO	O
clomipramine	VB	O
with	IN	O
response	NN	O
to	TO	O
haloperidol	VB	O
in	IN	O
8	CD	O
subjects	NNS	O
,	,	O
mean	JJ	O
age	NN	O
5.62	CD	O
years	NNS	O
,	,	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
autism	NN	O
.	.	O

They	PRP	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
clomipramine	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
or	CC	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
haloperidol	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
.	.	O

Live	JJ	O
ratings	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
pre-treatment	JJ	O
placebo	NN	O
baseline	NN	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
period	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
and	CC	O
the	DT	O
CGI	NNP	O
and	CC	O
were	VBD	O
videotaped	VBN	O
.	.	O

Employing	VBG	O
the	DT	O
same	JJ	O
instruments	NNS	O
,	,	O
these	DT	O
videotapes	NNS	O
were	VBD	O
rated	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
who	WP	O
did	VBD	O
not	RB	O
know	VB	O
the	DT	O
subjects	NNS	O
and	CC	O
were	VBD	O
blind	NNS	O
to	TO	O
study	VB	O
design	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
study	NN	O
phase	NN	O
.	.	O

Ratings	NNS	Others
of	IN	Others
videotapes	NNS	Others
significantly	RB	O
differed	VBN	O
from	IN	O
live	JJ	Others
ratings	NNS	Others
.	.	O

A	DT	O
treatment	NN	O
effect	NN	O
for	IN	O
haloperidol	NN	O
was	VBD	O
detected	VBN	O
only	RB	O
on	IN	O
live	JJ	Others
ratings	NNS	Others
and	CC	O
not	RB	O
on	IN	O
ratings	NNS	Others
of	IN	Others
videotapes	NNS	Others
.	.	O

No	DT	O
treatment	NN	O
effect	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
clomipramine	NN	O
in	IN	O
either	CC	O
live	JJ	Others
or	CC	O
videotape	JJ	Others
ratings	NNS	Others
.	.	O

[	JJ	O
Efficacy	NNP	O
observation	NN	O
on	IN	O
chronic	JJ	Physical
tension-type	JJ	Physical
headache	NN	Physical
treated	VBN	O
with	IN	O
acupuncture	NN	O
at	IN	O
galea	NN	O
tendon-muscle	NN	O
node	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
better	JJR	O
therapy	NN	O
for	IN	O
chronic	JJ	Physical
tension-type	JJ	Physical
headache	NN	Physical
(	(	Physical
CTTH	NNP	Physical
)	)	Physical
.	.	Physical

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
and	CC	O
eighty-eight	JJ	O
cases	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
sticking	VBG	O
needling	NN	O
group	NN	O
(	(	O
150	CD	O
cases	NNS	O
)	)	O
and	CC	O
an	DT	O
acupuncture	NN	O
group	NN	O
(	(	O
138	CD	O
cases	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
sticking	VBG	O
needling	NN	O
group	NN	O
,	,	O
the	DT	O
manual	JJ	O
sticking	NN	O
needling	NN	O
technique	NN	O
was	VBD	O
adopted	VBN	O
to	TO	O
stimulate	VB	O
the	DT	O
galea	NN	O
tendon-muscle	NN	O
node	NN	O
.	.	O

In	IN	O
the	DT	O
acupuncture	NN	O
group	NN	O
,	,	O
the	DT	O
conventional	JJ	O
acupuncture	NN	O
therapy	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
Baihui	NNP	O
(	(	O
GV	NNP	O
20	CD	O
)	)	O
,	,	O
Sishencong	NNP	O
(	(	O
EX-HN	NNP	O
1	CD	O
)	)	O
,	,	O
Fengchi	NNP	O
(	(	O
GB	NNP	O
20	CD	O
)	)	O
,	,	O
Taiyang	NNP	O
(	(	O
EX-HN	NNP	O
5	CD	O
)	)	O
,	,	O
Touwei	NNP	O
(	(	O
ST	NNP	O
18	CD	O
)	)	O
,	,	O
Hegu	NNP	O
(	(	O
LI	NNP	O
4	CD	O
)	)	O
,	,	O
etc	FW	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
once	RB	O
a	DT	O
day	NN	O
,	,	O
and	CC	O
30	CD	O
days	NNS	O
made	VBD	O
one	CD	O
session	NN	O
.	.	O

After	IN	O
two	CD	O
sessions	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
after	IN	O
three	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
CTTH	NNP	Physical
score	NN	Physical
(	(	Physical
including	VBG	Physical
the	DT	Physical
score	NN	Physical
of	IN	Physical
headache	NN	Physical
attack	NN	Physical
frequency	NN	Physical
and	CC	Physical
the	DT	Physical
score	NN	Physical
of	IN	Physical
headache	NN	Physical
severity	NN	Physical
)	)	Physical
was	VBD	O
observed	VBN	O
and	CC	O
compared	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
separately	RB	O
.	.	O

The	DT	O
efficacy	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
CTTH	NNP	Physical
score	NN	Physical
was	VBD	O
all	DT	O
reduced	VBN	O
after	IN	O
treatment	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
score	NN	Physical
in	IN	Physical
the	DT	Physical
sticking	VBG	Physical
needling	VBG	Physical
group	NN	Physical
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
acupuncture	NN	O
group	NN	O
(	(	O
2.38	CD	O
+/-	JJ	O
1.22	CD	O
vs	JJ	O
4.16	CD	O
+/-	JJ	O
2.54	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
effective	JJ	O
rate	NN	O
was	VBD	O
97.3	CD	O
%	NN	O
(	(	O
146/150	CD	O
)	)	O
in	IN	O
the	DT	O
sticking	VBG	O
needling	NN	O
group	NN	O
,	,	O
which	WDT	O
was	VBD	O
better	JJR	O
than	IN	O
88.4	CD	O
%	NN	O
(	(	O
122/138	CD	O
)	)	O
in	IN	O
the	DT	O
acupuncture	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
manual	JJ	O
sticking	NN	O
needling	NN	O
technique	NN	O
at	IN	O
galea	JJ	O
tendon-muscle	JJ	O
node	NN	O
achieves	VBZ	O
the	DT	O
superior	JJ	O
results	NNS	O
of	IN	O
reducing	VBG	Pain
the	DT	Pain
pain	NN	Pain
attack	NN	Pain
frequency	NN	Pain
and	CC	Physical
severity	NN	Physical
of	IN	Physical
CTTH	NNP	Physical
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
acupuncture	NN	O
therapy	NN	O
of	IN	O
the	DT	O
routine	JJ	O
acupoint	NN	O
selection	NN	O
.	.	O

Dual-task-related	JJ	O
gait	NN	O
changes	NNS	O
in	IN	O
transitionally	RB	O
frail	JJ	O
older	JJR	O
adults	NNS	O
:	:	O
the	DT	O
type	NN	O
of	IN	O
the	DT	O
walking-associated	JJ	O
cognitive	JJ	O
task	NN	O
matters	NNS	O
.	.	O

BACKGROUND	NNP	O
Changes	NNP	O
in	IN	O
gait	NN	O
patterns	NNS	O
due	JJ	O
to	TO	O
a	DT	O
simultaneously	RB	O
performed	VBN	O
cognitive	JJ	O
task	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
previously	RB	O
and	CC	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
falling	VBG	O
risk	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
.	.	O

Little	NNP	O
is	VBZ	O
known	VBN	O
whether	IN	O
the	DT	O
type	NN	O
of	IN	O
cognitive	JJ	O
task	NN	O
performed	VBN	O
while	IN	O
walking	VBG	O
is	VBZ	O
important	JJ	O
concerning	VBG	O
possible	JJ	O
gait	NN	O
interference	NN	O
in	IN	O
older	JJR	O
fall-prone	NN	O
individuals	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
quantify	VB	O
and	CC	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
cognitive	JJ	O
tasks	NNS	O
on	IN	O
gait	NN	O
in	IN	O
transitionally	RB	O
frail	JJ	O
older	JJR	O
adults	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Gait	NNP	O
was	VBD	O
tested	VBN	O
in	IN	O
30	CD	O
transitionally	RB	O
frail	JJ	O
older	JJR	O
adults	NNS	O
(	(	O
mean	JJ	O
age	NN	O
82.6	CD	O
+/-	JJ	O
7.1	CD	O
years	NNS	O
,	,	O
90	CD	O
%	NN	O
female	NN	O
)	)	O
while	IN	O
either	CC	O
walking	VBG	Mental
alone	RB	Mental
,	,	O
performing	VBG	Mental
a	DT	Mental
simple	JJ	Mental
arithmetic	JJ	Mental
task	NN	Mental
,	,	O
or	CC	O
performing	VBG	O
a	DT	O
task	NN	O
of	IN	O
verbal	JJ	O
fluency	NN	O
.	.	O

Walking	JJ	Mental
time	NN	Mental
in	IN	Mental
seconds	NNS	Mental
,	,	O
number	NN	Mental
of	IN	Mental
steps	NNS	Mental
,	,	O
frequency	NN	Mental
of	IN	Mental
lateral	JJ	Mental
line	NN	Mental
stepping-over	NN	Mental
,	,	Mental
and	CC	Mental
stops	NNS	Mental
were	VBD	O
recorded	VBN	O
.	.	O

Health	NNP	Physical
status	NN	Physical
was	VBD	O
assessed	VBN	O
using	VBG	O
standard	JJ	O
instruments	NNS	O
of	IN	O
geriatric	JJ	O
assessment	NN	O
.	.	O

The	DT	O
classification	NN	O
of	IN	O
Speechley	NNP	O
and	CC	O
Tinetti	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
define	VB	O
the	DT	O
participants	NNS	O
'	POS	O
degree	NN	O
of	IN	O
frailty	NN	O
.	.	O

RESULTS	NNP	O
Walking	JJ	Mental
time	NN	Mental
and	CC	O
number	NN	Mental
of	IN	Mental
steps	NNS	Mental
increased	VBN	O
significantly	RB	O
under	IN	O
both	DT	O
dual-task	JJ	O
conditions	NNS	O
compared	VBN	O
to	TO	O
walking	VBG	O
alone	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
without	IN	O
reaching	VBG	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
dual-task	JJ	O
conditions	NNS	O
(	(	O
respectively	RB	O
,	,	O
p	JJ	O
=	NN	O
0.131	CD	O
and	CC	O
p	VB	O
=	NNP	O
0.407	CD	O
)	)	O
,	,	O
whereas	JJ	O
lateral	JJ	Mental
gait	NN	Mental
instability	NN	Mental
(	(	O
frequency	NN	O
of	IN	O
lateral	JJ	O
line	NN	O
stepping-over	NN	O
)	)	O
increased	VBD	O
significantly	RB	O
in	IN	O
association	NN	O
with	IN	O
counting	VBG	O
backward	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
but	CC	O
not	RB	O
with	IN	O
the	DT	O
verbal	JJ	O
fluency	NN	O
task	NN	O
(	(	O
p	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
studied	JJ	O
sample	NN	O
of	IN	O
transitional	JJ	O
older	NN	O
adults	NNS	O
,	,	O
a	DT	O
walking-	JJ	Mental
associated	VBN	Mental
arithmetic	JJ	Mental
task	NN	Mental
significantly	RB	O
interfered	VBN	O
with	IN	O
lateral	JJ	Mental
gait	NN	Mental
stability	NN	Mental
,	,	O
whereas	IN	O
no	DT	O
lateral	JJ	O
gait	NN	O
deviations	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
association	NN	O
with	IN	O
a	DT	O
verbal	JJ	Mental
fluency	NN	Mental
task	NN	Mental
.	.	O

We	PRP	O
,	,	O
therefore	RB	O
,	,	O
suggest	VBP	O
that	IN	O
the	DT	O
choice	NN	O
of	IN	O
the	DT	O
attention-splitting	JJ	O
task	NN	O
in	IN	O
dual-task	JJ	O
gait	JJ	O
assessment	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
must	MD	O
be	VB	O
made	VBN	O
carefully	RB	O
.	.	O

Spinal	JJ	O
2-chloroprocaine	JJ	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
added	JJ	O
clonidine	NN	O
.	.	O

Preservative-free	JJ	O
2-chloroprocaine	JJ	O
(	(	O
2-CP	JJ	O
)	)	O
is	VBZ	O
being	VBG	O
investigated	VBN	O
for	IN	O
short-acting	JJ	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Clonidine	NNP	O
improves	VBZ	O
the	DT	O
quality	NN	O
of	IN	O
spinal	JJ	Physical
bupivacaine	NN	Physical
and	CC	O
ropivacaine	NN	Physical
,	,	O
but	CC	O
in	IN	O
traditional	JJ	O
doses	NNS	O
(	(	O
1-2	JJ	O
microg/kg	NN	O
)	)	O
it	PRP	O
produces	VBZ	O
systemic	JJ	O
side	NN	O
effects	NNS	O
.	.	O

It	PRP	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
combination	NN	O
with	IN	O
2-CP	JJ	O
.	.	O

In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
we	PRP	O
compared	VBN	O
spinal	JJ	O
2-CP	JJ	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
with	IN	O
and	CC	O
without	IN	O
clonidine	NN	O
(	(	O
15	CD	O
microg	NN	O
)	)	O
in	IN	O
eight	CD	O
volunteers	NNS	O
.	.	O

Pinprick	NNP	Others
anesthesia	NN	Others
,	,	Physical
motor	NN	Physical
strength	NN	Physical
,	,	Physical
tolerance	NN	Physical
to	TO	Physical
electrical	JJ	Physical
stimulation	NN	Physical
and	CC	Physical
thigh	JJ	Physical
tourniquet	NN	Physical
,	,	Physical
and	CC	Physical
time	NN	Others
to	TO	Others
ambulation	NN	Others
were	VBD	O
assessed	VBN	O
.	.	O

Peak	NNP	Others
block	NN	Others
height	NN	Others
was	VBD	O
similar	JJ	O
between	IN	O
2-CP	JJ	O
(	(	O
T8	NNP	O
[	NNP	O
range	NN	O
,	,	O
T6	NNP	O
to	TO	O
L2	NNP	O
]	NNP	O
)	)	O
and	CC	O
2-CP	JJ	O
with	IN	O
clonidine	NN	O
(	(	O
T8	NNP	O
[	NNP	O
range	NN	O
,	,	O
T4	NNP	O
to	TO	O
T11	NNP	O
]	NNP	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.57	CD	O
)	)	O
.	.	O

Sensory	JJ	Others
anesthesia	NN	Others
was	VBD	O
prolonged	VBN	O
with	IN	O
clonidine	NN	O
at	IN	O
L1	NNP	O
(	(	O
51	CD	O
+/-	JJ	O
23	CD	O
min	NN	O
versus	NN	O
76	CD	O
+/-	JJ	O
11	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
as	IN	O
was	VBD	O
complete	JJ	Others
block	NN	Others
regression	NN	Others
(	(	O
99	CD	O
+/-	JJ	O
18	CD	O
min	NN	O
versus	NN	O
131	CD	O
+/-	JJ	O
15	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Lower	JJR	Others
extremity	NN	Others
motor	NN	Others
blockade	NN	Others
was	VBD	O
increased	VBN	O
with	IN	O
clonidine	NN	O
(	(	O
return	NN	O
to	TO	O
baseline	VB	O
Bromage	NNP	O
score	NN	O
:	:	O
65	CD	O
+/-	JJ	O
13	CD	O
min	NN	O
versus	NN	O
79	CD	O
+/-	JJ	O
19	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
;	:	O
return	NN	O
to	TO	O
90	CD	O
%	NN	O
gastrocnemius	JJ	Physical
strength	NN	Physical
:	:	Physical
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

Clonidine	NNP	O
increased	VBD	O
tourniquet	JJ	Others
tolerance	NN	Others
from	IN	O
33	CD	O
to	TO	O
45	CD	O
min	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
and	CC	O
increased	JJ	O
time	NN	Others
to	TO	Others
ambulation	NN	Others
,	,	Others
spontaneous	JJ	Others
voiding	NN	Others
,	,	Others
and	CC	Others
discharge	NN	Others
(	(	O
99	CD	O
+/-	JJ	O
18	CD	O
min	NN	O
versus	NN	O
131	CD	O
+/-	JJ	O
15	CD	O
min	NN	O
for	IN	O
all	DT	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
hemodynamic	JJ	Physical
measurements	NNS	Physical
,	,	O
and	CC	O
no	DT	O
subject	NN	O
reported	VBD	O
transient	JJ	Physical
neurologic	NN	Physical
symptoms	NNS	Physical
.	.	Adverseeffect

We	PRP	O
conclude	VBP	O
that	IN	O
small-dose	JJ	O
clonidine	NN	O
increases	VBZ	O
the	DT	O
duration	NN	O
and	CC	O
improves	VBZ	O
the	DT	O
quality	NN	Others
of	IN	Others
2-CP	JJ	Others
spinal	JJ	Others
anesthesia	NN	Others
without	IN	O
systemic	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

A	DT	O
simplified	VBN	O
score	NN	O
for	IN	O
transfer	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
mechanical	JJ	O
ventilation	NN	O
to	TO	O
a	DT	O
long-term	JJ	O
care	NN	O
hospital	NN	O
.	.	O

BACKGROUND	NNP	O
Long-term	NNP	O
care	NN	O
hospitals	NNS	O
are	VBP	O
Medicare	NNP	O
providers	NNS	O
of	IN	O
postacute	NN	O
care	NN	O
that	WDT	O
have	VBP	O
a	DT	O
mean	JJ	O
length	NN	O
of	IN	O
stay	NN	O
of	IN	O
25	CD	O
days	NNS	O
or	CC	O
more	JJR	O
.	.	O

Early	JJ	O
identification	NN	O
and	CC	O
timely	JJ	O
transfer	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
mechanical	JJ	O
ventilation	NN	O
to	TO	O
such	JJ	O
hospitals	NNS	O
may	MD	O
improve	VB	O
the	DT	O
efficiency	NN	Others
of	IN	O
inpatient	NN	O
care	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
develop	VB	O
a	DT	O
predictive	JJ	O
model	NN	O
and	CC	O
a	DT	O
simplified	VBN	O
score	NN	O
for	IN	O
use	NN	O
on	IN	O
day	NN	O
7	CD	O
of	IN	O
hospitalization	NN	O
to	TO	O
assess	VB	O
whether	IN	O
a	DT	O
patient	NN	O
receiving	VBG	O
mechanical	JJ	O
ventilation	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
require	VB	O
an	DT	O
additional	JJ	O
25	CD	O
days	NNS	O
of	IN	O
hospitalization	NN	O
(	(	O
ie	JJ	O
,	,	O
would	MD	O
qualify	VB	O
for	IN	O
transfer	NN	O
to	TO	O
a	DT	O
long-term	JJ	O
care	NN	O
hospital	NN	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
retrospective	JJ	O
,	,	O
cross-sectional	JJ	O
study	NN	O
using	VBG	O
hospital	JJ	O
discharge	NN	O
and	CC	O
billing	NN	O
data	NNS	O
from	IN	O
the	DT	O
2005	CD	O
Nationwide	NNP	O
Inpatient	NNP	O
Sample	NNP	O
for	IN	O
54	CD	O
686	CD	O
Medicare	NNP	O
beneficiaries	NNS	O
admitted	VBD	O
to	TO	O
US	NNP	O
community	NN	O
hospitals	NNS	O
who	WP	O
met	VBD	O
the	DT	O
study	NN	O
's	POS	O
eligibility	NN	O
criteria	NNS	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
overall	JJ	Others
length	NN	Others
of	IN	Others
stay	NN	Others
(	(	O
?32	JJ	O
vs	NN	O
<	$	O
32	CD	O
days	NNS	O
)	)	O
.	.	O

Split-sample	JJ	O
validation	NN	O
was	VBD	O
used	VBN	O
.	.	O

Multivariable	JJ	O
survey-logistic	JJ	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
assess	VB	O
predictors	NNS	O
and	CC	O
probability	NN	O
of	IN	O
the	DT	O
outcome	NN	O
.	.	O

A	DT	O
simplified	JJ	O
score	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
the	DT	O
final	JJ	O
predictive	NN	O
model	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
discriminatory	JJ	O
power	NN	O
of	IN	O
the	DT	O
predictive	JJ	O
model	NN	O
was	VBD	O
0.75	CD	O
and	CC	O
that	IN	O
of	IN	O
the	DT	O
simplified	VBN	O
score	NN	O
was	VBD	O
0.72	CD	O
.	.	O

The	DT	O
model	NN	O
calibrated	VBN	O
well	RB	O
.	.	O

All	DT	O
predictors	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
associated	VBN	O
with	IN	O
a	DT	O
hospitalization	NN	O
of	IN	O
32	CD	O
days	NNS	O
or	CC	O
longer	JJR	O
;	:	O
having	VBG	O
a	DT	O
tracheostomy	NN	O
was	VBD	O
the	DT	O
strongest	JJS	O
predictor	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
4.74	CD	O
)	)	O
.	.	O

The	DT	O
simplified	JJ	O
scores	NNS	O
ranged	VBD	O
from	IN	O
-5	NN	O
to	TO	O
110	CD	O
points	NNS	O
and	CC	O
were	VBD	O
categorized	VBN	O
into	IN	O
3	CD	O
classes	NNS	O
of	IN	O
risk	NN	O
.	.	O

CONCLUSIONS	NNP	O
Efforts	NNPS	O
to	TO	O
aid	VB	O
discharge	NN	O
decision	NN	O
making	NN	O
and	CC	O
optimize	VB	O
hospital	JJ	O
resource	NN	O
planning	NN	O
could	MD	O
take	VB	O
advantage	NN	O
of	IN	O
our	PRP$	O
predictive	JJ	O
model	NN	O
and	CC	O
the	DT	O
simplified	JJ	O
scoring	NN	O
tool	NN	O
.	.	O

Treatment	NN	O
of	IN	O
renal	JJ	Physical
failure	NN	Physical
associated	VBN	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Plasmapheresis	NN	O
,	,	O
hemodialysis	NN	O
,	,	O
and	CC	O
chemotherapy	NN	O
.	.	O

The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
plasmapheresis	NN	O
in	IN	O
preventing	VBG	O
irreversible	JJ	Physical
renal	JJ	Physical
failure	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
and	CC	O
to	TO	O
study	VB	O
the	DT	O
renal	JJ	O
biopsy	NN	O
tissues	NNS	O
from	IN	O
such	JJ	O
patients	NNS	O
.	.	O

Twenty-one	CD	O
patients	NNS	O
with	IN	O
active	JJ	O
myeloma	NN	O
and	CC	O
progressive	JJ	O
renal	JJ	O
failure	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
,	,	O
forced	VBN	O
diuresis	NN	O
and	CC	O
chemotherapy	NN	O
(	(	O
10	CD	O
patients	NNS	O
)	)	O
,	,	O
and	CC	O
group	NN	O
2	CD	O
,	,	O
forced	VBN	O
diuresis	NN	O
,	,	O
chemotherapy	NN	O
,	,	O
and	CC	O
plasmapheresis	NN	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

Plasmapheresis	NN	O
and	CC	O
chemotherapy	NN	O
lowered	VBD	O
the	DT	O
serum	NN	Physical
myeloma	NN	Physical
protein	IN	Physical
value	NN	Physical
much	RB	O
more	RBR	O
rapidly	RB	O
than	IN	O
chemotherapy	VB	O
alone	JJ	O
.	.	O

Of	IN	O
5	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
oliguric	JJ	O
and	CC	O
undergoing	JJ	O
dialysis	NN	O
at	IN	O
presentation	NN	O
,	,	O
only	RB	O
3	CD	O
who	WP	O
were	VBD	O
treated	VBN	O
by	IN	O
plasmapheresis	NN	O
recovered	VBN	O
.	.	O

Of	IN	O
16	CD	O
polyuric	JJ	O
patients	NNS	O
,	,	O
5	CD	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
7	CD	O
in	IN	O
group	NN	O
2	CD	O
showed	VBD	O
improvement	NN	O
in	IN	O
renal	JJ	Physical
function	NN	Physical
.	.	O

The	DT	O
main	JJ	O
factor	NN	O
that	WDT	O
determined	VBD	O
irreversibility	NN	O
of	IN	O
renal	JJ	O
failure	NN	O
was	VBD	O
the	DT	O
severity	NN	O
of	IN	O
myeloma	NN	O
cast	NN	O
formation	NN	O
.	.	O

Hunter	NNP	O
DBT	NNP	O
project	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
dialectical	JJ	O
behaviour	NN	O
therapy	NN	O
in	IN	O
women	NNS	O
with	IN	O
borderline	JJ	O
personality	NN	O
disorder	NN	O
.	.	O

OBJECTIVE	JJ	O
Deliberate	NNP	O
self-harm	NN	O
(	(	O
DSH	NNP	O
)	)	O
,	,	O
general	JJ	O
hospital	NN	O
admission	NN	O
and	CC	O
psychiatric	JJ	O
hospital	NN	O
admission	NN	O
are	VBP	O
common	JJ	O
in	IN	O
women	NNS	O
meeting	VBG	O
criteria	NNS	O
for	IN	O
borderline	NN	O
personality	NN	O
disorder	NN	O
(	(	O
BPD	NNP	O
)	)	O
.	.	O

Dialectical	JJ	O
behaviour	NN	O
therapy	NN	O
(	(	O
DBT	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
DSH	NNP	O
and	CC	O
hospitalization	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
73	CD	O
female	JJ	O
subjects	NNS	O
meeting	VBG	O
criteria	NNS	O
for	IN	O
BPD	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
intention-to-treat	JJ	O
analyses	NNS	O
and	CC	O
per-protocol	JJ	O
analyses	NNS	O
.	.	O

The	DT	O
intervention	NN	O
was	VBD	O
DBT	NNP	O
and	CC	O
the	DT	O
control	NN	O
condition	NN	O
was	VBD	O
treatment	NN	O
as	IN	O
usual	JJ	O
plus	CC	O
waiting	JJ	O
list	NN	O
for	IN	O
DBT	NNP	O
(	(	O
TAU+WL	NNP	O
)	)	O
,	,	O
with	IN	O
outcomes	NNS	O
measured	VBN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
were	VBD	O
differences	NNS	O
in	IN	O
proportions	NNS	O
and	CC	O
event	NN	O
rates	NNS	O
of	IN	O
:	:	O
any	DT	O
DSH	NNP	O
;	:	O
general	JJ	Others
hospital	NN	Others
admission	NN	Others
for	IN	Others
DSH	NNP	Others
and	CC	O
any	DT	O
psychiatric	JJ	Others
admission	NN	Others
;	:	O
and	CC	O
mean	VB	O
difference	NN	O
in	IN	O
length	NN	O
of	IN	O
stay	NN	O
for	IN	O
any	DT	O
hospitalization	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
disability	NN	Others
and	CC	Others
quality	NN	Others
of	IN	Others
life	NN	Others
measures	NNS	Others
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
DSH	NNP	Physical
and	CC	Physical
hospitalizations	NNS	Physical
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	Physical
in	IN	O
DSH	NNP	Others
,	,	Others
hospital	JJ	Others
admissions	NNS	Others
or	CC	Others
length	NN	Others
of	IN	Others
stay	NN	Others
in	IN	O
hospital	NN	O
between	IN	O
groups	NNS	O
.	.	O

Disability	NNP	Physical
(	(	Physical
days	NNS	Physical
spent	VBN	Physical
in	IN	Physical
bed	NN	Physical
)	)	Physical
and	CC	O
quality	NN	Others
of	IN	Others
life	NN	Others
(	(	Others
Physical	NNP	Others
,	,	Others
Psychological	NNP	Others
and	CC	Others
Environmental	NNP	Others
domains	NNS	Others
)	)	Others
were	VBD	O
significantly	RB	O
improved	VBN	O
for	IN	O
the	DT	O
DBT	NNP	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
DBT	NNP	O
produced	VBD	O
non-significant	JJ	O
reductions	NNS	O
in	IN	O
DSH	NNP	Mental
and	CC	O
hospitalization	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
the	DT	O
TAU+WL	NNP	O
control	NN	O
,	,	O
due	JJ	O
in	IN	O
part	NN	O
to	TO	O
the	DT	O
lower	JJR	O
than	IN	O
expected	VBN	O
rates	NNS	O
of	IN	O
hospitalization	NN	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
.	.	O

Nevertheless	NNP	O
,	,	O
DBT	NNP	O
showed	VBD	O
significant	JJ	O
benefits	NNS	O
for	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
of	IN	O
improved	JJ	O
disability	NN	Others
and	CC	Others
quality	NN	Others
of	IN	Others
life	NN	Others
scores	NNS	Others
,	,	O
a	DT	O
clinically	RB	O
useful	JJ	O
result	NN	O
that	WDT	O
is	VBZ	O
also	RB	O
in	IN	O
keeping	VBG	O
with	IN	O
the	DT	O
theoretical	JJ	O
constructs	NNS	O
of	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
DBT	NNP	O
.	.	O

Randomized	VBN	O
trial	NN	O
comparing	VBG	O
induction	NN	O
chemotherapy	NN	O
versus	NN	O
induction	NN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

European	JJ	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
.	.	O

PURPOSE	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
European	NNP	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
(	(	O
ELCWP	NNP	O
)	)	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
to	TO	O
determine	VB	O
if	IN	O
maintenance	NN	O
chemotherapy	NN	O
with	IN	O
12	CD	O
courses	NNS	O
of	IN	O
etoposide	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
vindesine	NN	O
(	(	O
3	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
3	CD	O
)	)	O
could	MD	O
improve	VB	O
progression-free	JJ	Mortality
survival	NN	Mortality
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
six	CD	O
courses	NNS	O
of	IN	O
induction	NN	O
chemotherapy	NN	O
with	IN	O
ifosfamide	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
an	DT	O
anthracycline	NN	O
(	(	O
doxorubicin	NN	O
or	CC	O
epirubicin	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
235	CD	O
eligible	JJ	O
patients	NNS	O
initially	RB	O
registered	VBD	O
,	,	O
91	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
maintenance	NN	O
therapy	NN	O
,	,	O
including	VBG	O
seven	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
no	RB	O
longer	RBR	O
responding	VBG	O
.	.	O

Among	IN	O
84	CD	O
randomized	JJ	O
responders	NNS	O
,	,	O
progression-free	JJ	Mortality
survival	NN	Mortality
was	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
by	IN	O
maintenance	NN	O
therapy	NN	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
(	(	O
maintenance	NN	O
v	IN	O
follow-up	JJ	O
)	)	O
of	IN	O
25	CD	O
versus	NNS	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
second	JJ	O
randomization	NN	O
,	,	O
but	CC	O
survival	NN	Mortality
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
of	IN	O
48	CD	O
and	CC	O
38	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
multi-variate	JJ	O
analysis	NN	O
that	WDT	O
took	VBD	O
into	IN	O
account	NN	Physical
disease	NN	Physical
extent	NN	Physical
,	,	Physical
maintenance	NN	Physical
therapy	NN	Physical
,	,	Physical
Karnofsky	NNP	Physical
performance	NN	Physical
status	NN	Physical
(	(	Physical
PS	NNP	Physical
)	)	Physical
,	,	Physical
and	CC	Physical
absolute	JJ	Physical
dose-intensity	NN	Physical
(	(	Physical
ADI	NNP	Physical
)	)	Physical
of	IN	Physical
anthracycline	NN	Physical
given	VBN	O
during	IN	O
induction	NN	O
,	,	O
limited	JJ	Physical
disease	NN	Physical
(	(	Physical
LD	NNP	Physical
)	)	Physical
and	CC	Physical
maintenance	NN	Physical
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
independent	JJ	O
positive	JJ	O
predictors	NNS	O
of	IN	O
survival	NN	Mortality
.	.	Mortality

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
responding	VBG	O
patients	NNS	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
SCLC	NNP	O
.	.	O

Improvement	NN	O
in	IN	O
sensory	JJ	O
impairment	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
following	VBG	O
treatment	NN	O
with	IN	O
an	DT	O
original	JJ	O
Qigong	NNP	O
massage	NN	O
methodology	NN	O
.	.	O

In	IN	O
clinical	JJ	O
research	NN	O
,	,	O
sensory	JJ	O
impairment	NN	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
core	NN	O
deficits	NNS	O
in	IN	O
autism	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
impaired	JJ	O
socialization	NN	O
,	,	O
behavioral	JJ	O
disturbances	NNS	O
and	CC	O
bowel	NN	O
and	CC	O
sleep	JJ	O
problems	NNS	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Cignolini	NNP	O
methodology	NN	O
,	,	O
an	DT	O
original	JJ	O
Qigong	NNP	O
massage	NN	O
methodology	NN	O
,	,	O
in	IN	O
treating	VBG	O
sensory	JJ	O
impairment	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
small	JJ	O
,	,	O
controlled	VBN	O
study	NN	O
.	.	O

Thirteen	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
three	CD	O
and	CC	O
six	CD	O
received	VBD	O
daily	JJ	O
treatment	NN	O
according	VBG	O
to	TO	O
the	DT	O
methodology	NN	O
for	IN	O
5	CD	O
months	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
untreated	JJ	O
children	NNS	O
,	,	O
treated	VBD	O
children	NNS	O
experienced	VBD	O
significant	JJ	O
improvement	NN	O
of	IN	O
their	PRP$	O
sensory	JJ	Mental
impairment	NN	Mental
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
demonstrated	VBD	O
increased	VBN	O
social	JJ	Mental
skills	NNS	Mental
(	(	O
p	JJ	O
<	NNP	O
0.04	CD	O
)	)	O
and	CC	O
basic	JJ	Mental
living	NN	Mental
skills	NNS	Mental
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
on	IN	O
standardized	JJ	O
measures	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
all	DT	O
of	IN	O
the	DT	O
children	NNS	O
with	IN	O
bowel	NN	O
and	CC	O
sleep	JJ	O
abnormalities	NNS	O
demonstrated	VBD	O
improvement	NN	O
after	IN	O
treatment	NN	O
.	.	O

Intrathecal	JJ	O
lentivirus-mediated	JJ	O
transfer	NN	O
of	IN	O
interleukin-10	JJ	O
attenuates	NNS	O
chronic	JJ	Others
constriction	NN	Others
injury-induced	JJ	Others
neuropathic	JJ	Others
pain	NN	Others
through	IN	O
modulation	NN	O
of	IN	O
spinal	JJ	O
high-mobility	NN	O
group	NN	O
box	VBZ	O
1	CD	O
in	IN	O
rats	NNS	O
.	.	O

BACKGROUND	NNP	O
Neuropathic	NNP	O
pain	NN	O
is	VBZ	O
a	DT	O
complex	JJ	O
state	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
that	WDT	O
is	VBZ	O
usually	RB	O
accompanied	VBN	O
by	IN	O
peripheral	JJ	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
damage	NN	O
or	CC	O
dysfunction	NN	O
.	.	O

Previous	JJ	O
studies	NNS	O
have	VBP	O
indicated	VBN	O
that	DT	O
neuroinflammation	NN	O
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
contributor	NN	O
to	TO	O
neuropathological	JJ	O
and	CC	O
behavioral	JJ	O
abnormalities	NNS	O
.	.	O

A	DT	O
series	NN	O
of	IN	O
early	JJ	O
inflammatory	NN	O
markers	NNS	O
,	,	O
such	JJ	O
as	IN	O
IL-1	NNP	O
,	,	O
TNF-?	NNP	O
,	,	O
and	CC	O
IFN-?	NNP	O
,	,	O
and	CC	O
advanced	VBD	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
such	JJ	O
as	IN	O
high-mobility	NN	O
group	NN	O
box	VBZ	O
1	CD	O
(	(	O
HMGB1	NNP	O
)	)	O
,	,	O
are	VBP	O
involved	VBN	O
in	IN	O
neuroinflammation	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
controlled	VBD	O
animal	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
lentivirus	NN	O
delivering	VBG	O
human	JJ	O
IL-10	NNP	O
(	(	O
LV/hIL-10	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
intrathecally	RB	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
IL-10	NNP	O
on	IN	O
allodynia	NN	O
and	CC	O
hyperalgesia	NN	O
in	IN	O
a	DT	O
chronic	JJ	O
constriction	NN	O
injury-induced	JJ	O
(	(	O
CCI	NNP	O
)	)	O
rat	VBP	O
model	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
.	.	O

METHODS	NNP	O
Sprague-Dawley	NNP	O
rats	NNS	O
weighting	VBG	O
260	CD	O
-	:	O
320	CD	O
g	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
Sham	NNP	O
(	(	O
Sham	NNP	O
)	)	O
,	,	O
Group	NNP	O
CCI?Normal	NNP	O
Saline	NNP	O
(	(	O
NS	NNP	O
)	)	O
,	,	O
Group	NNP	O
CCI?LV/hIL-10	NNP	O
(	(	O
LV/hIL-10	NNP	O
)	)	O
,	,	O
and	CC	O
Group	NNP	O
CCI?LV/control	NNP	O
(	(	O
vector	NN	O
)	)	O
.	.	O

Rats	NNPS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
intrathecally	RB	O
delivered	VBN	O
with	IN	O
NS	NNP	O
,	,	O
LV/control	NNP	O
,	,	O
or	CC	O
recombinant	JJ	O
vector	NN	O
LV/hIL-10	NNP	O
in	IN	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
10	CD	O
?l	NN	O
.	.	O

Paw	NNP	O
withdrawal	VBD	O
mechanical	JJ	O
thresholds	NNS	O
(	(	O
PWMT	NNP	O
)	)	O
and	CC	O
paw	$	O
withdrawal	NN	O
thermal	JJ	O
latency	NN	O
PWTL	NNP	O
were	VBD	O
measured	VBN	O
one	CD	O
day	NN	O
before	IN	O
CCI	NNP	O
(	(	O
baseline	NN	O
)	)	O
and	CC	O
0	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
intrathecal	JJ	O
administration	NN	O
.	.	O

Cerebrospinal	JJ	O
fluid	NN	O
(	(	O
CSF	NNP	O
)	)	O
samples	NNS	O
were	VBD	O
collected	VBN	O
during	IN	O
surgical	JJ	O
plane	NN	O
anesthesia	NN	O
and	CC	O
the	DT	O
collected	JJ	O
CSF	NNP	O
samples	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
assay	VB	O
for	IN	O
human	JJ	O
IL-10	NNP	O
,	,	O
rat	VBZ	O
IL-1?	NNP	O
,	,	O
rat	VBZ	O
IL-6	NNP	O
,	,	O
and	CC	O
rat	VB	O
TNF-?	JJ	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

Animals	NNS	O
were	VBD	O
sacrificed	VBN	O
and	CC	O
the	DT	O
L4-5	NNP	O
lumbar	NN	O
segment	NN	O
of	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
was	VBD	O
removed	VBN	O
for	IN	O
determination	NN	O
of	IN	O
green	JJ	O
fluorescent	NN	O
protein	NN	O
(	(	O
GFP	NNP	O
)	)	O
expression	NN	O
.	.	O

Immunohistochemical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
anti	JJ	O
HMGB1	NNP	O
antibodies	NNS	O
and	CC	O
the	DT	O
expression	NN	O
of	IN	O
HMGB1	NNP	O
protein	NN	O
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
western	JJ	O
blot	NN	O
analysis	NN	O
after	IN	O
intrathecal	JJ	O
delivery	NN	O
(	(	O
n	JJ	O
=	RB	O
8	CD	O
each	DT	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
show	VBP	O
that	DT	O
intrathecal	JJ	O
LV/hIL-10	NNP	O
reverses	NNS	O
enhanced	VBD	O
pain	NN	O
states	NNS	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
increased	VBN	O
level	NN	O
of	IN	O
HMGB1	NNP	O
exhibited	VBD	O
in	IN	O
a	DT	O
late	JJ	O
stage	NN	O
of	IN	O
CCI	NNP	O
was	VBD	O
inhibited	VBN	O
by	IN	O
exogenous	JJ	O
overexpression	NN	O
of	IN	O
hIL-10	NN	O
in	IN	O
the	DT	O
CCI	NNP	O
model	NN	O
.	.	O

Expression	NN	O
of	IN	O
HMGB1	NNP	O
,	,	O
RAGE	NNP	O
,	,	O
and	CC	O
pAkt	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
CCI-induced	NNP	O
rats	NNS	O
treated	VBD	O
with	IN	O
LV/hIL-10	NNP	O
than	IN	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
LV/control	NNP	O
(	(	O
vector	NN	O
)	)	O
or	CC	O
saline	NN	O
(	(	O
NS	NNP	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
showed	VBD	O
that	IN	O
IL-10	NNP	O
inhibits	VBZ	O
activation	NN	O
of	IN	O
the	DT	O
inflammatory	JJ	O
HMGB1-RAGE	NNP	O
pathway	NN	O
in	IN	O
the	DT	O
CCI	NNP	O
rat	NN	O
model	NN	O
.	.	O

LIMITATIONS	NNP	O
Further	NNP	O
experimental	JJ	O
investigations	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
clarify	VB	O
the	DT	O
specific	JJ	O
biological	JJ	O
roles	NNS	O
played	VBN	O
by	IN	O
HMGB1	NNP	O
in	IN	O
IL-10-mediated	NNP	O
regulation	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	DT	O
intrathecal	JJ	O
lentiviral-mediated	JJ	O
transfer	NN	O
of	IN	O
IL-10	NNP	O
attenuates	VBZ	O
CCI-induced	NNP	O
neuropathic	JJ	O
pain	NN	O
in	IN	O
rats	NNS	O
.	.	O

The	DT	O
anti-thermal	JJ	O
hyperalgesia	NN	O
and	CC	O
anti-mechanical	JJ	O
allodynia	NN	O
may	MD	O
be	VB	O
partly	RB	O
attributable	JJ	O
to	TO	O
the	DT	O
decreased	JJ	O
expression	NN	O
of	IN	O
HMGB1	NNP	O
and	CC	O
inhibition	NN	O
of	IN	O
HMGB1-RAGE	NNP	O
pathway	NN	O
.	.	O

PDE5	NNP	O
inhibition	NN	O
with	IN	O
sildenafil	JJ	O
improves	NNS	O
left	VBD	O
ventricular	JJ	O
diastolic	JJ	O
function	NN	O
,	,	O
cardiac	JJ	O
geometry	NN	O
,	,	O
and	CC	O
clinical	JJ	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
systolic	JJ	O
heart	NN	O
failure	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
,	,	O
a	DT	O
defective	JJ	O
nitric	JJ	O
oxide	IN	O
signaling	VBG	O
is	VBZ	O
involved	VBN	O
in	IN	O
left	JJ	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
diastolic	NN	O
abnormalities	NNS	O
and	CC	O
remodeling	VBG	O
.	.	O

PDE5	NNP	O
inhibition	NN	O
,	,	O
by	IN	O
blocking	VBG	O
degradation	NN	O
of	IN	O
nitric	JJ	O
oxide	IN	O
second-messenger	JJ	O
cyclic	JJ	O
guanosine	NN	O
monophosphate	NN	O
,	,	O
might	MD	O
be	VB	O
beneficial	JJ	O
.	.	O

In	IN	O
a	DT	O
cohort	NN	O
of	IN	O
systolic	JJ	O
HF	NNP	O
patients	NNS	O
,	,	O
we	PRP	O
tested	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
PDE5	NNP	O
inhibition	NN	O
(	(	O
sildenafil	NN	O
)	)	O
on	IN	O
LV	NNP	O
ejection	NN	O
fraction	NN	O
,	,	O
diastolic	JJ	O
function	NN	O
,	,	O
cardiac	JJ	O
geometry	NN	O
,	,	O
and	CC	O
clinical	JJ	O
status	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Forty-five	JJ	O
HF	NNP	O
patients	NNS	O
(	(	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
class	NN	O
II-III	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
sildenafil	VB	O
(	(	O
50	CD	O
mg	NN	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
,	,	O
with	IN	O
assessment	NN	O
(	(	O
6	CD	O
months	NNS	O
and	CC	O
1	CD	O
year	NN	O
)	)	O
of	IN	O
LV	NNP	Physical
ejection	NN	Physical
fraction	NN	Physical
,	,	Physical
diastolic	JJ	Physical
function	NN	Physical
,	,	Physical
geometry	NN	Physical
,	,	Physical
cardiopulmonary	JJ	Physical
exercise	NN	Physical
performance	NN	Physical
,	,	Physical
and	CC	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
.	.	Physical

In	IN	O
the	DT	O
sildenafil	NN	O
group	NN	O
only	RB	O
,	,	O
at	IN	O
6	CD	O
months	NNS	O
and	CC	O
1	CD	O
year	NN	O
,	,	O
LV	NNP	Physical
ejection	NN	Physical
fraction	NN	Physical
,	,	Physical
early	JJ	Physical
diastolic	JJ	Physical
tissue	NN	Physical
Doppler	NNP	Physical
velocities	NNS	Physical
(	(	Physical
E	NNP	Physical
'	POS	Physical
)	)	Physical
at	IN	Physical
the	DT	Physical
mitral	JJ	Physical
lateral	JJ	Physical
(	(	O
from	IN	O
4.62	CD	O
to	TO	O
5.20	CD	O
and	CC	O
5.19	CD	O
m/s	NN	O
)	)	O
and	CC	O
septal	JJ	Physical
(	(	O
from	IN	O
4.71	CD	O
to	TO	O
5.23	CD	O
and	CC	O
5.24	CD	O
m/s	NN	O
)	)	O
annuli	VBZ	Physical
significantly	RB	Physical
increased	VBN	O
,	,	O
whereas	IN	O
the	DT	O
ratio	NN	O
of	IN	O
early	JJ	O
transmitral	NN	O
(	(	O
E	NNP	O
)	)	O
to	TO	O
E	NNP	O
'	POS	O
lateral	JJ	O
decreased	VBN	O
(	(	O
from	IN	O
13.1	CD	O
to	TO	O
9.8	CD	O
to	TO	O
9.4	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Changes	NNS	O
were	VBD	O
accompanied	VBN	O
by	IN	O
a	DT	O
reverse	NN	Physical
remodeling	NN	Physical
of	IN	Physical
left	JJ	Physical
atrial	JJ	Physical
volume	NN	Physical
index	NN	Physical
(	(	O
from	IN	O
32.0	CD	O
to	TO	O
29.0	CD	O
and	CC	O
29.1	CD	O
mL/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
LV	NNP	Physical
mass	NNP	Physical
index	NN	Physical
(	(	O
from	IN	O
148.0	CD	O
to	TO	O
130.0	CD	O
and	CC	O
128.0	CD	O
g/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
sildenafil	JJ	O
improved	VBN	O
exercise	NN	Physical
performance	NN	Physical
(	(	Physical
peak	JJ	Physical
Vo	NNP	Physical
(	(	Physical
2	CD	Physical
)	)	Physical
)	)	Physical
,	,	Physical
ventilation	NN	Physical
efficiency	NN	Physical
(	(	Physical
ventilation	NN	Physical
to	TO	Physical
CO	NNP	Physical
(	(	Physical
2	CD	Physical
)	)	Physical
production	NN	Physical
slope	NN	Physical
)	)	Physical
,	,	Physical
and	CC	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Minor	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
noted	VBN	O
:	:	O
flushing	NN	Physical
in	IN	O
4	CD	O
and	CC	O
headache	NN	Physical
in	IN	O
2	CD	O
treated	JJ	O
patients	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Findings	NNP	O
confirm	NN	O
that	IN	O
in	IN	O
HF	NNP	O
,	,	O
sildenafil	NN	O
improves	VBZ	O
functional	JJ	Others
capacity	NN	Others
and	CC	Others
clinical	JJ	Others
status	NN	Others
and	CC	O
provide	VB	O
the	DT	O
first	JJ	O
human	JJ	O
evidence	NN	O
that	IN	O
LV	NNP	Physical
diastolic	JJ	Physical
function	NN	Physical
and	CC	O
cardiac	JJ	Physical
geometry	NN	Physical
are	VBP	O
additional	JJ	O
targets	NNS	O
of	IN	O
benefits	NNS	O
related	VBN	O
to	TO	O
chronic	JJ	O
PDE5	NNP	O
inhibition	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
enterostatin	JJ	O
intake	NN	O
on	IN	O
food	NN	Physical
intake	NN	Physical
and	CC	Physical
energy	NN	Physical
expenditure	NN	Physical
.	.	Physical

Enterostatin	NNP	O
(	(	O
ENT	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
inhibit	VB	O
food	NN	O
intake	NN	O
and	CC	O
selectively	RB	O
inhibit	VB	O
fat	JJ	O
intake	NN	O
in	IN	O
rats	NNS	O
.	.	O

Both	DT	O
peripheral	JJ	O
and	CC	O
central	JJ	O
mechanisms	NNS	O
have	VBP	O
been	VBN	O
proposed	VBN	O
.	.	O

It	PRP	O
also	RB	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
ENT	NNP	O
may	MD	O
increase	VB	O
thermogenesis	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
ENT	NNP	O
administration	NN	O
on	IN	O
food	NN	Mental
intake	NN	Mental
,	,	O
energy	NN	Physical
expenditure	NN	Physical
and	CC	O
body	NN	Physical
weight	NN	Physical
in	IN	O
subjects	NNS	O
with	IN	O
a	DT	O
preference	NN	O
for	IN	O
a	DT	O
high-fat	JJ	O
diet	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
and	CC	O
crossover	JJ	O
design	NN	O
,	,	O
nine	CD	O
female	NN	O
and	CC	O
three	CD	O
male	NN	O
healthy	JJ	O
subjects	NNS	O
(	(	O
age	NN	O
34	CD	O
(	(	O
sd	VB	O
11	CD	O
)	)	O
years	NNS	O
,	,	O
BMI	NNP	O
24.5	CD	O
(	(	O
sd	VB	O
2.5	CD	O
)	)	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
with	IN	O
a	DT	O
preference	NN	O
for	IN	O
a	DT	O
high-fat	JJ	O
diet	NN	O
ingested	VBN	O
ENT	NNP	O
(	(	O
3	CD	O
x	RB	O
15	CD	O
mg/d	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
PLA	NNP	O
)	)	O
while	IN	O
consuming	VBG	O
a	DT	O
high-fat	JJ	O
diet	JJ	O
ad	NN	O
libitum	NN	O
for	IN	O
4	CD	O
d.	NNS	O
Eight	JJ	O
subjects	NNS	O
ended	VBD	O
each	DT	O
intervention	NN	O
with	IN	O
a	DT	O
36	CD	O
h	NN	O
stay	NN	O
in	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
,	,	O
continuing	VBG	O
the	DT	O
diet	JJ	O
and	CC	O
treatment	NN	O
.	.	O

Body-weight	JJ	Physical
loss	NN	Physical
was	VBD	O
significant	JJ	O
(	(	O
ENT	NNP	O
0.8	CD	O
(	(	O
se	VB	O
0.3	CD	O
)	)	O
kg	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
;	:	O
PLA	NNP	O
1.3	CD	O
(	(	O
se	VB	O
0.3	CD	O
)	)	O
kg	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
different	JJ	O
between	IN	O
treatments	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatments	NNS	O
in	IN	O
total	JJ	Physical
energy	NN	Physical
intake	NN	Physical
(	(	O
ENT	NNP	O
37.1	CD	O
(	(	O
se	VB	O
2.6	CD	O
)	)	O
,	,	O
PLA	NNP	O
35.9	CD	O
(	(	O
se	VB	O
3.2	CD	O
)	)	O
MJ	NNP	O
)	)	O
,	,	O
macronutrient	JJ	Physical
composition	NN	Physical
,	,	Physical
hunger	NN	Physical
,	,	Physical
satiety	NN	Physical
and	CC	Physical
hedonic	JJ	Physical
scores	NNS	Physical
during	IN	O
the	DT	O
4	CD	O
d	JJ	O
high-fat	JJ	O
diet	NN	O
.	.	O

Energy	NNP	Others
expenditure	NN	Others
(	(	O
24	CD	O
h	NN	O
)	)	O
(	(	O
ENT	$	O
9.6	CD	O
(	(	O
se	VB	O
0.4	CD	O
)	)	O
,	,	O
PLA	NNP	O
9.5	CD	O
(	(	O
se	VB	O
0.4	CD	O
)	)	O
MJ	NNP	O
)	)	O
,	,	O
sleeping	VBG	Physical
and	CC	Physical
resting	VBG	Physical
metabolic	JJ	Physical
rate	NN	Physical
,	,	Physical
diet-induced	JJ	Physical
thermogenesis	NN	Physical
,	,	Physical
activity-induced	JJ	Physical
energy	NN	Physical
expenditure	NN	Physical
and	CC	Physical
24	CD	Physical
h	NN	Physical
RQ	NNP	Physical
(	(	O
ENT	NNP	O
0.77	CD	O
(	(	O
se	VB	O
0.01	CD	O
)	)	O
,	,	O
PLA	NNP	O
0.77	CD	O
(	(	O
se	VB	O
0.01	CD	O
)	)	O
)	)	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
treatments	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
oral	JJ	O
ENT	NNP	O
administration	NN	O
did	VBD	O
not	RB	O
affect	VB	O
food	NN	Mental
intake	NN	Mental
,	,	O
energy	NN	Physical
expenditure	NN	Physical
or	CC	O
body	NN	Physical
weight	NN	Physical
in	IN	O
subjects	NNS	O
with	IN	O
a	DT	O
preference	NN	O
for	IN	O
a	DT	O
high-fat	JJ	O
diet	JJ	O
experiencing	VBG	O
a	DT	O
negative	JJ	O
energy	NN	O
and	CC	O
fat	JJ	O
balance	NN	O
.	.	O

Citalopram	NNP	O
for	IN	O
post-stroke	JJ	O
pathological	JJ	O
crying	NN	O
.	.	O

Post-stroke	NNP	O
pathological	JJ	O
crying	NN	O
is	VBZ	O
a	DT	O
distressing	VBG	O
condition	NN	O
in	IN	O
which	WDT	O
episodes	VBZ	O
occur	VBP	O
in	IN	O
response	NN	O
to	TO	O
minor	VB	O
stimuli	NNS	O
without	IN	O
associated	VBN	O
mood	NN	O
changes	NNS	O
.	.	O

There	EX	O
is	VBZ	O
preliminary	JJ	O
evidence	NN	O
of	IN	O
disturbed	JJ	O
serotoninergic	JJ	O
neurotransmission	NN	O
in	IN	O
such	JJ	O
cases	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
selective	JJ	Physical
serotonin	NN	Physical
reuptake	NN	Physical
inhibitor	NN	Physical
citalopram	NN	Physical
on	IN	O
uncontrolled	JJ	Mental
crying	NN	Mental
in	IN	O
stroke	NN	O
patients	NNS	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

16	CD	O
consecutive	JJ	O
patients	NNS	O
(	(	O
median	JJ	O
age	NN	O
58.5	CD	O
years	NNS	O
,	,	O
range	VB	O
40-83	JJ	O
)	)	O
entered	VBD	O
the	DT	O
9-week	JJ	O
study	NN	O
a	DT	O
median	NN	O
of	IN	O
168	CD	O
days	NNS	O
(	(	O
range	VB	O
6-913	NNP	O
)	)	O
post	NN	O
stroke	NN	O
and	CC	O
were	VBD	O
treated	VBN	O
with	IN	O
citalopram	JJ	O
10-20	JJ	O
mg	NNS	O
daily	RB	O
for	IN	O
3	CD	O
weeks	NNS	O
.	.	O

Crying	VBG	Mental
history	NN	Mental
was	VBD	O
determined	VBN	O
from	IN	O
semistructured	VBN	O
interviews	NNS	O
and	CC	O
from	IN	O
diaries	NNS	O
kept	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
.	.	O

Psychiatric	NNP	Mental
assessment	NN	Mental
was	VBD	O
made	VBN	O
with	IN	O
the	DT	O
Hamilton	NNP	Mental
depression	NN	Mental
scale	NN	Mental
(	(	O
HDS	NNP	O
)	)	O
,	,	O
and	CC	O
unwanted	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
measured	VBN	O
with	IN	O
the	DT	O
UKU	NNP	Adverseeffect
side-effect	JJ	Adverseeffect
scale	NN	Adverseeffect
.	.	O

In	IN	O
13	CD	O
patients	NNS	O
in	IN	O
whom	WP	O
frequency	NN	Mental
of	IN	Mental
crying	NN	Mental
could	MD	O
be	VB	O
assessed	VBN	O
,	,	O
the	DT	O
number	NN	Mental
of	IN	Mental
daily	JJ	Mental
crying	VBG	Mental
episodes	NNS	Mental
decreased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
in	IN	O
all	DT	O
cases	NNS	O
during	IN	O
citalopram	JJ	O
treatment	NN	O
vs	NN	O
2	CD	O
patients	NNS	O
during	IN	O
placebo	JJ	O
treatment	NN	O
(	(	O
p	JJ	O
<	NN	O
0.005	CD	O
,	,	O
McNemar	NNP	O
's	POS	O
test	NN	O
)	)	O
,	,	O
the	DT	O
effect	NN	O
being	VBG	O
rapid	JJ	O
(	(	O
1-3	JJ	O
days	NNS	O
)	)	O
and	CC	O
pronounced	VBN	O
in	IN	O
11	CD	O
(	(	O
73	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
concomitant	JJ	O
significant	JJ	O
decrease	NN	Mental
in	IN	Mental
depression	NN	Mental
rating	NN	Mental
from	IN	O
HDS	NNP	O
8.9	CD	O
to	TO	O
5.3	CD	O
(	(	O
p	NN	O
<	VBZ	O
0.005	CD	O
,	,	O
Wilcoxon	NNP	O
's	POS	O
test	NN	O
)	)	O
.	.	O

Citalopram	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
the	DT	O
few	JJ	O
side-effects	NNS	O
being	VBG	O
mild	JJ	O
and	CC	O
transient	JJ	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
serotoninergic	JJ	O
neurotransmission	NN	O
plays	VBZ	O
an	DT	O
important	JJ	O
part	NN	O
in	IN	O
post-stroke	JJ	O
pathological	JJ	O
crying	NN	O
and	CC	O
that	DT	O
citalopram	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
.	.	O

Cycle	NNP	O
control	NN	O
with	IN	O
oral	JJ	O
contraceptives	NNS	O
containing	VBG	O
20	CD	O
micrograms	NNS	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
randomized	VBD	O
comparison	NN	O
of	IN	O
levonorgestrel/ethinyl	JJ	O
estradiol	NN	O
(	(	O
100	CD	O
micrograms/20	NN	O
micrograms	NNS	O
)	)	O
and	CC	O
norethindrone/ethinyl	JJ	O
estradiol	NN	O
(	(	O
1000	CD	O
micrograms/20	NN	O
micrograms	NNS	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
open-label	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OC	NNP	O
)	)	O
containing	VBG	O
100	CD	O
micrograms	NNS	O
levonorgestrel	NN	O
(	(	O
LNG	NNP	O
)	)	O
/20	VBP	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
(	(	O
EE	NNP	O
)	)	O
(	(	O
Aless/Loette	NNP	O
)	)	O
and	CC	O
1000	CD	O
micrograms	NNS	O
norethindrone	JJ	O
acetate	NN	O
(	(	O
NETA	NNP	O
)	)	O
/20	VBP	O
micrograms	NNS	O
EE	NNP	O
(	(	O
Loestrin	NNP	O
Fe	NNP	O
1/20	CD	O
)	)	O
on	IN	O
menstrual	JJ	O
cycle	NN	O
control	NN	O
over	IN	O
four	CD	O
cycles	NNS	O
of	IN	O
use	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
84	CD	O
evaluable	JJ	O
women	NNS	O
provided	VBD	O
274	CD	O
cycles	NNS	O
of	IN	O
exposure	NN	O
in	IN	O
the	DT	O
LNG/EE	NNP	O
group	NN	O
,	,	O
and	CC	O
89	CD	O
women	NNS	O
provided	VBD	O
289	CD	O
cycles	NNS	O
of	IN	O
exposure	NN	O
in	IN	O
the	DT	O
NETA/EE	NNP	O
group	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
LNG/EE	NNP	O
group	NN	O
achieved	VBD	O
a	DT	O
consistently	RB	O
higher	JJR	O
percentage	NN	Physical
of	IN	Physical
normal	JJ	Physical
menstrual	JJ	Physical
cycles	NNS	Physical
as	RB	O
well	RB	O
as	IN	O
a	DT	O
lower	JJR	O
rate	NN	Physical
of	IN	Physical
intermenstrual	JJ	Physical
bleeding	NN	Physical
and	CC	O
amenorrhea	NN	Physical
than	IN	O
the	DT	O
NETA/EE	NNP	O
group	NN	O
.	.	O

In	IN	O
cycle	NN	O
4	CD	O
,	,	O
63.8	CD	O
%	NN	O
of	IN	O
cycles	NNS	O
were	VBD	O
normal	JJ	O
in	IN	O
the	DT	O
LNG/EE	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
41.9	CD	O
%	NN	O
in	IN	O
the	DT	O
NETA/EE	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
cycles	NNS	O
in	IN	O
the	DT	O
NETA/EE	NNP	O
group	NN	O
,	,	O
10	CD	O
%	NN	O
were	VBD	O
amenorrheic	RB	Physical
,	,	O
compared	VBN	O
with	IN	O
1.1	CD	O
%	NN	O
in	IN	O
the	DT	O
LNG/EE	NNP	O
group	NN	O
.	.	O

The	DT	O
occurrence	NN	Physical
of	IN	Physical
bleeding	VBG	Physical
and/or	JJ	O
spotting	NN	Physical
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
cycles	NNS	O
2	CD	O
and	CC	O
3	CD	O
in	IN	O
the	DT	O
LNG/EE	NNP	O
group	NN	O
(	(	O
41.7	CD	O
%	NN	O
and	CC	O
34.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
NETA/EE	NNP	O
group	NN	O
(	(	O
62.3	CD	O
%	NN	O
and	CC	O
56.3	CD	O
%	NN	O
;	:	O
p	CC	O
<	VB	O
0.05	CD	O
)	)	O
.	.	O

Other	JJ	O
cycle	NN	O
variables	NNS	O
were	VBD	O
generally	RB	O
similar	JJ	O
between	IN	O
groups	NNS	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	O

These	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
good	JJ	O
cycle	NN	O
control	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
an	DT	O
OC	NNP	O
containing	VBG	O
20	CD	O
micrograms	NNS	O
EE	NNP	O
and	CC	O
that	IN	O
100	CD	O
micrograms	NNS	O
LNG/20	NNP	O
micrograms	NNS	O
EE	NNP	O
produces	VBZ	O
better	JJR	O
cycle	NN	O
control	NN	O
than	IN	O
1000	CD	O
micrograms	NNS	O
NETA/20	NNP	O
micrograms	NNS	O
EE	NNP	O
.	.	O

Low-frequency	NNP	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
rTMS	NN	O
)	)	O
affects	VBZ	O
event-related	JJ	O
potential	JJ	O
measures	NNS	O
of	IN	O
novelty	NN	O
processing	NN	O
in	IN	O
autism	NN	O
.	.	O

In	IN	O
our	PRP$	O
previous	JJ	O
study	NN	O
on	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
(	(	O
Sokhadze	NNP	O
et	RB	O
al.	RB	O
,	,	O
Appl	NNP	O
Psychophysiol	NNP	O
Biofeedback	NNP	O
34:37-51	JJ	O
,	,	O
2009a	CD	O
)	)	O
we	PRP	O
reported	VBD	O
abnormalities	NNS	O
in	IN	O
the	DT	O
attention-orienting	JJ	O
frontal	JJ	O
event-related	JJ	O
potentials	NNS	O
(	(	O
ERP	NNP	O
)	)	O
and	CC	O
the	DT	O
sustained-attention	JJ	O
centro-parietal	JJ	O
ERPs	NNP	O
in	IN	O
a	DT	O
visual	JJ	O
oddball	NN	O
experiment	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
over-process	JJ	O
information	NN	O
needed	VBN	O
for	IN	O
the	DT	O
successful	JJ	O
differentiation	NN	O
of	IN	O
target	NN	O
and	CC	O
novel	JJ	O
stimuli	NNS	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
examine	VBP	O
the	DT	O
effects	NNS	O
of	IN	O
low-frequency	NN	O
,	,	O
repetitive	JJ	O
Transcranial	NNP	O
Magnetic	NNP	O
Stimulation	NNP	O
(	(	O
rTMS	NN	O
)	)	O
on	IN	O
novelty	NN	O
processing	NN	O
as	RB	O
well	RB	O
as	IN	O
behavior	NN	O
and	CC	O
social	JJ	O
functioning	NN	O
in	IN	O
13	CD	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Our	PRP$	O
hypothesis	NN	O
was	VBD	O
that	IN	O
low-frequency	NN	O
rTMS	NN	O
application	NN	O
to	TO	O
dorsolateral	JJ	O
prefrontal	JJ	O
cortex	NN	O
(	(	O
DLFPC	NNP	O
)	)	O
would	MD	O
result	VB	O
in	IN	O
an	DT	O
alteration	NN	O
of	IN	O
the	DT	O
cortical	JJ	O
excitatory/inhibitory	NN	O
balance	NN	O
through	IN	O
the	DT	O
activation	NN	O
of	IN	O
inhibitory	JJ	O
GABAergic	NNP	O
double	JJ	O
bouquet	NN	O
interneurons	NNS	O
.	.	O

We	PRP	O
expected	VBD	O
to	TO	O
find	VB	O
post-TMS	JJ	O
differences	NNS	O
in	IN	O
amplitude	NN	O
and	CC	O
latency	NN	O
of	IN	O
early	JJ	O
and	CC	O
late	JJ	O
ERP	NNP	O
components	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
our	PRP$	O
current	JJ	O
study	NN	O
validate	VBP	O
the	DT	O
use	NN	O
of	IN	O
low-frequency	NN	O
rTMS	NN	O
as	IN	O
a	DT	O
modulatory	NN	O
tool	NN	O
that	WDT	O
altered	VBD	O
the	DT	O
disrupted	VBN	O
ratio	NN	O
of	IN	O
cortical	JJ	O
excitation	NN	O
to	TO	O
inhibition	NN	O
in	IN	O
autism	NN	O
.	.	O

After	IN	O
rTMS	VBG	O
the	DT	O
parieto-occipital	JJ	Physical
P50	NNP	Physical
amplitude	NN	Physical
decreased	VBD	Physical
to	TO	Physical
novel	JJ	Physical
distracters	NNS	Physical
but	CC	Physical
not	RB	Physical
to	TO	Physical
targets	NNS	Physical
;	:	O
also	RB	O
the	DT	O
amplitude	NN	Physical
and	CC	Physical
latency	NN	Physical
to	TO	Physical
targets	NNS	Physical
increased	VBN	Physical
for	IN	Physical
the	DT	Physical
frontal	JJ	Physical
P50	NNP	Physical
while	IN	Physical
decreasing	VBG	Physical
to	TO	Physical
non-target	JJ	Physical
stimuli	NNS	Physical
.	.	O

Low-frequency	NNP	O
rTMS	NN	O
minimized	VBD	Physical
early	JJ	Physical
cortical	JJ	Physical
responses	NNS	Physical
to	TO	Physical
irrelevant	VB	Physical
stimuli	JJ	Physical
and	CC	O
increased	JJ	Physical
responses	NNS	Physical
to	TO	Physical
relevant	VB	Physical
stimuli	NN	Physical
.	.	O

Improved	VBN	O
selectivity	NN	O
in	IN	O
early	JJ	O
cortical	JJ	O
responses	NNS	O
lead	VBP	O
to	TO	O
better	JJR	Physical
stimulus	JJ	Physical
differentiation	NN	Physical
at	IN	Physical
later-stage	JJ	Physical
responses	NNS	Physical
as	IN	O
was	VBD	O
made	VBN	O
evident	JJ	O
by	IN	O
our	PRP$	O
P3b	NNP	O
and	CC	O
P3a	NNP	O
component	NN	O
findings	NNS	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
significant	JJ	Physical
change	NN	Physical
in	IN	Physical
early	JJ	Physical
,	,	Physical
middle-latency	JJ	Physical
and	CC	Physical
late	JJ	Physical
ERP	NNP	Physical
components	NNS	Physical
at	IN	Physical
the	DT	Physical
frontal	JJ	Physical
,	,	Physical
centro-parietal	JJ	Physical
,	,	Physical
and	CC	Physical
parieto-occipital	JJ	Physical
regions	NNS	Physical
of	IN	Physical
interest	NN	Physical
in	IN	Physical
response	NN	Physical
to	TO	Physical
target	VB	Physical
and	CC	Physical
distracter	VB	Physical
stimuli	NNS	Physical
as	IN	O
a	DT	O
result	NN	O
of	IN	O
rTMS	NN	O
treatment	NN	O
.	.	O

Overall	JJ	O
,	,	O
our	PRP$	O
preliminary	JJ	O
results	NNS	O
show	VBP	O
that	IN	O
rTMS	NN	O
may	MD	O
prove	VB	O
to	TO	O
be	VB	O
an	DT	O
important	JJ	O
research	NN	O
tool	NN	O
or	CC	O
treatment	NN	O
modality	NN	O
in	IN	O
addressing	VBG	O
the	DT	O
stimulus	JJ	O
hypersensitivity	NN	O
characteristic	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Maternal	NNP	O
dietary	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
healthy	JJ	Physical
eating	VBG	Physical
index	NN	Physical
in	IN	O
childhood	NN	O
.	.	O

Food	NNP	O
preferences	NNS	O
are	VBP	O
established	VBN	O
in	IN	O
early	JJ	O
childhood	NN	O
and	CC	O
track	NN	O
later	RB	O
in	IN	O
life	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
promote	VB	O
healthy	JJ	O
feeding	NN	O
practices	NNS	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
.	.	O

A	DT	O
randomized	JJ	O
field	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
500	CD	O
mother-child	JJ	O
pairs	NNS	O
from	IN	O
a	DT	O
low-income	JJ	O
area	NN	O
of	IN	O
S?o	NNP	O
Leopoldo	NNP	O
,	,	O
State	NNP	O
of	IN	O
Rio	NNP	O
Grande	NNP	O
do	VBP	O
Sul	NNP	O
,	,	O
Brazil	NNP	O
,	,	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
nutritional	JJ	O
intervention	NN	O
in	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
on	IN	O
the	DT	O
dietary	JJ	O
quality	NN	O
of	IN	O
3-	JJ	O
to	TO	O
4-y-old	JJ	O
children	NNS	O
.	.	O

Mother-child	JJ	O
pairs	NNS	O
were	VBD	O
randomized	VBN	O
either	RB	O
to	TO	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
and	CC	O
dietary	JJ	O
counseling	NN	O
was	VBD	O
provided	VBN	O
for	IN	O
mothers	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
during	IN	O
10	CD	O
home	NN	O
visits	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
.	.	O

These	DT	O
visits	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
fieldworkers	NNS	O
who	WP	O
counseled	VBD	O
the	DT	O
mothers	NNS	O
about	IN	O
the	DT	O
Ten	NNP	O
Steps	NNP	O
for	IN	O
Healthy	NNP	O
Feeding	VBG	O
from	IN	O
Birth	NNP	O
to	TO	O
Two	CD	O
Years	NNS	O
of	IN	O
Age	NNP	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
WHO	NNP	O
guidelines	NNS	O
.	.	O

Dietary	JJ	O
intake	NN	O
was	VBD	O
assessed	VBN	O
at	IN	O
3-4	JJ	O
y	NN	O
of	IN	O
age	NN	O
for	IN	O
345	CD	O
children	NNS	O
using	VBG	O
two	CD	O
24-h	JJ	O
food	NN	O
recalls	NNS	O
.	.	O

Overall	JJ	O
diet	JJ	O
quality	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
Healthy	NNP	O
Eating	NNP	O
Index	NNP	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
poor	JJ	O
diet	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
[	NNP	O
relative	NN	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
=	VBZ	O
0.30	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.13-0.71	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
children	NNS	O
who	WP	O
achieved	VBD	O
the	DT	O
75th	CD	O
percentile	NN	O
for	IN	O
the	DT	O
vegetable	JJ	O
and	CC	O
fruit	JJ	O
component	NN	O
score	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
intervention	NN	O
than	IN	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
RR	NNP	O
=	NNP	O
1.95	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.31-2.89	JJ	O
and	CC	O
RR	NNP	O
=	NNP	O
1.49	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.07-2.07	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Such	JJ	O
data	NNS	O
provide	VBP	O
evidence	NN	O
that	IN	O
dietary	JJ	O
counseling	NN	O
for	IN	O
mothers	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
improves	VBZ	O
the	DT	O
overall	JJ	O
dietary	JJ	O
quality	NN	O
of	IN	O
children	NNS	O
in	IN	O
a	DT	O
low-income	JJ	O
population	NN	O
.	.	O

Identification	NN	O
,	,	O
course	NN	O
,	,	O
and	CC	O
treatment	NN	O
of	IN	O
depression	NN	O
after	IN	O
admission	NN	O
for	IN	O
a	DT	O
cardiac	JJ	O
condition	NN	O
:	:	O
rationale	NN	O
and	CC	O
patient	JJ	O
characteristics	NNS	O
for	IN	O
the	DT	O
Identifying	NNP	O
Depression	NNP	O
As	IN	O
a	DT	O
Comorbid	NNP	O
Condition	NNP	O
(	(	O
IDACC	NNP	O
)	)	O
project	NN	O
.	.	O

BACKGROUND	NNP	O
Given	NNP	O
the	DT	O
prevalence	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
and	CC	O
the	DT	O
high	JJ	O
rates	NNS	O
of	IN	O
depression	NN	O
among	IN	O
cardiac	JJ	O
patients	NNS	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
need	NN	O
to	TO	O
develop	VB	O
practical	JJ	O
ways	NNS	O
to	TO	O
identify	VB	O
this	DT	O
population	NN	O
and	CC	O
provide	VB	O
pragmatic	JJ	O
general-practitioner-based	JJ	O
interventions	NNS	O
for	IN	O
managing	VBG	O
depression	NN	O
as	IN	O
a	DT	O
comorbid	NN	O
condition	NN	O
.	.	O

METHOD	NNP	O
The	DT	O
Identifying	NNP	O
Depression	NNP	O
As	IN	O
a	DT	O
Comorbid	NNP	O
Condition	NNP	O
(	(	O
IDACC	NNP	O
)	)	O
study	NN	O
employed	VBD	O
a	DT	O
hybrid	JJ	O
design	NN	O
,	,	O
incorporating	VBG	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
nested	VBN	O
within	IN	O
a	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
.	.	O

IDACC	NNP	O
screened	VBD	O
for	IN	O
depression	NN	O
in	IN	O
patients	NNS	O
hospitalized	VBN	O
in	IN	O
South	NNP	O
Australia	NNP	O
for	IN	O
a	DT	O
range	NN	O
of	IN	O
cardiac	JJ	O
conditions	NNS	O
,	,	O
with	IN	O
outcome	JJ	O
measures	NNS	O
monitored	VBD	O
for	IN	O
12	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

The	DT	O
subgroup	NN	O
identified	VBD	O
as	IN	O
depressed	VBN	O
was	VBD	O
entered	VBN	O
into	IN	O
the	DT	O
nested	JJ	O
IDACC	NNP	O
trial	NN	O
,	,	O
which	WDT	O
tests	VBZ	O
the	DT	O
hypothesis	NN	O
that	IN	O
identifying	VBG	O
depression	NN	O
and	CC	O
offering	VBG	O
an	DT	O
evidence-based	JJ	O
intervention	NN	O
to	TO	O
general	JJ	O
practitioners	NNS	O
,	,	O
incorporating	VBG	O
multidisciplinary	JJ	O
telephone	NN	O
case	NN	O
conferencing	NN	O
,	,	O
will	MD	O
reduce	VB	O
levels	NNS	O
of	IN	O
depression	NN	Mental
,	,	O
improve	VB	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
reduce	VB	O
associated	VBN	O
economic	JJ	Others
costs	NNS	Others
.	.	Others

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
46.3	CD	O
%	NN	O
of	IN	O
1455	CD	O
participants	NNS	O
screened	VBN	O
were	VBD	O
classified	VBN	O
as	IN	O
depression	NN	Mental
cases	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
their	PRP$	O
score	NN	O
on	IN	O
the	DT	O
Center	NNP	Mental
for	IN	Mental
Epidemiological	NNP	Mental
Studies	NNPS	Mental
Depression	NNP	Mental
Scale	NNP	Mental
(	(	O
>	CD	O
or	CC	O
=16	VB	O
)	)	O
or	CC	O
the	DT	O
Hospital	NNP	Mental
Anxiety	NNP	Mental
and	CC	Mental
Depression	NNP	Mental
Scale	NNP	Mental
(	(	O
>	CD	O
or	CC	O
=8	NNP	O
)	)	O
.	.	O

Elevated	VBN	O
scores	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
being	VBG	O
younger	JJR	O
,	,	O
female	JJ	O
,	,	O
divorced	VBD	O
or	CC	O
separated	VBN	O
,	,	O
not	RB	O
employed	VBN	O
,	,	O
living	VBG	O
alone	RB	O
,	,	O
having	VBG	O
a	DT	O
lower	JJR	O
level	NN	O
of	IN	O
education	NN	O
,	,	O
and	CC	O
having	VBG	O
poorer	JJR	O
health	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Nearly	RB	O
one	CD	O
fifth	NN	O
(	(	O
19.4	CD	O
%	NN	O
)	)	O
of	IN	O
participants	NNS	O
had	VBD	O
Center	NNP	Mental
for	IN	Mental
Epidemiological	NNP	Mental
Studies	NNPS	Mental
Depression	NNP	Mental
Scale	NNP	Mental
scores	VBZ	Mental
>	JJ	Mental
27	CD	Mental
,	,	O
which	WDT	O
is	VBZ	O
indicative	CD	O
of	IN	O
major	JJ	O
depression	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
project	NN	O
confirms	VBZ	O
,	,	O
in	IN	O
an	DT	O
Australian	JJ	O
setting	NN	O
,	,	O
the	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
depressive	JJ	Mental
symptoms	NNS	Mental
among	IN	O
hospitalized	JJ	O
cardiac	JJ	O
patients	NNS	O
.	.	O

Follow-up	NNP	O
over	IN	O
12	CD	O
months	NNS	O
will	MD	O
enhance	VB	O
understanding	NN	O
of	IN	O
the	DT	O
natural	JJ	O
history	NN	O
of	IN	O
depression	NN	O
in	IN	O
cardiac	JJ	O
patients	NNS	O
,	,	O
while	IN	O
the	DT	O
nested	JJ	O
trial	NN	O
will	MD	O
inform	VB	O
on	IN	O
effectiveness	NN	O
of	IN	O
an	DT	O
intervention	NN	O
involving	VBG	O
tailored	VBN	O
advice	NN	O
and	CC	O
support	NN	O
to	TO	O
general	JJ	O
practitioners	NNS	O
.	.	O

Equivalent	JJ	O
efficacy	NN	Others
of	IN	O
mitomycin	NN	O
C	NNP	O
plus	CC	O
doxorubicin	JJ	O
instillation	NN	O
to	TO	O
bacillus	VB	O
Calmette-Guerin	NNP	O
therapy	NN	O
for	IN	O
carcinoma	NN	O
in	IN	O
situ	NN	O
of	IN	O
the	DT	O
bladder	NN	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
elucidate	VB	O
the	DT	O
most	RBS	O
efficient	JJ	O
topical	JJ	O
therapy	NN	O
for	IN	O
carcinoma	NN	O
in	IN	O
situ	NN	O
of	IN	O
the	DT	O
bladder	NN	O
,	,	O
the	DT	O
efficacy	NN	O
of	IN	O
intravesical	JJ	O
mitomycin	NN	O
C	NNP	O
plus	CC	O
doxorubicin	JJ	O
therapy	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
bacillus	JJ	O
Calmette-Guerin	NNP	O
(	(	O
BCG	NNP	O
)	)	O
therapy	NN	O
.	.	O

The	DT	O
clinical	JJ	O
behavior	NN	O
of	IN	O
the	DT	O
tumor	NN	O
was	VBD	O
analysed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
histological	JJ	O
grade	NN	O
.	.	O

METHODS	NNP	O
Forty-two	JJ	O
patients	NNS	O
with	IN	O
carcinoma	NN	O
in	IN	O
situ	NN	O
of	IN	O
the	DT	O
bladder	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
intravesical	JJ	O
BCG	NNP	O
(	(	O
21	CD	O
patients	NNS	O
)	)	O
or	CC	O
mitomycin	JJ	O
C	NNP	O
plus	CC	O
doxorubicin	JJ	O
sequential	JJ	O
therapy	NN	O
(	(	O
21	CD	O
patients	NNS	O
)	)	O
as	IN	O
first	JJ	O
line	NN	O
treatment	NN	O
.	.	O

The	DT	O
non-responders	JJ	O
underwent	NN	O
the	DT	O
subsequent	JJ	O
instillation	NN	O
of	IN	O
the	DT	O
other	JJ	O
intravesical	JJ	O
therapy	NN	O
alternately	RB	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
,	,	O
27	CD	O
had	VBD	O
grade	VBN	O
2	CD	O
and	CC	O
15	CD	O
had	VBD	O
grade	VBN	O
3	CD	O
cancer	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
topical	JJ	O
therapies	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
with	IN	O
initial	JJ	O
response	NN	Others
rates	NNS	Others
of	IN	O
86	CD	O
%	NN	O
(	(	O
18/21	CD	O
)	)	O
for	IN	O
BCG	NNP	O
and	CC	O
81	CD	O
%	NN	O
(	(	O
17/21	CD	O
)	)	O
for	IN	O
mitomycin	NN	O
C	NNP	O
plus	CC	O
doxorubicin	NN	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
tumor	NN	O
grade	NN	O
.	.	O

Of	IN	O
seven	CD	O
initial	JJ	O
non-responders	NNS	O
,	,	O
five	CD	O
patients	NNS	O
achieved	VBD	O
a	DT	O
complete	JJ	O
response	NN	O
by	IN	O
subsequent	JJ	O
instillation	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	Others
response	NN	Others
rate	NN	Others
of	IN	O
95	CD	O
%	NN	O
.	.	O

After	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
47	CD	O
months	NNS	O
,	,	O
five	CD	O
patients	NNS	O
(	(	O
12	CD	O
%	NN	O
)	)	O
developed	VBD	O
disease	JJ	Adverseeffect
progression	NN	Adverseeffect
.	.	O

The	DT	O
progression	NN	Physical
rates	NNS	Physical
were	VBD	O
not	RB	O
different	JJ	O
between	IN	O
the	DT	O
topical	JJ	O
therapies	NNS	O
,	,	O
but	CC	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
grade	NN	O
3	CD	O
than	IN	O
in	IN	O
grade	JJ	O
2	CD	O
cases	NNS	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
appears	VBZ	O
likely	JJ	O
that	IN	O
mitomycin	VBZ	O
C	NNP	O
plus	CC	O
doxorubicin	JJ	O
instillation	NN	O
has	VBZ	O
an	DT	O
equivalent	JJ	O
efficacy	NN	Others
to	TO	Others
BCG	NNP	Others
as	IN	O
the	DT	O
initial	JJ	O
therapy	NN	O
of	IN	O
carcinoma	NN	O
in	IN	O
situ	NN	O
and	CC	O
the	DT	O
combination	NN	O
of	IN	O
them	PRP	O
would	MD	O
be	VB	O
the	DT	O
most	RBS	O
efficient	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
disease	NN	O
.	.	O

Moreover	RB	O
,	,	O
histological	JJ	O
grading	NN	O
would	MD	O
be	VB	O
clinically	RB	O
useful	JJ	O
in	IN	O
defining	VBG	O
the	DT	O
tumor	NN	O
characteristics	NNS	O
and	CC	O
behavior	NN	O
of	IN	O
carcinoma	NN	O
in	IN	O
situ	NN	O
of	IN	O
the	DT	O
bladder	NN	O
.	.	O

Paraesthesia	NN	O
during	IN	O
the	DT	O
needle-through-needle	JJ	O
and	CC	O
the	DT	O
double	JJ	O
segment	NN	O
technique	NN	O
for	IN	O
combined	JJ	O
spinal	JJ	O
epidural	JJ	O
anaesthesia	NN	O
.	.	O

Paraesthesia	NNP	O
during	IN	O
regional	JJ	O
anaesthesia	NN	O
is	VBZ	O
an	DT	O
unpleasant	JJ	O
sensation	NN	O
for	IN	O
patients	NNS	O
and	CC	O
,	,	O
more	RBR	O
importantly	RB	O
,	,	O
in	IN	O
some	DT	O
cases	NNS	O
it	PRP	O
is	VBZ	O
related	VBN	O
to	TO	O
neurological	JJ	O
injury	NN	O
.	.	O

Relatively	RB	O
few	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
on	IN	O
the	DT	O
frequency	NN	O
of	IN	O
paraesthesia	NN	O
during	IN	O
combined	JJ	O
spinal	JJ	O
epidural	JJ	O
anaesthesia	NN	O
.	.	O

We	PRP	O
compared	VBN	O
two	CD	O
combined	JJ	O
spinal	JJ	O
epidural	JJ	O
anaesthesia	NN	O
techniques	NNS	O
:	:	O
the	DT	O
needle-through-needle	JJ	O
technique	NN	O
and	CC	O
the	DT	O
double	JJ	O
segment	NN	O
technique	NN	O
in	IN	O
this	DT	O
respect	NN	O
.	.	O

We	PRP	O
randomly	RB	O
allocated	VBD	O
116	CD	O
parturients	NNS	O
undergoing	JJ	O
elective	JJ	O
Caesarean	JJ	O
section	NN	O
to	TO	O
receive	VB	O
anaesthesia	NN	O
using	VBG	O
one	CD	O
of	IN	O
these	DT	O
techniques	NNS	O
.	.	O

Both	DT	O
techniques	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
a	DT	O
27G	CD	O
pencil	NN	O
point	NN	O
needle	NN	O
,	,	O
an	DT	O
18G	CD	O
Tuohy	NNP	O
needle	NN	O
,	,	O
and	CC	O
a	DT	O
20G	CD	O
multiport	NN	O
epidural	JJ	O
catheter	NN	O
from	IN	O
the	DT	O
same	JJ	O
manufacturer	NN	O
.	.	O

The	DT	O
overall	JJ	Physical
frequency	NN	Physical
of	IN	Physical
paraesthesia	NN	Physical
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
needle-through-needle	JJ	O
technique	NN	O
group	NN	O
(	(	O
56.9	CD	O
%	NN	O
vs.	FW	O
31.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

The	DT	O
frequency	NN	Physical
of	IN	Physical
paraesthesia	NN	Physical
at	IN	O
spinal	JJ	O
needle	JJ	O
insertion	NN	O
was	VBD	O
20.7	CD	O
%	NN	O
in	IN	O
the	DT	O
needle-through-needle	JJ	O
technique	NN	O
group	NN	O
and	CC	O
8.8	CD	O
%	NN	O
in	IN	O
the	DT	O
double	JJ	O
segment	NN	O
technique	NN	O
group	NN	O
;	:	O
whereas	VBZ	O
the	DT	O
frequency	NN	Others
of	IN	Others
paraesthesia	NN	Others
at	IN	O
epidural	JJ	O
catheter	NN	O
insertion	NN	O
was	VBD	O
46.6	CD	O
%	NN	O
in	IN	O
the	DT	O
needle-through-needle	JJ	O
technique	NN	O
group	NN	O
and	CC	O
24.6	CD	O
%	NN	O
in	IN	O
the	DT	O
double	JJ	O
segment	NN	O
technique	NN	O
group	NN	O
.	.	O

Prediction	NN	O
of	IN	O
creatinine	JJ	Physical
clearance	NN	Physical
from	IN	Physical
serum	JJ	Physical
creatinine	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
:	:	O
comparison	NN	O
of	IN	O
six	CD	O
formulae	NNS	O
and	CC	O
one	CD	O
nomogram	NN	O
.	.	O

The	DT	O
estimation	NN	O
of	IN	O
glomerular	JJ	Physical
filtration	NN	Physical
rate	NN	Physical
is	VBZ	O
important	JJ	O
for	IN	O
the	DT	O
medical	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
determination	NN	O
of	IN	O
endogenous	JJ	Physical
creatinine	JJ	Physical
clearance	NN	Physical
(	(	Physical
Clcr	NNP	Physical
)	)	Physical
from	IN	O
a	DT	O
24-h	JJ	O
urine	JJ	O
collection	NN	O
is	VBZ	O
an	DT	O
unreliable	JJ	O
and	CC	O
time-consuming	JJ	O
procedure	NN	O
.	.	O

We	PRP	O
therefore	RB	O
tested	VBD	O
the	DT	O
accuracy	NN	O
of	IN	O
six	CD	O
equations	NNS	O
and	CC	O
one	CD	O
nomogram	NN	O
for	IN	O
the	DT	O
prediction	NN	O
of	IN	O
Clcr	NNP	Physical
from	IN	Physical
serum	JJ	Physical
creatinine	NN	Physical
(	(	Physical
Scr	NNP	Physical
)	)	O
in	IN	O
38	CD	O
patients	NNS	O
with	IN	O
RA	NNP	O
and	CC	O
20	CD	O
controls	NNS	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	Physical
was	VBD	O
found	VBN	O
for	IN	O
all	DT	O
methods	NNS	O
in	IN	O
the	DT	O
controls	NNS	O
(	(	O
r	VB	O
=	NNP	O
0.83-0.94	NN	O
)	)	O
and	CC	O
RA	NNP	O
patients	NNS	O
(	(	O
r	JJ	O
=	NNP	O
0.51-0.69	NN	O
)	)	O
.	.	O

The	DT	O
methods	NNS	O
did	VBD	O
not	RB	O
overestimate	VB	O
Clcr	NNP	O
in	IN	O
RA	NNP	O
.	.	O

In	IN	O
the	DT	O
RA	NNP	O
group	NN	O
the	DT	O
simple	JJ	O
formula	NN	O
published	VBN	O
by	IN	O
Cockcroft	NNP	O
[	NNP	O
Clcr	NNP	O
=	NNP	O
(	(	O
(	(	O
140	CD	O
-	:	O
age	NN	O
)	)	O
x	VBZ	O
body	NN	O
weight	NN	O
)	)	O
/	NN	O
(	(	O
72	CD	O
x	NNP	O
Scr	NNP	O
)	)	O
,	,	O
x	$	O
0.85	CD	O
for	IN	O
females	NNS	O
]	VBP	O
showed	VBD	O
the	DT	O
best	JJS	O
correlation	NN	O
with	IN	O
the	DT	O
measured	VBN	Physical
Clcr	NNP	Physical
.	.	O

In	IN	O
RA	NNP	O
the	DT	O
Cockroft	NNP	O
formula	NN	O
can	MD	O
reliably	RB	Others
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
Clcr	NNP	O
from	IN	O
Scr	NNP	O
.	.	O

Endoscopic	NNP	O
versus	NN	O
operative	JJ	O
gastrostomy	NN	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
operative	JJ	O
gastrostomy	NN	O
(	(	O
OG	NNP	O
)	)	O
(	(	O
by	IN	O
surgeons	NNS	O
)	)	O
with	IN	O
endoscopic	NN	O
gastrostomy	NN	O
(	(	O
PEG	NNP	O
)	)	O
(	(	O
by	IN	O
physicians	NNS	O
)	)	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
fashion	NN	O
to	TO	O
determine	VB	O
whether	IN	O
one	CD	O
technique	NN	O
was	VBD	O
superior	JJ	O
.	.	O

PEG	NNP	O
(	(	O
Sachs-Vine	NNP	O
)	)	O
and	CC	O
OG	NNP	O
(	(	O
Stamm	NNP	O
)	)	O
were	VBD	O
done	VBN	O
using	VBG	O
local	JJ	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
complications	NNS	Adverseeffect
,	,	O
mortality	NN	Mortality
,	,	O
tube	NN	Others
function	NN	Others
,	,	O
and	CC	O
cost	NN	Others
.	.	O

Groups	NNP	O
were	VBD	O
equally	RB	O
matched	VBN	O
for	IN	O
indications	NNS	O
and	CC	O
underlying	JJ	O
disease	NN	O
.	.	O

Fifty-seven	NNP	O
had	VBD	O
OG	NNP	O
and	CC	O
64	CD	O
had	VBD	O
attempted	VBN	O
PEG	NNP	O
.	.	O

Complications	NNS	Adverseeffect
occurred	VBD	O
in	IN	O
26	CD	O
%	NN	O
of	IN	O
OG	NNP	O
patients	NNS	O
and	CC	O
9	CD	O
%	NN	O
died	VBD	Mortality
.	.	O

Complications	NNS	Adverseeffect
occurred	VBD	O
in	IN	O
25	CD	O
%	NN	O
of	IN	O
PEG	NNP	O
patients	NNS	O
and	CC	O
12	CD	O
%	NN	O
died	VBD	Mortality
.	.	O

Tube	NNP	O
feeding	NN	O
was	VBD	O
initiated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
within	IN	O
a	DT	O
mean	NN	O
of	IN	O
29	CD	O
(	(	O
24	CD	O
to	TO	O
72	CD	O
)	)	O
hours	NNS	O
of	IN	O
the	DT	O
gastrostomy	JJ	O
placement	NN	O
.	.	O

OG	NNP	Others
cost	VBD	Others
$	$	O
1675	CD	O
and	CC	O
PEG	NNP	O
$	$	O
979	CD	O
to	TO	O
perform	VB	O
.	.	O

Twenty-one	CD	O
PEG	NNP	O
patients	NNS	O
required	VBD	O
endoscopic	JJ	Others
tube	NN	Others
change	NN	Others
which	WDT	O
raised	VBD	Others
their	PRP$	Others
total	JJ	Others
cost	NN	Others
to	TO	O
$	$	O
1574	CD	O
.	.	O

We	PRP	O
conclude	VBP	O
there	EX	O
is	VBZ	O
no	DT	O
difference	NN	O
between	IN	O
OG	NNP	O
(	(	O
using	VBG	O
local	JJ	O
anesthesia	NN	O
)	)	O
and	CC	O
PEG	NNP	O
with	IN	O
regard	NN	O
to	TO	O
morbidity	NN	Others
,	,	O
mortality	NN	Mortality
,	,	O
or	CC	O
tube	NN	Others
function	NN	Others
.	.	O

The	DT	O
endoscopic	NN	O
technique	NN	O
does	VBZ	O
appear	VB	O
to	TO	O
have	VB	O
economic	JJ	Others
advantage	NN	Others
.	.	O

Conservative	JJ	O
surgery	NN	O
with	IN	O
and	CC	O
without	IN	O
radiotherapy	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
multicentre	JJ	O
trial	NN	O
.	.	O

Breast	NNP	O
conserving	VBG	O
therapy	NN	O
(	(	O
BCT	NNP	O
)	)	O
including	VBG	O
postoperative	JJ	O
irradiation	NN	O
of	IN	O
the	DT	O
remaining	VBG	O
breast	NN	O
tissue	NN	O
is	VBZ	O
generally	RB	O
accepted	VBN	O
as	IN	O
the	DT	O
best	JJS	O
treatment	NN	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
with	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
question	NN	O
is	VBZ	O
whether	IN	O
there	EX	O
is	VBZ	O
a	DT	O
necessity	NN	O
for	IN	O
irradiating	VBG	O
all	DT	O
patients	NNS	O
.	.	O

Between	JJ	O
2001	CD	O
and	CC	O
2005	CD	O
,	,	O
749	CD	O
women	NNS	O
aged	VBN	O
55-75	JJ	O
years	NNS	O
with	IN	O
infiltrating	VBG	O
breast	NN	O
carcinoma	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
breast	VB	O
conservative	JJ	O
surgery	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
,	,	O
to	TO	O
evaluate	VB	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
in-breast	JJ	Physical
recurrence	NN	Physical
(	(	Physical
IBR	NNP	Physical
)	)	Physical
.	.	O

After	IN	O
5	CD	O
years	NNS	O
of	IN	O
median	JJ	O
follow-up	NN	O
,	,	O
the	DT	O
cumulative	JJ	Physical
incidence	NN	Physical
of	IN	Physical
IBR	NNP	Physical
was	VBD	O
2.5	CD	O
%	NN	O
in	IN	O
the	DT	O
surgery-only	JJ	O
arm	NN	O
and	CC	O
0.7	CD	O
%	NN	O
in	IN	O
the	DT	O
surgery	NN	O
plus	CC	O
RT	NNP	O
arm	NN	O
.	.	O

There	EX	O
are	VBP	O
no	DT	Others
differences	NNS	Others
in	IN	O
terms	NNS	O
of	IN	O
overall	JJ	Mortality
survival	NN	Mortality
and	CC	O
distant	JJ	Mortality
disease-free	JJ	Mortality
survival	NN	Mortality
.	.	O

The	DT	O
preliminary	JJ	O
evaluation	NN	O
suggests	VBZ	O
that	IN	O
breast	NN	O
irradiation	NN	O
after	IN	O
conservative	JJ	O
surgery	NN	O
can	MD	O
be	VB	O
avoided	VBN	O
without	IN	O
exposing	VBG	O
these	DT	O
patients	NNS	O
to	TO	O
an	DT	O
increased	VBN	O
risk	NN	Physical
of	IN	Physical
distant-disease	JJ	Physical
recurrence	NN	Physical
.	.	O

Prolonged	VBN	O
follow-up	NN	O
will	MD	O
further	RBR	O
clarify	VB	O
the	DT	O
possible	JJ	O
risks	NNS	O
and	CC	O
late	JJ	O
sequelae	NN	O
potentially	RB	O
induced	VBN	O
by	IN	O
breast	NN	O
RT	NNP	O
.	.	O

Postoperative	JJ	O
dreaming	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
incidence	NN	O
following	VBG	O
pentazocine	NN	O
and	CC	O
morphine	JJ	O
premedication	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
dreaming	NN	O
following	VBG	O
the	DT	O
use	NN	O
of	IN	O
morphine	NN	O
and	CC	O
pentazocine	NN	O
as	IN	O
premedicants	NNS	O
in	IN	O
an	DT	O
otherwise	RB	O
standard	JJ	O
anaesthetic	JJ	O
sequence	NN	O
is	VBZ	O
compared	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
.	.	O

The	DT	O
causes	NNS	O
of	IN	O
psychotomimetic	JJ	O
problems	NNS	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
and	CC	O
the	DT	O
difficulty	NN	O
of	IN	O
precise	JJ	O
definition	NN	O
of	IN	O
hallucinations	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Riluzole	NNP	O
as	IN	O
an	DT	O
adjunctive	JJ	O
therapy	NN	O
to	TO	O
risperidone	VB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	Mental
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
hyperglutamatergic	NN	O
state	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
play	VB	O
a	DT	O
possible	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathophysiology	NN	O
of	IN	O
autistic	JJ	O
disorders	NNS	O
.	.	O

Riluzole	NNP	O
is	VBZ	O
a	DT	O
glutamate-modulating	JJ	O
agent	NN	O
with	IN	O
neuroprotective	JJ	O
properties	NNS	O
,	,	O
which	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
positive	JJ	O
effects	NNS	O
in	IN	O
many	JJ	O
neuropsychiatric	JJ	Physical
disorders	NNS	Physical
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
tolerability	NN	Others
of	IN	O
riluzole	NN	O
as	IN	O
an	DT	O
adjunctive	JJ	O
to	TO	O
risperidone	VB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
who	WP	O
were	VBD	O
not	RB	O
optimally	RB	O
responding	VBG	O
to	TO	O
previous	JJ	O
medications	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
This	DT	O
was	VBD	O
a	DT	O
10-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

PARTICIPANTS	VB	O
The	DT	O
study	NN	O
enrolled	VBD	O
male	NN	O
and	CC	O
female	JJ	O
outpatients	NNS	O
aged	VBN	O
5-12	CD	O
years	NNS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
based	VBN	O
on	IN	O
the	DT	O
DSM-IV-TR	NNP	O
criteria	NNS	O
and	CC	O
a	DT	O
score	NN	O
of	IN	O
?12	NN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
irritability	NN	O
subscale	NN	O
who	WP	O
had	VBD	O
discontinued	VBN	O
other	JJ	O
medications	NNS	O
because	IN	O
of	IN	O
a	DT	O
lack	NN	O
of	IN	O
efficacy	NN	O
.	.	O

INTERVENTIONS	NNP	O
Subjects	NNPS	O
received	VBD	O
riluzole	JJ	O
(	(	O
titrated	VBN	O
to	TO	O
50	CD	O
or	CC	O
100	CD	O
mg/day	NNS	O
based	VBN	O
on	IN	O
bodyweight	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
risperidone	VB	O
(	(	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
or	CC	O
3	CD	O
mg/day	NNS	O
based	VBN	O
on	IN	O
bodyweight	NN	O
)	)	O
for	IN	O
10	CD	O
weeks	NNS	O
.	.	O

OUTCOME	NN	O
Patients	NNPS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
,	,	O
week	NN	O
5	CD	O
,	,	O
and	CC	O
week	NN	O
10	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
the	DT	O
ABC-C	NNP	O
irritability	NN	O
subscale	NN	O
score	NN	O
from	IN	O
baseline	NN	O
to	TO	O
week	NN	O
10	CD	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

We	PRP	O
also	RB	O
compared	VBN	O
changes	NNS	O
in	IN	O
other	JJ	O
ABC-C	JJ	O
subscale	NN	O
scores	NNS	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impressions-Improvement	NNP	O
(	(	O
CGI-I	NNP	O
)	)	O
scale	NN	O
scores	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Forty-nine	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
forty	JJ	O
children	NNS	O
completed	VBD	O
the	DT	O
trial	NN	O
(	(	O
dropouts	NNS	O
:	:	O
placebo	NN	O
=	VBZ	O
4	CD	O
,	,	O
riluzole	JJ	O
=	FW	O
5	CD	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
the	DT	O
study	NN	O
primary	JJ	O
outcome	NN	O
(	(	O
the	DT	O
ABC-C	NNP	O
irritability	NN	O
subscale	NN	O
score	NN	O
)	)	O
was	VBD	O
achieved	VBN	O
by	IN	O
the	DT	O
riluzole-treated	JJ	O
children	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
riluzole	NN	O
group	NN	O
also	RB	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
on	IN	O
the	DT	O
lethargy/social	JJ	O
withdrawal	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
stereotypic	JJ	O
behavior	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
and	CC	O
hyperactivity/non-compliance	NN	O
subscales	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
on	IN	O
the	DT	O
inappropriate	JJ	O
speech	NN	O
subscale	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.20	CD	O
)	)	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Eleven	CD	O
patients	NNS	O
in	IN	O
the	DT	O
riluzole	NN	O
group	NN	O
and	CC	O
five	CD	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
classified	VBN	O
as	IN	O
responders	NNS	O
based	VBN	O
on	IN	O
their	PRP$	O
CGI-I	JJ	O
scores	NNS	O
[	VBN	O
?	.	O
(	(	O
2	CD	O
)	)	O
(	(	O
1	CD	O
)	)	O
=	NN	O
3.750	CD	O
,	,	O
P	NNP	O
=	VBZ	O
0.05	CD	O
]	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
riluzole	NN	O
group	NN	O
experienced	VBD	O
significantly	RB	O
more	RBR	O
increases	NNS	O
in	IN	O
their	PRP$	O
appetite	NN	O
and	CC	O
bodyweight	NN	O
than	IN	O
children	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSION	NNP	O
Riluzole	NNP	O
add-on	JJ	O
therapy	NN	O
shows	VBZ	O
several	JJ	O
therapeutic	JJ	O
outcomes	NNS	O
,	,	O
particularly	RB	O
for	IN	O
improving	VBG	O
irritability	NN	O
,	,	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
add-on	JJ	O
to	TO	O
risperidone	VB	O
also	RB	O
results	NNS	O
in	IN	O
significantly	RB	O
increased	VBN	O
appetite	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
.	.	O

Topical	JJ	O
adrenaline	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
intraoperative	JJ	Physical
bleeding	NN	Physical
in	IN	O
adenoidectomy	NN	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
topical	JJ	O
racemic	JJ	O
adrenaline	NN	O
(	(	O
RA	NNP	O
)	)	O
(	(	O
Micronefrin	NNP	O
;	:	O
Bird	NNP	O
Products	NNPS	O
,	,	O
Palm	NNP	O
Springs	NNP	O
,	,	O
CA	NNP	O
,	,	O
USA	NNP	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
intraoperative	JJ	Physical
bleeding	NN	Physical
and	CC	O
the	DT	O
prevention	NN	Others
of	IN	Others
postoperative	JJ	Others
bleeding	NN	Others
,	,	O
laryngeal	JJ	Physical
spasm	NN	Physical
and	CC	Physical
postoperative	JJ	Physical
pain	NN	Physical
in	IN	O
adenoidectomy	NN	O
among	IN	O
children	NNS	O
<	VBP	O
6	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomised	VBD	O
,	,	O
blinded	VBD	O
and	CC	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

SETTING	CC	O
Kanta-Hame	JJ	O
Central	NNP	O
Hospital	NNP	O
,	,	O
a	DT	O
district	NN	O
referral	NN	O
center	NN	O
in	IN	O
Finland	NNP	O
.	.	O

PATIENTS	VB	O
A	DT	O
consecutive	JJ	O
sample	NN	O
of	IN	O
93	CD	O
children	NNS	O
undergoing	JJ	O
outpatient	JJ	O
adenoidectomy	NN	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
topical	JJ	O
gauze	NN	O
sponges	NNS	O
soaked	VBN	O
in	IN	O
either	DT	O
1:500	CD	O
RA	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
(	(	O
physiological	JJ	O
saline	NN	O
)	)	O
for	IN	O
3	CD	O
min	NN	O
after	IN	O
adenoidectomy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Amount	NNP	O
of	IN	O
intraoperative	JJ	Physical
bleeding	NN	Physical
(	(	O
surgeons	NNS	O
'	POS	O
subjective	JJ	O
estimate	NN	O
)	)	O
,	,	O
need	VBP	Others
for	IN	Others
additional	JJ	Others
packings	NNS	Others
,	,	Others
need	VBP	Others
for	IN	Others
electrocautery	NN	Others
,	,	Others
laryngeal	JJ	Others
spasm	NN	Others
,	,	Others
postoperative	JJ	Others
bleeding	NN	Others
and	CC	Others
pain	NN	Others
,	,	Others
duration	NN	Others
of	IN	Others
procedure	NN	Others
and	CC	Others
duration	NN	Others
of	IN	Others
patients	NNS	Others
'	POS	Others
stay	NN	Others
in	IN	Others
the	DT	Others
operation	NN	Others
room	NN	Others
(	(	Others
OR	NNP	Others
)	)	Others
.	.	O

RESULTS	NNP	O
Adrenaline	NNP	O
significantly	RB	O
decreased	VBD	O
surgeons	NNS	O
'	POS	O
subjective	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
amount	NN	Physical
of	IN	Physical
intraoperative	JJ	Physical
bleeding	NN	Physical
(	(	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
significant	JJ	O
decrease	NN	O
67	CD	O
versus	NN	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
reduced	VBD	O
the	DT	O
mean	JJ	O
number	NN	Others
of	IN	Others
packings	NNS	Others
needed	VBN	Others
(	(	O
0.6	CD	O
versus	NN	O
1.2	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
use	NN	Others
of	IN	Others
electrocautery	NN	Others
(	(	O
22	CD	O
versus	RB	O
45	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.015	CD	O
)	)	O
,	,	O
and	CC	O
shortened	VBD	O
the	DT	O
mean	JJ	O
duration	NN	Others
of	IN	Others
the	DT	Others
procedure	NN	Others
(	(	O
13	CD	O
versus	NN	O
18	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
and	CC	O
the	DT	O
mean	JJ	O
stay	NN	Others
in	IN	Others
the	DT	Others
OR	NNP	Others
(	(	O
31	CD	O
versus	NN	O
35	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.058	CD	O
)	)	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
adrenaline	NN	O
was	VBD	O
even	RB	O
more	RBR	O
pronounced	JJ	O
among	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
adenoids	NNS	Physical
and/or	VBP	O
profuse	RB	O
intraoperative	JJ	Physical
bleeding	NN	Physical
.	.	O

A	DT	O
slight	JJ	O
elevation	NN	Physical
of	IN	Physical
heart	NN	Physical
rate	NN	Physical
was	VBD	O
observed	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
adrenaline	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
topical	JJ	O
adrenaline	NN	O
can	MD	O
be	VB	O
recommended	VBN	O
in	IN	O
adenoidectomy	NN	O
among	IN	O
children	NNS	O
.	.	O

It	PRP	O
helps	VBZ	O
control	VB	O
the	DT	O
intraoperative	JJ	Physical
bleeding	NN	Physical
,	,	O
reduces	VBZ	O
the	DT	O
use	NN	O
of	IN	O
electrocautery	NN	Others
and	CC	O
shortens	VBZ	O
the	DT	O
durations	NNS	O
of	IN	O
procedure	NN	Others
and	CC	Others
stay	VB	Others
in	IN	Others
the	DT	Others
OR	NNP	Others
.	.	O

Enhancing	VBG	O
antiepileptic	JJ	O
drug	NN	O
adherence	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Suboptimal	JJ	O
adherence	NN	O
to	TO	O
antiepileptic	JJ	O
drug	NN	O
(	(	O
AED	NNP	O
)	)	O
treatment	NN	O
is	VBZ	O
commonplace	NN	O
,	,	O
and	CC	O
increases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
status	NN	O
epilepticus	NN	O
and	CC	O
sudden	JJ	O
unexplained	JJ	O
death	NN	O
in	IN	O
epilepsy	NN	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
demonstrate	VB	O
whether	IN	O
an	DT	O
implementation	NN	O
intention	NN	O
intervention	NN	O
involving	VBG	O
the	DT	O
completion	NN	O
of	IN	O
a	DT	O
simple	JJ	O
self-administered	JJ	O
questionnaire	NN	O
linking	VBG	O
the	DT	O
intention	NN	O
of	IN	O
taking	VBG	O
medication	NN	O
with	IN	O
a	DT	O
particular	JJ	O
time	NN	O
,	,	O
place	NN	O
,	,	O
and	CC	O
other	JJ	O
activity	NN	O
can	MD	O
improve	VB	O
AED	NNP	O
treatment	NN	O
schedule	NN	O
adherence	NN	O
.	.	O

Of	IN	O
the	DT	O
81	CD	O
patients	NNS	O
with	IN	O
epilepsy	NN	O
who	WP	O
were	VBD	O
randomized	VBN	O
,	,	O
69	CD	O
completed	VBD	O
a	DT	O
1-month	JJ	O
monitoring	NN	O
period	NN	O
with	IN	O
an	DT	O
objective	JJ	O
measure	NN	O
of	IN	O
tablet	NN	O
taking	NN	O
(	(	O
electronic	JJ	O
registration	NN	O
of	IN	O
pill	NN	O
bottle	JJ	O
openings	NNS	O
,	,	O
Medication	NNP	O
Event	NNP	O
Monitoring	NNP	O
System	NNP	O
[	NNP	O
MEMS	NNP	O
]	NNP	O
)	)	O
.	.	O

Intervention	NN	O
participants	NNS	O
showed	VBD	O
improved	JJ	Mental
adherence	RB	Mental
relative	JJ	Mental
to	TO	Mental
controls	VB	Mental
on	IN	O
all	DT	O
three	CD	O
outcomes	NNS	O
:	:	O
doses	NNS	Others
taken	VBN	Others
in	IN	Others
total	JJ	Others
(	(	O
93.4	CD	O
%	NN	O
vs.	FW	O
79.1	CD	O
%	NN	O
)	)	O
,	,	O
days	NNS	O
on	IN	O
which	WDT	O
correct	VBP	Others
dose	NN	Others
was	VBD	Others
taken	VBN	Others
(	(	O
88.7	CD	O
%	NN	O
vs.	FW	O
65.3	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
doses	VBZ	Others
taken	VBN	Others
on	IN	Others
schedule	NN	Others
(	(	O
78.8	CD	O
%	NN	O
vs.	FW	O
55.3	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
implementation	NN	O
intention	NN	O
intervention	NN	O
may	MD	O
be	VB	O
an	DT	O
easy-to-administer	JJ	O
and	CC	O
effective	JJ	O
means	NNS	O
of	IN	O
promoting	VBG	O
AED	NNP	O
adherence	NN	O
.	.	O

Measurement	NN	O
of	IN	O
peptidase	NN	Physical
activity	NN	Physical
and	CC	O
evaluation	NN	O
of	IN	O
effectiveness	NN	O
of	IN	O
administration	NN	O
of	IN	O
minocycline	NN	O
for	IN	O
treatment	NN	O
of	IN	O
dogs	NNS	O
with	IN	O
periodontitis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
clinical	JJ	Physical
,	,	Physical
enzymatic	JJ	Physical
,	,	Physical
and	CC	Physical
microbiologic	JJ	Adverseeffect
effects	NNS	Adverseeffect
of	IN	O
controlled-release	NN	O
localized	JJ	O
administration	NN	O
of	IN	O
minocycline	NN	O
on	IN	O
dogs	NNS	O
with	IN	O
periodontitis	NN	O
.	.	O

ANIMALS	NNP	O
Five	CD	O
adult	NN	O
Beagles	NNS	O
with	IN	O
periodontitis	NN	O
.	.	O

PROCEDURE	NNP	O
After	IN	O
tooth	CC	O
scaling	VBG	O
and	CC	O
root	NN	O
planing	NN	O
,	,	O
2	CD	O
treatment	NN	O
,	,	O
1	CD	O
placebo	NN	O
,	,	O
and	CC	O
1	CD	O
control	NN	O
site	NN	O
were	VBD	O
selected	VBN	O
for	IN	O
each	DT	O
dog	NN	O
.	.	O

Treatment	NN	O
sites	NNS	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
received	VBD	O
a	DT	O
periodontal	JJ	O
formulation	NN	O
of	IN	O
minocycline	NN	O
hydrochloride	NN	O
,	,	O
placebo	NN	O
sites	NNS	O
(	(	O
5	CD	O
)	)	O
received	VBD	O
ointment	JJ	O
without	IN	O
minocycline	NN	O
,	,	O
and	CC	O
control	VB	O
sites	NNS	O
(	(	O
5	CD	O
)	)	O
did	VBD	O
not	RB	O
receive	VB	O
ointment	NN	O
.	.	O

Treatments	NNS	O
were	VBD	O
administered	VBN	O
4	CD	O
times	NNS	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

Peptidase	NNP	Adverseeffect
activity	NN	Adverseeffect
and	CC	Adverseeffect
clinical	JJ	Adverseeffect
and	CC	Adverseeffect
microbiologic	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
evaluated	VBN	O
and	CC	O
compared	VBN	O
among	IN	O
sites	NNS	O
for	IN	O
17	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Bleeding	NNP	Physical
of	IN	Physical
the	DT	Physical
gums	NNS	Physical
on	IN	Physical
probing	VBG	Physical
(	(	Physical
BOP	NNP	Physical
)	)	Physical
and	CC	Physical
pocket	NN	Physical
depth	NN	Physical
(	(	Physical
PD	NNP	Physical
)	)	Physical
improved	VBD	Physical
at	IN	O
the	DT	O
treatment	NN	O
site	NN	O
and	CC	O
were	VBD	O
maintained	VBN	O
for	IN	O
13	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
BOP	NNP	Physical
and	CC	O
PD	NNP	Physical
in	IN	O
placebo	NN	O
and	CC	O
control	VB	O
sites	NNS	O
increased	VBN	O
from	IN	O
weeks	NNS	O
9	CD	O
to	TO	O
17	CD	O
Peptidase	NNP	Physical
activity	NN	Physical
in	IN	O
the	DT	O
periodontal	JJ	O
pocket	NN	O
decreased	VBD	O
noticeably	RB	O
from	IN	O
week	NN	O
1	CD	O
to	TO	O
17	CD	O
,	,	O
compared	VBN	O
with	IN	O
baseline	NN	O
values	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
site	NN	O
.	.	O

However	RB	O
,	,	O
peptidase	NN	Physical
activity	NN	Physical
for	IN	O
placebo	NN	O
and	CC	O
control	VB	O
sites	NNS	O
increased	VBN	O
and	CC	O
were	VBD	O
above	RB	O
baseline	JJ	O
values	NNS	O
on	IN	O
week	NN	O
9	CD	O
and	CC	O
week	NN	O
13	CD	O
,	,	O
respectively	RB	O
.	.	O

Total	JJ	Physical
bacterial	JJ	Physical
counts	NNS	Physical
decreased	VBN	O
by	IN	O
90	CD	O
%	NN	O
for	IN	O
treatment	NN	O
sites	NNS	O
and	CC	O
remained	VBD	O
at	IN	O
that	DT	O
value	NN	O
for	IN	O
13	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
control	NN	O
sites	NNS	O
,	,	O
bacterial	JJ	Physical
counts	NNS	Physical
increased	VBD	O
and	CC	O
reached	VBD	O
the	DT	O
baseline	NN	O
value	NN	O
on	IN	O
week	NN	O
17	CD	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
Increased	VBD	Physical
peptidase	NN	Physical
activity	NN	Physical
is	VBZ	O
correlated	VBN	O
with	IN	O
the	DT	O
progression	NN	O
of	IN	O
periodontitis	NN	O
in	IN	O
dogs	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
minocycline	NN	O
,	,	O
using	VBG	O
a	DT	O
localized	VBN	O
delivery	NN	O
system	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
dogs	NNS	O
for	IN	O
at	IN	O
least	JJS	O
13	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
drug	NN	O
administration	NN	O
.	.	O

The	DT	O
assessment	NN	O
of	IN	O
erythema	NN	Physical
and	CC	Physical
thickness	NN	Physical
on	IN	Physical
burn	NN	Physical
related	JJ	Physical
scars	NNS	Physical
during	IN	O
pressure	NN	O
garment	NN	O
therapy	NN	O
as	IN	O
a	DT	O
preventive	JJ	O
measure	NN	O
for	IN	O
hypertrophic	JJ	O
scarring	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
threefold	VBN	O
:	:	O
(	(	O
1	CD	O
)	)	O
Assess	IN	O
the	DT	O
pressure	NN	O
loss	NN	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
pressure	NN	O
garments	NNS	O
that	WDT	O
are	VBP	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertrophic	JJ	O
scars	NNS	O
after	IN	O
burn	JJ	O
injury	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
two	CD	O
different	JJ	O
levels	NNS	O
of	IN	O
compression	NN	O
on	IN	O
erythema	NN	Physical
and	CC	Physical
thickness	NN	Physical
of	IN	Physical
burn	NN	Physical
scars	NNS	Physical
and	CC	O
(	(	O
3	CD	O
)	)	O
examine	VBP	O
the	DT	O
association	NN	O
between	IN	O
erythema	NN	Physical
and	CC	Physical
thickness	NN	Physical
.	.	Physical

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
76	CD	O
burn	NN	O
scars	NNS	O
in	IN	O
60	CD	O
patients	NNS	O
were	VBD	O
objectively	RB	O
assessed	VBN	O
with	IN	O
the	DT	O
Minolta	NNP	Others
Chromameter	NNP	Others
CR-300	NNP	Others
for	IN	O
erythema	NN	O
and	CC	O
with	IN	O
the	DT	O
Dermascan	NNP	Physical
C	NNP	Physical
for	IN	Physical
thickness	NN	Physical
of	IN	Physical
the	DT	Physical
scar	NN	Physical
over	IN	O
a	DT	O
period	NN	O
of	IN	O
3	CD	O
months	NNS	O
.	.	O

Each	DT	O
patient	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
normal	JJ	O
or	CC	O
lower	JJR	O
compression	NN	O
class	NN	O
treatment	NN	O
,	,	O
with	IN	O
respectively	JJ	O
mean	JJ	O
values	NNS	O
of	IN	O
15	CD	O
and	CC	O
10	CD	O
mmHg	NN	O
pressure	NN	O
after	IN	O
wearing	VBG	O
the	DT	O
garment	NN	O
for	IN	O
1	CD	O
month	NN	O
.	.	O

Measurements	NNS	O
for	IN	O
both	DT	O
parameters	NNS	O
were	VBD	O
taken	VBN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Pressure	NN	O
garments	NNS	O
with	IN	O
normal	JJ	O
compression	NN	O
did	VBD	O
lose	VB	O
significantly	RB	O
more	JJR	O
compression	NN	Others
over	IN	O
1	CD	O
month	NN	O
(	(	O
4.82	CD	O
mmHg	NN	O
)	)	O
than	IN	O
did	VBD	O
the	DT	O
garments	NNS	O
from	IN	O
the	DT	O
low	JJ	O
compression	NN	O
class	NN	O
(	(	O
2.57	CD	O
mmHg	NN	O
)	)	O
.	.	O

Scars	NNS	Physical
that	WDT	O
were	VBD	O
treated	VBN	O
with	IN	O
garments	NNS	O
from	IN	O
a	DT	O
normal	JJ	O
compression	NN	O
class	NN	O
did	VBD	O
score	RB	O
significantly	RB	O
better	RBR	O
for	IN	O
thickness	NN	Physical
compared	VBN	O
to	TO	O
the	DT	O
low	JJ	O
compression	NN	O
class	NN	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
thickness	NN	Physical
was	VBD	O
most	RBS	O
evident	JJ	O
at	IN	O
1	CD	O
month	NN	O
.	.	O

Thereafter	NNP	O
no	DT	O
further	JJ	O
significant	JJ	O
improvement	NN	O
between	IN	O
the	DT	O
two	CD	O
different	JJ	O
treatments	NNS	O
over	IN	O
time	NN	O
could	MD	O
be	VB	O
obtained	VBN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
found	VBN	O
for	IN	O
erythema	NN	Physical
.	.	Physical

Positive	JJ	O
correlations	NNS	O
could	MD	O
be	VB	O
found	VBN	O
between	IN	O
erythema	NN	Physical
and	CC	Physical
thickness	NN	Physical
values	NNS	Physical
at	IN	O
all	DT	O
of	IN	O
the	DT	O
three	CD	O
test	NN	O
points	NNS	O
while	IN	O
changes	NNS	O
in	IN	O
erythema	NN	Physical
and	CC	Physical
thickness	NN	Physical
only	RB	O
correlated	VBD	O
significantly	RB	O
after	IN	O
the	DT	O
first	JJ	O
month	NN	O
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
change	NN	O
of	IN	O
both	DT	O
parameters	NNS	O
correlated	VBN	O
at	IN	O
a	DT	O
high	JJ	O
level	NN	O
of	IN	O
significance	NN	O
after	IN	O
3	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
pressure	NN	O
garments	NNS	O
that	WDT	O
deliver	VBP	O
a	DT	O
pressure	NN	O
of	IN	O
at	IN	O
least	JJS	O
15	CD	O
mmHg	JJ	O
pressure	NN	O
tend	VBP	O
to	TO	O
accelerate	VB	O
scar	NN	Physical
maturation	NN	Physical
and	CC	O
that	IN	O
measurements	NNS	O
of	IN	O
the	DT	O
pattern	NN	O
of	IN	O
change	NN	O
of	IN	O
the	DT	O
erythema	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
changes	NNS	O
in	IN	O
scar	NN	O
thickness	NN	O
and	CC	O
vice	NN	O
versa	NN	O
.	.	O

Clinical	JJ	O
benefit	NN	O
with	IN	O
docetaxel	JJ	O
plus	CC	O
fluorouracil	JJ	O
and	CC	O
cisplatin	NNS	O
compared	VBN	O
with	IN	O
cisplatin	NN	O
and	CC	O
fluorouracil	NN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
of	IN	O
advanced	JJ	O
gastric	NN	O
or	CC	O
gastroesophageal	NN	O
cancer	NN	O
adenocarcinoma	NN	O
:	:	O
the	DT	O
V-325	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
For	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	NN	O
or	CC	O
gastroesophageal	NN	O
cancer	NN	O
(	(	O
AGGEC	NNP	O
)	)	O
providing	VBG	O
clinical	JJ	O
benefit	NN	O
with	IN	O
improved	JJ	O
palliation	NN	O
is	VBZ	O
highly	RB	O
desirable	JJ	O
.	.	O

However	RB	O
,	,	O
a	DT	O
prospective	JJ	O
evaluation	NN	O
of	IN	O
clinical	JJ	O
benefit	NN	O
in	IN	O
AGGEC	NNP	O
patients	NNS	O
has	VBZ	O
never	RB	O
before	RB	O
been	VBN	O
reported	VBN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
setting	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
multinational	JJ	O
trial	NN	O
(	(	O
V325	NNP	O
)	)	O
,	,	O
445	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
and	CC	O
treated	VBN	O
with	IN	O
either	DT	O
docetaxel	JJ	O
plus	CC	O
cisplatin	JJ	O
and	CC	O
fluorouracil	NN	O
(	(	O
DCF	NNP	O
)	)	O
or	CC	O
cisplatin	NN	O
and	CC	O
fluorouracil	NN	O
(	(	O
CF	NNP	O
)	)	O
.	.	O

Clinical	JJ	O
benefit	NN	O
was	VBD	O
prospectively	RB	O
evaluated	VBN	O
in	IN	O
this	DT	O
trial	NN	O
as	IN	O
a	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
.	.	O

The	DT	O
primary	JJ	O
measure	NN	O
for	IN	O
clinical	JJ	O
benefit	NN	O
analysis	NN	O
was	VBD	O
time	NN	Physical
to	TO	Physical
definitive	VB	Physical
worsening	NN	Physical
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
categories	NNS	O
of	IN	O
Karnofsky	NNP	Physical
performance	NN	Physical
status	NN	Physical
(	(	O
KPS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
clinical	JJ	O
benefit	NN	O
end	NN	O
points	NNS	O
included	VBD	O
time	NN	Physical
to	TO	Physical
5	CD	Physical
%	NN	Physical
definitive	JJ	Physical
weight	NN	Physical
loss	NN	Physical
,	,	Physical
time	NN	Physical
to	TO	Physical
definitive	JJ	Physical
worsening	NN	Physical
of	IN	Physical
appetite	NN	Physical
by	IN	Physical
one	CD	Physical
grade	NN	Physical
,	,	Physical
pain-free	JJ	Mortality
survival	NN	Mortality
(	(	Physical
defined	VBN	Physical
as	IN	Physical
time	NN	Pain
to	TO	Pain
first	JJ	Pain
appearance	NN	Pain
of	IN	Pain
pain	NN	Pain
)	)	Physical
,	,	Physical
and	CC	Physical
time	NN	Physical
to	TO	Physical
first	JJ	Physical
cancer	NN	Physical
pain-related	JJ	Physical
opioid	JJ	Physical
intake	NN	Physical
.	.	Physical

Clinical	JJ	O
benefit	NN	O
assessments	NNS	O
were	VBD	O
recorded	VBN	O
at	IN	O
each	DT	O
clinic	JJ	O
visit	NN	O
.	.	O

RESULTS	NNP	O
Clinical	JJ	O
benefit	NN	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
more	JJR	O
than	IN	O
75	CD	O
%	NN	O
of	IN	O
patients	NNS	O
throughout	IN	O
V325	NNP	O
.	.	O

DCF	NNP	O
significantly	RB	O
prolonged	VBD	O
time	NN	Physical
to	TO	Physical
definitive	JJ	Physical
worsening	NN	Physical
of	IN	Physical
KPS	NNP	Physical
compared	VBN	O
with	IN	O
CF	NNP	O
(	(	O
median	JJ	O
,	,	O
6.1	CD	O
v	NN	O
4.8	CD	O
months	NNS	O
;	:	O
hazard	RB	O
ratio	NN	O
,	,	O
1.38	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.08	CD	O
to	TO	O
1.76	CD	O
;	:	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
.009	NNP	O
)	)	O
.	.	O

Although	IN	O
time	NN	Physical
to	TO	Physical
definitive	JJ	Physical
weight	NN	Physical
loss	NN	Physical
and	CC	Physical
time	NN	Physical
to	TO	Physical
definitive	JJ	Physical
worsening	NN	Physical
of	IN	Physical
appetite	NN	Physical
favored	VBN	O
DCF	NNP	O
,	,	O
the	DT	O
results	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Pain-free	JJ	Pain
survival	NN	Pain
and	CC	Pain
time	NN	Pain
to	TO	Pain
first	JJ	Pain
cancer	NN	Pain
pain-related	JJ	Pain
opioid	JJ	Pain
intake	NN	Pain
were	VBD	O
comparable	JJ	O
.	.	O

CONCLUSION	NN	O
To	TO	O
our	PRP$	O
knowledge	NN	O
,	,	O
V325	NNP	O
is	VBZ	O
the	DT	O
first	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
to	TO	O
report	VB	O
clinical	JJ	O
benefit	NN	O
in	IN	O
AGGEC	NNP	O
patients	NNS	O
.	.	O

Clinical	JJ	O
benefit	NN	O
was	VBD	O
assessed	VBN	O
beyond	IN	O
protocol-specific	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
D	NNP	O
to	TO	O
CF	NNP	O
not	RB	O
only	RB	O
significantly	RB	O
improved	VBN	O
clinical	JJ	O
benefit	NN	O
but	CC	O
also	RB	O
improved	JJ	O
quality	NN	Others
of	IN	Others
life	NN	Others
,	,	Physical
time	NN	Physical
to	TO	Physical
progression	NN	Physical
,	,	Physical
and	CC	Physical
overall	JJ	Mortality
survival	NN	Mortality
compared	VBN	O
with	IN	O
CF	NNP	O
.	.	O

Quantification	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	O
human	JJ	O
plasma	NN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
in	IN	O
a	DT	O
bioequivalence	NN	O
study	NN	O
.	.	O

A	DT	O
rapid	JJ	O
,	,	O
sensitive	JJ	O
and	CC	O
specific	JJ	O
method	NN	O
to	TO	O
quantify	VB	O
cyproheptadine	NN	O
in	IN	O
human	JJ	O
plasma	NN	O
using	VBG	O
amitriptyline	NN	O
as	IN	O
the	DT	O
internal	JJ	O
standard	NN	O
(	(	O
IS	NNP	O
)	)	O
is	VBZ	O
described	VBN	O
.	.	O

The	DT	O
analyte	NN	O
and	CC	O
the	DT	O
IS	NNP	O
were	VBD	O
extracted	VBN	O
from	IN	O
plasma	NN	O
by	IN	O
liquid-liquid	JJ	O
extraction	NN	O
using	VBG	O
a	DT	O
diethyl-ether/dichloromethane	NN	O
(	(	O
70/30	CD	O
;	:	O
v/v	NN	O
)	)	O
solvent	NN	O
.	.	O

After	IN	O
removing	VBG	O
and	CC	O
drying	VBG	O
the	DT	O
organic	JJ	O
phase	NN	O
,	,	O
the	DT	O
extracts	NNS	O
were	VBD	O
reconstituted	VBN	O
with	IN	O
a	DT	O
fixed	JJ	O
volume	NN	O
of	IN	O
acetonitrile/water	NN	O
(	(	O
50/50	CD	O
v/v	NN	O
)	)	O
+0.1	CD	O
%	NN	O
of	IN	O
acetic	JJ	O
acid	NN	O
.	.	O

The	DT	O
extracts	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
high	JJ	O
performance	NN	O
liquid	NN	O
chromatography	NN	O
coupled	VBD	O
to	TO	O
electrospray	VB	O
tandem	JJ	O
mass	NN	O
spectrometry	NN	O
(	(	O
LC-MS/MS	NNP	O
)	)	O
.	.	O

Chromatography	NNP	O
was	VBD	O
performed	VBN	O
isocratically	RB	O
using	VBG	O
an	DT	O
Alltech	NNP	O
Prevail	NNP	O
C18	NNP	O
5	CD	O
?m	NNP	O
analytical	JJ	O
column	NN	O
,	,	O
(	(	O
150	CD	O
mm	NN	O
x	VBD	O
4.6	CD	O
mm	NNS	O
I.D.	NNP	O
)	)	O
.	.	O

The	DT	O
method	NN	O
had	VBD	O
a	DT	O
chromatographic	JJ	O
run	NN	O
time	NN	O
of	IN	O
4	CD	O
min	NNS	O
and	CC	O
a	DT	O
linear	JJ	O
calibration	NN	O
curve	NN	O
ranging	VBG	O
from	IN	O
0.05	CD	O
to	TO	O
10	CD	O
ng/mL	NNS	O
(	(	O
r2	VB	O
>	RB	O
0.99	CD	O
)	)	O
.	.	O

The	DT	O
limit	NN	O
of	IN	O
quantification	NN	O
was	VBD	O
0.05	CD	O
ng/mL	RB	O
.	.	O

This	DT	O
HPLC/MS/MS	NNP	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
bioequivalence	NN	O
of	IN	O
cyproheptadine	NN	O
in	IN	O
two	CD	O
cyproheptadine	NN	O
+	NNS	O
cobamamide	VBP	O
(	(	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
)	)	O
tablet	NN	O
formulations	NNS	O
(	(	O
Cobactin?	NNP	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
test	NN	O
formulation	NN	O
supplied	VBN	O
from	IN	O
Zambon	NNP	O
Laborat?rios	NNP	O
Farmac?uticos	NNP	O
Ltda	NNP	O
.	.	O

and	CC	O
Cobavital?	NNP	O
from	IN	O
Solvay	NNP	O
Farma	NNP	O
(	(	O
standard	JJ	O
reference	NN	O
formulation	NN	O
)	)	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
4	CD	O
mg	NN	O
+	VBD	O
1	CD	O
mg	NN	O
[	NNP	O
cyproheptadine	NN	O
+	NNP	O
cobamamide	NN	O
]	NNP	O
dose	NN	O
of	IN	O
each	DT	O
formulation	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
two-period	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
interval	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
CI	NNP	O
for	IN	O
Cmax	NNP	O
and	CC	O
AUCs	NNP	O
ratios	NNS	O
were	VBD	O
all	DT	O
within	IN	O
the	DT	O
80-125	JJ	O
%	NN	O
bioequivalence	NN	O
limit	NN	O
proposed	VBN	O
by	IN	O
the	DT	O
US	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
,	,	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
cyproheptadine	JJ	O
test	NN	O
formulation	NN	O
(	(	O
Cobactin?	NNP	O
)	)	O
is	VBZ	O
bioequivalent	JJ	O
to	TO	O
the	DT	O
Cobavital?	NNP	O
formulation	NN	O
for	IN	O
both	DT	O
the	DT	O
rate	NN	O
and	CC	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
cyproheptadine	NN	O
.	.	O

Therapeutic	JJ	Physical
angiogenesis	NN	Physical
for	IN	O
patients	NNS	O
with	IN	O
limb	JJ	O
ischaemia	NN	O
by	IN	O
autologous	JJ	O
transplantation	NN	O
of	IN	O
bone-marrow	JJ	O
cells	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
and	CC	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Preclinical	NNP	O
studies	NNS	O
have	VBP	O
established	VBN	O
that	IN	O
implantation	NN	O
of	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
,	,	O
including	VBG	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
,	,	O
into	IN	O
ischaemic	JJ	O
limbs	NN	O
increases	VBZ	O
collateral	JJ	Physical
vessel	NN	Physical
formation	NN	Physical
.	.	O

We	PRP	O
investigated	VBD	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
autologous	JJ	O
implantation	NN	O
of	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ischaemic	JJ	O
limbs	NNS	O
because	IN	O
of	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
first	RB	O
did	VBD	O
a	DT	O
pilot	NN	O
study	NN	O
,	,	O
in	IN	O
which	WDT	O
25	CD	O
patients	NNS	O
(	(	O
group	NN	O
A	DT	O
)	)	O
with	IN	O
unilateral	JJ	O
ischaemia	NN	O
of	IN	O
the	DT	O
leg	NN	O
were	VBD	O
injected	VBN	O
with	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
into	IN	O
the	DT	O
gastrocnemius	NN	O
of	IN	O
the	DT	O
ischaemic	JJ	O
limb	NN	O
and	CC	O
with	IN	O
saline	NN	O
into	IN	O
the	DT	O
less	JJR	O
ischaemic	JJ	O
limb	NN	O
.	.	O

We	PRP	O
then	RB	O
recruited	VBD	O
22	CD	O
patients	NNS	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
with	IN	O
bilateral	JJ	O
leg	NN	O
ischaemia	NN	O
,	,	O
who	WP	O
were	VBD	O
randomly	RB	O
injected	VBN	O
with	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
in	IN	O
one	CD	O
leg	NN	O
and	CC	O
peripheral	JJ	O
blood-mononuclear	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
other	JJ	O
as	IN	O
a	DT	O
control	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
were	VBD	O
safety	NN	Others
and	CC	Others
feasibility	NN	Others
of	IN	Others
treatment	NN	Others
,	,	O
based	VBN	O
on	IN	O
ankle-brachial	JJ	Physical
index	NN	Physical
(	(	Physical
ABI	NNP	Physical
)	)	Physical
and	CC	O
rest	NN	Pain
pain	NN	Pain
,	,	O
and	CC	O
analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

FINDINGS	NNP	O
Two	CD	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
group	NN	O
B	NNP	O
after	IN	O
randomisation	NN	O
.	.	O

At	IN	O
4	CD	O
weeks	NNS	O
in	IN	O
group	NN	O
B	NNP	O
patients	NNS	O
,	,	O
ABI	NNP	Physical
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
legs	NNS	O
injected	VBN	O
with	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
injected	VBN	O
with	IN	O
peripheral	JJ	O
blood-mononuclear	JJ	O
cells	NNS	O
(	(	O
difference	NN	O
0.09	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
0.06-0.11	CD	O
]	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.0001	CD	O
)	)	O
.	.	O

Similar	JJ	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
transcutaneous	JJ	Physical
oxygen	NN	Physical
pressure	NN	Physical
(	(	O
13	CD	O
[	RB	O
9-17	CD	O
]	NNS	O
;	:	O
p	VB	O
<	$	O
0.0001	CD	O
)	)	O
,	,	O
rest	VBP	Pain
pain	NN	Pain
(	(	O
-0.85	JJ	O
[	NNP	O
-1.6	NN	O
to	TO	O
-0.12	VB	O
]	NNP	O
;	:	O
p=0.025	NN	O
)	)	O
,	,	O
and	CC	O
pain-free	JJ	Pain
walking	NN	Pain
time	NN	Pain
(	(	O
1.2	CD	O
[	RB	O
0.7-1.7	JJ	O
]	NN	O
;	:	O
p=0.0001	NN	O
)	)	O
.	.	O

These	DT	O
improvements	NNS	O
were	VBD	O
sustained	VBN	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Similar	JJ	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
group	NN	O
A	DT	O
patients	NNS	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
died	VBD	Mortality
after	IN	Mortality
myocardial	JJ	Mortality
infarction	NN	Mortality
unrelated	VBD	O
to	TO	O
treatment	NN	O
.	.	O

INTERPRETATION	NNP	O
Autologous	NNP	O
implantation	NN	O
of	IN	O
bone	NN	O
marrow-mononuclear	JJ	O
cells	NNS	O
could	MD	O
be	VB	O
safe	JJ	Others
and	CC	Others
effective	JJ	Others
for	IN	O
achievement	NN	O
of	IN	O
therapeutic	JJ	Physical
angiogenesis	NN	Physical
,	,	O
because	IN	O
of	IN	O
the	DT	O
natural	JJ	O
ability	NN	O
of	IN	O
marrow	NN	O
cells	NNS	O
to	TO	O
supply	VB	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
and	CC	O
to	TO	O
secrete	VB	O
various	JJ	O
angiogenic	JJ	O
factors	NNS	O
or	CC	O
cytokines	NNS	O
.	.	O

A	DT	O
study	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
duration	NN	O
of	IN	O
subcutaneous	JJ	O
heparin	NN	O
injection	NN	O
on	IN	O
bruising	NN	O
and	CC	O
pain	NN	O
.	.	O

AIM	NNP	O
This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
injection	NN	O
duration	NN	O
on	IN	O
bruising	NN	O
and	CC	O
pain	NN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
subcutaneous	JJ	O
injection	NN	O
of	IN	O
heparin	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
different	JJ	O
methods	NNS	O
to	TO	O
prevent	VB	O
bruising	NN	O
and	CC	O
pain	NN	O
following	VBG	O
the	DT	O
subcutaneous	JJ	O
injection	NN	O
of	IN	O
heparin	NNS	O
have	VBP	O
been	VBN	O
widely	RB	O
studied	VBN	O
and	CC	O
described	VBN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
injection	NN	O
duration	NN	O
on	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
bruising	NN	O
and	CC	O
pain	NN	O
is	VBZ	O
little	RB	O
documented	JJ	O
.	.	O

DESIGN	VB	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
within-subject	JJ	O
,	,	O
quasi-experimental	JJ	O
research	NN	O
.	.	O

METHOD	NNP	O
The	DT	O
sample	NN	O
for	IN	O
the	DT	O
study	NN	O
consisted	VBD	O
of	IN	O
50	CD	O
patients	NNS	O
to	TO	O
whom	WP	O
subcutaneous	JJ	O
heparin	NN	O
was	VBD	O
administered	VBN	O
.	.	O

Heparin	NNP	O
was	VBD	O
injected	VBN	O
over	IN	O
10	CD	O
seconds	NNS	O
on	IN	O
the	DT	O
right	JJ	O
abdominal	JJ	O
site	NN	O
and	CC	O
30	CD	O
seconds	NNS	O
on	IN	O
the	DT	O
left	JJ	O
abdominal	JJ	O
site	NN	O
.	.	O

Injections	NNS	O
areas	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
bruising	VBG	Physical
at	IN	O
48	CD	O
and	CC	O
72	CD	O
hours	NNS	O
after	IN	O
each	DT	O
injection	NN	O
.	.	O

Dimensions	NNS	O
of	IN	O
the	DT	O
bruising	NN	O
on	IN	O
the	DT	O
heparin	NN	O
applied	VBN	O
areas	NNS	O
were	VBD	O
measured	VBN	O
using	VBG	O
transparent	JJ	O
millimetric	JJ	O
measuring	VBG	O
paper	NN	O
.	.	O

The	DT	O
visual	JJ	Others
analog	NN	Others
scale	NN	Others
(	(	Others
VAS	NNP	Others
)	)	Others
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
pain	NN	O
intensity	NN	O
and	CC	O
a	DT	O
stop-watch	NN	O
was	VBD	O
used	VBN	O
to	TO	O
time	NN	O
the	DT	O
pain	NN	O
period	NN	O
.	.	O

Data	NNS	O
were	VBD	O
analysed	VBN	O
using	VBG	O
chi-square	JJ	O
test	NN	O
,	,	O
Mann-Whitney	NNP	O
U	NNP	O
,	,	O
Wilcoxon	NNP	O
signed	VBD	O
ranks	NNS	O
tests	NNS	O
and	CC	O
correlation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
percentage	NN	Physical
of	IN	Physical
bruising	VBG	Physical
occurrence	NN	Physical
was	VBD	O
64	CD	O
%	NN	O
with	IN	O
the	DT	O
injection	NN	O
of	IN	O
10	CD	O
seconds	NNS	O
duration	NN	O
and	CC	O
42	CD	O
%	NN	O
in	IN	O
the	DT	O
30-second	JJ	O
injection	NN	O
.	.	O

It	PRP	O
was	VBD	O
determined	VBN	O
that	IN	O
the	DT	O
size	NN	Physical
of	IN	Physical
the	DT	Physical
bruising	NN	Physical
was	VBD	O
smaller	JJR	O
in	IN	O
the	DT	O
30-second	JJ	O
injection	NN	O
.	.	O

Pain	NNP	Pain
intensity	NN	Pain
and	CC	Pain
pain	NN	Pain
period	NN	Pain
were	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
for	IN	O
the	DT	O
30-second	JJ	O
injection	NN	O
than	IN	O
for	IN	O
the	DT	O
10-second	JJ	O
injection	NN	O
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
was	VBD	O
determined	VBN	O
that	IN	O
injection	NN	O
duration	NN	O
had	VBD	O
an	DT	O
effect	NN	O
on	IN	O
bruising	NN	O
and	CC	O
pain	NN	O
following	VBG	O
the	DT	O
subcutaneous	JJ	O
administration	NN	O
of	IN	O
heparin	NN	O
.	.	O

This	DT	O
study	NN	O
should	MD	O
be	VB	O
repeated	VBN	O
on	IN	O
a	DT	O
larger	JJR	O
sample	NN	O
.	.	O

RELEVANCE	NNP	O
TO	NNP	O
CLINICAL	NNP	O
PRACTICE	NNP	O
When	WRB	O
administering	VBG	O
subcutaneous	JJ	O
heparin	NN	O
injections	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
extend	VB	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
injection	NN	O
.	.	O

Standardized	NNP	O
preoperative	JJ	O
corticosteroid	NN	O
treatment	NN	O
in	IN	O
neonates	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
A	DT	O
heightened	JJ	O
inflammatory	NN	O
response	NN	O
occurs	VBZ	O
after	IN	O
cardiac	JJ	O
surgery	NN	O
.	.	O

The	DT	O
perioperative	JJ	O
use	NN	O
of	IN	O
glucocorticoids	NNS	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
method	NN	O
to	TO	O
improve	VB	O
postoperative	JJ	O
outcomes	NNS	O
.	.	O

Randomized	VBN	O
prospective	JJ	O
studies	NNS	O
to	TO	O
quantify	VB	O
the	DT	O
effect	NN	O
of	IN	O
methylprednisolone	NN	O
on	IN	O
perioperative	JJ	O
outcomes	NNS	O
in	IN	O
neonatal	JJ	O
cardiac	NN	O
surgery	NN	O
have	VBP	O
not	RB	O
been	VBN	O
performed	VBN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
preoperative	JJ	O
methylprednisolone	NN	O
would	MD	O
improve	VB	O
postoperative	JJ	O
recovery	NN	O
in	IN	O
neonates	NNS	O
requiring	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
Neonates	NNP	O
scheduled	VBD	O
for	IN	O
cardiac	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
2-dose	JJ	O
(	(	O
8	CD	O
hours	NNS	O
preoperatively	RB	O
and	CC	O
operatively	RB	O
,	,	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
or	CC	O
single-dose	JJ	O
(	(	O
operatively	RB	O
,	,	O
n	JJ	O
=	NNP	O
37	CD	O
)	)	O
methylprednisolone	NN	O
(	(	O
30	CD	O
mg/kg	NN	O
per	IN	O
dose	NN	O
)	)	O
in	IN	O
a	DT	O
prospective	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
low	JJ	O
cardiac	JJ	O
output	NN	O
syndrome	NN	O
(	(	O
standardized	VBN	O
score	NN	O
)	)	O
or	CC	O
death	NN	O
36	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
death	NN	O
at	IN	O
30	CD	O
days	NNS	O
,	,	O
interleukin-6	JJ	O
levels	NNS	O
,	,	O
inotropic	NN	O
score	NN	O
,	,	O
fluid	NN	O
balance	NN	O
,	,	O
serum	JJ	O
creatinine	NN	O
,	,	O
and	CC	O
intensive	JJ	O
care	NN	O
unit	NN	O
and	CC	O
hospital	NN	O
stay	NN	O
.	.	O

RESULTS	NNP	O
Preoperative	NNP	O
plasma	NN	O
levels	NNS	O
of	IN	O
the	DT	O
inflammatory	JJ	O
cytokine	JJ	O
interleukin-6	NN	O
were	VBD	O
reduced	VBN	O
by	IN	O
2-fold	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
2-dose	JJ	O
methylprednisolone	NN	O
group	NN	O
,	,	O
consistent	NN	O
with	IN	O
the	DT	O
anti-inflammatory	JJ	O
effects	NNS	O
of	IN	O
methylprednisolone	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
low	JJ	O
cardiac	JJ	O
output	NN	O
syndrome	NN	O
was	VBD	O
46	CD	O
%	NN	O
(	(	O
17/37	CD	O
)	)	O
in	IN	O
the	DT	O
single-dose	JJ	O
and	CC	O
38	CD	O
%	NN	O
(	(	O
15/39	CD	O
)	)	O
in	IN	O
the	DT	O
2-dose	JJ	O
methylprednisolone	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.51	NNP	O
)	)	O
.	.	O

Two-dose	JJ	O
methylprednisolone	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
serum	NN	Physical
creatinine	NN	Physical
(	(	O
0.61	CD	O
?	.	O
0.18	CD	O
mg/dL	NN	O
vs	NN	O
0.53	CD	O
?	.	O
0.12	CD	O
mg/dL	NN	O
,	,	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
and	CC	O
poorer	$	O
postoperative	JJ	O
diuresis	NN	O
(	(	O
-96	VB	O
?	.	O
49	CD	O
mL	NN	O
,	,	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
.	.	O

Inotropic	NNP	O
requirement	NN	O
,	,	O
duration	NN	O
of	IN	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
intensive	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
hospital	JJ	O
stay	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Combined	NNP	O
preoperative	NN	O
and	CC	O
intraoperative	JJ	O
use	NN	O
of	IN	O
glucocorticoids	NNS	O
in	IN	O
neonatal	JJ	O
cardiac	JJ	O
surgery	NN	O
does	VBZ	O
not	RB	O
favorably	RB	O
affect	VBP	O
early	JJ	O
clinical	JJ	O
outcomes	NNS	O
and	CC	O
may	MD	O
exacerbate	VB	O
perioperative	JJ	O
renal	JJ	O
dysfunction	NN	O
.	.	O

Decompressive	JJ	O
craniectomy	NN	O
in	IN	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
:	:	O
the	DT	O
randomized	JJ	O
multicenter	NN	O
RESCUEicp	NNP	O
study	NN	O
(	(	O
www.RESCUEicp.com	NN	O
)	)	O
.	.	O

The	DT	O
RESCUEicp	NNP	O
(	(	O
Randomized	NNP	O
Evaluation	NNP	O
of	IN	O
Surgery	NNP	O
with	IN	O
Craniectomy	NNP	O
for	IN	O
Uncontrollable	JJ	O
Elevation	NN	O
of	IN	O
intracranial	JJ	O
pressure	NN	O
)	)	O
study	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
decompressive	JJ	O
craniectomy	NN	O
has	VBZ	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
and	CC	O
raised	VBD	O
intracranial	JJ	O
pressure	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
respond	VB	O
to	TO	O
initial	JJ	O
treatment	NN	O
measures	NNS	O
.	.	O

We	PRP	O
describe	VBP	O
the	DT	O
concept	NN	O
of	IN	O
decompressive	JJ	O
craniectomy	NN	O
in	IN	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
and	CC	O
the	DT	O
rationale	NN	O
and	CC	O
protocol	NN	O
of	IN	O
the	DT	O
RESCUEicp	NNP	O
study	NN	O
.	.	O

Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
adenosine	JJ	O
monophosphate	NN	O
bronchoprovocation	NN	O
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

AIMS	NNP	O
Adenosine	NNP	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
acts	VBZ	O
indirectly	RB	O
via	IN	O
primed	VBN	O
airway	RB	O
mast	JJ	O
cells	NNS	O
to	TO	O
induce	VB	O
bronchial	JJ	O
hyper-responsiveness	NN	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
correlates	NNS	O
with	IN	O
eosinophilic	JJ	Physical
asthmatic	JJ	Physical
inflammation	NN	Physical
and	CC	Physical
atopic	JJ	Physical
disease	NN	Physical
expression	NN	Physical
.	.	Physical

We	PRP	O
evaluated	VBD	O
single	JJ	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
a	DT	O
modern	JJ	O
histamine	NN	O
H1-receptor	NNP	O
antagonist	NN	O
,	,	O
levocetirizine	NN	O
,	,	O
given	VBN	O
at	IN	O
the	DT	O
usual	JJ	O
clinically	RB	O
recommended	VBD	O
dose	NN	O
,	,	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
AMP	NNP	O
bronchoprovocation	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	O
atopic	NN	O
asthmatics	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
fashion	NN	O
to	TO	O
receive	VB	O
for	IN	O
1	CD	O
week	NN	O
either	CC	O
levocetirizine	JJ	O
5	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

The	DT	O
provocative	JJ	O
concentration	NN	O
of	IN	O
AMP	NNP	O
producing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
after	IN	O
each	DT	O
washout	NN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
4-6	JJ	O
h	NN	O
following	VBG	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
mean	JJ	Physical
+/-	JJ	Physical
SEM	NNP	Physical
values	NNS	Physical
after	IN	O
washout	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
for	IN	O
prechallenge	NN	O
FEV1	NNP	Physical
(	(	O
%	NN	O
predicted	VBN	O
)	)	O
83	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
AMP	NNP	Physical
PC20	NNP	Physical
(	(	O
mg	JJ	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
45	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
45	CD	O
+/-	JJ	O
22	CD	O
,	,	O
respectively	RB	O
.	.	O

Airway	NNP	Physical
calibre	NN	Physical
as	IN	Physical
prechallenge	NN	Physical
FEV1	NNP	Physical
for	IN	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
86	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
85	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
83	CD	O
+/-	JJ	O
4	CD	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
improvements	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
AMP	NNP	Physical
PC20	NNP	Physical
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
123	CD	O
+/-	JJ	O
73	CD	O
vs	JJ	O
48	CD	O
+/-	JJ	O
24	CD	O
,	,	O
a	DT	O
1.4	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.8	CD	O
,	,	O
1.9	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
127	CD	O
+/-	JJ	O
74	CD	O
vs	JJ	O
53	CD	O
+/-	JJ	O
29	CD	O
,	,	O
a	DT	O
1.2	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.5	CD	O
,	,	O
2.0	CD	O
)	)	O
.	.	O

AMP	NNP	Physical
PC20	NNP	Physical
was	VBD	O
also	RB	O
improved	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
levocetirizine	NN	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
vs	FW	O
respective	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
between	IN	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
with	IN	O
levocetirizine	NN	O
conferred	VBN	O
similar	JJ	O
improvements	NNS	O
in	IN	O
bronchial	JJ	Physical
hyper-responsiveness	NN	Physical
to	TO	Physical
AMP	NNP	Physical
challenge	NN	O
,	,	O
which	WDT	O
was	VBD	O
unrelated	JJ	O
to	TO	O
prechallenge	VB	O
airway	RB	O
calibre	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
longer-term	JJ	O
effects	NNS	O
of	IN	O
levocetirizine	NN	O
on	IN	O
asthma	JJ	Physical
exacerbations	NNS	Physical
.	.	Physical

Lack	NN	O
of	IN	O
efficacy	NN	Others
of	IN	O
citalopram	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
high	JJ	O
levels	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
:	:	O
citalopram	NN	O
ineffective	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

CONTEXT	NNP	O
Selective	NNP	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
are	VBP	O
widely	RB	O
prescribed	VBN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
citalopram	JJ	O
hydrobromide	NN	O
therapy	NN	O
for	IN	O
repetitive	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

DESIGN	NNP	O
National	NNP	O
Institutes	NNPS	O
of	IN	O
Health-sponsored	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Six	NNP	O
academic	JJ	O
centers	NNS	O
,	,	O
including	VBG	O
Mount	NNP	O
Sinai	NNP	O
School	NNP	O
of	IN	O
Medicine	NNP	O
,	,	O
North	NNP	O
Shore-Long	NNP	O
Island	NNP	O
Jewish	NNP	O
Health	NNP	O
System	NNP	O
,	,	O
University	NNP	O
of	IN	O
North	NNP	O
Carolina	NNP	O
at	IN	O
Chapel	NNP	O
Hill	NNP	O
,	,	O
University	NNP	O
of	IN	O
California	NNP	O
at	IN	O
Los	NNP	O
Angeles	NNP	O
,	,	O
Yale	NNP	O
University	NNP	O
,	,	O
and	CC	O
Dartmouth	NNP	O
Medical	NNP	O
School	NNP	O
.	.	O

PARTICIPANTS	NNP	O
One	CD	O
hundred	VBD	O
forty-nine	JJ	O
volunteers	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
old	JJ	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
9.4	CD	O
[	NN	O
3.1	CD	O
]	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
citalopram	NN	O
(	(	O
n	JJ	O
=	NNP	O
73	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Participants	NNS	O
had	VBD	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
,	,	O
Asperger	NNP	O
disorder	NN	O
,	,	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
;	:	O
had	VBD	O
illness	JJ	O
severity	NN	O
ratings	NNS	O
of	IN	O
at	IN	O
least	JJS	O
moderate	JJ	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
,	,	O
Severity	NNP	O
of	IN	O
Illness	NNP	O
Scale	NNP	O
;	:	O
and	CC	O
scored	VBD	O
at	IN	O
least	JJS	O
moderate	JJ	O
on	IN	O
compulsive	JJ	O
behaviors	NNS	O
measured	VBN	O
with	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
(	(	O
10	CD	O
mg/5	RB	O
mL	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
maximum	JJ	O
dosage	NN	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
was	VBD	O
16.5	CD	O
(	(	O
6.5	CD	O
)	)	O
mg/d	NN	O
by	IN	O
mouth	NN	O
(	(	O
maximum	JJ	O
,	,	O
20	CD	O
mg/d	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Positive	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
a	DT	O
score	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	NNP	Mental
Global	NNP	Mental
Impressions	NNP	Mental
,	,	Mental
Improvement	NNP	Mental
subscale	NN	Mental
.	.	Mental

An	DT	O
important	JJ	O
secondary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
score	NN	O
on	IN	O
the	DT	O
Children	NNP	Mental
's	POS	Mental
Yale-Brown	JJ	Mental
Obsessive	NNP	Mental
Compulsive	NNP	Mental
Scales	NNP	Mental
modified	VBD	Mental
for	IN	Mental
pervasive	JJ	Mental
developmental	NN	Mental
disorders	NNS	Mental
.	.	Mental

Adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
systematically	RB	O
elicited	VBN	O
using	VBG	O
the	DT	O
Safety	NNP	O
Monitoring	NNP	O
Uniform	NNP	O
Report	NNP	O
Form	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	Mental
of	IN	Mental
positive	JJ	Mental
response	NN	Mental
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
,	,	O
Improvement	NNP	O
subscale	NN	O
between	IN	O
the	DT	O
citalopram-treated	JJ	O
group	NN	O
(	(	O
32.9	CD	O
%	NN	O
)	)	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
34.2	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk	NN	O
,	,	O
0.96	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.61-1.51	JJ	O
;	:	O
P	NNP	O
>	NNP	O
.99	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
score	NN	O
reduction	NN	O
on	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	JJ	O
disorders	NNS	O
from	IN	O
baseline	NN	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
,	,	O
-2.0	NNP	O
[	VBZ	O
3.4	CD	O
]	NN	O
points	NNS	O
for	IN	O
the	DT	O
citalopram-treated	JJ	O
group	NN	O
and	CC	O
-1.9	NNP	O
[	NNP	O
2.5	CD	O
]	NN	O
points	NNS	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
;	:	O
P	NNP	O
=	NNP	O
.81	NNP	O
)	)	O
.	.	O

Citalopram	NNP	O
use	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
particularly	RB	O
increased	VBD	O
energy	NN	O
level	NN	O
,	,	O
impulsiveness	NN	O
,	,	O
decreased	VBN	O
concentration	NN	Adverseeffect
,	,	Adverseeffect
hyperactivity	NN	Adverseeffect
,	,	Adverseeffect
stereotypy	NN	Adverseeffect
,	,	Adverseeffect
diarrhea	NN	Adverseeffect
,	,	Adverseeffect
insomnia	NN	Adverseeffect
,	,	Adverseeffect
and	CC	Adverseeffect
dry	JJ	Adverseeffect
skin	NN	Adverseeffect
or	CC	Adverseeffect
pruritus	NN	Adverseeffect
.	.	Adverseeffect

CONCLUSION	NNP	O
Results	NNP	O
of	IN	O
this	DT	O
trial	NN	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
citalopram	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Trial	JJ	O
Registration	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00086645	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
venepuncture	NN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
EMLA	NNP	O
cream	NN	O
and	CC	O
Ametop	NNP	O
gel	NN	O
in	IN	O
providing	VBG	O
analgesia	NN	O
for	IN	O
venous	JJ	O
cannulation	NN	O
.	.	O

METHODS	NNP	O
Single	NNP	O
blind	NN	O
study	NN	O
in	IN	O
120	CD	O
children	NNS	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
anaesthetic	JJ	O
agents	NNS	O
produced	VBN	O
adequate	JJ	Pain
analgesia	NN	Pain
.	.	O

However	RB	O
,	,	O
Ametop	NNP	O
gel	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
,	,	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
pain	NN	Pain
scores	NNS	Pain
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Project	NN	O
Towards	NNP	O
No	NNP	O
Drug	NNP	O
Abuse	NNP	O
:	:	O
long-term	JJ	O
substance	NN	O
use	NN	O
outcomes	VBZ	O
evaluation	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
paper	NN	O
presents	VBZ	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
post-program	JJ	O
outcomes	NNS	O
of	IN	O
Project	NNP	O
Towards	NNP	O
No	NNP	O
Drug	NNP	O
Abuse	NNP	O
(	(	O
Project	NNP	O
TND	NNP	O
)	)	O
,	,	O
a	DT	O
drug	NN	O
abuse	NN	O
prevention	NN	O
program	NN	O
conducted	VBN	O
in	IN	O
South	NNP	O
California	NNP	O
alternative	JJ	O
high	JJ	O
school	NN	O
system	NN	O
during	IN	O
years	NNS	O
1994-1999	JJ	O
.	.	O

METHODS	PDT	O
The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
9-session	JJ	O
health	NN	O
motivation	NN	O
--	:	O
social	JJ	O
skills	NNS	O
--	:	O
decision-making	JJ	O
curriculum	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

Twenty-one	CD	O
schools	NNS	O
recruited	VBN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
standard	VB	O
care	NN	O
(	(	O
control	NN	O
)	)	O
,	,	O
classroom	NN	O
only	RB	O
,	,	O
or	CC	O
a	DT	O
classroom	NN	O
plus	CC	O
semester-long	JJ	O
school-as-community	JJ	O
component	NN	O
.	.	O

Last	JJ	O
30-day	JJ	O
use	NN	O
of	IN	O
cigarettes	NNS	O
,	,	O
alcohol	NN	O
,	,	O
marijuana	NN	O
,	,	O
and	CC	O
hard	JJ	O
drugs	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
three	CD	O
time	NN	O
intervals	NNS	O
:	:	O
short-term	JJ	O
(	(	O
year	NN	O
1	CD	O
)	)	O
,	,	O
middle-term	JJ	O
(	(	O
years	NNS	O
2	CD	O
or	CC	O
3	CD	O
)	)	O
,	,	O
and	CC	O
long-term	JJ	O
(	(	O
years	NNS	O
4	CD	O
or	CC	O
5	CD	O
)	)	O
.	.	O

Multilevel	NNP	O
random	JJ	O
coefficients	NNS	O
modeling	VBG	O
were	VBD	O
employed	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
adjusted	JJ	O
levels	NNS	O
of	IN	O
substance	NN	O
use	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
1578	CD	O
baseline	NN	O
subjects	NNS	O
,	,	O
follow-up	JJ	O
data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
68	CD	O
%	NN	O
(	(	O
year	NN	O
1	CD	O
)	)	O
,	,	O
66	CD	O
%	NN	O
(	(	O
years	NNS	O
2	CD	O
or	CC	O
3	CD	O
)	)	O
,	,	O
and	CC	O
46	CD	O
%	NN	O
(	(	O
years	NNS	O
4	CD	O
or	CC	O
5	CD	O
)	)	O
of	IN	O
subjects	NNS	O
,	,	O
respectively	RB	O
.	.	O

Results	NNS	O
revealed	VBD	O
significant	JJ	O
positive	JJ	O
long-term	JJ	O
program	NN	O
effects	NNS	O
for	IN	O
hard	JJ	O
drug	NN	O
use	NN	O
at	IN	O
year	NN	O
4	CD	O
or	CC	O
5	CD	O
for	IN	O
the	DT	O
two	CD	O
program	NN	O
interventions	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Project	NNP	O
TND	NNP	O
reduced	VBD	O
hard	JJ	O
drug	NN	O
use	NN	O
in	IN	O
the	DT	O
46	CD	O
%	NN	O
who	WP	O
were	VBD	O
successfully	RB	O
followed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
the	DT	O
first	JJ	O
program	NN	O
to	TO	O
demonstrate	VB	O
long-term	JJ	O
self-reported	JJ	O
behavioral	JJ	O
effects	NNS	O
on	IN	O
hard	JJ	O
drug	NN	O
use	NN	O
among	IN	O
high-risk	JJ	O
youth	NN	O
by	IN	O
using	VBG	O
a	DT	O
school-based	JJ	O
,	,	O
limited-session	JJ	O
model	NN	O
.	.	O

Intravenous	JJ	O
sodium	NN	O
valproate	NN	O
versus	NN	O
diazepam	NN	O
infusion	NN	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
refractory	NN	O
status	NN	O
epilepticus	NN	O
in	IN	O
children	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

An	DT	O
open-label	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
a	DT	O
tertiary	JJ	O
care	NN	O
teaching	VBG	O
hospital	NN	O
to	TO	O
compare	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
intravenous	JJ	O
sodium	NN	O
valproate	NN	O
versus	NN	O
diazepam	NN	O
infusion	NN	O
for	IN	O
control	NN	O
of	IN	O
refractory	NN	O
status	NN	O
epilepticus	NN	O
.	.	O

Forty	NNP	O
children	NNS	O
with	IN	O
refractory	NN	O
status	NN	O
epilepticus	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
intravenous	JJ	O
sodium	NN	O
valproate	NN	O
or	CC	O
diazepam	JJ	O
infusion	NN	O
.	.	O

Refractory	JJ	Physical
status	NN	Physical
epilepticus	NN	Physical
was	VBD	O
controlled	VBN	O
in	IN	O
80	CD	O
%	NN	O
of	IN	O
the	DT	O
valproate	NN	O
and	CC	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
diazepam	NN	O
patients	NNS	O
.	.	O

The	DT	O
median	JJ	Others
time	NN	Others
to	TO	Others
control	VB	Others
refractory	JJ	Others
status	NN	Others
epilepticus	NN	Others
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
valproate	NN	O
group	NN	O
(	(	O
5	CD	O
minutes	NNS	O
)	)	O
than	IN	O
the	DT	O
diazepam	NN	O
group	NN	O
(	(	O
17	CD	O
minutes	NNS	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
valproate	NN	O
group	NN	O
required	VBN	O
ventilation	NN	Physical
or	CC	Physical
developed	JJ	Physical
hypotension	NN	Physical
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
diazepam	NN	O
group	NN	O
60	CD	O
%	NN	O
required	VBN	O
ventilation	NN	Physical
and	CC	O
50	CD	O
%	NN	O
developed	JJ	O
hypotension	NN	Physical
after	IN	O
starting	VBG	O
diazepam	JJ	O
infusion	NN	O
.	.	O

No	DT	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
on	IN	Adverseeffect
liver	NN	Adverseeffect
functions	NNS	Adverseeffect
were	VBD	O
seen	VBN	O
with	IN	O
valproate	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
intravenous	JJ	O
sodium	NN	O
valproate	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
diazepam	VB	O
infusion	NN	O
in	IN	O
controlling	VBG	O
refractory	NN	O
status	NN	O
epilepticus	NN	O
in	IN	O
children	NNS	O
and	CC	O
is	VBZ	O
free	JJ	O
of	IN	O
respiratory	JJ	O
depression	NN	O
and	CC	O
hypotension	NN	O
.	.	O

[	JJ	O
Obstetrical	NNP	O
analgesia	NN	O
with	IN	O
tramadol	JJ	O
]	NN	O
.	.	O

Parenteral	JJ	O
analgesia	NN	O
with	IN	O
Tramal	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
23	CD	O
normal	JJ	O
deliveries	NNS	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
of	IN	O
normal	JJ	O
deliveries	NNS	O
in	IN	O
which	WDT	O
analgesia	NN	Pain
was	VBD	O
achieved	VBN	O
with	IN	O
pethidine	NN	O
.	.	O

Both	DT	O
medicaments	NNS	O
excerted	VBD	O
an	DT	O
identical	JJ	Others
analgetic	JJ	Pain
efficiency	NN	Pain
.	.	O

No	DT	O
adverse	JJ	Adverseeffect
side	NN	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
with	IN	O
Tramal	NNP	O
concerning	VBG	O
the	DT	O
follow-up	NN	O
of	IN	O
labour	NN	O
or	CC	O
the	DT	O
newborn	JJ	O
.	.	O

Tramal	JJ	O
can	MD	O
be	VB	O
recommended	VBN	O
for	IN	O
obstetrical	JJ	Pain
analgesia	NN	Pain
since	IN	O
it	PRP	O
does	VBZ	O
not	RB	O
excert	VB	O
inhibitory	JJ	Physical
effects	NNS	Physical
upon	IN	O
the	DT	O
respiratory	NN	O
center	NN	O
.	.	O

Playing	VBG	O
on	IN	O
the	DT	O
typewriter	NN	O
,	,	O
typing	VBG	O
on	IN	O
the	DT	O
piano	NN	O
:	:	O
manipulation	NN	O
knowledge	NN	O
of	IN	O
objects	NNS	O
.	.	O

Two	CD	O
experiments	NNS	O
investigated	VBD	O
sensory/motor-based	JJ	Physical
functional	JJ	Physical
knowledge	NN	Physical
of	IN	O
man-made	JJ	O
objects	NNS	O
:	:	O
manipulation	NN	O
features	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
actual	JJ	O
usage	NN	O
of	IN	O
objects	NNS	O
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
prime-target	JJ	O
pairs	NNS	O
was	VBD	O
presented	VBN	O
auditorily	RB	O
,	,	O
and	CC	O
participants	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
make	VB	O
a	DT	O
lexical	JJ	O
decision	NN	O
on	IN	O
the	DT	O
target	NN	O
word	NN	O
.	.	O

Participants	NNS	O
made	VBD	O
a	DT	O
significantly	RB	O
faster	JJR	O
decision	NN	Physical
about	IN	O
the	DT	O
target	NN	O
word	NN	O
(	(	O
e.g	NN	O
.	.	O

'typewriter	CC	O
'	POS	O
)	)	O
following	VBG	O
a	DT	O
related	JJ	O
prime	NN	O
that	WDT	O
shared	VBD	O
manipulation	NN	O
features	NNS	O
with	IN	O
the	DT	O
target	NN	O
(	(	O
e.g	JJ	O
.	.	O

'piano	CC	O
'	POS	O
)	)	O
than	IN	O
an	DT	O
unrelated	JJ	O
prime	NN	O
(	(	O
e.g	NN	O
.	.	O

'blanket	CC	O
'	POS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
participants	NNS	O
'	POS	O
eye	NN	O
movements	NNS	O
were	VBD	O
monitored	VBN	O
when	WRB	O
they	PRP	O
viewed	VBD	O
a	DT	O
visual	JJ	O
display	NN	O
on	IN	O
a	DT	O
computer	NN	O
screen	NN	O
while	IN	O
listening	VBG	O
to	TO	O
a	DT	O
concurrent	JJ	O
auditory	NN	O
input	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
simply	RB	O
identify	VB	O
the	DT	O
auditory	NN	O
input	NN	O
and	CC	O
touch	VB	O
the	DT	O
corresponding	JJ	O
object	NN	O
on	IN	O
the	DT	O
computer	NN	O
display	NN	O
.	.	O

Participants	NNS	O
fixated	VBD	Physical
an	DT	O
object	JJ	O
picture	NN	O
(	(	O
e.g	JJ	O
.	.	O

typewriter	NN	O
)	)	O
related	VBN	O
to	TO	O
a	DT	O
target	NN	O
word	NN	O
(	(	O
e.g	NN	O
.	.	O

'piano	CC	O
'	POS	O
)	)	O
significantly	RB	O
more	RBR	O
often	RB	O
than	IN	O
an	DT	O
unrelated	JJ	O
object	JJ	O
picture	NN	O
(	(	O
e.g	JJ	O
.	.	O

bucket	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
visually	RB	O
matched	VBN	O
control	NN	O
(	(	O
e.g	JJ	O
.	.	O

couch	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
two	CD	O
experiments	NNS	O
suggest	VBP	O
that	IN	O
manipulation	NN	Physical
knowledge	NN	Physical
of	IN	Physical
words	NNS	Physical
is	VBZ	O
retrieved	VBN	O
without	IN	O
conscious	JJ	O
effort	NN	O
and	CC	O
that	DT	O
manipulation	NN	Physical
knowledge	NN	Physical
constitutes	VBZ	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
lexical-semantic	JJ	O
representation	NN	O
of	IN	O
objects	NNS	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
actinic	JJ	O
keratosis	NN	O
treatment	NN	O
with	IN	O
3	CD	O
%	NN	O
diclofenac	JJ	O
sodium	NN	O
and	CC	O
5	CD	O
%	NN	O
5-fluorouracil	JJ	O
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	O
keratosis	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
lesion	NN	O
which	WDT	O
occurs	VBZ	O
in	IN	O
sunlight	NN	O
exposed	VBN	O
areas	NNS	O
.	.	O

Diclofenac	NNP	O
sodium	NN	O
and	CC	O
5-Fluorouracil	JJ	O
are	VBP	O
effective	JJ	O
,	,	O
non-invasive	JJ	O
and	CC	O
easy-to-apply	JJ	O
topical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
assess	VB	Others
and	CC	Others
compare	VB	Others
the	DT	Others
effectiveness	NN	Others
of	IN	O
3	CD	O
%	NN	O
diclofenac	JJ	O
sodium	NN	O
associated	VBN	O
with	IN	O
2.5	CD	O
%	NN	O
hyaluronic	JJ	O
acid	NN	O
and	CC	O
of	IN	O
5	CD	O
%	NN	O
5-Fluorouracil	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
actinic	JJ	O
keratosis	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
degree	NN	O
of	IN	O
satisfaction	NN	O
and	CC	O
tolerability	NN	O
.	.	O

METHODS	NNP	O
28	CD	O
patients	NNS	O
with	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
actinic	JJ	O
keratosis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
diclofenac	JJ	O
sodium	NN	O
or	CC	O
5-Fluorouracil	JJ	O
and	CC	O
were	VBD	O
clinically	RB	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
as	RB	O
well	RB	O
as	IN	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

Modified	NNP	Physical
versions	NNS	Physical
of	IN	Physical
the	DT	Physical
Investigator	NNP	Physical
and	CC	Physical
Patient	NNP	Physical
Global	NNP	Physical
Improvement	NNP	Physical
Scores	NNP	Physical
were	VBD	O
used	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	Physical
number	NN	Physical
of	IN	Physical
lesions	NNS	Physical
in	IN	Others
the	DT	Others
diclofenac	NN	Others
sodium	NN	Others
group	NN	Others
before	IN	Others
and	CC	Others
after	IN	Others
treatment	NN	Others
was	VBD	O
13.6	CD	O
and	CC	O
6.6	CD	O
(	(	O
p	NN	O
<	RB	O
0,001	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
17.4	CD	O
and	CC	O
3.15	CD	O
(	(	O
p	NN	O
<	RB	O
0.001	CD	O
)	)	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	Others
of	IN	Others
lesions	NNS	Others
in	IN	Others
the	DT	Others
5-Fluorouracil	JJ	Others
group	NN	Others
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

To	TO	O
the	DT	O
non-blinded	JJ	O
physician	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
satisfactory	JJ	O
therapeutic	JJ	Physical
response	NN	Physical
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
to	TO	O
the	DT	O
blinded	JJ	O
physician	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
satisfactory	JJ	O
response	NN	O
in	IN	O
this	DT	O
same	JJ	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p=0.09	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
satisfaction	NN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
73	CD	O
%	NN	O
in	IN	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
and	CC	O
77	CD	O
%	NN	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
;	:	O
p=0.827	NN	O
)	)	O
.	.	O

Regarding	VBG	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
,	,	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
presented	VBD	O
a	DT	O
higher	JJR	O
degree	NN	O
of	IN	O
satisfaction	NN	O
(	(	O
93.3	CD	O
%	NN	O
vs	JJ	O
38.4	CD	O
%	NN	O
;	:	O
p=0.008	NN	O
)	)	O
.	.	O

Erythema	NNP	Adverseeffect
,	,	Adverseeffect
edema	NN	Adverseeffect
,	,	Adverseeffect
crusts	NNS	Adverseeffect
and	CC	Adverseeffect
itching	VBG	Adverseeffect
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
5-Fluorouracil	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
;	:	O
however	RB	O
,	,	O
it	PRP	O
showed	VBD	O
lower	JJR	O
tolerability	NN	O
than	IN	O
diclofenac	JJ	O
sodium	NN	O
.	.	O

Safety	NN	O
of	IN	O
intravitreous	JJ	O
fomivirsen	NN	O
for	IN	O
treatment	NN	O
of	IN	O
cytomegalovirus	NN	O
retinitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
report	VB	O
data	NNS	O
regarding	VBG	O
the	DT	O
safety	NN	O
of	IN	O
intravitreous	JJ	O
fomivirsen	NN	O
for	IN	O
treatment	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
retinitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Critical	NNP	O
review	NN	O
of	IN	O
safety	NN	O
data	NNS	O
from	IN	O
three	CD	O
randomized	NNS	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
with	IN	O
supplemental	JJ	O
information	NN	O
from	IN	O
an	DT	O
expanded	VBN	O
drug	NN	O
access	NN	O
program	NN	O
.	.	O

METHODS	NNP	O
Adverse	NNP	O
ocular	JJ	O
events	NNS	O
reported	VBN	O
by	IN	O
clinician	JJ	O
investigators	NNS	O
were	VBD	O
listed	VBN	O
using	VBG	O
terms	NNS	O
modified	VBN	O
from	IN	O
the	DT	O
COSTART	NNP	O
dictionary	NN	O
.	.	O

Data	NNP	O
for	IN	O
two	CD	O
doses	NNS	O
(	(	O
165-microg/injection	JJ	O
[	NN	O
35	CD	O
eyes	NNS	O
,	,	O
30	CD	O
patients	NNS	O
]	JJ	O
and	CC	O
330-microg/injection	JJ	O
[	NN	O
153	CD	O
eyes	NNS	O
,	,	O
120	CD	O
patients	NNS	O
]	JJ	O
)	)	O
and	CC	O
two	CD	O
330-microg/injection	JJ	O
dose	JJ	O
schedules	NNS	O
of	IN	O
different	JJ	O
intensity	NN	O
were	VBD	O
pooled	VBN	O
to	TO	O
calculate	VB	O
incidence	NN	O
rates	NNS	O
for	IN	O
each	DT	O
event	NN	O
.	.	O

Rates	NNS	O
were	VBD	O
calculated	VBN	O
as	IN	O
events/patient-year	JJ	O
(	(	O
based	VBN	O
on	IN	O
total	JJ	O
cumulative	JJ	O
reported	VBD	O
events	NNS	O
and	CC	O
duration	NN	O
of	IN	O
treatment	NN	O
)	)	O
for	IN	O
events	NNS	O
that	WDT	O
could	MD	O
recur	VB	O
during	IN	O
treatment	NN	O
.	.	O

Rates	NNS	O
were	VBD	O
calculated	VBN	O
as	IN	O
patients	NNS	O
with	IN	O
events/person-year	JJ	O
for	IN	O
the	DT	O
following	JJ	O
events	NNS	O
:	:	O
retinal	JJ	O
detachment	NN	O
,	,	O
cataract	NN	O
,	,	O
visual	JJ	O
field	NN	O
disturbance	NN	O
,	,	O
and	CC	O
retinal	JJ	O
pigment	NN	O
epitheliopathy	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
ability	NN	O
to	TO	O
manage	VB	O
events	NNS	O
,	,	O
we	PRP	O
reviewed	VBD	O
treatments	NNS	O
given	VBN	O
for	IN	O
two	CD	O
events	NNS	O
(	(	O
anterior	JJ	O
chamber	NN	O
inflammation	NN	O
,	,	O
increased	VBD	O
intraocular	JJ	O
pressure	NN	O
)	)	O
in	IN	O
one	CD	O
trial	NN	O
.	.	O

We	PRP	O
also	RB	O
report	VBP	O
an	DT	O
analysis	NN	O
comparing	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
eyes	NNS	O
that	WDT	O
developed	VBD	O
one	CD	O
or	CC	O
more	JJR	O
key	JJ	O
events	NNS	O
to	TO	O
the	DT	O
cumulative	JJ	O
number	NN	O
of	IN	O
injections	NNS	O
.	.	O

RESULTS	JJ	O
Incidence	NN	O
rates	NNS	O
were	VBD	O
dose	JJ	O
and	CC	O
schedule	JJ	O
dependent	NN	O
(	(	O
165	CD	O
microg/injection	NN	O
,	,	O
4.06	CD	O
events/patient-year	JJ	O
;	:	O
330	CD	O
microg/injection	NN	O
,	,	O
6.58	CD	O
events/patient-year	JJ	O
[	NNP	O
less	JJR	O
intense	JJ	O
regimen	NNS	O
]	VBP	O
and	CC	O
8.35	CD	O
events/patient-year	JJ	O
[	NNP	O
more	JJR	O
intense	JJ	O
regimen	NNS	O
]	VBP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBN	O
events	NNS	O
were	VBD	O
anterior	JJ	Adverseeffect
chamber	NN	Adverseeffect
inflammation	NN	Adverseeffect
and	CC	O
increased	VBD	Adverseeffect
intraocular	JJ	Adverseeffect
pressure	NN	Adverseeffect
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
proportion	NN	Others
of	IN	Others
patients	NNS	Others
with	IN	Others
events	NNS	Others
increased	VBN	O
as	IN	O
the	DT	O
number	NN	Others
of	IN	Others
injections	NNS	Others
increased	VBN	Others
.	.	Others

CONCLUSIONS	NNP	O
Intravitreous	NNP	O
fomivirsen	NN	O
is	VBZ	O
well	RB	Others
tolerated	VBN	Others
with	IN	Others
an	DT	Others
acceptable	JJ	Others
safety	NN	Others
profile	NN	Others
.	.	Others

Adverse	JJ	Adverseeffect
ocular	JJ	Adverseeffect
events	NNS	Adverseeffect
associated	VBN	O
with	IN	O
doses	NNS	O
and	CC	O
schedules	NNS	O
used	VBN	O
clinically	RB	O
can	MD	O
be	VB	O
managed	VBN	O
successfully	RB	O
with	IN	O
medical	JJ	O
therapy	NN	O
.	.	O

Xuezhikang	NN	O
,	,	O
an	DT	O
extract	NN	O
of	IN	O
cholestin	NN	O
,	,	O
decreases	VBZ	O
plasma	JJ	O
inflammatory	JJ	O
markers	NNS	O
and	CC	O
endothelin-1	NN	O
,	,	O
improve	VB	O
exercise-induced	JJ	O
ischemia	NN	O
and	CC	O
subjective	JJ	O
feelings	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	O
syndrome	NN	O
X	NNP	O
.	.	O

Previous	JJ	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
Xuezhikang	NNP	O
,	,	O
an	DT	O
extract	NN	O
of	IN	O
cholestin	NN	O
,	,	O
available	JJ	O
from	IN	O
Chinese	JJ	O
red	JJ	O
yeast	NN	O
rice	NN	O
,	,	O
could	MD	O
effectively	RB	O
modify	VB	O
lipid	JJ	O
profile	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
investigate	VB	O
whether	IN	O
Xuezhikang	NN	O
could	MD	O
modify	VB	O
endothelin-1	JJ	O
(	(	O
ET-1	NNP	O
)	)	O
,	,	O
interleukin-6	JJ	O
(	(	O
IL-6	NNP	O
)	)	O
,	,	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
and	CC	O
exercise-induced	JJ	O
ischemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	O
syndrome	NN	O
X	NNP	O
(	(	O
CSX	NNP	O
)	)	O
.	.	O

Thirty-six	JJ	O
patients	NNS	O
with	IN	O
CSX	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1200	CD	O
mg/d	NN	O
of	IN	O
Xuezhikang	NNP	O
or	CC	O
placebo	VBN	O
group	NN	O
(	(	O
n=18	RB	O
respectively	RB	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
day	NN	O
0	CD	O
and	CC	O
day	NN	O
90	CD	O
for	IN	O
measuring	VBG	O
above	IN	O
parameters	NNS	O
.	.	O

The	DT	O
treadmill	NN	O
exercise	NN	O
tests	NNS	O
and	CC	O
subjective	JJ	O
feelings	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
at	IN	O
day	NN	O
0	CD	O
and	CC	O
day	NN	O
90	CD	O
.	.	O

The	DT	O
data	NN	O
showed	VBD	O
that	IN	O
Xuezhikang	NNP	O
therapy	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
total	JJ	Physical
cholesterol	NN	Physical
(	(	Physical
TC	NNP	Physical
,	,	O
19	CD	O
%	NN	O
)	)	O
,	,	O
low-density	JJ	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
LDL-C	NNP	Physical
)	)	Physical
(	(	O
26	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
triglycerides	NNS	Physical
(	(	Physical
TG	NNP	Physical
)	)	Physical
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
16	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.01	CD	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
showed	VBD	O
that	IN	O
Xuezhikang	NNP	O
led	VBD	O
significantly	RB	O
to	TO	O
reductions	NNS	Physical
in	IN	Physical
median	JJ	Physical
and	CC	Physical
log-CRP	JJ	Physical
levels	NNS	Physical
(	(	O
38	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.01	CD	O
respectively	RB	O
)	)	O
,	,	O
IL-6	NNP	Physical
(	(	O
20	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
ET-1	NNP	Physical
(	(	O
47	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

The	DT	O
exercise	NN	O
duration	NN	O
,	,	O
and	CC	O
time	NN	Physical
to	TO	Physical
1	CD	Physical
mm	NNS	Physical
ST-segment	JJ	Physical
depression	NN	Physical
was	VBD	O
significantly	RB	O
prolonged	VBN	O
after	IN	O
Xuezhikang	NNP	O
therapy	NN	O
(	(	O
9	CD	O
%	NN	O
and	CC	O
6	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
respectively	RB	O
)	)	O
accompanied	VBN	O
by	IN	O
improvement	NN	Physical
of	IN	Physical
subjective	JJ	Physical
feelings	NNS	Physical
.	.	O

Data	NNP	O
suggested	VBD	O
that	IN	O
the	DT	O
benefit	NN	O
of	IN	O
Xuezhikang	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
modification	NN	O
vascular	JJ	Physical
function	NN	Physical
by	IN	O
reduction	NN	O
of	IN	O
ET-1	NNP	Physical
,	,	Physical
inflammatory	JJ	Physical
markers	NNS	Physical
and	CC	O
LDL	NNP	Physical
cholesterol	NN	Physical
,	,	O
which	WDT	O
may	MD	O
be	VB	O
clinically	RB	O
important	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
temafloxacin	NN	O
and	CC	O
ciprofloxacin	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
caffeine	NN	O
.	.	O

A	DT	O
number	NN	O
of	IN	O
quinolone	JJ	O
antibacterial	JJ	O
agents	NNS	O
,	,	O
particularly	RB	O
enoxacin	NN	O
,	,	O
pefloxacin	NN	O
,	,	O
pipemidic	JJ	O
acid	NN	O
and	CC	O
ciprofloxacin	NN	O
,	,	O
are	VBP	O
known	VBN	O
to	TO	O
decrease	VB	O
the	DT	O
clearance	NN	O
of	IN	O
methylxanthines	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
temafloxacin	NN	O
and	CC	O
ciprofloxacin	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
caffeine	NN	O
were	VBD	O
therefore	RB	O
compared	VBN	O
in	IN	O
a	DT	O
3-way	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
12	CD	O
healthy	JJ	O
young	JJ	O
volunteers	NNS	O
.	.	O

Each	DT	O
volunteer	NN	O
received	VBD	O
183mg	CD	O
once-daily	JJ	O
doses	NNS	O
of	IN	O
caffeine	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
twice-daily	JJ	O
placebo	NN	O
,	,	O
temafloxacin	CC	O
600mg	CD	O
and	CC	O
ciprofloxacin	VB	O
750mg	CD	O
in	IN	O
3	CD	O
separate	JJ	O
phases	NNS	O
according	VBG	O
to	TO	O
a	DT	O
randomised	JJ	O
sequence	NN	O
.	.	O

A	DT	O
doubling	NN	O
of	IN	O
the	DT	O
area	NN	Others
under	IN	Others
the	DT	Others
plasma	JJ	Others
concentration-time	JJ	Others
curve	NN	Others
(	(	O
77.8	CD	O
vs	RB	O
31.8	CD	O
mg/L.h	NN	O
)	)	O
and	CC	O
terminal-phase	JJ	Others
half-life	NN	Others
(	(	O
9.7	CD	O
vs	RB	O
4.5h	CD	O
)	)	O
of	IN	O
caffeine	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
ciprofloxacin	NN	O
.	.	O

The	DT	O
magnitude	NN	Others
of	IN	Others
the	DT	Others
reduction	NN	Others
in	IN	Others
the	DT	Others
intrinsic	JJ	Others
clearance	NN	Others
of	IN	Others
caffeine	NN	Others
produced	VBN	O
by	IN	O
ciprofloxacin	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
that	DT	O
described	VBN	O
in	IN	O
the	DT	O
literature	NN	O
for	IN	O
ciprofloxacin	NN	O
and	CC	O
theophylline	NN	O
.	.	O

This	DT	O
may	MD	O
partly	RB	O
be	VB	O
explained	VBN	O
by	IN	O
intertrial	JJ	O
differences	NNS	O
in	IN	O
dosage	NN	O
and	CC	O
study	NN	O
design	NN	O
.	.	O

Coadministration	NN	O
of	IN	O
temafloxacin	NN	O
did	VBD	O
not	RB	O
have	VB	O
any	DT	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	Others
of	IN	Others
caffeine	NN	Others
,	,	O
confirming	VBG	O
results	NNS	O
of	IN	O
other	JJ	O
studies	NNS	O
suggesting	VBG	O
that	IN	O
this	DT	O
agent	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
methylxanthine	JJ	Others
clearance	NN	Others
.	.	Physical

Accordingly	RB	O
,	,	O
it	PRP	O
appears	VBZ	O
that	IN	O
restriction	NN	O
of	IN	O
caffeine	JJ	O
intake	NN	O
during	IN	O
temafloxacin	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
necessary	JJ	O
.	.	O

The	DT	O
gluten-free	JJ	O
,	,	O
casein-free	JJ	O
diet	NN	O
in	IN	O
autism	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
preliminary	JJ	O
double	NN	O
blind	VB	O
clinical	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
gluten-free	JJ	O
and	CC	O
casein-free	JJ	O
(	(	O
GFCF	NNP	O
)	)	O
diet	NN	O
in	IN	O
treating	VBG	O
autism	NN	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
repeated	VBD	O
measures	NNS	O
crossover	RB	O
design	NN	O
.	.	O

The	DT	O
sample	NN	O
included	VBD	O
15	CD	O
children	NNS	O
aged	VBN	O
2-16	CD	O
years	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Data	NNP	O
on	IN	O
autistic	JJ	Physical
symptoms	NNS	Physical
and	CC	O
urinary	JJ	Physical
peptide	NN	Physical
levels	NNS	Physical
were	VBD	O
collected	VBN	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
homes	NNS	O
over	IN	O
the	DT	O
12	CD	O
weeks	NNS	O
that	IN	O
they	PRP	O
were	VBD	O
on	IN	O
the	DT	O
diet	JJ	O
.	.	O

Group	NNP	O
data	VBD	O
indicated	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
findings	NNS	O
even	RB	O
though	IN	O
several	JJ	O
parents	NNS	O
reported	VBD	O
improvement	NN	Mental
in	IN	O
their	PRP$	O
children	NNS	O
.	.	O

Although	IN	O
preliminary	JJ	O
,	,	O
this	DT	O
study	NN	O
demonstrates	VBZ	O
how	WRB	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
the	DT	O
GFCF	NNP	O
diet	NN	O
can	MD	O
be	VB	O
conducted	VBN	O
,	,	O
and	CC	O
suggests	VBZ	O
directions	NNS	O
for	IN	O
future	JJ	O
research	NN	O
.	.	O

Hemodynamic	JJ	O
effects	NNS	O
during	IN	O
induction	NN	O
,	,	O
laryngoscopy	NN	O
,	,	O
and	CC	O
intubation	NN	O
with	IN	O
eltanolone	NN	O
(	(	O
5	CD	O
beta-pregnanolone	NN	O
)	)	O
or	CC	O
propofol	NN	O
.	.	O

A	DT	O
study	NN	O
in	IN	O
ASA	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
cardiovascular	JJ	O
changes	NNS	O
following	VBG	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
laryngoscopy	NN	O
,	,	O
and	CC	O
intubation	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
a	DT	O
bolus	NN	O
dose	NN	O
of	IN	O
either	CC	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
blind	NN	O
,	,	O
prospective	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
General	NNP	O
operating	VBG	O
theaters	NNS	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
40	CD	O
ASA	NNP	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
surgery	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
premedicated	VBN	O
with	IN	O
oral	JJ	O
temazepam	NN	O
20	CD	O
mg.	NN	O
Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
either	DT	O
eltanolone	NN	O
0.58	CD	O
mg/kg	NN	O
or	CC	O
propofol	VB	O
1.7	CD	O
mg/kg	NN	O
,	,	O
neuromuscular	JJ	O
blockade	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
vecuronium	NN	O
0.1	CD	O
mg/kg	NN	O
,	,	O
and	CC	O
anesthesia	NN	O
was	VBD	O
maintained	VBN	O
with	IN	O
enflurane	JJ	O
0.5	CD	O
%	NN	O
to	TO	O
1.0	CD	O
%	NN	O
in	IN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Blood	NNP	Physical
pressure	NN	Physical
was	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
automatic	JJ	Physical
oscillometric	NN	Physical
technique	NN	Physical
,	,	O
heart	NN	Physical
rate	NN	Physical
(	(	Physical
HR	NNP	Physical
)	)	Physical
was	VBD	O
derived	VBN	O
from	IN	O
the	DT	O
ECG	NNP	O
,	,	O
oxygen	NN	Physical
saturation	NN	Physical
was	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
oximetry	NN	O
,	,	O
and	CC	O
cardiac	JJ	Physical
output	NN	Physical
(	(	Physical
Q	NNP	Physical
)	)	Physical
was	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
thoracic	JJ	O
bioimpedance	NN	O
technique	NN	O
.	.	O

Induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
either	DT	O
drug	NN	O
,	,	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
,	,	O
decreased	VBN	O
arterial	JJ	Physical
systolic	NN	Physical
(	(	Physical
SAP	NNP	Physical
)	)	Physical
and	CC	O
diastolic	JJ	Physical
(	(	Physical
DAP	NNP	Physical
)	)	Physical
blood	NN	Physical
pressure	NN	Physical
,	,	Physical
Q	NNP	Physical
,	,	O
and	CC	O
stroke	NN	Physical
volume	NN	Physical
(	(	Physical
SV	NNP	Physical
)	)	Physical
.	.	O

HR	NNP	Physical
increased	VBD	O
.	.	O

Systemic	NNP	Physical
vascular	JJ	Physical
resistance	NN	Physical
(	(	Physical
SVR	NNP	Physical
)	)	Physical
was	VBD	O
unaltered	VBN	O
.	.	O

After	IN	O
laryngoscopy	NN	O
and	CC	O
intubation	NN	O
,	,	O
SAP	NNP	Physical
and	CC	O
DAP	NNP	Physical
increased	VBD	O
secondary	JJ	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
SVR	NNP	O
.	.	O

HR	NNP	Physical
also	RB	O
increased	VBD	O
;	:	O
SV	NNP	Physical
decreased	VBD	O
in	IN	O
patients	NNS	O
receiving	VBG	O
eltanolone	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
(	(	O
e.g.	NN	O
,	,	O
apnea	NN	Adverseeffect
occurring	VBG	Adverseeffect
for	IN	Adverseeffect
more	JJR	Adverseeffect
than	IN	Adverseeffect
30	CD	Adverseeffect
seconds	NNS	Adverseeffect
,	,	Adverseeffect
involuntary	JJ	Adverseeffect
movements	NNS	Adverseeffect
,	,	Adverseeffect
limb	FW	Adverseeffect
hypertonus	NN	Adverseeffect
)	)	O
occurred	VBD	O
at	IN	O
a	DT	O
similar	JJ	O
incidence	NN	O
with	IN	O
both	DT	O
treatments	NNS	O
,	,	O
but	CC	O
pain	VBP	O
following	VBG	O
injection	NN	O
was	VBD	O
greater	JJR	O
with	IN	O
propofol	NN	O
(	(	O
59	CD	O
%	NN	O
vs.	FW	O
9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
receiving	VBG	O
either	CC	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
showed	VBD	O
similar	JJ	O
cardiovascular	JJ	O
changes	NNS	O
to	TO	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
although	IN	O
there	EX	O
were	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
arterial	JJ	O
pressure	NN	O
and	CC	O
HR	NNP	O
in	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
eltanolone	NN	O
.	.	O

Metformin	NNP	O
does	VBZ	O
not	RB	O
enhance	VB	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
metformin	NN	O
pretreatment	NN	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
in	IN	O
an	DT	O
infertility	NN	O
clinic	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
placebo	NN	O
controlled	VBD	O
double-blind	NN	O
crossover	NN	O
study	NN	O
of	IN	O
3	CD	O
months	NNS	O
metformin	RB	O
(	(	O
1500	CD	O
mg	IN	O
day-1	NN	O
)	)	O
/placebo	NN	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
metformin/placebo	VBN	O
together	RB	O
with	IN	O
clomiphene	NN	O
(	(	O
50-100	JJ	O
mg	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
for	IN	O
three	CD	O
cycles	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
were	VBD	O
restoration	NN	Physical
of	IN	Physical
spontaneous	JJ	Physical
menses	NNS	Physical
,	,	Physical
ovulation	NN	Physical
induction	NN	Physical
(	(	Physical
spontaneous	JJ	Physical
or	CC	Physical
clomiphene	NN	Physical
induced	VBN	Physical
)	)	Physical
and	CC	Physical
pregnancy	NN	Physical
.	.	Physical

Secondary	JJ	Physical
endpoints	NNS	Physical
were	VBD	O
changes	NNS	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
related	VBN	O
to	TO	O
androgens	NNS	O
and	CC	O
insulin	NN	O
.	.	O

RESULTS	NNP	O
Twelve	NNP	O
women	NNS	O
completed	VBD	O
the	DT	O
metformin	NN	O
arm	NN	O
and	CC	O
14	CD	O
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

Spontaneous	JJ	Physical
menstruation	NN	Physical
resumed	VBD	O
in	IN	O
five	CD	O
metformin	NNS	O
treated	VBD	O
patients	NNS	O
and	CC	O
in	IN	O
six	CD	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

No	NNP	O
women	NNS	O
given	VBN	O
metformin	NNS	O
spontaneously	RB	Physical
ovulated	VBD	Physical
,	,	O
although	IN	O
one	CD	O
patient	NN	O
given	VBN	O
placebo	NN	O
did	VBD	O
,	,	O
P=0.30	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
efficacy	NN	Physical
of	IN	Physical
clomiphene	NN	Physical
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
ovulation	NN	Physical
being	VBG	Physical
induced	VBN	Physical
in	IN	O
five	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
metformin	NN	O
treated	VBN	O
women	NNS	O
and	CC	O
four	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
placebo	NN	O
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

Pregnancy	NN	Physical
occurred	VBD	O
in	IN	O
three	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
women	NNS	O
given	VBN	O
metformin	NNS	O
and	CC	O
two	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
women	NNS	O
given	VBN	O
placebo	NNS	O
,	,	O
P=0.59	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Metformin	NNP	O
is	VBZ	O
not	RB	O
always	RB	O
beneficial	JJ	O
when	WRB	O
given	VBN	O
to	TO	O
clomiphene	VB	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
combined	VBN	O
with	IN	O
task-related	JJ	O
training	NN	O
improves	NNS	O
lower	JJR	Physical
limb	NN	Physical
functions	NNS	Physical
in	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
stroke	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
PURPOSE	NNP	O
Previous	NNP	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
repeated	VBD	O
sensory	JJ	O
inputs	NNS	O
could	MD	O
enhance	VB	O
brain	NN	Physical
plasticity	NN	Physical
and	CC	O
cortical	JJ	Physical
motor	NN	Physical
output	NN	Physical
.	.	Physical

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
combining	VBG	O
electrically	RB	O
induced	JJ	O
sensory	NN	O
inputs	NNS	O
through	IN	O
transcutaneous	JJ	O
electrical	JJ	O
nerve	NN	O
stimulation	NN	O
(	(	O
TENS	NNP	O
)	)	O
with	IN	O
task-related	JJ	O
training	NN	O
(	(	O
TRT	NNP	O
)	)	O
in	IN	O
a	DT	O
home-based	JJ	O
program	NN	O
would	MD	O
augment	VB	O
voluntary	JJ	Physical
motor	NN	Physical
output	NN	Physical
in	IN	O
chronic	JJ	O
stroke	NN	O
survivors	NNS	O
better	RBR	O
than	IN	O
either	DT	O
treatment	NN	O
alone	RB	O
or	CC	O
no	DT	O
treatment	NN	O
.	.	O

METHODS	NNP	O
Eighty-eight	JJ	O
patients	NNS	O
with	IN	O
stroke	NN	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
a	DT	O
home-based	JJ	O
program	NN	O
of	IN	O
(	(	O
1	CD	O
)	)	O
TENS	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
TENS+TRT	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
placebo	NN	O
TENS+TRT	NNP	O
,	,	O
or	CC	O
(	(	O
4	CD	O
)	)	O
no	DT	O
treatment	NN	O
(	(	O
control	NN	O
)	)	O
5	CD	O
days	NNS	O
a	DT	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Outcome	NN	O
measurements	NNS	O
included	VBD	O
Composite	NNP	Physical
Spasticity	NNP	Physical
Scale	NNP	Physical
,	,	Physical
peak	NN	Physical
torques	NNS	Physical
generated	VBD	Physical
during	IN	Physical
maximum	JJ	Physical
isometric	JJ	Physical
voluntary	JJ	Physical
contraction	NN	Physical
of	IN	Physical
ankle	JJ	Physical
dorsiflexors	NNS	Physical
and	CC	Physical
plantarflexors	NNS	Physical
,	,	Physical
and	CC	Physical
gait	VBP	Physical
velocity	NN	Physical
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
4	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
ended	VBN	O
.	.	O

RESULTS	VB	O
When	WRB	O
compared	VBN	O
with	IN	O
TENS	NNP	O
,	,	O
the	DT	O
combined	JJ	O
TENS+TRT	NNP	O
group	NN	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
ankle	JJ	Physical
dorsiflexion	NN	Physical
torque	NN	Physical
at	IN	O
follow-up	JJ	O
and	CC	O
in	IN	O
ankle	JJ	Physical
plantarflexion	NN	Physical
torque	NN	Physical
at	IN	O
week	NN	O
2	CD	O
and	CC	O
follow-up	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
placebo+TRT	NN	O
,	,	O
the	DT	O
TENS+TRT	NNP	O
group	NN	O
produced	VBD	O
earlier	JJR	O
and	CC	O
greater	JJR	O
reduction	NN	O
of	IN	O
plantarflexor	NN	Physical
spasticity	NN	Physical
and	CC	O
improvement	NN	Others
in	IN	Others
ankle	JJ	Others
dorsiflexion	NN	Others
torque	NN	Others
at	IN	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
all	DT	O
3	CD	O
groups	NNS	O
,	,	O
the	DT	O
TENS+TRT	NNP	O
group	NN	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
gait	NN	Physical
velocity	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
stroke	NN	O
,	,	O
20	CD	O
sessions	NNS	O
of	IN	O
a	DT	O
combined	JJ	O
TENS+TRT	NNP	O
home-based	JJ	O
program	NN	O
decreased	VBN	Physical
plantarflexor	JJ	Physical
spasticity	NN	Physical
,	,	Physical
improved	VBN	Physical
dorsiflexor	NN	Physical
and	CC	Physical
plantarflexor	NN	Physical
strength	NN	Physical
,	,	Physical
and	CC	Physical
increased	VBD	Physical
gait	NN	Physical
velocity	NN	Physical
significantly	RB	O
more	RBR	O
than	IN	O
TENS	NNP	O
alone	RB	O
,	,	O
placebo+TRT	NN	O
,	,	O
or	CC	O
no	DT	O
treatment	NN	O
.	.	O

Such	JJ	O
improvements	NNS	O
can	MD	O
even	RB	O
be	VB	O
maintained	VBN	O
4	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
ended	VBD	O
.	.	O

The	DT	O
maximal	JJ	O
double	JJ	O
step	NN	O
length	RB	O
test	NN	O
can	MD	O
evaluate	VB	O
more	RBR	O
adequately	RB	O
the	DT	O
decrease	NN	O
of	IN	O
physical	JJ	O
function	NN	O
with	IN	O
age	NN	O
,	,	O
than	IN	O
the	DT	O
maximal	JJ	O
single	JJ	O
step	NN	O
length	JJ	O
test	NN	O
.	.	O

The	DT	O
maximal	JJ	O
double	JJ	O
step	NN	O
length	NN	O
(	(	O
MDSL	NNP	O
)	)	O
test	NN	O
is	VBZ	O
a	DT	O
modified	JJ	O
version	NN	O
of	IN	O
the	DT	O
maximal	JJ	O
step	NN	O
length	NN	O
(	(	O
MSL	NNP	O
)	)	O
test	NN	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
dynamic	JJ	O
balance	NN	O
related	VBN	O
to	TO	O
falls	NNS	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

Although	IN	O
this	DT	O
test	NN	O
can	MD	O
evaluate	VB	O
their	PRP$	O
physical	JJ	O
function	NN	O
using	VBG	O
movements	NNS	O
similar	JJ	O
to	TO	O
daily	JJ	O
activities	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
MSL	NNP	O
,	,	O
it	PRP	O
has	VBZ	O
not	RB	O
been	VBN	O
clarified	VBN	O
whether	IN	O
it	PRP	O
can	MD	O
adequately	RB	O
evaluate	VB	O
the	DT	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
(	(	O
ADL	NNP	O
)	)	O
abilities	NNS	O
of	IN	O
the	DT	O
elderly	JJ	O
,	,	O
as	IN	O
they	PRP	O
decrease	VBP	O
with	IN	O
age	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
between	IN	O
both	DT	O
MSL	NNP	O
and	CC	O
MDSL	NNP	O
on	IN	O
age	NN	O
and	CC	O
ADL	NNP	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Fifty-seven	CD	O
elderly	JJ	O
females	NNS	O
who	WP	O
live	VBP	O
independently	RB	O
(	(	O
age	NN	O
74.8?5.6	CD	O
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
.	.	O

MSL	NNP	O
and	CC	O
MDSL	NNP	O
were	VBD	O
conducted	VBN	O
twice	RB	O
after	IN	O
completing	VBG	O
an	DT	O
ADL	NNP	O
questionnaire	NN	O
.	.	O

Intra-class	JJ	O
correlation	NN	O
coefficients	NNS	O
(	(	O
ICCs	NNP	O
)	)	O
of	IN	O
both	DT	O
tests	NNS	O
were	VBD	O
high	JJ	O
(	(	O
for	IN	O
MSL	NNP	O
:	:	O
ICC=0.95	NNP	O
,	,	O
for	IN	O
MDSL	NNP	O
:	:	O
ICC=0.81-0.82	NN	O
)	)	O
.	.	O

Age	NNP	O
and	CC	O
ADL	NNP	O
significantly	RB	O
correlated	VBD	O
to	TO	O
MDSL	NNP	O
(	(	O
age	NN	O
:	:	O
r=-0.32-0.41	NN	O
,	,	O
ADL	NNP	O
:	:	O
r=0.28-0.48	NN	O
)	)	O
,	,	O
but	CC	O
not	RB	O
to	TO	O
MSL	NNP	O
(	(	O
age	NN	O
:	:	O
r=-0.19	NN	O
,	,	O
ADL	NNP	O
:	:	O
r=0.15	NN	O
)	)	O
.	.	O

MDSL	NNP	O
has	VBZ	O
high	JJ	O
reliability	NN	O
as	IN	O
it	PRP	O
relates	VBZ	O
to	TO	O
age	NN	O
and	CC	O
ADL	NNP	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
more	JJR	O
useful	JJ	O
to	TO	O
evaluate	VB	O
ADL	NNP	O
required	VBN	O
for	IN	O
independent	JJ	O
living	NN	O
and	CC	O
prevent	NN	O
falls	NNS	O
in	IN	O
the	DT	O
elderly	JJ	O
better	JJR	O
than	IN	O
MSL	NNP	O
.	.	O

The	DT	O
instruction	NN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
affects	NNS	O
auditory	JJ	Physical
P3	NNP	Physical
and	CC	Physical
N1	NNP	Physical
amplitudes	NNS	Physical
.	.	Physical

Often	NNP	O
subjects	VBZ	O
have	VBP	O
been	VBN	O
instructed	VBN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
lest	JJS	O
their	PRP$	O
evoked	JJ	O
EEG	NNP	O
potentials	NNS	O
should	MD	O
be	VB	O
distorted	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
these	DT	O
very	RB	O
instructions	NNS	O
have	VBP	O
any	DT	O
impact	NN	O
on	IN	O
P3	NNP	Physical
amplitude	NN	Physical
.	.	Physical

Two	CD	O
tones	NNS	O
were	VBD	O
presented	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
and	CC	O
subjects	NNS	O
had	VBD	O
to	TO	O
count	VB	O
the	DT	O
high-pitched	JJ	O
tones	NNS	O
.	.	O

Half	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
instructed	VBN	O
not	RB	O
to	TO	O
blink	VB	O
,	,	O
whereas	IN	O
this	DT	O
instruction	NN	O
was	VBD	O
omitted	VBN	O
for	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
.	.	O

Target	NNP	O
tones	NNS	O
evoked	VBD	O
larger	JJR	O
P3s	NNP	Physical
than	IN	O
non-targets	NNS	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
former	JJ	O
,	,	O
in	IN	O
particular	JJ	O
not	RB	O
in	IN	O
those	DT	O
subjects	NNS	O
that	WDT	O
actually	RB	O
blinked	VBD	O
rarely	RB	O
.	.	O

The	DT	O
groups	NNS	O
also	RB	O
differed	VBN	O
in	IN	O
their	PRP$	O
N1	NNP	Physical
amplitudes	NNS	Physical
.	.	Physical

These	DT	O
findings	NNS	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
P3	NNP	O
studies	NNS	O
working	VBG	O
with	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
:	:	O
the	DT	O
harder	NN	O
some	DT	O
frequently	RB	O
blinking	JJ	O
subjects	NNS	O
try	VBP	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	NN	O
,	,	O
the	DT	O
smaller	JJR	O
might	MD	O
become	VB	O
their	PRP$	O
P3	NNP	Physical
amplitudes	NNS	Physical
.	.	Physical

Omitting	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
using	VBG	O
off-line	JJ	O
blink	NN	O
subtraction	NN	O
procedures	NNS	O
seems	VBZ	O
a	DT	O
viable	JJ	O
alternative	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
actually	RB	O
motivated	VBN	O
by	IN	O
discrepant	JJ	O
findings	NNS	O
on	IN	O
the	DT	O
effects	NNS	Physical
of	IN	Physical
the	DT	Physical
preceding	VBG	Physical
tone	NN	Physical
sequence	NN	Physical
on	IN	Physical
P3	NNP	Physical
.	.	O

These	DT	O
discrepancies	NNS	O
could	MD	O
be	VB	O
largely	RB	O
resolved	VBN	O
by	IN	O
the	DT	O
instructional	JJ	O
variable	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
different	JJ	O
tone	NN	Physical
intensities	NNS	Physical
.	.	Physical

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
subjects	NNS	O
who	WP	O
are	VBP	O
discouraged	VBN	O
from	IN	O
blinking	VBG	O
try	NN	O
to	TO	O
protect	VB	O
themselves	PRP	O
against	IN	O
the	DT	O
arousing	JJ	O
effects	NNS	O
of	IN	O
stimuli	NN	O
.	.	O

An	DT	O
open	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
comparison	NN	O
of	IN	O
quinapril	NN	O
and	CC	O
captopril	NN	O
,	,	O
when	WRB	O
added	VBN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
,	,	Others
tolerability	NN	Others
and	CC	Others
first-dose	JJ	Others
blood-pressure	JJ	Others
response	NN	Others
of	IN	O
once-daily	JJ	O
quinapril	NN	O
and	CC	O
twice-daily	JJ	O
captopril	NN	O
when	WRB	O
added	VBD	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
a	DT	O
single	JJ	O
centre	NN	O
as	IN	O
an	DT	O
open	JJ	O
randomised	VBD	O
parallel-group	NN	O
study	NN	O
,	,	O
patients	NNS	O
being	VBG	O
selected	VBN	O
for	IN	O
inclusion	NN	O
from	IN	O
the	DT	O
outpatient	JJ	O
population	NN	O
.	.	O

Following	VBG	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
either	CC	O
2.5	CD	O
mg	JJ	O
once-daily	RB	O
quinapril	NN	O
,	,	O
or	CC	O
6.25	CD	O
mg	JJ	O
twice-daily	JJ	O
captopril	NN	O
,	,	O
patients	NNS	O
were	VBD	O
reviewed	VBN	O
at	IN	O
two-weekly	JJ	O
intervals	NNS	O
,	,	O
and	CC	O
following	VBG	O
clinical	JJ	O
assessment	NN	O
a	DT	O
decision	NN	O
was	VBD	O
made	VBN	O
either	DT	O
to	TO	O
titrate	VB	O
up	RP	O
to	TO	O
the	DT	O
next	JJ	O
medication	NN	O
stage	NN	O
or	CC	O
to	TO	O
enter	VB	O
the	DT	O
patient	NN	O
into	IN	O
the	DT	O
16-week	JJ	O
maintenance	NN	O
phase	NN	O
.	.	O

Efficacy	NN	Others
was	VBD	O
assessed	VBN	Others
using	VBG	O
a	DT	O
six-minute	JJ	Others
walking	NN	Others
test	NN	Others
,	,	Others
the	DT	Others
New	NNP	Others
York	NNP	Others
Heart	NNP	Others
Association	NNP	Others
(	(	Others
NYHA	NNP	Others
)	)	Others
class	NN	Others
,	,	Others
a	DT	Others
functional	JJ	Others
lifescale	NN	Others
(	(	Others
FLS	NNP	Others
)	)	Others
questionnaire	NN	Others
and	CC	Others
the	DT	Others
cardiothoracic	NN	Others
ratio	NN	Others
(	(	Others
CTR	NNP	Others
)	)	Others
-at	NN	Others
study	NN	Others
entry	NN	Others
and	CC	Others
at	IN	Others
the	DT	Others
end	NN	Others
of	IN	Others
the	DT	Others
maintenance	NN	Others
phase	NN	Others
.	.	Others

Blood	NNP	Physical
pressure	NN	Physical
was	VBD	O
measured	VBN	O
for	IN	O
5	CD	O
h	JJ	O
post-first-dose	JJ	O
of	IN	O
medication	NN	O
.	.	O

Sixty-one	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
treatment	NN	O
:	:	O
30	CD	O
to	TO	O
quinapril	VB	O
and	CC	O
31	CD	O
to	TO	O
captopril	VB	O
.	.	O

Following	VBG	O
withdrawals	NNS	O
,	,	O
data	NNS	O
from	IN	O
36	CD	O
patients	NNS	O
(	(	O
20	CD	O
on	IN	O
quinapril	NN	O
,	,	O
16	CD	O
on	IN	O
captopril	NN	O
)	)	O
were	VBD	O
available	JJ	O
for	IN	O
analysis	NN	O
.	.	O

The	DT	O
distance	NN	Physical
walked	VBD	Physical
during	IN	Physical
the	DT	Physical
six-minute	JJ	Physical
walking	NN	Physical
test	NN	Physical
improved	VBN	Physical
in	IN	O
both	DT	O
groups	NNS	O
;	:	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
was	VBD	O
not	RB	O
statistically	RB	Others
significant	JJ	Others
.	.	Others

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
FLS	NNP	Physical
or	CC	Physical
CTR	NNP	Physical
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
change	NN	O
in	IN	O
the	DT	O
NYHA	NNP	O
status	NN	O
from	IN	O
study	NN	O
entry	NN	O
to	TO	O
study	VB	O
end	NN	O
showed	VBD	O
a	DT	O
statistically	RB	Others
significant	JJ	Others
difference	NN	Others
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
in	IN	O
favour	NN	O
of	IN	O
quinapril	NN	O
.	.	O

Five	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
experienced	VBD	O
hypotension	NN	Physical
during	IN	O
the	DT	O
5	CD	O
h	NN	O
following	VBG	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
medication	NN	O
.	.	O

This	DT	O
study	NN	O
has	VBZ	O
shown	VBN	O
heart	NN	O
failure	NN	O
to	TO	O
be	VB	O
as	RB	O
well	RB	O
controlled	VBN	O
by	IN	O
once-daily	JJ	O
quinapril	NN	O
as	IN	O
by	IN	O
twice-daily	JJ	O
captopril	NN	O
,	,	O
with	IN	O
comparable	JJ	O
effects	NNS	O
on	IN	O
first-dose	JJ	Physical
blood-pressure	JJ	Physical
response	NN	Physical
.	.	Others

Treatments	NNS	O
of	IN	O
preterm	JJ	O
premature	JJ	O
rupture	NN	O
of	IN	O
the	DT	O
membranes	NNS	O
:	:	O
a	DT	O
meta-analysis	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
overview	NN	O
was	VBD	O
to	TO	O
critically	RB	O
evaluate	VB	O
published	VBN	O
randomized	JJ	O
controlled	VBN	O
trials	NNS	O
on	IN	O
treatments	NNS	O
in	IN	O
preterm	JJ	O
premature	JJ	O
rupture	NN	O
of	IN	O
the	DT	O
membranes	NNS	O
.	.	O

The	DT	O
Oxford	NNP	O
data	NN	O
base	NN	O
on	IN	O
perinatal	JJ	O
trials	NNS	O
,	,	O
MEDLINE	NNP	O
,	,	O
Excerpta	NNP	O
Medica	NNP	O
,	,	O
and	CC	O
Index	NNP	O
Medicus	NNP	O
were	VBD	O
searched	VBN	O
.	.	O

Through	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
review	NN	O
with	IN	O
preset	JJ	O
inclusion	NN	O
criteria	NNS	O
,	,	O
two	CD	O
independent	JJ	O
judges	NNS	O
identified	VBD	O
27	CD	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
,	,	O
of	IN	O
which	WDT	O
13	CD	O
met	VBD	O
inclusion	NN	O
criteria	NNS	O
.	.	O

The	DT	O
quality	NN	O
of	IN	O
these	DT	O
randomized	VBN	O
controlled	VBD	O
trials	NNS	O
was	VBD	O
scored	VBN	O
.	.	O

Five	CD	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
regarding	VBG	O
antenatal	JJ	O
use	NN	O
of	IN	O
corticosteroids	NNS	O
to	TO	O
prevent	VB	O
respiratory	JJ	Physical
distress	JJ	Physical
syndrome	NN	Physical
could	MD	O
be	VB	O
combined	VBN	O
meta-analytically	RB	O
and	CC	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
respiratory	NN	Physical
distress	NN	Physical
syndrome	NN	Physical
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
respiratory	NN	Physical
distress	NN	Physical
syndrome	NN	Physical
(	(	O
p	JJ	O
=	NNP	O
0.286	CD	O
)	)	O
was	VBD	O
found	VBN	O
after	IN	O
one	CD	O
study	NN	O
,	,	O
with	IN	O
the	DT	O
lowest	JJS	O
quality	NN	O
score	NN	O
,	,	O
was	VBD	O
excluded	VBN	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
endometritis	NN	Physical
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
an	DT	O
increase	NN	O
in	IN	O
neonatal	JJ	Physical
infections	NNS	Physical
and	CC	Physical
cesarean	JJ	Physical
section	NN	Physical
rates	NNS	Physical
were	VBD	O
noted	VBN	O
with	IN	O
treatment	NN	O
.	.	O

Tocolysis	NN	O
,	,	O
prophylactic	JJ	O
antibiotics	NNS	O
,	,	O
and	CC	O
other	JJ	O
interventions	NNS	O
studied	VBN	O
were	VBD	O
not	RB	O
found	VBN	O
to	TO	O
be	VB	O
of	IN	O
proved	JJ	O
benefit	NN	O
and	CC	O
therefore	RB	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
outside	IN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

Incidence	NN	O
of	IN	O
infectious	JJ	Physical
symptoms	NNS	Physical
after	IN	O
radiation	NN	O
therapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Long-term	JJ	O
effects	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
symptoms	NNS	O
generally	RB	O
associated	VBN	O
with	IN	O
infectious	JJ	O
disease	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
questionnaire	NN	O
sent	VBD	O
out	RB	O
to	TO	O
519	CD	O
disease-free	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
7	CD	O
to	TO	O
12	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
treatment	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
where	WRB	O
pre-	NN	O
and	CC	O
postoperative	JJ	O
radiation	NN	O
(	(	O
45	CD	O
Gy	NNP	O
)	)	O
was	VBD	O
evaluated	VBN	O
versus	NN	O
surgery	NN	O
only	RB	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
significantly	RB	O
higher	JJR	Physical
morbidity	NN	Physical
among	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
preoperative	JJ	O
irradiation	NN	O
compared	VBN	O
with	IN	O
those	DT	O
irradiated	JJ	O
postoperative	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
increased	JJ	O
morbidity	NN	O
mainly	RB	O
seemed	VBD	O
to	TO	O
be	VB	O
caused	VBN	O
by	IN	O
symptoms	NNS	O
usually	RB	O
associated	VBN	O
with	IN	O
respiratory	JJ	O
tract	JJ	O
infection	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Although	IN	O
statistically	RB	O
not	RB	O
significant	JJ	O
the	DT	O
preoperatively	RB	O
irradiated	JJ	O
patients	NNS	O
also	RB	O
had	VBD	O
a	DT	O
higher	JJR	O
morbidity	NN	Physical
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
surgery	NN	O
alone	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
postoperatively	RB	O
irradiated	JJ	O
patients	NNS	O
and	CC	O
patients	NNS	O
treated	VBN	O
with	IN	O
surgery	NN	O
only	RB	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
integral	JJ	O
dose	NN	O
(	(	O
absorbed	JJ	O
energy	NN	O
within	IN	O
the	DT	O
body	NN	O
)	)	O
of	IN	O
the	DT	O
pre-	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
postoperative	JJ	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
differences	NNS	O
in	IN	O
morbidity	NN	O
between	IN	O
the	DT	O
two	CD	O
irradiated	JJ	O
groups	NNS	O
.	.	O

An	DT	O
explanation	NN	O
for	IN	O
the	DT	O
increased	JJ	O
morbidity	NN	Physical
seems	VBZ	O
to	TO	O
be	VB	O
that	IN	O
the	DT	O
volume	NN	O
of	IN	O
lung	NN	O
tissue	NN	O
,	,	O
encompassed	VBD	O
within	IN	O
the	DT	O
full-dose	JJ	O
target	NN	O
volume	NN	O
,	,	O
is	VBZ	O
the	DT	O
crucial	JJ	O
factor	NN	O
.	.	O

This	DT	O
volume	NN	O
was	VBD	O
considerable	JJ	O
in	IN	O
the	DT	O
preoperatively	RB	O
treated	JJ	O
patients	NNS	O
but	CC	O
kept	VBD	O
at	IN	O
a	DT	O
minimum	NN	O
in	IN	O
the	DT	O
postoperative	JJ	O
group	NN	O
.	.	O

Cholesterol-lowering	JJ	O
effect	NN	O
of	IN	O
stanol	NN	O
ester	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
of	IN	O
mildly	RB	O
hypercholesterolemic	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stanol	NN	O
esters	NNS	O
in	IN	O
lowering	VBG	O
cholesterol	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
After	IN	O
a	DT	O
run-in	JJ	O
phase	NN	O
,	,	O
318	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
margarine-like	JJ	O
spreads	NNS	O
containing	VBG	O
stanol	JJ	O
ester	NN	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
:	:	O
EU	NNP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
European	JJ	O
formula	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
2	CD	O
G	NNP	O
:	:	O
0.67	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
or	CC	O
placebo	VB	O
spread	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	Physical
+/-	JJ	Physical
SD	NNP	Physical
baseline	NN	Physical
total	NN	Physical
cholesterol	NN	Physical
(	(	Physical
TC	NNP	Physical
)	)	Physical
and	CC	O
low-density	JJ	Physical
lipoprotein	NN	Physical
cholesterol	NN	Physical
(	(	Physical
LDL-C	NNP	Physical
)	)	Physical
levels	NNS	Physical
were	VBD	O
233+/-20	JJ	O
and	CC	O
153+21	CD	O
mg+/-dL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
US	NNP	O
3	CD	O
G	NNP	O
group	NN	O
,	,	O
3	CD	O
g	JJ	O
daily	NN	O
of	IN	O
stanol	JJ	O
esters	NNS	O
lowered	VBD	O
TC	NNP	Physical
and	CC	O
LDL-C	NNP	Physical
levels	NNS	Physical
by	IN	O
6.4	CD	O
%	NN	O
and	CC	O
10.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
response	NN	O
compared	VBN	O
with	IN	O
2	CD	O
g	NNS	O
daily	RB	O
(	(	O
US	PRP	O
2	CD	O
G	NNP	O
)	)	O
.	.	O

Triglyceride	NNP	Physical
and	CC	Physical
high-density	NN	Physical
lipoprotein	NNS	Physical
cholesterol	NN	Physical
levels	NNS	Physical
were	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	O
.	.	O

Serum	NNP	Physical
vitamin	VBD	Physical
A	DT	Physical
and	CC	Physical
25-hydroxyvitamin	JJ	Physical
D	NNP	Physical
levels	NNS	Physical
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Stanol	NNP	O
esters	NNS	O
lowered	VBD	O
TC	NNP	Physical
and	CC	O
LDL-C	NNP	Physical
levels	NNS	Physical
in	IN	O
a	DT	O
mildly	RB	O
hypercholesterolemic	JJ	O
US	NNP	O
population	NN	O
without	IN	O
evidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
dietary	JJ	O
adjunct	NN	O
to	TO	O
lower	VB	O
cholesterol	NN	O
.	.	O

Ipratropium	NNP	O
bromide	NN	O
nasal	NN	O
spray	NN	O
for	IN	O
treatment	NN	O
of	IN	O
rhinorrhea	NN	O
in	IN	O
the	DT	O
laryngectomized	JJ	O
patient	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

Many	NNP	O
who	WP	O
have	VBP	O
had	VBD	O
a	DT	O
total	JJ	O
laryngectomy	NN	O
complain	NN	O
of	IN	O
unrelenting	VBG	O
rhinorrhea	NN	O
that	WDT	O
is	VBZ	O
often	RB	O
very	RB	O
difficult	JJ	O
to	TO	O
control	VB	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
ipratropium	NN	O
bromide	NN	O
(	(	O
IB	NNP	O
)	)	O
,	,	O
an	DT	O
anticholinergic	JJ	O
nasal	NN	O
spray	NN	O
,	,	O
on	IN	O
rhinorrhea	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

This	DT	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
pilot	NN	O
study	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
selected	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
a	DT	O
total	JJ	O
laryngectomy	NN	O
and	CC	O
complained	VBD	O
of	IN	O
rhinorrhea	NN	O
.	.	O

They	PRP	O
were	VBD	O
asked	VBN	O
to	TO	O
rate	NN	O
the	DT	O
severity	NN	Physical
and	CC	O
duration	NN	Physical
of	IN	Physical
their	PRP$	Physical
rhinorrhea	JJ	Physical
each	DT	O
day	NN	O
throughout	IN	O
the	DT	O
study	NN	O
on	IN	O
a	DT	O
scale	NN	O
from	IN	O
zero	CD	O
to	TO	O
six	CD	O
.	.	O

Each	DT	O
participant	NN	O
was	VBD	O
initially	RB	O
given	VBN	O
a	DT	O
saline	NN	O
nasal	NN	O
spray	NN	O
for	IN	O
one	CD	O
week	NN	O
.	.	O

They	PRP	O
were	VBD	O
then	RB	O
randomized	VBN	O
to	TO	O
use	VB	O
either	DT	O
IB	NNP	O
or	CC	O
saline	NN	O
for	IN	O
the	DT	O
double-blinded	JJ	O
portion	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Two	CD	O
sprays	NNS	O
of	IN	O
IB	NNP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
42	CD	O
micrograms/spray	NN	O
(	(	O
0.06	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
saline	NN	O
,	,	O
were	VBD	O
administered	VBN	O
intranasally	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
two	CD	O
weeks	NNS	O
,	,	O
after	IN	O
which	WDT	O
time	NN	O
the	DT	O
participants	NNS	O
were	VBD	O
given	VBN	O
another	DT	O
nasal	NN	O
spray	NN	O
(	(	O
either	CC	O
IB	NNP	O
or	CC	O
saline	NN	O
)	)	O
for	IN	O
the	DT	O
crossover	NN	O
portion	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Six	CD	O
patients	NNS	O
entered	VBD	O
and	CC	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Those	DT	O
patients	NNS	O
using	VBG	O
the	DT	O
IB	NNP	O
recorded	VBD	O
a	DT	O
mean	JJ	O
55	CD	O
%	NN	O
decline	NN	Others
in	IN	Others
severity	NN	Others
and	CC	O
a	DT	O
mean	JJ	O
51	CD	O
%	NN	O
decline	NN	Physical
in	IN	Physical
duration	NN	Physical
of	IN	Physical
the	DT	Physical
rhinorrhea	NN	Physical
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
relief	NN	O
in	IN	O
both	DT	O
severity	NN	Physical
and	CC	Physical
duration	NN	Physical
of	IN	Physical
rhinorrhea	NN	Physical
obtained	VBN	O
by	IN	O
patients	NNS	O
was	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
Wilcoxon	NNP	Others
signed-rank	JJ	Others
test	NN	Others
and	CC	O
found	VBN	O
to	TO	O
be	VB	O
highly	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Despite	IN	O
the	DT	O
limitations	NNS	O
of	IN	O
a	DT	O
small	JJ	O
sample	NN	O
size	NN	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
ipratropium	NN	O
bromide	NN	O
nasal	NN	O
spray	NN	O
significantly	RB	O
reduced	VBD	O
both	DT	O
the	DT	O
severity	NN	Physical
and	CC	Physical
duration	NN	Physical
of	IN	Physical
rhinorrhea	NN	Physical
in	IN	O
laryngectomized	JJ	O
patients	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
ipratropium	JJ	O
nasal	NN	O
spray	NN	O
as	IN	O
a	DT	O
safe	JJ	O
,	,	O
effective	JJ	O
way	NN	O
to	TO	O
treat	VB	O
chronic	JJ	O
rhinorrhea	NN	O
in	IN	O
laryngectomized	JJ	O
patients	NNS	O
,	,	O
improving	VBG	O
their	PRP$	O
quality	NN	Others
of	IN	Others
life	NN	Others
.	.	O

Efficacy	NN	O
and	CC	O
long-term	JJ	O
tolerability	NN	O
of	IN	O
sublingual	JJ	O
fentanyl	NN	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Breakthrough	NNP	O
cancer	NN	O
pain	NN	O
(	(	O
BTcP	NNP	O
)	)	O
represents	VBZ	O
an	DT	O
important	JJ	O
clinical	JJ	O
challenge	NN	O
in	IN	O
the	DT	O
care	NN	O
of	IN	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

This	DT	O
trial	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
long-term	JJ	O
tolerability	NN	O
of	IN	O
a	DT	O
sublingual	JJ	O
formulation	NN	O
of	IN	O
the	DT	O
fast-acting	JJ	O
opioid	NN	O
fentanyl	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
BTcP	NNP	O
in	IN	O
opioid-tolerant	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
multi-center	JJ	O
,	,	O
phase	JJ	O
III	NNP	O
trial	NN	O
,	,	O
conducted	VBN	O
in	IN	O
opioid-tolerant	JJ	O
male	NN	O
and	CC	O
female	JJ	O
patients	NNS	O
(	(	O
aged	VBN	O
>	NN	O
or	CC	O
=17	CD	O
years	NNS	O
)	)	O
with	IN	O
BTcP	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
36	CD	O
centers	NNS	O
across	IN	O
the	DT	O
USA	NNP	O
.	.	O

The	DT	O
study	NN	O
comprised	VBD	O
a	DT	O
2-week	JJ	O
open-label	JJ	O
titration	NN	O
phase	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
double-blind	JJ	O
efficacy	NN	O
phase	NN	O
,	,	O
during	IN	O
which	WDT	O
patients	NNS	O
received	VBD	O
sublingual	JJ	O
fentanyl	NN	O
citrate	NN	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
(	(	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
in	IN	O
a	DT	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
sum	NN	Pain
of	IN	Pain
pain	NN	Pain
intensity	NN	Pain
difference	NN	Pain
(	(	Pain
SPID	NNP	Pain
)	)	Pain
over	IN	Physical
30	CD	Physical
min	JJ	Physical
post-administration	NN	Physical
.	.	O

Secondary	JJ	O
efficacy	NN	O
endpoints	NNS	O
included	VBD	O
pain	NN	Pain
intensity	NN	Pain
difference	NN	Pain
(	(	Pain
PID	NNP	Pain
)	)	Pain
and	CC	O
pain	NN	Pain
relief	NN	Pain
(	(	Pain
PR	NNP	Pain
)	)	Pain
throughout	IN	O
the	DT	O
60-min	JJ	O
post-dose	JJ	O
assessment	NN	O
period	NN	O
.	.	O

Following	VBG	O
efficacy	NN	O
evaluation	NN	O
,	,	O
patients	NNS	O
entered	VBD	O
a	DT	O
long-term	JJ	Others
safety	NN	Others
phase	NN	Others
of	IN	Others
up	IN	Others
to	TO	Others
12	CD	Others
months	NNS	Others
.	.	O

Adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

[	VB	O
CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
NCT00262678	NNP	O
]	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
131	CD	O
patients	NNS	O
entered	VBD	O
the	DT	O
titration	NN	O
phase	NN	O
,	,	O
of	IN	O
whom	WP	O
61	CD	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
SPID	NNP	Pain
relative	VBP	O
to	TO	O
placebo	VB	O
at	IN	O
30	CD	O
min	NN	O
(	(	O
49.5	CD	O
vs.	FW	O
36.6	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0004	CD	O
)	)	O
and	CC	O
60	CD	O
min	NNS	O
post-administration	NN	O
(	(	O
143.0	CD	O
vs.	FW	O
104.5	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0002	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
PID	NNP	Pain
and	CC	O
PR	NNP	Pain
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
from	IN	O
10	CD	O
min	NNS	O
post-dose	JJ	O
(	(	O
p	JJ	O
=	NN	O
0.0055	CD	O
and	CC	O
p	VB	O
=	$	O
0.049	CD	O
for	IN	O
PID	NNP	O
and	CC	O
PR	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Patient	JJ	O
recruitment	NN	O
was	VBD	O
stopped	VBN	O
early	RB	O
,	,	O
due	JJ	O
to	TO	O
positive	JJ	O
interim	JJ	O
analysis	NN	O
results	NNS	O
(	(	O
significant	JJ	O
at	IN	O
prespecified	JJ	O
level	NN	O
,	,	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.0414	CD	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
well-tolerated	JJ	Others
both	DT	Others
systemically	RB	Others
and	CC	Others
sublingually	RB	Others
,	,	O
with	IN	O
41	CD	O
patients	NNS	O
experiencing	VBG	O
>	NN	O
or	CC	O
=1	NN	O
study	NN	O
drug-related	JJ	Adverseeffect
adverse	JJ	Adverseeffect
event	NN	Adverseeffect
(	(	O
AE	NNP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
AEs	NNP	O
included	VBD	O
nausea	NN	Adverseeffect
(	(	O
12.2	CD	O
%	NN	O
)	)	O
,	,	O
vomiting	VBG	Adverseeffect
(	(	O
5.3	CD	O
%	NN	O
)	)	O
and	CC	O
somnolence	NN	Adverseeffect
(	(	O
4.6	CD	O
%	NN	O
)	)	O
.	.	O

One	CD	O
serious	JJ	Adverseeffect
AE	NNP	Adverseeffect
(	(	Adverseeffect
mild	JJ	Adverseeffect
affect	VBP	Adverseeffect
lability	NN	Adverseeffect
)	)	Adverseeffect
was	VBD	O
considered	VBN	O
possibly	RB	O
related	VBN	O
to	TO	O
study	VB	O
medication	NN	O
.	.	O

The	DT	O
observed	JJ	O
pattern	NN	O
of	IN	O
AEs	NNP	O
was	VBD	O
consistent	JJ	O
with	IN	O
that	DT	O
previously	RB	O
observed	VBN	O
with	IN	O
fentanyl	NN	O
.	.	O

CONCLUSIONS	NNP	O
Sublingual	NNP	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
efficacious	JJ	O
and	CC	O
well-tolerated	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
BTcP	NNP	O
in	IN	O
opioid-tolerant	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
pain	NN	O
intensity	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
from	IN	O
10	CD	O
min	JJ	O
post-administration	NN	O
and	CC	O
throughout	IN	O
the	DT	O
60-min	JJ	O
post-dose	JJ	O
assessment	NN	O
period	NN	O
.	.	O

Sublingual	JJ	O
fentanyl	NN	O
ODT	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
over	IN	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Iontophoretic	JJ	O
administration	NN	O
of	IN	O
dexamethasone	NN	O
sodium	NN	O
phosphate	NN	O
for	IN	O
acute	JJ	O
epicondylitis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
A	NNP	O
better	RBR	O
treatment	NN	O
modality	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
control	VB	O
the	DT	O
pain	NN	Pain
of	IN	O
medial	NN	Physical
or	CC	Physical
lateral	JJ	Physical
epicondylitis	NN	Physical
(	(	Physical
tennis	IN	Physical
elbow	NN	Physical
)	)	Physical
.	.	Physical

HYPOTHESIS	NNP	O
Dermal	NNP	O
iontophoretic	JJ	O
administration	NN	O
of	IN	O
dexamethasone	NN	O
sodium	NN	O
phosphate	NN	O
will	MD	O
be	VB	O
significantly	RB	O
more	RBR	O
effective	JJ	O
in	IN	O
controlling	VBG	O
pain	NN	Pain
than	IN	O
a	DT	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
medial	JJ	O
or	CC	O
lateral	JJ	O
elbow	NN	O
epicondylitis	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
On	IN	O
six	CD	O
occasions	NNS	O
,	,	O
1	CD	O
to	TO	O
3	CD	O
days	NNS	O
apart	RB	O
within	IN	O
15	CD	O
days	NNS	O
,	,	O
199	CD	O
patients	NNS	O
with	IN	O
elbow	JJ	O
epicondylitis	NN	O
received	VBD	O
40	CD	O
mA-minutes	NNS	O
of	IN	O
either	DT	O
active	JJ	O
or	CC	O
placebo	JJ	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Dexamethasone	NNP	O
produced	VBD	O
a	DT	O
significant	JJ	O
23-mm	JJ	O
improvement	NN	O
on	IN	O
the	DT	O
100-mm	JJ	Pain
patient	NN	Pain
visual	JJ	Pain
analog	NN	Pain
scale	NN	Pain
ratings	NNS	Pain
,	,	O
compared	VBN	O
with	IN	O
14	CD	O
mm	NNS	O
for	IN	O
placebo	NN	O
at	IN	O
2	CD	O
days	NNS	O
and	CC	O
24	CD	O
mm	NNS	O
compared	VBN	O
with	IN	O
19	CD	O
mm	NNS	O
at	IN	O
1	CD	O
month	NN	O
.	.	O

More	JJR	O
patients	NNS	O
treated	VBN	O
with	IN	O
dexamethasone	NN	O
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
placebo	NN	O
scored	VBN	O
moderate	JJ	O
or	CC	O
better	JJR	O
on	IN	O
the	DT	O
investigator	NN	Physical
's	POS	Physical
global	JJ	Physical
improvement	NN	Physical
scale	NN	Physical
(	(	O
52	CD	O
%	NN	O
versus	IN	O
33	CD	O
%	NN	O
)	)	O
at	IN	O
2	CD	O
days	NNS	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
at	IN	O
1	CD	O
month	NN	O
(	(	O
54	CD	O
%	NN	O
versus	IN	O
49	CD	O
%	NN	O
)	)	O
.	.	O

Investigator-rated	JJ	Pain
pain	NN	Pain
and	CC	Pain
tenderness	NN	Pain
scores	NNS	Pain
favored	VBD	O
dexamethasone	NN	O
over	IN	O
placebo	NN	O
at	IN	O
2	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
completing	VBG	O
six	CD	O
treatments	NNS	O
in	IN	O
10	CD	O
days	NNS	O
or	CC	O
less	JJR	O
had	VBD	O
better	RBR	O
results	NNS	O
than	IN	O
those	DT	O
treated	VBN	O
over	IN	O
a	DT	O
longer	JJR	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
Iontophoresis	NNP	O
treatment	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
by	IN	O
most	JJS	O
patients	NNS	O
and	CC	O
was	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
symptoms	NNS	Physical
of	IN	Physical
epicondylitis	NN	Physical
at	IN	O
short-term	JJ	O
follow-up	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
external	JJ	O
beam	NN	O
radiotherapy	NN	O
versus	NN	O
cryoablation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
:	:	O
quality	NN	O
of	IN	O
life	NN	O
outcomes	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
recent	JJ	O
randomized	JJ	O
trial	NN	O
to	TO	O
compare	VB	O
external	JJ	O
beam	NN	O
radiation	NN	O
therapy	NN	O
(	(	O
EBRT	NNP	O
)	)	O
to	TO	O
cryoablation	NN	O
for	IN	O
localized	JJ	O
disease	NN	O
showed	VBD	O
cryoablation	NN	O
to	TO	O
be	VB	O
noninferior	JJ	O
to	TO	O
external	JJ	O
beam	NN	O
EBRT	NNP	O
in	IN	O
disease	NN	O
progression	NN	O
and	CC	O
overall	JJ	O
and	CC	O
disease-specific	JJ	O
survival	NN	O
.	.	O

We	PRP	O
report	VBP	O
on	IN	O
the	DT	O
quality	NN	Others
of	IN	Others
life	NN	Others
(	(	Others
QOL	NNP	Others
)	)	Others
outcomes	VBZ	O
for	IN	O
this	DT	O
trial	NN	O
.	.	O

METHODS	NN	O
From	IN	O
December	NNP	O
1997	CD	O
through	IN	O
February	NNP	O
2003	CD	O
,	,	O
244	CD	O
men	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
cryoablation	NN	O
or	CC	O
EBRT	NNP	O
(	(	O
median	JJ	O
dose	NN	O
68	CD	O
Gy	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
neoadjuvant	JJ	O
antiandrogen	NN	O
therapy	NN	O
.	.	O

Patients	NNS	O
completed	VBD	O
the	DT	O
EORTC	NNP	O
QLQ	NNP	O
C30	NNP	O
and	CC	O
the	DT	O
Prostate	NNP	O
Cancer	NNP	O
Index	NNP	O
(	(	O
PCI	NNP	O
)	)	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
1.5	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
and	CC	O
36	CD	O
months	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Regardless	NNP	O
of	IN	O
treatment	NN	O
arm	NN	O
,	,	O
participants	NNS	O
reported	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
QOL	NNP	Others
with	IN	O
few	JJ	O
exceptions	NNS	O
.	.	O

cryoablation	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
more	RBR	O
acute	JJ	Physical
urinary	JJ	Physical
dysfunction	NN	Physical
(	(	O
mean	JJ	O
PCI	NNP	O
urinary	JJ	O
function	NN	O
cryoablation=69.4	NN	O
;	:	O
mean	JJ	O
EBRT=90.7	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
which	WDT	O
resolved	VBD	O
over	IN	O
time	NN	O
.	.	O

No	DT	Others
late	JJ	Others
arising	NN	Others
QOL	NNP	Others
issues	NNS	Others
were	VBD	O
observed	VBN	O
.	.	O

Both	DT	O
EBRT	NNP	O
and	CC	O
cryoablation	NN	O
participants	NNS	O
reported	VBD	O
decreases	NNS	Physical
in	IN	Physical
sexual	JJ	Physical
function	NN	Physical
at	IN	O
3	CD	O
months	NNS	O
with	IN	O
the	DT	O
cryoablation	NN	O
patients	NNS	O
reporting	VBG	O
poorer	NN	O
functioning	NN	O
(	(	O
mean	JJ	O
cryoablation=7.2	NN	O
:	:	O
mean	JJ	O
EBRT=32.9	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Mean	JJ	Physical
sexual	JJ	Physical
function	NN	Physical
score	NN	Physical
was	VBD	O
15	CD	O
points	NNS	O
lower	JJR	O
at	IN	O
3	CD	O
years	NNS	O
for	IN	O
the	DT	O
cryoablation	NN	O
group	NN	O
and	CC	O
13	CD	O
%	NN	O
more	JJR	O
of	IN	O
the	DT	O
cryoablation	NN	O
men	NNS	O
said	VBD	O
that	IN	O
sexuality	NN	O
was	VBD	O
a	DT	O
moderate	JJ	O
or	CC	O
big	JJ	O
problem	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
trial	NN	O
,	,	O
no	DT	O
long-term	JJ	O
QOL	NNP	Others
advantage	NN	O
for	IN	O
either	DT	O
treatment	NN	O
was	VBD	O
apparent	JJ	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
poorer	JJR	O
sexual	JJ	Mental
function	NN	Mental
reported	VBN	O
by	IN	O
those	DT	O
treated	VBN	O
with	IN	O
cryoablation	NN	O
.	.	O

Men	NN	O
who	WP	O
wish	VBZ	O
to	TO	O
increase	VB	O
their	PRP$	O
odds	NNS	O
of	IN	O
retaining	VBG	O
sexual	JJ	Mental
function	NN	Mental
might	MD	O
be	VB	O
counseled	VBN	O
to	TO	O
choose	VB	O
EBRT	NNP	O
over	IN	O
cryoablation	NN	O
.	.	O

A	DT	O
phase	NN	O
I	PRP	O
study	VBP	O
of	IN	O
recombinant	JJ	O
human	JJ	O
ciliary	JJ	O
neurotrophic	JJ	O
factor	NN	O
(	(	O
rHCNTF	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
amyotrophic	JJ	O
lateral	JJ	O
sclerosis	NN	O
.	.	O

The	DT	O
ALS	NNP	O
CNTF	NNP	O
Treatment	NNP	O
Study	NNP	O
(	(	O
ACTS	NNP	O
)	)	O
Phase	NNP	O
I-II	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Fifty-seven	CD	O
patients	NNS	O
with	IN	O
amyotrophic	JJ	O
lateral	JJ	O
sclerosis	NN	O
(	(	O
ALS	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
30	CD	O
micrograms/kg	NN	O
recombinant	JJ	O
human	JJ	O
ciliary	JJ	O
neurotrophic	JJ	O
factor	NN	O
(	(	O
rHCNTF	NN	O
)	)	O
or	CC	O
placebo	VB	O
subcutaneously	RB	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Dose-limiting	JJ	Physical
toxicity	NN	Physical
,	,	Physical
consisting	VBG	Physical
of	IN	Physical
febrile	JJ	Physical
reactions	NNS	Physical
in	IN	Physical
some	DT	Physical
patients	NNS	Physical
,	,	Physical
fatigue	NN	Physical
,	,	Physical
and	CC	Physical
nonproductive	JJ	Physical
cough	NN	Physical
,	,	O
was	VBD	O
observed	VBN	O
at	IN	O
a	DT	O
dose	JJ	O
level	NN	O
of	IN	O
30	CD	O
micrograms/kg	NNS	O
.	.	O

Dose-related	JJ	Physical
changes	NNS	Physical
in	IN	Physical
parameters	NNS	Physical
of	IN	Physical
the	DT	Physical
acute-phase	JJ	Physical
response	NN	Physical
were	VBD	O
noted	VBN	O
,	,	O
consistent	JJ	O
with	IN	O
the	DT	O
relationship	NN	O
of	IN	O
CNTF	NNP	O
and	CC	O
its	PRP$	O
receptor	NN	O
system	NN	O
to	TO	O
the	DT	O
cytokine	NN	O
interleukin-6	NN	O
(	(	O
IL-6	NNP	O
)	)	O
and	CC	O
its	PRP$	O
receptor	NN	O
.	.	O

No	DT	O
adverse	JJ	Adverseeffect
neurologic	JJ	Adverseeffect
consequences	NNS	Adverseeffect
of	IN	Adverseeffect
rHCNTF	JJ	Adverseeffect
administration	NN	Adverseeffect
were	VBD	O
observed	VBN	O
.	.	O

Antibodies	NNS	Physical
to	TO	Physical
rHCNTF	VB	Physical
were	VBD	O
observed	VBN	O
in	IN	O
sera	NN	O
of	IN	O
most	JJS	O
patients	NNS	O
tested	VBN	O
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
continuous	JJ	O
treatment	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
'	POS	O
withdrawal	NN	O
period	NN	O
.	.	O

rHCNTF	NN	O
was	VBD	O
safe	JJ	Others
and	CC	Others
tolerated	VBD	Others
within	IN	O
acceptable	JJ	O
limits	NNS	O
when	WRB	O
administered	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
ALS	NNP	O
in	IN	O
this	DT	O
study	NN	O
at	IN	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
30	CD	O
micrograms/kg	NN	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
to	TO	O
explore	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
rHCNTF	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
human	JJ	O
motor	NN	O
neuron	NN	O
diseases	NNS	O
are	VBP	O
justified	VBN	O
.	.	O

Acute	NNP	O
cardiac	JJ	O
effects	NNS	O
of	IN	O
nicotine	NN	O
in	IN	O
healthy	JJ	O
young	JJ	O
adults	NNS	O
.	.	O

BACKGROUND	NNP	O
Nicotine	NNP	O
is	VBZ	O
known	VBN	O
to	TO	O
have	VB	O
many	JJ	O
physiologic	JJ	O
effects	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
nicotine	NN	O
delivered	VBN	O
in	IN	O
chewing	VBG	O
gum	NN	O
upon	IN	O
cardiac	JJ	O
hemodynamics	NNS	O
and	CC	O
conduction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
well-characterized	JJ	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
nicotine	NN	O
in	IN	O
nonsmoking	VBG	O
adults	NNS	O
(	(	O
6	CD	O
male	NN	O
,	,	O
5	CD	O
female	NN	O
;	:	O
ages	VBZ	O
23-36	CD	O
years	NNS	O
)	)	O
using	VBG	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
chewed	VBD	O
nicotine	JJ	O
gum	NN	O
(	(	O
4	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

After	IN	O
20	CD	O
minutes	NNS	O
(	(	O
approximate	JJ	O
time	NN	O
to	TO	O
peak	VB	O
nicotine	JJ	O
levels	NNS	O
)	)	O
,	,	O
echocardiograms	JJ	O
and	CC	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
(	(	O
SAECG	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
.	.	O

After	IN	O
40	CD	O
minutes	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
again	RB	O
given	VBN	O
nicotine	JJ	O
gum	NN	O
or	CC	O
placebo	NN	O
in	IN	O
cross-over	JJ	O
fashion	NN	O
.	.	O

Standard	NNP	O
echocardiographic	JJ	O
measurements	NNS	O
were	VBD	O
made	VBN	O
from	IN	O
two-dimensional	JJ	O
images	NNS	O
.	.	O

We	PRP	O
then	RB	O
calculated	VBD	O
end-systolic	JJ	Physical
wall	NN	Physical
stress	NN	Physical
(	(	Physical
ESWS	NNP	Physical
)	)	Physical
,	,	Physical
shortening	VBG	Physical
fraction	NN	Physical
(	(	Physical
SF	NNP	Physical
)	)	Physical
,	,	Physical
systemic	JJ	Physical
vascular	NN	Physical
resistance	NN	Physical
(	(	Physical
SVR	NNP	Physical
)	)	Physical
,	,	Physical
velocity	NN	Physical
for	IN	Physical
circumferential	JJ	Physical
fiber	NN	Physical
shortening	NN	Physical
corrected	VBN	Physical
for	IN	Physical
heart	NN	Physical
rate	NN	Physical
(	(	Physical
Vcfc	NNP	Physical
)	)	Physical
,	,	Physical
stroke	VBD	Physical
volume	NN	Physical
,	,	Physical
and	CC	Physical
cardiac	JJ	Physical
output	NN	Physical
.	.	Physical

P	NNP	Physical
wave	NN	Physical
and	CC	Physical
QRS	NNP	Physical
duration	NN	Physical
were	VBD	O
measured	VBN	O
from	IN	O
SAECG	NNP	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
control	NN	O
or	CC	O
placebo	NN	O
were	VBD	O
found	VBN	O
for	IN	O
ESWS	NNP	Others
,	,	O
mean	JJ	O
blood	NN	Physical
pressure	NN	Physical
,	,	O
cardiac	JJ	Others
output	NN	Others
,	,	O
SVR	NNP	Others
,	,	O
heart	NN	Others
rate	NN	Others
,	,	O
and	CC	O
P	NNP	Others
wave	VBP	Others
duration	NN	Others
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
left	JJ	Physical
ventricular	JJ	Physical
ejection	NN	Physical
time	NN	Physical
(	(	Physical
LVET	NNP	Physical
)	)	Physical
,	,	Physical
LV	NNP	Physical
dimensions	NNS	Physical
,	,	O
SF	NNP	Physical
,	,	O
contractility	NN	Physical
(	(	Physical
Vcfc	NNP	Physical
)	)	Physical
,	,	O
or	CC	O
QRS	NNP	Physical
duration	NN	Physical
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
nicotine	JJ	O
chewing	VBG	O
gum	NN	O
increases	NNS	O
afterload	NN	Physical
and	CC	Physical
cardiac	JJ	Physical
output	NN	Physical
.	.	Physical

Cardiac	JJ	Physical
contractility	NN	Physical
does	VBZ	O
not	RB	O
change	VB	O
acutely	RB	O
in	IN	O
response	NN	O
to	TO	O
nicotine	VB	O
gum	NN	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
and	CC	O
P	NNP	Physical
wave	VBP	Physical
duration	NN	Physical
are	VBP	O
increased	VBN	O
by	IN	O
chewing	VBG	O
nicotine	JJ	O
gum	NN	O
.	.	O

Comparing	VBG	O
microvascular	JJ	Physical
alterations	NNS	Physical
during	IN	O
minimal	JJ	O
extracorporeal	JJ	O
circulation	NN	O
and	CC	O
conventional	JJ	O
cardiopulmonary	JJ	O
bypass	NN	O
in	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
Minimal	NNP	O
extracorporeal	NN	O
circulation	NN	O
(	(	O
MECC	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
introduced	VBN	O
in	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
(	(	O
CABG	NNP	O
)	)	O
surgery	NN	O
,	,	O
offering	VBG	O
clinical	JJ	O
benefits	NNS	O
owing	VBG	O
to	TO	O
reduced	VBN	O
hemodilution	NN	O
and	CC	O
no	DT	O
blood-air	JJ	O
interface	NN	O
.	.	O

Yet	CC	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
MECC	NNP	O
on	IN	O
the	DT	O
intraoperative	JJ	O
microvascular	JJ	O
perfusion	NN	O
in	IN	O
comparison	NN	O
with	IN	O
conventional	JJ	O
extracorporeal	JJ	O
circulation	NN	O
(	(	O
CECC	NNP	O
)	)	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
so	RB	O
far	RB	O
.	.	O

METHODS	VB	O
The	DT	O
current	JJ	O
study	NN	O
aimed	VBD	O
to	TO	O
analyze	VB	O
alterations	NNS	Physical
in	IN	Physical
microvascular	JJ	Physical
perfusion	NN	Physical
at	IN	O
4	CD	O
predefined	JJ	O
time	NN	O
points	NNS	O
(	(	O
T1-T4	NNP	O
)	)	O
during	IN	O
on-pump	JJ	O
CABG	NNP	O
using	VBG	O
orthogonal	JJ	O
polarization	NN	O
spectral	JJ	O
imaging	NN	O
.	.	O

Forty	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
for	IN	O
being	VBG	O
operated	VBN	O
on	IN	O
with	IN	O
either	DT	O
MECC	NNP	O
or	CC	O
CECC	NNP	O
.	.	O

Changes	NNS	O
in	IN	O
functional	JJ	Physical
capillary	JJ	Physical
density	NN	Physical
(	(	Physical
FCD	NNP	Physical
)	)	Physical
,	,	O
blood	NN	Physical
flow	NN	Physical
velocity	NN	Physical
,	,	O
and	CC	O
vessel	RB	Physical
diameter	NN	Physical
were	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
blinded	JJ	O
investigator	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
start	NN	O
of	IN	O
extracorporeal	JJ	O
circulation	NN	O
(	(	O
ECC	NNP	O
)	)	O
and	CC	O
aortic	JJ	O
crossclamping	NN	O
(	(	O
T2	NNP	O
)	)	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
drop	NN	O
of	IN	O
FCD	NNP	Physical
,	,	O
with	IN	O
a	DT	O
significantly	RB	O
higher	JJR	O
FCD	NNP	Physical
in	IN	O
the	DT	O
MECC	NNP	O
group	NN	O
(	(	O
206.8	CD	O
?	.	O
33.6	CD	O
cm/cm?	NN	O
in	IN	O
CECC	NNP	O
group	NN	O
versus	VBD	O
217.8	CD	O
?	.	O
35.3	CD	O
cm/cm?	NN	O
in	IN	O
MECC	NNP	O
group	NN	O
;	:	O
P	NNP	O
=	NNP	O
.034	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
late	JJ	O
phase	NN	O
of	IN	O
the	DT	O
ECC	NNP	O
(	(	O
T3	NNP	O
)	)	O
,	,	O
FCD	NNP	O
in	IN	O
the	DT	O
MECC	NNP	O
group	NN	O
was	VBD	O
already	RB	O
recovered	VBN	O
,	,	O
whereas	JJ	O
FCD	NNP	O
in	IN	O
the	DT	O
CECC	NNP	O
group	NN	O
was	VBD	O
still	RB	O
significantly	RB	O
depressed	VBN	O
(	(	O
223.1	CD	O
?	.	O
35.6	CD	O
cm/cm?	NN	O
in	IN	O
MECC	NNP	O
group	NN	O
;	:	O
P	NNP	O
=	NNP	O
.100	NNP	O
vs	NN	O
T1	NNP	O
;	:	O
211.1	CD	O
?	.	O
36.9	CD	O
cm/cm?	NN	O
in	IN	O
CECC	NNP	O
group	NN	O
;	:	O
P	NNP	O
=	NNP	O
.017	NNP	O
vs	NNP	O
T1	NNP	O
)	)	O
.	.	O

After	IN	O
termination	NN	O
of	IN	O
ECC	NNP	O
(	(	O
T4	NNP	O
)	)	O
,	,	O
FCD	NNP	O
recovered	VBD	O
in	IN	O
both	DT	O
groups	NNS	O
to	TO	O
baseline	VB	O
.	.	O

Blood	NNP	O
flow	JJ	O
velocity	NN	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
in	IN	O
the	DT	O
MECC	NNP	O
group	NN	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
intergroup	NN	O
difference	NN	O
after	IN	O
aortic	JJ	O
crossclamping	NN	O
(	(	O
T2	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Orthogonal	NNP	O
polarization	NN	O
spectral	JJ	O
imaging	VBG	O
data	NNS	O
reveal	VBP	O
an	DT	O
impairment	NN	O
of	IN	O
microvascular	JJ	O
perfusion	NN	O
during	IN	O
on-pump	JJ	O
CABG	NNP	O
.	.	O

Changes	NNS	O
in	IN	O
FCD	NNP	O
indicate	VBP	O
a	DT	O
faster	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
microvascular	JJ	O
perfusion	NN	O
in	IN	O
MECC	NNP	O
during	IN	O
the	DT	O
reperfusion	NN	O
period	NN	O
.	.	O

Beneficial	JJ	O
recovery	NN	O
of	IN	O
microvascular	JJ	O
organ	JJ	O
perfusion	NN	O
could	MD	O
partly	RB	O
explain	VB	O
the	DT	O
perioperative	JJ	O
advantages	NNS	O
reported	VBN	O
for	IN	O
MECC	NNP	O
.	.	O

Predictors	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
and	CC	O
negative	JJ	O
caregiving	NN	O
experiences	NNS	O
in	IN	O
carers	NNS	O
of	IN	O
adolescents	NNS	O
with	IN	O
bulimia	NN	O
nervosa	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
exploratory	NN	O
study	NN	O
focuses	VBZ	O
on	IN	O
the	DT	O
mental	JJ	O
health	NN	O
(	(	O
MH	NNP	O
)	)	O
and	CC	O
caregiving	VBG	O
experience	NN	O
of	IN	O
carers	NNS	O
of	IN	O
adolescents	NNS	O
with	IN	O
Bulimia	NNP	O
Nervosa	NNP	O
(	(	O
BN	NNP	O
)	)	O
/Eating	VBG	O
Disorder	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
(	(	O
EDNOS	NNP	O
)	)	O
,	,	O
aiming	VBG	O
to	TO	O
determine	VB	O
:	:	O
levels	NNS	O
of	IN	O
MH	NNP	O
problems	NNS	O
in	IN	O
carers	NNS	O
and	CC	O
if	IN	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
predicts	NNS	O
carer	VBP	O
MH	NNP	O
status	NN	O
and	CC	O
which	WDT	O
factors	NNS	O
predict	VBP	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

METHOD	NNP	O
Hundred	NNP	O
and	CC	O
twelve	VB	O
carers	NNS	O
and	CC	O
68	CD	O
adolescents	NNS	O
with	IN	O
BN/EDNOS	NNP	O
completed	VBD	O
self-report	JJ	O
measures	NNS	O
(	(	O
General	NNP	O
Health	NNP	O
Questionnaire	NNP	O
,	,	O
Experience	NNP	O
of	IN	O
Caregiving	NNP	O
Inventory	NNP	O
,	,	O
Level	NNP	O
of	IN	O
Expressed	JJ	O
Emotion	NNP	O
,	,	O
Self-report	NNP	O
Family	NNP	O
Inventory	NNP	O
,	,	O
Inventory	NNP	O
of	IN	O
Interpersonal	NNP	O
Problems	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Over	IN	O
half	NN	O
of	IN	O
the	DT	O
carers	NNS	O
reported	VBD	O
some	DT	O
MH	NNP	Adverseeffect
problems	NNS	Adverseeffect
and	CC	O
a	DT	O
minority	NN	O
(	(	O
5.4	CD	O
%	NN	O
)	)	O
were	VBD	O
experiencing	VBG	O
considerable	JJ	O
difficulties	NNS	O
.	.	O

A	DT	Physical
negative	JJ	Physical
experience	NN	Physical
of	IN	Physical
caregiving	VBG	Physical
predicted	VBN	O
carer	NN	O
MH	NNP	O
status	NN	O
.	.	O

Higher	JJR	Physical
weekly	JJ	Physical
contact	NN	Physical
hours	NNS	Physical
and	CC	Physical
patient	JJ	Physical
ratings	NNS	Physical
of	IN	Physical
expressed	VBN	Physical
emotion	NN	Physical
(	(	Physical
EE	NNP	Physical
)	)	Physical
predicted	VBD	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

CONCLUSIONS	NNP	O
Interventions	NNPS	O
focusing	VBG	O
on	IN	O
reducing	VBG	O
EE	NNP	Others
and	CC	O
contact	NN	Others
hours	NNS	Others
could	MD	O
prove	VB	O
beneficial	JJ	O
for	IN	O
both	DT	O
patient	NN	O
and	CC	O
caregiver	NN	O
outcomes	NNS	O
.	.	O

Pharmacokinetic	JJ	Physical
and	CC	Physical
safety	NN	Physical
assessments	NNS	Physical
of	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
risperidone	NN	O
and	CC	O
donepezil	NN	O
.	.	O

Treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
sometimes	RB	O
uses	VBZ	O
combinations	NNS	O
of	IN	O
drugs	NNS	O
because	IN	O
dementia	NN	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
behavioral	JJ	O
symptoms	NNS	O
.	.	O

Risperidone	NN	O
and	CC	O
donepezil	NN	O
are	VBP	O
both	DT	O
metabolized	VBN	O
through	IN	O
cytochrome	NN	O
P450	NNP	O
2D6	CD	O
and	CC	O
3A4	CD	O
,	,	O
raising	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
drug	NN	O
interactions	NNS	O
with	IN	O
combination	NN	O
therapy	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
significant	JJ	O
drug	NN	Physical
interactions	NNS	Physical
occur	VBP	O
with	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
donepezil	NN	O
and	CC	O
risperidone	NN	O
.	.	O

In	IN	O
an	DT	O
open-label	JJ	O
,	,	O
three-way	JJ	O
crossover	NN	O
study	NN	O
,	,	O
24	CD	O
healthy	JJ	O
men	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
0.5	CD	O
mg	NN	O
of	IN	O
risperidone	NN	O
twice	JJ	O
daily	RB	O
,	,	O
5	CD	O
mg	NN	O
of	IN	O
donepezil	NN	O
once	RB	O
daily	JJ	O
,	,	O
or	CC	O
both	DT	O
drugs	NNS	O
for	IN	O
14	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
21-day	JJ	O
washout	NN	O
period	NN	O
.	.	O

The	DT	O
treatment	NN	O
ratios	NNS	Physical
of	IN	Physical
AUC	NNP	Physical
and	CC	O
associated	VBD	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
for	IN	O
risperidone	NN	O
active	JJ	O
moiety	NN	O
,	,	O
defined	VBD	O
as	IN	O
risperidone	NN	O
plus	CC	O
9-hydroxyrisperidone	CD	O
(	(	O
ratio	VB	O
=	RB	O
110.2	CD	O
%	NN	O
;	:	O
90	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
103.7-117.2	JJ	O
)	)	O
,	,	O
and	CC	O
for	IN	O
donepezil	NN	O
(	(	O
ratio	JJ	O
=	RB	O
97.1	CD	O
%	NN	O
;	:	O
90	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
90.0-103.6	CD	O
)	)	O
were	VBD	O
within	IN	O
the	DT	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
of	IN	O
bioequivalence	NN	O
range	NN	O
.	.	O

The	DT	O
treatment	NN	Others
ratios	NNS	Others
of	IN	Others
Cmax	NNP	Others
and	CC	Others
associated	VBD	Others
90	CD	Others
%	NN	Others
CIs	NNP	Others
for	IN	O
risperidone	NN	O
active	JJ	O
moiety	NN	O
(	(	O
ratio	JJ	O
=	RB	O
114.6	CD	O
%	NN	O
;	:	O
90	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
107.0-122.8	JJ	O
)	)	O
and	CC	O
for	IN	O
donepezil	NN	O
(	(	O
ratio	JJ	O
=	RB	O
96.1	CD	O
%	NN	O
;	:	O
90	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
90.0-102.6	CD	O
)	)	O
were	VBD	O
also	RB	O
within	IN	O
the	DT	O
bioequivalence	NN	O
range	NN	O
.	.	O

Therefore	NNP	O
,	,	O
no	DT	O
significant	JJ	O
pharmacokinetic	JJ	Others
differences	NNS	O
occurred	VBD	O
in	IN	O
either	CC	O
risperidone	VB	O
active	JJ	O
moiety	NN	O
or	CC	O
donepezil	NN	O
when	WRB	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
.	.	O

Adverse	JJ	Others
events	NNS	Others
(	(	Others
predominantly	RB	Others
headache	NN	Others
,	,	Others
nervousness	NN	Others
,	,	Others
and	CC	Others
somnolence	NN	Others
)	)	Others
were	VBD	O
minor	JJ	O
and	CC	O
comparable	JJ	O
for	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
no	DT	O
clinically	RB	Others
meaningful	JJ	Others
drug	NN	Others
interactions	NNS	Others
occurred	VBD	O
between	IN	O
risperidone	NN	O
1	CD	O
mg	JJ	O
daily	JJ	O
and	CC	O
donepezil	JJ	O
5	CD	O
mg	JJ	O
daily	RB	O
at	IN	O
steady	JJ	O
state	NN	O
,	,	O
and	CC	O
therefore	RB	O
no	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
required	VBN	O
when	WRB	O
both	DT	O
drugs	NNS	O
are	VBP	O
combined	VBN	O
with	IN	O
the	DT	O
dosage	NN	O
regimen	NNS	O
studied	VBN	O
.	.	O

Additional	JJ	O
investigations	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
potential	NN	O
for	IN	O
interactions	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
dementia	NNS	O
who	WP	O
may	MD	O
eliminate	VB	O
risperidone	NN	O
and	CC	O
donepezil	VB	O
more	JJR	O
slowly	RB	O
and	CC	O
thus	RB	O
be	VB	O
more	RBR	O
vulnerable	JJ	O
to	TO	O
clinical	JJ	O
drug	NN	O
interactions	NNS	O
than	IN	O
the	DT	O
young	JJ	O
healthy	JJ	O
subjects	NNS	O
examined	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
in	IN	O
patients	NNS	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
order	NN	O
to	TO	O
accommodate	VB	O
increasing	VBG	O
patient	JJ	O
preferences	NNS	O
a	DT	O
new	JJ	O
aqueous	JJ	O
formulation	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	NN	O
nasal	NN	O
spray	NN	O
was	VBD	O
developed	VBN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
seasonal	JJ	O
and	CC	O
perennial	JJ	O
allergic	NN	O
rhinitis	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
once-daily	JJ	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
(	(	O
220	CD	O
micrograms/day	NN	O
)	)	O
with	IN	O
placebo	NN	O
in	IN	O
relieving	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
seasonal	JJ	Physical
allergic	JJ	Physical
rhinitis	NN	Physical
due	JJ	O
to	TO	O
ragweed	VB	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
forty	NN	O
patients	NNS	O
received	VBD	O
either	CC	O
a	DT	O
once	RB	O
daily	JJ	O
220-microgram	JJ	O
dose	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
or	CC	O
placebo	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
evaluated	VBD	O
the	DT	O
severity	NN	O
of	IN	O
seasonal	JJ	Physical
allergic	JJ	Physical
rhinitis	NN	Physical
symptoms	NNS	Physical
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
according	VBG	O
to	TO	O
a	DT	O
4-point	JJ	O
scale	NN	O
(	(	O
0	CD	O
=	NNP	O
absent	NN	O
,	,	O
1	CD	O
=	NN	O
mild	NN	O
,	,	O
2	CD	O
=	NN	O
moderate	NN	O
,	,	O
3	CD	O
=	NNP	O
severe	RB	O
)	)	O
.	.	O

Physician	JJ	O
and	CC	O
patient	JJ	O
global	JJ	O
evaluations	NNS	O
of	IN	O
overall	JJ	O
treatment	NN	O
effectiveness	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
receiving	VBG	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
,	,	O
220	CD	O
micrograms/day	NN	O
,	,	O
had	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
greater	JJR	O
improvements	NNS	Physical
in	IN	O
all	DT	O
rhinitis	NN	Physical
symptoms	NNS	Physical
at	IN	O
weeks	NNS	O
1	CD	O
and	CC	O
2	CD	O
and	CC	O
overall	JJ	O
for	IN	O
the	DT	O
2-week	JJ	O
treatment	NN	O
period	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

A	DT	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
improvement	NN	Physical
in	IN	Physical
the	DT	Physical
nasal	JJ	Physical
index	NN	Physical
occurred	VBD	Physical
as	RB	O
early	RB	O
as	IN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
.	.	O

Both	DT	O
patients	NNS	O
and	CC	O
physicians	NNS	O
reported	VBD	O
a	DT	O
greater	JJR	O
overall	JJ	O
improvement	NN	O
in	IN	O
symptoms	NNS	O
for	IN	O
the	DT	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
.	.	Adverseeffect

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
confirmed	VBD	O
that	IN	O
a	DT	O
220-microgram	JJ	O
dose	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	RB	O
aqueous	JJ	O
nasal	NN	O
spray	NN	O
,	,	O
administered	VBN	O
once	RB	O
daily	JJ	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
reduces	NNS	Physical
effectively	RB	Physical
the	DT	Physical
severity	NN	Physical
of	IN	Physical
symptoms	NNS	Physical
of	IN	Physical
seasonal	JJ	Physical
allergic	JJ	Physical
rhinitis	NN	Physical
due	JJ	Physical
to	TO	Physical
ragweed	VB	Physical
.	.	Physical

Effects	NNS	O
of	IN	O
supplementation	NN	O
of	IN	O
whole	JJ	O
corn	NN	O
germ	NN	O
on	IN	O
reproductive	JJ	Physical
performance	NN	Physical
,	,	O
calf	JJ	Physical
performance	NN	Physical
,	,	O
and	CC	O
leptin	JJS	Physical
concentration	NN	Physical
in	IN	O
primiparous	JJ	O
and	CC	O
mature	JJ	O
beef	NN	O
cows	NNS	O
.	.	O

A	DT	O
2-yr	JJ	O
study	NN	O
using	VBG	O
primiparous	JJ	O
and	CC	O
multiparous	JJ	O
,	,	O
spring-calving	JJ	O
,	,	O
crossbred	JJ	O
beef	NN	O
cows	NNS	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
supplemental	JJ	O
whole	JJ	O
corn	NN	O
germ	NN	O
on	IN	O
reproductive	JJ	Physical
performance	NN	Physical
,	,	O
calf	JJ	Physical
performance	NN	Physical
,	,	O
and	CC	O
serum	NN	Physical
leptin	NN	Physical
concentrations	NNS	Physical
.	.	O

Each	DT	O
year	NN	O
,	,	O
cows	NNS	O
were	VBD	O
blocked	VBN	O
by	IN	O
age	NN	O
and	CC	O
BCS	NNP	O
and	CC	O
assigned	VBD	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatments	NNS	O
:	:	O
PRE	NNP	O
(	(	O
n	JJ	O
=	NNP	O
115	CD	O
)	)	O
cows	NNS	O
received	VBD	O
1.14	CD	O
kg/d	NNS	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
of	IN	O
whole	JJ	O
corn	NN	O
germ	NN	O
for	IN	O
approximately	RB	O
45	CD	O
d	NN	O
before	IN	O
calving	VBG	O
;	:	O
POST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
109	CD	O
)	)	O
cows	NNS	O
were	VBD	O
fed	VBN	O
1.14	CD	O
kg/d	NNS	O
of	IN	O
whole	JJ	O
corn	NN	O
germ	NN	O
for	IN	O
approximately	RB	O
45	CD	O
d	NN	O
after	IN	O
calving	VBG	O
;	:	O
and	CC	O
control	VB	O
cows	NNS	O
(	(	O
n	JJ	O
=	NNP	O
118	CD	O
)	)	O
were	VBD	O
fed	VBN	O
similar	JJ	O
energy	NN	O
and	CC	O
protein	NN	O
from	IN	O
dry-rolled	JJ	O
corn	NN	O
(	(	O
1.82	CD	O
kg	NN	O
of	IN	O
DM/d	NNP	O
)	)	O
for	IN	O
45	CD	O
d	NN	O
before	IN	O
and	CC	O
after	IN	O
calving	VBG	O
.	.	O

Additionally	RB	O
,	,	O
PRE	NNP	O
cows	NNS	O
were	VBD	O
grouped	VBN	O
with	IN	O
controls	NNS	O
after	IN	O
calving	VBG	O
,	,	O
and	CC	O
POST	NNP	O
cows	NNS	O
were	VBD	O
grouped	VBN	O
with	IN	O
control	NN	O
cows	NNS	O
before	IN	O
calving	NN	O
,	,	O
so	IN	O
that	DT	O
corn	NN	O
germ-supplemented	JJ	O
cows	NNS	O
received	VBD	O
the	DT	O
control	NN	O
supplement	NN	O
in	IN	O
the	DT	O
alternate	NN	O
feeding	NN	O
period	NN	O
.	.	O

Cow	NNP	Physical
BW	NNP	Physical
(	(	O
538	CD	O
+/-	JJ	O
13	CD	O
kg	NN	O
)	)	O
and	CC	O
BCS	NNP	O
(	(	O
5.4	CD	O
+/-	JJ	O
0.13	CD	O
)	)	O
did	VBD	O
not	RB	O
differ	VB	O
among	IN	O
treatments	NNS	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
the	DT	O
experiment	NN	O
.	.	O

Calf	NNP	Physical
birth	NN	Physical
weight	NN	Physical
(	(	O
39	CD	O
+/-	JJ	O
2	CD	O
kg	NN	O
)	)	O
,	,	O
weaning	VBG	Physical
weight	NN	Physical
(	(	O
225	CD	O
+/-	JJ	O
7	CD	O
kg	NN	O
)	)	O
,	,	O
and	CC	O
age-adjusted	JJ	Physical
weaning	NN	Physical
weight	NN	Physical
(	(	O
234	CD	O
+/-	JJ	O
8	CD	O
kg	NN	O
)	)	O
did	VBD	O
not	RB	O
differ	VB	O
because	IN	O
of	IN	O
dam	JJ	O
supplementation	NN	O
regimen	NNS	O
.	.	O

Treatment	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
proportion	NN	O
of	IN	O
cows	NNS	O
exhibiting	VBG	O
ovarian	JJ	Physical
luteal	NN	Physical
activity	NN	Physical
before	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
breeding	NN	O
season	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
or	CC	O
pregnancy	NN	O
rate	NN	O
(	(	O
91	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
interval	NN	O
from	IN	O
exposure	NN	O
to	TO	O
bulls	NNS	O
until	IN	O
subsequent	JJ	O
calving	VBG	O
did	VBD	O
not	RB	O
differ	VB	O
(	(	O
P	NNP	O
=	NNP	O
0.16	CD	O
)	)	O
among	IN	O
PRE	NNP	O
(	(	O
298	CD	O
+/-	JJ	O
2.3	CD	O
d	NN	O
)	)	O
,	,	O
POST	NNP	O
(	(	O
303	CD	O
+/-	JJ	O
2.6	CD	O
d	NN	O
)	)	O
,	,	O
and	CC	O
control	NN	O
(	(	O
304	CD	O
+/-	JJ	O
2.3	CD	O
d	NN	O
)	)	O
cows	VBZ	O
.	.	O

Leptin	NNP	Physical
concentrations	NNS	Physical
did	VBD	O
not	RB	O
differ	VB	O
among	IN	O
treatments	NNS	O
and	CC	O
were	VBD	O
2.15	CD	O
+/-	JJ	O
0.75	CD	O
,	,	O
1.88	CD	O
+/-	JJ	O
0.76	CD	O
,	,	O
and	CC	O
1.91	CD	O
+/-	JJ	O
0.75	CD	O
ng/mL	NN	O
for	IN	O
control	NN	O
,	,	O
POST	NNP	O
,	,	O
and	CC	O
PRE	NNP	O
cows	NNS	O
,	,	O
respectively	RB	O
.	.	O

Age	NNP	O
and	CC	O
week	NN	O
relative	VBP	O
to	TO	O
calving	VBG	O
influenced	JJ	O
leptin	JJ	O
concentration	NN	O
.	.	O

Primiparous	JJ	O
cows	NNS	O
had	VBD	O
similar	JJ	O
leptin	NN	Physical
concentrations	NNS	Physical
to	TO	O
3-yr-old	JJ	O
and	CC	O
mature	JJ	O
cows	NNS	O
for	IN	O
wk	NN	O
-7	NN	O
and	CC	O
-6	JJ	O
relative	NN	O
to	TO	O
calving	NN	O
,	,	O
but	CC	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.10	CD	O
)	)	O
concentrations	NNS	O
than	IN	O
mature	NN	O
cows	NNS	O
for	IN	O
wk	NN	O
-5	NN	O
,	,	O
and	CC	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
concentrations	NNS	O
than	IN	O
either	DT	O
3-yr-old	JJ	O
or	CC	O
mature	JJ	O
cows	NNS	O
for	IN	O
wk	NN	O
-4	NN	O
to	TO	O
+7	VB	O
relative	JJ	O
to	TO	O
calving	VBG	O
.	.	O

Serum	NNP	O
leptin	NN	O
was	VBD	O
correlated	VBN	O
with	IN	O
BCS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
;	:	O
r	NN	O
=	VBZ	O
0.35	CD	O
)	)	O
at	IN	O
initiation	NN	O
of	IN	O
the	DT	O
feeding	JJ	O
period	NN	O
and	CC	O
was	VBD	O
correlated	VBN	O
with	IN	O
BCS	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
;	:	O
r	NN	O
=	VBZ	O
0.12	CD	O
)	)	O
and	CC	O
weight	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
;	:	O
r	NN	O
=	VBZ	O
0.14	CD	O
)	)	O
at	IN	O
the	DT	O
completion	NN	O
of	IN	O
the	DT	O
supplement	JJ	O
period	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
not	RB	O
correlated	VBN	O
with	IN	O
initial	JJ	O
BW	NNP	O
or	CC	O
interim	JJ	O
BCS	NNP	O
.	.	O

Calving	VBG	O
interval	NN	O
was	VBD	O
not	RB	O
correlated	VBN	O
(	(	O
P	NNP	O
>	NNP	O
0.12	CD	O
)	)	O
with	IN	O
weekly	JJ	O
measures	NNS	O
of	IN	O
serum	NN	Physical
leptin	NN	Physical
concentration	NN	Physical
.	.	O

Supplementing	VBG	O
beef	NN	O
cows	NNS	O
with	IN	O
whole	JJ	O
corn	NN	O
germ	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
cow	NN	O
performance	NN	O
,	,	O
calf	JJ	O
performance	NN	O
,	,	O
or	CC	O
serum	NN	O
leptin	JJ	O
concentrations	NNS	O
of	IN	O
cows	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	VBN	O
pilot	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
N-acetylcysteine	NNP	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
imbalance	NN	O
in	IN	O
the	DT	O
excitatory/inhibitory	JJ	O
systems	NNS	O
with	IN	O
abnormalities	NNS	O
in	IN	O
the	DT	O
glutamatergic	NN	O
pathways	VBZ	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
the	DT	O
pathophysiology	NN	O
of	IN	O
autism	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
chronic	JJ	O
redox	NN	O
imbalance	NN	O
was	VBD	O
also	RB	O
recently	RB	O
linked	VBN	O
to	TO	O
this	DT	O
disorder	NN	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
using	VBG	O
oral	JJ	O
N-acetylcysteine	NNP	O
(	(	O
NAC	NNP	O
)	)	O
,	,	O
a	DT	O
glutamatergic	JJ	O
modulator	NN	O
and	CC	O
an	DT	O
antioxidant	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
behavioral	JJ	O
disturbance	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
12-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
NAC	NNP	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Subjects	VBZ	O
randomized	VBN	O
to	TO	O
NAC	NNP	O
were	VBD	O
initiated	VBN	O
at	IN	O
900	CD	O
mg	NNS	O
daily	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
then	RB	O
900	CD	O
mg	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
900	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
behavioral	JJ	O
measure	NN	O
(	(	O
Aberrant	NNP	Mental
Behavior	NNP	Mental
Checklist	NNP	Mental
[	NNP	Mental
ABC	NNP	Mental
]	NNP	Mental
irritability	NN	Mental
subscale	NN	Mental
)	)	O
and	CC	O
safety	NN	O
measures	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
the	DT	O
ABC	NNP	Mental
stereotypy	NN	Mental
subscale	NN	Mental
,	,	Mental
Repetitive	JJ	Mental
Behavior	NNP	Mental
Scale-Revised	JJ	Mental
,	,	Mental
and	CC	Mental
Social	NNP	Mental
Responsiveness	NNP	Mental
Scale	NNP	Mental
.	.	O

RESULTS	NNP	O
Thirty-three	JJ	O
subjects	NNS	O
(	(	O
31	CD	O
male	NN	O
subjects	NNS	O
,	,	O
2	CD	O
female	JJ	O
subjects	NNS	O
;	:	O
aged	VBN	O
3.2-10.7	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Follow-up	NNP	O
data	NN	O
was	VBD	O
available	JJ	O
on	IN	O
14	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
NAC	NNP	O
group	NN	O
and	CC	O
15	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Oral	NNP	O
NAC	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
with	IN	O
limited	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
NAC	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
improvements	NNS	O
on	IN	O
ABC	NNP	Mental
irritability	NN	Mental
subscale	NN	Mental
(	(	O
F	NNP	O
=	NNP	O
6.80	CD	O
;	:	O
p	NN	O
<	NNP	O
.001	NNP	O
;	:	O
d	VBZ	O
=	NNP	O
.96	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Data	NNP	O
from	IN	O
this	DT	O
pilot	NN	O
investigation	NN	O
support	NN	O
the	DT	O
potential	JJ	O
usefulness	NN	O
of	IN	O
NAC	NNP	O
for	IN	O
treating	VBG	O
irritability	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Large	NNP	O
randomized	VBD	O
controlled	VBN	O
investigations	NNS	O
are	VBP	O
warranted	VBN	O
.	.	O

Bright	NNP	O
light	JJ	O
therapy	NN	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

Several	JJ	O
observations	NNS	O
suggest	VBP	O
a	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
melatonin	NN	O
antagonism	NN	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
.	.	O

Although	IN	O
bright	JJ	O
light	JJ	O
therapy	NN	O
(	(	O
BLT	NNP	O
)	)	O
suppresses	VBZ	O
melatonin	JJ	O
release	NN	O
and	CC	O
is	VBZ	O
an	DT	O
established	JJ	O
treatment	NN	O
for	IN	O
depression	NN	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
,	,	O
it	PRP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
PD	NNP	O
.	.	O

We	PRP	O
examined	VBD	O
effects	NNS	O
of	IN	O
BLT	NNP	O
on	IN	O
motor	NN	Mental
symptoms	NNS	Mental
,	,	Mental
depression	NN	Mental
,	,	O
and	CC	O
sleep	NN	Mental
in	IN	O
PD	NNP	O
in	IN	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
double-blind	NN	O
study	NN	O
in	IN	O
36	CD	O
PD	NNP	O
patients	NNS	O
,	,	O
using	VBG	O
Parkinson	NNP	Mental
's	POS	Mental
Disease	NNP	Mental
Rating	NNP	Mental
Scale	NNP	Mental
(	(	Mental
UPDRS	NNP	Mental
)	)	Mental
I-IV	NNP	Mental
,	,	Mental
Beck	NNP	Mental
's	POS	Mental
Depression	NNP	Mental
Inventory	NNP	Mental
,	,	O
and	CC	O
Epworth	NNP	Mental
Sleepiness	NNP	Mental
Scale	NNP	Mental
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
BLT	NNP	O
for	IN	O
15	CD	O
days	NNS	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
30	CD	O
min	JJ	O
daily	RB	O
.	.	O

Illuminance	NNP	Mental
was	VBD	O
7.500	CD	O
lux	NN	O
in	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
and	CC	O
950	CD	O
lux	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Although	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
small	JJ	O
,	,	O
BLT	NNP	O
led	VBD	O
to	TO	O
significant	JJ	O
improvement	NN	Mental
of	IN	Mental
tremor	NN	Mental
,	,	Mental
UPDRS	NNP	Mental
I	PRP	Mental
,	,	Mental
II	NNP	Mental
,	,	Mental
and	CC	Mental
IV	NNP	Mental
,	,	Mental
and	CC	Mental
depression	NN	Mental
in	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

It	PRP	O
was	VBD	O
very	RB	O
well	RB	O
tolerated	VBN	Others
.	.	O

Follow	VB	O
up	RP	O
studies	NNS	O
in	IN	O
more	RBR	O
advanced	JJ	O
patient	JJ	O
populations	NNS	O
employing	VBG	O
longer	RBR	O
treatment	NN	O
durations	NNS	O
are	VBP	O
warranted	VBN	O
.	.	O

Using	VBG	O
repeated	JJ	O
measures	NNS	O
of	IN	O
symptom	NN	O
score	NN	O
,	,	O
uroflowmetry	NN	O
and	CC	O
prostate	NN	O
specific	JJ	O
antigen	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
management	NN	O
of	IN	O
prostate	NN	O
disease	NN	O
.	.	O

Benign	NNP	O
Prostatic	NNP	O
Hyperplasia	NNP	O
Treatment	NNP	O
Outcomes	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Measurements	NNS	O
of	IN	O
American	NNP	Physical
Urological	NNP	Physical
Association	NNP	Physical
symptom	VBD	Physical
score	RB	Physical
,	,	O
peak	JJ	Physical
urine	JJ	Physical
flow	NN	Physical
rate	NN	Physical
and	CC	O
prostate	NN	Physical
specific	JJ	Physical
antigen	NN	Physical
(	(	Physical
PSA	NNP	Physical
)	)	Physical
are	VBP	O
often	RB	O
followed	VBN	O
over	RP	O
time	NN	O
in	IN	O
urological	JJ	O
management	NN	O
.	.	O

However	RB	O
,	,	O
their	PRP$	O
interpretation	NN	O
is	VBZ	O
confounded	VBN	O
by	IN	O
within-patient	JJ	O
variability	NN	O
due	JJ	O
to	TO	O
chance	NN	O
.	.	O

Data	NNP	O
from	IN	O
2	CD	O
clinical	JJ	O
trials	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
magnitude	NN	O
of	IN	O
this	DT	O
variation	NN	O
.	.	O

When	WRB	O
these	DT	O
measures	NNS	O
are	VBP	O
repeated	VBN	O
at	IN	O
a	DT	O
short	JJ	O
interval	NN	O
variation	NN	O
is	VBZ	O
modest	JJ	O
and	CC	O
might	MD	O
easily	RB	O
be	VB	O
misinterpreted	VBN	O
as	IN	O
a	DT	O
true	JJ	O
change	NN	O
in	IN	O
patient	JJ	O
condition	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
approximately	RB	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
might	MD	O
be	VB	O
expected	VBN	O
to	TO	O
have	VB	O
a	DT	O
chance	NN	O
increase	NN	O
or	CC	O
decrease	NN	O
in	IN	O
symptom	NN	O
score	NN	O
by	IN	O
at	IN	O
least	JJS	O
4.9	CD	O
points	NNS	O
,	,	O
in	IN	O
peak	JJ	O
urine	JJ	O
flow	NN	O
rate	NN	O
by	IN	O
at	IN	O
least	JJS	O
4.1	CD	O
ml	NN	O
.	.	O

per	IN	O
second	NN	O
or	CC	O
in	IN	O
PSA	NNP	O
by	IN	O
at	IN	O
least	JJS	O
1.6	CD	O
ng./ml	NN	O
.	.	O

Clinicians	NNS	O
can	MD	O
use	VB	O
these	DT	O
data	NNS	O
to	TO	O
help	VB	O
interpret	VB	O
repeated	JJ	O
measures	NNS	O
of	IN	O
these	DT	O
variables	NNS	O
in	IN	O
patients	NNS	O
,	,	O
and	CC	O
can	MD	O
consider	VB	O
obtaining	VBG	O
paired	JJ	O
measurements	NNS	O
to	TO	O
decrease	VB	O
the	DT	O
effect	NN	O
of	IN	O
chance	NN	O
variation	NN	O
when	WRB	O
they	PRP	O
plan	VBP	O
on	IN	O
following	VBG	O
them	PRP	O
over	IN	O
time	NN	O
.	.	O

Pharmacokinetic	JJ	Others
and	CC	Physical
safety	NN	Others
assessments	NNS	Physical
of	IN	O
galantamine	NN	O
and	CC	O
risperidone	NN	O
after	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
are	VBP	O
administered	VBN	O
alone	RB	O
and	CC	O
together	RB	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
steady-state	JJ	O
pharmacokinetic	JJ	O
profile	NN	O
after	IN	O
coadministration	NN	O
of	IN	O
galantamine	NN	O
and	CC	O
risperidone	NN	O
,	,	O
an	DT	O
open-label	JJ	O
,	,	O
randomized	VBN	O
,	,	O
single-center	JJ	O
,	,	O
two-way	JJ	O
crossover	NN	O
drug-drug	JJ	O
interaction	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
16	CD	O
healthy	JJ	O
elderly	JJ	O
subjects	NNS	O
,	,	O
ages	VBZ	O
60	CD	O
years	NNS	O
and	CC	O
older	JJR	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
risperidone	NN	O
,	,	O
when	WRB	O
administered	VBN	O
with	IN	O
galantamine	NN	O
,	,	O
did	VBD	O
not	RB	O
change	VB	O
the	DT	O
bioavailability	NN	Others
of	IN	O
galantamine	NN	O
at	IN	O
steady	JJ	O
state	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
systemic	JJ	O
exposure	NN	O
of	IN	O
risperidone	NN	O
active	JJ	O
moiety	NN	O
(	(	O
risperidone	JJ	O
plus	CC	O
9-hydroxyrisperidone	CD	O
)	)	O
,	,	O
the	DT	O
most	RBS	O
clinically	RB	O
relevant	JJ	O
component	NN	O
of	IN	O
risperidone	NN	O
treatment	NN	O
,	,	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
galantamine	JJ	O
coadministration	NN	O
,	,	O
while	IN	O
systemic	JJ	Others
exposure	NN	Others
was	VBD	O
increased	VBN	O
by	IN	O
approximately	RB	O
10	CD	O
%	NN	O
for	IN	O
risperidone	NN	O
and	CC	O
decreased	VBN	O
by	IN	O
about	IN	O
10	CD	O
%	NN	O
for	IN	O
9-hydroxyrisperidone	CD	O
(	(	O
active	JJ	O
metabolite	NN	O
of	IN	O
risperidone	NN	O
)	)	O
.	.	O

Galantamine	NNP	O
and	CC	O
risperidone	NN	O
were	VBD	O
both	DT	O
safe	JJ	Others
and	CC	Others
well	RB	Others
tolerated	VBN	Others
administered	VBN	O
either	CC	O
alone	RB	O
or	CC	O
together	RB	O
.	.	O

Thus	NNP	O
,	,	O
no	DT	O
dose	JJ	O
adjustment	NN	O
for	IN	O
either	DT	O
risperidone	NN	O
orgalantamine	NN	O
is	VBZ	O
necessary	JJ	O
when	WRB	O
these	DT	O
two	CD	O
drugs	NNS	O
are	VBP	O
administered	VBN	O
together	RB	O
in	IN	O
the	DT	O
dose	JJ	O
range	NN	O
evaluated	VBD	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
preventive	JJ	O
intervention	NN	O
for	IN	O
child	JJ	O
anxiety	NN	O
in	IN	O
two	CD	O
randomized	JJ	O
attention-control	JJ	O
school	NN	O
trials	NNS	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	Mental
therapy	NN	Mental
(	(	O
CBT	NNP	O
)	)	O
based	VBN	O
intervention	NN	O
program	NN	O
,	,	O
FRIENDS	NNP	O
,	,	O
for	IN	O
children	NNS	O
from	IN	O
grades	NNS	O
4	CD	O
to	TO	O
6	CD	O
,	,	O
using	VBG	O
random	JJ	O
assignment	NN	O
at	IN	O
the	DT	O
school-level	NN	O
and	CC	O
an	DT	O
attention-control	JJ	O
design	NN	O
in	IN	O
two	CD	O
longitudinal	JJ	O
studies	NNS	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
targeted	VBD	O
children	NNS	O
with	IN	O
anxiety	NN	Mental
symptoms	NNS	Mental
(	(	O
N=191	NNP	O
,	,	O
mean	JJ	O
age=10.1	NN	O
)	)	O
as	IN	O
screened	VBN	O
with	IN	O
self	NN	O
,	,	O
parent	NN	O
,	,	O
and	CC	O
teacher-reports	NNS	O
;	:	O
the	DT	O
second	JJ	O
study	NN	O
took	VBD	O
a	DT	O
universal	JJ	O
approach	NN	O
with	IN	O
full	JJ	O
classrooms	NNS	O
of	IN	O
children	NNS	O
participating	VBG	O
(	(	O
N=253	NNP	O
,	,	O
mean	JJ	O
age=9.8	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
no	DT	O
intervention	NN	O
effect	NN	O
in	IN	O
both	DT	O
studies	NNS	O
,	,	O
with	IN	O
children	NNS	Mental
's	POS	Mental
anxiety	NN	Mental
symptoms	NNS	Mental
decreasing	VBG	O
over	IN	O
time	NN	O
regardless	NN	O
of	IN	O
whether	IN	O
they	PRP	O
were	VBD	O
in	IN	O
the	DT	O
story-reading	NN	O
(	(	O
attention	NN	O
control	NN	O
)	)	O
or	CC	O
FRIENDS	JJ	O
condition	NN	O
.	.	O

The	DT	O
findings	NNS	O
also	RB	O
indicated	VBD	O
that	IN	O
girls	NNS	O
reported	VBD	O
a	DT	O
higher	JJR	O
level	NN	O
of	IN	O
anxiety	NN	O
than	IN	O
boys	NNS	O
and	CC	O
children	NNS	O
in	IN	O
higher	JJR	O
grades	NNS	O
reported	VBD	O
lower	JJR	O
anxiety	NN	O
relative	NN	O
to	TO	O
younger	JJR	O
children	NNS	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
similar	JJ	O
patterns	NNS	O
were	VBD	O
found	VBN	O
using	VBG	O
a	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
with	IN	O
high-anxiety	NN	O
symptoms	NNS	O
from	IN	O
both	DT	O
studies	NNS	O
.	.	O

Insulin	NNP	O
pump	NN	O
therapy	NN	O
started	VBD	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
diagnosis	NN	O
:	:	O
effects	NNS	O
on	IN	O
glycemic	JJ	Physical
control	NN	Physical
and	CC	O
pancreatic	JJ	O
?-cell	NN	O
function	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
the	DT	O
interest	NN	O
of	IN	O
preserving	VBG	O
residual	JJ	O
insulin	NN	O
secretory	NN	O
capacity	NN	O
present	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
diagnosis	NN	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
(	(	O
T1D	NNP	O
)	)	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
starting	VBG	O
insulin	JJ	O
pump	NN	O
therapy	NN	O
at	IN	O
diagnosis	NN	O
with	IN	O
standard	JJ	O
multiple	JJ	O
daily	JJ	O
insulin	NN	O
injections	NNS	O
(	(	O
MDIs	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
pilot	JJ	O
trial	NN	O
comparing	VBG	O
MDI	NNP	O
therapy	NN	O
with	IN	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
therapy	NN	O
(	(	O
pump	JJ	O
therapy	NN	O
)	)	O
in	IN	O
24	CD	O
patients	NNS	O
,	,	O
8-18	CD	O
years	NNS	O
old	JJ	O
,	,	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
T1D	NNP	O
.	.	O

Subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrollment	NN	O
and	CC	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
initial	JJ	O
diagnosis	NN	O
of	IN	O
T1D	NNP	O
.	.	O

Preservation	NN	O
of	IN	O
insulin	NN	O
secretion	NN	O
,	,	O
measured	VBN	O
by	IN	O
mixed-meal-stimulated	JJ	O
C-peptide	JJ	O
secretion	NN	O
,	,	O
was	VBD	O
compared	VBN	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Between-group	JJ	O
differences	NNS	O
in	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
(	(	O
HbA1c	NNP	O
)	)	O
,	,	O
continuous	JJ	O
glucose	NN	O
sensor	NN	O
data	NNS	O
,	,	O
insulin	NN	O
utilization	NN	O
,	,	O
anthropometric	JJ	O
measures	NNS	O
,	,	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
therapy	NN	O
were	VBD	O
also	RB	O
compared	VBN	O
at	IN	O
multiple	JJ	O
time	NN	O
points	NNS	O
.	.	O

RESULTS	NNP	O
Initiation	NNP	O
of	IN	O
pump	NN	O
therapy	NN	O
within	IN	O
1	CD	O
month	NN	O
of	IN	O
diagnosis	NN	O
resulted	VBD	O
in	IN	O
consistently	RB	O
higher	JJR	O
mixed-meal	JJ	O
tolerance	NN	O
test-stimulated	JJ	O
C-peptide	JJ	O
values	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
,	,	O
although	IN	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Nonetheless	NNP	O
,	,	O
improved	JJ	O
glycemic	JJ	O
control	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
insulin	JJ	O
pump-treated	JJ	O
subjects	NNS	O
(	(	O
more	JJR	O
time	NN	O
spent	VBN	O
with	IN	O
normoglycemia	NN	O
,	,	O
better	JJR	O
mean	JJ	O
HbA1c	NNP	O
)	)	O
,	,	O
and	CC	O
pump-treated	JJ	O
subjects	NNS	O
reported	VBN	O
comparatively	RB	O
greater	JJR	O
satisfaction	NN	O
with	IN	O
route	NN	O
of	IN	O
treatment	NN	O
administration	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initiation	NNP	O
of	IN	O
insulin	NN	O
pump	NN	O
therapy	NN	O
at	IN	O
diagnosis	NN	O
improved	JJ	O
glycemic	JJ	O
control	NN	O
,	,	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
contributed	VBD	O
to	TO	O
improved	VBN	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
also	RB	O
suggests	VBZ	O
that	IN	O
earlier	JJR	O
use	NN	O
of	IN	O
pump	NN	O
therapy	NN	O
might	MD	O
help	VB	O
to	TO	O
preserve	VB	O
residual	JJ	O
?-cell	NNP	O
function	NN	O
,	,	O
although	IN	O
a	DT	O
larger	JJR	O
clinical	JJ	O
trial	NN	O
would	MD	O
be	VB	O
required	VBN	O
to	TO	O
confirm	VB	O
this	DT	O
.	.	O

Comparison	NNP	O
of	IN	O
double-	JJ	O
and	CC	O
single-dose	JJ	O
methotrexate	NN	O
protocols	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
ectopic	JJ	O
pregnancy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
efficacy	NN	O
between	IN	O
double-dose	JJ	O
methotrexate	NN	O
and	CC	O
single-dose	JJ	O
methotrexate	NN	O
for	IN	O
treatment	NN	O
of	IN	O
tubal	JJ	O
ectopic	NN	O
pregnancy	NN	O
(	(	O
EP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Between	NNP	O
March	NNP	O
2008	CD	O
and	CC	O
February	NNP	O
2011,157	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
tubal	JJ	O
EP	NNP	O
diagnosed	VBN	O
by	IN	O
a	DT	O
non-laparoscopic	JJ	O
approach	NN	O
and	CC	O
were	VBD	O
hemodynamically	RB	O
stable	JJ	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
study	NN	O
in	IN	O
Qassim	NNP	O
,	,	O
Saudi	NNP	O
Arabia	NNP	O
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
double-dose	JJ	O
(	(	O
50mg/m	CD	O
(	(	O
2	CD	O
)	)	O
intramuscularly	RB	O
on	IN	O
days	NNS	O
0	CD	O
and	CC	O
4	CD	O
;	:	O
group	NN	O
1	CD	O
)	)	O
or	CC	O
single-dose	JJ	O
(	(	O
50mg/m	CD	O
(	(	O
2	CD	O
)	)	O
intramuscularly	RB	O
on	IN	O
day	NN	O
0	CD	O
;	:	O
group	NN	O
2	CD	O
)	)	O
methotrexate	NN	O
.	.	O

Serum	NNP	O
human	JJ	O
chorionic	NN	O
gonadotropin	NN	O
(	(	O
?-hCG	JJ	O
)	)	O
levels	NNS	O
were	VBD	O
followed	VBN	O
until	IN	O
negative	JJ	O
.	.	O

RESULTS	VB	O
The	DT	O
overall	JJ	O
success	NN	O
rate	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
groups	NNS	O
1	CD	O
and	CC	O
2	CD	O
(	(	O
88.6	CD	O
%	NN	O
versus	IN	O
82.0	CD	O
%	NN	O
,	,	O
P=0.1	NNP	O
)	)	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
follow	JJ	O
up	IN	O
until	IN	O
negative	JJ	O
?-hCG	NN	O
was	VBD	O
shorter	JJR	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
P=0.001	NNP	O
)	)	O
.	.	O

Receiver	NNP	O
operative	JJ	O
characteristics	NNS	O
showed	VBD	O
that	IN	O
higher	JJR	O
cut-off	NN	O
levels	NNS	O
of	IN	O
?-hCG	NN	O
and	CC	O
gestational	JJ	O
mass	NN	O
diameter	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
successful	JJ	O
outcome	NN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

Among	IN	O
participants	NNS	O
with	IN	O
initial	JJ	O
?-hCG	NNS	O
of	IN	O
3600-5500	JJ	O
mIU/mL	NN	O
,	,	O
the	DT	O
success	NN	O
rate	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
P=0.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
in	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

CONCLUSION	NNP	O
For	IN	O
treatment	NN	O
of	IN	O
EP	NNP	O
,	,	O
double-dose	JJ	O
methotrexate	NN	O
had	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
comparable	JJ	O
to	TO	O
that	DT	O
of	IN	O
single-dose	JJ	O
methotrexate	NN	O
;	:	O
it	PRP	O
had	VBD	O
better	JJR	O
success	NN	O
among	IN	O
patients	NNS	O
with	IN	O
moderately	RB	O
high	JJ	O
?-hCG	NN	O
and	CC	O
led	VBD	O
to	TO	O
a	DT	O
shorter	NN	O
follow	VB	O
up	RP	O
.	.	O

Oral	NNP	O
sucrose	VBD	O
as	IN	O
an	DT	O
analgesic	JJ	O
drug	NN	O
for	IN	O
procedural	JJ	O
pain	NN	O
in	IN	O
newborn	JJ	O
infants	NNS	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Many	JJ	O
infants	NNS	O
admitted	VBN	O
to	TO	O
hospital	VB	O
undergo	RB	O
repeated	VBN	O
invasive	JJ	O
procedures	NNS	O
.	.	O

Oral	NNP	O
sucrose	NN	O
is	VBZ	O
frequently	RB	O
given	VBN	O
to	TO	O
relieve	VB	O
procedural	JJ	O
pain	NN	O
in	IN	O
neonates	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
behavioural	JJ	O
and	CC	O
physiological	JJ	O
pain	NN	O
scores	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
whether	IN	O
sucrose	JJ	O
administration	NN	O
reduces	NNS	O
pain-specific	JJ	Pain
brain	NN	Pain
and	CC	Pain
spinal	JJ	Pain
cord	NN	Pain
activity	NN	Pain
after	IN	O
an	DT	O
acute	JJ	O
noxious	JJ	O
procedure	NN	O
in	IN	O
newborn	JJ	O
infants	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
,	,	O
59	CD	O
newborn	JJ	O
infants	NNS	O
at	IN	O
University	NNP	O
College	NNP	O
Hospital	NNP	O
(	(	O
London	NNP	O
,	,	O
UK	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
0?5	CD	O
mL	JJ	O
24	CD	O
%	NN	O
sucrose	JJ	O
solution	NN	O
or	CC	O
0?5	CD	O
mL	NNS	O
sterile	JJ	O
water	NN	O
2	CD	O
min	NN	O
before	IN	O
undergoing	VBG	O
a	DT	O
clinically	RB	O
required	VBN	O
heel	NN	O
lance	NN	O
.	.	O

Randomisation	NN	O
was	VBD	O
by	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
code	NN	O
,	,	O
and	CC	O
researchers	NNS	O
,	,	O
clinicians	NNS	O
,	,	O
participants	NNS	O
,	,	O
and	CC	O
parents	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
the	DT	O
identity	NN	O
of	IN	O
the	DT	O
solutions	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
pain-specific	JJ	O
brain	NN	O
activity	NN	O
evoked	VBN	O
by	IN	O
one	CD	O
time-locked	JJ	O
heel	NN	O
lance	NN	O
,	,	O
recorded	VBN	O
with	IN	O
electroencephalography	NN	O
and	CC	O
identified	VBN	O
by	IN	O
principal	JJ	O
component	NN	O
analysis	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
were	VBD	O
baseline	JJ	O
behavioural	JJ	O
and	CC	O
physiological	JJ	O
measures	NNS	O
,	,	O
observational	JJ	O
pain	NN	O
scores	NNS	O
(	(	O
PIPP	NNP	O
)	)	O
,	,	O
and	CC	O
spinal	JJ	Physical
nociceptive	JJ	Physical
reflex	NN	Physical
withdrawal	NN	Physical
activity	NN	Physical
.	.	O

Data	NNS	O
were	VBD	O
analysed	VBN	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
,	,	O
number	NN	O
ISRCTN78390996	NNP	O
.	.	O

FINDINGS	NNP	O
29	CD	O
infants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
sucrose	NN	O
and	CC	O
30	CD	O
to	TO	O
sterilised	JJ	O
water	NN	O
;	:	O
20	CD	O
and	CC	O
24	CD	O
infants	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
of	IN	O
the	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
.	.	O

Nociceptive	JJ	O
brain	NN	O
activity	NN	O
after	IN	O
the	DT	O
noxious	JJ	O
heel	NN	O
lance	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
infants	NNS	O
who	WP	O
received	VBD	O
sucrose	JJ	O
and	CC	O
those	DT	O
who	WP	O
received	VBD	O
sterile	JJ	O
water	NN	O
(	(	O
sucrose	JJ	O
:	:	O
mean	JJ	O
0?10	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0?04-0?16	CD	O
;	:	O
sterile	JJ	O
water	NN	O
:	:	O
mean	NN	O
0?08	CD	O
,	,	O
0?04-0?12	CD	O
;	:	O
p=0?46	NN	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
recorded	VBN	O
between	IN	O
the	DT	O
sucrose	NN	O
and	CC	O
sterile	JJ	O
water	NN	O
groups	NNS	O
in	IN	O
the	DT	O
magnitude	NN	O
or	CC	O
latency	NN	O
of	IN	O
the	DT	O
spinal	JJ	O
nociceptive	JJ	O
reflex	NN	O
withdrawal	NN	O
recorded	VBN	O
from	IN	O
the	DT	O
biceps	NNS	O
femoris	NN	O
of	IN	O
the	DT	O
stimulated	JJ	O
leg	NN	O
.	.	O

The	DT	O
PIPP	NNP	O
score	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
infants	NNS	O
given	VBN	O
sucrose	JJR	O
than	IN	O
in	IN	O
those	DT	O
given	VBN	O
sterile	JJ	O
water	NN	O
(	(	O
mean	JJ	O
5?8	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
3?7-7?8	CD	O
vs	NN	O
8?5	CD	O
,	,	O
7?3-9?8	CD	O
;	:	O
p=0?02	NN	O
)	)	O
and	CC	O
significantly	RB	O
more	JJR	O
infants	NNS	O
had	VBD	O
no	DT	O
change	NN	O
in	IN	O
facial	JJ	O
expression	NN	O
after	IN	O
sucrose	JJ	O
administration	NN	O
(	(	O
seven	CD	O
of	IN	O
20	CD	O
[	JJ	O
35	CD	O
%	NN	O
]	JJ	O
vs	NN	O
none	NN	O
of	IN	O
24	CD	O
;	:	O
p	NN	O
<	VBZ	O
0?0001	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
oral	JJ	O
sucrose	NN	O
does	VBZ	O
not	RB	O
significantly	RB	O
affect	JJ	O
activity	NN	O
in	IN	O
neonatal	JJ	O
brain	NN	O
or	CC	O
spinal	JJ	O
cord	NN	O
nociceptive	JJ	O
circuits	NNS	O
,	,	O
and	CC	O
therefore	RB	O
might	MD	O
not	RB	O
be	VB	O
an	DT	O
effective	JJ	O
analgesic	JJ	O
drug	NN	O
.	.	O

The	DT	O
ability	NN	O
of	IN	O
sucrose	NN	O
to	TO	O
reduce	VB	O
clinical	JJ	O
observational	JJ	O
scores	NNS	O
after	IN	O
noxious	JJ	O
events	NNS	O
in	IN	O
newborn	JJ	O
infants	NNS	O
should	MD	O
not	RB	O
be	VB	O
interpreted	VBN	O
as	IN	O
pain	NN	O
relief	NN	O
.	.	O

FUNDING	NNP	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
.	.	O

Anemia	NNP	O
and	CC	O
associated	VBN	O
clinical	JJ	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
due	JJ	O
to	TO	O
reduced	VB	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
function	NN	O
.	.	O

BACKGROUND	NNP	O
Anemia	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
decreased	JJ	O
functional	JJ	O
capacity	NN	O
,	,	O
reduced	VBD	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
worsened	VBD	O
outcomes	NNS	O
among	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
due	JJ	O
to	TO	O
reduced	VB	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
HFREF	NNP	O
)	)	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
independent	JJ	O
effect	NN	O
of	IN	O
anemia	NN	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
among	IN	O
those	DT	O
with	IN	O
HFREF	NNP	O
.	.	O

HYPOTHESIS	NNP	O
Anemia	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

METHODS	PDT	O
The	DT	O
HF-ACTION	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
exercise	NN	O
therapy	NN	O
vs	NN	O
usual	JJ	O
care	NN	O
in	IN	O
2331	CD	O
patients	NNS	O
with	IN	O
HFREF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
class	NN	O
II	NNP	O
to	TO	O
IV	NNP	O
HF	NNP	O
and	CC	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fractions	NNS	O
of	IN	O
?	.	O
35	CD	O
%	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

Hemoglobin	NNP	O
(	(	O
Hb	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
up	RB	O
to	TO	O
1	CD	O
year	NN	O
prior	RB	O
to	TO	O
entry	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
quintile	NN	O
.	.	O

Anemia	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
baseline	NN	O
Hb	NNP	O
<	VBZ	O
13	CD	O
g/dL	NN	O
and	CC	O
<	$	O
12	CD	O
g/dL	NN	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
respectively	RB	O
.	.	O

Hemoglobin	NNP	O
was	VBD	O
assessed	VBN	O
in	IN	O
2	CD	O
models	NNS	O
:	:	O
a	DT	O
global	JJ	O
prediction	NN	O
model	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
previously	RB	O
developed	VBN	O
,	,	O
and	CC	O
a	DT	O
modified	JJ	O
model	NN	O
including	VBG	O
variables	NNS	O
associated	VBN	O
with	IN	O
anemia	NN	O
and	CC	O
the	DT	O
studied	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Hemoglobin	NNP	O
was	VBD	O
available	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
1763	CD	O
subjects	NNS	O
(	(	O
76	CD	O
%	NN	O
of	IN	O
total	JJ	O
study	NN	O
population	NN	O
)	)	O
;	:	O
their	PRP$	O
median	JJ	O
age	NN	O
was	VBD	O
59.0	CD	O
years	NNS	O
,	,	O
73	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
and	CC	O
62	CD	O
%	NN	O
were	VBD	O
Caucasian	JJ	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
anemia	NN	O
was	VBD	O
515/1763	CD	O
(	(	O
29	CD	O
%	NN	O
)	)	O
.	.	O

Older	JJR	O
age	NN	O
,	,	O
female	JJ	O
sex	NN	O
,	,	O
African	JJ	O
American	NNP	O
race	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
hypertension	NN	O
,	,	O
and	CC	O
lower	JJR	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rates	NNS	O
were	VBD	O
all	DT	O
more	RBR	O
frequent	JJ	O
in	IN	O
lower	JJR	O
Hb	NNP	O
quintiles	NNS	O
.	.	O

Over	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
30	CD	O
months	NNS	O
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
all-cause	JJ	O
hospitalization	NN	O
occurred	VBD	O
in	IN	O
78	CD	O
%	NN	O
of	IN	O
those	DT	O
with	IN	O
anemia	NN	O
and	CC	O
64	CD	O
%	NN	O
in	IN	O
those	DT	O
without	IN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
secondary	JJ	O
outcomes	NNS	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
alone	RB	O
,	,	O
cardiovascular	JJ	O
(	(	O
CV	NNP	O
)	)	O
mortality	NN	O
or	CC	O
CV	NNP	O
hospitalization	NN	O
,	,	O
and	CC	O
CV	NNP	O
mortality	NN	O
or	CC	O
HF	NNP	O
hospitalization	NN	O
occurred	VBD	O
in	IN	O
23	CD	O
%	NN	O
vs	JJ	O
15	CD	O
%	NN	O
,	,	O
67	CD	O
%	NN	O
vs	JJ	O
54	CD	O
%	NN	O
,	,	O
and	CC	O
44	CD	O
vs	NNS	O
29	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Heart	NNP	O
failure	NN	O
hospitalizations	NNS	O
occurred	VBD	O
in	IN	O
36	CD	O
%	NN	O
vs	JJ	O
22	CD	O
%	NN	O
,	,	O
and	CC	O
urgent	JJ	O
outpatient	NN	O
visits	NNS	O
for	IN	O
HF	NNP	O
exacerbations	NNS	O
occurred	VBD	O
in	IN	O
67	CD	O
%	NN	O
and	CC	O
55	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

For	IN	O
the	DT	O
global	JJ	O
model	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
association	NN	O
observed	VBD	O
for	IN	O
anemia	NN	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
hospitalization	NN	O
(	(	O
adjusted	VBN	O
hazard	RB	O
ratio	JJ	O
[	NNP	O
HR	NNP	O
]	NN	O
:	:	O
1.15	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
1.01-1.32	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
but	CC	O
other	JJ	O
outcomes	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
at	IN	O
P	NNP	O
<	NNP	O
0.05	CD	O
.	.	O

In	IN	O
the	DT	O
modified	JJ	O
model	NN	O
,	,	O
the	DT	O
adjusted	JJ	O
HR	NNP	O
for	IN	O
anemia	NN	O
and	CC	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
or	CC	O
all-cause	JJ	O
hospitalization	NN	O
was	VBD	O
1.25	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.10-1.42	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
independent	JJ	O
associations	NNS	O
between	IN	O
anemia	NN	O
and	CC	O
all-cause	JJ	O
death	NN	O
(	(	O
HR	NNP	O
:	:	O
1.11	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.87-1.42	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
,	,	O
CV	NNP	O
death	NN	O
or	CC	O
CV	NNP	O
hospitalization	NN	O
(	(	O
HR	NNP	O
:	:	O
1.16	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.01-1.33	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
and	CC	O
CV	NNP	O
death	NN	O
and	CC	O
HF	NNP	O
hospitalization	NN	O
(	(	O
HR	NNP	O
:	:	O
1.27	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.06-1.51	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Anemia	NNP	O
modestly	RB	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
rates	NNS	O
of	IN	O
death	NN	O
,	,	O
hospitalization	NN	O
,	,	O
and	CC	O
HF	NNP	O
exacerbation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
HFREF	NNP	O
.	.	O

After	IN	O
adjusting	VBG	O
for	IN	O
other	JJ	O
important	JJ	O
covariates	NNS	O
,	,	O
anemia	NN	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
an	DT	O
excess	JJ	O
hazard	NN	O
for	IN	O
all-cause	JJ	O
mortality	NN	O
and	CC	O
all-cause	JJ	O
hospitalization	NN	O
.	.	O

Anemia	NNP	O
is	VBZ	O
also	RB	O
associated	VBN	O
with	IN	O
combinations	NNS	O
of	IN	O
CV	NNP	O
death	NN	O
and	CC	O
CV/HF	NNP	O
hospitalizations	NNS	O
as	IN	O
composite	JJ	O
endpoints	NNS	O
.	.	O

Eltrombopag	NNP	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
(	(	O
RAISE	NNP	O
)	)	O
:	:	O
a	DT	O
6-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
3	CD	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
thrombopoietin	NN	O
receptor	NN	O
agonist	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	Physical
to	TO	O
once	RB	O
daily	JJ	O
eltrombopag	NNS	O
versus	VBP	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
immune	JJ	O
thrombocytopenia	NN	O
during	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
undertook	VBD	O
a	DT	O
phase	NN	O
3	CD	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
adults	NNS	O
with	IN	O
previously	RB	O
treated	VBN	O
immune	JJ	O
thrombocytopenia	NN	O
of	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
'	POS	O
duration	NN	O
who	WP	O
had	VBD	O
baseline	NN	O
platelet	NN	O
counts	VBZ	O
lower	JJR	O
than	IN	O
30,000	CD	O
per	IN	O
?L	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
(	(	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
)	)	O
treatment	NN	O
with	IN	O
local	JJ	O
standard	NN	O
of	IN	O
care	NN	O
plus	CC	O
50	CD	O
mg	NN	O
eltrombopag	NN	O
or	CC	O
matching	VBG	O
placebo	JJ	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
centrally	RB	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
schedule	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
baseline	JJ	O
platelet	NN	O
count	NN	O
(	(	O
?	.	O
15,000	CD	O
per	IN	O
?L	NN	O
)	)	O
,	,	O
use	NN	O
of	IN	O
treatment	NN	O
for	IN	O
immune	JJ	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
splenectomy	JJ	O
status	NN	O
.	.	O

Patients	NNS	O
,	,	O
investigators	NNS	O
,	,	O
and	CC	O
those	DT	O
assessing	VBG	O
data	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
allocation	NN	O
.	.	O

Dose	JJ	O
modifications	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
platelet	NN	Physical
response	NN	Physical
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
response	NN	O
to	TO	O
treatment	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
platelet	NN	O
count	NN	O
of	IN	O
50,000-400,000	CD	O
per	IN	O
?L	NN	O
)	)	O
weekly	NN	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
weeks	NNS	O
and	CC	O
at	IN	O
least	JJS	O
once	RB	O
every	DT	O
4	CD	O
weeks	NNS	O
thereafter	RB	O
;	:	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
odds	NNS	Physical
of	IN	Physical
response	NN	Physical
to	TO	O
eltrombopag	VB	O
versus	NN	O
placebo	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00370331	NNP	O
.	.	O

FINDINGS	NNP	O
Between	NNP	O
Nov	NNP	O
22	CD	O
,	,	O
2006	CD	O
,	,	O
and	CC	O
July	NNP	O
31	CD	O
,	,	O
2007	CD	O
,	,	O
197	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
groups	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
135	CD	O
eltrombopag	NN	O
,	,	O
62	CD	O
placebo	NN	O
)	)	O
.	.	O

106	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
responded	VBD	O
to	TO	O
treatment	NN	O
at	IN	O
least	JJS	O
once	RB	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
compared	VBN	O
with	IN	O
17	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
odds	NNS	O
of	IN	O
responding	VBG	O
were	VBD	O
greater	JJR	O
in	IN	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
throughout	IN	O
the	DT	O
6-month	JJ	O
treatment	NN	O
period	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
8?2	CD	O
,	,	O
99	CD	O
%	NN	O
CI	NNP	O
3?59-18?73	CD	O
;	:	O
p	CC	O
<	VB	O
0?0001	CD	O
)	)	O
.	.	O

37	CD	O
(	(	O
59	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
reduced	VBD	Physical
concomitant	JJ	Physical
treatment	NN	Physical
versus	NN	O
ten	NN	O
(	(	O
32	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?016	NN	O
)	)	O
.	.	O

24	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
needed	VBN	O
rescue	NN	Others
treatment	NN	Others
compared	VBN	O
with	IN	O
25	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?001	NN	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
2	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
had	VBD	O
thromboembolic	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
patients	NNS	O
on	IN	O
placebo	NN	O
.	.	O

Nine	NNP	O
(	(	O
7	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
and	CC	O
two	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
mild	VBN	O
increases	NNS	O
in	IN	O
alanine	JJ	O
aminotransferase	NN	O
concentration	NN	O
,	,	O
and	CC	O
five	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
(	(	O
vs	IN	O
none	NN	O
allocated	VBN	O
to	TO	O
placebo	VB	O
)	)	O
had	VBD	O
increases	NNS	O
in	IN	O
total	JJ	O
bilirubin	NN	O
.	.	O

Four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
had	VBD	O
serious	JJ	Adverseeffect
bleeding	VBG	Adverseeffect
events	NNS	Adverseeffect
,	,	O
compared	VBN	O
with	IN	O
one	CD	O
(	(	O
<	VB	O
1	CD	O
%	NN	O
)	)	O
patient	NN	O
treated	VBN	O
with	IN	O
eltrombopag	NN	O
.	.	O

INTERPRETATION	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
effective	JJ	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
could	MD	O
be	VB	O
particularly	RB	O
beneficial	JJ	O
for	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
not	RB	O
responded	VBN	O
to	TO	O
splenectomy	VB	O
or	CC	O
previous	JJ	O
treatment	NN	O
.	.	O

These	DT	O
benefits	NNS	O
should	MD	O
be	VB	O
balanced	VBN	O
with	IN	O
the	DT	O
potential	JJ	O
risks	NNS	O
associated	VBN	O
with	IN	O
eltrombopag	JJ	O
treatment	NN	O
.	.	O

FUNDING	NN	O
GlaxoSmithKline	NNP	O
.	.	O

The	DT	O
value	NN	Physical
of	IN	Physical
transbronchial	JJ	Physical
lung	NN	Physical
biopsy	NN	Physical
using	VBG	O
jumbo	JJ	O
forceps	NNS	O
via	IN	O
rigid	JJ	O
bronchoscope	NN	O
in	IN	O
diffuse	NN	O
lung	NN	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
Transbronchial	NNP	O
lung	NN	O
biopsy	NN	O
(	(	O
TBLB	NNP	O
)	)	O
is	VBZ	O
a	DT	O
valuable	JJ	O
procedure	NN	O
used	VBN	O
to	TO	O
obtain	VB	O
a	DT	O
parenchymal	JJ	Physical
specimen	NNS	Physical
in	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
diffuse	NN	O
lung	NN	O
infiltrates	NNS	O
.	.	O

Large	JJ	O
forceps	NNS	O
are	VBP	O
expected	VBN	O
to	TO	O
result	VB	O
in	IN	O
larger	JJR	O
specimens	NNS	O
and	CC	O
improve	VB	O
diagnostic	JJ	O
yield	NN	O
.	.	O

AIM	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
TBLB	NNP	O
using	VBG	O
large	JJ	O
modified	VBN	O
flexible	JJ	O
gastroenterological	JJ	O
forceps	NNS	O
(	(	O
Jumbo	NNP	O
forceps	NNS	O
)	)	O
compared	VBN	O
with	IN	O
'normal	NNP	O
'	POS	O
flexible	JJ	O
forceps	NNS	O
via	IN	O
rigid	JJ	O
bronchoscopy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diffuse	NN	O
parenchymal	JJ	O
lung	NN	O
disease	NN	O
(	(	O
DPLD	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
analysis	NN	O
of	IN	O
95	CD	O
patients	NNS	O
who	WP	O
underwent	VBP	O
fluoroscopy	NN	O
guided	VBD	O
TBLB	NNP	O
over	IN	O
a	DT	O
two	CD	O
year	NN	O
period	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
lung	NN	O
mass	NN	O
or	CC	O
solitary	JJ	O
lung	NN	O
nodule	NN	O
undergoing	VBG	O
TBLB	NNP	O
were	VBD	O
excluded	VBN	O
.	.	O

The	DT	O
larger	JJR	O
and	CC	O
small	JJ	O
forceps	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
a	DT	O
random	JJ	O
sequence	NN	O
to	TO	O
avoid	VB	O
a	DT	O
reduction	NN	O
in	IN	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
the	DT	O
second	JJ	O
series	NN	O
of	IN	O
biopsies	NNS	O
related	VBN	O
to	TO	O
possible	JJ	O
bleeding	NN	O
by	IN	O
first	JJ	O
series	NN	O
of	IN	O
biopsies	NNS	O
.	.	O

To	TO	O
minimize	VB	O
the	DT	O
consequence	NN	O
of	IN	O
haemorrhage	NN	O
,	,	O
we	PRP	O
performed	VBD	O
every	DT	O
rigid	JJ	O
bronchoscopy	NN	O
,	,	O
placing	VBG	O
a	DT	O
non	NN	O
inflated	VBN	O
Fogarty	NNP	O
balloon	NN	O
and	CC	O
a	DT	O
rigid	JJ	O
aspirator	NN	O
(	(	O
diameter	JJ	O
4	CD	O
mm	NN	O
)	)	O
in	IN	O
lobar	NN	O
bronchus	NN	O
near	IN	O
the	DT	O
biopsy	NN	O
segment	NN	O
.	.	O

The	DT	O
Fogarty	NNP	O
balloon	NN	O
has	VBZ	O
been	VBN	O
inflated	VBN	O
in	IN	O
case	NN	O
of	IN	O
bleeding	NN	O
.	.	O

After	IN	O
the	DT	O
bleeding	NN	O
was	VBD	O
controlled	VBN	O
we	PRP	O
continued	VBD	O
to	TO	O
operate	VB	O
up	RP	O
to	TO	O
the	DT	O
biopsy	NN	O
segment	NN	O
.	.	O

RESULTS	NNP	O
Diagnostic	JJ	Others
yield	NN	Others
of	IN	O
TBLB	NNP	O
using	VBG	O
Jumbo	NNP	O
forceps	NNS	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
using	VBG	O
normal	JJ	O
flexible	JJ	O
forceps	NNS	O
via	IN	O
rigid	JJ	O
bronchoscopy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
DPLD	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
74	CD	O
out	IN	O
of	IN	O
95	CD	O
patients	NNS	O
(	(	O
78	CD	O
%	NN	O
)	)	O
the	DT	O
diagnosis	NN	O
was	VBD	O
placed	VBN	O
with	IN	O
Jumbo	NNP	O
forcep	NN	O
while	IN	O
the	DT	O
smaller	JJR	O
forcep	NN	O
was	VBD	O
diagnostic	JJ	O
in	IN	O
62	CD	O
out	IN	O
of	IN	O
95	CD	O
patients	NNS	O
(	(	O
65	CD	O
%	NN	O
)	)	O
.	.	O

Large	JJ	O
forceps	NNS	O
obtained	VBD	O
significantly	RB	O
more	RBR	O
tissue	NN	Physical
than	IN	O
the	DT	O
small	JJ	O
forceps	NNS	O
;	:	O
the	DT	O
biopsy	NN	O
specimen	NNS	O
taken	VBN	O
with	IN	O
normal	JJ	O
forcep	NNS	O
measured	VBN	O
in	IN	O
average	JJ	O
1.4	CD	O
x	JJ	O
1.0	CD	O
mm	NN	O
and	CC	O
the	DT	O
larger	JJR	O
biopsy	NN	O
taken	VBN	O
with	IN	O
jumbo	JJ	O
forcep	NNS	O
measured	VBN	O
in	IN	O
average	JJ	O
2.5	CD	O
x	JJ	O
1.9	CD	O
mm	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
use	NN	O
of	IN	O
large	JJ	O
biopsy	NN	O
forceps	NNS	O
to	TO	O
perform	VB	O
TBLB	NNP	O
via	IN	O
rigid	JJ	O
bronchoscope	NN	O
can	MD	O
significantly	RB	O
increase	VB	O
diagnostic	JJ	O
yield	NN	O
in	IN	O
the	DT	O
pathological	JJ	O
diagnosis	NN	O
of	IN	O
diffuse	NN	O
infiltrative	JJ	O
lung	NN	O
disease	NN	O
.	.	O

Effects	NNS	Others
of	IN	O
nutritional	JJ	O
supplementation	NN	O
on	IN	O
IQ	NNP	Mental
and	CC	O
certain	JJ	O
other	JJ	O
variables	NNS	O
associated	VBN	O
with	IN	O
Down	NNP	O
syndrome	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
,	,	O
24	CD	O
Down	NNP	O
syndrome	NN	O
children	NNS	O
,	,	O
ages	VBZ	O
6	CD	O
to	TO	O
17	CD	O
years	NNS	O
living	VBG	O
at	IN	O
home	NN	O
,	,	O
were	VBD	O
given	VBN	O
a	DT	O
megadose	JJ	O
multi-vitamin/mineral	JJ	O
supplement	NN	O
for	IN	O
4	CD	O
months	NNS	O
.	.	O

A	DT	O
matched	JJ	O
group	NN	O
of	IN	O
23	CD	O
children	NNS	O
received	VBD	O
a	DT	O
placebo	NN	O
in	IN	O
identical	JJ	O
form	NN	O
.	.	O

The	DT	O
children	NNS	Mental
's	POS	Mental
IQ	NNP	Mental
,	,	Mental
vision	NN	Physical
,	,	O
and	CC	O
visual-motor	JJ	Physical
integration	NN	Physical
were	VBD	O
tested	VBN	O
before	IN	O
and	CC	O
after	IN	O
supplementation	NN	O
,	,	O
and	CC	O
weekly	JJ	O
checks	NNS	O
were	VBD	O
made	VBN	O
to	TO	O
monitor	VB	O
behavioral	JJ	O
changes	NNS	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
any	DT	O
measures	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
supplementation	NN	O
.	.	O

Metabolic	NNP	O
and	CC	O
circulatory	JJ	O
effects	NNS	O
of	IN	O
oral	JJ	O
salbutamol	NN	O
in	IN	O
the	DT	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
in	IN	O
diabetic	JJ	O
and	CC	O
non-diabetic	JJ	O
women	NNS	O
.	.	O

Metabolic	NNP	Physical
and	CC	Physical
cardiovascular	JJ	Physical
effects	NNS	Physical
of	IN	O
4	CD	O
mg	JJ	O
oral	JJ	O
salbutamol	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
ten	JJ	O
non-diabetic	JJ	O
,	,	O
ten	JJ	O
chemical	JJ	O
diabetic	NN	O
and	CC	O
five	CD	O
juvenile	NN	O
diabetic	JJ	O
women	NNS	O
in	IN	O
late	JJ	O
pregnancy	NN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
women	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
beta-sympathomimetic	JJ	O
drugs	NNS	O
earlier	RBR	O
in	IN	O
their	PRP$	O
pregnancy	NN	O
.	.	O

Heart	NNP	Physical
rate	NN	Physical
and	CC	O
blood	NN	Physical
pressure	NN	Physical
were	VBD	O
recorded	VBN	O
and	CC	O
blood	NN	Physical
samples	NNS	Physical
for	IN	Physical
measurement	NN	Physical
of	IN	Physical
plasma	JJ	Physical
cyclic	JJ	Physical
AMP	NNP	Physical
,	,	Physical
insulin	NN	Physical
,	,	Physical
C-peptide	NNP	Physical
,	,	Physical
glucose	NN	Physical
,	,	Physical
lactate	NN	Physical
,	,	Physical
glycerol	NN	Physical
,	,	Physical
non-esterified	JJ	Physical
fatty	JJ	Physical
acids	NNS	Physical
(	(	Physical
NEFA	NNP	Physical
)	)	Physical
and	CC	Physical
3-hydroxybutyrate	JJ	Physical
(	(	Physical
3-HB	JJ	Physical
)	)	Physical
were	VBD	O
collected	VBN	O
every	DT	O
30	CD	O
minutes	NNS	O
for	IN	O
120	CD	O
minutes	NNS	O
after	IN	O
salbutamol	NN	O
.	.	O

All	DT	O
women	NNS	O
underwent	VBD	O
the	DT	O
same	JJ	O
procedure	NN	O
at	IN	O
random	NN	O
without	IN	O
salbutamol	NN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
cardiovascular	JJ	Physical
effects	NNS	Physical
of	IN	O
salbutamol	NN	O
in	IN	O
all	PDT	O
the	DT	O
groups	NNS	O
but	CC	O
no	DT	O
differences	NNS	O
in	IN	O
these	DT	O
effects	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Salbutamol	NNP	O
caused	VBD	O
significant	JJ	O
increases	NNS	O
of	IN	O
glycogenolysis	NN	Physical
and	CC	Physical
lipolysis	NN	Physical
in	IN	O
all	PDT	O
the	DT	O
groups	NNS	O
,	,	O
significantly	RB	O
larger	JJR	O
in	IN	O
the	DT	O
juvenile	NN	O
diabetic	NN	O
than	IN	O
the	DT	O
non-diabetic	JJ	O
and	CC	O
chemical	JJ	O
diabetic	JJ	O
women	NNS	O
.	.	O

This	DT	O
observation	NN	O
could	MD	O
be	VB	O
explained	VBN	O
by	IN	O
the	DT	O
inability	NN	O
of	IN	O
the	DT	O
juvenile	NN	O
diabetics	NNS	O
to	TO	O
secrete	VB	O
insulin	NN	O
,	,	O
shown	VBN	O
by	IN	O
their	PRP$	O
non-measureable	JJ	O
plasma	JJ	O
C-peptide	JJ	O
levels	NNS	O
.	.	O

The	DT	O
metabolic	JJ	Physical
responses	NNS	Physical
following	VBG	O
salbutamol	NN	O
in	IN	O
the	DT	O
chemical	NN	O
diabetics	NNS	O
were	VBD	O
intermediate	JJ	O
between	IN	O
the	DT	O
non-diabetic	JJ	O
and	CC	O
juvenile	JJ	O
diabetic	JJ	O
groups	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
diabetes	VBZ	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
sensitivity	NN	O
of	IN	O
beta-receptors	NNS	O
involved	VBN	O
in	IN	O
cardiovascular	JJ	O
regulation	NN	O
,	,	O
while	IN	O
the	DT	O
metabolic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
salbutamol	NN	O
are	VBP	O
enhanced	VBN	O
,	,	O
especially	RB	O
in	IN	O
juvenile	JJ	O
diabetics	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
during	IN	O
treatment	NN	O
with	IN	O
beta-sympathomimetic	JJ	O
drugs	NNS	O
,	,	O
blood	NN	O
glucose	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
showing	VBG	O
criteria	NNS	O
of	IN	O
potential	JJ	O
diabetes	NNS	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
timolol/pilocarpine	JJ	O
combination	NN	O
drops	NNS	O
in	IN	O
glaucoma	NN	O
patients	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
with	IN	O
two	CD	O
parallel	JJ	O
groups	NNS	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
safety	NN	O
,	,	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
two	CD	O
combination	NN	O
eye	NN	O
drops	VBZ	O
containing	VBG	O
0.5	CD	O
%	NN	O
timolol	NN	O
and	CC	O
2	CD	O
%	NN	O
pilocarpine	NN	O
(	(	O
Fotil	NNP	O
,	,	O
Leiras	NNP	O
,	,	O
Finland	NNP	O
,	,	O
and	CC	O
Timpilo	NNP	O
,	,	O
MSD	NNP	O
,	,	O
USA	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
glaucoma	NN	O
or	CC	O
ocular	JJ	O
hypertension	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
determined	VBN	O
based	VBN	O
on	IN	O
daytime	JJ	O
intraocular	JJ	O
pressure	NN	O
curve	NN	O
and	CC	O
safety	NN	O
by	IN	O
examining	VBG	O
visual	JJ	O
fields	NNS	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
optic	JJ	O
discs	NN	O
,	,	O
by	IN	O
determining	VBG	O
blood	NN	O
pressure	NN	O
and	CC	O
pulse	JJ	O
rate	NN	O
,	,	O
and	CC	O
by	IN	O
performing	VBG	O
Schirmer	NNP	O
and	CC	O
fluorescein	JJ	O
tests	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
89	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
and	CC	O
71	CD	O
completed	VBD	O
the	DT	O
10-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
the	DT	O
two	CD	O
combinations	NNS	O
of	IN	O
0.5	CD	O
%	NN	O
timolol	JJ	O
maleate	NN	O
and	CC	O
2	CD	O
%	NN	O
pilocarpine	NN	O
HCl	NNP	O
compared	VBN	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
intraocular	JJ	Physical
pressure	NN	Physical
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
mean	JJ	Physical
daily	JJ	Physical
intraocular	JJ	Physical
pressure	NN	Physical
from	IN	O
0	CD	O
to	TO	O
10	CD	O
weeks	NNS	O
was	VBD	O
7.48	CD	O
mmHg	NN	O
for	IN	O
Fotil	NNP	O
,	,	O
and	CC	O
6.31	CD	O
for	IN	O
Timpilo	NNP	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
mean	JJ	Physical
daily	JJ	Physical
intraocular	JJ	Physical
pressure	NN	Physical
was	VBD	O
29.3	CD	O
%	NN	O
for	IN	O
Fotil	NNP	O
,	,	O
and	CC	O
26.0	CD	O
%	NN	O
for	IN	O
Timpilo	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Adverse	JJ	Adverseeffect
event	NN	Adverseeffect
were	VBD	O
reported	VBN	O
by	IN	O
70	CD	O
out	IN	O
of	IN	O
89	CD	O
patients	NNS	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
,	,	O
but	CC	O
were	VBD	O
severe	RB	O
enough	RB	O
only	RB	O
in	IN	O
11	CD	O
for	IN	O
the	DT	O
treatment	NN	O
to	TO	O
be	VB	O
discontinued	VBN	O
.	.	O

In	IN	O
all	DT	O
others	NNS	O
,	,	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
of	IN	O
transient	JJ	O
nature	NN	O
and	CC	O
considered	VBN	O
mild	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
study	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
burning	VBG	Physical
was	VBD	O
more	RBR	O
common	JJ	O
in	IN	O
patients	NNS	O
on	IN	O
Fotil	NNP	O
,	,	O
and	CC	O
blurring	NN	Physical
of	IN	Physical
vision	NN	Physical
and	CC	Physical
light	JJ	Physical
sensitivity	NN	Physical
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
patients	NNS	O
on	IN	O
Timpilo	NNP	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
no	DT	O
contraindication	NN	O
to	TO	O
beta-blockers	NNS	O
,	,	O
these	DT	O
drugs	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Randomized	VBN	O
controlled	JJ	O
trial	NN	O
for	IN	O
early	JJ	O
intervention	NN	O
for	IN	O
autism	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
Autism	NNP	O
1-2-3	JJ	O
Project	NNP	O
.	.	O

We	PRP	O
piloted	VBD	O
a	DT	O
2-week	JJ	O
Autism-1-2-3	NNP	O
early	JJ	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
their	PRP$	O
parents	NNS	O
immediately	RB	O
after	IN	O
diagnosis	NN	O
that	WDT	O
targeted	VBD	O
at	IN	O
(	(	O
1	CD	O
)	)	O
eye	NN	O
contact	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
gesture	NN	O
and	CC	O
(	(	O
3	CD	O
)	)	O
vocalization/words	NNS	O
.	.	O

Seventeen	JJ	O
children	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
the	DT	O
Intervention	NNP	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
and	CC	O
Control	NNP	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
groups	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Autism	NNP	Mental
Diagnostic	NNP	Mental
Observation	NNP	Mental
Schedule	NNP	Mental
,	,	Mental
Ritvo-Freeman	NNP	Mental
Real	NNP	Mental
Life	NNP	Mental
Rating	NNP	Mental
Scale	NNP	Mental
,	,	O
Symbolic	NNP	Mental
Play	NNP	Mental
Test	NNP	Mental
,	,	O
and	CC	O
Parenting	NNP	Mental
Stress	NNP	Mental
Index	NNP	Mental
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
improved	VBN	O
in	IN	O
language/communication	NN	Mental
,	,	Mental
reciprocal	JJ	Mental
social	JJ	Mental
interaction	NN	Mental
,	,	Mental
and	CC	Mental
symbolic	JJ	Mental
play	NN	Mental
.	.	Mental

Parents	NNS	O
perceived	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
children	NNS	Mental
's	POS	Mental
language	NN	Mental
,	,	Mental
social	JJ	Mental
interaction	NN	Mental
,	,	O
and	CC	O
their	PRP$	Mental
own	JJ	Mental
stress	NN	Mental
level	NN	Mental
.	.	O

This	DT	O
intervention	NN	O
can	MD	O
serve	VB	O
as	IN	O
short-term	JJ	O
training	NN	O
on	IN	O
communication	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
reduce	VB	O
the	DT	O
stress	NN	O
of	IN	O
their	PRP$	O
parents	NNS	O
during	IN	O
the	DT	O
long	JJ	O
waiting	NN	O
time	NN	O
for	IN	O
public	JJ	O
health	NN	O
services	NNS	O
.	.	O

Impacts	NNS	O
of	IN	O
a	DT	O
disease	JJ	O
management	NN	O
program	NN	O
for	IN	O
dually	RB	O
eligible	JJ	O
beneficiaries	NNS	O
.	.	O

The	DT	O
LifeMasters	NNPS	O
Supported	NNP	O
SelfCare	NNP	O
demonstration	NN	O
program	NN	O
provides	VBZ	O
disease	JJ	O
management	NN	O
(	(	O
DM	NNP	O
)	)	O
services	NNS	O
to	TO	O
Florida	NNP	O
Medicare	NNP	O
beneficiaries	NNS	O
who	WP	O
are	VBP	O
also	RB	O
enrolled	VBN	O
in	IN	O
Medicaid	NNP	O
and	CC	O
have	VBP	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
,	,	O
diabetes	VBZ	O
,	,	O
or	CC	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
population-based	JJ	O
program	NN	O
provides	VBZ	O
primarily	RB	O
telephonic	JJ	O
patient	JJ	O
education	NN	O
and	CC	O
monitoring	NN	O
services	NNS	O
.	.	O

Findings	NNS	O
from	IN	O
the	DT	O
randomized	VBN	O
,	,	O
intent-to-treat	JJ	O
design	NN	O
over	IN	O
the	DT	O
first	JJ	O
18	CD	O
months	NNS	O
of	IN	O
operations	NNS	O
show	VBP	O
virtually	RB	O
no	DT	O
overall	JJ	O
impacts	NNS	Others
on	IN	Others
hospital	NN	Others
or	CC	Others
emergency	NN	Others
room	NN	Others
(	(	Others
ER	NNP	Others
)	)	Others
use	NN	Others
,	,	O
Medicare	NNP	Others
expenditures	VBZ	Others
,	,	O
quality	NN	Others
of	IN	Others
care	NN	Others
,	,	O
or	CC	O
prescription	NN	Others
drug	NN	Others
use	NN	Others
for	IN	O
the	DT	O
33,000	CD	O
enrollees	NNS	O
.	.	O

However	RB	O
,	,	O
for	IN	O
beneficiaries	NNS	O
with	IN	O
CHF	NNP	O
who	WP	O
resided	VBD	O
in	IN	O
high-cost	NN	O
South	NNP	O
Florida	NNP	O
counties	NNS	O
,	,	O
the	DT	O
program	NN	O
reduced	VBN	O
Medicare	NNP	Others
expenditures	NNS	Others
by	IN	O
9.6	CD	O
percent	NN	O
.	.	O

Randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
comparing	VBG	O
two	CD	O
doses	NNS	O
of	IN	O
arzoxifene	NN	O
(	(	O
LY353381	NNP	O
)	)	O
in	IN	O
hormone-sensitive	JJ	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
phase	NN	O
II	NNP	O
study	NN	O
assessed	VBD	O
two	CD	O
doses	NNS	O
of	IN	O
the	DT	O
selective	JJ	O
estrogen	NN	O
receptor	NN	O
modulator	NN	O
arzoxifene	NN	O
in	IN	O
women	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
to	TO	O
choose	VB	O
the	DT	O
best	JJS	O
of	IN	O
two	CD	O
doses	NNS	O
of	IN	O
arzoxifene	NN	O
based	VBN	O
on	IN	O
the	DT	O
response	NN	Physical
rate	NN	Physical
or	CC	Physical
the	DT	Physical
clinical	JJ	Physical
benefit	NN	Physical
rate	NN	Physical
(	(	Physical
CBR	NNP	Physical
)	)	Physical
.	.	O

Pharmacokinetics	NNPS	Physical
and	CC	O
toxicities	NNS	Physical
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Ninety-two	NNP	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
received	VBD	O
arzoxifene	JJ	O
20	CD	O
or	CC	O
50	CD	O
mg/day	NN	O
.	.	O

Tumor	NNP	Physical
response	NN	Physical
was	VBD	O
assessed	VBN	O
using	VBG	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
criteria	NNS	O
.	.	O

Toxicities	NNS	Adverseeffect
were	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
Common	NNP	O
Toxicity	NNP	O
Criteria	NNP	O
(	(	O
NCI-CTC	NNP	O
)	)	O
system	NN	O
.	.	O

Pharmacokinetic	JJ	Physical
data	NNS	Physical
were	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
NONMEM	NNP	O
software	NN	O
program	NN	O
(	(	O
GloboMax	NNP	O
,	,	O
Hanover	NNP	O
,	,	O
MD	NNP	O
,	,	O
USA	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Response	JJ	Physical
rates	NNS	Physical
in	IN	O
the	DT	O
20	CD	O
mg	NN	O
arm	NN	O
were	VBD	O
numerically	RB	O
higher	JJR	O
than	IN	O
the	DT	O
50-mg	JJ	O
arm	NN	O
according	VBG	O
to	TO	O
the	DT	O
investigator	NN	O
(	(	O
40.5	CD	O
%	NN	O
versus	IN	O
36.4	CD	O
%	NN	O
)	)	O
and	CC	O
the	DT	O
independent	JJ	O
review	NN	O
panel	NN	O
(	(	O
42.9	CD	O
%	NN	O
versus	IN	O
27.3	CD	O
%	NN	O
)	)	O
.	.	O

CBR	NNP	Physical
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
20	CD	O
mg	NN	O
arm	NN	O
according	VBG	O
to	TO	O
the	DT	O
investigator	NN	O
(	(	O
64.3	CD	O
%	NN	O
versus	IN	O
61.4	CD	O
%	NN	O
)	)	O
and	CC	O
the	DT	O
independent	JJ	O
review	NN	O
panel	NN	O
(	(	O
59.5	CD	O
%	NN	O
versus	IN	O
47.7	CD	O
%	NN	O
)	)	O
.	.	O

Arzoxifene	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
study	NN	O
drug-related	JJ	Mortality
deaths	NNS	Mortality
.	.	Mortality

Mean	NNP	O
observed	VBD	O
steady-state	JJ	Physical
plasma	JJ	Physical
concentrations	NNS	Physical
of	IN	O
arzoxifene	NN	O
were	VBD	O
3.62	CD	O
and	CC	O
7.48	CD	O
ng/ml	NN	O
for	IN	O
the	DT	O
20	CD	O
and	CC	O
50	CD	O
mg	NN	O
doses	NNS	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
efficacy	NN	Others
or	CC	O
safety	NN	Others
between	IN	O
20	CD	O
and	CC	O
50	CD	O
mg	NN	O
of	IN	O
arzoxifene	NN	O
.	.	O

Accordingly	RB	O
,	,	O
arzoxifene	VBZ	O
20	CD	O
mg/day	NN	O
was	VBD	O
selected	VBN	O
for	IN	O
further	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
common	JJ	O
variant	NN	O
in	IN	O
the	DT	O
CD38	NNP	O
gene	NN	O
on	IN	O
social	JJ	Mental
processing	NN	Mental
in	IN	O
an	DT	O
oxytocin	NN	O
challenge	NN	O
study	NN	O
:	:	O
possible	JJ	O
links	NNS	O
to	TO	O
autism	NN	O
.	.	O

The	DT	O
intranasal	JJ	O
application	NN	O
of	IN	O
oxytocin	NN	O
(	(	O
OT	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
influence	VB	O
behavioral	JJ	Mental
and	CC	Mental
neural	JJ	Mental
correlates	NNS	Mental
of	IN	Mental
social	JJ	Mental
processing	NN	Mental
.	.	Mental

These	DT	O
effects	NNS	O
are	VBP	O
probably	RB	O
mediated	VBN	O
by	IN	O
genetic	JJ	O
variations	NNS	O
within	IN	O
the	DT	O
OT	NNP	O
system	NN	O
.	.	O

One	CD	O
potential	JJ	O
candidate	NN	O
could	MD	O
be	VB	O
the	DT	O
CD38	NNP	O
gene	NN	O
,	,	O
which	WDT	O
codes	VBZ	O
for	IN	O
a	DT	O
transmembrane	NN	O
protein	NN	O
engaged	VBD	O
in	IN	O
OT	NNP	O
secretion	NN	O
processes	VBZ	O
.	.	O

A	DT	O
common	JJ	O
variation	NN	O
in	IN	O
this	DT	O
gene	NN	O
(	(	O
rs3796863	NN	O
)	)	O
was	VBD	O
recently	RB	O
found	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Using	VBG	O
an	DT	O
imaging	NN	O
genetics	NNS	O
approach	NN	O
,	,	O
we	PRP	O
studied	VBD	O
differential	JJ	O
effects	NNS	O
of	IN	O
an	DT	O
intranasal	NN	O
OT	NNP	O
application	NN	O
on	IN	O
neural	JJ	Mental
processing	NN	Mental
of	IN	Mental
social	JJ	Mental
stimuli	NNS	Mental
in	IN	O
55	CD	O
healthy	JJ	O
young	JJ	O
men	NNS	O
depending	VBG	O
on	IN	O
their	PRP$	O
CD38	NNP	O
gene	NN	O
variant	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Genotype	NNP	O
had	VBD	O
a	DT	O
significant	JJ	O
influence	NN	O
on	IN	O
both	DT	O
behavioral	JJ	Mental
and	CC	Mental
neuronal	JJ	Mental
measures	NNS	Mental
of	IN	Mental
social	JJ	Mental
processing	NN	Mental
.	.	Mental

Homozygotic	JJ	O
risk	NN	O
allele	NN	O
carriers	NNS	O
showed	VBD	O
slower	JJR	Mental
reaction	NN	Mental
times	NNS	Mental
(	(	Mental
RT	NNP	Mental
)	)	Mental
and	CC	O
higher	JJR	Mental
activation	NN	Mental
of	IN	Mental
left	JJ	Mental
fusiform	NN	Mental
gyrus	NN	Mental
during	IN	O
visual	JJ	O
processing	NN	O
of	IN	O
social	JJ	Mental
stimuli	NNS	Mental
.	.	O

Under	IN	O
OT	NNP	O
activation	NN	Mental
differences	NNS	Mental
between	IN	O
genotypes	NNS	O
were	VBD	O
more	RBR	O
evident	JJ	O
(	(	O
though	IN	O
not	RB	O
statistically	RB	O
significantly	RB	O
increased	VBN	O
)	)	O
and	CC	O
RT	NNP	O
were	VBD	O
accelerated	VBN	O
in	IN	O
homozygotic	JJ	O
risk	NN	O
allele	NN	O
carriers	NNS	O
.	.	O

According	VBG	O
to	TO	O
our	PRP$	O
data	NNS	O
,	,	O
rs3796863	NN	Mental
mainly	RB	Mental
influences	VBZ	Mental
fusiform	NN	Mental
gyrus	NN	Mental
activation	NN	Mental
,	,	O
an	DT	O
area	NN	O
which	WDT	O
has	VBZ	O
been	VBN	O
widely	RB	O
discussed	VBN	O
in	IN	O
ASD	NNP	O
research	NN	O
.	.	O

OT	CC	O
seems	VBZ	O
to	TO	O
modulate	VB	O
this	DT	O
effect	NN	O
by	IN	O
enhancing	VBG	O
activation	NN	Mental
differences	NNS	Mental
between	IN	O
allele	JJ	O
groups	NNS	O
,	,	O
which	WDT	O
suggests	VBZ	O
an	DT	O
interaction	NN	O
between	IN	O
genetic	JJ	Physical
makeup	NN	Physical
and	CC	O
OT	NNP	Physical
availability	NN	Physical
on	IN	O
fusiform	NN	Mental
gyrus	NN	Mental
activation	NN	Mental
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
recent	JJ	O
approaches	NNS	O
to	TO	O
apply	VB	O
OT	NNP	O
as	IN	O
a	DT	O
pharmacological	JJ	O
treatment	NN	O
of	IN	O
ASD	NNP	O
symptoms	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
encoding	VBG	O
in	IN	O
hypnosis	NN	O
and	CC	O
post-hypnotic	JJ	O
suggestion	NN	O
on	IN	O
academic	JJ	O
performance	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
proactive	JJ	O
learning	NN	O
in	IN	O
hypnosis	NN	O
,	,	O
post-hypnotic	JJ	O
suggestion	NN	O
,	,	O
and	CC	O
academic	JJ	O
performance	NN	O
.	.	O

Participants	NNS	O
(	(	O
N	NNP	O
=	NNP	O
56	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
hypnotized	VBN	O
and	CC	O
read	VB	O
a	DT	O
passage	NN	O
while	IN	O
in	IN	O
hypnosis	NN	O
.	.	O

Concurrently	RB	O
,	,	O
they	PRP	O
were	VBD	O
given	VBN	O
a	DT	O
post-hypnotic	JJ	O
suggestion	NN	O
,	,	O
which	WDT	O
attempted	VBD	O
to	TO	O
aid	VB	O
recognition	NN	O
and	CC	O
performance	NN	O
on	IN	O
a	DT	O
test	NN	O
immediately	RB	O
following	VBG	O
the	DT	O
hypnosis	NN	O
session	NN	O
.	.	O

Both	DT	O
groups	NNS	O
completed	VBD	O
a	DT	O
multiple-choice	JJ	O
test	NN	O
based	VBN	O
on	IN	O
the	DT	O
aforementioned	JJ	O
passage	NN	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
covariance	NN	O
discerned	VBD	O
the	DT	O
effect	NN	Mental
of	IN	Mental
proactive	JJ	Mental
learning	NN	Mental
and	CC	O
post-hypnotic	JJ	Mental
suggestion	NN	Mental
on	IN	O
test	NN	Mental
performance	NN	Mental
,	,	O
while	IN	O
controlling	VBG	O
for	IN	O
the	DT	O
variance	NN	O
introduced	VBN	O
by	IN	O
scholastic	JJ	Others
aptitude	NN	Others
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
ACT	NNP	O
.	.	O

Results	NNP	O
indicated	VBD	O
that	IN	O
the	DT	O
hypnosis	NN	O
sessions	NNS	O
predicted	VBD	O
significantly	RB	O
impaired	JJ	Mental
test	NN	Mental
performance	NN	Mental
.	.	O

Blood	NNP	Physical
purification	NN	Physical
for	IN	O
critical	JJ	O
care	NN	O
medicine	NN	O
:	:	O
endotoxin	NN	O
adsorption	NN	O
.	.	O

Many	JJ	O
kinds	NNS	O
of	IN	O
blood	NN	O
purifying	VBG	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
since	IN	O
1979	CD	O
when	WRB	O
plasma	JJ	O
exchange	NN	O
with	IN	O
hollow-fiber	JJ	O
membranes	NNS	O
was	VBD	O
developed	VBN	O
.	.	O

These	DT	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
not	RB	O
only	RB	O
to	TO	O
the	DT	O
removal	NN	O
of	IN	O
toxic	JJ	O
substances	NNS	O
,	,	O
but	CC	O
also	RB	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
objective	JJ	O
diseases	NNS	O
and	CC	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
factors	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
associated	VBN	O
inflammation	NN	O
.	.	O

This	DT	O
article	NN	O
summarizes	VBZ	O
these	DT	O
methods	NNS	O
and	CC	O
their	PRP$	O
efficacies	NNS	O
for	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
,	,	O
especially	RB	O
those	DT	O
with	IN	O
severe	JJ	O
sepsis	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
endotoxin	NN	O
,	,	O
the	DT	O
main	JJ	O
cause	NN	O
of	IN	O
sepsis	NN	O
,	,	O
from	IN	O
the	DT	O
circulation	NN	O
using	VBG	O
polymyxin	NN	O
B	NNP	O
immobilized	VBD	O
fiber	NN	O
,	,	O
charcoal	NN	O
hemoperfusion	NN	O
,	,	O
and	CC	O
plasma	NN	O
or	CC	O
whole	JJ	O
blood	NN	O
exchange	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
proinflammatory	NN	O
cytokines	NNS	O
,	,	O
eicosanoides	NNS	O
,	,	O
and	CC	O
coagulative	JJ	O
factors	NNS	O
from	IN	O
the	DT	O
circulation	NN	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
.	.	O

Continuous	JJ	O
hemofiltration	NN	O
or	CC	O
hemodiafiltration	NN	O
is	VBZ	O
the	DT	O
representative	JJ	O
technology	NN	O
.	.	O

The	DT	O
efficacy	NN	Others
of	IN	O
these	DT	O
methods	NNS	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
but	CC	O
several	JJ	O
issues	NNS	O
remain	VBP	O
unresolved	JJ	O
.	.	O

All	DT	O
methods	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
sepsis	NN	O
are	VBP	O
discussed	VBN	O
with	IN	O
reference	NN	O
to	TO	O
treatment	NN	O
indications	NNS	Others
,	,	O
efficacy	NN	Others
,	,	O
and	CC	O
outcome	JJ	O
parameters	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
clinical	JJ	O
results	NNS	O
of	IN	O
endotoxin	JJ	O
removal	NN	O
with	IN	O
polymyxin	NN	O
B	NNP	O
immobilized	JJ	O
fiber	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
this	DT	O
article	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
enoxaparin	NN	O
and	CC	O
standard	JJ	O
heparin	NN	O
in	IN	O
gynaecologic	JJ	O
oncologic	JJ	O
surgery	NN	O
:	:	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
double-blind	NN	O
clinical	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
haemorrhagic	JJ	O
complications	NNS	O
and	CC	O
efficacy	NN	O
of	IN	O
enoxaparin	NN	O
,	,	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMWH	NNP	O
)	)	O
,	,	O
and	CC	O
conventional	JJ	O
standard	NN	O
heparin	NN	O
(	(	O
SH	NNP	O
)	)	O
in	IN	O
gynaecological	JJ	O
oncologic	NN	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
METHODS	NNP	O
A	NNP	O
double	JJ	O
blind	NN	O
,	,	O
randomised	VBD	O
trial	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
102	CD	O
consecutive	JJ	O
women	NNS	O
undergoing	VBG	O
gynaecologic	JJ	O
cancer	NN	O
surgery	NN	O
with	IN	O
pelvic	NN	O
and	CC	O
paraaortic	JJ	O
lymphadenectomy	NN	O
.	.	O

The	DT	O
women	NNS	O
were	VBD	O
separated	VBN	O
into	IN	O
those	DT	O
who	WP	O
were	VBD	O
given	VBN	O
2,500	CD	O
IU	NNP	O
enoxaparin	NN	O
once	RB	O
daily	JJ	O
and	CC	O
SH	NNP	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
5,000	CD	O
IU	NNP	O
three	CD	O
times	NNS	O
daily	RB	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
analysed	VBN	O
for	IN	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
drainage	NN	O
,	,	O
transfusion	NN	O
requirements	NNS	O
,	,	O
perioperative	JJ	O
haemoglobin	NN	O
decrease	NN	O
,	,	O
wound	NN	O
haematoma	NN	O
,	,	O
and	CC	O
clinical	JJ	O
deep	NN	O
venous	JJ	O
thrombosis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
other	JJ	O
factors	NNS	O
,	,	O
which	WDT	O
could	MD	O
predispose	VB	O
to	TO	O
the	DT	O
development	NN	Physical
of	IN	Physical
deep	JJ	Physical
venous	JJ	Physical
thrombosis	NN	Physical
(	(	Physical
DVT	NNP	Physical
)	)	Physical
and	CC	O
haemorrhage	NN	Physical
.	.	O

No	DT	O
patient	NN	O
developed	VBD	O
clinical	JJ	O
significant	JJ	O
DVT	NNP	Physical
,	,	O
wound	NN	Physical
haematoma	NN	Physical
or	CC	O
intra-abdominal	JJ	Physical
bleeding	NN	Physical
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
bleeding	VBG	Physical
complications	NNS	Physical
between	IN	O
the	DT	O
two	CD	O
regimens	NNS	O
.	.	O

The	DT	O
antiFXa	JJ	Physical
level	NN	Physical
in	IN	O
the	DT	O
plasma	NN	O
was	VBD	O
correlated	VBN	O
strongly	RB	O
with	IN	O
patient	JJ	O
weight	NN	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
dose	NN	O
of	IN	O
2,500	CD	O
IU	NNP	O
enoxaparin/day	NN	O
does	VBZ	O
not	RB	O
cause	VB	O
more	RBR	O
bleeding	JJ	O
complications	NNS	O
than	IN	O
SH	NNP	O
5,000	CD	O
IU	NNP	O
three	CD	O
times	NNS	O
daily	RB	O
when	WRB	O
used	VBN	O
to	TO	O
prevent	VB	O
thrombosis	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
enoxaparin	NN	O
must	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
reducing	VBG	O
postoperative	JJ	O
hip	NN	O
precautions	NNS	O
in	IN	O
total	JJ	O
hip	JJ	O
replacement	NN	O
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

Currently	NNP	O
,	,	O
many	JJ	O
rehabilitation	NN	O
protocols	NNS	O
for	IN	O
total	JJ	O
hip	NN	O
replacements	NNS	O
(	(	O
THRs	NNP	O
)	)	O
include	VBP	O
activity	NN	O
restrictions	NNS	O
to	TO	O
prevent	VB	O
postoperative	JJ	O
dislocation	NN	O
.	.	O

There	EX	O
is	VBZ	O
increasing	VBG	O
demand	NN	O
for	IN	O
more	RBR	O
efficient	JJ	O
and	CC	O
safe	JJ	O
rehabilitation	NN	O
protocols	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
evaluates	VBZ	O
the	DT	O
need	NN	O
for	IN	O
hip	NN	O
restrictions	NNS	O
following	VBG	O
a	DT	O
modified	JJ	O
anterolateral	JJ	O
procedure	NN	O
.	.	O

From	IN	O
2004	CD	O
to	TO	O
2008	CD	O
,	,	O
81	CD	O
patients	NNS	O
seeking	VBG	O
elective	JJ	O
THRs	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
a	DT	O
standard	JJ	O
rehabilitation	NN	O
group	NN	O
or	CC	O
an	DT	O
early	JJ	O
rehabilitation	NN	O
group	NN	O
.	.	O

The	DT	O
standard	JJ	O
group	NN	O
included	VBD	O
restrictions	NNS	O
to	TO	O
avoid	VB	O
hip	NN	O
flexion	NN	O
>	VBD	O
90	CD	O
degrees	NNS	O
and	CC	O
avoidance	NN	O
of	IN	O
riding	VBG	O
in	IN	O
a	DT	O
car	NN	O
for	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
month	NN	O
.	.	O

The	DT	O
early	JJ	O
group	NN	O
had	VBD	O
no	DT	O
flexion	NN	O
or	CC	O
car	NN	O
riding	NN	O
restrictions	NNS	O
.	.	O

Forty-three	JJ	O
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
standard	JJ	O
group	NN	O
and	CC	O
38	CD	O
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
early	JJ	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
demographic	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
Short	JJ	O
Form	NNP	O
12-question	JJ	O
Health	NNP	O
Survey	NNP	O
and	CC	O
Harris	NNP	O
Hip	NNP	O
Score	NNP	O
preoperatively	RB	O
and	CC	O
at	IN	O
4	CD	O
weeks	NNS	O
,	,	O
1	CD	O
month	NN	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
and	CC	O
1	CD	O
year	NN	O
postoperatively	RB	O
.	.	O

The	DT	O
time-points	NNS	Others
at	IN	Others
which	WDT	Others
the	DT	Others
patient	NN	Others
first	RB	Others
drove	VBD	Others
and	CC	Others
ambulated	VBD	Others
with	IN	O
a	DT	O
cane	NN	O
,	,	O
without	IN	O
a	DT	O
cane	NN	O
,	,	O
and	CC	O
without	IN	O
a	DT	O
limp	NN	O
were	VBD	O
also	RB	O
collected	VBN	O
.	.	O

No	DT	O
incidents	NNS	O
of	IN	O
dislocation	NN	Physical
occurred	VBD	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
group	NN	O
were	VBD	O
faster	JJR	O
to	TO	O
ambulate	VB	Physical
with	IN	Physical
only	RB	Physical
a	DT	Physical
cane	NN	Physical
(	(	O
P=.03	NNP	O
)	)	O
,	,	O
without	IN	Others
a	DT	Others
cane	NN	Others
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
without	IN	Others
a	DT	Others
limp	NN	Others
(	(	O
P=.003	NNP	O
)	)	O
.	.	O

They	PRP	O
also	RB	O
drove	VBD	Others
earlier	RBR	O
(	(	O
P=.02	NNP	O
)	)	O
.	.	O

Pace	NN	Physical
of	IN	Physical
recovery	NN	Physical
was	VBD	O
the	DT	O
only	JJ	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
early	JJ	O
rehabilitation	NN	O
protocol	NN	O
increases	VBZ	O
the	DT	O
pace	NN	O
of	IN	O
recovery	NN	O
compared	VBN	O
to	TO	O
a	DT	O
pathway	NN	O
with	IN	O
hip	NN	O
precautions	NNS	O
without	IN	O
increasing	VBG	O
complications	NNS	Adverseeffect
.	.	O

[	JJ	O
Pharmacological	NNP	O
correction	NN	O
of	IN	O
free	JJ	Physical
radical	JJ	Physical
disturbances	NNS	Physical
and	CC	Physical
endotoxicosis	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
diffuse	NN	O
peritonitis	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
]	NNP	O
.	.	O

The	DT	O
examination	NN	O
and	CC	O
treatment	NN	O
of	IN	O
64	CD	O
patients	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
inclusion	NN	O
of	IN	O
complex	JJ	O
antioxidant	NN	O
cytoflavin	NN	O
in	IN	O
intensive	JJ	O
therapy	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
allows	VBZ	O
the	DT	O
hypoxia	NN	O
degree	NN	O
to	TO	O
be	VB	O
decreased	VBN	O
that	IN	O
in	IN	O
its	PRP$	O
turn	NN	O
results	NNS	O
in	IN	O
quicker	JJ	O
recovery	NN	Physical
of	IN	Physical
the	DT	Physical
antioxidant	JJ	Physical
system	NN	Physical
and	CC	Physical
decreased	JJ	Physical
activity	NN	Physical
of	IN	Physical
peroxidation	NN	Physical
and	CC	Physical
endotoxicosis	NN	Physical
level	NN	Physical
.	.	O

The	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
with	IN	O
cytoflavin	NN	O
included	VBN	O
in	IN	O
intensive	JJ	O
therapy	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
shorter	JJR	O
terms	NNS	O
of	IN	O
artificial	JJ	Others
lung	NN	Others
ventilation	NN	Others
,	,	O
shorter	JJR	O
time	NN	O
of	IN	O
staying	VBG	Others
in	IN	Others
critical	JJ	Others
condition	NN	Others
,	,	O
more	RBR	O
favorable	JJ	O
course	NN	Adverseeffect
of	IN	Adverseeffect
complications	NNS	Adverseeffect
.	.	O

Effects	NNS	O
of	IN	O
topical	JJ	O
boswellic	JJ	O
acid	NN	O
on	IN	O
photo	NN	O
and	CC	O
age-damaged	JJ	O
skin	NN	O
:	:	O
clinical	JJ	Physical
,	,	O
biophysical	JJ	Physical
,	,	O
and	CC	O
echographic	JJ	Physical
evaluations	NNS	Physical
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
split-face	JJ	O
study	NN	O
.	.	O

Boswellic	NNP	O
acids	NNS	O
(	(	O
BAs	NNP	O
)	)	O
are	VBP	O
pentacyclic	JJ	O
triterpenes	NNS	O
with	IN	O
strong	JJ	O
anti-inflammatory	JJ	O
activity	NN	O
;	:	O
their	PRP$	O
most	RBS	O
important	JJ	O
source	NN	O
is	VBZ	O
the	DT	O
extract	NN	O
of	IN	O
the	DT	O
gum	NN	O
resin	NN	O
of	IN	O
Boswellia	NNP	O
serrata	NN	O
,	,	O
a	DT	O
tropical	JJ	O
tree	NN	O
that	WDT	O
grows	VBZ	O
in	IN	O
India	NNP	O
and	CC	O
Africa	NNP	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
split-face	JJ	O
,	,	O
comparative	JJ	O
study	NN	O
we	PRP	O
have	VBP	O
assessed	VBN	O
efficacy	NN	Others
,	,	Others
tolerability	NN	Others
,	,	Others
and	CC	Others
safety	NN	Others
of	IN	O
a	DT	O
base	NN	O
cream	NN	O
containing	VBG	O
0.5	CD	O
%	NN	O
BAs	NNP	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
same	JJ	O
cream	NN	O
without	IN	O
these	DT	O
active	JJ	O
ingredients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinical	JJ	O
manifestations	NNS	O
of	IN	O
photoaging	NN	O
of	IN	O
facial	JJ	O
skin	NN	O
.	.	O

Fifteen	NNP	O
female	JJ	O
volunteers	NNS	O
were	VBD	O
enrolled	VBN	O
;	:	O
they	PRP	O
applied	VBD	O
creams	NNS	O
once	RB	O
daily	RB	O
for	IN	O
30	CD	O
days	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
2-month	JJ	O
follow-up	NN	O
,	,	O
clinical	JJ	O
findings	NNS	O
were	VBD	O
assessed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Dover	NNP	Others
classification	NN	Others
scale	NN	Others
for	IN	Others
photoaging	VBG	Others
and	CC	O
by	IN	O
biophysical	JJ	Others
and	CC	Others
ecographic	JJ	Others
measurements	NNS	Others
.	.	O

We	PRP	O
registered	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
tactile	JJ	Others
roughness	NN	Others
and	CC	Others
fine	JJ	Others
lines	NNS	Others
in	IN	O
the	DT	O
half	JJ	O
side	NN	O
of	IN	O
the	DT	O
face	NN	O
treated	VBD	O
with	IN	O
BAs	NNP	O
;	:	O
noninvasive	JJ	O
instrumental	JJ	O
diagnostic	JJ	O
investigations	NNS	O
showed	VBD	O
an	DT	O
improvement	NN	O
of	IN	O
elasticity	NN	Others
,	,	O
a	DT	O
decrease	NN	O
of	IN	O
sebum	JJ	Others
excretion	NN	Others
,	,	O
and	CC	O
a	DT	O
change	NN	O
of	IN	O
echographic	JJ	Others
parameters	NNS	Others
suggesting	VBG	O
a	DT	O
reshaping	NN	Others
of	IN	Others
dermal	JJ	Others
tissue	NN	Others
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
always	RB	O
well	RB	O
tolerated	VBN	Others
without	IN	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
.	.	O

The	DT	O
present	JJ	O
findings	NNS	O
seem	VBP	O
to	TO	O
indicate	VB	O
that	IN	O
the	DT	O
topical	JJ	O
application	NN	O
of	IN	O
BAs	NNP	O
may	MD	O
represent	VB	O
a	DT	O
suitable	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
selected	VBN	O
features	NNS	O
of	IN	O
skin	NN	O
photoaging	NN	O
.	.	O

Study	NNP	O
design	NN	O
and	CC	O
rationale	NN	O
of	IN	O
a	DT	O
dose-ranging	JJ	O
trial	NN	O
of	IN	O
LX4211	NNP	O
,	,	O
a	DT	O
dual	JJ	O
inhibitor	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
,	,	O
in	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
inadequately	RB	O
controlled	VBN	O
on	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

Sodium-glucose	JJ	O
cotransporters	NNS	O
1	CD	O
(	(	O
SGLT1	NNP	O
)	)	O
and	CC	O
2	CD	O
(	(	O
SGLT2	NNP	O
)	)	O
are	VBP	O
the	DT	O
major	JJ	O
cellular	JJ	O
transporters	NNS	O
responsible	JJ	O
for	IN	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
glucose	VBP	O
absorption	NN	O
and	CC	O
renal	JJ	O
glucose	NN	O
reabsorption	NN	O
,	,	O
respectively	RB	O
.	.	O

LX4211	NNP	O
,	,	O
a	DT	O
dual	JJ	O
inhibitor	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
,	,	O
reduces	VBZ	O
glucose	JJ	O
absorption	NN	O
from	IN	O
the	DT	O
GI	NNP	O
tract	NN	O
and	CC	O
enhances	NNS	O
urinary	JJ	O
glucose	JJ	O
excretion	NN	O
.	.	O

Although	IN	O
several	JJ	O
SGLT2-selective	JJ	O
inhibitors	NNS	O
have	VBP	O
been	VBN	O
tested	VBN	O
in	IN	O
large	JJ	O
phase	NN	O
2	CD	O
studies	NNS	O
,	,	O
dual	JJ	O
inhibition	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
is	VBZ	O
novel	JJ	O
at	IN	O
this	DT	O
stage	NN	O
of	IN	O
drug	NN	O
development	NN	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
implications	NNS	O
for	IN	O
clinical-trial	JJ	O
design	NN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
we	PRP	O
describe	VBP	O
the	DT	O
design	NN	O
and	CC	O
rationale	NN	O
of	IN	O
a	DT	O
phase	NN	O
2	CD	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	Others
and	CC	Others
efficacy	NN	Others
of	IN	Physical
LX4211	NNP	Physical
in	IN	O
subjects	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
mellitus	NN	O
who	WP	O
have	VBP	O
inadequate	JJ	O
glycemic	NNS	Physical
control	NN	Physical
on	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
change	NN	O
in	IN	O
glycated	JJ	Physical
hemoglobin	NN	Physical
A1c	NNP	Physical
from	IN	O
baseline	NN	O
to	TO	O
week	NN	O
12	CD	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
include	VBP	O
the	DT	O
proportion	NN	Physical
of	IN	Physical
subjects	NNS	Physical
achieving	VBG	Physical
a	DT	Physical
glycated	JJ	Physical
hemoglobin	NN	Physical
A1c	NNP	Physical
value	NN	Physical
of	IN	Physical
<	$	Physical
7	CD	Physical
%	NN	Physical
,	,	Physical
change	NN	Physical
from	IN	Physical
baseline	NN	Physical
in	IN	Physical
fasting	VBG	Physical
plasma	NN	Physical
glucose	NN	Physical
and	CC	Physical
postprandial	JJ	Physical
glucose	NN	Physical
(	(	Physical
as	IN	Physical
part	NN	Physical
of	IN	Physical
an	DT	Physical
oral	JJ	Physical
glucose	NN	Physical
tolerance	NN	Physical
test	NN	Physical
)	)	Physical
,	,	Physical
body	NN	Physical
weight	NN	Physical
,	,	Physical
and	CC	Physical
blood	NN	Physical
pressure	NN	Physical
.	.	Physical

Safety	NN	Others
is	VBZ	O
evaluated	VBN	O
with	IN	O
particular	JJ	O
focus	NN	O
on	IN	O
hypoglycemia	NN	Physical
,	,	Physical
GI	NNP	Physical
symptoms	NNS	Physical
,	,	Physical
and	CC	Physical
incidence	NN	Physical
of	IN	Physical
genitourinary	JJ	Physical
tract	NN	Physical
infections	NNS	Physical
.	.	O

Lowering	VBG	O
of	IN	O
glucose	NN	O
in	IN	O
critical	JJ	O
care	NN	O
:	:	O
a	DT	O
randomized	JJ	O
pilot	NN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Similar	NNP	O
to	TO	O
cardiac	VB	O
surgery	NN	O
patients	NNS	O
,	,	O
medical-surgical	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
pilot	NN	O
trial	NN	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
with	IN	O
respect	NN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
achieving	VBG	O
target	NN	O
glucose	JJ	O
values	NNS	O
in	IN	O
the	DT	O
2	CD	O
ranges	NNS	O
of	IN	O
5	CD	O
to	TO	O
7	CD	O
and	CC	O
8	CD	O
to	TO	O
10	CD	O
mmol/L	NNS	O
and	CC	O
(	(	O
b	NN	O
)	)	O
uncovering	VBG	O
problems	NNS	O
with	IN	O
the	DT	O
protocol	NN	O
in	IN	O
anticipation	NN	O
of	IN	O
a	DT	O
larger	JJR	O
trial	NN	O
.	.	O

SETTING	VB	O
The	DT	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
a	DT	O
15-bed	JJ	O
medical-surgical	JJ	O
university-affiliated	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
included	VBD	O
patients	NNS	O
older	JJR	O
than	IN	O
18	CD	O
years	NNS	O
,	,	O
expected	VBN	O
to	TO	O
be	VB	O
in	IN	O
ICU	NNP	O
for	IN	O
more	JJR	O
than	IN	O
72	CD	O
hours	NNS	O
,	,	O
with	IN	O
a	DT	O
glucose	JJ	O
value	NN	O
of	IN	O
more	JJR	O
than	IN	O
10	CD	O
mmol/L	NNS	O
within	IN	O
48	CD	O
hours	NNS	O
of	IN	O
ICU	NNP	O
admission	NN	O
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
diabetic	JJ	O
ketoacidosis	NN	O
,	,	O
severe	JJ	O
hepatic	JJ	O
failure	NN	O
or	CC	O
hepatic	JJ	O
resection	NN	O
,	,	O
pancreatitis	NN	O
,	,	O
glucose	NN	O
of	IN	O
less	JJR	O
than	IN	O
2.2	CD	O
mmol/L	NN	O
on	IN	O
admission	NN	O
to	TO	O
hospital	NN	O
,	,	O
insulin	JJ	O
infusion	NN	O
on	IN	O
admission	NN	O
to	TO	O
ICU	NNP	O
,	,	O
planned	VBD	O
withdrawal	NN	O
of	IN	O
life	NN	O
support	NN	O
,	,	O
and	CC	O
inability	NN	O
to	TO	O
obtain	VB	O
informed	JJ	O
consent	NN	O
.	.	O

Patients	NNS	O
underwent	JJ	O
concealed	JJ	O
random	NN	O
allocation	NN	O
to	TO	O
a	DT	O
target	NN	O
glucose	JJ	O
range	NN	O
of	IN	O
5	CD	O
to	TO	O
7	CD	O
or	CC	O
8	CD	O
to	TO	O
10	CD	O
mmol/L	NNS	O
using	VBG	O
pretested	JJ	O
algorithms	NN	O
of	IN	O
insulin	NN	O
infusions	NNS	O
.	.	O

Dedicated	VBN	O
glucometer	JJ	O
measurement	NN	O
of	IN	O
arterial	JJ	O
glucose	NN	O
values	NNS	O
was	VBD	O
calibrated	VBN	O
daily	RB	O
to	TO	O
values	NNS	O
measured	VBN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
20	CD	O
patients	NNS	O
with	IN	O
a	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
Acute	NNP	Physical
Physiology	NNP	Physical
and	CC	Physical
Chronic	NNP	Physical
Health	NNP	Physical
Evaluation	NNP	Physical
(	(	Physical
APACHE	NNP	Physical
)	)	Physical
II	NNP	Physical
score	NN	Physical
of	IN	O
32	CD	O
(	(	O
10.2	CD	O
)	)	O
;	:	O
14	CD	O
were	VBD	O
insulin-dependent	JJ	O
pre-ICU	JJ	O
,	,	O
and	CC	O
all	DT	O
were	VBD	O
medical	JJ	O
admissions	NNS	O
.	.	O

Mean	NNP	Physical
glucose	JJ	Physical
values	NNS	Physical
were	VBD	O
different	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
7.1	CD	O
+/-	JJ	O
2.6	CD	O
vs	JJ	O
9.4	CD	O
+/-	JJ	O
2.1	CD	O
mmol/L	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
group	NN	O
had	VBD	O
more	RBR	O
glucose	JJ	Physical
measurements	NNS	Physical
performed	VBN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
similar	JJ	O
proportion	NN	O
of	IN	O
values	NNS	O
were	VBD	O
within	IN	O
the	DT	O
target	NN	O
range	NN	O
(	(	O
682	CD	O
[	RB	O
42.4	CD	O
%	NN	O
]	NN	O
of	IN	O
1607	CD	O
values	NNS	O
in	IN	O
the	DT	O
5-	JJ	O
to	TO	O
7-mmol/L	JJ	O
range	NN	O
;	:	O
250	CD	O
[	$	O
38.7	CD	O
%	NN	O
]	NN	O
of	IN	O
660	CD	O
values	NNS	O
in	IN	O
the	DT	O
8-	JJ	O
to	TO	O
10-mmol/L	JJ	O
range	NN	O
,	,	O
P	NNP	O
=	NNP	O
.35	NNP	O
)	)	O
.	.	O

Glucose	NNP	Physical
values	NNS	Physical
of	IN	O
less	JJR	O
than	IN	O
2.5	CD	O
mmol/L	NN	O
developed	VBD	O
7	CD	O
times	NNS	O
in	IN	O
5	CD	O
patients	NNS	O
,	,	O
4	CD	O
of	IN	O
whom	WP	O
were	VBD	O
in	IN	O
the	DT	O
intensive	JJ	O
insulin	NN	O
therapy	NN	O
group	NN	O
;	:	O
however	RB	O
,	,	O
no	DT	O
adverse	JJ	O
consequences	NNS	O
were	VBD	O
documented	VBN	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
clinically	RB	O
important	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
pilot	JJ	O
trial	NN	O
of	IN	O
ICU	NNP	O
patients	NNS	O
with	IN	O
high	JJ	O
illness	NN	O
severity	NN	O
,	,	O
glucose	JJ	Physical
values	NNS	Physical
were	VBD	O
in	IN	O
the	DT	O
2	CD	O
target	NN	O
ranges	VBZ	O
only	RB	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
time	NN	O
,	,	O
using	VBG	O
well-accepted	JJ	O
initiation	NN	O
and	CC	O
maintenance	NN	O
insulin	NN	O
infusion	NN	O
algorithms	NN	O
.	.	O

A	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
glycemic	JJ	O
control	NN	O
is	VBZ	O
feasible	JJ	O
in	IN	O
this	DT	O
population	NN	O
to	TO	O
examine	VB	O
clinically	RB	O
important	JJ	O
outcomes	NNS	O
,	,	O
but	CC	O
will	MD	O
require	VB	O
refined	JJ	O
insulin	NN	O
algorithms	NN	O
and	CC	O
more	RBR	O
comprehensive	JJ	O
behavior	NN	O
change	NN	O
strategies	NNS	O
to	TO	O
achieve	VB	O
target	NN	O
values	NNS	O
.	.	O

Netilmicin	NNP	O
versus	NN	O
tobramycin	NN	O
in	IN	O
multi-centre	JJ	O
studies	NNS	O
.	.	O

In	IN	O
two	CD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
studies	NNS	O
conducted	VBN	O
in	IN	O
West	NNP	O
Germany	NNP	O
and	CC	O
involving	VBG	O
80	CD	O
patients	NNS	O
,	,	O
netilmicin-ticarcillin	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
tobramycin-ticarcillin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
serious	JJ	O
systemic	JJ	O
infections	NNS	O
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
essentially	RB	O
identical	JJ	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
clinical	JJ	O
and	CC	O
bacteriological	JJ	O
results	NNS	O
they	PRP	O
produced	VBD	O
.	.	O

The	DT	O
netilmicin	JJ	O
group	NN	O
developed	VBD	O
significantly	RB	O
less	JJR	O
nephrotoxicity	NN	Physical
than	IN	O
the	DT	O
tobramycin	NN	O
group	NN	O
(	(	O
0	CD	O
%	NN	O
versus	IN	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Ototoxicity	NNP	Physical
also	RB	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
in	IN	O
the	DT	O
netilmicin-treated	JJ	O
patients	NNS	O
(	(	O
3	CD	O
%	NN	O
versus	IN	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.4	CD	O
)	)	O
.	.	O

In	IN	O
a	DT	O
large	JJ	O
collaborative	NN	O
study	NN	O
involving	VBG	O
15	CD	O
centres	NNS	O
,	,	O
254	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Clinical	JJ	Physical
and	CC	Physical
bacteriological	JJ	Physical
responses	NNS	Physical
were	VBD	O
excellent	JJ	O
,	,	O
with	IN	O
netilmicin	JJ	O
and	CC	O
tobramycin	JJ	O
equally	RB	O
effective	JJ	Others
,	,	O
but	CC	O
the	DT	O
incidences	NNS	O
of	IN	O
nephrotoxicity	NN	Physical
and	CC	O
ototoxicity	NN	Physical
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
netilmicin	NN	O
than	IN	O
those	DT	O
receiving	VBG	O
tobramycin	NN	O
.	.	O

Prospective	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
value	NN	O
of	IN	O
brushings	NNS	O
before	IN	O
and	CC	O
after	IN	O
biopsy	NN	O
in	IN	O
the	DT	O
endoscopic	JJ	O
diagnosis	NN	O
of	IN	O
gastroesophageal	JJ	O
malignancy	NN	O
.	.	O

The	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
cytodiagnostic	JJ	O
results	NNS	O
on	IN	O
endoscopic	JJ	O
brushings	NNS	O
obtained	VBN	O
before	IN	O
biopsy	NN	O
may	MD	O
be	VB	O
superior	JJ	O
to	TO	O
those	DT	O
brushings	NNS	O
obtained	VBN	O
after	IN	O
biopsy	NN	O
,	,	O
but	CC	O
with	IN	O
the	DT	O
accuracy	NN	O
of	IN	O
the	DT	O
subsequent	JJ	O
biopsy	NN	O
reduced	VBD	O
,	,	O
was	VBD	O
examined	VBN	O
for	IN	O
300	CD	O
consecutive	JJ	O
patients	NNS	O
,	,	O
including	VBG	O
256	CD	O
with	IN	O
esophageal	NN	O
or	CC	O
gastric	JJ	O
carcinomas	NN	O
.	.	O

Following	VBG	O
stratification	NN	O
by	IN	O
site	NN	O
and	CC	O
endoscopic	JJ	O
appearance	NN	O
of	IN	O
their	PRP$	O
lesions	NNS	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
brushing	VBG	O
either	CC	O
before	IN	O
or	CC	O
after	IN	O
forceps	JJ	O
biopsy	NN	O
.	.	O

The	DT	O
accuracy	NN	Others
of	IN	Others
brushing	VBG	Others
cytology	NN	Others
in	IN	O
patients	NNS	O
with	IN	O
carcinoma	NN	Physical
was	VBD	O
significantly	RB	O
higher	JJR	O
when	WRB	O
the	DT	O
brushing	NN	Others
was	VBD	O
performed	VBN	O
before	IN	O
biopsy	NN	O
than	IN	O
after	IN	O
biopsy	NN	O
(	(	O
93.5	CD	O
%	NN	O
versus	IN	O
82.6	CD	O
%	NN	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
.01	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	Others
yield	NN	Others
of	IN	O
the	DT	O
biopsy	NN	Others
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
whether	IN	O
the	DT	O
lesions	NNS	O
were	VBD	O
brushed	VBN	O
before	IN	O
or	CC	O
after	IN	O
the	DT	O
biopsy	NN	O
(	(	O
92.7	CD	O
%	NN	O
versus	IN	O
93.2	CD	O
%	NN	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
.5	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	Others
superiority	NN	Others
of	IN	O
brushings	NNS	Others
obtained	VBN	O
before	IN	O
biopsy	NN	O
did	VBD	O
not	RB	O
relate	VB	O
to	TO	O
the	DT	O
site	NN	O
or	CC	O
endoscopic	JJ	O
appearance	NN	O
of	IN	O
the	DT	O
tumor	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	Others
false-positive	JJ	Others
cytologic	NN	Others
or	CC	Others
histologic	JJ	Others
reports	NNS	Others
.	.	O

For	IN	O
all	DT	O
256	CD	O
carcinomas	NNS	O
,	,	O
the	DT	O
cumulative	JJ	Others
accuracy	NN	Others
(	(	O
brushing	VBG	Others
cytology	NN	Others
plus	CC	Others
biopsy	NN	Others
)	)	O
reached	VBD	O
98.8	CD	O
%	NN	O
and	CC	O
was	VBD	O
significantly	RB	O
better	JJR	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.001	NN	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
biopsy	NN	Others
alone	RB	O
(	(	O
93.9	CD	O
%	NN	O
)	)	O
or	CC	O
cytology	NN	Others
alone	RB	O
(	(	O
87.9	CD	O
%	NN	O
)	)	O
.	.	O

Apart	RB	O
from	IN	O
reinforcing	VBG	O
the	DT	O
belief	NN	O
that	IN	O
the	DT	O
combined	JJ	Others
application	NN	Others
of	IN	Others
brushing	NN	Others
and	CC	Others
biopsy	NN	Others
is	VBZ	O
mandatory	JJ	O
for	IN	O
achieving	VBG	O
optimal	JJ	O
results	NNS	O
,	,	O
this	DT	O
study	NN	O
indicated	VBD	O
that	IN	O
the	DT	O
brushing	NN	O
should	MD	O
be	VB	O
performed	VBN	O
before	IN	O
the	DT	O
biopsy	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
physiotherapy	JJ	O
management	NN	O
of	IN	O
knee	NN	O
joint	JJ	O
osteoarthritis	NN	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
a	DT	O
multimodal	JJ	O
physiotherapy	NN	O
programme	NN	O
including	VBG	O
taping	VBG	O
,	,	O
exercises	NNS	O
,	,	O
and	CC	O
massage	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
knee	NN	O
osteoarthritis	NN	O
,	,	O
and	CC	O
if	IN	O
benefits	NNS	O
can	MD	O
be	VB	O
maintained	VBN	O
with	IN	O
self	JJ	O
management	NN	O
.	.	O

METHODS	NNP	O
Randomised	VBD	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
;	:	O
140	CD	O
community	NN	O
volunteers	NNS	O
with	IN	O
knee	NN	O
osteoarthritis	NN	O
participated	VBD	O
and	CC	O
119	CD	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Physiotherapy	NNP	O
and	CC	O
placebo	JJ	O
interventions	NNS	O
were	VBD	O
applied	VBN	O
by	IN	O
10	CD	O
physiotherapists	NNS	O
in	IN	O
private	JJ	O
practices	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Physiotherapy	NNP	O
included	VBD	O
exercise	NN	O
,	,	O
massage	NN	O
,	,	O
taping	VBG	O
,	,	O
and	CC	O
mobilisation	NN	O
,	,	O
followed	VBN	O
by	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
self	JJ	O
management	NN	O
.	.	O

Placebo	NNP	O
was	VBD	O
sham	VBN	O
ultrasound	JJ	O
and	CC	O
light	JJ	O
application	NN	O
of	IN	O
a	DT	O
non-therapeutic	JJ	O
gel	NN	O
,	,	O
followed	VBN	O
by	IN	O
no	DT	O
treatment	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
were	VBD	O
pain	RB	Pain
measured	VBN	Pain
by	IN	O
visual	JJ	Others
analogue	NN	Others
scale	NN	Others
and	CC	Others
patient	JJ	Others
global	JJ	Others
change	NN	Others
.	.	Pain

Secondary	JJ	O
measures	NNS	O
included	VBD	O
WOMAC	NNP	Others
,	,	O
knee	NN	Pain
pain	NN	Pain
scale	NN	Pain
,	,	O
SF-36	NNP	Others
,	,	O
assessment	NN	Others
of	IN	Others
quality	NN	Others
of	IN	Others
life	NN	Others
index	NN	Others
,	,	O
quadriceps	JJ	Others
strength	NN	Others
,	,	O
and	CC	O
balance	NN	Others
test	NN	Others
.	.	O

RESULTS	NNP	O
Using	VBG	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
,	,	O
physiotherapy	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
showed	VBD	O
similar	JJ	O
pain	NN	Pain
reductions	NNS	Pain
at	IN	O
12	CD	O
weeks	NNS	O
:	:	O
-2.2	NN	O
cm	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-2.6	NNP	O
to	TO	O
-1.7	VB	O
)	)	O
and	CC	O
-2.0	$	O
cm	NN	O
(	(	O
-2.5	UH	O
to	TO	O
-1.5	VB	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
24	CD	O
weeks	NNS	O
,	,	O
pain	NN	Pain
remained	VBD	Pain
reduced	VBN	Pain
from	IN	O
baseline	NN	O
in	IN	O
both	DT	O
groups	NNS	O
:	:	O
-2.1	NN	O
(	(	O
-2.6	UH	O
to	TO	O
-1.6	VB	O
)	)	O
and	CC	O
-1.6	NNP	O
(	(	O
-2.2	UH	O
to	TO	O
-1.0	VB	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Global	JJ	Others
improvement	NN	Others
was	VBD	O
reported	VBN	O
by	IN	O
70	CD	O
%	NN	O
of	IN	O
physiotherapy	NN	O
participants	NNS	O
(	(	O
51/73	CD	O
)	)	O
at	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
by	IN	O
59	CD	O
%	NN	O
(	(	O
43/73	CD	O
)	)	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Similarly	RB	O
,	,	O
global	JJ	Others
improvement	NN	Others
was	VBD	O
reported	VBN	O
by	IN	O
72	CD	O
%	NN	O
of	IN	O
placebo	NN	O
participants	NNS	O
(	(	O
48/67	CD	O
)	)	O
at	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
by	IN	O
49	CD	O
%	NN	O
(	(	O
33/67	CD	O
)	)	O
at	IN	O
24	CD	O
weeks	NNS	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
physiotherapy	NN	O
programme	NN	O
tested	VBN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
no	DT	O
more	RBR	O
effective	JJ	O
than	IN	O
regular	JJ	O
contact	NN	O
with	IN	O
a	DT	O
therapist	NN	O
at	IN	O
reducing	VBG	O
pain	NN	O
and	CC	O
disability	NN	O
.	.	O

Desmopressin	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nocturia	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
investigate	VB	O
efficacy	NN	Others
,	,	Others
safety	NN	Others
,	,	O
and	CC	O
impact	NN	O
on	IN	O
quality	NN	Physical
of	IN	Physical
sleep	NN	Physical
of	IN	O
desmopressin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nocturia	NNS	O
.	.	O

METHODS	NNP	O
Adults	NNP	O
aged	VBD	O
>	NNP	O
or	CC	O
=18	NNP	O
yr	NN	O
with	IN	O
nocturia	NNS	O
(	(	O
>	CD	O
or	CC	O
=2	VB	O
voids/night	NN	O
)	)	O
received	VBD	O
desmopressin	JJ	O
tablets	NNS	O
(	(	O
0.1	CD	O
,	,	O
0.2	CD	O
,	,	O
or	CC	O
0.4	CD	O
mg	NN	O
)	)	O
during	IN	O
a	DT	O
3-wk	JJ	O
dose-titration	NN	O
period	NN	O
.	.	O

Patients	NNS	O
should	MD	O
show	VB	O
sufficient	JJ	O
response	NN	O
during	IN	O
the	DT	O
dose-titration	JJ	O
period	NN	O
(	(	O
>	CD	O
or	CC	O
=20	CD	O
%	NN	O
reduction	NN	O
in	IN	O
nocturnal	JJ	O
diuresis	NN	O
)	)	O
and	CC	O
a	DT	O
return	NN	O
of	IN	O
nocturnal	JJ	O
diuresis	NN	O
to	TO	O
>	VB	O
or	CC	O
=80	VB	O
%	NN	O
of	IN	O
baseline	NN	O
levels	NNS	O
during	IN	O
washout	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
then	RB	O
entered	VBD	O
a	DT	O
3-wk	JJ	O
double-blind	JJ	O
treatment	NN	O
period	NN	O
and	CC	O
received	VBD	O
either	CC	O
desmopressin	NN	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	CC	O
127	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
desmopressin	NN	O
(	(	O
n=61	JJ	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=66	JJ	O
)	)	O
.	.	O

Twenty	NNP	O
(	(	O
33	CD	O
%	NN	O
)	)	O
desmopressin-treated	JJ	O
patients	NNS	O
compared	VBN	O
with	IN	O
seven	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
placebo-treated	JJ	O
patients	NNS	O
showed	VBD	O
a	DT	O
clinical	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
a	DT	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	Physical
of	IN	Physical
nocturnal	JJ	Physical
voids	NNS	Physical
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p=0.0014	NN	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
desmopressin	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
mean	JJ	Physical
number	NN	Physical
of	IN	Physical
nocturnal	JJ	Physical
voids	NNS	Physical
(	(	O
39	CD	O
%	NN	O
reduction	NN	O
with	IN	O
desmopressin	NN	O
vs.	FW	O
15	CD	O
%	NN	O
with	IN	O
placebo	NN	O
;	:	O
absolute	JJ	O
difference	NN	O
-0.84	NN	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
duration	NN	Physical
of	IN	Physical
the	DT	Physical
first	JJ	Physical
sleep	JJ	Physical
period	NN	Physical
(	(	O
prolonged	VBN	O
by	IN	O
108	CD	O
min	NNS	O
with	IN	O
desmopressin	NN	O
vs.	FW	O
41	CD	O
min	NN	O
with	IN	O
placebo	NN	O
;	:	O
p	CC	O
<	VB	O
0.0001	CD	O
)	)	O
.	.	O

Quality	NN	Physical
of	IN	Physical
sleep	NN	Physical
was	VBD	O
also	RB	O
improved	VBN	O
with	IN	O
desmopressin	NN	O
versus	NN	O
placebo	NN	O
(	(	O
statistically	RB	O
significant	JJ	O
for	IN	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
parameters	NNS	O
evaluated	VBD	O
)	)	O
.	.	O

Adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
mainly	RB	O
mild	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
desmopressin	NN	O
tablets	NNS	O
provide	VBP	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
nocturia	NN	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
nocturnal	JJ	Physical
voiding	NN	Physical
frequency	NN	Physical
is	VBZ	O
reduced	VBN	O
,	,	O
duration	NN	O
of	IN	O
the	DT	O
first	JJ	O
sleep	JJ	O
period	NN	O
is	VBZ	O
increased	VBN	O
,	,	O
and	CC	O
sleep	JJ	Physical
quality	NN	Physical
may	MD	O
be	VB	O
improved	VBN	O
.	.	O

[	JJ	O
Initial	NNP	O
nuclear	JJ	O
magnetic	JJ	O
resonance	NN	O
tomography	NN	O
results	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
course	NN	O
of	IN	O
avascular	JJ	O
femur	NNS	O
head	VBP	O
necrosis	NN	O
after	IN	O
femoral	JJ	O
core	NN	O
decompression	NN	O
]	NNP	O
.	.	O

The	DT	O
vascular	JJ	O
femoral	JJ	O
head	NN	O
necrosis	NN	O
is	VBZ	O
a	DT	O
serious	JJ	O
illness	NN	O
,	,	O
especially	RB	O
when	WRB	O
appearing	VBG	O
in	IN	O
patients	NNS	O
aged	VBD	O
30	CD	O
to	TO	O
50	CD	O
years	NNS	O
.	.	O

Many	JJ	O
etiologic	JJ	O
factors	NNS	O
cause	VBP	O
a	DT	O
femoral	JJ	O
head	NN	O
necrosis	NN	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
high-dose	JJ	O
steroids	NNS	O
,	,	O
abuse	NN	O
of	IN	O
alcohol	NN	O
,	,	O
defect	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
and	CC	O
trauma	NN	O
of	IN	O
the	DT	O
hip	NN	O
.	.	O

Often	VB	O
the	DT	O
X-ray	JJ	O
photograph	NN	O
leads	VBZ	O
to	TO	O
the	DT	O
diagnosis	NN	O
in	IN	O
the	DT	O
second	JJ	O
stage	NN	O
(	(	O
ARCO	NNP	O
1992	CD	O
)	)	O
or	CC	O
in	IN	O
the	DT	O
third	JJ	O
stage	NN	O
,	,	O
when	WRB	O
the	DT	O
femoral	JJ	O
head	NN	O
has	VBZ	O
begun	VBN	O
to	TO	O
collapse	VB	O
.	.	O

The	DT	O
stage	NN	O
IIc	NNP	O
and	CC	O
III	NNP	O
shows	VBZ	O
an	DT	O
evident	JJ	O
enhancement	NN	O
in	IN	O
contrast	NN	O
media	NNS	O
in	IN	O
MRI	NNP	O
.	.	O

Contrast	NNP	O
enhancement	NN	O
is	VBZ	O
demonstrated	VBN	O
by	IN	O
STIR	NNP	O
,	,	O
FATSAT	NNP	O
,	,	O
T1-weighted	NNP	O
and	CC	O
dynamic	JJ	O
screening	NN	O
sequence	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
contrast	NN	O
media	NNS	O
enhancement	VBP	O
argue	NN	O
for	IN	O
an	DT	O
active	JJ	O
concomitant	NN	O
process	NN	O
of	IN	O
destruction	NN	O
and	CC	O
regeneration	NN	O
.	.	O

This	DT	O
stage	NN	O
has	VBZ	O
the	DT	O
best	JJS	O
chances	NNS	O
for	IN	O
a	DT	O
drug	NN	O
or	CC	O
a	DT	O
surgical	JJ	O
therapy	NN	O
.	.	O

The	DT	O
evaluation	NN	O
of	IN	O
the	DT	O
signal	JJ	O
intensity	NN	O
by	IN	O
the	DT	O
dynamic	JJ	Physical
screening	NN	Physical
sequence	NN	Physical
is	VBZ	O
considered	VBN	O
as	IN	O
an	DT	O
objective	JJ	O
contribution	NN	O
for	IN	O
the	DT	O
staging	NN	Physical
of	IN	Physical
the	DT	Physical
femoral	JJ	Physical
head	NN	Physical
necrosis	NN	Physical
.	.	O

This	DT	O
enables	VBZ	O
one	CD	O
to	TO	O
differentiate	VB	O
between	IN	O
the	DT	O
curable	JJ	Physical
stage	NN	Physical
IIc	NNP	Physical
and	CC	O
the	DT	O
stage	NN	Physical
III	NNP	Physical
,	,	O
showing	VBG	O
the	DT	O
beginning	NN	O
of	IN	O
breakdown	NN	Physical
of	IN	Physical
the	DT	Physical
femoral	JJ	Physical
head	NN	Physical
.	.	O

Comparison	NNP	O
of	IN	O
yoga	NNP	O
versus	NN	O
stretching	VBG	O
for	IN	O
chronic	JJ	Pain
low	JJ	Pain
back	RB	Pain
pain	NN	Pain
:	:	O
protocol	NN	O
for	IN	O
the	DT	O
Yoga	NNP	O
Exercise	NNP	O
Self-care	NNP	O
(	(	O
YES	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Back	NNP	Pain
pain	NN	Pain
,	,	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
prevalent	JJ	O
conditions	NNS	O
afflicting	VBG	O
American	JJ	O
adults	NNS	O
,	,	O
is	VBZ	O
the	DT	O
leading	VBG	O
reason	NN	O
for	IN	O
using	VBG	O
complementary	JJ	O
and	CC	O
alternative	JJ	O
medicine	NN	O
(	(	O
CAM	NNP	O
)	)	O
therapies	NNS	O
.	.	O

Yoga	NNP	O
is	VBZ	O
an	DT	O
increasingly	RB	O
popular	JJ	O
mind-body	NN	O
CAM	NNP	O
therapy	NN	O
often	RB	O
used	VBN	O
for	IN	O
relieving	VBG	Pain
back	RB	Pain
pain	NN	Pain
and	CC	O
several	JJ	O
small	JJ	O
studies	NNS	O
have	VBP	O
found	VBN	O
yoga	RB	O
effective	JJ	O
for	IN	O
this	DT	O
condition	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
whether	IN	O
yoga	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
chronic	JJ	Pain
low	JJ	Pain
back	RB	Pain
pain	NN	Pain
compared	VBN	O
with	IN	O
self	PRP	O
care	NN	O
and	CC	O
exercise	NN	O
and	CC	O
will	MD	O
explore	VB	O
the	DT	O
mechanisms	NNS	O
responsible	JJ	O
for	IN	O
any	DT	O
observed	JJ	O
benefits	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	O
participants	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
lasting	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
from	IN	O
primary	JJ	O
care	NN	O
clinics	NNS	O
of	IN	O
a	DT	O
large	JJ	O
healthcare	NN	O
system	NN	O
based	VBN	O
in	IN	O
Seattle	NNP	O
.	.	O

They	PRP	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
2:2:1	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
12	CD	O
weekly	JJ	O
yoga	NN	O
classes	NNS	O
,	,	O
12	CD	O
weekly	JJ	O
conventional	JJ	O
therapeutic	JJ	O
exercise	NN	O
classes	NNS	O
of	IN	O
comparable	JJ	O
physical	JJ	O
exertion	NN	O
,	,	O
or	CC	O
a	DT	O
self-care	JJ	O
book	NN	O
.	.	O

Interviewers	NNS	O
masked	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
treatment	NN	O
group	NN	O
will	MD	O
assess	VB	O
outcomes	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
26	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
back-related	JJ	Physical
dysfunction	NN	Physical
and	CC	Physical
symptom	NN	Physical
bothersomeness	NN	Physical
.	.	Physical

In	IN	O
addition	NN	O
,	,	O
data	NNS	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
physical	JJ	Physical
measurements	NNS	Physical
(	(	O
e.g.	NN	O
,	,	O
flexion	NN	Physical
)	)	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
and	CC	O
saliva	NN	O
samples	NNS	O
will	MD	O
be	VB	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Information	NN	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
specific	JJ	O
physical	JJ	O
,	,	O
psychological	JJ	O
,	,	O
and	CC	O
physiological	JJ	O
factors	NNS	O
to	TO	O
allow	VB	O
exploration	NN	O
of	IN	O
possible	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
through	IN	O
which	WDT	O
yoga	NN	O
could	MD	O
relieve	VB	Pain
back	RB	Pain
pain	NN	Pain
and	CC	Pain
dysfunction	NN	Pain
.	.	Pain

The	DT	O
effectiveness	NN	O
of	IN	O
yoga	NN	O
will	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
(	(	O
using	VBG	O
general	JJ	O
estimating	VBG	O
equations	NNS	O
-	:	O
GEE	NNP	O
)	)	O
within	IN	O
an	DT	O
intention-to-treat	JJ	O
context	NN	O
.	.	O

If	IN	O
yoga	NN	O
is	VBZ	O
found	VBN	O
effective	JJ	O
,	,	O
further	JJ	O
analyses	NNS	O
will	MD	O
explore	VB	O
whether	IN	O
yoga	NN	O
's	POS	O
benefits	NNS	O
are	VBP	O
attributable	JJ	O
to	TO	O
physical	JJ	O
,	,	O
psychological	JJ	O
and/or	NN	O
physiological	JJ	O
factors	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
will	MD	O
provide	VB	O
the	DT	O
clearest	JJS	O
evidence	NN	O
to	TO	O
date	NN	O
about	IN	O
the	DT	O
value	NN	O
of	IN	O
yoga	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
option	NN	O
for	IN	O
treating	VBG	O
chronic	JJ	Pain
back	RB	Pain
pain	NN	Pain
,	,	O
and	CC	O
if	IN	O
the	DT	O
results	NNS	O
are	VBP	O
positive	JJ	O
,	,	O
will	MD	O
help	VB	O
focus	VB	O
future	JJ	O
,	,	O
more	RBR	O
in-depth	JJ	O
,	,	O
research	NN	O
on	IN	O
the	DT	O
most	RBS	O
promising	JJ	O
potential	JJ	O
mechanisms	NN	O
of	IN	O
action	NN	O
identified	VBN	O
by	IN	O
this	DT	O
study	NN	O
.	.	O

Thrombin-activatable	JJ	O
fibrinolysis	NN	O
inhibitor	NN	O
in	IN	O
hypothyroidism	NN	O
and	CC	O
hyperthyroxinaemia	NN	O
.	.	O

Endocrine	JJ	O
disorders	NNS	O
affect	VBP	O
both	DT	O
the	DT	O
coagulation	NN	O
and	CC	O
fibrinolytic	JJ	O
systems	NNS	O
,	,	O
and	CC	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O

Thrombin-activatable	JJ	O
fibrinolysis	NN	O
inhibitor	NN	O
(	(	O
TAFI	NNP	O
)	)	O
is	VBZ	O
a	DT	O
link	NN	O
between	IN	O
coagulation	NN	O
and	CC	O
the	DT	O
fibrinolytic	JJ	O
system	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
thyroid	NN	O
hormone	NN	O
excess	NN	O
and	CC	O
deficiency	NN	O
on	IN	O
TAFI	NNP	O
levels	NNS	O
and	CC	O
function	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hyperthyroxinemia	NN	O
on	IN	O
TAFI	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
levothyroxine	NN	O
or	CC	O
no	DT	O
medication	NN	O
for	IN	O
14	CD	O
days	NNS	O
in	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hypothyroidism	NN	O
on	IN	O
TAFI	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
multicentre	JJ	O
observational	JJ	O
cohort	NN	O
study	NN	O
.	.	O

Blood	NNP	O
was	VBD	O
drawn	VBN	O
before	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
hypothyroidism	NN	O
and	CC	O
when	WRB	O
euthyroidism	NN	O
was	VBD	O
achieved	VBN	O
.	.	O

Plasma	NNP	Physical
clot-lysis	NN	Physical
times	NNS	Physical
,	,	O
activated	VBD	Physical
TAFI	NNP	Physical
(	(	Physical
TAFIa	NNP	Physical
)	)	Physical
-dependent	NN	Physical
prolongation	NN	Physical
of	IN	Physical
clot-lysis	NN	Physical
and	CC	O
TAFI	NNP	Physical
levels	NNS	Physical
were	VBD	O
measured	VBN	O
.	.	O

Thyroid	NNP	Physical
hormone	NN	Physical
excess	NN	Physical
resulted	VBD	O
in	IN	O
a	DT	O
hypofibrinolytic	JJ	Physical
condition	NN	Physical
and	CC	O
in	IN	O
an	DT	O
enhanced	JJ	O
TAFIa-dependent	JJ	Physical
prolongation	NN	Physical
of	IN	Physical
clot	NN	Physical
lysis	NN	Physical
.	.	O

A	DT	O
trend	NN	O
towards	NNS	O
decreased	VBD	Physical
plasma	JJ	Physical
TAFI	NNP	Physical
levels	NNS	Physical
was	VBD	O
observed	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
used	VBD	O
levothyroxine	NN	O
.	.	O

Hypothyroidism	NNP	O
resulted	VBD	O
in	IN	O
hyperfibrinolysis	NN	Physical
and	CC	O
a	DT	O
reduced	JJ	Physical
TAFIa-dependent	JJ	Physical
prolongation	NN	Physical
of	IN	Physical
clot	NN	Physical
lysis	NN	Physical
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
alterations	NNS	O
of	IN	O
TAFIa-dependent	JJ	Physical
prolongation	NN	Physical
of	IN	Physical
clot	NN	Physical
lysis	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
thyroid	JJ	O
disorders	NNS	O
may	MD	O
cause	VB	O
an	DT	O
impaired	JJ	O
haemostatic	JJ	Physical
balance	NN	Physical
.	.	O

The	DT	O
disturbed	JJ	Physical
haemostatic	JJ	Physical
balance	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
hyperthyroidism	NN	O
might	MD	O
make	VB	O
them	PRP	O
prone	VB	O
to	TO	O
thrombosis	VB	O
,	,	O
while	IN	O
the	DT	O
risk	NN	O
for	IN	O
bleeding	VBG	Physical
may	MD	O
increase	VB	O
in	IN	O
patients	NNS	O
with	IN	O
hypothyroidism	NN	O
.	.	O

Single-dose	JJ	O
pharmacokinetics	NNS	O
of	IN	O
delavirdine	NN	O
mesylate	NN	O
and	CC	O
didanosine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
infection	NN	O
.	.	O

Delavirdine	NNP	O
is	VBZ	O
a	DT	O
nonnucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitor	NN	O
with	IN	O
in	IN	O
vitro	JJ	O
activity	NN	O
against	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
type	NN	O
1	CD	O
(	(	O
HIV-1	NNP	O
)	)	O
that	WDT	O
is	VBZ	O
currently	RB	O
being	VBG	O
evaluated	VBN	O
in	IN	O
combination	NN	O
regimens	NNS	O
with	IN	O
various	JJ	O
nucleoside	JJ	O
analogs	NNS	O
,	,	O
including	VBG	O
didanosine	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
pH-dependent	JJ	O
solubility	NN	O
of	IN	O
delavirdine	NN	O
,	,	O
the	DT	O
buffering	NN	O
agents	NNS	O
in	IN	O
didanosine	JJ	O
formulations	NNS	O
may	MD	O
reduce	VB	O
delavirdine	NN	O
absorption	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
potential	JJ	O
interaction	NN	O
between	IN	O
these	DT	O
agents	NNS	O
,	,	O
12	CD	O
HIV-infected	JJ	O
patients	NNS	O
(	(	O
mean	JJ	O
[	NNP	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
]	NNP	O
CD4+	NNP	O
cell	NN	O
count	NN	O
,	,	O
304	CD	O
+/-	JJ	O
213/mm3	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
three-way	JJ	O
crossover	NN	O
single-dose	JJ	O
study	NN	O
.	.	O

Didanosine	NNP	O
(	(	O
125	CD	O
to	TO	O
200	CD	O
mg	NNS	O
given	VBN	O
as	IN	O
buffered	JJ	O
tablets	NNS	O
)	)	O
and	CC	O
delavirdine	JJ	O
mesylate	NN	O
(	(	O
400	CD	O
mg	NN	O
)	)	O
pharmacokinetics	NNS	O
were	VBD	O
evaluated	VBN	O
when	WRB	O
each	DT	O
drug	NN	O
was	VBD	O
given	VBN	O
alone	RB	O
(	(	O
treatments	NNS	O
A	DT	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
when	WRB	O
the	DT	O
two	CD	O
drugs	NNS	O
were	VBD	O
given	VBN	O
concurrently	RB	O
(	(	O
treatment	NN	O
C	NNP	O
)	)	O
,	,	O
and	CC	O
when	WRB	O
didanosine	NN	O
was	VBD	O
given	VBN	O
1	CD	O
h	NN	O
after	IN	O
delavirdine	NN	O
(	(	O
treatment	NN	O
D	NNP	O
)	)	O
.	.	O

Delavirdine	NNP	Others
exposure	NN	Others
was	VBD	O
reduced	VBN	O
by	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
didanosine	NN	O
.	.	O

The	DT	O
maximum	JJ	Others
drug	NN	Others
concentration	NN	Others
in	IN	Others
serum	NN	Others
(	(	Others
Cmax	NNP	Others
)	)	Others
was	VBD	O
reduced	VBN	O
from	IN	O
7.22	CD	O
+/-	JJ	O
4.0	CD	O
to	TO	O
3.51	CD	O
+/-	JJ	O
1.9	CD	O
microM	NN	O
,	,	O
and	CC	O
the	DT	O
area	NN	Others
under	IN	Others
the	DT	Others
concentration-time	JJ	Others
curve	NN	Others
from	IN	O
0	CD	O
h	NN	O
to	TO	O
infinity	NN	O
(	(	O
AUC0	NNP	O
--	:	O
>	JJ	O
infinity	NN	O
)	)	O
was	VBD	O
reduced	VBN	O
from	IN	O
22.5	CD	O
+/-	JJ	O
14	CD	O
to	TO	O
14	CD	O
+/-	JJ	O
5.7	CD	O
microM.h	NN	O
.	.	O

The	DT	O
extent	NN	Others
of	IN	Others
N-dealkylation	NNP	Others
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
the	DT	O
ratio	NN	Others
of	IN	Others
the	DT	Others
N-dealkylated	JJ	Others
delavirdine	NN	Others
AUC0	NNP	Others
--	:	Others
>	JJ	Others
infinity	NN	Others
to	TO	O
the	DT	O
delavirdine	NN	Others
AUC0	NNP	Others
--	:	Others
>	JJ	Others
infinity	NN	Others
,	,	O
was	VBD	O
unchanged	JJ	O
across	IN	O
study	NN	O
treatments	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.708	CD	O
)	)	O
.	.	O

Reductions	NNPS	O
in	IN	O
didanosine	NN	Others
exposure	NN	Others
were	VBD	O
observed	VBN	O
during	IN	O
concurrent	JJ	O
administration	NN	O
with	IN	O
delavirdine	NN	O
with	IN	O
a	DT	O
Cmax	NNP	Others
reduction	NN	O
from	IN	O
4.65	CD	O
+/-	JJ	O
2.0	CD	O
to	TO	O
3.22	CD	O
+/-	JJ	O
0.59	CD	O
microM	NN	O
and	CC	O
an	DT	O
AUC0	NNP	O
--	:	O
>	JJ	O
infinity	NN	O
reduction	NN	O
from	IN	O
7.93	CD	O
+/-	JJ	O
3.9	CD	O
to	TO	O
6.54	CD	O
+/-	JJ	O
2.3	CD	O
microM.h	NN	O
.	.	O

Thus	RB	O
,	,	O
concurrent	JJ	O
administration	NN	O
of	IN	O
delavirdine	NN	O
and	CC	O
didanosine	NN	O
may	MD	O
reduce	VB	O
the	DT	O
AUC0	NNP	Others
--	:	Others
>	JJ	Others
infinity	NN	Others
of	IN	O
both	DT	O
drugs	NNS	O
,	,	O
although	IN	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
this	DT	O
reduction	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Administration	NN	O
of	IN	O
delavirdine	JJ	O
1	CD	O
h	NN	O
before	IN	O
didanosine	NN	O
avoided	VBD	O
the	DT	O
interaction	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
single-dose	JJ	O
nature	NN	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
these	DT	O
findings	NNS	O
require	VBP	O
further	JJ	O
evaluation	NN	O
at	IN	O
steady	JJ	O
state	NN	O
.	.	O

Removal	NN	O
of	IN	O
hypertrophied	JJ	O
anal	JJ	O
papillae	NN	O
and	CC	O
fibrous	JJ	O
anal	JJ	O
polyps	NN	O
increases	NNS	O
patient	JJ	Others
satisfaction	NN	Others
after	IN	O
anal	JJ	O
fissure	NN	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
Hypertrophied	NNP	O
anal	JJ	O
papillae	NN	O
and	CC	O
fibrous	JJ	O
anal	JJ	O
polyps	NNS	O
are	VBP	O
frequently	RB	O
found	VBN	O
in	IN	O
association	NN	O
with	IN	O
chronic	JJ	O
fissure	NN	O
in	IN	O
ano	NN	O
.	.	O

Usually	RB	O
,	,	O
no	DT	O
specific	JJ	O
attention	NN	O
is	VBZ	O
given	VBN	O
to	TO	O
them	PRP	O
and	CC	O
they	PRP	O
are	VBP	O
considered	VBN	O
normal	JJ	O
findings	NNS	O
.	.	O

The	DT	O
present	JJ	O
prospective	JJ	O
study	NN	O
was	VBD	O
aimed	VBN	O
at	IN	O
determining	VBG	O
whether	IN	O
removal	NN	O
of	IN	O
hypertrophied	JJ	O
anal	JJ	O
papillae	NN	O
and	CC	O
fibrous	JJ	O
anal	JJ	O
polyps	NNS	O
while	IN	O
dealing	VBG	O
with	IN	O
chronic	JJ	O
fissure	NN	O
in	IN	O
ano	JJ	O
confers	NNS	O
long-term	JJ	Others
benefit	NN	Others
to	TO	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Between	NNP	O
July	NNP	O
1999	CD	O
and	CC	O
December	NNP	O
2000	CD	O
,	,	O
140	CD	O
patients	NNS	O
undergoing	JJ	O
anal	JJ	O
sphincterotomy	NN	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
to	TO	O
have	VB	O
their	PRP$	O
fibrous	JJ	O
polyps	NNS	O
and	CC	O
hypertrophied	VBD	O
anal	JJ	O
papillae	NN	O
either	DT	O
removed	VBN	O
by	IN	O
radiofrequency	NN	O
surgery	NN	O
or	CC	O
left	VBN	O
intact	JJ	O
.	.	O

After	IN	O
two	CD	O
years	NNS	O
,	,	O
they	PRP	O
underwent	VBP	O
a	DT	O
detailed	JJ	O
interview	NN	Others
by	IN	Others
an	DT	Others
independent	JJ	Others
,	,	Others
masked	JJ	Others
investigator	NN	Others
.	.	Others

RESULTS	NNP	O
Overall	JJ	O
84	CD	O
%	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
polyp	NN	O
and	CC	O
papilla	NN	O
removal	NN	O
rated	VBD	O
the	DT	O
outcome	NN	O
of	IN	O
their	PRP$	O
surgery	NN	O
as	IN	O
excellent	NN	O
or	CC	O
good	JJ	O
in	IN	O
comparison	NN	O
to	TO	O
58	CD	O
%	NN	O
of	IN	O
controls	NNS	O
.	.	O

The	DT	O
mean	JJ	O
satisfaction	NN	O
grading	NN	O
was	VBD	O
9.2	CD	O
on	IN	O
a	DT	O
visual	JJ	Others
analogue	NN	Others
scale	NN	Others
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
compared	VBN	O
to	TO	O
8.1	CD	O
in	IN	O
controls	NNS	O
(	(	O
p=0.004	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Removal	NNP	O
of	IN	O
hypertrophied	JJ	O
anal	JJ	O
papillae	NN	O
and	CC	O
fibrous	JJ	O
anal	JJ	O
polyps	NNS	O
should	MD	O
be	VB	O
an	DT	O
essential	JJ	O
part	NN	O
of	IN	O
treatment	NN	O
of	IN	O
chronic	JJ	O
fissure	NN	O
in	IN	O
ano	NN	O
.	.	O

Persistence	NN	O
of	IN	O
these	DT	O
structures	NNS	O
leaves	VBZ	O
behind	IN	O
a	DT	O
sense	NN	O
of	IN	O
incomplete	JJ	O
treatment	NN	O
,	,	O
reducing	VBG	O
the	DT	O
overall	JJ	Others
satisfaction	NN	Others
on	IN	O
the	DT	O
part	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Radiofrequency	NNP	O
procedure	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
eradication	NN	O
of	IN	O
these	DT	O
concomitant	JJ	O
pathologies	NNS	O
.	.	O

Effect	NN	O
of	IN	O
laquinimod	NN	O
on	IN	O
MRI-monitored	JJ	Physical
disease	NN	Physical
activity	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
multiple	JJ	O
sclerosis	NN	O
:	:	O
a	DT	O
multicentre	NN	O
,	,	O
randomised	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
IIb	NNP	O
study	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
24-week	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
0.3	CD	O
mg	NN	O
of	IN	O
laquinimod	JJ	O
given	VBN	O
daily	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
multiple	JJ	O
sclerosis	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
reduced	VBN	O
the	DT	O
formation	NN	O
of	IN	O
active	JJ	Physical
lesions	NNS	Physical
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
effect	NN	O
of	IN	O
oral	JJ	O
daily	JJ	O
0.3	CD	O
and	CC	O
0.6	CD	O
mg	NN	O
laquinimod	NN	O
on	IN	O
MRI-monitored	JJ	Physical
disease	NN	Physical
activity	NN	O
in	IN	O
a	DT	O
36-week	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
IIb	NNP	O
study	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
done	VBN	O
in	IN	O
51	CD	O
centres	NNS	O
in	IN	O
nine	CD	O
countries	NNS	O
.	.	O

Inclusion	NN	O
criteria	NNS	O
were	VBD	O
one	CD	O
or	CC	O
more	JJR	O
relapses	NNS	O
in	IN	O
the	DT	O
year	NN	O
before	IN	O
entry	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
gadolinium	NN	Physical
enhancing	NN	Physical
(	(	Physical
GdE	NNP	Physical
)	)	Physical
lesion	NN	Physical
on	IN	O
screening	VBG	O
MRI	NNP	O
.	.	O

Of	IN	O
720	CD	O
patients	NNS	O
screened	VBD	O
,	,	O
306	CD	O
eligible	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
,	,	O
aged	VBN	O
18-50	CD	O
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
(	(	O
n=102	NN	O
)	)	O
,	,	O
laquinimod	$	O
0.3	CD	O
mg	NN	O
a	DT	O
day	NN	O
(	(	O
n=98	NN	O
)	)	O
,	,	O
or	CC	O
0.6	CD	O
mg	NNS	O
a	DT	O
day	NN	O
(	(	O
n=106	JJ	O
)	)	O
.	.	O

Brain	NNP	Physical
MRI	NNP	Physical
scans	NNS	Physical
and	CC	Physical
clinical	JJ	Physical
assessments	NNS	Physical
were	VBD	O
done	VBN	O
at	IN	O
week	NN	O
-4	NN	O
,	,	O
baseline	NN	O
,	,	O
and	CC	O
monthly	RB	O
from	IN	O
week	NN	O
12	CD	O
to	TO	O
week	NN	O
36	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
cumulative	JJ	Physical
number	NN	Physical
of	IN	Physical
GdE	NNP	Physical
lesions	NNS	Physical
at	IN	O
weeks	NNS	O
24	CD	O
,	,	O
28	CD	O
,	,	O
32	CD	O
,	,	O
and	CC	O
36	CD	O
.	.	O

The	DT	O
principal	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
done	VBN	O
on	IN	O
the	DT	O
intention-to-treat	JJ	O
cohort	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00349193	NNP	O
.	.	O

FINDINGS	NNP	O
Compared	NNP	O
with	IN	O
placebo	NN	O
,	,	O
treatment	NN	O
with	IN	O
laquinimod	JJ	O
0.6	CD	O
mg	JJ	O
per	IN	O
day	NN	O
showed	VBD	O
a	DT	O
40.4	CD	O
%	NN	O
reduction	NN	O
of	IN	O
the	DT	O
baseline	NN	O
adjusted	VBN	O
mean	JJ	O
cumulative	JJ	Physical
number	NN	Physical
of	IN	Physical
GdE	NNP	Physical
lesions	NNS	Physical
per	IN	Physical
scan	NN	Physical
on	IN	O
the	DT	O
last	JJ	O
four	CD	O
scans	NNS	O
(	(	O
simple	JJ	O
means	VBZ	O
4.2	CD	O
[	NN	O
SD	NNP	O
9.2	CD	O
]	NNP	O
vs	NN	O
2.6	CD	O
[	NN	O
5.3	CD	O
]	NN	O
,	,	O
p=0.0048	NN	O
)	)	O
;	:	O
treatment	NN	O
with	IN	O
0.3	CD	O
mg	NNS	O
per	IN	O
day	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
(	(	O
3.9	CD	O
[	RB	O
5.5	CD	O
]	JJ	O
vs	NN	O
placebo	NN	O
,	,	O
p=0.6740	NN	O
)	)	O
.	.	O

Both	DT	O
doses	NNS	O
of	IN	O
laquinimod	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
some	DT	O
transient	NN	O
and	CC	O
dose-dependent	JJ	O
increases	NNS	O
in	IN	O
liver	NN	Physical
enzymes	NNS	Physical
.	.	O

A	DT	O
case	NN	O
of	IN	O
Budd-Chiari	NNP	Adverseeffect
syndrome-ie	NN	Adverseeffect
,	,	O
a	DT	O
thrombotic	JJ	Physical
venous	JJ	Physical
outflow	JJ	Physical
obstruction	NN	Adverseeffect
of	IN	Adverseeffect
the	DT	Adverseeffect
liver-occurred	JJ	Adverseeffect
after	IN	O
1	CD	O
month	NN	O
of	IN	O
exposure	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
underlying	JJ	O
hypercoagulability	NN	O
who	WP	O
received	VBD	O
0.6	CD	O
mg	NN	O
laquinimod	NN	O
.	.	O

Anticoagulant	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
decline	NN	O
of	IN	O
liver	NN	Physical
enzymes	NNS	Physical
to	TO	O
normal	JJ	O
without	IN	O
any	DT	O
clinical	JJ	O
signs	NNS	O
of	IN	O
hepatic	JJ	Physical
decompensation	NN	Physical
.	.	O

INTERPRETATION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
relapsing-remitting	JJ	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
0.6	CD	O
mg	NNS	O
per	IN	O
day	NN	O
laquinimod	NN	O
significantly	RB	O
reduced	VBN	O
MRI-measured	JJ	Physical
disease	NN	Physical
activity	NN	Physical
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Protection	NN	Physical
of	IN	O
man	NN	O
from	IN	O
natural	JJ	Physical
infection	NN	Physical
with	IN	Physical
influenza	JJ	Physical
A2	NNP	Physical
Hong	NNP	Physical
Kong	NNP	Physical
virus	NN	Physical
by	IN	O
amantadine	NN	O
:	:	O
a	DT	O
controlled	JJ	O
field	NN	O
trial	NN	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
of	IN	O
amantadine	NN	O
in	IN	O
doses	NNS	O
of	IN	O
100	CD	O
mg.	NN	O
twice	RB	O
a	DT	O
day	NN	O
offered	VBN	O
statistically	RB	O
significant	JJ	O
protection	NN	Physical
against	IN	Physical
influenza	JJ	Physical
A2	NNP	Physical
infection	NN	Physical
in	IN	O
a	DT	O
double-blind	JJ	O
field	NN	O
trial	NN	O
involving	VBG	O
391	CD	O
medical	JJ	O
student	NN	O
volunteers	NNS	O
during	IN	O
the	DT	O
influenza	JJ	O
A2	NNP	O
Hong	NNP	O
Kong	NNP	O
epidemic	VBP	O
in	IN	O
Helsinki	NNP	O
in	IN	O
the	DT	O
winter	NN	O
of	IN	O
1969	CD	O
.	.	O

Serologically	RB	Physical
verified	JJ	Physical
influenza	NN	Physical
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
complement	JJ	Physical
fixation	NN	Physical
and/or	NN	Physical
haemagglutination	NN	Physical
inhibition	NN	Physical
,	,	O
occurred	VBD	O
in	IN	O
27	CD	O
out	IN	O
of	IN	O
192	CD	O
students	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
against	IN	O
57	CD	O
out	IN	O
of	IN	O
199	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
giving	VBG	O
a	DT	O
protection	NN	O
rate	NN	O
of	IN	O
52	CD	O
%	NN	O
.	.	O

Cimetidine	NNP	O
as	IN	O
an	DT	O
immunomodulator	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
herpes	NNS	O
zoster	NN	O
.	.	O

As	IN	O
there	EX	O
is	VBZ	O
evidence	NN	O
of	IN	O
a	DT	O
possible	JJ	O
immunoregulatory	JJ	O
role	NN	O
for	IN	O
H2-histamine	NNP	O
receptor	NN	O
antagonists	NNS	O
,	,	O
we	PRP	O
carried	VBD	O
out	RP	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
in	IN	O
vivo	NN	O
and	CC	O
in	IN	O
vitro	JJ	O
effect	NN	O
of	IN	O
cimetidine	NN	O
,	,	O
an	DT	O
H2-blocker	NNP	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
herpes	NNS	O
zoster	JJ	O
infection	NN	O
.	.	O

Cimetidine	NNP	O
treatment	NN	O
shortened	VBD	O
the	DT	O
median	JJ	Pain
interval	NN	Pain
until	IN	Pain
the	DT	Pain
first	JJ	Pain
decrease	NN	Pain
in	IN	Pain
pain	NN	Pain
,	,	O
the	DT	O
median	JJ	Pain
interval	NN	Pain
until	IN	Pain
the	DT	Pain
complete	JJ	Pain
resolution	NN	Pain
of	IN	Pain
pain	NN	Pain
and	CC	O
promoted	VBN	O
faster	RBR	Pain
complete	JJ	Physical
healing	NN	Physical
of	IN	Physical
skin	NN	Physical
lesions	NNS	Physical
than	IN	O
symptomatic	JJ	O
treatment	NN	O
.	.	O

The	DT	O
immunological	JJ	O
trends	NNS	O
observed	VBN	O
in	IN	O
vitro	JJ	O
support	NN	O
an	DT	O
important	JJ	O
role	NN	O
for	IN	O
histamine	NN	O
in	IN	O
the	DT	O
induction	NN	O
of	IN	O
immunosuppression	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
response	NN	O
to	TO	O
the	DT	O
mitogen	NN	O
phytohemagglutinin	NN	O
.	.	O

This	DT	O
effect	NN	O
of	IN	O
histamine	NN	O
was	VBD	O
antagonized	VBN	O
by	IN	O
cimetidine	NN	O
.	.	O

The	DT	O
utility	NN	O
of	IN	O
laparoscopy	NN	O
in	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
appendicitis	NN	O
in	IN	O
women	NNS	O
of	IN	O
reproductive	JJ	O
age	NN	O
.	.	O

AIM	NNP	O
To	TO	O
see	VB	O
whether	IN	O
laparoscopy	NN	O
improves	VBZ	O
the	DT	O
accuracy	NN	O
of	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
appendicitis	NN	O
in	IN	O
women	NNS	O
of	IN	O
reproductive	JJ	O
age	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
what	WP	O
the	DT	O
long-term	JJ	O
sequelae	NN	O
are	VBP	O
of	IN	O
not	RB	O
removing	VBG	O
an	DT	O
appendix	NN	O
deemed	VBN	O
at	IN	O
laparoscopy	NN	O
to	TO	O
be	VB	O
normal	JJ	O
.	.	O

METHOD	NNP	O
The	DT	O
initial	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
during	IN	O
1991-1992	JJ	O
.	.	O

Female	JJ	O
patients	NNS	O
between	IN	O
16	CD	O
and	CC	O
45	CD	O
years	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
once	RB	O
a	DT	O
clinical	JJ	O
decision	NN	O
had	VBD	O
been	VBN	O
made	VBN	O
to	TO	O
perform	VB	O
an	DT	O
appendicectomy	NN	O
for	IN	O
suspected	JJ	O
acute	JJ	O
appendicitis	NN	O
.	.	O

Following	VBG	O
consent	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
had	VBD	O
open	JJ	O
appendicectomy	NN	O
,	,	O
as	IN	O
planned	VBN	O
.	.	O

The	DT	O
other	JJ	O
group	NN	O
had	VBD	O
laparoscopy	VBN	O
,	,	O
followed	VBN	O
by	IN	O
open	JJ	O
appendicectomy	NN	O
only	RB	O
if	IN	O
the	DT	O
appendix	NN	O
was	VBD	O
seen	VBN	O
to	TO	O
be	VB	O
inflamed	VBN	O
or	CC	O
was	VBD	O
not	RB	O
visualized	VBN	O
.	.	O

The	DT	O
end	NN	O
points	NNS	O
for	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
clinical	JJ	O
outcomes	NNS	O
of	IN	O
all	DT	O
patients	NNS	O
,	,	O
and	CC	O
the	DT	O
results	NNS	O
of	IN	O
histology	NN	Others
,	,	O
where	WRB	O
appropriate	NN	O
.	.	O

An	DT	O
attempt	NN	O
was	VBD	O
made	VBN	O
to	TO	O
contact	VB	O
all	DT	O
patients	NNS	O
at	IN	O
10	CD	O
years	NNS	O
to	TO	O
determine	VB	O
whether	IN	O
they	PRP	O
had	VBD	O
had	VBN	O
a	DT	O
subsequent	JJ	O
appendicectomy	NN	O
,	,	O
or	CC	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
with	IN	O
another	DT	O
abdominal	JJ	O
condition	NN	O
that	WDT	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
the	DT	O
initial	JJ	O
presentation	NN	O
in	IN	O
1991-1992	JJ	O
.	.	O

RESULTS	NNP	O
Laparoscopic	NNP	O
assessment	NN	O
was	VBD	O
correct	JJ	O
in	IN	O
all	DT	O
cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
appendix	NN	O
was	VBD	O
visualized	VBN	O
.	.	O

Diagnostic	JJ	Others
accuracy	NN	Others
was	VBD	O
improved	VBN	O
from	IN	O
75	CD	O
%	NN	O
to	TO	O
97	CD	O
%	NN	O
.	.	O

Laparoscopy	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
no	DT	Physical
added	JJ	Physical
complications	NNS	Physical
,	,	Others
no	DT	Others
increase	NN	Others
in	IN	Others
hospital	JJ	Others
stay	NN	Others
in	IN	O
patients	NNS	O
who	WP	O
went	VBD	O
on	IN	O
to	TO	O
appendicectomy	VB	O
,	,	O
and	CC	O
a	DT	O
reduction	NN	Others
in	IN	Others
hospital	NN	Others
stay	NN	Others
for	IN	O
those	DT	O
who	WP	O
underwent	JJ	O
laparoscopy	NN	O
alone	RB	O
.	.	O

No	UH	O
patients	NNS	O
developed	VBD	O
a	DT	O
problem	NN	O
over	IN	O
the	DT	O
10-year	JJ	O
follow-up	JJ	O
period	NN	O
from	IN	O
having	VBG	O
a	DT	O
normal-looking	JJ	O
appendix	NN	O
not	RB	O
removed	VBN	O
at	IN	O
laparoscopy	NN	O
.	.	O

CONCLUSION	NNP	O
Laparoscopic	NNP	O
assessment	NN	O
of	IN	O
the	DT	O
appendix	NN	O
is	VBZ	O
reliable	JJ	O
,	,	O
and	CC	O
to	TO	O
leave	VB	O
a	DT	O
normal-looking	JJ	O
appendix	NN	O
at	IN	O
laparoscopy	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
cause	VB	O
any	DT	O
long-term	JJ	O
problems	NNS	O
.	.	O

Efficacy	NN	O
of	IN	O
intramuscular	JJ	O
oxytetracycline	NN	O
as	IN	O
a	DT	O
dry	JJ	O
cow	NN	O
treatment	NN	O
for	IN	O
Staphylococcus	NNP	O
aureus	NN	O
mastitis	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
intramuscular	JJ	O
oxytetracycline	NN	O
as	IN	O
a	DT	O
supplemental	JJ	O
dry	JJ	O
cow	NN	O
treatment	NN	O
for	IN	O
Staphylococcus	NNP	O
aureus	NN	O
mastitis	NN	O
,	,	O
37	CD	O
Holstein	NNP	O
cows	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
intracisternal	JJ	O
infusion	NN	O
with	IN	O
a	DT	O
commercial	JJ	O
preparation	NN	O
of	IN	O
cephapirin	JJ	O
benzathine	NN	O
at	IN	O
drying	VBG	O
off	RP	O
(	(	O
20	CD	O
cows	NNS	O
)	)	O
and	CC	O
infusion	NN	O
with	IN	O
cephapirin	JJ	O
benzathine	NN	O
at	IN	O
drying	VBG	O
off	RP	O
and	CC	O
intramuscular	JJ	O
oxytetracycline	NN	O
at	IN	O
11	CD	O
mg/kg	NNS	O
once	RB	O
daily	RB	O
on	IN	O
d	NN	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
10	CD	O
after	IN	O
drying	VBG	O
off	RB	O
(	(	O
17	CD	O
cows	NNS	O
)	)	O
.	.	O

Milk	NN	O
samples	NNS	O
collected	VBD	O
7	CD	O
,	,	O
14	CD	O
,	,	O
30	CD	O
,	,	O
and	CC	O
60	CD	O
d	NN	O
after	IN	O
calving	VBG	O
were	VBD	O
plated	VBN	O
for	IN	O
bacterial	JJ	O
isolation	NN	O
within	IN	O
24	CD	O
h	NN	O
after	IN	O
collection	NN	O
and	CC	O
after	IN	O
24	CD	O
to	TO	O
72	CD	O
h	NN	O
of	IN	O
storage	NN	O
at	IN	O
-20	NNP	O
degrees	NNS	O
C.	NNP	O
Quarters	NNS	O
were	VBD	O
defined	VBN	O
as	IN	O
infected	JJ	O
if	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
fresh	JJ	O
and	CC	O
frozen	JJ	O
cultures	NNS	O
from	IN	O
any	DT	O
one	CD	O
sample	NN	O
collected	VBD	O
before	IN	O
drying	VBG	O
off	RP	O
.	.	O

An	DT	O
infected	JJ	O
quarter	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
cured	JJ	O
if	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
not	RB	O
isolated	VBN	O
from	IN	O
the	DT	O
fresh	JJ	O
or	CC	O
frozen	JJ	O
culture	NN	O
from	IN	O
milk	NN	O
samples	NNS	O
obtained	VBD	O
following	VBG	O
calving	NN	O
.	.	O

The	DT	O
rate	NN	Others
of	IN	Others
cure	NN	Others
by	IN	O
30	CD	O
d	NN	O
after	IN	O
calving	VBG	O
for	IN	O
systemic	JJ	O
oxytetracycline	NN	O
(	(	O
in	IN	O
combination	NN	O
with	IN	O
cephapirin	JJ	O
treatment	NN	O
)	)	O
was	VBD	O
29.4	CD	O
%	NN	O
for	IN	O
infected	JJ	O
quarters	NNS	O
and	CC	O
29.4	CD	O
%	NN	O
for	IN	O
infected	JJ	O
cows	NNS	O
,	,	O
compared	VBN	O
with	IN	O
27.5	CD	O
and	CC	O
25.0	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
cephapirin	NN	O
treatment	NN	O
only	RB	O
.	.	O

Results	NNS	O
including	VBG	O
the	DT	O
culture	NN	O
at	IN	O
60	CD	O
d	NN	O
after	IN	O
calving	VBG	O
were	VBD	O
21.2	CD	O
and	CC	O
22.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
combination	NN	O
therapy	NN	O
and	CC	O
cephapirin	NN	O
therapy	NN	O
only	RB	O
.	.	O

Systemic	NNP	O
oxytetracycline	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
intramammary	JJ	O
dry	JJ	O
cow	NN	O
treatment	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
the	DT	O
rate	NN	Others
of	IN	Others
cure	NN	Others
for	IN	O
S.	NNP	O
aureus	JJ	O
mastitis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
canalith	NN	O
repositioning	NN	O
procedure	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	Others
and	CC	Others
complications	NNS	Physical
of	IN	Others
our	PRP$	Others
adaptation	NN	Others
of	IN	Others
the	DT	Others
canalith	NN	Others
repositioning	NN	Others
procedure	NN	Others
(	(	Others
CRP	NNP	Others
)	)	Others
with	IN	O
the	DT	O
expectation	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
a	DT	O
neurotological	JJ	O
clinic	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

METHODS	NNP	O
Fifty-eight	JJ	O
patients	NNS	O
with	IN	O
posterior	JJ	O
benign	NN	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
using	VBG	O
a	DT	O
block	NN	O
of	IN	O
four	CD	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
modified	JJ	O
CRP	NNP	O
technique	NN	O
until	IN	O
the	DT	O
nystagmus	NN	O
disappeared	VBD	O
.	.	O

A	DT	O
mastoid	JJ	O
oscillator	NN	O
was	VBD	O
not	RB	O
used	VBN	O
,	,	O
nor	CC	O
were	VBD	O
any	DT	O
instructions	NNS	O
given	VBN	O
for	IN	O
patients	NNS	O
after	IN	O
the	DT	O
maneuver	NN	O
.	.	O

Both	DT	O
groups	NNS	O
recorded	VBD	O
the	DT	O
daily	JJ	Physical
grading	NN	Physical
of	IN	Physical
symptoms	NNS	Physical
and	CC	Physical
the	DT	Physical
amount	NN	Physical
of	IN	Physical
anti-vertiginous	JJ	Physical
drugs	NNS	Physical
(	(	Physical
cinnarizine	NN	Physical
)	)	Physical
taken	VBN	Physical
.	.	O

Objective	JJ	Others
and	CC	Others
subjective	JJ	Others
assessments	NNS	Others
were	VBD	O
made	VBN	O
weekly	RB	O
until	IN	O
the	DT	O
nystagmus	NN	Physical
disappeared	VBD	O
or	CC	O
until	IN	O
4	CD	O
weeks	NNS	O
had	VBD	O
passed	VBN	O
since	IN	O
treatment	NN	O
began	VBD	O
.	.	O

RESULTS	VB	O
The	DT	O
rates	NNS	Others
of	IN	Others
effectiveness	NN	Others
of	IN	Others
CRP	NNP	Others
treatment	NN	Others
and	CC	O
the	DT	O
control	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
were	VBD	O
75.9	CD	O
%	NN	O
and	CC	O
48.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
treatment	NN	O
outcomes	NNS	O
of	IN	O
the	DT	O
CRP	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=.03	NNP	O
)	)	O
.	.	O

The	DT	O
CRP	NNP	O
group	NN	O
used	VBD	Others
significantly	RB	Others
fewer	JJR	Others
drugs	NNS	Others
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

Complications	NNS	O
in	IN	O
the	DT	O
CRP	NNP	O
group	NN	O
,	,	O
such	JJ	O
as	IN	O
lateral	JJ	Adverseeffect
canalithiasis	NN	Adverseeffect
and	CC	Adverseeffect
fainting	NN	Adverseeffect
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
13.8	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CRP	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
expectation	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
insofar	NN	O
as	IN	O
it	PRP	O
provided	VBD	O
faster	RBR	O
recovery	NN	Physical
and	CC	O
required	VBD	O
less	JJR	O
dependence	NN	Mental
on	IN	Mental
medication	NN	Mental
.	.	Mental

Complications	NNS	Physical
of	IN	O
CRP	NNP	O
were	VBD	O
limited	VBN	O
to	TO	O
13.8	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Dose-response	JJ	O
relationship	NN	O
of	IN	O
sertindole	NN	O
and	CC	O
haloperidol	NN	O
using	VBG	O
the	DT	O
pharmacopsychometric	JJ	O
triangle	NN	O
.	.	O

OBJECTIVE	NNP	O
Renewed	NNP	O
insight	VBD	O
into	IN	O
dose-related	JJ	O
effects	NNS	O
of	IN	O
sertindole	NN	O
and	CC	O
haloperidol	NN	O
was	VBD	O
sought	VBN	O
by	IN	O
re-analysing	NN	O
published	VBN	O
data	NNS	O
for	IN	O
antipsychotic	JJ	O
effect	NN	O
,	,	O
extrapyramidal	JJ	O
effect	NN	O
,	,	O
and	CC	O
patient	JJ	O
wellbeing	VBG	O
-	:	O
i.e.	NN	O
,	,	O
the	DT	O
important	JJ	O
pharmacopsychometric	JJ	O
triangle	NN	O
domains	NNS	O
.	.	O

METHOD	NNP	O
Selected	NNP	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
(	(	O
PANSS	NNP	O
)	)	O
subscales	NNS	O
and	CC	O
the	DT	O
Simpson-Angus	JJ	O
scale	NN	O
were	VBD	O
tested	VBN	O
for	IN	O
validity	NN	O
.	.	O

Standardized	JJ	O
effect	NN	O
sizes	VBZ	O
[	NNP	O
last	JJ	O
observation	NN	O
carried	VBD	O
forward	RB	O
(	(	O
LOCF	NNP	O
)	)	O
]	NN	O
at	IN	O
endpoint	NN	O
were	VBD	O
calculated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
scales	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
valid	JJ	O
instruments	NNS	O
.	.	O

The	DT	O
PANSS	NNP	O
(	(	O
11	CD	O
)	)	O
psychotic	JJ	O
subscale	NN	O
showed	VBD	O
clinically	RB	O
significant	JJ	O
effect	NN	Others
sizes	NNS	Others
for	IN	O
all	DT	O
doses	NNS	O
of	IN	O
sertindole	NN	O
(	(	O
12	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
24	CD	O
mg	NN	O
)	)	O
and	CC	O
haloperidol	NN	O
(	(	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
16	CD	O
mg	NN	O
)	)	O
.	.	O

Extrapyramidal	JJ	Others
effects	NNS	Others
were	VBD	O
evident	JJ	O
for	IN	O
all	DT	O
doses	NNS	O
of	IN	O
haloperidol	NN	O
,	,	O
but	CC	O
absent	NN	O
for	IN	O
the	DT	O
lower	JJR	O
doses	NNS	O
of	IN	O
sertindole	NN	O
.	.	O

The	DT	O
PANSS	NNP	O
(	(	O
6	CD	O
)	)	O
depression	NN	O
subscale	NN	O
,	,	O
a	DT	O
proxy	JJ	O
measure	NN	O
of	IN	O
quality	NN	Others
of	IN	Others
life	NN	Others
,	,	O
showed	VBD	O
a	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
for	IN	O
sertindole	JJ	O
20	CD	O
mg	NN	O
and	CC	O
no	DT	O
effect	NN	O
for	IN	O
haloperidol	NN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
re-analysis	NN	O
confirmed	VBD	O
the	DT	O
antipsychotic	JJ	O
effect	NN	O
and	CC	O
absence	NN	O
of	IN	O
extrapyramidal	JJ	O
effects	NNS	O
for	IN	O
sertindole	NN	O
and	CC	O
,	,	O
in	IN	O
addition	NN	O
,	,	O
showed	VBD	O
a	DT	O
clinically	RB	O
significant	JJ	O
antidepressant	JJ	O
effect	NN	O
.	.	O

A	DT	O
profile	NN	O
for	IN	O
bipolar	JJ	O
states	NNS	O
emerged	VBD	O
.	.	O

Effects	NNS	O
of	IN	O
misoprostol	NN	Physical
on	IN	O
human	JJ	O
circulation	NN	O
.	.	O

Prostaglandins	NNP	O
(	(	O
PGs	NNP	O
)	)	O
of	IN	O
the	DT	O
E-type	NNP	O
are	VBP	O
potent	JJ	O
vasodilators	NNS	O
in	IN	O
most	JJS	O
species	NNS	O
and	CC	O
in	IN	O
most	JJS	O
vascular	JJ	O
beds	NNS	O
.	.	O

However	RB	O
,	,	O
vasoconstrictor	JJ	O
effects	NNS	O
of	IN	O
PGEs	NNP	O
have	VBP	O
also	RB	O
been	VBN	O
noted	VBN	O
at	IN	O
selected	VBN	O
sites	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
misoprostol	NN	Physical
,	,	O
a	DT	O
PGE1	NNP	O
analog	NN	O
with	IN	O
antiulcer	NN	O
activity	NN	O
,	,	O
on	IN	O
the	DT	O
human	JJ	O
cardiovascular	NN	O
system	NN	O
.	.	O

Twenty	NNP	O
healthy	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
.	.	O

Following	VBG	O
a	DT	O
12	CD	O
hour	NN	O
fast	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
light	JJ	O
reflex	JJ	O
plethysmography	NN	O
of	IN	O
the	DT	O
finger	NN	O
,	,	O
resting	VBG	O
blood	NN	O
flow	NN	O
volume	NN	O
in	IN	O
the	DT	O
lower	JJR	O
arm	NN	O
and	CC	O
leg	NN	O
and	CC	O
peripheral	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
were	VBD	O
measured	VBN	O
at	IN	O
10	CD	O
min	NN	O
.	.	O

intervals	NNS	O
for	IN	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
drug	NN	O
administration	NN	O
,	,	O
to	TO	O
permit	VB	O
calculating	VBG	O
baseline	NN	O
values	NNS	O
.	.	O

Misoprostol	NNP	O
(	(	O
400	CD	O
mcg	NN	O
)	)	O
or	CC	O
its	PRP$	O
matching	JJ	O
placebo	NN	O
were	VBD	O
administered	VBN	O
orally	RB	O
,	,	O
and	CC	O
the	DT	O
measurements	NNS	O
were	VBD	O
repeated	VBN	O
at	IN	O
10	CD	O
min	NN	O
.	.	O

intervals	NNS	O
over	IN	O
the	DT	O
next	JJ	O
2	CD	O
hours	NNS	O
.	.	O

A	DT	O
decrease	NN	O
in	IN	O
leg	NN	Physical
blood	NN	Physical
flow	NN	Physical
volume	NN	Physical
and	CC	O
a	DT	O
corresponding	JJ	Physical
increase	NN	Physical
in	IN	Physical
leg	JJ	Physical
peripheral	JJ	Physical
vascular	JJ	Physical
resistance	NN	Physical
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
misoprostol	NN	O
group	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
in	IN	O
heart	NN	Physical
rate	NN	Physical
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
was	VBD	O
also	RB	O
noted	VBN	O
.	.	O

These	DT	O
small	JJ	O
changes	NNS	O
were	VBD	O
not	RB	O
considered	VBN	O
to	TO	O
be	VB	O
of	IN	O
clinical	JJ	O
importance	NN	O
.	.	O

No	DT	O
adverse	JJ	Physical
experiences	NNS	Physical
were	VBD	O
reported	VBN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
misoprostol	NN	O
(	(	O
400	CD	O
mcg	NN	O
)	)	O
has	VBZ	O
no	DT	O
clinically	RB	O
significant	JJ	O
vasoconstrictive	JJ	Physical
or	CC	Physical
vasodilative	JJ	Physical
properties	NNS	O
in	IN	O
man	NN	O
.	.	O

Anti-IgG	JJ	O
antibodies	NNS	O
during	IN	O
immunotherapy	NN	O
with	IN	O
purified	JJ	O
grass	NN	O
pollen	NN	O
extracts	NNS	O
.	.	O

In	IN	O
a	DT	O
double	JJ	O
blind	NN	O
study	NN	O
40	CD	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
specific	JJ	O
immunotherapy	NN	O
(	(	O
hyposensitization	NN	O
)	)	O
with	IN	O
partially	RB	O
purified	VBN	O
timothy	JJ	O
extract	NN	O
or	CC	O
two	CD	O
timothy	JJ	O
major	JJ	O
allergens	NNS	O
19	CD	O
,	,	O
25	CD	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
typical	JJ	O
grass	NN	O
pollen	NN	O
hay	NN	O
fever	NN	O
,	,	O
in	IN	O
27	CD	O
%	NN	O
associated	VBN	O
with	IN	O
grass	NN	O
pollen	NN	O
asthma	NN	O
and	CC	O
in	IN	O
13	CD	O
%	NN	O
with	IN	O
birch	NN	O
pollen	NN	O
allergy	NN	O
.	.	O

Serum	NNP	Physical
IgG	NNP	Physical
anti-IgG	JJ	Physical
antibodies	NNS	Physical
were	VBD	O
determined	VBN	O
after	IN	O
dithiothreitol	JJ	O
treatment	NN	O
.	.	O

Before	IN	O
hyposensitization	NN	O
,	,	O
IgG	NNP	Physical
anti-IgG	JJ	Physical
titres	NNS	Physical
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
9	CD	O
were	VBD	O
demonstrated	VBN	O
in	IN	O
45	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

During	IN	O
hyposensitization	NN	O
IgG	NNP	Physical
anti-IgG	NN	Physical
titres	NNS	Physical
showed	VBD	O
a	DT	O
slight	JJ	O
initial	JJ	O
increase	NN	O
followed	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
below	IN	O
pretreatment	JJ	O
level	NN	O
.	.	O

Neither	CC	O
increase	VB	O
nor	CC	O
decrease	VB	O
was	VBD	O
statistically	RB	O
significant	JJ	O
.	.	O

Reactions	NNS	Physical
to	TO	Physical
rabbit	VB	Physical
IgG	NNP	Physical
F	NNP	Physical
(	(	Physical
ab	IN	Physical
'	POS	Physical
)	)	Physical
2	CD	Physical
fractions	NNS	O
were	VBD	O
only	RB	O
obtained	VBN	O
during	IN	O
hyposensitization	NN	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
anti-IgG	JJ	Physical
antibodies	NNS	Physical
did	VBD	O
no	DT	O
correlate	NN	O
with	IN	O
symptoms	NNS	Physical
,	,	O
side	NN	Adverseeffect
effects	NNS	Adverseeffect
,	,	Adverseeffect
or	CC	O
the	DT	Physical
level	NN	Physical
of	IN	Physical
allergen-specific	JJ	Physical
IgG	NNP	Physical
.	.	O

In	IN	O
a	DT	O
previous	JJ	O
study	NN	O
it	PRP	O
was	VBD	O
demonstrated	VBN	O
that	IN	O
patients	NNS	O
with	IN	O
multiallergy	JJ	O
hyposensitized	VBN	O
with	IN	O
combined	JJ	O
allergen	NN	O
extracts	NNS	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
IgG	NNP	Physical
anti-IgG	JJ	Physical
titres	NNS	Physical
during	IN	O
treatment	NN	O
.	.	O

The	DT	O
increase	NN	O
failed	VBD	O
to	TO	O
appear	VB	O
in	IN	O
the	DT	O
present	JJ	O
patients	NNS	O
allergic	VBZ	O
only	RB	O
to	TO	O
pollen	VB	O
and	CC	O
treated	VBN	O
with	IN	O
purified	JJ	O
allergen	NN	O
extracts	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
suggested	VBN	O
that	IN	O
a	DT	O
multiallergic	JJ	O
condition	NN	O
and	CC	O
the	DT	O
combination	NN	O
and/or	JJ	O
purification	NN	O
of	IN	O
allergen	NN	O
extracts	NNS	O
administered	VBN	O
during	IN	O
hyposensitization	NN	O
may	MD	O
influence	VB	O
the	DT	O
production	NN	O
of	IN	O
IgG	NNP	Physical
anti-	JJ	Physical
IgG	NNP	Physical
antibodies	NNS	Physical
.	.	O

RAB-plate	JJ	O
versus	NN	O
sliding	VBG	O
hip	NN	O
screw	NN	O
for	IN	O
unstable	JJ	O
trochanteric	JJ	O
hip	NN	O
fractures	NNS	O
:	:	O
stability	NN	O
of	IN	O
the	DT	O
fixation	NN	O
and	CC	O
modes	NNS	O
of	IN	O
failure	NN	O
--	:	O
radiographic	JJ	O
analysis	NN	O
of	IN	O
218	CD	O
fractures	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
sliding	VBG	O
hip	NN	O
screw	NN	O
has	VBZ	O
gained	VBN	O
considerable	JJ	O
acceptance	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
unstable	JJ	O
trochanteric	JJ	O
fractures	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
new	JJ	O
type	NN	O
of	IN	O
120	CD	O
degrees	NNS	O
fixed	VBN	O
angle	JJ	O
blade-plate	NN	O
with	IN	O
a	DT	O
buttress	NN	O
rod	NN	O
(	(	O
RAB-plate	NNP	O
)	)	O
showed	VBD	O
encouraging	JJ	O
clinical	JJ	O
results	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	JJ	O
stability	NN	O
of	IN	O
fixation	NN	O
and	CC	O
analyze	JJ	O
modes	NNS	O
of	IN	O
failure	NN	O
in	IN	O
unstable	JJ	O
trochanteric	JJ	O
hip	NN	O
fractures	NNS	O
treated	VBN	O
with	IN	O
these	DT	O
devices	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
retrospective	JJ	O
radiographic	JJ	O
review	NN	O
of	IN	O
218	CD	O
unstable	JJ	O
fractures	NNS	O
was	VBD	O
performed	VBN	O
.	.	O

Linear	JJ	O
and	CC	O
angular	JJ	O
displacements	NNS	O
of	IN	O
the	DT	O
major	JJ	O
fragments	NNS	O
and	CC	O
implant	JJ	Physical
migration	NN	Physical
into	IN	Physical
the	DT	Physical
femoral	JJ	Physical
head	NN	Physical
during	IN	O
healing	VBG	O
were	VBD	O
assessed	VBN	O
.	.	O

Additionally	RB	O
,	,	O
adequacy	NN	O
of	IN	O
the	DT	O
reduction	NN	O
and	CC	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
implant	NN	O
within	IN	O
the	DT	O
femoral	JJ	O
head	NN	O
as	IN	O
predictors	NNS	O
of	IN	O
fixation	NN	O
failure	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
postreduction	NN	O
neck-shaft	JJ	O
angle	NN	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
fractures	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
incidence	NN	O
of	IN	O
varus	NN	O
angulation	NN	O
by	IN	O
10	CD	O
degrees	NNS	O
or	CC	O
more	JJR	O
by	IN	O
the	DT	O
completion	NN	O
of	IN	O
healing	VBG	O
among	IN	O
fractures	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
sliding	VBG	O
hip	NN	O
screw	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
vertical	JJ	Physical
migration	NN	Physical
of	IN	Physical
the	DT	Physical
device	NN	Physical
into	IN	Physical
the	DT	Physical
femoral	JJ	Physical
head	NN	Physical
between	IN	O
the	DT	O
implants	NNS	O
used	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.3	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
relationship	NN	O
between	IN	O
failure	NN	O
of	IN	O
the	DT	O
fixation	NN	O
and	CC	O
varus	NN	O
reduction	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
screw/neck	NN	O
angle	NN	O
deviation	NN	O
more	JJR	O
than	IN	O
20	CD	O
degrees	NNS	O
in	IN	O
the	DT	O
lateral	JJ	O
projection	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
or	CC	O
if	IN	O
the	DT	O
implant	NN	O
was	VBD	O
in	IN	O
a	DT	O
superior	JJ	O
or	CC	O
posterior	JJ	O
position	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
RAB-plate	NNP	O
provided	VBD	O
a	DT	O
more	RBR	O
stable	JJ	O
fixation	NN	O
,	,	O
especially	RB	O
with	IN	O
regard	NN	O
to	TO	O
maintained	VBN	O
postoperative	JJ	O
alignment	NN	O
.	.	O

However	RB	O
,	,	O
positive	JJ	O
predictors	NNS	O
for	IN	O
fixation	NN	Physical
failure	NN	Physical
were	VBD	O
identical	JJ	O
for	IN	O
both	DT	O
devices	NNS	O
.	.	O

Here	RB	O
,	,	O
the	DT	O
screw/neck	NN	O
angle	NN	O
deviation	NN	O
has	VBZ	O
had	VBN	O
the	DT	O
strongest	JJS	O
significance	NN	O
for	IN	O
prediction	NN	O
of	IN	O
fixation	NN	O
failure	NN	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
phase	VB	O
II	NNP	O
trial	NN	O
of	IN	O
two	CD	O
dose	JJ	O
schedules	NNS	O
of	IN	O
carboplatin/paclitaxel/cetuximab	NN	O
in	IN	O
stage	NN	O
IIIB/IV	NNP	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

BACKGROUND	VB	O
This	DT	O
trial	NN	O
investigated	VBD	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
weekly	JJ	O
cetuximab	NN	O
combined	VBN	O
with	IN	O
two	CD	O
different	JJ	O
schedules	NNS	O
of	IN	O
paclitaxel/carboplatin	NN	O
for	IN	O
stage	NN	O
IIIB/IV	NNP	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
total	NN	O
of	IN	O
168	CD	O
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
stage	NN	O
IIIB/IV	NNP	O
NSCLC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
arm	VB	O
A	NNP	O
,	,	O
cetuximab	NN	O
(	(	O
400	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
followed	VBN	O
by	IN	O
weekly	JJ	O
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
+	FW	O
paclitaxel	NN	O
(	(	O
Taxol	NNP	O
)	)	O
(	(	O
225	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
/carboplatin	NN	O
(	(	O
AUC6	NNP	O
)	)	O
day	NN	O
1	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
or	CC	O
arm	NN	O
B	NNP	O
,	,	O
same	JJ	O
cetuximab	NN	O
regimen	NNS	O
plus	CC	O
paclitaxel	NN	O
(	(	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
and	CC	O
carboplatin	NN	O
(	(	O
AUC6	NNP	O
)	)	O
day	NN	O
1	CD	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
a	DT	O
four-cycle	JJ	O
maximum	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
complete	JJ	O
response	NN	O
,	,	O
partial	JJ	O
response	NN	O
,	,	O
or	CC	O
stable	JJ	O
disease	NN	O
after	IN	O
four	CD	O
cycles	NNS	O
could	MD	O
receive	VB	O
cetuximab	NN	O
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/week	NN	O
until	IN	O
disease	JJ	Physical
progression	NN	Physical
or	CC	Physical
unacceptable	JJ	Physical
toxicity	NN	Physical
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
progression-free	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
PFS	NNP	Mortality
)	)	Mortality
.	.	O

RESULTS	NNP	O
Median	JJ	O
PFS	NNP	Physical
was	VBD	O
4.7	CD	O
and	CC	O
4.3	CD	O
months	NNS	O
for	IN	O
arms	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
6-month	JJ	O
PFS	NNP	O
,	,	O
27.3	CD	O
%	NN	O
versus	IN	O
30.9	CD	O
%	NN	O
)	)	O
.	.	O

Median	JJ	Mortality
overall	JJ	Mortality
survival	NN	Mortality
was	VBD	O
11.4	CD	O
versus	NN	O
9.8	CD	O
months	NNS	O
for	IN	O
arms	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
;	:	O
estimated	VBN	O
1-year	JJ	O
survival	NN	O
,	,	O
47.7	CD	O
%	NN	O
versus	IN	O
39.3	CD	O
%	NN	O
;	:	O
and	CC	O
objective	JJ	O
response	NN	O
rate	NN	O
,	,	O
29.6	CD	O
%	NN	O
versus	IN	O
25	CD	O
%	NN	O
.	.	O

The	DT	O
regimen	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
with	IN	O
rash	NN	Physical
and	CC	Physical
hematologic	JJ	Physical
toxicity	NN	Physical
being	VBG	O
most	RBS	O
common	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
did	VBD	O
not	RB	O
meet	VB	O
the	DT	O
prespecified	JJ	O
benchmark	NN	O
of	IN	O
35	CD	O
%	NN	O
6-month	JJ	O
PFS	NNP	O
rate	NN	O
;	:	O
both	DT	O
combination	NN	O
schedules	NNS	O
of	IN	O
cetuximab	NN	O
plus	CC	O
paclitaxel/carboplatin	NN	O
were	VBD	O
feasible	JJ	O
and	CC	O
equivalent	JJ	O
for	IN	O
treating	VBG	O
advanced	JJ	O
NSCLC	NNP	O
.	.	O

Effect	NN	O
of	IN	O
ibuprofen	NN	O
on	IN	O
cyclooxygenase	NN	Physical
and	CC	Physical
nitric	JJ	Physical
oxide	JJ	Physical
synthase	NN	Physical
of	IN	Physical
gastric	JJ	Physical
mucosa	NN	Physical
:	:	Physical
correlation	NN	O
with	IN	O
endoscopic	JJ	Physical
lesions	NNS	Physical
and	CC	O
adverse	JJ	Adverseeffect
reactions	NNS	Adverseeffect
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
ibuprofen	NN	O
on	IN	O
gastric	JJ	Physical
mucosa	NN	Physical
and	CC	Physical
enzymes	NNS	Physical
involved	VBN	Physical
in	IN	Physical
gastroprotection	NN	Physical
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

Twenty-four	JJ	O
Helicobacter	NNP	O
pylori-negative	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
ibuprofen	NN	O
or	CC	O
ibuprofen-arginate	NN	O
(	(	O
each	DT	O
600	CD	O
mg/6	NN	O
hr	NN	O
during	IN	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Endoscopies	NNS	O
were	VBD	O
performed	VBN	O
1	CD	O
week	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
the	DT	O
gastric	JJ	O
antrum	NN	O
and	CC	O
corpus	NN	O
for	IN	O
determination	NN	O
of	IN	O
prostaglandin	NN	O
E2	NNP	O
(	(	O
PGE2	NNP	O
)	)	O
by	IN	O
ELISA	NNP	O
and	CC	O
cyclooxygenase	NN	O
(	(	O
COX-1	JJ	O
and	CC	O
COX-2	NNP	O
)	)	O
and	CC	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(	(	O
eNOS	JJ	O
and	CC	O
iNOS	NN	O
)	)	O
by	IN	O
western	JJ	O
blot	NN	O
.	.	O

All	DT	O
subjects	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
gastric	JJ	O
lesion	NN	O
except	IN	O
for	IN	O
two	CD	O
individuals	NNS	O
taking	VBG	O
ibuprofen-arginate	NN	O
.	.	O

Ibuprofen-arginate	NNP	O
caused	VBD	O
a	DT	O
lower	JJR	O
rate	NN	O
of	IN	O
clinical	JJ	Physical
adverse	JJ	Physical
reactions	NNS	Physical
than	IN	O
ibuprofen	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
gastric	JJ	Physical
lesions	NNS	Physical
or	CC	O
adverse	JJ	O
reactions	NNS	O
had	VBD	O
lower	JJR	O
PGE2	NNP	O
levels	NNS	O
.	.	O

COX-1	NNP	Physical
,	,	Physical
COX-2	NNP	Physical
,	,	Physical
eNOS	NN	Physical
,	,	Physical
and	CC	Physical
iNOS	NNS	Physical
were	VBD	O
detectable	JJ	O
in	IN	O
all	DT	O
subjects	NNS	O
.	.	O

The	DT	O
constitutive	JJ	O
enzymes	NNS	O
(	(	O
COX-1	NNP	O
and	CC	O
eNOS	NN	O
)	)	O
did	VBD	O
not	RB	O
change	VB	O
after	IN	O
treatment	NN	O
.	.	O

COX-2	NNP	O
was	VBD	O
higher	RBR	O
in	IN	O
corpus	NN	O
than	IN	O
antrum	NN	O
and	CC	O
it	PRP	O
increased	VBD	O
after	IN	O
ibuprofen	JJ	O
treatment	NN	O
.	.	O

iNOS	NN	O
tended	VBD	O
to	TO	O
increase	VB	O
mildly	RB	O
in	IN	O
the	DT	O
corpus	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
adverse	JJ	O
reactions	NNS	O
or	CC	O
endoscopic	JJ	O
lesions	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
ibuprofen	NN	O
and	CC	O
ibuprofen-arginate	NN	O
in	IN	O
PGE2	NNP	O
,	,	O
or	CC	O
enzymes	NNS	O
.	.	O

[	NN	O
Relationship	NNP	O
between	IN	O
sCD44v6	JJ	Physical
expression	NN	Physical
and	CC	O
TCM	NNP	O
differentiation	NN	O
type	NN	O
of	IN	O
gastric	JJ	O
carcinoma	NN	O
patients	NNS	O
and	CC	O
influence	NN	O
of	IN	O
weitai	NN	O
capsule	NN	O
on	IN	O
the	DT	O
expression	NN	Physical
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
of	IN	O
TCM	NNP	O
type	NN	O
with	IN	O
serum	JJ	Physical
level	NN	Physical
of	IN	Physical
soluble	JJ	Physical
CD44v6	NNP	Physical
(	(	Physical
sCD44v6	NN	Physical
)	)	Physical
and	CC	O
different	JJ	O
histologic	NN	Physical
parameters	NNS	Physical
in	IN	O
gastric	JJ	O
carcinoma	NN	O
patients	NNS	O
and	CC	O
to	TO	O
observe	VB	O
the	DT	O
influence	NN	O
of	IN	O
Weitai	NNP	O
capsule	NN	O
(	(	O
WTC	NNP	O
)	)	O
on	IN	O
the	DT	O
sCD44v6	JJ	Physical
expression	NN	Physical
.	.	O

METHODS	NNP	O
TCM	NNP	Physical
typing	NN	Physical
and	CC	O
sCD44v6	JJ	Physical
expression	NN	Physical
were	VBD	O
determined	VBN	O
in	IN	O
all	PDT	O
the	DT	O
enrolled	JJ	O
patients	NNS	O
(	(	O
30	CD	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
32	CD	O
in	IN	O
the	DT	O
trial	NN	O
group	NN	O
)	)	O
before	IN	O
operation	NN	O
,	,	O
and	CC	O
3-4	JJ	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
them	PRP	O
from	IN	O
3-4	JJ	O
weeks	NNS	O
after	IN	O
operation	NN	O
.	.	O

To	TO	O
the	DT	O
patients	NNS	O
of	IN	O
trial	NN	O
group	NN	O
,	,	O
oral	JJ	O
administration	NN	O
of	IN	O
WTC	NNP	O
was	VBD	O
given	VBN	O
additionally	RB	O
with	IN	O
4	CD	O
capsules	NNS	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
consecutive	JJ	O
3	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
sCD44v6	NN	Physical
was	VBD	O
significantly	RB	O
positive	JJ	O
correlated	VBN	O
with	IN	O
the	DT	O
degree	NN	Physical
of	IN	Physical
cancer	NN	Physical
cell	NN	Physical
differentiation	NN	Physical
,	,	Physical
infiltration	NN	Physical
and	CC	Physical
lymph	NN	Physical
node	JJ	Physical
metastasis	NN	Physical
;	:	O
(	(	O
2	CD	O
)	)	O
Level	NN	Physical
of	IN	Physical
sCD44v6	NN	Physical
was	VBD	O
the	DT	O
highest	JJS	O
in	IN	O
patients	NNS	O
of	IN	O
blood	NN	O
stasis	NN	O
type	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
patients	NNS	O
of	IN	O
Pi-deficiency	NNP	O
type	NN	O
or	CC	O
of	IN	O
damp-heat	JJ	O
type	NN	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
;	:	O
(	(	O
3	CD	O
)	)	O
After	IN	O
ending	VBG	O
treatment	NN	O
,	,	O
level	NN	Physical
of	IN	Physical
sCD44v6	NN	Physical
in	IN	O
the	DT	O
trial	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
1	CD	O
)	)	O
Serum	NNP	Physical
level	NN	Physical
of	IN	Physical
sCD44v6	NN	Physical
could	MD	O
be	VB	O
taken	VBN	O
as	IN	O
the	DT	O
criterion	NN	O
for	IN	O
evaluating	VBG	O
the	DT	O
development	NN	Physical
and	CC	Physical
prognosis	NN	Physical
of	IN	Physical
gastric	JJ	Physical
cancer	NN	Physical
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
therapeutic	JJ	O
target	NN	O
for	IN	O
anti-metastasis	JJ	O
treatment	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
Serum	NNP	Physical
level	NN	Physical
of	IN	Physical
sCD44v6	NN	Physical
is	VBZ	O
related	VBN	O
to	TO	O
some	DT	O
extent	NN	O
with	IN	O
TCM	NNP	Physical
type	NN	Physical
of	IN	Physical
blood	NN	Physical
stasis	NN	Physical
and	CC	Physical
Pi-deficiency	NN	Physical
;	:	O
(	(	O
3	CD	O
)	)	O
WTC	NNP	O
combined	VBN	O
with	IN	O
chemotherapy	NN	O
could	MD	O
further	RB	O
inhibit	VB	O
the	DT	O
expression	NN	Physical
of	IN	Physical
serum	NN	Physical
sCD44v6	NN	Physical
in	IN	O
gastric	JJ	O
carcinoma	NN	O
patients	NNS	O
.	.	O

Epirubicin-based	JJ	O
chemotherapy	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
:	:	O
role	NN	O
of	IN	O
dose-intensity	NN	O
and	CC	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
duration	NN	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
epirubicin	JJ	O
modify	VB	O
the	DT	O
long-term	JJ	O
outcome	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Four	NNP	O
hundred	VBD	O
seventeen	JJ	O
anthracycline-naive	JJ	O
MBC	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
regimens	NNS	O
:	:	O
arm	NN	O
A	NN	O
:	:	O
11	CD	O
cycles	NNS	O
of	IN	O
fluorouracil	NN	O
500	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
cyclophosphamide	RB	O
500	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
FEC	NNP	O
75	CD	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
;	:	O
arm	NN	O
B	NN	O
:	:	O
four	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
100	CD	O
(	(	O
same	JJ	O
regimen	NNS	O
but	CC	O
with	IN	O
epirubicin	JJ	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
then	RB	O
eight	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
50	CD	O
(	(	O
epirubicin	JJ	O
50	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
;	:	O
and	CC	O
arm	JJ	O
C	NNP	O
:	:	O
four	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
100	CD	O
then	RB	O
restart	VB	O
the	DT	O
same	JJ	O
regimen	NN	O
at	IN	O
disease	NN	O
progression	NN	O
in	IN	O
case	NN	O
of	IN	O
prior	JJ	O
response	NN	O
or	CC	O
stabilization	NN	O
.	.	O

RESULTS	NNP	O
Hematologic	NNP	Adverseeffect
toxicity	NN	Adverseeffect
was	VBD	O
similar	JJ	O
.	.	O

Nausea/vomiting	NN	Adverseeffect
and	CC	Adverseeffect
stomatitis	NN	Adverseeffect
were	VBD	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
in	IN	O
arm	NN	O
A	NN	O
as	IN	O
was	VBD	O
left	VBN	Physical
ventricular	JJ	Physical
ejection	NN	Physical
fraction	NN	Physical
decrease	NN	O
in	IN	O
arm	NN	O
C	NNP	O
(	(	O
A	NNP	O
=	NNP	O
six	CD	O
patients	NNS	O
,	,	O
B	NNP	O
=	NNP	O
five	CD	O
patients	NNS	O
,	,	O
and	CC	O
C	NNP	O
=	NNP	O
one	CD	O
patient	NN	O
)	)	O
.	.	O

Six	CD	O
patients	NNS	O
died	VBD	Mortality
of	IN	Mortality
infections	NNS	Mortality
(	(	O
A	DT	O
=	RB	O
four	CD	O
patients	NNS	O
and	CC	O
C	NNP	O
=	NNP	O
two	CD	O
patients	NNS	O
)	)	O
.	.	O

After	IN	O
four	CD	O
cycles	NNS	O
,	,	O
the	DT	O
objective	JJ	Physical
response	NN	Physical
rate	NN	Physical
(	(	Physical
ORR	NNP	Physical
)	)	Physical
was	VBD	O
better	RBR	O
with	IN	O
FEC	NNP	O
100	CD	O
than	IN	O
with	IN	O
FEC	NNP	O
75	CD	O
(	(	O
49.2	CD	O
%	NN	O
v	JJ	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
:	:	O
=.07	NN	O
)	)	O
.	.	O

The	DT	O
ORR	NNP	Physical
was	VBD	O
better	RBR	O
with	IN	O
the	DT	O
longer	JJR	O
regimens	NNS	O
(	(	O
arm	NN	O
A	NNP	O
,	,	O
56.9	CD	O
%	NN	O
;	:	O
B	NNP	O
,	,	O
64	CD	O
%	NN	O
;	:	O
and	CC	O
C	NNP	O
,	,	O
47.6	CD	O
%	NN	O
;	:	O
P	NNP	O
:	:	O
=.06	NN	O
)	)	O
and	CC	O
was	VBD	O
41	CD	O
%	NN	O
after	IN	O
second-line	JJ	O
FEC	NNP	O
100	CD	O
.	.	O

After	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
41	CD	O
months	NNS	O
,	,	O
the	DT	O
response	NN	Physical
duration	NN	Physical
and	CC	Physical
time	NN	Physical
to	TO	Physical
progression	NN	Physical
(	(	Physical
TTP	NNP	Physical
)	)	Physical
were	VBD	O
significantly	RB	O
better	RBR	O
with	IN	O
arm	NN	O
B	NNP	O
,	,	O
the	DT	O
longer	JJR	O
regimen	NNS	O
(	(	O
P	NNP	O
:	:	O
=.012	NN	O
and	CC	O
P	NNP	O
:	:	O
<	NN	O
10	CD	O
(	(	O
-3	NN	O
)	)	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
median	JJ	Physical
survival	NN	Physical
times	NNS	Physical
for	IN	O
arms	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
were	VBD	O
similar	JJ	O
(	(	O
17.9	CD	O
,	,	O
18.9	CD	O
,	,	O
and	CC	O
16	CD	O
.	.	O

3	CD	O
months	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
:	:	O
=.49	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
MBC	NNP	O
,	,	O
longer	JJR	O
epirubicin-based	JJ	O
regimens	NNS	O
are	VBP	O
better	RBR	O
in	IN	O
terms	NNS	O
of	IN	O
response	NN	Physical
duration	NN	Physical
and	CC	Physical
TTP	NNP	Physical
.	.	O

FEC	NNP	O
100	CD	O
regimens	NNS	O
improve	VBP	O
the	DT	O
ORR	NNP	Physical
.	.	O

However	RB	O
,	,	O
four	CD	O
initial	JJ	O
cycles	NNS	O
of	IN	O
FEC	NNP	O
100	CD	O
and	CC	O
identical	JJ	O
retreatment	NN	O
at	IN	O
disease	NN	O
progression	NN	O
yielded	VBN	O
equivalent	JJ	O
overall	JJ	Physical
survival	NN	Physical
to	TO	O
longer	JJR	O
regimens	NNS	O
.	.	O

Chemotherapy	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
:	:	O
the	DT	O
surgical	JJ	O
setting	NN	O
of	IN	O
the	DT	O
Big	NNP	O
Lung	NNP	O
Trial	NNP	O
.	.	O

OBJECTIVES	VB	O
The	DT	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
meta-analysis	NN	O
suggested	VBD	O
a	DT	O
survival	JJ	O
benefit	NN	O
for	IN	O
cisplatin-based	JJ	O
chemotherapy	NN	O
when	WRB	O
given	VBN	O
in	IN	O
addition	NN	O
to	TO	O
surgery	NN	O
,	,	O
radical	JJ	O
radiotherapy	NN	O
or	CC	O
'best	JJS	O
supportive	JJ	O
care	NN	O
'	POS	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
included	VBD	O
many	JJ	O
small	JJ	O
trials	NNS	O
and	CC	O
trials	NNS	O
with	IN	O
differing	VBG	O
eligibility	NN	O
criteria	NNS	O
and	CC	O
chemotherapy	NN	O
regimens	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
Big	NNP	O
Lung	NNP	O
Trial	NNP	O
was	VBD	O
therefore	RB	O
to	TO	O
run	VB	O
a	DT	O
large	JJ	O
pragmatic	JJ	O
trial	NN	O
to	TO	O
confirm	VB	O
the	DT	O
survival	NN	Mortality
benefits	NNS	Mortality
seen	VBN	O
in	IN	O
the	DT	O
meta-analysis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
surgery	NN	O
setting	NN	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
381	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
chemotherapy	VB	O
(	(	O
C	NNP	O
,	,	O
192	CD	O
patients	NNS	O
)	)	O
or	CC	O
no	DT	O
chemotherapy	NN	O
(	(	O
NoC	NNP	O
,	,	O
189	CD	O
patients	NNS	O
)	)	O
.	.	O

C	NNP	O
was	VBD	O
three	CD	O
3-weekly	JJ	O
cycles	NNS	O
of	IN	O
cisplatin/vindesine	NN	O
,	,	O
mitomycin/ifosfamide/cisplatin	NN	O
,	,	O
mitomycin/vinblastine/cisplatin	NN	O
or	CC	O
vinorelbine/cisplatin	NN	O
.	.	O

RESULTS	NNP	O
Chemotherapy	NNP	O
was	VBD	O
given	VBN	O
before	RB	O
surgery	NN	O
in	IN	O
3	CD	O
%	NN	O
of	IN	O
patients	NNS	O
whilst	VBP	O
97	CD	O
%	NN	O
received	VBD	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

Baseline	NNP	O
characteristics	NNS	O
were	VBD	O
:	:	O
median	JJ	O
age	NN	O
61	CD	O
years	NNS	O
,	,	O
69	CD	O
%	NN	O
male	NN	O
,	,	O
48	CD	O
%	NN	O
squamous	JJ	O
cell	NN	O
,	,	O
93	CD	O
%	NN	O
WHO	NNP	O
PS	NNP	O
0-1	NNP	O
,	,	O
27	CD	O
%	NN	O
stage	NN	O
I	PRP	O
,	,	O
38	CD	O
%	NN	O
stage	NN	O
II	NNP	O
,	,	O
and	CC	O
34	CD	O
%	NN	O
stage	NN	O
III	NNP	O
.	.	O

Complete	NNP	Others
resection	NN	Others
was	VBD	O
achieved	VBN	O
in	IN	O
approximately	RB	O
95	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
C	NNP	O
group	NN	O
,	,	O
13	CD	O
%	NN	O
received	VBD	O
no	DT	O
chemotherapy	NN	O
,	,	O
21	CD	O
%	NN	O
one	CD	O
or	CC	O
two	CD	O
cycles	NNS	O
,	,	O
and	CC	O
64	CD	O
%	NN	O
all	DT	O
three	CD	O
cycles	NNS	O
of	IN	O
their	PRP$	O
prescribed	JJ	O
chemotherapy	NN	O
(	(	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
latter	NN	O
with	IN	O
no	DT	O
delays	NNS	O
or	CC	O
modification	NN	O
)	)	O
.	.	O

30	CD	O
%	NN	O
had	VBD	O
grade	VBN	O
3/4	CD	O
toxicity	NN	Adverseeffect
,	,	Adverseeffect
mainly	RB	Adverseeffect
haematological	JJ	Adverseeffect
,	,	Adverseeffect
nausea/vomiting	JJ	Adverseeffect
and	CC	Adverseeffect
neutropenic	JJ	Adverseeffect
fever	NN	Adverseeffect
,	,	O
and	CC	O
six	CD	O
patients	NNS	O
were	VBD	O
reported	VBN	O
as	IN	O
having	VBG	O
a	DT	O
treatment-related	JJ	O
death	NN	Mortality
.	.	O

198	CD	O
(	(	O
52	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
have	VBP	O
died	VBN	O
,	,	O
but	CC	O
there	EX	O
is	VBZ	O
currently	RB	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
benefit	NN	Mortality
in	IN	Mortality
overall	JJ	Mortality
survival	NN	Mortality
to	TO	O
the	DT	O
C	NNP	O
group	NN	O
:	:	O
HR	$	O
1.02	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.77-1.35	NN	O
)	)	O
,	,	O
P	NNP	O
=	NNP	O
0.90	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
trial	NN	O
has	VBZ	O
failed	VBN	O
to	TO	O
observe	VB	O
a	DT	O
survival	JJ	Mortality
benefit	NN	Mortality
with	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
following	VBG	O
complete	JJ	O
resection	NN	O
of	IN	O
stage	NN	O
I-III	JJ	O
NSCLC	NNP	O
.	.	O

However	RB	O
,	,	O
the	DT	O
hazard	NN	O
ratio	NN	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
previously	RB	O
reported	VBN	O
meta-analysis	NN	O
and	CC	O
two	CD	O
large	JJ	O
recently	RB	O
reported	VBD	O
trials	NNS	O
,	,	O
which	WDT	O
suggest	VBP	O
a	DT	O
small	JJ	O
survival	NN	O
benefit	NN	O
with	IN	O
cisplatin-based	JJ	O
chemotherapy	NN	O
.	.	O

Relief	NN	O
of	IN	O
osteoporotic	JJ	Pain
backache	NN	Pain
with	IN	O
fluoride	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
calciferol	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
comprising	VBG	O
22	CD	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
backache	NN	O
and	CC	O
a	DT	O
halisteretic	JJ	O
spine	NN	O
with	IN	O
crush	JJ	O
fracture	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
12	CD	O
women	NNS	O
completed	VBD	O
a	DT	O
12-week	JJ	O
therapy	NN	O
with	IN	O
sodium	NN	O
fluoride	NN	O
,	,	O
calcium	NN	O
and	CC	O
calciferol	NN	O
and	CC	O
10	CD	O
with	IN	O
placebo	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
,	,	O
evaluated	VBN	O
by	IN	O
a	DT	O
four-stage	JJ	Pain
scale	NN	Pain
on	IN	Pain
pains	NNS	Pain
,	,	Pain
infirmity	NN	Pain
,	,	Pain
and	CC	Pain
consumption	NN	Others
of	IN	Others
analgesics	NNS	Others
,	,	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
actively	RB	O
treated	JJ	O
patients	NNS	O
.	.	O

[	JJ	O
Prevention	NNP	O
of	IN	O
migraine	NN	Mental
with	IN	O
flunarizine	NN	O
and	CC	O
acetylsalicylic	JJ	O
acid	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
study	NN	O
]	NNP	O
.	.	O

UNLABELLED	CC	O
30	CD	O
children	NNS	O
between	IN	O
7	CD	O
and	CC	O
17	CD	O
years	NNS	O
suffering	VBG	O
from	IN	O
at	IN	O
least	JJS	O
2	CD	O
attacks/month	NN	O
of	IN	O
common	JJ	O
or	CC	O
classical	JJ	O
migraine	NN	O
since	IN	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
were	VBD	O
studied	VBN	O
.	.	O

After	IN	O
clinical	JJ	O
exclusion	NN	O
of	IN	O
symptomatic	JJ	O
headache	NN	O
4	CD	O
weeks	NNS	O
were	VBD	O
documented	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
migraine	NN	O
diary	NN	O
.	.	O

Prophylaxis	NNP	O
with	IN	O
Calcium	NNP	O
entry	NN	O
blocker	NN	O
Flunarizine	NNP	O
(	(	O
Sibelium	NNP	O
)	)	O
or	CC	O
Thromboxane	VB	O
A	DT	O
inhibitor	NN	O
Acetylsalicylic	NNP	O
acid	NN	O
(	(	O
ASS	NNP	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
design	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

Medication	NNP	O
was	VBD	O
given	VBN	O
as	IN	O
one	CD	O
dosage	NN	O
in	IN	O
the	DT	O
evening	NN	O
:	:	O
2-5	JJ	O
mg/kg	NN	O
KG	NNP	O
ASS	NNP	O
or	CC	O
5-10	JJ	O
mg	NN	O
Flunarizine	NNP	O
.	.	O

Documented	NNP	O
attack	NN	Physical
frequency	NN	Physical
and	CC	Physical
duration	NN	Physical
were	VBD	O
controlled	VBN	O
at	IN	O
monthly	JJ	O
physical	JJ	O
examinations	NNS	O
.	.	O

Final	JJ	O
results	NNS	O
showed	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
significant	JJ	O
reduction	NN	Physical
of	IN	Physical
attack	NN	Physical
frequency	NN	Physical
or	CC	Physical
symptoms	NNS	Physical
between	IN	O
both	DT	O
different	JJ	O
therapeutic	JJ	O
principals	NNS	O
.	.	O

72.4	CD	O
%	NN	O
(	(	O
ASS	NNP	O
73.3	CD	O
%	NN	O
;	:	O
Flunarizine	NNP	O
71.4	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
were	VBD	O
attack-free	JJ	O
or	CC	O
had	VBD	O
at	IN	O
least	JJS	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
.	.	O

Migraine	NNP	Physical
frequency	NN	Physical
of	IN	O
initially	RB	O
7-8	NNP	O
was	VBD	O
reduced	VBN	O
to	TO	O
1-2	JJ	O
attacks/month	NN	O
.	.	O

Duration	NN	Physical
remained	VBD	O
constant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
1-3	JJ	O
h	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
slight	JJ	Adverseeffect
body	NN	Adverseeffect
weight	VBD	Adverseeffect
gain	NN	Adverseeffect
or	CC	O
abdominal	JJ	Adverseeffect
pain	NN	Adverseeffect
after	IN	O
intake	NN	O
,	,	O
prophylaxis	NN	O
had	VBD	O
not	RB	O
to	TO	O
be	VB	O
interrupted	VBN	O
therefore	RB	O
.	.	O

Longtime	JJ	O
prognosis	NN	O
is	VBZ	O
not	RB	O
yet	RB	O
possible	JJ	O
because	IN	O
the	DT	O
time	NN	O
of	IN	O
observation	NN	O
is	VBZ	O
too	RB	O
short	JJ	O
so	RB	O
far	RB	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
substances	NNS	O
are	VBP	O
definitely	RB	O
useful	JJ	O
and	CC	O
have	VBP	O
few	JJ	O
side	NN	O
effects	NNS	O
in	IN	O
childhood	NN	O
migraine	NN	O
.	.	O

If	IN	O
the	DT	O
response	NN	O
to	TO	O
one	CD	O
is	VBZ	O
insufficient	JJ	O
the	DT	O
other	JJ	O
substance	NN	O
should	MD	O
be	VB	O
tried	VBN	O
.	.	O

Which	JJ	O
women	NNS	O
default	NN	O
from	IN	O
follow-up	JJ	O
cervical	JJ	O
cytology	NN	O
tests	NNS	O
?	.	O
A	DT	O
cohort	NN	O
study	NN	O
within	IN	O
the	DT	O
TOMBOLA	NNP	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
default	NN	O
from	IN	O
follow-up	JJ	Mental
cervical	JJ	Mental
cytology	NN	Mental
tests	NNS	Mental
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
involving	VBG	O
2166	CD	O
women	NNS	O
,	,	O
aged	VBD	O
20-59	JJ	O
,	,	O
with	IN	O
recent	JJ	O
low-grade	JJ	O
cervical	JJ	O
cytology	NN	O
taken	VBN	O
within	IN	O
the	DT	O
NHS	NNP	O
Cervical	NNP	O
Screening	NNP	O
Programmes	NNP	O
in	IN	O
Scotland	NNP	O
and	CC	O
England	NNP	O
,	,	O
and	CC	O
managed	VBN	O
by	IN	O
6-monthly	JJ	O
cytology	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

For	IN	O
the	DT	O
first	JJ	O
(	(	O
6-month	JJ	O
)	)	O
and	CC	O
second	JJ	O
(	(	O
12-month	JJ	O
)	)	O
surveillance	NN	O
cytology	NN	O
tests	NNS	O
separately	RB	O
,	,	O
women	NNS	O
were	VBD	O
categorized	VBN	O
as	IN	O
'on-time	JJ	O
attendees	NNS	O
'	POS	O
(	(	O
attended	JJ	O
?6	NNP	O
months	NNS	O
of	IN	O
test	NN	O
being	VBG	O
due	JJ	O
)	)	O
,	,	O
'late	''	O
attendees	NNS	O
'	POS	O
(	(	O
attended	VBD	O
greater	JJR	O
than	IN	O
6	CD	O
months	NNS	O
after	IN	O
test	NN	O
was	VBD	O
due	JJ	O
)	)	O
or	CC	O
'non-attendees	NNS	O
'	POS	O
(	(	O
failed	VBN	O
to	TO	O
attend	VB	O
)	)	O
.	.	O

Multivariate	NNP	O
odds	JJ	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
were	VBD	O
computed	VBN	O
for	IN	O
factors	NNS	O
associated	VBN	O
with	IN	O
late	JJ	O
and	CC	O
non-attendance	JJ	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
first	JJ	O
surveillance	NN	O
test	NN	O
,	,	O
risk	NN	O
of	IN	O
non-attendance	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
younger	JJR	O
women	NNS	O
,	,	O
those	DT	O
without	IN	O
post-secondary	JJ	O
education	NN	O
,	,	O
and	CC	O
non-users	NNS	O
of	IN	O
prescribed	JJ	O
contraception	NN	O
.	.	O

Factors	NNS	O
significantly	RB	O
associated	VBN	O
with	IN	O
late	JJ	O
attendance	NN	O
for	IN	O
the	DT	O
first	JJ	O
test	NN	O
were	VBD	O
the	DT	O
same	JJ	O
as	IN	O
for	IN	O
non-attendance	NN	O
,	,	O
plus	CC	O
current	JJ	O
smoking	NN	O
and	CC	O
having	VBG	O
children	NNS	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
predictor	NN	O
of	IN	O
non-attendance	NN	O
for	IN	O
the	DT	O
second	JJ	O
surveillance	NN	O
test	NN	O
was	VBD	O
late	JJ	O
attendance	NN	O
for	IN	O
the	DT	O
first	JJ	O
test	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
9.65	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
6.60-16.62	JJ	O
)	)	O
.	.	O

Non-attendance	NN	O
for	IN	O
the	DT	O
second	JJ	O
test	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
higher	JJR	O
among	IN	O
women	NNS	O
who	WP	O
were	VBD	O
younger	JJR	O
,	,	O
smokers	NNS	O
and	CC	O
had	VBD	O
negative	JJ	O
cytology	NN	O
on	IN	O
the	DT	O
first	JJ	O
surveillance	NN	O
test	NN	O
.	.	O

Late	JJ	O
attendance	NN	O
for	IN	O
the	DT	O
second	JJ	O
surveillance	NN	O
test	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
women	NNS	O
who	WP	O
were	VBD	O
younger	JJR	O
,	,	O
smokers	NNS	O
,	,	O
had	VBD	O
children	NNS	O
and	CC	O
attended	VBD	O
late	RB	O
for	IN	O
the	DT	O
first	JJ	O
test	NN	O
.	.	O

CONCLUSIONS	NNP	O
Women	NNP	O
at	IN	O
highest	JJS	O
risk	NN	O
of	IN	O
default	NN	O
from	IN	O
follow-up	JJ	O
cytology	NN	O
tend	NN	O
to	TO	O
be	VB	O
young	JJ	O
,	,	O
smoke	NN	O
,	,	O
lack	NN	O
post-secondary	JJ	O
education	NN	O
,	,	O
and	CC	O
have	VBP	O
defaulted	VBN	O
from	IN	O
a	DT	O
previous	JJ	O
surveillance	NN	O
appointment	NN	O
.	.	O

Tackling	VBG	O
default	NN	O
will	MD	O
require	VB	O
development	NN	O
of	IN	O
targeted	JJ	O
strategies	NNS	O
to	TO	O
encourage	VB	O
attendance	NN	O
and	CC	O
research	NN	O
to	TO	O
better	JJR	O
understand	VB	O
the	DT	O
reasons	NNS	O
underpinning	VBG	O
default	NN	O
.	.	O

Making	VBG	O
the	DT	O
connection	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
at	IN	O
school	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
interventions	NNS	O
for	IN	O
improving	VBG	O
the	DT	O
social	JJ	Mental
skills	NNS	Mental
of	IN	O
high	JJ	O
functioning	VBG	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
.	.	O

One	CD	O
intervention	NN	O
involved	VBN	O
a	DT	O
peer-mediated	JJ	O
approach	NN	O
(	(	O
PEER	NNP	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
involved	VBD	O
a	DT	O
child-assisted	JJ	O
approach	NN	O
(	(	O
CHILD	NNP	O
)	)	O
.	.	O

METHOD	PDT	O
The	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
crossed	VBN	O
in	IN	O
a	DT	O
2	CD	O
?	.	O
2	CD	O
factorial	JJ	O
design	NN	O
yielding	VBG	O
control	NN	O
,	,	O
PEER	NNP	O
,	,	O
CHILD	NNP	O
,	,	O
and	CC	O
both	DT	O
PEER	NNP	O
and	CC	O
CHILD	NNP	O
conditions	NNS	O
.	.	O

Sixty	NNP	O
children	NNS	O
participated	VBD	O
from	IN	O
56	CD	O
classrooms	NNS	O
in	IN	O
30	CD	O
schools	NNS	O
.	.	O

Interventions	NNS	O
involved	VBD	O
12	CD	O
sessions	NNS	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
self	NN	O
,	,	O
peer	NN	O
and	CC	O
teacher	JJR	O
reports	NNS	O
of	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
independent	JJ	O
weekly	JJ	O
observations	NNS	O
of	IN	O
children	NNS	O
on	IN	O
their	PRP$	O
school	NN	O
playground	NN	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
social	JJ	O
network	NN	O
salience	NN	O
,	,	O
number	NN	O
of	IN	O
friendship	JJ	O
nominations	NNS	O
,	,	O
teacher	JJ	O
report	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
in	IN	O
the	DT	O
classroom	NN	O
,	,	O
and	CC	O
decreased	JJ	O
isolation	NN	O
on	IN	O
the	DT	O
playground	NN	O
for	IN	O
children	NNS	O
who	WP	O
received	VBD	O
PEER	NNP	O
interventions	NNS	O
.	.	O

Changes	NNS	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
persisted	VBD	O
to	TO	O
the	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
significant	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
peer	JJ	O
social	JJ	O
connections	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
general	JJ	O
education	NN	O
classrooms	NNS	O
with	IN	O
a	DT	O
brief	JJ	O
intervention	NN	O
,	,	O
and	CC	O
that	IN	O
these	DT	O
gains	NNS	O
persist	VBP	O
over	IN	O
time	NN	O
.	.	O

Effect	NN	Physical
of	IN	O
motivational	JJ	O
music	NN	O
on	IN	O
lactate	NN	Physical
levels	NNS	Physical
during	IN	O
recovery	NN	O
from	IN	O
intense	JJ	O
exercise	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
music	NN	O
played	VBN	O
during	IN	O
an	DT	O
exercise	NN	O
task	NN	O
on	IN	O
athletic	JJ	O
performance	NN	O
have	VBP	O
been	VBN	O
previously	RB	O
studied	VBN	O
.	.	O

Yet	CC	O
,	,	O
these	DT	O
results	NNS	O
are	VBP	O
not	RB	O
applicable	JJ	O
for	IN	O
competitive	JJ	O
athletes	NNS	O
,	,	O
who	WP	O
can	MD	O
use	VB	O
music	NN	O
only	RB	O
during	IN	O
warm-up	NN	O
or	CC	O
recovery	NN	O
from	IN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
motivational	JJ	O
music	NN	O
(	(	O
music	NN	O
that	WDT	O
stimulates	VBZ	O
or	CC	O
inspires	VBZ	O
physical	JJ	O
activity	NN	O
)	)	O
during	IN	O
recovery	NN	Physical
from	IN	Physical
intense	JJ	Physical
exercise	NN	Physical
,	,	O
on	IN	O
activity	NN	Physical
pattern	NN	Physical
,	,	Physical
rate	NN	Physical
of	IN	Physical
perceived	VBN	Physical
exertion	NN	Physical
(	(	Physical
RPE	NNP	Physical
)	)	Physical
,	,	Physical
and	CC	Physical
blood	NN	Physical
lactate	NN	Physical
concentration	NN	Physical
.	.	Physical

Twenty	NNP	O
young	JJ	O
,	,	O
active	JJ	O
men	NNS	O
(	(	O
mean	JJ	O
age	NN	O
26.2	CD	O
?	.	O
2.1	CD	O
years	NNS	O
)	)	O
performed	VBD	O
a	DT	O
6-minute	JJ	O
run	NN	O
at	IN	O
peak	NN	O
oxygen	NN	O
consumption	NN	O
speed	NN	O
(	(	O
predetermined	VBN	O
from	IN	O
the	DT	O
VO	NNP	O
(	(	O
2	CD	O
)	)	O
max	FW	O
test	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
,	,	O
RPE	NNP	O
,	,	O
number	NN	O
of	IN	O
steps	NNS	O
(	(	O
determined	VBN	O
by	IN	O
step	NN	O
counter	NN	O
)	)	O
,	,	O
and	CC	O
blood	NN	O
lactate	NN	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
15	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
recovery	NN	O
from	IN	O
the	DT	O
exercise	NN	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
motivational	JJ	O
music	NN	O
(	(	O
2	CD	O
separate	JJ	O
sessions	NNS	O
,	,	O
at	IN	O
random	JJ	O
order	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	O
HR	NNP	O
during	IN	O
the	DT	O
recovery	NN	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
.	.	O

Listening	VBG	O
to	TO	O
motivational	JJ	O
music	NN	O
during	IN	O
the	DT	O
recovery	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
voluntary	JJ	O
activity	NN	O
of	IN	O
the	DT	O
participants	NNS	O
,	,	O
determined	VBN	O
by	IN	O
increased	JJ	O
number	NN	O
of	IN	O
steps	NNS	O
(	(	O
499.4	CD	O
?	.	O
220.1	CD	O
vs.	IN	O
413.2	CD	O
?	.	O
150.6	CD	O
steps	NNS	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increased	JJ	O
number	NN	O
of	IN	O
steps	NNS	O
during	IN	O
the	DT	O
recovery	NN	O
was	VBD	O
accompanied	VBN	O
by	IN	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
blood	NN	O
lactate	NN	O
concentration	NN	O
percentage	NN	O
(	(	O
28.1	CD	O
?	.	O
12.2	CD	O
vs.	IN	O
22.8	CD	O
?	.	O
10.9	CD	O
%	NN	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
,	,	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
decrease	NN	O
in	IN	O
RPE	NNP	O
(	(	O
77.7	CD	O
?	.	O
14.4	CD	O
vs.	IN	O
73.1	CD	O
?	.	O
14.7	CD	O
%	NN	O
with	IN	O
and	CC	O
without	IN	O
music	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
listening	VBG	O
to	TO	O
motivational	JJ	O
music	NN	O
during	IN	O
nonstructured	JJ	O
recovery	NN	O
from	IN	O
intense	JJ	O
exercise	NN	O
leads	VBZ	O
to	TO	O
increased	VBN	O
activity	NN	O
,	,	O
faster	JJR	O
lactate	JJ	O
clearance	NN	O
,	,	O
and	CC	O
reduced	VBD	O
RPE	NNP	O
and	CC	O
therefore	RB	O
may	MD	O
be	VB	O
used	VBN	O
by	IN	O
athletes	NNS	O
in	IN	O
their	PRP$	O
effort	NN	O
to	TO	O
enhance	VB	O
recovery	NN	O
.	.	O

Personalized	VBN	O
smoking	NN	O
cessation	NN	O
:	:	O
interactions	NNS	O
between	IN	O
nicotine	NN	O
dose	NN	O
,	,	O
dependence	NN	O
and	CC	O
quit-success	JJ	O
genotype	NN	O
score	NN	O
.	.	O

Improving	NNP	O
and	CC	O
targeting	VBG	O
nicotine	JJ	O
replacement	NN	O
therapy	NN	O
(	(	O
NRT	NNP	O
)	)	O
are	VBP	O
cost-effective	JJ	O
strategies	NNS	O
for	IN	O
reducing	VBG	O
adverse	JJ	O
health	NN	O
consequences	NNS	O
for	IN	O
smokers	NNS	O
.	.	O

Treatment	NNP	O
studies	NNS	O
document	VBP	O
the	DT	O
efficacy	NN	O
of	IN	O
precessation	NN	O
NRT	NNP	O
and	CC	O
support	NN	O
important	JJ	O
roles	NNS	O
for	IN	O
level	NN	O
of	IN	O
nicotine	JJ	O
dependence	NN	O
and	CC	O
precessation	NN	O
smoking	NN	O
reduction	NN	O
in	IN	O
successful	JJ	O
quitting	NN	O
.	.	O

However	RB	O
,	,	O
prior	JJ	O
work	NN	O
has	VBZ	O
not	RB	O
identified	VBN	O
the	DT	O
optimal	JJ	O
precessation	NN	O
dose	NN	O
or	CC	O
means	NNS	O
for	IN	O
personalizing	VBG	O
NRT	NNP	O
.	.	O

Genome-wide	NNP	O
association	NN	O
has	VBZ	O
identified	VBN	O
groups	NNS	O
of	IN	O
genomic	JJ	O
markers	NNS	O
associated	VBN	O
with	IN	O
successful	JJ	O
quitting	NN	O
,	,	O
allowing	VBG	O
us	PRP	O
to	TO	O
develop	VB	O
a	DT	O
v1.0	JJ	O
quit-success	JJ	O
genotype	NN	O
score	NN	O
.	.	O

We	PRP	O
now	RB	O
report	VBP	O
influences	NNS	O
of	IN	O
v1.0	JJ	Mental
quit-success	JJ	Mental
genotype	NN	Mental
score	NN	Mental
,	,	O
level	NN	Mental
of	IN	Mental
dependence	NN	Mental
and	CC	Mental
precessation	NN	Mental
smoking	NN	Mental
reduction	NN	Mental
in	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
trial	NN	O
that	WDT	O
examined	VBD	O
effects	NNS	O
of	IN	O
21	CD	O
versus	NN	O
42	CD	O
mg/24	NN	O
h	NN	O
precessation	NN	O
NRT	NNP	O
.	.	O

Four	CD	O
hundred	VBD	O
seventy-nine	JJ	O
smokers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
21	CD	O
or	CC	O
42	CD	O
mg	NN	O
NRT	NNP	O
,	,	O
initiated	VBD	O
2	CD	O
wks	NN	O
prior	RB	O
to	TO	O
target	VB	O
quit	NN	O
dates	NNS	O
.	.	O

We	PRP	O
monitored	VBD	O
self-reported	JJ	Mental
abstinence	NN	Mental
and	CC	O
end-expired	JJ	Others
air	NN	Others
carbon	NN	Others
monoxide	NN	Others
(	(	Others
CO	NNP	Others
)	)	Others
.	.	O

Genotyping	VBG	O
used	VBN	O
Affymetrix	NNP	Others
arrays	NNS	Others
(	(	O
Santa	NNP	O
Clara	NNP	O
,	,	O
CA	NNP	O
,	,	O
USA	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
10-wk	JJ	Mental
continuous	JJ	Mental
smoking	NN	Mental
abstinence	NN	Mental
.	.	O

NRT	NNP	Mental
dose	NN	Mental
,	,	O
level	NN	Mental
of	IN	Mental
nicotine	JJ	Mental
dependence	NN	Mental
and	CC	O
genotype	NN	Physical
scores	NNS	Physical
displayed	VBD	O
significant	JJ	Others
interactive	JJ	Others
effects	NNS	Others
on	IN	O
successful	JJ	O
quitting	NN	O
.	.	O

Successful	JJ	Mental
abstinence	NN	Mental
also	RB	O
was	VBD	O
predicted	VBN	O
by	IN	O
CO	NNP	Others
reductions	NNS	Others
during	IN	O
precessation	NN	O
NRT	NNP	O
.	.	O

These	DT	O
results	NNS	O
document	VBP	O
ways	NNS	O
in	IN	O
which	WDT	O
smoking	VBG	O
cessation	NN	O
strategies	NNS	O
can	MD	O
be	VB	O
personalized	VBN	O
based	VBN	O
on	IN	O
levels	NNS	Mental
of	IN	Mental
nicotine	JJ	Mental
dependence	NN	Mental
,	,	O
genotype	NN	Others
scores	NNS	Others
and	CC	Others
CO	NNP	Others
monitoring	NN	Others
.	.	O

These	DT	O
assessments	NNS	O
,	,	O
taken	VBN	O
together	RB	O
,	,	O
can	MD	O
help	VB	O
match	VB	O
most	JJS	O
smokers	NNS	O
with	IN	O
optimal	JJ	O
NRT	NNP	O
doses	NNS	O
and	CC	O
help	VB	O
rapidly	RB	O
identify	VB	O
some	DT	O
who	WP	O
may	MD	O
be	VB	O
better	RB	O
treated	VBN	O
using	VBG	O
other	JJ	O
methods	NNS	O
.	.	O

PRL-8-53	NN	O
:	:	O
enhanced	VBN	O
learning	NN	Mental
and	CC	O
subsequent	JJ	O
retention	NN	Mental
in	IN	O
humans	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
low	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
new	JJ	O
psychotropic	NN	O
agent	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
3-	JJ	O
(	(	O
2-benzylmethylaminoethyl	JJ	O
)	)	O
benzoic	NN	O
acid	JJ	O
methyl	NN	O
ester	NN	O
hydrochloride	NN	O
(	(	O
PRL-8-53	NNP	O
)	)	O
on	IN	O
learning	NN	Mental
and	CC	O
on	IN	O
retention	NN	Mental
of	IN	Mental
verbal	JJ	Mental
information	NN	Mental
in	IN	O
human	JJ	O
subjects	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

Using	VBG	O
the	DT	O
serial	JJ	O
anticipation	NN	O
method	NN	O
under	IN	O
double-blind	JJ	O
conditions	NNS	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
PRL-8-53	NNP	O
causes	NNS	O
slight	JJ	O
improvement	NN	O
of	IN	O
acquisition	NN	Mental
.	.	Mental

Retinetion	NN	Mental
of	IN	Mental
verbal	JJ	Mental
information	NN	Mental
was	VBD	O
found	VBN	O
improved	VBN	O
to	TO	O
a	DT	O
statistically	RB	O
significant	JJ	O
degree	NN	O
(	(	O
most	RBS	O
P	NNP	O
values	NNS	O
better	RBR	O
than	IN	O
0.01	CD	O
,	,	O
some	DT	O
better	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
either	DT	O
visual	JJ	Mental
reaction	NN	Mental
time	NN	Mental
or	CC	Mental
motor	NN	Mental
control	NN	Mental
after	IN	O
drug	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
values	NNS	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
analgesic	JJ	Pain
effects	NNS	Pain
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
and	CC	O
aspirin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
postoperative	JJ	O
dental	NN	O
pain	NN	O
.	.	O

The	DT	O
pain	NN	O
experienced	VBD	O
after	IN	O
third	JJ	O
molar	JJ	O
surgery	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
analgesic	JJ	Pain
efficacy	NN	Pain
of	IN	O
a	DT	O
new	JJ	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
,	,	O
lornoxicam	NN	O
,	,	O
in	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
study	NN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
fifty	JJ	O
fit	NN	O
,	,	O
young	JJ	O
adults	NNS	O
participated	VBD	O
in	IN	O
this	DT	O
randomised	VBN	O
,	,	O
single	JJ	O
dose	NN	O
,	,	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
clinical	JJ	O
study	NN	O
.	.	O

Three	CD	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
(	(	O
2	CD	O
mg	NN	O
,	,	O
4	CD	O
mg	NN	O
,	,	O
and	CC	O
8	CD	O
mg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
aspirin	JJ	O
650	CD	O
mg	NN	O
and	CC	O
placebo	NN	O
.	.	O

Patients	NNS	O
suffering	VBG	O
from	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
pain	NN	O
following	VBG	O
surgery	NN	O
were	VBD	O
monitored	VBN	O
for	IN	O
up	RB	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

All	DT	O
indices	NNS	O
of	IN	O
efficacy	NN	Others
showed	VBD	O
similar	JJ	O
results	NNS	O
,	,	O
all	DT	O
active	JJ	O
treatments	NNS	O
being	VBG	O
associated	VBN	O
with	IN	O
highly	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
reductions	NNS	Pain
in	IN	Pain
pain	NN	Pain
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Lornoxicam	NNP	O
8	CD	O
mg	NN	O
demonstrated	VBD	O
significant	JJ	O
analgesic	JJ	Pain
efficacy	NN	Pain
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
two	CD	O
lower	JJR	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
and	CC	O
aspirin	VB	O
all	DT	O
showed	VBD	O
apparent	JJ	O
degrees	NNS	O
of	IN	O
efficacy	NN	O
intermediate	NN	O
between	IN	O
that	DT	O
of	IN	O
placebo	NN	O
and	CC	O
lornoxicam	$	O
8	CD	O
mg	NN	O
,	,	O
although	IN	O
the	DT	O
trial	NN	O
proved	VBD	O
to	TO	O
have	VB	O
inadequate	JJ	O
power	NN	O
to	TO	O
show	VB	O
significant	JJ	O
differences	NNS	O
between	IN	O
these	DT	O
three	CD	O
treatments	NNS	O
.	.	O

Lornoxicam	NNP	O
was	VBD	O
very	RB	O
well	RB	Others
tolerated	VBN	Others
at	IN	O
all	DT	O
three	CD	O
doses	NNS	O
studied	VBN	O
,	,	O
with	IN	O
no	DT	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
definitely	RB	O
attributable	JJ	O
to	TO	O
its	PRP$	O
administration	NN	O
.	.	O

Combined	VBN	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
:	:	O
conventional	JJ	O
versus	NN	O
escalated	VBD	O
chemotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
mediastinal	JJ	O
B-cell	NNP	O
lymphoma	NN	O
(	(	O
PMBCL	NNP	O
)	)	O
remains	VBZ	O
controversial	JJ	O
.	.	O

We	PRP	O
started	VBD	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
toxicity	NN	Others
of	IN	O
a	DT	O
conventional	JJ	O
versus	NN	O
more	RBR	O
intensive	JJ	O
regimen	NNS	O
of	IN	O
combined	JJ	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
.	.	O

From	IN	O
1989	CD	O
to	TO	O
1997	CD	O
,	,	O
68	CD	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
previously	RB	O
untreated	VBN	O
PMBCL	NNP	O
,	,	O
aged	VBD	O
18-65	CD	O
years	NNS	O
and	CC	O
negative	JJ	O
for	IN	O
immunodeficiency	NN	O
virus	NN	O
test	NN	O
,	,	O
were	VBD	O
considered	VBN	O
candidates	NNS	O
to	TO	O
receive	VB	O
either	DT	O
conventional	JJ	O
chemotherapy	NN	O
with	IN	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	VB	O
750	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	JJ	O
1.4	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
prednisone	RB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
70	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
bleomycin	$	O
10	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
mega	JJ	O
CEOP-Bleo	NNP	O
(	(	O
cyclophosphamide	JJ	O
1000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
epirubicin	$	O
120	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
bleomycin	NN	O
at	IN	O
the	DT	O
same	JJ	O
doses	NNS	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
for	IN	O
six	CD	O
cycles	NNS	O
,	,	O
followed	VBN	O
by	IN	O
radiotherapy	NN	O
to	TO	O
the	DT	O
mediastinum	NN	O
with	IN	O
the	DT	O
mantle	NN	O
technique	NN	O
(	(	O
35-45	JJ	O
Gy	NNP	O
,	,	O
mean	VBP	O
38	CD	O
Gy	NNP	O
)	)	O
.	.	O

Complete	JJ	Others
response	NN	Others
(	(	Others
CR	NNP	Others
)	)	Others
rates	NNS	Others
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
:	:	O
64	CD	O
%	NN	O
[	CC	O
95	CD	O
percent	NN	O
confidence	NN	Others
interval	NN	Others
(	(	Others
CI	NNP	Others
)	)	Others
:	:	Others
58	CD	O
percent	NN	O
to	TO	O
70	CD	O
percent	NN	O
]	NN	O
for	IN	O
conventional	JJ	O
arm	NN	O
vs	NN	O
81	CD	O
percent	NN	O
(	(	O
95	CD	O
CI	NN	O
:	:	O
77-86	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
group	NN	O
(	(	O
p=0.2	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
failure-free	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
FFS	NNP	Mortality
)	)	Mortality
and	CC	Mortality
overall	JJ	Mortality
survival	NN	Mortality
(	(	Mortality
OS	NNP	Mortality
)	)	Mortality
had	VBD	Mortality
statistical	JJ	Mortality
differences	NNS	Mortality
.	.	Mortality

At	IN	O
5	CD	O
years	NNS	O
,	,	O
actuarial	JJ	Mortality
FFS	NNP	Mortality
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
conventional	JJ	O
chemotherapy	NN	O
was	VBD	O
51	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
44-59	JJ	O
percent	NN	O
)	)	O
compared	VBN	O
to	TO	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
in	IN	O
the	DT	O
intensive	JJ	O
arm	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

OS	CC	Mortality
rates	NNS	Mortality
were	VBD	O
also	RB	O
different	JJ	O
:	:	O
54	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
48-57	JJ	O
percent	NN	O
)	)	O
vs	VBZ	O
70	CD	O
percent	NN	O
(	(	O
95	CD	O
percent	NN	O
CI	NN	O
:	:	O
65-76	JJ	O
percent	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Toxicity	NN	Adverseeffect
was	VBD	O
mild	JJ	O
and	CC	O
no	DT	O
therapy-related	JJ	Mortality
deaths	NNS	Mortality
were	VBD	O
observed	VBN	O
.	.	O

At	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
7.3	CD	O
years	NNS	O
,	,	O
no	DT	O
second	JJ	O
neoplasia	NN	Physical
or	CC	Physical
acute	NN	Physical
leukemia	NN	Physical
has	VBZ	O
been	VBN	O
observed	VBN	O
.	.	O

The	DT	Physical
international	JJ	Physical
prognostic	JJ	Physical
index	NN	Physical
was	VBD	O
not	RB	O
useful	JJ	O
to	TO	O
define	VB	O
clinical	JJ	O
risk	NN	O
in	IN	O
this	DT	O
selected	VBN	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBN	O
pleural	JJ	Physical
and	CC	Physical
pericardial	JJ	Physical
effusion	NN	Physical
and	CC	Physical
chemotherapy	NN	Physical
regimen	NNS	Physical
as	IN	O
prognostic	JJ	O
factors	NNS	O
influencing	VBG	O
FFS	NNP	Mortality
and	CC	Mortality
OS	NNP	Mortality
.	.	Mortality

We	PRP	O
feel	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
PMBCL	NNP	O
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
more	RBR	O
intensive	JJ	O
,	,	O
but	CC	O
not	RB	O
myeloablative	JJ	O
chemotherapy	NN	O
,	,	O
followed	VBN	O
by	IN	O
adjuvant	JJ	O
radiotherapy	NN	O
to	TO	O
achieve	VB	O
an	DT	O
improvement	NN	O
in	IN	O
outcome	NN	O
in	IN	O
this	DT	O
setting	NN	O
of	IN	O
patients	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
pleural	JJ	O
or	CC	O
pericardial	JJ	O
effusion	NN	O
are	VBP	O
considered	VBN	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
failure	NN	O
with	IN	O
the	DT	O
actual	JJ	O
programs	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
probably	RB	O
will	MD	O
be	VB	O
considered	VBN	O
for	IN	O
experimental	JJ	O
therapeutic	JJ	O
approaches	NNS	O
.	.	O

Caudal	NNP	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
surgery	NN	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
bupivacaine	NN	O
and	CC	O
diamorphine	NN	O
.	.	O

Seventy-three	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
perianal	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
a	DT	O
caudal	JJ	O
injection	NN	O
of	IN	O
20	CD	O
ml	NNS	O
bupivacaine	VBP	O
0.5	CD	O
%	NN	O
plain	NN	O
and	CC	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
diamorphine	JJ	O
2.5	CD	O
mg	NN	O
in	IN	O
10	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
by	IN	O
caudal	JJ	O
injection	NN	O
;	:	O
a	DT	O
comparison	NN	O
was	VBD	O
then	RB	O
made	VBN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
requirements	NNS	O
.	.	O

The	DT	O
bupivacaine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	Physical
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
8	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
.	.	O

The	DT	O
diamorphine	NN	O
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	Physical
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

Side	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
diamorphine	NN	O
group	NN	O
than	IN	O
the	DT	O
control	NN	O
,	,	O
or	CC	O
the	DT	O
bupivacaine	NN	O
group	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
41	CD	O
%	NN	O
of	IN	O
the	DT	O
bupivacaine	NN	O
group	NN	O
complained	VBD	O
of	IN	O
some	DT	Adverseeffect
degree	NN	Adverseeffect
of	IN	Adverseeffect
urinary	JJ	Adverseeffect
retention	NN	Adverseeffect
and	CC	O
one	CD	O
patient	NN	O
required	VBN	O
temporary	JJ	Adverseeffect
catheterisation	NN	Adverseeffect
.	.	Adverseeffect

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
caudal	JJ	O
diamorphine	NN	O
gives	VBZ	O
good	JJ	O
postoperative	JJ	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
operations	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
motor	NN	O
blockade	NN	O
is	VBZ	O
not	RB	O
wanted	VBN	O
by	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Classroom	NNP	O
intervention	NN	O
for	IN	O
illness-related	JJ	O
problem	NN	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

There	EX	O
is	VBZ	O
growing	VBG	O
evidence	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
physical	JJ	O
illness	NN	O
and	CC	O
problem	NN	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

Such	JJ	O
behavior	NN	O
can	MD	O
compromise	VB	O
school	NN	O
performance	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
,	,	O
using	VBG	O
a	DT	O
group	NN	O
design	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
medical	JJ	O
intervention	NN	O
alone	RB	O
(	(	O
N	NNP	O
=	NNP	O
11	CD	O
)	)	O
versus	NN	O
behavioral	JJ	O
plus	CC	O
medical	JJ	O
intervention	NN	O
(	(	O
N	NNP	O
=	NNP	O
10	CD	O
)	)	O
for	IN	O
illness-related	JJ	O
problem	NN	O
behavior	NN	O
in	IN	O
a	DT	O
school	NN	O
setting	VBG	O
.	.	O

Following	VBG	O
intervention	NN	O
,	,	O
the	DT	O
behavioral	JJ	O
plus	CC	O
medical	JJ	O
intervention	NN	O
group	NN	O
showed	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
problem	NN	Mental
behavior	NN	Mental
and	CC	O
completed	VBD	Mental
more	JJR	Mental
academic	JJ	Mental
tasks	NNS	Mental
than	IN	O
did	VBD	O
the	DT	O
medical	JJ	O
intervention	NN	O
alone	RB	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
concept	NN	Pain
of	IN	Pain
illness	NN	Pain
and	CC	Pain
pain	NN	Pain
as	IN	O
a	DT	O
setting	NN	O
event	NN	O
for	IN	O
problem	NN	O
behavior	NN	O
.	.	O

The	DT	O
need	NN	O
for	IN	O
research	NN	O
to	TO	O
develop	VB	O
algorithms	NN	O
that	WDT	O
allow	VBP	O
one	CD	O
to	TO	O
select	VB	O
the	DT	O
best	JJS	O
combination	NN	O
of	IN	O
medical	JJ	O
and	CC	O
behavioral	JJ	O
interventions	NNS	O
for	IN	O
specific	JJ	O
illnesses	NNS	O
and	CC	O
contexts	NN	O
is	VBZ	O
noted	VBN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
parallel-group	JJ	O
trial	NN	O
of	IN	O
routine	JJ	O
prophylaxis	NN	O
vs.	IN	O
on-demand	JJ	O
treatment	NN	O
with	IN	O
sucrose-formulated	JJ	O
recombinant	JJ	O
factor	NN	O
VIII	NNP	O
in	IN	O
adults	NNS	O
with	IN	O
severe	JJ	O
hemophilia	NN	O
A	NNP	O
(	(	O
SPINART	NNP	O
)	)	O
.	.	O

BACKGROUND	IN	O
The	DT	O
benefits	NNS	O
of	IN	O
routine	JJ	O
prophylaxis	NN	O
vs.	IN	O
on-demand	JJ	O
treatment	NN	O
with	IN	O
factor	NN	O
VIII	NNP	O
products	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
in	IN	O
older	JJR	O
patients	NNS	O
with	IN	O
hemophilia	PDT	O
A	NNP	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
report	VB	O
results	NNS	O
from	IN	O
a	DT	O
preplanned	JJ	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
the	DT	O
3-year	JJ	O
SPINART	NNP	O
study	NN	O
,	,	O
which	WDT	O
compares	VBZ	O
routine	JJ	O
prophylaxis	NN	O
with	IN	O
on-demand	JJ	O
treatment	NN	O
with	IN	O
sucrose-formulated	JJ	O
recombinant	JJ	O
FVIII	NNP	O
(	(	O
rFVIII-FS	NN	O
)	)	O
.	.	O

PATIENTS/METHODS	NNP	O
SPINART	NNP	O
is	VBZ	O
an	DT	O
open-label	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
parallel-group	NN	O
,	,	O
multinational	JJ	O
trial	NN	O
.	.	O

Males	NNS	O
aged	VBN	O
12-50	CD	O
years	NNS	O
with	IN	O
severe	JJ	O
hemophilia	NN	O
A	NNP	O
,	,	O
?	.	O
150	CD	O
days	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
FVIII	NNP	O
,	,	O
no	DT	O
FVIII	NNP	O
inhibitors	NNS	O
,	,	O
no	DT	O
prophylaxis	NN	O
for	IN	O
>	$	O
12	CD	O
consecutive	JJ	O
months	NNS	O
in	IN	O
the	DT	O
past	JJ	O
5	CD	O
years	NNS	O
and	CC	O
6-24	JJ	O
bleeding	NN	O
episodes	NNS	O
in	IN	O
the	DT	O
preceding	VBG	O
6	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
1	CD	O
:	:	O
1	CD	O
to	TO	O
rFVIII-FS	JJ	O
prophylaxis	NN	O
(	(	O
25	CD	O
IU	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
three	CD	O
times	NNS	O
weekly	JJ	O
)	)	O
or	CC	O
on-demand	JJ	O
treatment	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
,	,	O
number	NN	O
of	IN	O
total	JJ	O
bleeding	VBG	O
episodes	NNS	O
in	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
,	,	O
was	VBD	O
analyzed	VBN	O
after	IN	O
the	DT	O
last	JJ	O
patient	NN	O
had	VBD	O
completed	VBN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

A	DT	O
negative	JJ	O
binomial	JJ	O
model	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
analysis	NN	O
;	:	O
analysis	NN	O
of	IN	O
variance	NN	O
was	VBD	O
used	VBN	O
for	IN	O
confirmatory	JJ	O
analysis	NN	O
of	IN	O
annualized	JJ	O
bleeding	NN	O
rates	NNS	O
.	.	O

RESULTS	NNP	O
Eighty-four	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
analyzed	VBN	O
(	(	O
n	JJ	O
=	$	O
42	CD	O
per	IN	O
group	NN	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
30.6	CD	O
years	NNS	O
;	:	O
median	JJ	O
treatment	NN	O
duration	NN	O
,	,	O
1.7	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
number	NN	O
of	IN	O
total	JJ	O
bleeding	NN	O
episodes	NNS	O
and	CC	O
total	JJ	O
bleeding	NN	O
episodes	NNS	O
per	IN	O
year	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
with	IN	O
prophylaxis	NN	O
than	IN	O
with	IN	O
on-demand	JJ	O
treatment	NN	O
(	(	O
total	JJ	O
,	,	O
0	CD	O
vs.	FW	O
54.5	CD	O
;	:	O
total	JJ	O
per	IN	O
year	NN	O
,	,	O
0	CD	O
vs.	FW	O
27.9	CD	O
;	:	O
both	DT	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

No	DT	O
treatment-related	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
,	,	O
and	CC	O
no	DT	O
patients	NNS	O
developed	VBD	O
FVIII	NNP	O
inhibitors	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Routine	NNP	O
prophylaxis	NN	O
with	IN	O
rFVIII-FS	JJ	O
leads	NNS	O
to	TO	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
bleeding	VBG	O
as	IN	O
compared	VBN	O
with	IN	O
on-demand	JJ	O
treatment	NN	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
consistent	JJ	O
with	IN	O
the	DT	O
established	VBN	O
rFVIII-FS	NN	O
safety	NN	O
profile	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
intravenous	JJ	O
and	CC	O
intra-arterial	JJ	O
urokinase	JJ	O
thrombolysis	NN	O
for	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
.	.	O

Intravenous	JJ	O
fibrinolysis	NN	O
(	(	O
IVF	NNP	O
)	)	O
with	IN	O
rt-PA	NN	O
(	(	O
alteplase	NN	O
)	)	O
provides	VBZ	O
significant	JJ	O
benefits	NNS	O
in	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
three	CD	O
hours	NNS	O
following	VBG	O
stroke	NN	O
onset	VBN	O
.	.	O

Intra-arterial	JJ	O
fibrinolysis	NN	O
(	(	O
IAF	NNP	O
)	)	O
with	IN	O
pro-urokinase	NN	O
in	IN	O
PROACT	NNP	O
II	NNP	O
study	NN	O
provides	VBZ	O
quite	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
in	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
.	.	O

IVF	NNP	O
and	CC	O
IAF	NNP	O
have	VBP	O
never	RB	O
been	VBN	O
compared	VBN	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
IVF	NNP	O
and	CC	O
IAF	NNP	O
with	IN	O
urokinase	JJ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
of	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
.	.	O

Patients	NNS	O
fulfilling	VBG	O
the	DT	O
selection	NN	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
urokinase	JJ	O
900,000	CD	O
units	NNS	O
via	IN	O
intravenous	JJ	O
or	CC	O
intra-arterial	JJ	O
routes	NNS	O
.	.	O

This	DT	O
randomised	VBD	O
monocentre	NN	O
study	NN	O
was	VBD	O
done	VBN	O
between	IN	O
December	NNP	O
1995	CD	O
and	CC	O
August	NNP	O
1997	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
number	NN	Others
of	IN	Others
patients	NNS	Others
with	IN	Others
a	DT	Others
modified	JJ	Others
Rankin	NNP	Others
score	NN	Others
of	IN	Others
2	CD	Others
or	CC	Others
less	JJR	Others
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
mortality	NN	Mortality
,	,	O
frequency	NN	Physical
of	IN	Physical
symptomatic	JJ	Physical
intracranial	JJ	Physical
haemorrhage	NN	Physical
(	(	Physical
SIH	NNP	Physical
)	)	Physical
,	,	O
neurological	JJ	Others
and	CC	Others
functional	JJ	Others
scores	NNS	Others
.	.	O

Fourteen	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
IVF	NNP	O
and	CC	O
13	CD	O
IAF	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Health	NNP	O
Authorities	NNP	O
when	WRB	O
27	CD	O
patients	NNS	O
had	VBD	O
been	VBN	O
included	VBN	O
because	IN	O
of	IN	O
the	DT	O
mortality	NN	O
rate	NN	O
.	.	O

Seven	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
died	VBD	O
,	,	O
4	CD	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
(	(	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
3	CD	O
and	CC	O
recurrence	NN	O
in	IN	O
1	CD	O
)	)	O
,	,	O
3	CD	O
in	IN	O
the	DT	O
IA	NNP	O
group	NN	O
(	(	O
SIH	NNP	O
in	IN	O
2	CD	O
,	,	O
and	CC	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
given	VBN	O
IVF	NNP	O
were	VBD	O
treated	VBN	O
significantly	RB	O
earlier	RBR	O
(	(	O
4:16	CD	O
h	NN	O
vs	NN	O
5:24	CD	O
h	NN	O
;	:	O
p=.007	NN	O
)	)	O
.	.	O

Although	IN	O
IA	NNP	O
patients	NNS	O
showed	VBD	O
greater	JJR	O
and	CC	O
earlier	RBR	O
improvement	NN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Because	IN	O
of	IN	O
premature	NN	O
termination	NN	O
,	,	O
the	DT	O
trial	NN	O
was	VBD	O
too	RB	O
small	JJ	O
to	TO	O
provide	VB	O
any	DT	O
reliable	JJ	O
and	CC	O
conclusive	JJ	O
results	NNS	O
.	.	O

Intra-arterial	JJ	O
fibrinolysis	NN	O
began	VBD	O
significantly	RB	O
later	RBR	O
than	IN	O
IV	NNP	O
fibrinolysis	NN	O
but	CC	O
it	PRP	O
gave	VBD	O
non-significantly	RB	O
better	JJ	O
results	NNS	O
in	IN	O
this	DT	O
prematurely	RB	O
terminated	VBN	O
study	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
calcium	NN	O
and	CC	O
magnesium	NN	O
infusions	NNS	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
neurotoxicity	NN	O
and	CC	O
clinical	JJ	O
outcome	NN	O
of	IN	O
oxaliplatin-based	JJ	O
systemic	JJ	O
treatment	NN	O
in	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Peripheral	NNP	O
sensory	JJ	O
neurotoxicity	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
and	CC	O
potentially	RB	O
debilitating	JJ	O
side	NN	O
effect	NN	O
of	IN	O
oxaliplatin	NN	O
treatment	NN	O
.	.	O

Calcium	NN	O
and	CC	O
magnesium	NN	O
(	(	O
Ca/Mg	NNP	O
)	)	O
infusions	NNS	O
are	VBP	O
frequently	RB	O
used	VBN	O
to	TO	O
prevent	VB	O
this	DT	O
toxicity	NN	O
.	.	O

However	RB	O
,	,	O
concerns	NNS	O
about	IN	O
a	DT	O
negative	JJ	O
impact	NN	O
of	IN	O
Ca/Mg	NNP	O
infusions	NNS	O
on	IN	O
outcome	NN	O
have	VBP	O
been	VBN	O
raised	VBN	O
.	.	O

We	PRP	O
retrospectively	RB	O
assessed	VBD	O
the	DT	O
effect	NN	O
of	IN	O
Ca/Mg	NNP	O
infusions	NNS	O
on	IN	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
neurotoxicity	NN	Physical
and	CC	O
on	IN	O
clinical	JJ	Physical
outcome	NN	Physical
in	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
(	(	O
ACC	NNP	O
)	)	O
patients	NNS	O
treated	VBN	O
in	IN	O
the	DT	O
phase	NN	O
III	NNP	O
CAIRO2	NNP	O
study	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Seven	NNP	O
hundred	VBD	O
and	CC	O
fifty	JJ	O
five	CD	O
previously	RB	O
untreated	JJ	O
ACC	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
between	IN	O
treatment	NN	O
with	IN	O
capecitabine	NN	O
,	,	O
oxaliplatin	NN	O
and	CC	O
bevacizumab	NN	O
or	CC	O
the	DT	O
same	JJ	O
combination	NN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
cetuximab	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
retrospectively	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
patients	NNS	O
in	IN	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
+	NNP	O
)	)	O
group	NN	O
received	VBD	O
Ca/Mg	NNP	O
at	IN	O
least	JJS	O
during	IN	O
their	PRP$	O
first	JJ	O
treatment	NN	O
cycle	NN	O
,	,	O
and	CC	O
patients	NNS	O
in	IN	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
-	:	O
)	)	O
group	NN	O
did	VBD	O
not	RB	O
.	.	O

RESULTS	VB	O
Seven	NNP	O
hundred	CD	O
and	CC	O
thirty	VB	O
two	CD	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
this	DT	O
analysis	NN	O
.	.	O

The	DT	O
Ca/Mg	NNP	O
(	(	O
+	NNP	O
)	)	O
group	NN	O
consisted	VBD	O
of	IN	O
551	CD	O
patients	NNS	O
,	,	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
-	:	O
)	)	O
group	NN	O
consisted	VBD	O
of	IN	O
181	CD	O
patients	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
all	DT	Physical
grade	JJ	Physical
neurotoxicity	NN	Physical
in	IN	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
+	NNP	O
)	)	O
group	NN	O
and	CC	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
-	:	O
)	)	O
group	NN	O
was	VBD	O
85	CD	O
%	NN	O
and	CC	O
92	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
grade	NN	O
?	.	O
2	CD	O
neurotoxicity	NN	O
was	VBD	O
40	CD	O
%	NN	O
and	CC	O
45	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.22	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
PFS	NNP	O
in	IN	O
the	DT	O
Ca/Mg	NNP	O
(	(	O
+	NNP	O
)	)	O
versus	NN	O
Ca/Mg	NNP	O
(	(	O
-	:	O
)	)	O
group	NN	O
was	VBD	O
10.1	CD	O
versus	NN	O
10.7	CD	O
months	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.92	CD	O
)	)	O
,	,	O
the	DT	O
median	JJ	O
OS	NNP	O
was	VBD	O
19.8	CD	O
versus	NN	O
20.7	CD	O
months	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
response	NN	O
rate	NN	O
was	VBD	O
43.1	CD	O
%	NN	O
versus	IN	O
50	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.11	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
largest	JJS	O
retrospective	JJ	O
analysis	NN	O
to	TO	O
date	NN	O
we	PRP	O
observed	VBD	O
that	IN	O
Ca/Mg	NNP	O
infusions	NNS	O
significantly	RB	O
reduced	VBD	O
all	DT	O
grade	JJ	O
oxaliplatin-related	JJ	O
neurotoxicity	NN	O
.	.	O

Ca/Mg	NNP	O
infusions	NNS	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
treatment	NN	O
.	.	O

Iloprost	NN	O
in	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
procedures	NNS	O
.	.	O

The	DT	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
during	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
and	CC	O
effects	NNS	O
on	IN	O
post-operative	JJ	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
145	CD	O
patients	NNS	O
.	.	O

Significant	JJ	O
preservation	NN	O
of	IN	O
platelet	NN	O
numbers	NNS	O
and	CC	O
function	NN	O
were	VBD	O
shown	VBN	O
without	IN	O
significant	JJ	O
haemodynamic	JJ	O
problems	NNS	O
,	,	O
but	CC	O
no	DT	O
effect	NN	O
on	IN	O
cerebral	JJ	O
deficits	NNS	O
could	MD	O
be	VB	O
found	VBN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
iloprost	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
thrombocytopenia	NN	O
seems	VBZ	O
justified	JJ	O
,	,	O
but	CC	O
the	DT	O
clinical	JJ	O
benefits	NNS	O
from	IN	O
its	PRP$	O
use	NN	O
in	IN	O
routine	JJ	O
cardiopulmonary	JJ	O
bypass	NN	O
remain	NN	O
to	TO	O
be	VB	O
shown	VBN	O
.	.	O

Can	MD	O
simvastatin	VB	O
improve	VB	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
?	.	O
Results	NNS	O
of	IN	O
the	DT	O
Erectile	NNP	O
Dysfunction	NNP	O
and	CC	O
Statins	NNP	O
Trial	NNP	O
[	NNP	O
ISRCTN66772971	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
ED	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
and	CC	O
impacts	NNS	O
upon	VBP	O
their	PRP$	O
overall	JJ	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
that	IN	O
of	IN	O
their	PRP$	O
partners	NNS	O
.	.	O

Men	NNP	O
aged	VBD	O
?40	CD	O
years	NNS	O
who	WP	O
were	VBD	O
not	RB	O
receiving	VBG	O
lipid	JJ	O
lowering	NN	O
or	CC	O
anti-hypertensive	JJ	O
medication	NN	O
and	CC	O
not	RB	O
at	IN	O
high	JJ	O
cardiovascular	JJ	O
risk	NN	O
were	VBD	O
recruited	VBN	O
from	IN	O
10	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
the	DT	O
East	NNP	O
of	IN	O
England	NNP	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
173	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
untreated	JJ	O
ED	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
three	CD	O
points	NNS	O
over	IN	O
30	CD	O
weeks	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
erectile	JJ	Physical
function	NN	Physical
(	(	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function-5	NNP	O
score	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
male	JJ	Physical
ED-specific	JJ	Physical
quality	NN	Physical
of	IN	Physical
life	NN	Physical
(	(	Physical
MED-QoL	NNP	Physical
)	)	Physical
,	,	O
quality-adjusted	JJ	O
life	NN	O
years	NNS	O
(	(	O
QALYs	NNP	O
)	)	O
using	VBG	O
the	DT	O
generic	JJ	O
Euroqol	NNP	O
measure	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
endothelial	JJ	Physical
function	NN	Physical
,	,	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
cholesterol	NN	Physical
and	CC	O
health	NN	O
service	NN	O
costs	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
erectile	JJ	Physical
function	NN	Physical
between	IN	O
the	DT	O
simvastatin	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
(	(	O
mean	JJ	O
change	NN	O
,	,	O
1.28	CD	O
vs	NN	O
0.07	CD	O
,	,	O
z	NN	O
=	VBD	O
1.1	CD	O
,	,	O
p	NN	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
although	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
MED-QoL	NNP	Physical
was	VBD	O
observed	VBN	O
(	(	O
5	CD	O
%	NN	O
vs	JJ	O
2	CD	O
%	NN	O
,	,	O
z	NN	O
=	VBD	O
2.09	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Both	DT	O
10-year	JJ	O
cardiovascular	NN	O
risk	NN	O
and	CC	O
low-density	NN	O
lipoprotein	NN	O
were	VBD	O
reduced	VBN	O
(	(	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
z	NN	O
=	NNP	O
-3.67	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
low-density	JJ	O
lipoprotein	NN	O
,	,	O
z	NN	O
=	NNP	O
-5.46	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
consistent	JJ	O
change	NN	O
in	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
sexual	JJ	O
encounters	NNS	O
is	VBZ	O
correlated	VBN	O
with	IN	O
improved	JJ	O
erectile	JJ	O
function	NN	O
.	.	O

The	DT	O
joint	JJ	O
distribution	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
probability	NN	O
of	IN	O
simvastatin	NN	O
being	VBG	O
cost-effective	JJ	O
for	IN	O
willingness-to-pay	JJ	O
thresholds	NNS	O
of	IN	O
?20,000	NN	O
and	CC	O
?30,000	NN	O
is	VBZ	O
86	CD	O
%	NN	O
and	CC	O
83	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Identifying	VBG	O
men	NNS	O
with	IN	O
ED	NNP	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
modify	VB	O
future	JJ	O
cardiovascular	JJ	O
risk	NN	O
and	CC	O
to	TO	O
improve	VB	O
MED-QoL	NNP	O
by	IN	O
treating	VBG	O
them	PRP	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
.	.	O

The	DT	O
joint	JJ	O
analysis	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
suggests	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
high	JJ	O
probability	NN	O
that	IN	O
simvastatin	NN	O
is	VBZ	O
a	DT	O
cost-effective	JJ	O
strategy	NN	O
in	IN	O
men	NNS	O
with	IN	O
ED	NNP	O
.	.	O

The	DT	O
findings	NNS	O
could	MD	O
influence	VB	O
urological	JJ	O
and	CC	O
primary	JJ	O
care	NN	O
practice	NN	O
by	IN	O
including	VBG	O
questions	NNS	O
on	IN	O
ED	NNP	O
during	IN	O
routine	JJ	O
consultations	NNS	O
and	CC	O
relevant	JJ	O
clinical	JJ	O
protocols	NNS	O
.	.	O

This	DT	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
impart	VB	O
lifestyle	JJ	O
advice	NN	O
.	.	O

Effect	NN	O
of	IN	O
adhesive	JJ	O
system	NN	O
type	NN	O
and	CC	O
tooth	DT	O
region	NN	O
on	IN	O
the	DT	O
bond	NN	O
strength	NN	O
to	TO	O
dentin	VB	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
bond	NN	O
strength	NN	O
of	IN	O
two	CD	O
etch-and-rinse	JJ	O
adhesive	JJ	O
systems	NNS	O
(	(	O
two-	JJ	O
and	CC	O
three-step	NN	O
)	)	O
and	CC	O
a	DT	O
self-etching	JJ	O
system	NN	O
to	TO	O
coronal	VB	Physical
and	CC	Physical
root	VB	Physical
canal	JJ	Physical
dentin	NN	Physical
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
root	NN	O
canals	NNS	O
of	IN	O
30	CD	O
human	JJ	O
incisors	NNS	O
and	CC	O
canines	NNS	O
were	VBD	O
instrumented	VBN	O
and	CC	O
prepared	VBN	O
with	IN	O
burs	NNS	O
.	.	O

The	DT	O
posts	NNS	O
used	VBD	O
for	IN	O
luting	VBG	O
were	VBD	O
duplicated	VBN	O
with	IN	O
dual	JJ	O
resin	NN	O
cement	NN	O
(	(	O
Duo-link	NNP	O
)	)	O
inside	IN	O
Aestheti	NNP	O
Plus	NNP	O
#	#	O
2	CD	O
molds	NNS	O
.	.	O

Thus	RB	O
,	,	O
three	CD	O
groups	NNS	O
were	VBD	O
formed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
adhesive	JJ	O
system	NN	O
employed	VBN	O
:	:	O
All-Bond	JJ	O
2	CD	O
(	(	O
TE3	NNP	O
)	)	O
+	VBP	O
resin	JJ	O
cement	NN	O
post	NN	O
(	(	O
rcp	NN	O
)	)	O
+	VBZ	O
Duo-link	NNP	O
(	(	O
Dl	NNP	O
)	)	O
;	:	O
One-Step	JJ	O
Plus	NNP	O
(	(	O
TE2	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
;	:	O
Tyrian/One-Step	JJ	O
Plus	NNP	O
(	(	O
SE	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
.	.	O

Afterwards	NNP	O
,	,	O
8	CD	O
transverse	NN	O
sections	NNS	O
(	(	O
1.5	CD	O
mm	NN	O
)	)	O
were	VBD	O
cut	VBN	O
from	IN	O
4	CD	O
mm	NNS	O
above	IN	O
the	DT	O
CEJ	NNP	O
up	RB	O
to	TO	O
4	CD	O
mm	NNS	O
short	JJ	O
of	IN	O
the	DT	O
root	NN	O
canal	JJ	O
apex	NN	O
,	,	O
comprising	VBG	O
coronal	JJ	O
and	CC	O
root	JJ	O
canal	JJ	O
dentin	NN	O
.	.	O

The	DT	O
sections	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
push-out	JJ	O
testing	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
EMIC	NNP	O
(	(	O
1	CD	O
mm/min	NN	O
)	)	O
.	.	O

Bond	NNP	Others
strength	NN	Others
data	NNS	Others
were	VBD	O
analyzed	VBN	O
with	IN	O
two-way	JJ	Others
repeated	JJ	Others
measures	NNS	Others
ANOVA	NNP	Others
and	CC	Others
Tukey	NNP	Others
's	POS	Others
test	NN	Others
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
relationship	NN	Others
between	IN	Others
the	DT	Others
adhesives	NNS	Others
was	VBD	O
not	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
different	JJ	O
regions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
means	NNS	O
achieved	VBN	O
with	IN	O
the	DT	O
adhesives	NNS	O
in	IN	O
each	DT	O
region	NN	O
(	(	O
Tukey	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.05	CD	O
)	)	O
revealed	VBD	O
that	IN	O
TE3	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
:	:	O
5.22	CD	O
+/-	JJ	O
1.70	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
TE2	NNP	O
(	(	O
2.60	CD	O
+/-	JJ	O
1.74	CD	O
)	)	O
and	CC	O
SE	NNP	O
(	(	O
1.68	CD	O
+/-	JJ	O
1.85	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
better	JJR	O
bonding	VBG	O
to	TO	O
dentin	VB	O
was	VBD	O
achieved	VBN	O
using	VBG	O
the	DT	O
three-step	JJ	O
etch-and-rinse	JJ	O
system	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
coronal	JJ	O
region	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
traditional	JJ	O
etch-and-rinse	JJ	O
three-step	NN	O
adhesive	JJ	O
system	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
teeth	NN	O
needing	VBG	O
adhesive	JJ	O
endodontic	JJ	O
restorations	NNS	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
caregiver	RB	O
mediated	VBN	O
joint	JJ	O
engagement	NN	O
intervention	NN	O
for	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
joint	JJ	O
attention	NN	O
intervention	NN	O
would	MD	O
result	VB	O
in	IN	O
greater	JJR	O
joint	JJ	O
engagement	NN	O
between	IN	O
caregivers	NNS	O
and	CC	O
toddlers	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
24	CD	O
caregiver-mediated	JJ	O
sessions	NNS	O
with	IN	O
follow-up	JJ	O
1	CD	O
year	NN	O
later	RB	O
.	.	O

Compared	VBN	O
to	TO	O
caregivers	NNS	O
and	CC	O
toddlers	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
waitlist	NN	O
control	NN	O
group	NN	O
the	DT	O
immediate	JJ	O
treatment	NN	O
(	(	O
IT	NNP	O
)	)	O
group	NN	O
made	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
targeted	JJ	O
areas	NNS	O
of	IN	O
joint	JJ	Mental
engagement	NN	Mental
.	.	O

The	DT	O
IT	NNP	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvements	NNS	O
with	IN	O
medium	NN	O
to	TO	O
large	JJ	O
effect	NN	O
sizes	NNS	O
in	IN	O
their	PRP$	O
responsiveness	NN	Mental
to	TO	Mental
joint	VB	Mental
attention	NN	Mental
and	CC	Mental
their	PRP$	Mental
diversity	NN	Mental
of	IN	Mental
functional	JJ	Mental
play	NN	Mental
acts	NNS	Mental
after	IN	O
the	DT	O
intervention	NN	O
with	IN	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
1	CD	O
year	NN	O
post-intervention	NN	O
.	.	O

These	DT	O
are	VBP	O
among	IN	O
the	DT	O
first	JJ	O
randomized	VBN	O
controlled	VBN	O
data	NNS	O
to	TO	O
suggest	VB	O
that	IN	O
short-term	JJ	O
parent-mediated	JJ	O
interventions	NNS	O
can	MD	O
have	VB	O
important	JJ	O
effects	NNS	O
on	IN	O
core	NN	O
impairments	NNS	O
in	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
.	.	O

Clinical	JJ	O
Trials	NNS	O
#	#	O
:	:	O
NCT00065910	NN	O
.	.	O

Effect	NN	O
of	IN	O
secretin	NN	O
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	O
porcine	NN	O
secretin	NN	O
on	IN	O
autistic	JJ	O
behaviours	NNS	O
in	IN	O
children	NNS	O
aged	VBD	O
2	CD	O
to	TO	O
7	CD	O
years	NNS	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	O
on	IN	O
(	(	O
1	CD	O
)	)	O
performance	NN	O
on	IN	O
a	DT	O
standardized	JJ	O
language	NN	O
measure	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
autistic	JJ	O
behaviours	NN	O
,	,	O
as	IN	O
rated	VBN	O
by	IN	O
parents	NNS	O
and	CC	O
child	NN	O
development	NN	O
professionals	NNS	O
was	VBD	O
examined	VBN	O
.	.	O

Employing	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
,	,	O
95	CD	O
participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
and	CC	O
administered	VBD	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
either	DT	O
secretin	NN	O
or	CC	O
placebo	NN	O
.	.	O

A	DT	O
follow-up	JJ	O
assessment	NN	O
was	VBD	O
conducted	VBN	O
3	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
injection	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
language	NN	Mental
or	CC	Mental
autistic	JJ	Mental
behaviour	NN	Mental
measures	NNS	Mental
were	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
3-week	JJ	O
follow-up	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Also	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
individuals	NNS	O
who	WP	O
improved	VBN	O
by	IN	O
>	NN	Mental
or	CC	Mental
=	$	Mental
6	CD	Mental
points	NNS	Mental
on	IN	Mental
the	DT	Mental
language	NN	Mental
measure	NN	Mental
at	IN	O
follow-up	NN	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
of	IN	O
secretin	NN	O
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
systematic	JJ	O
review	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Influence	NN	O
of	IN	O
asimadoline	NN	O
,	,	O
a	DT	O
new	JJ	O
kappa-opioid	JJ	O
receptor	NN	O
agonist	NN	O
,	,	O
on	IN	O
tubular	JJ	O
water	NN	O
absorption	NN	O
and	CC	O
vasopressin	NN	O
secretion	NN	O
in	IN	O
man	NN	O
.	.	O

AIMS	VBZ	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	Others
of	IN	O
asimadoline	NN	O
,	,	O
a	DT	O
new	JJ	O
kappa-opioid	JJ	O
agonist	NN	O
,	,	O
on	IN	O
renal	JJ	O
function	NN	O
and	CC	O
on	IN	O
hormones	NNS	O
related	VBN	O
to	TO	O
body	NN	O
fluid	JJ	O
balance	NN	O
as	RB	O
well	RB	O
as	IN	O
its	PRP$	O
tolerability	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
we	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
1	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
10	CD	O
mg	NN	O
of	IN	O
asimadoline	NN	O
,	,	O
in	IN	O
24	CD	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

Two	CD	O
hour	NN	O
control	NN	O
urine	JJ	O
collections	NNS	O
were	VBD	O
followed	VBN	O
by	IN	O
2	CD	O
h	NNS	O
postdose	JJ	O
urine	JJ	O
collections	NNS	O
and	CC	O
subsequently	RB	O
2.5	CD	O
%	NN	O
saline	NN	O
was	VBD	O
given	VBN	O
i.v	NN	O
.	.	O

at	IN	O
a	DT	O
rate	NN	O
of	IN	O
0.3	CD	O
ml	NNS	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
kg	NN	O
(	(	O
-1	JJ	O
)	)	O
during	IN	O
another	DT	O
2	CD	O
h	NN	O
urine	JJ	O
collection	NN	O
.	.	O

Blood	NNP	O
was	VBD	O
obtained	VBN	O
hourly	RB	O
.	.	O

Arginine-vasopressin	NNP	Physical
(	(	Physical
AVP	NNP	Physical
)	)	Physical
,	,	Physical
atrial	JJ	Physical
natriuretic	JJ	Physical
peptide	NN	Physical
(	(	Physical
alpha-hANP	JJ	Physical
)	)	Physical
,	,	O
endothelin	FW	Physical
(	(	Physical
ET-1	NNP	Physical
)	)	Physical
and	CC	O
cAMP	NN	Physical
were	VBD	O
determined	VBN	O
by	IN	O
r.i.a	NN	O
.	.	O

or	CC	O
ELISA	NNP	O
.	.	O

RESULTS	NNP	O
GC-MS	JJ	O
measurements	NNS	O
revealed	VBD	O
Cmax	NNP	Physical
values	NNS	Physical
of	IN	Physical
asimadoline	NN	Physical
in	IN	Physical
plasma	NN	Physical
ranging	VBG	O
from	IN	O
18	CD	O
ng	JJ	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
at	IN	O
the	DT	O
1	CD	O
mg	NN	O
dose	NN	O
,	,	O
91	CD	O
ng	NN	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
at	IN	O
the	DT	O
5	CD	O
mg	NN	O
dose	NN	O
,	,	O
to	TO	O
214	CD	O
ng	NNS	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
at	IN	O
the	DT	O
10	CD	O
mg	NN	O
dose	NN	O
after	IN	O
an	DT	O
average	NN	O
of	IN	O
1.1-1.4	JJ	O
h.	NN	O
Without	NNP	O
effects	NNS	O
on	IN	O
blood	NN	Physical
pressure	NN	Physical
,	,	O
heart	NN	Physical
rate	NN	Physical
,	,	O
GFR	NNP	Physical
or	CC	O
urine	JJ	Physical
electrolyte	JJ	Physical
excretion	NN	Physical
,	,	O
urine	JJ	Physical
volume	NN	Physical
increased	VBD	O
after	IN	O
1-2	JJ	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NNS	O
asimadoline	VBP	O
from	IN	O
3.3+/-1.3	JJ	O
to	TO	O
5.6+/-1.4	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
from	IN	O
3.2	CD	O
+/-1.6	JJ	O
to	TO	O
5.5+/-2.2	JJ	O
ml	NN	O
min	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

CH2O	NNP	Physical
rose	VBD	O
from	IN	O
0.2+/-1.5	JJ	O
to	TO	O
2.0+/-1.6	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
from	IN	O
0.6+/-1.6	JJ	O
to	TO	O
3.0+/-1.6	JJ	O
ml	NN	O
min	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Urinary	JJ	Physical
excretion	NN	Physical
of	IN	O
AVP	NNP	O
was	VBD	O
suppressed	VBN	O
only	RB	O
with	IN	O
the	DT	O
10	CD	O
mg	NNS	O
dose	RB	O
from	IN	O
46+/-23	JJ	O
to	TO	O
25+/-15	JJ	O
fmol	NN	O
min	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
without	IN	O
and	CC	O
from	IN	O
410+/-206	JJ	O
to	TO	O
181+/-125	JJ	O
fmol	NN	O
min	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
stimulation	NN	O
by	IN	O
2.5	CD	O
%	NN	O
saline	NN	O
.	.	O

Plasma	NNP	Physical
AVP	NNP	Physical
was	VBD	O
suppressed	VBN	O
only	RB	O
by	IN	O
the	DT	O
10	CD	O
mg	NN	O
dose	NN	O
of	IN	O
asimadoline	NN	O
in	IN	O
six	CD	O
of	IN	O
eight	CD	O
subjects	NNS	O
during	IN	O
the	DT	O
2.5	CD	O
%	NN	O
saline	JJ	O
infusion	NN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
alpha-hANP	JJ	O
or	CC	O
ET-1	JJ	O
systems	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
asimadoline	NN	O
.	.	O

CONCLUSIONS	NNP	O
Asimadoline	NNP	O
is	VBZ	O
diuretic	JJ	O
in	IN	O
man	NN	O
after	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
5	CD	O
or	CC	O
10	CD	O
mg	NN	O
probably	RB	O
through	IN	O
a	DT	O
direct	JJ	O
effect	NN	O
at	IN	O
the	DT	O
renal	JJ	O
tubular	JJ	O
level	NN	O
.	.	O

Suppression	NN	O
of	IN	O
AVP	NNP	O
secretion	NN	O
was	VBD	O
observed	VBN	O
only	RB	O
at	IN	O
the	DT	O
highest	JJS	O
dose	JJ	O
level	NN	O
of	IN	O
10	CD	O
mg	NN	O
of	IN	O
asimadoline	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
mastectomy	NN	O
with	IN	O
tamoxifen	NN	O
for	IN	O
treating	VBG	O
elderly	JJ	O
patients	NNS	O
with	IN	O
operable	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
Comparison	NNP	O
of	IN	O
tamoxifen	NN	O
and	CC	O
mastectomy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
trial	NN	O
of	IN	O
treatment	NN	O
of	IN	O
operable	JJ	O
breast	NN	O
cancer	NN	O
by	IN	O
wedge	NN	O
mastectomy	NN	O
or	CC	O
tamoxifen	NN	O
,	,	O
with	IN	O
median	JJ	O
follow	VBP	O
up	RP	O
24	CD	O
and	CC	O
25	CD	O
months	NNS	O
respectively	RB	O
(	(	O
range	VB	O
1-63	CD	O
)	)	O
.	.	O

SETTING	NN	O
University	NNP	O
hospital	NN	O
;	:	O
most	JJS	O
patients	NNS	O
from	IN	O
primary	JJ	O
catchment	JJ	O
area	NN	O
.	.	O

PATIENTS	CC	O
135	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
aged	VBD	O
over	IN	O
70	CD	O
with	IN	O
operable	JJ	O
tumours	NNS	O
(	(	O
less	JJR	O
than	IN	O
5	CD	O
cm	JJ	O
maximum	JJ	O
diameter	NN	O
)	)	O
;	:	O
68	CD	O
were	VBD	O
allocated	VBN	O
to	TO	O
tamoxifen	VB	O
group	NN	O
and	CC	O
67	CD	O
to	TO	O
mastectomy	VB	O
group	NN	O
.	.	O

Histological	JJ	O
diagnosis	NN	O
by	IN	O
biopsy	NN	O
.	.	O

Two	CD	O
incorrect	JJ	O
randomisations	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Patient	NNP	O
characteristics	NNS	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
all	DT	O
under	IN	O
care	NN	O
of	IN	O
one	CD	O
surgical	JJ	O
team	NN	O
.	.	O

INTERVENTIONS	NNP	O
Mastectomy	NNP	O
group	NN	O
received	VBD	O
wedge	JJ	O
mastectomy	NN	O
plus	CC	O
excision	NN	O
of	IN	O
symptomatic	JJ	O
axillary	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Tamoxifen	NNP	O
group	NN	O
received	VBD	O
continuous	JJ	O
treatment	NN	O
with	IN	O
tamoxifen	JJ	O
20	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
.	.	O

Patients	NNS	O
in	IN	O
tamoxifen	JJ	O
group	NN	O
received	VBD	O
wedge	WP	O
mastectomy	NN	O
if	IN	O
there	EX	O
was	VBD	O
sign	NN	O
of	IN	O
local	JJ	O
progression	NN	O
.	.	O

Those	DT	O
in	IN	O
mastectomy	JJ	O
group	NN	O
received	VBD	O
further	JJ	O
excision	NN	O
or	CC	O
radiotherapy	NN	O
for	IN	O
locoregional	JJ	O
recurrence	NN	O
and	CC	O
when	WRB	O
local	JJ	O
treatments	NNS	O
had	VBD	O
been	VBN	O
exhausted	VBN	O
or	CC	O
metastatic	JJ	O
disease	NN	O
diagnosed	VBD	O
they	PRP	O
received	VBD	O
tamoxifen	NN	O
.	.	O

END	JJ	O
POINT	NNP	O
Treatment	NNP	Others
efficacy	NN	Others
was	VBD	O
assessed	VBN	O
by	IN	O
local	JJ	Physical
control	NN	Physical
of	IN	Physical
disease	NN	Physical
and	CC	Physical
by	IN	Physical
survival	NN	Mortality
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Mortality	NNP	Mortality
from	IN	O
metastatic	JJ	O
cancer	NN	O
in	IN	O
tamoxifen	NN	O
group	NN	O
was	VBD	O
7	CD	O
(	(	O
10.6	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
mastectomy	JJ	O
group	NN	O
10	CD	O
(	(	O
15.3	CD	O
%	NN	O
)	)	O
(	(	O
NS	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	Mortality
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
mastectomy	JJ	O
group	NN	O
70	CD	O
%	NN	O
remained	VBD	O
alive	JJ	O
and	CC	O
free	JJ	Physical
of	IN	Physical
local	JJ	Physical
recurrence	NN	Physical
at	IN	O
24	CD	O
months	NNS	O
;	:	O
in	IN	O
tamoxifen	NN	O
group	NN	O
only	RB	O
47	CD	O
%	NN	O
remained	VBD	O
alive	JJ	O
and	CC	O
free	JJ	O
of	IN	O
local	JJ	O
progression	NN	O
.	.	O

In	IN	O
mastectomy	JJ	O
group	NN	O
locoregional	JJ	Physical
recurrence	NN	Physical
occurred	VBD	O
in	IN	O
16	CD	O
patients	NNS	O
and	CC	O
metastatic	JJ	O
disease	NN	O
in	IN	O
13	CD	O
;	:	O
in	IN	O
tamoxifen	NN	O
group	NN	O
locoregional	JJ	Physical
progression	NN	Physical
occurred	VBD	O
in	IN	O
29	CD	O
patients	NNS	O
and	CC	O
metastatic	JJ	O
disease	NN	O
in	IN	O
seven	CD	O
.	.	O

CONCLUSIONS	NNP	O
As	IN	O
a	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	NNS	O
eventually	RB	O
required	VBN	O
surgery	NN	O
treatment	NN	O
of	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
should	MD	O
include	VB	O
mastectomy	NN	O
.	.	O

Optimum	NNP	O
treatment	NN	O
may	MD	O
include	VB	O
both	DT	O
mastectomy	NNS	O
and	CC	O
tamoxifen	NN	O
.	.	O

Control	NN	O
of	IN	O
the	DT	O
lumbar	NN	O
neutral	JJ	O
zone	NN	O
decreases	VBZ	O
low	JJ	Pain
back	RB	Pain
pain	NN	Pain
and	CC	O
improves	VBZ	Physical
self-evaluated	JJ	Mental
work	NN	Mental
ability	NN	Mental
:	:	O
a	DT	O
12-month	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	NN	O
controlled	VBD	O
study	NN	O
with	IN	O
12	CD	O
months	NNS	O
intervention	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
training	NN	O
intervention	NN	O
with	IN	O
emphases	NNS	O
on	IN	O
the	DT	O
control	NN	O
of	IN	O
lumbar	JJ	O
neutral	JJ	O
zone	NN	O
(	(	O
NZ	NNP	O
)	)	O
and	CC	O
behavior	JJ	O
modeling	NN	O
as	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
low	JJ	Pain
back	RB	Pain
pain	NN	Pain
(	(	Pain
LBP	NNP	Pain
)	)	Pain
and	CC	O
disability	NN	Physical
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
Improving	NNP	O
the	DT	O
control	NN	O
of	IN	O
lumbar	NN	O
NZ	NNP	O
and	CC	O
enhancing	VBG	O
muscle	NN	O
activation	NN	O
patterns	NNS	O
ensuring	VBG	O
spinal	JJ	O
stability	NN	O
have	VBP	O
been	VBN	O
proposed	VBN	O
as	IN	O
means	NNS	O
for	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
LBP	NNP	Pain
and	CC	O
disability	NN	Physical
.	.	O

In	IN	O
addition	NN	O
,	,	O
cognitive	JJ	O
behavior	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
recurrence	NN	O
of	IN	O
LBP	NNP	Pain
and	CC	O
long-term	JJ	Physical
disability	NN	Physical
.	.	O

METHODS	NNP	O
Middle-aged	JJ	O
working	VBG	O
men	NNS	O
with	IN	O
recent	JJ	O
LBP	NNP	O
but	CC	O
without	IN	O
severe	JJ	O
disability	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
training	NN	O
(	(	O
TG	NNP	O
,	,	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
CG	NNP	O
,	,	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
exercise	VB	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
12	CD	O
months	NNS	O
,	,	O
once	RB	O
guided	VBN	O
and	CC	O
once	RB	O
independently	RB	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
changes	NNS	O
in	IN	O
intensity	NN	O
of	IN	O
LBP	NNP	Pain
,	,	O
disability	NN	Physical
,	,	O
self-evaluated	JJ	Physical
future	NN	Physical
work	NN	Physical
ability	NN	Physical
,	,	O
and	CC	O
neuromuscular	JJ	Physical
fitness	NN	Physical
.	.	O

RESULTS	VB	O
The	DT	O
intensity	NN	Pain
of	IN	Pain
LBP	NNP	Pain
decreased	VBD	O
significantly	RB	O
more	JJR	O
(	(	O
39	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TG	NNP	O
than	IN	O
in	IN	O
CG	NNP	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

The	DT	O
proportion	NN	Physical
of	IN	Physical
subjects	NNS	Physical
with	IN	Physical
negative	JJ	Physical
expectations	NNS	Physical
about	IN	Physical
their	PRP$	Physical
future	NN	Physical
work	NN	Physical
ability	NN	Physical
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
;	:	O
however	RB	O
,	,	O
the	DT	O
proportion	NN	O
was	VBD	O
significantly	RB	O
bigger	JJR	O
in	IN	O
TG	NNP	O
compared	VBN	O
with	IN	O
CG	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
.	.	O

There	EX	O
effects	NNS	O
on	IN	O
disability	NN	Others
indexes	NNS	Others
and	CC	Others
fitness	NN	Others
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Controlling	NNP	O
lumbar	NN	O
NZ	NNP	O
is	VBZ	O
a	DT	O
specific	JJ	O
form	NN	O
of	IN	O
exercise	NN	O
and	CC	O
daily	JJ	O
self-care	NN	O
with	IN	O
potential	JJ	O
for	IN	O
prevention	NN	O
of	IN	O
recurrent	NN	O
nonspecific	JJ	O
LBP	NNP	O
and	CC	O
disability	NN	O
among	IN	O
middle	JJ	O
aged	VBN	O
working	VBG	O
men	NNS	O
.	.	O

Adjuvant	NNP	O
goserelin	NN	O
and	CC	O
ovarian	JJ	O
preservation	NN	O
in	IN	O
chemotherapy	NN	O
treated	VBD	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
if	IN	O
goserelin	JJ	O
concomitant	NN	O
to	TO	O
CMF-chemotherapy	NNP	O
as	IN	O
adjuvant	JJ	O
treatment	NN	O
for	IN	O
premenopausal	NN	O
breast	NN	O
cancer	NN	O
,	,	O
protects	VBZ	Mental
the	DT	Mental
ovaries	NNS	Mental
from	IN	O
premature	JJ	O
failure	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
285	CD	O
premenopausal	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
adjuvant	JJ	O
trial	NN	O
(	(	O
Zoladex	NNP	O
in	IN	O
premenopausal	NN	O
patients	NNS	O
(	(	O
ZIPP	NNP	O
)	)	O
)	)	O
,	,	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
study	NN	O
on	IN	O
ovarian	JJ	O
function	NN	O
.	.	O

Node	NNP	O
positive	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
CMF-	NNP	O
(	(	O
cyclophosphamide	NN	O
,	,	O
methotrexate	NN	O
and	CC	O
5-fluorouracil	NN	O
)	)	O
chemotherapy	NN	O
in	IN	O
addition	NN	O
to	TO	O
endocrine	VB	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
2	CD	O
years	NNS	O
of	IN	O
goserelin	NN	O
,	,	O
goserelin	NN	O
plus	CC	O
tamoxifen	NN	O
,	,	O
tamoxifen	VB	O
alone	RB	O
or	CC	O
no	DT	O
endocrine	JJ	O
treatment	NN	O
.	.	O

We	PRP	O
studied	VBD	O
,	,	O
if	IN	O
menses	NNS	Pain
were	VBD	O
affected	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
up	RB	O
to	TO	O
36	CD	O
months	NNS	O
after	IN	O
randomization	NN	O
.	.	O

One	CD	O
year	NN	O
after	IN	O
completed	VBN	O
CMF-	NNP	O
and	CC	O
endocrine	JJ	O
therapy	NN	O
,	,	O
36	CD	O
%	NN	O
of	IN	O
the	DT	O
women	NNS	O
in	IN	O
the	DT	O
goserelin	NN	O
group	NN	O
reported	VBD	O
menses	NNS	Physical
,	,	O
compared	VBN	O
to	TO	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
goserelin	NN	O
plus	CC	O
tamoxifen	JJ	O
group	NN	O
,	,	O
13	CD	O
%	NN	O
in	IN	O
the	DT	O
tamoxifen	NN	O
group	NN	O
and	CC	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
controls	NNS	O
.	.	O

Among	IN	O
women	NNS	O
treated	VBN	O
with	IN	O
goserelin	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	Physical
in	IN	O
the	DT	O
proportion	NN	Physical
of	IN	Physical
menstruating	VBG	Physical
women	NNS	Physical
,	,	O
1	CD	O
year	NN	O
after	IN	O
completed	VBN	O
treatment	NN	O
compared	VBN	O
to	TO	O
at	IN	O
24	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
all	DT	O
other	JJ	O
treatment	NN	O
groups	NNS	O
,	,	O
who	WP	O
were	VBD	O
unchanged	JJ	O
or	CC	O
more	RBR	O
often	RB	O
amenorrheic	JJ	Others
.	.	Others

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
there	EX	O
is	VBZ	O
some	DT	O
evidence	NN	O
of	IN	O
protective	JJ	Others
effect	NN	Others
of	IN	Others
goserelin	NN	Others
on	IN	Others
ovarian	JJ	Others
function	NN	Others
in	IN	O
CMF	NNP	O
treated	VBD	O
women	NNS	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
the	DT	O
combined	JJ	O
tamoxifen	NN	O
and	CC	O
goserelin	NN	O
treatment	NN	O
.	.	O

Safety	NN	Others
,	,	O
tolerability	NN	Others
,	,	O
and	CC	O
changes	NNS	Physical
in	IN	Physical
amyloid	JJ	Physical
beta	NN	Physical
concentrations	NNS	Physical
after	IN	O
administration	NN	O
of	IN	O
a	DT	O
gamma-secretase	JJ	O
inhibitor	NN	O
in	IN	O
volunteers	NNS	O
.	.	O

Amyloid	NNP	O
beta	NN	O
(	(	O
Abeta	NNP	O
)	)	O
may	MD	O
play	VB	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
Alzheimer	NNP	O
disease	NN	O
.	.	O

A	DT	O
functional	JJ	O
gamma-secretase	NN	O
inhibitor	NN	O
,	,	O
LY450139	NNP	O
,	,	O
was	VBD	O
developed	VBN	O
that	IN	O
inhibits	NNS	O
Abeta	NNP	O
formation	NN	O
in	IN	O
whole	JJ	O
cell	NN	O
assays	NNS	O
,	,	O
transgenic	JJ	O
mice	NN	O
,	,	O
and	CC	O
beagle	JJ	O
dogs	NNS	O
.	.	O

The	DT	O
authors	NNS	O
wished	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
this	DT	O
drug	NN	O
,	,	O
and	CC	O
the	DT	O
reduction	NN	O
of	IN	O
Abeta	NNP	Physical
in	IN	Physical
plasma	NN	Physical
and	CC	Physical
cerebrospinal	JJ	Physical
fluid	NN	Physical
(	(	Physical
CSF	NNP	Physical
)	)	Physical
after	IN	O
multiple	JJ	O
doses	NNS	O
.	.	O

Volunteer	NNP	O
subjects	NNS	O
(	(	O
N	NNP	O
=	NNP	O
37	CD	O
)	)	O
were	VBD	O
studied	VBN	O
using	VBG	O
doses	NNS	O
from	IN	O
5	CD	O
to	TO	O
50	CD	O
mg/day	NN	O
given	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Plasma	NNP	Physical
and	CC	Physical
CSF	NNP	Physical
concentrations	NNS	Physical
of	IN	Physical
LY450139	NNP	Physical
,	,	Physical
Abeta	NNP	Physical
(	(	Physical
1-40	JJ	Physical
)	)	Physical
and	CC	O
Abeta	NNP	Physical
(	(	Physical
1-X	JJ	Physical
)	)	Physical
(	(	Physical
Abeta	NNP	Physical
(	(	Physical
total	JJ	Physical
)	)	Physical
)	)	Physical
were	VBD	O
determined	VBN	O
,	,	O
and	CC	O
safety	NN	O
and	CC	O
tolerability	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
plasma	JJ	O
half-life	NN	O
of	IN	O
LY450139	NNP	O
was	VBD	O
approximately	RB	O
2.5	CD	O
hours	NNS	O
.	.	O

Pharmacokinetic	JJ	O
analyses	NNS	O
showed	VBD	O
a	DT	O
linear	JJ	O
relationship	NN	O
between	IN	O
dose	NN	O
and	CC	O
plasma	JJ	O
concentrations	NNS	O
,	,	O
with	IN	O
a	DT	O
Cmax	NNP	O
of	IN	O
828	CD	O
+/-	JJ	O
19.2	CD	O
ng/mL	NN	O
after	IN	O
a	DT	O
50-mg	JJ	O
dose	NN	O
.	.	O

Plasma	NNP	Physical
Abeta	NNP	Physical
concentrations	NNS	Physical
decreased	VBD	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
over	IN	O
a	DT	O
6-hour	JJ	O
interval	NN	O
following	VBG	O
drug	NN	O
administration	NN	O
,	,	O
with	IN	O
a	DT	O
maximum	JJ	O
decrease	NN	O
of	IN	O
approximately	RB	O
40	CD	O
%	NN	O
relative	JJ	O
to	TO	O
baseline	VB	O
.	.	O

After	IN	O
returning	VBG	O
to	TO	O
baseline	VB	O
,	,	O
Abeta	NNP	Physical
concentrations	NNS	Physical
were	VBD	O
transiently	RB	O
increased	VBN	O
.	.	O

CSF	NNP	Physical
Abeta	NNP	Physical
concentrations	NNS	Physical
were	VBD	O
unchanged	JJ	O
.	.	O

Adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
5-mg	JJ	O
,	,	O
20-mg	JJ	O
,	,	O
or	CC	O
40-mg	JJ	O
doses	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
placebo	NN	O
.	.	O

Two	CD	O
of	IN	O
7	CD	O
subjects	NNS	O
taking	VBG	O
50	CD	O
mg/day	NN	O
experienced	VBD	O
adverse	JJ	O
events	NNS	O
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
drug	NN	O
related	VBN	O
.	.	O

In	IN	O
this	DT	O
phase	NN	O
1	CD	O
volunteer	NN	O
study	NN	O
,	,	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
after	IN	O
taking	VBG	O
LY450139	NNP	O
were	VBD	O
manageable	JJ	O
.	.	O

A	DT	O
dose-dependent	JJ	O
reduction	NN	O
in	IN	O
plasma	NN	Physical
Abeta	NNP	Physical
was	VBD	O
demonstrated	VBN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
plasma	NN	Physical
Abeta	NNP	Physical
concentrations	NNS	O
were	VBD	O
temporally	RB	O
related	VBN	O
to	TO	O
the	DT	O
pharmacokinetic	JJ	O
characteristics	NNS	O
of	IN	O
LY450139	NNP	O
.	.	O

Effect	NN	O
of	IN	O
an	DT	O
induction	NN	O
period	NN	O
of	IN	O
pegylated	JJ	O
interferon-?2a	JJ	O
and	CC	O
ribavirin	VB	O
on	IN	O
early	JJ	O
virological	JJ	O
response	NN	O
in	IN	O
HIV-HCV-coinfected	JJ	O
patients	NNS	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
CORAL-2	NNP	O
study	NN	O
.	.	O

BACKGROUND	IN	O
It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
a	DT	O
4-week	JJ	O
induction	NN	O
period	NN	O
of	IN	O
pegylated	JJ	O
interferon	NN	O
and	CC	O
ribavirin	NN	O
increases	NNS	O
early	RB	O
virological	JJ	O
response	NN	O
(	(	O
EVR	NNP	O
)	)	O
in	IN	O
HIV-HCV-coinfected	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
HIV	NNP	O
and	CC	O
HCV	NNP	O
genotype	VBP	O
1-	JJ	O
and	CC	O
4-coinfected	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
pegylated	VBN	O
interferon-?2a	JJ	O
270	CD	O
?g/week	JJ	O
plus	CC	O
ribavirin	JJ	O
1,600	CD	O
mg	JJ	O
daily	JJ	O
and	CC	O
epoetin-?	JJ	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
pegylated	JJ	O
interferon-?2a	NN	O
at	IN	O
standard	JJ	O
dosages	NNS	O
plus	CC	O
weight-based	JJ	O
ribavirin	NN	O
(	(	O
WBR	NNP	O
)	)	O
dosage	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
(	(	O
induction	NN	O
arm	NN	O
[	NNP	O
IA	NNP	O
]	NNP	O
)	)	O
,	,	O
or	CC	O
pegylated	VBD	O
interferon-?2a	JJ	O
plus	CC	O
WBR	NNP	O
for	IN	O
12	CD	O
weeks	NNS	O
(	(	O
standard	JJ	O
therapy	NN	O
arm	NN	O
[	NNP	O
SA	NNP	O
]	NNP	O
)	)	O
.	.	O

HCV	NNP	O
RNA	NNP	O
was	VBD	O
determined	VBN	O
at	IN	O
weeks	NNS	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
and	CC	O
12	CD	O
.	.	O

Ribavirin	NNP	O
plasma	VBD	O
trough	JJ	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
at	IN	O
weeks	NNS	O
4	CD	O
(	(	O
RBV-C	NNP	O
(	(	O
4	CD	O
)	)	O
)	)	O
and	CC	O
12	CD	O
(	(	O
RBV-C	NNP	O
(	(	O
12	CD	O
)	)	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
67	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
;	:	O
33	CD	O
in	IN	O
the	DT	O
SA	NNP	O
and	CC	O
34	CD	O
in	IN	O
the	DT	O
IA	NNP	O
.	.	O

Overall	NNP	O
,	,	O
25	CD	O
%	NN	O
received	VBD	O
nucleoside	JJ	O
reverse	NN	O
transcriptase	NN	O
inhibitor	NN	O
(	(	O
NRTI	NNP	O
)	)	O
-sparing	VBG	O
regimens	NNS	O
.	.	O

More	JJR	O
patients	NNS	O
achieved	VBD	O
an	DT	O
HCV	NNP	O
RNA	NNP	O
decrease	NN	O
?1	NNP	O
log	NN	O
(	(	O
10	CD	O
)	)	O
at	IN	O
week	NN	O
4	CD	O
in	IN	O
the	DT	O
IA	NNP	O
than	IN	O
in	IN	O
the	DT	O
SA	NNP	O
(	(	O
62	CD	O
%	NN	O
versus	IN	O
38	CD	O
%	NN	O
;	:	O
P=0.017	NNP	O
)	)	O
,	,	O
but	CC	O
EVR	NNP	O
rates	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
74	CD	O
%	NN	O
versus	IN	O
59	CD	O
%	NN	O
in	IN	O
the	DT	O
IA	NNP	O
and	CC	O
SA	NNP	O
,	,	O
respectively	RB	O
;	:	O
P=0.15	NNP	O
)	)	O
.	.	O

Independent	JJ	O
predictors	NNS	O
of	IN	O
faster	NN	O
HCV	NNP	O
RNA	NNP	O
decrease	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
were	VBD	O
higher	JJR	O
RBV-C	NNP	O
(	(	O
4	CD	O
)	)	O
and	CC	O
younger	JJR	O
age	NN	O
.	.	O

RBV-C	NNP	O
(	(	O
4	CD	O
)	)	O
were	VBD	O
higher	JJR	O
in	IN	O
patients	NNS	O
allocated	VBN	O
in	IN	O
the	DT	O
IA	NNP	O
and	CC	O
in	IN	O
those	DT	O
receiving	VBG	O
NRTIs	NNP	O
(	(	O
P=0.039	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
4-week	JJ	O
induction	NN	O
with	IN	O
pegylated	JJ	O
interferon-?2a	JJ	O
plus	CC	O
ribavirin	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
greater	JJR	O
decrease	NN	O
in	IN	O
HCV	NNP	O
RNA	NNP	O
at	IN	O
week	NN	O
4	CD	O
;	:	O
however	RB	O
,	,	O
this	DT	O
did	VBD	O
not	RB	O
translate	VB	O
into	IN	O
higher	JJR	O
EVR	NN	O
rates	NNS	O
.	.	O

Higher	JJR	O
RBV	NNP	O
doses	NNS	O
and	CC	O
avoidance	NN	O
of	IN	O
NRTI-sparing	NNP	O
antiretroviral	JJ	O
regimens	NNS	O
might	MD	O
improve	VB	O
HCV	NNP	O
treatment	NN	O
efficacy	NN	O
.	.	O

Final	JJ	O
report	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
with	IN	O
streptococcal	JJ	O
preparation	NN	O
OK-432	NNP	O
as	IN	O
a	DT	O
supplementary	JJ	O
immunopotentiator	NN	O
for	IN	O
laryngeal	JJ	O
cancer	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
of	IN	O
streptococcal	JJ	O
preparation	NN	O
OK-432	NNP	O
on	IN	O
120	CD	O
newly	RB	O
identified	VBN	O
cases	NNS	O
of	IN	O
laryngeal	JJ	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
who	WP	O
were	VBD	O
registered	VBN	O
at	IN	O
10	CD	O
participating	VBG	O
institutions	NNS	O
between	IN	O
November	NNP	O
1984	CD	O
and	CC	O
October	NNP	O
1989	CD	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
those	DT	O
in	IN	O
early	JJ	O
stages	NNS	O
(	(	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
)	)	O
and	CC	O
those	DT	O
in	IN	O
advanced	JJ	O
stages	NNS	O
(	(	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
)	)	O
;	:	O
these	DT	O
groups	NNS	O
were	VBD	O
further	RB	O
subdivided	VBN	O
into	IN	O
an	DT	O
immunotherapy	NN	O
group	NN	O
(	(	O
receiving	VBG	O
OK-432	NNP	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
OK-432	NNP	O
)	)	O
.	.	O

The	DT	O
usefulness	NN	O
of	IN	O
OK-432	NNP	O
was	VBD	O
studied	VBN	O
using	VBG	O
the	DT	O
sealed	VBN	O
envelope	NN	O
method	NN	O
.	.	O

The	DT	O
basic	JJ	O
therapy	NN	O
for	IN	O
all	DT	O
cases	NNS	O
was	VBD	O
radiotherapy	NN	O
and	CC	O
,	,	O
when	WRB	O
required	VBN	O
,	,	O
surgery	NN	O
.	.	O

As	IN	O
adjuvant	JJ	O
therapy	NN	O
,	,	O
5Fu	CD	O
or	CC	O
derivatives	NNS	O
were	VBD	O
administered	VBN	O
to	TO	O
all	DT	O
cases	NNS	O
from	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
to	TO	O
one	CD	O
year	NN	O
after	IN	O
the	DT	O
basic	JJ	O
therapy	NN	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
cases	NNS	O
in	IN	O
whom	WP	O
side	NN	O
effects	NNS	O
were	VBD	O
serious	JJ	O
enough	RB	O
to	TO	O
contraindicate	VB	O
use	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

The	DT	O
target	NN	O
administration	NN	O
period	NN	O
was	VBD	O
5	CD	O
years	NNS	O
.	.	O

Of	IN	O
the	DT	O
initial	JJ	O
120	CD	O
cases	NNS	O
,	,	O
11	CD	O
cases	NNS	O
were	VBD	O
disqualified	VBN	O
(	(	O
3	CD	O
cases	NNS	O
of	IN	O
double	JJ	O
cancer	NN	O
and	CC	O
8	CD	O
of	IN	O
incomplete	JJ	O
primary	JJ	O
therapy	NN	O
)	)	O
and	CC	O
the	DT	O
remaining	VBG	O
109	CD	O
were	VBD	O
used	VBN	O
for	IN	O
evaluation	NN	O
.	.	O

The	DT	O
5-year	JJ	Mental
survival	NN	Mental
rate	NN	Mental
and	CC	Mental
the	DT	Mental
5-year	JJ	Mental
recurrence-free	JJ	Mental
rate	NN	Mental
were	VBD	O
76	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
immunized	JJ	O
groups	NNS	O
(	(	O
both	DT	O
the	DT	O
early	JJ	O
and	CC	O
advanced	JJ	O
groups	NNS	O
)	)	O
,	,	O
whereas	VBP	O
the	DT	O
same	JJ	O
rates	NNS	O
for	IN	O
the	DT	O
control	NN	O
groups	NNS	O
were	VBD	O
78	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
tendency	NN	O
for	IN	O
the	DT	O
immunized	JJ	O
groups	NNS	O
to	TO	O
enjoy	VB	O
a	DT	O
slightly	RB	Mental
longer	RBR	Mental
recurrence-free	JJ	Mental
period	NN	Mental
.	.	Physical

Over	IN	O
a	DT	O
24-month	JJ	O
observation	NN	O
period	NN	O
the	DT	O
immunized	JJ	O
group	NN	O
always	RB	O
had	VBD	O
higher	JJR	O
levels	NNS	Physical
of	IN	Physical
peripheral	JJ	Physical
leukocytes	NNS	Physical
and	CC	Physical
peripheral	JJ	Physical
lymphocytes	NNS	Physical
;	:	Physical
this	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
first	JJ	O
21	CD	O
months	NNS	O
.	.	O

Inhibition	NN	Physical
of	IN	Physical
bone	NN	Physical
marrow	NN	Physical
function	NN	Physical
is	VBZ	O
sometimes	RB	O
observed	VBN	O
with	IN	O
radiotherapy	NN	O
.	.	O

It	PRP	O
is	VBZ	O
hoped	VBN	O
that	IN	O
,	,	O
if	IN	O
this	DT	O
inhibition	NN	O
can	MD	O
be	VB	O
mitigated	VBN	O
,	,	O
it	PRP	O
will	MD	O
be	VB	O
possible	JJ	O
to	TO	O
assist	VB	O
the	DT	O
compromised	VBN	O
immune	NN	O
system	NN	O
and	CC	O
maintain	VB	O
a	DT	O
certain	JJ	Physical
level	NN	Physical
of	IN	Physical
immune	JJ	Physical
performance	NN	Physical
which	WDT	O
will	MD	O
prevent	VB	O
recurrence	NN	O
and	CC	O
improve	VB	Mortality
survival	NN	Mortality
rate	NN	Mortality
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
observed	VBD	O
a	DT	O
tendency	NN	O
of	IN	O
the	DT	O
lower	JJR	O
recurrence	NN	O
rate	NN	O
in	IN	O
the	DT	O
immunized	JJ	O
group	NN	O
,	,	O
and	CC	O
we	PRP	O
hypothesize	VBP	O
that	IN	O
OK-432	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
extending	VBG	O
the	DT	O
recurrence-free	JJ	O
period	NN	O
.	.	O

Dose	NNP	O
dependent	JJ	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
:	:	O
Michaelis-Menten	JJ	O
parameters	NNS	O
for	IN	O
its	PRP$	O
major	JJ	O
metabolic	JJ	O
pathways	NNS	O
.	.	O

Dose	NNP	O
Dependency	NNP	O
for	IN	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
,	,	O
3-methylxanthine	JJ	O
(	(	O
3-MX	JJ	O
)	)	O
;	:	O
1-methyluric	JJ	O
acid	NN	O
(	(	O
1-MU	JJ	O
)	)	O
;	:	O
1,3-dimethyluric	JJ	O
acid	NN	O
(	(	O
DMU	NNP	O
)	)	O
,	,	O
were	VBD	O
examined	VBN	O
by	IN	O
administering	VBG	O
three	CD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
250	CD	O
,	,	O
375	CD	O
,	,	O
500	CD	O
mg	NN	O
)	)	O
of	IN	O
theophylline	NN	O
to	TO	O
six	CD	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
serum	NN	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
theophylline	NN	O
and	CC	O
the	DT	O
metabolites	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Total	JJ	Others
clearance	NN	Others
of	IN	O
theophylline	NN	O
decreased	VBN	O
and	CC	O
its	PRP$	O
half	JJ	O
life	NN	O
increased	VBD	O
over	IN	O
the	DT	O
range	NN	O
of	IN	O
doses	NNS	O
administered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
dose	NN	O
related	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
fractional	JJ	O
recovery	NN	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
related	JJ	O
increase	NN	O
in	IN	O
fractional	JJ	Mental
excretion	NN	Mental
of	IN	Mental
DMU	NNP	Mental
and	CC	O
unchanged	JJ	O
theophylline	NN	O
(	(	O
p	JJ	O
<	NN	O
0.01	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
dose	NN	O
related	VBN	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
renal	JJ	Mental
clearance	NN	Mental
of	IN	Mental
3-MX	JJ	Mental
,	,	O
1-MU	JJ	Mental
and	CC	O
DMU	NNP	Mental
,	,	O
indicating	VBG	O
linear	JJ	O
urinary	JJ	O
excretion	NN	O
kinetics	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
.	.	O

Theophylline	NNP	Mental
metabolic	JJ	Mental
clearance	NN	Mental
to	TO	Mental
3-MX	JJ	Mental
as	RB	O
well	RB	O
as	IN	O
to	TO	O
1-MU	CD	O
decreased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
but	CC	O
clearance	NN	O
to	TO	O
DMU	NNP	O
remained	VBD	O
unnaffected	JJ	O
by	IN	O
the	DT	O
size	NN	O
of	IN	O
dose	NN	O
.	.	O

The	DT	O
individual	JJ	O
Michaelis-Menten	NNP	Others
parameters	NNS	Others
Km	NNP	Others
and	CC	Others
Vmax	NNP	Others
were	VBD	O
estimated	VBN	O
for	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
three	CD	O
different	JJ	O
single	JJ	O
doses	NNS	O
.	.	O

The	DT	O
Km	NNP	Others
values	NNS	Others
for	IN	Others
theophylline	JJ	Others
metabolism	NN	Others
to	TO	Others
3-MX	JJ	Others
,	,	O
1-MU	JJ	Mental
and	CC	O
DMU	NNP	Mental
were	VBD	O
2.4+/-0.6	JJ	O
,	,	O
5.1+/-1.8+/-	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/L	NN	O
respectively	RB	O
and	CC	O
the	DT	O
Vmax	NNP	Others
values	NNS	Others
were	VBD	O
3.5+/-0.7	JJ	O
,	,	O
7.5+/-2.6	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/hr	NN	O
respectively	RB	O
.	.	O

The	DT	O
Km	NNP	Others
values	NNS	Others
for	IN	Others
the	DT	Others
N-demethylation	NNP	Others
pathways	NNS	Others
(	(	Others
3MX	CD	Others
and	CC	Others
1-MU	JJ	Others
)	)	Others
were	VBD	O
lower	JJR	O
corresponding	VBG	O
to	TO	O
therapeutic	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
drug	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
theophylline	NN	O
is	VBZ	O
nonlinear	JJ	O
in	IN	O
the	DT	O
human	NN	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
of	IN	O
serum	JJ	Physical
concenntrations	NNS	Physical
and	CC	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
saturable	JJ	O
formation	NN	O
kinetics	NNS	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
we	PRP	O
did	VBD	O
n't	RB	O
find	VB	O
obvious	JJ	O
indication	NN	O
for	IN	O
nonlinear	JJ	O
formation	NN	O
of	IN	O
DMU	NNP	O
at	IN	O
therapeutic	JJ	O
concentration	NN	O
range	NN	O
.	.	O

Epileptogenic	JJ	O
activity	NN	O
of	IN	O
folic	JJ	O
acid	NN	O
after	IN	O
drug	NN	O
induces	NNS	O
SLE	NNP	O
(	(	O
folic	JJ	O
acid	NN	O
and	CC	O
epilepsy	NN	O
)	)	O
OBJECTIVE	NN	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
folic	JJ	O
acid-containing	JJ	O
multivitamin	NN	O
supplementation	NN	O
in	IN	O
epileptic	JJ	O
women	NNS	O
before	IN	O
and	CC	O
during	IN	O
pregnancy	NN	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
rate	NN	O
of	IN	O
structural	JJ	O
birth	NN	O
defects	NNS	O
and	CC	O
epilepsy-related	JJ	O
side	NN	O
effects	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
First	NNP	O
a	DT	O
randomised	JJ	O
trial	NN	O
,	,	O
later	RB	O
periconception	NN	O
care	NN	O
including	VBG	O
in	IN	O
total	JJ	O
12225	CD	O
females	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
60	CD	O
epileptic	JJ	O
women	NNS	O
with	IN	O
periconceptional	JJ	O
folic	JJ	O
acid	NN	O
(	(	O
0.8	CD	O
mg	NN	O
)	)	O
-containing	VBG	O
multivitamin	JJ	O
supplementation	NN	O
,	,	O
no	DT	O
one	NN	O
developed	VBD	O
epilepsy-related	JJ	O
side	NN	O
effects	NNS	O
during	IN	O
the	DT	O
periconception	NN	O
period	NN	O
.	.	O

One	CD	O
epileptic	JJ	O
woman	NN	O
delivered	VBD	O
a	DT	O
newborn	JJ	O
with	IN	O
cleft	NN	O
lip	NN	O
and	CC	O
palate	NN	O
.	.	O

Another	DT	O
patient	NN	O
exhibited	VBN	O
with	IN	O
a	DT	O
cluster	NN	Adverseeffect
of	IN	Adverseeffect
seizures	NNS	Adverseeffect
after	IN	O
the	DT	O
periconception	NN	O
period	NN	O
using	VBG	O
another	DT	O
multivitamin	NN	O
.	.	O

This	DT	O
22-year-old	JJ	O
epileptic	JJ	O
woman	NN	O
was	VBD	O
treated	VBN	O
continuously	RB	O
by	IN	O
carbamazepine	NN	O
and	CC	O
a	DT	O
folic	JJ	O
acid	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
-containing	VBG	O
multivitamin	NN	O
from	IN	O
the	DT	O
20th	JJ	O
week	NN	O
of	IN	O
gestation	NN	O
.	.	O

She	PRP	O
developed	VBD	O
status	NN	Adverseeffect
epilepticus	NN	Adverseeffect
and	CC	O
later	RB	O
symptoms	NNS	Adverseeffect
of	IN	Adverseeffect
systemic	JJ	Adverseeffect
lupus	NN	Adverseeffect
erythematodes	NNS	Adverseeffect
.	.	O

Her	PRP$	O
pregnancy	NN	O
ended	VBN	O
with	IN	O
stillbirth	NN	Mortality
.	.	O

CONCLUSIONS	VB	O
The	DT	O
epileptic	JJ	O
pregnant	JJ	O
patient	NN	O
's	POS	O
autoimmune	JJ	O
disease	NN	O
(	(	O
probably	RB	O
drug-induced	JJ	O
lupus	NN	O
)	)	O
could	MD	O
damage	VB	O
the	DT	O
blood-brain	JJ	O
barrier	NN	O
,	,	O
therefore	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
(	(	O
>	CD	O
or	CC	O
=1	VB	O
mg	NN	O
)	)	O
of	IN	O
folic	JJ	O
acid	NN	O
triggered	VBD	O
a	DT	O
cluster	NN	Adverseeffect
of	IN	Adverseeffect
seizures	NNS	Adverseeffect
.	.	O

Physiological	NNP	O
dose	NN	O
(	(	O
<	JJ	O
1	CD	O
mg	NN	O
)	)	O
of	IN	O
folic	JJ	O
acid	NNS	O
both	DT	O
in	IN	O
healthy	JJ	O
and	CC	O
60	CD	O
epileptic	JJ	O
women	NNS	O
,	,	O
all	DT	O
without	IN	O
any	DT	O
autoimmune	JJ	O
disease	NN	O
,	,	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	Physical
for	IN	Physical
epileptic	JJ	Physical
seizures	NNS	Physical
.	.	O

Identifying	VBG	O
the	DT	O
indications	NNS	O
for	IN	O
laparoscopically	RB	O
assisted	VBN	O
vaginal	JJ	O
hysterectomy	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
comparison	NN	O
with	IN	O
abdominal	JJ	O
hysterectomy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
uterine	JJ	O
fibroids	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
laparoscopically	RB	O
assisted	VBN	O
vaginal	JJ	O
hysterectomy	NN	O
(	(	O
LAVH	NNP	O
)	)	O
and	CC	O
total	JJ	O
abdominal	JJ	O
hysterectomy	NN	O
(	(	O
TAH	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
uterine	JJ	O
fibroids	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
randomised	VBN	O
study	NN	O
.	.	O

SETTING	CC	O
The	DT	O
San	NNP	O
Paolo	NNP	O
Hospital	NNP	O
,	,	O
Milan	NNP	O
.	.	O

POPULATION	NNP	O
Sixty-two	JJ	O
patients	NNS	O
,	,	O
who	WP	O
were	VBD	O
not	RB	O
suitable	JJ	O
for	IN	O
a	DT	O
vaginal	JJ	O
hysterectomy	NN	O
,	,	O
requiring	VBG	O
treatment	NN	O
for	IN	O
uterine	JJ	O
fibroids	NNS	O
.	.	O

METHODS	NNP	O
Randomisation	NNP	O
between	IN	O
LAVH	NNP	O
and	CC	O
TAH	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
outcomes	NNS	O
on	IN	O
the	DT	O
whole	JJ	O
series	NN	O
,	,	O
patients	NNS	O
with	IN	O
uteri	JJ	O
<	NN	O
or	CC	O
=	$	O
500	CD	O
g	NN	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
and	CC	O
patients	NNS	O
with	IN	O
uteri	JJ	O
>	$	O
500	CD	O
g	NN	O
(	(	O
Group	NNP	O
2	CD	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
To	TO	O
establish	VB	O
operating	NN	Others
time	NN	Others
,	,	O
blood	NN	Physical
loss	NN	Physical
,	,	O
complications	NNS	Adverseeffect
,	,	O
febrile	JJ	Mortality
morbidity	NN	Mortality
,	,	O
analgesics	NNS	Others
administration	NN	Others
and	CC	O
hospital	JJ	Others
stay	NN	Others
for	IN	O
both	DT	O
treatment	NN	O
approaches	NNS	O
.	.	O

RESULTS	NNP	O
Median	JJ	Physical
uterine	JJ	Physical
weight	NN	Physical
was	VBD	O
400	CD	O
g	NN	O
in	IN	O
both	DT	O
LAVH	NNP	O
and	CC	O
TAH	NNP	O
group	NN	O
.	.	O

Median	JJ	Others
operating	NN	Others
time	NN	Others
was	VBD	O
longer	RBR	O
for	IN	O
LAVH	NNP	O
(	(	O
135	CD	O
min	NNS	O
compared	VBN	O
with	IN	O
120	CD	O
min	NNS	O
for	IN	O
TAH	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
patients	NNS	O
undergoing	JJ	O
LAVH	NNP	O
had	VBD	O
less	RBR	O
analgesics	JJ	Physical
administration	NN	Physical
(	(	O
23	CD	O
%	NN	O
compared	VBN	O
with	IN	O
77	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
shorter	NN	O
median	JJ	Others
hospital	NN	Others
stay	NN	Others
(	(	O
3.8	CD	O
compared	VBN	O
with	IN	O
5.8	CD	O
days	NNS	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

LAVH	NNP	O
,	,	O
when	WRB	O
compared	VBN	O
with	IN	O
TAH	NNP	O
in	IN	O
the	DT	O
two	CD	O
weight	NN	O
subgroups	NNS	O
,	,	O
required	VBD	O
a	DT	O
significantly	RB	O
longer	RBR	O
operating	VBG	Others
time	NN	Others
only	RB	O
in	IN	O
Group	NNP	O
2	CD	O
,	,	O
significantly	RB	O
reduced	VBN	O
analgesics	NNS	Physical
administration	NN	Physical
only	RB	O
in	IN	O
Group	NNP	O
1	CD	O
,	,	O
and	CC	O
significantly	RB	O
reduced	VBN	O
hospital	NN	Others
stay	NN	Others
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Conversions	NNS	O
of	IN	O
LAVH	NNP	O
to	TO	O
laparotomy	VB	O
were	VBD	O
significantly	RB	O
more	RBR	O
frequent	JJ	O
in	IN	O
Group	NNP	O
2	CD	O
(	(	O
3/11	CD	O
)	)	O
than	IN	O
in	IN	O
Group	NNP	O
1	CD	O
(	(	O
0/20	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
TAH	NNP	O
,	,	O
LAVH	NNP	O
has	VBZ	O
advantages	NNS	Others
in	IN	O
removing	VBG	O
uteri	JJ	O
weighing	VBG	O
<	NN	O
or	CC	O
=	$	O
500	CD	O
g	NN	O
,	,	O
with	IN	O
comparable	JJ	O
operating	NN	Others
time	NN	Others
,	,	O
less	JJR	O
post-operative	JJ	Pain
pain	NN	Pain
and	CC	O
shorter	JJR	O
recovery	NN	Physical
.	.	O

Among	IN	O
uteri	JJ	O
weighing	VBG	O
>	JJ	O
500	CD	O
g	NN	O
LAVH	NNP	O
showed	VBD	O
a	DT	O
shorter	NN	O
recovery	NN	O
,	,	O
but	CC	O
longer	JJR	O
operating	NN	O
time	NN	O
than	IN	O
TAH	NNP	O
and	CC	O
a	DT	O
27	CD	O
%	NN	O
rate	NN	O
of	IN	O
conversion	NN	Physical
to	TO	Physical
laparotomy	VB	Physical
.	.	O

A	DT	O
1.5-year	JJ	O
follow-up	NN	O
of	IN	O
an	DT	O
Internet-based	JJ	O
intervention	NN	O
for	IN	O
complicated	JJ	O
grief	NN	O
.	.	O

Only	RB	O
recently	RB	O
have	VBP	O
psychotherapeutic	JJ	O
interventions	NNS	O
for	IN	O
complicated	JJ	O
grief	NN	O
been	VBN	O
developed	VBN	O
and	CC	O
evaluated	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

These	DT	O
trials	NNS	O
have	VBP	O
reported	VBN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
complicated	JJ	O
grief	NN	O
and	CC	O
related	JJ	O
symptoms	NNS	O
in	IN	O
response	NN	O
to	TO	O
treatment	NN	O
relative	JJ	O
to	TO	O
control	VB	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
long-term	JJ	O
outcomes	NNS	O
of	IN	O
these	DT	O
treatments	NNS	O
.	.	O

The	DT	O
authors	NNS	O
present	VBP	O
an	DT	O
evaluation	NN	O
of	IN	O
a	DT	O
1.5-year	JJ	O
follow-up	NN	O
of	IN	O
an	DT	O
Internet-based	JJ	O
cognitive-behavioral	JJ	O
intervention	NN	O
for	IN	O
complicated	JJ	O
grief	NN	O
.	.	O

Treatment	NNP	O
group	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
were	VBD	O
administered	VBN	O
various	JJ	O
assessments	NNS	O
of	IN	O
complicated	JJ	O
grief	NN	O
indicators	NNS	O
,	,	O
including	VBG	O
the	DT	O
Impact	NN	Mental
of	IN	Mental
Event	NNP	Mental
Scale	NNP	Mental
,	,	O
the	DT	O
anxiety	NN	Mental
and	CC	Mental
depression	NN	Mental
subscales	NNS	Mental
of	IN	Mental
the	DT	Mental
Brief	NNP	Mental
Symptom	NNP	Mental
Inventory	NNP	Mental
,	,	Mental
and	CC	Mental
the	DT	Mental
SF-12	NNP	Mental
.	.	Mental

Results	NNP	O
indicate	VBP	O
that	IN	O
the	DT	O
reduction	NN	O
in	IN	O
symptoms	NNS	Mental
of	IN	Mental
complicated	JJ	Mental
grief	NN	Mental
observed	VBN	O
at	IN	O
posttreatment	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
1.5-year	JJ	O
follow-up	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
porcine	NN	O
versus	NN	O
synthetic	JJ	O
secretin	NN	O
for	IN	O
reducing	VBG	O
symptoms	NNS	Physical
of	IN	Physical
autism	NN	Physical
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
biologic	NN	O
and	CC	O
synthetic	JJ	O
porcine	NN	O
secretin	NN	O
to	TO	O
placebo	VB	O
on	IN	O
a	DT	O
variety	NN	O
of	IN	O
autism	NN	O
symptoms	NNS	O
.	.	O

METHOD	NNP	O
Eighty-five	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
without	IN	O
other	JJ	O
medical	JJ	O
conditions	NNS	O
and	CC	O
not	RB	O
taking	VBG	O
other	JJ	O
psychotropic	NN	O
medications	NNS	O
participated	VBD	O
(	(	O
ages	NNS	O
between	IN	O
3	CD	O
and	CC	O
12	CD	O
years	NNS	O
,	,	O
mean	JJ	O
IQ	NNP	O
=	NNP	O
55	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
grouped	VBN	O
into	IN	O
trios	NNS	O
matched	VBN	O
by	IN	O
age	NN	O
and	CC	O
communication	NN	O
level	NN	O
and	CC	O
then	RB	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
biologic	NN	O
secretin	NN	O
(	(	O
2	CD	O
CU/kg	NNP	O
)	)	O
,	,	O
synthetic	JJ	O
secretin	NN	O
(	(	O
0.4	CD	O
microg/kg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

Measures	NNS	O
collected	VBD	O
1	CD	O
week	NN	O
before	RB	O
and	CC	O
4	CD	O
weeks	NNS	O
after	IN	O
infusion	NN	O
included	VBD	O
autism	NN	Mental
symptoms	NNS	Mental
,	,	Mental
language	NN	Mental
skills	NNS	Mental
,	,	Mental
and	CC	Mental
problem	NN	Mental
behaviors	NNS	Mental
,	,	O
gathered	VBN	Others
from	IN	Others
parents	NNS	Others
,	,	Others
teachers	NNS	Others
,	,	Others
and	CC	Others
investigators	NNS	Others
,	,	O
who	WP	O
were	VBD	O
all	DT	O
blind	NNS	O
to	TO	O
treatment	NN	O
.	.	O

Two-factor	NN	O
,	,	O
repeated-measures	JJ	O
analyses	NNS	O
of	IN	O
variance	NN	O
(	(	O
3	CD	O
treatment	NN	O
levels	NNS	O
by	IN	O
2	CD	O
repeated	JJ	O
measures	NNS	O
,	,	O
pre-	NN	O
and	CC	O
postinfusion	NN	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
efficacy	NN	O
.	.	O

RESULTS	NNP	O
Direct	JJ	O
observation	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
show	VB	O
change	NN	O
over	IN	O
time	NN	O
related	VBN	O
to	TO	O
secretin	VB	O
.	.	O

Parent	NN	O
reports	NNS	O
showed	VBD	O
an	DT	O
overall	JJ	O
reduction	NN	O
of	IN	O
symptom	JJ	Physical
severity	NN	Physical
for	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
including	VBG	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

One	CD	O
teacher-report	NN	O
measure	NN	O
showed	VBD	O
decreases	NNS	O
in	IN	O
autism	NN	O
symptoms	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
and	CC	O
synthetic	JJ	O
secretin	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
evidence	NN	O
that	IN	O
either	DT	O
biologic	NN	O
or	CC	O
synthetic	JJ	O
secretin	NN	O
provided	VBD	O
amelioration	NN	O
of	IN	O
symptoms	NNS	O
beyond	IN	O
placebo	NN	O
was	VBD	O
observed	VBN	O
.	.	O

This	DT	O
held	VBD	O
true	JJ	O
when	WRB	O
children	NNS	O
with	IN	O
and	CC	O
without	IN	O
gastrointestinal	JJ	O
problems	NNS	O
were	VBD	O
examined	VBN	O
separately	RB	O
.	.	O

[	JJ	O
Prevention	NNP	O
of	IN	O
thromboembolism	NN	Physical
in	IN	O
patients	NNS	O
operated	VBN	O
on	IN	O
for	IN	O
hip	NN	O
prosthesis	NN	O
]	NNP	O
.	.	O

The	DT	O
latest	JJS	O
research	NN	O
into	IN	O
the	DT	O
prevention	NN	O
of	IN	O
peri-	NN	Physical
and	CC	Physical
postoperative	JJ	Physical
thromboembolic	NN	Physical
disease	NN	Physical
has	VBZ	O
found	VBN	O
orthopaedic	JJ	O
surgery	NN	O
patients	NNS	O
to	TO	O
be	VB	O
most	VBN	O
at	IN	O
risk	NN	O
.	.	O

As	IN	O
the	DT	O
genesis	NN	O
of	IN	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
is	VBZ	O
due	JJ	O
to	TO	O
haemodynamic	VB	O
,	,	O
hemorheologic	NN	O
and	CC	O
parietal	JJ	O
factors	NNS	O
,	,	O
various	JJ	O
prophylactic	JJ	O
measures	NNS	O
have	VBP	O
been	VBN	O
considered	VBN	O
in	IN	O
the	DT	O
past	NN	O
,	,	O
measures	NNS	O
which	WDT	O
have	VBP	O
not	RB	O
proved	VBN	O
able	JJ	O
to	TO	O
provide	VB	O
satisfactory	JJ	O
protection	NN	O
in	IN	O
orthopaedics	NNS	O
.	.	O

The	DT	O
results	NNS	O
obtained	VBD	O
with	IN	O
Defibrotide	NNP	O
in	IN	O
a	DT	O
random	NN	O
and	CC	O
controlled	VBD	O
clinical	JJ	O
study	NN	O
versus	IN	O
calcium	NN	O
heparin	NN	O
involving	VBG	O
211	CD	O
patients	NNS	O
of	IN	O
both	DT	O
sexes	NNS	O
candidates	NNS	O
to	TO	O
receive	VB	O
total	JJ	O
hip	NN	O
arthroplasty	NN	O
and	CC	O
presenting	NN	O
at	IN	O
least	JJS	O
one	CD	O
major	JJ	O
thromboembolic	NN	O
risk	NN	O
factor	NN	O
are	VBP	O
reported	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
at	IN	O
random	NN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
treatments	NNS	O
:	:	O
1	CD	O
)	)	O
Defibrotide	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
400	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

i.v	NN	O
.	.	O

in	IN	O
50	CD	O
ml	JJ	O
phleboclysis	NN	O
in	IN	O
5	CD	O
minutes	NNS	O
(	(	O
n	JJ	O
=	NNP	O
108	CD	O
)	)	O
;	:	O
2	CD	O
)	)	O
calcium	NN	O
heparin	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
5000	CD	O
IU	NNP	O
t.i.d	NN	O
.	.	O

subcutaneously	RB	O
(	(	O
n	JJ	O
=	NNP	O
103	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
began	VBD	O
the	DT	O
day	NN	O
before	IN	O
operation	NN	O
and	CC	O
continued	VBN	O
on	IN	O
average	NN	O
up	RB	O
to	TO	O
the	DT	O
eighth	JJ	O
day	NN	O
for	IN	O
the	DT	O
Defibrotide	NNP	O
group	NN	O
.	.	O

With	IN	O
the	DT	O
control	NN	O
group	NN	O
it	PRP	O
continued	VBD	O
until	IN	O
discharge	NN	O
(	(	O
usually	RB	O
on	IN	O
the	DT	O
15th	JJ	O
day	NN	O
)	)	O
and	CC	O
at	IN	O
home	NN	O
for	IN	O
about	RB	O
three	CD	O
weeks	NNS	O
until	IN	O
the	DT	O
completion	NN	O
of	IN	O
the	DT	O
physiotherapy	NN	O
cycle	NN	O
.	.	O

In	IN	O
the	DT	O
108	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
Defibrotide	NNP	O
only	RB	O
one	CD	O
case	NN	O
of	IN	O
DVT	NNP	Physical
was	VBD	O
reported	VBN	O
and	CC	O
in	IN	O
none	NN	O
of	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
symptoms	NNS	Physical
or	CC	Physical
signs	NNS	Physical
of	IN	Physical
pulmonary	JJ	Physical
embolism	NN	Physical
encountered	VBN	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
calcium	NN	O
heparin	NN	O
2	CD	O
cases	NNS	O
of	IN	O
clinically	RB	O
and	CC	O
radiologically	RB	Physical
diagnosed	VBD	Physical
pulmonary	JJ	Physical
embolism	NN	Physical
and	CC	O
4	CD	O
cases	NNS	Physical
of	IN	Physical
DVT	NNP	Physical
were	VBD	O
observed	VBN	O
.	.	O

Although	IN	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
,	,	O
the	DT	O
tendency	NN	O
favours	VBZ	O
Defibrotide	NNP	O
.	.	O

Statistically	NNP	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
was	VBD	O
the	DT	O
difference	NN	O
in	IN	O
postoperative	JJ	Physical
bleeding	NN	Physical
evaluated	VBN	Physical
with	IN	O
particular	JJ	O
attention	NN	O
in	IN	O
patients	NNS	O
of	IN	O
advanced	JJ	O
age	NN	O
.	.	O

Further	NNP	O
,	,	O
in	IN	O
the	DT	O
Defibrotide	NNP	O
group	NN	O
,	,	O
scarring	VBG	Physical
was	VBD	O
considered	VBN	O
excellent	JJ	O
in	IN	O
96	CD	O
%	NN	O
of	IN	O
cases	NNS	O
while	IN	O
in	IN	O
the	DT	O
heparin	NN	O
group	NN	O
scarring	VBG	Physical
was	VBD	O
excellent	JJ	O
in	IN	O
85	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

To	TO	O
conclude	VB	O
,	,	O
the	DT	O
sure	JJ	O
clinical	JJ	Others
effectiveness	NN	Others
,	,	Others
tolerance	NN	Others
,	,	Others
handiness	NN	Others
and	CC	Others
lack	NN	Others
of	IN	Others
interference	NN	Others
with	IN	Others
clotting	VBG	Others
functions	NNS	Others
make	VBP	O
Defibrotide	VB	O
a	DT	O
really	RB	O
useful	JJ	O
drug	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
thromboembolic	JJ	Physical
episodes	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
major	JJ	O
orthopaedic	JJ	O
surgery	NN	O
.	.	O

Effects	NNS	O
of	IN	O
body	NN	O
orientation	NN	O
on	IN	O
maximum	JJ	O
voluntary	JJ	O
arm	NN	O
torques	NNS	O
.	.	O

INTRODUCTION	NNP	O
Increased	VBD	O
reliance	NN	O
on	IN	O
bulbospinal	JJ	O
motor	NN	O
systems	NNS	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
individuals	NNS	O
with	IN	O
chronic	JJ	O
stroke	NN	O
during	IN	O
maximum	JJ	O
voluntary	JJ	O
arm	NN	O
joint	NN	O
torque	NN	O
generation	NN	O
.	.	O

METHODS	NNP	O
Maximum	NNP	O
isometric	JJ	Physical
single-joint	NN	Physical
and	CC	Physical
multi-joint	NN	Physical
arm	NN	Physical
strength	NN	Physical
was	VBD	O
observed	VBN	O
in	IN	O
two	CD	O
body	NN	O
orientations	NNS	O
(	(	O
sitting	VBG	O
and	CC	O
supine	NN	O
)	)	O
while	IN	O
maintaining	VBG	O
identical	JJ	O
head/neck/trunk/extremity	NN	O
joint	JJ	O
configurations	NNS	O
in	IN	O
order	NN	O
to	TO	O
identify	VB	O
bulbospinal	JJ	O
contributions	NNS	O
to	TO	O
maximum	VB	O
joint	JJ	O
torque	NN	O
generation	NN	O
in	IN	O
11	CD	O
individuals	NNS	O
with	IN	O
stroke	NN	O
and	CC	O
10	CD	O
individuals	NNS	O
without	IN	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
sitting	VBG	O
,	,	O
shoulder	JJR	Physical
flexion	NN	Physical
was	VBD	O
greater	JJR	O
for	IN	O
both	DT	O
groups	NNS	O
,	,	O
whereas	NNS	O
shoulder	VBP	Physical
extension	NN	Physical
and	CC	Physical
elbow	JJ	Physical
flexion	NN	Physical
,	,	O
part	NN	O
of	IN	O
the	DT	O
flexion	NN	O
synergy	NN	O
,	,	O
were	VBD	O
greater	JJR	O
only	RB	O
in	IN	O
individuals	NNS	O
with	IN	O
stroke	NN	O
.	.	O

CONCLUSIONS	NNP	O
Body	NNP	O
orientation	NN	O
influenced	VBD	O
isometric	JJ	Physical
arm	NN	Physical
strength	NN	Physical
,	,	O
notably	RB	O
the	DT	O
constituents	NNS	O
of	IN	O
flexion	NN	Physical
synergy	NN	Physical
in	IN	O
individuals	NNS	O
with	IN	O
stroke	NN	O
,	,	O
suggesting	VBG	O
bulbospinal	JJ	O
motor	NN	O
pathway	NN	O
involvement	NN	O
.	.	O

From	IN	O
a	DT	O
practical	JJ	O
perspective	NN	O
,	,	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
single	JJ	Physical
joint	JJ	Physical
strength	NN	Physical
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
may	MD	O
underestimate	VB	O
strength	NN	O
available	JJ	O
during	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
that	WDT	O
are	VBP	O
performed	VBN	O
in	IN	O
an	DT	O
upright	JJ	O
orientation	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
phenytoin	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
We	PRP	O
determine	VBP	O
the	DT	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
phenytoin	NN	O
in	IN	O
preventing	VBG	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
younger	JJR	O
than	IN	O
16	CD	O
years	NNS	O
and	CC	O
experiencing	VBG	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
phenytoin	NN	O
or	CC	O
placebo	NN	O
within	IN	O
60	CD	O
minutes	NNS	O
of	IN	O
presentation	NN	O
at	IN	O
3	CD	O
pediatric	JJ	O
trauma	NN	O
centers	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
posttraumatic	JJ	Physical
seizures	NNS	Physical
within	IN	O
48	CD	O
hours	NNS	O
;	:	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
survival	JJ	O
and	CC	O
neurologic	JJ	O
outcome	NN	O
30	CD	O
days	NNS	O
after	IN	O
injury	NN	O
.	.	O

A	DT	O
Bayesian	JJ	O
decision-theoretic	JJ	O
clinical	JJ	O
trial	NN	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
probability	NN	O
of	IN	O
remaining	VBG	O
posttraumatic	JJ	O
seizure	NN	O
free	JJ	O
for	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
6.1	CD	O
years	NNS	O
.	.	O

Sixty-eight	JJ	O
percent	NN	O
were	VBD	O
boys	NNS	O
.	.	O

The	DT	O
2	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
.	.	O

During	IN	O
the	DT	O
48-hour	JJ	O
observation	NN	O
period	NN	O
,	,	O
3	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
of	IN	O
46	CD	O
patients	NNS	O
given	VBN	O
phenytoin	NNS	O
and	CC	O
3	CD	O
(	(	O
5	CD	O
%	NN	O
)	)	O
of	IN	O
56	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	O
experienced	VBD	O
a	DT	O
posttraumatic	JJ	Physical
seizure	NN	Physical
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
survival	NN	Mortality
or	CC	O
neurologic	JJ	Physical
outcome	NN	Physical
after	IN	O
30	CD	O
days	NNS	O
.	.	O

According	VBG	O
to	TO	O
these	DT	O
results	NNS	O
,	,	O
the	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	O
has	VBZ	O
the	DT	O
originally	RB	O
hypothesized	VBN	O
effect	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
rate	NN	Physical
of	IN	Physical
early	JJ	Physical
posttraumatic	JJ	Physical
seizures	NNS	Physical
by	IN	O
12.5	CD	O
%	NN	O
is	VBZ	O
0.0053	CD	O
.	.	O

The	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	O
has	VBZ	O
any	DT	O
prophylactic	JJ	Others
efficacy	NN	Others
is	VBZ	O
0.383	CD	O
.	.	O

The	DT	O
median	JJ	O
effect	NN	O
size	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
-0.015	NNP	O
(	(	O
seizure	JJ	O
rate	NN	O
increased	VBN	O
by	IN	O
1.5	CD	O
%	NN	O
in	IN	O
the	DT	O
phenytoin	NN	O
group	NN	O
)	)	O
,	,	O
95	CD	O
%	NN	O
probability	NN	O
interval	NN	O
-0.127	NN	O
to	TO	O
0.091	CD	O
(	(	O
12.7	CD	O
%	NN	O
higher	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	Physical
seizures	NNS	Physical
to	TO	O
a	DT	O
9.1	CD	O
%	NN	O
lower	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	O
seizures	NNS	O
with	IN	O
phenytoin	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
rate	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
may	MD	O
be	VB	O
much	RB	O
lower	JJR	O
than	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Phenytoin	VB	O
did	VBD	O
not	RB	O
substantially	RB	O
reduce	VB	O
that	DT	O
rate	NN	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
leptin	JJ	O
single	JJ	O
nucleotide	NN	O
polymorphism	NN	O
and	CC	O
zilpaterol	NN	O
hydrochloride	NN	O
on	IN	O
growth	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
in	IN	O
finishing	VBG	O
steers	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
4,178	CD	O
steers	NNS	O
(	(	O
mean	JJ	O
initial	JJ	O
BW	NNP	O
=	NN	O
403.9	CD	O
?	.	O
16.04	CD	O
kg	NN	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
interactive	JJ	O
effects	NNS	O
,	,	O
if	IN	O
any	DT	O
,	,	O
of	IN	O
leptin	JJ	O
R25C	NNP	O
genotypes	NNS	O
(	(	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
or	CC	O
TT	NNP	O
)	)	O
and	CC	O
zilpaterol	$	O
hydrochloride	NN	O
(	(	O
ZH	NNP	O
)	)	O
feeding	VBG	O
duration	NN	O
on	IN	O
growth	NN	O
performance	NN	O
and	CC	O
carcass	NN	O
traits	NNS	O
.	.	O

Steers	NNS	O
were	VBD	O
blocked	VBN	O
by	IN	O
arrival	NN	O
at	IN	O
the	DT	O
feed	NN	O
yard	NN	O
,	,	O
genotyped	VBD	O
for	IN	O
the	DT	O
leptin	NN	O
SNP	NNP	O
,	,	O
allotted	VBD	O
to	TO	O
genotype-specific	JJ	O
pens	NNS	O
(	(	O
90	CD	O
steers/pen	NN	O
)	)	O
,	,	O
and	CC	O
assigned	VBD	O
randomly	RB	O
within	IN	O
genotype	NN	O
and	CC	O
block	NN	O
to	TO	O
0	CD	O
or	CC	O
21	CD	O
d	NN	O
of	IN	O
dietary	JJ	O
ZH	NNP	O
.	.	O

All	DT	O
pens	NNS	O
within	IN	O
a	DT	O
block	NN	O
were	VBD	O
slaughtered	VBN	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
(	(	O
132.1	CD	O
?	.	O
10.9	CD	O
d	NN	O
on	IN	O
feed	NN	O
)	)	O
.	.	O

Final	NNP	O
BW	NNP	O
of	IN	O
steers	NNS	O
fed	VBP	O
ZH	NNP	O
was	VBD	O
6.0	CD	O
kg	NN	O
heavier	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
,	,	O
and	CC	O
ZH-fed	NNP	O
steers	NNS	O
had	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
ADG	NNP	O
than	IN	O
steers	NNS	O
not	RB	O
fed	VBN	O
ZH	NNP	O
.	.	O

Feeding	VBG	O
ZH	NNP	O
decreased	VBD	O
DMI	NNP	O
in	IN	O
steers	NNS	O
with	IN	O
increased	JJ	O
frequency	NN	O
of	IN	O
the	DT	O
T	NNP	O
allele	NN	O
(	(	O
9.67	CD	O
,	,	O
9.53	CD	O
,	,	O
and	CC	O
9.28	CD	O
kg/d	NN	O
for	IN	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
and	CC	O
TT	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
DMI	NNP	O
increased	VBD	O
with	IN	O
the	DT	O
frequency	NN	O
of	IN	O
the	DT	O
T	NNP	O
allele	NN	O
(	(	O
9.68	CD	O
,	,	O
9.90	CD	O
,	,	O
and	CC	O
10.1	CD	O
kg	NN	O
for	IN	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
and	CC	O
TT	NNP	O
,	,	O
respectively	RB	O
)	)	O
when	WRB	O
ZH	NNP	O
was	VBD	O
not	RB	O
fed	VBN	O
(	(	O
leptin	JJ	O
genotype	NN	O
?	.	O
ZH	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
ultrasonic	JJ	Physical
fat	NN	Physical
was	VBD	O
greatest	JJS	O
for	IN	O
TT	NNP	O
steers	NNS	O
(	(	O
11.4	CD	O
?	.	O
0.28	CD	O
mm	NN	O
)	)	O
and	CC	O
least	JJS	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
for	IN	O
CC	NNP	O
steers	NNS	O
(	(	O
11.0	CD	O
?	.	O
0.25	CD	O
mm	NN	O
)	)	O
.	.	O

Regardless	NNP	O
of	IN	O
ZH-feeding	NNP	O
duration	NN	O
,	,	O
TT	NNP	O
steers	NNS	O
produced	VBD	O
a	DT	O
greater	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
percentage	NN	O
of	IN	O
USDA	NNP	O
yield	NN	O
grade	NN	O
(	(	O
YG	NNP	O
)	)	O
4	CD	O
or	CC	O
higher	JJR	O
carcasses	NNS	O
(	(	O
5.4	CD	O
vs.	FW	O
2.7	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
lesser	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
percentage	NN	O
of	IN	O
YG	NNP	O
1	CD	O
carcasses	NNS	O
(	(	O
17.7	CD	O
vs.	FW	O
26.8	CD	O
%	NN	O
)	)	O
than	IN	O
CC	NNP	O
steers	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
ZH-fed	NNP	O
steers	NNS	O
produced	VBD	O
a	DT	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
percentage	NN	O
of	IN	O
USDA	NNP	O
YG	NNP	O
1	CD	O
carcasses	NNS	O
(	(	O
25.9	CD	O
vs.	FW	O
16.2	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
lesser	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
percentage	NN	O
of	IN	O
YG	NNP	O
4	CD	O
or	CC	O
higher	JJR	O
carcasses	NNS	O
(	(	O
1.6	CD	O
vs.	FW	O
6.0	CD	O
%	NN	O
)	)	O
than	IN	O
steers	NNS	O
fed	VBP	O
the	DT	O
control	NN	O
diet	NN	O
.	.	O

Marbling	VBG	O
scores	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
carcasses	NNS	O
grading	VBG	O
USDA	NNP	O
Choice	NNP	O
and	CC	O
Prime	NNP	O
were	VBD	O
greater	JJR	O
in	IN	O
TT	NNP	O
than	IN	O
CC	NNP	O
steers	NNS	O
when	WRB	O
fed	VBN	O
diets	NNS	O
devoid	VBP	O
of	IN	O
ZH	NNP	O
,	,	O
but	CC	O
both	DT	O
marbling	NN	O
and	CC	O
quality	NN	O
grades	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
among	IN	O
leptin	JJ	O
genotypes	NNS	O
when	WRB	O
fed	VBN	O
ZH	NNP	O
for	IN	O
21	CD	O
d	NN	O
(	(	O
leptin	JJ	O
genotype	NN	O
?	.	O
ZH	NNP	O
,	,	O
P	NNP	O
?	.	O
0.03	CD	O
)	)	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
HCW	NNP	O
gain	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.095	CD	O
)	)	O
for	IN	O
steers	NNS	O
of	IN	O
the	DT	O
TT	NNP	O
genotype	NN	O
(	(	O
12.7	CD	O
kg	NN	O
)	)	O
than	IN	O
either	DT	O
CC	NNP	O
(	(	O
16.3	CD	O
kg	NN	O
)	)	O
or	CC	O
CT	NNP	O
(	(	O
17.0	CD	O
kg	NN	O
)	)	O
genotypes	NNS	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
leptin	NN	O
R25C	NNP	O
genotype	NN	O
impacted	VBD	O
most	RBS	O
traits	NNS	O
associated	VBN	O
with	IN	O
fatness	JJ	O
whereas	NNS	O
feeding	VBG	O
ZH	NNP	O
for	IN	O
21	CD	O
d	NN	O
affected	VBD	O
HCW	NNP	O
and	CC	O
ADG	NNP	O
positively	RB	O
but	CC	O
impacted	VBD	O
feed	NN	O
intake	NN	O
,	,	O
marbling	NN	O
,	,	O
and	CC	O
USDA	NNP	O
quality	NN	O
grades	NNS	O
negatively	RB	O
.	.	O

Future	NNP	O
therapeutic	JJ	O
directions	NNS	O
for	IN	O
factor	NN	O
Xa	NNP	O
inhibition	NN	O
in	IN	O
the	DT	O
prophylaxis	NN	O
and	CC	O
treatment	NN	O
of	IN	O
thrombotic	JJ	O
disorders	NNS	O
.	.	O

The	DT	O
targeted	JJ	O
mechanism	NN	O
of	IN	O
factor	NN	O
Xa	NNP	O
inhibition	NN	O
has	VBZ	O
been	VBN	O
studied	VBN	O
extensively	RB	O
,	,	O
initially	RB	O
as	IN	O
prophylaxis	NN	O
for	IN	O
venous	JJ	O
thromboembolism	NN	O
(	(	O
VTE	NNP	O
)	)	O
in	IN	O
the	DT	O
orthopedic	JJ	O
surgical	JJ	O
setting	NN	O
.	.	O

Future	NNP	O
therapeutic	JJ	O
directions	NNS	O
for	IN	O
selective	JJ	O
factor	NN	O
Xa	NNP	O
inhibition	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
other	JJ	O
thrombotic	JJ	O
diseases	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Thromboembolic	JJ	O
diseases	NNS	O
can	MD	O
occur	VB	O
in	IN	O
the	DT	O
venous	JJ	O
or	CC	O
arterial	JJ	O
sides	NNS	O
of	IN	O
the	DT	O
circulatory	NN	O
system	NN	O
.	.	O

Factor	NNP	O
Xa	NNP	O
inhibition	NN	O
is	VBZ	O
a	DT	O
targeted	JJ	O
approach	NN	O
to	TO	O
anticoagulation	VB	O
that	IN	O
resulted	VBD	O
from	IN	O
significant	JJ	O
advances	NNS	O
in	IN	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
coagulation	NN	O
cascade	NN	O
.	.	O

The	DT	O
factor	NN	O
Xa	NNP	O
inhibitor	NN	O
fondaparinux	NN	O
has	VBZ	O
been	VBN	O
studied	VBN	O
extensively	RB	O
in	IN	O
the	DT	O
orthopedic	JJ	O
surgical	JJ	O
setting	NN	O
for	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
VTE	NNP	O
.	.	O

Current	NNP	O
investigations	NNS	O
that	WDT	O
are	VBP	O
under	IN	O
way	NN	O
or	CC	O
completed	VBN	O
evaluate	VBP	O
the	DT	O
efficacy	NN	Others
and	CC	Others
safety	NN	Others
of	IN	O
fondaparinux	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
various	JJ	O
thrombotic	JJ	O
diseases	NNS	O
.	.	O

The	DT	O
future	NN	O
development	NN	O
of	IN	O
fondaparinux	NN	O
resides	NNS	O
primarily	RB	O
in	IN	O
three	CD	O
therapeutic	JJ	O
areas	NNS	O
:	:	O
prevention	NN	O
of	IN	O
VTE	NNP	O
,	,	O
treatment	NN	O
of	IN	O
VTE	NNP	O
,	,	O
and	CC	O
treatment	NN	O
of	IN	O
acute	JJ	Physical
coronary	JJ	Physical
syndromes	NNS	Physical
.	.	Physical

For	IN	O
the	DT	O
prevention	NN	O
of	IN	O
VTE	NNP	O
,	,	O
fondaparinux	NN	O
has	VBZ	O
been	VBN	O
studied	VBN	O
as	IN	O
extended	JJ	O
prophylaxis	NN	O
following	VBG	O
hip	NN	O
fracture	NN	O
surgery	NN	O
(	(	O
PENTHIFRA	NNP	O
Plus	NNP	O
)	)	O
,	,	O
for	IN	O
use	NN	O
in	IN	O
high-risk	JJ	O
abdominal	JJ	O
surgical	JJ	O
patients	NNS	O
(	(	O
PEGASUS	NNP	O
and	CC	O
APOLLO	NNP	O
)	)	O
,	,	O
and	CC	O
for	IN	O
use	NN	O
in	IN	O
medical	JJ	O
patients	NNS	O
(	(	O
ARTEMIS	NNP	O
)	)	O
.	.	O

Studies	NNPS	O
evaluating	VBG	O
fondaparinux	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
VTE	NNP	O
are	VBP	O
part	NN	O
of	IN	O
the	DT	O
large	JJ	O
MATISSE	NNP	O
clinical	JJ	O
program	NN	O
(	(	O
MATISSE	NNP	O
DVT	NNP	O
and	CC	O
MATISSE	NNP	O
PE	NNP	O
)	)	O
.	.	O

Fondaparinux	NNP	O
was	VBD	O
investigated	VBN	O
in	IN	O
phase	NN	O
2	CD	O
studies	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
coronary	JJ	O
syndromes	NNS	O
,	,	O
including	VBG	O
acute	JJ	Physical
ST-segment	JJ	Physical
myocardial	JJ	Physical
infarction	NN	Physical
(	(	Physical
PENTALYSE	NNP	Physical
)	)	Physical
and	CC	Physical
unstable	JJ	Physical
angina	NN	Physical
(	(	Physical
PENTUA	NNP	Physical
)	)	Physical
.	.	Physical

Encouraging	VBG	O
data	NNS	O
from	IN	O
these	DT	O
trials	NNS	O
are	VBP	O
the	DT	O
basis	NN	O
for	IN	O
phase	NN	O
3	CD	O
programs	NNS	O
in	IN	O
this	DT	O
area	NN	O
(	(	O
MICHELANGELO	NNP	O
)	)	O
.	.	O

The	DT	O
orthopedic	JJ	O
prophylactic	JJ	O
and	CC	O
nonorthopedic	JJ	O
clinical	JJ	O
programs	NNS	O
for	IN	O
fondaparinux	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
thrombosis	NN	O
support	NN	O
the	DT	O
concept	NN	O
that	WDT	O
targeted	VBD	Physical
inhibition	NN	Physical
of	IN	Physical
coagulation	NN	Physical
is	VBZ	O
an	DT	O
effective	JJ	Physical
advance	NN	Physical
in	IN	Physical
antithrombotic	JJ	Physical
therapy	NN	Physical
.	.	Physical

Multiple	JJ	Physical
sclerosis	NN	Physical
risk	NN	Physical
after	IN	O
optic	JJ	O
neuritis	NN	O
:	:	O
final	JJ	O
optic	JJ	O
neuritis	NN	O
treatment	NN	O
trial	NN	O
follow-up	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
risk	NN	Physical
of	IN	Physical
developing	VBG	Physical
multiple	JJ	Physical
sclerosis	NN	Physical
(	(	Physical
MS	NNP	Physical
)	)	Physical
after	IN	O
optic	JJ	O
neuritis	NN	O
and	CC	O
the	DT	O
factors	NNS	O
predictive	VBP	O
of	IN	O
high	JJ	O
and	CC	O
low	JJ	O
risk	NN	O
.	.	O

DESIGN	NNP	O
Subjects	NNPS	O
in	IN	O
the	DT	O
Optic	NNP	O
Neuritis	NNP	O
Treatment	NNP	O
Trial	NNP	O
,	,	O
who	WP	O
were	VBD	O
enrolled	VBN	O
between	IN	O
July	NNP	O
1	CD	O
,	,	O
1988	CD	O
,	,	O
and	CC	O
June	NNP	O
30	CD	O
,	,	O
1991	CD	O
,	,	O
were	VBD	O
followed	VBN	O
up	RP	O
prospectively	RB	O
for	IN	O
15	CD	O
years	NNS	O
,	,	O
with	IN	O
the	DT	O
final	JJ	O
examination	NN	O
in	IN	O
2006	CD	O
.	.	O

SETTING	CC	O
Neurologic	NNP	O
and	CC	O
ophthalmologic	JJ	O
examinations	NNS	O
at	IN	O
13	CD	O
clinical	JJ	O
sites	NNS	O
.	.	O

PARTICIPANTS	NNP	O
Three	CD	O
hundred	VBD	O
eighty-nine	JJ	O
subjects	NNS	O
with	IN	O
acute	JJ	O
optic	JJ	O
neuritis	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Development	NNP	Physical
of	IN	Physical
MS	NNP	Physical
and	CC	Mental
neurologic	JJ	Physical
disability	NN	Physical
assessment	NN	Physical
.	.	Mental

RESULTS	VB	O
The	DT	O
cumulative	JJ	Physical
probability	NN	Physical
of	IN	Physical
developing	VBG	Physical
MS	NNP	Physical
by	IN	Physical
15	CD	Physical
years	NNS	Physical
after	IN	Physical
onset	NN	Physical
of	IN	Physical
optic	JJ	Physical
neuritis	NN	Physical
was	VBD	O
50	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
44	CD	O
%	NN	O
-56	NNP	O
%	NN	O
)	)	O
and	CC	O
strongly	RB	O
related	VBN	O
to	TO	O
presence	NN	O
of	IN	O
lesions	NNS	O
on	IN	O
a	DT	O
baseline	JJ	O
non-contrast-enhanced	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
MRI	NNP	O
)	)	O
of	IN	O
the	DT	O
brain	NN	O
.	.	O

Twenty-five	JJ	O
percent	NN	O
of	IN	O
patients	NNS	O
with	IN	O
no	DT	O
lesions	NNS	O
on	IN	O
baseline	NN	O
brain	NN	O
MRI	NNP	O
developed	VBD	O
MS	NNP	Physical
during	IN	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
1	CD	O
or	CC	O
more	JJR	O
lesions	NNS	O
.	.	O

After	IN	O
10	CD	O
years	NNS	O
,	,	O
the	DT	O
risk	NN	Physical
of	IN	Physical
developing	VBG	Physical
MS	NNP	Physical
was	VBD	O
very	RB	O
low	JJ	O
for	IN	O
patients	NNS	O
without	IN	O
baseline	JJ	O
lesions	NNS	O
but	CC	O
remained	VBD	O
substantial	JJ	O
for	IN	O
those	DT	O
with	IN	O
lesions	NNS	O
.	.	O

Among	IN	O
patients	NNS	O
without	IN	O
lesions	NNS	O
on	IN	O
MRI	NNP	O
,	,	O
baseline	NN	O
factors	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
substantially	RB	O
lower	JJR	O
risk	NN	Physical
for	IN	Physical
MS	NNP	Physical
included	VBD	O
male	JJ	O
sex	NN	O
,	,	O
optic	JJ	O
disc	NN	O
swelling	NN	O
,	,	O
and	CC	O
certain	JJ	O
atypical	JJ	O
features	NNS	O
of	IN	O
optic	JJ	O
neuritis	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
presence	NN	O
of	IN	O
brain	NN	O
MRI	NNP	O
abnormalities	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
an	DT	O
optic	JJ	O
neuritis	NN	O
attack	NN	O
is	VBZ	O
a	DT	O
strong	JJ	O
predictor	NN	O
of	IN	O
the	DT	Physical
15-year	JJ	Physical
risk	NN	Physical
of	IN	Physical
MS	NNP	Physical
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
MRI-detected	JJ	O
lesions	NNS	O
,	,	O
male	JJ	O
sex	NN	O
,	,	O
optic	JJ	O
disc	NN	O
swelling	NN	O
,	,	O
and	CC	O
atypical	JJ	O
clinical	JJ	O
features	NNS	O
of	IN	O
optic	JJ	O
neuritis	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
low	JJ	O
likelihood	NN	O
of	IN	O
developing	VBG	Physical
MS	NNP	Physical
.	.	O

This	DT	O
natural	JJ	O
history	NN	O
information	NN	O
is	VBZ	O
important	JJ	O
when	WRB	O
considering	VBG	O
prophylactic	JJ	O
treatment	NN	O
for	IN	O
MS	NNP	Physical
at	IN	O
the	DT	O
time	NN	O
of	IN	O
a	DT	O
first	JJ	O
acute	JJ	O
onset	NN	O
of	IN	O
optic	JJ	O
neuritis	NN	O
.	.	O

Effect	NN	O
of	IN	O
ranitidine	NN	O
on	IN	O
the	DT	O
disposition	NN	Others
of	IN	O
orally	RB	O
and	CC	O
intravenously	RB	O
administered	VBN	O
triazolam	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
orally	RB	O
administered	VBN	O
ranitidine	NN	O
on	IN	O
the	DT	O
pharmacokinetic	JJ	Physical
properties	NNS	Physical
of	IN	O
orally	RB	O
and	CC	O
intravenously	RB	O
administered	VBD	O
triazolam	NN	O
was	VBD	O
determined	VBN	O
.	.	O

Twelve	NNP	O
healthy	JJ	O
males	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
35	CD	O
years	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
four-way	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Each	DT	O
subject	NN	O
received	VBD	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
treatments	NNS	O
,	,	O
each	DT	O
separated	VBN	O
by	IN	O
one	CD	O
week	NN	O
.	.	O

The	DT	O
treatments	NNS	O
consisted	VBN	O
of	IN	O
(	(	O
1	CD	O
)	)	O
one	CD	O
orally	RB	O
administered	VBN	O
0.25-mg	JJ	O
triazolam	NN	O
tablet	NN	O
after	IN	O
treatment	NN	O
with	IN	O
ranitidine	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
one	CD	O
orally	RB	O
administered	VBN	O
0.25-mg	JJ	O
triazolam	NN	O
tablet	NN	O
,	,	O
with	IN	O
no	DT	O
ranitidine	JJ	O
pretreatment	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
a	DT	O
0.25-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
triazolam	NN	O
after	IN	O
treatment	NN	O
with	IN	O
ranitidine	NN	O
;	:	O
and	CC	O
(	(	O
4	CD	O
)	)	O
a	DT	O
0.25-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
triazolam	NN	O
,	,	O
with	IN	O
no	DT	O
ranitidine	NN	O
pretreatment	NN	O
.	.	O

Ranitidine	NNP	O
pretreatment	NN	O
consisted	VBD	O
of	IN	O
five	CD	O
150-mg	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
as	IN	O
the	DT	O
hydrochloride	NN	O
salt	NN	O
)	)	O
given	VBN	O
every	DT	O
12	CD	O
hours	NNS	O
;	:	O
the	DT	O
last	JJ	O
dose	NN	O
was	VBD	O
given	VBN	O
two	CD	O
hours	NNS	O
before	IN	O
triazolam	NN	O
was	VBD	O
administered	VBN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
at	IN	O
intervals	NNS	O
up	RB	O
to	TO	O
12	CD	O
hours	NNS	O
after	IN	O
triazolam	JJ	O
treatment	NN	O
.	.	O

Serum	NNP	Physical
triazolam	JJ	Physical
concentrations	NNS	Physical
were	VBD	O
measured	VBN	O
by	IN	O
modified	JJ	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
,	,	O
and	CC	O
pharmacokinetic	JJ	Physical
values	NNS	Physical
were	VBD	O
calculated	VBN	O
.	.	O

Pretreatment	NN	O
with	IN	O
ranitidine	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
disposition	NN	Physical
of	IN	Physical
intravenously	RB	Physical
administered	VBN	Physical
triazolam	NN	Physical
but	CC	O
significantly	RB	O
increased	VBD	O
the	DT	O
area	NN	Physical
under	IN	Physical
the	DT	Physical
serum	JJ	Physical
drug	NN	Physical
concentration-time	JJ	Physical
curve	NN	Physical
of	IN	Physical
oral	JJ	Physical
triazolam	NN	Physical
.	.	Physical

Ranitidine	NNP	O
pretreatment	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
triazolam	NN	Physical
's	POS	Physical
terminal	JJ	Physical
elimination	NN	Physical
rate	NN	Physical
constant	JJ	Physical
or	CC	O
on	IN	O
the	DT	O
time	NN	Physical
to	TO	Physical
reach	VB	Physical
maximum	JJ	Physical
serum	JJ	Physical
triazolam	NN	Physical
concentration	NN	Physical
.	.	Physical

Ranitidine	JJ	O
pretreatment	NN	O
increased	VBD	O
the	DT	O
systemic	JJ	Physical
availability	NN	Physical
of	IN	Physical
triazolam	NN	Physical
by	IN	O
increasing	VBG	O
its	PRP$	O
absorption	NN	Physical
.	.	Physical

Health-education	JJ	O
package	NN	O
to	TO	O
prevent	VB	O
worm	NN	O
infections	NNS	O
in	IN	O
Chinese	JJ	O
schoolchildren	NNS	O
.	.	O

BACKGROUND	NNP	O
Soil-transmitted	JJ	O
helminths	NNS	O
are	VBP	O
among	IN	O
the	DT	O
most	RBS	O
prevalent	JJ	O
sources	NNS	O
of	IN	O
human	JJ	O
infections	NNS	O
globally	RB	O
.	.	O

We	PRP	O
determined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
educational	JJ	O
package	NN	O
at	IN	O
rural	JJ	O
schools	NNS	O
in	IN	O
Linxiang	NNP	O
City	NNP	O
District	NNP	O
,	,	O
Hunan	NNP	O
province	NN	O
,	,	O
China	NNP	O
,	,	O
where	WRB	O
these	DT	O
worms	NNS	O
are	VBP	O
prevalent	JJ	O
.	.	O

The	DT	O
intervention	NN	O
aimed	VBN	O
to	TO	O
increase	VB	O
knowledge	NN	O
about	IN	O
soil-transmitted	JJ	O
helminths	NNS	O
,	,	O
induce	VB	O
behavioral	JJ	Mental
change	NN	Mental
,	,	O
and	CC	O
reduce	VB	O
the	DT	O
rate	NN	Physical
of	IN	Physical
infection	NN	Physical
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
single-blind	NN	O
,	,	O
unmatched	JJ	O
,	,	O
cluster-randomized	JJ	O
intervention	NN	O
trial	NN	O
involving	VBG	O
1718	CD	O
children	NNS	O
,	,	O
9	CD	O
to	TO	O
10	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
in	IN	O
38	CD	O
schools	NNS	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
1	CD	O
school	NN	O
year	NN	O
.	.	O

Schools	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
health-education	NN	O
package	NN	O
,	,	O
which	WDT	O
included	VBD	O
a	DT	O
cartoon	NN	O
video	NN	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
package	NN	O
,	,	O
which	WDT	O
involved	VBD	O
only	RB	O
the	DT	O
display	NN	O
of	IN	O
a	DT	O
health-education	NN	O
poster	NN	O
.	.	O

Infection	NN	Physical
rates	NNS	Physical
,	,	O
knowledge	VB	Mental
about	IN	Mental
soil-transmitted	JJ	Mental
helminths	NNS	Mental
(	(	Mental
as	IN	Mental
assessed	VBN	Mental
with	IN	Mental
the	DT	Mental
use	NN	Mental
of	IN	Mental
a	DT	Mental
questionnaire	NN	Mental
)	)	Mental
,	,	Mental
and	CC	O
hand-washing	JJ	Mental
behavior	NN	Mental
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

Albendazole	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
all	PDT	O
the	DT	O
participants	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
in	IN	O
all	PDT	O
the	DT	O
children	NNS	O
who	WP	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
positive	JJ	O
for	IN	O
infection	NN	O
with	IN	O
soil-transmitted	JJ	O
helminths	NNS	O
at	IN	O
the	DT	O
follow-up	JJ	O
assessment	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
school	NN	O
year	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
follow-up	JJ	O
assessment	NN	O
,	,	O
the	DT	O
mean	NN	Mental
score	NN	Mental
for	IN	Mental
the	DT	Mental
knowledge	NN	Mental
of	IN	Mental
helminths	NNS	Mental
,	,	O
calculated	VBD	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
a	DT	O
total	NN	O
of	IN	O
43	CD	O
points	NNS	O
on	IN	O
a	DT	O
questionnaire	NN	O
,	,	O
was	VBD	O
90	CD	O
%	NN	O
higher	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
63.3	CD	O
vs.	FW	O
33.4	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
children	NNS	Mental
who	WP	Mental
washed	VBD	Mental
their	PRP$	Mental
hands	NNS	Mental
after	IN	Mental
using	VBG	Mental
the	DT	Mental
toilet	NN	Mental
was	VBD	O
nearly	RB	Others
twice	RB	Others
as	RB	O
high	JJ	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
98.9	CD	O
%	NN	O
,	,	O
vs.	FW	O
54.2	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	Physical
of	IN	Physical
infection	NN	Physical
with	IN	O
soil-transmitted	JJ	O
helminths	NNS	O
was	VBD	O
50	CD	O
%	NN	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
4.1	CD	O
%	NN	O
vs.	FW	O
8.4	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
adverse	JJ	Adverseeffect
events	NNS	Adverseeffect
were	VBD	O
observed	VBN	O
immediately	RB	O
(	(	O
within	IN	O
15	CD	O
minutes	NNS	O
)	)	O
after	IN	O
albendazole	JJ	O
treatment	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
health-education	JJ	O
package	NN	O
increased	VBD	O
students	NNS	O
'	POS	O
knowledge	NN	O
about	IN	O
soil-transmitted	JJ	O
helminths	NNS	O
and	CC	O
led	VBD	O
to	TO	O
a	DT	O
change	NN	O
in	IN	O
behavior	NN	O
and	CC	O
a	DT	O
reduced	JJ	O
incidence	NN	O
of	IN	O
infection	NN	O
within	IN	O
1	CD	O
school	NN	O
year	NN	O
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
UBS	NNP	O
Optimus	NNP	O
Foundation	NNP	O
,	,	O
Zurich	NNP	O
,	,	O
Switzerland	NNP	O
;	:	O
Australian	JJ	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
number	NN	O
,	,	O
ACTRN12610000048088	NNP	O
.	.	O

)	)	O
.	.	O

Analysis	NN	Others
of	IN	Others
treatment	NN	Others
in	IN	O
childhood	NN	O
leukaemia	NN	O
.	.	O

I.	NNP	O
Predisposition	NNP	O
to	TO	O
methotrexate-induced	JJ	O
neutropenia	NN	O
after	IN	O
craniospinal	JJ	O
irradiation	NN	O
.	.	O

Report	NNP	O
to	TO	O
the	DT	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
of	IN	O
the	DT	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	O
in	IN	O
Childhood	NNP	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
drug-induced	JJ	O
neutropenia	NNS	Physical
resulting	VBG	O
from	IN	O
a	DT	O
controlled	VBN	O
trial	NN	O
(	(	O
UKALL	NNP	O
I	PRP	O
)	)	O
of	IN	O
treatment	NN	O
in	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
was	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
main	JJ	O
agent	NN	O
associated	VBN	O
with	IN	O
severe	JJ	O
neutropenia	NN	O
was	VBD	O
methotrexate	NN	O
,	,	O
and	CC	O
methotrexate-induced	JJ	Physical
neutropenia	NN	Physical
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
craniospinal	JJ	O
irradiation	NN	O
.	.	O

The	DT	O
synergistic	JJ	Adverseeffect
toxic	NN	Adverseeffect
effect	NN	Adverseeffect
of	IN	O
irradiation	NN	O
followed	VBN	O
by	IN	O
methotrexate	NN	O
treatment	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
contributed	VBN	O
to	TO	O
three	CD	O
of	IN	O
the	DT	O
five	CD	O
deaths	NNS	O
which	WDT	O
occurred	VBD	O
in	IN	O
complete	JJ	O
remission	NN	Physical
in	IN	O
this	DT	O
trial	NN	O
;	:	O
all	DT	O
deaths	NNS	O
in	IN	O
remission	NN	O
occurred	VBD	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
central	JJ	O
nervous	JJ	O
system	NN	O
prophylaxis	NN	O
.	.	O

Analysis	NN	O
of	IN	O
patients	NNS	O
who	WP	O
subsequently	RB	O
relapsed	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
still	RB	O
in	IN	O
remission	NN	O
after	IN	O
18	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
indicated	VBD	O
that	IN	O
the	DT	O
former	JJ	O
,	,	O
on	IN	O
average	NN	O
,	,	O
had	VBD	O
slightly	RB	O
lower	JJR	O
neutrophil	NN	Physical
counts	NNS	Physical
.	.	Physical

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
children	NNS	O
who	WP	O
relapsed	VBD	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
less	RBR	O
aggressive	JJ	O
treatment	NN	O
than	IN	O
those	DT	O
who	WP	O
remained	VBD	O
in	IN	O
remission	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
genetic	JJ	O
and	CC	O
environmental	JJ	O
risk	NN	O
assessment	NN	O
(	(	O
GERA	NNP	O
)	)	O
for	IN	O
colorectal	JJ	O
cancer	NN	O
risk	NN	O
in	IN	O
primary	JJ	O
care	NN	O
:	:	O
trial	NN	O
design	NN	O
and	CC	O
baseline	NN	O
findings	NNS	O
.	.	O

PURPOSE	VB	O
This	DT	O
paper	NN	O
describes	VBZ	O
an	DT	O
ongoing	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	Others
of	IN	O
genetic	JJ	O
and	CC	O
environmental	JJ	O
risk	NN	O
assessment	NN	O
(	(	O
GERA	NNP	O
)	)	O
on	IN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
CRC	NNP	O
)	)	O
screening	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
trial	NN	O
includes	VBZ	O
asymptomatic	JJ	O
patients	NNS	O
who	WP	O
are	VBP	O
50-79years	NNS	O
and	CC	O
are	VBP	O
not	RB	O
up-to-date	JJ	O
with	IN	O
CRC	NNP	O
screening	VBG	O
guidelines	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
a	DT	O
baseline	NN	O
telephone	NN	Others
survey	NN	Others
are	VBP	O
randomized	VBN	O
to	TO	O
a	DT	O
GERA	NNP	O
or	CC	O
Control	NNP	O
group	NN	O
.	.	O

GERA	NNP	O
group	NN	O
participants	NNS	O
meet	VBP	O
with	IN	O
a	DT	O
nurse	NN	O
,	,	O
decide	VB	O
whether	IN	O
to	TO	O
have	VB	O
a	DT	O
GERA	NNP	O
blood	NN	O
test	NN	O
(	(	O
a	DT	O
combination	NN	O
of	IN	O
genetic	JJ	O
polymorphism	NN	O
and	CC	O
folate	NN	O
)	)	O
,	,	O
and	CC	O
,	,	O
if	IN	O
tested	VBN	O
,	,	O
receive	VBP	O
GERA	NNP	O
feedback	NN	O
.	.	O

Follow-up	NNP	O
telephone	NN	Others
surveys	NNS	Others
are	VBP	O
conducted	VBN	O
at	IN	O
1	CD	O
and	CC	O
6months	CD	O
.	.	O

A	DT	O
chart	NN	Others
audit	NN	Others
is	VBZ	O
performed	VBN	O
at	IN	O
6months	CD	O
.	.	O

RESULTS	NNP	O
Of	IN	O
2,223	CD	O
eligible	JJ	O
patients	NNS	O
,	,	O
562	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
have	VBP	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
who	WP	O
enrolled	VBD	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
significantly	RB	O
younger	JJR	O
than	IN	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Participants	NNS	O
tended	VBD	O
to	TO	O
be	VB	O
50-59years	JJ	O
(	(	O
64	CD	O
%	NN	O
)	)	O
,	,	O
female	JJ	O
(	(	O
58	CD	O
%	NN	O
)	)	O
,	,	O
white	JJ	O
(	(	O
52	CD	O
%	NN	O
)	)	O
,	,	O
married	VBD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
have	VBP	O
more	JJR	O
than	IN	O
a	DT	O
high	JJ	O
school	NN	O
education	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
most	JJS	O
participants	NNS	O
had	VBD	O
some	DT	O
knowledge	NN	Others
of	IN	Others
CRC	NNP	Others
screening	NN	Others
and	CC	O
GERA	NNP	O
,	,	O
viewed	VBD	O
CRC	NNP	O
screening	VBG	O
favorably	RB	O
,	,	O
and	CC	O
reported	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
decided	VBN	O
to	TO	O
do	VB	O
screening	VBG	O
.	.	O

Almost	NNP	O
half	NN	O
had	VBD	O
worries	NNS	Others
and	CC	Others
concerns	NNS	Others
about	IN	O
CRC	NNP	O
.	.	O

CONCLUSIONS	NNP	O
One	CD	O
in	IN	O
four	CD	O
eligible	JJ	O
primary	JJ	O
care	NN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Age	NNP	O
was	VBD	O
negatively	RB	O
associated	VBN	O
with	IN	O
enrollment	NN	O
.	.	O

Prospective	JJ	O
analyses	NNS	O
using	VBG	O
data	NNS	O
for	IN	O
all	DT	O
participants	NNS	O
will	MD	O
provide	VB	O
more	RBR	O
definitive	JJ	O
information	NN	O
on	IN	O
GERA	NNP	O
uptake	NN	O
and	CC	O
the	DT	O
impact	NN	O
of	IN	O
GERA	NNP	O
feedback	NN	O
.	.	O

Effects	NNS	O
of	IN	O
cuff	NN	O
inflation	NN	O
on	IN	O
self-recorded	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
.	.	O

Changes	NNS	O
in	IN	O
continuously	RB	O
recorded	VBN	O
'Finapres	NNS	Physical
'	POS	Physical
finger	NN	Physical
blood	NN	Physical
pressure	NN	Physical
in	IN	O
ten	JJ	O
normotensive	JJ	O
and	CC	O
seven	CD	O
hypertensive	JJ	O
subjects	NNS	O
induced	VBN	O
by	IN	O
self-inflation	NN	O
of	IN	O
the	DT	O
cuff	NN	O
or	CC	O
just	RB	O
wearing	VBG	O
the	DT	O
inflated	JJ	O
cuff	NN	O
were	VBD	O
studied	VBN	O
.	.	O

Inflating	VBG	O
the	DT	O
cuff	NN	O
caused	VBD	O
an	DT	O
instantaneous	JJ	O
rise	NN	O
in	IN	O
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
of	IN	O
13	CD	O
and	CC	O
12	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
hypertensive	JJ	O
and	CC	O
normotensive	JJ	O
subjects	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Wearing	VBG	O
the	DT	O
inflated	JJ	O
cuff	NN	O
did	VBD	O
not	RB	O
change	VB	O
blood	NN	Physical
pressure	NN	Physical
.	.	O

Thus	VB	O
the	DT	O
rise	NN	O
in	IN	O
pressure	NN	Physical
was	VBD	O
related	VBN	O
to	TO	O
the	DT	O
muscular	JJ	O
activity	NN	O
required	VBN	O
for	IN	O
cuff	NN	O
inflation	NN	O
.	.	O

Systolic	NNP	Physical
blood	NN	Physical
pressure	NN	Physical
took	VBD	O
on	IN	O
average	JJ	O
7	CD	O
s	NN	O
and	CC	O
at	IN	O
most	JJS	O
21	CD	O
s	NN	O
to	TO	O
return	VB	O
to	TO	O
baseline	VB	O
level	NN	O
after	IN	O
stopping	VBG	O
cuff	NN	O
inflation	NN	O
.	.	O

Since	IN	O
first	JJ	O
Korotkoff	NNP	O
sounds	NNS	O
may	MD	O
already	RB	O
be	VB	O
heard	VBN	O
after	IN	O
10-15	JJ	O
s	NN	O
when	WRB	O
following	VBG	O
recommended	VBD	O
procedures	NNS	O
,	,	O
self-recorded	JJ	Physical
systolic	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
may	MD	O
be	VB	O
recorded	VBN	O
as	IN	O
too	RB	O
high	JJ	O
when	WRB	O
subjects	NNS	O
inflate	VBP	O
their	PRP$	O
cuff	NN	O
at	IN	O
too	RB	O
low	JJ	O
a	DT	O
pressure	NN	O
or	CC	O
deflate	VB	O
it	PRP	O
too	RB	O
fast	RB	O
.	.	O

Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
:	:	O
an	DT	O
RCT	NNP	O
of	IN	O
a	DT	O
parenting	VBG	O
program	NN	O
with	IN	O
parents	NNS	O
of	IN	O
a	DT	O
child	NN	O
diagnosed	VBN	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Whilst	IN	O
the	DT	O
Triple	NNP	O
P	NNP	O
Positive	NNP	O
Parenting	NNP	O
Program	NNP	O
has	VBZ	O
a	DT	O
large	JJ	O
evidence	NN	O
base	NN	O
(	(	O
Sanders	NNP	O
,	,	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Family	NNP	O
Psychology	NNP	O
Review	NNP	O
2:71-90	CD	O
,	,	O
1999	CD	O
;	:	O
Sanders	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Consulting	NNP	O
and	CC	O
Clinical	NNP	O
Psychology	NNP	O
68:624-640	CD	O
,	,	O
2000	CD	O
)	)	O
and	CC	O
preliminary	JJ	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
also	RB	O
efficacious	JJ	O
(	(	O
Roberts	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Psychology	NNP	O
,	,	O
35	CD	O
(	(	O
2	CD	O
)	)	O
:180-193	NN	O
,	,	O
2006	CD	O
)	)	O
,	,	O
to	TO	O
date	NN	O
Stepping	NNP	O
Stones	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
with	IN	O
the	DT	O
ASD	NNP	O
population	NN	O
.	.	O

Fifty-nine	JJ	O
families	NNS	O
with	IN	O
a	DT	O
child	NN	O
with	IN	O
ASD	NNP	O
aged	VBD	O
between	IN	O
2	CD	O
and	CC	O
9	CD	O
participated	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	Mental
reports	NNS	Mental
of	IN	Mental
child	JJ	Mental
behaviour	NN	Mental
and	CC	Mental
parenting	NN	Mental
styles	NNS	Mental
with	IN	Mental
the	DT	Mental
treatment	NN	Mental
effects	NNS	Mental
for	IN	Mental
child	NN	Mental
behaviour	NN	Mental
,	,	Mental
parental	NN	Mental
over	IN	Mental
reactivity	NN	Mental
and	CC	Mental
parental	JJ	Mental
verbosity	NN	Mental
being	VBG	O
maintained	VBN	O
at	IN	O
follow-up	JJ	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Further	RBR	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	Mental
satisfaction	NN	Mental
and	CC	Mental
conflict	NN	Mental
about	RB	Mental
parenting	VBG	Mental
as	RB	O
well	RB	O
as	IN	O
a	DT	O
sleeper	JJ	Mental
effect	NN	Mental
for	IN	Mental
parental	JJ	Mental
efficacy	NN	Mental
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
Stepping	VBG	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
a	DT	O
promising	JJ	O
intervention	NN	O
for	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
future	JJ	O
research	NN	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

Hypertension	NN	O
and	CC	O
non-insulin-dependent	JJ	O
diabetes	NNS	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
and	CC	O
a	DT	O
calcium	NN	O
antagonist	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
lisinopril	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
calcium	NN	O
antagonist	NN	O
nifedipine	NN	O
in	IN	O
162	CD	O
non-insulin-dependent	JJ	O
diabetic	JJ	O
hypertensive	NN	O
patients	NNS	O
for	IN	O
a	DT	O
24-week	JJ	O
period	NN	O
.	.	O

In	IN	O
83	CD	O
and	CC	O
79	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
lisinopril	JJ	O
and	CC	O
slow-release	JJ	O
nifedipine	NN	O
produced	VBD	O
similar	JJ	O
reductions	NNS	Physical
in	IN	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	O
systolic/diastolic	JJ	O
:	:	O
-16/-13	NN	O
mmHg	NN	O
supine	NN	O
and	CC	O
-14/-11	NN	O
mmHg	NN	O
standing	NN	O
after	IN	O
lisinopril	NN	O
;	:	O
-15/-12	CC	O
mmHg	VB	O
supine	NN	O
and	CC	O
-14/-11	NN	O
mmHg	NN	O
standing	VBG	O
nifedipine	NN	O
)	)	O
.	.	O

Fasting	VBG	Physical
and	CC	Physical
post-prandial	JJ	Physical
plasma	NN	Physical
glucose	NN	Physical
,	,	O
glycosylated	VBN	Physical
haemoglobin	NN	Physical
and	CC	O
plasma	JJ	Physical
lipids	NNS	Physical
appeared	VBD	O
to	TO	O
be	VB	O
unaffected	VBN	O
by	IN	O
either	DT	O
agent	NN	O
.	.	O

Also	RB	O
,	,	O
28	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
on	IN	O
lisinopril	NN	O
and	CC	O
30	CD	O
%	NN	O
of	IN	O
those	DT	O
on	IN	O
nifedipine	JJ	O
presented	VBN	O
microalbuminuria	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
induced	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
albumin	JJ	Physical
excretion	NN	Physical
rate	NN	Physical
(	(	Physical
AER	NNP	Physical
)	)	Physical
.	.	O

The	DT	O
geometric	JJ	O
mean	NN	O
x	NN	O
:	:	O
tolerance	NN	O
factor	NN	O
of	IN	O
the	DT	O
reduction	NN	Physical
in	IN	Physical
AER	NNP	Physical
among	IN	O
the	DT	O
23	CD	O
microalbuminuric	JJ	O
patients	NNS	O
on	IN	O
lisinopril	NN	O
(	(	O
-10.0	JJ	O
x:1.3	NNP	O
micrograms/min	NN	O
)	)	O
was	VBD	O
greater	JJR	O
,	,	O
though	IN	O
not	RB	O
significantly	RB	O
so	RB	O
,	,	O
than	IN	O
that	DT	O
observed	VBD	O
in	IN	O
the	DT	O
26	CD	O
on	IN	O
nifedipine	NN	O
(	(	O
-0.9	JJ	O
x	$	O
1.2	CD	O
micrograms/min	NN	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
lisinopril	RB	O
appeared	VBD	O
to	TO	O
be	VB	O
better	RB	O
tolerated	VBN	Others
than	IN	O
nifedipine	NN	O
in	IN	O
our	PRP$	O
study	NN	O
population	NN	O
.	.	O

Microalbuminuria	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiovascular	JJ	O
mortality	NN	O
in	IN	O
non-insulin-dependent	JJ	O
diabetic	JJ	O
patients	NNS	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

To	TO	O
what	WP	O
extent	VB	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
AER	NNP	Physical
could	MD	O
ameliorate	VB	O
diabetic	JJ	O
patients	NNS	O
is	VBZ	O
,	,	O
at	IN	O
present	JJ	O
,	,	O
unknown	JJ	O
.	.	O

Finally	RB	O
,	,	O
both	DT	O
lisinopril	FW	O
and	CC	O
nifedipine	NN	O
showed	VBD	O
a	DT	O
similar	JJ	O
antihypertensive	JJ	Physical
effect	NN	Physical
in	IN	O
these	DT	O
patients	NNS	O
which	WDT	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	O
differences	NNS	O
in	IN	O
plasma	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
or	CC	O
lipid	JJ	O
concentrations	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
consequences	NNS	O
of	IN	O
the	DT	O
insignificant	JJ	O
differences	NNS	O
in	IN	O
AER	NNP	Physical
remain	VBP	O
unclear	JJ	O
.	.	O

Effect	NN	O
of	IN	O
preoperative	JJ	O
skull	NN	O
block	NN	O
on	IN	O
pediatric	JJ	O
moyamoya	NN	O
disease	NN	O
.	.	O

OBJECT	NNP	O
Stable	JJ	O
hemodynamics	NNS	O
,	,	O
normocapnia	NN	O
,	,	O
and	CC	O
adequate	JJ	O
pain	NN	O
relief	NN	O
are	VBP	O
considered	VBN	O
important	JJ	O
factors	NNS	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
neurological	JJ	O
complications	NNS	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
undergoing	JJ	O
encephaloduroarteriomyosynangiosis	NN	O
(	(	O
EDAMS	NNP	O
)	)	O
operations	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moyamoya	JJ	O
disease	NN	O
.	.	O

A	DT	O
preoperative	JJ	O
skull	NN	O
block	NN	O
may	MD	O
reduce	VB	O
hemodynamic	JJ	Physical
fluctuations	NNS	Physical
and	CC	Physical
hypo-	NN	Physical
or	CC	Physical
hyperventilation	NN	Physical
due	JJ	O
to	TO	O
emergence	VB	O
delirium	NN	O
or	CC	O
oversedation	NN	O
and	CC	O
provide	VB	O
adequate	JJ	O
pain	NN	O
relief	NN	O
,	,	O
thereby	RB	O
reducing	VBG	O
postoperative	JJ	Others
morbidity	NN	Others
.	.	Others

METHODS	NNP	O
Pediatric	NNP	O
patients	NNS	O
(	(	O
age	NN	O
3-13	CD	O
years	NNS	O
)	)	O
undergoing	VBG	O
EDAMS	NNP	O
surgery	NN	O
for	IN	O
moyamoya	JJ	O
disease	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
nerve	NN	O
block	NN	O
(	(	O
NB	NNP	O
)	)	O
group	NN	O
(	(	O
18	CD	O
cases	NNS	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
21	CD	O
cases	NNS	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
patients	NNS	O
received	VBD	O
a	DT	O
preoperative	JJ	O
NB	NNP	O
(	(	O
0.25	CD	O
%	NN	O
5-8	JJ	O
ml	NN	O
bupivacaine	NN	O
mixed	JJ	O
with	IN	O
20-40	JJ	O
mg	NNS	O
methylprednisolone	NN	O
)	)	O
targeting	VBG	O
the	DT	O
supraorbital	NN	O
,	,	O
supratrochlear	JJ	O
,	,	O
auriculotemporal	JJ	O
,	,	O
and	CC	O
posterior	JJ	O
auricular	JJ	O
nerves	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
receive	VB	O
NB	NNP	O
.	.	O

General	NNP	O
anesthesia	NN	O
with	IN	O
sevoflurane	NN	O
was	VBD	O
induced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
NB	NNP	O
group	NN	O
,	,	O
stable	JJ	Physical
hemodynamic	JJ	Physical
parameters	NNS	Physical
were	VBD	O
obtained	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
sevoflurane	NN	O
concentration	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

For	IN	O
delirious	JJ	Physical
awakening	NN	Physical
,	,	O
the	DT	O
odds	NNS	O
ratio	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
was	VBD	O
4.9	CD	O
compared	VBN	O
with	IN	O
the	DT	O
NB	NNP	O
group	NN	O
.	.	O

Pain	NNP	Pain
and	CC	O
analgesic	JJ	Physical
requirement	NN	Physical
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
control	NN	O
patients	NNS	O
than	IN	O
in	IN	O
the	DT	O
NB-treated	JJ	O
patients	NNS	O
during	IN	O
the	DT	O
postanesthesia	NN	O
care	NN	O
unit	NN	O
stay	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
arterial	JJ	Physical
CO	NNP	Physical
(	(	Physical
2	CD	Physical
)	)	Physical
tension	NN	Physical
in	IN	Physical
the	DT	Physical
postanesthesia	NN	Physical
care	NN	Physical
unit	NN	Physical
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
odds	NNS	Physical
ratio	NN	Physical
in	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
rate	NN	Physical
of	IN	Physical
morbidity	NN	Physical
(	(	Physical
cerebral	JJ	Physical
infarction	NN	Physical
and	CC	Physical
reversible	JJ	Physical
ischemic	JJ	Physical
neurological	JJ	Physical
deficits	NNS	Physical
)	)	Physical
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
following	VBG	O
the	DT	O
operation	NN	O
was	VBD	O
3.2	CD	O
compared	VBN	O
with	IN	O
the	DT	O
NB	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
use	NN	O
of	IN	O
skull	JJ	O
block	NN	O
during	IN	O
EDAMS	NNP	O
surgery	NN	O
provided	VBD	O
easy	JJ	O
hemodynamic	JJ	Physical
control	NN	Physical
,	,	Physical
calm	JJ	Physical
awakening	NN	Physical
,	,	Physical
and	CC	Physical
better	JJR	Physical
pain	NN	Pain
relief	NN	Pain
and	CC	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
reduced	VBN	O
postoperative	JJ	Others
morbidity	NN	Others
.	.	Physical

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
to	TO	O
assess	VB	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
multiple	JJ	Physical
actinic	JJ	Physical
keratoses	NNS	Physical
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	Physical
keratoses	NNS	Physical
(	(	Physical
AKs	NNP	Physical
)	)	Physical
are	VBP	O
precancerous	JJ	O
epidermal	JJ	O
lesions	NNS	O
found	VBD	O
most	JJS	O
frequently	RB	O
on	IN	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
exposed	VBD	O
to	TO	O
the	DT	O
sun	NN	O
.	.	O

Several	JJ	O
case	NN	O
studies	NNS	O
published	VBN	O
recently	RB	O
have	VBP	O
indicated	VBN	O
that	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
,	,	O
currently	RB	O
licensed	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
,	,	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
imiquimod	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
AK	NNP	Physical
.	.	O

DESIGN	NNP	O
Patients	NNPS	O
in	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
applied	VBD	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
or	CC	O
vehicle	NN	O
to	TO	O
AK	NNP	Physical
lesions	NNS	Physical
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
or	CC	O
until	IN	O
lesions	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
an	DT	O
adverse	JJ	O
reaction	NN	O
,	,	O
application	NN	O
of	IN	O
imiquimod	NN	O
was	VBD	O
reduced	VBN	O
to	TO	O
1	CD	O
or	CC	O
2	CD	O
times	NNS	O
per	IN	O
week	NN	O
.	.	O

Rest	JJS	O
periods	NNS	O
were	VBD	O
also	RB	O
allowed	VBN	O
if	IN	O
necessary	JJ	O
.	.	O

SETTING	VB	O
A	DT	O
specialized	JJ	O
outpatient	NN	O
dermatology	NN	O
clinic	NN	O
within	IN	O
a	DT	O
state-funded	JJ	O
hospital	NN	O
in	IN	O
Germany	NNP	O
.	.	O

PATIENTS	VB	O
The	DT	O
study	NN	O
population	NN	O
was	VBD	O
aged	VBN	O
45	CD	O
to	TO	O
85	CD	O
years	NNS	O
.	.	O

Of	IN	O
52	CD	O
patients	NNS	O
screened	VBD	O
,	,	O
36	CD	O
men	NNS	O
and	CC	O
women	NNS	O
with	IN	O
AK	NNP	O
confirmed	VBN	O
by	IN	O
histological	JJ	O
diagnosis	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
histological	JJ	O
diagnosis	NN	O
for	IN	O
AK	NNP	O
,	,	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
than	IN	O
85	CD	O
years	NNS	O
,	,	O
or	CC	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
comply	VB	O
with	IN	O
the	DT	O
protocol	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
responded	VBN	O
to	TO	O
a	DT	O
notice	NN	O
asking	VBG	O
for	IN	O
volunteers	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
number	NN	Physical
and	CC	Physical
appearance	NN	Physical
of	IN	Physical
lesions	NNS	Physical
were	VBD	O
evaluated	VBN	O
before	RB	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
adverse	JJ	Adverseeffect
effects	NNS	Adverseeffect
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Lesions	NNP	O
treated	VBD	O
with	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
were	VBD	O
clinically	RB	Physical
cleared	VBN	Physical
in	IN	O
21	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
patients	NNS	O
and	CC	O
partially	RB	Physical
cleared	VBN	Physical
in	IN	O
2	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Clearance	NN	Physical
was	VBD	O
histologically	RB	O
confirmed	VBN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
application	NN	O
of	IN	O
imiquimod	NN	O
in	IN	O
all	DT	O
patients	NNS	O
clinically	RB	O
diagnosed	VBN	O
as	IN	O
lesion	NN	O
free	NN	O
.	.	O

Only	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
were	VBD	O
clinically	RB	O
diagnosed	VBN	O
with	IN	O
recurrence	NN	O
1	CD	O
year	NN	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	O
reduction	NN	Physical
in	IN	Physical
the	DT	Physical
size	NN	Physical
or	CC	Physical
number	NN	Physical
of	IN	Physical
AK	NNP	Physical
lesions	NNS	Physical
was	VBD	O
observed	VBN	O
in	IN	O
vehicle-treated	JJ	O
patients	NNS	O
.	.	O

Adverse	JJ	O
effects	NNS	O
reported	VBN	O
by	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
included	VBD	O
erythema	NN	Adverseeffect
,	,	O
edema	NN	Adverseeffect
,	,	O
induration	NN	Adverseeffect
,	,	O
vesicles	NNS	Adverseeffect
,	,	O
erosion	NN	Adverseeffect
,	,	O
ulceration	NN	Adverseeffect
,	,	O
excoriation	NN	Adverseeffect
,	,	O
and	CC	O
scabbing	VBG	Adverseeffect
.	.	O

However	RB	O
,	,	O
imiquimod	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	Others
since	IN	O
all	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
12-week	JJ	O
treatment	NN	O
.	.	O

Only	RB	O
a	DT	O
few	JJ	O
,	,	O
mild	JJ	O
adverse	JJ	O
reactions	NNS	O
to	TO	O
the	DT	O
vehicle	NN	O
cream	NN	O
were	VBD	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
Application	NNP	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	Physical
.	.	O

